PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ohtani, K; Tsujimoto, A; Ikeda, M; Nakamura, M				Ohtani, K; Tsujimoto, A; Ikeda, M; Nakamura, M			Regulation of cell growth-dependent expression of mammalian CDC6 gene by the cell cycle transcription factor E2F	ONCOGENE			English	Article						mammalian CDC6; E2F; promoter; cell cycle; DNA synthesis	ORIGIN RECOGNITION COMPLEX; S-PHASE ENTRY; DNA-REPLICATION; MCM-PROTEINS; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; FISSION YEAST; DISTINCT ROLES; HUMAN HOMOLOG; HUMAN MEMBER	CDC6 of Saccharomyces cerevisiae regulates the DNA replication initiation through the origin recognition complex (ORC), Identification of a human homolog of the CDC6 gene (HsCdc6) suggests a universal role of the gene product in DNA replication. Expression of HsCdc6 is growth-regulated. We investigated the molecular basis of growth-regulated expression of mammalian Cdc6. The promoter activity of isolated HsCdc6 upstream region was activated at late G1 and G1/S boundary in the cell cycle of rat embryonic fibroblast REF52 cells by the addition of serum. The isolated promoter was activated by exogenous expression of E2F without serum stimulation. However a mutant promoter lacking the E2F recognition sites failed to respond to serum stimulation and exogenous expression of E2F, Expression of endogenous Cdc6 was induced by exogenous expression of E2F, Therefore, we concluded that the growth-regulated expression of mammalian Cdc6 was mediated by E2F, Moreover, we demonstrated that exogenous overexpression of either HsCdc6 or HsOrc1 failed to induce DNA synthesis unlike overexpression of E2F1, even though E2F1 induced both Cdc6 and Orc1, suggesting that E2F may regulate the expression of another gene(s), besides Cdc6 and Orc1, required for induction of cellular DNA synthesis in mammalian cells.	Tokyo Med & Dent Univ, Grad Sch Dent, Human Gene Sci Ctr, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch Dent, Dept Dev Biol, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Nakamura, M (corresponding author), Tokyo Med & Dent Univ, Grad Sch Dent, Human Gene Sci Ctr, Tokyo 1138510, Japan.							Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Fujita M, 1996, J BIOL CHEM, V271, P4349; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Geng Y, 1996, ONCOGENE, V12, P1173; Hardy CFJ, 1997, GENE, V187, P239, DOI 10.1016/S0378-1119(96)00761-5; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lin SY, 1996, MOL CELL BIOL, V16, P1668; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NEVINS JR, 1992, SCIENCE, V258, P424; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tsuruga H, 1997, GENES CELLS, V2, P381, DOI 10.1046/j.1365-2443.1997.1290327.x; Tsuruga H, 1997, BIOCHEM BIOPH RES CO, V236, P118, DOI 10.1006/bbrc.1997.6865; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	46	89	90	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1777	1785		10.1038/sj.onc.1202105	http://dx.doi.org/10.1038/sj.onc.1202105			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778043				2022-12-28	WOS:000076303300003
J	Jaakkola, P; Maatta, A; Jalkanen, M				Jaakkola, P; Maatta, A; Jalkanen, M			The activation and composition of FiRE (an FGF-inducible response element) differ in a cell type- and growth factor-specific manner	ONCOGENE			English	Article						AP-1; EGF; FGF; FIN-1; KGF; syndecan-1; transcription	HEPARAN-SULFATE PROTEOGLYCANS; LATE TRANSCRIPTION FACTOR; TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; GENE-EXPRESSION; SYNDECAN-1 GENE; WOUND REPAIR; IN-VIVO; C-FOS; PROMOTER	The expression of the heparan sulfate proteoglycan, syndecan-1, is induced both in keratinocytes and in fibroblasts during development and tissue regeneration. Here we report that in keratinocytes the syndecan-1 gene was stimulated by EGF but not by FGF-2, In fibroblasts it was stimulated by FGF-2 but not by EGF, Likewise, the recently discovered FGF-inducible response element (FiRE) on the gene of syndecan-1 was stimulated by FGF-2 in fibroblasts and by EGF in keratinocytes, but not vice vel sn. The FIRE has two binding sites for an activator protein-1 (AP-1), one for an FGF-inducible nuclear factor (FIN-1) and one for an upstream stimulatory factor-1 (USF-1), The growth factor-stimulated binding of these transcription factors, as well as their requirement for FiRE activation, varied between the two cell types. First, although AP-ls were required for activation of FIRE in both cell types, the binding of AP-1 to FiRE was increased by growth factor-stimulation only in fibroblasts and not in keratinocytes, Secondly, FiRE did not bind FIN-1 nor needed the FIN-1 binding site for EGF-stimulated activation in keratinocytes, in contrast to the FGF-stimulated activation of FiRE in fibroblasts, Thirdly, EGF, which did not activate FIRE in fibroblasts, failed to activate FIN-1 in these cells. Finally, an USF-1 binding site that was necessary for activation of FIRE in keratinocytes was not needed in fibroblasts, These data suggest mechanisms by which members of the EGF- and FGF-families can differentially stimulate transcription through AP-1 regulated elements in a cell type-specific manner.	Univ Turku, Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University	Jalkanen, M (corresponding author), Univ Turku, Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.		Jaakkola, Panu M/B-4355-2012	Maatta, Arto/0000-0003-3759-1310; Jaakkola, Panu/0000-0002-2365-4985				ANDREE C, 1994, P NATL ACAD SCI USA, V91, P12188, DOI 10.1073/pnas.91.25.12188; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; BENZEEV A, 1990, CELL REGUL, V1, P621, DOI 10.1091/mbc.1.9.621; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROWN GL, 1989, NEW ENGL J MED, V321, P76, DOI 10.1056/NEJM198907133210203; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON JM, 1991, ANN NY ACAD SCI, V638, P306, DOI 10.1111/j.1749-6632.1991.tb49041.x; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KLUCHER KM, 1990, J VIROL, V64, P4189, DOI 10.1128/JVI.64.9.4189-4198.1990; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LORET C, 1989, J BIOL CHEM, V264, P8319; PESTELL RG, 1995, J BIOL CHEM, V270, P18301, DOI 10.1074/jbc.270.31.18301; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994; VAINIO S, 1992, DEV DYNAM, V194, P105, DOI 10.1002/aja.1001940204; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; VIHINEN T, 1993, J BIOL CHEM, V268, P17261	32	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1279	1286		10.1038/sj.onc.1202002	http://dx.doi.org/10.1038/sj.onc.1202002			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771971				2022-12-28	WOS:000075803300010
J	Le Gall, M; Grall, D; Chambard, JC; Pouyssegur, J; Van Obberghen-Schilling, E				Le Gall, M; Grall, D; Chambard, JC; Pouyssegur, J; Van Obberghen-Schilling, E			An anchorage-dependent signal distinct from p42/44 MAP kinase activation is required for cell cycle progression	ONCOGENE			English	Article						anchorage; cell cycle; MAP kinase; cyclin D1; pRb; p21(Cip/Wafl)	PROTEIN-KINASE; EXTRACELLULAR-MATRIX; ADHESION COMPLEXES; GROWTH-FACTORS; D1 EXPRESSION; PROLIFERATION; PATHWAY; ARREST; CYTOSKELETON; FIBROBLASTS	Most normal cells require both mitogens and integrin-mediated attachment for growth. It is generally accepted that the p42/p44 MAP kinase module, which can be activated by both growth factors and adhesion, prays a critical role in G0 to S phase progression of quiescent cells, Studies on various cultured fibroblasts have shown that removal of anchorage leads to cell cycle arrest in G1 and it has been proposed that adhesion-dependent G1 progression requires the joint regulation of p42/p44 MAP kinase by integrins and growth factors. In quiescent CCL39 lung fibroblasts, MAP kinase activation in response to serum becomes compromised when cells are placed in suspension. Under these conditions, serum-stimulated cells arrest their growth in mid-G1 with reduced cyclin D1 expression and increased p21(Cip/Waf1) expression, as compared to their attached counterparts. To determine whether a casual link exists between suboptimal activation of MAP kinase in non-adherent cells and the observed G1 block,we used a variant of CCL39 stably expressing an estrogen-inducible activated-Raf-1 construct (Delta Raf-1:ER), We found that even strong and sustained activation of MAP kinase with estradiol, in addition to serum, is not able to boost cyclin D1 expression levels or stimulate hyperphosphorylation of pRb in suspended CCL39-Delta Raf-1:ER cells. These results indicate that p42/p44 MAP kinase activation is not a limiting factor for G1 to S phase transit in absence of anchorage. Thus, at least one adhesion-mediated signalling event, distinct from MAP kinase activation is required for maximal cyclin D1 induction and hyperphosphorylation of pRb.	CNRS, UMR 6543, Ctr Biochim, F-06108 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Van Obberghen-Schilling, E (corresponding author), CNRS, UMR 6543, Ctr Biochim, Parc Valrose, F-06108 Nice 2, France.		Le Gall, Maude/C-3917-2017; Van Obberghen-Schilling, Ellen/O-1581-2016; Van Obberghen-Schilling, Ellen/Q-4372-2019; Le Gall, Maude/W-2593-2019	Le Gall, Maude/0000-0002-5372-4585; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Le Gall, Maude/0000-0002-5372-4585; CHAMBARD, Jean Claude/0000-0003-4722-2308				Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bottazzi ME, 1997, TRENDS CELL BIOL, V7, P348, DOI 10.1016/S0962-8924(97)01114-8; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHULZE A, 1996, MOL CELL BIOL, V16, P4632; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VANOBBERGHENSCHILLING E, 1983, J CELL PHYSIOL, V115, P123, DOI 10.1002/jcp.1041150204; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	38	42	42	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1271	1277		10.1038/sj.onc.1202057	http://dx.doi.org/10.1038/sj.onc.1202057			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771970				2022-12-28	WOS:000075803300009
J	Ponzio, G; Loubat, A; Rochet, N; Turchi, L; Rezzonico, R; Far, DF; Dulic, V; Rossi, B				Ponzio, G; Loubat, A; Rochet, N; Turchi, L; Rezzonico, R; Far, DF; Dulic, V; Rossi, B			Early G(1) growth arrest of hybridoma B cells by DMSO involves cyclin D2 inhibition and p21([CIP1]) induction	ONCOGENE			English	Article						cyclin D2; cell cycle; DMSO; CDKs; p21([CIP1]); p27([KIP1])	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT KINASE-ACTIVITY; REVERSIBLE G1 ARREST; NEUROBLASTOMA-CELLS; DIMETHYL-SULFOXIDE; SUSCEPTIBILITY GENE; PHASE PROGRESSION; NUCLEAR-PROTEIN; MAMMALIAN-CELLS; DOWN-REGULATION	Dimethylsulfoxide (DMSO) was shown to inhibit the proliferation of several B cell lines including Raji, Daudi, and SKW6-CL4 but the mechanisms involved in this growth arrest are still unclear. We show that in 7TD1 mouse hybridoma cells a DMSO-induced reversible G(1) arrest involves inactivation of Rb kinases, cyclin D2/CDK4 and cyclin E/CDK2. This occurs by at least three distinct mechanisms. Inhibition of cyclin D2 neosynthesis leads to a dramatic decrease of cyclinD2/CDK4 complexes. This in turn enables the redistribution of p27([KIP1]) from cyclin D2/CDK4 to cyclin E/CDK2 complexes. In addition, the simultaneous accumulation of p21([CIP1]) entails increasing association with cyclin D3/CDK4 and cyclin E/CDK2. Thus, p21([CIP1]) and p27([KIP1]), act in concert to inhibit cyclin E/CDK2 activity which, together with CDK4 inactivation, confers a G(1)-phase arrest.	Fac Med, INSERM U364, F-06107 Nice 02, France; Hop Cantonal Geneva, Lab Immunol Clin, CH-1211 Geneva 14, Switzerland; CNRS, CRBM, ERS 155, F-34033 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Ponzio, G (corresponding author), Fac Med, INSERM U364, Ave Valombrose, F-06107 Nice 02, France.		ROCHET, Nathalie/N-1819-2018; ROCHET, Nathalie/S-3027-2019; Ponzio, Gilles/Q-1256-2016; REZZONICO, Roger/N-9626-2016	ROCHET, Nathalie/0000-0002-9995-6699; ROCHET, Nathalie/0000-0002-9995-6699; Ponzio, Gilles/0000-0003-2741-0248; REZZONICO, Roger/0000-0002-8460-1641; Dulic, Vjekoslav/0000-0003-1201-3901; Turchi, Laurent/0000-0003-2020-5831				BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BURGER C, 1994, J CELL SCI, V107, P2047; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Florenes VA, 1996, ONCOGENE, V13, P2447; GIRARD F, 1992, J CELL BIOL, V118, P785, DOI 10.1083/jcb.118.4.785; Gorospe M, 1996, MOL CELL BIOL, V16, P762; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HORIGUCHIYAMADA J, 1993, MOL CELL BIOCHEM, V119, P29, DOI 10.1007/BF00926850; JIANG HP, 1994, ONCOGENE, V9, P3397; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; KLINKEN SP, 1988, EXP CELL RES, V178, P185, DOI 10.1016/0014-4827(88)90390-4; KLUGE N, 1976, P NATL ACAD SCI USA, V73, P1237, DOI 10.1073/pnas.73.4.1237; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; MAEDA S, 1978, J CELL PHYSIOL, V94, P181, DOI 10.1002/jcp.1040940207; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Musgrove EA, 1997, MOL ENDOCRINOL, V11, P54, DOI 10.1210/me.11.1.54; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; PROUDFOOT AEI, 1993, J PROTEIN CHEM, V12, P489, DOI 10.1007/BF01025050; REAGAN LP, 1990, MOL PHARMACOL, V38, P878; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNERI LM, 1995, NEURAL PROCESS LETT, V2, P2, DOI 10.1007/BF02311571; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; SAWAI M, 1990, EXP CELL RES, V187, P4, DOI 10.1016/0014-4827(90)90108-M; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAKASE K, 1992, CELL GROWTH DIFFER, V3, P515; TAKASE K, 1994, CELL GROWTH DIFFER, V5, P1051; Teraoka H, 1996, EXP CELL RES, V222, P218, DOI 10.1006/excr.1996.0027; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Vadiveloo PK, 1996, ONCOGENE, V13, P599; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503	60	36	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1159	1166		10.1038/sj.onc.1202040	http://dx.doi.org/10.1038/sj.onc.1202040			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764826				2022-12-28	WOS:000075598400011
J	Yuan, J; Tirabassi, RS; Bush, AB; Cole, MD				Yuan, J; Tirabassi, RS; Bush, AB; Cole, MD			The C-elegans MDL-1 and MXL-1 proteins can functionally substitute for vertebrate MAD and MAX	ONCOGENE			English	Article						C-elegans; MAD; MAX	NEMATODE CAENORHABDITIS-ELEGANS; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; MYC-MAX; ONCOGENIC ACTIVITY; CELL-GROWTH; N-COR; COMPLEX; TRANSFORMATION; GENE	The genes of the myc/max/mad family play an important role in controlling cell proliferation and differentiation. We have identified the first homologues of the mad and max genes in the nematode C. elegans, which we have named mdl-1 and mxl-1 respectively. Like the vertebrate MAD proteins, MDL-1 binds an E-box DNA sequence (CACGTG) when dimerized with MXL-1. However, unlike vertebrate MAX, MXL-1 can not form homodimers and bind to DNA alone. Promoter fusions to a GFP reporter suggest that these genes are coexpressed in posterior intestinal and post-mitotic neuronal cells during larval development. The coexpression in the posterior intestinal cells occurs before their final division at the end of the L1 stage and persists afterwards, demonstrating that mad and max expression can be correlated directly to the cell cycle state of an individual cell type. These data also show that mxl-1 is an obligate partner for mdl-1 in vivo and in vitro and indicate that these genes may play an important role in post-embryonic development. Finally, MDL-1 can suppress activated c-MYC/RAS-induced focus formation in a rat embryo fibroblast transformation assay. Like the vertebrate MAD protein, MDL-1 activity in suppressing transformation is dependent on a functional SIN3 interaction domain.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Cole, MD (corresponding author), Merck & Co Inc, Dept Bioinformat, POB 2000,RY80A-1, Rahway, NJ 07065 USA.				NCI NIH HHS [CA55248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; ARMAND P, 1994, MOL CELL BIOL, V13, P383; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; AYER DE, 1993, CELL, V72, P1; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; CERNI C, 1995, ONCOGENE, V11, P587; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; MADURO M, 1995, GENETICS, V141, P977; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Wood WB, 1988, NEMATODE CAENORHABDI; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	44	31	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1109	1118		10.1038/sj.onc.1202036	http://dx.doi.org/10.1038/sj.onc.1202036			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764821				2022-12-28	WOS:000075598400006
J	Cadoret, A; Baron-Delage, S; Bertrand, F; Kornprost, M; Groyer, A; Gespach, C; Capeau, J; Cherqui, G				Cadoret, A; Baron-Delage, S; Bertrand, F; Kornprost, M; Groyer, A; Gespach, C; Capeau, J; Cherqui, G			Oncogene-induced up-regulation of Caco-2 cell proliferation involves IGF-II gene activation through a protein kinase C-mediated pathway	ONCOGENE			English	Article						Ha-ras; polyoma middle T; IGF-II gene; PKC; Spl; Caco-2 cells	GROWTH-FACTOR-I; MIDDLE-T-ONCOGENES; TRANSCRIPTION FACTOR SP1; MOUSE EMBRYO FIBROBLASTS; FACTOR BINDING-PROTEINS; COLON-CARCINOMA CELLS; HUMAN HA-RAS; MESSENGER-RNA; FACTOR (IGF)-II; DOWN-REGULATION	We previously reported that I as and polyoma middle T (PyMT), a constitutive activator of the src protooncogene product, up-regulated Caco-2 cell proliferation along with protein kinase C (PKC) alpha expression and PKC activity. We aimed to investigate whether oncogene-induced up-regulation of Caco-2 cell proliferation involved stimulation of the autocrine IGF-II/IGF-I receptor (IGF1R) loop described in these cells and if so, to analyse the role of overexpressed and activated PKC, Compared with control vector transfected Caco-2 cells, ras- and PyMT-transfected cells exhibited increased expression of the 6.0 and 4.8 kb IGF-II transcripts. This was due to increased activity of the P3 and P4 promoters of the IGF-II gene which correlated with increased expression and DNA-binding activity of Spl, a transcription factor interacting with several specific sites in P3 and P4 promoters. Oncogene-transfected cells displayed enhanced autocrine IGF-II production, which was fully responsible for the oncogene-induced increase in their proliferation since this increase was blunted by anti-human IGF-II and IGF1R (alpha IR3) antibodies. PKC mediated oncogene activation of the IGF-II gene presumably through action on Spl since (i) PKC activation by phorbol 12-myristate 13-acetate increased Spl expression, P3 and P4 activity and IGF-II mRNA in control but not in oncogene-transfected cells; and (ii) PKC inhibition by the PKC inhibitor Go6976 reduced Spl, P3 and P4 activity and IGF-II mRNA in all three cell lines. This is the first evidence that ras- and PyMT/src oncogenes up-regulate Caco-2 cell proliferation through a PKC-mediated pathway which stimulates IGF-II gene transcription and thereby increases autocrine IGF-II production, The mechanisms underlying IGF-II gene activation by PKC most probably involve action on Sp1.	Fac Med St Antoine, Biol Cellulaire Lab, INSERM, U402, F-75571 Paris 12, France; Fac Med Xavier Bichat, INSERM, U327, F-75018 Paris, France; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Cherqui, G (corresponding author), Fac Med St Antoine, Biol Cellulaire Lab, INSERM, U402, 27 Rue Chaligny, F-75571 Paris 12, France.		Cadoret, Axelle/L-2529-2017	Cadoret, Axelle/0000-0002-4283-6864				ADENIS A, 1995, EUR J CANCER, V31A, P50, DOI 10.1016/0959-8049(94)00368-F; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BaronDelage S, 1996, AM J PHYSIOL-GASTR L, V270, pG314, DOI 10.1152/ajpgi.1996.270.2.G314; BARONDELAGE S, 1994, J BIOL CHEM, V269, P18686; BASERGA R, 1995, CANCER RES, V55, P249; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BINOUX M, 1986, J CLIN ENDOCR METAB, V63, P1151, DOI 10.1210/jcem-63-5-1151; BISSONNETTE M, 1994, AM J PHYSIOL, V267, pG465, DOI 10.1152/ajpgi.1994.267.3.G465; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; CULOUSCOU JM, 1991, CANCER RES, V51, P2813; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DELAGE S, 1993, CANCER RES, V53, P2762; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GUO YS, 1992, GASTROENTEROLOGY, V102, P1101; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HOEFLICH A, 1994, MOL CELL ENDOCRINOL, V101, P141, DOI 10.1016/0303-7207(94)90228-3; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HOLTHUIZEN PE, 1993, REGUL PEPTIDES, V48, P77, DOI 10.1016/0167-0115(93)90337-8; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAHM H, 1994, INT J CANCER, V58, P452, DOI 10.1002/ijc.2910580325; LAMBERT S, 1990, INT J CANCER, V46, P405, DOI 10.1002/ijc.2910460313; LAMONERIE T, 1995, INT J CANCER, V61, P587, DOI 10.1002/ijc.2910610425; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Levy P, 1996, BRIT J CANCER, V74, P423, DOI 10.1038/bjc.1996.376; Marais R, 1996, CANCER SURV, V27, P101; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; NODA M, 1988, J BIOL CHEM, V263, P18574; OBEID LM, 1992, J BIOL CHEM, V267, P20804; Park JHY, 1996, J CELL PHYSIOL, V166, P396, DOI 10.1002/(SICI)1097-4652(199602)166:2<396::AID-JCP18>3.0.CO;2-9; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SUSSENBACH JS, 1991, MODERN CONCEPTS INSU, P639; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; TRICOLI JV, 1986, CANCER RES, V46, P6169; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Yurochko AD, 1997, J VIROL, V71, P4638, DOI 10.1128/JVI.71.6.4638-4648.1997; ZARRILLI R, 1994, CELL GROWTH DIFFER, V5, P1085; Zarrilli R, 1996, J BIOL CHEM, V271, P8108, DOI 10.1074/jbc.271.14.8108; Zenilman ME, 1997, CANCER INVEST, V15, P1, DOI 10.3109/07357909709018911; ZHANG Y, 1995, AM J PHYSIOL-ENDOC M, V269, pE804, DOI 10.1152/ajpendo.1995.269.5.E804	54	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					877	887		10.1038/sj.onc.1202013	http://dx.doi.org/10.1038/sj.onc.1202013			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780004				2022-12-28	WOS:000075448800009
J	Kaul, SC; Duncan, EL; Englezou, A; Takano, S; Reddel, RR; Mitsui, Y; Wadhwa, R				Kaul, SC; Duncan, EL; Englezou, A; Takano, S; Reddel, RR; Mitsui, Y; Wadhwa, R			Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein	ONCOGENE			English	Article						NIH3T3; malignant transformation; mot-2 protein	3' UNTRANSLATED REGION; MOUSE EMBRYO CELLS; SPONTANEOUS IMMORTALIZATION; REPLICATIVE SENESCENCE; CELLULAR MORTALITY; TUMOR SUPPRESSION; EPITHELIAL-CELLS; HSP70 FAMILY; FIBROBLASTS; EXPRESSION	The murine mortalin genes, mot-1 and mot-2, are members of the hsp70 family of proteins and differ from each other by only two amino acid residues. Mot-1 is expressed in normal cells and has pancytosolic cellular distribution whereas mot-2 is found in the perinuclear region of immortal cells. We report here that a high level of expression of mot-2 protein resulted in malignant transformation of cells as analysed by anchorage independent growth and nude mice assays. A high level of protein expression is attributed to the 900 bp 3' untranslated region of the cDNA which does not have any transforming activity per se. Mortalin cDNA clones isolated from human transformed cells were also found to have transforming activity in similar assays and a high level of expression was apparent in some of the human immortalized cells that showed non-pancytosolic mortalin immunofluorescence, Taken together, the data suggest that nonpancytosolic mortalin may have a role in tumorigenesis.	AIST, Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; Childrens Med Res Inst, Sydney, NSW 2145, Australia; Chugai Res Inst Mol Med, Niihari, Ibaraki 30041, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Children's Medical Research Institute - Australia; University of Sydney	Kaul, SC (corresponding author), AIST, Natl Inst Biosci & Human Technol, 1-1 Higashi, Tsukuba, Ibaraki 305, Japan.		Takano, Shuichi/I-6512-2013; Kaul, Sunil C/L-8671-2018; Reddel, Roger R/A-6635-2014; Wadhwa, Renu/L-8898-2018	Kaul, Sunil C/0000-0002-0046-3916; Reddel, Roger R/0000-0002-6302-6107; Wadhwa, Renu/0000-0001-8248-5192				BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Derventzi A, 1996, ANTICANCER RES, V16, P2901; DESILVA R, 1993, CELL MOL BIOL RES, V39, P101; DESILVA R, 1994, EXP CELL RES, V213, P418, DOI 10.1006/excr.1994.1218; Gallie DR, 1996, NUCLEIC ACIDS RES, V24, P1954, DOI 10.1093/nar/24.10.1954; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; Jupe ER, 1996, EXP CELL RES, V224, P128, DOI 10.1006/excr.1996.0120; Kaul SC, 1997, EXP CELL RES, V232, P56, DOI 10.1006/excr.1997.3503; Kaul SC, 1996, ONCOGENE, V13, P1231; KAUL SC, 1994, BBA-GEN SUBJECTS, V1201, P389, DOI 10.1016/0304-4165(94)90067-1; MEEK RL, 1977, EXP CELL RES, V107, P277, DOI 10.1016/0014-4827(77)90350-0; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; RITTLING SR, 1992, ONCOGENE, V7, P935; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Sambrook J., 2002, MOL CLONING LAB MANU; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; SUGHARA T, 1997, J BIOL CHEM, V273, P3033; SUGIHARA T, 1994, BBA-MOL CELL RES, V1224, P365, DOI 10.1016/0167-4889(94)90269-0; Takano S, 1997, EXP CELL RES, V237, P38, DOI 10.1006/excr.1997.3754; TOKUMITSU M, 1994, MOL CARCINOGEN, V10, P52, DOI 10.1002/mc.2940100109; WADHWA R, 1991, MUTAT RES, V256, P243, DOI 10.1016/0921-8734(91)90015-4; Wadhwa R, 1996, EXP CELL RES, V226, P381, DOI 10.1006/excr.1996.0239; WADHWA R, 1993, J BIOL CHEM, V268, P22239; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WADHWA R, 1995, INT J ONCOL, V7, P69; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; WORMINGTON M, 1994, BIOESSAYS, V16, P533, DOI 10.1002/bies.950160804	31	72	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					907	911		10.1038/sj.onc.1202017	http://dx.doi.org/10.1038/sj.onc.1202017			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780007				2022-12-28	WOS:000075448800012
J	Barley, RDC; Enns, L; Paterson, MC; Mirzayans, R				Barley, RDC; Enns, L; Paterson, MC; Mirzayans, R			Aberrant p21(WAF1)-dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li-Fraumeni syndrome fibroblast strains heterozygous for TP53 mutations	ONCOGENE			English	Article						Li-Fraumeni syndrome; UV; apoptosis; DNA repair; p53; p21(WAF1)	CANCER-PRONE FAMILY; P53 TUMOR-SUPPRESSOR; TRANSCRIPTION-COUPLED REPAIR; WILD-TYPE P53; CELL-CYCLE; DNA-DAMAGE; EXCISION-REPAIR; ATAXIA-TELANGIECTASIA; PYRIMIDINE DIMERS; AFFECTED MEMBERS	The purpose of this study is to better understand the roles of the p53 tumor suppressor protein and the product of the p53-regulated gene p21(WAF1) in the response of diploid human dermal fibroblast cultures to 254 nm ultraviolet (UV) light. We report that Li - Fraumeni syndrome (LFS) fibroblast strains heterozygous for TP53 mutation at either codon 245 or 234 exhibit markedly reduced or no expression of p21(WAF1) following UV irradiation, respectively. These strains also exhibit defective nucleotide excision repair and pronounced inhibition of RNA synthesis following UV exposure, both of which are molecular hallmarks of cells derived from patients with the UV-sensitive syndrome xeroderma pigmentosum, In sharp contrast to xeroderma pigmentosum cells, however, the repair-deficient LFS cells show abnormal resistance, rather than hypersensitivity, to the killing effect of UV light. We further demonstrate that exposure of normal human fibroblasts to biologically relevant fluences (less than or equal to 15 J/m(2)) of UV does not induce apoptotic cell death, indicating that UV resistant phenotype displayed by LFS strains is not associated with deregulated apoptosis, In normal fibroblasts, such treatment results in a moderate (similar to threefold) up-regulation of p53 protein, induction of the p21(WAF1) gene, and a senescence-like growth arrest. On the other hand, exposure to greater than or equal to,20 J/m(2) UV results in a striking up-regulation of p53, inhibition of p21(WAF1) expression, and activation of an apoptotic pathway. We conclude that: (i) p21(WAF1)-mediated senescence is the principal mode of cell death induced by less than or equal to 15 J/m(2) UV light in normal human fibroblasts; (ii) there is a threshold effect for p53-dependent apoptosis and that, in normal human cells, this threshold level is induced upon exposure to similar to 20 J/m(2) UV; (iii) the p53 signaling pathway is malfunctional in the TP53 heterozygous LFS strains examined; and (iv) the enhanced resistance to UV-induced cell killing displayed by these LFS strains is a consequence of diminished growth arrest, which is presumably mediated by p21(WAF1) nd not abnormalities in an apoptotic pathway.	Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res MBC 03, Riyadh 11211, Saudi Arabia	University of Alberta; King Faisal Specialist Hospital & Research Center	Mirzayans, R (corresponding author), Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada.							ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; BECHHANSEN NT, 1981, LANCET, V1, P1335; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Chung DH, 1998, RADIAT RES, V149, P187, DOI 10.2307/3579929; Cistulli CA, 1998, CANCER RES, V58, P1993; DeFrank JS, 1996, CANCER RES, V56, P5365; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DOVER R, 1994, J CELL SCI, V107, P1181; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Enns L, 1998, RADIAT RES, V150, P11, DOI 10.2307/3579639; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Gadbois DM, 1997, CANCER RES, V57, P1151; GALLOWAY AM, 1994, J BIOL CHEM, V269, P974; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; JARVIS WD, 1994, CANCER RES, V54, P1707; JONES JC, 1991, MUTAT RES, V255, P155, DOI 10.1016/0921-8777(91)90049-U; JUVAN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; LI CY, 1995, INT J ONCOL, V6, P233; LI Y, 1994, ONCOGENE, V9, P2261; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1996, ONCOGENE, V13, P823; Loignon M, 1997, CANCER RES, V57, P3390; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Martin Seamus J., 1994, Current Opinion in Oncology, V6, P616, DOI 10.1097/00001622-199411000-00015; MEYN MS, 1995, CANCER RES, V55, P5991; Milas Luka, 1994, In Vivo (Attiki), V8, P665; MIRZAYANS R, 1992, INT J RADIAT BIOL, V62, P417, DOI 10.1080/09553009214552301; MIRZAYANS R, 1993, CARCINOGENESIS, V14, P2621, DOI 10.1093/carcin/14.12.2621; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; MIRZAYANS R, 1995, BRIT J CANCER, V71, P1221, DOI 10.1038/bjc.1995.237; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OConnor PM, 1997, CANCER RES, V57, P4285; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; PALCIC B, 1990, BIOINSTRUMENTATION D, P923; PARSHAD R, 1993, RADIAT RES, V136, P236, DOI 10.2307/3578616; PAVELETICH NP, 1993, GENE DEV, V7, P2556; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1997, CANCER RES, V57, P3434; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; STRONG LC, 1992, AM J EPIDEMIOL, V135, P190, DOI 10.1093/oxfordjournals.aje.a116271; TOMMASI S, 1996, ONCOGENE, V13, P413; VARLEY JM, 1997, BRIT J CANCER, V75, P1; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Worner W, 1996, CANCER RES, V56, P1272; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2; Yount GL, 1996, CANCER RES, V56, P500	76	39	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					533	543		10.1038/sj.onc.1202271	http://dx.doi.org/10.1038/sj.onc.1202271			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704919				2022-12-28	WOS:000075195300001
J	Davison, TS; Yin, P; Nie, E; Kay, C; Arrowsmith, CH				Davison, TS; Yin, P; Nie, E; Kay, C; Arrowsmith, CH			Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome	ONCOGENE			English	Article						p53; oligomerization; Li-Fraumeni syndrome; DNA binding	TUMOR-SUPPRESSOR P53; TETRAMERIZATION DOMAIN; DNA-BINDING; MUTATIONS; GENE; INHIBITOR; KINASES; SYSTEM; P21	Recently two germline mutations in the oligomerization domain of p53 have been identified in patients with Li-Fraumeni and Li-Fraumeni-like Syndromes. We have used biophysical and biochemical methods to characterize these two mutants in order to better understand their functional defects and the role of the p53 oligomerization domain (residues 325 -355) in oncogenesis, We find that residues 310-360 of the L344P mutant are monomeric, apparently unfolded and cannot interact with wild-type (WT) p53. The full length L344P protein is unable to bind sequence specifically to DNA and is therefore an inactive, but not a dominant negative mutant, R337C, on the other hand, can form dimers and tetramers, can hetero-oligomerize with WTp53 and can bind to a p53 consensus element. However, the thermal stability of R337C is much lower than that of M'Tp53 and at physiological temperatures more than half of this mutant is less than tetrameric, Thus, the R337C mutant retains some functional activity yet leads to a predisposition to cancer, suggesting that even partial inactivation of p53 oligomerization is sufficient for accelerated tumour progression.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Alberta	Arrowsmith, CH (corresponding author), Univ Toronto, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Arrowsmith, Cheryl/0000-0002-4971-3250				CARIELLO NF, 1994, CANCER RES, V54, P4454; Casey G, 1996, ONCOGENE, V13, P1971; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lomax ME, 1997, ONCOGENE, V14, P1869, DOI 10.1038/sj.onc.1201133; LOMAX ME, 1998, IN PRESS ONCOGENE; MIYASHITA T, 1995, CELL, V80, P293; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sambrook J., 1989, MOL CLONING; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TARUNINA M, 1993, ONCOGENE, V8, P3165; Varley JM, 1996, ONCOGENE, V12, P2437; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Wagner P, 1995, FEBS LETT, V377, P155, DOI 10.1016/0014-5793(95)01329-6; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	32	86	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					651	656		10.1038/sj.onc.1202062	http://dx.doi.org/10.1038/sj.onc.1202062			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704931				2022-12-28	WOS:000075195300013
J	Fulop, V; Colitti, CV; Genest, D; Berkowitz, RS; Yiu, GK; Ng, SW; Szepesi, J; Mok, SC				Fulop, V; Colitti, CV; Genest, D; Berkowitz, RS; Yiu, GK; Ng, SW; Szepesi, J; Mok, SC			DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases	ONCOGENE			English	Article						trophoblastic diseases; DOC-2; Dab2; tumor suppressor; cancer	PROLINE-RICH PEPTIDES; SUSCEPTIBILITY GENE; OVARIAN-CANCER; SH3 DOMAINS; BINDING; SEQUENCE; CLONING; PHOSPHOTYROSINE; IDENTIFICATION; PROTEINS	Gestational trophoblastic diseases comprise a spectrum of interrelated diseases including partial mole, complete mole and gestational choriocarcinoma, Using reverse transcriptase PCR (RT-PCR) analysis, we identified higher levels of DOC-2/hDab2 expression in the normal trophoblast cells in culture than in choriocarcinoma cell lines. Subsequent study using immunohistochemistry showed high levels of DOC-2/hDab2 protein expression in normal trophoblast tissues but significantly lower levels of expression in gestational trophoblastic disease tissues, particularly in complete mole and choriocarcinoma. When DOC-2/hDab2 was transfected into the choriocarcinoma cell lines, Jar, JEG and BeWo, the stable transfectants showed significantly reduced growth rate in culture. These data suggest that down regulation of DOC-2/hDab2 may play an important role in the development of gestational trophoblastic diseases.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol,Lab Gynecol Oncol, Boston, MA 02115 USA; Haymal Imre Univ Hlth Sci, Dept Obstet & Gynecol, Budapest, Hungary	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mok, SC (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol,Lab Gynecol Oncol, Boston, MA 02115 USA.		Yiu, Glenn/AAF-2858-2020		NATIONAL CANCER INSTITUTE [R01CA069291, R01CA069453, R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63381, R01CA69291, R01CA69453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEUNG ANY, 1993, J CLIN PATHOL, V46, P204, DOI 10.1136/jcp.46.3.204; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FULOP V, 1998, IN PRESS J REPROD ME; Hancock BW, 1997, GESTATIONAL TROPHOBL; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MOK SC, 1998, IN PRESS ONCOGENE, V15; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; XU X, 1997, AM ASS CANC RES P, V38, P157; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	19	73	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	1998	17	4					419	424		10.1038/sj.onc.1201955	http://dx.doi.org/10.1038/sj.onc.1201955			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696034				2022-12-28	WOS:000075043000003
J	Petersen, S; Rudolf, J; Bockmuhl, U; Gellert, K; Wolf, G; Dietel, M; Petersen, I				Petersen, S; Rudolf, J; Bockmuhl, U; Gellert, K; Wolf, G; Dietel, M; Petersen, I			Distinct regions of allelic imbalance on chromosome 10q22-q26 in squamous cell carcinomas of the lung	ONCOGENE			English	Article						lung cancer; tumor genetics; loss of heterozygosity	PROSTATE-CANCER; HUMAN GLIOBLASTOMAS; LONG ARM; PROGRESSION; LOCI; HETEROZYGOSITY; GENE; HUMAN-CHROMOSOME-10; ADENOCARCINOMA; ABNORMALITIES	The genetic mechanisms underlying the progression to the metastatic phenotype of lung cancer are poorly understood. We recently showed that small cell lung cancer (SCLC) and metastasizing squamous cell carcinomas are characterized by an increased incidence of allelic loss on chromosome 10q, In the present study we performed a deletion mapping using 24 polymorphic markers on chromosome 10q22-q26 in 39 squamous cell carcinomas (SCC) of the lung identifying 14 metastatic carcinomas (74%) and three non-metastatic SCC (15%) with allelic imbalance. The allelotype analysis indicated three regions of allelic loss that were clustered at the loci Afm086/D10S541, D10S185 and D10S1782/D10S169. A localized microsatellite instability was observed in two carcinomas for the markers D10S1686 and D10S1782, In addition the PTEN/MMAC1 gene was analysed by direct DNA sequencing and Southern blot analysis in 25 and 28 carcinomas, respectively, without detecting any genomic alterations. Similarly, no altered transcript was detected in 15 tumor cell lines and 20 primary tumors by Northern blot analysis or RT-PCR, In summary, three distinct regions of allelic imbalance were identified suggesting that multiple tumor suppressor genes on chromosome 10q contribute to tumor progression and metastases formation of lung cancer.	Univ Hosp Charite, Inst Pathol, D-10098 Berlin, Germany; Univ Hosp Charite, Dept Otorhinolaryngol, D-10098 Berlin, Germany; Univ Hosp Charite, Dept Surg, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Petersen, I (corresponding author), Univ Hosp Charite, Inst Pathol, D-10098 Berlin, Germany.							Bockmuhl U, 1997, CANCER RES, V57, P5213; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FONG KM, 1995, CANCER RES, V55, P28; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; GRAY IC, 1995, CANCER RES, V55, P4800; Guldberg P, 1997, CANCER RES, V57, P3660; HERBST RA, 1994, CANCER RES, V54, P3111; Ittmann M, 1996, CANCER RES, V56, P2143; KARLBOM AE, 1993, HUM GENET, V92, P169; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; MOIR DT, 1994, GENOMICS, V22, P1, DOI 10.1006/geno.1994.1338; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MORITA R, 1991, CANCER RES, V51, P5817; Nagase S, 1997, CANCER RES, V57, P1630; Nagase S, 1996, BRIT J CANCER, V74, P1979, DOI 10.1038/bjc.1996.663; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; NIHEI N, 1995, GENE CHROMOSOME CANC, V14, P112, DOI 10.1002/gcc.2870140205; PEIFFER SL, 1995, CANCER RES, V55, P1922; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Petersen I, 1997, CANCER RES, V57, P2331; Petersen S, 1998, BRIT J CANCER, V77, P270, DOI 10.1038/bjc.1998.43; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; RASHEED BKA, 1995, ONCOGENE, V10, P2243; REMPEL SA, 1993, CANCER RES, V53, P2386; Rhei E, 1997, CANCER RES, V57, P3657; SATO S, 1994, CANCER RES, V54, P5652; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; Teng DHF, 1997, CANCER RES, V57, P5221; TESTA JR, 1992, CANCER RES, V52, pS2702; THIBERVILLE L, 1995, CANCER RES, V55, P5133	40	48	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					449	454		10.1038/sj.onc.1201949	http://dx.doi.org/10.1038/sj.onc.1201949			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696038				2022-12-28	WOS:000075043000007
J	Yokomizo, A; Tindall, DJ; Drabkin, H; Gemmill, R; Franklin, W; Yang, P; Sugio, K; Smith, DI; Liu, WG				Yokomizo, A; Tindall, DJ; Drabkin, H; Gemmill, R; Franklin, W; Yang, P; Sugio, K; Smith, DI; Liu, WG			PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers	ONCOGENE			English	Article						PTEN/MMAC1; mutation; deletion; lung cancer; DHPLC	GENE; CHROMOSOME-10; HETEROZYGOSITY; PROGRESSION	A putative tumor suppressor, PTEN/MMAC1 gene at 10q23 was recently identified and found to be mutated in many different human tumors. To determine the role of the PTEN/MMAC1 gene in lung cancer, we screened 34 small cell lung cancer (SCLC) cell lines, 10 SCLC tumors, 13 non-small cell lung cancer (NSCLC) cell lines and 10 NSCLC tumors using Denaturing HPLC (DHPLC) and direct sequencing methods. In SCLC, six (18%) of the cell lines and one of the primary tumor samples (10%) showed alterations of the PTEN/ MMAC1 gene including point mutations, small fragment deletions, and homozygous deletions. All of the point mutations and small fragment deletions were observed in hemizygously deleted cell lines. In contrast to SCLC, none of the NSCLC tumors or cell lines had mutations in the PTEN/MMAC1 gene. These data indicate that PTEN/MMAC1 mutations contribute to the pathogenesis and neoplastic evolution in SCLC but not in NSCLC.	Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Urol, Rochester, MN 55905 USA; Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Kyushu Univ, Fac Med, Dept Surg 2, Fukuoka 81282, Japan	Mayo Clinic; Mayo Clinic; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Kyushu University	Liu, WG (corresponding author), Mayo Clin & Mayo Fdn, Dept Expt Pathol & Med, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL CANCER INSTITUTE [R01CA048031, P50CA058187] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031, CA58187] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartsch D, 1996, CANCER LETT, V102, P73, DOI 10.1016/0304-3835(96)04167-5; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; Giaccone G, 1996, CHEST, V109, pS130, DOI 10.1378/chest.109.5_Supplement.130S; Guldberg P, 1997, CANCER RES, V57, P3660; HERBST RA, 1994, CANCER RES, V54, P3111; JAMES CD, 1988, CANCER RES, V48, P5546; JOHNSON BE, 1995, LUNG CANCER-J IASLC, V12, pS5, DOI 10.1016/S0169-5002(10)80014-5; Kawamata N, 1996, PROSTATE, V29, P191, DOI 10.1002/1097-0045(199609)29:3<191::AID-PROS2990290305>3.0.CO;2-1; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; LEENSTRA S, 1994, BRIT J CANCER, V70, P684, DOI 10.1038/bjc.1994.373; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; LEVIN NA, 1994, CANCER RES, V54, P5086; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIU W, 1998, IN PRESS NUCL ACIDS; Liu WG, 1997, CANCER RES, V57, P5254; Liu WG, 1996, HUM MOL GENET, V5, P1581, DOI 10.1093/hmg/5.10.1581; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Oefner P. J., 1995, American Journal of Human Genetics, V57, pA266; OPHOFF RA, 1996, CELL, V87, P1; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PEIFFER SL, 1995, CANCER RES, V55, P1922; Pennisi E, 1997, SCIENCE, V275, P1876, DOI 10.1126/science.275.5308.1876; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; REMPEL SA, 1993, CANCER RES, V53, P2386; Rhei E, 1997, CANCER RES, V57, P3657; RIED T, 1994, CANCER RES, V54, P1801; Risinger JI, 1997, CANCER RES, V57, P4736; RSAHEED BKA, 1997, CANCER RES, V57, P4187; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Schwendel A, 1997, INT J CANCER, V74, P86, DOI 10.1002/(SICI)1097-0215(19970220)74:1<86::AID-IJC15>3.0.CO;2-G; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tashiro H, 1997, CANCER RES, V57, P3935; Testa JR, 1997, CANCER GENET CYTOGEN, V95, P20, DOI 10.1016/S0165-4608(96)00337-8; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Underhill PA, 1996, P NATL ACAD SCI USA, V93, P196, DOI 10.1073/pnas.93.1.196; Wang SI, 1997, CANCER RES, V57, P4183	39	143	154	4	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					475	479		10.1038/sj.onc.1201956	http://dx.doi.org/10.1038/sj.onc.1201956			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696041				2022-12-28	WOS:000075043000010
J	Tamir, Y; Bengal, E				Tamir, Y; Bengal, E			p53 Protein is activated during muscle differentiation and participates with MyoD in the transcription of muscle creatine kinase gene	ONCOGENE			English	Article						p53; MyoD; cooperativity; muscle creatine kinase gene; muscle differentiation; transcriptional activation	WILD-TYPE P53; DNA-BINDING FUNCTION; CELL DIFFERENTIATION; SEQUENCE; EXPRESSION; ENHANCER; IDENTIFICATION; SUPPRESSOR; DISTINCT; ELEMENT	The p53 protein is a transcription factor involved in processes of cell growth and differentiation. The muscle creatine kinase (MCK) gene whose transcription is induced during muscle differentiation contains p53-binding sites. In this study we tested the involvement of p53 in the activation of MCK transcription during muscle differentiation of C2 cells. We have shown that the p53 protein is stabilized and its DNA binding and transcriptional activities are induced during muscle differentiation. At the stage of muscle-differentiation, p53 protein can induce the accurate transcription of a minimal p53-dependent MCK reporter gene. Moreover, p53 cooperates with MyoD in the induction of MCK transcription. The expression of a dominant negative p53 protein in muscle cells reduced the expression of endogenous MCK gene. The dominant negative p53 protein abolished the cooperativity of wild type p53 with MyoD. Amino and carboxy terminal residues of MyoD required for the cooperation with p53 in transcription were identified. The cooperativity between the two proteins occurs also at the stage of DNA binding. We suggest that p53 protein is activated during myoblast differentiation and participates with MyoD in the induction of MCK transcription.	Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, Dept Biochem, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Bengal, E (corresponding author), Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, Dept Biochem, Efron St,POB 9649, IL-31096 Haifa, Israel.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; JACKSON P, 1995, GENE EXPRESSION, V5, P19; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum M, 1996, ONCOGENE, V13, P2527; Lu X, 1996, ONCOGENE, V13, P413; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; PROKOCIMER M, 1994, BLOOD, V84, P2391; REGIMOVE N, 1993, ONCOGENE, V8, P1183; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	51	50	50	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					347	356		10.1038/sj.onc.1201929	http://dx.doi.org/10.1038/sj.onc.1201929			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690516				2022-12-28	WOS:000074947500009
J	Bissonnette, N; Hunting, DJ				Bissonnette, N; Hunting, DJ			p21-induced cycle arrest in G(1) protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage	ONCOGENE			English	Article						DNA; p21(Waf1/Cip1); PARP; RNA polymerase III apoptosis; p53	CASEIN KINASE-II; CELLULAR TUMOR-ANTIGEN; HUMAN CANCER-CELLS; WILD-TYPE P53; DEPENDENT KINASES; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; P53-MEDIATED APOPTOSIS; ATAXIA-TELANGIECTASIA; POTENTIAL MEDIATOR	Cells expressing the R273H mutant of p53, which lacks sequence specific DNA binding capacity, do not undergo cell cycle arrest in G(1) following exposure to ionizing or UV radiation because of their inability to induce p21(Waf1/Cip1), a cyclin-dependent kinase inhibitor and downstream mediator of p53-dependent DNA damage-induced growth arrest. Following UV-irradiation or treatment with an inhibitor of RNA pol II, we observed a rapid induction of the apoptotic process, as evidenced by DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase. Using mimosine, a p21(Waf1/Cip1) inducer that bypasses the requirement for transcriptional transactivation by p53, we demonstrated that a G(1) cell cycle arrest can prevent apoptosis following UV-irradiation or treatment with an RNA polymerase II inhibitor, Serum starvation, which also synchronized cells in G(1) but did not induce p21(Waf1/Cip1), did not protect cells from apoptosis, These results demonstrate that restoring a late G(1) checkpoint by inducing p21(Waf1/Cip1) expression can protect cells from DNA damage induced apoptosis, Our results suggest that p21(Waf2/Cip1) can interrupt the apoptotic process at a point downstream from p53 accumulation but upstream from caspase-3 activation.	Univ Sherbrooke, Fac Med, MRC, Grp Radiat Sci, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Hunting, DJ (corresponding author), Univ Sherbrooke, Fac Med, MRC, Grp Radiat Sci, Sherbrooke, PQ J1H 5N4, Canada.							ADDISON C, 1990, ONCOGENE, V5, P423; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DelSal G, 1996, ONCOGENE, V12, P177; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P85024; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1990, GENE DEV, V4, P74; FISCELLA M, 1994, ONCOGENE, V9, P3249; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; Guillot C, 1997, ONCOGENE, V14, P45, DOI 10.1038/sj.onc.1200803; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kastan MB, 1996, BIOESSAYS, V18, P617, DOI 10.1002/bies.950180804; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KHANNA KK, 1995, ONCOGENE, V11, P609; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1996, ONCOGENE, V13, P823; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MAYNE LV, 1982, CANCER RES, V42, P1473; McDonald E, 1996, CANCER RES, V56, P2250; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MIYASHITA T, 1995, CELL, V80, P293; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK D, 1994, GENE DEV, V10, P1945; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRICE BD, 1995, ONCOGENE, V11, P73; Schroter M, 1996, EUR J CELL BIOL, V69, P143; SELBY PC, 1997, NUCLEIC ACIDS RES, V25, P787; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STURZBECHER HW, 1990, ONCOGENE, V5, P795; Tarunina M, 1996, ONCOGENE, V13, P589; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WATSON JV, 1987, CYTOMETRY, V8, P1, DOI 10.1002/cyto.990080101; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZANDOMENI RO, 1989, BIOCHEM J, V262, P469, DOI 10.1042/bj2620469	82	132	134	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3461	3469		10.1038/sj.onc.1201899	http://dx.doi.org/10.1038/sj.onc.1201899			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692554				2022-12-28	WOS:000074544100013
J	Lee, KK; Murakawa, M; Nishida, E; Tsubuki, S; Kawashima, S; Sakamaki, K; Yonehara, S				Lee, KK; Murakawa, M; Nishida, E; Tsubuki, S; Kawashima, S; Sakamaki, K; Yonehara, S			Proteolytic activation of MST/Krs, STE20-related protein kinase, by caspase during apoptosis	ONCOGENE			English	Article						Fas (Apo-1/CD95); apoptosis; caspase; protein kinase; signal transduction	TUMOR-NECROSIS-FACTOR; INDUCED CELL-DEATH; MONOCLONAL-ANTIBODY; FAS; PROTEASES; CLONING; DOMAIN; INTERACTS; CONTAINS; RECEPTOR	The Fas system has been extensively investigated as a model of apoptosis and the caspase cascade has been shown to be a characteristic mechanism of signaling of apoptosis. We have identified and purified a kinase that was activated after the stimulation of Fas on human thymoma-derived HPB-ALL cells. Partial amino acid sequencing of the purified kinase revealed it to be MST/ Krs, member of the yeast STE20 family of protein kinases. MST/Krs was activated by proteolytic cleavage and proteolytic activation was blocked by the caspase inhibitor, Z-VAD-FK. A mutant MST with Asp-->Asn replacement at a putative caspase cleavage site was resistant to either the proteolytic cleavage or the activation of the kinase activity. These findings suggest that proteolytic activation is one activation mechanism of MST and plays a role in apoptosis.	Kyoto Univ, Inst Virus Res, Kyoto 60601, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 113, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Kyoto 60601, Japan	Kyoto University; Tokyo Metropolitan Institute of Medical Science; Kyoto University	Yonehara, S (corresponding author), Kyoto Univ, Inst Virus Res, Kyoto 60601, Japan.			Sakamaki, Kazuhiro/0000-0002-7072-9628				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cahill MA, 1996, ONCOGENE, V13, P2087; CASCIOLA RL, 1995, J EXP MED, V12, P1625; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lu ML, 1996, P NATL ACAD SCI USA, V93, P8977, DOI 10.1073/pnas.93.17.8977; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	35	116	119	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3029	3037		10.1038/sj.onc.1201840	http://dx.doi.org/10.1038/sj.onc.1201840			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662336				2022-12-28	WOS:000074125300010
J	Wellbrock, C; Geissinger, E; Gomez, A; Fischer, P; Friedrich, K; Schartl, M				Wellbrock, C; Geissinger, E; Gomez, A; Fischer, P; Friedrich, K; Schartl, M			Signalling by the oncogenic receptor tyrosine kinase Xmrk leads to activation of STAT5 in Xiphophorus melanoma	ONCOGENE			English	Article						receptor tyrosine kinase; melanoma; STAT5; signal transduction	EPIDERMAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; COLONY-STIMULATING FACTOR; GENE-EXPRESSION; BETA-CHAIN; TRANSCRIPTIONAL ACTIVATION; CELL-PROLIFERATION; ONCOSTATIN-M; ERYTHROPOIETIN; INTERLEUKIN-2	Overexpression of the mutationally activated Xmrk receptor initiates the formation of hereditary malignant melanoma in the fish Xiphophorus, In addition to transcriptional overexpression a cell-type specific signal transduction is essential for Xmrk mediated tumor formation. To elucidate the consequence of Xmrk signalling and to identify target proteins that characterize the tumor phenotype, we analysed proteins that are strongly tyrosine phosphorylated in the fish melanoma cell line PSM, One of the most prominent phosphotyrosine proteins was found to be the signal transducer and activator of transcription STAT5. In a heterologous cell system (murine pro B-cells), activation of the Xmrk kinase in a chimeric receptor induced tyrosine phosphorylation, nuclear translocation and DNA binding of STAT5. Following receptor stimulation, expression of the STAT5 specific target genes cis, osm and pim-1 was induced, In Xiphophorus PSM cells STAT5 was found to be preferentially localized in the nucleus, but treatment with tyrphostin AG555, a specific Xmrk kinase-inhibitor, blocked nuclear localization. In these cells as well as in Xiphophorus melanoma expression of pim-1 and constitutive DNA-binding activity of STATS was detectable. This constitutive activity was higher in malignant than in benign melanomas, indicating that STATS activation is correlated with the malignancy of these tumors.	Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Physiol Chem 1, D-97074 Wurzburg, Germany; Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Phys Chem 2, D-97074 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Schartl, M (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Physiol Chem 1, Am Hubland, D-97074 Wurzburg, Germany.		Gómez, Ana/K-6998-2014	Gómez, Ana/0000-0003-4714-8064; Wellbrock, Claudia/0000-0002-3825-6381; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DOMEN J, 1993, LEUKEMIA S2, V7, P108; FENDLY BM, 1990, CANCER RES, V50, P1550; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; HOOVER D, 1991, J BIOL CHEM, V266, P14018; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KUHN C, 1979, IN VITRO CELL DEV B, V15, P537, DOI 10.1007/BF02618156; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LILLY M, 1992, ONCOGENE, V7, P727; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MALITSCHEK B, 1994, J BIOL CHEM, V14, P10423; MAUELER W, 1993, INT J CANCER, V55, P288, DOI 10.1002/ijc.2910550220; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SCHARTL M, 1995, TRENDS GENET, V11, P185, DOI 10.1016/S0168-9525(00)89041-1; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Shuai K, 1996, ONCOGENE, V13, P247; STEWART BE, 1995, J INVEST DERMATOL, V105, P699, DOI 10.1111/1523-1747.ep12324482; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VIELKIND U, 1976, J EXP ZOOL, V196, P197, DOI 10.1002/jez.1401960207; VIGNAIS ML, 1996, MOL CELL BIOL, V16, P17759; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WELLBROCK C, 1995, ONCOGENE, V10, P2135; WELLBROCK C, 1998, IN PRESS INT J CANC; WINKLER C, 1994, ONCOGENE, V9, P1517; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; Xu BXC, 1996, J BIOL CHEM, V271, P19768, DOI 10.1074/jbc.271.33.19768; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	61	30	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3047	3056		10.1038/sj.onc.1201844	http://dx.doi.org/10.1038/sj.onc.1201844			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662338	Bronze			2022-12-28	WOS:000074125300012
J	Cabibbo, A; Consalez, GG; Sardella, M; Sitia, R; Rubartelli, A				Cabibbo, A; Consalez, GG; Sardella, M; Sitia, R; Rubartelli, A			Changes in gene expression during the growth arrest of HepG2 hepatoma cells induced by reducing agents or TGF beta 1	ONCOGENE			English	Article						redox regulation; redox signalling; proliferation; RNA fingerprinting; placental type alkaline phosphatase; Cytokeratin K17	DNA-BINDING ACTIVITY; DIFFERENTIAL DISPLAY; REDOX REGULATION; CYSTEINE RESIDUES; FACTOR-I; IDENTIFICATION; RECEPTOR; INVITRO; LINE; TRANSCRIPTION	The growth of hepatoma cells can be inhibited by treatment with TGF beta 1 or with exogenous reducing agents. To gain information on the molecular mechanisms underlying growth arrest, we visualized and compared gene expression profiles of proliferating ver sus non proliferating HepG2 cells by computer-assisted gene fishing, an improved technique of RNA fingerprinting that allows the selective amplification of coding regions within transcripts. While many transcripts are selectively regulated by either treatment, a set of bands appear to be coordinately regulated by 2ME and TGF beta 1, suggesting their possible involvement in the mechanisms of growth arrest. Display tags corresponding to 18 differentially expressed genes were cloned and, in most cases, identified as known genes or, more frequently, as their homospecific/cross-specific homologues. A novel member of the kinesin superfamily was identified amongst the genes induced by both 2ME and TGF beta 1. This gene, KIF3C, is upregulated in several cell lines undergoing growth arrest. Taken together, our findings show that computer-assisted gene fishing is a powerful tool for the identification and cloning of genes involved in the control of cell proliferation and indicate that extracellular reducing agents can regulate cell growth through modulation of gene expression.	Hosp San Raffaele, San Raffaele Sci Inst, Dept Biol & Technol Res, DIBIT, I-20132 Milan, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Genoa; IRCCS AOU San Martino IST	Cabibbo, A (corresponding author), Hosp San Raffaele, San Raffaele Sci Inst, Dept Biol & Technol Res, DIBIT, Via Olgettina 58, I-20132 Milan, Italy.		Consalez, Giacomo/AAA-2146-2019; Sitia, Roberto/AAB-5005-2019; Rubartelli, Anna/AAA-1259-2021	Consalez, Giacomo/0000-0003-4594-6273; Sitia, Roberto/0000-0001-7086-4152; 				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; COLLINS SJ, 1987, BLOOD, V70, P1233; Consalez GG, 1996, TRENDS GENET, V12, P455; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Francia G, 1996, CANCER RES, V56, P3855; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HUANG LE, 1994, J BIOL CHEM, V269, P30718; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; IWATA S, 1994, J IMMUNOL, V152, P5633; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LIANG P, 1992, CANCER RES, V52, P6966; LIN JK, 1992, CANCER RES, V52, P385; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NARAYANAN S, 1983, ANN CLIN LAB SCI, V13, P133; RUBARTELLI A, 1995, CANCER RES, V55, P675; SALESIOTIS AN, 1995, CANCER LETT, V91, P47, DOI 10.1016/0304-3835(95)03717-B; Sambrook J., 2002, MOL CLONING LAB MANU; Sardella M, 1998, GENOMICS, V47, P405, DOI 10.1006/geno.1997.5123; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SIDELL N, 1982, J NATL CANCER I, V68, P589; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Vignali G, 1996, EUR J NEUROSCI, V8, P536, DOI 10.1111/j.1460-9568.1996.tb01238.x; Wang FL, 1996, CANCER RES, V56, P3634; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	36	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2935	2943		10.1038/sj.onc.1201825	http://dx.doi.org/10.1038/sj.onc.1201825			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671414				2022-12-28	WOS:000073988200012
J	Connolly, JA; Morgan, IM; Jackson, ME; Campo, MS				Connolly, JA; Morgan, IM; Jackson, ME; Campo, MS			The BPV-4 co-carcinogen quercetin induces cell cycle arrest and up-regulates transcription from the LCR of BPV-4	ONCOGENE			English	Article						BPV-4; cell transformation; transcriptional regulation; transcription factors; quercetin; co-carcinogens	BOVINE PAPILLOMAVIRUS TYPE-4; LONG CONTROL REGION; ESTROGEN-BINDING SITES; COLON-CANCER; TRANSFORMATION INVITRO; TUMOR PROMOTION; PROTEIN; DNA; INHIBITION; COMPLEX	Bracken fern is the environmental co-carcinogen of BPV-4 in the induction of neoplasias of the upper alimentary canal of cattle. The flavonoid quercetin is one of the most potent and best characterised mutagens present in the fern. We have shown that transfection with BPV-4 DNA and exposure to a single dose of quercetin leads to tumorigenic transformation of primary bovine cells. We now show that quercetin induces cell cycle arrest and up-regulates transcription from the BPV-4 long control region (LCR). This up-regulation is mediated by a 21 nucleotide-long cis-element in the LCR, designated QRE-1, which is located immediately downstream of the TATA box. Cellular proteins bind to QRE-1 and removal or substitution of QRE-1 lead to the abrogation of the response to quercetin. As expression of the viral oncogenes is controlled by the LCR, perturbation in this control and increased oncoprotein expression are likely to contribute to fully malignant cell transformation by overcoming the cell cycle arrest induced by quercetin, thus forcing damaged cells to proliferate.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Campo, MS (corresponding author), Beatson Inst Canc Res, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.							AHMED MS, 1994, CARCINOGENESIS, V15, P1627, DOI 10.1093/carcin/15.8.1627; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AVILA MA, 1994, CANCER RES, V54, P2425; BJIELDANES LF, 1977, SCIENCE, V197, P577; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAIRNEY M, 1995, CARCINOGENESIS, V16, P1997, DOI 10.1093/carcin/16.8.1997; CAMPO MS, 1994, CARCINOGENESIS, V15, P1597, DOI 10.1093/carcin/15.8.1597; CONNOLLY JA, 1997, THESIS U GLASGOW GLA; CUTHILL S, 1993, MOL CARCINOGEN, V8, P96, DOI 10.1002/mc.2940080206; DOEBERITZ MV, 1994, J VIROL, V68, P2811; FAZAL F, 1990, CARCINOGENESIS, V11, P2005, DOI 10.1093/carcin/11.11.2005; GRAZIANI Y, 1983, EUR J BIOCHEM, V135, P583, DOI 10.1111/j.1432-1033.1983.tb07692.x; GSCHWENDT M, 1984, BIOCHEM BIOPH RES CO, V124, P63, DOI 10.1016/0006-291X(84)90916-1; HOSOKAWA N, 1990, INT J CANCER, V45, P1119, DOI 10.1002/ijc.2910450622; JACKSON ME, 1993, CRIT REV ONCOGENESIS, V4, P277; JACKSON ME, 1991, J GEN VIROL, V72, P877, DOI 10.1099/0022-1317-72-4-877; JACKSON ME, 1995, J VIROL, V69, P6038, DOI 10.1128/JVI.69.10.6038-6046.1995; JAGGAR RT, 1990, J GEN VIROL, V71, P3041, DOI 10.1099/0022-1317-71-12-3041; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KATO R, 1983, CARCINOGENESIS, V4, P1301, DOI 10.1093/carcin/4.10.1301; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Knowles G, 1996, J VIROL, V70, P8451, DOI 10.1128/JVI.70.12.8451-8458.1996; MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006-291X(92)90792-J; MCCAFFERY RE, 1994, J GEN VIROL, V75, P3047, DOI 10.1099/0022-1317-75-11-3047; NAKAYASU M, 1986, MUTAT RES, V174, P79, DOI 10.1016/0165-7992(86)90081-3; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; PENNIE WD, 1992, VIROLOGY, V190, P861, DOI 10.1016/0042-6822(92)90926-G; Pereira MA, 1996, CARCINOGENESIS, V17, P1305, DOI 10.1093/carcin/17.6.1305; PIANTELLI M, 1995, J INVEST DERMATOL, V105, P248, DOI 10.1111/1523-1747.ep12317599; Plaumann B, 1996, ONCOGENE, V13, P1605; RAHMAN A, 1990, CARCINOGENESIS, V11, P2001, DOI 10.1093/carcin/11.11.2001; RANELLETTI FO, 1992, INT J CANCER, V50, P486, DOI 10.1002/ijc.2910500326; SAKAI A, 1990, TERATOGEN CARCIN MUT, V10, P333, DOI 10.1002/tcm.1770100406; SCAMBIA G, 1990, Anti-Cancer Drugs, V1, P45, DOI 10.1097/00001813-199010000-00008; SCAMBIA G, 1993, INT J CANCER, V54, P462, DOI 10.1002/ijc.2910540318; SMITH KT, 1987, CANC CELLS PAPILLOMA, P267; Trujillo JM, 1996, VIROLOGY, V220, P1, DOI 10.1006/viro.1996.0279; VANWARTHOOD JE, 1989, ONCOGENE, V4, P1267; WITHAM SE, 1986, BIOCHEM J, V240, P913	41	18	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2739	2746		10.1038/sj.onc.1201796	http://dx.doi.org/10.1038/sj.onc.1201796			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652740				2022-12-28	WOS:000073812200005
J	Ottini, L; Falchetti, M; D'Amico, C; Amorosi, A; Saieva, C; Masala, G; Frati, L; Cama, A; Palli, D; Mariani-Costantini, R				Ottini, L; Falchetti, M; D'Amico, C; Amorosi, A; Saieva, C; Masala, G; Frati, L; Cama, A; Palli, D; Mariani-Costantini, R			Mutations at coding mononucleotide repeats in gastric cancer with the microsatellite mutator phenotype	ONCOGENE			English	Article						gastric cancer; microsatellite instability; TGF beta-RII; IGFIIR; BAX; hMSH3; hMSH6; BRCA2; mutation	II RECEPTOR GENE; BETA RECEPTOR; INSTABILITY; COLON; CELLS; BAX	We analysed 50 gastric carcinomas (GCs) to verify whether mutations at coding repeats were associated with microsatellite instability (MSI), The tumors included: ten cases with no MSI, 14 cases with MSI=1 locus, 13 cases with MSI=two loci and 13 cases with MSI greater than or equal to 3 loci, We investigated coding repeats within the TGF-beta RII, IGFIIR, BAX, hMSH6, AMSH3 and BRCA2 genes. The TGF-beta RII, IGIIR, BAX, hMSH6 and hMSH3 repeats were altered in 11 (22%), five (10%), four (8%), 16 (32%) and five (10%) cases respectively. Mutations occurred only in MSI-positive (MSI+) tumors and correlated with increasing MSI levels. No alterations of the BRCA2 repeat were found. Mutations in genes other than hMSH6 were strongly associated to kMSH6 mutations, suggesting a key role of this gene. The non-coding BAT-26 and E-Cadherin 3' UTR poly(A)8/(T)15 repeats were analysed in 44 of the 50 cases. Novel tumor-associated alleles were observed only in MSI-positive GCs and were in most cases associated with mutations at coding repeats. Further investigations with BAT-40 confirmed that four cases manifested mononucleotide repeat alterations restricted to hMSH6 and one case to TGF-beta XII. A subset of tumors,vith MSI at two or more dinucleotide loci resulted negative for mutations at coding and non-coding mononucleotide repeats.	Univ Gabriele DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy; Univ La Sapienza, Dept Expt Med & Pathol, Rome, Italy; Careggi Hosp, CSPO, Epidemiol Unit, Florence, Italy; Univ Florence, Dept Pathol, Florence, Italy; CSPO, IST, Epidemiol Satellite Unit, Florence, Italy; IMNS, Isernia, Italy	G d'Annunzio University of Chieti-Pescara; Sapienza University Rome; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence	Mariani-Costantini, R (corresponding author), Univ Gabriele DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy.		Mariani-Costantini, Renato/B-6637-2012; CAMA, Alessandro/J-3964-2018; Frati, Luigi/ABI-7437-2020; Saieva, Calogero/AAC-2611-2019; Masala, Giovanna/AAC-5474-2022	Mariani-Costantini, Renato/0000-0002-4440-1848; CAMA, Alessandro/0000-0003-3647-1368; Saieva, Calogero/0000-0002-0117-1608; Masala, Giovanna/0000-0002-5758-9069; PALLI, Domenico/0000-0002-5558-2437; OTTINI, LAURA/0000-0001-8030-0449; tumino, rosario/0000-0003-2666-414X				Akiyama Y, 1997, CANCER RES, V57, P3920; Arnheim N, 1997, CURR OPIN GENET DEV, V7, P364, DOI 10.1016/S0959-437X(97)80150-5; BUIATTI E, 1991, INT J CANCER, V48, P369, DOI 10.1002/ijc.2910480310; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Chung YJ, 1996, CANCER RES, V56, P4662; Chung YJ, 1997, ONCOGENE, V15, P1719, DOI 10.1038/sj.onc.1201343; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Hoang JM, 1997, CANCER RES, V57, P300; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIYASHITA T, 1995, CELL, V80, P293; MYEROFF LL, 1995, CANCER RES, V55, P5545; Ohue M, 1996, INT J CANCER, V68, P203, DOI 10.1002/(SICI)1097-0215(19961009)68:2<203::AID-IJC11>3.0.CO;2-B; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTTINI L, 1995, CANCER RES, V55, P5677; Ottini L, 1997, CANCER RES, V57, P4523; Ouyang H, 1997, CANCER RES, V57, P1851; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; Perucho M, 1996, NAT MED, V2, P630, DOI 10.1038/nm0696-630; Prolla TA, 1996, SEMIN CANCER BIOL, V7, P241, DOI 10.1006/scbi.1996.0032; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Stratton MR, 1996, CURR OPIN GENET DEV, V6, P93, DOI 10.1016/S0959-437X(96)90017-9; Takahashi H, 1996, CANCER RES, V56, P2738; Zhou XP, 1997, ONCOGENE, V15, P1713, DOI 10.1038/sj.onc.1201337	28	45	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2767	2772		10.1038/sj.onc.1201816	http://dx.doi.org/10.1038/sj.onc.1201816			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652743	Green Published			2022-12-28	WOS:000073812200008
J	Kim, J; Lee, K; Pelletier, J				Kim, J; Lee, K; Pelletier, J			The desmoplastic small round cell tumor t(11;22) translocation produces EWS/WT1 isoforms with differing oncogenic properties	ONCOGENE			English	Article						EWS; WT1; DSRCT; oncogene; transformation; cancer genetics	EWINGS-SARCOMA TRANSLOCATION; WILMS-TUMOR; TRANSCRIPTION FACTOR; GENE FUSION; UROGENITAL DEVELOPMENT; SUPPRESSOR GENE; EWS GENE; WT1; BINDING; MUTATIONS	Structural alterations of the Wilms' tumor locus (WT1) at 11p13 have been implicated in the etiology of two human cancers - Wilms' tumor (WT), a pediatric renal malignancy, and Desmoplastic Small Round Cell Tumor (DSRCT), an aggressive cancer of the abdomenal serosal lining with predilection for male adolescents, Germline mutations within the WT1 tumor suppressor gene predispose to WT and are associated with congenital malformations of the urogenital system, and somatic mutations are associated with initiation of transformation in WTs, In DSRCT, a recurrent translocation, t(11;22)(p13;q12), fuses the amino terminal domain of the EWS1 gene product to three of the four WT1 zinc fingers. Two EWS/WT1 isoforms are generated as a result of an alternative splicing event between zinc fingers III and IV, inserting or removing three amino acids (+/-KTS), We demonstrate that introduction of EWS/ WT1(-KTS) into NIH3T3 cells causes their tumorigenic transformation as determined by: formation of transformed foci on a monolayer of cells; anchorage-independent growth; and tumor formation in nude mice. EWS/WT1(+ KTS) showed no transforming potential in these assays. These results indicate the oncogenic effect of the t(11;22) translocation is mediated by the EWS/ WT1(-KTS) isoform and that fusion of the EWS amino terminal domain to the WT1 DNA binding domain produces a chimeric product showing a gain of function.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong	McGill University; McGill University; Hong Kong University of Science & Technology	Pelletier, J (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BROWN AD, 1995, ONCOGENE, V10, P1749; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; GERALD WL, 1991, AM J SURG PATHOL, V15, P499, DOI 10.1097/00000478-199106000-00001; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; JEON IS, 1995, ONCOGENE, V10, P1229; Karnieli E, 1996, J BIOL CHEM, V271, P19304, DOI 10.1074/jbc.271.32.19304; KRAUSS RS, 1992, MOL CELL BIOL, V12, P3117, DOI 10.1128/MCB.12.7.3117; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LADANYI M, 1994, CANCER RES, V54, P2837; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MCMASTER ML, 1995, CELL GROWTH DIFFER, V6, P1609; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1995, MOL CELL BIOL, V15, P3516; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	31	48	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1973	1979		10.1038/sj.onc.1201716	http://dx.doi.org/10.1038/sj.onc.1201716			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591781				2022-12-28	WOS:000073079400009
J	Latil, A; Bieche, I; Fournier, G; Cussenot, O; Pesche, S; Lidereau, R				Latil, A; Bieche, I; Fournier, G; Cussenot, O; Pesche, S; Lidereau, R			Molecular analysis of the FHIT gene in human prostate cancer	ONCOGENE			English	Article						FHIT; tumor suppressor gene; prostate cancer; reverse transcription; single stage PCR; nested PCR	TUMOR-SUPPRESSOR GENE; ALLELIC LOSS; CELL-LINES; MICROSATELLITE INSTABILITY; HOMOZYGOUS DELETIONS; LUNG-CANCER; 3P14.2; CARCINOMAS; HETEROZYGOSITY; ADENOCARCINOMA	A variety of studies suggest that the FHIT gene, which encompasses the fragile site at 3p14.2, is a candidate tumor suppressor gene in several forms of human cancer. To determine whether the FHIT gene is altered in prostate carcinomas, we examined 15 prostate tumors, four normal prostate tissue specimens and RNA from a pool of 62 normal human prostate tissues (Clontech) for the integrity of FHIT transcripts, using a robust single-stage PCR and a nested PCR method. In each case a major FHIT-specific full-length product was observed, Additional aberrantly sized products, which were more numerous in the nested PCR strategy, were present at a far lower level than the full-length transcripts in 14 of 15 tumors, three of four normal human prostate tissues and in the pooled normal prostate RNA. Sequence analysis revealed that these aberrant products corresponded to alternatively spliced FHIT transcripts, which were neither more numerous nor more prominent in the tumors than in the normal prostate specimens. Deletion at the FHIT locus was also evaluated by using three intragenic polymorphic markers (D13S1481, D3S1300, and D3S1234). Allelic loss was observed in two tumors, but these genomic alterations did not correspond to the aberrant FHIT transcripts. DNA analysis, furthermore, suggested that the tumor heterogeneity was not a likely explanation for presence of normal and alternatively spliced FHIT transcripts in the prostate tumors. In conclusion, we detected neither frequent loss of heterozygosity nor tumor specific transcripts of the FHIT gene in human prostate cancer.	Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France; Hop Cavale Blanche, Dept Urol, F-29609 Brest, France; CHU St Louis, Dept Urol, F-75010 Paris, France	Rene Huguenin Hospital; CHU Brest; Universite de Bretagne Occidentale; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Lidereau, R (corresponding author), Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France.		Bièche, Ivan/O-7399-2017	Bièche, Ivan/0000-0002-2430-5429; cussenot, olivier/0000-0002-9912-0533				Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BOVA GS, 1993, CANCER RES, V53, P3869; CAIRNS P, 1994, CANCER RES, V54, P1422; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooney KA, 1996, CANCER RES, V56, P1142; Cunningham JM, 1996, CANCER RES, V56, P4475; Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.3.CO;2-G; Druck T, 1997, CANCER RES, V57, P504; Fong KM, 1997, CANCER RES, V57, P2256; GAO X, 1995, CANCER RES, V55, P1002; GAO X, 1993, CANCER RES, V53, P2723; Hayashi S, 1997, CANCER RES, V57, P1981; Hendricks DT, 1997, CANCER RES, V57, P2112; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; Ittmann M, 1996, CANCER RES, V56, P2143; Kastury K, 1996, CANCER RES, V56, P978; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; Luan XD, 1997, ONCOGENE, V15, P79, DOI 10.1038/sj.onc.1201164; Mao L, 1996, CANCER RES, V56, P5128; MCGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Panagopoulos I, 1996, CANCER RES, V56, P4871; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Sozzi G, 1996, CANCER RES, V56, P2472; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Thiagalingam S, 1996, CANCER RES, V56, P2936; UMBAS R, 1992, CANCER RES, V52, P5104; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; WATANABE M, 1995, BRIT J CANCER, V72, P562, DOI 10.1038/bjc.1995.374; Yanagisawa K, 1996, CANCER RES, V56, P5579; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; Zou TT, 1997, ONCOGENE, V15, P101, DOI 10.1038/sj.onc.1201169	35	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1863	1868		10.1038/sj.onc.1201703	http://dx.doi.org/10.1038/sj.onc.1201703			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583683				2022-12-28	WOS:000072994600009
J	Dimitrijevic, N; Winkler, C; Wellbrock, C; Gomez, A; Duschl, J; Altschmied, J; Schartl, M				Dimitrijevic, N; Winkler, C; Wellbrock, C; Gomez, A; Duschl, J; Altschmied, J; Schartl, M			Activation of the Xmrk proto-oncogene of Xiphophorus by overexpression and mutational alterations	ONCOGENE			English	Article						transgenic medaka; melanoma; receptor tyrosine kinase; Xiphophorus; Xmrk; proto-oncogene	RECEPTOR TYROSINE KINASE; MESSENGER-RNA; MELANOMA; GENE; EXPRESSION; DNA; PROMOTER; EMBRYOS; LIGAND; FISH	Xmrk is a receptor tyrosine kinase closely related to the human EGF receptor, In the teleost fish Xiphophorus two versions of the Xmrk gene exist, an oncogene (ONC) and a proto-oncogene (INV), While ONC-Xmrk is the melanoma-inducing gene, INV-Xmrk appears not to be involved in transformation of pigment cells, To elucidate the mechanism that converts the proto-oncogene into a transforming oncogene a comparative analysis of the structure, expression and function of both versions of the gene was performed, In contrast to ONC-Xmrk which is expressed at high levels in melanoma cells, the protooncogene INV-Xmrk is ubiquitously expressed at very low levels indicating overexpression as one possible reason for tumorigenicity by ONC-Xmrk. As sequence comparison of the proto-oncogene and the oncogene revealed a number of amino acid changes, a possible effect of these mutations on the activation of the ONC-Xmrk receptor was determined, A constitutive activation of the oncogenic receptor was found and ectopic expression of INV-Xmrk after microinjection into medakafish embryos did not lead to the high tumour rate in transgenic fish as observed for the oncogene. Our data therefore suggest that overexpression of the receptor alone is not sufficient for melanoma induction, but that in addition activating mutations in ONC-Xmrk are responsible for its full tumorigenic potential.	Univ Wurzburg, Bioctr, Theodor Boveri Inst Biosci, D-97074 Wurzburg, Germany	University of Wurzburg	Schartl, M (corresponding author), Univ Wurzburg, Bioctr, Theodor Boveri Inst Biosci, D-97074 Wurzburg, Germany.		Winkler, Christoph/G-4822-2012; Gómez, Ana/K-6998-2014	Gómez, Ana/0000-0003-4714-8064; Winkler, Christoph/0000-0003-4688-6241; Wellbrock, Claudia/0000-0002-3825-6381; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; ANDERS F, 1991, PIGM CELL RES, V3, P7; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENDLY BM, 1990, CANCER RES, V50, P1550; Fornzler D, 1996, GENOME RES, V6, P102, DOI 10.1101/gr.6.2.102; FRIEND SH, 1993, SCIENCE, V259, P774, DOI 10.1126/science.8430329; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Kallman K.D., 1975, P81; Katz WS, 1996, MOL CELL BIOL, V16, P529; KUHN C, 1979, IN VITRO CELL DEV B, V15, P537, DOI 10.1007/BF02618156; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEMEUR M, 1981, CELL, V23, P561, DOI 10.1016/0092-8674(81)90152-5; MALITSCHEK B, 1994, J BIOL CHEM, V269, P10423; MAUELER W, 1988, ONCOGENE, V2, P421; MAUELER W, 1993, INT J CANCER, V55, P288, DOI 10.1002/ijc.2910550220; MICHIELS F, 1989, EMBO J, V8, P1559, DOI 10.1002/j.1460-2075.1989.tb03540.x; Nei M., 1987, MOL EVOLUTIONARY GEN; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHARTL M, 1995, EVOLUTION, V49, P827, DOI 10.1111/j.1558-5646.1995.tb02319.x; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WELLBROCK C, 1995, ONCOGENE, V10, P2135; WINKLER C, 1994, ONCOGENE, V9, P1517; WINKLER C, 1991, MOL GEN GENET, V226, P129, DOI 10.1007/BF00273596; WINKLER C, 1997, TRANSGENIC ANIMALS, P387; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; WITTBRODT J, 1994, GENE DEV, V8, P1448, DOI 10.1101/gad.8.12.1448; WOOLCOCK BW, 1994, CELL GROWTH DIFFER, V5, P575; YAMAMOTO TO, 1961, INT REV CYTOL, V12, P361	36	26	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1681	1690		10.1038/sj.onc.1201693	http://dx.doi.org/10.1038/sj.onc.1201693			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582016				2022-12-28	WOS:000072807600006
J	Ramaswamy, NT; Ronai, Z; Pelling, JC				Ramaswamy, NT; Ronai, Z; Pelling, JC			Rapid activation of JNK1 in UV-B irradiated epidermal keratinocytes	ONCOGENE			English	Article						UV-B; UV-C; JNK1; keratinocytes; skin cancer and MAPK	P53 PROTEIN; KINASE; LIGHT; RADIATION; SIGNAL; CELLS; SKIN; PHOSPHORYLATION; SPECIFICITY	Jun N-terminal kinase (JNK1) is a member of a family of stress-activated protein kinases which are activated by many forms of stress including UV radiation, resulting in the phosphorylation of c-Jun, ATF-2, Elk-1 and p53, As UV-B radiation is mainly responsible for ultraviolet (UV)-induced skin cancers, we chose to elucidate JNK1 activation in keratinocytes, which represent a UV-relevant system, We have demonstrated rapid activation of JNK1 in a keratinocyte cell Line, C50, in response to multiple doses of UV-B irradiation, JNK1 activation occurred within 1 min, peaked by 10 min and returned to near basal levels within 2 h following the UV-B treatments, Our data provide the first evidence to show that keratinocytes do respond to multiple doses of the physiologically relevant UV-B radiation through rapid activation of the JNK1 pathway.	Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66160 USA; Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	University of Kansas; University of Kansas Medical Center; Icahn School of Medicine at Mount Sinai	Pelling, JC (corresponding author), Univ Kansas, Med Ctr, Dept Pathol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA71040, CA 72987] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072987] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; Adler V, 1996, CARCINOGENESIS, V17, P2073, DOI 10.1093/carcin/17.9.2073; Berg RJW, 1997, CANCER RES, V57, P581; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; Chatterjee ML, 1996, BIOCHEM BIOPH RES CO, V229, P590, DOI 10.1006/bbrc.1996.1848; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DHANWADA KR, 1995, ONCOGENE, V11, P1947; FITZPATRICK J, 1997, COLOR ATLAS SYNOPSIS, P228; Goldsmith LA, 1996, OTOLARYNG HEAD NECK, V114, P217, DOI 10.1016/S0194-5998(96)70169-9; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALL PA, 1993, ONCOGENE, V8, P203; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MATSUI MS, 1995, SKIN CANC MECH HUMAN, P21; MEDRANO EE, 1995, CANCER RES, V55, P4047; Mukhtar H., 1995, SKIN CANC MECH HUMAN, P3; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396	23	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1501	1505		10.1038/sj.onc.1201628	http://dx.doi.org/10.1038/sj.onc.1201628			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525748				2022-12-28	WOS:000072572400014
J	Suminami, Y; Kashii, Y; Law, JC; Lin, WC; Stanson, J; Reichert, TE; Rabinowich, H; Whiteside, TL				Suminami, Y; Kashii, Y; Law, JC; Lin, WC; Stanson, J; Reichert, TE; Rabinowich, H; Whiteside, TL			Molecular analysis of the IL-2 receptor beta chain gene expressed in human tumor cells	ONCOGENE			English	Article						IL-2R; IL-2; tumor cells; IL-2R on carcinomas; tumor growth	INTERLEUKIN-2 RECEPTOR; GAMMA-CHAIN; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; LIGAND-BINDING; GROWTH; CARCINOMA; CYTOKINES; CANCER; SYSTEM	Interleukin-2 (IL-2) is recognized as a T cell growth factor. We have previously reported that human carcinoma cell lines are inhibited in growth by exogenous IL-2, which binds to the IL-2 receptor beta (IL-2R beta) chain ubiquitously expressed on the surface of tumor cells. A possibility was considered that IL-2R beta on carcinomas responsible for negative signaling was different from that expressed on hematopoietic cells. To investigate this possibility, mRNA for the IL-2R beta chain was amplified and compared in carcinoma and lymphoid cells. Using RT-PCR with pairs of sense-antisense oligonucleotide primers specific for the various regions of extracellular, transmembrane and intracellular domains of the IL-2R beta chain, we amplified mRNA obtained from three human carcinoma cell lines and human lymphoid cells as controls. The identity of the amplicons was confirmed by Southern analysis with the P-32-labeled cDNA probe coding for the entire span of the IL-2R beta chain. In addition, genomic DNA obtained from the tumor cell lines was sequenced to examine the possibility that a mutation is present in the gene coding for the intracellular IL-2R beta chain domain. No mutations or deletions were detected. The message for all three domains of the beta chain was identical in tumor cells and in normal lymphoid cells used as controls. Also, by Western blot and northern analyses no differences between IL-2R beta chain in tumors vs that expressed in lymphoid cells were demonstrable. The IL-2R gamma chain, which participates in IL-2/IL-2R signaling pathway, was expressed in tumor cells. Expression of JAK1 transcripts in these cells was comparable to that in lymphocytes. However, RT-PCR analysis identified differences in expression of JAK3 splice variants (B and M) in tumor cells. These differences may be responsible for altered downstream signaling by IL-2. Overall, our data indicate that the same IL-2/IL-2R pathway is operative in human carcinomas and in normal epithelial or lymphoid cells.	Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Human Genet Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Whiteside, TL (corresponding author), Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA.		Lin, Wen-chang/ABH-7976-2020; Lin, Wen-chang/B-3100-2011	Lin, Wen-chang/0000-0003-0194-1745; Lin, Wen-chang/0000-0003-0194-1745	NCI NIH HHS [R0-1 CA63513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAMFORD RN, 1997, IMMUNOLOGIST, V5, P52; CHEN K, 1987, LAB INVEST, V56, P114; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HEO DS, 1990, CANCER RES, V50, P3681; Johnston JA, 1996, J LEUKOCYTE BIOL, V60, P441, DOI 10.1002/jlb.60.4.441; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LAI KS, 1995, J BIOL CHEM, V270, P25028, DOI 10.1074/jbc.270.42.25028; LIN WC, 1995, J IMMUNOL, V155, P4805; LIN WC, 1993, ARCH OTOLARYNGOL, V119, P1229; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; RABINOWICH H, 1992, J IMMUNOL, V149, P340; REICHERT T, 1997, UNPUB ROLE ENDOGENOU; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANIGUCHI T, 1986, IMMUNOL REV, V92, P121, DOI 10.1111/j.1600-065X.1986.tb01497.x; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WEIDMANN E, 1992, CANCER RES, V52, P5963; YASUMURA S, 1994, INT J CANCER, V59, P225, DOI 10.1002/ijc.2910590215	30	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1309	1317		10.1038/sj.onc.1201640	http://dx.doi.org/10.1038/sj.onc.1201640			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546432				2022-12-28	WOS:000072422000009
J	Tamir, I; Cambier, JC				Tamir, I; Cambier, JC			Antigen receptor signaling: integration of protein tyrosine kinase functions	ONCOGENE			English	Review						signal transduction; antigen receptors; protein tyrosine kinases	T-CELL-RECEPTOR; B-LYMPHOCYTE DEVELOPMENT; X-LINKED AGAMMAGLOBULINEMIA; PHOSPHORYLATED IG-ALPHA; SEVERE COMBINED IMMUNODEFICIENCY; PLECKSTRIN HOMOLOGY DOMAINS; PROTOONCOGENE C-CBL; BETA-GAMMA-SUBUNITS; SRC FAMILY KINASES; FC-EPSILON-RI	Antigen receptors on T and B cells function to transduce signals leading to a variety of biologic responses minimally including antigen receptor editing, apoptotic death, developmental progression, cell activation, proliferation and survival. The response to antigen depends upon antigen affinity and valence, involvement of coreceptors in signaling and differentiative stage of the responding cell. The requirement that these receptors integrate signals that drive an array of responses may explain their evolved structural complexity. Antigen receptors are composed of multiple subunits compartmentalized to provide antigen recognition and signal transduction function. In lieu of on-board enzymatic activity these receptors rely on associated Protein Tyrosine Kinases (PTKs) for their signaling function. By aggregating the receptors, and hence their appended PTKs, antigens induce PTK transphosphorylation, activating them to phosphorylate the receptor within conserved motifs termed Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) found in transducer subunits, The tyrosyl phosphorylated ITAMs then interact with Src Homology 2 (SH2) domains within the PTKs leading to their further activation. As receptor phosphorylation is amplified, other effecters, such as Shc, dock by virtue of SH2 binding, and serve, in-turn, as substrates for these PTKs, This sequence of events not only provides a signal amplification mechanism by combining multiple consecutive steps with positive feedback, but also allows for signal diversification by differential recruitment of effecters that provide access to distinct parallel downstream signaling pathways. The subject of antigen receptor signaling has been recently reviewed in depth (DeFranco, 1997; Kurosaki, 1997), Here we discuss the biochemical basis of antigen receptor signal transduction, using the B cell receptor (BCR) as a paradigm, with specific emphasis on the involved PTKs, We review several specific mechanisms by which responses through these receptors are propagated and modified by accessory molecules, and discuss how signal amplification and diversification are achieved.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA	National Jewish Health	Cambier, JC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.			Cambier, John/0000-0002-7803-242X				Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; AOKI Y, 1995, J BIOL CHEM, V270, P15658, DOI 10.1074/jbc.270.26.15658; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; Benatar T, 1996, J EXP MED, V183, P329, DOI 10.1084/jem.183.1.329; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BonnefoyBerard N, 1996, STEM CELLS, V14, P250, DOI 10.1002/stem.140250; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BROWN VK, 1994, J BIOL CHEM, V269, P17238; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CARRERA AC, 1992, J IMMUNOL, V149, P3142; Carter RH, 1997, J IMMUNOL, V158, P3062; CHALUPNY NJ, 1993, EMBO J, V12, P2691, DOI 10.1002/j.1460-2075.1993.tb05930.x; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Couture C, 1997, EUR J BIOCHEM, V246, P447, DOI 10.1111/j.1432-1033.1997.00447.x; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; Couture C, 1996, J BIOL CHEM, V271, P24294, DOI 10.1074/jbc.271.39.24294; Cyster JG, 1997, IMMUNITY, V6, P509, DOI 10.1016/S1074-7613(00)80339-8; DAmbrosio D, 1996, EUR J IMMUNOL, V26, P1960, DOI 10.1002/eji.1830260842; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Desiderio S, 1997, CURR OPIN IMMUNOL, V9, P534, DOI 10.1016/S0952-7915(97)80107-0; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FitzerAttas CJ, 1997, J BIOL CHEM, V272, P8551, DOI 10.1074/jbc.272.13.8551; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; Gauen LKT, 1996, J CELL BIOL, V133, P1007, DOI 10.1083/jcb.133.5.1007; GOLD MR, 1994, J IMMUNOL, V153, P2369; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GOLD MR, 1992, J IMMUNOL, V148, P2012; Gong Q, 1997, IMMUNITY, V7, P369, DOI 10.1016/S1074-7613(00)80358-1; Graef IA, 1997, EMBO J, V16, P5618, DOI 10.1093/emboj/16.18.5618; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; Itano A, 1996, J EXP MED, V183, P731, DOI 10.1084/jem.183.3.731; JabrilCuenod B, 1996, J BIOL CHEM, V271, P16268, DOI 10.1074/jbc.271.27.16268; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; Justement LB, 1997, ADV IMMUNOL, V66, P1, DOI 10.1016/S0065-2776(08)60595-7; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KAWAUCHI K, 1994, J IMMUNOL, V152, P3306; Keshvara LM, 1997, J BIOL CHEM, V272, P10377; KIESEL S, 1988, IMMUNOLOGY, V64, P445; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Koretzky GA, 1997, IMMUNOL TODAY, V18, P401, DOI 10.1016/S0167-5699(97)01088-8; Krop I, 1996, J IMMUNOL, V157, P48; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Law CL, 1996, MOL CELL BIOL, V16, P1305; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Li XL, 1997, J IMMUNOL, V158, P5649; LIN JJ, 1992, J IMMUNOL, V149, P1548; LINDSBERG ML, 1991, J IMMUNOL, V147, P3774; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; Mayer BJ, 1997, CURR BIOL, V7, pR295, DOI 10.1016/S0960-9822(06)00141-2; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; Nagata K, 1997, IMMUNITY, V7, P559, DOI 10.1016/S1074-7613(00)80377-5; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Pao LI, 1998, J IMMUNOL, V160, P3305; Pao LI, 1997, J IMMUNOL, V158, P2663; Pao LI, 1997, J IMMUNOL, V158, P1116; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; Peters JD, 1996, J BIOL CHEM, V271, P4755; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; PLEIMAN CM, 1994, J IMMUNOL, V152, P2837; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Razi N, 1997, BLOOD, V90, P2022; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Richards JD, 1996, J BIOL CHEM, V271, P6458, DOI 10.1074/jbc.271.11.6458; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P2081, DOI 10.1002/eji.1830191117; ROIFMAN CM, 1993, BIOCHEM BIOPH RES CO, V194, P222, DOI 10.1006/bbrc.1993.1807; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Sato S, 1997, J IMMUNOL, V159, P3278; Sato S, 1997, P NATL ACAD SCI USA, V94, P13158, DOI 10.1073/pnas.94.24.13158; Sato S, 1997, J IMMUNOL, V158, P4662; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; SAXTON TM, 1994, J IMMUNOL, V153, P623; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; Sgroi D, 1996, J BIOL CHEM, V271, P18803, DOI 10.1074/jbc.271.31.18803; SHINKAI Y, 1995, IMMUNITY, V2, P401; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SHORES EW, 1994, SCIENCE, V266, P1047, DOI 10.1126/science.7526464; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SMIT L, 1994, J BIOL CHEM, V269, P20209; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TEDDER TF, 1989, J IMMUNOL, V143, P712; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Tuscano JM, 1996, EUR J IMMUNOL, V26, P1246, DOI 10.1002/eji.1830260610; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WECHSLER RJ, 1995, J IMMUNOL, V154, P3234; Weiser P, 1997, SCIENCE, V276, P407, DOI 10.1126/science.276.5311.407; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Wiest DL, 1997, IMMUNITY, V6, P663, DOI 10.1016/S1074-7613(00)80442-2; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMADA H, 1993, J EXP MED, V177, P1613, DOI 10.1084/jem.177.6.1613; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	203	96	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1353	1364		10.1038/sj.onc.1202187	http://dx.doi.org/10.1038/sj.onc.1202187			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779983				2022-12-28	WOS:000076161900004
J	Husmann, K; Sers, C; Fietze, E; Mincheva, A; Lichter, P; Schafer, R				Husmann, K; Sers, C; Fietze, E; Mincheva, A; Lichter, P; Schafer, R			Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11-12	ONCOGENE			English	Article						expression genetics; cellular transformation; RAS; oncogenic signalling; transcriptional target	HRAS-TRANSFORMED CELLS; BREAST-CANCER CELLS; LYSYL OXIDASE; WILMS TUMOR; H-RAS; DIFFERENTIAL DISPLAY; PROTEIN-KINASE; MESSENGER-RNAS; EXPRESSION; GROWTH	The H-rev107 tumour suppressor was isolated as a gene specifically expressed in rat fibroblasts resistant toward malignant transformation by the activated HRAS gene (Sers et al., 1997; Hajnal et al., 1994), Here we describe the human homologue of the rat H-rev107 gene. The predicted rat and human proteins are highly conserved exhibiting an overall amino acid identity of 83%, The HREV107-1 gene is ubiquitously expressed with the exception of haematopoetic cells and tissues, In contrast, H-REV107-1 mRNA was found only in eight of 27 cell lines derived from mammary carcinoma, lung carcinoma, gastric carcinoma, kidney carcinoma, melanoma, neuroblastoma and other tumours, The H-REV107-1 protein was not detectable in any of these tumour cells. Loss of H-REV107-1 expression was not restricted to cultured human tumour cell lines, but also found in primary squamous cell carcinomas. Gross structural aberrations of the H-REV107-1 gene were absent in tumorigenic cell lines. Thus, the block to H-REV107-1 expression is achieved both at the level of transcription and translation. By fluorescence in situ hybridisation the human H-REV107-1 gene was localised to chromosome 11q11-12.	Univ Zurich, Dept Pathol, Div Canc Res, CH-8091 Zurich, Switzerland; Humboldt Univ, Univ Hosp Charite, Inst Pathol, D-10117 Berlin, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany	University of Zurich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ)	Schafer, R (corresponding author), Univ Zurich, Dept Pathol, Div Canc Res, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Schäfer, Reinhold/AAB-5110-2021; Sers, Christine/B-5438-2010	Schafer, Reinhold/0000-0001-7952-2124; Sers, christine/0000-0002-6219-1514				BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOAK AM, 1994, AM J RESP CELL MOL, V11, P751, DOI 10.1165/ajrcmb.11.6.7946403; BOS JL, 1989, CANCER RES, V49, P4682; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Gioeli D, 1997, CANCER RES, V57, P1157; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HAJNAL A, 1993, CANCER RES, V53, P4670; HAJNAL A, 1994, ONCOGENE, V9, P479; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; JANES PW, 1994, ONCOGENE, V9, P3601; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATZ E, 1986, J NATL CANCER I, V77, P909; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIESS M, 1995, ONCOGENE, V10, P61; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kuchinke W, 1995, NEUROIMMUNOMODULAT, V2, P347, DOI 10.1159/000097214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NEGRINI M, 1994, CANCER RES, V54, P1331; OBERHUBER H, 1995, MOL CARCINOGEN, V12, P198, DOI 10.1002/mc.2940120404; PENG JW, 1990, CANCER GENET CYTOGEN, V45, P101; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFER R, 1994, REV PHYSIOL BIOCH P, V124, P29, DOI 10.1007/BFb0031031; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHIPPER JH, 1991, CANCER RES, V51, P6328; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; Szpirer C, 1996, MAMM GENOME, V7, P701, DOI 10.1007/s003359900211; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	55	51	52	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1305	1312		10.1038/sj.onc.1202060	http://dx.doi.org/10.1038/sj.onc.1202060			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771974				2022-12-28	WOS:000075803300013
J	Oh, Y; Proctor, ML; Fan, YH; Su, LK; Hong, WK; Fong, KM; Sekido, YS; Gazdar, DF; Minna, JD; Mao, L				Oh, Y; Proctor, ML; Fan, YH; Su, LK; Hong, WK; Fong, KM; Sekido, YS; Gazdar, DF; Minna, JD; Mao, L			TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer	ONCOGENE			English	Article						non-small cell lung cancer; tumor suppressor	HUMAN BREAST-CANCER; P53 MUTATIONS; FHIT GENE; HETEROZYGOSITY; TUMORS; LINES; PHOSPHOPROTEIN; ONCOPROTEIN-18; CHROMOSOME-11; ABNORMALITIES	TSG101 is a candidate tumor suppressor gene whose deletion in NIH3T3 cells leads to spontaneous lung metastases in nude mice. Aberrant transcripts of TSG101 have been identified in 47% of primary breast carcinomas, without evidence of intragenic deletions at the TSG101 locus on 11p15, To investigate the possible role of TSG101 in lung cancer, which often shows 11p allele loss, we performed transcript analysis and mutational analysis of TSG101 in lung cancer cell lines. Reverse transcriptase RT-PCR and Northern analysis detected a common TSG101 transcript, shortened because of an internal deletion, which was expressed simultaneously with the wild-type transcript in 89% of small cell lung cancer (SCLC) lines. In contrast, the wild-type transcript was expressed alone in normal tissues, primary non-small cell lung cancer (NSCLC) specimens, and the majority of NSCLC cell lines. Sequence of the shortened SCLC transcript was identical to that of the most common aberrant transcript identified in breast cancer, consisting of a deletion of exons 2-4 and part of 1 and 5, Southern analysis of SCLC lines expressing the shortened transcript did not detect any intragenic deletions, Single strand conformational polymorphism (SSCP) analysis and direct sequencing of TSG101 cDNAs also identified no mutations or deletions. These results suggest that TSG101 is not mutated in lung cancer but that aberrant splicing of TSG101 occurs in SCLC.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Mao, Li/C-7570-2011; Fong, Kwun M/G-6369-2010	Mao, Li/0000-0001-7263-3358; Fong, Kwun/0000-0002-6507-1403; Sekido, Yoshitaka/0000-0002-2428-3848	NCI NIH HHS [5T32CA66187-03, CA 16672, P50 CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA066187, P50CA070907, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; COOK RM, 1993, CURR PROB CANCER, V17, P71; DAMICO D, 1992, ONCOGENE, V7, P339; DEVESA SS, 1991, CANCER EPIDEM BIOMAR, V1, P29; DiPaolo G, 1996, J CELL BIOL, V133, P1383, DOI 10.1083/jcb.133.6.1383; DOYE V, 1990, J BIOL CHEM, V265, P11650; Druck T, 1997, CANCER RES, V57, P504; FONG KM, 1994, GENE CHROMOSOME CANC, V10, P183, DOI 10.1002/gcc.2870100306; Fong KM, 1997, CANCER RES, V57, P2256; GRATIOTDEANS J, 1992, J CLIN INVEST, V90, P1576, DOI 10.1172/JCI116026; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HAILAT N, 1990, ONCOGENE, V5, P1615; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; Kim SK, 1997, CANCER RES, V57, P400; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; KOPPEL J, 1993, FEBS LETT, V331, P65, DOI 10.1016/0014-5793(93)80298-9; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Liang H., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P68; MAO L, 1994, CANCER RES, V54, P1634; Mao L, 1996, CANCER RES, V56, P5128; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MATTHEWS MJ, 1973, CANCER CHEMOTH REP 3, V4, P63; MILLER CW, 1992, CANCER RES, V52, P1695; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Roberts GC, 1996, EMBO J, V15, P6301, DOI 10.1002/j.1460-2075.1996.tb01020.x; ROOS G, 1993, LEUKEMIA, V7, P1538; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RYGAARD K, 1992, CANCER RES, V50, P5312; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Sundareshan TS, 1996, CANCER GENET CYTOGEN, V91, P53, DOI 10.1016/S0165-4608(96)00031-3; VIRMANI AK, 1998, IN PRESS GEN CHROM C; West CA, 1996, BONE, V19, P41, DOI 10.1016/8756-3282(96)00105-6; WINQVIST R, 1995, CANCER RES, V55, P2660	41	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1141	1148		10.1038/sj.onc.1202029	http://dx.doi.org/10.1038/sj.onc.1202029			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764824				2022-12-28	WOS:000075598400009
J	Wright, K; Wilson, PJ; Kerr, J; Do, K; Hurst, T; Khoo, SK; Ward, B; Chenevix-Trench, G				Wright, K; Wilson, PJ; Kerr, J; Do, K; Hurst, T; Khoo, SK; Ward, B; Chenevix-Trench, G			Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas	ONCOGENE			English	Article						loss of heterozygosity; ovarian adenocarcinomas; tumour suppressor gene	TUMOR-SUPPRESSOR GENE; PROSTATE-CANCER; ALLELIC LOSS; CARCINOMAS; ALLELOTYPE; DELETION	Many chromosomal regions undergo loss of heterozygosity (LOH) in ovarian adenocarcinomas but few of the target regions have been finely mapped. One of the chromosome arms likely to harbour one or more tumour suppressor genes inactivated in ovarian cancer is the short arm of chromosome 8 which is frequently deleted in many other solid tumours, We have examined a large panel of microsatellite markers on 8p for LOH in 53 ovarian adenocarcinomas. LOH was observed in 27 tumours (51%), with a significant trend towards a higher frequency of LOH in more advanced tumours, Detailed examination of nine tumours with partial deletions defined three regions of overlap, two in 8p23 and one in 8p22, which suggests that there might be as many as three tumour or metastasis suppressor genes on 8p which are inactivated during ovarian tumorigenesis. LOH on 8p was significantly associated with 9p LOH which suggests that inactivation of target genes on these chromosomes may be cooperative events.	Queensland Inst Med Res, Queensland Canc Res Unit, Brisbane, Qld 4029, Australia; Univ Queensland, Royal Brisbane Hosp, Dept Obstet & Gynaecol, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland	Chenevix-Trench, G (corresponding author), Queensland Inst Med Res, Queensland Canc Res Unit, Brisbane, Qld 4029, Australia.			Chenevix-Trench, Georgia/0000-0002-1878-2587				Becker SA, 1996, CANCER RES, V56, P5092; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; CLIBY W, 1993, CANCER RES, V53, P2393; FIELD JK, 1995, BRIT J CANCER, V72, P1180, DOI 10.1038/bjc.1995.483; Gustafson CE, 1996, CANCER RES, V56, P5238; ICHIKAWA T, 1994, CANCER RES, V54, P2299; IWABUCHI T, 1994, CANCER RES, V55, P6172; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; Takle LA, 1996, ONCOGENE, V12, P1083; TENERIELLO MG, 1993, CANCER RES, V53, P3103; Vocke CD, 1996, CANCER RES, V56, P2411; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V	21	61	62	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1185	1188		10.1038/sj.onc.1202028	http://dx.doi.org/10.1038/sj.onc.1202028			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764830				2022-12-28	WOS:000075598400015
J	Sawyer, C; Hiles, I; Page, M; Crompton, M; Dean, C				Sawyer, C; Hiles, I; Page, M; Crompton, M; Dean, C			Two erbB-4 transcripts are expressed in normal breast and in most breast cancers	ONCOGENE			English	Article						receptor tyrosine kinase; breast cancer; erbB-4; signal transduction; phosphatidylinositol 3-kinase	GROWTH-FACTOR RECEPTOR; DIFFERENTIATION FACTOR; MONOCLONAL-ANTIBODY; SIGNAL-TRANSDUCTION; CELLULAR-RESPONSE; HEREGULIN; CELLS; FAMILY; ACTIVATION; NEUREGULIN	ErbB-4 is a recently described member of the epidermal growth factor receptor (EGFR) family which together with erbB-3 acts as a receptor for a group of ligands known as the neuregulins (NRGs) or heregulins (HRGs), Unlike the EGFR and erbB-2 relatively little is known about the expression of erbB-4 in human tumours. Using RT-PCR and Southern blotting analysis we have investigated the expression of erbB-4 mRNA in a range of human tumour cell lines and in normal and malignant breast tissue. Using primers which amplified a 658 base pair (bp) region corresponding to part of the cytoplasmic domain of c-erbB-4 we found the receptor was expressed in some but not all breast and ovarian tumour cell lines and also in a glioma cell line. The highest level of erbB-4 expression was found in the ovarian carcinoma OVCAR-3 and the breast carcinoma T-47D, In all cell lines where the 'full-length' erbB-4 was detected, a second previously undescribed c-erbB-4 sequence was also found as a 610 bp PCR product. The alternative PCR product was identical in sequence to c-erbB-4 except for a deletion of 48 bp which encodes a consensus phosphatidylinositol 3-kinase (PI3K) binding site. This suggested that the two forms of erbB-4 might interact with different intracellular signalling pathways and therefore influence a wider variety of cellular responses to heregulin than previously thought. Expression of both erbB-4 variants was found in 7/7 normal breast tissues but only in 9/12 breast tumours analysed. In line with the terminology of Elenius et nl, (1997b) we have designated the two isoforms of the C-terminal transcripts as CT-a (full-length) and CT-b which lacks the PI3K binding motif, These results identify suitable cell lines for the further investigation of erbB-4 expression and function and suggest that the role of erbB-4 in breast cancer warrants further investigation with larger numbers of normal and malignant breast tissues.	Inst Canc Res, Immunol Sect, McElwain Labs, Sutton SM2 5NG, Surrey, England; Inst Canc Res, Sect Cell Biol & Expt Pathol, Sutton SM2 5NG, Surrey, England; Glaxo Wellcome Res Labs, Oncol Res Unit, Stevenage, Herts, England	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; GlaxoSmithKline; Wellcome Research Laboratories	Sawyer, C (corresponding author), Inst Canc Res, Immunol Sect, McElwain Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.			Box, Carol/0000-0002-8919-8724				ANDERSEN AS, 1992, BIOTECHNIQUES, V13, P678; Bacus SS, 1996, ONCOGENE, V12, P2535; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; CHAN SDH, 1995, J BIOL CHEM, V270, P22608, DOI 10.1074/jbc.270.38.22608; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Cohen BM, 1996, J BIOL CHEM, V271, P4813; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MODJTAHEDI H, 1994, INT J ONCOL, V4, P277; Modjtahedi H, 1996, BRIT J CANCER, V73, P228, DOI 10.1038/bjc.1996.40; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER C, 1997, THESIS U LONDON; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	33	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					919	924		10.1038/sj.onc.1202015	http://dx.doi.org/10.1038/sj.onc.1202015			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780009				2022-12-28	WOS:000075448800014
J	Badache, A; Muja, N; De Vries, GH				Badache, A; Muja, N; De Vries, GH			Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with type 1 neurofibromatosis	ONCOGENE			English	Article						neurofibromatosis; Schwann cells; c-kit proto-oncogene; stem cell factor; growth factors	PERIPHERAL-NERVE; TYROSINE KINASE; C-KIT; GENE; TUMOR; PROLIFERATION; PROTEIN; GROWTH; TYRPHOSTINS; SEQUENCE	Type 1 Neurofibromatosis (NF1) is characterized by the formation of neurofibromas, benign tumors composed mainly of Schwann cells, which can turn malignant to form neurofibrosarcomas. Neurofibromin, the protein product of the Nf1 gene, is believed to act as a tumor suppressor, accelerating the conversion of the oncogene Ras to its inactive form. The absence of neurofibromin could therefore lead to higher Ras activity in Schwann cells, resulting in uncontrolled growth through a cascade of events not yet elucidated. We describe the abnormal expression of high levels of the Kit tyrosine kinase receptor in both NF1-derived Schwann cell lines and tissue, as compared to primary Schwann cells or schwannoma-derived cells. High levels of Kit expression in the neurofibrosarcoma-derived Schwann cells correlate with a decrease in neurofibromin expression. Using inhibitors of tyrosine kinase receptors, we found that proliferation of the neurofibrosarcoma-derived cells is dependent: upon activation of a subclass of tyrosine-kinase receptors. The proliferation of these cells is not dependent upon an autocrine loop involving typical Schwann cell mitogens. Finally, the proliferation of the neurofibrosarcoma-derived Schwann cells can be increased by stimulation with Kit ligand. These data implicate Kit as one of the components leading to the Schwann cell hyperplasia observed in NF1.	Loyola Univ, Dept Anat Cell Biol & Neurobiol, Chicago, IL 60611 USA; Hines VA Hosp, Hines, IL 60141 USA	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	Badache, A (corresponding author), Loyola Univ, Dept Anat Cell Biol & Neurobiol, Chicago, IL 60611 USA.		Badache, Ali/Q-6098-2017	Badache, Ali/0000-0001-7710-2505				BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BLEECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DATSON MM, 1992, NEURON, V8, P415; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6; FLEMING TP, 1992, ONCOGENE, V7, P1355; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; Guha A, 1996, ONCOGENE, V12, P507; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; Halling KC, 1996, AM J CLIN PATHOL, V106, P282; He JL, 1997, P NATL ACAD SCI USA, V94, P3954, DOI 10.1073/pnas.94.8.3954; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KIM HA, 1995, ONCOGENE, V11, P325; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Lee MMS, 1996, J NEUROSCI RES, V46, P204; LEVITZKI A, 1991, TRENDS PHARMACOL SCI, V12, P171, DOI 10.1016/0165-6147(91)90538-4; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; NITTA T, 1994, NEUROSURGERY, V34, P309, DOI 10.1227/00006123-199402000-00014; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RYAN JJ, 1994, J NEUROSCI RES, V37, P415, DOI 10.1002/jnr.490370314; Sudhalter J, 1996, GLIA, V17, P28, DOI 10.1002/(SICI)1098-1136(199605)17:1<28::AID-GLIA3>3.0.CO;2-3; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	31	49	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					795	800		10.1038/sj.onc.1201978	http://dx.doi.org/10.1038/sj.onc.1201978			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715282				2022-12-28	WOS:000075337200015
J	Lomax, ME; Barnes, DM; Hupp, TR; Picksley, SM; Camplejohn, RS				Lomax, ME; Barnes, DM; Hupp, TR; Picksley, SM; Camplejohn, RS			Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members	ONCOGENE			English	Article						p53; Li-Fraumeni syndrome; oligomerization domain; MDM2; apoptosis; transactivation	TUMOR-SUPPRESSOR P53; TETRAMERIZATION DOMAIN; DNA-BINDING; BAX GENE; IN-VIVO; EXPRESSION; CANCER; MDM2; APOPTOSIS; SARCOMAS	p53 is a tumour suppressor gene which functions as a transcription factor to upregulate genes for growth arrest and apoptosis following DNA damage. p53 mutations are associated with Li-Fraumeni and Li-Fraumeni like syndromes. Recently mutations of the oligomerization domain have been isolated from an LFS and an LFL family affecting respectively codon 344 (Leu to Pro) and 337 (Arg to Cys). The present study was designed to determine the affect of these mutations on the function of pJ3 protein, p53 344 Leu to Pro existed only in a monomeric form and could not bind to DIVA. It was inactive at inducing apoptosis, transactivating luciferase from a bax promoter and inhibiting cell growth. In contrast, p53 337 Arg to (Cys could form tetramers and could bind to DNA. However, p53 337 Arg to Cys was not fully active and could only induce apoptosis, transactivate luciferase from a bax promoter and inhibit cell growth with approximate to 60% of the ability of wild-type p53. Both mutant proteins had reduced ability to bind to MDM2, p53 337 Arg to Cys being more reduced than p53 344 Leu to Pro. These results indicate that point mutations in the oligomerization domain can disrupt p53 function. In addition, the value of LFS and LFL families for the further understanding of the biological and biochemical properties of p53 is demonstrated.	United Med & Dent Sch Guys & St Thomas Hosp, Richard Dimbleby Dept Canc Res, London SE1 7EH, England; Guys Hosp, Clin Oncol Unit, ICRF, London SE1 9RT, England; Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of Dundee; University of Bradford	Camplejohn, RS (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Richard Dimbleby Dept Canc Res, Lambeth Palace Rd, London SE1 7EH, England.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BIRCH JM, 1994, EUR J CANCER, V30A, P1935, DOI 10.1016/0959-8049(94)00383-G; Casey G, 1996, ONCOGENE, V13, P1971; DAVISON T, UNPUB ONCOGENE SIMUL; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KERN SE, 1991, SCIENCE, V251, P1708; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Lomax ME, 1997, ONCOGENE, V14, P1869, DOI 10.1038/sj.onc.1201133; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; Picksley SM, 1996, ACTA ONCOL, V35, P429, DOI 10.3109/02841869609109917; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1996, ONCOGENE, V12, P2437; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	34	78	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					643	649		10.1038/sj.onc.1201974	http://dx.doi.org/10.1038/sj.onc.1201974			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704930				2022-12-28	WOS:000075195300012
J	Qu, CK; Feng, GS				Qu, CK; Feng, GS			Shp-2 has a positive regulatory role in ES cell differentiation and proliferation	ONCOGENE			English	Article						tyrosine phosphatase; ES cell differentiation; cell proliferation; signal transduction	PROTEIN-TYROSINE-PHOSPHATASE; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; EMBRYONIC STEM-CELLS; FACTOR RECEPTOR-BETA; SIGNAL-TRANSDUCTION; MOTH-EATEN; ANTIGEN RECEPTOR; SH2 DOMAINS; IN-VITRO; SYP	Shp-2 is a ubiquitously expressed tyrosine phosphatase with two SH2 domains. Homozygous mutant mice with a targeted deletion of 65 amino acid residues in the N-terminal SH2 domain of Shp-2 die in utero at midgestation, with multiple defects in mesodermal patterning To surpass the embryonic lethality in dissecting the Shp-2 function in cell growth and differentiation, we established homozygous Shp-2 mutant embryonic stem (ES) cell lines. Our previous data showed a severe suppression of hematopoietic cell differentiation from Shp-2 mutant ES cells. Here rye demonstrate that development of cardiac muscle cells was dramatically delayed and impaired in embryoid bodies (EBs) of Shp-2 mutant origin. Shp-2 mutant ES cells failed to differentiate into epithelial and fibroblast cells in vitro. However, higher efficiency of secondary EB formation was observed from the mutant than the wild-type ES cells. Further, mutant ES cells were more sensitive than wild-type cells to the differentiation suppressing effect of leukemia inhibitory factor (LIF). In addition, mutant ES cells showed a reduced growth rate compared to wildtype cells. These results suggest that the Shp-2 tyrosine phosphatase is a positive regulator for both cell differentiation and proliferation, in contrast to the Src-family kinases which promote cell growth but block differentiation.	Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Feng, GS (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053660] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29GM53660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOULTER CA, 1988, ONCOGENE, V2, P207; BOULTER CA, 1991, DEVELOPMENT, V111, P357; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; TSUI FWL, 1994, IMMUNOL REV, V138, P185, DOI 10.1111/j.1600-065X.1994.tb00852.x; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; Wurst W., 1993, Gene targeting: a practical approach., P33; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	43	63	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					433	439		10.1038/sj.onc.1201920	http://dx.doi.org/10.1038/sj.onc.1201920			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696036				2022-12-28	WOS:000075043000005
J	Lutz, W; Fulda, S; Jeremias, I; Debatin, KM; Schwab, M				Lutz, W; Fulda, S; Jeremias, I; Debatin, KM; Schwab, M			MycN and IFN gamma cooperate in apoptosis of human neuroblastoma cells	ONCOGENE			English	Article						oncogenes; amplification; APO-1; FAS; cytokines; CD95	BCL-2 HOMOLOG BAK; C-MYC; N-MYC; ORNITHINE DECARBOXYLASE; DEATH; ALPHA; PROTEIN; GROWTH; EXPRESSION; INDUCTION	Neuroblastomas undergo spontaneous regression at an unusually high rate. The mechanisms are not clear, but apoptosis may be involved. A large proportion of neuroblastomas is characterized by amplification of MYCN. Using human neuroblastoma cells harbouring tetracycline controlled expression of MYCN we have analysed the role of the MycN protein and IFN gamma in cell death decision. Neither conditional expression of MYCN nor treatment with IFN gamma alone was sufficient to trigger cell death. However, when acting in concert MycN and IFN gamma efficiently triggered cell death, which was accompanied by DNA fragmentation and required caspase activity, two hallmarks of apoptosis, MycN and IFN gamma may cooperate along at least two different pathways. First, IFN gamma increased the CD95 cell surface expression while MycN enhanced the cellular susceptibility for the CD95 mediated death signal. Second, IFN gamma, treatment induced expression of BAK mRNA while MycN and IFN gamma in combination increased the amount of Bax protein, another activator of apoptosis, without a concomitant increase in BAX mRNA. MycN also increased cell death in response to TRAIL and TNF alpha, suggesting that enforced MYCN expression in general increases the susceptibility of neuroblastoma cells towards a variety of death stimuli.	German Canc Res Ctr, Dept Cytogenet 0825, D-69120 Heidelberg, Germany; Heidelberg Univ, Childrens Hosp, Div Hematol Oncol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Mol Oncol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Schwab, M (corresponding author), German Canc Res Ctr, Dept Cytogenet 0825, Neuheimer Feld 280, D-69120 Heidelberg, Germany.		Fulda, Simone/D-5864-2011; Jeremias, Irmela/C-6090-2015; Jeremias, Irmela/Q-5934-2019; Debatin, Klaus-Michael/J-9704-2014	Jeremias, Irmela/0000-0003-1773-7677; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				ASKEW DS, 1991, ONCOGENE, V6, P1915; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BERTHOLD F, 1990, NEUROBLASTOMA TUMOR, P1; CASTLE VP, 1993, AM J PATHOL, V143, P1543; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P3823; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ikeda H, 1996, AM J SURG PATHOL, V20, P649, DOI 10.1097/00000478-199606000-00001; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; Lutz W, 1996, ONCOGENE, V13, P803; MIYASHITA T, 1995, CELL, V80, P293; Montaldo PG, 1997, CELL DEATH DIFFER, V4, P150, DOI 10.1038/sj.cdd.4400215; Nakagawara A, 1997, CANCER RES, V57, P4578; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OITVAI ZN, 1993, CELL, V74, P609; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PONZONI M, 1992, CANCER RES, V52, P931; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; Sato T, 1997, BRIT J HAEMATOL, V97, P356, DOI 10.1046/j.1365-2141.1997.562704.x; Schwab M, 1995, NEUROSCIENTIST, V1, P277; SCHWAB M, 1998, BIOESSAYS        JUN; Schwab M, 1997, PATHOLOGY GENETICS T, P117; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P7227, DOI 10.1073/pnas.94.14.7227; ZORNIG M, 1995, ONCOGENE, V11, P2165; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	55	98	102	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	1998	17	3					339	346		10.1038/sj.onc.1200201	http://dx.doi.org/10.1038/sj.onc.1200201			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690515				2022-12-28	WOS:000074947500008
J	O'Brien, V; Campo, MS				O'Brien, V; Campo, MS			BPV-4 E8 transforms NIH3T3 cells, up-regulates cyclin A and cyclin A-associated kinase activity and de-regulates expression of the cdk inhibitor p27(Kip1)	ONCOGENE			English	Article						BPV-4; cell transformation; cyclin A; cyclin A-associated kinase; E8; p27(Kip1)	BOVINE PAPILLOMAVIRUS TYPE-4; PHASE-TRANSITION; GROWTH-FACTOR; PROTEIN; ONCOPROTEIN; INACTIVATION; FIBROBLASTS; RECEPTOR; GOLGI; BINDS	The E8 open reading frame of Bovine papillomavirus type 4 (BPV-4) encodes a small (42 amino acid) hydrophobic polypeptide localized to cellular membranes and capable of conferring an anchorage-independent (AI) growth phenotype on primary bovine cells co-transfected with BPV-4 E7 ORF and an activated ras gene. To further study the function of E8 independently of other viral gene products, we have expressed it in the murine fibroblast cell line, NIH3T3, Cells expressing E8 are capable of AI growth and escape growth arrest after serum withdrawal. E8 deregulates cyclin A expression, induces transactivation of the human cyclin A gene promoter and increases endogenous protein levels in cells maintained in short-term suspension culture and in low-serum (LS), Both these culture conditions promote downregulation of cyclin A in control cells. In LS growth conditions E8 permits sustained cyclin A-associated kinase activity but not cyclin E-cdk2 activity, Cyclin A-cdk2 activity and, in part, cyclin A gene expression are regulated by the cdk inhibitor p27(Kip1). Expression of this cdk inhibitor is also de-regulated in E8 cells, with high levels being detected under all culture conditions tested. These data suggest that the ability of BPV-4 E8 to transform NIH3T3 cells is associated with upregulation of cyclin A-associated kinase activity and de-regulated expression of the cdk inhibitor p27(Kip1) and does not rely on down-regulation of p27(Kip1) expression. Analysis of E8 mutants indicate that the hydrophilic 'tail' of the molecule (residues 31 - 42) is required for cell transformation, as assessed by anchorage-independent growth, while a form of E8 with expression restricted to the Endoplasmic Reticulum/cis-Golgi membranes by addition of a 'KDEL' retention signal revealed that the sub-cellular localization is an important determinant of E8 biological activity.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	O'Brien, V (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.			O'Brien, Vincent/0000-0002-2418-7768				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CAMPO MS, 1994, CARCINOGENESIS, V15, P1597, DOI 10.1093/carcin/15.8.1597; CARMICHAEL J, 1987, CANCER RES, V47, P943; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GIRARD F, 1991, CELL, V67, P1; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Jackson ME, 1996, INT J ONCOL, V9, P1189; JAGGAR RT, 1990, J GEN VIROL, V71, P3041, DOI 10.1099/0022-1317-71-12-3041; Kramer A, 1996, J BIOL CHEM, V271, P6579; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SETTLEMAN J, 1989, MOL CELL BIOL, V9, P5563, DOI 10.1128/MCB.9.12.5563; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPARKOWSKI J, 1995, EMBO J, V14, P3055, DOI 10.1002/j.1460-2075.1995.tb07308.x; THOME KZ, 1997, MOL CELL BIOL, V17, P407; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZerfassThome K, 1996, ONCOGENE, V13, P2323	33	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					293	301		10.1038/sj.onc.1201937	http://dx.doi.org/10.1038/sj.onc.1201937			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690511				2022-12-28	WOS:000074947500004
J	Fan, SJ; Wang, JA; Yuan, RQ; Rockwell, S; Andres, J; Zlatapolskiy, A; Goldberg, ID; Rosen, EM				Fan, SJ; Wang, JA; Yuan, RQ; Rockwell, S; Andres, J; Zlatapolskiy, A; Goldberg, ID; Rosen, EM			Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents	ONCOGENE			English	Article						scatter factor (SF); hepatocyte growth factor (HGF); c-Met; breast cancer; adriamycin (doxorubicin); apoptosis	HEPATOCYTE GROWTH-FACTOR; HUMAN BREAST-CANCER; C-MYC; MEDIATED APOPTOSIS; MET PROTOONCOGENE; IN-VIVO; TUMOR; INDUCTION; DEATH; GENE	Scatter factor (SF) (hepatocyte growth factor) is a cytokine that may play a role in human breast cancer invasiveness and angiogenesis, We now report that SF can block the induction of apoptosis by various DNA damaging-agents, including cytotoxic agents used in breast cancer therapy. SF protected MDA-MB-453 human breast cancer cells, EMT6 mouse mammary tumor cells and MDCK renal epithelial cells against apoptosis induced by adriamycin (ADR), X-rays, ultraviolet radiation, and other agents. Protection was observed in assays of DNA fragmentation, cell viability (;MTT), and clonogenic survival. Protection of MDA-MB-453 cells against ADR was dose- and time-dependent; maximal protection required pre-incubation with 75-100 ng/ml of SF for 48 h or more. Protection required functional SF receptor (c-Met), but was not dependent on p53. Western blotting analysis revealed that pre-treatment of MDA-MB-453 cells with SF inhibited the ADR-induced decreases in the levels of Bcl-X-L, an anti-apoptotic protein related to Bcl-2; and the dose-response and time course characteristics for SF-mediated increases in the Bcl-X-L protein levels of ADR-treated cells were consistent with the degrees of protection against apoptosis observed under the same conditions. Furthermore, Bcl-X-L levels were not down-regulated by ADR in MDA-MB-231 breast cancer cells, consistent with the finding that SF failed to protect these cells against ADR, despite the fact that they contain functional c-Mrt receptor. In contrast to Bcl-X-L, SF blocked ADR-induced increases in c-Myc and inhibited the expression of p2(WAF1/CIP1) and of the BRCA1 protein in MDA-MB-453 cells. However, SF did not cause significant changes in the cell cycle distribution of ADR-treated cells. These findings suggest that SF-mediated protection of human breast cancer cells may involve inhibition of one or more pathways required for the activation of apoptosis and may particularly target the anti-apoptotic mitochondrial membrane pore-forming protein Bcl-X-L as a component of the protective mechanism. By implication, the accumulation of SF within human breast cancers may contribute to the development of a radio- or chemoresistant phenotype.	Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, New Hyde Park, NY 11040 USA; Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA	Northwell Health; Yeshiva University; Yale University	Rosen, EM (corresponding author), Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Park, NY 11040 USA.		Rockwell, Sara/B-8458-2009		NATIONAL CANCER INSTITUTE [R01CA064869] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA64869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; APTE SS, 1995, GENOMICS, V26, P292; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN S, 1994, CANCER RES, V5, P5824; FAN SJ, 1995, CANCER RES, V55, P1649; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; HURLIN PJ, 1993, EMBO J, V94, P5646; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Lamszus K, 1997, LAB INVEST, V76, P339; Laterra J, 1997, LAB INVEST, V76, P565; Lenahan MK, 1996, ONCOGENE, V12, P1847; LOKKER NA, 1992, EMBO J, V11, P2403; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Nagy P, 1996, HEPATOLOGY, V23, P71, DOI 10.1053/jhep.1996.v23.pm0008550051; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Packham G, 1996, ONCOGENE, V13, P461; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Rao VN, 1996, ONCOGENE, V12, P523; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROCKWELL S, 1981, CANCER RES, V41, P527; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SATTLER MM, 1996, NATURE, V382, P335; SCHECHTER RL, 1992, BIOCHEM CELL BIOL, V70, P349, DOI 10.1139/o92-054; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shao NS, 1996, ONCOGENE, V13, P1; SHEIKH MS, 1995, ONCOGENE, V11, P1899; STOKER M, 1987, NATURE, V327, P238; TAKANO H, 1992, ANTI-CANCER DRUG, V3, P323, DOI 10.1097/00001813-199208000-00002; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yao Y, 1996, AM J PATHOL, V149, P1707; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	49	127	132	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					131	141		10.1038/sj.onc.1201943	http://dx.doi.org/10.1038/sj.onc.1201943			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674697				2022-12-28	WOS:000074706700001
J	Ankoma-Sey, V; Matli, M; Chang, KB; Lalazar, A; Donner, DB; Wong, L; Warren, RS; Friedman, SL				Ankoma-Sey, V; Matli, M; Chang, KB; Lalazar, A; Donner, DB; Wong, L; Warren, RS; Friedman, SL			Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing	ONCOGENE			English	Article						hepatic stellate cells; sinusoidal endothelium; hepatic fibrosis; receptor tyrosine kinases	ENDOTHELIAL GROWTH-FACTOR; HUMAN HEPATOCELLULAR-CARCINOMA; FACTOR-BETA-RECEPTOR; HUMAN COLON-CANCER; FAT-STORING CELLS; TYROSINE KINASE; GENE-EXPRESSION; IN-VIVO; LIVER; LIPOCYTES	Homology PCR has been used to identify receptor tyrosine kinases (RTKs) expressed during activation of rat hepatic stellate cells, the key fibrogenic mesenchymal element in the liver. Partial cDNAs encoding several RTKs were cloned from stellate cells activated in vivo, including those of Flt-1, Flk-1, c-met, PDGFR, and Tyro10/DDR2, RNAse protection from cells activated in vivo demonstrated biphasic induction of flt-1 and flk-1 mRNAs, receptors for vascular endothelial growth factor (VEGF), Culture-activation of stellate cells was associated with increased [I-125]VEGF binding and Flt-1 and Flk-1 receptor protein. Induction of VEGF binding sites correlated with an 2.5-fold increase in DNA synthesis in response to VEGF, but only if cells were activated by growth on collagen I, whereas cells maintained in a quiescent state on a basement membrane-like substratum (EHS matrix) were nonproliferative, In both stellate and endothelial cells VEGF-induced mitogenesis was augmented by co-incubation with basic fibroblast growth factor (bFGF), a cytokine with known synergy with VEGF, These findings suggest that the cellular targets of VEGF in liver may not be confined to sinusoidal endothelial cells, and that VEGF responses reflect combined effects on both hepatic stellate cells and sinusoidal endothelium.	Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Indiana Univ, Sch Med, Dept Physiol & Biophys, Indianapolis, IN 46202 USA; Indiana Univ, Walther Oncol Ctr, Indianapolis, IN 46202 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Friedman, SL (corresponding author), CUNY Mt Sinai Sch Med, Div Liver Dis, Box 1123,1425 Madison Ave,Room 11-70F, New York, NY 10029 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743, T32DK007007, R01DK037340] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26743, DK 07007, DK37340] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DAVIS BH, 1988, J CELL PHYSIOL, V136, P547, DOI 10.1002/jcp.1041360323; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1993, ONCOGENE, V8, P1293; ENZAN H, 1994, HEPATOLOGY, V19, P895, DOI 10.1016/0270-9139(94)90289-5; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Friedman S L, 1996, Prog Liver Dis, V14, P101; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; FRIEDMAN SL, 1993, METHODS TOXICOL, V1, P292; GEERTS A, 1991, HEPATOLOGY, V13, P1193, DOI 10.1002/hep.1840130628; GRESSNER AM, 1995, J HEPATOL, V22, P28; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hioki O, 1996, J HEPATOL, V24, P217, DOI 10.1016/S0168-8278(96)80032-8; Ikeda H., 1996, Hepatology, V24, p460A; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KAWADA N, 1992, BIOCHEM J, V285, P367, DOI 10.1042/bj2850367; LAI C, 1994, ONCOGENE, V9, P877; Lalazar A, 1997, GENE, V195, P235, DOI 10.1016/S0378-1119(97)00159-5; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; Mise M, 1996, HEPATOLOGY, V23, P455; Mochida S, 1996, BIOCHEM BIOPH RES CO, V226, P176, DOI 10.1006/bbrc.1996.1329; MORI S, 1991, J BIOL CHEM, V266, P21158; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; NOMURA M, 1995, J BIOL CHEM, V270, P28316; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P9082; PROCTOR E, 1982, GASTROENTEROLOGY, V83, P1183; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAZ V, 1991, ONCOGENE, V6, P753; ROCKEY DC, 1993, J CLIN INVEST, V92, P1795, DOI 10.1172/JCI116769; Rodewald HR, 1996, ONCOGENE, V12, P397; ROSENBAUM J, 1995, GASTROENTEROLOGY, V109, P1986, DOI 10.1016/0016-5085(95)90767-X; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schlessinger J, 1993, Harvey Lect, V89, P105; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11; Suzuki K, 1996, CANCER RES, V56, P3004; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WONG L, 1994, J CLIN INVEST, V94, P1563, DOI 10.1172/JCI117497; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; YAMANE A, 1994, ONCOGENE, V9, P2683	54	102	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					115	121		10.1038/sj.onc.1201912	http://dx.doi.org/10.1038/sj.onc.1201912			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671320	Bronze			2022-12-28	WOS:000074677800013
J	Ko, TC; Yu, WS; Sakai, T; Sheng, HM; Shao, JY; Beauchamp, RD; Thompson, EA				Ko, TC; Yu, WS; Sakai, T; Sheng, HM; Shao, JY; Beauchamp, RD; Thompson, EA			TGF-beta 1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression	ONCOGENE			English	Article						TGF-beta 1; cyclin D1; cyclin-dependent kinase; gut epithelial cells; antisense oligonucleotide	TGF-BETA RECEPTOR; GROWTH-FACTOR; GENE-EXPRESSION; DIFFERENTIAL SENSITIVITY; RETINOBLASTOMA PROTEIN; PRB PHOSPHORYLATION; POTENTIAL MEDIATOR; TRANSGENIC MICE; CARCINOMA-CELLS; CDK INHIBITORS	Transforming growth factor-beta 1 (TGF-beta 1) arrests intestinal epithelial cells (RIE-1 and IEC-6) in the G1 phase of the cell cycle and inhibits cyclin D1 expression, This report describes experiments designed to elucidate the mechanism of cyclin D1 inhibition and to determine whether inhibition of cyclin D1 expression is the cause, rather than the result, of TGF-beta 1-mediated cell cycle arrest, TGF-beta 1 inhibition of IEC-6 cell proliferation mas associated with a decrease in the abundance of cyclin D1/Cdk4 complexes and a corresponding decrease in Cdk4-dependent phosphorylation of the retinoblastoma protein, Metabolic labeling studies indicated that TGF-beta 1 inhibited cyclin D1 synthesis without altering the rate of cyclin DI protein degradation. Cyclin D1 antisense oligonucleotides blocked serum-stimulated induction of cyclin D1 and DNA synthesis, whereas cyclin D1 sense oligonucleotides had no effect. RIE-1 cells were engineered to overexpress human cyclin D1 under the control of a tetracycline-repressible promoter, These cells entered S phase in the presence of TGF-beta 1 only when human cyclin D1 was derepressed by the withdrawal of tetracycline. These data indicate that TGF-beta 1 inhibits the synthesis of cyclin D1 in gut epithelial cells and that this inhibition is the cause, rather than the result, of TGF-beta 1-mediated arrest of intestinal epithelial cell proliferation.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Showa Univ, Sch Med, Dept Internal Med 3, Tokyo 142, Japan	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University; Vanderbilt University; Showa University	Thompson, EA (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.			Beauchamp, Robert Daniel/0000-0002-8446-4114	NCI NIH HHS [CA64191, CA64701, CA69457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069457, R01CA064701, K08CA064191] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABAYATSKY MW, 1991, TXB GASTROENTEROLOGY, P475; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Arber N, 1997, CANCER RES, V57, P1569; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BLAY J, 1985, J CELL PHYSIOL, V124, P107, DOI 10.1002/jcp.1041240117; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Bresnahan WA, 1996, VIROLOGY, V224, P150, DOI 10.1006/viro.1996.0516; CAIRNIE AB, 1965, EXP CELL RES, V39, P528, DOI 10.1016/0014-4827(65)90055-8; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIACCI C, 1993, GASTROENTEROLOGY, V105, P93, DOI 10.1016/0016-5085(93)90014-4; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FILMUS J, 1992, ONCOGENE, V7, P521; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FROST GH, 1993, J BIOL CHEM, V268, P6748; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALL PA, 1994, J CELL SCI, V107, P3569; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; Hung WC, 1996, BIOCHEM BIOPH RES CO, V220, P719, DOI 10.1006/bbrc.1996.0470; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KATO J, 1993, GENE DEV, V7, P331; KO TC, 1995, ONCOGENE, V10, P177; KO TC, 1994, AM J SURG, V167, P14, DOI 10.1016/0002-9610(94)90048-5; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MUNGER K, 1992, CELL GROWTH DIFFER, V3, P291; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; PALMERO I, 1993, ONCOGENE, V8, P1049; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RHEE K, 1995, CANCER RES, V55, P4188; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TRABER PG, 1994, J LAB CLIN MED, V123, P467; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang T, 1997, CANCER RES, V57, P169; Zhang T, 1997, CANCER RES, V57, P1638	68	68	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3445	3454		10.1038/sj.onc.1201902	http://dx.doi.org/10.1038/sj.onc.1201902			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692552				2022-12-28	WOS:000074544100011
J	Matsumoto, Y; Kosugi, S; Shinbo, T; Chou, DZ; Ohashi, M; Wakabayashi, Y; Sakai, K; Okumoto, M; Mori, N; Aizawa, S; Niwa, O; Kominami, R				Matsumoto, Y; Kosugi, S; Shinbo, T; Chou, DZ; Ohashi, M; Wakabayashi, Y; Sakai, K; Okumoto, M; Mori, N; Aizawa, S; Niwa, O; Kominami, R			Allelic loss analysis of gamma-ray-induced mouse thymic lymphomas: two candidate tumor suppressor gene loci on chromosomes 12 and 16	ONCOGENE			English	Article						tumor suppressor gene; allelic loss (or LOH) analysis; thymic lymphoma; gamma-ray irradiation; p53	RADIATION-INDUCED APOPTOSIS; P53 MUTATIONS; P53-DEFICIENT MICE; FREQUENT LOSS; CANCER; IRRADIATION; HETEROZYGOSITY; DEFICIENCY; RESISTANCE; SUSCEPTIBILITY	A total of 429 gamma-ray-induced thymic lymphomas were obtained from F-1 and backcross mice between BALB/c and MSM strains, about a half of which carried a p53-deficient allele. A genome-wide allelic loss analysis has revealed two loci exhibiting frequent alleLic losses but no allelic preference, one is localized within a 2.9 cM region between D12Mit53 and D12Mit279 loci on chromosome 12, and the other is near the D16Mit122/D16Mit162 loci on chromosome 16, The frequency of allelic loss in the D12Mit279 region is 62% and does not differ in tumors between the presence and absence of the p53-deficient allele, In contrast, the loss frequency of D16Mit122 is raised by the existence of p53-deficient allele: 62% for p63(-/+) and 13% for p53(+/+), suggesting cooperative function of the two losses. The D12Mit279 and D16Mit122 regions probably harbor different types of tumor suppressor gene that play key roles in lymphoma development.	Niigata Univ, Sch Med, Dept Biochem, Niigata 951, Japan; Niigata Univ, Sch Med, Dept Radiat Med, Niigata 951, Japan; Univ Osaka Prefecture, Adv Sci & Technol Res Inst, Sakai, Osaka 593, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 60601, Japan; Kumamoto Univ, Dept Morphogenesis, Inst Mol Embryol & Genet, Kumamoto 860, Japan	Niigata University; Niigata University; Japan Advanced Institute of Science & Technology (JAIST); Osaka Metropolitan University; Kyoto University; Kumamoto University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem, Asahimachi 1-757, Niigata 951, Japan.		Kosugi, S./K-5142-2019	Kosugi, Shin-ichi/0000-0002-6602-7412				BONHOMME F, 1989, GENETIC VARIANTS STR, P658; BRATHWAITE O, 1992, CANCER RES, V52, P3791; CHANG WYH, 1995, CANCER RES, V55, P3246; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALEVY O, 1991, ONCOGENE, V6, P1593; Hamatani K, 1996, IMMUNOGENETICS, V45, P1, DOI 10.1007/s002510050159; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HAYASHI T, 1993, GENOMICS, V17, P490, DOI 10.1006/geno.1993.1352; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KNUDSON AG, 1985, CANCER RES, V45, P1437; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIEBERMAN M, 1992, J EXP MED, V176, P399, DOI 10.1084/jem.176.2.399; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAFUNE Y, 1994, ONCOGENE, V9, P2191; MILLER RD, 1995, P NATL ACAD SCI USA, V92, P10792, DOI 10.1073/pnas.92.23.10792; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORI N, 1995, GENOMICS, V25, P609, DOI 10.1016/0888-7543(95)80001-3; Ohashi M, 1996, JPN J CANCER RES, V87, P696, DOI 10.1111/j.1349-7006.1996.tb00280.x; OKUMOTO M, 1989, J RADIAT RES, V30, P135, DOI 10.1269/jrr.30.135; OKUMOTO M, 1990, CANCER RES, V50, P3848; OOTSUYAMA A, 1994, MOL CARCINOGEN, V11, P236, DOI 10.1002/mc.2940110409; SAEZ GT, 1994, MOL CARCINOGEN, V9, P40, DOI 10.1002/mc.2940090108; Santos J, 1996, ONCOGENE, V12, P669; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Suda T, 1994, DNA Res, V1, P169, DOI 10.1093/dnares/1.4.169; SUZUKI T, 1989, CANCER RES, V49, P1095; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSUKADA T, 1993, ONCOGENE, V8, P3313; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; YOUNG J, 1993, ONCOGENE, V8, P671; Zhuang SM, 1996, CANCER RES, V56, P3338	40	60	61	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2747	2754		10.1038/sj.onc.1201810	http://dx.doi.org/10.1038/sj.onc.1201810			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652741				2022-12-28	WOS:000073812200006
J	Oldham, SM; Cox, AD; Reynolds, ER; Sizemore, NS; Coffey, RJ; Der, CJ				Oldham, SM; Cox, AD; Reynolds, ER; Sizemore, NS; Coffey, RJ; Der, CJ			Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade	ONCOGENE			English	Article						autocrine; epidermal growth factor receptor; Raf	NUCLEOTIDE DISSOCIATION STIMULATOR; RECEPTOR TYROSINE KINASE; ONCOGENIC RAS; PLASMA-MEMBRANE; GROWTH-FACTORS; REQUIREMENT; SUFFICIENT; EFFECTOR; PATHWAY; CAAX	Src transformation of NIH3T3 mouse fibroblasts has been shown to be dependent on Ras function. Since we recently showed that the signaling pathways that mediate Ras transformation of RIE-1 rat intestinal epithelial cells are distinct from those that cause Ras transformation of fibroblasts, we utilized three approaches to determine if Src transformation of RIE-1 cells is dependent on Ras, First, although both Ras and Src cause upregulation of an epidermal growth factor (EGF) receptor-dependent autocrine growth loop, only Ras transformation required this activity, Second, whereas both Src and Ras caused upregulation of the p42 and p44 mitogen-activated protein kinases (MAPKs), only Ras transformation was blocked by the inhibition of MAPK activation by treatment with the PD 98059 MEK inhibitor, Third, treatment with the farnesyltransferase inhibitor FTI-277 blocked Ras, but not Src, transformation. Taken together, these observations suggest that Src transformation of RIE-1 cells is not dependent on Ras, Finally, we determined that Ras activation of Raf-independent pathways alone is sufficient to cause growth transformation of RIE-1 cells. Thus, both Ras and Src cause transformation of RIE-1 cells via pathways distinct from those required to cause transformation of NIH3T3 cells.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Vanderbilt Univ, Dept Med, Nashville, TN USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Der, CJ (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.			Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA 63071, CA 69577, CA 42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069577, R01CA063071, R01CA042978] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, J BIOL CHEM, V269, P19203; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LIU XQ, 1993, ONCOGENE, V8, P1119; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STACEY DW, 1991, ONCOGENE, V6, P2297; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1996, ONCOGENE, V13, P353; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	55	43	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2565	2573		10.1038/sj.onc.1201784	http://dx.doi.org/10.1038/sj.onc.1201784			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632133				2022-12-28	WOS:000073698200001
J	de Vries, A; Berg, RJW; Wijnhoven, S; Westerman, A; Wester, PW; van Kreijl, CF; Capel, PJA; de Gruijl, FR; van Kranen, HJ; van Steeg, H				de Vries, A; Berg, RJW; Wijnhoven, S; Westerman, A; Wester, PW; van Kreijl, CF; Capel, PJA; de Gruijl, FR; van Kranen, HJ; van Steeg, H			XPA-deficiency in hairless mice causes a shift in skin tumor types and mutational target genes after exposure to low doses of UVB	ONCOGENE			English	Article						XPA; UVB; p53; ras; papilloma; squamous cell carcinoma	XERODERMA-PIGMENTOSUM PATIENTS; SQUAMOUS-CELL CARCINOMAS; P53 GENE; ULTRAVIOLET-RADIATION; MOLECULAR ANALYSIS; EXCISION-REPAIR; RAS MUTATIONS; MOUSE SKIN; GROUP-A; CANCER	Xeroderma pigmentosum (XP) patients with a defect in the nucleotide excision repair gene XPA, develop tumors with a high frequency on sun-exposed areas of the skin. Here we describe that hairless XPA-deficient mice also develop skin tumors with a short latency time and a 100% prevalence after daily exposure to low doses of U.V.B. Surprisingly and in contrast to U.V.B.-exposed repair proficient hairless mice who mainly develop squamous cell carcinomas, the XPA-deficient mice developed papillomas with a high frequency (31%) at a U.V. dose of 32 J/m(2) daily, At the highest daily dose of 80 J/m(2) mainly squamous cell carcinomas (56%) and only 10% of papillomas were found in XPA-deficient hairless mice, p53 gene mutations were examined in exons 5, 7 and 8 and were detected in only 3 out of 37 of these skin tumors, whereas in tumors of control U.V.B.-irradiated wild type littermates this frequency was higher (45%) and more in line with our previous data. Strikingly, a high incidence of activating ras gene mutations were observed in U.V.B.-induced papillomas (in 11 out of 14 tumors analysed). In only two out of 14 squamous cell carcinomas we found similar ras gene mutations. The observed shift from squamous cell carcinomas in wild type hairless mice to papillomas in XPA-deficient hairless mice, and a corresponding shift in mutated cancer genes in these tumors, provide new clues on the pathogenesis of chemically-versus U.V.B.-induced skin carcinogenesis.	Natl Inst Publ Hlth & Environm, Dept Carcinogenesis Mutagenesis & Genet, Hlth Effects Res Lab, NL-3720 BA Bilthoven, Netherlands; Natl Inst Publ Hlth & Environm, Lab Pathol & Immunobiol, NL-3720 BA Bilthoven, Netherlands; Univ Utrecht, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Dept Dermatol, NL-3584 CX Utrecht, Netherlands	Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University	van Steeg, H (corresponding author), Natl Inst Publ Hlth & Environm, Dept Carcinogenesis Mutagenesis & Genet, Hlth Effects Res Lab, POB 1, NL-3720 BA Bilthoven, Netherlands.							Berg RJW, 1997, CANCER RES, V57, P581; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; Brown K, 1995, TOXICOL LETT, V82-3, P123, DOI 10.1016/0378-4274(95)03549-4; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; CAMPBELL C, 1993, BRIT J DERMATOL, V128, P111, DOI 10.1111/j.1365-2133.1993.tb15137.x; Cleaver JE, 1995, METABOLIC MOL BASES, VIII, P4393; DAYAGROSJEAN L, 1995, J PHOTOCH PHOTOBIO B, V28, P115, DOI 10.1016/1011-1344(95)07130-T; DEGRUIJL FR, 1993, CANCER RES, V53, P53; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; DORADO G, 1991, J MOL BIOL, V217, P217, DOI 10.1016/0022-2836(91)90533-C; DUMAZ N, 1994, MUTAT RES, V307, P375, DOI 10.1016/0027-5107(94)90311-5; Dumaz N, 1997, CARCINOGENESIS, V18, P897, DOI 10.1093/carcin/18.5.897; *IARC, 1992, MON EV CARC RISK HUM, V55; KANJILAL S, 1993, CANCER RES, V53, P2961; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; KRESS S, 1992, CANCER RES, V52, P6400; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; LUNGMANN M, 1996, ONCOGENE, V13, P823; MATSUMURA Y, 1995, J INVEST DERMATOL, V105, P399, DOI 10.1111/1523-1747.ep12321051; Matsumura Y, 1996, INT J CANCER, V65, P778; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MiyauchiHashimoto H, 1996, J INVEST DERMATOL, V107, P343, DOI 10.1111/1523-1747.ep12363295; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; REES J, 1994, J INVEST DERMATOL, V103, P747, DOI 10.1111/1523-1747.ep12412256; RUVEN HJT, 1994, ONCOGENE, V9, P3427; SATO M, 1993, CANCER RES, V53, P2944; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; vanKranen HJ, 1997, CANCER RES, V57, P1238; VANKRANEN HJ, 1995, CARCINOGENESIS, V16, P1141; YAGI T, 1991, CANCER RES, V51, P3177; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	36	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	1998	16	17					2205	2212		10.1038/sj.onc.1201744	http://dx.doi.org/10.1038/sj.onc.1201744			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619829				2022-12-28	WOS:000073298000005
J	Maheswaran, S; Englert, C; Lee, SB; Ezzel, RM; Settleman, J; Haber, DA				Maheswaran, S; Englert, C; Lee, SB; Ezzel, RM; Settleman, J; Haber, DA			E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells	ONCOGENE			English	Article						Wilms tumor; WT1; adenovirus; E1B 55K; sequestation; nuclear body	WILMS-TUMOR GENE; TRANSCRIPTIONAL REPRESSION; T-ANTIGEN; PROTEIN; APOPTOSIS; LOCALIZATION; ASSOCIATION; COMPLEX; DOMAIN; INHIBITION	WT1 encodes a tumor suppressor that is expressed in cells of the developing kidney and is inactivated in Wilms tumor, a pediatric kidney cancer. The adenovirus E1B 55K gene product contributes to the transformation of primary baby rat kidney (BRK) cells by binding and inactivating the product of the p53 tumor suppressor. We have previously demonstrated that WT1 and p53 are present within a protein complex in vivo. We non show that WT1 is physically associated with E1B 55K in adenovirus-transformed cells, an interaction that is mediated by the first two zinc fingers of WT1. Immunodepletion of p53 abrogates the coimmunoprecipitation of E1B 55K and WT1, consistent with the presence of a trimeric protein complex containing these three proteins. In the presence of E1B 55K, WT1 which is normally localized in the nucleus, is retained within a very high molecular weight complex and sequestered in the characteristic perinuclear cytoplasmic body that contains E1B 55K and p53, Expression of E1B 55K in osteosarcoma cells that undergo apoptosis following expression of WT1 inhibits WT1-mediated cell death. We conclude that E1B 55K may target WT1 along with p53, resulting in the functional inactivation of both tumor suppressor gene products by this viral oncoprotein.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Surg Res Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.			Lee, Sean/0000-0001-6211-3498; Englert, Christoph/0000-0002-5931-3189	NATIONAL CANCER INSTITUTE [R01CA058596, R37CA058596] Funding Source: NIH RePORTER; NCI NIH HHS [CA58596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAITHWAITE AW, 1989, J VIROL, V63, P1792, DOI 10.1128/JVI.63.4.1792-1799.1989; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GESSLER M, 1990, NATURE, V343, P744; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; Harlow E., 1988, ANTIBODIES LAB MANUA; HASTIE ND, 1994, ANNU REV GENET, V28, P523; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; Jones N C, 1990, Semin Cancer Biol, V1, P425; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Menke AL, 1996, ONCOGENE, V12, P537; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STILLMAN B, 1986, CANCER SURV, V5, P389; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDENHEUVEL SJL, 1993, J VIROL, V67, P5226, DOI 10.1128/JVI.67.9.5226-5234.1993; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	34	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2041	2050		10.1038/sj.onc.1201741	http://dx.doi.org/10.1038/sj.onc.1201741			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572485				2022-12-28	WOS:000073177200002
J	Lee, SJ; Dimtchev, A; Lavin, MF; Dritschilo, A; Jung, M				Lee, SJ; Dimtchev, A; Lavin, MF; Dritschilo, A; Jung, M			A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-kappa B	ONCOGENE			English	Article						ionizing radiation; NF-kappa B; I kappa B-alpha; ataxia-telangiectasia (AT); ATM	ATAXIA-TELANGIECTASIA CELLS; DNA-DAMAGE; ALPHA PROTEOLYSIS; KINASE COMPLEX; C-ABL; PHOSPHORYLATION; PROTEIN; DEGRADATION; INDUCTION; GENE	The signaling pathway through which ionizing radiation induces NF-kappa B activation is not fully understood. I kappa B-alpha, an inhibitory protein of NF-kappa B mediates the activation of NF-kappa B in response to various stimuli, including cytokines, mitogens, oxidants and other stresses. We have now identified an ionizing radiation-induced signaling pathway that is independent of TNF-alpha. I kappa B-alpha degradation is rapid in response to TNF-alpha induction, but it is absent in response to ionizing radiation exposure in cells from individuals with ataxia-telangiectasia (AT). Overexpression of wild-type ATM, the product of the gene defective in AT patients, restores radiation-induced degradation of I kappa B-alpha. Furthermore, phosphorylation of I kappa B-alpha. by immunoprecipitated ATM kinase is increased in control fibroblasts and transfected AT cells following ionizing radiation exposure. These data provide support for a novel ionizing radiation-induced signaling pathway for activation of NF-kappa B and a molecular basis for the sensitivity of AT patients to oxidative stresses.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Ctr, Dept Radiat Med,Div Radiat Res, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Microbiol, Washington, DC 20007 USA; Queensland Inst Med Res, Bancroft Ctr, Brisbane, Qld 4006, Australia	Georgetown University; Georgetown University; QIMR Berghofer Medical Research Institute	Jung, M (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Ctr, Dept Radiat Med,Div Radiat Res, Washington, DC 20007 USA.		Lavin, Martin/F-5961-2014	Lavin, Martin/0000-0002-5940-4769	NCI NIH HHS [CA45408, CA74175, CA 63023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045408, P01CA074175, R29CA063023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEG A, 1998, SCIENCE, V274, P782; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FUKS Z, 1993, RADIAT ONCOL INVEST, V1, P81; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jung M, 1997, CANCER RES, V57, P24; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MOHAN N, 1994, RADIAT RES, V140, P97, DOI 10.2307/3578574; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; TEOULE R, 1987, INT J RADIAT BIOL, V51, P573, DOI 10.1080/09553008414552111; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	37	117	120	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1821	1826		10.1038/sj.onc.1202088	http://dx.doi.org/10.1038/sj.onc.1202088			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778048				2022-12-28	WOS:000076303300008
J	Nason-Burchenal, K; Takle, G; Pace, U; Flynn, S; Allopenna, J; Martin, P; George, ST; Goldberg, AR; Dmitrovsky, E				Nason-Burchenal, K; Takle, G; Pace, U; Flynn, S; Allopenna, J; Martin, P; George, ST; Goldberg, AR; Dmitrovsky, E			Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells	ONCOGENE			English	Article						acute promyelocytic leukemia; PML/RAR alpha; retinoic acid; differentiation; apoptosis	RETINOIC ACID RECEPTOR; PML-RAR-ALPHA; INDUCED GRANULOCYTIC DIFFERENTIATION; BRONCHIAL EPITHELIAL-CELLS; FUSION PROTEIN; T(15-17) TRANSLOCATION; T(15,17) TRANSLOCATION; NONREARRANGED ALLELES; TRANSCRIPTION FACTOR; GROWTH SUPPRESSION	The t(15;17) rearrangement found in acute promyelocytic leukemia (APL) yields a fusion transcript, PML/RAR alpha. PML/RAR alpha. expression is linked to leukemogenesis and to clinical sensitivity to all-trans retinoic acid (RA), Paradoxically, RA treatment causes transient complete remissions in most t(15;17) APL cases. The precise roles of PML/RAR alpha in triggering leukemia or in causing a maturation block are not yet known. This study explores directly these PML/RAR alpha. functions in the growth and differentiation of APL cells using a hammerhead ribozyme to target PML/RAR alpha mRNA in the NB4 APL cell line. When the PML/RAR alpha cleaving but not the non-catalytic control ribozyme is introduced into the NB4 APL cell line, PML/RAR alpha protein expression is reduced. This catalysis signals growth suppression, cytotoxicity, and apoptosis without overcoming the maturation block found in these leukemic cells. These biologic effects depend on the selective pressure used to express the ribozyme from an episomal vector. Introduction of a non-catalytic, control ribozyme into NB4 cells caused no observed phenotype due to anti-sense activities, Expression of the catalytic or non-catalytic ribozymes in control cells lacking PML/RAR alpha mRNA yielded no apparent growth or differentiation effects. Thus, use of a hammerhead ribozyme that targets PML/RAR alpha. expression in APL cells reveals the anti-apoptotic function of this translocation product and demonstrates that PML/RAR alpha cleavage is insufficient to overcome the differentiation block observed in these leukemic cells. Taken together, these findings indicate that persistent PML/RAR alpha expression is required to maintain basal leukemic cell growth and point to the therapeutic potential of targeting PML/RAR alpha in APL.	Mem Hosp, Dept Med, Mol Med Lab, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA; Innovir Labs, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nason-Burchenal, K (corresponding author), Mem Hosp, Dept Med, Mol Med Lab, 1272 York Ave, New York, NY 10021 USA.				NCI NIH HHS [1F32CA61646-01A1, 2PO1-CA29502-14A2, R01-CA62275-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA061646, P01CA029502, R01CA062275] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn MJ, 1995, ONCOGENE, V11, P2357; AHN MJ, 1995, ONCOGENE, V10, P2307; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; BRUEL A, 1995, LEUKEMIA, V9, P1173; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chen GQ, 1996, BLOOD, V88, P1052; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DELIA D, 1993, CANCER RES, V53, P6036; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DUPREZ E, 1992, LEUKEMIA, V6, P1281; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Fu SQ, 1995, CLIN CANCER RES, V1, P583; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GRIGNANI F, 1995, CANCER RES, V55, P440; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; IKEDA K, 1994, AM J HEMATOL, V45, P212, DOI 10.1002/ajh.2830450304; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1080; LINRJ, 1998, NATURE, V391, P811; LOCOCO F, 1992, EUR J HAEMATOL, V48, P173; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Mangelsdorf David J., 1994, P319; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; MOASSER MM, 1995, ONCOGENE, V10, P1537; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NasonBurchenal K, 1997, DIFFERENTIATION, V61, P321, DOI 10.1046/j.1432-0436.1997.6150321.x; NASONBURCHENAL K, IN PRESS BLOOD; NERVI C, 1992, CANCER RES, V52, P3687; PACE U, 1994, CANCER RES, V54, P6365; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; REDDEL RR, 1988, CANCER RES, V48, P1904; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; ROGAIA D, 1995, LEUKEMIA, V9, P1467; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; TAIRA K, 1991, NUCLEIC ACIDS RES, V19, P5125, DOI 10.1093/nar/19.19.5125; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Yoshida H, 1996, CANCER RES, V56, P2945; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009	59	39	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1759	1768		10.1038/sj.onc.1202075	http://dx.doi.org/10.1038/sj.onc.1202075			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778041				2022-12-28	WOS:000076303300001
J	Zancai, P; Cariati, R; Rizzo, S; Boiocchi, M; Dolcetti, R				Zancai, P; Cariati, R; Rizzo, S; Boiocchi, M; Dolcetti, R			Retinoic acid-mediated growth arrest of EBV-immortalized B lymphocytes is associated with multiple changes in G(1) regulatory proteins: p27(Kip1) up-regulation is a relevant early event	ONCOGENE			English	Article						retinoic acid; cell cycle; p27(kip1); B lymphocytes; EBV	DEPENDENT KINASE INHIBITOR; ACUTE PROMYELOCYTIC LEUKEMIA; BREAST-CANCER CELLS; IN-VITRO; DIFFERENTIATION THERAPY; CARCINOMA CELLS; DNA-REPLICATION; DOWN-REGULATION; CDK INHIBITOR; HL-60 CELLS	EBV-immortalized lymphoblastoid B cell lines (LCLs) are a suitable in vitro model for the study of EBV-related lymphoproliferative disorders of immunosuppressed patients, We have previously shown that 9-cis-, 13-cis- and all-trans-retinoic acid (RA) powerfully inhibit LCL proliferation at concentrations corresponding to therapeutically achievable plasma levels (10(-6) M). Herein we show that RA-induced LCL accumulation in the G(0)/G(1) phases correlated with the loss of the catalytic activity of all three G(1)-associated CDKs (CDK2, CDK4 and CDK6) and with increased levels of underphosphorylated pRb and, in some LCLs, p130, LCLs arrested in G(0)/G(1) by RA also showed a significant decrease in the protein levels of cyclins D2, D3 and A, together with a reduction in the amount of cyclin D associated with CDK4 and CDK6, probably accounting for the inhibition of the relative kinase activity. In addition, RA-treated LCLs showed a marked upregulation of the CDK inhibitor (CKI) p27(Kip-1) at the protein but not mRNA level, which correlated with a progressive increase of p27(Kip-1) in CDK2 complexes (more than 2.5-fold) and with a reduction in the active phosphorylated form of CDK2, p27(Kip-1) may also contribute to the inhibition of CDK4 kinase activity, as the amount of CDK4-associated p27(Kip-1) was increased by 50% after RA exposure. p27(Kip-1) up-regulation stably persisted for more than one week after RA withdrawal concomitantly with the maintenance of the proliferative block. Moreover, neutralization of TGF beta did not affect the growth inhibitory activity of RA, suggesting that LCL growth arrest induced by these retinoids is probably not mediated by a pathway directly involving TGF beta. Overall, these results demonstrate that RA treatment of EBV-immortalized B lymphocytes is associated with multiple effects on G(1) regulatory proteins, including p27(Kip1) up-regulation, decreased levels of cyclins D2, D3 and A, and inhibition of CDK2, CDK4 and CDK6 activity, which ultimately result in reduced pRb phosphorylation and G(0)/G(1) growth arrest.	Ctr Riferimento Oncol, Div Expt Oncol 1, I-33081 Aviano, PN, Italy	IRCCS Aviano (CRO)	Boiocchi, M (corresponding author), Ctr Riferimento Oncol, Div Expt Oncol 1, I-33081 Aviano, PN, Italy.		Dolcetti, Riccardo/O-3832-2015; Rizzo, Silvana/AAW-1132-2020	Dolcetti, Riccardo/0000-0003-1625-9853; Rizzo, Silvana/0000-0002-7156-1783				Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; ASIEDU C, 1995, CANCER RES, V55, P3716; Blanchard DA, 1997, J IMMUNOL, V158, P3054; Bouchard C, 1997, J IMMUNOL, V159, P4155; CASTAIGNE S, 1990, BLOOD, V76, P1704; FALK LA, 1991, BLOOD, V77, P1248; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Florenes VA, 1996, ONCOGENE, V13, P2447; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; KALEMKERIAN GP, 1994, CELL GROWTH DIFFER, V5, P55; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kuniyasu H, 1997, CELL GROWTH DIFFER, V8, P47; Kwon TK, 1996, CELL GROWTH DIFFER, V7, P1305; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MIYATAKE S, 1995, J EXP MED, V182, P401, DOI 10.1084/jem.182.2.401; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; NALESNIK MA, 1988, AM J PATHOL, V133, P173; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Peng D, 1996, CANCER RES, V56, P3666; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pomponi F, 1996, BLOOD, V88, P3147, DOI 10.1182/blood.V88.8.3147.bloodjournal8883147; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; SHAO ZM, 1995, ONCOGENE, V11, P493; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; URBANI L, 1995, EXP CELL RES, V219, P159, DOI 10.1006/excr.1995.1216; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang QM, 1996, CANCER RES, V56, P264; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1994, SEMIN HEMATOL, V31, P1; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	47	28	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1827	1836		10.1038/sj.onc.1202089	http://dx.doi.org/10.1038/sj.onc.1202089			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778049				2022-12-28	WOS:000076303300009
J	Campbell, SL; Khosravi-Far, R; Rossman, KL; Clark, GJ; Der, CJ				Campbell, SL; Khosravi-Far, R; Rossman, KL; Clark, GJ; Der, CJ			Increasing complexity of Ras signaling	ONCOGENE			English	Review						Ras; review; signal transduction; effector; Ras sub-family	ACTIVATED PROTEIN-KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; C-HA-RAS; TUMOR-SUPPRESSOR ACTIVITY; RALGDS-RELATED PROTEIN; CYSTEINE-RICH REGION; NIH 3T3 CELLS; MAP KINASE; ONCOGENIC RAS; R-RAS	The initial discovery that ras genes endowed retroviruses with potent carcinogenic properties and the subsequent determination that mutated ras genes were present in a wide variety of human cancers, prompted a strong suspicion that the growth-promoting actions of mutated Ras proteins contribute to their aberrant regulation of growth stimulatory signaling pathways. In 1993, a remarkable convergence of experimental observations from genetic analyses of Drosophila, S. cerevisiae and C. elegans as well as biochemical and biological studies in mammalian cells came together to define a clear role for Ras in signal transduction, What emerged was an elegant linear signaling pathway where Ras functions as a relay switch that is positioned downstream of cell surface receptor tyrosine kinases and upstream of a cytoplasmic cascade of kinases that included the mitogen-activated protein kinases (MAPKs). Activated MAPKs in turn regulated the activities of nuclear transcription factors. Thus, a signaling cascade where every component between the cell surface and the nucleus was defined and conserved in worms, flies and man. This was a remarkable achievement in our efforts to appreciate how the aberrant function of Ras proteins may contribute to the malignant growth properties of the cancer cell, However, the identification of this pathway has proven to be just the beginning, rather than the culmination, of our understanding of Ras in signal transduction, Instead, we now appreciate that this simple linear pathway represents but a minor component of a very complex signaling circuitry. Ras signaling has emerged to involve a complex array of signaling pathways, where cross-talk, feedback loops, branch points and multi-component signaling complexes are recurring themes. The simplest concept of a signaling cascade, where each component simply relays the same message to the next, is clearly not the case. In this review, we summarize our current understanding of Ras signal transduction with an emphasis on new complexities associated with the recognition and/or activation of cellular effecters, and the diverse array of signaling, pathways mediated by interaction between Ras and Ras-subfamily proteins with multiple effecters.	MIT, Dept Biochem & Biophys, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; NCI, Dept Cell & Cellular Canc Biol, NIH, Rockville, MD 20850 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Campbell, SL (corresponding author), MIT, Dept Biochem & Biophys, Cambridge, MA 02139 USA.		Khosravi-Far, Roya/C-3789-2008	campbell, sharon/0000-0003-0311-409X; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA052072, R01CA042978, R01CA055008] Funding Source: NIH RePORTER; NCI NIH HHS [CA55008, CA52072, CA42978] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Afar DEH, 1997, IMMUNITY, V6, P773, DOI 10.1016/S1074-7613(00)80452-5; Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Clark GJ, 1996, P NATL ACAD SCI USA, V93, P1577, DOI 10.1073/pnas.93.4.1577; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CLARK GJ, 1997, UNPUB J BIOL CHEM; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DER CJ, 1996, ANTI-CANCER DRUG, V7, P165; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EMERSON SD, 1995, BIOCHEMISTRY-US, V34, P6911, DOI 10.1021/bi00021a001; EYCHENE A, 1995, ONCOGENE, V10, P1159; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; Geyer M, 1996, BIOCHEMISTRY-US, V35, P10308, DOI 10.1021/bi952858k; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; Graham SM, 1996, MOL CELL BIOL, V16, P6132; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HATA Y, 1990, J BIOL CHEM, V265, P7104; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Hwang MCC, 1996, J BIOL CHEM, V271, P8196, DOI 10.1074/jbc.271.14.8196; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Ito Y, 1997, BIOCHEMISTRY-US, V36, P9109, DOI 10.1021/bi970296u; Izawa I, 1996, FEBS LETT, V382, P53, DOI 10.1016/0014-5793(96)00137-8; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kalhammer G, 1997, FEBS LETT, V414, P599, DOI 10.1016/S0014-5793(97)01076-4; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Lee CHJ, 1996, J NEUROSCI, V16, P6784; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; LI R, 1993, NATURE, V366, P82, DOI 10.1038/366082a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Li Y, 1996, CANCER RES, V56, P2872; LopezBarahona M, 1996, ONCOGENE, V12, P463; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARSHALL MS, 1993, ONCOGENE, V8, P425; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MAYO MW, 1997, IN PRESS SCIENCE; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MCCORMICK F, 1991, COLD SH Q B, V56, P237; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mineo C, 1997, J BIOL CHEM, V272, P10345; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1995, ONCOGENE, V11, P447; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morcos P, 1996, MOL CELL BIOL, V16, P2496; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; MORRISON DK, 1997, IN PRESS CURR OPIN C; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NISHIDA E, 1993, TIBS, V18; OGara MJ, 1997, BIOCHEM BIOPH RES CO, V238, P425, DOI 10.1006/bbrc.1997.7299; Okazaki M, 1996, CANCER RES, V56, P2387; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Parker F, 1996, MOL CELL BIOL, V16, P2561; Parrini MC, 1996, EMBO J, V15, P1107, DOI 10.1002/j.1460-2075.1996.tb00448.x; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; PRASAD R, 1993, CANCER RES, V53, P5624; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAEZ R, 1994, ONCOGENE, V9, P2977; SATO KY, 1994, CANCER RES, V54, P552; Satoh T, 1992, Semin Cancer Biol, V3, P169; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOZERI O, 1992, ONCOGENE, V7, P2259; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; Stang S, 1997, MOL CELL BIOL, V17, P3047, DOI 10.1128/MCB.17.6.3047; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUEN KL, 1995, ONCOGENE, V11, P825; Taki T, 1996, ONCOGENE, V13, P2121; TAMANOI F, 1988, BIOCHIM BIOPHYS ACTA, V948, P1, DOI 10.1016/0304-419X(88)90002-9; Tanabe S, 1996, GENE CHROMOSOME CANC, V15, P206, DOI 10.1002/(SICI)1098-2264(199604)15:4<206::AID-GCC2>3.0.CO;2-5; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THORBURN A, 1993, J BIOL CHEM, V268, P2244; TOCQUE B, 1997, IN PRESS CELL SIGNAL; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Treisman R, 1990, Semin Cancer Biol, V1, P47; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Williams Lewis T., 1992, Current Biology, V2, P601, DOI 10.1016/0960-9822(92)90169-B; Winkler DG, 1997, J BIOL CHEM, V272, P24402, DOI 10.1074/jbc.272.39.24402; Wittinghofer A, 1997, FEBS LETT, V410, P63, DOI 10.1016/S0014-5793(97)00321-9; Wolthuis RMF, 1996, ONCOGENE, V13, P353; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YAN MH, 1994, NATURE, V372, P798; Yan ZF, 1997, J BIOL CHEM, V272, P27902, DOI 10.1074/jbc.272.44.27902; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YODERHILL J, 1995, J BIOL CHEM, V270, P27615, DOI 10.1074/jbc.270.46.27615; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zimmermann S, 1997, ONCOGENE, V15, P1503, DOI 10.1038/sj.onc.1201322	254	869	895	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1395	1413		10.1038/sj.onc.1202174	http://dx.doi.org/10.1038/sj.onc.1202174			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779987				2022-12-28	WOS:000076161900008
J	Theis, S; Roemer, K				Theis, S; Roemer, K			c-Abl tyrosine kinase can mediate tumor cell apoptosis independently of the Rb and p53 tumor suppressors	ONCOGENE			English	Article						programmed cell death; tyrosine kinase; c-Abl; p53; retinoblastoma	RNA-POLYMERASE-II; RETINOBLASTOMA PROTEIN FUNCTION; TERMINAL REPEATED DOMAIN; GENE-PRODUCT; DNA-DAMAGE; BINDING; GROWTH; PHOSPHORYLATION; CYCLE; ONCOPROTEIN	Tumor cells frequently lack the p53 tumor suppressor because p53 mediates apoptosis in these cells. We report here that c-Abl, and to a greater extent a c-Abl mutant defective for DNA-binding, can provoke programmed cell death in p53-deficient tumor cells. Tyrosine kinase mutant K290R is less cytotoxic, In contrast, a C-terminal deletion mutant that lacks the RNA polymerase II (PolII)/actin interaction domain, fails to mediate apoptosis unless expressed to very high levels. Cytotoxicity is overcome by coexpression of the apoptosis antagonist E1B 19K protein, and partially overcome by full-length retinoblastoma protein (Rb) or the C pocket fragment of Rb (SE Delta) that associates with c-Abl, c-Abl is also highly toxic to Saos-2 cells that are deficient for both Rb and p53, indicating that cell death is not the result of inhibition through c-Abl of the anti-apoptotic function of Rb. Finally, p53 and c-Abl combined induce apoptosis stronger than either protein alone. Unlike Abl-mediated cell death, apoptosis by p53 is antagonized efficiently only by full-length Rb with intact A/B pocket but not by SE Delta. Mutant p53 inhibits apoptosis by p53 but not c-Abl, Thus, c-Abl with intact kinase and PolIII actin-binding domains can affect tumor cell survival independently of Rb and p53.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany	Saarland University	Roemer, K (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.							Baskaran R, 1996, MOL CELL BIOL, V16, P3361; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GOGA A, 1995, ONCOGENE, V11, P791; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; MIYASHITA T, 1995, CELL, V80, P293; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Roemer K, 1996, ONCOGENE, V12, P2069; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THEIS S, 1997, INT J CANCER, V72, P1; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	40	20	20	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					557	564		10.1038/sj.onc.1201973	http://dx.doi.org/10.1038/sj.onc.1201973			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704921				2022-12-28	WOS:000075195300003
J	Wakeman, JA; Walsh, J; Andrews, PW				Wakeman, JA; Walsh, J; Andrews, PW			Human Wnt-13 is developmentally regulated during the differentiation of NTERA-2 pluripotent human embryonal carcinoma cells	ONCOGENE			English	Article						Wnt-13; teratocarcinoma; human; neuron	PROTO-ONCOGENE INT-1; RETINOIC ACID; XENOPUS EMBRYOS; EXPRESSION; GENE; TERATOCARCINOMA; DROSOPHILA; LINES; POLARITY; HOMOLOG	The Wnt gene family encodes a series of conserved glycoproteins that regulate pattern formation during embryogenesis, in a variety of tissues including the nervous system. As with other genes that control embryonic cell differentiation, members of the Wnt family have also been implicated in tumourigenesis, To search for Wnt genes involved in human teratocarcinomas, with a possible role in human embryogenesis, we used RT-PCR primed with degenerate oligonucleotides to analyse mRNA from differentiating cultures of the pluripotent human embryonal carcinoma (EC) cell line NTERA-2, NTERA-2 EC cells differentiate into neurons and other cell types when induced with retinoic acid. Wnt gene expression was not detected in the undifferentiated EC cells, but Wnt-related PCR fragments were amplified from differentiating cultures, 4-14 days after induction with retinoic acid, The RT-PCR products were composed primarily of DNA fragments corresponding to the recently identified human Wnt-13 gene, No other Wnt-related genes were identified. Northern analysis confirmed induction of Wnt-13 as a 2.4 kb mRNA during the early phases of retinoic acid-induced differentiation, and during differentiation along a non-neural pathway induced by hexamethylene bisacetamide (HMBA), but not in the terminally differentiated neurons, Wnt-13 remained expressed in non-neural differentiated NTERA-2 cells, even several weeks after the induction of differentiation. The time course of induction, its induction by HMBA, and its persistence in differentiated cells indicate that Wnt-13 expression is not dependent upon direct activation by retinoic acid. Wnt-13 was not detected, or only detected at low levels, in other human EC cells, However, it was found to be expressed at a high level in one malignant teratoma cell line, 577MF, that does not exhibit an EC phenotype although it was derived from a testicular teratocarcinoma. At least two members of the human frizzled gene family, thought to encode receptors for Wnt proteins, were also expressed in the NTERA-2 cells, suggesting the presence of a mechanism by which endogenously expressed Wnt-13 could modulate the histogenesis of teratocarcinomas by mediating interactions between subpopulations of differentiating EC cells. We note that Wnt-13 maps to chromosome 1p13, a region reported to be subject to relatively frequent loss of heterozygosity in germ cell tumours, Further analysis indicated that 465 bp of the published Wnt-13 sequence, within the predicted 5' UTR, is incorrect and is possibly derived from a human mitochondrial DNA sequence.	Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Andrews, PW (corresponding author), Univ Sheffield, Dept Biomed Sci, Western Bank, Sheffield S10 2TN, S Yorkshire, England.			Wakeman, Jane/0000-0002-7561-634X; Andrews, Peter/0000-0001-7215-4410	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKERMAN SL, 1994, MOL BRAIN RES, V25, P157, DOI 10.1016/0169-328X(94)90293-3; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1980, INT J CANCER, V26, P269, DOI 10.1002/ijc.2910260304; ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; ANDREWS PW, 1984, LAB INVEST, V50, P147; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Andrews PW, 1996, INT J CANCER, V66, P806, DOI 10.1002/(SICI)1097-0215(19960611)66:6<806::AID-IJC17>3.0.CO;2-0; ANDREWS PW, 1997, IN PRESS ACTA PATH M; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HUGUET EL, 1994, CANCER RES, V54, P2615; Katoh M, 1996, ONCOGENE, V13, P873; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MATHEW S, 1994, CANCER RES, V54, P6265; MATTHAEI KI, 1983, EXP CELL RES, V143, P471, DOI 10.1016/0014-4827(83)90076-9; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MILLER JM, 1996, GENE DEV, V10, P257; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PARR BA, 1993, DEVELOPMENT, V119, P247; PATTILLO RA, 1971, IN VITRO CELL DEV B, V6, P398; PATTILLO RA, 1968, CANCER RES, V28, P1231; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; RAMAKRISHNA NR, 1993, DEVELOPMENT S, V119, P95; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; Vider BZ, 1996, ONCOGENE, V12, P153; Wang YS, 1996, J BIOL CHEM, V271, P4468; WOLDA SL, 1992, ONCOGENE, V7, P1941; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZHAO ZY, 1995, GENOMICS, V27, P370, DOI 10.1006/geno.1995.1060	45	27	29	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					179	186		10.1038/sj.onc.1201942	http://dx.doi.org/10.1038/sj.onc.1201942			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674702				2022-12-28	WOS:000074706700006
J	Vallian, S; Gaken, JA; Gingold, EB; Kouzarides, T; Chang, KS; Farzaneh, F				Vallian, S; Gaken, JA; Gingold, EB; Kouzarides, T; Chang, KS; Farzaneh, F			Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein	ONCOGENE			English	Article						AP-1; PML; Fos; APL; transcription	RETINOIC ACID RECEPTOR; PML-RAR-ALPHA; CBP-INDUCED STIMULATION; C-FOS; DNA-BINDING; IN-VITRO; ACTIVATION DOMAIN; NUCLEAR RECEPTORS; JUN; GENE	The growth and transformation suppressor function of promyelocytic leukemia (PML) protein are disrupted in acute promyelocytic leukemia (APL) as a result of its fusion to the RAR alpha gene by t(15;17) translocation. There is significant sequence homology between the dimerization domain of PML and the Fos family of proteins, which imply that PML may be involved in AP-1 activity. Here we show that PML can cooperate with Fos to stimulate its AP-1-mediated transcriptional activity. Cotransfection of PML with GAL4/Fos strongly induced Fos-mediated activation of GAL4-responsive reporters, indicating a functional interaction between Fos and PML in vivo. Deletion analysis of Fos and PML demonstrated that the intact C-terminal domain of Fos (containing the dimerization domain), and the RING-finger, B1 box and nuclear localization domains of PML are involved in the cooperative activity of Fos and PML. Immunoprecipitation and electrophoretic mobility shift assay showed that PML is associated with the AP-1 complex. PMLRAR alpha was also found to enhance the transcriptional activity of GAL4/Fos. The addition of retinoic acid abrogated the PMLRAR alpha, but not PML-induced stimulation of GAL4/Fos activity in a dose-dependent manner. This study demonstrated that PML is involved in the AP-1 complex and can modulate Fos-mediated transcriptional activity, which may contribute to its growth suppressor function.	Univ Texas, MD Anderson Cancer Ctr, Div Lab Med, Houston, TX 77030 USA; Univ London Kings Coll, Sch Med & Dent, Dept Mol Med, London SE5 9NU, England; Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England	University of Texas System; UTMD Anderson Cancer Center; University of London; King's College London; University of Cambridge	Chang, KS (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Div Lab Med, Houston, TX 77030 USA.		Farzaneh, Farzin/B-4902-2009; Vallian, Sadeq/AAA-7085-2020	Farzaneh, Farzin/0000-0002-9275-2415; Vallian, Sadeq/0000-0002-5151-5923; Kouzarides, Tony/0000-0002-8918-4162	NATIONAL CANCER INSTITUTE [R01CA055577] Funding Source: NIH RePORTER; NCI NIH HHS [CA55577] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; Boddy MN, 1996, ONCOGENE, V13, P971; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CURRAN T, 1996, ONCOGENE, V9, P675; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1996, BBA-REV CANCER, V1288, pM25, DOI 10.1016/S0304-419X(96)00028-5; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; He DL, 1997, CANCER RES, V57, P1868; HIRAI SI, 1990, ONCOGENE, V5, P39; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KOLLA SS, 1993, J CELL PHYSIOL, V156, P63, DOI 10.1002/jcp.1041560110; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Sambrook J., 1989, MOL CLONING LAB MANU, P655; Stadler M, 1995, ONCOGENE, V11, P2565; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANG-YEN H-F, 1990, New Biologist, V2, P351; Yoshida H, 1996, CANCER RES, V56, P2945	53	44	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2843	2853		10.1038/sj.onc.1201837	http://dx.doi.org/10.1038/sj.onc.1201837			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671405				2022-12-28	WOS:000073988200003
J	Mills, JJ; Falls, JG; De Souza, AT; Jirtle, RL				Mills, JJ; Falls, JG; De Souza, AT; Jirtle, RL			Imprinted M6p/Igf2 receptor is mutated in rat liver tumors	ONCOGENE			English	Article						M6p/Igf2r; genomic imprinting; liver cancer; tumor suppressor	FACTOR-II RECEPTOR; FACTOR TYPE-2 RECEPTOR; GROWTH-FACTOR-BETA; MOUSE; GENE; LOCUS; IGF2R; HETEROZYGOSITY; BINDING	We have previously shown that inactivation of mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/ IGF2R) is a common early event in both human liver and breast carcinogenesis. The M6p/Igf2r is imprinted in mice while expression is biallelic in most humans. In this investigation the M6p/Igf2r gene is shown to also be imprinted in the liver of Fischer 344, Lewis and Brown Norway rats. In addition, we have identified mutations in the expressed allele of the M6p/Igf2r in 40% of diethylnitrosamine-initiated rat liver tumors. These results provide further evidence that the M6P/IGF2R functions as a liver tumor suppressor gene. They also suggest that mice and rats would be more sensitive than humans to those hepatocarcinogens in which the M6p/ Igf2r is mechanistically involved in transformation since one rather than two alleles would need to be inactivated.	Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Zeneca Pharmaceut, Dept Safety Med, Macclesfield SK10 4TG, Cheshire, England	Duke University	Jirtle, RL (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA.			Mills, Jeremy James/0000-0003-1719-9047	NATIONAL CANCER INSTITUTE [R01CA025951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008823] Funding Source: NIH RePORTER; NCI NIH HHS [CA25951] Funding Source: Medline; NIEHS NIH HHS [ES08823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Dahms NM, 1996, BIOCHEM SOC T, V24, P136, DOI 10.1042/bst0240136; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167; Franklin GC, 1996, PLACENTA, V17, P3, DOI 10.1016/S0143-4004(05)80638-1; Hankins GR, 1996, ONCOGENE, V12, P2003; HASEMAN JK, 1987, ENVIRON HEALTH PERSP, V74, P229, DOI 10.2307/3430453; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; MILLS JJ, 1995, LIVER REGENERATION C, P199; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Moser GJ, 1996, CARCINOGENESIS, V17, P1835, DOI 10.1093/carcin/17.9.1835; Ouyang H, 1997, CANCER RES, V57, P1851; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SZEBENYI G, 1994, GENOMICS, V19, P120, DOI 10.1006/geno.1994.1021; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351	25	46	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2797	2802		10.1038/sj.onc.1201801	http://dx.doi.org/10.1038/sj.onc.1201801			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652747	Green Submitted			2022-12-28	WOS:000073812200012
J	Schafer, H; Trauzold, A; Sebens, T; Deppert, W; Folsch, UR; Schmidt, WE				Schafer, H; Trauzold, A; Sebens, T; Deppert, W; Folsch, UR; Schmidt, WE			The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene	ONCOGENE			English	Article						early response gene; tumor suppressor; transcription factor; growth control	WILD-TYPE P53; NUCLEAR ANTIGEN PROMOTER; TUMOR-SUPPRESSOR P53; CARCINOMA CELL-LINE; ADENYLATE-CYCLASE; DNA-BINDING; MUTANT P53; GROWTH ARREST; BAX GENE; APOPTOSIS	The novel early response gene p22/PRG1 is linked to cell cycle entry and the induction of proliferation in various cell types although its exact function is still unknown. The p22/PRG1 promoter region contains a 20 bp sequence matching the consensus binding motif for the tumor suppressor protein p53, Gel shift assays demonstrated that p53 specifically binds to an oligonucleotide derived from the p53 binding site of the p22/PRG1 promoter. Chloramphenicol acetyltransferase (CAT) reporter gene assays confirmed that this site confers p53-dependent transcriptional activity to the p22/PRG1 promoter. In Hela cells, p22/PRG1 promoter constructs induced CAT expression only when cotransfected with an expression plasmid for wild-type, but not for mutant p53, Similarly, CAT expression was inducible at the permissive (31 degrees C) but not at the non-permissive temperature (39 degrees C) in the rat embryo fibroblast-derived cell line clone-6 that expresses a temperature-sensitive mutant p53, Conversion of this mutant p53 to a functional p53 at the permissive temperature was accompanied by a significant increase of endogenous p22/PRG1 mRNA level in this cell line. gamma-irradiation of rat splenocytes or doxorubicin-treatment of Hela cells increased p53 levels followed by transcriptional activation of p22/PRG1 and p21/Waf1 in parallel. Our data demonstrate that p22/PRG1 transcription is induced by p53 during p53-dependent cell cycle arrest and apoptosis, Therefore, p22/PRG1 represents a novel target for transcriptional activation by p53.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany	University of Kiel; Heinrich Pette Institute; University of Hamburg	Schmidt, WE (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, Schittenhelmstr 12, D-24105 Kiel, Germany.		Schäfer, Heiner/C-1055-2011; Trauzold, Anna/P-4398-2014					ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BAE IS, 1995, CANCER RES, V55, P2387; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; BUSCAIL L, 1992, GASTROENTEROLOGY, V103, P1002, DOI 10.1016/0016-5085(92)90035-W; CHARLES CH, 1993, ONCOGENE, V8, P797; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1988, ONCOGENE, V3, P313; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GISH WR, 1987, J VIROL, V61, P2864, DOI 10.1128/JVI.61.9.2864-2876.1987; Hecker D, 1996, ONCOGENE, V12, P953; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Knippschild U, 1996, ONCOGENE, V12, P1755; Kondratyev AD, 1996, CANCER RES, V56, P1498; KRUISBEEK AM, 1993, CURRENT PROTOCOLS IM, V1; LING YH, 1993, CANCER RES, V53, P1845; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Molinari M, 1996, ONCOGENE, V13, P2077; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; SAITO Y, 1995, ONCOGENE, V11, P1013; Schafer H, 1996, CANCER RES, V56, P2641; Schafer H, 1996, BIOCHEM BIOPH RES CO, V221, P111, DOI 10.1006/bbrc.1996.0554; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6148; SEKI H, 1994, EUR J IMMUNOL, V24, P2914, DOI 10.1002/eji.1830241150; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TISHLER RB, 1993, CANCER RES, V53, P2212; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZERRAHN J, 1992, ONCOGENE, V7, P1371	48	38	38	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2479	2487		10.1038/sj.onc.1201788	http://dx.doi.org/10.1038/sj.onc.1201788			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627114				2022-12-28	WOS:000073672300006
J	Kubota, S; Pomerantz, RJ				Kubota, S; Pomerantz, RJ			A cis-acting peptide signal in human immunodeficiency virus type I Rev which inhibits nuclear entry of small proteins	ONCOGENE			English	Article						Rev; HIV-1; nucleus; entry; transport	VIRAL MESSENGER-RNA; NUCLEOLAR-TARGETING SIGNAL; NF-KAPPA-B; HIV-1 REV; EXPORT SIGNAL; ACTIVATION DOMAIN; CYTOPLASMIC ACCUMULATION; SEQUENCE REQUIREMENTS; MUTATIONAL ANALYSIS; TRANS-ACTIVATOR	A peptide signal, which may control nucleo-cytoplasmic protein trafficking, was newly identified in human immunodeficiency virus type I (HIV-1) Rev, a lentiviral post-transcriptional transactivator. The sequence, in the amino-terminal portion of HIV-1 Rev, maintains a Rev mutant with a dysfunctional nuclear/nucleolar targeting signal outside of the nucleus, although this Rev molecule itself is small enough to pass through the nuclear pores. Transition of this sequence to the N-terminus of human T-lymphocytic leukemia/lymphoma virus type I (HTLV-I) p21(x), which is usually located evenly distributed throughout the cell, resulted in capture of p21(x) in the cytoplasm. Mutational analysis clarified that a 14 residue peptide sequence was sufficient to display this inhibitory effect against nuclear entry. Furthermore, this HIV-1 Rev sequence was capable of inhibiting nuclear entry of a fragment of a human ribosomal protein, when it was fused to the carboxy terminus. The identified nuclear entry inhibitory signal (NIS) contains a conserved hydrophilicity motif, which forms an amphipathic helix. Significantly, this motif and its helical structure were shown to be important for NIS function and the HIV-1 Rev function itself. Possible roles for NIS as a molecular anchor are proposed herein.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Labs, Div Infect Dis,Ctr Human Virol, Philadelphia, PA 19107 USA	Jefferson University	Pomerantz, RJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Labs, Div Infect Dis,Ctr Human Virol, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036552, R01AI031836] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31836, AI36552] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; AUER M, 1994, BIOCHEMISTRY-US, V33, P2988, DOI 10.1021/bi00176a031; BERGER J, 1991, VIROLOGY, V183, P630, DOI 10.1016/0042-6822(91)90992-K; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; DALY TJ, 1995, J MOL BIOL, V253, P243, DOI 10.1006/jmbi.1995.0549; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; FURUKAWA K, 1991, FEBS LETT, V295, P141, DOI 10.1016/0014-5793(91)81404-V; FURUTA RA, 1995, J VIROL, V69, P1591, DOI 10.1128/JVI.69.3.1591-1599.1995; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Goldfarb DS, 1997, SCIENCE, V276, P1814, DOI 10.1126/science.276.5320.1814; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KAISER ET, 1987, ANNU REV BIOPHYS BIO, V16, P561; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUBOTA S, 1992, J VIROL, V66, P2510, DOI 10.1128/JVI.66.4.2510-2513.1992; Kubota S, 1996, VIROLOGY, V220, P502, DOI 10.1006/viro.1996.0339; KUBOTA S, 1991, J VIROL, V65, P2452, DOI 10.1128/JVI.65.5.2452-2456.1991; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; KUBOTA S, 1995, EUR J BIOCHEM, V233, P48, DOI 10.1111/j.1432-1033.1995.048_1.x; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LI ML, 1991, GENE, V107, P329, DOI 10.1016/0378-1119(91)90335-9; MADORE SJ, 1994, VIROLOGY, V202, P186, DOI 10.1006/viro.1994.1334; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MICHAEL WM, 1995, CELL, V83, P415; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; ORITA S, 1991, FEBS LETT, V295, P127, DOI 10.1016/0014-5793(91)81402-T; Palmeri D, 1996, J VIROL, V70, P6442, DOI 10.1128/JVI.70.9.6442-6445.1996; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; POMERANTZ RJ, 1992, J VIROL, V66, P1809, DOI 10.1128/JVI.66.3.1809-1813.1992; RICHARD N, 1994, VIROLOGY, V204, P123, DOI 10.1006/viro.1994.1516; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SCHMIDT C, 1995, MOL BIOL CELL, V6, P1875, DOI 10.1091/mbc.6.12.1875; SCHWARZ E, 1994, BBA-BIOENERGETICS, V1187, P270, DOI 10.1016/0005-2728(94)90125-2; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Szilvay AM, 1997, VIROLOGY, V235, P73, DOI 10.1006/viro.1997.8671; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEN W, 1994, J BIOL CHEM, V269, P32214; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	68	20	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1851	1861		10.1038/sj.onc.1201738	http://dx.doi.org/10.1038/sj.onc.1201738			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583682				2022-12-28	WOS:000072994600008
J	Janssen, JWG; Schleithoff, L; Bartram, CR; Schulz, AS				Janssen, JWG; Schleithoff, L; Bartram, CR; Schulz, AS			An oncogenic fusion product of the phosphatidylinositol 3-kinase p85 beta subunit and HUMORF8, a putative deubiquitinating enzyme	ONCOGENE			English	Article						p85 beta; phosphatidylinositol 3-kinase; HUMORF8; deubiquitinating enzyme	EXPRESSION CDNA CLONING; NUCLEOTIDE EXCHANGE FACTORS; HUMAN MYELOID-LEUKEMIA; GTP-BINDING PROTEINS; T-CELL ACTIVATION; TRANSFORMING GENE; MOLECULAR-CLONING; P85 SUBUNIT; TYROSINE KINASE; PHOSPHOINOSITIDE 3-KINASE	Peripheral blood cell DNA from a patient with a chronic myeloproliferative disorder was tested in the tumorigenicity assay. Upon tumor induction in nude mice we isolated a human oncogene by means of genomic cloning, exon trap analysis and cDNA cloning. Sequence analysis revealed a fusion product of the p85 beta subunit of phosphatidylinositol (PI) 3-kinase and HUMORF8, a putative deubiquitinating enzyme, which has been generated during the DNA transfection process. Application of the tumorigenicity assay to various p85 beta and HUMORF8 cDNA constructs indicated that the recombination of both genes rather than the truncation of one of the fusion partners renders the chimeric protein tumorigenic. Moreover, sequence analysis of human wildtype p85 beta revealed an alanine for serine substitution at a site important for the regulation of the Lipid kinase activity of PI 3-kinase in human p85 alpha. This variation may relate to differences in the mode of signal transduction from both p85 isoforms.	Univ Heidelberg, Inst Humangenet, D-69120 Heidelberg, Germany; Univ Ulm, Kinderklin, D-89075 Ulm, Germany	Ruprecht Karls University Heidelberg; Ulm University	Janssen, JWG (corresponding author), Univ Heidelberg, Inst Humangenet, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.							AUCH D, 1990, NUCLEIC ACIDS RES, V18, P6743, DOI 10.1093/nar/18.22.6743; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; CHAN AML, 1993, ONCOGENE, V8, P1329; Chan AML, 1996, ONCOGENE, V12, P1259; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHAN AML, 1994, ONCOGENE, V9, P1057; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUPTA K, 1994, ONCOGENE, V9, P1729; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HEMMINGS A, 1997, SCIENCE, V275, P1899; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JANSSEN JWG, 1985, CANCER RES, V45, P3262; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Klippel A, 1996, MOL CELL BIOL, V16, P4117; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LORENZI MV, 1995, ONCOGENE, V10, P2051; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OCHIYA T, 1986, P NATL ACAD SCI USA, V83, P4993, DOI 10.1073/pnas.83.14.4993; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PONS S, 1995, MOL CELL BIOL, V15, P4453; REIF K, 1993, J BIOL CHEM, V268, P10780; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; Susa M, 1996, BIOCHEM BIOPH RES CO, V220, P729, DOI 10.1006/bbrc.1996.0472; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKSOZ D, 1994, ONCOGENE, V9, P621; VOGELSTEIN B, 1987, ANAL BIOCHEM, V160, P115, DOI 10.1016/0003-2697(87)90620-8; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WANG SM, 1993, ONCOGENE, V8, P1009; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YANG SS, 1990, CANCER RES, V50, pS5658; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	64	36	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1767	1772		10.1038/sj.onc.1201695	http://dx.doi.org/10.1038/sj.onc.1201695			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582025				2022-12-28	WOS:000072807600015
J	Zhang, HB; Somasundaram, K; Peng, Y; Tian, H; Zhang, HX; Bi, DK; Weber, BL; El-Deiry, WS				Zhang, HB; Somasundaram, K; Peng, Y; Tian, H; Zhang, HX; Bi, DK; Weber, BL; El-Deiry, WS			BRCA1 physically associates with p53 and stimulates its transcriptional activity	ONCOGENE			English	Article						BRCA1; p53; p21WAF1/CIP1; bax; transcription; apoptosis; breast cancer	SUPPRESSOR GENE BRCA1; BREAST-CANCER; DNA-DAMAGE; TUMOR; ACTIVATION; APOPTOSIS; GROWTH; CELLS; PROGRESSION; EXPRESSION	Mutations of the BRCA1 tumor suppressor gene are the most commonly detected alterations in familial breast and ovarian cancer, Although BRCA1 is required for normal mouse development, the molecular basis for its tumor suppressive function remains poorly understood, We show here that BRCA1 increases p53-dependent transcription from the p21(WAF1/CIP1) and bas promoters. We also show that BRCA1 and p53 proteins interact both in vitro and in vivo. The interacting regions map, in vitro, to aa 224-500 of BRCA1 and the C-terminal domain of p53, Tumor-derived transactivation-deficient BRCA1 mutants are defective in co-activation of p53-dependent transcription and a truncation mutant of BRCA1 that retains the p53-interacting region acts as a dominant inhibitor of p53-dependent transcription, BRCA1 and p53 cooperatively induce apoptosis of cancer cells, The results indicate that BRCA1 and p53 may coordinately regulate gene expression in their role as tumor suppressors.	Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NCI NIH HHS [CA57601] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057601] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blagosklonny MV, 1997, INT J ONCOL, V11, P1165; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; COUCH FJ, 1994, HUM MUTAT, V8, P8; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARCUS NJ, 1997, CANCER, V80, P543; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; McDonald E, 1996, CANCER RES, V56, P2250; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Rao VN, 1996, ONCOGENE, V12, P523; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; Tashiro S, 1996, ONCOGENE, V12, P2165; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	37	403	413	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1713	1721		10.1038/sj.onc.1201932	http://dx.doi.org/10.1038/sj.onc.1201932			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582019				2022-12-28	WOS:000072807600009
J	Stoll, SW; Benedict, M; Mitra, R; Hiniker, A; Elder, JT; Nunez, G				Stoll, SW; Benedict, M; Mitra, R; Hiniker, A; Elder, JT; Nunez, G			EGF receptor signaling inhibits keratinocyte apoptosis: evidence for mediation by Bcl-X-L	ONCOGENE			English	Article						apoptosis; EGF receptor; Bcl-X-L; keratinocytes; signal transduction	EPIDERMAL GROWTH-FACTOR; MAMMARY EPITHELIAL-CELLS; TYROSINE KINASE; MONOCLONAL-ANTIBODY; AUTO-INDUCTION; FACTOR-ALPHA; EXPRESSION; BINDING; ERYTHROPOIETIN; INSULIN	Signaling through the epidermal growth factor receptor (EGFR) has been primarily implicated in the growth of epithelial cells including keratinocytes. However, the mechanism by which EGFR stimulation promotes keratinocyte cell growth is poorly understood, Here we report that human keratinocytes undergo apoptosis when incubated with the blocking EGFR monoclonal antibody 225 IgG, or PD153035, a highly specific EGFR tyrosine kinase inhibitor, Endogenous mRNA and protein levels of Bcl-X-L, a member the Bcl-2 family which suppresses apoptosis, were specifically inhibited by EGFR blockade, Furthermore, stimulation of EGFR signaling through two natural ligands, transforming growth factor (TGF)-alpha and epidermal growth factor (EGF), increased the expression of Bcl-X-L in quiescent keratinocytes and HaCaT cells, Finally, ectopic expression of Bcl-X-L in HaCaT cells increased survival after EGFR blockade when compared to untransfected cells or HaCaT keratinocytes transfected with empty vector. These results suggest that the anti-apoptotic protein Bcl-X-L plays an important role in the maintenance of keratinocyte survival in response to EGFR signaling.	Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014		NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042248, R29AR040016] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline; NIAMS NIH HHS [R29 AR40016, R01 AR 42248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOYER SH, 1992, BLOOD, V80, P2503; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; DANILENKO DM, 1995, J CLIN INVEST, V95, P842, DOI 10.1172/JCI117734; Elder J T, 1995, Adv Dermatol, V10, P99; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; ELDER JT, 1990, J INVEST DERMATOL, V94, P19, DOI 10.1111/1523-1747.ep12873313; ELDER JT, 1994, EPIDERMAL GROWTH FAC, P205; EVAN GI, 1996, APOPTOSIS CELL CYCLE; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fry DW, 1997, BIOCHEM PHARMACOL, V54, P877, DOI 10.1016/S0006-2952(97)00242-6; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTLIEB AB, 1992, J INVEST DERMATOL, V98, P302, DOI 10.1111/1523-1747.ep12499782; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HEBDA PA, 1988, J INVEST DERMATOL, V91, P440, DOI 10.1111/1523-1747.ep12476480; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KLEIN SB, 1992, J CELL PHYSIOL, V151, P326, DOI 10.1002/jcp.1041510214; KOBRIN MS, 1994, BIOCHEM BIOPH RES CO, V202, P1705, DOI 10.1006/bbrc.1994.2131; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Mitra RS, 1997, LAB INVEST, V76, P99; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Naef M, 1996, INT J CANCER, V66, P315; NANNEY LB, 1986, J INVEST DERMATOL, V86, P260, DOI 10.1111/1523-1747.ep12285389; Nass SJ, 1996, BIOCHEM BIOPH RES CO, V227, P248, DOI 10.1006/bbrc.1996.1497; NICKOLOFF BJ, 1989, BRIT J DERMATOL, V121, P161, DOI 10.1111/j.1365-2133.1989.tb01795.x; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PORTA DG, 1997, EMBO J, V16, P1647; POUMAY Y, 1995, J INVEST DERMATOL, V104, P574; RACHWAL WJ, 1995, BRIT J CANCER, V72, P56, DOI 10.1038/bjc.1995.277; Ram TG, 1996, MOL CARCINOGEN, V15, P227, DOI 10.1002/(SICI)1098-2744(199603)15:3<227::AID-MC8>3.0.CO;2-E; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rodeck U, 1997, J CELL SCI, V110, P113; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Stoll S, 1997, J CLIN INVEST, V100, P1271, DOI 10.1172/JCI119641; STOSCHECK CM, 1992, J INVEST DERMATOL, V99, P645, DOI 10.1111/1523-1747.ep12668143; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WENCZAK BA, 1992, J CLIN INVEST, V90, P2392, DOI 10.1172/JCI116130; WRONESMITH T, 1995, AM J PATHOL, V146, P1079; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Xian WJ, 1997, ONCOGENE, V14, P1435, DOI 10.1038/sj.onc.1200980; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	60	107	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	1998	16	11					1493	1499		10.1038/sj.onc.1201657	http://dx.doi.org/10.1038/sj.onc.1201657			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9580112				2022-12-28	WOS:000072572400013
J	Rosel, M; Claas, C; Seiter, S; Herlevsen, M; Zoller, M				Rosel, M; Claas, C; Seiter, S; Herlevsen, M; Zoller, M			Cloning and functional characterization of a new phosphatidyl-inositol anchored molecule of a metastasizing rat pancreatic tumor	ONCOGENE			English	Article						rat; metastasis; phosphatidyl-inositol anchor; matrix degradation	UROKINASE PLASMINOGEN-ACTIVATOR; CELL-SURFACE RECEPTOR; COLON-CARCINOMA CELLS; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; CANCER METASTASIS; GLYCOSYL-PHOSPHATIDYLINOSITOL; SIGNAL TRANSDUCTION; LAMININ DEGRADATION; ADHESION MOLECULES	We have described recently a panel of metastasis-associated antigens expressed on a rat pancreatic tumor. One of these molecules, recognized by the monoclonal antibody C4.4 and named accordingly C4.4A, was under physiological conditions expressed only in the gravid uterus and on epithelial of the upper gastrointestinal tract. The cDNA of the antigen has been isolated and cloned. The 1,637 b cDNA codes for a 352 amino acid long glycosylphosphatidy-inositol (GP) anchored molecule, whose molecular weight varies in different cells between 94-98 kD according to the degree of N- and O-glycosylation. Data base searches have revealed a low degree of homology to the receptor for the plasminogen activator (uPAR). After intrafootpad and intravenous application of C4.4A transfected and mocktransfected tumor cells, an increased number of lung nodules was detected with the former, whereby the individual metastatic nodules amalgamated without any encapsulation of the tumor tissue. Furthermore, C4.4A is involved in adhesion to laminin and, although transfection of a non-metastasizing tumor line with the molecule was not sufficient, constitutively C4.4A-positive tumor cells penetrated through matrigel. This process could be completely prevented by C4.4. Finally, we could demonstrate that uPA, albeit weakly, bound to the C4.4A molecule. In view of the observed influence of C4.4A on metastasis formation and matrix penetration it is tempting to speculate that this newly described metastasis-associated molecule may exert functional activity similar to the uPAR, i.e. via activation of matrix degrading enzymes. By the very restricted expression of the molecule in the adult organism, modulation of C4.4A could well be of therapeutic interest.	German Canc Res Ctr, Dept Tumor Progress & Immune Def, D-69120 Heidelberg, Germany; Univ Karlsruhe, Dept Appl Genet, D-78000 Karlsruhe, Germany; Univ Hosp, Dept Dermatol, D-66424 Homburg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology; Universitatsklinikum des Saarlandes	Zoller, M (corresponding author), German Canc Res Ctr, Dept Tumor Progress & Immune Def, D-69120 Heidelberg, Germany.							Anderson R G, 1994, Semin Immunol, V6, P89, DOI 10.1006/smim.1994.1013; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BEHRENS J, 1993, BREAST CANCER RES TR, V24, P175, DOI 10.1007/BF01833258; BERGSAGEL PL, 1992, J IMMUNOL, V148, P590; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BURGLE M, 1997, BIOL CHEM, V378, P3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claas C, 1996, CELL GROWTH DIFFER, V7, P663; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; COOK RG, 1992, CELL IMMUNOL, V144, P367, DOI 10.1016/0008-8749(92)90252-K; CRAWFORD HC, 1994, INVAS METAST, V14, P234; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Dasgupta A, 1996, BIOCHEM BIOPH RES CO, V227, P110, DOI 10.1006/bbrc.1996.1475; De Clerck Yves A., 1993, P121; DeClerck YA, 1996, ENZYME PROTEIN, V49, P72, DOI 10.1159/000468617; DIMANCHEBOITREL MT, 1994, INT J CANCER, V56, P512, DOI 10.1002/ijc.2910560410; DURLIAT M, 1992, BRIT J CANCER, V66, P51, DOI 10.1038/bjc.1992.215; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; EVANS CW, 1992, CELL BIOL INT REP, V16, P1, DOI 10.1016/S0309-1651(06)80150-5; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; FERGUSON RM, 1988, CLIN TRANSPLANT, V2, P285; FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GLINSKY GV, 1993, CRIT REV ONCOL HEMAT, V14, P229, DOI 10.1016/1040-8428(93)90011-R; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUBE M, 1994, EUR J IMMUNOL, V24, P731; Jardi M, 1996, THROMB HAEMOSTASIS, V76, P1009; Jones PH, 1996, CELL ADHES COMMUN, V4, P297, DOI 10.3109/15419069609010773; KHOKHA R, 1993, J NEUROONCOL, V18, P123; KO YG, 1995, ANAL BIOCHEM, V224, P166, DOI 10.1006/abio.1995.1024; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LIOTTA LA, 1983, LAB INVEST, V49, P636; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Malek T R, 1994, Semin Immunol, V6, P105, DOI 10.1006/smim.1994.1015; Mareel M. M., 1991, MECH INVASION METAST; MAREEL MM, 1993, CRIT REV ONCOGENESIS, V4, P559; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATZKU S, 1983, INVAS METAST, V3, P109; MATZKU S, 1989, CANCER RES, V49, P1294; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOLLER LB, 1993, BLOOD COAGUL FIBRIN, V4, P293; MOLLER LB, 1992, FEBS LETT, V301, P493; MORGAN BP, 1993, EUR J IMMUNOL, V23, P2841, DOI 10.1002/eji.1830231118; Nagase H, 1997, BIOL CHEM, V378, P151; NazihSanderson F, 1997, BBA-LIPID LIPID MET, V1346, P45, DOI 10.1016/S0005-2760(97)00017-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OSSOWSKI L, 1992, CANCER RES, V52, P6754; PLOUG M, 1991, J BIOL CHEM, V266, P1926; REISSER D, 1993, INT J CANCER, V53, P651, DOI 10.1002/ijc.2910530421; Resta R, 1997, CELL SIGNAL, V9, P131, DOI 10.1016/S0898-6568(96)00132-5; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLECHTE JW, 1990, CANCER COMMUN, V2, P261, DOI 10.3727/095535490820874245; SCHLECHTE W, 1989, CANCER RES, V49, P6064; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SOLBERG H, 1992, EUR J BIOCHEM, V205, P451, DOI 10.1111/j.1432-1033.1992.tb16799.x; SORDAT BC, 1995, INVAS METAST, V14, P223; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Strohmeier GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447; SUH TT, 1994, J BIOL CHEM, V269, P25992; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRYGVASSON K, 1989, INFLUENCE TUMOR DEV, P72; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; ZOLLER M, 1978, BRIT J CANCER, V37, P61, DOI 10.1038/bjc.1978.9; ZOLLER M, 1992, J NUCL MED, V33, P1366; Zoller M, 1996, CURR TOP MICROBIOL, V213, P215	76	53	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1989	2002		10.1038/sj.onc.1202079	http://dx.doi.org/10.1038/sj.onc.1202079			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788443				2022-12-28	WOS:000076423500013
J	Dhanasekaran, N				Dhanasekaran, N			Cell signaling: An overview	ONCOGENE			English	Editorial Material						signal transduction; receptors; G proteins; GTPases; kinases; oncogenes			Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.								0	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1329	1330		10.1038/sj.onc.1202170	http://dx.doi.org/10.1038/sj.onc.1202170			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779980				2022-12-28	WOS:000076161900001
J	Mandal, M; Adam, L; Mendelsohn, J; Kumar, R				Mandal, M; Adam, L; Mendelsohn, J; Kumar, R			Nuclear targeting of Bax during apoptosis in human colorectal cancer cells	ONCOGENE			English	Article						apoptosis; Bax; colorectal cancer; growth; factor receptor	EPIDERMAL GROWTH-FACTOR; RECEPTOR MONOCLONAL-ANTIBODY; BUTYRATE-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; IN-VIVO PATTERNS; WILD-TYPE P53; FACTOR-ALPHA; HUMAN-COLON; ENDOPLASMIC-RETICULUM; CARCINOMA CELLS	Homeostasis in colonic epithelial cells is regulated by the balance between proliferative activity and cell loss by apoptosis. Because epithelial cells at the apex of colonic crypts undergo apoptosis and proliferative activity is usually restricted to the base of the crypts, it has been proposed that the limited availability of growth factor-signals at the upper portions of the crypts may trigger apoptosis. In the present studies, we investigate the mechanism of apoptosis mediated by growth factor deprivation in colorectal carcinoma cells by delineating the possible involvement of Bax and its subcellular localization. We report that inhibition of epidermal growth factor receptor (EGFR) tyrosine kinase activity and downregulation of EGFR by anti-EGFR mAb 225 induces apoptosis in human colorectal carcinoma DiFi and FET cells. Induction of apoptosis was preceded by enhanced expression of newly synthesized Bax protein, and required protein synthesis. In the mAb 225-treated cells, Bax was redistributed from the cytosol to the nucleus and subsequently, to the nuclear membranes. The observed induction of Bax expression by mAb 225 was not associated with p53 induction. However, mAb 225 treatment also triggered relocalization of p53 from the cytosol to a nuclear membrane-bound form. Induction of Bax and its redistribution to the nucleus of DiFi cells during apoptosis was also demonstrated in response to butyrate, a physiological relevant molecule in colonic epithelial cells as it is the principal short-chain fatty acid produced by bacterial fermentation of dietary fiber in colonic epithelium. Using immunofluorescence and confocal microscopy, we observed that Bax is predominantly localized in the cytosol, but during apoptosis it is localized both inside and along the nuclear membrane. Taken together, these findings suggest that apoptosis induced by growth factor-deprivation or butyrate may involve the subcellular redistribution of Bax in human colorectal carcinoma cells.	Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Cell Growth Regulat Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Cell Growth Regulat Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323	NCI NIH HHS [CA65746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065746, U01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATLAS I, 1992, CANCER RES, V52, P3335; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; BEDI A, 1995, CANCER RES, V55, P1811; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BOISE LH, 1993, CELL, V79, P341; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Brattain Michael G., 1994, Current Opinion in Oncology, V6, P77, DOI 10.1097/00001622-199401000-00011; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; COFFEY RJ, 1986, CANCER RES, V46, P1164; COLES HSR, 1993, DEVELOPMENT, V118, P777; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Fabregat I, 1996, FEBS LETT, V384, P14, DOI 10.1016/0014-5793(96)00266-9; FAN Z, 1993, J BIOL CHEM, V268, P21073; GarciaLloret MI, 1996, J CELL PHYSIOL, V167, P324, DOI 10.1002/(SICI)1097-4652(199605)167:2<324::AID-JCP17>3.0.CO;2-7; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; HUANG S, 1992, INT J CANCER, V52, P978, DOI 10.1002/ijc.2910520625; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Krajewska M, 1997, CANCER RES, V57, P1605; Krajewski S, 1997, BLOOD, V89, P3817, DOI 10.1182/blood.V89.10.3817.3817_3817_3825; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; KUMAR R, 1991, Current Opinion in Oncology, V3, P70, DOI 10.1097/00001622-199102000-00011; KUMAR R, 1995, EXP CELL RES, V216, P143, DOI 10.1006/excr.1995.1018; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; LUCIANO AM, 1994, BIOL REPROD, V51, P646, DOI 10.1095/biolreprod51.4.646; MALDEN LT, 1989, INT J CANCER, V43, P380, DOI 10.1002/ijc.2910430305; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; Mandal M, 1997, CARCINOGENESIS, V18, P229, DOI 10.1093/carcin/18.1.229; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAKAJIMA M, 1994, NEUROSCI LETT, V176, P161, DOI 10.1016/0304-3940(94)90072-8; OLIVE M, 1993, IN VITRO CELL DEV-AN, V29A, P239; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Posmantur R, 1997, J NEUROCHEM, V68, P2328; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; UNTAWALE S, 1993, CANCER RES, V53, P1630; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; ZHU YM, 1994, BRIT J CANCER, V69, P468, DOI 10.1038/bjc.1994.85	63	122	127	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					999	1007		10.1038/sj.onc.1202020	http://dx.doi.org/10.1038/sj.onc.1202020			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747879				2022-12-28	WOS:000075560900008
J	Troppmair, J; Hartkamp, J; Rapp, UR				Troppmair, J; Hartkamp, J; Rapp, UR			Activation of NF-Kappa B by oncogenic Raf in HEK 293 cells occurs through autocrine recruitment of the stress kinase cascade	ONCOGENE			English	Article						Raf; stress kinase pathway; NF-Kappa B	TRANSCRIPTION FACTOR; C-JUN; MAMMALIAN-CELLS; TYROSINE KINASE; REQUIRES RAF-1; TRANSFORMATION; EXPRESSION; SITE; PROTEINS; PATHWAY	Raf-l kinase has been implicated in the induction of NF-kappa B activity by serum growth factors, phorbol ester and PTK oncogenes. Here we show that Raf activation of NF-kappa B, as measured in reporter gene assays, occurs indirectly and requires the stress kinase cascade. The stress pathway presumably becomes activated through induction of an autocrine loop by activated Raf (Raf-BXB) as suramin, the tyrphostin AG1478 and a dominant negative mutant of the EGF-R blocked NF-kappa B activation. Raf-BXB synergizes with SAPKs and a dominant negative mutant of SEK significantly reduces activation of NF-kappa B consistent with a role of this signaling pathway in the activation of NF-kappa B.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacher Str 5, D-97078 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837; Hartkamp, Joerg/0000-0002-6863-9228				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FLORY E, 1998, IN PRESS J VIROL; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GARRETT JS, 1984, P NATL ACAD SCI-BIOL, V81, P7466, DOI 10.1073/pnas.81.23.7466; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEE S, 1997, CELL, V88, P213; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIU ZG, 1996, CELL, V87, P567; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; QUI RG, 1995, NATURE, V374, P457; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SCHRECK R, 1997, IN PRESS TRANSCRIPTI; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7070; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	48	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					685	690		10.1038/sj.onc.1201981	http://dx.doi.org/10.1038/sj.onc.1201981			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715269				2022-12-28	WOS:000075337200002
J	Lu, XL; Qu, CK; Shi, ZQ; Feng, GS				Lu, XL; Qu, CK; Shi, ZQ; Feng, GS			Downregulation of platelet-derived growth factor receptor-beta in Shp-2 mutant fibroblast cell lines	ONCOGENE			English	Article						phosphatase; kinase; SH2 domain; signal transduction	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; FACTOR-ALPHA-RECEPTOR; MOTH-EATEN MICE; SIGNAL-TRANSDUCTION; DNA-SYNTHESIS; SH3 DOMAINS; SYP; SH-PTP2; ACTIVATION	The SH2-containing tyrosine phosphatase Shp-2 appears to function downstream of a variety of growth factor receptors and might play a positive role in cell proliferation, Here we report that expression of the beta subunit of platelet-derived growth factor receptor (PDGFR-beta) was specifically downregulated in mutant fibroblasts lacking a functional Shp-2, while the levels of PDGFR-alpha EGFR and IGFIR were not changed, PDGF-stimulated DNA synthesis and extracellular signal regulated kinase (Erk) activation was severely suppressed in mutant cells, RasGAP, that responds to activation of PDGFR-beta but not PDGFR-alpha, was not phosphorylated on tyrosine in mutant cells upon PDGF-treatment, Northern blot analysis failed to detect PDGFR-beta mRNA in mutant cells. The transcription initiation from the PDGFR-beta gene promoter was not significantly changed, but the half-life of its mRNA was shortened in Shp-2 mutant cells. These observations indicate that Shp-2 not only participates in transmission of signals from growth factor receptors but also plays a specific role in the control of the PDGFR-beta expression. We propose that this is an important mechanism for the positive control of cell proliferation by Shp-2.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Feng, GS (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.				NIGMS NIH HHS [R29GM53660] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053660] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; AUSUBEL FM, 1994, CURRENT PROTOCOLS, V1; BAZENET CE, 1994, ONCOGENE, V9, P517; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PaasinenSohns A, 1997, ONCOGENE, V15, P1953, DOI 10.1038/sj.onc.1201366; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHI ZQ, 1998, IN PRESS J BIOL CHEM; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3864, DOI 10.1128/MCB.8.9.3864; XIAO S, 1994, J BIOL CHEM, V269, P21244; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHANG QX, 1995, BBA-MOL CELL RES, V1266, P9, DOI 10.1016/0167-4889(94)00232-4	40	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					441	448		10.1038/sj.onc.1201988	http://dx.doi.org/10.1038/sj.onc.1201988			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696037				2022-12-28	WOS:000075043000006
J	Lafon, I; Carballes, F; Brewer, G; Poiret, M; Morello, D				Lafon, I; Carballes, F; Brewer, G; Poiret, M; Morello, D			Developmental expression of AUF1 and HuR, two c-myc mRNA binding proteins	ONCOGENE			English	Article						c-myc; AUF1 alternative exon; fetal liver; RNA stability	MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGIONS; TRANSGENIC MICE; RICH ELEMENTS; POSTTRANSCRIPTIONAL REGULATION; STABILITY INVITRO; CODING REGION; HALF-LIFE; GENE; SEQUENCE	Several proteins that may regulate c-myc mRNA posttranscriptionally were previously isolated and characterized. Two of them, HuR and AUF1, bind specifically to the 3' untranslated region (UTR) of c-myc mRNA. Because c-myc is regulated post-transcriptionally in various mouse tissues, including quiescent tissues, fetal liver and regenerating liver, we investigated whether HuR and AUF1 expression was also regulated in these tissues. Concerning AUF1, we analysed the expression of various mRNA and protein isoforms, We discovered a new AUF1 mRNA variant with a long AU-rich 3' UTR. We show that AUF1 expression, regardless of the RNA isoform considered, and HuR mRNA expression parallel C-myc expression in quiescent tissues and during liver development; their expression is high in lymphoid tissues and fetal liver and low in adult liver. However, no upregulation of HuR or AUF1 accompanies the upregulation of c-myc mRNA following partial hepatectomy. We discuss our results in relation to the current hypothesis that HuR and AUF1 act as mRNA destabilizing factors.	Univ Toulouse 3, CNRS UMR 5547, Ctr Dev Biol, F-31062 Toulouse 04, France; Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Wake Forest University; Wake Forest Baptist Medical Center	Morello, D (corresponding author), Univ Toulouse 3, CNRS UMR 5547, Ctr Dev Biol, 118 Rte Narbonne, F-31062 Toulouse 04, France.				NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [CA52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN X, 1993, BIOCHEM BIOPH RES CO, V191, P18, DOI 10.1006/bbrc.1993.1178; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DREZEN JM, 1993, J IMMUNOL, V150, P2805; EHRENMAN K, 1994, GENE, V149, P315, DOI 10.1016/0378-1119(94)90168-6; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1985, IMMUNOGENETICS, V22, P441, DOI 10.1007/BF00418090; MORELLO D, 1993, ONCOGENE, V8, P1921; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Pistoi S, 1996, MOL CELL BIOL, V16, P5107; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; SOBCZAK J, 1989, ONCOGENE, V4, P1503; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WAGNER BJ, 1998, IN PRESS GENOMICS; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	44	60	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	1998	16	26					3413	3421		10.1038/sj.onc.1201895	http://dx.doi.org/10.1038/sj.onc.1201895			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692549				2022-12-28	WOS:000074544100008
J	King, JA; Bridger, JM; Lochelt, M; Lichter, P; Schulz, TF; Schirrmacher, V; Khazaie, K				King, JA; Bridger, JM; Lochelt, M; Lichter, P; Schulz, TF; Schirrmacher, V; Khazaie, K			Nucleocytoplasmic transport of HTLV-1 RNA is regulated by two independent LTR encoded nuclear retention elements	ONCOGENE			English	Article						HTLV-1; RxRE; CRS; nuclear export	VIRUS TYPE-I; STRUCTURAL GENE-EXPRESSION; REV-RESPONSIVE ELEMENT; CIS-ACTING ELEMENTS; ENV MESSENGER-RNA; PROTEIN; SEQUENCE; BINDING; EXPORT; IDENTIFICATION	Appropriate expression of HTLV-1 genes requires transcriptional transactivation by Tax and post-transcriptional regulation by Rex, both mediated by LTR encoded RNA sequences. Using a combination of deletion mutagenesis, Rex-reporter CAT assays, fluorescence in situ hybridization (FISH) and confocal laser scanning microscopy it was established that in the absence of Rex, CAT mRNAs harboring HTLV-1 LTR sequences were unable to leave the nucleus. Deletion of the known U5 encoded cis-acting repressing sequence (CRS) led to a partial release of nuclear retention. A novel regulatory element overlapping the 3' Rex responsive element (RxRE) region was shown to prevent export and expression of these transcripts. Deletion of both the 5' LTR encoded CRS and 3' LTR encoded downstream repressive sequence (3' CRS) led to constitutive mRNA nuclear export and gene expression, independently of Rex. The locations of the two regulatory elements indicate that while the 5' CRS selectively acts to hinder export of unspliced transcripts, the 3' CRS has the capacity to induce nuclear retention of all HTLV-1 transcripts, and therefore could potentially contribute to viral latency in infected cells.	German Canc Res Ctr, Dept Cellular Immunol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Dept Org Complex Genomes, D-69120 Heidelberg, Germany; German Canc Res Ctr, Dept Retroviral Gene Express, D-69120 Heidelberg, Germany; Royal Liverpool Univ Hosp, Dept Med Microbiol & Genet Urinary Med, Liverpool L69 3BX, Merseyside, England; Dept Surg, Sect Mol Diag & Therapy, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Khazaie, K (corresponding author), German Canc Res Ctr, Dept Cellular Immunol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.			King, Jason/0000-0001-6886-8728; Schulz, Thomas/0000-0001-8792-5345				BLACK AC, 1991, VIROLOGY, V181, P433, DOI 10.1016/0042-6822(91)90875-C; BOGERD HP, 1992, J VIROL, V66, P7572, DOI 10.1128/JVI.66.12.7572-7575.1992; BRIGHTY DW, 1994, P NATL ACAD SCI USA, V91, P8314, DOI 10.1073/pnas.91.18.8314; CAMPBELL LH, 1994, J VIROL, V68, P5433, DOI 10.1128/JVI.68.9.5433-5438.1994; Chlichlia K, 1997, ONCOGENE, V14, P2265, DOI 10.1038/sj.onc.1201070; CHLICHLIA K, 1995, ONCOGENE, V10, P269; Churchill MJ, 1996, J VIROL, V70, P5786, DOI 10.1128/JVI.70.9.5786-5790.1996; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; HASELTINE WA, 1991, REGULATION HIV 1 REP; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; INOUE JI, 1986, FEBS LETT, V209, P187, DOI 10.1016/0014-5793(86)81108-5; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; Mikaelian I, 1996, J MOL BIOL, V257, P246, DOI 10.1006/jmbi.1996.0160; NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Rehberger S, 1997, EXP CELL RES, V233, P363, DOI 10.1006/excr.1997.3562; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992; SEIKI M, 1990, VIROLOGY, V176, P81, DOI 10.1016/0042-6822(90)90232-G; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; Zhang GH, 1996, J CELL BIOL, V135, P9, DOI 10.1083/jcb.135.1.9; Zirbel RM, 1993, CHROMOSOME RES, V1, P93, DOI 10.1007/BF00710032	32	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3309	3316		10.1038/sj.onc.1201884	http://dx.doi.org/10.1038/sj.onc.1201884			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681830				2022-12-28	WOS:000074343600012
J	Sweeney, KJ; Swarbrick, A; Sutherland, RL; Musgrove, EA				Sweeney, KJ; Swarbrick, A; Sutherland, RL; Musgrove, EA			Lack of relationship between CDK activity and G(1) cyclin expression in breast cancer cells	ONCOGENE			English	Article						cyclin D1; cyclin E; CDK; CKI; breast cancer; kinase activity	DEPENDENT KINASES; INHIBITS GROWTH; D1; OVEREXPRESSION; LINE; PROTEINS; PRB; DIFFERENTIATION; PROLIFERATION; AMPLIFICATION	The G(1) cyclins, cyclin D1 and E, are rate limiting for progression through G(1) phase of the cell cycle in breast epithelial cells and are oncogenic when expressed in the mammary epithelium of transgenic mice. These genes are frequently overexpressed in clinical breast cancer where overexpression appears to be associated with specific disease phenotypes, altered responsiveness to therapeutic intervention and patient survival. In order to investigate the functional correlates of cyclin D1 and cyclin E overexpression we employed a panel of normal, immortalized and neoplastic breast epithelial cell lines to examine the relationships between cyclin gene expression, cyclin-CDK complex formation and CDK activity. In agreement with earlier studies cyclin D1 and E expression varied over an approximately tenfold range among the 18 cell lines studied. There was no apparent relationship, however, between cyclin D1 expression and the in vitro activity of its major kinase partner, Cdk4, although MDA-MB-134 cells displayed the highest level of both cyclin D1 expression and Cdk4 activity. Similarly, there was no significant relationship between cyclin E expression and cyclin E-Cdk2 activity. Fractionation of whole cell lysates by gel filtration chromatography revealed that similar to 90% of the cyclin E protein was present in inactive complexes containing the CDK inhibitors p21 and p27. Much of the small fraction of active cyclin E protein was of very high apparent molecular mass, >400 kDa, suggesting that formation of these complexes is a more important determinant of cyclin E-Cdk2 activity than cyclin E abundance. These data suggest that properties of cyclins D1 and E in addition to their ability to activate Cdk4 and Cdk2 may contribute to the effects of overexpression on the breast cancer phenotype.	St Vincents Hosp, Gardiner Inst, Canc Res Program, Sydney, NSW 2010, Australia	St Vincents Hospital Sydney	Musgrove, EA (corresponding author), St Vincents Hosp, Gardiner Inst, Canc Res Program, Sydney, NSW 2010, Australia.		Swarbrick, Alexander/E-6107-2010; Sutherland, Robert L/A-8378-2008	Swarbrick, Alexander/0000-0002-3051-5676; 				ALLE KM, 1997, IN PRESS CLIN CANC R; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; Florenes VA, 1996, ONCOGENE, V13, P2447; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAN EKH, 1995, ONCOGENE, V10, P953; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Higashi H, 1996, EUR J BIOCHEM, V237, P460, DOI 10.1111/j.1432-1033.1996.0460k.x; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Hui R, 1996, CLIN CANCER RES, V2, P923; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KRANENBURG O, 1995, ONCOGENE, V10, P87; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Musgrove EA, 1996, J CELL BIOCHEM, V60, P363; MUSGROVE EA, 1989, CANCER RES, V49, P2398; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; Sgambato A, 1996, CANCER RES, V56, P1389; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; Tan P, 1997, CANCER RES, V57, P1259; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	59	68	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2865	2878		10.1038/sj.onc.1201814	http://dx.doi.org/10.1038/sj.onc.1201814			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671407				2022-12-28	WOS:000073988200005
J	Maru, Y; Yamaguchi, S; Shibuya, M				Maru, Y; Yamaguchi, S; Shibuya, M			Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials	ONCOGENE			English	Article						Flt-1; VEGF; BCR-ABL; tyrosine kinase; transformation	BCR-ABL ONCOGENE; TYROSINE KINASE; SIGNAL-TRANSDUCTION; V-ABL; PHILADELPHIA-CHROMOSOME; C-ABL; PROTEIN; ACTIVATION; LEUKEMIA; DOMAIN	A paradox of Flt-1, a tyrosine kinase receptor for vascular endothelial growth factor (VEGF), is that the ligand cannot activate the receptor to stimulate growth of cells that exogenously overexpress the receptor. In order to find Flt-1 kinase-dependent biological systems, we obtained for the first time activated forms of the Flt-1 kinase in a ligand-independent manner. Replacement of the ABL sequences in the human leukemia oncoprotein BCR-ABL with the cytoplasmic domain of Flt-1 (BCR-FLT) followed by a retroviral random mutagenesis scheme gave constitutively active artificial chimera BCR-FLTm with mutations within the Flt-1 sequence. Like BCR-ABL it could, but not the original BCR-FLT, transform Rat1 fibroblasts, abrogate cytokine dependence in Ba/F3 cells, and induce neurite-like structures in neuronal PC12 cells. Interestingly, Rat1 cells transformed by BCR-FLTm formed tube-like structures in basement membrane matrix. BCR-FLTm retroviruses may be a very useful tool to investigate an as yet uncovered functions of the Flt-1 kinase.	Univ Tokyo, Inst Med Sci, Dept Genet, Tokyo, Japan	University of Tokyo	Maru, Y (corresponding author), Univ Tokyo, Inst Med Sci, Dept Genet, Tokyo, Japan.							AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Ahmed A, 1997, LAB INVEST, V76, P779; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FREEMAN AE, 1973, P NATL ACAD SCI USA, V70, P2415, DOI 10.1073/pnas.70.8.2415; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Maru Y, 1996, EXP CELL RES, V229, P438, DOI 10.1006/excr.1996.0389; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MATHEYPREVOT B, 1988, MOL CELL BIOL, V8, P234, DOI 10.1128/MCB.8.1.234; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; NILSEN T, 1995, CELL, V41, P719; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAJUSOLA K, 1992, CANCER RES, V52, P5738; Parmar K, 1996, J VIROL, V70, P1009, DOI 10.1128/JVI.70.2.1009-1015.1996; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; SEETHARAM L, 1995, ONCOGENE, V10, P135; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Ziche M, 1997, LAB INVEST, V76, P517	58	49	50	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2585	2595		10.1038/sj.onc.1201786	http://dx.doi.org/10.1038/sj.onc.1201786			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632135				2022-12-28	WOS:000073698200003
J	Nees, M; van Wijngaarden, E; Bakos, E; Schneider, A; Durst, M				Nees, M; van Wijngaarden, E; Bakos, E; Schneider, A; Durst, M			Identification of novel molecular markers which correlate with HPV-induced tumor progression	ONCOGENE			English	Article						HPV (human papillomavirus); cervical cancer; prognostic markers; differential display; tumor progression	HUMAN PAPILLOMAVIRUS INFECTION; DIFFERENTIAL DISPLAY; TRANSMEMBRANE-4 SUPERFAMILY; EPITHELIAL-CELLS; ALVEOLAR RHABDOMYOSARCOMA; MI-2 AUTOANTIGEN; GENETIC-ANALYSIS; CERVICAL-CANCER; UTERINE CERVIX; MESSENGER-RNAS	High risk HPVs (human papillomaviruses) are causally involved in the development of cervical cancer, However, other factors, such as somatic genetic alterations also play a decisive role in malignant conversion of cervical keratinocytes, Mutations and chromosomal aberrations are known to influence the pattern of gene expression, Therefore we used the recently developed RT-PCR based method of differential display of mRNAs to detect differences in gene expression which correlate with tumorigenicity. Non-tumorigenic HPV16-immortalized human foreskin keratinocytes (HPK IA) were compared with their tumorigenic counterparts and 49 different genes were identified which were either up-or downregulated. The identified genes encode proteins of the cytoskeleton and the extracellular matrix, the nuclear splicing apparatus, transcription regulators and membrane-associated proteins. The expression pattern of all genes was also examined by RNA-RNA in situ hybridization in biopsies of normal cervical epithelium, precancerous lesions and cancers. Two genes, C4.8 and C21.7, are of particular interest because their expression is upregulated in a subset of high grade precancerous lesions and in over 58% of cancers. These two genes may therefore be considered as putative progression markers. C4.8 is a new member of the transmembrane 4 (TM-4) protein family which includes tumor-associated antigens such as CD63 and TAPA-1, whereas C21.7 shows no significant homologies to any known genes or proteins.	Univ Jena, Abt Frauenheilkunde, D-07740 Jena, Germany; Deutsch Krebsforschungszentrum, ATV 0615, D-69120 Heidelberg, Germany	Friedrich Schiller University of Jena; Helmholtz Association; German Cancer Research Center (DKFZ)	Durst, M (corresponding author), Univ Jena, Abt Frauenheilkunde, Bachstr 18, D-07740 Jena, Germany.		Nees, Matthias/AAT-5577-2020; Nees, Matthias/W-6596-2018	Nees, Matthias/0000-0002-9034-301X				Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; Barr FG, 1997, CURR TOP MICROBIOL, V220, P113; BAUER D, 1994, PCR METH APPL, V4, P97; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Berthod F, 1997, J INVEST DERMATOL, V108, P737, DOI 10.1111/1523-1747.ep12292122; BUIJS A, 1995, ONCOGENE, V10, P1511; CALVIO C, 1995, RNA, V1, P724; CHEN TM, 1993, CANCER RES, V53, P1167; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cuzick J, 1996, EUR J CANCER, V32A, P836, DOI 10.1016/0959-8049(95)00650-8; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; DEPREZ RHL, 1995, ONCOGENE, V10, P1521; DESPRES N, 1995, J CLIN INVEST, V95, P1891, DOI 10.1172/JCI117870; Durst M, 1995, CANCER GENET CYTOGEN, V85, P105, DOI 10.1016/0165-4608(95)00155-7; DURST M, 1987, ONCOGENE, V1, P251; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; Gerecke DR, 1997, GENOMICS, V41, P236, DOI 10.1006/geno.1997.4638; Gress TM, 1996, ONCOGENE, V13, P1819; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Herrington CS, 1996, J CLIN PATHOL, V49, P493, DOI 10.1136/jcp.49.6.493; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; HOPPESEYLER F, 1995, J MOL MED, V73, P529; KIVIAT NB, 1992, INT J GYNECOL PATHOL, V11, P197, DOI 10.1097/00004347-199207000-00005; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Londesborough P, 1996, INT J CANCER, V69, P364; Mannion BA, 1996, J IMMUNOL, V157, P2039; Muir C.S., 1987, CANC INCIDENCE 5 CON; Nindl I, 1996, J VIROL METHODS, V62, P81, DOI 10.1016/0166-0934(96)02084-8; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PONTEN J, 1995, INT J CANCER, V63, P317, DOI 10.1002/ijc.2910630229; REID R, 1991, AM J OBSTET GYNECOL, V164, P1461, DOI 10.1016/0002-9378(91)91425-V; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SCHIFFMAN MH, 1992, JNCI-J NATL CANCER I, V84, P394, DOI 10.1093/jnci/84.6.394; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; Schneider A, 1996, AM J OBSTET GYNECOL, V174, P1534, DOI 10.1016/S0002-9378(96)70602-6; SEAGON S, 1994, CANCER RES, V54, P5593; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; TSUTSUMI K, 1992, AM J PATHOL, V140, P255; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531; WOODWORTH CD, 1988, CANCER RES, V48, P4620; WOODWORTH CD, 1989, J VIROL, V57, P572; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; XI LF, 1995, J INFECT DIS, V172, P747, DOI 10.1093/infdis/172.3.747; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854	59	27	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2447	2458		10.1038/sj.onc.1201785	http://dx.doi.org/10.1038/sj.onc.1201785			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627111				2022-12-28	WOS:000073672300003
J	Dahia, PLM; FitzGerald, MG; Zhang, X; Marsh, DJ; Zheng, ZM; Pietsch, T; von Deimling, A; Haluska, FG; Haber, DA; Eng, C				Dahia, PLM; FitzGerald, MG; Zhang, X; Marsh, DJ; Zheng, ZM; Pietsch, T; von Deimling, A; Haluska, FG; Haber, DA; Eng, C			A highly conserved processed PTEN pseudogene is located on chromosome band 9p21	ONCOGENE			English	Article						MMAC1; TEP1; 9p; Cowden; pseudogene	COWDEN DISEASE; DELETIONS; GENE	PTEN/MMAC1/TEP1, encoding a dual-specificity phosphatase, is a tumor suppressor gene which has recently been cloned and mapped to chromosome 10q23.3. We have shown that germline mutations of PTEN are present in individuals with two hamartoma syndromes: Cowden Syndrome, associated with a predisposition to breast and thyroid cancers, and Bannayan-Zonana syndrome. Somatic mutations of PTEN have been reported in a variety of human cancer cell lines, suggesting a potential role for this gene in the pathogenesis of human malignancies. We report the identification of a highly conserved PTEN processed pseudogene, psi PTEN, which shares over 98% homology with the coding region of functional PTEN, and its localisation to chromosome 9p21. The high sequence homology of psi PTEN with the PTEN transcript may potentially lead to misinterpretation when performing mutation analyses based on cDNA templates. Caution should be exerted when using such screening approaches.	Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Dept Adult Oncol, Translat Res Lab, Boston, MA 02115 USA; Dana Farber Canc Inst, Program Populat Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA; Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; Univ Cambridge, Canc Res Campaign, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Bonn; CRUK Cambridge Institute; University of Cambridge	Eng, C (corresponding author), Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Dept Adult Oncol, Translat Res Lab, SM822, Boston, MA 02115 USA.		Marsh, Deborah J/I-1491-2014; von Deimling, Andreas/F-7774-2013	Marsh, Deborah J/0000-0001-5899-4931; von Deimling, Andreas/0000-0002-5863-540X; Eng, Charis/0000-0002-3693-5145				Dahia PLM, 1997, CANCER RES, V57, P4710; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; EINHORN S, 1993, LEUKEMIA LYMPHOMA, V11, P191, DOI 10.3109/10428199309086995; Eng C, 1997, J Genet Couns, V6, P181, DOI 10.1023/A:1025664119494; GOJOBORI T, 1982, J MOL EVOL, V18, P36; Ivanchuk SM, 1997, ONCOGENE, V14, P1811, DOI 10.1038/sj.onc.1201016; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LI WH, 1987, J MOL EVOL, V25, P333; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Longy M, 1996, ANN GENET-PARIS, V39, P35; Maestre J, 1995, EMBO J, V14, P6333, DOI 10.1002/j.1460-2075.1995.tb00324.x; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253	18	80	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2403	2406		10.1038/sj.onc.1201762	http://dx.doi.org/10.1038/sj.onc.1201762			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620558				2022-12-28	WOS:000073428000013
J	Jefferson, AB; Klippel, A; Williams, LT				Jefferson, AB; Klippel, A; Williams, LT			Inhibition of mSOS-activity by binding of phosphatidylinositol 4,5-P-2 to the mSOS pleckstrin homology domain	ONCOGENE			English	Article						SOS; Ras; pleckstrin homology domain; phosphatidylinositol 4,5P(2)	NUCLEOTIDE EXCHANGE FACTOR; BRUTON TYROSINE KINASE; PH DOMAIN; G(BETA-GAMMA) SUBUNITS; SIGNAL-TRANSDUCTION; FACTOR SOS; RAS; PROTEINS; RECEPTOR; GRB2	There are several recently reported examples of inositol phospholipids binding to pleckstrin homology (PH) domains of proteins. The PH domain of SOS, a guanine nucleotide exchange factor for Ras, binds to phosphatidylinositol 4,5 bisphosphate (PtdIns4,5P(2)). We found that binding of PtdIns4,5P(2) to 6-his-tagged recombinant mSOS in vitro inhibits the ability of SOS to catalyze the association of GTP on p21(RAS). This inhibition was specific for PtdIns4,5P(2): a number of other phosphatidylinositols and phosphatidylserine failed to inhibit Ras GTP-association. We confirmed that the specificity of binding of PtdIns's to recombinant GST-SOS-PH domain is the same as the specificity of PtdIns's for inhibition of SOS activity: namely, that only Ptdins4,5P(2) binds significantly to the SOS-PH domain. In addition, the inhibition of Ras GTP-binding is not blocked by excess free inositols suggesting that SOS binds to PtdIns4,5P(2) with higher affinity than it binds to free inositols. Addition of SOS-PH domain protein prevented the inhibition of SOS by PtdIns4,5P(2) as did addition of the high affinity PtdIns4,5P(2)-binding drug neomycin. This confirmed that SOS inhibition is mediated by the SOS-PH domain binding to the inositol moiety of PtdIns4,5P(2). Binding of Grb2 to SOS did not prevent the inhibition of SOS by Ptdins4,5P(2) suggesting that there must be another mechanism for regulating this inhibition. These findings show that the phospholipid PtdIns4,5P(2) can suppress the activity of an enzyme involved in signal transduction and suggest that this inhibitory effect must be relieved when SOS is activated.	Chiron Corp, Emeryville, CA 94608 USA	Novartis	Jefferson, AB (corresponding author), Chiron Corp, 4560 Horton St, Emeryville, CA 94608 USA.							ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLEY WB, 1994, INFECT DIS CLIN PRAC, V3, P168, DOI 10.1097/00019048-199405000-00004; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; INGLEY E, 1994, J CELL BIOCHEM, V56, P436, DOI 10.1002/jcb.240560403; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LODHI S, 1979, BIOCHIM BIOPHYS ACTA, V557, P1, DOI 10.1016/0005-2736(79)90084-1; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	41	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2303	2310		10.1038/sj.onc.1201891	http://dx.doi.org/10.1038/sj.onc.1201891			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620547				2022-12-28	WOS:000073428000002
J	Kruger, A; Sanchez-Sweatman, OH; Martin, DC; Fata, JE; Ho, AT; Orr, FW; Ruther, U; Khokha, R				Kruger, A; Sanchez-Sweatman, OH; Martin, DC; Fata, JE; Ho, AT; Orr, FW; Ruther, U; Khokha, R			Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line	ONCOGENE			English	Article						TIMP-1; metastasis inhibition; transgenic mice; lacZ tagging	EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; MELANOMA-CELLS; IN-VIVO; EXPRESSION; INVASION; TUMOR; ANGIOGENESIS; SUPPRESSION; PROTEIN	Within the tumor-stromal microenvironment a disrupted balance between matrix metalloproteinases (MMPs) and their inhibitors compromises the integrity of the extracellular matrix and promotes malignancy. Tissue inhibitors of metalloproteinases (TIMPs) have been linked to tumor suppression in studies of genetically altered tissue culture cells and in analyses of clinical specimens in situ. We generated transgenic mice as a model system to test the relationship between TIMP-1 levels in a host organ and susceptibility to experimentally targeted metastasis. Ectopically overexpressed TIMP-1 in the brain resulted in a tissue microenvironment with elevated protein levels of this natural MMP inhibitor. Metastatic challenge provided by lacZ-tagged fibrosarcoma cells permitted high-resolution analysis of metastatic load and pattern. We found that elevated host TIMP-1 imposed resistance to experimental metastasis of fibrosarcoma: In TIMP-1 overexpressing mice, brain metastases were significantly reduced by 75% compared to wild-type littermates. Our findings demonstrate that ectopic TIMP-1 expression efficiently exerts a suppressive effect on metastasizing tumor cells.	Univ Western Ontario, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Biochem, London, ON N6A 4L6, Canada; Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Dept Pathol, Toronto, ON M5G 2M9, Canada; Univ Manitoba, Hlth Sci Ctr, Dept Pathol, Winnipeg, MB R3A 1R9, Canada; Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; Hannover Medical School	Khokha, R (corresponding author), Univ Western Ontario, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada.		Ho, Andrew Tri Van/D-9681-2019	Ho, Andrew Tri Van/0000-0002-5501-6419				BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUGNO M, 1995, SCIENCE, V5, P1; DECLERCK YA, 1992, CANCER RES, V52, P701; DERCOLE AJ, 1994, DEV BRAIN RES, V82, P213; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KOOP S, 1995, CANCER RES, V55, P2520; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Martinson I, 1996, J PALLIATIVE CARE, V12, P13, DOI 10.1177/082585979601200303; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MULLER M, 1995, PEDIATR NEUROSURG, V22, P204, DOI 10.1159/000120902; NUOVO GJ, 1995, CANCER RES, V55, P267; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; ROEB E, 1994, FEBS LETT, V349, P45, DOI 10.1016/0014-5793(94)00636-9; SanchezSweatman OH, 1996, INT J ONCOL, V8, P371; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0	21	80	88	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2419	2423		10.1038/sj.onc.1201774	http://dx.doi.org/10.1038/sj.onc.1201774			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620561				2022-12-28	WOS:000073428000016
J	Siddique, H; Zou, JP; Rao, VN; Reddy, ESP				Siddique, H; Zou, JP; Rao, VN; Reddy, ESP			The BRCA2 is a histone acetyltransferase	ONCOGENE			English	Article						BRCA2; histone acetyl transferase; protein-protein interaction; tumor suppressor	BREAST-CANCER SUSCEPTIBILITY; TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; GENE BRCA1; FAMILIES; ACETYLATION; MUTATION; YEAST; CBP	Patients carrying mutations in BRCA1 or BRCA2 tumor suppressor genes have shown to have high risk in developing breast and ovarian cancers. Two potential functions of BRCA2 were proposed which includes role in the regulation of transcription and also in DNA repair. Forty-five-amino acid region encoded by exon 3 of BRCA2 was shown to have transcriptional activation function. Recent studies of the several enzymes involved in acetylation and deacetylation of histone residues have revealed a possible relationship between gene transcriptional activation and histone acetylation, Since BRCA2 appear to function as a transcriptional factor, we have tested for Histone acetyl transferase (HAT) activity of BRCA2, Here, we present evidence that BRCA2 has intrinsic HAT activity, which maps to the aminoterminal region of BRCA2, Our results demonstrate that BRCA2 proteins acetylate primarily H3 and H4 of free histones. These observations suggest that HAT activity of BRCA2 may play an important role in the regulation of transcription and tumor suppressor function.	Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Philadelphia, PA 19102 USA	Drexel University	Reddy, ESP (corresponding author), Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, MS 481,Broad & Vine St, Philadelphia, PA 19102 USA.				NCI NIH HHS [CA57322, CA51083, CA58642] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R01CA058642, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CUI J, 1998, IN PRESS ONCOL REP; EASTON DF, 1993, AM J HUM GENET, V52, P678; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Herrera JE, 1997, J BIOL CHEM, V272, P27253, DOI 10.1074/jbc.272.43.27253; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shao NS, 1996, ONCOGENE, V13, P1; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; TONIN P, 1995, J MED GENET, V32, P982, DOI 10.1136/jmg.32.12.982; Vaughn JP, 1996, CANCER RES, V56, P4590; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; WOOSTER R, 1995, TRENDS GENET, V11, P3, DOI 10.1016/S0168-9525(00)88974-X; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8	35	61	63	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2283	2285		10.1038/sj.onc.1202003	http://dx.doi.org/10.1038/sj.onc.1202003			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619837	Bronze			2022-12-28	WOS:000073298000013
J	Dehbi, M; Hiscott, J; Pelletier, J				Dehbi, M; Hiscott, J; Pelletier, J			Activation of the wt1 Wilms' tumor suppressor gene by NF-kappa B	ONCOGENE			English	Article						WT1; NF-kappa B; gene regulation; Wilms' tumor	TRANSCRIPTION FACTOR; NECROSIS-FACTOR; HL-60 CELLS; EXPRESSION; ENHANCER; ALPHA; PROMOTER; DIFFERENTIATION; INHIBITOR; MUTATIONS	The Wilm's tumor suppressor gene, wt1, is expressed in a very defined spatial-temporal fashion and plays a key role in development of the urogenital system, Transacting factors governing wt1 expression are poorly defined. The presence of putative kappa B binding sites within the wt1 gene prompted us to investigate whether members of the NF-kappa B/Rel family of transcription factors are involved in regulating wt1 expression. In transient transfection assays, ectopic expression of p50 and p65 subunits of NF-kappa B stimulated wt1 promoter activity 10-30-fold. Deletion mutagenesis revealed that NF-kappa B responsiveness is mediated by a short DNA fragment located within promoter proximal sequences of the major transcription start site. Two kappa B-binding sites are present in this region and form specific complexes with purified NF-kappa B proteins, as revealed by electrophoretic mobility gel shift assays. Ectopic expression of p50 and p65 resulted in increased transcription of the endogenous wt1 gene, as revealed by nuclear run-on experiments. Taken together, these results indicate that members of the NF-kappa B/Rel family are important for activating expression of wt1 and reside upstream of the regulatory cascade leading to wt1 activation.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	McGill University; McGill University; Lady Davis Institute; McGill University	Pelletier, J (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; Dehbi M, 1996, ONCOGENE, V13, P447; Dehbi M, 1996, EMBO J, V15, P4297, DOI 10.1002/j.1460-2075.1996.tb00804.x; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HOFFMANN W, 1993, ONCOGENE, V8, P3123; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; MATSUNAGA E, 1981, HUM GENET, V57, P231; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PARK S, 1993, NAT GENET, V5, P363, DOI 10.1038/ng1293-363; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKIYA M, 1994, BLOOD, V83, P1876; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944	34	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2033	2039		10.1038/sj.onc.1201747	http://dx.doi.org/10.1038/sj.onc.1201747			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572484				2022-12-28	WOS:000073177200001
J	Ohnishi, T; Wang, XJ; Ohnishi, K; Takahashi, A				Ohnishi, T; Wang, XJ; Ohnishi, K; Takahashi, A			p53-dependent induction of WAF1 by cold shock in human glioblastoma cells	ONCOGENE			English	Article						p53; WAF1; signal transduction; cold shock; non-genotoxic stress	GROWTH ARREST; P53; APOPTOSIS; PROTEINS	Induction of WAF1 expression was investigated in human glioblastoma cell lines differing in p53 gene statuses after cold shock treatment, Accumulation of both wild-type (wt) and mutant p53 (mp53) was induced by cold shock at 4 degrees C for 60 min, however, WAF1 accumulation was induced by cold shock in A-172 cells carrying the wtp53 but not in T98G cells carrying the mp53, Inactivation of wtp53 by a dominant negative p53 mutant (p53Trp248) abolished cold shock-induced WAF1 expression in A-172 transfectant cells, Furthermore, no WAF1 expression was induced by cold shock in p530-deficient human osteosarcoma Saos-2 cells. Northern blot analysis showed that the WAF1 but not p53 gene was activated by cold shock only in A-172 cells, These findings suggest that WAF1 expression is cold shock-inducible in human glioblastoma cells, and that this induction may be due to signal transduction mediated by p53 in response to non-genotoxic stress, cold shock.	Nara Med Univ, Dept Biol, Nara 634, Japan	Nara Medical University	Ohnishi, T (corresponding author), Nara Med Univ, Dept Biol, 840 Shijo Cho, Nara 634, Japan.			Takahashi, Akihisa/0000-0002-9960-2153				AOKI H, 1997, IN PRESS MOL CARCINO; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DROBNIS EZ, 1993, J EXP ZOOL, V265, P432, DOI 10.1002/jez.1402650413; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRUMAN II, 1992, J CELL PHYSIOL, V153, P112, DOI 10.1002/jcp.1041530115; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MATSUMOTO H, 1994, CANCER LETT, V87, P39, DOI 10.1016/0304-3835(94)90407-3; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; Ohtsubo T, 1997, CANCER RES, V57, P3910; Ota T, 1996, PHOTOCHEM PHOTOBIOL, V64, P984, DOI 10.1111/j.1751-1097.1996.tb01865.x; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WANG X, 1997, IN PRESS EXP CELL RE; Wang XJ, 1997, J RADIAT RES, V38, P179, DOI 10.1269/jrr.38.179	19	51	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1507	1511		10.1038/sj.onc.1201663	http://dx.doi.org/10.1038/sj.onc.1201663			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525749				2022-12-28	WOS:000072572400015
J	Villanueva, A; Garcia, C; Paules, AB; Vicente, M; Megias, M; Reyes, G; de Villalonga, P; Agell, N; Lluis, F; Bachs, O; Capella, G				Villanueva, A; Garcia, C; Paules, AB; Vicente, M; Megias, M; Reyes, G; de Villalonga, P; Agell, N; Lluis, F; Bachs, O; Capella, G			Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells	ONCOGENE			English	Article						pancreatic cancer; p15; Smad4; Smad2; TGF beta-RII; CDC25A	TUMOR-SUPPRESSOR GENE; MAD-RELATED PROTEIN; DPC4 GENE; TRANSFORMING GROWTH-FACTOR-BETA-1; RECEPTOR; ADENOCARCINOMA; MUTATIONS; CARCINOMA; DELETION; PHOSPHATASES	Resistance to TGF-beta 1 occurred in pancreatic cancer cells suggesting that inactivation of TGF-beta inhibitory signaling pathways may play an important role in human pancreatic cancer. The aim of our study was to determine the presence of alterations in the main putative components of the TGF-beta inhibitory signaling pathways (p15, Smad4, Smad2, TGF beta-RII, CDC25A). A panel of human carcinomas of the exocrine pancreas orthotopically implanted and perpetuated in nude mice and pancreatic cancer cell lines were studied. p15 gene alterations, mainly homozygous deletions that involved exons 1 and/or 2, were found in the 62.5% (5 of 8) of pancreatic xenografts whereas Smad4 gene aberrations were found in one of eight xenografts and in two of seven cell lines, Additional aberrations in these genes were acquired during in vivo perpetuation and distal dissemination. Paradoxically, TGF beta-RII overexpression and a decrease in CDC25A protein levels were found in all tumors and cell lines. In one cell line, resistance to TGF-beta 1 occurred in the absence of alterations in the genes analysed so far. We conclude that all human pancreatic tumor cells analysed herein have non-functional TGF-beta pathways. The majority of cells harbor alterations in at least one of the putative components of TGF-beta pathways, mainly in p15 and Smad4 genes. These results suggest that inactivation of TGF-beta signaling pathways plays an important role in human pancreatic tumorigenesis.	Hosp de la Santa Creu & Sant Pau, Inst Recerca, Lab Invest Gastrointestinal, Barcelona, Spain; Univ Barcelona, Fac Med, Dept Cellular Biol, Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of Barcelona	Capella, G (corresponding author), Hosp de la Santa Creu & Sant Pau, Inst Recerca, Lab Invest Gastrointestinal, Barcelona, Spain.		Villalonga, Priam/K-4350-2014; Capella, Gabriel/I-1879-2015; Agell, Neus/E-9640-2016	Villalonga, Priam/0000-0002-7190-6884; Capella, Gabriel/0000-0002-4669-7320; Agell, Neus/0000-0002-1205-6074; Lluis, Felix/0000-0002-4770-0923				Akiyama Y, 1997, GASTROENTEROLOGY, V112, P33, DOI 10.1016/S0016-5085(97)70216-6; BALDWIN RL, 1993, GROWTH FACTORS, V8, P23, DOI 10.3109/08977199309029131; Barrett MT, 1996, CANCER RES, V56, P4351; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRIESS H, 1993, CANCER RES, V53, P2704; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; HAHN SA, 1995, CANCER RES, V55, P4670; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Huang LY, 1996, CANCER RES, V56, P1137; IVARAONE A, 1997, NATURE, V87, P417; JEN J, 1994, CANCER RES, V54, P6353; Kim IY, 1996, CANCER RES, V56, P44; Kim SK, 1996, CANCER RES, V56, P2519; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MATO E, 1993, J PINEAL RES, V15, P43, DOI 10.1111/j.1600-079X.1993.tb00508.x; Nagatake M, 1996, CANCER RES, V56, P2718; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; Reyes G, 1996, CANCER RES, V56, P5713; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Riggins GJ, 1997, CANCER RES, V57, P2578; SCARPA A, 1994, INT J CANCER, V57, P167; Schutte M, 1996, CANCER RES, V56, P2527; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Tsubari M, 1997, CANCER RES, V57, P2966; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	41	165	173	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1969	1978		10.1038/sj.onc.1202118	http://dx.doi.org/10.1038/sj.onc.1202118			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788440				2022-12-28	WOS:000076423500010
J	Wang, YC; Blandino, G; Oren, M; Givol, D				Wang, YC; Blandino, G; Oren, M; Givol, D			Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs	ONCOGENE			English	Article						inducible p53; senescence; anti-cancer drugs; p21(waf1)	WILD-TYPE P53; HUMAN-DIPLOID FIBROBLASTS; P53-DEFICIENT MICE; MUTANT P53; P53-MEDIATED APOPTOSIS; ANTICANCER AGENTS; TUMOR SUPPRESSION; IN-VIVO; GROWTH; GENE	The p53-null human lung cancer cell line H1299 was used in order to generate clones with ecdysone-inducible p53 as well as ecdysone-inducible p21(waf1). Induced expression of p53 resulted in irreversible cell growth arrest with characteristics of replicative senescence, suggesting that p53 can prevent immortalization by activating a senescence program. The effect of induced p53 and p21(waf1) expression on the cytotoxic action of the anti-cancer drugs etoposide and cisplatin was also analysed. Whereas p21(waf1) overexpression conferred increased resistance to killing by either drug, p53 overexpression enhanced the cytotoxic effect of cisplatin but protected against etoposide cytotoxicity. These results imply that the impact of p53 on susceptibility to chemotherapy may depend greatly on the particular drug and type of DNA damage. Moreover, these data demonstrate the importance of using isogenic cell lines to address this issue.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BODNER SM, 1992, ONCOGENE, V7, P743; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1994, ONCOGENE, V9, P1885; CHEDID M, 1994, ONCOGENE, V9, P3021; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Fazeli A, 1997, P NATL ACAD SCI USA, V94, P10199, DOI 10.1073/pnas.94.19.10199; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1997, CANCER RES, V57, P1171; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; MALCOMSON RDG, 1995, BRIT J CANCER, V72, P952, DOI 10.1038/bjc.1995.440; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; OConnor PM, 1997, CANCER RES, V57, P4285; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Sambrook J., 2002, MOL CLONING LAB MANU; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TSUKADA T, 1993, ONCOGENE, V8, P3313; VIKHANSKAYA F, 1995, INT J CANCER, V61, P397, DOI 10.1002/ijc.2910610320; Vikhanskaya F, 1996, EXP CELL RES, V227, P380, DOI 10.1006/excr.1996.0288; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; ZAKUT R, 1995, ONCOGENE, V11, P393	43	92	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1923	1930		10.1038/sj.onc.1202113	http://dx.doi.org/10.1038/sj.onc.1202113			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788435	Bronze			2022-12-28	WOS:000076423500005
J	Fujii, M; Hayashi, K; Niki, M; Chiba, N; Meguro, K; Endo, K; Kameoka, J; Ito, S; Abe, K; Watanabe, T; Satake, M				Fujii, M; Hayashi, K; Niki, M; Chiba, N; Meguro, K; Endo, K; Kameoka, J; Ito, S; Abe, K; Watanabe, T; Satake, M			Overexpression of AML1 renders a T hybridoma resistant to T cell receptor-mediated apoptosis	ONCOGENE			English	Article						AML1/PEBP2 alpha B/CBFA2; T lymphocyte; apoptosis; transcription factor; Fas-ligand	ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; PROTEIN-PROTEIN INTERACTIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; RUNT DOMAIN; TRANSCRIPTION FACTOR; FUSION TRANSCRIPT; DNA-BINDING; PROTOONCOGENE PRODUCT; DELTA-ENHANCER	The AML1 gene, which encodes the DNA binding subunit of the heterodimeric transcription factor, PEBP2/CBF, is involved in several types of chromosomal translocations associated with human acute myeloid leukemia, and has been shown by gene targeting to be essential for the development of definitive hematopoiesis in the murine fetal liver. In addition, the gene is expressed abundantly in T lymphocytes and has been implicated in T cell specific gene expression. In the present study we examined the function of AML1 in T cell receptor (TCR)-mediated, Fas/Fas-ligand dependent apoptosis of a T hybridoma Line, DO11.10, Several independent cell clones overexpressing the AML1 protein were isolated by transfecting AML1 cDNA into these cells. These clones possessed an increased level of PEBP2/CBF DNA binding activity and were found to be resistant to apoptosis induced by anti-CD3 antibody treatment. Northern blot analysis revealed that induction of the Fas-ligand transcript was markedly suppressed in the anti-CD3 treated clones. Instead, expression of IL-2 receptor alpha subunit (IL-2R alpha), which is a manifestation of proliferative TCR signaling, was induced. This was in contrast to the parental, anti-CD3 treated DO11.10 cells where induction of Fas-ligand but not of IL-2R alpha was observed. Resistance of the AML1 overexpressing cell clones to TCR-mediated apoptosis is most likely attributable to the lack of Fas-ligand induction, since simultaneous treatment with anti-CD3 and anti-Fas antibodies caused apoptosis of the clones. The overall results suggest that the AML1 protein may play a pivotal role in switching TCR signaling between apoptosis and cell proliferation in T lymphocytes.	Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Dept Internal Med 2, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University	Satake, M (corresponding author), Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Seiryo Machi, Sendai, Miyagi 9808575, Japan.		Ito, Sadayoshi/A-3933-2015	Ito, Sadayoshi/0000-0002-5092-3626				BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CALNAN BJ, 1995, IMMUNITY, V3, P273; Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; Cui HL, 1996, CELL IMMUNOL, V167, P276, DOI 10.1006/cimm.1996.0036; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ERICKSON P, 1992, BLOOD, V80, P1825; Frank R, 1995, ONCOGENE, V11, P2667; Fujioka M, 1996, GENES CELLS, V1, P741, DOI 10.1111/j.1365-2443.1996.tb00014.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Latinis KM, 1997, J IMMUNOL, V158, P4602; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OKABE T, 1995, J IMMUNOL, V154, P3871; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SHIMIZU A, 1985, NUCLEIC ACIDS RES, V139, P1505; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Tanaka Y, 1997, ONCOGENE, V15, P677, DOI 10.1038/sj.onc.1201235; Uchida H, 1997, J IMMUNOL, V158, P2251; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WARGNIER A, 1995, P NATL ACAD SCI USA, V92, P6930, DOI 10.1073/pnas.92.15.6930; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WIJMENGA C, 1995, GENOMICS, V26, P611, DOI 10.1016/0888-7543(95)80185-O; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Zhang H, 1996, J AUTOM REASONING, V16, P1, DOI 10.1007/BF00244457	67	24	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1813	1820		10.1038/sj.onc.1202087	http://dx.doi.org/10.1038/sj.onc.1202087			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778047				2022-12-28	WOS:000076303300007
J	Hitomi, M; Shu, JY; Agarwal, M; Agarwal, A; Stacey, DW				Hitomi, M; Shu, JY; Agarwal, M; Agarwal, A; Stacey, DW			p21(Waf1) inhibits the activity of cyclin dependent kinase 2 by preventing its activating phosphorylation	ONCOGENE			English	Article						prostaglandin A2; cyclin; cyclin dependent kinase; gadd45; gadd153; p27(Kip1); p21(Waf1); p53	GROWTH ARREST; POTENTIAL MEDIATOR; PROSTAGLANDIN A(2); CDK2 ACTIVITY; DNA-DAMAGE; P53; P21; P27(KIP1); GENE; CLONING	Prostaglandin A2 (PGA2), a potent inhibitor of the growth of many cell types, inhibits G1 phase cyclin dependent kinases (cdk). Although PGA2 suppresses cyclin D1 and elevates p21(Waf1) levels, it was the failure of cdk2 to become activated by phosphorylation which correlated best with growth inhibition. In kinetic studies, cdk2 activation was inhibited efficiently only if p21(Waf1) levels increased prior to the activating phosphorylation; suggesting that p21(Waf1) had blocked this phosphorylation. This model was confirmed in cells from p21(Waf1) knockout mice where PGA2 was completely unable to block the activating phosphorylation of cdk2, or inhibit cdk2 activity. As expected, growth inhibition of p21(Waf1-/-) cells was not observed at PGA2 concentrations which inhibited cdk2 activity and growth of p21Waf1-/- cells.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hitomi, M (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NIGMS NIH HHS [GM52271] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052271] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN TM, 1992, ONCOGENE, V7, P1541; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gorospe M, 1996, MOL CELL BIOL, V16, P762; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hitomi M, 1996, J BIOL CHEM, V271, P9376, DOI 10.1074/jbc.271.16.9376; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOWE PH, 1993, J BIOL CHEM, V268, P21448; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Maniatis T., 1982, MOL CLONING; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; PRICE BD, 1993, ONCOGENE, V8, P3055; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sambrook J., 1989, MOL CLONING; Shu JY, 1996, ONCOGENE, V13, P2421; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	41	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					959	969		10.1038/sj.onc.1202005	http://dx.doi.org/10.1038/sj.onc.1202005			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747875	Bronze			2022-12-28	WOS:000075560900004
J	Stucki, M; Pascucci, B; Parlanti, E; Fortini, P; Wilson, SH; Hubscher, U; Dogliotti, E				Stucki, M; Pascucci, B; Parlanti, E; Fortini, P; Wilson, SH; Hubscher, U; Dogliotti, E			Mammalian base excision repair by DNA polymerases delta and epsilon	ONCOGENE			English	Article						DNA repair; DNA polymerases; abasic sites	CELL NUCLEAR ANTIGEN; REPLICATION PROTEIN-A; MISMATCH REPAIR; ESCHERICHIA-COLI; CALF THYMUS; LIGASE-I; FACTOR-C; BETA; REQUIREMENT; BINDING	Two distinct pathways for completion of base excision repair (BER) have been discovered in eukaryotes: the DNA polymerase beta (Pol beta)-dependent short-patch pathway that involves the replacement of a single nucleotide and the long-patch pathway that entails the resynthesis of 2-6 nucleotides and requires PCNA, We have used cell extracts from Pol beta-deleted mouse fibroblasts to separate subfractions containing either Pol delta or Pol epsilon. These fractions were then tested for their ability to perform both short- and long-patch BER in an in vitro repair assay, using a circular DNA template, containing a single abasic site at a defined position. Remarkably, both Pol delta and Pol epsilon were able to replace a single nucleotide at the lesion site, but the repair reaction is delayed compared to single nucleotide replacement by Pol beta, Furthermore, our observations indicated, that either Pol delta and/or Pol epsilon participate in the long-patch BER. PCNA and RF-C, but not RP-A are required for this process. Our data show for the first time that Pol delta and/or Pol epsilon are directly involved in the long-patch BER of abasic sites and might function as back-up system for Pol beta in one-gap filling reactions.	Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy; Univ Zurich, Inst Vet Biochem, CH-8057 Zurich, Switzerland; NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA	Istituto Superiore di Sanita (ISS); University of Zurich; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Dogliotti, E (corresponding author), Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, Vle Regina Elena 299, I-00161 Rome, Italy.		Stucki, Manuel/H-4739-2017; Parlanti, Eleonora/AAC-5978-2021; Fortini, Paola/K-1197-2018; Wilson, Samuel H/E-6644-2019	Fortini, Paola/0000-0001-6206-8498; Wilson, Samuel H/0000-0002-1702-5293; PASCUCCI, BARBARA/0000-0002-8383-8751				CHEN M, 1992, P NATL ACAD SCI USA, V89, P2516, DOI 10.1073/pnas.89.7.2516; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; CULLMANN G, 1993, GENE, V134, P191, DOI 10.1016/0378-1119(93)90093-I; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FROSINA G, 1994, BIOCHEM J, V304, P699, DOI 10.1042/bj3040699; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P6284, DOI 10.1073/pnas.76.12.6284; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; JONSSON ZO, 1998, IN PRESS EMBO J; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Longley MJ, 1997, J BIOL CHEM, V272, P10917; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; UITTO L, 1995, NUCLEIC ACIDS RES, V23, P244, DOI 10.1093/nar/23.2.244; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wang ZG, 1997, J BIOL CHEM, V272, P24064, DOI 10.1074/jbc.272.38.24064; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WEISER T, 1991, J BIOL CHEM, V266, P10420; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919	38	158	162	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					835	843		10.1038/sj.onc.1202001	http://dx.doi.org/10.1038/sj.onc.1202001			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780000				2022-12-28	WOS:000075448800005
J	Suzuki, M; Okuyama, S; Okamoto, S; Shirasuna, K; Nakajima, T; Hachiya, T; Nojima, H; Sekiya, S; Oda, K				Suzuki, M; Okuyama, S; Okamoto, S; Shirasuna, K; Nakajima, T; Hachiya, T; Nojima, H; Sekiya, S; Oda, K			A novel E2F binding protein with Myc-type HLH motif stimulates E2F-dependent transcription by forming a heterodimer	ONCOGENE			English	Article						human EC cells; E2F binding protein; E2F-dependent transcription	EMBRYONAL CARCINOMA-CELLS; RETINOBLASTOMA PROTEIN; MAMMALIAN-CELLS; IN-VIVO; FACTOR DRTF1/E2F; CYCLE CONTROL; DP FAMILY; DIFFERENTIATION; CLONING; GENE	The human embryonal carcinoma cells NEC14 can be induced to differentiate morphologically by the addition of 10(-2) M N, N'-hexamethylene-bis-acetamide and cease to grow in several days. Transcription factors of the E2F/DP family have been shown to be closely related to the regulation of cell proliferation. To analyse cellular proteins which interact with E2F in NEC14 cells, cDNA clones encoding E2F binding proteins were isolated from a lambda ZAP II NEC14 cell library with the P-32-labeled GST (Glutathione S-transferase)-E2F-l fusion protein as a probe. One of the clones encodes E2FBP1 which has the helix-loop-helix (HLH) motif, but lacks the basic domain and the zipper structure usually found at N- and C-terminal sides to the HLH motif, respectively, The arrangement of amino acids in the helix 1 and helix 2 regions is quite similar to those of Mxi and Mad, but different from those of E2F-1 and DP-1, Western blot analysis of the immunoprecipitates prepared with anti-E2FBP1 antibody showed that E2FBP1 associates with both E2F-1 and DP-1 in vivo. E2FBP1 alone has no DNA binding activity, but bind to the E2F site through heterodimerization with E2F-1 but not with DP-1, Although E2FBP1 lacks the transactivation domain, it stimulates E2F site-dependent transcription in cooperation with E2F-1.	Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan; MBL Co Ltd, Ina Labs, Nagano 396, Japan; Osaka Univ, Microbial Dis Res Inst, Suita, Osaka 565, Japan; Chiba Univ, Sch Med, Dept Obstet & Gynecol, Chiba 280, Japan	Tokyo University of Science; Osaka University; Chiba University	Oda, K (corresponding author), Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BUCK V, 1995, ONCOGENE, V11, P31; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBEIL HB, 1995, ONCOGENE, V11, P909; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; ELIZABETH AK, 1987, J BIOL CHEM, V262, P9136; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARA E, 1993, ONCOGENE, V8, P1023; HARA E, 1991, NUCLEIC ACIDS RES, V19, P7097, DOI 10.1093/nar/19.25.7097; HARA E, 1995, METH NEUROSCI, V26, P262; HASEGAWA T, 1991, DIFFERENTIATION, V47, P107, DOI 10.1111/j.1432-0436.1991.tb00228.x; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; NEVINS JR, 1992, SCIENCE, V258, P424; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; PEASON BE, 1991, MOL CELL BIOL, V11, P2081; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SEKIYA S, 1990, GYNECOL ONCOL, V36, P69, DOI 10.1016/0090-8258(90)90111-W; SEKIYA S, 1985, DIFFERENTIATION, V29, P259, DOI 10.1111/j.1432-0436.1985.tb00325.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU CL, 1995, MOL CELL BIOL, V15, P2536; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; ZAMANIAN M, 1993, MOL CELL BIOL, V13, P389; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	35	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					853	865		10.1038/sj.onc.1202163	http://dx.doi.org/10.1038/sj.onc.1202163			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780002				2022-12-28	WOS:000075448800007
J	Santoro, MM; Penengo, L; Minetto, M; Orecchia, S; Cilli, M; Gaudino, G				Santoro, MM; Penengo, L; Minetto, M; Orecchia, S; Cilli, M; Gaudino, G			Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor	ONCOGENE			English	Article						metastasis; Ron; signal transduction; tumorigenesis; tyrosine kinase	MACROPHAGE-STIMULATING PROTEIN; LIGAND-INDEPENDENT ACTIVATION; NEOPLASIA TYPE 2B; NIH 3T3 CELLS; C-KIT; CONSERVED FEATURES; RET PROTOONCOGENE; TRANSFORMING GENE; CATALYTIC DOMAIN; GROWTH	Ron (the receptor for Macrophage Stimulating Protein) has never been implicated before in human malignancies or in cell transformation. In this report we show that Ron can acquire oncogenic potential by means of two amino acid substitutions-D1232V and M1254T-affecting highly conserved residues in the tyrosine kinase domain, The same mutations in Kit and Pet have been found associated with two human malignancies, mastocytosis and Multiple Endocrine Neoplasia type 2B (MEN2B), respectively. Both mutations caused Ron-mediated transformation of 3T3 fibroblasts and tumour formation in nude mice. Moreover, cells transformed by the oncogenic Ron mutants displayed high metastatic potential. The Ron mutant receptors were constitutively active and the catalytic efficiency of the mutated kinase was higher than that of wild-type Ron. Oncogenic Ron mutants enhanced activation of the Ras/MAPK cascade with respect to wild type Ron, without affecting the JNK/SAPK pathway. Expression of Ron mutants in 3T3 fibroblasts led to different patterns of tyrosine-phosphorylated proteins. These data show that point mutations altering catalytic properties and possibly substrate specificity of the Ron kinase may force cells toward tumorigenesis and metastasis.	Univ Torino, Dipartimento Sci & Tecnol Avanzate, I-15100 Alessandria, Italy; Ist Sci San Raffaele, DIBIT, I-20138 Milan, Italy; Ist Nazl Ric Canc, Ctr Biotecnol Avanzate, I-16132 Genoa, Italy	University of Eastern Piedmont Amedeo Avogadro; University of Turin; Vita-Salute San Raffaele University; University of Genoa; IRCCS AOU San Martino IST	Gaudino, G (corresponding author), Univ Torino, Dipartimento Sci Med, Sede Novara,Via Solaroli 17, I-28100 Novara, Italy.		Cilli, Michele/AAB-8529-2019	PENENGO, Lorenza/0000-0001-7888-4473; SANTORO, Massimo Mattia/0000-0003-4605-5085; Cilli, Michele/0000-0003-4083-8986				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Banu N, 1996, J IMMUNOL, V156, P2933; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Collesi C, 1996, MOL CELL BIOL, V16, P5518; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Correll Pamela H., 1997, Genes and Function, V1, P69; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; del Peso L, 1997, ONCOGENE, V15, P3047; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; Pandit SD, 1996, J BIOL CHEM, V271, P5850, DOI 10.1074/jbc.271.10.5850; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SAWYERS CL, 1994, CELL, V77, P1; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STACEY DW, 1991, ONCOGENE, V6, P2297; TSUJIMURA T, 1994, BLOOD, V83, P2619; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; Wang MH, 1996, ONCOGENE, V13, P2167; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493	49	81	81	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	1998	17	6					741	749		10.1038/sj.onc.1201994	http://dx.doi.org/10.1038/sj.onc.1201994			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715276	Green Submitted			2022-12-28	WOS:000075337200009
J	Kunimura, C; Kikuchi, K; Ahmed, N; Shimizu, A; Yasumoto, S				Kunimura, C; Kikuchi, K; Ahmed, N; Shimizu, A; Yasumoto, S			Telomerase activity in a specific cell subset co-expressing integrin beta 1/EGFR but not p75(NGFR)/bcl2/integrin beta 4 in normal human epithelial cells	ONCOGENE			English	Article						bcl-2; epithelial cells; integrin beta 1, beta 4; p75(NGFR); telomerase regulation	GROWTH-FACTOR RECEPTOR; STEM-CELLS; IMMORTAL CELLS; HUMAN FIBROBLASTS; HUMAN SKIN; INTEGRIN; DIFFERENTIATION; ALPHA-6-BETA-4; HEMIDESMOSOMES; KERATINOCYTES	Telomerase activity is correlated with the immortality of various cultured cells and cancer cells. The activity, however, is also demonstrated in various normal regenerating cells which normally have a finite life span in vivo and in vitro, though its biological implication remains unclear. Using cultured normal human epithelial cells, we show that telomerase activity is associated with epithelial cell subsets which actively proliferate in vitro. Unlike in most cancer cell lines, telomerase activity was evidently up-regulated when the cells entered into S phase in primary human epithelial cells. To characterize the cells which have telomerase activity, the primary human epithelial cell population of uterine cervix was dissociated into several distinctive cellular subsets by means of immunocytochemical cell fractionation. Telomerase activity was found to be closely associated with the subset which expressed predominantly integrin pi and epidermal growth factor receptor. We further identified the telomerase-negative subpopulation which contained a small subset that strongly coexpresses p75(NGFR) low affinity nerve growth factor receptor, integrin beta 4 and bcl-2 protein. The location of the p75(NGFR)-expressing cells contrasts to that of the Ki-67 positive cells in vivo and is distinctive of telomerase positive cycling cells, indicating that these cells remain at the G0 phase, The present study supports the notion that telomerase activity is linked to cell cycle regulation, implying that telomerase is activated upon cell proliferation in regenerating normal human epithelial cells.	Kanagawa Canc Ctr, Res Inst, Lab Mol Cell Biol, Asahi Ku, Yokohama, Kanagawa 241, Japan	Kanagawa Prefectural Cancer Center	Yasumoto, S (corresponding author), Kanagawa Canc Ctr, Res Inst, Lab Mol Cell Biol, Asahi Ku, 1-1-2 Nakao, Yokohama, Kanagawa 241, Japan.							Albanell J, 1996, CANCER RES, V56, P1503; ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Bestilny LJ, 1996, CANCER RES, V56, P3796; BUCK CR, 1987, P NATL ACAD SCI USA, V84, P3060, DOI 10.1073/pnas.84.9.3060; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Harada H, 1998, J ORAL PATHOL MED, V27, P11; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1995, TELOMERES, P247; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1996, MOL CELL BIOL, V16, P2932; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; Kikuchi K, 1997, CELL GROWTH DIFFER, V8, P571; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Kyo S, 1997, CANCER RES, V57, P610; LAVKER RM, 1991, ANN NY ACAD SCI, V642, P214; LAVKER RM, 1982, SCIENCE, V215, P1239, DOI 10.1126/science.7058342; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Loeffler Markus, 1997, P1, DOI 10.1016/B978-012563455-7/50002-7; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Ohta Y, 1997, JPN J CANCER RES, V88, P644, DOI 10.1111/j.1349-7006.1997.tb00432.x; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; POTTEN CS, 1988, J CELL SCI, P45; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SARIOLA H, 1991, SCIENCE, V254, P571, DOI 10.1126/science.1658930; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; TSUTSUMI K, 1993, AM J PATHOL, V143, P1150; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; YASUMOTO S, 1991, J VIROL, V65, P2000, DOI 10.1128/JVI.65.4.2000-2009.1991; Yasumoto S, 1996, ONCOGENE, V13, P433; YASUMOTO S, 1992, TISSUE CULT RES COMM, V11, P13; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	59	42	43	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	1998	17	2					187	197		10.1038/sj.onc.1201916	http://dx.doi.org/10.1038/sj.onc.1201916			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674703				2022-12-28	WOS:000074706700007
J	Froeschle, A; Alric, S; Kitzmann, M; Carnac, G; Aurade, F; Rochette-Egly, C; Bonnieu, A				Froeschle, A; Alric, S; Kitzmann, M; Carnac, G; Aurade, F; Rochette-Egly, C; Bonnieu, A			Retinoic acid receptors and muscle b-HLH proteins: partners in retinoid-induced myogenesis	ONCOGENE			English	Article						retinoic acid receptors; muscle b-HLH proteins; protein-protein interaction; myogenesis	THYROID-HORMONE RECEPTOR; HELIX-LOOP-HELIX; BOX TRANSCRIPTION FACTORS; LIGAND-BINDING DOMAIN; CELL-LINE BA-HAN-1C; X RECEPTOR; NUCLEAR RECEPTORS; RXR-ALPHA; ALL-TRANS; IN-VITRO	The results reported here indicate that retinoic acid (RA) induces growth arrest and differentiation only in MyoD-expressing muscle cells. Transient transfection assays reveal a functional interaction between MyoD, a key myogenic regulator and RA-receptors, principal mediators of RA actions, Interestingly, we demonstrate that RXR-MyoD-containing complexes are recruited at specific MyoD DNA-binding sites in muscle cells, Furthermore, we also demonstrate that RA-receptors and the muscle basic helix-loop-helix (b-HLH) proteins interact physically. Mutational analysis suggests that this interaction occurs via the basic region of muscle b-HLH proteins and the DIVA-binding domain of RA-receptors and is important for functional interactions between these two families of transcription factors. In conclusion, these results highlight novel interactions between two distinct groups of regulatory proteins that influence cell growth and differentiation.	INRA, Lab Differenciat Cellulaire & Croissance, F-34060 Montpellier 1, France; CNRS, CRBM, Cell Biol Unit, F-34033 Montpellier, France; Inst Pasteur, Dept Biol Mol, URA 1148 CNRS, F-75724 Paris 15, France; CU Strasbourg, GBMC, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	INRAE; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bonnieu, A (corresponding author), INRA, Lab Differenciat Cellulaire & Croissance, Pl Pierre Viala, F-34060 Montpellier 1, France.		Bonnieu, Anne/ABA-7182-2020; Carnac, Gilles/N-6744-2018	Carnac, Gilles/0000-0002-3518-8774				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ARNOLD HH, 1992, J CELL BIOL, V118, P877, DOI 10.1083/jcb.118.4.877; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DE LUCA LM, 1991, FASEB J, V5, P2924; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Froeschle A, 1996, ONCOGENE, V12, P411; GABBERT HE, 1988, CANCER RES, V48, P5264; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Groisman R, 1996, J BIOL CHEM, V271, P5258; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Gudas L. J., 1994, RETINOIDS BIOL CHEM, P443; HALEVY O, 1993, J CELL PHYSIOL, V154, P566, DOI 10.1002/jcp.1041540315; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hofmann Clementine, 1994, P387; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE IJ, 1994, P NATL ACAD SCI USA, V91, P1647, DOI 10.1073/pnas.91.5.1647; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOMOI T, 1992, BIOCHEM BIOPH RES CO, V187, P245, DOI 10.1016/S0006-291X(05)81484-6; Montarras D, 1996, J CELL SCI, V109, P551; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; REZNIKOFF CA, 1973, CANCER RES, V33, P3239; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; VOMBAUR E, 1995, EMBO J, V15, P110; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	79	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	1998	16	26					3369	3378		10.1038/sj.onc.1201894	http://dx.doi.org/10.1038/sj.onc.1201894			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692544				2022-12-28	WOS:000074544100003
J	Fukuda, K; Kawata, S; Tamura, S; Matsuda, Y; Inui, Y; Igura, T; Inoue, S; Kudara, T; Matsuzawa, Y				Fukuda, K; Kawata, S; Tamura, S; Matsuda, Y; Inui, Y; Igura, T; Inoue, S; Kudara, T; Matsuzawa, Y			Transforming growth factor-beta 1-induced degradation of activated Src tyrosine kinase in rat fibroblasts	ONCOGENE			English	Article						TGF-beta 1; c-Src; v-Src; MAPK; PDGF	HUMAN-COLON-CARCINOMA; FACTOR-BETA-RECEPTOR; SMOOTH-MUSCLE CELLS; ROUS-SARCOMA VIRUS; TGF-BETA; PHOSPHOLIPASE C-GAMMA-1; ANGIOTENSIN-II; CANCER CELLS; INHIBITION; FAMILY	Transforming growth factors-beta (TGF-beta s) play pivotal roles in the regulation of cell growth and differentiation, although little is known regarding the regulation of cytoplasmic components by TGF-beta s, Src tyrosine kinase is required for signal transduction of various cytokine receptors, including epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and G-protein coupled receptors, Moreover, Src tyrosine kinase is important in signal cross-talk between these receptors, To determine whether Src kinase is also involved in TGF-beta signaling,,ce examined the effects of TGF-beta 1 on Src in the rat fibroblast cell line 3Y1 and in v-Src-transformed 3Y1 (SR-3Y1), TGF-beta 1 inhibited mitogen-activated protein kinase activity and inhibited growth in SR-3Y1 cells, while it did not affect the growth of 3Y1 cells. TGF-beta 1 significantly decreased v-Src kinase activity and protein abundance in SR-3Y1 cells, mainly by accelerating the degradation of v-Src. In contrast, in 3Y1 cells, TGF-beta 1 did not affect c-Src abundance or kinase activity. However, upon activation of c-Src in 3Y1 cells by PDGF, TGF-beta 1 decreased Src abundance. Additionally, in 3Y1 cells transfected with an activated c-Src mutant which lacks the SH3 domain, its level was decreased by TGF-beta 1 treatment. These findings suggest that TGF-beta 1 specifically induces degradation of activated Src kinase, This may be a novel mechanism for cross-talk between growth factors and TGF-beta.	Osaka Univ, Sch Med, Dept Internal Med 2, Suita, Osaka 565, Japan	Osaka University	Fukuda, K (corresponding author), Osaka Univ, Sch Med, Dept Internal Med 2, 2-2 Yamadaoka, Suita, Osaka 565, Japan.							ATFI A, 1994, J BIOL CHEM, V269, P30688; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; FILMUS J, 1992, ONCOGENE, V7, P521; GRUPPUSO PA, 1991, J BIOL CHEM, V266, P3444; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HOWE PH, 1993, J BIOL CHEM, V268, P21448; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KISO S, 1994, HEPATOLOGY, V20, P1303, DOI 10.1016/0270-9139(94)90772-2; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kumble S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/gast.1997.v112.pm9024288; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LESCHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MORI S, 1993, J BIOL CHEM, V268, P577; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; Oshikawa O, 1996, BIOCHEM BIOPH RES CO, V222, P770, DOI 10.1006/bbrc.1996.0819; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARK S, 1992, J BIOL CHEM, V267, P17194; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PENG ZY, 1995, ONCOGENE, V11, P1955; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	50	15	16	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3349	3356		10.1038/sj.onc.1201896	http://dx.doi.org/10.1038/sj.onc.1201896			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692542				2022-12-28	WOS:000074544100001
J	Carrere, S; Verger, A; Flourens, A; Stehelin, D; Duterque-Coquillaud, M				Carrere, S; Verger, A; Flourens, A; Stehelin, D; Duterque-Coquillaud, M			Erg proteins, transcription factors of the Ets family, form homo, heterodimers and ternary complexes via two distinct domains	ONCOGENE			English	Article						Ets family; protein interaction; transcription regulation	DNA-BINDING MOTIF; MURINE ETS-1; SECONDARY STRUCTURE; MOLECULAR-CLONING; GENE-EXPRESSION; ONCOGENE; MEMBER; CELLS; PEA3; PROTOONCOGENES	The ets genes family encodes a group of proteins which function as transcription factors under physiological conditions. We report here that the Erg proteins, members of the Ets family, form homo and heterodimeric complexes in vitro. We demonstrate that the Ergp55 protein isoform forms dimers,vith itself and with the two other isoforms, Ergp49 and Ergp38. Using a set of Erg protein deletion mutants, we define two distinct domains independently involved in dimerization. The first one is located in the amino-terminal part of the protein containing the pointed domain (PNT), conserved in a subset of Ets proteins. The second one resides within the ETS domain, the DNA-binding domain. We also show that the Erg protein central region behaves as an inhibitory domain of dimerization and its removal enhances the Ergp55 transactivation properties. Furthermore, Ergp55 forms heterodimers with some other Ets proteins. Among the latter, we show that Fli-1, Ets-2, Er81 and Pu-1 physically interact with Erg. Finally, rye show that the formation of the previously described ternary complex Ergp55/Fos/jun is mediated by ETS domain and Jun protein, while the ternary complex Ergp49/Fos/Jun is mediated by Fos protein.	Inst Biol, CNRS, UMR 319, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS)	Duterque-Coquillaud, M (corresponding author), Inst Biol, CNRS, UMR 319, BP447,1 Rue Calmette, F-59021 Lille, France.			verger, alexis/0000-0002-0299-2344; Duterque-Coquillaud, Martine/0000-0003-3943-5629				Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BAUD V, 1991, GENOMICS, V11, P223, DOI 10.1016/0888-7543(91)90124-W; Bornemann D, 1996, DEVELOPMENT, V122, P1621; Buttice G, 1996, ONCOGENE, V13, P2297; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRAVES BJ, 1998, IN PRESS ADV CANC RE, V75; Grevin D, 1996, GENE, V174, P185, DOI 10.1016/0378-1119(96)00357-5; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; JEON IS, 1995, ONCOGENE, V10, P1229; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KHERROUCHE Z, 1998, ONCOGENE; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Melet F, 1996, MOL CELL BIOL, V16, P2708; MONTE D, 1994, ONCOGENE, V9, P1397; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SETH A, 1990, ONCOGENE, V5, P1761; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920	42	88	91	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3261	3268		10.1038/sj.onc.1201868	http://dx.doi.org/10.1038/sj.onc.1201868			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681824				2022-12-28	WOS:000074343600006
J	Lanyi, A; Deb, D; Seymour, RC; Ludes-Meyers, JH; Subler, MA; Deb, S				Lanyi, A; Deb, D; Seymour, RC; Ludes-Meyers, JH; Subler, MA; Deb, S			'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain	ONCOGENE			English	Article						mutant p53; transcriptional activation, domain	FACTOR RECEPTOR PROMOTER; WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; TRANSFORMING MUTANTS; FUNCTION MUTATIONS; SUPPRESSOR GENE; MDR1 GENE; PROTEIN; CELLS	Tumor-derived p53 mutants can transcriptionally activate a number of promoters of genes involved in cellular proliferation. For this transactivation, mutant p53 does not use the wild-type p53 DNA-binding site, suggesting a mechanism of transactivation that is independent of direct DNA binding. Here me describe our analysis of the domain requirements for mutant p53 to transactivate promoters of the human epidermal growth factor receptor (EGFR), human multiple drug resistance 1 (MDR-1) and human proliferating cell nuclear antigen (PCNA) genes. We also report the identification of a structural domain required for the 'Gain of function' property of mutant p53-281G, 'Gain of function' is measured as the tumorigenicity (in nude mice) of 10(3) murine cells expressing mutant p53 constitutively. We have generated internal deletion mutants of p53-281G deleting conserved domains I, II, III, IV and V, individually. We have also generated one deletion mutant eliminating amino acids 100 through 300 that removes four of the five conserved domains (II-V); another mutant, p53-281G del 393-327, deletes the oligomerization and nonsequence-specific nucleic acid-binding domains of p53, For the EGFR and MDR-1 promoters, all these mutants have significantly lower transactivation ability than intact p53-281G, These deletion mutants, however, significantly activated the pCNA promoter, suggesting that the mechanism of transactivation of the PCNA promoter is different from that of the EGFR and MDR-I promoters, When expressed constitutively in 10(3) cells, p53-281G del 393-327 was found to be defective in inducing tumor formation in nude mice although intact p53-281G was very efficient. Thus, our results suggest that structural domains near the C-terminus are needed for 'gain of function'.	Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Deb, S (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NATIONAL CANCER INSTITUTE [R01CA070712] Funding Source: NIH RePORTER; NCI NIH HHS [CA70712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHEN CJ, 1990, J BIOL CHEM, V265, P506; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSIAO M, 1994, AM J PATHOL, V145, P702; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE W, 1994, STRUCT BIOL, V1, P877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1995, ONCOGENE, V10, P2387; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; Muller BF, 1996, ONCOGENE, V12, P1941; OROURKE RW, 1990, ONCOGENE, V5, P1829; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHALUSKI G, 1991, CANCER RES, V51, P5232; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	47	74	75	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	1998	16	24					3169	3176		10.1038/sj.onc.1201857	http://dx.doi.org/10.1038/sj.onc.1201857			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671396				2022-12-28	WOS:000074261300010
J	Landesman-Bollag, E; Channavajhala, PL; Cardiff, RD; Seldin, DC				Landesman-Bollag, E; Channavajhala, PL; Cardiff, RD; Seldin, DC			p53 deficiency and misexpression of protein kinase CK2 alpha collaborate in the development of thymic lymphomas in mice	ONCOGENE			English	Article						casein kinase II; lymphoma; oncogene; protein kinase; p53; transgenic mice	TUMOR SUPPRESSOR PROTEIN; STRANDED-DNA ENDS; C-TERMINAL DOMAIN; T-CELL TUMORS; WILD-TYPE P53; TRANSGENIC MICE; CASEIN KINASE-2; PHOSPHORYLATION SITE; CONSENSUS SEQUENCES; P53-DEFICIENT MICE	Protein kinase CK2 (casein kinase II) is a serine-threonine protein kinase with many substrates, some of which are involved in cell cycle regulation. CK2 activity is elevated in human solid tumors and leukemia, and dysregulated expression of CK2 induces lymphoma in transgenic mice. Mice that are deficient in p53 also develop lymphomas, and p53 activity may be regulated by CK2 phosphorylation, Here we demonstrate that CK2 alpha transgenic mice partially or completely deficient in p53 develop thymic lymphomas at a markedly accelerated rate when compared to p53-deficient mice lacking the transgene, Lymphomas originating from CK2 alpha transgenic mice that are heterozygous for p53 generally Lose the wild type p53 allele, indicating that loss of p53 is an important step in tumor progression. Moreover, though lymphomas occur as early as 3 weeks of age in the transgenic mice that are nullizygous for p53, they are still monoclonal, indicating that additional stochastic mutations are required for their development. These lymphomas express high levels of myc mRNA and frequently ectopically express Lmo-2, a transcription factor involved in human T cell acute lymphocytic leukemia. The p53-null CK2 alpha transgenic lymphomas grow rapidly but are highly prone to apoptosis, suggesting that transformation occurs through synergistic dysregulation of cell cycle control induced by misexpression of CK2 and loss of function of p53.	Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Pathol, Boston, MA 02118 USA; Univ Calif Davis, Dept Pathol, Davis, CA 95616 USA	Boston University; Boston University; Boston University; University of California System; University of California Davis	Seldin, DC (corresponding author), Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA.			Seldin, David C/0000-0003-0168-2333	NCI NIH HHS [CA71796] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLYTH K, 1995, ONCOGENE, V10, P1717; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BOUSSET K, 1993, ONCOGENE, V8, P3211; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Condorelli GL, 1996, CANCER RES, V56, P5113; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELSON A, 1995, ONCOGENE, V11, P181; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; FILHOL O, 1992, J BIOL CHEM, V267, P20577; Filhol O, 1996, BIOCHEM J, V316, P331, DOI 10.1042/bj3160331; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FRIEDRICH TD, 1989, BIOCHIM BIOPHYS ACTA, V992, P41, DOI 10.1016/0304-4165(89)90048-2; FUKASAWA K, 1996, SCIENCE, V271, P174; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HRUBEY TW, 1990, BIOCHEM BIOPH RES CO, V172, P190, DOI 10.1016/S0006-291X(05)80192-5; HSU B, 1995, ONCOGENE, V11, P175; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HWANG LY, 1995, CURR OPIN IMMUNOL, V7, P659, DOI 10.1016/0952-7915(95)80074-3; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; LARSON RC, 1994, ONCOGENE, V9, P3675; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; Lowsky R, 1997, BLOOD, V89, P2276, DOI 10.1182/blood.V89.7.2276; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; Matthews DE, 1996, USING UNDERSTANDING; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1991, FEBS LETT, V279, P307, DOI 10.1016/0014-5793(91)80174-2; MESTRES P, 1994, ACTA ANAT, V149, P13; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MIYASHITA T, 1995, CELL, V80, P293; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; NEALE GAM, 1995, BLOOD, V86, P3060; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PURDIE CA, 1994, ONCOGENE, V9, P603; ROLIEY N, 1994, ONCOGENE, V9, P3067; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SELDIN DC, 1995, CURR OPIN IMMUNOL, V7, P665, DOI 10.1016/0952-7915(95)80075-1; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SIU G, 1984, CELL, V37, P393, DOI 10.1016/0092-8674(84)90369-6; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	78	140	143	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2965	2974		10.1038/sj.onc.1201854	http://dx.doi.org/10.1038/sj.onc.1201854			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662328				2022-12-28	WOS:000074125300002
J	Schmidt-Kastner, PK; Jardine, K; Cormier, M; McBurney, MW				Schmidt-Kastner, PK; Jardine, K; Cormier, M; McBurney, MW			Absence of p53-dependent cell cycle regulation in pluripotent mouse cell lines	ONCOGENE			English	Article						embryonal carcinoma; stem cells; insertional mutation; DNA methylation	EMBRYONAL CARCINOMA-CELLS; WILD-TYPE P53; MURINE LEUKEMIA-VIRUS; DNA-DAMAGE; GENE-EXPRESSION; INDUCED APOPTOSIS; STEM-CELLS; TUMOR SUPPRESSORS; FACTOR FAMILY; MUTANT P53	We examined the expression of p53 in three lines of pluripotent embryonal carcinoma (EC) and ES cells, p53 mRNA and protein levels were constitutively high in two lines but absent from one. In the P19 line of EC cells neither p53 protein nor mRNA was detected. The first intron of the p53 gene in these cells had been invaded by murine leukemia virus and there was extensive hypermethylation of the p53 gene accompanying its inactivation. In all three cell lines, irradiation resulted in arrest of the cells in the G2 but not in the G1 phase of the cell cycle despite the induction of p21(cip1) in the cell lines expressing p53. Thus, the chromosomal stability of EC and ES cells appears to be not dependent on the p53 protein and we interpret our results to suggest that these cells may require the deletion of p53 dependent cell cycle regulation in order to become immortalized.	Univ Ottawa, Ottawa Reg Canc Ctr, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	McBurney, MW (corresponding author), Univ Ottawa, Ottawa Reg Canc Ctr, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BOND JA, 1994, ONCOGENE, V9, P1885; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CZOSNEK HH, 1984, MOL CELL BIOL, V4, P1638, DOI 10.1128/MCB.4.8.1638; DAVID YB, 1988, ONCOGENE, V3, P179; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GAUTSCH JW, 1983, NATURE, V301, P32, DOI 10.1038/301032a0; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAGGARTY A, 1991, CELL GROWTH DIFFER, V2, P503; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; HARPER JW, 1993, CELL, V75, P805; HARTUNG S, 1986, NATURE, V320, P365, DOI 10.1038/320365a0; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HUPPI K, 1994, ONCOGENE, V9, P3017; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1976, J CELL PHYSIOL, V89, P441, DOI 10.1002/jcp.1040890310; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MITREITER K, 1994, VIROLOGY, V200, P837, DOI 10.1006/viro.1994.1253; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; NICOLAS JF, 1975, ANN INST PASTEUR MIC, VA126, P3; Okazawa H, 1996, J CELL BIOL, V132, P955, DOI 10.1083/jcb.132.5.955; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Sambrook J., 2002, MOL CLONING LAB MANU; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SITHANANDAM G, 1988, J VIROL, V62, P932, DOI 10.1128/JVI.62.3.932-943.1988; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; SLACK RS, 1993, ONCOGENE, V8, P1585; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Staines WA, 1996, NEUROSCIENCE, V71, P845, DOI 10.1016/0306-4522(95)00494-7; Stevens L C, 1967, Adv Morphog, V6, P1; STEWART N, 1995, ONCOGENE, V10, P109; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	60	42	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3003	3011		10.1038/sj.onc.1201835	http://dx.doi.org/10.1038/sj.onc.1201835			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662333				2022-12-28	WOS:000074125300007
J	Blattner, C; Bender, K; Herrlich, P; Rahmsdorf, HJ				Blattner, C; Bender, K; Herrlich, P; Rahmsdorf, HJ			Photoproducts in transcriptionally active DNA induce signal transduction to the delayed U.V.-responsive genes for collagenase and metallothionein	ONCOGENE			English	Article						ultraviolet irradiation; p53 stabilization; collagenase 1; metallothionein; transcription-coupled repair; pyrimidine dimers	IMMUNODEFICIENCY VIRUS TYPE-1; CYCLOBUTANE PYRIMIDINE DIMERS; RECEPTOR TYROSINE KINASES; GROUP-C FIBROBLASTS; XERODERMA-PIGMENTOSUM; UV-LIGHT; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR FACTOR; NONIRRADIATED CELLS; ULTRAVIOLET-LIGHT	Mammalian cells in culture react to ultraviolet irradiation with the massive transcriptional activation of several genes and with the stabilization of the p53 protein. While U.V.-induced transcription of several immediate-response genes depends on U.V.-induced activation of signal transduction generated by non-nuclear mechanisms, stabilization of p53 and the transcription of several delayed-response genes are triggered by U.V.-induced DNA damage. By comparing dose responses for the activation by U.V. of delayed-responsive genes (collagenase 1, metallothionein IIA) in cells from patients with different DNA repair deficiencies (complementation groups of Xeroderma pigmentosum, Cockayne's syndrome and Trichothiodystrophy), we show here that U.V.-induced transcription of these genes does depend on pyrimidine dimers in transcribed regions of the genome (but not on damage in its silent part). Since all cells with defects in DNA repair that had been tested and which lack different enzymes, respond to U.V. with expression of these same genes, functional repair does not appear to be required for the induction of expression, and repair intermediates (which would not be identical in cells of different repair deficiency) cannot be responsible for signal generation.	Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Herrlich, P (corresponding author), Forschungszentrum Karlsruhe, Inst Genet, POB 3640, D-76021 Karlsruhe, Germany.		Blattner, Christine/ABI-2152-2020; Blattner, Christine/H-2105-2013	Blattner, Christine/0000-0002-7250-5273; Blattner, Christine/0000-0002-7250-5273				ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; [Anonymous], 1985, DNA REPAIR; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERNDER K, 1997, J PHOTOCH PHOTOBIO B, V37, P1; BLATTNER C, 1994, ENVIRON MOL MUTAGEN, V24, P3, DOI 10.1002/em.2850240103; BOOTSMA D, 1994, MUTAT RES, V307, P15, DOI 10.1016/0027-5107(94)90273-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUGHTON BC, 1994, NAT GENET, V7, P189, DOI 10.1038/ng0694-189; BROUGHTON BC, 1990, MUTAT RES, V235, P33, DOI 10.1016/0921-8777(90)90020-6; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; EVENO E, 1995, CANCER RES, V55, P4325; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HANAWALT PC, 1995, MUTAT RES-DNA REPAIR, V336, P101, DOI 10.1016/0921-8777(94)00061-A; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRLICH P, 1997, MOL BIOL TOXICOLOGY, pCH31; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Isaacs JS, 1997, ONCOGENE, V14, P1669, DOI 10.1038/sj.onc.1201001; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRAMER M, 1993, J BIOL CHEM, V268, P6734; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEHMANN AR, 1988, CANCER RES, V48, P6090; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MISKIN R, 1981, P NATL ACAD SCI-BIOL, V78, P6236, DOI 10.1073/pnas.78.10.6236; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RENZING J, 1995, ONCOGENE, V10, P1865; ROTEM N, 1987, MOL CELL BIOL, V7, P622, DOI 10.1128/MCB.7.2.622; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SIEGEL J, 1995, ONCOGENE, V11, P1363; STEFANINI M, 1993, CARCINOGENESIS, V14, P1101, DOI 10.1093/carcin/14.6.1101; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; Tolmie J L, 1994, Clin Dysmorphol, V3, P1; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Weeda G, 1997, AM J HUM GENET, V60, P320; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YAROSH DB, 1993, J INVEST DERMATOL, V100, P790, DOI 10.1111/1523-1747.ep12476573	57	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2827	2834		10.1038/sj.onc.1201827	http://dx.doi.org/10.1038/sj.onc.1201827			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671403				2022-12-28	WOS:000073988200001
J	Li, JJ; Rhim, JS; Schlegel, R; Vousden, KH; Colburn, NH				Li, JJ; Rhim, JS; Schlegel, R; Vousden, KH; Colburn, NH			Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappa B transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes	ONCOGENE			English	Article						dominant negative c-Jun; transcription factor; HPV; transformation; human keratinocytes	HUMAN PAPILLOMAVIRUS TYPE-16; PROMOTER-INDUCED TRANSFORMATION; TRANSGENIC MICE; GENE-PRODUCT; C-JUN; MULTISTAGE CARCINOGENESIS; TRANSCRIPTION FACTORS; RESISTANT VARIANTS; EPIDERMAL-CELLS; JB6 CELLS	AP-1 transactivation appears to be required for mouse JB6 cell neoplastic transformation induced by the tumor promoter TPA or epidermal growth factor (EGF). Exposure to AP-1 transrepressing retinoids and glucocorticoids and expression of a dominant negative c-jun (TAM67) blocked tumor promoter-induced AP-1 transactivation and neoplastic transformation. The aim of the present study was to extend the inquiry of the role of AP-1 and other transcription factors to human neoplastic progression. Expression of human papilloma-virus (HPV) 16 or 18 E6 and E7 immortalizes human keratinocytes and inhibits serum/calcium-stimulated differentiation. Further transformation by v-fos coexpression renders these keratinocytes tumorigenic in nude mice. We have analysed two series of E6/E7 immortalized human keratinocyte cell lines that show progressing phenotypes ranging from differentiation sensitive to anchorage-independent to tumorigenic in nude mice. We analysed the activities of AP-1 and NF-kappa B which may 'cross-talk'. Both DNA binding and transactivation of AP-1 and NF-kappa B transcription factors showed elevation in the anchorage-independent (16RH) and tumorigenic (18 v-fos) keratinocyte lines compared to the less progressed but immortalized cell lines. HPV E7 was expressed at a constant level shown by quantitative RT-PCR in both the more and the less progressed lines, indicating that E7 is not the factor limiting this progression. Blocked shift/supershift analysis indicates that Fos family member proteins especially Fra-1 and Fra-2 are related to progression and no changes found in the Jun family member proteins although they are present in the AP-1/DNA binding complex. When a dominant negative mutant c-jun driven by a human keratin 14 promoter was cotransfected with AP-1 or NF-kappa B reporters, both AP-1 and NF-kappa B activities were suppressed in the more progressed cell lines 16RH add 18 v-fos but not in the less progressed 16RL or 18 cell lines. Overexpression of the same dominant negative c-jun did not inhibit p53 dependent reporter transactivation, indicating the specificity of inhibition of AP-1 and NF-kappa B transactivation in the HPV-immortalized cells. Stable transfectants of this mutant c-jun in the two more progressed cell lines 16RH and 18 v-fos showed reduced AP-1 and NF-kappa B activation and reduced anchorage-independent growth. Together, these results indicate that activation of AP-1, NF-kappa B or both may contribute to neoplastic progression in HPV immortalized human keratinocytes and that specific targeting of the elevated levels seen in benign or malignant tumors might be effective for prevention or treatment of human cancer.	NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21702 USA; Georgetown Univ, Washington, DC USA; NCI, Frederick Canc Res & Dev Ctr, ABL, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Li, JJ (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21702 USA.			Li, Jian Jian/0000-0003-3694-9675				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CARROLL R, 1991, J VIROL, V65, P3460, DOI 10.1128/JVI.65.7.3460-3467.1991; CHEN TM, 1993, CANCER RES, V53, P1167; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; COLBURN NH, 1982, J CELL BIOCHEM, V18, P261, DOI 10.1002/jcb.1982.240180302; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CZEGLEDY J, 1994, INT J CANCER, V56, P182, DOI 10.1002/ijc.2910560206; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DRINKWATER NR, 1989, GENES SIGNAL TRANSDU, P3; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GREENHALGH DA, 1995, CELL GROWTH DIFFER, V6, P579; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; Joseloff E, 1997, MOL CARCINOGEN, V18, P26, DOI 10.1002/(SICI)1098-2744(199701)18:1<26::AID-MC4>3.0.CO;2-P; KEMP CJ, 1994, COLD SPRING HARB SYM, V59, P427, DOI 10.1101/SQB.1994.059.01.048; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1997, CANCER RES, V57, P3569; LI JJ, 1995, ONCOGENE, V10, P1989; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; Rosenberger SF, 1996, ONCOGENE, V12, P2301; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; WEINBERG RA, 1989, CANCER RES, V49, P3713; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wilding J, 1996, CANCER RES, V56, P5285; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272	49	101	104	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	1998	16	21					2711	2721		10.1038/sj.onc.1201798	http://dx.doi.org/10.1038/sj.onc.1201798			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652737				2022-12-28	WOS:000073812200002
J	David, G; Alland, L; Hong, SH; Wong, CW; DePinho, RA; Dejean, A				David, G; Alland, L; Hong, SH; Wong, CW; DePinho, RA; Dejean, A			Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein	ONCOGENE			English	Article						mSin3; histone deacetylases; APL; PLZF; Kruppel-like proteins	ZINC-FINGER GENE; RETINOIC ACID; TRANSCRIPTIONAL REPRESSION; ENCODING GENE; RAR-ALPHA; TRANSLOCATION; DOMAIN; RECEPTORS; REGULATOR; SIN3	The PLZF gene was identified first by its fusion with the retinoic acid receptor alpha gene in the t(11;17) translocation associated with a retinoic acid resistant form of acute promyelocytic leukemia (APL). It encodes a kruppel-like zinc finger protein with a POZ domain shared with a subset of regulatory proteins including the BCL6 leukemogenic protein. PLZF, like BCL6, strongly represses transcription initiated from different promoters. Here we show that PLZF associates in vitro and in vivo with the Mad co-repressor mSin3A and the histone deacetylase HDAC1. Two domains in PLZF and the PAH1 structure of mSin3A mediate these interactions. Trichostatin A, a specific inhibitor of histone deacetylases, significantly reduces PLZF repression. These data strongly suggest that, like nuclear receptors and Mad, PLZF represses transcription by recruiting a histone deacetylase through the SMRT-mSin3-HDAC co-repressor complex. We also show that BCL6 associates with HDAC1 indicating that this type of regulation might be common to POZ/Zinc finger proteins involved in human leukemias. This work supports a role far deregulated histone deacetylation in the development of both lymphoid and myeloid neoplasia in human and suggests that targeted histone deacetylase inhibitors may be useful for treatment of certain types of malignancies.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris 15, France; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA; Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California Davis	Dejean, A (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, 28 Rue Dr Roux, F-75724 Paris 15, France.		Dejean, Anne/L-5145-2018	DePinho, Ronald/0000-0002-5625-577X; Hong, Suk-Hyun/0000-0001-7541-4847; , gregory/0000-0002-3371-4558				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BREITMAN TR, 1990, CANCER RES, V50, P6268; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, ANTURE, V377, P454; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Rao G, 1996, ONCOGENE, V12, P1165; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEYFERT VL, 1996, ONCOGENE, V12, P2113; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YEYATI PL, 1997, UNPUB; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	43	248	276	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2549	2556		10.1038/sj.onc.1202043	http://dx.doi.org/10.1038/sj.onc.1202043			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627120				2022-12-28	WOS:000073672300012
J	Halaban, R; Cheng, E; Zhang, Y; Mandigo, CE; Miglarese, MR				Halaban, R; Cheng, E; Zhang, Y; Mandigo, CE; Miglarese, MR			Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1(E132), but not by deletion of p16(INK4A) or p21(WAF/CIP1)	ONCOGENE			English	Review						E2F1; cyclin D1; cyclin A; Rb; TPA; transcription	RETINOBLASTOMA GENE-PRODUCT; UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR E2F1; ACTIVATED PROTEIN-KINASE; FAMILIAL MELANOMA; GROWTH-FACTOR; MURINE MELANOCYTES; MALIGNANT-MELANOMA; FIBROBLASTS LEADS; INHIBITOR P21	Compared to normal melanocytes, melanoma cell lines exhibit overexpression of hyperphosphorylated retinoblastoma tumor suppressor protein (Rb) or a marked decrease in, or lack of, expression of Rb. Hyperphosphorylation of Rb results in increased E2F-mediated transactivation of target genes and cell cycle progression. Using a combination of gene disruption and ectopic expression in growth factor-dependent mouse melanocytes, we studied the roles of E2F1 and the p16(INK4A) and p21(WAF1/CIP1) CKIs (cyclin dependent kinase inhibitors) in the acquisition of TPA (12-O-tetradecanoyl phorbol-13-acetate)-independent growth in culture, a hallmark of melanomas. Surprisingly, melanocytes from p16(INK4A)-or p21(WAF1/CIP1)-null mice remained TPA-dependent, and disruption of p21(WAF1/CIP1) accelerated cell death in the absence of this mitogen. Disruption of E2F1 had the most profound effect on melanocyte growth, resulting in a fourfold decrease in growth rate in the presence of TPA. Furthermore, enforced overexpression of the DNA-binding-defective E2F1(E132) mutant conferred TPA-independence upon melanocytes and was associated with sequestration of Rb and constitutive expression of E2F1 target genes, including p21(WAF1/CIP1). We conclude that neutralization of Rb by E2F1(E132), but not the disruption of pl6(INK4A) or p21(WAF1/CIP1), resulted in the accumulation of free E2F and cell cycle progression. Thus, mechanisms other than the loss of p16(INK4A) or p21(WAF1/CIP1) that activate E2F may play an important role in melanomas.	Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA	Yale University	Halaban, R (corresponding author), Yale Univ, Sch Med, Dept Dermatol, POB 208059, New Haven, CT 06520 USA.							Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Bartkova J, 1996, CANCER RES, V56, P5475; BATAILLE V, 1995, BRIT J DERMATOL, V132, P134, DOI 10.1111/j.1365-2133.1995.tb08639.x; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P667; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1994, J CELL SCI, P81; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Flores JF, 1997, ONCOGENE, V15, P2999, DOI 10.1038/sj.onc.1201470; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; Geng Y, 1996, ONCOGENE, V12, P1173; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; Guldberg P, 1997, INT J CANCER, V72, P780, DOI 10.1002/(SICI)1097-0215(19970904)72:5<780::AID-IJC13>3.0.CO;2-D; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; Halaban R, 1996, SEMIN ONCOL, V23, P673; HALABAN R, 1998, IN PRESS INT J MOL M, V1; Haluska FG, 1995, CANCER SURV, V25, P277; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Healy E, 1996, J INVEST DERMATOL, V107, P318, DOI 10.1111/1523-1747.ep12363118; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Jiang HP, 1996, MOL CELL DIFFER, V4, P67; JIANG HP, 1995, ONCOGENE, V10, P1855; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; LIU L, 1995, ONCOGENE, V11, P405; Liu Y, 1996, CANCER RES, V56, P31; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maelandsmo GM, 1996, AM J PATHOL, V149, P1813; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Moll AC, 1997, OPHTHALMIC GENET, V18, P27, DOI 10.3109/13816819709057880; Moore DD, 1995, GLOB MOB SURV; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEEPER DS, 1995, ONCOGENE, V10, P39; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PUIG S, 1995, AM J HUM GENET, V57, P395; Puntoni F, 1997, BIOCHEM BIOPH RES CO, V235, P704, DOI 10.1006/bbrc.1997.6886; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REYMOND A, 1995, ONCOGENE, V11, P1173; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Trotter MJ, 1997, J CUTAN PATHOL, V24, P265, DOI 10.1111/j.1600-0560.1997.tb00790.x; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Wang HS, 1997, CANCER RES, V57, P1750; Wang YP, 1996, ONCOGENE, V12, P1069; Weinberg RA, 1996, CYTOKINES MOL THER, V2, P105; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yang XH, 1997, BIOCHEM BIOPH RES CO, V232, P336, DOI 10.1006/bbrc.1997.6284; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	104	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2489	2501		10.1038/sj.onc.1201773	http://dx.doi.org/10.1038/sj.onc.1201773			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627115				2022-12-28	WOS:000073672300007
J	Bongarzone, I; Vigano, E; Alberti, L; Borrello, MG; Pasini, B; Greco, A; Mondellini, P; Smith, DP; Ponder, BAJ; Romeo, G; Pierotti, MA				Bongarzone, I; Vigano, E; Alberti, L; Borrello, MG; Pasini, B; Greco, A; Mondellini, P; Smith, DP; Ponder, BAJ; Romeo, G; Pierotti, MA			Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation	ONCOGENE			English	Article						RET; MEN2B; GDNF	MEDULLARY-THYROID CARCINOMA; NEOPLASIA TYPE 2B; TYROSINE KINASE; ADAPTER PROTEINS; C-RET; PROTOONCOGENE; DISEASE; RECEPTOR; GERMLINE; 2A	Germline mutations of RET gene, encoding a receptor tyrosine kinase, have been associated with the MEN2A and MEN2B inherited cancer syndromes, In MEN2A mutations affecting cysteine residues in the extracellular domain of the receptor cause constitutive activation of the tyrosine kinase by the formation of disulfide-bonded homodimers. In MEN2B a single mutation in the tyrosine kinase domain (Met918Thr) has been identified. This mutation does not lead to dimer formation, but has been shown (both biologically and biochemically) to cause ligand-independent activation of the Ret protein, but to a lesser extent than MEN2A mutations. Intramolecular activation by cis-autophosphorylation of RetMEN2B monomers has been proposed as a model for activation, although alternative mechanisms can be envisaged, Here we show that the activity of RetMEN2B can be increased by stable dimerization of the receptor. Dimerization was achieved experimentally by constructing a double mutant receptor with a MEN2A mutation (Cys634Arg) in addition to the MEN2B mutation, and by chronic exposure of RetMEN2B-expressing cells to the Ret ligand GDNF. In both cases full activation of RetMEN2B, measured by 'in vitro' transfection assays and biochemical parameters, was seen. These results indicate that the MEN2B phenotype could be influenced by the tissue distribution or concentration of Ret ligand(s).	Ist Nazl Tumori, Div Expt Oncol A, I-20133 Milan, Italy; Ist Nazl Tumori, Sci Direct, I-20133 Milan, Italy; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England; Int Agcy Res Canc, F-69372 Lyon 08, France	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Cambridge; World Health Organization; International Agency for Research on Cancer (IARC)	Bongarzone, I (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Via Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Pasini, Barbara/AHI-2004-2022; Greco, Angela/C-1953-2017; Bongarzone, Italia/B-9544-2017; Borrello, Maria Grazia/C-3161-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Pasini, Barbara/0000-0002-4373-1212; Greco, Angela/0000-0003-2994-0349; Bongarzone, Italia/0000-0003-2530-9170; Borrello, Maria Grazia/0000-0002-6854-2848				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1995, ONCOGENE, V11, P2419; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Eng C, 1996, CANCER RES, V56, P2167; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Marsh DJ, 1996, CANCER RES, V56, P1241; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; Ponder BAJ, 1996, ADV CANCER RES, V70, P179, DOI 10.1016/S0065-230X(08)60875-1; Rizzo C, 1996, J BIOL CHEM, V271, P29497, DOI 10.1074/jbc.271.46.29497; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Suvanto P, 1997, HUM MOL GENET, V6, P1267, DOI 10.1093/hmg/6.8.1267; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1997, J NEUROSCI, V17, P3554; Widenfalk J, 1997, J NEUROSCI, V17, P8506	34	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2295	2301		10.1038/sj.onc.1201759	http://dx.doi.org/10.1038/sj.onc.1201759			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620546				2022-12-28	WOS:000073428000001
J	Epstein, CB; Attiyeh, EF; Hobson, DA; Silver, AL; Broach, JR; Levine, AJ				Epstein, CB; Attiyeh, EF; Hobson, DA; Silver, AL; Broach, JR; Levine, AJ			p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	ONCOGENE			English	Article						p53; yeast; mutations; cancer	WILD-TYPE P53; TEMPERATURE-SENSITIVE MUTANT; CELL-CYCLE ARREST; DNA-BINDING SITE; TERMINAL DOMAIN; SUPPRESSOR GENE; PROTEIN; ACTIVATION; MDM-2; EXPRESSION	p53 is a transcriptional activator that plays a key role in the integration of signals inducing cell division arrest and programed cell death, Moreover, p53 is a tumor suppressor gene, mutations of which are the most commonly detected mutations in diverse malignancies. In order to better understand the significance of p53 mutations to human cancer, me isolated mutant alleles of p53 that had lost transcription factor activity in yeast. These mutant alleles mere evaluated for their precise changes, their activity against three different p53 responsive enhancers and their ability to act in a transdominant fashion to the wild type allele, While many of the mutations isolated in yeast resembled those found in human tumors, consistent with the importance of transcription factor activity for p53 in mammalian cells, the mutational spectrum obtained was dependent upon the p53 enhancer employed for the selection. Some mutations specifically inactivated p53 in yeast for a single enhancer element. Virtually all missense mutations tested had a dominant inhibitory effect on wild type p53 in yeast, Since some of these transdominant mutations are virtually unknown in human tumors me conclude that transdominance, per se, fails to predict which mutations occur frequently in cancer.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Epstein, CB (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Epstein, Charles B./0000-0001-8358-8345; Broach, James/0000-0003-1197-0312				Ausubel FM, 1994, CURRENT PROTOCOLS MO; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Rose MD., 1990, METHODS YEAST GENETI; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THIAGALINGAM S, 1995, P NATL ACAD SCI USA, V92, P6062, DOI 10.1073/pnas.92.13.6062; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH F, 1991, NATURE, V32, P345; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG W, 1993, CANCER RES, V53, P4772	53	35	35	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2115	2122		10.1038/sj.onc.1201734	http://dx.doi.org/10.1038/sj.onc.1201734			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572492				2022-12-28	WOS:000073177200009
J	Arama, E; Yanai, A; Kilfin, G; Bernstein, A; Motro, B				Arama, E; Yanai, A; Kilfin, G; Bernstein, A; Motro, B			Murine NIMA-related kinases are expressed in patterns suggesting distinct functions in gametogenesis and a role in the nervous system	ONCOGENE			English	Article						NIMA; protein kinase; mitosis; meiosis; nervous system	CYCLIN-DEPENDENT KINASE-5; CELL-CYCLE; PROTEIN-KINASE; ASPERGILLUS-NIDULANS; FISSION YEAST; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; MITOTIC REGULATOR; PROMOTING FACTOR; MESSENGER-RNAS	NIMA protein kinase is a major regulator of progression into mitosis in Aspergillus nidulans. Dominant negative forms of NIMA protein prevent entrance into mitosis in HeLa cells, suggesting that mammals have a similar pathway, We have reported previously the isolation of a murine NIMA-related kinase, designated Nek1, and more recently several additional NIMA-related human kinases have been cloned. The existence of several mammalian NIMA-related genes raises the questions of whether the different mammalian members have redundant, overlapping or distinct functions, and whether these functions are related to the role of NIMA in controlling mitosis. To address these questions we have studied the expression patterns of the different murine nek genes. To this end, we isolated a murine nek2 cDNA and compared its patterns of expression, during both gametogenesis and embryogenesis, to those of nek1. Both genes were highly expressed in developing germ cells, albeit in distinct patterns. In both females and males, nek1 is expressed much earlier than nek2, suggesting only limited ability for functional redundancy. Surprisingly, a striking specificity of nek1 expression was found: high levels of nek1 RNA were observed in distinct regions of the nervous system, most notably in neurons of the peripheral ganglia, These patterns suggest that the different mammalian NIMA-related kinases participate in different phases of the meiotic process and may also have functions other than cell cycle control.	Bar Ilan Univ, Dept Life Sci, IL-52900 Ramat Gan, Israel; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada	Bar Ilan University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Motro, B (corresponding author), Bar Ilan Univ, Dept Life Sci, IL-52900 Ramat Gan, Israel.		Arama, Eli/GYJ-0491-2022; /ABF-8487-2022					AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BORUM K, 1961, EXP CELL RES, V24, P495, DOI 10.1016/0014-4827(61)90449-9; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; CHAPMAN DL, 1994, DEV BIOL, V165, P500, DOI 10.1006/dbio.1994.1270; CHAPMAN DL, 1993, DEVELOPMENT, V118, P229; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; FRY AM, 1995, CURR BIOL, V5, P1122, DOI 10.1016/S0960-9822(95)00227-2; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; MINSHULL J, 1989, J CELL SCI, P77; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; Osmani SA, 1996, BIOCHEM J, V317, P633, DOI 10.1042/bj3170633; PETERS H, 1969, ACTA ENDOCRINOL-COP, V62, P98, DOI 10.1530/acta.0.0620098; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SIMS TJ, 1979, J COMP NEUROL, V183, P707, DOI 10.1002/cne.901830403; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Stern B, 1996, TRENDS GENET, V12, P345; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; WU S, 1995, DEV BIOL, V170, P195, DOI 10.1006/dbio.1995.1207; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	47	40	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	1998	16	14					1813	1823		10.1038/sj.onc.1201710	http://dx.doi.org/10.1038/sj.onc.1201710			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583679				2022-12-28	WOS:000072994600005
J	Brimmell, M; Mendiola, R; Mangion, J; Packham, G				Brimmell, M; Mendiola, R; Mangion, J; Packham, G			BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability	ONCOGENE			English	Article						BAX; MSH2; microsatellite instability; apoptosis; leukaemia; lymphoma	NONPOLYPOSIS COLORECTAL-CANCER; MUTATOR PHENOTYPE; MISMATCH REPAIR; DEFICIENT MICE; GENE BAX; B-CELLS; DEATH; BCL-2; EXPRESSION; MSH2	Bax suppresses tumorigenesis in a mouse model system and Bax-deficient mice exhibit lymphoid hyperplasia suggesting that BAX functions as a tumour suppressor in human haemopoietic cells. We examined BAX expression in 20 cell lines derived from human haemopoietic malignancies and consistent with a potential tumour suppressor function, identified two cell lines, DG75 (a Burkitt lymphoma cell line) and Jurkat (a T-cell leukaemia line), which lacked detectable BAX expression. Apoptosis of DG75 cells induced by low serum or ionomycin was significantly delayed relative to similar Burkitt lymphoma cell lines with normal BAX levels, Although DG75 and Jurkat cells expressed several BAX RNA species including the prototypical BAX alpha RNA, the absence of BAX protein was due to single base deletions and additions in a polyguanine tract within the BAX open reading frame. These frameshift mutations result in premature termination of translation and have recently also been identified in some colon cancers with microsatellite instability, Although mismatch repair defects are not considered a common feature of haemopoietic malignancies, DG75 and Jurkat cells had widespread microsatellite instability and did not express detectable levels of MSH2. In Jurkat cells, lack of MSH2 expression was due to a point mutation in exon 13 of MSH2 resulting in premature termination of translation. Our results suggest that a pathway linking mismatch repair defects, BAX tumour suppressor frameshift mutations and resistance to apoptosis may be a key feature of some lymphomas and leukaemias.	Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Ludwig Inst Canc Res, London W2 1PG, England; Inst Canc Res, Haddow Labs, Mol Carcinogenesis Sect, Sutton SM2 5NG, Surrey, England; Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Dept Med Microbiol, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research; University of London; Institute of Cancer Research - UK; Imperial College London	Packham, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Ludwig Inst Canc Res, Norfolk Pl, London W2 1PG, England.							APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; ASKEW DS, 1991, ONCOGENE, V6, P1815; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BEDI GC, 1995, NAT MED, V1, P65, DOI 10.1038/nm0195-65; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BenYehuda D, 1996, BLOOD, V88, P4296; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GALA JL, 1994, ANN HEMATOL, V69, P17, DOI 10.1007/BF01757343; Gartenhaus R, 1996, BLOOD, V87, P38; GAZDAR AF, 1980, BLOOD, V55, P409; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Larson RS, 1996, CANCER RES, V56, P4378; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1994, CANCER RES, V54, P4590; Lowsky R, 1997, BLOOD, V89, P2276, DOI 10.1182/blood.V89.7.2276; MEIJERINK JPP, 1995, LEUKEMIA, V9, P1828; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Randerson J, 1996, BRIT J HAEMATOL, V93, P160, DOI 10.1046/j.1365-2141.1996.456994.x; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; ROBLEDO M, 1995, LEUKEMIA, V9, P960; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; VOLPE G, 1996, ANN HEMATOL, V72, P62; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	39	145	147	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1803	1812		10.1038/sj.onc.1201704	http://dx.doi.org/10.1038/sj.onc.1201704			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583678				2022-12-28	WOS:000072994600004
J	Kherrouche, Z; Beuscart, A; Huguet, C; Flourens, A; Moreau-Gachelin, F; Stehelin, D; Coll, J				Kherrouche, Z; Beuscart, A; Huguet, C; Flourens, A; Moreau-Gachelin, F; Stehelin, D; Coll, J			Isolation and characterization of a chicken homologue of the Spi-1/PU.1 transcription factor	ONCOGENE			English	Article						Spi-1/PU.1; ets genes; transcription factor; chicken; in-situ-hybridization	PUTATIVE ONCOGENE SPI-1; ETS GENE FAMILY; FACTOR PU.1; CHAIN GENE; C-MYB; HEMATOPOIETIC-CELLS; BINDING-SITE; PROMOTER; EXPRESSION; ENHANCER	Spi-1/PU.1 is a member of the Ets family of transcription factors important in regulation of hematopoiesis. We have isolated a chicken cDNA homologuous to the mammalian Spi-1/PU.1 gene with an open reading frame of 250 amino acids (aa). The chicken Spi-1/PU.1 protein is 14 aa and 16 aa shorter than its human and mouse counterparts but is extremely well conserved with 78.8% and 75.2% identity respectively. The carboxy terminal DNA binding region, or ETS binding domain, is 100% identical to that of human and mouse. Some differences with the mammalian homologues are seen in the N-terminal part of the protein and in the PEST connecting domain. However, the differences are mainly conservative and all the features underlying functional aspects seem preserved. The major discrepancy lies in a 12 aa deletion in an already poorly conserved part of the PEST sequence. Spi-1/PU.1 transcripts were detected at high levels in spleen and Fabricius bursa of chick embryos by Northern blot and in situ hybridization. Our results show that the chicken Spi-1/PU.1 protein behaves like a bonafide Spi-1/PU.1 transcription factor in its DNA binding and transactivating properties.	Univ Lille 1, Inst Pasteur, CNRS, UMR 319,Inst Biol Lille, F-59021 Lille, France; Inst Curie, INSERM, U248, F-75231 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Coll, J (corresponding author), Univ Lille 1, Inst Pasteur, CNRS, UMR 319,Inst Biol Lille, 1 Rue Calmette,BP 441, F-59021 Lille, France.		KHERROUCHE, Zoulika/HHN-0213-2022; Coll, Jean-Luc/G-2520-2013; KHERROUCHE, Zoulika/L-6549-2019	Coll, Jean-Luc/0000-0002-2453-3552; 				AHNE B, 1994, J BIOL CHEM, V269, P17794; ANSIEAU S, 1993, GENOMICS, V18, P537, DOI 10.1016/S0888-7543(11)80010-8; Carey JO, 1996, BLOOD, V87, P4316, DOI 10.1182/blood.V87.10.4316.bloodjournal87104316; CARVALHO M, 1993, J VIROL, V67, P6586, DOI 10.1128/JVI.67.11.6586-6595.1993; CHEN HM, 1995, ONCOGENE, V11, P1549; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DELGADO MD, 1994, ONCOGENE, V9, P1723; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KISTLER B, 1995, ONCOGENE, V11, P1095; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; KOLMER JA, 1945, APPROVED LAB TECHNIC, P71; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; Mao C, 1996, ONCOGENE, V12, P863; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; QUANG CT, 1995, ONCOGENE, V11, P1229; QUEVA C, 1992, DEVELOPMENT, V114, P125; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x	52	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1357	1367		10.1038/sj.onc.1201650	http://dx.doi.org/10.1038/sj.onc.1201650			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546438				2022-12-28	WOS:000072422000015
J	Elliott, J; Jones, MD; Griffin, BE; Krauzewicz, N				Elliott, J; Jones, MD; Griffin, BE; Krauzewicz, N			Regulation of cytoskeletal association by a basic amino acid motif in polyoma virus middle T antigen	ONCOGENE			English	Article						CaaX box; cytoskeleton; green fluorescent protein; middle T antigen	MEDIUM TUMOR-ANTIGEN; SRC GENE-PRODUCT; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL KINASE; ONCOGENIC TRANSFORMATION; SIGNAL-TRANSDUCTION; STRUCTURAL PROTEINS; COMPLEX-FORMATION; CELL-MEMBRANES; EARLY REGION	The subcellular localization of many oncogenic proteins is thought to be important for their function. In the case of the middle T antigen of the DNA tumour virus, polyoma, localization to membranes in a specific manner is essential for its cellular transforming activity. To investigate factors that influence this localization, heterologous membrane targetting sequences were substituted for the middle T antigen transmembrane domain and the properties of the resulting proteins studied. Whereas G-terminal lipid modification derived from the H-ras CaaX box restored oncogenic activity to nontransforming truncated middle T antigen species, N-terminal myristylation from pp60c-src did not. Furthermore, a region, rich in basic amino acids and adjacent to the middle T transmembrane domain, was found to mediate association with detergent-insoluble cytoskeleton. Go-operation between the basic motif and neighbouring membrane binding domains resulted in specific localization of proteins to particular membrane sites, characterized by the association with subcellular structures, likely to be cytoskeletal in nature. These results demonstrate that the cellular localization of MT is regulated by at least two determinants, a transmembrane sequence which confers membrane binding and a basic motif which specifies a particular site within the membrane.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis, London W12 0NN, England	Imperial College London	Krauzewicz, N (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis, 7th Floor,Du Cane Rd, London W12 0NN, England.							ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; BALLMERHOFER K, 1987, VIRUS RES, V6, P345, DOI 10.1016/0168-1702(87)90066-9; BOLEN JB, 1984, J BIOL CHEM, V259, P1686; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1989, ONCOGENE RES, V4, P75; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DAHL J, 1992, MOL CELL BIOL, V12, P5050, DOI 10.1128/MCB.12.11.5050; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; DILWORTH SM, 1986, EMBO J, V5, P491, DOI 10.1002/j.1460-2075.1986.tb04238.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; Doherty J, 1997, ONCOGENE, V14, P1923, DOI 10.1038/sj.onc.1201025; FORSTOVA J, 1993, J VIROL, V67, P1405; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRIFFIN BE, 1979, J VIROL, V31, P645, DOI 10.1128/JVI.31.3.645-656.1979; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; ITO Y, 1977, P NATL ACAD SCI USA, V74, P4666, DOI 10.1073/pnas.74.10.4666; JANIAK F, 1994, J BIOL CHEM, V269, P9842; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KRAUZEWICZ N, 1994, ONCOGENE, V9, P2283; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Messerschmitt A, 1996, J GEN VIROL, V77, P17, DOI 10.1099/0022-1317-77-1-17; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; PALLAS DC, 1989, J VIROL, V63, P4533, DOI 10.1128/JVI.63.11.4533-4539.1989; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SCHAFFHAUSEN BS, 1982, MOL CELL BIOL, V2, P1187, DOI 10.1128/MCB.2.10.1187; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SOEDA E, 1980, NATURE, V283, P445, DOI 10.1038/283445a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STRAUSS M, 1986, GENE, V49, P331, DOI 10.1016/0378-1119(86)90369-0; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TEMPLETON D, 1984, MOL CELL BIOL, V4, P282, DOI 10.1128/MCB.4.2.282; Topp WC, 1981, DNA TUMOR VIRUSES 2, P205; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1987, J VIROL, V61, P405, DOI 10.1128/JVI.61.2.405-410.1987; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WYSS A, 1990, J VIROL, V64, P5163, DOI 10.1128/JVI.64.10.5163-5166.1990; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	61	9	9	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1797	1806		10.1038/sj.onc.1202083	http://dx.doi.org/10.1038/sj.onc.1202083			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778045				2022-12-28	WOS:000076303300005
J	Townsend, KJ; Trusty, JL; Traupman, MA; Eastman, A; Craig, RW				Townsend, KJ; Trusty, JL; Traupman, MA; Eastman, A; Craig, RW			Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C	ONCOGENE			English	Article						MCL1; BCL2; mitogen activated protein kinase; extracellular signal-regulated kinase	MYELOID-LEUKEMIA CELLS; NECROSIS-FACTOR-ALPHA; HAMSTER OVARY CELLS; MAP KINASE; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; TRANSCRIPTIONAL REGULATION; INDUCED APOPTOSIS; FAMILY MEMBER; DNA-SYNTHESIS	Members of both the mitogen activated protein (MAP) kinase and BCL2 gene families, acting in concert with other gene products, are involved in the regulation of cell viability. However, the relationship between these families, and the signal transduction networks that control viability-regulating genes, are only beginning to be elucidated, MCL1 is a viability-promoting member of the BCL2 family that exhibits a rapid increase in expression in response to specific differentiation- and apoptosis-inducing stimuli. The signal transduction pathway involved in eliciting this increase has now been investigated. In the ML-1 human myeloblastic leukemia cell line, a rapid and sustained increase in phosphorylation of the extracellular signal-regulated kinase (ERK) members of the MAP kinase family was found to precede the increase in MCL1 expression produced by 12-O-tetradecanoylphorbol 13-acetate (TPA) or the microtubule-disrupting agents colchicine and vinblastine. ERK activation was necessary for the increase in MCL1, as inhibition of the increase in ERK phosphorylation (with the inhibitor PD 98059) prevented the increase in MCL1 expression and caused rapid cell death by apoptosis, In addition, other agents that markedly increased ERK phosphorylation (lipopolysaccharide, okadaic acid) also increased MCL1 expression. In contrast, agents that did not have this marked effect did not increase MCL1, Upstream components in this ERK-mediated pathway were also identified, where the pathway was found to be stimulated by microtubule disruption acting through protein kinase C (PKC). These results indicate that expression of the MCL1 viability-enhancing gene is regulated through a cytoskeletal disruption-induced ERK-mediated signal, transduction pathway. They therefore suggest a mechanism through which the cytoskeleton and MAP kinases can exert effects on cell viability.	Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	Craig, RW (corresponding author), Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.				NATIONAL CANCER INSTITUTE [R01CA057359, T32CA009658, R55CA050224, R01CA050224] Funding Source: NIH RePORTER; NCI NIH HHS [CA57359, CA50224, CA09658, R01 CA057359] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BASU A, 1992, BIOCHEMISTRY-US, V31, P3824, DOI 10.1021/bi00130a013; BHALLA K, 1993, LEUKEMIA, V7, P563; Blagosklonny MV, 1997, CANCER RES, V57, P130; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BRADSHAW TD, 1992, INT J CANCER, V51, P144, DOI 10.1002/ijc.2910510125; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; CARNEY DH, 1986, ANN NY ACAD SCI, V466, P919, DOI 10.1111/j.1749-6632.1986.tb38477.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; CRAIG RW, 1984, CANCER RES, V44, P2421; CROSSIN KL, 1981, CELL, V23, P61, DOI 10.1016/0092-8674(81)90270-1; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Ding AH, 1996, J EXP MED, V183, P1899, DOI 10.1084/jem.183.4.1899; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Duke R. C., 1991, CURRENT PROTOCOLS IM, V1; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; Glanz J, 1997, SCIENCE, V276, P678; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; Guan X P, 1989, Cancer Commun, V1, P111; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1997, CANCER RES, V57, P229; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Itoh T, 1996, J BIOL CHEM, V271, P27931, DOI 10.1074/jbc.271.44.27931; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KILEY SC, 1995, J CELL SCI, V108, P1003; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; LIU MK, 1994, J IMMUNOL, V153, P2642; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MANIE S, 1993, J BIOL CHEM, V268, P13675; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MAY WS, 1994, J BIOL CHEM, V269, P26865; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; Plevin R, 1996, BIOCHEM J, V318, P657, DOI 10.1042/bj3180657; REYNOLDS JE, 1994, CANCER RES, V54, P6348; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; SAKAGAMI H, 1984, CANCER RES, V44, P3330; SAKAMAKI K, 1994, FEBS LETT, V353, P133, DOI 10.1016/0014-5793(94)01024-2; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SHINOHARAGOTOH Y, 1991, EXP CELL RES, V193, P161, DOI 10.1016/0014-4827(91)90551-5; SORENSON CM, 1988, CANCER RES, V48, P4484; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wilkie N, 1996, J BIOL CHEM, V271, P32447, DOI 10.1074/jbc.271.50.32447; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	69	94	96	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1223	1234		10.1038/sj.onc.1202035	http://dx.doi.org/10.1038/sj.onc.1202035			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771965				2022-12-28	WOS:000075803300004
J	Poirel, H; Lacronique, V; Mauchauffe, M; Le Coniat, M; Raffoux, E; Daniel, MT; Erickson, P; Drabkin, H; MacLeod, RAF; Drexler, HG; Ghysdael, J; Berger, R; Bernard, OA				Poirel, H; Lacronique, V; Mauchauffe, M; Le Coniat, M; Raffoux, E; Daniel, MT; Erickson, P; Drabkin, H; MacLeod, RAF; Drexler, HG; Ghysdael, J; Berger, R; Bernard, OA			Analysis of TEL proteins in human leukemias	ONCOGENE			English	Article						TEL/ETV6 proteins; AML1 proteins; t(12;21) translocation; acute leukemias; gene inactivation	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CELL-LINE; TRANSCRIPTIONAL ACTIVATION; MYELOMONOCYTIC LEUKEMIA; AML1 GENE; FUSION; TRANSLOCATION; T(12-21); DELETION	Chromosomal translocations involving the human 12p13 band frequently affect the TEL gene, usually resulting in gene fusion between TEL and genes encoding proteins of various types. The most frequent 12p13 translocation is the t(12;21)(p13;q22), which recombines TEL with the AMI;I gene on chromosome 21 and is frequently associated with deletion of the untranslocated TEL allele. Using antisera against different parts of TEL and against the AML1 proteins, we undertook Western blot and immunofluorescence analyses of leukemic samples with and without 12p13 abnormalities. In t(12;21) samples, TEL-AML1 was detected as several protein species in the nuclei, whereas the AML1-TEL protein, was inconsistently expressed. AML1 was found to be expressed but no normal TEL proteins were detected. A survey of the TEL proteins in a panel of human leukemic samples without t(12;21) revealed a variation in the ratio of TEL protein isoforms. We also analysed a leukemic cell line bearing a t(12;22)(p13;q11) that was found to affect the 5' untranslated CUT) region of TEL and to be associated with inactivation of the untranslocated TEL allele. No MN1-TEL fusion could be detected upon RT-PCR analysis, in contrast to the previously investigated t(12;22). Strikingly, extremely low levels of apparently normal TEL proteins, expressed from the translocated allele, were detected by Western blot analysis. These results suggest that the level of TEL expression can be important for leukemogenesis.	INSERM, U301, F-75010 Paris, France; Inst Genet Mol, CNRS, SD 301, F-75010 Paris, France; Hop St Louis, Cent Hematol Lab, Paris, France; Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Deutsch Sammlung Mikroorganism Zellkultur GmbH, German Collect Microorganisms & Cell Cultures, Braunschweig, Germany; Ctr Univ, Inst Curie, Sect Rech, CNRS,UMR 146, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Bernard, OA (corresponding author), INSERM, U301, 27 Rue Juliette Dodu, F-75010 Paris, France.		Penard-Lacronique, Virginie/R-1938-2019; Bernard, Olivier A./E-5721-2016; GHYSDAEL, Jacques/F-3377-2013; Penard-Lacronique, Virginie/E-5729-2016	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Bernard, Olivier/0000-0002-0463-9747				Andreasson P, 1997, GENE CHROMOSOME CANC, V19, P77, DOI 10.1002/(SICI)1098-2264(199706)19:2<77::AID-GCC2>3.0.CO;2-X; Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; Bernard OA, 1996, LEUKEMIA LYMPHOMA, V23, P459, DOI 10.3109/10428199609054854; BUIJS A, 1995, ONCOGENE, V10, P1511; CAVE H, 1995, BLOOD, V86, P3869, DOI 10.1182/blood.V86.10.3869.bloodjournal86103869; Erickson PF, 1996, BLOOD, V88, P1813; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim DH, 1996, BLOOD, V88, P785, DOI 10.1182/blood.V88.3.785.bloodjournal883785; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LANOTTE M, 1991, BLOOD, V77, P1080; MacLeod RAF, 1996, GENE CHROMOSOME CANC, V16, P144; McLean TW, 1996, BLOOD, V88, P4252; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, CANCER RES, V57, P564; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Raynaud SD, 1996, BLOOD, V88, P682, DOI 10.1182/blood.V88.2.682.bloodjournal882682; Romana SP, 1996, LEUKEMIA, V10, P167; ROMANA SP, 1994, GENE CHROMOSOME CANC, V9, P186, DOI 10.1002/gcc.2870090307; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; Stegmaier K, 1996, CANCER RES, V56, P1413; Suto Y, 1997, GENE CHROMOSOME CANC, V18, P254, DOI 10.1002/(SICI)1098-2264(199704)18:4<254::AID-GCC3>3.0.CO;2-#; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tanaka T, 1996, MOL CELL BIOL, V16, P3967	34	34	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	1998	16	22					2895	2903		10.1038/sj.onc.1201817	http://dx.doi.org/10.1038/sj.onc.1201817			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671410				2022-12-28	WOS:000073988200008
J	Dugimont, T; Montpellier, C; Adriaenssens, E; Lottin, S; Dumont, L; Iotsova, V; Lagrou, C; Stehelin, D; Coll, J; Curgy, JJ				Dugimont, T; Montpellier, C; Adriaenssens, E; Lottin, S; Dumont, L; Iotsova, V; Lagrou, C; Stehelin, D; Coll, J; Curgy, JJ			The H19 TATA-less promoter is efficiently repressed by wild-type tumor suppressor gene product p53	ONCOGENE			English	Article						H19; p53; tumor suppressor; gene regulation; TATA-less promoter	SMOOTH-MUSCLE CELLS; BINDING PROTEIN; FUNCTIONAL INTERACTION; MOUSE EMBRYOGENESIS; IMPRINTED GENES; IGF2 EXPRESSION; BREAST-CANCER; DNA-BINDING; MUTANT P53; IN-VIVO	The developmentally regulated H19 gene displays several remarkable properties: expression of an apparently non-translated mRNA, genomic imprinting (maternal allele only expressed), relaxation of the imprinting and/or epigenetic lesions demonstrated in some tumors. Despite several observations after relaxation of imprinting status of the gene, data on tr ans and cis-acting factors required for the human H19 gene expression are still missing. As a first approach to address identification of factors involved in the regulation of the gene, we found that cells from a p53 antisense-transfected HeLa clone displayed increased amounts of H19 transcripts when compared to the non-transfected cells. Moreover, a HeLa clone stably transfected with a temperature sensitive (ts) 143 Ala p53 mutant exhibited temperature-dependent regulation of H19 expression. This preliminary indication of the repressing effect of the p53 protein on H19 expression has been confirmed by transient cotransfection experiments in HeLa cells, using luciferase surrogate constructs under the control of the 823 bp sequence immediately upstream of the transcription start point of the H19 gene, and different constructs containing sense, antisense or a ts 143 Ala mutant p53 cDNA. We observed an increase of H19 promoter-driven activity in transient cotransfections with the antisense p53 cDNA and the temperature sensitive mutant p53 at the non-permissive temperature, but a decrease with sense wild-type p53 cDNA. Furthermore, the cotransfection experiments were repeated in a cell line lacking endogenous p53, (Calu 6 cells) and the results provided additional evidence for a down regulation of the expression of the H19 gene by the p53 protein.	Univ Sci & Technol Lille, Ctr Biol Cellulaire, Unite Dynam Cellules Embryonnaires & Cancereuses, EA 1033, F-59655 Villeneuve Dascq, France; Univ Artois, Fac Sci Jean Perrin, F-62307 Lens, France; Inst Pasteur, Unite Oncol Mol, CNRS, URA 1160, F-59019 Lille, France	Universite de Lille - ISITE; Universite de Lille; Universite d'Artois; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Curgy, JJ (corresponding author), Univ Sci & Technol Lille, Ctr Biol Cellulaire, Unite Dynam Cellules Embryonnaires & Cancereuses, EA 1033, SN3, F-59655 Villeneuve Dascq, France.			MONTPELLIER, Claire/0000-0002-3112-8491				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ariel I, 1997, J CLIN PATHOL-MOL PA, V50, P34, DOI 10.1136/mp.50.1.34; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barbareschi M, 1996, APPL IMMUNOHISTOCHEM, V4, P106; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cooper MJ, 1996, J UROLOGY, V155, P2120, DOI 10.1016/S0022-5347(01)66120-2; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEB SP, 1994, ONCOGENE, V9, P1341; DOUCRASY S, 1993, INT J ONCOL, V2, P753; DoucRasy S, 1996, ONCOGENE, V12, P423; Dugimont T, 1995, BIOL CELL, V85, P117, DOI 10.1016/0248-4900(96)85272-5; EDEN S, 1995, NATURE, V375, P16, DOI 10.1038/375016a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELKIN M, 1995, FEBS LETT, V374, P57, DOI 10.1016/0014-5793(95)01074-O; Elson DA, 1997, MOL CELL BIOL, V17, P309, DOI 10.1128/MCB.17.1.309; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; FAILLE A, 1994, BRIT J CANCER, V69, P1145, DOI 10.1038/bjc.1994.225; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRIEDRICHS K, 1993, CANCER, V72, P3641, DOI 10.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-8; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAN DKM, 1992, CIRC RES, V71, P711, DOI 10.1161/01.RES.71.3.711; Han DKM, 1996, J CLIN INVEST, V97, P1276, DOI 10.1172/JCI118543; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Iotsova V, 1996, ONCOGENE, V13, P2331; IOTSOVA V, 1995, EUR J CELL BIOL, V68, P122; JINNO Y, 1995, NAT GENET, V10, P318, DOI 10.1038/ng0795-318; JOOSS K, 1995, ONCOGENE, V10, P1529; Joubel A, 1996, CELL MOL BIOL, V42, P1159; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIM DK, 1994, J CLIN INVEST, V93, P355, DOI 10.1172/JCI116967; KONDO M, 1995, ONCOGENE, V10, P1193; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; Pellegata NS, 1996, EUR J HISTOCHEM, V40, P273; PERREM K, 1995, ONCOGENE, V11, P1299; POIRIER F, 1991, DEVELOPMENT, V113, P1105; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; RACHMILEWITZ J, 1992, MOL REPROD DEV, V32, P196, DOI 10.1002/mrd.1080320303; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reid LH, 1996, HUM MOL GENET, V5, P239, DOI 10.1093/hmg/5.2.239; Sambrook J., 1989, MOL CLONING LABORATO, V2, P916; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMID P, 1991, DEVELOPMENT, V113, P857; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SURANI MA, 1993, NATURE, V366, P302, DOI 10.1038/366302a0; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; vanderKooy K, 1996, AM J EPIDEMIOL, V144, P924, DOI 10.1093/oxfordjournals.aje.a008862; Velculescu VE, 1996, CLIN CHEM, V42, P858; VOUTILAINEN R, 1994, ENDOCRINOLOGY, V134, P2051, DOI 10.1210/en.134.5.2051; WALSH C, 1995, CANCER RES, V55, P1111; WILES MV, 1988, DEVELOPMENT, V104, P403; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	90	91	96	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	1998	16	18					2395	2401		10.1038/sj.onc.1201742	http://dx.doi.org/10.1038/sj.onc.1201742			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620557				2022-12-28	WOS:000073428000012
J	Riordan, FA; Bravery, CA; Mengubas, K; Ray, N; Borthwick, NJ; Akbar, AN; Hart, SM; Hoffbrand, AV; Mehta, AB; Wickremasinghe, RG				Riordan, FA; Bravery, CA; Mengubas, K; Ray, N; Borthwick, NJ; Akbar, AN; Hart, SM; Hoffbrand, AV; Mehta, AB; Wickremasinghe, RG			Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr/abl-positive leukaemia cells	ONCOGENE			English	Article						apoptosis; leukaemia; Philadelphia chromosome; bcr/abl; herbimycin A; etoposide	ABL TYROSINE KINASE; PH(1)-POSITIVE LEUKEMIA-CELLS; CHRONIC MYELOID-LEUKEMIA; CANCER-THERAPY; DEATH; PROTEIN; LINES; BCL-2; INHIBITOR; GROWTH	Philadelphia chromosome (Ph)-positive leukaemia cells express the chimeric bcr/abl oncoprotein, whose deregulated protein tyrosine kinase (PTK) activity antagonizes the induction of apoptosis by DNA damaging agents, Treatment of Ph-positive K562, TOM 1 and KCL-22 cells with etoposide for 2d induced cytosolic vacuolation, but not nuclear condensation or DNA fragmentation, The bcr/abl kinase-selective inhibitor herbimycin A increased the induction of nuclear apoptosis by etoposide or gamma-radiation. The concentration of herbimycin required to synergize with etoposide was similar to that required to decrease the level of tyrosine phosphorylated proteins or of the protein tyrosine kinase activity of anti-abl immune complexes in K562 cells, The ability of herbimycin A to sensitize K562, TOM 1 or KCL-22 cells to apoptosis induction correlated with its ability to decrease the cellular content of phosphotyrosyl proteins in these Philadelphia-positive lines. Enhancement of nuclear apoptosis by herbimycin was not attributable to downregulation of the bcl-2 or bcl-X-L anti-apoptotic proteins, In contrast, herbimycin protected Philadelphia-negative HL60 cells from apoptosis induction by etoposide and did not affect killing of NC37 and CEM cells, The data suggest that the induction of apoptosis is blocked in cells expressing the bcr/abl oncoprotein and that herbimycin A increases induction of programmed cell death following DNA damage, Selective PTK inhibitors may therefore be of value in securing the genetic death of Ph-positive leukaemia cells.	Royal Free Hosp, Sch Med, Dept Hematol, London NW3 2QG, England; Royal Free Hosp, Sch Med, Dept Clin Immunol, London NW3 2QG, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Wickremasinghe, RG (corresponding author), Royal Free Hosp, Sch Med, Dept Hematol, Pond St, London NW3 2QG, England.		Mehta, Atul/GPC-7364-2022	Akbar, Arne/0000-0002-3763-9380				BEDI A, 1994, BLOOD, V83, P2036; BERGAMASCHI G, 1993, LEUKEMIA, V7, P2012; BERTRAND R, 1993, EXP CELL RES, V207, P388, DOI 10.1006/excr.1993.1206; BLAGOSKLONNY MV, 1996, LEUKEMIA, V12, P101; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK RE, 1995, LEUKEMIA LYMPHOMA, V19, P189, DOI 10.3109/10428199509107888; CORY S, 1994, NATURE, V367, P317, DOI 10.1038/367317a0; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; EVANS JPM, 1987, LEUKEMIA, V1, P524; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GinestierVerne C, 1996, ANAL CELL PATHOL, V11, P115; HONMA Y, 1992, CANCER RES, V52, P4017; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LOTEM J, 1992, BLOOD, V80, P1750; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; NALDINI L, 1986, MOL CELL BIOL, V6, P1803, DOI 10.1128/MCB.6.5.1803; Nishii K, 1996, ONCOGENE, V13, P2225; OBRIEN SG, 1994, LEUKEMIA, V8, P2156; OKABE M, 1993, LEUKEMIA LYMPHOMA, V12, P41, DOI 10.3109/10428199309059570; OKABE M, 1994, LEUKEMIA RES, V18, P213, DOI 10.1016/0145-2126(94)90117-1; OKABE M, 1992, BLOOD, V80, P1330; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; *PROM CORP, 1993, PROM TECHN MAN LUC R; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed JC, 1996, LEUKEMIA RES, V20, P109, DOI 10.1016/0145-2126(95)00135-2; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SATO S, 1994, LEUKEMIA RES, V18, P221, DOI 10.1016/0145-2126(94)90118-X; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SMETSERS TFCM, 1995, LEUKEMIA, V9, P118; SMETSERS TFCM, 1995, BLOOD, V85, P597; STEUBE KG, 1995, LEUKEMIA, V9, P1841; TOMEI LD, 1993, P NATL ACAD SCI USA, V90, P853, DOI 10.1073/pnas.90.3.853; TWENTYMAN PR, 1989, BRIT J HAEMATOL, V71, P19, DOI 10.1111/j.1365-2141.1989.tb06268.x; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; VAERMAN JL, 1995, BLOOD, V86, P3891, DOI 10.1182/blood.V86.10.3891.bloodjournal86103891; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhu JY, 1996, BLOOD, V87, P4368, DOI 10.1182/blood.V87.10.4368.bloodjournal87104368	52	28	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1533	1542		10.1038/sj.onc.1201680	http://dx.doi.org/10.1038/sj.onc.1201680			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569020				2022-12-28	WOS:000072743200003
J	Mixan, B; Cohen, BD; Bacus, SS; Fell, HP; Siegall, CB				Mixan, B; Cohen, BD; Bacus, SS; Fell, HP; Siegall, CB			Betacellulin-Pseudomonas toxin fusion proteins bind but are not cytotoxic to cells expressing HER4; correlation of EGFR for cytotoxic activity	ONCOGENE			English	Article						cancer; toxin; betacellulin; cytotoxicity; receptor	EPIDERMAL GROWTH-FACTOR; SINGLE-CHAIN IMMUNOTOXIN; FACTOR RECEPTOR; BIOLOGICAL-ACTIVITIES; RECOMBINANT TOXINS; CANCER-TREATMENT; ERBB RECEPTORS; BR96 SFV-PE40; DISTINCT; EXOTOXIN	Betacellulin (BTC) is a member of the EGF ligand family that directly binds to both EGFR and HER4 and induces the growth of certain epithelial cell types, Fusion proteins composed of the terminal 48 or 50 amino acids of mature betacellulin and a binding defective form of Pseudomonas exotoxin (BTC-TX48 and BTC-TX50, respectively), have been produced, BTC-TX50 induced tyrosine phosphorylation of both EGFR and HER4, whereas BTC-TX48 induced phosphorylation of HER4 but to a much lesser extent EGFR, indicating that the presence of two additional amino acid residues, Arg(62) and Lys(63), contribute to full kinase activity, BTC-TX50 was up to 300-fold more active at inhibiting protein synthesis than BTC-TX48 on cell lines expressing EGFR, most likely due to the >tenfold higher affinity of BTC-TX50. MDA-MB-453 breast carcinoma cells which express HER4 but not EGFR, were not sensitive to either BTC-TX form, These data indicate that despite the ability of BTC-TX to bind and phosphorylate HER4, it was only cytotoxic to cells expressing EGFR, The inability of BTC-TX to kill cells was likely due to its failure to internalize through HER4.	Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Mol Immunol, Seattle, WA 98121 USA; Adv Cellular Diagnost Inc, Elmhurst, IL 60126 USA	Bristol-Myers Squibb	Siegall, CB (corresponding author), Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Mol Immunol, 3005 1st Ave, Seattle, WA 98121 USA.							BACUS SS, 1993, CANCER RES, V53, P5251; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; Baulida J, 1996, J BIOL CHEM, V271, P5251; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Cohen BM, 1996, J BIOL CHEM, V271, P4813; COLOUSCOU JM, 1995, J BIOL CHEM, V270, P12857; Francisco JA, 1996, J IMMUNOL, V157, P1652; FRIEDMAN PN, 1993, CANCER RES, V53, P334; GOLDBERG MR, 1995, CLIN CANCER RES, V1, P57; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Kreitman R J, 1994, Adv Pharmacol, V28, P193, DOI 10.1016/S1054-3589(08)60496-2; LEMAISTRE CF, 1994, BREAST CANCER RES TR, V32, P97, DOI 10.1007/BF00666210; MESRI EA, 1994, J CELL SCI, V107, P2599; Pai L H, 1994, Important Adv Oncol, P3; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; Seno M, 1996, GROWTH FACTORS, V13, P181, DOI 10.3109/08977199609003220; SHAW JP, 1991, J BIOL CHEM, V266, P21118; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SIEGALL CB, 1994, J IMMUNOL, V152, P2377; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; SIEGALL CB, 1995, J BIOL CHEM, V270, P7625, DOI 10.1074/jbc.270.13.7625; WATANABE T, 1994, J BIOL CHEM, V269, P9966; Zhang K, 1996, J BIOL CHEM, V271, P3884	25	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1209	1215		10.1038/sj.onc.1201632	http://dx.doi.org/10.1038/sj.onc.1201632			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528863				2022-12-28	WOS:000072336000012
J	Wang, Q; Zhang, HT; Kajino, K; Greene, MI				Wang, Q; Zhang, HT; Kajino, K; Greene, MI			BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells	ONCOGENE			English	Article						BRCA1; breast cancer; c-Myc; transcription; transformation	ORNITHINE DECARBOXYLASE GENE; EPIDERMAL GROWTH-FACTOR; NUCLEAR PHOSPHOPROTEIN; EMBRYO FIBROBLASTS; PROTEIN COMPLEX; TRANSGENIC MICE; BREAST-CANCER; IN-VIVO; EXPRESSION; CYCLE	c-Myc, a proto-oncogene that is implicated in tumorigenesis, embryonic development and apoptosis, can physically associate with BRCA1. We have found that BRCA1 interacts with c-Myc in yeast, in in vitro assays and in mammalian cells. Endogenous interactions between BRCA1 and c-Myc were also observed. Efficient BRCA1-Myc association requires the intact helix-loop-helix region of c-Myc, a motif involved in Myc-Max dimerization. BRCA1 does not however bind to Max. Our studies revealed that BRCA1 represses Myc-mediated transcription while having no effect on some other transcriptional activities. Furthermore, BRCA1 reverses the phenotype of embryonic fibroblasts transformed by the activation of Myc and Ras, but only minimally affects the transformed phenotype induced by SV40 virus. These data indicate that BRCA1 may function as a tumor suppressor by regulating the behavior of c-Myc and provide a molecular explanation for some of the effects of the BRCA1 gene product.	Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA	University of Pennsylvania	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA.		Kajino, Kiichi/F-6873-2012; Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, CANCER RES, V56, P3168; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; EASTON DF, 1995, AM J HUM GENET, V56, P265; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GREENE MI, 1982, J IMMUNOL, V128, P732; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Hou XY, 1996, CANCER RES, V56, P2616; KARN J, 1989, ONCOGENE, V4, P773; KIRKLAND JL, 1992, ENDOCRINOLOGY, V130, P3223, DOI 10.1210/en.130.6.3223; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEMAITRE JM, 1996, ADV CANC RES, V70; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; MAI S, 1995, GENOME, V38, P780, DOI 10.1139/g95-099; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MOSHIER JA, 1995, CANCER RES, V55, P5358; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; PENA A, 1993, J BIOL CHEM, V268, P27277; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Rao VN, 1996, ONCOGENE, V12, P523; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SANDGREN EP, 1995, CANCER RES, V55, P3915; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang SC, 1997, BIOCHEM BIOPH RES CO, V234, P247, DOI 10.1006/bbrc.1997.6544; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu SJ, 1996, ONCOGENE, V12, P621; Xu CF, 1997, GENE CHROMOSOME CANC, V18, P102, DOI 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.3.CO;2-A; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang HT, 1997, ONCOGENE, V14, P2863, DOI 10.1038/sj.onc.1201140	71	179	182	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1939	1948		10.1038/sj.onc.1202403	http://dx.doi.org/10.1038/sj.onc.1202403			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788437				2022-12-28	WOS:000076423500007
J	Carson-Walter, EB; Smith, DP; Ponder, BAJ; Baylin, SB; Nelkin, BD				Carson-Walter, EB; Smith, DP; Ponder, BAJ; Baylin, SB; Nelkin, BD			Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells	ONCOGENE			English	Article						RET; raf-1; differentiation	ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; NEOPLASIA TYPE 2B; PC12 CELLS; NEURONAL DIFFERENTIATION; TRANSFORMING GENE; RAS ONCOGENE; PROTOONCOGENE; MUTATIONS	Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor of the calcitonin secreting thyroid C-cells, Somatic and germline mutations in the RET proto-oncogene are associated with sporadic and inherited cases of MTC, respectively. The human MTC cell Line, TT, can be differentiated by activated raf-1, This differentiation is characterized, in part, by down-regulation of the RET proto-oncogene, We now show that raf-1 induction is followed by activation of the downstream kinases MEK1/2 and ERK1/2 and that differentiation is dependent on activation of MEK1/2, The concurrent down-regulation of RET appears to involve altered nuclear compartmentalization and transport of RET mRNA, Although RET is down-regulated during raf-1 mediated differentiation, overexpression of activated RET alleles which resist down-regulation does not alter the raf-1 mediated differentiation response. These data suggest that RET down-regulation is associated with, but not required, for raf-1 mediated MTC cell differentiation and that the raf-1 signal transduction pathway plays a dominant role in promoting MTC cell differentiation.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Program Human Genet & Mol Biol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Univ Cambridge, Human Canc Genet Grp, Cambridge CB2 2OQ, England	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of Cambridge	Nelkin, BD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA.				NCI NIH HHS [R01-CA47480] Funding Source: Medline; PHS HHS [2T32G07814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; CALIFANO D, 1995, ONCOGENE, V11, P107; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARSON EB, 1995, CANCER RES, V55, P2048; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HAZARD JB, 1959, J CLIN ENDOCR METAB, V19, P152, DOI 10.1210/jcem-19-1-152; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Holt KH, 1996, MOL CELL BIOL, V16, P577; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P249, DOI 10.1046/j.1365-2265.1996.681503.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NELKIN BD, 1990, BIOCHEM BIOPH RES CO, V170, P140, DOI 10.1016/0006-291X(90)91251-M; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Richardson GM, 1996, HUM ECOL RISK ASSESS, V2, P44, DOI 10.1080/10807039.1996.10387459; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	41	23	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					367	376		10.1038/sj.onc.1201938	http://dx.doi.org/10.1038/sj.onc.1201938			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690518				2022-12-28	WOS:000074947500011
J	Doza, YN; Hall-Jackson, CA; Cohen, P				Doza, YN; Hall-Jackson, CA; Cohen, P			Arsenite blocks growth factor induced activation of the MAP kinase cascade, upstream of Ras and downstream of Grb2-Sos	ONCOGENE			English	Article						Raf; MAP kinase kinase (MKK); p70 S6 kinase; mSos; EGF-receptor; stress	MITOGENIC SIGNAL-TRANSDUCTION; PROTEIN-TYROSINE-PHOSPHATASE; L6 MUSCLE-CELLS; NUCLEOTIDE EXCHANGE; PLASMA-MEMBRANE; PC12 CELLS; DOWN-REGULATION; HEAT-SHOCK; RECEPTOR; PATHWAY	Pretreatment of cells with 0.5 mM sodium arsenite (but not other activators of stress-activated MAP kinase cascades) prevents the activation of p21Ras and strongly suppresses the activation of c-Raf and the MAP kinase cascade by a variety of growth factors. Arsenite appears to exert its effect by preventing the guanine nucleotide exchange factor mSos from converting Pas to its active GTP-bound state. Exposure to arsenite may be a simple way of assessing whether Pas plays an essential role in mediating activation of the MAP kinase cascade by extracellular signals.	Univ Dundee, Inst Med Sci, Dept Biochem, MRC Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland	University of Dundee	Cohen, P (corresponding author), Univ Dundee, Inst Med Sci, Dept Biochem, MRC Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland.							ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1995, ONCOGENE, V11, P1327; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DOWNWARD J, 1995, METHOD ENZYMOL, V255, P110; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HUNDAL HS, 1992, ENDOCRINOLOGY, V131, P1165, DOI 10.1210/en.131.3.1165; JOHNSTON D, 1980, J BIOL CHEM, V255, P6975; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TANGUAY RM, 1983, CAN J BIOCHEM CELL B, V61, P414, DOI 10.1139/o83-056; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TRAVERSE S, 1993, ONCOGENE, V8, P3175; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIAO S, 1994, J BIOL CHEM, V269, P21244	41	22	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					19	24		10.1038/sj.onc.1202168	http://dx.doi.org/10.1038/sj.onc.1202168			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671310				2022-12-28	WOS:000074677800003
J	Barnache, S; Wendling, F; Lacombe, C; Denis, N; Titeux, M; Vainchenker, W; Moreau-Gachelin, F				Barnache, S; Wendling, F; Lacombe, C; Denis, N; Titeux, M; Vainchenker, W; Moreau-Gachelin, F			Spi-1 transgenic mice develop a clonal erythroleukemia which does not depend on p53 mutation	ONCOGENE			English	Article						Spi-1/PU.1; p53; transgenic; leukemia; Friend	VIRUS-INDUCED ERYTHROLEUKEMIA; FOCUS-FORMING VIRUS; FRIEND-VIRUS; ERYTHROPOIETIN RECEPTOR; TRANSCRIPTION FACTOR; TUMORIGENIC CELLS; PUTATIVE ONCOGENE; LEUKEMIA-VIRUS; GENE; ACTIVATION	Spi-1 transcriptional activation and wild-type p53 extinction are two oncogenic alterations involved in the malignant transformation of erythroblasts during the Friend acute erythroleukemia, To dissect the contribution of these alterations in the deregulation of the differentiation and proliferation of erythroblasts, we generated spi-1 transgenic mice. Analysis of these animals revealed that Spi-1 overexpression was directly involved in the block of proerythroblast differentiation. However, the erythroleukemia that develops in these animals evolved in two steps. During the early step (HS1 step), non tumorigenic proerythroblasts remained strictly dependent upon erythropoietin (Epo) for their survival and proliferation. Later on, Epo-independent and tumorigenic proerythroblasts emerged (HS2 step) suggesting that other oncogenes cooperate with Spi-1 to lead to a fully malignant phenotype, By provirus tagging, we demonstrate that the HS1 step was clonal indicating that a cell selection must occur in vivo. Analysis of the nature of p53 in both the in vivo HS1 and HS2 proerythroblasts and in cultured erythroblastic cell lines showed that-p53 was normal in the HS1 primary tissues but was mutated in the HS1 cultured cell lines-p53 was frequently altered in HS2 primary tissues but was found normal in some mice. These data indicate that (1) the blockage of the erythroblast differentiation by Spi-1 occurs independently of p53 alteration (ii) p53 alteration is not necessary to confer Epo independence and tumorigenicity to spi-1 transgenic proerythroblasts.	Inst Curie, INSERM U248, F-75005 Paris, France; Inst Gustave Roussy, INSERM U362, F-94800 Villejuif, France; Hop Cochin, ICGM, INSERM U363, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM U248, 26 Rue Ulm, F-75005 Paris, France.			Vainchenker, William/0000-0003-4705-202X				AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; BASSIN RH, 1971, NATURE, V229, P564, DOI 10.1038/229564b0; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID YB, 1988, ONCOGENE, V3, P179; ELIYAHU D, 1988, ONCOGENE, V3, P313; ELLIOTT JI, 1995, EMBO J, V14, P575, DOI 10.1002/j.1460-2075.1995.tb07033.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; MOREAUGACHELIN F, 1986, J VIROL, V57, P349, DOI 10.1128/JVI.57.1.349-352.1986; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1985, J VIROL, V53, P292, DOI 10.1128/JVI.53.1.292-295.1985; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1983, BIOCHIMIE, V65, P259, DOI 10.1016/S0300-9084(83)80277-6; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; MUNROE DG, 1988, ONCOGENE, V2, P621; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SITBON M, 1986, CELL, V47, P851, DOI 10.1016/0092-8674(86)90800-7; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; WENDLING F, 1983, TUMOR VIRUSES DIFFER, P357; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034	46	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	1998	16	23					2989	2995		10.1038/sj.onc.1202095	http://dx.doi.org/10.1038/sj.onc.1202095			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662331				2022-12-28	WOS:000074125300005
J	Liu, NS; Lucibello, FC; Engeland, K; Muller, R				Liu, NS; Lucibello, FC; Engeland, K; Muller, R			A new model of cell cycle-regulated transcription: Repression of the cyclin A promoter by CDF-1 and anti-repression by E2F	ONCOGENE			English	Article						cyclin A; CDF; E2F; transcriptional repression	B-MYB TRANSCRIPTION; CDC25C TRANSCRIPTION; IN-VIVO; A GENE; SITE; EXPRESSION; INITIATION; ELEMENT; COMPLEX	Cell cycle regulation of the cyclin A gene is determined by a bipartite repressor binding site in the region of the basal promoter, termed CDE-CHR, which also controls the expression of cell cycle genes upregulated in S or G(2) (such as cdc25C). The CDE-CHR in the cyclin A promoter is recognized by both E2F complexes and CDF-1, but the contribution of each of these factors in cell cycle regulation is unknown. In the present study, we have introduced mutations into the cyclin A promoter which lead to either a loss or enhancement of E2F binding, while having only marginal effects on the interaction with CDF-1. Unlike mutants deficient for CDF-1 binding, promoter variants lacking E2F binding showed an unchanged repression in G(0), thus identifying CDF-1 as the principal repressor of the cyclin A gene. The same mutants did show, however, a delayed derepression while a mutation leading to increased E2F binding resulted in premature up-regulation. These findings clearly suggest that E2F contributes to the correct timing of cyclin A transcription, presumably by acting as an anti-repressor. In agreement with this conclusion, we find that the cyclin A promoter only poorly interacts with E2F-4, which is the major E2F family member in G, cells, while a clear binding is seen with E2F-1 and -3, which are up-regulated in late G(1).	Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Molekularbiol & Tumorforsch, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Müller, Rolf/L-4997-2016; Engeland, Kurt/AAW-9965-2020	Müller, Rolf/0000-0003-3339-4248; Engeland, Kurt/0000-0003-3525-0440				DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Huet X, 1996, MOL CELL BIOL, V16, P3789; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Muller H, 1997, MOL CELL BIOL, V17, P5508; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Oswald F, 1996, MOL CELL BIOL, V16, P1889; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	31	75	75	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2957	2963		10.1038/sj.onc.1201838	http://dx.doi.org/10.1038/sj.onc.1201838			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662327				2022-12-28	WOS:000074125300001
J	Zachos, G; Spandidos, DA				Zachos, G; Spandidos, DA			Transcriptional regulation of the c-H-ras1 gene by the P53 protein is implicated in the development of human endometrial and ovarian tumours	ONCOGENE			English	Article						H-ras proto-oncogene; P53 protein; DNA binding; endometrial tumours; ovarian tumours	H-RAS PROTOONCOGENE; WILD-TYPE P53; ESTROGEN-RECEPTORS; CARCINOMA; EXPRESSION; SEQUENCE; ONCOGENE; CELLS; OVEREXPRESSION; SUPPRESSOR	The human c-H-ras1 gene contains within the first intron a p53 element, which functions as a transcriptional enhancer. Using nuclear extracts from human endometrial and ovarian tumours in gel retardation assays, we examined the binding levels of the P53 protein to the H-ras element in tumour versus the adjacent normal tissue. Elevated P53 binding in the tumour tissue was found in 5/12 (42%) endometrial and in 2/5 (40%) ovarian specimens and these cases were found to overexpress wild-type P53, Loss of P53 binding to the H-l as element due to p53 mutations, was observed in 3/12 (25%) endometrial and in 1/5 (20%) ovarian cases, Similar P53 binding levels to the H-uas element were found in 4/12 (33%) endometrial and in 2/5 (40%) ovarian pairs showing normal expression of wild-type P53, Overexpression of the Ras p21 protein correlated with elevated binding and increased nuclear levels of wildtype P53. Our results suggest that P53 protein alterations, participate in the development of human gynecological neoplasias through aberrant transcriptional regulation of the H-ras proto-oncogene.	Univ Crete, Sch Med, Div Virol, Heraklion 71409, Greece; Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Athens 11635, Greece	University of Crete; National Hellenic Research Foundation	Spandidos, DA (corresponding author), Univ Crete, Sch Med, Div Virol, Heraklion 71409, Greece.			Spandidos, Demetrios/0000-0002-1146-931X				Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hurd C, 1997, ONCOGENE, V15, P991, DOI 10.1038/sj.onc.1201233; Hwang DY, 1997, J VIROL, V71, P6416, DOI 10.1128/JVI.71.9.6416-6426.1997; JUVEN T, 1993, ONCOGENE, V8, P3411; KIHANA T, 1995, CANCER, V76, P72, DOI 10.1002/1097-0142(19950701)76:1<72::AID-CNCR2820760110>3.0.CO;2-3; KLEMI PJ, 1995, CANCER, V76, P1201, DOI 10.1002/1097-0142(19951001)76:7<1201::AID-CNCR2820760716>3.0.CO;2-L; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVESQUE MA, 1995, CANCER-AM CANCER SOC, V75, P1327, DOI 10.1002/1097-0142(19950315)75:6<1327::AID-CNCR2820750615>3.0.CO;2-P; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liloglou T, 1997, BRIT J CANCER, V75, P1119, DOI 10.1038/bjc.1997.193; LONG CA, 1988, AM J OBSTET GYNECOL, V159, P1512, DOI 10.1016/0002-9378(88)90586-8; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Maniatis T., 1989, MOL CLONING LAB MANU; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Miturski R, 1996, ACTA HISTOCHEM, V98, P411, DOI 10.1016/S0065-1281(96)80008-0; Scambia G, 1997, BRIT J CANCER, V75, P1547, DOI 10.1038/bjc.1997.264; SCAMBIA G, 1993, AM J OBSTET GYNECOL, V168, P71, DOI 10.1016/S0002-9378(12)90888-1; Soong R, 1996, BRIT J CANCER, V74, P562, DOI 10.1038/bjc.1996.401; SPANDIDOS DA, 1995, INT J ONCOL, V7, P1029; Varras MN, 1996, ONCOLOGY-BASEL, V53, P505; Zachos G, 1997, CRIT REV ONCOL HEMAT, V26, P65, DOI 10.1016/S1040-8428(97)00013-9; Zachos G, 1996, J Exp Ther Oncol, V1, P335; Zachos G, 1996, JPN J CANCER RES, V87, P916, DOI 10.1111/j.1349-7006.1996.tb02120.x; ZACHOS G, 1995, INT J ONCOL, V6, P595; ZOUMPOURLIS V, 1995, INT J ONCOL, V7, P1035	29	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3013	3017		10.1038/sj.onc.1201836	http://dx.doi.org/10.1038/sj.onc.1201836			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662334				2022-12-28	WOS:000074125300008
J	Yin, XY; Grove, L; Prochownik, EV				Yin, XY; Grove, L; Prochownik, EV			Lack of transcriptional repression by max homodimers	ONCOGENE			English	Article						myc; max; mad; mnt; USF; transcriptional repression	C-MYC PROTEIN; DNA-BINDING; EPIDERMAL DIFFERENTIATION; PHOSPHORYLATION SITES; OPPOSITE REGULATION; ONCOGENIC ACTIVITY; LEUCINE ZIPPER; B/HLH/Z DOMAIN; IN-VIVO; GENE	Max, a basic-helix-loop-helix-leucine zipper (bHLH-ZIP) protein, plays a central role in the transcriptional regulation of myc oncoprotein-responsive genes, Myc-max heterodimers bind to consensus E-box motifs near or within the promoters of these genes and activate gene expression, whereas heterodimers between max and members of the mad family of bHLH-ZIP proteins promote transcriptional repression. In contrast to all other members of the myc network, max readily homodimerizes and binds to identical E-box sites in vitro. However, the role for max homodimers in transcriptional repression in vivo is unclear. Upstream stimulatory factor (USF) is a bHLH-ZIP protein which does not interact with members of the myc-max-mad family. By replacing the HLH-ZIP domain of max with that from USF, we created a chimeric protein, max(USF), which was indistinguishable from max with respect to its ability to homodimerize and bind DNA. As expected, however, max(USF) was unable to heterodimerize with any of the tested max partner proteins and was incapable of suppressing c-myc target genes. Thus, transcriptional repression is an exclusive property of max-mad heterodimers and cannot be achieved by max homodimers alone.	Childrens Hosp Pittsburgh, Dept Pediat, Sect Hematol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, Sect Hematol, Pittsburgh, PA 15213 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; AYER DE, 1998, CELL, P211; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BILLAUD M, 1993, P NATL ACAD SCI USA, V90, P2739, DOI 10.1073/pnas.90.7.2739; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1993, ONCOGENE, V8, P3211; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Langlands K, 1997, ANAL BIOCHEM, V249, P250, DOI 10.1006/abio.1997.2184; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE LA, 1995, J CLIN INVEST, V95, P900, DOI 10.1172/JCI117741; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; MIN S, 1992, ONCOGENE, V9, P1531; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZERVOS AS, 1994, CELL, V79, P389; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	54	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2629	2637		10.1038/sj.onc.1201777	http://dx.doi.org/10.1038/sj.onc.1201777			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632139				2022-12-28	WOS:000073698200007
J	Kristjuhan, A; Jaks, V; Rimm, I; Tooming, T; Maimets, T				Kristjuhan, A; Jaks, V; Rimm, I; Tooming, T; Maimets, T			Oligomerization of p53 is necessary to inhibit its transcriptional transactivation property at high protein concentration	ONCOGENE			English	Article						p53; oligomerization; transactivation	WILD-TYPE P53; DOWN-REGULATES TRANSCRIPTION; TATA-BINDING PROTEIN; REPRESSION FUNCTIONS; ACTIVATION DOMAINS; DNA; PROMOTERS; GROWTH; SITE; REGIONS	We have previously shown that transactivation by tumor suppressor protein p53 can be inhibited in vivo at elevated protein concentrations. In this study we characterize the structural requirements of this function. We show that oligomerization domain of p53 is involved in loss of transactivation at high protein concentrations: mutants not able to oligomerize are neither able to suppress transactivation, although these transactivating properties can be untouched.	Tartu State Univ, Estonian Bioctr, Inst Mol & Cell Biol, EE-2400 Tartu, Estonia	Estonian Biocentre; University of Tartu	Maimets, T (corresponding author), Tartu State Univ, Estonian Bioctr, Inst Mol & Cell Biol, Riia 23, EE-2400 Tartu, Estonia.		Jaks, Viljar/H-2467-2012; Maimets, Toivo/E-9268-2017	Jaks, Viljar/0000-0002-2221-6262; Maimets, Toivo/0000-0001-6461-3365; Kristjuhan, Arnold/0000-0002-5842-4952				BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DESAINTES C, 1995, ONCOGENE, V10, P2155; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; JACKSON P, 1993, ONCOGENE, V8, P589; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kristjuhan A, 1995, EUR J BIOCHEM, V234, P827, DOI 10.1111/j.1432-1033.1995.827_a.x; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LIU X, 1995, MOL CELL BIOL, V15, P6474; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu X, 1996, ONCOGENE, V13, P413; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MIYASHITA T, 1995, CELL, V80, P293; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SANG BC, 1994, ONCOGENE, V9, P853; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SOUSSI T, 1990, ONCOGENE, V5, P945; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TARUNINA M, 1993, ONCOGENE, V8, P3165; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013	45	4	4	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2413	2418		10.1038/sj.onc.1201749	http://dx.doi.org/10.1038/sj.onc.1201749			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620560				2022-12-28	WOS:000073428000015
J	Sun, L; Carpenter, G				Sun, L; Carpenter, G			Epidermal growth factor activation of NF-kappa B is mediated through I kappa B alpha degradation and intracellular free calcium	ONCOGENE			English	Article						EGF; NF-kB; calcium	C-FOS GENE; MOUSE-LIVER; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; BINDING-PROTEINS; EXPRESSION; CELLS; INDUCTION; SITES; TRANSFORMATION	The transcription factor NF-kappa B is normally sequestered in the cytoplasm by its inhibitory subunit I kappa B. Most extracellular signals activate NF-kappa B through a mechanism involving the phosphorylation and proteasome-dependent degradation of I kappa B, EGF activates NF-kappa B in A-431 carcinoma cells, which overexpress EGF receptors and in mouse embryo fibroblasts, which have a normal complement of receptors, Supershift experiments indicate that the NF-kappa B complexes induced by EGF are composed of p50/p50 homodimers and p65/p50 heterodimers, but not c-rel, EGF stimulation enhances the degradation of I kappa B alpha, but not I kappa-B beta nor an N-terminal deletion mutant of II;Ba. Treatment of cells with a proteasome inhibitor, such as ALLN or MG132, blocks EGF-mediated NF-kappa B activation, indicating that EGF-induced NF-kappa B activation requires proteasome-dependent I kappa B degradation, Also, Bapta A/M (a cell-permeable chelator of intracellular calcium) blocks EGF-induced NF-kappa B activation and I kappa B alpha degradation, suggesting a requirement of intracellular free Ca2+ for this growth factor response, Protein kinase C inhibition, in contrast, did not influence EGF activation of NF-kappa B.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [T32CA009582, R01CA075195] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA75195, T32 CA09582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Cabannes E, 1997, ONCOGENE, V15, P29, DOI 10.1038/sj.onc.1201162; CARPENTER G, 1993, FORUM, V3, P616; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FISHER DA, 1990, ENDOCR REV, V11, P418, DOI 10.1210/edrv-11-3-418; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALANG CK, 1994, ONCOGENE, V9, P2913; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Kanno T, 1996, J IMMUNOL, V157, P5277; LAROSA F, 1993, MOL CELL BIOL, V14, P1039; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHOUTEN GJ, 1997, EMBO J, V16, P3133; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THEVENIN C, 1990, New Biologist, V2, P793; WILHELM D, 1995, IMMUNOBIOLOGY, V193, P143, DOI 10.1016/S0171-2985(11)80537-1	47	107	110	2	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2095	2102		10.1038/sj.onc.1201731	http://dx.doi.org/10.1038/sj.onc.1201731			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572490	Bronze			2022-12-28	WOS:000073177200007
J	Noe, V; Alemany, C; Chasin, LA; Ciudad, CJ				Noe, V; Alemany, C; Chasin, LA; Ciudad, CJ			Retinoblastoma protein associates with Sp1 and activates the hamster dihydrofolate reductase promoter	ONCOGENE			English	Article						DHFR; Sp1; Rb	TRANSCRIPTION FACTOR E2F; SUSCEPTIBILITY GENE-PRODUCT; CELL-CYCLE; SP1-MEDIATED TRANSCRIPTION; GROWTH-REGULATION; BINDING PROTEIN; EXPRESSION; REPRESSION; ELEMENT; CLONING	The dihydrofolate reductase (dhfr) promoter is powerfully activated by the transcription factor Sp1. It has been suggested that Sp1 is a potential target for transcriptional regulation by the cell cycle regulator retinoblastoma protein (Rb), and so we have explored this possibility using the hamster dhfr gene as a model. By the use of DNA probes from the hamster dhfr gene promoter, containing the most proximal GC box (minimal promoter), and nuclear extracts from cultured hamster cells (CHO K1), we show that polyclonal and monoclonal antibodies against Rb supershift the binding of Sp1. Nuclear extract immunoprecipitation with anti- Rb followed by Western analysis using anti-Sp1 also shows that Rb is complexed to Sp1. Complementary Immunoprecipitation/WB analysis shows both forms of Rh protein in the anti-Sp1 immunoprecipitates. Moreover, nuclear extract immunodepletion of Rb abolishes Sp1 gel-shift. The interaction between Rb and Sp1 is maintained in all the phases of the cell cycle. Transient overexpression of Rb in dhfr negative cells co-transfected with a dhfr minigene driven by its minimal promoter increases DHFR activity and potentiates transcription when overexpressing Sp1. Both effects are severely reduced when the co-transfections are performed with a homologous dhfr minigene containing a single point mutation in the GC box. Thus, the activation by Rb of the dhfr gene may be exerted through Sp1. Stable transfectants of pCMVRb in K1 cells show an increase in both mRNA and DHFR activity. It is concluded that Sp1 is physically associated with Rb, and that this association increases Sp1-mediated transcription of the hamster dhfr gene.	Univ Barcelona, Sch Pharm, Biochem Unit, E-08028 Barcelona, Spain; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of Barcelona; Columbia University	Ciudad, CJ (corresponding author), Univ Barcelona, Sch Pharm, Biochem Unit, E-08028 Barcelona, Spain.		Noe, Veronique/K-3615-2014; Ciudad, Carlos J./D-7917-2014	Noe, Veronique/0000-0001-7937-8038; Ciudad, Carlos J./0000-0002-7855-392X	NIGMS NIH HHS [GM-22529] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CIUDAD CJ, 1988, J BIOL CHEM, V263, P16274; CIUDAD CJ, 1992, J BIOL CHEM, V267, P3650; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P365, DOI 10.1128/MCB.6.2.365; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Noe V, 1997, EUR J BIOCHEM, V249, P13, DOI 10.1111/j.1432-1033.1997.00013.x; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Rohde M, 1996, ONCOGENE, V12, P2393; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; URLAUB G, 1985, SOMAT CELL MOLEC GEN, V11, P71, DOI 10.1007/BF01534736; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; YU DH, 1992, J BIOL CHEM, V267, P10203	42	45	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1931	1938		10.1038/sj.onc.1201718	http://dx.doi.org/10.1038/sj.onc.1201718			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591776				2022-12-28	WOS:000073079400004
J	Megonigal, MD; Rappaport, EF; Nowell, PC; Lange, BJ; Felix, CA				Megonigal, MD; Rappaport, EF; Nowell, PC; Lange, BJ; Felix, CA			Potential role for wild-type p53 in leukemias with MLL gene translocations	ONCOGENE			English	Article						p53; MLL; DNA topoisomerase II; DNA damage; translocation	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DNA TOPOISOMERASE-II; CHILDRENS-CANCER-GROUP; MUTATIONS; CHILDHOOD; BREAKPOINTS; 11Q23; CELLS; MYELODYSPLASIA	We used single-strand conformation polymorphism (SSCP) analysis of p53 exons 4-8 to screen for possible mutations in 25 pediatric de novo leukemias with translocations of the MLL gene at chromosome band 11q23, Of the 25 patients, 21 were infants. Fifteen cases were acute myeloid leukemia (AML), eight were acute lymphoblastic leukemia (ALL), and two cases were biphenotypic, Nineteen cases were studied at diagnosis and six at time of relapse, p53 mutations were absent in all 19 cases studied at the time of diagnosis. The only mutation was a TGC-->TTC transversion (cys-->phe) at codon 141 in exon 5 in a case of infant ALL at relapse that occurred by subclone evolution after MLL gene translocation, We previously showed that p53 mutations are also absent in pediatric treatment-related leukemias with MLL gene translocations. The absence of p53 mutations at initial transformation may suggest that the anti-apoptotic effect of mutant p53 is not important in leukemias with MLL gene translocations. Alternatively, exogenous DNA damage may be the common feature in treatment-related and de novo cases. Since MLL gene translocations may occur through DNA repair and wild-type p53 is central to DNA repair, the absence of p53 mutations raises the possibility that wild-type p53, not mutant p53, may be important in the genesis of leukemias with these translocations.	Univ Penn, Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania	Felix, CA (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.		Rappaport, Eric/GRO-4051-2022		NCI NIH HHS [CA42232, 1R29CA66140-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA066140, R35CA042232] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413; BODLEY AL, 1993, MOL CELL BIOL, V13, P6190, DOI 10.1128/MCB.13.10.6190; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; BUCKLEY JD, 1989, CANCER RES, V49, P4030; CARBONE D, 1991, ONCOGENE, V6, P1691; Cimino G, 1997, BRIT J HAEMATOL, V96, P308, DOI 10.1046/j.1365-2141.1997.d01-2044.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; DARPA P, 1990, CANCER RES, V50, P6919; DICCIANNI MB, 1994, BLOOD, V84, P3105; FELIX C, UNPUB; Felix CA, 1996, BLOOD, V87, P4376, DOI 10.1182/blood.V87.10.4376.bloodjournal87104376; FELIX CA, 1995, CANCER RES, V55, P4287; FELIX CA, 1995, BLOOD, V85, P3250, DOI 10.1182/blood.V85.11.3250.bloodjournal85113250; FELIX CA, 1994, LEUKEMIA, V8, P963; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FELIX CA, 1992, J CLIN INVEST, V90, P653, DOI 10.1172/JCI115907; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; KASTAN MB, 1991, CANCER RES, V51, P6304; KAWAMURA M, 1995, BLOOD, V85, P2546, DOI 10.1182/blood.V85.9.2546.bloodjournal8592546; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANZA C, 1995, LEUKEMIA, V9, P955; Lanza C, 1996, GENE CHROMOSOME CANC, V15, P48, DOI 10.1002/(SICI)1098-2264(199601)15:1<48::AID-GCC7>3.0.CO;2-4; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Marks DI, 1997, J CLIN ONCOL, V15, P1158, DOI 10.1200/JCO.1997.15.3.1158; MISUDOMI T, 1992, ONCOGENE, V7, P171; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PEDERSENBJERGAARD J, 1995, BLOOD, V86, P3542, DOI 10.1182/blood.V86.9.3542.bloodjournal8693542; POMMIER Y, 1993, CAUSES CONSEQUENCES, P277; PROKOCIMER M, 1994, BLOOD, V84, P2391; PUI CH, 1995, LEUKEMIA, V9, P762; PUI CH, 1990, LANCET, V336, P417, DOI 10.1016/0140-6736(90)91956-B; ROBISON LL, 1989, CANCER, V63, P1904; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; SEVERSON RK, 1993, CANCER EPIDEM BIOMAR, V2, P433; WADA M, 1993, BLOOD, V82, P3163; WINICK NJ, 1993, J CLIN ONCOL, V11, P209, DOI 10.1200/JCO.1993.11.2.209; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608	41	22	23	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1351	1356		10.1038/sj.onc.1201637	http://dx.doi.org/10.1038/sj.onc.1201637			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546437				2022-12-28	WOS:000072422000014
J	Simms, LA; Radford-Smith, G; Biden, KG; Buttenshaw, R; Cummings, M; Jass, JR; Young, J; Meltzer, SJ; Leggett, BA				Simms, LA; Radford-Smith, G; Biden, KG; Buttenshaw, R; Cummings, M; Jass, JR; Young, J; Meltzer, SJ; Leggett, BA			Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers	ONCOGENE			English	Article						microsatellite instability; p53; BAX; colorectal cancer	WILD-TYPE P53; MICROSATELLITE MUTATOR PHENOTYPE; II RECEPTOR GENE; DNA-DAMAGE; GASTROINTESTINAL TUMORS; GENOMIC INSTABILITY; SOMATIC MUTATIONS; GASTRIC-CANCER; CELL-LINES; EXPRESSION	Though most colorectal cancers show allelic losses, a subset of colorectal cancers (microsatellite instability or MSI-positive cancers) develop numerous small insertion and deletion mutations in repetitive DNA, Some of these sequences occur in coding regions of cancer related genes which, when targeted by frameshift mutations, produce truncations in their protein product, Such a gene is the proapoptotic tumor suppressor, BAX, mutated by frameshifts within a polyG sequence in approximately 50% of MSI-positive colorectal cancers. BAX is directly transactivated by p53, a gene commonly mutated in colorectal cancers but not often in MSI-positive lesions. Here we sought to characterize the relationship between BAX and p53 by simultaneously analysing a selected series of 65 colorectal tumors for mutations in the entire coding regions of both genes. The tumors comprised 19 MSI-high, 12 MSI-low and 34 MSI-null cancers. Eight of 19 MSI-high sporadic colorectal cancers (42%) contained insertions and deletions at the polyG tract in the BAX gene, In addition, three somatic BAX missense mutations were identified in two tumors. A single missense mutation was detected in an MSI-high tumor that also contained a frameshift microdeletion, and two missense mutations were identified in an MSI-null tumor wild-type for p53, p53 mutations were detected in 5/12 MSI-low tumors (42%) and 12/34 MSI-null tumors (35%), Of significance, no p53 mutations were detected in MSI-high tumors. This study demonstrates that a reciprocal relationship exists between p53 and BAX in sporadic colorectal cancers, and further supports the hypothesis that MSI-low tumors are biologically similar to MSI-null tumors.	Royal Brisbane Hosp Fdn, Clin Res Ctr, Conjoint Gastroenterol Lab, Bancroft Ctr, Herston, Qld 4029, Australia; Univ Queensland, Royal Brisbane Hosp, Dept Gastroenterol, Herston, Qld 4029, Australia; Univ Queensland, Sch Med, Dept Pathol, Herston, Qld 4006, Australia; Univ Maryland, Sch Med, Dept Pathol & Med, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Grad Program Mol & Cell Biol, Baltimore, MD 21201 USA; Vet Affairs Med Ctr, Baltimore, MD 21201 USA	Royal Brisbane & Women's Hospital; University of Queensland; University of Queensland; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Simms, LA (corresponding author), Royal Brisbane Hosp Fdn, Clin Res Ctr, Conjoint Gastroenterol Lab, Bancroft Ctr, Herston, Qld 4029, Australia.		Radford-Smith, Graham L/G-5749-2017; Young, Joanne P/B-9981-2011; Young, Joanne P/H-7774-2014; Radford-Smith, Graham/H-2792-2013; Leggett, Barbara A/D-3579-2011; Cummings, Margaret/B-5747-2011	Radford-Smith, Graham L/0000-0002-2047-6239; Radford-Smith, Graham/0000-0002-2047-6239; Cummings, Margaret/0000-0002-7657-0240; Simms, Lisa/0000-0002-5387-7397; Leggett, Barbara/0000-0003-2062-7380	NATIONAL CANCER INSTITUTE [R01CA067497, R01CA077057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA67497, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chou D, 1996, CANCER GENET CYTOGEN, V88, P136, DOI 10.1016/0165-4608(95)00341-X; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cottu PH, 1996, ONCOGENE, V13, P2727; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gallagher WM, 1997, ONCOGENE, V14, P185; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hanski C, 1996, CANCER LETT, V103, P163, DOI 10.1016/0304-3835(96)04208-5; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jass JR, 1998, GUT, V42, P673, DOI 10.1136/gut.42.5.673; Kahlenberg MS, 1996, J NATL CANCER I, V88, P1665, DOI 10.1093/jnci/88.22.1665; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTRINAKIS WV, 1995, ONCOGENE, V11, P647; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTHE RA, 1993, CANCER RES, V53, P5849; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MIYASHITA T, 1995, CELL, V80, P293; PARSONS R, 1995, CANCER RES, V55, P5548; Perego P, 1996, CANCER RES, V56, P556; Perucho M, 1996, NAT MED, V2, P630, DOI 10.1038/nm0696-630; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Renault B, 1996, HUM GENET, V98, P601, DOI 10.1007/s004390050267; RHYU MG, 1994, ONCOGENE, V9, P29; Simms LA, 1997, ONCOGENE, V14, P2613, DOI 10.1038/sj.onc.1201094; SMITH ML, 1995, ONCOGENE, V10, P1053; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; Souza RF, 1997, CANCER RES, V57, P2350; STRICKLER JG, 1994, CANCER RES, V54, P4750; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Watatani M, 1996, CANCER, V77, P1688, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1688::AID-CNCR16>3.0.CO;2-U; Yamamoto H, 1997, CANCER RES, V57, P4420; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yin J, 1997, HUM MUTAT, V10, P474, DOI 10.1002/(SICI)1098-1004(1997)10:6<474::AID-HUMU9>3.0.CO;2-D; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544; ZHAN QM, 1994, ONCOGENE, V9, P3743	57	59	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					2003	2008		10.1038/sj.onc.1202109	http://dx.doi.org/10.1038/sj.onc.1202109			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788444				2022-12-28	WOS:000076423500014
J	Dhanasekaran, N; Tsim, ST; Dermott, JM; Onesime, D				Dhanasekaran, N; Tsim, ST; Dermott, JM; Onesime, D			Regulation of cell proliferation by G proteins	ONCOGENE			English	Review						G proteins; oncogene; signaling; ERK; JNK; Ras	MUTANT ALPHA-SUBUNIT; MUSCARINIC ACETYLCHOLINE-RECEPTOR; GTPASE-DEFICIENT G-ALPHA(16); NUCLEOTIDE EXCHANGE FACTOR; EMBRYONAL CARCINOMA-CELLS; HETEROTRIMERIC G-PROTEINS; RAS-DEPENDENT ACTIVATION; KINASE SIGNALING PATHWAY; BETA-GAMMA-SUBUNITS; SWISS 3T3 CELLS	G Proteins provide signal transduction mechanisms to seven transmembrane receptors. Recent studies have indicated that the alpha-subunits as well as the beta gamma-subunits of these proteins regulate several critical signaling pathways involved in cell proliferation, differentiation and apoptosis. Of the 17 alpha-subunits that have been cloned, at least ten of them have been shown to couple mitogenic signaling in fibroblast cells. Activating mutations in G alpha(s), G alpha(12), and G alpha(12) have been correlated with different types of tumors. In addition, the ability of the beta gamma-subunits to activate mitogenic pathways in different cell-types has been defined. The present review briefly summarizes the diverse and novel signaling pathways regulated by the alpha- as well as the beta gamma-subunits of G proteins in regulating cell proliferation.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.				NIGMS NIH HHS [GM49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chen JF, 1997, J MOL MED, V75, P283, DOI 10.1007/s001090050113; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COPELAND NG, 1979, CELL, V17, P993, DOI 10.1016/0092-8674(79)90338-6; CORRE I, 1995, BLOOD, V86, P1776, DOI 10.1182/blood.V86.5.1776.bloodjournal8651776; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CZECH MP, 1988, J BIOL CHEM, V263, P11017; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEVIVO M, 1994, J BIOL CHEM, V269, P19671; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Dhanasekaran N, 1998, BIOL SIGNAL RECEPT, V7, P109; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Ham J, 1997, MOL CELL ENDOCRINOL, V127, P41, DOI 10.1016/S0303-7207(96)03987-1; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hermouet S, 1996, CELL SIGNAL, V8, P159, DOI 10.1016/0898-6568(95)02049-7; HERMOUET S, 1996, CELL SIGNAL, V5, P215; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirai A, 1997, J BIOL CHEM, V272, P13; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KATAOKA R, 1993, J BIOL CHEM, V268, P19851; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liu JL, 1997, J BIOL CHEM, V272, P29438, DOI 10.1074/jbc.272.47.29438; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MUCA C, 1994, ONCOGENE, V9, P3647; Offermanns S, 1996, J BIOL CHEM, V271, P26044, DOI 10.1074/jbc.271.42.26044; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; QIAN NX, 1994, J BIOL CHEM, V269, P17417; RAHMATULLAH M, 1995, J BIOL CHEM, V270, P2946, DOI 10.1074/jbc.270.7.2946; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROCCA GJD, 1997, J BIOL CHEM, V272, P19125; RODBELL M, 1971, J BIOL CHEM, V246, P1872; ROSS EM, 1977, J BIOL CHEM, V252, P6966; SA G, 1994, J BIOL CHEM, V269, P3219; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; TORDJMAN K, 1993, J CLIN ENDOCR METAB, V77, P765, DOI 10.1210/jc.77.3.765; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Vallar L, 1996, CANCER SURV, V27, P325; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WONG YH, 1995, ONCOGENE, V10, P1927; WU DQ, 1992, J BIOL CHEM, V267, P1811; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XU N, 1993, P NATL ACAD SCI USA, V90, P11354; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yan K, 1997, J BIOL CHEM, V272, P2056; YANG LJ, 1993, J BIOL CHEM, V268, P3739; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zeiger MA, 1996, ENDOCRINOLOGY, V137, P5392, DOI 10.1210/en.137.12.5392; Zhang YH, 1996, ONCOGENE, V12, P2377; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	139	124	129	4	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1383	1394		10.1038/sj.onc.1202242	http://dx.doi.org/10.1038/sj.onc.1202242			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779986				2022-12-28	WOS:000076161900007
J	Petermann, R; Mossier, BM; Aryee, DNT; Khazak, V; Golemis, EA; Kovar, H				Petermann, R; Mossier, BM; Aryee, DNT; Khazak, V; Golemis, EA; Kovar, H			Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II	ONCOGENE			English	Article						ewing tumors; transcription; transformation; two-hybrid-system; sigma factors	EWINGS-SARCOMA TRANSLOCATION; TRANSCRIPTION FACTOR-TFIIB; BINDING PROTEIN; DNA-BINDING; CHROMOSOME-TRANSLOCATION; EWS GENE; MYXOID LIPOSARCOMA; MALIGNANT-MELANOMA; ACTIVATION DOMAIN; MYELOID-LEUKEMIA	As a result of the t(11;22)(q24;q12) chromosomal translocation characterizing the Ewing family of tumors (ET), the amino terminal portion of EWS, an RNA binding protein of unknown function, is fused to the DNA-binding domain of the ets transcription factor Fli1. The hybrid EWS-Fli1 protein acts as a strong transcriptional activator and, in contrast to wildtype Fli1, is a potent transforming agent. Similar rearrangements involving EWS or the highly homologous TLS with various transcription factors have been found in several types of human tumors. Employing yeast two-hybrid cloning we isolated the seventh largest subunit of human RNA polymerase II (hsRPB7) as a protein that specifically interacts with the amino terminus of EWS, This association was confirmed by in vitro immunocoprecipitation. In nuclear extracts, hsRPB7 was found to copurify with EWS-Fli1 but not with Fli1, Overexpression of recombinant hsRPB7 specifically increased gene activation by EWS-chimeric transcription factors. Replacement of the EWS portion by hsRPB7 in the oncogenic fusion protein restored the transactivating potential of the chimera. Our results suggest that the interaction of the amino terminus of EWS with hsRPB7 contributes to the transactivation function of EWS-Fli1 and, since hsRPB7 has characteristics of a regulatory subunit of RNA polymerase II, may influence promoter selectivity.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Saint Anna Children's Hospital; Fox Chase Cancer Center	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.			Kovar, Heinrich/0000-0001-6873-9109; Golemis, Erica/0000-0003-3618-3673	NIGMS NIH HHS [GM 708041] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alliegro MC, 1996, DEV BIOL, V174, P288, DOI 10.1006/dbio.1996.0074; [Anonymous], 1991, Methods Enzymol, V194, P1; AURIAS A, 1983, CR ACAD SCI III-VIE, V296, P1105; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BERTOLOTTI A, 1998, MOL CELL BIOL, V13, P6984; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CARE CT, 1983, C R SEANCES ACAD 3, V296, P1101; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; Clark J, 1996, ONCOGENE, V12, P229; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fujimura Y, 1996, ONCOGENE, V12, P159; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; Hackl W, 1996, J MOL BIOL, V264, P843, DOI 10.1006/jmbi.1996.0681; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEON IS, 1995, ONCOGENE, V10, P1229; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; KHAZAK V, 1998, IN PRESS MOL CELL BI; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; OHNO T, 1993, CANCER RES, V53, P5869; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO VN, 1993, ONCOGENE, V8, P2167; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	49	109	124	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	1998	17	5					603	610		10.1038/sj.onc.1201964	http://dx.doi.org/10.1038/sj.onc.1201964			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704926				2022-12-28	WOS:000075195300008
J	Wicking, C; Simms, LA; Evans, T; Walsh, M; Chawengsaksophak, K; Beck, F; Chenevix-Trench, G; Young, J; Jass, J; Leggett, B; Wainwright, B				Wicking, C; Simms, LA; Evans, T; Walsh, M; Chawengsaksophak, K; Beck, F; Chenevix-Trench, G; Young, J; Jass, J; Leggett, B; Wainwright, B			CDX2, a human homologue of Drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer	ONCOGENE			English	Article						CDX2; caudal; colorectal cancer; microsatellite instability	MICROSATELLITE INSTABILITY; EXPRESSION; CARCINOMA; RECEPTOR; MUCIN; GENE	The Cdx2 gene is one of three murine homologues of the Drosophila homeobox gene caudal, Mice heterozygous for a null mutation in Cdx2 exhibit a variable phenotype including tail abnormalities, stunted growth and a homeotic shift of vertebrae. Most strikingly, however, 90% of heterozygous mice were reported to develop multiple intestinal adenomatous polyps, most notably in the proximal colon (Chawengsaksophak et al., 1997). These observations led us to propose that mutation of CDX2 may be involved in the genesis of some human colorectal tumours, A survey of DNA from 85 colorectal tumours revealed that one with extensive microsatellite instability (RER+ phenotype) has mutations in both alleles of CDX2, Both mutations occur in coding regions which contain repetitive elements and are consistent with those found in RER+ tumours.	Univ Queensland, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia; Bancroft Ctr, Glaxo Gastroenterol Lab, Herston, Qld 4029, Australia; Univ Queensland, Sch Med, Dept Pathol, Brisbane, Qld 4006, Australia; Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3052, Australia; Queensland Inst Med Res, Herston, Qld 4029, Australia	University of Queensland; University of Queensland; Florey Institute of Neuroscience & Mental Health; University of Melbourne; QIMR Berghofer Medical Research Institute	Wainwright, B (corresponding author), Univ Queensland, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia.		Young, Joanne P/H-7774-2014; Chawengsaksophak, Kallayanee/G-4427-2014; Leggett, Barbara A/D-3579-2011; Young, Joanne P/B-9981-2011; Wicking, Carol/J-1814-2014	Chawengsaksophak, Kallayanee/0000-0001-9401-2122; Wainwright, Brandon/0000-0003-0406-2092; Chenevix-Trench, Georgia/0000-0002-1878-2587; Evans, Timothy/0000-0001-7962-6863; Leggett, Barbara/0000-0003-2062-7380; Simms, Lisa/0000-0002-5387-7397; Wicking, Carol/0000-0002-7225-3803				Ajioka Y, 1996, J CLIN PATHOL, V49, P560, DOI 10.1136/jcp.49.7.560; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; EE HC, 1995, AM J PATHOL, V147, P586; JAMES R, 1994, J BIOL CHEM, V269, P15229; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; WALSH MD, 1993, J CLIN PATHOL, V46, P922, DOI 10.1136/jcp.46.10.922	9	89	96	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					657	659		10.1038/sj.onc.1201971	http://dx.doi.org/10.1038/sj.onc.1201971			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704932				2022-12-28	WOS:000075195300014
J	Fedele, M; Berlingieri, MT; Scala, S; Chiariotti, L; Viglietto, G; Rippel, V; Bullerdiek, J; Santoro, M; Fusco, A				Fedele, M; Berlingieri, MT; Scala, S; Chiariotti, L; Viglietto, G; Rippel, V; Bullerdiek, J; Santoro, M; Fusco, A			Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts	ONCOGENE			English	Article						lipoma; chromatin; oncogene; tumor	NUCLEAR PROTEINS; THYROID-CELLS; CDNA CLONING; Y PROTEINS; BETA GENE; EXPRESSION; BINDING; PHOSPHOPROTEIN; ORGANIZATION; ELEMENTS	Overexpression of the high mobility group I (HMGI) proteins is often associated with the malignant phenotype. Moreover, many benign human tumors, mainly of mesenchymal origin, are characterized by rearrangements of the HMGI-C gene. In most cases, HMGI-C alterations involve breaks within the third intron of the gene resulting in aberrant transcripts carrying exons from 1-3, which encode the three DNA binding domains, fused to ectopic sequences. Here, we show that the expression of a truncated form of HMGI-C protein carrying only the three DNA-binding domains, or of a fusion protein carrying the three DNA-binding domains of HMGI-C and the LIM domains of the lipoma preferred partner gene (LPP) protein, causes malignant transformation of NIH3T3 cells. The unrearranged wildtype HMGI-C cDNA did not exert any transforming activity. These findings indicate that rearranged forms of HMGI-C play a role in cell transformation.	Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Ist Nazl Tumori, Fdn Senatore Pascale, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg Napoli, CNR,Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Bremen, Ctr Human Genet & Genet, Bremen, Germany	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Bremen	Fusco, A (corresponding author), Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, Via Tommaso Campanella, I-88100 Catanzaro, Italy.		Chiariotti, Lorenzo/AAC-5262-2022; Viglietto, Giuseppe/AAC-2852-2019; Scala, Stefania/K-1380-2016; Fedele, Monica/C-1417-2015	Viglietto, Giuseppe/0000-0003-2327-7515; Scala, Stefania/0000-0001-9524-2616; Fedele, Monica/0000-0002-9171-1312; CHIARIOTTI, Lorenzo/0000-0001-6097-4171; Fusco, Alfredo/0000-0003-3332-5197				ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Bol S, 1996, CANCER GENET CYTOGEN, V90, P88, DOI 10.1016/0165-4608(96)00062-3; CHAN KY, 1995, NUCLEIC ACIDS RES, V21, P4262; Chiappetta G, 1996, ONCOGENE, V13, P2439; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DU W, 1994, PNAS, V91, P113; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; Fedele M, 1996, CANCER RES, V56, P1896; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kazmierczak B, 1996, ONCOGENE, V12, P515; LEWIS H, 1994, MOL CELL BIOL, V15, P3738; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Staats B, 1996, BREAST CANCER RES TR, V38, P299, DOI 10.1007/BF01806149; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	36	111	114	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					413	418		10.1038/sj.onc.1201952	http://dx.doi.org/10.1038/sj.onc.1201952			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696033				2022-12-28	WOS:000075043000002
J	Shao, NS; Chai, YL; Cui, JQ; Wang, N; Aysola, K; Reddy, ESP; Rao, VN				Shao, NS; Chai, YL; Cui, JQ; Wang, N; Aysola, K; Reddy, ESP; Rao, VN			Induction of apoptosis by Elk-1 and Delta Elk-1 proteins	ONCOGENE			English	Article						Elk-1; Delta Elk-1; apoptosis; calcium ionophore; breast cancer; MCF-7; Rat-1	SIGNAL-TRANSDUCTION PATHWAYS; ETS TRANSCRIPTION FACTOR; TERNARY COMPLEX FACTORS; SERUM RESPONSE ELEMENT; PROGRAMMED CELL-DEATH; ACTIVATION; FAMILY; GENE; PROTOONCOGENE; FIBROBLASTS	Elk-1, an ets related gene codes for at least two splice variants Elk-1, which regulates c-fos transcription and Delta Elk-1, both of which function as transcriptional activators. To investigate the role of Elk-1 and Delta Elk-1 proteins in apoptosis; we have developed rat fibroblast cell lines and human breast cancer cell lines expressing Delta Elk-1 and Delta Elk-1. The expression of Elk-1 and Delta Elk-1 proteins in the Elk-1/Delta Elk-1 transfectants were analysed by immunofluorescence, immunohistochemistry, and Western blot analysis. The Elk-1 unlike Delta Elk-1 transfectants showed a shortened and flattened morphology compared to the parental cells. We have found that calcium ionophore treatment of Rat-1 Elk-1, MCF-7 Elk-1, Rat-1 Delta Elk-1 and MCF-7 Delta Elk-1 transfectants resulted in programmed cell death. These results indicate that constitutive expression of Elk-1 and Delta Elk-1 proteins triggers apoptosis in Rat-1 fibroblasts and breast cancer cells when treated with calcium ionophore.	Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Philadelphia, PA 19102 USA	Drexel University	Rao, VN (corresponding author), Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, MS 481,New Coll Bldg,Broad & Vine St, Philadelphia, PA 19102 USA.			Wang, Nan/0000-0003-0330-8636	NCI NIH HHS [CA57322, CA50507, CA58642] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050507, R01CA058642, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Athanasiou M, 1996, ONCOGENE, V12, P337; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COHEN JJ, 1984, J IMMUNOL, V132, P38; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JIMENEZ B, 1995, ONCOGENE, V10, P811; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; JOSEPH R, 1993, MOL BRAIN RES, V17, P70, DOI 10.1016/0169-328X(93)90074-Y; KONDO S, 1994, BRIT J CANCER, V70, P421, DOI 10.1038/bjc.1994.321; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MARIAS R, 1993, CELL, V73, P381; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Nozaki M, 1996, DNA CELL BIOL, V15, P855, DOI 10.1089/dna.1996.15.855; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Preston GA, 1996, MOL CELL BIOL, V16, P211; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAO VN, 1992, ONCOGENE, V7, P65; Rao VN, 1996, ONCOGENE, V12, P523; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SEARLE J, 1982, PATHOL ANNU, V17, P229; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Shao NS, 1996, ONCOGENE, V13, P1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YI HK, 1997, ONCOGENE, V14, P1250	42	40	43	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					527	532		10.1038/sj.onc.1201931	http://dx.doi.org/10.1038/sj.onc.1201931			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696047	Bronze			2022-12-28	WOS:000075043000016
J	Holmberg, C; Helin, K; Sehested, M; Karlstrom, O				Holmberg, C; Helin, K; Sehested, M; Karlstrom, O			E2F-1-induced p53-independent apoptosis in transgenic mice	ONCOGENE			English	Article						E2F; p53; apoptosis; testis; transgenic mice	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; S-PHASE ENTRY; UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE REGULATION; TUMOR-SUPPRESSOR; BINDING PROTEIN; IN-VIVO; DEREGULATED EXPRESSION; FIBROBLASTS LEADS	The E2F transcription factors are keg targets for the retinoblastoma protein, pRB, By inactivation of E2Fs, PRE prevents progression to the S phase. To test proliferative functions of E2F, we generated transgenic mice expressing human E2F-1 and/or human DP-1. When the hydroxymethyl glutaryl coenzyme A reductase promoter was used to express DP-1, overexpression occurred in a variety of tissues and did not confer phenotypic changes. In contrast, expression of E2F-1 from the same promoter was obtained only in testicles, in which E2F-1 overexpression caused atrophy and sterility through a process involving increased apoptosis in the germinal epithelium. This effect was potentiated by simultaneous overexpression of DP-1. Testicular atrophy as a result of overexpression of E2F-1 and DP-1 is independent of functional p53, since p53-nullizygous transgenic mice overexpressing E2F-1 and DP-1 also suffered testicular atrophy.	Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, DK-1353 Copenhagen K, Denmark; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Rigshosp, Dept Pathol, DK-2100 Copenhagen O, Denmark	University of Copenhagen; IRCCS European Institute of Oncology (IEO); Rigshospitalet	Karlstrom, O (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, Oster Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.		Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022; Holmberg, Christian/L-8011-2014	Helin, Kristian/0000-0003-1975-6097; Holmberg, Christian/0000-0001-9224-0543				Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRADL M, 1991, P NATL ACAD SCI USA, V88, P6447, DOI 10.1073/pnas.88.15.6447; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Dobie K, 1997, TRENDS GENET, V13, P127, DOI 10.1016/S0168-9525(97)01097-4; Dobie KW, 1996, P NATL ACAD SCI USA, V93, P6659, DOI 10.1073/pnas.93.13.6659; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GAUTIER C, 1989, NUCLEIC ACIDS RES, V17, P8389, DOI 10.1093/nar/17.20.8389; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Guy CT, 1996, MOL CELL BIOL, V16, P685; Harlow E., 1988, ANTIBODIES LAB MANUA; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HOGAN B, 1986, MANIPULATING MOUSE E; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KASTAN MB, 1991, CANCER RES, V51, P6304; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P2847; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MEHTALI M, 1990, GENE, V91, P179, DOI 10.1016/0378-1119(90)90086-7; MELLILO RM, 1994, MOL CELL BIOL, V14, P8241; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PURDIE CA, 1994, ONCOGENE, V9, P603; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Sambrook J., 2002, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	90	98	103	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					143	155		10.1038/sj.onc.1201915	http://dx.doi.org/10.1038/sj.onc.1201915			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674698				2022-12-28	WOS:000074706700002
J	Patel, AS; Schechter, GL; Wasilenko, WJ; Somers, KD				Patel, AS; Schechter, GL; Wasilenko, WJ; Somers, KD			Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro	ONCOGENE			English	Article						cortactin; overexpression; motility; invasion	HUMAN BREAST-CANCER; CYCLIN-DEPENDENT KINASES; TYROSINE PHOSPHORYLATION; ALTERED EXPRESSION; HUMAN CARCINOMAS; CONTACT SITES; AMPLIFICATION; CORTACTIN; SUBSTRATE; ONCOGENE	Cortactin, a p80/85 protein first identified as a src kinase substrate, is thought to be involved in the signaling pathway of mitogenic receptors and adhesion molecules mediating cytoskeletal reorganization. The cortactin gene, EMS1, maps to chromosome 11q13, a region amplified in head and neck squamous cell carcinomas (HNSCC) and breast cancer, which display lymph node metastasis and an unfavorable clinical outcome. To further address the role of cortactin in the malignant phenotype of cells, we stably overexpressed cortactin in NIH3T3 fibroblasts and evaluated the effects of elevated cortactin on cellular proliferation, motility and invasiveness. Cortactin overexpressing cells did not display any striking morphological changes, nor any significant differences in cell proliferation or saturation density as compared to control NIH3T3 cells. Furthermore, the cortactin overexpressing cells were anchorage dependent for growth. Interestingly, cortactin overexpressing cells were more motile and invasive in modified Boyden chamber assays. These results suggest that overexpression of cortactin may play a role in tumor progression by influencing tumor cell migration and invasion.	Eastern Virginia Med Sch, Dept Immunol Microbiol, Norfolk, VA 23501 USA; Eastern Virginia Med Sch, Dept Otolaryngol Head & Neck Surg, Head & Neck Tumor Biol Program, Norfolk, VA 23501 USA	Eastern Virginia Medical School; Eastern Virginia Medical School	Somers, KD (corresponding author), Eastern Virginia Med Sch, Dept Immunol Microbiol, Norfolk, VA 23501 USA.							ADELAIDE J, 1988, ONCOGENE, V2, P413; BATES S, 1994, ONCOGENE, V9, P71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; CUNNINGHAM CC, 1992, CANCER METAST REV, V11, P69; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; FANTL V, 1993, CANCER SURV, V18, P77; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; LOVEC H, 1994, ONCOGENE, V9, P323; MAA MC, 1992, ONCOGENE, V7, P2429; MULLER D, 1994, ORAL ONCOL, V30B, P113; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Patel AM, 1996, ONCOGENE, V12, P31; PETERS G, 1995, BREAST CANCER RES TR, V33, P125, DOI 10.1007/BF00682720; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WILLIAMS ME, 1993, ARCH OTOLARYNGOL, V119, P1238; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; XU L, 1994, INT J CANCER, V59, P383, DOI 10.1002/ijc.2910590316; ZHAN X, 1993, J BIOL CHEM, V268, P24427	33	124	131	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3227	3232		10.1038/sj.onc.1201850	http://dx.doi.org/10.1038/sj.onc.1201850			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681820				2022-12-28	WOS:000074343600002
J	El-Naggar, AK; Coombes, MM; Batsakis, JG; Hong, WK; Goepfert, H; Kagan, J				El-Naggar, AK; Coombes, MM; Batsakis, JG; Hong, WK; Goepfert, H; Kagan, J			Localization of chromosome 8p regions involved in early tumorigenesis of oral and laryngeal squamous carcinoma	ONCOGENE			English	Article						oral and laryngeal; chromosome 8p; squamous carcinoma; microsatellite; loss of heterozygosity	TUMOR-SUPPRESSOR GENES; PROSTATIC INTRAEPITHELIAL NEOPLASIA; CELL CARCINOMAS; ALLELIC LOSS; FREQUENT LOSS; SHORT ARM; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; BREAST-CANCER; NECK-CANCER	We analysed 30 primary invasive oral and laryngeal squamous carcinomas (SC), with concurrent dysplastic Lesions, for genetic alterations at 15 microsatellite loci on the short arm of chromosome 8. Overall, loss of heterozygosity (LOH) was observed, in at least one informative locus, in 27% of the dysplastic lesions and in 67% of the invasive carcinomas. The highest frequency of allele tosses in dysplasia (20% and 17%), and invasive carcinoma (40% and 48%) were detected in the same D8S298 and LPL-tet loci located on chromosomes 8p21 and 8p22 respectively. The minimal region with LOH was limited to 4.6 megaBases (mBs) at 8p22 and 7.1 mBs at 8p21. In addition, allelic losses in both dysplastic and corresponding invasive specimens were noted at the same loci in some tumors suggesting their emergence from a common preneoplastic clone. Allele losses correlated significantly with male gender, oral and laryngeal sites and high proliferative index. The data suggest that inactivation of tumor suppressor gene(s), within these loci, may constitute an early event in the evolution of oral and laryngeal SC.	Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Lab Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	El-Naggar, AK (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA.				NIH HHS [1P5ODE11906-01] Funding Source: Medline	NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALSEE KW, 1994, CANCER RES, V54, P1617; Bockmuhl U, 1996, CANCER RES, V56, P5325; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; BRZOSKA PM, 1995, CANCER RES, V55, P3055; Califano J, 1996, CANCER RES, V56, P2488; CHANG M, 1994, AM J PATHOL, V144, P1; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; EMI M, 1992, CANCER RES, V52, P5368; EMMERTBUCK MR, 1995, CANCER RES, V55, P2959; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELD JK, 1995, BRIT J CANCER, V72, P1180, DOI 10.1038/bjc.1995.483; FUJIWARA Y, 1995, ONCOGENE, V10, P891; Gustafson CE, 1996, CANCER RES, V56, P5238; ICHIKAWA T, 1994, CANCER RES, V54, P2299; JIN YS, 1995, CANCER RES, V55, P3204; KAGAN J, 1995, ONCOGENE, V11, P2121; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KERANGUEVEN F, 1994, ONCOL REP, V1, P393; KIARIS H, 1994, INT J ONCOL, V5, P1243; Kishimoto Y, 1996, J CANCER RES CLIN, V122, P585, DOI 10.1007/BF01221189; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEVINE AJ, 1992, CANC SURVEYS, V12; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MERLO GR, 1992, AM J PATHOL, V140, P215; NAWROZ H, 1994, CANCER RES, V54, P1617; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; RADFORD DM, 1995, CANCER RES, V55, P5180; RAO PH, 1994, CANCER GENET CYTOGEN, V77, P60, DOI 10.1016/0165-4608(94)90150-3; SAKR WA, 1994, IN VIVO, V8, P439; Scholnick SB, 1996, J NATL CANCER I, V88, P1676, DOI 10.1093/jnci/88.22.1676; Scully C, 1997, INT J ONCOL, V10, P5; SPEICHER MR, 1995, CANCER RES, V55, P1010; SREEKANTAIAH C, 1994, GENE CHROMOSOME CANC, V11, P29, DOI 10.1002/gcc.2870110106; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; TAMAKO K, 1996, ONCOGENE, V12, P405; TRAGANOS F, 1977, J HISTOCHEM CYTOCHEM, V25, P46, DOI 10.1177/25.1.64567; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOD S, 1994, GENOMICS, V24, P597, DOI 10.1006/geno.1994.1673; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102	47	64	65	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2983	2987		10.1038/sj.onc.1201808	http://dx.doi.org/10.1038/sj.onc.1201808			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662330				2022-12-28	WOS:000074125300004
J	Fan, SJ; Wang, JA; Yuan, RQ; Ma, YX; Meng, QH; Erdos, MR; Brody, LC; Goldberg, ID; Rosen, EM				Fan, SJ; Wang, JA; Yuan, RQ; Ma, YX; Meng, QH; Erdos, MR; Brody, LC; Goldberg, ID; Rosen, EM			BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins	ONCOGENE			English	Article						prostate cancer; DU-145; BRCA1; DNA damage; apoptosis; p300	OVARIAN-CANCER; GENE BRCA1; TRANSCRIPTIONAL ACTIVATION; BREAST-CANCER; MUTATIONS; REGION; P53; FRAGMENTS; CARRIERS; FAMILIES	In addition to breast and ovarian cancer in women, recent evidence suggests that germ-line mutations of the breast cancer susceptibility gene-1 (BRCA1) also confer an increased life-time risk for prostate cancer in male probands, However, it is not known if and how BRCA1 functions in prostate cancer, We stably expressed wildtype (wt) and tumor-associated mutant BRCA1 transgenes in DU-145, a human prostate cancer cell line with low endogenous expression of BRCA1, As compared with parental cells and vector transfected clones, wtBRCA1 clones exhibited: (1) a slightly decreased proliferation rate (doubling time = 25 h as compared with 22 h for control cells); (2) a (3-6)-fold increase in sensitivity to chemotherapy drugs (adriamycin, camptothecin, and taxol); (3) increased susceptibility to drug-induced apoptosis; (4) reduced repair of single-strand DNA strand breaks; and (5) alterations in expression of key cellular regulatory proteins (including BRCA2, p300, Mdm-2, p21(WAF1/CIP1), Bcl-2 and Bar). Clones transfected with the 5677insA breast cancer-associated mutant BRCA1 (insBRCA1) displayed a similar phenotype to wtBRCA1 clones, except that insBRCA1 clones had a significantly decreased proliferation rate (doubling time=42 h), On the other hand, cells transfected with with 185delAG mutant BRCA1 showed no obvious phenotype as compared with parental or vector transfected cells, These findings suggest that BRCA1 may function as a human prostate tumor suppressor by virtue of its ability to modulate proliferation and various components of the cellular damage response. They also suggest several potential target gene products for a BRCA1 prostate tumor suppressor function.	Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, New Hyde Park, NY 11040 USA; Natl Human Genome Res Inst, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA	Northwell Health; Yeshiva University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Fan, SJ (corresponding author), Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Park, NY 11040 USA.		Meng, Q./GSI-6185-2022					ALLEY MC, 1988, CANCER RES, V48, P589; ANDRES JL, IN PRESS ONCOGENE; BERTRAND R, 1995, CELL GROWTH APOPTOSI, P97; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; EASTON DF, 1995, AM J HUM GENET, V56, P265; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GAO X, 1995, ONCOGENE, V11, P1241; Garnick MB, 1996, ANN INTERN MED, V125, P205, DOI 10.7326/0003-4819-125-3-199608010-00009; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; JISHI MF, 1995, CANCER, V76, P1416, DOI 10.1002/1097-0142(19951015)76:8<1416::AID-CNCR2820760818>3.0.CO;2-D; Karp JE, 1996, CANCER RES, V56, P5547; Langston AA, 1996, AM J HUM GENET, V58, P881; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MURAKAMI YS, 1995, CANCER RES, V55, P3389; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STREUWING JP, 1997, NEW ENGL J MED, V336, P1401; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tirkkonen M, 1997, CANCER RES, V57, P1222; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Webber MM, 1997, PROSTATE, V30, P58; Williams BJ, 1996, J UROLOGY, V155, P720, DOI 10.1016/S0022-5347(01)66509-1; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	47	93	97	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3069	3082		10.1038/sj.onc.1202116	http://dx.doi.org/10.1038/sj.onc.1202116			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662340				2022-12-28	WOS:000074125300014
J	Mizutani, S; Koide, H; Kaziro, Y				Mizutani, S; Koide, H; Kaziro, Y			Isolation of a new protein factor required for activation of Raf-1 by Ha-Ras: partial purification from rat brain cytosols	ONCOGENE			English	Article						Ras; Raf; reconstitution; cell-free system	SIGNAL-TRANSDUCTION PATHWAY; KINASE KINASE KINASE; KSR-1 GENE ENCODES; PLASMA-MEMBRANE; IN-VITRO; TYROSINE PHOSPHORYLATION; C-ELEGANS; B-RAF; CASCADE; 14-3-3-PROTEINS	Ras-mediated signaling pathways play a critical role in cellular proliferation and differentiation. Although it has been demonstrated that Ras interacts with Raf-1 to stimulate the serine/threonine kinase activity of Raf-1, the precise mechanism by which Ras activates Raf-1 remains obscure. To address this question, we developed a cell-free system in which the activated form of H-Ras can induce Raf-1 activation. Using this system, we found the presence of a new protein factor, in cytosolic fractions of both human embryonic kidney 293 cells and rat brain tissues, that is required for Ras-dependent activation of Raf-1. The factor was purified from rat brain cytosols through successive column chromatographies on DEAE Sephacel, SP Sepharose and Sephacryl S-300, The approximate molecular weight of the activator was estimated as 400000 by gel filtration. Its activity was sensitive to heat and trypsin treatments. The purified activator did not contain Src, 14-3-3, protein kinase C, JAK2 or Ksr-1, as judged by immunoblotting, Further characterization of the activator is underway.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 227, Japan	Tokyo Institute of Technology	Kaziro, Y (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 227, Japan.		Koide, Hiroshi/E-9000-2011	Koide, Hiroshi/0000-0001-5916-3179				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GOTOH Y, 1994, ONCOGENE, V9, P1891; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; Miyake M, 1996, FEBS LETT, V378, P15, DOI 10.1016/0014-5793(95)01416-0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	45	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2781	2786		10.1038/sj.onc.1201806	http://dx.doi.org/10.1038/sj.onc.1201806			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652745				2022-12-28	WOS:000073812200010
J	Qian, Y; Baisden, JM; Westin, EH; Guappone, AC; Koay, TC; Flynn, DC				Qian, Y; Baisden, JM; Westin, EH; Guappone, AC; Koay, TC; Flynn, DC			Src can regulate carboxy terminal interactions with AFAP-110, which influence self-association, cell localization and actin filament integrity	ONCOGENE			English	Article						Src; AFAP-110; cytoskeleton; membrane; multimer	PP60C-SRC PROTEIN-KINASE; HUMAN-COLON CARCINOMA; LEUCINE-ZIPPER; V-SRC; MUTATIONAL ANALYSIS; STABLE ASSOCIATION; TYROSINE KINASES; IDENTIFICATION; ACTIVATION; DOMAIN	The SH2 and SH3 binding partner AFAP-110 is a tyrosine phosphorylated substrate of Src, AFAP-110 has been hypothesized to link Src to actin filaments, which may contribute to the effects of Src upon actin filament integrity, However, it has been unclear what effect activated Src (Src(527F)) has upon AFAP-110 structure or function and whether AFAP-110 plays a role in actin filament integrity. We report here that the carboxy terminal 127 amino acids of AFAP-110 are comprised of an alpha-helical region that contains a leucine zipper motif, This indicated the potential of AFAP-110 to self-associate, Expression of the carboxy terminus as a fusion protein (GST-cterm) mill permit affinity absorption of cellular AFAP-110, The integrity of the alpha-helical leucine zipper motif in GST-cterm is required for affinity absorption, but binding is not due to a classical leucine zipper interaction. Co-expression of Src(527F), unlike cSrc, mill abrogate affinity absorption of AFAP-110 with GST-cterm, These data indicate that Src(527F) has affected a change in the carboxy terminal structure that renders AFAP-110 unavailable for affinity absorption. Superose chromatography demonstrate that AFAP-110 will fractionate as a monomer or multimer, indicating AFAP-110 can be detected in a self-associated form in cell lysates. Go-expression of Src(527F) resulted in AFAP-110 fractionating with a molecular weight that predicts only a multimeric population. Deletional mutagenesis also indicate a biological role for the carboxy terminus in cellular localization and actin filament integrity. Deletion of the entire carboxy terminal alpha-helix (84 amino acids) will not permit AFAP-110 to efficiently colocalize with actin filaments or the cell membrane. Deletion of only the leucine zipper region of the carboxy terminal alpha-helix (44 amino acids) from AFAP-110 (AFAPA(Delta zip)) demonstrate that both AFAP(Delta lzip) and actin filaments are repositioned into rosette-like structures, similar to the effects of Src(527F), while co-expression of AFAP-110 with cSrc will not affect actin filaments. These data indicate that AFAP-110 can play an important role in modulating actin filament integrity through carboxy terminal interactions that can be affected by Sr-527F.	W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol & Immunol, Morgantown, WV 26506 USA	West Virginia University; West Virginia University	Flynn, DC (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, POB 9300, Morgantown, WV 26506 USA.		Baisden, Joseph/AAN-7747-2021	Baisden, Joseph/0000-0002-8986-407X	NCI NIH HHS [CA 60731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060731, R29CA060731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bikle DD, 1996, J BIOL CHEM, V271, P9075, DOI 10.1074/jbc.271.15.9075; BLENIS J, 1985, P NATL ACAD SCI USA, V82, P7621, DOI 10.1073/pnas.82.22.7621; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; COOPER JA, 1996, BIOCH BIOPHYS ACTA G, V1287, P121; EARL PL, 1993, AIDS RES HUM RETROV, V9, P589, DOI 10.1089/aid.1993.9.589; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; FLYNN DC, 1995, J BIOL CHEM, V270, P3894, DOI 10.1074/jbc.270.8.3894; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; GUAPPONE AC, UNPUB; GUAPPONE AC, 1996, METH CELL SCI, V18, P1; HODGES RS, 1992, CURR BIOL, V2, P22; HURST HC, 1994, PROTEIN PROFILE, V1, P123; JACKSON P, 1989, J VIROL, V63, P311, DOI 10.1128/JVI.63.1.311-318.1989; JACOBS C, 1983, CANCER RES, V43, P1696; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; KLEIN NJ, 1993, INT IMMUNOL, V5, P293, DOI 10.1093/intimm/5.3.293; MAEKAWA T, 1993, J CELL SCI, V105, P589; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; PEARLMAN JA, 1994, FEBS LETT, V354, P183, DOI 10.1016/0014-5793(94)01119-2; QURESHI SA, 1991, ONCOGENE, V6, P995; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Ruth P, 1997, J BIOL CHEM, V272, P10522; SARAS J, 1994, J BIOL CHEM, V269, P24082; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; STERNBERG DW, 1993, EMBO J, V12, P323, DOI 10.1002/j.1460-2075.1993.tb05660.x; STURGILL TW, 1988, NATURE, V353, P174; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U	45	43	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2185	2195		10.1038/sj.onc.1201753	http://dx.doi.org/10.1038/sj.onc.1201753			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619827				2022-12-28	WOS:000073298000003
J	Le, XF; Vallian, S; Mu, ZM; Hung, MC; Chang, KS				Le, XF; Vallian, S; Mu, ZM; Hung, MC; Chang, KS			Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis	ONCOGENE			English	Article						Ad-PML; breast cancer; tumorgenicity; G1 arrest; apoptosis	ACUTE PROMYELOCYTIC LEUKEMIA; GENE-THERAPY; RAR-ALPHA; T(15-17) TRANSLOCATION; NUCLEAR MATRIX; NUDE-MICE; PROTEIN; ONCOPROTEIN; EXPRESSION; BODIES	Our previous studies demonstrated that the promyelocytic leukemia gene, PML which involved in the 15;17 translocation in acute promyelocytic leukemia (APL) is a growth and transformation suppressor. In this study, recombinant PML adenovirus, Ad-PML was constructed and used to infect human breast cancer cells in vitro and in vivo, the anti-oncogenic function of PML and its mechanism of growth suppressing effect in breast cancer cells were examined. We showed that Ad-PML effectively infected the MCF-7 and SK-BR-3 cells. A high level of PML protein was expressed within 24 h post-infection and a detectable level remained at day 16. Ad-PML significantly suppressed the growth rate, clonogenicity, and tumorigenicity of breast cancer cells. Intratumoral injections of MCF-7-induced tumors by high titer Ad-PML suppressed tumor growth in nude mice by about 80%. The injection sites expressed high level of PML and associated with a massive apoptotic cell death. To elucidate the molecular mechanism of PML's growth suppressing function, we examined the effect of Ad-PML on cell cycle distribution in MCF-7 and SK-BR-3 cells. We found that Ad-PML infection caused a cell cycle arrest at the G1 phase, We further showed that G1 arrest of MCF-7 cells is associated with a significant decrease in cyclin DI and CDK2. An increased expression of p53, p21 and cyclin E was found. The Rb protein became predominantly hypophosphorylated 48 h post-infection. These findings indicate that PML exerts its growth suppressing effects by modulating several key G1 regulatory proteins. Our study provides important insight into the mechanism of tumor suppressing function of PML and suggests a potential application of Ad-PML in human cancer gene therapy.	Univ Texas, Md Anderson Canc Ctr, Div Lab Med, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chang, KS (corresponding author), Univ Texas, Md Anderson Canc Ctr, Div Lab Med, Houston, TX 77030 USA.		Vallian, Sadeq/AAA-7085-2020; Hung, Mien-Chie/ABD-5911-2021	Vallian, Sadeq/0000-0002-5151-5923; Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [CA-55577, CA-16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA055577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN MJ, 1995, ONCOGENE, V10, P2307; BENCHETRIT E, 1988, J EXP MED, V167, P1560, DOI 10.1084/jem.167.5.1560; Boddy MN, 1996, ONCOGENE, V13, P971; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Ealovega MW, 1996, CANCER RES, V56, P1965; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; FORBES JF, 1997, SEMIN ONCOL S1, V24; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gorospe M, 1996, MOL CELL BIOL, V16, P762; He DL, 1997, CANCER RES, V57, P1868; Hortobagyi GN, 1996, SEMIN ONCOL, V23, P1; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Katayose D, 1995, CLIN CANCER RES, V1, P889; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; Kwong YL, 1996, CANCER GENE THER, V3, P339; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mu ZM, 1996, LEUKEMIA LYMPHOMA, V23, P277, DOI 10.3109/10428199609054830; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MU ZM, 1997, IN PRESS CARCINOGENE; NASONBURCHENAL K, 1996, BLOOD, V88, P3928; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Piccart M, 1996, ANTI-CANCER DRUG, V7, P5, DOI 10.1097/00001813-199608001-00002; RUNNEBAUM IB, 1995, HYBRIDOMA, V14, P153, DOI 10.1089/hyb.1995.14.153; Seth P, 1996, CANCER RES, V56, P1346; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Stadler M, 1995, ONCOGENE, V11, P2565; SU N, 1994, BREAST CANCER RES TR, V31, P349, DOI 10.1007/BF00666167; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yee D, 1996, HUM GENE THER, V7, P1251, DOI 10.1089/hum.1996.7.10-1251; ZHANG JF, 1996, P NATL ACAD SCI USA, V93, P4518	52	90	106	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1839	1849		10.1038/sj.onc.1201705	http://dx.doi.org/10.1038/sj.onc.1201705			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583681				2022-12-28	WOS:000072994600007
J	Li, KKC; Lee, KAW				Li, KKC; Lee, KAW			MMSP tumor cells expressing the EWS/ATF1 oncogene do not support cAMP-inducible transcription	ONCOGENE			English	Article						EWS/ATF1; cAMP; oncogene; phosphorylation	DEPENDENT PROTEIN-KINASE; ELEMENT-BINDING PROTEIN; C-FOS PROMOTER; MULTIPLE SEQUENCE ELEMENTS; CYCLIC-AMP; FACTOR CREB; MALIGNANT-MELANOMA; DNA-BINDING; SOFT PARTS; CHROMOSOME-TRANSLOCATION	Malignant Melanoma of Soft Parts (MMSP) is associated with the EWS/ATF1 fusion protein that arises due to chromosomal fusion of the Ewings Sarcoma oncogene (EWS) and the cellular transcription factor ATF1. EWS/ATF1 can activate several cAMP-inducible promoters, suggesting that cellular transformation in MMSP might involve constitutive activation of cAMP-inducible promoters. To assess this possibility we have examined the status of the cAMP-signaling pathway in the available MMSP-derived cell lines (DTC1 and Su-ccs-1) and find that both cell lines share several features. First, in contrast to previous effects observed in transient assays, three chromosomal promoters containing ATF binding sites are not constitutively activated by endogenous EWS/ATF1 in MMSP cells. Second, all the components that are known to be required for cAMP-inducible transcription are present. Third, phosphorylation of the cAMP-response-element-binding protein (CREB) can be efficiently induced by cAMP, Fourth, cAMP is unable to activate transcription, as assessed by a GAL4/ATF1 reporter assay and analysis of the c-fos and adenovirus early promoters. Thus, cell lines derived from MMSP have a block to cAMP-signaling that lies downstream of CREB phosphorylation. In light of the cAMP-responsiveness of almost all mammalian cell types, our findings suggest that the inability to respond to cAMP might be an important feature of MMSP cells.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong	Hong Kong University of Science & Technology	Lee, KAW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay, Kowloon, Hong Kong.							ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bannister AJ, 1995, ONCOGENE, V11, P2509; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; BROWN AD, 1995, ONCOGENE, V10, P1749; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUNG EB, 1983, AM J SURG PATHOL, V7, P405, DOI 10.1097/00000478-198307000-00003; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPSTEIN AL, 1984, CANCER RES, V44, P1265; Favaloro J, 1980, Methods Enzymol, V65, P718; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; Fujimura Y, 1996, ONCOGENE, V12, P159; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUTIERREZ AA, 1992, LANCET, V339, P715, DOI 10.1016/0140-6736(92)90606-4; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HEMMINGS BA, 1986, FEBS LETT, V196, P126, DOI 10.1016/0014-5793(86)80226-5; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LADANYI M, 1994, CANCER RES, V54, P2837; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEE KAW, 1989, MOL CELL BIOL, V9, P4390, DOI 10.1128/MCB.9.10.4390; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; MASSON N, 1992, MOL CELL BIOL, V12, P1096, DOI 10.1128/MCB.12.3.1096; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OHNO T, 1993, CANCER RES, V53, P5859; Parker D, 1996, MOL CELL BIOL, V16, P694; RIBEIRO A, 1994, J BIOL CHEM, V269, P31124; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	62	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1325	1331		10.1038/sj.onc.1201649	http://dx.doi.org/10.1038/sj.onc.1201649			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546434				2022-12-28	WOS:000072422000011
J	Robles, SJ; Adami, GR				Robles, SJ; Adami, GR			Agents that cause DNA double strand breaks lead to p16(INK4a) enrichment and the premature senescence of normal fibrolasts	ONCOGENE			English	Article						p16(INK4a); p21; p53; cellular senescence; DNA damage	DEPENDENT KINASE INHIBITOR; HUMAN-DIPLOID FIBROBLASTS; CELL-CYCLE CHECKPOINT; G(1) ARREST; ULTRAVIOLET-IRRADIATION; REPLICATIVE SENESCENCE; ATAXIA-TELANGIECTASIA; POTENTIAL MEDIATOR; P53 PROTEIN; G1 ARREST	The occurrence of DNA double strand breaks induces cell cycle arrest in mortal and immortal human cells, In normal, mortal fibroblasts this block to proliferation is permanent, It depends on the growth regulator p53 and a protein p53 induces, the cyclin dependent kinase inhibitor, p21. We show here that following DNA damage in mortal fibroblasts, the induction of p21 and p53 is to a large degree shortlived. By 8 days after a brief exposure to DNA strand breaking agents, bleomycin or actinomycin D, p53 protein is at baseline levels, while the p53 transactivation level is only slightly above its baseline, By this time the concentration of p21 protein, which goes up as high as 100-fold shortly after treatment, is down to just 2-4-fold over baseline levels, Following the drop in p21 concentration a large increase in the expression level of the tumor suppressor gene p16(INK4a) is observed. This scenario, where a transient increase in p21 is followed by a delayed induction of p16(INK4a), also happens with the permanent arrest that occurs with cellular senescence. In fact, these cells treated with agents that cause DNA double strand breaks share a number of additional markers with senescent cells, Our findings indicate that these cells are very similar to senescent cells and that they have additional factor(s) beside p21 and p53 that maintain cell cycle arrest.	Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Dept Oral Med & Diagnost Sci, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Adami, GR (corresponding author), Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Dept Oral Med & Diagnost Sci, Chicago, IL 60612 USA.				NATIONAL INSTITUTE ON AGING [F32AG005652] Funding Source: NIH RePORTER; NIA NIH HHS [AG05652] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bates S, 1996, ONCOGENE, V13, P1103; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1994, ONCOGENE, V9, P1885; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; CANMAN CE, 1994, CANCER RES, V54, P5054; CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4130; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Isaacs JS, 1997, CANCER RES, V57, P2986; Kane SA, 1995, BIOCHEMISTRY-US, V34, P16715, DOI 10.1021/bi00051a021; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KO LJ, 1996, GENE DEV, V10, P587; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Lazo JS, 1996, CANC CHEMOTHERAPY BI, P379; LI CY, 1995, ONCOGENE, V11, P1885; LI Y, 1994, CANCER RES, V54, P6078; Linke SP, 1997, CANCER RES, V57, P1171; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOIS AF, 1995, CANCER RES, V55, P4010; Lombard DB, 1996, TRENDS GENET, V12, P283, DOI 10.1016/0168-9525(96)30065-6; Loughran O, 1996, ONCOGENE, V13, P561; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAO L, 1995, CANCER RES, V55, P2995; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; MERLO A, 1995, NAT MED, V1, P692; MILLIS AJT, 1992, EXP CELL RES, V201, P373, DOI 10.1016/0014-4827(92)90286-H; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1995, CELL, V83, P993; Reznikoff CA, 1996, CANCER RES, V56, P2886; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROSS WE, 1981, BIOCHIM BIOPHYS ACTA, V654, P129, DOI 10.1016/0005-2787(81)90145-3; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SERRANO M, 1997, CELL, V88, P693; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; SHORE D, 1995, TELOMERES, P247; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; WALKER DH, 1995, CELL GROWTH DIFFER, V6, P1053; Wang XQ, 1996, CANCER RES, V56, P2510; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	84	360	377	0	13	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1113	1123		10.1038/sj.onc.1201862	http://dx.doi.org/10.1038/sj.onc.1201862			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528853				2022-12-28	WOS:000072336000002
J	Zohar, M; Teramoto, H; Katz, BZ; Yamada, KM; Gutkind, JS				Zohar, M; Teramoto, H; Katz, BZ; Yamada, KM; Gutkind, JS			Effector domain mutants of Rho dissociate cytoskeletal changes from nuclear signaling and cellular transformation	ONCOGENE			English	Article						Rho A GTPase; Ras; small G-proteins; transformation; stress fibers; signal transduction	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE ELEMENT; SMALL GTPASE RHO; RAS TRANSFORMATION; FAMILY GTPASES; TRANSCRIPTIONAL ACTIVATION; SERINE/THREONINE KINASE; ACTIN POLYMERIZATION; INDEPENDENT PATHWAYS; CYCLE PROGRESSION	The small GTP-binding Rho proteins control a variety of biological activities, including organization of the actin cytoskeleton, regulation of gene expression and cellular transformation. In contrast, Ras proteins do not induce actin stress fibers, but potently transform cells which exhibit a morphology clearly distinct from that caused by activated forms of Rho. To investigate whether nuclear signaling and oncogenic potential of Rho are a consequence of its profound effect on cytoskeletal organization, we replaced each amino acid in the Rho effector loop with those of Ras, or replaced conserved residues with others known to result in differential signaling capability when introduced into Ras and Rad. These Rho mutants did not gain the ability to induce the MAPK, JNK or p38 pathways but, surprisingly, all Rho effector loop mutants still continued to induce actin stress fiber formation. However, three of these Rho mutants, with substitutions of leucine-39, glutamic acid-39, or cysteine-42, lost the ability to stimulate gene transcription via the serum response factor (SRF) and failed to induce neoplastic transformation. Thus, these results indicate that cytoskeletal changes are not sufficient to induce the transformed phenotype, and that Rho-effector molecules regulating the actin cytostructure are distinct from those signaling to the nucleus and subverting normal growth control.	NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Yamada, Kenneth/0000-0003-1512-6805				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hotchin NA, 1996, CANCER SURV, V27, P311; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SELF AJ, 1993, ONCOGENE, V8, P655; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	41	50	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					991	998		10.1038/sj.onc.1202022	http://dx.doi.org/10.1038/sj.onc.1202022			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747878				2022-12-28	WOS:000075560900007
J	Guo, XYD; Cuillerot, JM; Wang, T; Wu, Y; Arlinghaus, R; Claxton, D; Bachier, C; Greenberger, J; Colombowala, I; Deisseroth, AB				Guo, XYD; Cuillerot, JM; Wang, T; Wu, Y; Arlinghaus, R; Claxton, D; Bachier, C; Greenberger, J; Colombowala, I; Deisseroth, AB			Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210(bcr-abl) positive 32D myeloid leukemia cells	ONCOGENE			English	Article						p210(bcr-abl) oncoprotein; tetramerization; BCR; CML	ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; C-ABL; PHILADELPHIA-CHROMOSOME; ONCOGENIC ACTIVATION; HEMATOPOIETIC-CELLS; FUSION PROTEINS; GENE-PRODUCT; BINDING; INHIBITION	We first showed that the introduction of a bcr-abl transcription unit into the 32D murine myeloid cell line (P210bcrab132D) converts this cell line from an IL3 dependent cell line to an IL3 growth independent cell line, We next cloned a fragment of the bcr-abl cDNA, which codes for the bcr oligomerization domain and neighboring regions, To test for a transformation inhibitory effect of this oligomerization inhibitory peptide transcription unit on the p210(bcr-abl) mediated IL3 independent growth of the P210bcrab132D cell line, we transiently co-electroporated into the growth factor dependent 32D cells, mixtures of plasmids which contained varying ratios of the plasmid expression vectors for the bcr oligomerization inhibitory peptide along with a smaller amount of the plasmid expression vector for the full length p210(bcr-abl). (The P210(bcr-abl) protein converts the 32D from a growth factor dependent into a growth factor independent cell line.) We then showed that the oligomerization domain containing fragment from the bcr and bcr-abl proteins, can be used to inhibit the IL3 independent growth of p210(bcr-abl) positive 32D cells, These studies may be of eventual interest for those investigators whose goal is to design molecular therapeutic approaches to CML based on the use of peptidomimetic chemical functionalities, which mimic the structure and the inhibitory binding properties of the oligomerization domain containing fragment so as to inhibit the transforming function of the P210(bcr-abl) oncoprotein.	Yale Univ, Sch Med, Dept Internal Med, Med Oncol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Canc Ctr, Gene Therapy Program, New Haven, CT 06520 USA; Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA; Univ Pittsburgh, Med Ctr, Hanover, NH USA; Dartmouth Coll, Hanover, NH 03755 USA; S Texas Canc Inst, San Antonio, TX USA	Yale University; Yale University; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Dartmouth College	Deisseroth, AB (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Med Oncol Sect, 333 Cedar St, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 55162, P01 CA49639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDI A, 1994, BLOOD, V83, P2038; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; CARLESSO N, 1994, ONCOGENE, V9, P149; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBERGER JS, 1983, P NATL ACAD SCI USA, V80, P2391; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HOEVE J, 1994, BLOOD, V86, P1731; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Liu JX, 1996, MOL CELL BIOL, V16, P998; LU D, 1993, BLOOD, V82, P1257; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MITINORI S, 1995, NATURE, V374, P159; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUVRE C, 1989, CELL, V56, P777; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; USALA SJ, 1988, MOL ENDOCRINOL, V2, P1217, DOI 10.1210/mend-2-12-1217; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZAVACKI AM, 1993, MOL ENDOCRINOL, V7, P1319, DOI 10.1210/me.7.10.1319	55	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	1998	17	7					825	833		10.1038/sj.onc.1201999	http://dx.doi.org/10.1038/sj.onc.1201999			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9779999				2022-12-28	WOS:000075448800004
J	Kumar, A; Dhawan, S; Aggarwal, BB				Kumar, A; Dhawan, S; Aggarwal, BB			Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-kappa B activation, I kappa B degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells	ONCOGENE			English	Article						emodin; TNF; NF-kappa B; adhesion; I kappa-B alpha; endothelial cells	TYROSINE KINASE INHIBITOR; CANCER CELLS; MOLECULE-1; PHOSPHORYLATION; GENE	Most inflammatory agents activate nuclear transcription factor-kappa B (NF-kappa B) which results in expression of genes for cytokines, adhesion molecules, and enzymes involved in amplification and perpetuation of inflammation. Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) is an active component from the roots of Polygonum cuspidatum that has been reported to exhibit antiinflammatory properties but the mechanism is not known. In the present study we investigated the effects of emodin on the activation of NF-kappa B in human umbelical vein endothelial cells (EC), Treatment of EC with TNF activated NF-kappa B; preincubation with emodin inhibited this activation in a dose- and time-dependent manner. Emodin did not chemically modify NF-kappa B subunits but rather inhibited degradation of I kappa B, an inhibitory subunit of NF-kappa B. Since the promoter regions of ICAM-1, VCAM-1, and ELAM-1 contain NF-kappa B binding sites and these adhesion molecules are involved in the attachment of leukocytes to EC, the effect of emodin on the adhesion of monocytes to EC and the expression of these adhesion molecules was also studied. Treatment of EC with TNF for 6 h increased the adhesion of monocytes to EC, which correlated with increases in cell surface expression of ICAM-1, VCAM-1 and ELAM-1. Pretreatment of EC for Ih with emodin inhibited both monocyte-EC attachment and expression of ICAM-1, ELAM-1 and VCAM-1, These results indicate that emodin is a potent inhibitor of NF-kappa B activation and expression of adhesion molecules and thus could be useful in treating various inflammatory diseases.	Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Cytokine Res Sect, Houston, TX 77030 USA; US FDA, Lab Immunochem, Div Transfus Transmitted Dis, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	University of Texas System; UTMD Anderson Cancer Center; US Food & Drug Administration (FDA)	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Cytokine Res Sect, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; CARLOS TM, 1994, BLOOD, V84, P2068; CHAN TCK, 1993, BIOCHEM BIOPH RES CO, V193, P1152, DOI 10.1006/bbrc.1993.1746; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; Dhawan S, 1997, BLOOD, V90, P1535; FREDENHAGEN A, 1995, J ANTIBIOT, V48, P1355, DOI 10.7164/antibiotics.48.1355; FREW T, 1994, ANTICANCER RES, V14, P2425; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUANG HC, 1992, EUR J PHARMACOL, V211, P359, DOI 10.1016/0014-2999(92)90393-I; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; JAYASURIYA H, 1992, J NAT PROD, V55, P696, DOI 10.1021/np50083a026; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Lin CC, 1996, J ETHNOPHARMACOL, V52, P107, DOI 10.1016/0378-8741(96)01397-9; MCCARTY JM, 1995, FEBS LETT, V372, P194, DOI 10.1016/0014-5793(95)00976-G; Natarajan K, 1998, ARCH BIOCHEM BIOPHYS, V352, P59, DOI 10.1006/abbi.1998.0576; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; VORABERGER G, 1991, J IMMUNOL, V147, P2777; ZHANG LS, 1995, CANCER RES, V55, P3890; Zhang LS, 1996, ONCOGENE, V12, P571	26	141	168	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	1998	17	7					913	918		10.1038/sj.onc.1201998	http://dx.doi.org/10.1038/sj.onc.1201998			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780008				2022-12-28	WOS:000075448800013
J	de Lau, WBM; Hurenkamp, J; Berendes, P; Touw, IP; Clevers, HC; van Dijk, MA				de Lau, WBM; Hurenkamp, J; Berendes, P; Touw, IP; Clevers, HC; van Dijk, MA			The gene encoding the granulocyte colony-stimulating factor receptor is a target for deregulation in pre-B ALL by the t(1;19)-specific oncoprotein E2A-Pbx1	ONCOGENE			English	Article						G-CSF receptor; cDNA subtraction; leukemia; chromosomal translocation	ACUTE LYMPHOBLASTIC-LEUKEMIA; REPRESENTATIONAL DIFFERENCE ANALYSIS; CHROMOSOMAL TRANSLOCATIONS; TRANSCRIPTIONAL ACTIVATOR; HOMEODOMAIN PROTEIN; MAMMALIAN-CELLS; MESSENGER-RNA; FUSION; PBX1; E2A	Approximately 25-30% of childhood pre-B cell acute lymphoblastic leukemias (pre-B ALL) is characterized by the presence of a (1;19)(q23;p13.3) translocation, The presence of this translocation is generally accompanied by a poor prognosis. The chimeric gene resulting from this chromosomal rearrangement encodes a hybrid transcription factor, E2A-Pbx1, In an attempt to delineate the genetic cascade initiated by E2A-Pbx1, we sought to identify genes that are deregulated by this transcription factor in t(1;19) pre-B ALL, We show here that the gene encoding the granulocyte colony-stimulating factor receptor (G-CSFr) is specifically upregulated in pre-B cells expressing E2A-Pbx1. G-CSFr is also expressed in cell lines established from t(1;19) pre-B cell leukemia and on primary t(1;19) tumor cells, but not on control cells. These data indicate that G-CSFr gene is a target for deregulation by E2A-Pbx1.	Acad Hosp Utrecht, Dept Immunol F03 821, NL-3508 GA Utrecht, Netherlands; Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Dept Hematol, NL-3000 DR Rotterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus University Rotterdam	van Dijk, MA (corresponding author), Acad Hosp Utrecht, Dept Immunol F03 821, POB 85500, NL-3508 GA Utrecht, Netherlands.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AVALOS BR, 1990, BLOOD, V75, P851; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; BERENDES P, 1995, LEUKEMIA, V9, P1321; BRADSTOCK K, 1993, BLOOD, V82, P3437; BRADSTOCK KF, 1995, LEUKEMIA LYMPHOMA, V18, P1, DOI 10.3109/10428199509064917; BURROWS PD, 1993, CURR OPIN IMMUNOL, V5, P201, DOI 10.1016/0952-7915(93)90005-D; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; DREXLER HG, 1995, LEUKEMIA, V9, P480; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; JACK I, 1986, CANCER GENET CYTOGEN, V19, P261, DOI 10.1016/0165-4608(86)90055-5; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; KHWAJA A, 1993, BRIT J HAEMATOL, V85, P254, DOI 10.1111/j.1365-2141.1993.tb03164.x; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LIESCHKE GJ, 1994, BLOOD, V84, P1737; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LOWENBERG B, 1993, BLOOD, V81, P281; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MADSEN M, 1980, J IMMUNOL METHODS, V33, P323, DOI 10.1016/0022-1759(80)90003-4; Massari ME, 1996, MOL CELL BIOL, V16, P121; Matsushita K, 1997, BRIT J HAEMATOL, V96, P715, DOI 10.1046/j.1365-2141.1997.d01-2102.x; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; SCHUTTE M, 1995, NUCLEIC ACIDS RES, V23, P4127, DOI 10.1093/nar/23.20.4127; SETO Y, 1992, J IMMUNOL, V148, P259; TACHIBANA M, 1995, CANCER RES, V55, P3438; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	41	18	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					503	510		10.1038/sj.onc.1201967	http://dx.doi.org/10.1038/sj.onc.1201967			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696044				2022-12-28	WOS:000075043000013
J	Tsuji, T; Todd, R; Meyer, C; McBride, J; Liao, PH; Huang, MF; Chou, MY; Donoff, RB; Wong, DTW				Tsuji, T; Todd, R; Meyer, C; McBride, J; Liao, PH; Huang, MF; Chou, MY; Donoff, RB; Wong, DTW			Reduction of ornithine decarboxylase antizyme (ODC-Az) level in the 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model	ONCOGENE			English	Article						oral cancer; hamster; ornithine decarboxylase antizyme; proliferation; subtractive hybridization	POLYAMINE LEVELS; NECK-CANCER; GENE; EXPRESSION; HEAD; DEGRADATION; CARCINOMA; LESIONS; TUMORS; TISSUE	Ornithine decarboxylase (ODC) activity is elevated in and necessary for oral carcinogenesis, but the mechanism for its deregulation is unclear. Using subtractive hybridization, a 1029 bp full-length cDNA encoding a 222 amino acid open reading frame has been isolated from normal hamster oral keratinocytes. The hamster cDNA is homologous to the human, mouse and rat ornithine decarboxylase antizyme gene (ODC-Az). The hamster ODC-Az gene demonstrated a restriction fragment length polymorphism (RFLP) upon Southern blot analysis comparing normal and tumor hamster genomic DNA. Northern blot analysis revealed that normal hamster oral keratinocytes express readily detectable level of ODC-Az mRNA. Malignant oral keratinocytes demonstrate reduced expression of the ODC-Az mRNA, In contrast, malignant hamster oral keratinocytes have elevated ODC mRNA levels and lengthened ODC protein half-life when compared to the normal counterparts, This mas corroborated by direct measurement of ODC enzymatic activity. These data support the hypothesis that the reduced and/or loss of expression and function of the ODC-Az gene is an important event for the early de-regulation of cellular proliferation during oral tumor development.	Harvard Univ, Sch Dent Med, Div Oral Pathol, Dept Oral Med & Diagnost Sci, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA	Harvard University; Harvard School of Dental Medicine; Harvard University; Massachusetts General Hospital	Wong, DTW (corresponding author), Harvard Univ, Sch Dent Med, Div Oral Pathol, Dept Oral Med & Diagnost Sci, 188 Longwood Ave, Boston, MA 02115 USA.				NIDCR NIH HHS [P01 DE-12467, DE-00318, DE-08680] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE008680, P01DE012467, R01DE008680, K04DE000318] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Battey, 1986, BASIC METHODS MOL BI; Bedi GC, 1996, CANCER RES, V56, P2484; BOYLE JO, 1992, CANCER EPIDEM BIOMAR, V1, P131; Califano J, 1996, CANCER RES, V56, P2488; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAINES DW, 1988, ANAL BIOCHEM, V174, P88, DOI 10.1016/0003-2697(88)90522-2; GIMENEZCONTI IB, 1993, J CELL BIOCHEM, P83; GIMENEZCONTI IB, 1992, ADV EXP MED BIOL, V320, P63; HAYASHI SI, 1995, BIOCHEM J, V306, P1; HICKOK NJ, 1990, GENE, V93, P257, DOI 10.1016/0378-1119(90)90233-H; KLICKSTEIN LB, 1987, PRODUCTION SUBTRACTE; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LINDEN M, 1985, J CELL PHYSIOL, V125, P273, DOI 10.1002/jcp.1041250215; LUNDELL L, 1986, SCAND J GASTROENTERO, V21, P829, DOI 10.3109/00365528609011126; MATSUFUJI S, 1990, J BIOCHEM, V107, P87, DOI 10.1093/oxfordjournals.jbchem.a123018; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; MEGOSH L, 1995, CANCER RES, V55, P4205; MOROCO JR, 1990, LAB INVEST, V63, P298; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; RADFORD DM, 1990, CANCER RES, V50, P6146; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; ROMANO M, 1986, INT J BIOL MARKER, V2, P77; Roz L, 1996, CANCER RES, V56, P1228; RUSSELL DH, 1981, MED BIOL, V59, P286; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIN DM, 1990, CANCER RES, V50, P2505; SHKLAR G, 1984, EXPT PATHOLOGY ORAL, P41; SLAGA TJ, 1992, NATL CANCER I MONOGR, V13, P55; Svensson F, 1997, P NATL ACAD SCI USA, V94, P397, DOI 10.1073/pnas.94.2.397; TAMORI A, 1994, HEPATOLOGY, V20, P1179, DOI 10.1002/hep.1840200512; TODD R, 1995, FASEB J, V9, P1362, DOI 10.1096/fasebj.9.13.7557027; WEISS RL, 1992, LARYNGOSCOPE, V102, P855, DOI 10.1288/00005537-199208000-00003; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WILLIAMS HK, 1995, J ORAL PATHOL MED, V24, P322, DOI 10.1111/j.1600-0714.1995.tb01193.x	41	24	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	1998	16	26					3379	3385		10.1038/sj.onc.1201887	http://dx.doi.org/10.1038/sj.onc.1201887			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692545				2022-12-28	WOS:000074544100004
J	Hemenway, CS; Halligan, BW; Levy, LS				Hemenway, CS; Halligan, BW; Levy, LS			The Bmi-1 oncoprotein interacts with dinG and MPh2: the role of RING finger domains	ONCOGENE			English	Article						RING finger protein; polycomb group proteins; Bmi-1 oncoprotein	MYC TRANSGENIC MICE; ZINC-FINGER; AXIAL SKELETON; POLYCOMB; PROTEIN; DROSOPHILA; TRANSFORMATION; PROTOONCOGENE; GENE; IDENTIFICATION	Experimentally-induced mutations in the C3HC4 RING finger domain of the Bmi-1 oncoprotein block its ability to induce lymphomas in mice. In this report, the role of the Bmi-1 RING finger in mediating protein-protein interactions is examined using the yeast two-hybrid system. Bmi-1 interacts directly with the RING finger protein dinG/RING1B. Heterodimerization of the two proteins requires the intact RING finger structures of both Bmi-1 and dinG. Although the RING finger domains are necessary for dimerization, they are not sufficient for this process as residues outside the C3HC4 motif are also required. Thus, binding specificity may be partly conferred by residues outside the RING motif. Both Bmi-1 and dinG interact with the Polyhomeotic protein MPh2 through binding domains apart from the RING finger. The data suggest a model whereby Bmi-1, dinG, and MPh2 form a stable heterotrimeric complex in which each protein contributes to the binding of the others.	Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA	Tulane University; Tulane University; Tulane University	Hemenway, CS (corresponding author), Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA.				NATIONAL CANCER INSTITUTE [R55CA063483] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63483] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akasaka T, 1996, DEVELOPMENT, V122, P1513; ALKEMA MJ, 1993, HUM MOL GENET, V2, P1597, DOI 10.1093/hmg/2.10.1597; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bienstock RJ, 1996, CANCER RES, V56, P2539; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; CORMACK B, 1995, CURRENT PROTOCOLS MO; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EPSTEIN H, 1992, BIOESSAYS, V14, P411, DOI 10.1002/bies.950140612; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; James P, 1996, GENETICS, V144, P1425; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEVY LS, 1993, ONCOGENE, V8, P1833; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MULLER J, 1995, DEVELOPMENT, V121, P2847; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; Rose MD., 1990, METHODS YEAST GENETI; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; SINGH PB, 1994, J CELL SCI, V107, P2653; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	39	57	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2541	2547		10.1038/sj.onc.1202042	http://dx.doi.org/10.1038/sj.onc.1202042			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627119				2022-12-28	WOS:000073672300011
J	Kondo, Y; Kondo, S; Tanaka, Y; Haqqi, T; Barna, BP; Cowell, JK				Kondo, Y; Kondo, S; Tanaka, Y; Haqqi, T; Barna, BP; Cowell, JK			Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis	ONCOGENE			English	Article						telomerase; apoptosis; cisplatin; glioma	COMBINATION THERAPY; ANTICANCER AGENTS; GLIOMA-CELLS; P53; RESISTANCE; CANCER; CIS-DIAMMINEDICHLOROPLATINUM(II); INDUCTION; IDENTIFICATION; ACCUMULATION	Malignant glioblastomas grow very rapidly and are generally resistant to either DNA-damaging drugs or gamma-irradiation, If tumor cells could be made more susceptible to cell death with treatments, this would clearly represent a significant improvement in the success of treatment. Recently, telomerase has become a focus of interest among oncologists as a target for treating cancer cells. Telomerase elongates telomeric DNA repeats (TTAGGG)(n) and is important in protecting and replicating DNA, The vast majority of tumor cells, indeed, express telomerase activity whereas normal somatic cells, except for a few cells, do not, Since telomerase is essential for protecting DNA, we may be able to make tumors more sensitive to treatments with DNA-damaging drugs by inhibiting telomerase activity, In this study, we used cis-diamminedichloroplatinum (cisplatin)-sensitive U87-MG cells and cisplatin-resistant U251-MG of human malignant glioblastoma cell lines, U87-MG cells did not express telomerase activity, whereas telomerase was highly detected in U251-MG cells. Interestingly, inhibition of telomerase with an antisense telomerase expression vector not only decreased telomerase activity but also increased susceptibility to cisplatin-induced apoptotic cell death in U251-MG cells. These findings suggest that treatment with antisense telomerase may represent a new chemosensitisation for tumors resistant to anticancer drugs.	Cleveland Clin Fdn, Brain Tumor Neurooncol Ctr, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Brain Tumor Neurooncol Ctr, Dept Neurosurg, Cleveland, OH 44195 USA; Tokyo Metropolitan Inst Med Sci, Dept Microbiol, Tokyo 113, Japan; Metrohlth Med Ctr, Rammel Kamp Ctr Educ & Res, Cleveland, OH 44109 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Tokyo Metropolitan Institute of Medical Science; MetroHealth System	Kondo, S (corresponding author), Cleveland Clin Fdn, Brain Tumor Neurooncol Ctr, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950				ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; DeMasters BKK, 1997, AM J CLIN PATHOL, V107, P548; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FRITSCHE M, 1993, ONCOGENE, V8, P307; GATELY DP, 1993, BRIT J CANCER, V67, P1171, DOI 10.1038/bjc.1993.221; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hiyama E, 1997, CANCER RES, V57, P326; HIYAMA E, 1995, CANCER RES, V55, P3258; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; IKEDA H, 1987, CANCER RES, V47, P231; KATO H, 1997, P JAPAN CANC ASS, V56, P701; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAWAI K, 1990, J BIOL CHEM, V265, P13137; KELLEY SL, 1989, EUR J CANCER CLIN ON, V25, P1135, DOI 10.1016/0277-5379(89)90405-7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KONDO S, 1995, J NEUROSURG, V82, P469, DOI 10.3171/jns.1995.82.3.0469; KONDO S, 1995, CANCER RES, V55, P6166; KONDO S, 1995, BRIT J CANCER, V71, P282, DOI 10.1038/bjc.1995.57; Kondo S, 1996, ONCOGENE, V13, P1279; KONDO S, 1995, ONCOGENE, V10, P2001; LANGFORD LA, 1995, LANCET, V346, P1267, DOI 10.1016/S0140-6736(95)91865-5; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; ONODA JM, 1989, CANCER RES, V49, P2844; OZOLS RF, 1987, J CLIN ONCOL, V5, P641, DOI 10.1200/JCO.1987.5.4.641; PEREZ RP, 1990, PHARMACOL THERAPEUT, V48, P19, DOI 10.1016/0163-7258(90)90015-T; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Sallinen P, 1997, AM J PATHOL, V150, P1159; Strahl C, 1996, MOL CELL BIOL, V16, P53; TIMMERBOSSCHA H, 1989, J NATL CANCER I, V81, P1069, DOI 10.1093/jnci/81.14.1069; VAN MEIR EG, 1994, CANCER RES, V54, P649	38	147	169	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2243	2248		10.1038/sj.onc.1201754	http://dx.doi.org/10.1038/sj.onc.1201754			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619833				2022-12-28	WOS:000073298000009
J	Wu, GS; Saftig, P; Peters, C; El-Deiry, WS				Wu, GS; Saftig, P; Peters, C; El-Deiry, WS			Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity	ONCOGENE			English	Article						p53; protease; apoptosis; transcription	PROGRAMMED CELL-DEATH; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; APOPTOSIS; P53; DEFICIENT; GENE; MICE; P21; BAX	Cathepsin D (CD), the major intracellular aspartyl protease, is a mediator of IFN-gamma and TNF-alpha induced apoptosis, Using subtractive hybridization screening we isolated CD as an upregulated transcript in PA1 human ovarian cancer cells undergoing adriamycin-induced apoptosis, CD mRNA levels increased in wild-type p53-expressing PA1, ML1 leukemia and U1752 lung cancer cells but not in mutant p53-expressing cells following adriamycin exposure, Overexpression of CD inhibited growth of colon, liver, and ovarian cancer cells, CD protein expression was increased by exposure of ML1 cells to etoposide, adriamycin or gamma-radiation. Inhibition of CD protease with Pepstatin A suppressed p53-dependent apoptosis in lymphoid cells, suggesting a possible role for CD in p53-dependent cell death, CD-/- fibroblasts mere found to be more resistant to killing by adriamycin and etoposide, as compared to CD+/+ cells, Two p53 DNA-binding sites located in the CD-promoter specifically bound to p53 protein in vitro and appeared to mediate transactivation of a CD-promoter luciferase-reporter during p53-dependent apoptosis, These observations link CD protease to p53-dependent tumor suppression and chemosensitivity.	Univ Penn, Sch Med, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Genet & Canc Ctr,Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; Uniklin Freiburg Hugstetterstra DFe55, Innere Med Abt 1, Arbeitsgrp Med Mol Biol, D-79106 Freiburg, Germany	Howard Hughes Medical Institute; University of Pennsylvania; University of Gottingen	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Genet & Canc Ctr,Howard Hughes Med Inst, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020; Saftig, Paul/A-7966-2010	El-Deiry, Wafik/0000-0002-9577-8266; 				Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	31	192	198	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2177	2183		10.1038/sj.onc.1201755	http://dx.doi.org/10.1038/sj.onc.1201755			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619826				2022-12-28	WOS:000073298000002
J	Waddell, S; Jenkins, JR				Waddell, S; Jenkins, JR			Defining the minimal requirements for papilloma viral E6-mediated inhibition of human p53 activity in fission yeast	ONCOGENE			English	Article						p53; E6; E6-AP; Schizosaccharomyces pombe	CARCINOMA CELL-LINES; UBIQUITIN-CONJUGATING ENZYMES; TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; SCHIZOSACCHAROMYCES-POMBE; E6 ONCOPROTEIN; SV40-TRANSFORMED CELLS; RETINOBLASTOMA GENES; MUTATIONAL ANALYSIS; TRANSFORMED-CELLS	The majority of human anogenital carcinomas show evidence of papillomavirus infection. To facilitate viral replication, viruses disable key cellular responses which would otherwise precipitate cell suicide. An obligate factor in one such response is the p53 tumour suppressor protein, p53 gene mutation is an infrequent event in anogenital cancer, apparently due to the action of HPV E6 protein, which inhibits mild-type p53 function by stimulating the degradation of p53 protein, p53 is required for the apoptotic response that is triggered in untransformed cells following inappropriate cell-cycling, E6 directed inhibition of p53 function thus facilitates the survival of transformed cells, We have developed a genetically tractable model that reports E6 protein-mediated human p53 inactivation in the fission yeast Schizosaccharomyces pombe. Functional dissection of the requirements for E6 directed inhibition in this system reveal an absolute requirement for the presence of both E6 protein and the human E3 ubiquitin ligase, E6-AP. Using a defined set of E6 mutants we show that degradation of p53 protein rather than E6/p53 association is Likely required for E6-mediated inhibition, This S, pombe based system represents a candidate screen for novel antiviral agents that act by disrupting the E6/E6-AP/p53 interaction.	Marie Curie Res Inst, Cell Proliferat Lab, Surrey RH8 0TL, England		Jenkins, JR (corresponding author), Marie Curie Res Inst, Cell Proliferat Lab, Surrey RH8 0TL, England.			Waddell, Scott/0000-0003-4503-6229				BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; BERBERICH S, 1994, ONCOGENE, V9, P1469; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, ONCOGENE, V6, P1251; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HOWES KA, 1994, GENE DEV, V8, P1738; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; KEEN N, 1994, ONCOGENE, V9, P1493; LANDERS JE, 1994, ONCOGENE, V9, P2745; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; Matuschewski K, 1996, J BIOL CHEM, V271, P2789, DOI 10.1074/jbc.271.5.2789; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PIM D, 1994, ONCOGENE, V9, P1869; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; VANHUFFEL C, 1992, EUR J BIOCHEM, V205, P33; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WADDELL S, 1995, NUCLEIC ACIDS RES, V23, P1836, DOI 10.1093/nar/23.10.1836; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	47	6	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	1998	16	13					1759	1765		10.1038/sj.onc.1201848	http://dx.doi.org/10.1038/sj.onc.1201848			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582024				2022-12-28	WOS:000072807600014
J	Lang, D; Miknyoczki, SJ; Huang, LY; Ruggeri, BA				Lang, D; Miknyoczki, SJ; Huang, LY; Ruggeri, BA			Stable reintroduction of wild-type p53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells	ONCOGENE			English	Article						p53; pancreatic cancer; neuroendocrine; differentiation; apoptosis; temperature-sensitive p53 mutant	TUMOR-SUPPRESSOR GENE; THYMOCYTE APOPTOSIS; GROWTH SUPPRESSION; INHIBITS GROWTH; CYCLE CONTROL; HL-60 CELLS; CANCER; EXPRESSION; PROTEIN; MUTANT	Pancreatic ductal adenocarcinoma is one of the major causes of cancer mortality in the industrialized world, having among the poorest prognosis of any malignancy, Mutations or alterations in the p53 tumor suppressor gene/protein are observed in 50-70% of these cancers, yet little information is available regarding the phenotypic effects of restoration of wild-type (wt) p53 function in pancreatic ductal carcinoma cells, The consequences of stable reintroduction of wt p53 on apoptosis and differentiation was examined in a poorly differentiated pancreatic carcinoma cell line (Panc-1), possessing only mutant (mt) p53 (codon 273 mutation), Cells were transfected with a temperature-sensitive mouse p53(val135) (tsp53) vector under additional control of a genetically-modified metallothionein promoter, This tsp53 has a 'mt' phenotype at 37.5 degrees C, and a 'wt' phenotype at 32.5 degrees C and the presence of 100 mu M ZnCl2. Stable expression of wt p53 caused upregulation of the p21/WAF1 gene, and G(1) growth arrest as shown by flow cytometry and BrdU labeling. Additionally, apoptosis was induced 8-12 postinduction in the majority of the cells (60-70%), as demonstrated by morphological changes, ill situ TdT labeling and internucleosomal laddering. However, a subpopulation (30%) of the transfectants survived this apoptotic fate, Unlike the epithelial parental Pane-1 cells, these cells exhibited the appearance of a neuroendocrine-like phenotype with extensive branch-like processes, and marked cytoplasmic and cytoskeletal immunostaining for tau-2, synaptophysin, and chromogranin A. These studies suggest that stable and regulated expression of wt p53 can have multiple phenotypic consequences (apoptosis and altered differentiation to a neuroendocrine-like phenotype) in poorly-differentiate pancreatic carcinoma cells.	Allegheny Univ Hlth Sci, Dept Pathol & Lab Med, Philadelphia, PA 19102 USA	Drexel University	Ruggeri, BA (corresponding author), Allegheny Univ Hlth Sci, Dept Pathol & Lab Med, Broad & Vine St, Philadelphia, PA 19102 USA.			Lang, Deborah/0000-0003-1057-0923	NATIONAL CANCER INSTITUTE [R29CA060735] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60735-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BARTON CM, 1995, BRIT J CANCER, V71, P429, DOI 10.1038/bjc.1995.88; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; BATRA SK, 1991, J CELL SCI, V100, P841; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bold RJ, 1996, PANCREAS, V12, P189, DOI 10.1097/00006676-199603000-00014; BOND JA, 1995, CANCER RES, V55, P2404; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CIRIELLI C, 1995, INT J CANCER, V63, P673, DOI 10.1002/ijc.2910630512; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FUJIWARA T, 1993, CANCER RES, V53, P4129; GANNON JV, 1991, NATURE, V349, P802; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GULLO L, 1994, NEW ENGL J MED, V331, P81, DOI 10.1056/NEJM199407143310203; HAHN SA, 1995, SURG CLIN N AM, V75, P857, DOI 10.1016/S0039-6109(16)46732-0; HALEVY O, 1993, BIOCHEM BIOPH RES CO, V192, P714, DOI 10.1006/bbrc.1993.1473; HALL PA, 1993, CANCER SURV, V16, P135; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HORII A, 1992, CANCER RES, V52, P6696; ISHIURA M, 1982, MOL CELL BIOL, V2, P607, DOI 10.1128/MCB.2.6.607; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P6304; Kimura M, 1997, ANTICANCER RES, V17, P879; KOSAKA M, 1992, ONCOGENE, V7, P2455; LIU TJ, 1994, CANCER RES, V54, P3662; LOGSDON CD, 1995, GASTROENTEROLOGY, V109, P1005, DOI 10.1016/0016-5085(95)90415-8; MAKINO T, 1990, LAB INVESTI, V62, P522; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCNEALL J, 1989, GENE, V76, P81, DOI 10.1016/0378-1119(89)90010-3; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MULLINS TD, 1991, PANCREAS, V6, P578, DOI 10.1097/00006676-199109000-00012; MURR MM, 1994, CA-CANCER J CLIN, V44, P304, DOI 10.3322/canjclin.44.5.304; NGSEE JK, 1990, COLD SH Q B, V55, P111; PELLEGATA NS, 1994, CANCER RES, V54, P1556; RADINSKY R, 1994, ONCOGENE, V9, P1877; REDSTON MS, 1994, CANCER RES, V54, P3025; REZNEK RH, 1993, CLIN RADIOL, V47, P373, DOI 10.1016/S0009-9260(05)81056-6; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Rosenberg L, 1996, PANCREAS, V13, P38, DOI 10.1097/00006676-199607000-00005; RUGGERI B, 1992, ONCOGENE, V7, P1503; Ruggeri BA, 1997, CANCER, V79, P700, DOI 10.1002/(SICI)1097-0142(19970215)79:4<700::AID-CNCR7>3.0.CO;2-H; RUGGERI BA, 1994, CARCINOGENESIS, V15, P1613, DOI 10.1093/carcin/15.8.1613; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TAUPENOT L, 1995, REGUL PEPTIDES, V56, P71, DOI 10.1016/0167-0115(95)00008-Y; WANG RN, 1995, DIABETOLOGIA, V38, P1405, DOI 10.1007/BF00400600; WANG Y, 1993, J CELL BIOL, V121, P257, DOI 10.1083/jcb.121.2.257; Weyrer K, 1996, LAB INVEST, V74, P279; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	63	43	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1593	1602		10.1038/sj.onc.1201665	http://dx.doi.org/10.1038/sj.onc.1201665			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569027				2022-12-28	WOS:000072743200010
J	Counter, CM; Meyerson, M; Eaton, EN; Ellisen, LW; Caddle, SD; Haber, DA; Weinberg, RA				Counter, CM; Meyerson, M; Eaton, EN; Ellisen, LW; Caddle, SD; Haber, DA; Weinberg, RA			Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase	ONCOGENE			English	Article						telomerase; hTERT; hEST2; cellular immortalization	TERMINAL TRANSFERASE; IMMORTAL CELLS; IDENTIFICATION; TETRAHYMENA; CARCINOMA; CANCER; RNA	The expression of telomerase, the enzyme that synthesizes telomeric DNA de novo, is suppressed in normal somatic human cells but is reactivated during tumorigenesis. This reactivation appears to arrest the normal loss of telomeric DNA incurred as human cells divide, Since continual loss of telomeric DNA is predicted to eventually limit cell proliferation, activation of telomerase in cancer cells may represent an important step in the acquisition of the cell immortalization which occurs during tumor progression. The telomerase holoenzyme is composed of both RNA and protein subunits, In humans, mRNA expression of hTERT (hEST2), the candidate telomerase catalytic subunit gene, appears to parallel the levels of telomerase enzyme activity, suggesting that induction of hTERT is necessary and perhaps sufficient for expression of telomerase activity in tumor cells. To test this model directly, we ectopically expressed an epitope-tagged version of hTERT in telomerase-negative cells and show that telomerase activity was induced to levels comparable to those seen in immortal telomerase-positive cells and that the expressed hTERT protein was physically associated with the cellular telomerase activity. We conclude that synthesis of the hTERT telomerase subunit represents the rate-limiting determinant of telomerase activity in these cells and that this protein, once expressed, becomes part of the functional telomerase holoenzyme.	MIT, Dept Biol, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02114 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Weinberg, RA (corresponding author), MIT, Dept Biol, Whitehead Inst Biomed Res, 77 Massachusetts Ave, Cambridge, MA 02142 USA.		Ellisen, Leif W/AAA-6572-2022; Meyerson, Matthew L/E-7123-2012	Ellisen, Leif W/0000-0003-0444-7910; Counter, Christopher M/0000-0003-0748-3079	NCI NIH HHS [CA 39826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avilion AA, 1996, CANCER RES, V56, P645; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GREIDER CW, 1995, TELOMERES, P35; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2	26	348	401	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1217	1222		10.1038/sj.onc.1201882	http://dx.doi.org/10.1038/sj.onc.1201882			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528864				2022-12-28	WOS:000072336000013
J	Bauer, R; McGuffin, ME; Mattox, W; Tainsky, MA				Bauer, R; McGuffin, ME; Mattox, W; Tainsky, MA			Cloning and characterization of the Drosophila homologue of the AP-2 transcription factor	ONCOGENE			English	Article						Drosophila; AP-2 transcription factor; development regulation; functional conservation	MOUSE EMBRYOGENESIS; REGULATORY ELEMENTS; MAMMARY-CARCINOMA; RETINOIC ACID; GENE; CELLS; EXPRESSION; ACTIVATION; PROMOTER; BINDING	The AP-2 family of transcription factors (AP-2 alpha, AP-2 beta and AP-2 gamma) is temporally and spatially regulated in mammals and has also been implicated in oncogenesis. Here we report the isolation of genomic and cDNA clones encoding the Drosophila homologue of AP-2, designated DAP-2. The predicted amino acid sequence exhibits 42-45% overall identity with the vertebrate AP-2 proteins, A sequence of 107 amino acids within the DNA binding and dimerization domain of the vertebrate AP-2 proteins is highly conserved (90-92%) with the DAP-2 homologue. An in vitro translation product of DAP-2 cDNA binds specifically to AP-2 consensus binding sites. DAP-2 was also shown to be functionally conserved in vivo because transient transfection of a DAP-2 expression plasmid activated transcription through AP-2 binding sites in both mammalian and Drosophila cell lines. DAP-2 is expressed during early embryogenesis and DAP-2 transcripts are also detected in the adult. Whole-mount in situ hybridizations demonstrated that DAP-2 is expressed initially at stage 9 of Drosophila embryonic development and that DAP-2 transcripts are detected in regions of the brain, eye-antennal disc, optical lobe, antenno-maxillary complex, and in a subset of cells of the ventral nerve cord. The cloning of DAP-2 and the identification of the DAP-2 expression pattern during embryogenesis provides a starting point to address the function of AP-2 during differentiation and development in a well understood model system.	Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tainsky, MA (corresponding author), Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA.			Tainsky, Michael/0000-0002-0261-831X; Mattox, William/0000-0001-8084-9677	NCI NIH HHS [R01-CA53475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; Bisgrove DA, 1997, MOL CELL BIOL, V17, P5935, DOI 10.1128/MCB.17.10.5935; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BUETTNER R, 1991, MOL CELL BIOL, V11, P3573, DOI 10.1128/MCB.11.7.3573; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHAYETTE B, 1994, NEURON, V12, P977; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; CHUNG YT, 1990, MOL CELL BIOL, V10, P6172, DOI 10.1128/MCB.10.12.6172; Doerksen LF, 1996, NUCLEIC ACIDS RES, V24, P2849, DOI 10.1093/nar/24.14.2849; Gilbertson RJ, 1997, CANCER RES, V57, P3272; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hall B. K., 1988, NEURAL CREST; HOLLAND P, 1994, J MAR BIOL ASSOC UK, V75, P49; JAN YN, 1994, CURR OPIN NEUROBIOL, V4, P13; KANNAN P, 1994, GENE DEV, V12, P1258; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; LEWIS RA, 1980, GENETICS, V95, P383; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; Maniatis T., 1989, MOL CLONING LAB MANU; MATTOX W, 1990, GENE DEV, V4, P789, DOI 10.1101/gad.4.5.789; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; MOUNT SM, 1993, ATLAS DROSOPHILA GEN, P333; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SKINNER A, 1993, ONCOGENE, V8, P3393; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YounossiHartenstein A, 1996, J COMP NEUROL, V370, P313, DOI 10.1002/(SICI)1096-9861(19960701)370:3<313::AID-CNE3>3.0.CO;2-7	41	24	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1911	1922		10.1038/sj.onc.1202114	http://dx.doi.org/10.1038/sj.onc.1202114			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788434				2022-12-28	WOS:000076423500004
J	Ma, L; Broomfield, S; Lavery, C; Lin, SL; Xiao, W; Bacchetti, S				Ma, L; Broomfield, S; Lavery, C; Lin, SL; Xiao, W; Bacchetti, S			Up-regulation of CIR1/CROC1 expression upon cell immortalization and in tumor-derived human cell lines	ONCOGENE			English	Article						CIR1; CROC1; UEV-1; immortalization; tumorigenesis differential display	COMPARATIVE GENOMIC HYBRIDIZATION; BREAST-CANCER; HUMAN TELOMERASE; SV40-MEDIATED IMMORTALIZATION; REPLICATIVE SENESCENCE; DIFFERENTIAL DISPLAY; HUMAN FIBROBLASTS; GENE-EXPRESSION; T-ANTIGEN; AMPLIFICATION	Acquisition of the immortal phenotype by tumor cells represents an essential and potentially rate-limiting step in tumorigenesis, To identify changes in gene expression that are associated with the early stages of cell immortalization, we compared genetically matched pairs of pre-immortal and immortal human cell clones by mRNA differential display. Two transcripts, denoted CIR1 and CIR2, were identified which were up-regulated in immortal cells. Sequence analysis revealed CIR1 to be identical to the recently cloned CROC1/UEV-1 gene, whereas CIR2 corresponds to an as yet uncharacterized 1.2 kb mRNA, A 5-6-fold elevation in CIR1/CROC1 expression and a 2-3-fold elevation in CIR2 expression were observed in SV40-transformed human enbryonic kidney cells immediately following proliferative crisis, suggesting a potential role for these genes in immortalization, Expression of CIR1/CROC1 was found to be elevated also in a variety of immortal human tumor-derived cell lines, as compared to their normal tissue counterparts. These results are compatible with induction of CIR1/CROC1 being an early event in the acquisition of immortality and with a role for this gene in the immortal phenotype of tumor cells.	McMaster Univ, Dept Pathol, Canc Res Grp, Hamilton, ON L8N 3Z5, Canada; Univ Saskatchewan, Dept Microbiol, Saskatoon, SK S7N 5E5, Canada; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA	McMaster University; University of Saskatchewan; Rutgers State University New Brunswick; Rutgers State University Medical Center	Broomfield, S (corresponding author), McMaster Univ, Dept Pathol, Canc Res Grp, HSC-4H30,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			Xiao, Wei/0000-0001-7568-0782				Avilion AA, 1996, CANCER RES, V56, P645; Bacchetti S, 1996, CANCER SURV, V28, P197; Brinkmann U, 1996, GENOME RES, V6, P187, DOI 10.1101/gr.6.3.187; BROOMFIELD S, 1998, IN PRESS P NATL ACAD; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; EDWARDS PAW, 1993, CANCER SURV, V16, P79; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Harley CB, 1997, CANCER SURV, V29, P263; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; IMAI S, 1992, BIOCHEM BIOPH RES CO, V189, P148, DOI 10.1016/0006-291X(92)91537-Z; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; Pardinas J, 1997, J CELL PHYSIOL, V171, P325, DOI 10.1002/(SICI)1097-4652(199706)171:3<325::AID-JCP11>3.0.CO;2-9; Rothofsky ML, 1997, GENE, V195, P141, DOI 10.1016/S0378-1119(97)00097-8; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; SASAKI M, 1994, CANCER RES, V54, P6090; SATOH Y, 1994, MUTAT RES, V316, P25, DOI 10.1016/0921-8734(94)90005-1; Savelieva E, 1997, ONCOGENE, V14, P551, DOI 10.1038/sj.onc.1200868; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163	34	29	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1321	1326		10.1038/sj.onc.1202058	http://dx.doi.org/10.1038/sj.onc.1202058			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771976				2022-12-28	WOS:000075803300015
J	Dhulipala, PDK; Lee, L; Rao, VN; Reddy, ESP				Dhulipala, PDK; Lee, L; Rao, VN; Reddy, ESP			Fli-1b is generated by usage of differential splicing and alternative promoter	ONCOGENE			English	Article						Fli-1; Fli-1b; alternative splicing; alternative promoter; onco-protein; translocation; transcriptional activator	PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; ETS-RELATED PROTEIN; DNA-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; T-CELL; C-ETS; C-ETS-1 PROTOONCOGENE; EWING SARCOMA	The proto-oncogene Fli-1, a member of Ets family is rearranged or activated through proviral integration in erythroleukemias, induced by Friends' Murine Leukemia Virus. The DNA binding domain (ETS domain) of Fli-1 is fused to the RNA binding domain of EWS by t(11q24:22q12) chromosomal translocation in Ewing's sarcoma and primitive neuroectodermal tumors. Screening of human cDNA libraries has identified two different 5'-termini and alternatively spliced forms of the human Fli-1 gene (Fli-1b), suggesting the possible existence of two independent promoters. The genomic sequence adjacent to the alternate exon of human Fli-1b gene shows functional promoter activity when cloned in promoter-less CAT expression vector and transfected into QT-6 cells. The transcription initiation (CAP) site and minimum promoter region necessary for function were localized. The 5'-flanking regions of human Fli-1b and mouse Fli-1 show 80% homology suggesting conserved promoter regulatory elements. The Fli-1b 5'-flanking sequence lacks canonical TATA or CCAAT boxes but contains a partially conserved TATA-like sequence at position 242. Several transcription factor binding sequences like ATF/CREB, E2A-PBX1, EBP, PEA-3, ETS-2, Sp-1, c-Myc, TBP, GATA-1 and Oct-3 were conserved in the promoter sequence. Functional promoter assays revealed that Fli-1b promoter shows very strong transcriptional activation compared to Fli-1 promoter. We also showed that variant Fli-1b has transcriptional activation properties similar to those of Fli-1. Fli-1b and Fli-1 show differential expression in various hematopoietic cell lines. This differential expression and promoter activities of Fli-1 and Fli-1b suggests that several mechanisms are involved in Fli-1 gene regulation which are mediated by many transcription factors.	Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Philadelphia, PA 19102 USA; SAIC, Frederick, MD 21702 USA	Drexel University; Science Applications International Corporation (SAIC); SAIC-Frederick	Reddy, ESP (corresponding author), Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Broad & Vine St, Philadelphia, PA 19102 USA.				NATIONAL CANCER INSTITUTE [P01CA051083, R01CA058642, R01CA057322] Funding Source: NIH RePORTER; NCI NIH HHS [CA57322, CA 58642, CA 51083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Barbeau B, 1996, BBA-GENE STRUCT EXPR, V1307, P220, DOI 10.1016/0167-4781(96)00060-7; BAUD V, 1991, GENOMICS, V11, P223, DOI 10.1016/0888-7543(91)90124-W; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BROWN TA, 1992, GENE DEV, V6, P2500; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HIPSKIND RA, 1991, NATURE, V354, P53534; HROMAS R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P155, DOI 10.1016/0167-4781(93)90283-J; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JEON IS, 1995, ONCOGENE, V10, P1229; JORCYK CL, 1991, ONCOGENE, V6, P523; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MELTON DA, 1987, METHOD ENZYMOL, V152, P288; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OHNO T, 1993, CANCER RES, V53, P5859; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRIBYL LS, 1988, ONCOGENE, V6, P1175; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; SELLERI L, 1991, P NATL ACAD SCI USA, V88, P887, DOI 10.1073/pnas.88.3.887; SETH A, 1993, ONCOGENE, V8, P1783; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YE K, 1993, P NATL ACAD SCI USA, V90, P2295, DOI 10.1073/pnas.90.6.2295; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; YUNIS JJ, 1989, GENOMICS, V5, P84, DOI 10.1016/0888-7543(89)90090-6	62	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1149	1157		10.1038/sj.onc.1202030	http://dx.doi.org/10.1038/sj.onc.1202030			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764825				2022-12-28	WOS:000075598400010
J	Kim, JO; Nau, MM; Allikian, KA; Makela, TP; Alitalo, K; Johnson, BE; Kelley, MJ				Kim, JO; Nau, MM; Allikian, KA; Makela, TP; Alitalo, K; Johnson, BE; Kelley, MJ			Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines	ONCOGENE			English	Article						gene amplification; L-myc; cyclophilin; small cell lung cancer; tumor cell line; alternative splicing	NEURONAL CEROID-LIPOFUSCINOSIS; COMPLEX PATTERN; EXPRESSION; IDENTIFICATION; IMMUNOPHILINS; PROTEINS; ONCOGENE; BINDING; RLF	Specific genetic alterations affecting proto-oncogenes of the myc gene family are frequently detected in human lung cancer. Among 11 SCLC cell lines with L-myc gene amplification, four were found to have alteration of the RLF gene by Southern blot and RT-PCR analyses. One cell line, NCI-H378, contained aberrantly-sized L-myc-hybridizing bands by Southern and Northern blot hybridization but had no alteration of RLF: Some L-myc-hybridizing cDNAs from NCI-H378 contained a novel sequence with close homology to the cyclophilins joined to antisense L-myc exon 2 sequence. Full length cDNAs isolated from human skeletal muscle containing only the novel sequence identify open reading frames of 301 and 296 amino acids and differ in the C-terminal region by 22 and 17 amino acids. This gene, tentatively named PPIE (peptidyl-prolyl cis-trans isomerase E), has 83% amino acid identity with the central conserved region of cyclophilin A, is evolutionarily conserved by Southern blot, and exhibits differential tissue expression with highest levels found in muscle and brain. Coamplification of PPIE was observed in seven of eleven L-myc amplified cell lines. Analysis of radiation hybrids suggests that the gene order is RLF-PPIE-L-myc on chromosome Ip and pulse-field gel electrophoresis localizes all three genes to an 800 megabase Mlu I fragment. The prognostic and functional consequences of PPIE gene amplification in SCLC can now be determined.	NCI, Lung Canc Biol Sect, Med Branch, Div Clin Sci, Bethesda, MD 20889 USA; Univ Helsinki, Canc Biol Lab, Dept Virol & Pathol, FIN-00290 Helsinki, Finland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Helsinki	Kelley, MJ (corresponding author), NCI, Lung Canc Biol Sect, Med Branch, Div Clin Sci, Bethesda, MD 20889 USA.		Alitalo, Kari K/J-5013-2014; Kelley, Michael/AAC-8939-2019; makela, tomi/B-3734-2009	Alitalo, Kari K/0000-0002-7331-0902; Kelley, Michael/0000-0001-9523-6080; makela, tomi/0000-0002-4869-8044				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; CARNEY DN, 1985, CANCER RES, V45, P2913; CELANO P, 1992, J BIOL CHEM, V267, P15092; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; GAZDAR AF, 1985, CANCER RES, V45, P2924; HAENDLER B, 1990, EUR J BIOCHEM, V190, P477, DOI 10.1111/j.1432-1033.1990.tb15598.x; HELLSTEN E, 1995, GENOMICS, V25, P404, DOI 10.1016/0888-7543(95)80040-S; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; Johnson BE, 1996, J CELL BIOCHEM, P210; JOHNSON BE, 1996, LUNG CANC PRINCIPLES, P83; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MACLEANHUNTER S, 1994, ONCOGENE, V9, P3509; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; Phelps RM, 1996, J CELL BIOCHEM, P32; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SPICER DB, 1992, MOL CELL BIOL, V12, P1324, DOI 10.1128/MCB.12.3.1324; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	27	19	21	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	1998	17	8					1019	1026		10.1038/sj.onc.1202006	http://dx.doi.org/10.1038/sj.onc.1202006			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747881				2022-12-28	WOS:000075560900010
J	Yonetani, N; Akasaka, T; Akasaka, H; Ohno, H; Okuma, M; Miura, I; Takahashi, N; Miyanishi, S; Okumura, A; Muramatsu, M; Fukuhara, S				Yonetani, N; Akasaka, T; Akasaka, H; Ohno, H; Okuma, M; Miura, I; Takahashi, N; Miyanishi, S; Okumura, A; Muramatsu, M; Fukuhara, S			Molecular features of a new human lymphoma cell line carrying both BCL2 and BCL6 gene rearrangements	ONCOGENE			English	Article						non-Hodgkin's lymphoma; BCL2 gene; t(2 ; 18)(p11 ; q21); BCL6 gene; t(3;16)(q27;p11.2)	HUMAN FOLLICULAR LYMPHOMA; NON-HODGKINS-LYMPHOMAS; FINGER ENCODING GENE; CHROMOSOMAL TRANSLOCATIONS; 3Q27 TRANSLOCATION; LAZ3 GENE; REGION; EXPRESSION; NEOPLASMS; PROTEIN	Chromosomal translocations and/or their molecular equivalents involving the BCL6 gene on 3q27 band have been suggested to be involved in the development of non-Hodgkin's lymphoma of B-cell type (B-NHL), The rearrangement of BCL6 sometimes coexists with other translocations specific to B-NHL, Here, we report a novel B-cell lymphoma cell line, YM, established from a patient with diffuse large cell lymphoma, The YM cells expressed B-cell-associated antigens in addition to mu delta/kappa monoclonal immunoglobulin, Southern blot analysis of DNA from YM cells demonstrated rearrangement of the BCL2 gene within the 5' flanking region (5'-BCL2), Polymerase chain reaction (PCR) using primer pairs for the BCL2 exons 1 and 2, and for the constant region of the immunoglobulin re light chain gene (IG kappa) revealed PCR products encompassing the 5'-BCL2/IG kappa fusion, indicating that the YM cells had a t(2;18)(p11;q21) translocation, The BCL6 gene was rearranged at a point within the first intron, and cloning of the rearranged BCL6 revealed unidentified sequences juxtaposed to the 5' side of the gene, The isolated clones were mapped to 16p11.2 by high resolution fluorescence in situ chromosomal hybridization. Thus, the YM cells carried a 3q27 translocation involving 16p11.2 as a partner, Chromosome painting of metaphase spreads confirmed that the YM cells had both t(2;18) and t(3;16), Northern blot analysis using a fragment immediately adjacent to the breakpoint on 16p11.2 revealed transcriptional activity within this locus, The YM cells expressed abundant transcripts with aberrant sizes from BCL2 and BCL6, indicating deregulated overexpression of the two genes resulting from the t(2;18) and t(3;16). The YM cell line will therefore be useful to study whether BCL2 and BCL6 genes collaborate in the pathogenesis of B-NHL.	Kyoto Univ, Fac Med, Dept Internal Med, Div 1, Kyoto 6068507, Japan; Akita Univ, Sch Med, Dept Internal Med 3, Akita 0108543, Japan; Kansai Med Univ, Dept Internal Med 1, Moriguchi, Osaka 5708506, Japan; Tenri Med Res Inst, Tenri, Nara 6328552, Japan	Kyoto University; Akita University; Kansai Medical University	Ohno, H (corresponding author), Kyoto Univ, Fac Med, Dept Internal Med, Div 1, Kyoto 6068507, Japan.							ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1990, ONCOGENE, V5, P1653; Akasaka T, 1998, GENE CHROMOSOME CANC, V21, P17, DOI 10.1002/(SICI)1098-2264(199801)21:1<17::AID-GCC4>3.0.CO;2-B; Akasaka T, 1996, BLOOD, V88, P985; Akasaka T, 1997, CANCER RES, V57, P7; AMAKAWA R, 1991, BLOOD, V77, P1970; BASTARD C, 1994, BLOOD, V83, P2423; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CLEARY ML, 1986, J EXP MED, V164, P315, DOI 10.1084/jem.164.1.315; DALLERY E, 1995, ONCOGENE, V10, P2171; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; HIETER PA, 1982, J BIOL CHEM, V257, P1516; HORSMAN DE, 1995, BRIT J HAEMATOL, V89, P569, DOI 10.1111/j.1365-2141.1995.tb08365.x; KAWAMATA N, 1994, LEUKEMIA, V8, P1327; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KLUIN PM, 1994, NEW ENGL J MED, V331, P116, DOI 10.1056/NEJM199407143310210; KORSMEYER SJ, 1992, BLOOD, V80, P879; MARIN MC, 1995, EXP CELL RES, V217, P240, DOI 10.1006/excr.1995.1083; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIKI T, 1994, BLOOD, V83, P217; MIKI T, 1994, BLOOD, V83, P26; Muramatsu M, 1996, BRIT J HAEMATOL, V93, P911, DOI 10.1046/j.1365-2141.1996.d01-1728.x; OHNO H, 1994, JPN J CANCER RES, V85, P592, DOI 10.1111/j.1349-7006.1994.tb02401.x; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SEITE P, 1993, LEUKEMIA, V7, P410; SEITE P, 1993, ONCOGENE, V8, P3073; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TAKAHASHI E, 1992, GENOMICS, V13, P1047, DOI 10.1016/0888-7543(92)90018-N; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WLODARSKA I, 1995, GENE CHROMOSOME CANC, V14, P1, DOI 10.1002/gcc.2870140102; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575; Yabumoto K, 1996, LEUKEMIA, V10, P970; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YE BHH, 1993, CANCER RES, V53, P2732	41	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					971	979		10.1038/sj.onc.1202027	http://dx.doi.org/10.1038/sj.onc.1202027			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747876				2022-12-28	WOS:000075560900005
J	Eshleman, JR; Casey, G; Kochera, ME; Sedwick, WD; Swinler, SE; Veigl, ML; Willson, JKV; Schwartz, S; Markowitz, SD				Eshleman, JR; Casey, G; Kochera, ME; Sedwick, WD; Swinler, SE; Veigl, ML; Willson, JKV; Schwartz, S; Markowitz, SD			Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53	ONCOGENE			English	Article						RER; colorectal cancer; p53; karyotype instability; genomic instability	CARCINOMA CELL-LINES; WILD-TYPE P53; HUMAN UROEPITHELIAL CELLS; TUMOR-SUPPRESSOR GENES; MICROSATELLITE INSTABILITY; CYTOGENETIC ANALYSIS; CARCINOGENESIS; AMPLIFICATION; PATHOGENESIS; MALIGNANCIES	Fourteen colorectal cancer cell lines, categorized according to the presence or absence of microsatellite instability, were further analysed tor chromosomal stability by karyotyping, NonRER (microsatellite stable) cell lines typically displayed highly aberrant karyotypes with alterations not only of chromosome number but also of chromosome structure including chromosomal deletions, inversions, and translocations. RER (microsatellite unstable) cell lines, in contrast, displayed significantly fewer alterations of chromosome number, Moreover, RER cell lines also displayed significantly fewer cytogenetically evident alterations of chromosome structure, Compared to NonRER colon cancers, RER colon cancers are significantly less likely to have undergone chromosomal gain, loss, or breakage. Characterization of p53 gene status by gene sequencing was performed in an attempt to determine if p53 gene status correlated with the chromosomal stability of the RER cancers. Gene mutations in p53 were present in all of the NonRER colon cancers, However, p53 gene mutations were also found present in four of nine of the RER colon cancers, Unexpectedly, RER colon cancers bearing mutant p53 demonstrated the same stability of chromosome number, and the same stability of chromosome structure, as the RER colon cancers with wild-type p53, Therefore, in RER colon cancers specific p53 independent mechanisms actively maintain the stability of both chromosome number and structure.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA	Johns Hopkins University; Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eshleman, JR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Ross Bldg,Rm 632,720 Rutland Ave, Baltimore, MD 21205 USA.				NATIONAL CANCER INSTITUTE [R01CA072160, R01CA067409, K08CA066628] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67409, CA 72160, CA66628] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SJ, 1990, CANCER RES, V50, P7717; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1995, CANCER RES, V55, P2304; CAMPO E, 1994, CANCER-AM CANCER SOC, V73, P2913, DOI 10.1002/1097-0142(19940615)73:12<2913::AID-CNCR2820731207>3.0.CO;2-L; CARIELLO NF, 1994, CANCER RES, V54, P4454; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; Casey G, 1996, ONCOGENE, V13, P1971; CASEY G, 1991, ONCOGENE, V6, P1791; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Eshleman JR, 1996, ONCOGENE, V12, P1425; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FREI JV, 1992, CANCER, V69, P1108; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GAIDANO G, 1994, AM J PATHOL, V144, P1312; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAO CH, 1993, CARCINOGENESIS, V14, P2297, DOI 10.1093/carcin/14.11.2297; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOURI M, 1990, CANCER, V65, P1825, DOI 10.1002/1097-0142(19900415)65:8<1825::AID-CNCR2820650827>3.0.CO;2-H; LEHMAN TA, 1994, DRUG METAB REV, V26, P221, DOI 10.3109/03602539409029793; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; LOTHE RA, 1993, CANCER RES, V53, P5849; MCBAIN JA, 1984, CANCER RES, V44, P5813; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Sullivan BA, 1996, AM J HUM GENET, V59, P167; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	37	107	108	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					719	725		10.1038/sj.onc.1201986	http://dx.doi.org/10.1038/sj.onc.1201986			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715273				2022-12-28	WOS:000075337200006
J	Scotet, E; Houssaint, E				Scotet, E; Houssaint, E			Exon III splicing switch of fibroblast growth factor (FGF) receptor-2 and -3 can be induced by FGF-1 or FGF-2	ONCOGENE			English	Article						fibroblast growth factor receptor; fibroblast growth factor; splicing switch; epithelio-mesenchymal conversion	LIGAND-BINDING; SIGNAL TRANSDUCTION; MESSENGER-RNA; CELLS; GENE; ACTIVATION; PROTEINS; FAMILY; TRANSLOCATION; TRANSCRIPTION	An essential feature of fibroblast growth factor receptors (FGFRs) is the existence of multiple possibilities of alternative splicing. One of these concerns sequences of the mRNA coding for the C-terminal half of Ig domain 3 which corresponds to a part of the ligand-binding site: two alternative exons, IIIb and IIIc, encode the C-terminal half of Ig domain 3. The IIIb/lIIc choice in the FGFR-2 and FGFR-3 is strictly tissue-specific, the IIIb exon being expressed exclusively in epithelial cells. We describe here a reversible switch from IIIb to IIIc for FGFR-2 and FGFR-3 under the influence of exogenous and endogenous FGF-1 or FGF-2. We observed that EGF-induced FGF receptor exon switching (i) occurred as early as Ih after exposure to FGF (ii) was receptor-mediated (iii) was dependent on cell confluency and showed a link with the cell cycle (iv) was correlated with a reversible loss of epithelial properties. These results support a role for FGF in the regulation of expression of alternatively spliced FGFR mRNA.	Inst Biol, INSERM, U463, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Houssaint, E (corresponding author), Inst Biol, INSERM, U463, 9 Quai Moncousu, F-44035 Nantes 01, France.		SCOTET, Emmanuel/L-2576-2015; SCOTET, Emmanuel/AAC-9971-2019	SCOTET, Emmanuel/0000-0001-8010-9556; SCOTET, Emmanuel/0000-0001-8010-9556				BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWIN P, 1985, J CELL BIOL, V101, P1442, DOI 10.1083/jcb.101.4.1442; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HALLEY C, 1988, NUCLEIC ACIDS RES, V16, P10913, DOI 10.1093/nar/16.22.10913; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; KIEFER P, 1995, MOL CELL BIOL, V15, P4364; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MIGDAL M, 1995, J CELL PHYSIOL, V162, P266, DOI 10.1002/jcp.1041620212; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; Oliver L, 1992, GROWTH FACTORS, V7, P97, DOI 10.3109/08977199209046399; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SCOTET E, 1995, ONCOL REP, V2, P203; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N	39	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	1998	17	1					67	76		10.1038/sj.onc.1201908	http://dx.doi.org/10.1038/sj.onc.1201908			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671315				2022-12-28	WOS:000074677800008
J	Klotzsche, O; Etzrodt, D; Hohenberg, H; Bohn, W; Deppert, W				Klotzsche, O; Etzrodt, D; Hohenberg, H; Bohn, W; Deppert, W			Cytoplasmic retention of mutant tsp53 is dependent on an intermediate filament protein (Vimentin) scaffold	ONCOGENE			English	Article						nuclear exclusion; cytoplasmic anchorage; temperature sensitive mutant p53; vimentin; intermediate filaments; C6 rat glioma cells	HEAT-SHOCK PROTEINS; P53 PROTEIN; NUCLEAR EXCLUSION; CELL-LINES; KINASE-C; LOCALIZATION; MUTATIONS; PHOSPHORYLATION; ASSOCIATION; EXPRESSION	The temperature-sensitive mutant tsp(val135) accumulates in the cytoplasm of cells kept at the non-permissive temperature (39 degrees C), but is rapidly transported into the cell nucleus at the permissive temperature (30 degrees C). tsp53 thus may serve as a model for analysing cellular parameters influencing the subcellular location of p53. Here we provide evidence that retention of tsp53 in the cytoplasm at the non-permissive temperature is due to cytoskeletal anchorage of the p53 protein. Two sublines of C6 rat glioma cells differing in their expression of the intermediate filament protein vimentin (vimentin expressing or vimentin negative cells) were stably transfected with a vector encoding tsp53, Whereas cells of vimentin expressing C6 subclones retained tsp53 in the cytoplasm at the non-permissive temperature, cells of vimentin negative subclones exclusively harbored the tsp53 within their nuclei. Intermediate filament deficient cells that had been reconstituted with a full length vimentin protein again shelved a cytoplasmic localization of tsp53, whereas in cells expressing a C-terminally truncated (tail-less) vimentin tsp53 localized to the nucleus, We conclude that cytoplasmic sequestration of tsp53 requires an intact intermediate filament system.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Bohn, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; ALI IU, 1994, CANCER RES, V54, P1; BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; BOHN W, 1992, EXP CELL RES, V201, P1, DOI 10.1016/0014-4827(92)90341-5; BOHN W, 1993, J STRUCT BIOL, V111, P48, DOI 10.1006/jsbi.1993.1035; CHENG TJ, 1994, J CELL BIOCHEM, V54, P100, DOI 10.1002/jcb.240540111; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CIESIELSKITRESKA J, 1991, J NEUROSCI RES, V29, P362, DOI 10.1002/jnr.490290312; Deppert W, 1996, J CELL BIOCHEM, V62, P172, DOI 10.1002/(SICI)1097-4644(199608)62:2<172::AID-JCB5>3.0.CO;2-P; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1994, INT CONGR SER, V1050, P11; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ECKELT A, 1992, EUR J CELL BIOL, V58, P319; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; Foisner R, 1995, J STRUCT BIOL, V115, P304, DOI 10.1006/jsbi.1995.1055; GANNON JV, 1991, NATURE, V349, P802; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HEINS S, 1994, CURR OPIN CELL BIOL, V6, P25, DOI 10.1016/0955-0674(94)90112-0; HENNEKES H, 1990, MOL GEN GENET, V221, P33, DOI 10.1007/BF00280364; HERRMANN H, 1992, J MOL BIOL, V223, P637, DOI 10.1016/0022-2836(92)90980-X; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Knippschild U, 1996, ONCOGENE, V12, P1755; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIAO J, 1995, J BIOL CHEM, V270, P915, DOI 10.1074/jbc.270.2.915; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCCORMICK MB, 1993, J CELL BIOL, V122, P395, DOI 10.1083/jcb.122.2.395; MEDCALF EA, 1992, ONCOGENE, V7, P71; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nebe B, 1997, CYTOMETRY, V28, P66, DOI 10.1002/(SICI)1097-0320(19970501)28:1<66::AID-CYTO8>3.0.CO;2-F; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PORTER PL, 1992, AM J PATHOL, V140, P145; ROSER K, 1991, EXP CELL RES, V197, P200, DOI 10.1016/0014-4827(91)90423-R; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; STAUFENBIEL M, 1983, EUR J CELL BIOL, V31, P341; STEINMEYER K, 1988, ONCOGENE, V3, P501; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TRAUB P, 1983, J CELL SCI, V63, P43; TRONCOSO JC, 1990, J STRUCT BIOL, V103, P2, DOI 10.1016/1047-8477(90)90080-V; ZERRAHN J, 1992, ONCOGENE, V7, P1371	60	47	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3423	3434		10.1038/sj.onc.1202155	http://dx.doi.org/10.1038/sj.onc.1202155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692550				2022-12-28	WOS:000074544100009
J	Trink, B; Pai, SI; Spunt, SL; Raman, V; Cairns, P; Jen, J; Gabrielson, E; Sukumar, S; Sidransky, D				Trink, B; Pai, SI; Spunt, SL; Raman, V; Cairns, P; Jen, J; Gabrielson, E; Sukumar, S; Sidransky, D			Absence of TSG101 transcript abnormalities in human cancers	ONCOGENE			English	Article						breast cancer; Wilms' tumor; TSG101; RT-PCR	FHIT GENE; EXPRESSION; 3P14.2	The human TSG101 gene was cloned and mapped to chromosome 11p15, a site suspected to contain a tumor suppressor gene involved in a variety of human cancers. Subsequent investigation described the presence of abnormally spliced transcripts and point mutations of TSG101 in breast cancer, Thus, we performed RT-PCR amplification of the entire open reading frame of TSG101 to test for aberrant transcripts in various human tumor cell lines derived from breast, bladder, head and neck, and lung cancer. In addition, we performed RT-PCR on cDNA from primary human breast and Wilms' tumor tissue. We found a single band of the expected size in 10 of 11 breast cancers and 6 of 6 Wilms' tumor samples after the first round of PCR, The remaining breast cancer sample displayed a barely visible smaller band. However, aberrant bands appeared in most cases after performing nested PCR casting doubt on the physiologic relevance of these spliced variants, We then searched for small intragenic mutations by complete sequence analysis of TSG101 in breast cancer cell lines and tumors, as well as in Wilms' tumors and normal fetal and adult kidney, No point mutations were found in any of the samples, including four breast tumors with chormosomal loss at 11p15, We found no consistent evidence of aberrant splicing or point mutations in breast cancer or Wilms' tumor suggesting that TSG101 is not a primary target of inactivation in human cancer.	Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Ctr Oncol, Breast Canc Program, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Sidransky, D (corresponding author), Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA.			Spunt, Sheri/0000-0002-1669-2676; Pai, Sara/0000-0002-6341-9971				BRATTSAND G, 1993, LEUKEMIA, V7, P569; Feinberg AP, 1996, MED PEDIATR ONCOL, V27, P484; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; ROOS G, 1993, LEUKEMIA, V7, P1538; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Thiagalingam S, 1996, CANCER RES, V56, P2936; Todd S, 1997, CANCER RES, V57, P1344; WINQVIST R, 1995, CANCER RES, V55, P2660	16	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2815	2818		10.1038/sj.onc.1201795	http://dx.doi.org/10.1038/sj.onc.1201795			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652749				2022-12-28	WOS:000073812200014
J	Mostert, MC; Verkerk, AJMH; van de Pol, M; Heighway, J; Marynen, P; Rosenberg, C; van Kessel, AG; van Echten, J; de Jong, B; Oosterhuis, JW; Looijenga, LHJ				Mostert, MC; Verkerk, AJMH; van de Pol, M; Heighway, J; Marynen, P; Rosenberg, C; van Kessel, AG; van Echten, J; de Jong, B; Oosterhuis, JW; Looijenga, LHJ			Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults	ONCOGENE			English	Article						testicular germ cell tumors; 12p; overrepresentation; critical region; candidate gene(s)	COMPARATIVE GENOMIC HYBRIDIZATION; IN-SITU HYBRIDIZATION; LACTATE-DEHYDROGENASE ISOENZYME-1; MOLECULAR CYTOGENETIC ANALYSIS; CHROMOSOMAL LOCALIZATION; CARCINOMA-INSITU; SHORT ARM; ENDOPLASMIC-RETICULUM; EUROPEAN COUNTRIES; LECTIN SUPERFAMILY	Cytogenetically, testicular germ cell tumors of adolescents and adults (TGCTs) are characterized by gain of 12p-sequences, most often through isochromosome formation (i(12p)), Fluorescence in situ hybridization (FISH) has shown that i(12p))-negative TGCTs also cryptically contain extra 12p-sequences. The consistency of 12p-over-representation in all histological subtypes of TGCTs, including their preinvasive stage, suggests that gain of one or more genes on 12p is crucial in the development of this cancer. So far, studies aimed at the identification of the relevant gene(s) were based on the 'candidate-gene approach'. No convincing evidence in favor of or against a particular gene has been reported. We combined conventional karyotyping, comparative genomic hybridization, and FISH to identify TGCTs with amplifications of restricted regions of 12p, Out of 49 primary TGCTs (23 without i(12p), 13 with and 13 unknown), eight tumors (six without i(12p) and two unknown) showed amplifications corresponding to 12p11.1-p12.1. Using bicolour-FISH, physical mapping, and semi-quantitative polymerase chain reactions, the size of the shortest region of overlap of amplification (SROA) was estimated to be between 1750-3000 kb, In addition, we mapped a number of genes in and around this region. While fourteen known genes could be excluded as candidates based on their location outside this region, we demonstrate that KRAS2, JAW1 and SOX5 genes are localized within the SROA, While KRAS2 and JAW1 map to the proximal border of the SROA, SOX5 maps centrally in the SROA, KRAS2 and JAW1 are expressed in all TGCTs, whereas one 12p amplicon-positive TGCT lacks expression of SOX5, The critical region of 12p over-represented in TGCTs is less than 8% of the total length of the short arm of chromosome 12, It will be helpful in the identification of the gene(s) involved in TGCT-development.	Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Lab Expt Pathooncol, Rotterdam, Netherlands; Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Canc Genet, Manchester M20 4BX, Lancs, England; Katholieke Univ Leuven VIB, Ctr Human Genet, Louvain, Belgium; Leiden Univ, Dept Cytochem & Cytometry, Leiden, Netherlands; Univ Nijmegen, Dept Human Genet, Nijmegen, Netherlands; Univ Groningen Hosp, Dept Med Genet, Groningen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Flanders Institute for Biotechnology (VIB); KU Leuven; Leiden University; Leiden University - Excl LUMC; Radboud University Nijmegen; University of Groningen	Mostert, MC (corresponding author), Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Lab Expt Pathooncol, Rotterdam, Netherlands.		van Kessel, Ad Geurts/A-2810-2010; rosenberg, carla/N-4148-2015; Looijenga, Leendert/B-8145-2019	rosenberg, carla/0000-0003-3253-4448; Looijenga, Leendert/0000-0002-8146-1911; Verkerk, Annemieke JMH/0000-0002-7523-3656				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; ATKIN NB, 1983, CANCER GENET CYTOGEN, V10, P199, DOI 10.1016/0165-4608(83)90125-5; BEHRENS TW, 1994, J IMMUNOL, V153, P682; Behrens TW, 1996, J BIOL CHEM, V271, P23528, DOI 10.1074/jbc.271.38.23528; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; Betticher DC, 1996, BRIT J CANCER, V73, P294, DOI 10.1038/bjc.1996.52; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; CARICASOLE AAD, IN PRESS ONCOGENE; CASTEDO SMMJ, 1989, CANCER RES, V49, P439; CHANG CW, 1995, EUR J IMMUNOL, V25, P2433, DOI 10.1002/eji.1830250904; COTTER FE, 1991, GENOMICS, V9, P473, DOI 10.1016/0888-7543(91)90413-9; DMITROVSKY E, 1990, ONCOGENE, V5, P543; FEUER EJ, 1995, J NATL CANCER I, V87, P405; FUCHS P, 1992, GENOMICS, V13, P219, DOI 10.1016/0888-7543(92)90226-I; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GILLIS AJM, 1994, LAB INVEST, V71, P874; Heighway J, 1996, GENOMICS, V35, P207, DOI 10.1006/geno.1996.0340; HOOVERS JMN, 1993, GENOMICS, V15, P525, DOI 10.1006/geno.1993.1104; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KAWASE E, 1994, DEV BIOL, V161, P91, DOI 10.1006/dbio.1994.1011; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; KRAUTER K, 1995, NATURE, V377, P321; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; Larramendy ML, 1997, AM J PATHOL, V150, P685; LI SSL, 1988, CYTOGENET CELL GENET, V48, P16, DOI 10.1159/000132578; LOOIJENGA LHJ, 1990, CYTOGENET CELL GENET, V53, P216, DOI 10.1159/000132934; LOOIJENGA LHJ, 1991, LAB INVEST, V64, P113; LOOIJENGA LHJ, 1993, LAB INVEST, V68, P211; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; MANDICH P, 1994, GENOMICS, V22, P216, DOI 10.1006/geno.1994.1366; MANIATIS T, 1982, MOL CLONING LABORATO, P280; Marynen P, 1996, CYTOGENET CELL GENET, V73, P1, DOI 10.1159/000134308; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Mitelman F, 1995, ISCN INT SYSTEM HUMA; MOLLER H, 1995, INT J CANCER, V61, P761, DOI 10.1002/ijc.2910610604; Mostert MMC, 1996, CANCER GENET CYTOGEN, V87, P95, DOI 10.1016/0165-4608(95)00233-2; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; MOSTOFI FK, 1973, SEM DIAGN PATHOL; MOUL JW, 1992, GENE CHROMOSOME CANC, V5, P109, DOI 10.1002/gcc.2870050204; MUKHERJEE AB, 1991, GENE CHROMOSOME CANC, V3, P300, DOI 10.1002/gcc.2870030409; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; NUTTALL FQ, 1994, GENOMICS, V19, P404, DOI 10.1006/geno.1994.1086; OLIE RA, 1995, GENE CHROMOSOME CANC, V12, P110, DOI 10.1002/gcc.2870120205; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; POPESCU NC, 1985, SOMAT CELL MOLEC GEN, V11, P149, DOI 10.1007/BF01534703; PUGH RCB, 1976, PATHOLOGY TESTIS, P245; PURANAM KL, 1995, GENOMICS, V26, P595, DOI 10.1016/0888-7543(95)80181-K; RAAP AK, 1995, HUM MOL GENET, V4, P529, DOI 10.1093/hmg/4.4.529; RAEYMAEKERS P, 1995, GENOMICS, V29, P170, DOI 10.1006/geno.1995.1228; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; RODRIQUEZ E, 1993, CANCER RES, V52, P2285; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; SCHNITTGER S, 1993, EUR J IMMUNOL, V23, P2711, DOI 10.1002/eji.1830231051; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; SMOLAREK TA, 1995, GENE CHROMOSOME CANC, V14, P252, DOI 10.1002/gcc.2870140403; STAMP IM, 1995, AM J SURG PATHOL, V19, P489, DOI 10.1097/00000478-199504000-00019; SUIJKERBUIJK RF, 1993, CANCER GENET CYTOGEN, V70, P85, DOI 10.1016/0165-4608(93)90173-J; SUIJKERBUIJK RF, 1994, CANCER GENET CYTOGEN, V78, P145, DOI 10.1016/0165-4608(94)90082-5; TAYLOR RE, 1986, EUR J CANCER CLIN ON, V22, P647, DOI 10.1016/0277-5379(86)90161-6; VANECHTEN J, 1995, GENE CHROMOSOME CANC, V14, P133, DOI 10.1002/gcc.2870140208; VANKESSEL AG, 1989, CANCER GENET CYTOGEN, V40, P129, DOI 10.1016/0165-4608(89)90154-4; VONEYBEN FE, 1988, J UROLOGY, V140, P986, DOI 10.1016/S0022-5347(17)41906-9; VONEYBEN FE, 1992, MOL GEN GENET, V235, P140, DOI 10.1007/BF00286191; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; White GRM, 1996, BRIT J CANCER, V74, P863, DOI 10.1038/bjc.1996.449; Wunderle VM, 1996, GENOMICS, V36, P354, DOI 10.1006/geno.1996.0474	72	82	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2617	2627		10.1038/sj.onc.1201787	http://dx.doi.org/10.1038/sj.onc.1201787			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632138				2022-12-28	WOS:000073698200006
J	Orend, G; Hunter, T; Ruoslahti, E				Orend, G; Hunter, T; Ruoslahti, E			Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21(Cip1) and p27(Kip1) in anchorage-independent cells	ONCOGENE			English	Article						anchorage; p21Cip1; p27Kip1; cyclin E; cdk2; cell adhesion; cell cycle	BREAST-CANCER; NEOPLASTIC TRANSFORMATION; PROGNOSTIC MARKER; CDK INHIBITOR; EXPRESSION; GROWTH; OVEREXPRESSION; TRANSCRIPTION; PROLIFERATION; INACTIVATION	Loss of attachment to an extracellular matrix substrate arrests the growth of untransformed cells in the G1 phase. This anchorage-dependent cell cycle arrest is linked to increased expression of the p21(Cip1) (p21) and p27(Kip1) (p27) cyclin-dependent kinase inhibitors. The result is a loss of cdk2-associated kinase activity, especially that of cyclin E-cdk2, The levels of p21 and p27 are also upregulated in unattached transformed cells, but cyclin E-cdk2 activity remains high, and the cells are able to grow in an anchorage-independent manner. Increased expression of cyclin E and cdk2 appears to be partially responsible for the maintenance of cyclin E-cdk2 activity in transformed cells. To explore further the regulation of cyclin E-cdk2 in transformed cells, we have analysed the subcellular distribution of cyclin-cdk complexes and their inhibitors in normal human fibroblasts, their transformed counterparts, and in various human tumor cell lines. In substrate-attached normal fibroblasts, cyclin E and cdk2 were exclusively in the nuclear fraction, associated with one another. When normal fibroblasts were detached and held in suspension, cyclin E-cdk2 complexes remained nuclear, but were now found associated with the p21 and p27 cdk inhibitors and lacked histone I-Il phosphorylating activity. In contrast, the transformed fibroblasts and tumor cells, which are anchorage-independent, had more than half of their cyclin E, cdk2, p21 and p27 in the cytoplasmic fraction, both in attached and suspended cultures. The cytoplasmic p21 and p27 were bound to cyclin E-cdk2, as well as to complexes containing cyclin A and cyclin D. The nuclear cyclin E-cdk2 complexes from the transformed cells grown in suspension contained only low levels of p21 and p27 and had histone H1 kinase activity, Thus, at least three mechanisms contribute to keeping cyclin E-cdk2 complexes active in suspended anchorage-independent cells: cyclin E and cdk2 are upregulated, as reported previously, cdk inhibitors are sequestered away from the nucleus by cytoplasmic cyclin-cdk complexes, and the binding of the inhibitors to nuclear cyclin E-cdk2 complexes is impaired.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Salk Institute	Ruoslahti, E (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA.		Orend, Gertraud/E-8446-2015	Orend, Gertraud/0000-0003-2522-1195	NATIONAL CANCER INSTITUTE [P01CA028896, P30CA030199, R35CA042507] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42507, CA 28896, CA 30199] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dou QP, 1996, NAT MED, V2, P254, DOI 10.1038/nm0396-254a; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KAKUNAGA T, 1978, P NATL ACAD SCI USA, V75, P1334, DOI 10.1073/pnas.75.3.1334; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARIDOR G, 1993, J CELL SCI, V106, P535; Medcalf ASC, 1996, CANCER RES, V56, P4582; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miyajima M, 1996, J NEUROSCI RES, V46, P108, DOI 10.1002/(SICI)1097-4547(19961001)46:1<108::AID-JNR13>3.0.CO;2-1; Mumberg D, 1996, ONCOGENE, V13, P2493; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; RHEINWALD JG, 1974, CELL, V2, P287, DOI 10.1016/0092-8674(74)90023-3; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Samid D., 1989, CLIN BIOTECHNOL, V1, P21; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SEWING A, 1994, J CELL SCI, V107, P581; StCroix B, 1996, NAT MED, V2, P1204; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; ZerfassThome K, 1996, ONCOGENE, V13, P2323; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	44	123	126	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2575	2583		10.1038/sj.onc.1201791	http://dx.doi.org/10.1038/sj.onc.1201791			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632134				2022-12-28	WOS:000073698200002
J	Duerr, EM; Rollbrocker, B; Hayashi, Y; Peters, N; Meyer-Puttlitz, B; Louis, DN; Schramm, J; Wiestler, OD; Parsons, R; Eng, C; von Deimling, A				Duerr, EM; Rollbrocker, B; Hayashi, Y; Peters, N; Meyer-Puttlitz, B; Louis, DN; Schramm, J; Wiestler, OD; Parsons, R; Eng, C; von Deimling, A			PTEN mutations in gliomas and glioneuronal tumors	ONCOGENE			English	Article						PTEN mutations; glioblastoma; oligodendroglioma; ganglioglioma	LHERMITTE-DUCLOS DISEASE; HUMAN GLIOBLASTOMA-MULTIFORME; MOLECULAR-GENETIC-ANALYSIS; COWDEN SYNDROME; P53 MUTATIONS; CHROMOSOME-10; HETEROZYGOSITY; AMPLIFICATION; ASTROCYTOMA; LOCI	Cytogenetic and loss of heterozygosity studies have suggested the presence of at least one tumor suppressor gene on chromosome 10 involved in the formation of high grade gliomas, Recently, the PTEN gene, also termed MMAC1 or TEP1, on chromosomal band 10q23 has been identified. Initial studies revealed mutations of PTEN in limited series of glioma cell lines and glioblastomas. In order to systematically evaluate the involvement of PTEN in gliomas, we have analysed the entire PTEN coding sequence by SSCP and direct sequencing in a series of 331 gliomas and glioneuronal tumors. PTEN mutations mere detected in 20/142 glioblastomas, 1/7 giant cell glioblastomas, 1/2 gliosarcomas, 1/30 pilocytic astrocytomas and 2/22 oligodendrogliomas, No PTEN mutations were detected in 52 astrocytomas, 37 oligoastrocytomas, three subependymal giant cell astrocytomas, four pleomorphic xanthoastrocytomas, 15 ependymomas, 16 gangliogliomas and one dysembryoplastic neuroepithelial tumor. In addition, all tumors were examined for the presence of homozygous deletions of the PTEN gene; these were detected in 7 glioblastomas that did not have PTEN mutations. Therefore, PTEN mutations occur in approximately 20% of glioblastomas but are rare in lower grade gliomas, These findings confirm that PTEN is one of the chromosome 10 tumor suppressor genes involved in the development of glioblastomas.	Univ Bonn, Ctr Med, Dept Neuropathol, D-53105 Bonn, Germany; Massachusetts Gen Hosp, CS Kubik Lab Neuropathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Mol Neurooncol Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Bonn, Med Ctr, Dept Neurosurg, D-53105 Bonn, Germany; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	University of Bonn; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Bonn; Columbia University; Columbia University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	von Deimling, A (corresponding author), Univ Kliniken Bonn, Inst Neuropathol, Sigmund Freud Str 25, D-53105 Bonn, Germany.		von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X; Eng, Charis/0000-0002-3693-5145; Parsons, Ramon/0000-0002-6656-3514	NCI NIH HHS [CA57683] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057683] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; ALBRECHT S, 1992, CANCER-AM CANCER SOC, V70, P869, DOI 10.1002/1097-0142(19920815)70:4<869::AID-CNCR2820700424>3.0.CO;2-E; BENDER B, 1994, BIOTECHNIQUES, V16, P204; Eng C, 1997, J Genet Couns, V6, P181, DOI 10.1023/A:1025664119494; ENG C, 1994, J MED GENET, V31, P458, DOI 10.1136/jmg.31.6.458; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1990, CANCER RES, V50, P5784; Hayashi Y, 1997, BRAIN PATHOL, V7, P871, DOI 10.1111/j.1750-3639.1997.tb00890.x; Hsu SC, 1996, CANCER RES, V56, P5684; JAMES CD, 1988, CANCER RES, V48, P5546; Kleihues P, 1993, HISTOLOGICAL TYPING; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LOUIS DN, 1993, J NEUROPATH EXP NEUR, V52, P507, DOI 10.1097/00005072-199309000-00009; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MeyerPuttlitz B, 1997, AM J PATHOL, V151, P853; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; OHGAKI H, 1991, CANCER RES, V51, P6202; PADBERG GW, 1991, ANN NEUROL, V29, P517, DOI 10.1002/ana.410290511; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; REIFENBERGER G, 1994, CANCER RES, V54, P4299; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; Rollbrocker B, 1996, ACTA NEUROPATHOL, V92, P70, DOI 10.1007/s004010050491; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; VONDEIMLING A, 1992, J NEUROSURG, V77, P295, DOI 10.3171/jns.1992.77.2.0295; VONDEIMLING A, 1992, CANCER RES, V52, P4277; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; VONDEIMLING A, 1993, NEUROPATH APPL NEURO, V19, P524; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827	37	292	304	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2259	2264		10.1038/sj.onc.1201756	http://dx.doi.org/10.1038/sj.onc.1201756			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619835				2022-12-28	WOS:000073298000011
J	Kharbanda, S; Pandey, P; Morris, PL; Whang, Y; Xu, YH; Sawant, S; Zhu, LJ; Kumar, N; Yuan, ZM; Weichselbaum, R; Sawyers, CL; Pandita, TK; Kufe, D				Kharbanda, S; Pandey, P; Morris, PL; Whang, Y; Xu, YH; Sawant, S; Zhu, LJ; Kumar, N; Yuan, ZM; Weichselbaum, R; Sawyers, CL; Pandita, TK; Kufe, D			Functional role for the c-Abl tyrosine kinase in meiosis I	ONCOGENE			English	Article						meiosis; c-Abl; spermatogenesis	ACTIVATED PROTEIN-KINASE; STRESS-RESPONSE; CELLS; MOUSE; GENE; MICE; P53; RECOMBINATION; EXPRESSION; LETHALITY	The c-Abl tyrosine kinase is activated by ionizing radiation and certain other DNA-damaging agents. The DNA-dependent protein kinase (DNA-PK) and the ataxia telangiectasia mutated (ATM) gene product, effecters in the DNA damage response, contribute to the induction of c-Abl activity. The present study demonstrates that c-Abl is expressed in mouse and rat testes, and predominantly in pachytene spermatocytes of meiosis I. The results also demonstrate that c-Abl interacts directly with meiotic chromosomes. In concert with a requirement for c-Abl at the pachytene stage, me show that, in contrast to wild-type mice, testes from Abl(-/-) mice exhibit defects in spermatogenesis. These findings provide the first demonstration that c-Abl plays a functional role in meiosis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Populat Council, Ctr Biomed Res, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Population Council; Rockefeller University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Chicago; Columbia University	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.		Pandita, Tej K/AAM-9188-2020; Sawyers, Charles/G-5327-2016; Whang, Young/AAK-7435-2021	Whang, Young/0000-0002-1621-6661	NATIONAL CANCER INSTITUTE [R01CA075216, R01CA042802] Funding Source: NIH RePORTER; NCI NIH HHS [CA75216, CA42802, CA55241] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; FUJISAWA M, 1992, MOL CELL ENDOCRINOL, V84, P79, DOI 10.1016/0303-7207(92)90074-G; GOGA A, 1995, ONCOGENE, V11, P791; GOTTLIEB TM, 1993, CELL, V72, pU31; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Hardin JD, 1996, ONCOGENE, V12, P2669; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PONZETTO C, 1989, ONCOGENE, V4, P685; ROSS M. H., 1995, HISTOLOGY TEXT ATLAS, P636; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	33	40	43	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1773	1777		10.1038/sj.onc.1201934	http://dx.doi.org/10.1038/sj.onc.1201934			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583675				2022-12-28	WOS:000072994600001
J	Eliopoulos, AG; Young, LS				Eliopoulos, AG; Young, LS			Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1)	ONCOGENE			English	Article						LMP1; JNK/SAPK; AP1; NF-kappa B; signalling	KAPPA-B ACTIVATION; C-JUN; LYMPHOCYTE TRANSFORMATION; EPITHELIAL-CELLS; TRANSCRIPTION; DOMAIN; GENE; INDUCTION; CD40; MEMBRANE-PROTEIN-1	Expression of the oncogenic Epstein-Barr virus (EBV)-encoded Latent Membrane Protein 1 (LMP1) activates signalling on the NF-kappa B axis through two distinct domains in the cytoplasmic C-terminus of the protein, namely CTAR1 (aa 187-231) and CTAR2 (aa 351-386), Whilst this effect is responsible for some of the functional consequences of LMP1 expression, additional LMP1-mediated signalling pathways may exist which contribute to the pleiotropic activities of this protein, In this study me provide evidence of a kinase cascade being activated by LMP1. Thus, we demonstrate that stable or transient expression of the LMP1 prototype from B95.8 in cells of epithelial or B cell origin activates the c-Jun N-terminal kinase (JNK, also known as the stress-activated protein kinase, SAPK) pathway, an effect which was found to be mediated through CTAR2 but not CTAR1, LMP1 from the Cao viral strain or LMP1 homologoues from the simian EBV naturally infecting baboons and rhesus monkeys were also able to activate JNK, This phenomenon translates to induction of AP-1, a transcription factor which is readily activated by growth factors and mitogens, Interestingly, an LMP1/CD40 chimaera comprising of the N-terminus and transmembrane domain of LMP1 and the cytoplasmic tail of CD40 which shares a common TRAF binding motif with CTAR1, effectively induced JNK, As NF-kappa B and JNK are co-activated in LMP1-expressing cells, we investigated whether the two pathways are overlapping or independent, We have found that inhibition of NF-kappa B by metabolic inhibitors or a constitutively active mutated I kappa-B alpha does not impair the ability of LMP1 to signal on the JNK axis, Conversely, whilst a dominant negative mutated SEK (JNKK) inhibited LMP1-induced JNK activation, it did not affect NF-kappa B suggesting that these two LMP1-mediated pathways are divergent.	Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England	University of Birmingham	Young, LS (corresponding author), Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Vincent Dr, Birmingham B15 2TA, W Midlands, England.		ELIOPOULOS, ARISTIDES/ABI-6632-2020; Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/R-9449-2018	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; GONZALEZ AL, 1995, TRENDS GENET, V11, P216, DOI 10.1016/S0168-9525(00)89051-4; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HUEN DS, 1995, ONCOGENE, V10, P549; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liebowitz David, 1993, P107; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu JJY, 1996, J GEN VIROL, V77, P1883, DOI 10.1099/0022-1317-77-8-1883; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NAKAGOMI H, 1994, INT J CANCER, V57, P240, DOI 10.1002/ijc.2910570218; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAN MH, 1994, NATURE, V372, P798; Young L S, 1992, Semin Cancer Biol, V3, P273; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	45	236	246	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1731	1742		10.1038/sj.onc.1201694	http://dx.doi.org/10.1038/sj.onc.1201694			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582021				2022-12-28	WOS:000072807600011
J	Greenberg, RA; Allsopp, RC; Chin, L; Morin, GB; DePinho, RA				Greenberg, RA; Allsopp, RC; Chin, L; Morin, GB; DePinho, RA			Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation	ONCOGENE			English	Article						telomerase; reverse transcriptase; mouse; telomere; cancer	IMMORTAL CELL-LINES; RNA COMPONENT; CANCER	We have identified the mouse telomerase reverse transcriptase component (mTERT) and demonstrate both substantial sequence homology to the human ortholog (hTERT), and the presence of reverse transcriptase and telomerase specific motifs, Furthermore, we show functional interchangeability with hTERT in in vitro telomerase reconstitution experiments, as mTERT produces strong telomerase activity in combination with the human telomerase RNA component hTR, The mouse TERT is widely expressed at low levels in adult tissues, with greatest abundance during embryogenesis and in adult thymus and intestine, The mTERT component mRNA levels were regulated during both differentiation and proliferation, while mTR levels remained constant throughout both processes, Comparison of mTERT and mTR levels to telomerase activity indicates that mTERT expression is more tightly linked to the regulation of telomerase activity during these processes than is mTR, In contrast to the situation in human cell cultures, mTERT transcript levels are present at readily detectable levels in primary cultured cells and are not upregulated following crisis, The widespread expression of mTERT in primary cells and mouse tissues could explain the increased frequency of spontaneous immortalization of mouse cells in culture and tumorigenesis in vivo.	Geron Corp, Menlo Park, CA 94025 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Div Dermatol, Bronx, NY 10461 USA	Geron Corporation; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Morin, GB (corresponding author), Geron Corp, 230 Constitut Dr, Menlo Park, CA 94025 USA.		Morin, Gregg B/E-9123-2012	Morin, Gregg B/0000-0001-8949-4374; DePinho, Ronald/0000-0002-5625-577X	NEI NIH HHS [R01EY09300] Funding Source: Medline; NICHD NIH HHS [R01HD28317] Funding Source: Medline; NIGMS NIH HHS [5T32GMO7491] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Avilion AA, 1996, CANCER RES, V56, P645; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MILLER RA, 1991, CANCER, V68, P2496, DOI 10.1002/1097-0142(19911201)68:11+<2496::AID-CNCR2820681503>3.0.CO;2-B; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Rao G, 1996, ONCOGENE, V12, P1165; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Xu HP, 1996, MAMM GENOME, V7, P16, DOI 10.1007/s003359900005; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	35	279	300	1	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1723	1730		10.1038/sj.onc.1201933	http://dx.doi.org/10.1038/sj.onc.1201933			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582020				2022-12-28	WOS:000072807600010
J	Suzuki, A; Tsutomi, Y; Akahane, K; Araki, T; Miura, M				Suzuki, A; Tsutomi, Y; Akahane, K; Araki, T; Miura, M			Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21(WAF1) and IAP gene family ILP	ONCOGENE			English	Article						caspase 3; p21(WAF1); ILP; Fas-mediated apoptosis; HepG2 cell	TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; DEATH FACTOR; ICE-LIKE; B-CELLS; INVOLVEMENT; ANTIGEN; BCL-2; EXPRESSION; PROTEASES	The death receptor Fas transduces apoptotic death signaling mediated by caspases. In the present study, human hepatoma HepG2 cells showed the Fas-mediated apoptosis mediated by caspase, especially caspase 3, only in the presence of actinomycin D. Interestingly, cytosolic proteins extracted from intact HepG2. cells induced caspase 3 inactivation, Our results reveal that this inactivation was triggered by the direct inhibition of activated caspase 3 by IAP gene family ILP. In addition, a 53 kDa protein was co-immunoprecipitated with anti-human caspase 3 antibody from intact HepG2 cells. This protein was a complex-protein of procaspase 3 and the cell cycle regulator p21(WAF1) (p21), P21 bound to only procaspase 3, but not to activated caspase 3. We also demonstrate that p21 protein-loaded HepG2 cells resist to Fas-mediated apoptosis even in the presence of actinomycin D, Here we report that caspase 3 inactivation for the resistance to Fas-mediated apoptosis is induced by a procaspase 3/p21 complex formation and direct inhibition of activated caspase 3 by ILP.	Daiichi Pharmaceut Co Ltd, Drug Safety Res Lab, Tokyo R&D Ctr, Edogawa Ku, Tokyo 134, Japan; Daiichi Pharmaceut Co Ltd, New Prod Res Lab 4, Tokyo R&D Ctr, Edogawa Ku, Tokyo 134, Japan; Osaka Univ, Sch Med, Dept Neuroanat, Biomed Res Ctr, Suita, Osaka 565, Japan	Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Osaka University	Suzuki, A (corresponding author), Daiichi Pharmaceut Co Ltd, Drug Safety Res Lab, Tokyo R&D Ctr, Edogawa Ku, 16-13 Kitakasai 1, Tokyo 134, Japan.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Hasegawa J, 1996, CANCER RES, V56, P1713; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; LI Y, 1994, ONCOGENE, V9, P2261; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SMITH PK, 1985, ANAL BIOCHEM, V170, P203; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suzuki A, 1996, EMBO J, V15, P211, DOI 10.1002/j.1460-2075.1996.tb00351.x; Suzuki A, 1996, REPROD TOXICOL, V10, P465, DOI 10.1016/S0890-6238(96)00133-5; Suzuki A, 1997, EXP CELL RES, V233, P48, DOI 10.1006/excr.1997.3546; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; Suzuki A, 1996, ONCOGENE, V13, P31; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	37	318	332	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					931	939		10.1038/sj.onc.1202021	http://dx.doi.org/10.1038/sj.onc.1202021			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747872				2022-12-28	WOS:000075560900001
J	Salvat, C; Jariel-Encontre, I; Acquaviva, C; Omura, S; Piechaczyk, M				Salvat, C; Jariel-Encontre, I; Acquaviva, C; Omura, S; Piechaczyk, M			Differential directing of c-Fos and c-Jun proteins to the proteasome in serum-stimulated mouse embryo fibroblasts	ONCOGENE			English	Article						c-Fos; c-Jun; ubiquitin; proteasome; stimulation for growth	UBIQUITIN-ACTIVATING ENZYME; TEMPERATURE-SENSITIVE MUTANTS; CELL-CYCLE; TRANSCRIPTION FACTORS; V-FOS; MICROBIAL METABOLITE; G0-TO-G1 TRANSITION; NEUROBLASTOMA-CELLS; DNA-SYNTHESIS; TS85 CELLS	c-Fos and c-Jun proteins are highly unstable transcription factors that heterodimerize within the AP-1 transcription complex. Their accumulation is transilently induced at the beginning of the G(0)-to-S phase transition in quiescent cells stimulated for growth. To address the mechanisms responsible for rapid clearance of c-Fos and c-Jun proteins under these experimental conditions, we have used the ts20 mouse embryo fibroblasts which express a thermosensitive mutant of the E1 enzyme of the ubiquitin pathway. The use of cell-permeant protease inhibitors indicates that both proteins are degraded by the proteasome and excludes any major contribution for calpains and lysosomes during the G(0)-to-S phase transition. Synchronisation of ts20 cells at the non permissive temperature blocks the degradation of c-Jun, indicating that this process is E1-dependent. In contrast, c-Fos is broken down according to an apparently E1-independent pathway in ts20 cells, although a role for ubiquitinylation in this process cannot be formally ruled out. Interestingly, c-Jun is highly unstable in c-Fos-null mouse embryo fibroblasts stimulated for growth. Taken together, these observations show that in vivo during a G(0)-to-S phase transition (i) the precise mechanisms triggering c-Fos and c-Jun directing to the proteasome are not identical, (ii) the presence of c-Fos is not an absolute prerequisite for the degradation of c-Jun and (iii) the degradation of c-Jun is not required for that of c-Fos.	CNRS, UMR5535, Inst Med Genet, F-34293 Montpellier 05, France; Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 108, Japan; Kitasato Univ, Kitasato Inst, Biol Funct Res Ctr, Minato Ku, Tokyo 108, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Kitasato University; Kitasato University	Piechaczyk, M (corresponding author), CNRS, UMR5535, Inst Med Genet, 1919 Route Mende, F-34293 Montpellier 05, France.		Acquaviva, Claire/N-4306-2017; PIECHACZYK, Marc/E-7896-2013	Acquaviva, Claire/0000-0002-0227-9813; PIECHACZYK, Marc/0000-0003-1367-2597				Angel P. E., 1994, FOS JUN FAMILIES TRA; Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Carillo S, 1996, BIOCHEM J, V313, P245, DOI 10.1042/bj3130245; CARILLO S, 1994, ONCOGENE, V9, P1679; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Curran T, 1988, ONCOGENE HDB, P307; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fuchs SY, 1996, ONCOGENE, V13, P1531; HARLOW E, 1988, ANTIBODIES; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOPSUHAVU VK, 1997, PROTEOLYSIS CELL FUN; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; KULKA RG, 1988, J BIOL CHEM, V263, P15726; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mils V, 1997, ONCOGENE, V14, P1555, DOI 10.1038/sj.onc.1200991; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; MORI M, 1993, J BIOL CHEM, V268, P16803; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RABOY B, 1986, EMBO J, V5, P863, DOI 10.1002/j.1460-2075.1986.tb04296.x; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; ROUX P, 1994, C FOS C JUN FAMILIES, P87; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SLATER ML, 1976, CELL, V7, P289, DOI 10.1016/0092-8674(76)90028-3; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Steff AM, 1997, BIOCHEM J, V323, P685, DOI 10.1042/bj3230685; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; ZENG GC, 1984, MOL CELL BIOL, V4, P1815, DOI 10.1128/MCB.4.9.1815; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841	64	38	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					327	337		10.1038/sj.onc.1201922	http://dx.doi.org/10.1038/sj.onc.1201922			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690514				2022-12-28	WOS:000074947500007
J	Gum, R; Juarez, J; Allgayer, H; Mazar, A; Wang, Y; Boyd, D				Gum, R; Juarez, J; Allgayer, H; Mazar, A; Wang, Y; Boyd, D			Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules	ONCOGENE			English	Review						urokinase receptor; proteolysis; JNK; MAPK	PROTEIN-KINASE-C; PHORBOL-MYRISTATE ACETATE; HUMAN OVARIAN-CANCER; TERMINAL PHOSPHORYLATION; TRANSDUCTION PATHWAYS; BOUND UROKINASE; CELL-MIGRATION; MESSENGER-RNA; GROWTH-FACTOR; U937 CELLS	The urokinase-type plasminogen activator receptor (u-PAR) has been implicated in tumor progression, and previous studies have shown that the expression of this gene is strongly up-regulated by PMA, Although the signaling mechanism by which PMA modulates u-PAR expression is not known, the effect of this phorbol ester on the expression of other genes has been ascribed to activation of the c-Raf-1-ERK signaling pathway. However, in the current study we examined an alternate possibility that the inductive effect of PMA on u-PAR expression also required a JNK1-dependent signaling cascade usually associated with stress-inducing stimuli. PMA treatment of the u-PAR-deficient OVCAR-3 ovarian cancer cells, which contain low JNK activities, resulted in a rapid (5 min) increase in JNK activity, Maximal JNK activity (12-fold induction) occurred after 30 min; this preceding the earliest detected rise in u-PAR protein (2 h), Dose-response studies with PMA also indicated that the increased JNK activity was tightly correlated with elevated u-PAR protein levels. The stimulation of u-PAR promoter activity by PMA required an intact upstream AP-1 motif (- 184) and in PMA-treated cells this motif was bound with c-Jun as indicated from mobility shift assays, PMA up-regulated the c-Jun trans acting activity as indicated by the higher activity of a GAL4-regulated luciferase reporter in phorbol-ester-treated cells co-transfected with an expression vector encoding the c-Jun transactivation domain fused to the GAL4 DNA-binding domain, The ability of PMA to stimulate u-PAR promoter activity was effectively titrated out by the co-expression of either a kinase-defective JNK1 or a dominant negative MEKK1 the latter being an upstream activator of JNK1, Conversely, u-PAR promoter activity was stimulated by the co-expression of a constitutively active MEKK1 and this induction was antagonized by the inclusion of the kinase-defective JNK1 plasmid, We also determined the biological significance of the JNK1-dependent signaling cascade in regulating u-PAR promoter activity by c-Ha-ras since this oncogene is activated and/or overexpressed in a variety of tumors including ovarian cancer. Transfection of an activated c-Ha-ras into OVCAR-3 cells stimulated u-PAR promoter activity over 20-fold and this could be countered by the individual expression of dominant negative expression constructs to Rac-1, MEKK1 or JNK1, Taken together, these data suggest that the PMA- or c-Ha-Ras-dependent stimulation of u-PAR gene expression requires a JNK1-dependent signaling module and that, at least for PMA, the concurrent stimulation of a JNK1-independent signaling module is also required. Thus, caution should be exercised in invoking linear signaling modules to account for the regulation of inducible gene expression.	Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol Head & Neck Surg, Houston, TX 77030 USA; Angstrom Pharmaceut, San Diego, CA USA; Univ Sydney, Westmead Hosp, Dept Renal Med, Westmead, NSW 2145, Australia; SmithKline Beecham, Dept Mol Immunol, King Of Prussia, PA 19406 USA	University of Texas System; UTMD Anderson Cancer Center; University of Sydney; GlaxoSmithKline	Boyd, D (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.				NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [P50 DE11906-01, R01DE10845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906, R01DE010845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABDELHAFIZ H, 1996, MOL ENDOCRINOL, V6, P2079; ADLER V, 1994, J BIOL CHEM, V269, P11186; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Allgayer H, 1997, CANCER RES, V57, P1394; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BIANCHI E, 1994, CANCER RES, V54, P861; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BOS JL, 1989, CANCER RES, V49, P4682; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CANO E, 1995, J CELL SCI, V108, P3599; CASEY JR, 1994, BLOOD, V84, P1151; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHIEN CH, 1993, DNA CELL BIOL, V12, P623, DOI 10.1089/dna.1993.12.623; CONESE M, 1994, J BIOL CHEM, V269, P17886; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DENG T, 1995, NATURE, V371, P171; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVRIES TJ, 1994, AM J PATHOL, V144, P70; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELLIS V, 1991, J BIOL CHEM, V266, P12752; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; JONES LG, 1994, J BIOL CHEM, V269, P23790; KARIKO K, 1993, CANCER RES, V53, P3109; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; LUND LR, 1991, J BIOL CHEM, V266, P5177; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; MARQUARDT B, 1994, ONCOGENE, V9, P3213; Masuelli L, 1996, MOL CELL BIOL, V16, P5466; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Min HY, 1996, CANCER RES, V56, P2428; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; NICOLSON GL, 1990, ONCOGENE, V5, P747; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; OHagan RC, 1996, ONCOGENE, V13, P1323; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PALEJWALA S, 1996, P AM ASSOC CANC RES, V37, pA1429; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PULVERER BJ, 1993, ONCOGENE, V8, P407; PYKE C, 1993, FEBS LETT, V326, P69, DOI 10.1016/0014-5793(93)81763-P; QUATTRONE A, 1995, CANCER RES, V55, P90; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; RAO VN, 1993, CANCER RES, V53, P3449; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Sauma S, 1996, J BIOL CHEM, V271, P11422, DOI 10.1074/jbc.271.19.11422; Scambia G, 1997, BRIT J CANCER, V75, P1547, DOI 10.1038/bjc.1997.264; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; Sillaber C, 1997, J BIOL CHEM, V272, P7824, DOI 10.1074/jbc.272.12.7824; SOZERI O, 1992, ONCOGENE, V7, P2259; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; VAGNARELLI P, 1992, CYTOGENET CELL GENET, V60, P197, DOI 10.1159/000133335; VANDAM PA, 1994, J CLIN PATHOL, V47, P914, DOI 10.1136/jcp.47.10.914; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WANG Y, 1995, EUR J BIOCHEM, V227, P116, DOI 10.1111/j.1432-1033.1995.tb20366.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; Xing RH, 1997, CANCER RES, V57, P3585; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	109	45	46	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					213	225		10.1038/sj.onc.1201917	http://dx.doi.org/10.1038/sj.onc.1201917			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674706				2022-12-28	WOS:000074706700010
J	Amendt, C; Schirmacher, P; Weber, H; Blessing, M				Amendt, C; Schirmacher, P; Weber, H; Blessing, M			Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development	ONCOGENE			English	Article						TGF-beta; receptor; skin; carcinogenesis; growth control	GROWTH-FACTOR-BETA; TRANSGENIC MICE; TRANSFORMING GROWTH-FACTOR-BETA-1; MALIGNANT CONVERSION; KERATIN-5 GENE; HIGH-RISK; RAS GENE; HA-RAS; CELLS; CARCINOGENESIS	The role of Transforming growth factor beta (TGF-beta) in carcinogenesis is complex. There are reports on both tumor inhibition and tumor promotion by TGF-beta. To elucidate the complex role of TGF-beta in epithelial carcinogenesis, we generated transgenic mice overexpressing a dominant negative type II TGF-beta receptor in the basal cell compartment and in follicular cells of the skin, Despite the reduced responsiveness of transgenic keratinocytes to TGF-beta, both proliferation and differentiation were normal in non-irritated epidermis of these transgenic mice, Thus, interruption of signaling of all three isoforms of TGF-beta in basal and follicular cells does not disturb tissue homeostasis. However, during tumor promotion transgenic mice showed an elevated level of proliferation in the epidermis. This hyperproliferation correlated with a very early onset of carcinoma development and a malignant conversion frequency of 30% from benign papillomas to carcinomas. By comparison, the conversion frequency in wild-type mice of this strain has previously been reported as 5.5%, Even without induction of hyperproliferation by tumor promoters, transgenic mice developed far more carcinomas as controls when treated with a carcinogen. This result indicates that there is a synergistic effect between loss of TGF-beta responsiveness and mutations caused by initiation with a carcinogen leading to an endogeneous tumor promotion in initiated cells only.	Johannes Gutenberg Univ Mainz, Dept Med 1, Boehringer Ingelheim Res Grp, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Pathol, D-55101 Mainz, Germany	Boehringer Ingelheim; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Blessing, M (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med 1, Boehringer Ingelheim Res Grp, SFB-311,Obere Zahlbacher Str 63, D-55131 Mainz, Germany.							AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; Bottinger EP, 1997, CANCER RES, V57, P5564; BRAND T, 1993, J BIOL CHEM, V268, P11500; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHOI Y, 1990, CELL REGUL, V1, P791, DOI 10.1091/mbc.1.11.791; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COFFEY RJ, 1988, CANCER RES, V48, P1596; CUI W, 1995, GENE DEV, V9, P945, DOI 10.1101/gad.9.8.945; CUI W, 1994, CANCER RES, V54, P5831; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; DROZDOFF V, 1993, J CELL BIOL, V123, P909, DOI 10.1083/jcb.123.4.909; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESHERICK JS, 1993, CANCER RES, V53, P5517; FAFEUR V, 1993, MOL BIOL CELL, V4, P135, DOI 10.1091/mbc.4.2.135; Fowlis DJ, 1996, CELL GROWTH DIFFER, V7, P679; FURSTENBERGER G, 1989, INT J CANCER, V43, P915; GITELMAN SE, 1997, CALCIFIED TISSUE INT, V60, P283; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; HADDOW S, 1991, ONCOGENE, V6, P1465; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; HOGAN B, 1986, MANIPULATING MOUSE E; JORCANO JL, 1984, J MOL BIOL, V179, P257, DOI 10.1016/0022-2836(84)90468-6; JORCANO JL, 1984, DIFFERENTIATION, V28, P155, DOI 10.1111/j.1432-0436.1984.tb00278.x; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KITANO Y, 1983, BRIT J DERMATOL, V108, P555, DOI 10.1111/j.1365-2133.1983.tb01056.x; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MANSBRIDGE JN, 1988, J INVEST DERMATOL, V90, P336, DOI 10.1111/1523-1747.ep12456286; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MILLER SJ, 1993, J INVEST DERMATOL, V101, P591, DOI 10.1111/1523-1747.ep12366045; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhao Y, 1996, J BIOL CHEM, V271, P2369, DOI 10.1074/jbc.271.5.2369	64	97	101	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	1998	17	1					25	34		10.1038/sj.onc.1202161	http://dx.doi.org/10.1038/sj.onc.1202161			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671311				2022-12-28	WOS:000074677800004
J	D'Sa-Eipper, C; Chinnadurai, G				D'Sa-Eipper, C; Chinnadurai, G			Functional dissection of Bfl-1, a Bcl-2 homolog: anti-apoptosis, oncogene-cooperation and cell proliferation activities	ONCOGENE			English	Article						BCL-2 family; mutational analysis; conserved domains; apoptosis; p53; cell transformation; cell proliferation; gain-of-function	NECROSIS-FACTOR-ALPHA; DNA-DAMAGING AGENTS; ADENOVIRUS E1B 19K; CONSERVED DOMAINS; BHRF1 PROTEIN; VIRAL HOMOLOG; FAMILY MEMBER; B-CELLS; C-MYC; DEATH	The human Bfl-1 gene codes for a 175-amino acid BCL-2 family protein that has an anti-apoptosis activity and is overexpressed in certain human epithelial and hematopoietic malignancies. Bfl-1 efficiently suppresses apoptosis induced by the p53 tumor suppressor protein and cooperates with a dominant nuclear oncogene. EIA, in transformation of primary epithelial cells in vitro. Unlike other BCL-2 family proteins, expression of BFL-1 permits limited cell proliferation over an extended period of time when cells are induced to undergo apoptosis. We have carried out mutational analysis to dissect the various activities encoded by Bfl-1 and to determine the sequence requirements for these activities. BFL-1 shares four conserved domains, BH1, BH2, BH3 and BH4 with other BCL-2 family proteins. Mutations within BH1, BH2 and BH4 domains abolish or greatly attenuate the anti-apoptotic, oncogene cooperation and proliferation facilitating activities of BFL-1. In contrast, a mutation within the BH3 domain (which is essential for the activity of pro-apoptotic members of the BCL-2 family) does not significantly affect the BFL-1 functions. Although BFL-1 does not contain a well-defined C-terminal transmembrane domain, deletion of the C-terminal 24 amino acid region (corresponding to the transmembrane domain of other BCL-2 family proteins) partially reduces the various activities of BFL-1. All the mutants defective in the anti-apoptosis activity are also defective in the oncogene cooperation activity suggesting that these two activities may be linked. A unique feature of BFL-1 is the presence of a Gin-rich N-terminal region that overlaps with the BH4 domain. The GIn residues appear to be essential for the proliferation permitting activity of BFL-1. Since mutations of the GIn residues located within the BH4 domain appear to confer an extended cell survival activity in the absence of cell proliferation, our results suggest that BFL-1 communicates with both cell proliferation and apoptosis machineries and suggest a link between these two activities.	St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA.				NCI NIH HHS [CA-33616, R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CHOI SS, 1995, ONCOGENE, V11, P1693; DAWSON CW, 1995, ONCOGENE, V9, P69; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DSaEipper C, 1996, CANCER RES, V56, P3879; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Han J, 1996, MOL CELL BIOL, V16, P5857; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kenny JJ, 1997, ONCOGENE, V14, P997, DOI 10.1038/sj.onc.1200898; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Mangeney M, 1996, ONCOGENE, V13, P1441; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nava VE, 1997, J VIROL, V71, P4118, DOI 10.1128/JVI.71.5.4118-4122.1997; NEVINS JR, 1992, SCIENCE, V258, P424; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SMITH CA, 1995, TRENDS CELL BIOL, V5, P344, DOI 10.1016/S0962-8924(00)89061-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Subramanian T, 1995, ONCOGENE, V11, P2403; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; TAKAYAMA S, 1994, DNA CELL BIOL, V13, P679, DOI 10.1089/dna.1994.13.679; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; TARODI B, 1993, INT J ONCOL, V3, P467; Theodorakis P, 1996, ONCOGENE, V12, P1707; Uhlmann EJ, 1996, CANCER RES, V56, P2506; Vairo G, 1996, ONCOGENE, V13, P1511; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	57	58	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3105	3114		10.1038/sj.onc.1201851	http://dx.doi.org/10.1038/sj.onc.1201851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671389				2022-12-28	WOS:000074261300003
J	Almeida, A; Zhu, XX; Vogt, N; Tyagi, R; Muleris, M; Dutrillaux, AM; Dutrillaux, B; Ross, D; Malfoy, B; Hanash, S				Almeida, A; Zhu, XX; Vogt, N; Tyagi, R; Muleris, M; Dutrillaux, AM; Dutrillaux, B; Ross, D; Malfoy, B; Hanash, S			GAC1, a new member of the leucine-rich repeat superfamily on chromosome band 1q32.1, is amplified and overexpressed in malignant gliomas	ONCOGENE			English	Article						glioma; amplification; overexpression; leucine-rich repeat; chromosome 1	MOUSE NERVOUS-SYSTEM; 2-DIMENSIONAL SEPARATIONS; ADHESION MOLECULE; GENOMIC DNA; GENE; SEQUENCE; PROTEIN; CDNA; CLONING; AMPLIFICATION	We have used two-dimensional electrophoresis of enzyme-digested genomic DNA to identify a novel gene GAC1, which maps at 1q32.1 and which is overexpressed in malignant gliomas in which it is amplified. GAC1 encodes a protein which belongs to the leucine-rich repeat superfamily. Amplification and overexpression of GAC1 was demonstrated in two of eight tumors where amplifications were previously evidenced by comparative genomic hybridization (one glioblastoma multiforme and one anaplastic astrocytoma), and in one of eight unselected glioblastomas multiforme. GAC1 exhibits sequence homology with other proteins which function as cell-adhesion molecules or as signal transduction receptor and is a likely candidate for the target gene in the 1q32.1 amplicon in malignant gliomas.	CNRS UMR 147, Inst Curie, F-75248 Paris 05, France; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Michigan System; University of Michigan	Malfoy, B (corresponding author), CNRS UMR 147, Inst Curie, 26 Rue Ulm, F-75248 Paris 05, France.			Zhu, Charles/0000-0003-2922-0042				ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ALMEIDA A, 1994, GENE CHROMOSOME CANC, V11, P63, DOI 10.1002/gcc.2870110110; ASAKAWA J, 1994, P NATL ACAD SCI USA, V91, P9052, DOI 10.1073/pnas.91.19.9052; BUCHANAN SGS, 1996, PROG BIOPHYS MOL BIO, V25, P1; CHANG Z, 1993, DEV BIOL, V160, P315, DOI 10.1006/dbio.1993.1310; COLLINS VP, 1995, GLIA, V15, P289, DOI 10.1002/glia.440150309; Costello JF, 1997, CANCER RES, V57, P1250; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; Grover J, 1996, GENOMICS, V38, P109, DOI 10.1006/geno.1996.0605; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Kim D, 1996, BBA-GENE STRUCT EXPR, V1309, P183, DOI 10.1016/S0167-4781(96)00158-3; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; Kuick R, 1996, GENETICS, V144, P307; KUICK R, 1995, GENOMICS, V25, P345, DOI 10.1016/0888-7543(95)80032-H; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MULERIS M, 1994, ONCOGENE, V9, P2717; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; QIN H, 1993, HUM HERED, V43, P261, DOI 10.1159/000154142; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SCHROCK E, 1994, AM J PATHOL, V144, P1203; Suzuki Y, 1996, J BIOL CHEM, V271, P22522, DOI 10.1074/jbc.271.37.22522; SZTROLOVICS R, 1994, GENOMICS, V23, P715, DOI 10.1006/geno.1994.1567; Taguchi A, 1996, MOL BRAIN RES, V35, P31, DOI 10.1016/0169-328X(95)00178-U; Taniguchi H, 1996, MOL BRAIN RES, V36, P45, DOI 10.1016/0169-328X(95)00243-L; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wimmer K, 1997, BIOCHEM SOC T, V25, P262, DOI 10.1042/bst0250262	36	61	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2997	3002		10.1038/sj.onc.1201828	http://dx.doi.org/10.1038/sj.onc.1201828			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662332				2022-12-28	WOS:000074125300006
J	Bafico, A; Gazit, A; Wu-Morgan, SS; Yaniv, A; Aaronson, SA				Bafico, A; Gazit, A; Wu-Morgan, SS; Yaniv, A; Aaronson, SA			Characterization of Wnt-1 and Wnt-2 induced growth alterations and signaling pathways in NIH3T3 fibroblasts	ONCOGENE			English	Article						Wnt; oncogene; NIH3T3; cell adhesion; beta-catenin; MAPK	MAMMARY EPITHELIAL-CELLS; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; CADHERIN-CATENIN COMPLEX; BETA-CATENIN; TYROSINE PHOSPHORYLATION; MAP KINASE; PROTEIN; TRANSFORMATION; EXPRESSION	Members of the Wnt family induce mouse mammary tumors and partially transform mammary epithelial cells in culture. However, their mechanism of transformation remains to be elucidated. In NIH3T3 mouse embryo fibroblasts, a standard transformation model, Wnt-1 and Wnt-2 were shown to induce altered properties including increased saturation density and growth in soft agar, Such cells also exhibited increased cell-cell adhesiveness. However, unlike oncogenes such as PDGFB or ras, Wnt-1 and -2 failed to induce detectable transformed foci following transfection, and stable NIH3T3 transfectants lacked tumor forming capacity. Wnt-1 and -2 transfectants exhibited increased uncomplexed, cytosolic beta-catenin, which was not observed with PDGFB, ras or erbB2 transfectants. In transient transfection, Wnt-1 and -2 induced a rapid increase in cytosolic beta-catenin but no detectable increase in the phosphorylated activated forms of MAP kinase, In contrast, ras was a potent activator of MAP kinase but had no effect on free beta-catenin levels. These findings establish that both Wnt signaling and pattern of growth alterations differ from those of oncogenes which activate proliferative signaling pathways in NIH3T3 cells.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tel Aviv University; Sackler Faculty of Medicine	Aaronson, SA (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R01CA071672, R01CA066654] Funding Source: NIH RePORTER; NCI NIH HHS [1-R01-CA71672, 1-R01-CA66654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BLASBAND A, 1992, ONCOGENE, V7, P153; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRADBURY JM, 1994, ONCOGENE, V9, P2597; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Christiansen JH, 1996, ONCOGENE, V12, P2705; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FALCO JP, 1988, ONCOGENE, V2, P573; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; LIN TP, 1992, CANCER RES, V52, P4413; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MIKI T, 1995, METHOD ENZYMOL, V254, P196; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; ROELINK H, 1992, ONCOGENE, V7, P487; ROTHBACHER U, 1995, DEV BIOL, V170, P717, DOI 10.1006/dbio.1995.1249; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	46	70	74	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2819	2825		10.1038/sj.onc.1201797	http://dx.doi.org/10.1038/sj.onc.1201797			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652750				2022-12-28	WOS:000073812200015
J	Jensen, NA; Pedersen, KM; Celis, JE; West, MJ				Jensen, NA; Pedersen, KM; Celis, JE; West, MJ			Failure of central nervous system myelination in MBP/c-myc transgenic mice: evidence for c-myc cytotoxicity	ONCOGENE			English	Article						hypomyelination; programmed cell death; oligodendrocytes	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; GLIOMA CELL-LINES; NEU ONCOGENE; OPTIC-NERVE; EXPRESSION; BRAIN; DIFFERENTIATION; DEATH; OLIGODENDROCYTE; INDUCTION	c-myc is a member of the helix-loop-helix/leucine zipper family of proteins that modulate the transcriptional activity of specific target genes, Although aberrant c-myc expression has been reported to play a role in multistage carcinogenesis in astrocytic gliomas, little is known about the effects of the expression of c-myc on oligodendrocytes. Using transgenic animals expressing a human C-myc oncogene under transcriptional control of the myelin basic protein gene, we investigated the effect of overexpression of this oncogene in oligodendrocytes, The MBP/c-myc transgenic mice developed severe neurological disturbances characterized by action tremors and recurrent seizures? and premature death during postnatal weeks three to five. Affected transgenic mice of various strains had severely hypomyelinated central nervous systems and expressed low levels of c-myc, myelin basic protein (MBP) and proteolipid protein (PLP) mRNAs in the brain, These c-myc transgenic mice also exhibited an increased number of TUNEL positive nuclei, which in most cases were located in cells that expressed c-myc, as judged by double immunohistochemistry. There was no evidence of brain tumors in the c-myc transgenic mice, including heterozygous mice from two strains that had normal lifespans, These observations indicate that the myelin deficiency observed in the MBP/c-myc transgenic animals results from a cytotoxic effect of the c-myc transgene.	Univ Aarhus, Dept Biochem Med, DK-8000 Aarhus C, Denmark; Univ Aarhus, Dept Neurobiol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Jensen, NA (corresponding author), Univ Aarhus, Dept Biochem Med, DK-8000 Aarhus C, Denmark.							ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Banerjee M, 1996, INT J CANCER, V65, P730, DOI 10.1002/(SICI)1097-0215(19960315)65:6<730::AID-IJC3>3.0.CO;2-#; BARNETT SC, 1995, CELL GROWTH DIFFER, V6, P69; Benjamins JA, 1984, MYELIN, P225; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Bunge Richard P., 1995, P44; BUTT AM, 1993, J COMP NEUROL, V338, P141, DOI 10.1002/cne.903380110; Campagnoni Anthony T., 1995, P555; Chattopadhyay P, 1995, ONCOGENE, V11, P2711; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; FEDDERSEN RM, 1992, NEURON, V9, P955, DOI 10.1016/0896-6273(92)90247-B; GANJU V, 1994, CANCER-AM CANCER SOC, V74, P920, DOI 10.1002/1097-0142(19940801)74:3<920::AID-CNCR2820740320>3.0.CO;2-4; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HAYES C, 1992, J NEUROSCI RES, V31, P175, DOI 10.1002/jnr.490310123; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; HIRVONEN HE, 1994, BRIT J CANCER, V69, P16, DOI 10.1038/bjc.1994.3; JENSEN NA, 1993, J NEUROSCI RES, V34, P257, DOI 10.1002/jnr.490340302; LAROCCA RV, 1989, J NEUROSCI RES, V24, P97, DOI 10.1002/jnr.490240114; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; MACGREGOR DN, 1990, PEDIATR RES, V28, P63, DOI 10.1203/00006450-199007000-00014; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; Mirsky R, 1996, CURR OPIN NEUROBIOL, V6, P89, DOI 10.1016/S0959-4388(96)80013-4; Morell Pierre, 1994, P117; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; ORIAN JM, 1994, J NEUROSCI RES, V39, P604, DOI 10.1002/jnr.490390512; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; RADNER H, 1993, ACTA NEUROPATHOL, V86, P456; Raine C., 1984, MYELIN, P1, DOI 10.1007/978-1-4757-1830-0_1; Ransom BR, 1996, TRENDS NEUROSCI, V19, P352, DOI 10.1016/0166-2236(96)10045-X; REMAHL S, 1990, J NEUROCYTOL, V19, P313, DOI 10.1007/BF01188401; Rencic A, 1996, P NATL ACAD SCI USA, V93, P7352, DOI 10.1073/pnas.93.14.7352; Rosenbluth Jack, 1995, P613; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P83; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Szuchet Sara, 1995, P23; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; Waxman Stephen G., 1995, P587	41	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	1998	16	16					2123	2129		10.1038/sj.onc.1201739	http://dx.doi.org/10.1038/sj.onc.1201739			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572493				2022-12-28	WOS:000073177200010
J	Wise, SC; Burmeister, LA; Zhou, XF; Bubulya, A; Oberfield, JL; Birrer, MJ; Shemshedini, L				Wise, SC; Burmeister, LA; Zhou, XF; Bubulya, A; Oberfield, JL; Birrer, MJ; Shemshedini, L			Identification of domains of c-Jun mediating androgen receptor transactivation	ONCOGENE			English	Article						c-Jun; androgen receptor; transactivation	ACTIVATED PROTEIN-KINASES; MAMMARY-TUMOR VIRUS; NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; AP-1 ACTIVITY; FUNCTION AF-2; IN-VITRO	The proto-oncoprotein c-Jun, when complexed with c-Fos, forms the climeric complex identified as AP-1 which regulates transcription directly by binding to AP-1-responsive genes. We have previously reported an indirect mechanism by which c-Jun is able to regulate transcription by stimulating androgen receptor transactivation in the absence of c-Fos or any apparent DNA binding. A series of c-Jun mutants were tested in order to characterize the domains of c-Jun responsible for this effect. The studies reported here indicate that functional bZIP region and a portion of the N-terminal activation functions is necessary for c-Jun stimulation of androgen receptor transactivation. Testing c-Jun/v-Jun chimeras, we show that v-Jun is unable to stimulate androgen receptor transactivation and the effect is dependent on the c-Jun activation functions, c-Jun exhibits a bell-shaped activity on androgen receptor-mediated transactivation which appears to be distinct from c-Jun's transactivation ability. A c-Jun mutant deficient in transactivation is able to stimulate androgen receptor activity. These results indicate that c-Jun's transactivation ability can be separated from c-Jun's ability to stimulate the androgen receptor transactivation.	Univ Toledo, Dept Biol, Toledo, OH 43606 USA; NCI, Dept Cell & Canc Biol, Div Clin Sci, Rockville, MD 20850 USA	University System of Ohio; University of Toledo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shemshedini, L (corresponding author), Univ Toledo, Dept Biol, Toledo, OH 43606 USA.							ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Bannister AJ, 1995, ONCOGENE, V11, P2509; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DENG TL, 1992, P NATL ACAD SCI USA, V89, P8572, DOI 10.1073/pnas.89.18.8572; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Lee JS, 1996, MOL CELL BIOL, V16, P4312; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; Martin ML, 1996, MOL CELL BIOL, V16, P2110; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; OEHLER T, 1993, ONCOGENE, V8, P1141; ONATE SA, 1995, SCIENCE, V270, P1354; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; SCARLETT CO, 1995, MOL ENDOCRINOL, V9, P413, DOI 10.1210/me.9.4.413; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VOGT PK, 1990, ADV CANCER RES, V55, P2; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	55	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	1998	16	15					2001	2009		10.1038/sj.onc.1201697	http://dx.doi.org/10.1038/sj.onc.1201697			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591784				2022-12-28	WOS:000073079400012
J	Berasain, C; Patil, D; Perara, E; Huang, SM; Mouly, H; Brechot, C				Berasain, C; Patil, D; Perara, E; Huang, SM; Mouly, H; Brechot, C			Oncogenic activation of a human cyclin A2 targeted to the endoplasmic reticulum upon Hepatitis B virus genome insertion	ONCOGENE			English	Article						cyclin A; hepatitis B virus; hepatocellular carcinoma; oncogenic transformation	HUMAN HEPATOCELLULAR-CARCINOMA; HEPATOMA-CELL LINE; S-PHASE; DNA INTEGRATION; TRANSACTIVATOR MHBS(T); MEVALONATE KINASE; TRANSGENIC MICE; EXPRESSION; GENE; TRANSFORMATION	Cyclins are major cell cycle regulators which role in malignant transformation remains controversial. In this report we describe a new mechanism of cyclin oncogenic activation. We demonstrate that an altered form of cyclin A2 (S2A) which N-terminal part is replaced by the hepatitis B virus envelope protein transforms normal rat kidney cells and cooperates with ras to transform rat embryo fibroblasts. In contrast, neither the viral moiety, nor a full length or N-terminally deleted cyclin A2 show these oncogenic properties. S2A oncogenicity arises from its binding to cyclin dependent kinases, since mutation in the MRAIL sequence abolishes transformation and correlates with an abnormal cellular localization in the endoplasmic reticulum membrane. Together, these results implicate modification in the cellular distribution of a cell cycle regulator as a mechanism of virally-induced transformation.	Necker Inst, INSERM, U370, F-75015 Paris, France; Necker Hosp, Liver Unit, F-75015 Paris, France; San Francisco State Univ, Dept Biol, San Francisco, CA 94132 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; California State University System; San Francisco State University	Brechot, C (corresponding author), Necker Inst, INSERM, U370, 156 Rue Vangirard, F-75015 Paris, France.		Berasain, Carmen/E-4139-2016	Berasain, Carmen/0000-0001-7075-2476				ASH JF, 1977, P NATL ACAD SCI USA, V74, P5584, DOI 10.1073/pnas.74.12.5584; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; Bresnahan WA, 1996, CELL GROWTH DIFFER, V7, P1283; BUCHOU T, 1993, ONCOGENE, V8, P1765; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; Caselmann WH, 1996, ADV VIRUS RES, V47, P253, DOI 10.1016/S0065-3527(08)60737-X; CASTRO A, 1994, BIOCHEM BIOPH RES CO, V201, P1072, DOI 10.1006/bbrc.1994.1814; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; DavidPfeuty T, 1996, ONCOGENE, V13, P1447; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GRAEF E, 1994, ONCOGENE, V9, P81; GRAEF E, 1995, VIROLOGY, V208, P696, DOI 10.1006/viro.1995.1201; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; Hildt E, 1996, SEMIN VIROL, V7, P333, DOI 10.1006/smvy.1996.0041; HILDT E, 1993, ONCOGENE, V8, P3359; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LEBAER J, 1997, GENE DEV, V11, P847; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LOVEC H, 1994, ONCOGENE, V9, P323; Luber B, 1996, ONCOGENE, V12, P1597; MACKAY D, 1993, FEBS LETT, V336, P549, DOI 10.1016/0014-5793(93)80874-T; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Masuda A, 1996, ONCOGENE, V12, P2081; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; Mumberg D, 1996, ONCOGENE, V13, P2493; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pineau P, 1996, J VIROL, V70, P7280, DOI 10.1128/JVI.70.10.7280-7284.1996; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROGLER CE, 1992, SEMIN LIVER DIS, V12, P265, DOI 10.1055/s-2007-1007398; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STUART RA, 1993, J BIOL CHEM, V268, P4050; THOMAS L, 1992, J BIOL CHEM, V267, P6183; Verges M, 1997, BIOCHEM BIOPH RES CO, V230, P49, DOI 10.1006/bbrc.1996.5851; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WOODMAN PG, 1993, MOL BIOL CELL, V4, P541, DOI 10.1091/mbc.4.5.541; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; Zerfass K, 1996, J VIROL, V70, P2637, DOI 10.1128/JVI.70.4.2637-2642.1996; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZHANG XK, 1992, BIOCHEM BIOPH RES CO, V188, P344, DOI 10.1016/0006-291X(92)92391-A; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	68	40	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1277	1288		10.1038/sj.onc.1201893	http://dx.doi.org/10.1038/sj.onc.1201893			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546429				2022-12-28	WOS:000072422000006
J	Comer, KA; Dennis, PA; Armstrong, L; Catino, JJ; Kastan, MB; Kumar, CC				Comer, KA; Dennis, PA; Armstrong, L; Catino, JJ; Kastan, MB; Kumar, CC			Human smooth muscle alpha-actin gene is a transcriptional target of the p53 tumor suppressor protein	ONCOGENE			English	Article						alpha-actin; p53; transactivation; cytoskeleton	RAS-TRANSFORMED CELLS; WILD-TYPE P53; DNA-DAMAGE; CELLULAR-RESPONSE; BINDING PROTEIN; PROMOTER; EXPRESSION; GROWTH; CHECKPOINT; SEQUENCE	Smooth muscle (sm) alpha-actin is expressed in vascular smooth muscle cells and fibroblast cells. Its expression is regulated by cell proliferation and repressed during oncogenic transformation, In this study, we demonstrate that p53 activation is associated with a dramatic increase in organized microfilament bundles and an increase in sm alpha-actin mRNA level. Wild-type p53, but not mutant p53, strongly stimulated human sm alpha-actin promoter activity in p53 null cell lines. The sequences homologous to the p53 consensus sequence and to the p53 binding sequence from the muscle creatine kinase, were found within a specific region of the sm alpha-actin promoter. This sequence was sufficient to confer p53-dependent activation to a heterologous promoter and p53 was capable of binding to this sequence as assessed by gel shift analysis. Ionizing irradiation of colorectal tumor cells caused an increase in alpha-actin mRNA level in a p53-dependent manner. Taken together, these results demonstrate that human sm alpha-actin gene is a transcriptional target for p53 tumor suppressor protein and represents the first example of a cytoskeletal gene with a functionally defined p53 response element.	Schering Plough Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA	Merck & Company; Schering-Plough Research Institute; Johns Hopkins University; Johns Hopkins Medicine	Kumar, CC (corresponding author), Schering Plough Res Inst, Dept Tumor Biol, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.				NIEHS NIH HHS [R01ES05777] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005777] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BUSHEL P, 1995, ONCOGENE, V10, P1361; CHEN JY, 1993, ONCOGENE, V8, P2159; DENOFRIO D, 1989, J CELL BIOL, V109, P191, DOI 10.1083/jcb.109.1.191; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Herman IM, 1993, CURR OPIN CELL BIOL, V5, P48, DOI 10.1016/S0955-0674(05)80007-9; KAJSTURA J, 1993, CELL BIOL INT, V17, P1023, DOI 10.1006/cbir.1993.1032; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUMAR CC, 1995, J BIOCHEM-TOKYO, V118, P1285, DOI 10.1093/oxfordjournals.jbchem.a125020; KUMAR CC, 1992, CANCER RES, V52, P6877; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; MABUCHI I, 1986, INT REV CYTOL, V101, P175, DOI 10.1016/S0074-7696(08)60249-1; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCHUGH KM, 1988, NUCLEIC ACIDS RES, V16, P4167, DOI 10.1093/nar/16.9.4167; MIYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; OWENS GK, 1986, J BIOL CHEM, V261, P3373; POLLACK R, 1975, P NATL ACAD SCI USA, V72, P994, DOI 10.1073/pnas.72.3.994; REDDY S, 1990, J BIOL CHEM, V265, P1683; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SMALL JV, 1993, P SOC EXP BIOL MED, P57; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VANDEKERCKHOVE J, 1978, J MOL BIOL, V126, P783, DOI 10.1016/0022-2836(78)90020-7; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YAMASHIRO S, 1991, BIOESSAYS, V13, P563, DOI 10.1002/bies.950131103; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	45	62	62	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1299	1308		10.1038/sj.onc.1201645	http://dx.doi.org/10.1038/sj.onc.1201645			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546431				2022-12-28	WOS:000072422000008
J	Herrmann, C; Block, C; Geisen, C; Haas, K; Weber, C; Winde, G; Moroy, T; Muller, O				Herrmann, C; Block, C; Geisen, C; Haas, K; Weber, C; Winde, G; Moroy, T; Muller, O			Sulindac sulfide inhibits Ras signaling	ONCOGENE			English	Article						non-steroidal anti-inflammatory drugs; sulindac; p21ras	GTPASE-ACTIVATING PROTEIN; FAMILIAL ADENOMATOUS POLYPOSIS; GUANINE-NUCLEOTIDE EXCHANGE; COLON-CANCER CELLS; MALIGNANT TRANSFORMATION; DIFFERENTIAL REGULATION; PLASMA-MEMBRANE; GENE-PRODUCT; IN-VIVO; HA-RAS	The non-steroidal anti-inflammatory drug sulindac is used in cancer prevention and therapy, but the molecular aspects of its anti-tumor effect remain unresolved. In vivo the prodrug sulindac, is converted into the metabolite sulindac sulfide. We found that sulindac sulfide strongly inhibits Ras induced malignant transformation and Ras/Raf dependent transactivation, Sulindac sulfide decreases the Ras induced activation of its main effector, the c-Raf-1 kinase, In vitro sulindac sulfide directly binds to the Ras gene product p21ras in a non-covalent manner. Moreover, we can show that sulindac sulfide inhibits the interaction of p21ras with the p21ras binding domain of the Raf protein. In addition, sulindac sulfide can impair the nucleotide exchange on p21ras by CDC25 as well as the acceleration of the p21ras GTPase reaction by p120GAP. Due to its action at the most critical site in Ras signaling me propose sulindac sulfide as a lead compound in the search for novel anti-cancer drugs which directly inhibit Ras mediated cell proliferation and malignant transformation.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44139 Dortmund, Germany; Univ Essen Gesamthsch Klinikum, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany; Univ Wurzburg, Inst Med Strahltnkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Munster, Chirurg Klin, D-48129 Munster, Germany	Max Planck Society; University of Duisburg Essen; University of Wurzburg; University of Munster	Muller, O (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Rheinlanddamm 201, D-44139 Dortmund, Germany.		Moroy, Tarik/D-9923-2011; Winde, Guenther/AAA-3610-2020					Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; Chiu CH, 1997, CANCER RES, V57, P4267; CRAVCHIK A, 1993, GENE, V137, P139, DOI 10.1016/0378-1119(93)90262-2; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; GIARDIELLO FM, 1994, CANCER METAST REV, V13, P279, DOI 10.1007/BF00666098; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; Goldberg Y, 1996, ONCOGENE, V12, P893; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; LOVEC H, 1994, ONCOGENE, V9, P323; Luk GD, 1996, SCHWEIZ MED WSCHR, V126, P801; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2909; Piazza GA, 1997, CANCER RES, V57, P2452; QIAO L, 1995, BBA-LIPID LIPID MET, V1258, P215, DOI 10.1016/0005-2760(95)00100-Q; RAO CV, 1995, CANCER RES, V55, P1464; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14225, DOI 10.1021/bi961118o; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Thompson HJ, 1997, CANCER RES, V57, P267; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vane JR, 1996, SCAND J RHEUMATOL, P9; WINDE G, 1995, DIS COLON RECTUM, V38, P813, DOI 10.1007/BF02049838; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Wright JD, 1996, CLIN PHARMACOKINET, V30, P445, DOI 10.2165/00003088-199630060-00003	44	107	113	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1769	1776		10.1038/sj.onc.1202085	http://dx.doi.org/10.1038/sj.onc.1202085			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778042				2022-12-28	WOS:000076303300002
J	Bennoun, M; Grimber, G; Couton, D; Seye, A; Molina, T; Briand, P; Joulin, V				Bennoun, M; Grimber, G; Couton, D; Seye, A; Molina, T; Briand, P; Joulin, V			The amino-terminal region of SV40 large T antigen is sufficient to induce hepatic tumours in mice	ONCOGENE			English	Article						pRb; p300; p53; transgenic mice; hepatic tumour; SV40 large T-antigen	SIMIAN-VIRUS-40 LARGE-T; INDUCED TUMORIGENESIS; P53-DEFICIENT MICE; PROTEINS P130; J-DOMAIN; P53; P300; GENE; RETINOBLASTOMA; BINDING	The transforming activity of SV40 large T-antigen (Tag) depends on its binding to cellular proteins involved in the control of the cell cycle (p53, pRb, p300..) and on the J-domain region in the amino-terminus. We established transgenic lines expressing wild-type or Tag mutant proteins lacking one of the three transforming domains, to determine the respective contributions of these domains to hepatic tumour formation. Tag mutants with no pRb-binding domain or N-terminal fragment did not cause neoplastic liver abnormalities. The dl1137 Tag mutant protein, which inhibits pRb function without affecting p53, induced hepatic tumours, These tumours grew significantly faster than those induced by wild-type Tag. Our results demonstrate different requirements for each of the inactivating functions of SV40 Tag in hepatocyte transformation and show that the loss of p53 function has only a moderate effect on hepatic tumour formation.	Inst Cochin Genet Mol, INSERM, U380, F-75014 Paris, France; Lab Univ Rech Histopathol, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Joulin, V (corresponding author), Inst Cochin Genet Mol, INSERM, U380, 22 Rue Mechain, F-75014 Paris, France.		Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754; JOULIN, Virginie/0000-0003-1091-7819				Allemand I, 1995, ONCOGENE, V11, P2583; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; CHEN JD, 1992, ONCOGENE, V7, P1167; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eckner R, 1996, MOL CELL BIOL, V16, P3454; FAN GS, 1995, CELL GROWTH DIFFER, V6, P1463; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Williams BO, 1996, CURR OPIN GENET DEV, V6, P65; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116	29	16	16	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1253	1259		10.1038/sj.onc.1202047	http://dx.doi.org/10.1038/sj.onc.1202047			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771968				2022-12-28	WOS:000075803300007
J	Sato, S; Tunashima, K; Mafune, Y; Ohtsuka, H; Koide, N; Endo, Y; Saito, Y; Asakura, H; Kominami, R				Sato, S; Tunashima, K; Mafune, Y; Ohtsuka, H; Koide, N; Endo, Y; Saito, Y; Asakura, H; Kominami, R			Allele-specific inactivation of the alpha 4 integrin gene expression in fibrosarcoma cell lines and relevance for spontaneous metastasis	ONCOGENE			English	Article						allele-specific inactivation; alpha 4 integrin; metastasis	TUMOR-SUPPRESSOR GENE; E-CADHERIN; DNA METHYLATION; CPG METHYLATION; HUMAN CANCERS; HUMAN COLON; CARCINOMAS; MOUSE; ADHESION; RECEPTORS	Deregulated expression of genes is found in cancer cells, which may affect malignant properties, but it is unclear whether such modulation occurs allele-specifically. This study shows that the gene coding alpha 4 integrin, a cell adhesion molecule, underwent allelic inactivation in a series of heterozygous murine fibrosarcoma cell lines (MST lines) with different metastatic potentials. P4 cells expressed the alpha 4 integrin gene from one allele at a level comparable to that of the primary MST1 tumor, whereas the descendent lines of P4 exhibited decreased expression of both alleles, No allelic loss of DNA was observed in these cells, Other four clones derived from P4 and five clones from a different tumor also showed such two-step inactivation, Intriguingly, the loss of expression was correlated with the acquisition of spontaneous, but not artificial, metastatic ability, This is consistent with the previous result of inverse relation between the expression of alpha 4/beta 1 integrin and the invasive potential of B14 melanoma cells. Analysis of DNA methylation and chromatin state of the alpha 4 integrin gene failed to provide a clue to difference between the two alleles in the cell lines, These results suggest that the allelic inactivation is a process giving loss of function to one allele, although the mechanism is unclear.	Niigata Univ, Sch Med, Dept Biochem 1, Niigata 951, Japan; Niigata Univ, Sch Med, Dept Internal Med 3, Niigata 951, Japan	Niigata University; Niigata University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem 1, Asahimachi 1-757, Niigata 951, Japan.							ADAMS RLP, 1982, CRC CR REV BIOCH MOL, V13, P349, DOI 10.3109/10409238209108714; Akama TO, 1997, CANCER RES, V57, P3294; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; BONHOMME F, 1989, GENETIC VARIANTS STR, P649; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; Cost GJ, 1997, CANCER RES, V57, P926; DAMJANOVICH L, 1992, AM J RESP CELL MOL, V6, P197, DOI 10.1165/ajrcmb/6.2.197; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Gao AC, 1997, CANCER RES, V57, P846; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HAN KA, 1992, CANCER RES, V52, P749; HERMAN JG, 1995, CANCER RES, V55, P4525; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KNUDSON AG, 1985, CANCER RES, V45, P1437; KORETZ K, 1991, AM J PATHOL, V138, P741; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAFUNE Y, 1994, ONCOGENE, V9, P2191; MAKOS M, 1993, CANCER RES, V53, P2715; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORTON RA, 1993, CANCER RES, V53, P3585; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; NIGAM AK, 1993, BRIT J CANCER, V68, P507, DOI 10.1038/bjc.1993.377; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OHTSUKA H, 1994, JPN J CANCER RES, V85, P1015, DOI 10.1111/j.1349-7006.1994.tb02899.x; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAAVONEN T, 1994, INT J CANCER, V58, P298, DOI 10.1002/ijc.2910580225; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PIGNATELLI M, 1990, BRIT J CANCER, V61, P636, DOI 10.1038/bjc.1990.141; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; RODRIGUEZALFAGEME C, 1992, P NATL ACAD SCI USA, V89, P1482, DOI 10.1073/pnas.89.4.1482; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAI T, 1991, AM J HUM GENET, V48, P880; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; Suda T, 1994, DNA Res, V1, P169, DOI 10.1093/dnares/1.4.169; SUZUKI S, 1993, JPN J CANCER RES, V84, P168, DOI 10.1111/j.1349-7006.1993.tb02851.x; TAKADA T, 1992, JPN J CANCER RES, V83, P165, DOI 10.1111/j.1349-7006.1992.tb00082.x; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	52	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					105	113		10.1038/sj.onc.1201913	http://dx.doi.org/10.1038/sj.onc.1201913			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671319				2022-12-28	WOS:000074677800012
J	Tsao, HS; Zhang, X; Benoit, E; Haluska, FG				Tsao, HS; Zhang, X; Benoit, E; Haluska, FG			Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines	ONCOGENE			English	Article						cancer; genetics; mutation; PTEN/MMAC1; melanoma	PRIMARY CUTANEOUS MELANOMA; FAMILIAL MELANOMA; HETEROZYGOSITY; DELETIONS; MUTATIONS; GLIOMAS; NEVI; P16	A novel tumor suppressor gene, PTEN/MMAC1, has been recently shown to be mutated in gliomas, breast, prostate, kidney cancers and melanomas, Loss-of-heterozygosity studies in melanoma have suggested the presence of at least one chromosome 10q locus lost early in tumor progression. In this study, we screened 45 melanoma cell lines and 17 paired uncultured metastatic melanoma and peripheral blood specimens for PTEN/MMAC1 alterations using PCR-SSCP and direct sequencing. We found nine melanoma cell lines with homozygous deletions (five with intragenic loss) and four cell lines with mutations (one nonsense and one frameshift; two intronic); from among our uncultured melanoma specimens, me found one tumor with a somatic 17 bp duplication in exon 7 leading to a premature stop codon and one tumor with a possible homozygous deletion. Furthermore, we ha ce identified a novel intragenic polymorphism within intron 4 of PTEN/MMAC1. Taken together, these data suggest that PTEN/MMAC1 may be a chromosome 10q tumor suppressor important in melanoma turner formation or progression.	Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA; Dana Farber Partners Canc Care, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute	Haluska, FG (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, Fruit St, Boston, MA 02114 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007098] Funding Source: NIH RePORTER; NIAMS NIH HHS [5T32AR07098-23] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; Bartkova J, 1996, CANCER RES, V56, P5475; Dahia PLM, 1997, CANCER RES, V57, P4710; DREYLING MH, 1995, CANCER RES, V55, P984; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FRIEND SH, 1993, SCIENCE, V259, P774, DOI 10.1126/science.8430329; FULTS D, 1990, CANCER RES, V50, P5784; Guldberg P, 1997, CANCER RES, V57, P3660; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Healy E, 1996, CANCER RES, V56, P589; HERBST RA, 1994, CANCER RES, V54, P3111; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Ohta M, 1996, INT J CANCER, V65, P762, DOI 10.1002/(SICI)1097-0215(19960315)65:6<762::AID-IJC9>3.0.CO;2-X; PARMITER AH, 1988, CANCER GENET CYTOGEN, V30, P313, DOI 10.1016/0165-4608(88)90200-2; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rhei E, 1997, CANCER RES, V57, P3657; RICHMOND A, 1986, J INVEST DERMATOL, V86, P295, DOI 10.1111/1523-1747.ep12285452; Risinger JI, 1997, CANCER RES, V57, P4736; SHAPIRO SD, 1988, INT J DERMATOL, V27, P232, DOI 10.1111/j.1365-4362.1988.tb03214.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENES CHROMOSOM CANC, V12, P235; WALKER GJ, 1995, GENE CHROMOSOME CANC, V12, P134, DOI 10.1002/gcc.2870120208	30	188	189	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3397	3402		10.1038/sj.onc.1201881	http://dx.doi.org/10.1038/sj.onc.1201881			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692547				2022-12-28	WOS:000074544100006
J	Cairns, P; Evron, E; Okami, K; Halachmi, N; Esteller, M; Herman, JG; Bose, S; Wang, SI; Parsons, R; Sidransky, D				Cairns, P; Evron, E; Okami, K; Halachmi, N; Esteller, M; Herman, JG; Bose, S; Wang, SI; Parsons, R; Sidransky, D			Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers	ONCOGENE			English	Article						PTEN/MMAC1; bladder cancer; renal cell cancer; chromosome 10q; homozygous deletion	RENAL-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; COWDEN SYNDROME; IDENTIFICATION; DISEASE; INACTIVATION; METHYLATION; ALLELOTYPE	A new tumor suppressor gene PTEN/MMAC1 was recently isolated at chromosome 10q23 and found to be inactivated by point mutation or homozygous deletion in glioma, prostate and breast cancer. PTEN/MMAC1 was also identified as the gene predisposing to Cowden disease, an autosomal dominant cancer predisposition syndrome associated with an increased risk of breast, skin and thyroid tumors and occasional cases of other cancers including bladder and renal cell carcinoma. We screened 345 urinary tract cancers by microsatellite analysis and found chromosome 10q to be deleted in 65 of 285 (23%) bladder and 15 of 60 (25%) renal cell cancers, We then screened the entire PTEN/MMAC1 coding region for mutation in 25 bladder and 15 renal cell primary tumors with deletion of chromosome 10q, Two somatic point mutations, a frameshift and a splicing variant, were found in the panel of bladder tumors while no mutation was observed in the renal cell carcinomas. To screen for homozygous deletion, we isolated two polymorphic microsatellite repeats from genomic BAC clones containing the PTEN/MMAC1 gene. Using these new informative markers, we identified apparent retention at the gene locus indicative of homozygous deletion of PTEN/MMAC1 in four of 65 bladder and 0 of 15 renal cell tumors with LOH through chromosome 10q, Identification of the second inactivation event in six bladder tumors with LOH of 10q implies that the PTEN/MMAC1 gene is occasionally involved in bladder tumorigenesis. However, the low frequency of biallelic inactivation suggests that either PTEN/MMAC1 is inactivated by other mechanisms or it is not the only target of chromosome 10q deletion in primary bladder and renal cell cancer.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA; Columbia Univ Coll Phys & Surg, Dept Pathol & Med, New York, NY 10032 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Columbia University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol, Baltimore, MD 21205 USA.		Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Evron, Ella/0000-0002-1003-5042; Parsons, Ramon/0000-0002-6656-3514				CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CAIRNS P, 1991, ONCOGENE, V6, P2305; Cairns P, 1997, CANCER RES, V57, P4997; ENG C, 1994, J MED GENET, V31, P458, DOI 10.1136/jmg.31.6.458; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HABUCHI T, 1993, INT J CANCER, V53, P579, DOI 10.1002/ijc.2910530409; HAIBACH H, 1992, AM J CLIN PATHOL, V97, P705, DOI 10.1093/ajcp/97.5.705; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; ISHIKAWA J, 1991, CANCER RES, V51, P5736; KNOWLES MA, 1994, CANCER RES, V54, P531; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORITA R, 1991, CANCER RES, V51, P5817; MORITA R, 1991, CANCER RES, V51, P820; REITER RE, 1993, CANCER RES, V53, P3092; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STARINK TM, 1986, CLIN GENET, V29, P222; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; VANDERRIET P, 1994, CANCER RES, V54, P25; Wang SI, 1997, CANCER RES, V57, P4183	26	153	159	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	1998	16	24					3215	3218		10.1038/sj.onc.1201855	http://dx.doi.org/10.1038/sj.onc.1201855			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671402				2022-12-28	WOS:000074261300016
J	Frizelle, SP; Grim, J; Zhou, J; Gupta, P; Curiel, DT; Geradts, J; Kratzke, RA				Frizelle, SP; Grim, J; Zhou, J; Gupta, P; Curiel, DT; Geradts, J; Kratzke, RA			Re-expression of p16(INK4a) in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression	ONCOGENE			English	Article						p16(INK4a); mesothelioma; tumor suppressor	RETINOBLASTOMA-SUSCEPTIBILITY GENE; LUNG-CANCER; MALIGNANT MESOTHELIOMA; FAMILIAL MELANOMA; WILD-TYPE; RB; MUTATIONS; PRODUCT; PROTEIN; LINES	Absence of expression of the p16(INK4a) gene product is commonly observed in mesothelioma tumors and cell lines, while wild-type pRB expression is maintained. We have examined the biologic and potential therapeutic role of re-expressing p16(INK4a) gene product in mesothelioma cells and tumors. Following transduction with a p16(INK4a) expressing adenovirus (Adp16), over-expression of p16(INK4a) in mesothelioma cells resulted in cell cycle arrest, inhibition of pRB phosphorylation, diminished cell growth, and eventual death of the transduced cells. Expression of p16(INK4a) protein was accompanied by decreased expression of pRB as detected by immunoblot and immunohistochemistry. Experiments in mesothelioma xenografts demonstrated inhibition of tumor formation, tumor growth arrest and diminished tumor size and spread. p16(INK4a) gene product expression was also demonstrated in intraperitoneal xenografts of human mesothelioma cells, These results demonstrate that p16(INK4a) gene transfer may play a therapeutic role in the treatment of mesothelioma.	Vet Affairs Med Ctr, Dept Med, Hematol Oncol Sect, Minneapolis, MN 55417 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55417 USA; Univ Alabama Birmingham, Gene Therapy Program, Birmingham, AL 35294 USA; Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Kratzke, RA (corresponding author), Vet Affairs Med Ctr, Dept Med, Hematol Oncol Sect, Minneapolis, MN 55417 USA.				NATIONAL CANCER INSTITUTE [R01CA068245] Funding Source: NIH RePORTER; NCI NIH HHS [1 R01 CA 68245-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antman KH, 1989, CANCER PRINCIPLES PR, P1399; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BODNER SM, 1992, ONCOGENE, V7, P743; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; FUJIWARA T, 1994, J NATL CANCER I, V86, P1458, DOI 10.1093/jnci/86.19.1458; Geradts J, 1996, MODERN PATHOL, V9, P339; GERADTS J, 1995, CANCER RES, V55, P6006; GRIM J, 1997, IN PRESS CLIN CANC R; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; Kratzke RA, 1996, CANCER RES, V56, P3415; METCALF RA, 1992, CANCER RES, V52, P2610; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Parry D, 1996, MOL CELL BIOL, V16, P3844; PASS HI, 1995, ANN THORAC SURG, V59, P835, DOI 10.1016/0003-4975(95)00045-M; Pass HI, 1996, J CELL BIOCHEM, P142; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SEKIDO Y, 1995, CANCER RES, V55, P1227; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMYTHE WR, 1994, ANN THORAC SURG, V57, P1395, DOI 10.1016/0003-4975(94)90090-6; Treat J, 1996, HUM GENE THER, V7, P2047, DOI 10.1089/hum.1996.7.16-2047; Ueki K, 1996, CANCER RES, V56, P150; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	31	98	101	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	1998	16	24					3087	3095		10.1038/sj.onc.1201870	http://dx.doi.org/10.1038/sj.onc.1201870			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671387				2022-12-28	WOS:000074261300001
J	Chevillard, S; Radicella, JP; Levalois, C; Lebeau, J; Poupon, MF; Oudard, S; Dutrillaux, B; Boiteux, S				Chevillard, S; Radicella, JP; Levalois, C; Lebeau, J; Poupon, MF; Oudard, S; Dutrillaux, B; Boiteux, S			Mutations in OGG1, a gene involved in the repair of oxidative DNA damage, are found in human lung and kidney tumours	ONCOGENE			English	Article						oxidative DNA damage; DNA repair; missense mutations of OGG1 gene; human lung and kidney cancer; tumour suppressor gene	GENERATES G.C->T.A TRANSVERSIONS; NONPOLYPOSIS COLON-CANCER; ESCHERICHIA-COLI; MUTATOR LOCUS; BREAST-CANCER; MUTY GENE; GLYCOSYLASE; CLONING; HOMOLOG; 7,8-DIHYDRO-8-OXOGUANINE	The human OGG1 gene encodes a DNA glycosylase activity catalysing the excision of the mutagenic lesion 7,8-dihydro-8-oxoguanine from oxidatively damaged DNA, The OGG1 gene was localized to chromosome 3p25, a region showing frequent loss of heterozygosity (LOH) in lung and kidney tumours. In this study, we have analysed by RT-PCR the expression of OGG1 in 25 small cell lung cancers, in 15 kidney carcinomas and the 15 normal kidney counterparts. The results show that OGG1 messenger RNA can be detected in all tumours tested and that no significant difference was observed in the level of expression between normal and tumoral kidney tissues. Denaturing gradient gel electrophoresis (DGGE) was used to screen this series of human tumours for alterations in the OGG1 cDNA. The study revealed homozygous mutations in three tumours, two from lung and one from kidney, Sequencing analysis of the mutants identified a single base substitution in each of the three cases: two tranversions (GC to TA and TA to AT) and one transition (GC to AT), All three substitutions cause an amino acid change in the hOgg1 protein. For the mutant kidney tumour, the normal tissue counterpart shows a wild-type profile, These results suggest a role for OGG1 mutations in the course of the multistage process of carcinogenesis in lung or kidney.	CNRS CEA Radiobiol Mol & Cellulaire UMR217, Dept Radiobiol & Radiopathol, Lab Radiobiol DNA, F-92265 Fontenay Aux Roses, France; CNRS CEA Radiobiol Mol & Cellulaire UMR217, Dept Radiobiol & Radiopathol, Lab Cancerogenese Expt, F-92265 Fontenay Aux Roses, France; CNRS UMR147, Inst Curie, F-75005 Paris, France; Hotel Dieu, Med Oncol Serv, F-75004 Paris, France; CEA, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; CEA	Boiteux, S (corresponding author), CNRS CEA Radiobiol Mol & Cellulaire UMR217, Dept Radiobiol & Radiopathol, Lab Radiobiol DNA, F-92265 Fontenay Aux Roses, France.		Radicella, J. Pablo/AAU-3178-2020	Radicella, J. Pablo/0000-0002-8807-7226; Chevillard, Sylvie/0000-0001-5889-4041; OUDARD, Stephane/0000-0003-0893-285X				Aburatani H, 1997, CANCER RES, V57, P2151; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1998, IN PRESS DNA DAMAGE; Boiteux S., 1997, BASE EXCISION REPAIR, P31; BREIMER LH, 1990, MOL CARCINOGEN, V3, P188, DOI 10.1002/mc.2940030405; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Chevillard S, 1997, CLIN CANCER RES, V3, P2471; Chevillard S, 1996, CANCER, V77, P292, DOI 10.1002/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO;2-X; Chevillard S, 1996, BREAST CANCER RES TR, V41, P81, DOI 10.1007/BF01807039; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HIBI K, 1992, ONCOGENE, V7, P445; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; JIRICNY J, 1994, TRENDS GENET, V10, P164, DOI 10.1016/0168-9525(94)90093-0; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOEB LA, 1991, CANCER RES, V51, P3075; Loeb LA, 1997, SCIENCE, V277, P1449, DOI 10.1126/science.277.5331.1449; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Richards B, 1997, SCIENCE, V277, P1523, DOI 10.1126/science.277.5331.1523; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	43	197	202	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3083	3086		10.1038/sj.onc.1202096	http://dx.doi.org/10.1038/sj.onc.1202096			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662341				2022-12-28	WOS:000074125300015
J	Oliveira, MLS; Roberts, TM; Druker, BJ; Armelin, MCS				Oliveira, MLS; Roberts, TM; Druker, BJ; Armelin, MCS			Mapping of polyomavirus middle T domain that is responsible for AP-1 activation	ONCOGENE			English	Article						polyomavirus; middle T antigen; cell transformation; AP-1 activation; phosphatidylinositol-3 kinase	PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; SIZED TUMOR-ANTIGEN; RECOMBINANT RETROVIRUSES; CELL-TRANSFORMATION; PROTEIN-KINASES; INTACT-CELLS; WILD-TYPE; C-FOS; JUN; EXPRESSION	Cell transformation by Polyomavirus middle T (MT) oncoprotein involves binding and activation of several cytoplasmic proteins that participate in growth factors-induced mitogenic signal transduction to the nucleus. We have previously reported that the AP-I transcriptional complex is a target for MT during cell transformation. To analyse the interactions between MT and cellular proteins that are required for constitutive AP-1 activation, we compared wild type and transformation-defective MT mutant cell lines. High AP-1 activity, assessed by gel mobility shift assays, displayed by MT-overexpressing cells, is dependent on MT binding to phosphatidylinositol-3 kinase (PI3K). Treatment with wortmannin (a specific PI3K inhibitor) leads to decreased AP-I activity. Supershift and Western blot analysis with specific antisera, indicate that JunB and cJun, but not cFos or FosB are present in the AP-1 complex. The results confirm the AP-1 complex as a downstream MT target and indicate that AP-1 activation may not be sufficient for cell transformation, since two transformation-defective MT mutants (250phe and MT322) display high AP-1 activity.	Univ Sao Paulo, Inst Quim, BR-05599970 Sao Paulo, SP, Brazil; Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Cellular & Mol Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Universidade de Sao Paulo; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Oregon Health & Science University	Armelin, MCS (corresponding author), Univ Sao Paulo, Inst Quim, CP 26077, BR-05599970 Sao Paulo, SP, Brazil.		Oliveira, Maria Leonor S/F-4988-2012	Oliveira, Maria Leonor/0000-0003-4849-3062; Druker, Brian/0000-0001-8331-8206				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Armelin MCS, 1996, BRAZ J MED BIOL RES, V29, P1133; ARMELIN MCS, 1985, COLD SPRING HARBOR C, V3, P195; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOLENJB, 1994, CELL, V38, P767; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Dahl J, 1996, MOL CELL BIOL, V16, P2728; DEGROOT RP, 1992, ONCOGENE, V7, P841; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; DRUKER BJ, 1992, NUCLEIC ACIDS RES, V19, P6855; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORGAN WC, 1988, J VIROL, V62, P3407, DOI 10.1128/JVI.62.9.3407-3414.1988; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; POWIS G, 1994, CANCER RES, V54, P2419; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAMEH LE, 1992, MOL CELL BIOL, V12, P4612, DOI 10.1128/MCB.12.10.4612; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHLEGEL R, 1978, CELL, V14, P587, DOI 10.1016/0092-8674(78)90244-1; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; THOMAS JE, 1993, ONCOGENE, V8, P2521; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	51	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2975	2982		10.1038/sj.onc.1201841	http://dx.doi.org/10.1038/sj.onc.1201841			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662329				2022-12-28	WOS:000074125300003
J	Zhang, HT; O'Rourke, DM; Zhao, HZ; Murali, R; Mikami, Y; Davis, JG; Greene, MI; Qian, XL				Zhang, HT; O'Rourke, DM; Zhao, HZ; Murali, R; Mikami, Y; Davis, JG; Greene, MI; Qian, XL			Absence of autophosphorylation site Y882 in the p185(neu) oncogene product correlates with a reduction of transforming potential	ONCOGENE			English	Article						p185(neu); tyrosine kinase; Y882; transformation	EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; FACTOR-I RECEPTOR; NEU-ONCOGENE; SIGNAL-TRANSDUCTION; INTERMOLECULAR ASSOCIATION; CELL-TRANSFORMATION; RET PROTOONCOGENE; PROTEIN-KINASE; POINT MUTATION	Autophosphorylation of type I receptor tyrosine kinases (RTKs) comprises one step in the signaling events mediated by erbB receptors such as p185(neu) and EGFR. Previous analysis of p185(neu) has indicated that there are at least five tyrosine autophosphorylation sites, Y882, Y1028, E1143, Y1226/7 and Y1253, of which Y882 might be important because of its location in the kinase activity domain. We have specifically analysed the effect of a Y882F (phenylalanine substituted for tyrosine at position 882) mutation in the enzymatic active domain. We also deleted the carboxyl terminal 122 amino acids which contained three other autophosphorylation sites (TAPstop) and combined mutants of that deletion with Y882F (Y882F/APstop). Both in vitro and in vivo transformation assays showed that substitution of tyrosine(882) by phenylalanine significantly decreased the transforming potential of activated, oncogenic p185(neu), although no significant difference in the total phosphotyrosine levels of the mutant proteins were observed. To analyse mitogenic signaling in response to ligand, the intracellular domains of p185(neu) and Y882F were fused with the extracellular domain of the EGF receptor. The proliferation of cells expressing these chimeric receptors was EGF-dependent, and cells expressing EGFR/Y882F chimeric receptors were less responsive to EGF stimulation than those expressing EGFR/neu receptors. In vitro kinase assays demonstrated that abolishing the autophosphorylation site Y882 diminished the enzymatic tyrosine kinase activity of p185(neu). These studies, taken together with the phenotypic inhibition observed with cells expressing Y882F, suggest that the tyrosine(882). residue may be important for p185(neu)-mediated transformation by affecting the enzymatic kinase function of the p185(neu) receptor.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA	University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 36th & Hamilton Walk, Philadelphia, PA 19104 USA.		O'Rourke, Donald/AAC-3376-2021	Murali, Ramachandran/0000-0002-8384-2793; O'Rourke, Donald/0000-0002-8479-7314				CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARTER TH, 1994, CRIT REV ONCOGENESIS, V5, P389, DOI 10.1615/CritRevOncog.v5.i4.40; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; COLA C, 1989, BIOCHIM BIOPHYS ACTA, V1012, P191, DOI 10.1016/0167-4889(89)90095-5; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; Groenen LC, 1997, BIOCHEMISTRY-US, V36, P3826, DOI 10.1021/bi9614141; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LI NX, 1994, ONCOGENE, V9, P3457; MIKAMI Y, 1992, P NATL ACAD SCI USA, V89, P7335, DOI 10.1073/pnas.89.16.7335; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; MYERS JN, 1992, RECEPTOR, V2, P1; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIAN XL, 1995, ONCOGENE, V10, P211; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, ONCOGENE, V9, P1507; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; TIMMS JF, 1995, BIOCHEM J, V308, P219, DOI 10.1042/bj3080219; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6	42	15	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2835	2842		10.1038/sj.onc.1201820	http://dx.doi.org/10.1038/sj.onc.1201820			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671404				2022-12-28	WOS:000073988200002
J	Yawata, A; Adachi, M; Okuda, H; Naishiro, Y; Takamura, T; Hareyama, M; Takayama, S; Reed, JC; Imai, K				Yawata, A; Adachi, M; Okuda, H; Naishiro, Y; Takamura, T; Hareyama, M; Takayama, S; Reed, JC; Imai, K			Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells	ONCOGENE			English	Article						Bcl-2; BAG-1; gastric adenocarcinoma; peritoneal dissemination	BCL-2 PROTEIN; HGF RECEPTOR; GENE; EXPRESSION; BAG-1; APOPTOSIS; CARCINOMA; ADHESION; MATRIX; CHAIN	Bcl-2 and a Bcl-2-binding protein BAG-1 function in protection from apoptosis induced by a variety of stimuli. Deregulated expression of Bcl-2 leads to inhibition of apoptosis and is correlated with development of various cancers, Here, we provide evidence that prolonged cell survival introduced by overproduction of Bcl-2 or BAG-1 strongly enhances peritoneal dissemination of human gastric cancer MKN74 cells. Gene transfer-mediated overexpression of Bcl-2 or BAG-1 led to prolonged cell survival of MKN74 cells against serum-starved apoptosis and anoikis, When the viable transfectants were inoculated into the intraperitoneal cavity of BALB/c nude mice, the Bcl-2-expressing MKN74 cells and the BAG-1-expressing MKN74 cells exhibited strongly enhanced peritoneal dissemination in BALB/c nude mice and whole disseminated tumor weights were increased by ii-fold and 3.3-fold, respectively, compared with the control transfectants. The enhanced peritoneal dissemination of MKN74-Bcl-2 and MKN74-BAG-1 transfectants correlated well with resistance to cell death induced by serum-starvation and anoikis, However, the overexpression of Bcl-2 or BAG-1 caused no significant difference among the transfectants in cell growth rates, either in vitro of in vivo. Taken together, these studies demonstrate that resistance to apoptosis is a crucial factor for development of peritoneal dissemination of human gastric cancer cells.	Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 060, Japan; Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sapporo Medical University; Sanford Burnham Prebys Medical Discovery Institute	Adachi, M (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 060, Japan.				NCI NIH HHS [CA-67329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; Adachi M, 1996, BLOOD, V88, P4118, DOI 10.1182/blood.V88.11.4118.bloodjournal88114118; ASAO T, 1994, CANCER LETT, V78, P57, DOI 10.1016/0304-3835(94)90031-0; ASAO T, 1995, CANCER, V75, P1539, DOI 10.1002/1097-0142(19950315)75:6+<1539::AID-CNCR2820751526>3.0.CO;2-L; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRONNER MP, 1995, AM J PATHOL, V146, P20; BUCK RC, 1973, CANCER RES, V33, P3181; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAUWERS GY, 1995, CANCER, V75, P2209, DOI 10.1002/1097-0142(19950501)75:9<2209::AID-CNCR2820750904>3.0.CO;2-M; MCDONNELL TJ, 1992, CANCER RES, V52, P6904; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; REED JC, 1993, J CELL BIOL, V124, P1; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	20	120	123	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2681	2686		10.1038/sj.onc.1201792	http://dx.doi.org/10.1038/sj.onc.1201792			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632144				2022-12-28	WOS:000073698200012
J	Sorokin, A; Reed, E; Nnkemere, N; Dulin, NO; Schlessinger, J				Sorokin, A; Reed, E; Nnkemere, N; Dulin, NO; Schlessinger, J			Crk protein binds to PDGF receptor and insulin receptor substrate-1 with different modulating effects on PDGF- and insulin-dependent signaling pathways	ONCOGENE			English	Article						Crk; PDGF receptor; IRS-1; ERK cascade	EPIDERMAL-GROWTH-FACTOR; MEDIATED CELL-ADHESION; STIMULATES TYROSINE PHOSPHORYLATION; GUANINE-NUCLEOTIDE EXCHANGE; GTPASE-ACTIVATING PROTEIN; SH3 DOMAINS; C-CRK; V-CRK; FACTOR-I; BETA-SUBUNIT	We have studied the involvement of murine c-Crk, an SH2/SH3 containing adaptor protein, in signaling pathways stimulated by different receptor tyrosine kinases. We show here that c-Crk is associated with components of insulin-and PDGF-dependent signaling pathways. Insulin treatment of murine myoblast cells induces the formation of stable complex of endogenous c-Crk with insulin receptor substrate-1 (IRS-1) mediated via the SH2 domain of Crk. The ligand dependent physical association of c-Crk with IRS-1 is direct. However IRS-1 is also co-precipitated with c-Crk from quiescent L6 cells. The association of IRS-1 with c-Crk in quiescent cells is probably not direct since Far Western blot analysis did not reveal the binding of neither SH2 domain nor amino-terminal SH3 domain of c-Crk to IRS-1 from unstimulated cells. We also show that PDGF treatment of murine myoblast cells induces association of c-Crk with the PDGF receptor and tyrosine phosphorylation of c-Crk. Overexpression of c-Crk enhanced insulin-but not PDGF-induced activation of MAP kinases when compared to parental cell lines. Thus, the formation of the direct IRS-1/Crk complex appears to be crucial for Crk-mediated insulin-induced activation of MAP kinase, whereas Crk is probably involved in other PDGF-induced responses. These data provide support to the hypothesis that insulin and PDGF employ different mechanisms for activation of MAP kinase cascade.	Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA	Medical College of Wisconsin; Case Western Reserve University; New York University	Sorokin, A (corresponding author), Med Coll Wisconsin, Dept Med, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.			Sorokin, Andrey/0000-0002-5660-0190	NHLBI NIH HHS [HL22563] Funding Source: Medline; NIDDK NIH HHS [DK41684] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022563, R01HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hansen K, 1997, FEBS LETT, V409, P195, DOI 10.1016/S0014-5793(97)00495-X; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; HERRERA R, 1986, J BIOL CHEM, V261, P1980; Hoeve J.T., 1993, ONCOGENE, V8, P2469; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; Khwaja A, 1996, ONCOGENE, V12, P2491; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARUTA H, 1994, BIOESSAYS, V16, P489, DOI 10.1002/bies.950160708; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NANBERG E, 1993, J BIOL CHEM, V268, P18187; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ODA T, 1994, J BIOL CHEM, V269, P22925; OGAWA S, 1994, ONCOGENE, V9, P1669; OSTEROP APRM, 1993, EUR J BIOCHEM, V212, P477, DOI 10.1111/j.1432-1033.1993.tb17684.x; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; QUON MJ, 1994, J BIOL CHEM, V269, P27920; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RICE KM, 1994, BIOCHEM BIOPH RES CO, V198, P523, DOI 10.1006/bbrc.1994.1077; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHLESINGER J, 1994, CURR BIOL, V7, P25; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P24058; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VRIESSMITS AMM, 1992, NATURE, V357, P602; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1	94	16	16	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2425	2434		10.1038/sj.onc.1201781	http://dx.doi.org/10.1038/sj.onc.1201781			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627109				2022-12-28	WOS:000073672300001
J	Huang, HJ; Qian, JQ; Proffit, J; Wilber, K; Jenkins, R; Smith, DI				Huang, HJ; Qian, JQ; Proffit, J; Wilber, K; Jenkins, R; Smith, DI			FRA7G extends over a broad region: coincidence of human endogenous retroviral sequences (HERV-H) and small polydispersed circular DNAs (spcDNA) and fragile sites	ONCOGENE			English	Article						chromosome fragility; FRA7G; spcDNA; human endogenous retroviral sequence; fluorescence in situ hybridization	TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOMES; FREQUENT LOSS; X-SYNDROME; PROSTATE-CANCER; BREAST-CANCER; FHIT GENE; INTEGRATION; 3P14.2; CELL	FRA7G is an aphidicolin-inducible common fragile site at human chromosomal band 7q31.2. This region is frequently altered in a number of different tumor types including prostate, breast, and ovarian cancer. It has also been hypothesized that this region contains an important tumor suppressor gene which is mutated during the development of these cancers or an oncogene which is amplified, We previously used a FISH-based approach to isolate YAC clones which spanned FRA7G. In this report, we describe the Isolation and restriction endonuclease mapping of three overlapping P1 clones which cover FRA7G and the region frequently altered in the different cancers. FISH-based analysis of these clones reveals that aphidicolin-induced breakage in the FRA7G region occurs over a region of at least 300 Kb in length, We have also localized a previously sequenced BAC clone to this region. The sequence obtained from this clone reveals the presence of an endogenous retroviral sequence (HERV-H) in the midst of the FRA7G region as well as sequences with homology to small polydispersed circular DNAs (spcDNAs). Thus for the first two cloned common fragile sites, FRA7G and FRA3B, there is an association with both spcDNAs and hot-spots for viral integration.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; Vysis Inc, Downers Grove, IL USA	Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL CANCER INSTITUTE [R01CA048031, P20CA058225] Funding Source: NIH RePORTER; NCI NIH HHS [CA58225, CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BOLDOG FL, 1994, GENE CHROMOSOME CANC, V11, P216, DOI 10.1002/gcc.2870110403; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; CAPOROSSI D, 1991, CANCER GENET CYTOGEN, V54, P39, DOI 10.1016/0165-4608(91)90028-S; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P304, DOI 10.1002/gcc.2870120411; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Cohen S, 1996, MOL CELL BIOL, V16, P2002; Devilee P, 1997, GENE CHROMOSOME CANC, V18, P193; DURNAM D, 1986, CANCER CELL, V4, P349; GLOVER TW, 1984, HUM GENET, V67, P882; GREEN ED, 1991, GENOMICS, V11, P548, DOI 10.1016/0888-7543(91)90062-J; GREEN ED, 1994, HUM MOL GENET, V3, P489, DOI 10.1093/hmg/3.3.489; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HIRSCH B, 1991, HUM GENET, V87, P302; HUANG H, 1998, IN PRESS GENES CHROM; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; JONES NJ, 1990, MUTAGENESIS, V5, P15, DOI 10.1093/mutage/5.1.15; Kastury K, 1996, CANCER RES, V56, P978; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; KUWANO A, 1990, HUM GENET, V84, P527; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LATIL A, 1995, B CANCER, V82, P589; LEBEAU MM, 1998, IN PRESS HUM MOL GEN; LEDBETTER SA, 1990, GENOMICS, V8, P614, DOI 10.1016/0888-7543(90)90247-R; Lin JC, 1996, ONCOGENE, V13, P2001; MacLaren DC, 1996, GENOMICS, V35, P299, DOI 10.1006/geno.1996.0360; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pandis N, 1997, GENE CHROMOSOME CANC, V18, P241, DOI 10.1002/(SICI)1098-2264(199704)18:4<241::AID-GCC1>3.3.CO;2-7; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; PENNY LA, 1995, AM J HUM GENET, V56, P676; RASSOOL FV, 1991, P NATL ACAD SCI USA, V88, P6657, DOI 10.1073/pnas.88.15.6657; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; RASSOOL FV, 1992, AM J HUM GENET, V50, P1243; RITCHIE RJ, 1994, HUM MOL GENET, V3, P2115, DOI 10.1093/hmg/3.12.2115; Sambrook J., 2002, MOL CLONING LAB MANU; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SHIFMAN MI, 1995, J NEUROSCI METH, V59, P205, DOI 10.1016/0165-0270(94)00184-I; Shridhar R, 1996, CANCER RES, V56, P4347; Shridhar V, 1997, ONCOGENE, V14, P1269, DOI 10.1038/sj.onc.1201100; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SMITH PP, 1992, GENE CHROMOSOME CANC, V5, P150, DOI 10.1002/gcc.2870050209; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUNNERHAGEN P, 1989, SOMAT CELL MOLEC GEN, V15, P61, DOI 10.1007/BF01534670; SUTHERLAND GR, 1995, OXFORD MONOGRAPHS ME, V13; TAKAHASHI S, 1995, CANCER RES, V55, P4114; VANDERDRIFT P, 1994, HUM MOL GENET, V3, P2131, DOI 10.1093/hmg/3.12.2131; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WAGATSUMA M, 1990, J VIROL, V64, P813, DOI 10.1128/JVI.64.2.813-821.1990; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; WANG L, 1998, IN PRESS ONCOGENE; WILKE CM, 1996, HUM MOL GENET, V5, P973; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zimonjic DB, 1997, CANCER RES, V57, P1166	65	64	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2311	2319		10.1038/sj.onc.1200202	http://dx.doi.org/10.1038/sj.onc.1200202			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620548				2022-12-28	WOS:000073428000003
J	Soucek, T; Holzl, G; Bernaschek, G; Hengstschlager, M				Soucek, T; Holzl, G; Bernaschek, G; Hengstschlager, M			A role of the tuberous sclerosis gene-2 product during neuronal differentiation	ONCOGENE			English	Article						neuronal differentiation; tuberin; tuberous sclerosis; TSC2	DOMINANTLY INHERITED CANCER; TUBEROUS-SCLEROSIS-2 TSC2 GENE; NEUROBLASTOMA CELL-LINES; EKER RAT MODEL; RETINOIC ACID; RENAL-CARCINOMA; DNA-SYNTHESIS; EXPRESSION; HETEROZYGOSITY; BLASTOMA	Tuberous sclerosis is an autosomal dominant disorder, Besides the development of benign growths (hamartomas) in different tissues, one hallmark of this disease is the presence of highly epileptogenic dysplastic lesions in the cerebral cortex (tubers) composed of abnormal shaped neurones. Patients often show evidence of severe mental retardation. Linkage analysis revealed two disease-determining genes on chromosome 9 and chromosome 16, The TSC2 gene on chromosome 16 encodes a 1784-amino acid putative tumour suppressor protein, tuberin, that functions as a GTPase-activating protein. Here me show that tuberin expression is upregulated upon induction of neuronal differentiation in the neuroblastoma cell lines SK-N-SH and LAN-1. This upregulation occurs at post-transcriptional level and is independent of the proliferation status. TSC2 expression is unaffected during differentiation of C2C12 myoblasts into myotubes and of F9 embryonal carcinoma cells into cells resembling parietal endoderm, Antisense inhibition of tuberin expression in SK-N-SH or LAN-1 cells inhibits neuronal differentiation, but does not affect the differentiation of F9 cells, Ectopic overexpression of TSC2 not only reverts the antisense-associated phenotype but furthermore accelerates the neuronal differentiation process. Our data show for the first time that tuberin plays a critical role in neuronal differentiation. Such role is consistent with the phenotype of tuberous sclerosis patients, who inherit one defective TSC2 allele, and frequently lose the remaining normal allele in many of the tubers/hamartomas which develop in the central nervous system of these patients.	Univ Vienna, Dept Prenatal Diag & Therapy, A-1090 Vienna, Austria	University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Dept Prenatal Diag & Therapy, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.							ABEMAYOR E, 1989, ENVIRON HEALTH PERSP, V80, P3, DOI 10.2307/3430727; Carbonara C, 1996, GENE CHROMOSOME CANC, V15, P18, DOI 10.1002/(SICI)1098-2264(199601)15:1<18::AID-GCC3>3.0.CO;2-7; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; DEHOOP MJ, 1994, NEURON, V13, P11, DOI 10.1016/0896-6273(94)90456-1; GEIST RT, 1995, CELL GROWTH DIFFER, V6, P1477; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Hengstschlager M, 1996, ONCOGENE, V12, P1635; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HUTTENLOCHER PR, 1991, ANN NY ACAD SCI, V615, P140; JANSSEN B, 1994, HUM GENET, V94, P437, DOI 10.1007/BF00201608; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kerfoot C, 1996, BRAIN PATHOL, V6, P367, DOI 10.1111/j.1750-3639.1996.tb00866.x; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; KUMAR A, 1995, HUM MOL GENET, V4, P1471, DOI 10.1093/hmg/4.8.1471; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Menchine M, 1996, MODERN PATHOL, V9, P1071; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NELLIST M, 1993, CELL, V75, P1305; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; Pusch O, 1997, DNA CELL BIOL, V16, P737, DOI 10.1089/dna.1997.16.737; SAMPSON JR, 1994, HUM MOL GENET, V3, P1477, DOI 10.1093/hmg/3.suppl_1.1477; SAMPSON JR, 1992, J MED GENET, V29, P861, DOI 10.1136/jmg.29.12.861; SCHLINGENSIEPEN KH, 1992, GENE REGULATION BIOL, P317; SEEGER RC, 1977, CANCER RES, V37, P1364; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; SOUCEK T, 1997, J BIOL CHEM, V272, P29031; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TAHIRA T, 1991, ONCOGENE, V6, P2333; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WALKER C, 1992, SCIENCE, V255, P1693, DOI 10.1126/science.1553556; WIEDERHOLT WC, 1985, NEUROLOGY, V35, P600, DOI 10.1212/WNL.35.4.600; Wienecke R, 1996, ONCOGENE, V13, P913; Wienecke R, 1997, AM J PATHOL, V150, P43; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; XIAO GH, 1995, ONCOGENE, V11, P81; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	47	59	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	1998	16	17					2197	2204		10.1038/sj.onc.1201743	http://dx.doi.org/10.1038/sj.onc.1201743			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619828				2022-12-28	WOS:000073298000004
J	Willems, L; Grimonpont, C; Kerkhofs, P; Capiau, C; Gheysen, D; Conrath, K; Roussef, R; Mamoun, R; Portetelle, D; Burny, A; Adam, E; Lefebvre, L; Twizere, JC; Heremans, H; Kettmann, R				Willems, L; Grimonpont, C; Kerkhofs, P; Capiau, C; Gheysen, D; Conrath, K; Roussef, R; Mamoun, R; Portetelle, D; Burny, A; Adam, E; Lefebvre, L; Twizere, JC; Heremans, H; Kettmann, R			Phosphorylation of bovine leukemia virus Tax protein is required for in vitro transformation but not for transactivation	ONCOGENE			English	Article						ras cooperation; B lymphocyte; sheep; HTLV	CASEIN KINASE-II; NF-KAPPA-B; HTLV-I; CELLULAR-TRANSFORMATION; VIRAL REPLICATION; BZIP PROTEINS; RAS ONCOGENE; BINDING; SITE; GENE	The Tax proteins of the oncovirinae viruses are phosphorylated transcriptional activators that exhibit oncogenic potential. The role of phosphorylation in their functional activities remains unknown. As a model for the Human T-cell leukemia virus type I (HTLV-I), Bovine Leukemia Virus (BLV) permits the characterization of viral replication and leukemogenesis in vitro. Here, we show that the BLV Tax protein is phosphorylated on serine residues 106 and 293 both in insect and in mammalian cells. These sites can also be efficiently phosphorylated by the cdc2 and MAP kinases in vitro. Mutation of these residues does not affect the capacity of the Tax protein to function as a transactivator. Indeed, the Tax proteins mutated at one or both serines increase LTR-directed viral transcription at levels similar to those obtained with wild-type Tax in cell culture, Moreover, inhibition of Tax phosphorylation by W7, a calmodulin antagonist, does not alter its transactivation activity. Thus, phosphorylation on serines 106 and 293 is not required for transactivation by Tax, However, simultaneous substitution of both serines into alanine residues destroys the capacity of Tax to cooperate with the Haras oncogene to transform primary rat embryo fibroblasts and induce tumors in nude mice, When the serines were replaced with aspartic acid residues, the oncogenic potential of Tax was maintained indicating that the negative charge rather than the phosphate group itself was required for Tax oncogenicity, Finally, to assess the role of the serine residues in vivo, recombinant viruses which express the Tax mutants were constructed and injected into sheep. It appeared that the mutated proviruses replicate at levels similar to the wild-type virus in vivo. We conclude that Tax phosphorylation is dispensable for transactivation and viral replication in vivo but is required for its oncogenic potential in vitro.	Fac Univ Sci Agron, Dept Mol Biol, B-5030 Gembloux, Belgium; Smithkline Beecham, B-1330 Rixensart, Belgium; Inst Natl Rech Vet, Dept Bovine Virol, B-1120 Ucclc, Belgium; Bulgarian Acad Sci, Inst Expt Pathol & Parasitol, Sofia, Bulgaria; Univ Bordeaux 2, INSERM, F-33076 Bordeaux, France; Katholieke Univ Leuven, Rega Inst, B-3000 Louvain, Belgium	University of Liege; GlaxoSmithKline; Bulgarian Academy of Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; KU Leuven	Willems, L (corresponding author), Fac Univ Sci Agron, Dept Mol Biol, B-5030 Gembloux, Belgium.		robert, mamoun/G-3242-2013; Twizere, Jean-Claude/AAG-3706-2019	TWIZERE, Jean-Claude/0000-0002-8683-705X; Willems, Luc/0000-0002-0563-2213				Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BOROS IM, 1995, VIROLOGY, V214, P207, DOI 10.1006/viro.1995.9939; CHEN G, 1989, VIROLOGY, V172, P343; Cockerell GL, 1996, BLOOD, V87, P1030, DOI 10.1182/blood.V87.3.1030.bloodjournal8731030; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; FONTES JD, 1993, J VIROL, V67, P4436, DOI 10.1128/JVI.67.7.4436-4441.1993; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREEN PL, 1995, J VIROL, V69, P387, DOI 10.1128/JVI.69.1.387-394.1995; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; Kettmann R., 1994, RETROVIRIDAE, V3, P39, DOI DOI 10.1007/978-1-4899-1730-0_2; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NYUNOYA H, 1988, VIROLOGY, V167, P538, DOI 10.1016/S0042-6822(88)90116-X; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PORTETELLE D, 1989, J VIROL METHODS, V23, P211, DOI 10.1016/0166-0934(89)90135-3; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; WILLEMS L, 1992, P NATL ACAD SCI USA, V89, P3957, DOI 10.1073/pnas.89.9.3957; WILLEMS L, 1993, J VIROL, V67, P4078, DOI 10.1128/JVI.67.7.4078-4085.1993; WILLEMS L, 1994, P NATL ACAD SCI USA, V91, P11532, DOI 10.1073/pnas.91.24.11532; WILLEMS L, 1990, EMBO J, V9, P1577, DOI 10.1002/j.1460-2075.1990.tb08277.x; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 1996, J ACQ IMMUN DEF SYND, V13, pS63, DOI 10.1097/00042560-199600001-00012; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	40	24	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2165	2176		10.1038/sj.onc.1201765	http://dx.doi.org/10.1038/sj.onc.1201765			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619825	Green Published			2022-12-28	WOS:000073298000001
J	Chen, Y; Martinez, LA; LaCava, M; Coghlan, L; Conti, CJ				Chen, Y; Martinez, LA; LaCava, M; Coghlan, L; Conti, CJ			Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1	ONCOGENE			English	Article						prostate cancer cell lines; androgen; cyclin D1; gene transfection; cell proliferation; tumorigenicity	TUMOR-SUPPRESSOR PROTEIN; E2F TRANSCRIPTION FACTOR; HUMAN ESOPHAGEAL CANCER; ANDROGEN RECEPTOR; DEPENDENT KINASES; CHROMOSOME 11Q13; GENE-EXPRESSION; BREAST-CANCER; NUDE-MICE; PROGRESSION	Deregulated expression of cyclin D1 has been found in several types of human tumors. In order to investigate factors involved in human prostate cancer progression, we studied the effects of cyclin D1 overexpression on human prostate cancer cell proliferation and tumorigenicity by transfecting LNCaP cells with a retroviral vector containing human cyclin D1 cDNA. When compared to the parental and control-vector transfected LNCaP cells, these cyclin D1-transfected cells had more cells in S-phase and lower growth factor requirements. Furthermore, these cells grew more in androgen-free medium. We also detected higher levels of Rb phosphorylation and E2F-1 protein levels in LNCaP/cyclin D1 cells than that in the parental and vector control cells in medium with or without androgen. Cyclin D1 transfected clones formed tumors more rapidly than control and parental cells. These tumors mere refractory to the androgen-ablation treatment by castration, whereas tumors from parental and vector-control LNCaP cells regressed within 4 weeks after castration. These results suggest that overexpression of cyclin D1 changes the growth properties, increases tumorigenicity and decreases the requirement for androgen stimulation in LNCaP cells both in vitro and in vivo.	Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Conti, CJ (corresponding author), Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA.							BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BREEN B, 1987, STEROID HORMONES PRA; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen Y, 1995, Urol Oncol, V1, P101, DOI 10.1016/1078-1439(95)00027-F; Chen Y, 1996, CELL GROWTH DIFFER, V7, P1571; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; FURUYA Y, 1995, ENDOCRINOLOGY, V136, P1898, DOI 10.1210/en.136.5.1898; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; ISAACS WB, 1994, COLD SPRING HARB SYM, V59, P653, DOI 10.1101/SQB.1994.059.01.075; ISRAELI RS, 1994, CANCER RES, V54, P1807; JANIK P, 1975, CANCER RES, V35, P3698; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KALLAKURY BVS, 1994, HUM PATHOL, V25, P92, DOI 10.1016/0046-8177(94)90177-5; KATO J, 1993, GENE DEV, V7, P331; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; LAMMIE GA, 1991, ONCOGENE, V6, P439; LIM DJ, 1993, PROSTATE, V22, P109, DOI 10.1002/pros.2990220203; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, ONCOGENE, V9, P2159; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; NEVINS JR, 1992, SCIENCE, V258, P424; OSWALD F, 1994, ONCOGENE, V9, P2029; PRETLOW TG, 1991, CANCER RES, V51, P3814; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1991, ONCOGENE, V6, P449; SCHULZE A, 1994, ONCOGENE, V9, P3475; SCHUURING E, 1992, ONCOGENE, V7, P355; SHAO ZH, 1995, ONCOGENE, V10, P221; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; TAM SW, 1994, ONCOGENE, V9, P2663; TILLEY WD, 1994, CANCER RES, V54, P4096; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VOELLER HJ, 1994, J UROLOGY, V151, P492; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350; ZHOU P, 1995, ONCOGENE, V11, P571	55	73	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	1998	16	15					1913	1920		10.1038/sj.onc.1201719	http://dx.doi.org/10.1038/sj.onc.1201719			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591774	Bronze			2022-12-28	WOS:000073079400002
J	Shanmugam, M; Krett, NL; Peters, CA; Maizels, ET; Murad, FM; Kawakatsu, H; Rosen, ST; Hunzicker-Dunn, M				Shanmugam, M; Krett, NL; Peters, CA; Maizels, ET; Murad, FM; Kawakatsu, H; Rosen, ST; Hunzicker-Dunn, M			Association of PKC delta and active Src in PMA-treated MCF-7 human breast cancer cells	ONCOGENE			English	Article						Src; protein kinase C; breast cancer	PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; HIGH-AFFINITY RECEPTOR; TYROSINE PHOSPHORYLATION; 3T3 CELLS; SIGNAL-TRANSDUCTION; PHORBOL ESTER; ACTIVATION; IDENTIFICATION; STIMULATION	Phorbol ester treatment of MCF-7 cells led to the tyrosine phosphorylation and activation of PKC delta, However, through Western blot analysis and in vitro immunecomplex kinase assays, me detected a differential localization of tyrosine-phosphorylated PKC delta and catalytically active PK delta. Catalytically active PKC delta was concentrated in Triton X-100 solubilized-membrane fractions while tyrosine-phosphorylated PKC delta was localized to the cytosol fraction, Phorbol ester treatment of MCF-7 cells stimulated both the time-dependent in ville association of Src with PKC delta, evidenced in Src immunoprecipitates by the co-immunoprecipitation of PKC delta, and activation of Src, evidenced in Src immunoprecipitates as an increase in reactivity with a Src antibody (clone 28) reactive only with active Src (dephosphorylated on residue 530) and in Src and PKC delta immunoprecipitates by an increase in Src kinase activity. While our data are consistent with reports in the literature showing the activator/stimulus-dependent tyrosine phosphorylation of PKC delta, our data show that the tyrosine phosphorylation of PKC delta is not essential for kinase activity, These results are the first to demonstrate an in vivo association between PKC delta and active Src in the absence of over-expression of either PKC delta or Src, and support the association of Src and PKC delta towards a physiological function.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94110 USA	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of California System; University of California San Francisco	Hunzicker-Dunn, M (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.		Shanmugam, Mala/M-6491-2019	Shanmugam, Mala/0000-0002-4415-8083; Maizels, Evelyn/0000-0001-9072-1095	NCI NIH HHS [P30 CA60553] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CUTLER RE, 1993, BIOCHIM BIOPHYS ACTA, V1179, P260, DOI 10.1016/0167-4889(93)90081-Y; DARBON JM, 1986, BIOCHEM PHARMACOL, V35, P2683, DOI 10.1016/0006-2952(86)90175-9; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DeVente JE, 1996, J BIOL CHEM, V271, P32276, DOI 10.1074/jbc.271.50.32276; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FAUCHER C, 1993, J BIOL CHEM, V268, P15168; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; ISSANDOU M, 1988, CANCER RES, V48, P6943; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; Kosaka C, 1996, AM J PHYSIOL-CELL PH, V270, pC170, DOI 10.1152/ajpcell.1996.270.1.C170; LEHEL C, 1994, J BIOL CHEM, V269, P4761; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISHIMA K, 1994, BIOCHEM BIOPH RES CO, V201, P363, DOI 10.1006/bbrc.1994.1710; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; OHMICHI M, 1993, BIOCHEM J, V295, P767, DOI 10.1042/bj2950767; OHNO S, 1994, J BIOL CHEM, V269, P17495; Owen PJ, 1996, EXP CELL RES, V225, P366, DOI 10.1006/excr.1996.0187; REDMOND T, 1992, CELL GROWTH DIFFER, V3, P567; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; ROOS W, 1986, P NATL ACAD SCI USA, V83, P991, DOI 10.1073/pnas.83.4.991; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; WALKER F, 1993, J BIOL CHEM, V268, P19552; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	40	54	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1649	1654		10.1038/sj.onc.1201684	http://dx.doi.org/10.1038/sj.onc.1201684			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582012				2022-12-28	WOS:000072807600002
J	Luo, WP; Earley, K; Tantingco, V; Hixson, DC; Liang, TC; Lin, SH				Luo, WP; Earley, K; Tantingco, V; Hixson, DC; Liang, TC; Lin, SH			Association of an 80 kDa protein with C-CAM1 cytoplasmic domain correlates with C-CAM1-mediated growth inhibition	ONCOGENE			English	Article						cell adhesion molecule; tumor suppressor; cross linker; associated protein	CELL-ADHESION MOLECULE; RECEPTOR TYROSINE KINASE; C-CAM; ECTO-ATPASE; HEPATOCELLULAR CARCINOMAS; ENDOGENOUS SUBSTRATE; BILIARY GLYCOPROTEIN; IMMUNOGLOBULIN; EXPRESSION; ISOFORMS	Decreased expression of C-CAM, a member of the CEA family of immunoglobulin like cell adhesion molecules, occurs in carcinomas of the colon, liver and prostate. Down regulation of C-CAM during the early stages of carcinogenesis in rat liver and human prostate has also been reported, We have recently shown that restoration of the expression of the isoform with long cytoplasmic domain, C-CAM1, leads to suppression of the tumorigenicity of prostatic carcinoma cells in vivo and growth suppression in vitro. These observations suggest that C-CAM1 may play an important role in regulating cell growth in normal tissues, Previous studies have demonstrated that the function of many members of the Ig-supergene family is dependent on interactions with cytoplasmic proteins, Tn the present study, we have used a bifunctional cross-linker to identify cellular proteins that interact directly with C-CAM1, Immunoblot analysis of WGA bound membrane proteins crosslinked with DSS identified a 180 kDa complex composed of C-CAM1 and an 80 kDa protein designated CAP-80 (C-CAM Associated Protein), Immunoprecipitation with anti-C-CAM antibodies showed that CAP-80 was co-precipitated with C-CAM from detergent solubilized, WGA-purified proteins, To assess the specificity of CAP-80 binding, the ability of CAP-80 to form stable complexes with C-CAM1 mutants expressed in insect cells was tested, Deletion of the cytoplasmic domain of C-CAM1 abolished complex formation whereas deletion of the extracellular Ig domains had no effect, These results suggest that a CAP-80 homologue (ICAP-80) is present in insect cells and ICAP-80 interacts with the cytoplasmic domain of C-CAM1. Replacement of Tyr488, a residue in the cytoplasmic domain known to be phosphorylated in vivo, with Phe did not diminish the association between C-CAM1 and ICAP-80, suggesting that Tyr488 phosphorylation is not required for association, The ability of various C-CAM1 mutants to associate with ICAP-80 correlated with their growth inhibitory activities, suggesting that ICAP-80/CAP-80 may play an important role in C-CAM1-mediated growth inhibition.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Brown Univ, Rhode Isl Hosp, Dept Med Oncol, Providence, RI 02903 USA; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Texas System	Lin, SH (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.							AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; CAMBIER JC, 1992, FASEB J, V6, P3207, DOI 10.1096/fasebj.6.13.1397843; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; EDLUND M, 1993, FEBS LETT, V327, P90, DOI 10.1016/0014-5793(93)81046-3; HIXSON DC, 1989, CANCER RES, V49, P6788; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; LIM Y P, 1990, Journal of Cell Biology, V111, p355A; LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; OLSSON H, 1995, FEBS LETT, V365, P51, DOI 10.1016/0014-5793(95)00436-D; ROSENBERG M, 1993, CANCER RES, V53, P4938; SALAMOV AA, 1995, J MOL BIOL, V247, P11, DOI 10.1006/jmbi.1994.0116	22	15	15	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1141	1147		10.1038/sj.onc.1201619	http://dx.doi.org/10.1038/sj.onc.1201619			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528856				2022-12-28	WOS:000072336000005
J	Fujita, N; Nagahashi, A; Nagashima, K; Rokudai, S; Tsuruo, T				Fujita, N; Nagahashi, A; Nagashima, K; Rokudai, S; Tsuruo, T			Acceleration of apoptotic cell death after the cleavage of Bcl-X-L protein by caspase-3-like proteases	ONCOGENE			English	Article						Bcl-X-L; apoptosis; IL-2; caspase-3	CYTOCHROME-C; ICE/CED-3 PROTEASE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; PROTOONCOGENE BCL-2; MAMMALIAN HOMOLOG; FAMILY PROTEASES; GENE CED-3; ELEGANS; BCL-X(L)	Interleukin-2 (IL-2)-dependent T cell clone CTLL-2 underwent apoptosis by deprivation of IL-2 from culture medium. The decrease in the anti-apoptotic Bcl-X-L protein level was observed during apoptosis after IL-2 withdrawal, We found that Bcl-X-L protein was cleaved to produce two 18 kDa fragments during CTLL-2 cell apoptosis. When the activation of caspases was suppressed by overexpressing human Bcl-2 protein or by the addition of caspase inhibitors, cleavage of Bcl-X-L protein was suppressed in vivo. Bcl-X-L protein cleavage by incubation with apoptosed CTLL-2 cell lysate was suppressed by the caspase-3/CPP32-specific tetrapeptide inhibitor in vitro. Therefore, caspase-3/CPP32-like proteases were activated and involved in the cleavage of Bcl-X-L protein during CTLL-2 cell apoptosis. We found that Bcl-X-L protein was cleaved by caspase-3/CPP32 at two sites in the loop domain (i.e., HLAD(61 down arrow)S and SSLD(76 down arrow)A), The transfection of the carboxy-terminal 18 kDa Bcl-X-L fragment increased the sensitivity to apoptosis. These results indicate that caspase-3/CPP32-like proteases cleaved anti-apoptotic Bcl-X-L protein and resulted in accelerated apoptotic cell death.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Fujita, Naoya/A-7349-2010; Rokudai, Susumu/O-6771-2018	Fujita, Naoya/0000-0002-9631-9264; Rokudai, Susumu/0000-0003-0300-0391				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boulakia CA, 1996, ONCOGENE, V12, P529; BROOME HE, 1995, J IMMUNOL, V155, P2311; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FADOK VA, 1992, J IMMUNOL, V148, P2207; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Frankel A, 1997, CANCER RES, V57, P2388; FUJITA N, 1993, CANCER RES, V53, P5022; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu CKA, 1997, EXP CELL RES, V232, P17, DOI 10.1006/excr.1997.3509; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee SH, 1996, ONCOGENE, V13, P2131; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Naito M, 1997, CELL DEATH DIFFER, V4, P617, DOI 10.1038/sj.cdd.4400287; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Noguchi K, 1996, ONCOGENE, V13, P39; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Shimizu S, 1996, ONCOGENE, V12, P2251; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	54	140	143	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1295	1304		10.1038/sj.onc.1202065	http://dx.doi.org/10.1038/sj.onc.1202065			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771973				2022-12-28	WOS:000075803300012
J	Maouche-Chretien, L; Deleu, N; Badoual, C; Fraissignes, P; Berger, R; Gaulard, P; Romeo, PH; Leroy-Viard, K				Maouche-Chretien, L; Deleu, N; Badoual, C; Fraissignes, P; Berger, R; Gaulard, P; Romeo, PH; Leroy-Viard, K			Identification of a novel cDNA, encoding a cytoskeletal associated protein, differentially expressed in diffuse large B cell lymphomas	ONCOGENE			English	Article						lymphoma; cytoskeleton; cloning; DDRT	NON-HODGKINS-LYMPHOMA; GERMINAL CENTER FORMATION; MESSENGER-RNA; CHROMOSOMAL-ABNORMALITIES; CLINICAL CORRELATIONS; CYTOGENETIC ANALYSIS; KIEL CLASSIFICATION; ACTIN CYTOSKELETON; BTB/POZ DOMAIN; CROSS-LINKING	Diffuse large B-cell lymphomas (DLBL) constitute an heterogeneous clinico-pathological entity. To characterize molecular events related to histological subtypes, clinical presentation or outcome, we compared the mRNAs expressed in a limited series of DLBL by Differential display-reverse transcription (DDRT) and cloned a differential cDNA, that we called LB1, LB1 open reading frame encodes a 683 amino-acid polypeptide that does not show significant homology upon comparison to protein databases, nor any structural domain relating LB1 to an already known protein family, Immunofluorescence analysis of transfected COS cells showed a cytoplasmic filamentous staining, indicating that LB1 protein is tightly associated with cytoskeletal fibers, Two LB1 transcripts, a major 3,6 - 3.9 Kb and a minor 2.2 Kb transcripts, were detected among human haematopoietic and non-haematopoietic lines and tissues, LB1 transcripts were abundant in testis, thymus and in tumour derived cell lines, while barely detectable in liver, prostate and kidney, Concerning DLBL, LB1 expression was high in two cases of DLBL, and low or undetectable in four others, confirming the differential expression previously observed in the DDRT experiment. Furthermore, LB1 gene mapped to chromosome 13q14, a region that has been involved as a chromosomal breakpoint in DLBL, The cellular function of LB1 and its relationship with B cell maturation and/or oncogenesis remain to be established.	Hop Henri Mondor, INSERM, U474, F-94010 Creteil, France; Hop St Louis, Ctr G Hayem, INSERM, U301, F-75475 Paris, France; Hop Henri Mondor, Dept Pathol, F-94010 Creteil, France; Hop Henri Mondor, EA 2348, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Leroy-Viard, K (corresponding author), Hop Henri Mondor, INSERM, U474, 51 Av Mal De Lattre De Tassigny, F-94010 Creteil, France.		Romeo, Paul-Henri/L-5989-2017; maouche, leila/E-3887-2017; Leroy, Karen/E-9235-2011	Romeo, Paul-Henri/0000-0002-8294-0367; Leroy, Karen/0000-0002-4379-0140; CHRETIEN, LEILA/0000-0001-5747-9719; Badoual, Cecile/0000-0002-1143-3085				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; BASTARD C, 1994, BLOOD, V83, P2423; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Engelhard M, 1997, BLOOD, V89, P2291; Foisner R, 1996, MOL BIOL CELL, V7, P273, DOI 10.1091/mbc.7.2.273; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Gomez J, 1997, J IMMUNOL, V158, P1516; HAILAT N, 1990, ONCOGENE, V5, P1615; HARRIS NL, 1994, BLOOD, V84, P1361; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; JACOBSON JO, 1993, CANCER, V72, P231, DOI 10.1002/1097-0142(19930701)72:1<231::AID-CNCR2820720141>3.0.CO;2-5; Jugloff LS, 1997, J IMMUNOL, V159, P1096; JUNEJA S, 1990, BRIT J HAEMATOL, V76, P231, DOI 10.1111/j.1365-2141.1990.tb07877.x; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOCIALKOWSKI S, 1995, BRIT J HAEMATOL, V89, P55, DOI 10.1111/j.1365-2141.1995.tb08911.x; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LADANYI M, 1991, BLOOD, V77, P1057; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LO CF, 1994, BLOOD, V83, P1757; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; OFFIT K, 1991, BLOOD, V77, P1508; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; SCHOUTEN HC, 1990, BLOOD, V75, P1841; STANSFELD AG, 1988, LANCET, V1, P292; STAUDER R, 1995, BLOOD, V85, P2885, DOI 10.1182/blood.V85.10.2885.bloodjournal85102885; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VILLUENDAS R, 1993, BLOOD, V82, P3151; WHANGPENG J, 1995, BLOOD, V85, P203, DOI 10.1182/blood.V85.1.203.bloodjournal851203; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	42	34	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1245	1251		10.1038/sj.onc.1202048	http://dx.doi.org/10.1038/sj.onc.1202048			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771967				2022-12-28	WOS:000075803300006
J	Bai, RY; Jahn, T; Schrem, S; Munzert, G; Weidner, KM; Wang, JYJ; Duyster, J				Bai, RY; Jahn, T; Schrem, S; Munzert, G; Weidner, KM; Wang, JYJ; Duyster, J			The SH2-containing adapter protein GRB10 interacts with BCR-ABL	ONCOGENE			English	Article						SH2; CML; Grb10; Bcr-Abl; yeast two-hybrid; tyrosine kinase; signal transduction	ACUTE LYMPHOBLASTIC-LEUKEMIA; RECEPTOR TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; SH2 DOMAIN; C-ABL; HEMATOPOIETIC-CELLS; INSULIN-RECEPTOR; BINDING ACTIVITY; TRANSFORMATION; ONCOGENE	Bcr-Abl is an oncogenic tyrosine kinase expressed in tumor cells of CML and a subset of ALL which in its unregulated and activated state is thought to cause cell transformation and leukemia. Bcr-Abl contains several autophosphorylation sites which serve as potential docking sites for SH2-containing signaling molecules; Mutational analysis has indicated that these autophosphorylation sites play a critical role in the transforming capability of Bcr-Abl, It has been shown that the SH2-containing adapter protein Grb(2) binds to the autophosphorylation site Tyr(p)177 whereby it couples Bcr-Abl to the Ras pathway. The biological consequences of this interaction, however, are presently unclear, A Tyr177-mutated Bcr-Abl which lacks the ability to interact with the Grb2-SH2 domain still transforms myeloid cells and generates tumors in nude mice. We performed a yeast two-hybrid screen to identify signaling proteins which bind to distinct Bcr-Abl autophosphorylation sites. Autophosphorylation of Bcr-Abl in yeast was accomplished by using the DNA binding protein LexA which permits dimerization and crossphosphorylation of the fused bait. Using a LexA-Bcr-Abl full length fusion protein as bait, we identified several SH2-containing proteins. Among them we confirmed molecules already shown by others to interact with Bcr-Abl, irt vivo, including Grb2, PI-3-kinase and Crk indicating that dimerization in yeast leads to autophosphorylation of tyrosine residues crucial for Bcr-Abl signaling in vivo. More importantly, we identified the SH2-containing protein Grb10 as a new binding partner for Bcr-Abl. This binding occurs in a phosphotyrosine-dependent manner at Bcr sites of Bcr-Abl. Both Abl and Bcr alone, as well as a kinase-defective Bcr-Abl, failed to interact with Grb10 in yeast. Mutational analysis uncovered a new SH2 binding site in Bcr-Abl located between Bcr aa242-446, which is different from the Grb2 binding site. Binding could be demonstrated in vitro and also in vivo as shown by co-immunoprecipitation analysis in CML cells. Using a temperature sensitive Bcr-Abl stably overexpressed in hematopoetic cells, we demonstrated that complex formation of Grb10 with Bcr-Abl was kinase activation-dependent in vivo. Notably, a Bcr-Abl mutant protein (Bcr/1-242-Abl) which lacks the ability to interact with Grb10 partially alleviated IL-3 dependence of Ba/F3 cells, indicating that the Grb10/Bcr-Abl interaction is important for Bcr-Abl-induced IL-3 independence of Ba/F3 cells. In addition, the Bcr/1-242-Abl mutant has a reduced capacity to induce focus formation in fibroblasts.	Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-81675 Munich, Germany; Univ Ulm, Dept Hematol & Oncol, D-89069 Ulm, Germany; Boehringer Mannheim GmbH, Dept Therapeut Biotechnol, D-8122 Penzberg, Germany; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	Technical University of Munich; University of Munich; Ulm University; University of California System; University of California San Diego; University of California System; University of California San Diego	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, Ismaningerstr 22, D-81675 Munich, Germany.			schrem, stanley/0000-0003-2909-0794	NATIONAL CANCER INSTITUTE [R01CA043054, R37CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA043054, R01 CA043054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SM, 1996, BLOOD, V87, P238; Bedi Atul, 1995, Blood, V86, P1148; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOTOH A, 1995, EXP HEMATOL, V23, P1153; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUTO TG, 1990, SCIENCE, V247, P1079; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	48	47	48	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	1998	17	8					941	948		10.1038/sj.onc.1202024	http://dx.doi.org/10.1038/sj.onc.1202024			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747873				2022-12-28	WOS:000075560900002
J	Paramio, JM; Lain, S; Segrelles, C; Lane, EB; Jorcano, JL				Paramio, JM; Lain, S; Segrelles, C; Lane, EB; Jorcano, JL			Differential expression and functionally co-operative roles for the retinoblastoma family of proteins in epidermal differentiation	ONCOGENE			English	Article						cell cycle; epidermal differentiation; retinoblastoma family	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE CONTROL; HUMAN KERATINOCYTES; TRANSGENIC MICE; GROWTH SUPPRESSION; MUSCLE-CELLS; P107; E2F; RB	Terminal differentiation requires cell cycle withdrawal, suggesting the involvement of negative cell cycle controllers in the process, We have analysed the involvement of the retinoblastoma family of proteins (pRb, p107 and p130) in epidermal proliferation and differentiation. These proteins play key roles as inhibitors of cell cycle progression and are involved in muscle and neuron differentiation, We found that during in vitro differentiation of human HaCaT keratinocytes, pRb, p107 and p130 are sequentially expressed, in contrast to the co-expression observed during cell cycle progression in the same cells. Immunofluorescence studies on skin sections revealed the presence of pRb and p107 in basal and suprabasal cell layers, whilst p130 is restricted to cells already committed to differentiation in the suprabasal compartments, To explore the functional significance of the differential expression of these proteins, transfection experiments mere performed in HaCaT keratinocytes. We observed that the forced over-expression of pRb, p107 or p130 individually did not induce differentiation of the transfected cells, However, the co-transfection of pRb and p107 induced the expression of early differentiation markers (keratin k10) and triple transfectants pRb + p107 + p130 expressed markers representative of later stages of epidermal differentiation (involucrin). Finally, we observed that these three proteins repress keratinocyte proliferation, although to a different extent (p107 > pRb greater than or equal to p130). These results indicate that the members of the pRb family play specific, yet coordinated roles during epidermal differentiation, and that the ordered progression along the different stages of this process results from the effects of different combinations of these proteins.	CIEMAT, Cell & Mol Biol Program, E-28040 Madrid, Spain; Univ Dundee, Inst Med Sci, Dept Anat & Physiol, CRC,Cell Struct Grp, Dundee DD1 4HN, Scotland	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; University of Dundee	Paramio, JM (corresponding author), CIEMAT, Cell & Mol Biol Program, E-28040 Madrid, Spain.		Lain, Sonia/B-6980-2014; Paramio, Jesus M/M-8482-2014; Segrelles, Carmen/E-3655-2016	Lain, Sonia/0000-0001-9693-5246; Paramio, Jesus M/0000-0001-7520-3177; Segrelles, Carmen/0000-0001-9340-2102; Lane, Birgit/0000-0003-1457-2934				ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BANKSSCHLEGEL SP, 1983, J CELL BIOL, V96, P330, DOI 10.1083/jcb.96.2.330; BARRANDON Y, 1989, P NATL ACAD SCI USA, V86, P4102, DOI 10.1073/pnas.86.11.4102; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CORBEIL HB, 1995, ONCOGENE, V11, P909; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEE WH, 1994, COLD SPRING HARB SYM, V59, P97, DOI 10.1101/SQB.1994.059.01.013; Leigh I., 1994, KERATINOCYTE HDB; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MISSERO C, 1993, J CELL BIOL, V121, P1109, DOI 10.1083/jcb.121.5.1109; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; NEVINS JR, 1992, SCIENCE, V258, P424; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; PARAMIO JM, 1994, EXP CELL RES, V215, P319, DOI 10.1006/excr.1994.1348; Paramio JM, 1997, BRIT J DERMATOL, V137, P44, DOI 10.1111/j.1365-2133.1997.tb03699.x; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Richon VM, 1996, CELL GROWTH DIFFER, V7, P31; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	48	63	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	1998	17	8					949	957		10.1038/sj.onc.1202031	http://dx.doi.org/10.1038/sj.onc.1202031			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747874				2022-12-28	WOS:000075560900003
J	Lloyd, BH; Platt-Higgins, A; Rudland, PS; Barraclough, R				Lloyd, BH; Platt-Higgins, A; Rudland, PS; Barraclough, R			Human S100A4(p9Ka) induces the metastatic phenotype upon benign tumour cells	ONCOGENE			English	Article						breast cancer; calcium-binding protein; metastasis; p9Ka; S100A4	CALCIUM-BINDING PROTEIN; HUMAN BREAST-CANCER; RAT MAMMARY-GLAND; MESSENGER-RNA; MYOEPITHELIAL CELLS; MOLECULAR-CLONING; NONMUSCLE MYOSIN; GENE; P9KA; TRANSFECTION	The rodent S100-related calcium-binding protein, S100A4 induces metastasis in non-metastatic rat and mouse benign mammary cells and co-operates with benign-tumour-inducing changes in two transgenic mouse models, to yield metastatic mammary tumours, Cotransfection of the human gene for S100A4 with pSV2neo into the benign rat mammary cell line, Rama 37, yielded cells which expressed a low level of the endogenous S100A4 mRNA, and either high or undetectable levels of human S100A4 mRNA. The cells which expressed a high level of human S100A4 mRNA induced metastasis in the benign rat mammary cell line Rama 37 in an in vivo assay, whereas the cells which expressed an undetectable level of human S100A4 did not induce any detectable metastases. The primary tumours arising from the S100A4-expressing cells contained high levels of immunocytochemically-detected S100A4 and this high level of S100A4 and the metastatic potential were maintained when cells from a metastasis were re-injected into syngeneic rats, The results show that the human S100A4 possesses metastasis-inducing capabilities.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7BZ, Merseyside, England	University of Liverpool	Barraclough, R (corresponding author), Univ Liverpool, Sch Biol Sci, POB 147, Liverpool L69 7BZ, Merseyside, England.		Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194				Ambartsumian NS, 1996, ONCOGENE, V13, P1621; BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1984, BIOCHEM BIOPH RES CO, V120, P351, DOI 10.1016/0006-291X(84)91261-0; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V21, P8097; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES BR, 1993, ONCOGENE, V8, P999; DAVIES BR, 1994, CANCER RES, V54, P2785; Davies MPA, 1996, ONCOGENE, V13, P1631; DAVIES MPA, 1993, THESIS U LIVERPOOL; DEVILEE P, 1991, CANCER RES, V51, P1020; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; DUNNINGTON DJ, 1984, J NATL CANCER I, V72, P455; DUNNINGTON DJ, 1984, THESIS U LONDON; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ENGELKAMP D, 1992, BIOCHEMISTRY-US, V31, P10258, DOI 10.1021/bi00157a012; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Flynn AM, 1996, BIOCHEM SOC T, V24, pS341, DOI 10.1042/bst024341s; FORD HL, 1995, ONCOGENE, V10, P1597; GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309; GIBBS FEM, 1995, J HISTOCHEM CYTOCHEM, V43, P169, DOI 10.1177/43.2.7822773; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; JAMIESON S, 1990, INT J CANCER, V46, P1071, DOI 10.1002/ijc.2910460621; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; JAMIESON S, 1987, THESIS U LONDON; KAMBY C, 1990, CANCER TREAT REV, V17, P37, DOI 10.1016/0305-7372(90)90075-Q; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MERLO GR, 1989, CANCER RES, V49, P6966; MICALE MA, 1994, HUM PATHOL, V25, P29, DOI 10.1016/0046-8177(94)90167-8; NEWMAN RA, 1979, J NATL CANCER I, V63, P1339; PANDIS N, 1992, GENE CHROMOSOME CANC, V5, P235, DOI 10.1002/gcc.2870050310; RAMAEKERS FCS, 1983, P NATL ACAD SCI-BIOL, V80, P2618, DOI 10.1073/pnas.80.9.2618; RUDLAND PS, 1993, HISTOL HISTOPATHOL, V8, P385; Sambrook J., 2002, MOL CLONING LAB MANU; SLOANE J, 1981, CANCER, V41, P1786; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, TRANSCRIPTION TRANSL, P1; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; WARBURTON MJ, 1982, J HISTOCHEM CYTOCHEM, V30, P667, DOI 10.1177/30.7.6179984; WARBURTON MJ, 1989, HISTOCHEM J, V21, P679, DOI 10.1007/BF01002489; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	51	104	109	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					465	473		10.1038/sj.onc.1201948	http://dx.doi.org/10.1038/sj.onc.1201948			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696040				2022-12-28	WOS:000075043000009
J	Chen, YR; Tan, TH				Chen, YR; Tan, TH			Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin	ONCOGENE			English	Article						curcumin; JNK; c-Jun; AP-1; NF-kappa B; cell signaling	ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; KAPPA-B-ALPHA; TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTORS; COLON CARCINOGENESIS; DIETARY CURCUMIN; GAMMA-RADIATION; TUMOR PROMOTION; STRESS	Curcumin, a dietary pigment in curry, suppresses tumor initiation and tumor promotion. Curcumin is also a potent inhibitor for AP-1 and NF-kappa B activation. In this report, we show that curcumin inhibits JNK activation by various agonists including PMA plus ionomycin, anisomycin, UV-C, gamma radiation, TNF-alpha, and sodium orthovanadate. Although both JNK and ERK activation by phorbol 12-myristate 13-acetate (PMA) plus ionomycin were suppressed by curcumin, the JNK pathway was more sensitive. The IC50 (50% inhibition concentration) of curcumin was between 5-10 mu M for JNK activation and was 20 mu M for ERK activation. Tn transfection assays, curcumin moderately suppressed MEKK1-induced JNK activation; however, it effectively blocked JNK activation caused by co-transfection of TAK1, CCK, or HPK1. Curcumin did not directly inhibit JNK, SEK1, MEKK1 or HPK1 activity. Although cnrcumin suppressed TAK1 and GCK activities at high concentrations, this inhibition cannot fully account for the JNK inhibition by curcumin in vivo. Our data suggest that curcumin may affect the JNK pathway by interfering with the signaling molecule(s) at the same level or proximally upstream of the MAPKKK level. Taken together, the inhibition of the MEKK1-JNK pathway reveals a possible mechanism of suppression of AP-1 and NF-kappa B signaling by curcumin, and may explain the potent anti-inflammatory and anti-carcinogenic effects of this chemical.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	Baylor College of Medicine	Tan, TH (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA.		Tan, Tse-Hua/E-3983-2010; Chen, Yi-Rong/E-3991-2010; Chen, Yi-Rong/CAF-2186-2022; Chen, Yi-Rong/CAH-7991-2022; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170	NIAID NIH HHS [R01-AI38649] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; HUANG MT, 1994, CANCER RES, V54, P5841; HUANG MT, 1988, CANCER RES, V48, P5941; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KELLY K, 1995, CURR OPIN IMMUNOL, V7, P327, DOI 10.1016/0952-7915(95)80106-5; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RAO CV, 1995, CANCER RES, V55, P259; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378	52	352	366	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	1998	17	2					173	178		10.1038/sj.onc.1201941	http://dx.doi.org/10.1038/sj.onc.1201941			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674701				2022-12-28	WOS:000074706700005
J	Cmarik, JL; Li, Y; Ogram, SA; Min, HZ; Reeves, R; Colburn, NH				Cmarik, JL; Li, Y; Ogram, SA; Min, HZ; Reeves, R; Colburn, NH			Tumor promoter induces high mobility group HMG-Y protein expression in transformation-sensitive but not -resistant cells	ONCOGENE			English	Article						HMG-I(Y); tumor promotion; gene expression; neoplastic transformation; 12-O-tetradecanoylphorbol acetate	MOUSE EPIDERMAL-CELLS; JB6 CELLS; GENE-EXPRESSION; NEOPLASTIC TRANSFORMATION; NUCLEAR PROTEINS; THYROID-CELLS; E-SELECTIN; C PROTEIN; BETA GENE; HMG-I(Y)	Elevated levels of high mobility group (HMG) nonhistone chromosomal proteins I and Y, alternatively spliced members of the HMG-I(Y) family of architectural transcription factors? have been linked with human cancer and with neo-plastic and metastatic phenotypes in model systems, To investigate whether HMG-I(Y) proteins may influence susceptibility to neoplastic transformation, HMG-I(Y) mRNA and protein levels mere compared in the JB6 murine model of neoplastic progression, HMG-I(Y) mRNAs were expressed at very low levels in preneoplastic, transformation-resistant (P-) cell lines and were constitutively expressed at much higher levels in both transformation-sensitive (P+) and transformed (Tx) tumorigenic cell lines. HMG-I(Y) mRNAs mere induced to higher levels by the tumor promoter 12-O-tetradecanoylphorbol acetate (TPA) and were sustained longer in P+ than in P- cells. Nevertheless, in both P- and P+ cells, primer extension analysis revealed that the same four major HMG-I(Y) gene transcription start sites were utilized with or without TPA treatment. RT-PCR revealed that there nas always slightly more Y than I form mRNA present in all of the variant JB6 cell lines. Immunoblotting indicated that both HMG-I and -Y proteins increased in P+ cells in response to TPA treatment. Remarkably, in P- cells treated with TPA, only HMG-I (and not HMG-Y) protein levels increased. This unique differential TPA-induction of the HMG-Y protein in JB6 variants suggests a role for HMG-Y in mediating tumor promoter-induced neoplastic transformation, Furthermore, these results demonstrate that HMG-I and Y protein translation and/or stability is differently regulated in JB6 P- cells and provide the first indication that I and Y proteins may have different functions.	NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Sci Applicat Int Corp, Frederick, MD 21702 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA; Washington State Univ, Dept Genet & Cell Biol, Pullman, WA 99164 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Washington State University; Washington State University	Cmarik, JL (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21702 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046352] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM46352] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; BENARI ET, 1992, MOL CARCINOGEN, V5, P62, DOI 10.1002/mc.2940050111; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; CMARIK JL, 1994, MOL CARCINOGEN, V11, P115, DOI 10.1002/mc.2940110209; COLBURN N H, 1980, Teratogenesis Carcinogenesis and Mutagenesis, V1, P87; COLBURN NH, 1978, CANCER RES, V38, P624; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; DONG Z, 1997, IN PRESS MOL CARCINO; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; Fedele M, 1996, CANCER RES, V56, P1896; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GIANCOTTI V, 1991, EUR J BIOCHEM, V198, P211, DOI 10.1111/j.1432-1033.1991.tb16003.x; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GOODWIN GH, 1985, EUR J BIOCHEM, V149, P47, DOI 10.1111/j.1432-1033.1985.tb08891.x; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; HIRANO K, 1992, ONCOL RES, V4, P17; Holth LT, 1997, DNA CELL BIOL, V16, P1299, DOI 10.1089/dna.1997.16.1299; Huang ZQ, 1996, BIOTECHNIQUES, V20, P1012; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1990, EXP CELL RES, V187, P69, DOI 10.1016/0014-4827(90)90118-T; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KIM J, 1995, EUR J IMMUNOL, V25, P798, DOI 10.1002/eji.1830250326; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LI J, 1997, IN PRESS CANC RES; Li JJ, 1996, CANCER RES, V56, P483; MARGIS W, 1995, BIOCHEM BIOPH RES CO, V214, P927; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; OGRAM SA, 1995, J BIOL CHEM, V270, P14235, DOI 10.1074/jbc.270.23.14235; RAM TG, 1993, CANCER RES, V53, P2655; SKALNIK DG, 1992, BIOCHEM BIOPH RES CO, V187, P563, DOI 10.1016/0006-291X(92)91231-E; SUN Y, 1994, CANCER RES, V54, P1139; TAMIMI Y, 1993, CANCER RES, V53, P5512; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; Williams AJ, 1997, AM J PATHOL, V150, P911; Wunderlich V, 1997, J CANCER RES CLIN, V123, P133, DOI 10.1007/BF01214665; Xiao S, 1997, AM J PATHOL, V150, P901; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	53	29	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3387	3396		10.1038/sj.onc.1201888	http://dx.doi.org/10.1038/sj.onc.1201888			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692546				2022-12-28	WOS:000074544100005
J	Dejardin, E; Deregowski, V; Greimers, R; Cai, ZZ; Chouaib, S; Merville, MP; Bours, V				Dejardin, E; Deregowski, V; Greimers, R; Cai, ZZ; Chouaib, S; Merville, MP; Bours, V			Regulation of major histocompatibility complex class I expression by NF-kappa B-related proteins in breast cancer cells	ONCOGENE			English	Article						MHC class I; NF-kappa B, breast cancer	MHC CLASS-I; EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTION FACTORS; GENE-EXPRESSION; DOWN-REGULATION; ONCOPROTEIN BCL-3; ALPHA PROTEOLYSIS; FACTOR BINDING; REL ONCOGENE; TAX-PROTEIN	Downregulation of MHC Class I antigens has been observed in many cancers and usually results from a decreased gene transcription. A reporter CAT gene dependent on the MHC Class I kappa B site or on a longer promoter is transactivated by NF-kappa B complexes containing p65 or RelB. p100 as well as I kappa B-alpha are potent inhibitors of this transcription and p100 sequesters RelB and p65 complexes in the cytoplasm of breast cancer cells. However, although p100 is highly expressed in a number of breast cancer cell lines, MHC Class I antigen expression was observed on all the cell lines we analysed and could be further induced by stimulation with the cytokines IFN-gamma or TNF-alpha. Stable transfection of a unresponsive mutated I kappa B-alpha Ser 32-36 expression vector showed that TNF-alpha induced MHC Cl I expression in an NF-kappa B-dependent way while IFN-gamma did it independently of any NF-kappa B activation.	Univ Liege, Lab Med Chem Med Oncol, B-4000 Liege, Belgium; Univ Liege, Pathol Lab, B-4000 Liege, Belgium; Inst Gustave Roussy, INSERM, CJF Cytokines & Immun Antitumorale 9411, F-94805 Villejuif, France	University of Liege; University of Liege; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Bours, V (corresponding author), Univ Liege, Lab Med Chem Med Oncol, B-4000 Liege, Belgium.		Dejardin, Emmanuel/AAE-9076-2021; Chouaib, Salem/F-7939-2016					ACCOLLA RS, 1995, IMMUNOL TODAY, V16, P8, DOI 10.1016/0167-5699(95)80063-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BLANCHET O, 1992, P NATL ACAD SCI USA, V89, P3488, DOI 10.1073/pnas.89.8.3488; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CORDONCARDO C, 1991, CANCER RES, V51, P6372; DANIELVEDELE F, 1985, IMMUNOGENETICS, V21, P601, DOI 10.1007/BF00395884; DEJARDIN E, 1995, ONCOGENE, V11, P1835; DOBRZANSKI P, 1995, ONCOGENE, V10, P1003; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Drew PD, 1995, J INTERF CYTOK RES, V15, P1037, DOI 10.1089/jir.1995.15.1037; DREW PD, 1993, J IMMUNOL, V150, P3300; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Garrido F, 1995, ADV CANCER RES, V67, P155, DOI 10.1016/S0065-230X(08)60713-7; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; Liu XH, 1996, MOL CELL BIOL, V16, P398; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PLASKIN D, 1993, J EXP MED, V177, P1651; POTTER DA, 1993, J BIOL CHEM, V268, P18882; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Weih F, 1996, ONCOGENE, V12, P445; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	55	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3299	3307		10.1038/sj.onc.1201879	http://dx.doi.org/10.1038/sj.onc.1201879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681829	Green Published			2022-12-28	WOS:000074343600011
J	Ong, ST; Hackbarth, ML; Degenstein, LC; Baunoch, DA; Anastasi, J; McKeithan, TW				Ong, ST; Hackbarth, ML; Degenstein, LC; Baunoch, DA; Anastasi, J; McKeithan, TW			Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice	ONCOGENE			English	Article						BCL3; NF-kappa B; transgenic mice	NF-KAPPA-B; CANDIDATE PROTOONCOGENE BCL-3; CHRONIC LYMPHOCYTIC-LEUKEMIA; TRANSCRIPTION FACTOR; ONCOPROTEIN BCL-3; DNA-BINDING; CELL; ENCODES; EXPRESSION; HOMODIMERS	The candidate proto-oncogene BCL3 was isolated through its involvement in the t(14;19) found in chronic lymphocytic leukemia and other B-cell neoplasms. As a member of the I kappa B family, BCL3 plays a role in the immune response by interactions with the NF-kappa B family of transcription factors. In order to study the role of BCL3 overexpression in lymphoid malignancies, we generated five lines of E mu-BCL3 transgenic mice. Transgenic animals develop normally but show splenomegaly and an accumulation of mature B cells in lymph nodes, bone marrow and peritoneal cavity. A hyperresponsive immune system is suggested by the follicular hyperplasia and plasmacytosis in lymph nodes of unimmunized animals, increased incidence of antibodies to self-antigens, and a heightened response to crosslinking of surface ISM. Statistically significant decreases in serum IgM and IgG3, but an increase in IgG1 and IgA were also observed. No lymphoid neoplasms have been identified in transgenic animals. The expansion of B cells in vivo is consistent with the overexpression of BCL3 as being one step in the multi-step process of leukemogenesis. The phenotype also suggests that BCL3 plays a part in B cell proliferation and isotype switching.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	McKeithan, TW (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.			McKeithan, Timothy/0000-0003-2242-3074; Ong, S. Tiong/0000-0001-9460-3483	NCI NIH HHS [P30CA14599, CA55356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055356, P30CA014599] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASOU H, 1993, BRIT J HAEMATOL, V85, P492; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BHATIA K, 1991, ONCOGENE, V6, P1569; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; CROSSEN PE, 1993, GENE CHROMOSOME CANC, V8, P60, DOI 10.1002/gcc.2870080110; Datta SK, 1997, J CLIN IMMUNOL, V17, P11, DOI 10.1023/A:1027328226918; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FULLER KA, 1993, J IMMUNOL, V151, P4505; GERONDAKIS S, 1991, IMMUNOGENETICS, V34, P392, DOI 10.1007/BF01787490; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; KENTER AL, 1993, J IMMUNOL, V151, P4718; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; Lin SC, 1996, MOL CELL BIOL, V16, P4591; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MADAIO MP, 1984, J IMMUNOL, V132, P872; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; McKeithan TW, 1997, GENE CHROMOSOME CANC, V20, P64, DOI 10.1002/(SICI)1098-2264(199709)20:1<64::AID-GCC10>3.0.CO;2-F; Michaux L, 1997, CANCER GENET CYTOGEN, V94, P36, DOI 10.1016/S0165-4608(96)00247-6; NAKAJIMA A, 1995, EUR J IMMUNOL, V25, P3060, DOI 10.1002/eji.1830251112; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; SCHRIEVER F, 1992, ADV IMMUNOL, V51, P243, DOI 10.1016/S0065-2776(08)60489-7; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Snapper CM, 1996, J IMMUNOL, V156, P183; UESHIMA Y, 1985, INT J CANCER, V36, P287, DOI 10.1002/ijc.1985.36.3.287; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	39	62	64	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2333	2343		10.1038/sj.onc.1201771	http://dx.doi.org/10.1038/sj.onc.1201771			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620550				2022-12-28	WOS:000073428000005
J	Sirma, H; Weil, R; Rosmorduc, O; Urban, S; Israel, A; Kremsdorf, D; Brechot, C				Sirma, H; Weil, R; Rosmorduc, O; Urban, S; Israel, A; Kremsdorf, D; Brechot, C			Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome	ONCOGENE			English	Article						hepatitis B virus; X protein; proteasomes; NF-kappa B	NF-KAPPA-B; PROGRAMMED CELL-DEATH; HBX PROTEIN; IN-VIVO; VIRAL REPLICATION; DNA-BINDING; GENE; EXPRESSION; TRANSACTIVATOR; TRANSCRIPTION	The hepatitis B virus X protein plays an important role in the regulation of viral genome expression and has also been implicated in the development of liver cancer associated with chronic viral infection. Several effects have been attributed to X but their biological relevance remains elusive. One of the confusing issues has been so far the uncertainty concerning its cellular location. To gain insight into the mechanism(s) how X exerts its effects, me have analysed its subcellular distribution and its dependency on the cell cycle. We used two complementary approaches namely, immunolocalization using a cell line stably expressing X, and characterization of the dynamics of X location in living cells by means of the reporter gene GFP. Our data clearly define the cytosol as the prime location of X, irrespectively of the cell cycle and show in addition the close attachment of a fraction of X to the nuclear membrane. However, X does not associate with any cytoplasmic vesicles and organelles so far tested. In contrast, our study provides strong evidence for the codistribution of X with the cytosolic fraction of proteasomes. In pulse-chase experiments, X decayed with a half-life of less than 30 min and proteasome-inhibitors did not modify its turnover, suggesting that X colocalization with the proteasome does not simply point to its degradation pathway. The proteolytic processing of the p105 precursor of the p50 subunit of the NF-kappa B transcription factor, which has been shown to be proteasome-dependent, is markedly slow down in the presence of X. These findings suggest that X modulates the processing rate of p105 by acting presumably at the level of the proteasome. Thus, targeting of proteasomes by X might be one of the pathways employed by this viral protein to subvert pathways employed by cellular functions.	Necker Inst, INSERM U370, F-75015 Paris, France; Inst Pasteur, Unite Biol Mol Express Gen, URA 1149, F-75724 Paris 15, France; Max Planck Inst Biochem, Dept Virus Res, D-82152 Martinsried, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Max Planck Society	Brechot, C (corresponding author), Necker Inst, INSERM U370, 156 Rue de Vaugirard, F-75015 Paris, France.		Kremsdorf, Dina/O-9797-2017	Weil, Robert/0000-0001-5235-0932				AMSTERDAM A, 1993, P NATL ACAD SCI USA, V90, P99, DOI 10.1073/pnas.90.1.99; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; Buendia B, 1997, EXP CELL RES, V230, P133, DOI 10.1006/excr.1996.3395; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; DUPREZ V, 1994, J CELL SCI, V107, P1289; FISCHER M, 1995, VIRUS GENES, V10, P99, DOI 10.1007/BF01724303; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goldberg AL, 1997, MOL BIOL REP, V24, P69, DOI 10.1023/A:1006860828265; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HESS J, 1988, MED MICROBIOL IMMUN, V177, P195, DOI 10.1007/BF00211219; Hildt E, 1996, SEMIN VIROL, V7, P333, DOI 10.1006/smvy.1996.0041; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KLEIN R, 1991, VIRUS GENES, V5, P157, DOI 10.1007/BF00571930; KODAMA K, 1985, J VIROL, V56, P978, DOI 10.1128/JVI.56.3.978-986.1985; LEVRERO M, 1991, HEPATOLOGY, V13, P143, DOI 10.1002/hep.1840130121; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Maki CG, 1996, CANCER RES, V56, P2649; Nederlof PM, 1995, P NATL ACAD SCI USA, V92, P12060, DOI 10.1073/pnas.92.26.12060; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERSING DH, 1986, J VIROL, V60, P177, DOI 10.1128/JVI.60.1.177-184.1986; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Pitzer F, 1996, FEBS LETT, V394, P47, DOI 10.1016/0014-5793(96)00920-9; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RENNER M, 1995, J HEPATOL, V23, P53, DOI 10.1016/0168-8278(95)80311-4; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROSMORDUC O, 1995, HEPATOLOGY, V22, P10, DOI 10.1016/0270-9139(95)90346-1; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; SCHEK N, 1991, ONCOGENE, V6, P1735; Seeger M, 1997, J BIOL CHEM, V272, P8145, DOI 10.1074/jbc.272.13.8145; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TRIER M, 1994, CELL, V78, P787; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	58	92	102	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2051	2063		10.1038/sj.onc.1201737	http://dx.doi.org/10.1038/sj.onc.1201737			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572486				2022-12-28	WOS:000073177200003
J	Chang, DD; Park, NH; Denny, CT; Nelson, SF; Pe, M				Chang, DD; Park, NH; Denny, CT; Nelson, SF; Pe, M			Characterization of transformation related genes in oral cancer cells	ONCOGENE			English	Article						oncogenes; representational difference analysis; cDNA array hybridization; oral cancer; human papilloma virus	REPRESENTATIONAL DIFFERENCE ANALYSIS; TUMOR PROGRESSION; MESSENGER-RNA; EXPRESSION; CARCINOGENESIS; N-METHYL-N'-NITRO-N-NITROSOGUANIDINE; INDUCTION; CARCINOMA; ADHESION; PROTEIN	A cDNA representational difference analysis (cDNA-RDA) and an arrayed filter technique were used to characterize transformation-related genes in oral cancer. From an initial comparison of normal oral epithelial cells and a human papilloma virus (HPV)-immortalized oral epithelial cell line, we obtained 384 differentially expressed gene fragments and arrayed them on a filter. Two hundred and twelve redundant clones were identified by three rounds of back hybridization. Sequence analysis of the remaining clones revealed 99 unique clones corresponding to 69 genes. The expression of these transformation related gene fragments in three nontumorigenic HPV-immortalized oral epithelial cell lines and three oral cancer cell lines were simultaneously monitored using a cDNA array hybridization. Although there was a considerable cell line-to-cell line variability in the expression of these clones, a reliable prediction of their expression could be made from the cDNA array hybridization. Our study demonstrates the utility of combining cDNA-RDA and arrayed filters in high-throughput gene expression difference analysis. The differentially expressed genes identified in this study should be informative in studying oral epithelial cell carcinogenesis.	Univ Calif Los Angeles, Sch Dent, Dept Med Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Dent, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Dent, Inst Dent Res, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chang, DD (corresponding author), Univ Calif Los Angeles, Sch Dent, Dept Med Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Nelson, Stanley F/D-4771-2009	Nelson, Stanley F/0000-0002-2082-3114	NCI NIH HHS [P0-1CA32737] Funding Source: Medline; NIDCR NIH HHS [R03-DE11728, R01-DE11229] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011229, R03DE011728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BLOT WJ, 1988, CANCER RES, V48, P3282; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Gress TM, 1996, ONCOGENE, V13, P1819; Grossfeld GD, 1997, J NATL CANCER I, V89, P219, DOI 10.1093/jnci/89.3.219; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Itoh K, 1996, J BIOCHEM-TOKYO, V119, P385; Jendraschak E, 1996, SEMIN CANCER BIOL, V7, P139, DOI 10.1006/scbi.1996.0019; KANNAN S, 1994, HISTOPATHOLOGY, V24, P531; KANNAN S, 1994, TUMOR BIOL, V15, P73, DOI 10.1159/000217877; KARPATI S, 1993, J CELL BIOL, V122, P409, DOI 10.1083/jcb.122.2.409; KIM MS, 1993, CANCER RES, V53, P4811; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; Lazarova Z, 1995, Exp Dermatol, V4, P121, DOI 10.1111/j.1600-0625.1995.tb00235.x; LERSCH R, 1988, MOL CELL BIOL, V8, P486, DOI 10.1128/MCB.8.1.486; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Loda M, 1996, AM J PATHOL, V149, P1553; MathieuDaude F, 1996, NUCLEIC ACIDS RES, V24, P2080, DOI 10.1093/nar/24.11.2080; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; Mizushima H, 1996, J BIOCHEM-TOKYO, V120, P1196; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; PARK NH, 1995, ONCOGENE, V10, P2145; SARANATH D, 1989, JPN J CANCER RES, V80, P430, DOI 10.1111/j.1349-7006.1989.tb02332.x; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SHIN KH, 1994, MOL CARCINOGEN, V9, P76, DOI 10.1002/mc.2940090205; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; STEELE C, 1993, CANCER RES, V53, P2330; TADOKORO K, 1989, ONCOGENE, V4, P499; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WETMUR JG, 1968, J MOL BIOL, V31, P349, DOI 10.1016/0022-2836(68)90414-2; WOODS KV, 1993, J ORAL PATHOL MED, V22, P101, DOI 10.1111/j.1600-0714.1993.tb01038.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	40	50	53	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1921	1930		10.1038/sj.onc.1201715	http://dx.doi.org/10.1038/sj.onc.1201715			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591775				2022-12-28	WOS:000073079400003
J	Ravera, MW; Carcamo, J; Brissette, R; Alam-Moghe, A; Dedova, O; Cheng, W; Hsiao, KC; Klebanov, D; Shen, H; Tang, P; Blume, A; Mandecki, W				Ravera, MW; Carcamo, J; Brissette, R; Alam-Moghe, A; Dedova, O; Cheng, W; Hsiao, KC; Klebanov, D; Shen, H; Tang, P; Blume, A; Mandecki, W			Identification of an allosteric binding site on the transcription factor p53 using a phage-displayed peptide library	ONCOGENE			English	Article						antibody; PAb1620; epitope mapping; sequence; structure-function	MONOCLONAL-ANTIBODY; EPITOPE LIBRARY; MURINE P53; WILD-TYPE; ANTIGEN; PROTEIN; DNA; CONFORMATION; MUTATIONS; LIGANDS	Monoclonal antibody FAb1620 recognizes a conformational epitope on the transcription factor p53 and, upon binding, allosterically inhibits p53 binding to DNA, A highly diverse (1.5x10(10) members) phage-displayed library of peptides containing 40 random amino acids was used to identify the PAb1620 binding site on p53, Fanning this library against FAb1620 resulted in three unique peptides which have statistically significant sequence identities with p53 sufficient to identify the binding site as being composed of amino acids 106-113 and 146-156, Based on these results, we propose a mechanism by which PAb1620 can allosterically inhibit p53 binding to DNA through an indirect interaction between the antibody binding site and the L1 loop (amino acids 112-124) of p53, which is a component of the DNA binding region.	DGI BioTechnol, Edison, NJ 08818 USA		Mandecki, W (corresponding author), DGI BioTechnol, 40 Talmadge Rd,POB 424, Edison, NJ 08818 USA.							APPEL JR, 1990, J IMMUNOL, V144, P976; Chen YCJ, 1996, P NATL ACAD SCI USA, V93, P1997, DOI 10.1073/pnas.93.5.1997; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELLGAARD L, 1995, J IMMUNOL METHODS, V180, P53, DOI 10.1016/0022-1759(94)00298-B; Grihalde ND, 1995, GENE, V166, P187, DOI 10.1016/0378-1119(95)00658-3; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL AR, 1995, ONCOGENE, V10, P561; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; KAY BK, 1993, GENE, V128, P59, DOI 10.1016/0378-1119(93)90153-T; Lane DP, 1996, ONCOGENE, V12, P2461; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MANDECKI W, 1997, DISPLAY TECHNOLOGIES, P231; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1987, ONCOGENE, V1, P453; NIEWOLIK D, 1995, ONCOGENE, V10, P881; PINILLA C, 1993, GENE, V128, P71, DOI 10.1016/0378-1119(93)90155-V; RENSCHLER MF, 1994, P NATL ACAD SCI USA, V91, P3623, DOI 10.1073/pnas.91.9.3623; ROMANO JW, 1989, ONCOGENE, V4, P1483; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	26	26	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	1998	16	15					1993	1999		10.1038/sj.onc.1201717	http://dx.doi.org/10.1038/sj.onc.1201717			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591783				2022-12-28	WOS:000073079400011
J	Sawa, H; Ohshima, TA; Ukita, H; Murakami, H; Chiba, Y; Kamada, H; Hara, M; Saito, I				Sawa, H; Ohshima, TA; Ukita, H; Murakami, H; Chiba, Y; Kamada, H; Hara, M; Saito, I			Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner	ONCOGENE			English	Article						cyclin D1; cell cycle regulation; transfection; FACS; Ki-67 antigen; alternative splicing	DEPENDENT KINASE-4 CDK4; DNA-REPLICATION; RETINOBLASTOMA-PROTEIN; DIPLOID FIBROBLASTS; GENE AMPLIFICATION; GROWTH ARREST; BREAST-CANCER; S-PHASE; EXPRESSION; OVEREXPRESSION	Alternative splicing of cyclin D1 gene mRNA has recently been demonstrated, The novel transcript shows no splicing at the downstream exon 3 boundary and encodes a protein with an altered carboxyl-terminal domain that is a cyclin D1 variant; exon 5 is not included in the coding sequence which terminates downstream of exon 4, We here produced cells that exogenously express each form of cyclin D1 and analysed their cell cycle regulation. We found that (1) alternative splicing forms of cyclin D1 modulated entry into the cell cycle in an inverse manner; (2) both splicing forms suppressed cell growth; and (3) cells overexpressing form [a] were inhibited from entry into and completion of the S phase, although form [b]-expressing cells shelved no reduction of G1- to S transition. We also found that overexpression of either cyclin D1 form up-regulated Rb gene products, suggesting that this up-regulation may be one of the causes of growth suppression in cyclin D1 overexpressing cells.	Kyorin Univ, Sch Med, Dept Neurosurg, Tokyo, Japan; Kyorin Univ, Sch Med, Dept Biochem 2, Tokyo, Japan; Hokuto Hosp, Obihiro, Hokkaido, Japan	Kyorin University; Kyorin University	Sawa, H (corresponding author), Kyorin Univ, Sch Med, Dept Neurosurg, Tokyo, Japan.							ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Asano K, 1995, BIOCHEM BIOPH RES CO, V217, P1169, DOI 10.1006/bbrc.1995.2892; ATADJA P, 1995, EXP CELL RES, V217, P205, DOI 10.1006/excr.1995.1080; BARTKOVA J, 1995, ONCOGENE, V10, P775; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BETTICHER DC, 1995, ONCOGENE, V11, P1005; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CELLAPPAN SP, 1991, CELL, V65, P1053; CHEN XB, 1995, CANCER RES, V55, P4257; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; DelSal G, 1996, ONCOGENE, V12, P177; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; EBLEN ST, 1995, CELL GROWTH DIFFER, V6, P915; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GILLETT C, 1994, CANCER RES, V54, P1812; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HAN EKH, 1995, ONCOGENE, V10, P953; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KEY G, 1993, LAB INVEST, V68, P629; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Liu Y, 1996, CANCER RES, V56, P31; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MICHALIDES R, 1995, CANCER RES, V55, P973; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P761; PELLICCIARI C, 1995, CYTOMETRY, V21, P329, DOI 10.1002/cyto.990210404; Pusch O, 1996, FEBS LETT, V385, P143, DOI 10.1016/0014-5793(96)00369-9; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9639; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; TENAN M, 1995, BIOCHEM BIOPH RES CO, V217, P195, DOI 10.1006/bbrc.1995.2763; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zhou P, 1996, CANCER RES, V56, P36; ZWIJSEN RML, 1995, MOL CELL BIOL, V15, P2554	66	112	114	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1701	1712		10.1038/sj.onc.1201691	http://dx.doi.org/10.1038/sj.onc.1201691			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582018				2022-12-28	WOS:000072807600008
J	Pan, S; Ming, KY; Dunn, TA; Li, KKC; Lee, KAW				Pan, S; Ming, KY; Dunn, TA; Li, KKC; Lee, KAW			The EWS/ATF1 fusion protein contains a dispersed activation domain that functions directly	ONCOGENE			English	Article						EWS/ATF1; oncogene; MMSP; transcriptional activation; yeast	TRANSCRIPTION FACTOR; DNA-BINDING; CHROMOSOME-TRANSLOCATION; MALIGNANT-MELANOMA; RESPONSIVE ELEMENT; EWING SARCOMA; GENE FUSION; SOFT PARTS; IN-VITRO; EWS	Naturally occurring chromosomal fusion of the Ewings Sarcoma Oncogene (EWS) to distinct cellular transcription factors, produces aberrant transcriptional activators that function as dominant oncogenes, In Malignant Melanoma of Soft Parts the N-terminal region of EWS is fused to C-terminal region of the cAMP-inducible transcription factor ATF1. The EWS/ATF1 fusion protein binds to ATF sites present in cAMP-responsive promoters via the ATF1 bZIP domain and activates transcription constitutively in a manner that is dependent on an activation domain (EAD) present in EWS. To further define the requirements for transactivation we have performed mutational analysis of EWS/ATF1 in mammalian cells and report several new findings. First, trans-activation by EWS/ATF1 does not require dimerisation with other ATF family members present in mammalian cells. Second, in contrast to the earlier suggestion of an allosteric role, the EAD can act directly. Third, determinants of trans-activation are dispersed throughout the EAD and cooperate synergistically to produce potent trans-activation. We also report that the region of EWS containing the EAD can activate transcription in Yeast, This latter finding might enable a genetic approach to understanding the mechanism of transcriptional activation by EWS and development of high-throughput screens for EWS inhibitors.	Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Lee, KAW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Peoples R China.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BROWN AD, 1995, ONCOGENE, V10, P1749; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fujimura Y, 1996, ONCOGENE, V12, P159; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; JONES RH, 1989, P NATL ACAD SCI USA, V86, P2176, DOI 10.1073/pnas.86.7.2176; KIM J, 1997, IN PRESS ONCOGENE; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LADANYI M, 1994, CANCER RES, V54, P2837; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIN YS, 1989, P NATL ACAD SCI USA, V86, P109, DOI 10.1073/pnas.86.1.109; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P4166, DOI 10.1093/nar/21.18.4166; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RIBEIRO A, 1994, J BIOL CHEM, V269, P31124; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	36	34	36	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1625	1631		10.1038/sj.onc.1201671	http://dx.doi.org/10.1038/sj.onc.1201671			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569031				2022-12-28	WOS:000072743200014
J	Zhao, JQ; Hoare, SF; McFarlane, R; Muir, S; Parkinson, EK; Black, DM; Keith, WN				Zhao, JQ; Hoare, SF; McFarlane, R; Muir, S; Parkinson, EK; Black, DM; Keith, WN			Cloning and characterization of human and mouse telomerase RNA gene promoter sequences	ONCOGENE			English	Article						telomerase; gene expression; hTR; terc; gene promoter; gene transcription	IMMORTAL CELL-LINES; HUMAN-FIBROBLASTS; TRANSCRIPTION; ACTIVATION; MECHANISM; TISSUES; DRUGS; AP-1; RAS	Variation in telomerase activity is correlated with cellular senescence and tumour progression. However, although the enzymatic activity of telomerase has been well studied, very little is known about how expression of telomerase genes is regulated in mammalian cells. We have therefore cloned the promoter regions of the human (hTR), and mouse, (terc), telomerase RNA genes in order to identify the regulatory elements controlling telomerase RNA gene transcription, 1.76 kb encompassing the hTR gene promoter region was sequenced, as was 4 kb encompassing the terc promoter. No significant sequence similarity could be detected in comparisons between human and mouse 5'-regions, flanking the transcribed sequences. However, both the human and mouse telomerase RNA genes are within CpG islands and may therefore be under the regulation of DNA methylation. Transient expression of hTR-reporter gene constructs in HeLa and GM847 cells identified the elements responsible for promoter activity are contained in a 231 bp region upstream of the transcriptional start site, Transient expression of terc-reporter gene constructs in Swiss3T3 and A9 cells identified the elements responsible for promoter activity are contained in a 73 bp region upstream of the transcriptional start site. These studies have implications for novel transcription targeted cancer therapies.	Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland; Beatson Inst Canc Res, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow; Beatson Institute	Keith, WN (corresponding author), Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Alexander Stone Bldg,Garscube Estate,Switchback R, Glasgow G61 1BD, Lanark, Scotland.		Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Zhao, Jiangqin/0000-0003-4672-0735				Avilion AA, 1996, CANCER RES, V56, P645; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Bestilny LJ, 1996, CANCER RES, V56, P3796; Bird AP, 1996, CANCER SURV, V28, P87; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Broccoli D, 1997, HUM MOL GENET, V6, P69, DOI 10.1093/hmg/6.1.69; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; Cai WZ, 1996, CURR OPIN BIOTECH, V7, P608, DOI 10.1016/S0958-1669(96)80071-1; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Cheng AJ, 1997, BIOCHEM BIOPH RES CO, V237, P438, DOI 10.1006/bbrc.1997.7157; Connors TA, 1995, GENE THER, V2, P702; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GALANG CK, 1994, ONCOGENE, V9, P2913; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; IRVING J, 1992, EXP CELL RES, V202, P161, DOI 10.1016/0014-4827(92)90415-5; Kim NW, 1997, EUR J CANCER, V33, P781, DOI 10.1016/S0959-8049(97)00057-9; Kipling D, 1997, HUM MOL GENET, V6, P1999, DOI 10.1093/hmg/6.12.1999; Kipling D, 1997, EUR J CANCER, V33, P792, DOI 10.1016/S0959-8049(97)00060-9; Kuniyasu H, 1997, JPN J CANCER RES, V88, P103, DOI 10.1111/j.1349-7006.1997.tb00353.x; LAIRD PW, 1996, ANNU REV GENET, V30, P44; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Miller N, 1997, HUM GENE THER, V8, P803, DOI 10.1089/hum.1997.8.7-803; Morin GB, 1997, EUR J CANCER, V33, P750, DOI 10.1016/S0959-8049(97)00061-0; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Norrback KF, 1997, EUR J CANCER, V33, P774, DOI 10.1016/S0959-8049(97)00059-2; Pan CG, 1997, EXP CELL RES, V231, P346, DOI 10.1006/excr.1997.3475; PETERSON MG, 1993, TRENDS BIOTECHNOL, V11, P11, DOI 10.1016/0167-7799(93)90069-L; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Sharma S, 1997, ANN ONCOL, V8, P1063, DOI 10.1023/A:1008206420505; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Soder AI, 1997, GENOMICS, V41, P293, DOI 10.1006/geno.1997.4621; Soder AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/sj.onc.1201066; SODER AI, 1997, IN RPESS ONCOGENE; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; VERTINO PM, 1994, CELL GROWTH DIFFER, V5, P1395; WASYLYK C, 1994, ONCOGENE, V9, P3665; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; WILSON V L, 1983, Science (Washington D C), V220, P1055, DOI 10.1126/science.6844925; Wright WE, 1996, DEV GENET, V18, P173; Zakian VA, 1997, CELL, V91, P1, DOI 10.1016/S0092-8674(01)80001-5	48	64	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1345	1350		10.1038/sj.onc.1201892	http://dx.doi.org/10.1038/sj.onc.1201892			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546436				2022-12-28	WOS:000072422000013
J	Bonvini, P; Nguyen, P; Trepel, J; Neckers, LM				Bonvini, P; Nguyen, P; Trepel, J; Neckers, LM			In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome	ONCOGENE			English	Article						N-myc; ubiquitin; proteasome	MULTICATALYTIC PROTEINASE COMPLEX; NUCLEAR PROTEINS; NEURO-BLASTOMA; M-CALPAIN; ORNITHINE DECARBOXYLASE; SELECTIVE INHIBITORS; PROTEOLYTIC SYSTEM; KAPPA-B; UBIQUITIN; AMPLIFICATION	N-myc is a short-lived transcription factor, frequently amplified in human neuroblastomas. The ubiquitin-proteasome system is involved in the degradation of many short-lived cellular proteins and previous studies have shown that ubiquitin-dependent proteolysis is implicated in the turn-over of N-myc in vitro. However, calpain has also been implicated in N-myc degradation in vitro. Here we report that, in vivo, N-myc is a sensitive substrate for the 26S proteasome in N-myc amplified neuroblastoma cells. We observed that inhibition of the 26S proteasome with two inhibitors, ALLnL and lactacystin, led to an elevation of the N-myc protein steady-state and increased N-myc protein polyubiquitination, as revealed by ubiquitin Western blotting. Pulse-chase experiments have shown that the increased N-myc levels resulted from stabilization of the protein. In contrast treatment with several calpain and cathepsin inhibitors failed to block N-myc degradation in vivo. Furthermore, fluorescence microscopy of ALLnL-treated cells localized N-myc exclusively to the nuclear compartment, suggesting the absence of a requirement for transport to the cytoplasm prior to degradation.	NCI, Dept Cell & Canc Biol, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bonvini, P (corresponding author), NCI, Dept Cell & Canc Biol, Med Branch, NIH, Bethesda, MD 20892 USA.		Bonvini, Paolo/J-9877-2018	Bonvini, Paolo/0000-0003-2889-108X				AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; ATSMA DE, 1995, CIRC RES, V76, P1071, DOI 10.1161/01.RES.76.6.1071; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARILLO S, 1994, ONCOGENE, V9, P1679; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; COHN SL, 1990, ONCOGENE, V5, P1821; DIAS P, 1990, INT J CANCER, V45, P593, DOI 10.1002/ijc.2910450403; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fenteany G, 1996, CHEM BIOL, V3, P905, DOI 10.1016/S1074-5521(96)90179-9; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; HAYASHI Y, 1990, INT J CANCER, V45, P705, DOI 10.1002/ijc.2910450423; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KATAGIRI M, 1995, J ANTIBIOT, V48, P344, DOI 10.7164/antibiotics.48.344; Knuehl C, 1996, EXP CELL RES, V225, P67, DOI 10.1006/excr.1996.0157; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; Oda K, 1996, BIOCHEM BIOPH RES CO, V219, P800, DOI 10.1006/bbrc.1996.0314; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; Rivett AJ, 1990, CURR OPIN CELL BIOL, V2, P1143, DOI 10.1016/0955-0674(90)90168-E; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SATO M, 1992, INT J ONCOL, V1, P539; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; Umezawa H, 1976, Methods Enzymol, V45, P678; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E; WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120	62	46	46	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1131	1139		10.1038/sj.onc.1201625	http://dx.doi.org/10.1038/sj.onc.1201625			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528855				2022-12-28	WOS:000072336000004
J	Gutkind, JS				Gutkind, JS			Cell growth control by G protein-coupled receptors: from signal transduction to signal integration	ONCOGENE			English	Review						g proteins; g protein-coupled receptors; Ras; MAP kinases; Rho; cell growth	BETA-GAMMA-SUBUNITS; TERNARY COMPLEX FACTORS; SMOOTH-MUSCLE CELLS; MAP KINASE CASCADE; FACTOR RAS-GRF; CONSTITUTIVELY ACTIVATING MUTATION; INDUCED TYROSINE PHOSPHORYLATION; VAV PROTOONCOGENE PRODUCT; HETEROTRIMERIC G-PROTEIN; SERUM RESPONSE ELEMENT		NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482				Aaronson S A, 1985, Carcinog Compr Surv, V10, P35; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Akada R, 1996, GENETICS, V143, P103; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bankier A T, 1991, DNA Seq, V2, P1, DOI 10.3109/10425179109008433; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1995, EUR J CANCER, V31A, P1051, DOI 10.1016/0959-8049(95)00168-I; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Charlesworth A, 1997, ONCOGENE, V14, P2323, DOI 10.1038/sj.onc.1201075; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; CHEN J, 1995, BIOCHEM SOC T, V23, P129, DOI 10.1042/bst0230129; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1997, J BIOL CHEM, V272, P20691, DOI 10.1074/jbc.272.33.20691; Coso OA, 1996, J BIOL CHEM, V271, P3963; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CRESPO P, 1994, J BIOL CHEM, V269, P21103; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; Du J, 1996, BIOCHEM BIOPH RES CO, V218, P934, DOI 10.1006/bbrc.1996.0165; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FAURE M, 1994, J BIOL CHEM, V269, P7851; Freshney NW, 1997, FEBS LETT, V407, P111, DOI 10.1016/S0014-5793(97)00309-8; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gaits F, 1996, J BIOL CHEM, V271, P20151; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; HOOSEIN NM, 1988, CANCER RES, V48, P7179; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAUS MH, 1988, ANN NY ACAD SCI, V551, P320, DOI 10.1111/j.1749-6632.1988.tb22358.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LANGDON S, 1992, CANCER RES, V52, P4554; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOODY TW, 1993, LIFE SCI, V52, P1161, DOI 10.1016/0024-3205(93)90098-N; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; POUYSSEGUR J, 1988, PHILOS T ROY SOC B, V320, P427, DOI 10.1098/rstb.1988.0086; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; Schlaepfer DD, 1996, CELL STRUCT FUNCT, V21, P445, DOI 10.1247/csf.21.445; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHULLER HM, 1991, EXP LUNG RES, V17, P837, DOI 10.3109/01902149109064321; SCHULLER HM, 1991, CANCER CELL-MON REV, V3, P496; SETHI T, 1991, CANCER RES, V51, P3621; SETHI T, 1992, CANCER RES, V52, pS2737; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAHARA E, 1990, J CANCER RES CLIN, V116, P121, DOI 10.1007/BF01612665; Takahashi T, 1997, J BIOL CHEM, V272, P16018, DOI 10.1074/jbc.272.25.16018; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Teramoto H, 1997, J BIOL CHEM, V272, P10751; THOMAS F, 1992, CANCER RES, V52, P4872; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRONICK SR, 1988, ADV SEC MESS PHOSPH, V21, P201; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; UI M, 1990, ADV SEC MESS PHOSPH, V24, P63; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626	163	209	213	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1331	1342		10.1038/sj.onc.1202186	http://dx.doi.org/10.1038/sj.onc.1202186			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779981				2022-12-28	WOS:000076161900002
J	Zohn, IM; Campbell, SL; Khosravi-Far, R; Rossman, KL; Der, CJ				Zohn, IM; Campbell, SL; Khosravi-Far, R; Rossman, KL; Der, CJ			Rho family proteins and Ras transformation: the RHOad less traveled gets congested	ONCOGENE			English	Review						Ras superfamily; signal transduction; actin cytoskeleton; effectors	GTP-BINDING-PROTEIN; GDP-DISSOCIATION INHIBITOR; GUANINE-NUCLEOTIDE EXCHANGE; WISKOTT-ALDRICH SYNDROME; NF-KAPPA-B; CELL-CYCLE PROGRESSION; SERUM RESPONSE ELEMENT; VAV PROTOONCOGENE PRODUCT; SERINE-THREONINE KINASE; EPIDERMAL GROWTH-FACTOR	The Rho family of small GTPases has attracted considerable research interest over the past 5 years. During this time, we have witnessed a remarkable increase in our knowledge of the biochemistry and biology of these Ras-related proteins. Thus, Rho family proteins have begun to rival, if not overshadow, interest in their more celebrated cousins, the Ras oncogene proteins. The fascination in Rho family proteins is fueled primarily by two major observations. First, like Ras, Rho family proteins serve as guanine nucleotide-regulated binary switches that control signaling pathways that in turn regulate diverse cellular processes. Rho family proteins are key components in cellular processes that control the organization of the actin cytoskeleton, activate kinase cascades, regulate gene expression, regulate membrane trafficking, promote growth transformation and induce apoptosis, Second, at least five Rho family proteins have been implicated as critical regulators of oncogenic Ras transformation. Thus, it is suspected that Rho family proteins contribute significantly to the aberrant growth properties of Ras-transformed cells. Rho family proteins are also critical mediators of the transforming actions of other transforming proteins and include Dbl family oncogene proteins, G protein-coupled receptors and G protein cc subunits, Thus, Rho family proteins may be key components for the transforming actions of diverse oncogene proteins. Major aims of Rho family protein studies are to define the molecular mechanism by which Rho family proteins regulate such a diverse spectrum of cellular behavior. These efforts may reveal novel targets for the development of anti-Ras and anti-cancer drugs.	MIT, Dept Pharmacol, Cambridge, MA 02139 USA; MIT, Dept Biochem & Biophys, Cambridge, MA 02139 USA; MIT, Lineberger Comprehens Canc Ctr, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), MIT, Dept Pharmacol, Cambridge, MA 02139 USA.		Khosravi-Far, Roya/C-3789-2008	Der, Channing/0000-0002-7751-2747; campbell, sharon/0000-0003-0311-409X; Zohn, Irene/0000-0001-7688-682X	NCI NIH HHS [CA42978, CA55008, CA52072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055008, R01CA042978, R01CA052072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Allen WE, 1997, J CELL SCI, V110, P707; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Best A, 1996, J BIOL CHEM, V271, P3756; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brill S, 1996, MOL CELL BIOL, V16, P4869; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CAMPBELL SL, 1998, IN PRESS ONCOGENE; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHARDIN P, 1993, GTPASES BIOL, V1, P159; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; CHUANG TH, 1993, J BIOL CHEM, V268, P775; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DALLERY E, 1995, ONCOGENE, V10, P2171; DECREMOUX P, 1994, INT J CANCER, V59, P408, DOI 10.1002/ijc.2910590320; DER CJ, 1988, ONCOGENE, V3, P105; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; DIEKMANN D, 1995, EMBO J, V14, P5338; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; DSOUZASCHOREY C, 1997, IN PRESS EMBO J; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; EZOE K, 1994, ONCOGENE, V9, P935; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hirai A, 1997, J BIOL CHEM, V272, P13; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; ING YL, 1994, ONCOGENE, V9, P1745; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kirchhausen T, 1996, CURR BIOL, V6, P676, DOI 10.1016/S0960-9822(09)00447-3; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Larochelle DA, 1996, J CELL BIOL, V133, P1321, DOI 10.1083/jcb.133.6.1321; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; LINARESCRUZ G, 1994, J MICROSC-OXFORD, V173, P27, DOI 10.1111/j.1365-2818.1994.tb03425.x; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARHOUL JF, 1995, GENETICS, V139, P537; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MASUDA T, 1995, J BIOL CHEM, V270, P1979, DOI 10.1074/jbc.270.5.1979; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Osada S, 1997, FEBS LETT, V404, P227, DOI 10.1016/S0014-5793(97)00139-7; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Park SH, 1995, ONCOGENE, V11, P2349; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PETERSEN J, 1995, MOL CELL BIOL, V15, P3697; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Schuebel KE, 1996, ONCOGENE, V13, P363; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKALO H, 1994, BIOCONJUGATE CHEM, V5, P278, DOI 10.1021/bc00027a015; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; UEDA T, 1990, J BIOL CHEM, V265, P9373; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Verschueren H, 1997, EUR J CELL BIOL, V73, P182; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITEHEAD I, 1995, ONCOGENE, V10, P713; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WU DQ, 1992, J BIOL CHEM, V267, P1811; Wu WJ, 1997, J BIOL CHEM, V272, P26153, DOI 10.1074/jbc.272.42.26153; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; YOSHIOKA K, 1995, FEBS LETT, V372, P25, DOI 10.1016/0014-5793(95)00937-5; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P5339, DOI 10.1073/pnas.85.14.5339; Yu WP, 1997, J BIOL CHEM, V272, P10030; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225	255	319	324	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1415	1438		10.1038/sj.onc.1202181	http://dx.doi.org/10.1038/sj.onc.1202181			24	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779988				2022-12-28	WOS:000076161900009
J	Greco, A; Fusetti, L; Villa, R; Sozzi, G; Minoletti, F; Mauri, P; Pierotti, MA				Greco, A; Fusetti, L; Villa, R; Sozzi, G; Minoletti, F; Mauri, P; Pierotti, MA			Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans	ONCOGENE			English	Article						dermatofibrosarcoma; gene rearrangement; transformation; PDGFB gene	SIMIAN SARCOMA-VIRUS; CHRONIC MYELOMONOCYTIC LEUKEMIA; IN-SITU HYBRIDIZATION; SOFT-TISSUE TUMORS; CELL-LINES; TYROSINE KINASES; HUMAN GLIOMA; EXPRESSION; RECEPTORS; PROLIFERATION	As a consequence of a reciprocal translocation t(17;22)(q22;q13) and of supernumerary ring chromosomes derived from the t(17;22), a fusion between the platelet-derived growth factor b-chain (PDGF, c-sis proto-oncogene) and the collagen type 1A1 (COL1A1) genes has been recently described in dermatofibrosarcoma protuberans (DP), an infiltrating skin tumor (Simon ct al,, 1997), Although PDGFB has been implicated in transforming processes via autocrine and paracrine pathways, by the activation of the cognate receptor, no direct evidence of its involvement in neoplastic transformation of human tumours has been so far provided. In this report, we have tested the DNA from four DPs in the classical DNA transfection assay onto NIH3T3 fibroblast cell line. All the DNAs induced the formation of transformed foci in the transfected cultures whose derived cell lines were shown to contain a fused sequence comprising the human COL1A1 and PDGF genes. The relative breakpoint regions have been sequenced revealing that this gene fusion deleted exon 1 of PDGF and released the growth factor from its normal regulation, All the biochemical and biological assays were consistent with the model of an autocrine mechanism for NIH3T3 transformation by the human rearranged PDGFB gene involving the activation of the endogeneous PDGF receptor.	Ist Nazl Tumori, Div Expt Oncol A, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Greco, A (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Milan, Italy.		sozzi, gabriella/G-8259-2011; Greco, Angela/C-1953-2017; Pierotti, Marco Alessandro/AAC-4728-2022	sozzi, gabriella/0000-0001-9360-6914; Greco, Angela/0000-0003-2994-0349; Pierotti, Marco Alessandro/0000-0002-7431-8332; Villa, Riccardo/0000-0001-8385-800X				BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CAMBY I, 1994, PROSTATE, V24, P187, DOI 10.1002/pros.2990240404; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Chin LS, 1997, CLIN CANCER RES, V3, P771; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRECO A, 1992, ONCOGENE, V7, P237; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; HERMANSON M, 1992, CANCER RES, V52, P3213; KIKUCHI K, 1993, BIOCHEM BIOPH RES CO, V196, P409, DOI 10.1006/bbrc.1993.2264; MAXWELL M, 1986, J CLIN INVEST, P131; MINOLETTI F, 1995, GENE CHROMOSOME CANC, V13, P62, DOI 10.1002/gcc.2870130110; Pedeutour F, 1996, CYTOGENET CELL GENET, V72, P171, DOI 10.1159/000134178; PEDEUTOUR F, 1993, CANCER GENET CYTOGEN, V67, P149, DOI 10.1016/0165-4608(93)90171-H; PERES R, 1987, CANCER RES, V47, P3425; ROBBINS KC, 1982, SCIENCE, V218, P1131, DOI 10.1126/science.6293053; Sambrook J., 2002, MOL CLONING LAB MANU; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; TAPLEY P, 1992, ONCOGENE, V7, P371; TSAI LH, 1994, BLOOD, V83, P51; WANG J, 1994, CANCER RES, V54, P560; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEINER TM, 1994, ANN SURG ONCOL, V1, P18, DOI 10.1007/BF02303537; WEINSTEIN IB, 1987, J CELL BIOCHEM, V33, P213, DOI 10.1002/jcb.240330308; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; WESTERMARK B, 1993, CYTOKINES, P1	34	80	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1313	1319		10.1038/sj.onc.1202051	http://dx.doi.org/10.1038/sj.onc.1202051			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771975				2022-12-28	WOS:000075803300014
J	Bartkova, J; Lukas, J; Strauss, M; Bartek, J				Bartkova, J; Lukas, J; Strauss, M; Bartek, J			Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation	ONCOGENE			English	Article						cell cycle; cyclin D3; cell and tissue differentiation; G1/S transition	CELL-CYCLE; RETINOBLASTOMA-PROTEIN; DEPENDENT KINASES; D1 PROTEIN; PHASE PROGRESSION; EXPRESSION; G(1); GENE; FIBROBLASTS; LINES	The mammalian D-type cyclins DI, D2, and D3 activate the cyclin-dependent kinases CDK4 and CDK6 in G1 and thereby promote the cell's commitment to enter S phase. To elucidate the extent of functional overlap among the D-type cyclins, we have examined several aspects of the least characterized member of this subfamily of G1 cyclin proteins, cyclin D3. Microinjection of cyclin D3-neutralizing antibody inhibited G1/S transition in human (IMR-90) and rat (R12) diploid fibroblasts, indicating that analogous to cyclins D1 and D2, cyclin D3 is essential for timely progression through Gf. In contrast to cyclins D1 and D2, cyclin D3 was (i) ubiquitously expressed among a panel of 70 human cultured cell types; (ii) strongly upregulated upon induction of HL-60 leukaemia cells to differentiate; and (iii) accumulated to high levels in a wide range of quiescent cell types in mouse and human differentiated tissues. Complementary analyses of human biopsies and mouse tissues at different stages of foetal and postnatal development revealed lineage-dependent transient or long-term accumulation of the cyclin D3 protein, correlating with initiation/establishment or maintenance of the mature phenotypes, respectively. Our data support the notion that the biological roles of the individual D-type cyclins are not fully redundant, and suggest a possible dual role for cyclin D3 in cell proliferation and induction and/or maintenance of terminal differentiation.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; Humboldt Univ, Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Danish Cancer Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; COLLINS SJ, 1987, BLOOD, V70, P1233; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JAHN L, 1994, EXP CELL RES, V212, P297, DOI 10.1006/excr.1994.1147; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; KIESS M, 1995, ONCOGENE, V10, P159; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LOVEC H, 1994, ONCOGENE, V9, P322; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MURAO S, 1994, CELL BIOL LAB HDB, P207; PALMERO I, 1993, ONCOGENE, V8, P1049; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Pokrovskaja K, 1996, CELL GROWTH DIFFER, V7, P1723; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Savatier P, 1996, ONCOGENE, V12, P309; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sun W, 1996, MOL REPROD DEV, V43, P414, DOI 10.1002/(SICI)1098-2795(199604)43:4<414::AID-MRD2>3.0.CO;2-S; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TAM SW, 1994, ONCOGENE, V9, P2663; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Zimmet JM, 1997, MOL CELL BIOL, V17, P7248, DOI 10.1128/MCB.17.12.7248	50	171	174	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1027	1037		10.1038/sj.onc.1202016	http://dx.doi.org/10.1038/sj.onc.1202016			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747882				2022-12-28	WOS:000075560900011
J	Huang, JH; Logsdon, N; Schmieg, FI; Simmons, DT				Huang, JH; Logsdon, N; Schmieg, FI; Simmons, DT			p53-mediated transcription induces resistance of DNA to UV inactivation	ONCOGENE			English	Article						p53; DNA repair; transcriptional activation; genetic reactivation	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; LI-FRAUMENI SYNDROME; TUMOR-SUPPRESSOR; PYRIMIDINE DIMER; GENE-PRODUCT; HOMOLOGOUS RECOMBINATION	A possible role of p53-dependent transcription in the induction of DIVA repair was explored by transfecting a UV-irradiated chloramphenicol acetyl transferase (CAT) reporter plasmid (pRGC.FOS.CAT), containing a minimal FOS promoter driven by a consensus p53 binding site, into a p53 negative-mouse cell line [(10)1], When a p53-expressing plasmid (pSV.p53) was cotransfected into these cells, CAT expression levels persisted even after prolonged UV irradiation. In comparison, CAT expression from pSV2.CAT, which lacks a p53-responsive element in its SV40 promoter, dropped off much more precipitously after UV irradiation in the absence or presence of WT p53 expression. A similar sharp drop was observed with three other constructs when the reporter gene was under the control of the ras, beta-actin or fos promoter. Mouse cells (A1-5) that constitutively express a temperature-sensitive mutant (135 AV) of mouse p53 also generated, at 32 degrees C, higher levels of enzyme expressed from UV-irradiated pRGC,FOS,CAT than from UV-irradiated pSV2.CAT. The frequency of cyclobutane pyrimidine dimers in UV-irradiated pRGC,FOS,CAT was determined with T4 endo V, and the probability of having an undamaged CAT coding strand was calculated by the Poisson distribution for various times of UV-irradiation, The observed relative CAT expression levels from irradiated pSV2,CAT and pRGC,FOS,CAT in the absence of p53 were consistent with those numbers. These results show that WT p53-mediated transcription directs a resistance of the transcribed DNA to UV inactivation and reactivates the reporter gene. Furthermore, some single point substitution mutants of p53 that maintain a near normal ability to activate transcription had lost their ability to extend CAT gene expression after UV irradiation. Conversely, other mutants with reduced transcriptional activity retained this ability. This indicates that although resistance to UV inactivation is transcriptionally-dependent, these two activities are genetically distinct. These data, taken together, suggest that the transcription of UV-damaged DNA by a p53-dependent process promotes its repair.	Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA	University of Delaware	Simmons, DT (corresponding author), Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA.				NATIONAL CANCER INSTITUTE [R55CA055234] Funding Source: NIH RePORTER; NCI NIH HHS [CA55234] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAVRE PA, 1995, CANCER RES, V55, P4420; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KERN SE, 1991, SCIENCE, V252, P1707; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li G, 1997, AM J PATHOL, V150, P1457; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LINK CJ, 1991, CANCER CELL-MON REV, V3, P427; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; MCKEEL KL, 1997, ONCOGENE, V14, P1847; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MIRZAYANS R, 1995, ONCOGENE, V11, P1597; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; NAKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; PROTICSABLJIC M, 1985, P NATL ACAD SCI USA, V82, P6622, DOI 10.1073/pnas.82.19.6622; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; RADANY EH, 1980, NATURE, V286, P182, DOI 10.1038/286182a0; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SCHMIEG FI, 1993, ONCOGENE, V8, P2043; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wiesmuller L, 1996, J VIROL, V70, P737; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	94	17	17	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	1998	17	4					401	411		10.1038/sj.onc.1201951	http://dx.doi.org/10.1038/sj.onc.1201951			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696032				2022-12-28	WOS:000075043000001
J	Brown, LA; Amores, A; Schilling, TF; Jowett, T; Baert, JL; de Launoit, Y; Sharrocks, AD				Brown, LA; Amores, A; Schilling, TF; Jowett, T; Baert, JL; de Launoit, Y; Sharrocks, AD			Molecular characterization of the zebrafish PEA3 ETS-domain transcription factor	ONCOGENE			English	Article						ETS-domain; PEA3; transcription factors; zebrafish	DNA-BINDING SPECIFICITIES; PROTEIN-PROTEIN; ONCOGENE FAMILY; FACTORS ELK-1; FACTOR ER81; MAP KINASE; MEMBER; ERM; CASCADES; DISTINCT	The PEA3 subfamily of ETS-domain proteins play important roles in regulating transcriptional activation and have been implicated in several tumorigenic processes. Here we describe the identification of a further member of this family from zebrafish which most likely represents a homologue of PEA3, A high degree of sequence conservation is observed in the ETS DNA-binding domain and acidic transcriptional activation domain. The DNA binding specificity of zebrafish PEA3 is virtually identical to that exhibited by mammalian family members and is autoregulated by cisacting inhibitory domains. Transcriptional activation by zebrafish PEA3 is potentiated by the ERK MAP kinase and protein kinase A pathways. During embryogenesis, PEA3 is expressed in complex spatial and temporal patterns in both mesodermal somites and ectodermal tissues including the brain, dorsal spinal chord and neural crest. Our characterisation of zebrafish PEA3 furthers our understanding of its molecular function and its expression profile suggests a novel role in cell patterning in the early vertebrate embryo.	Univ Newcastle Upon Tyne, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Imperial Canc Res Fund, London WC2A 3PX, England; Inst Pasteur, Inst Biol, CNRS, UMR 319, F-59021 Lille, France	Newcastle University - UK; Cancer Research UK; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Sharrocks, AD (corresponding author), Zeneca Pharmaceut, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.			Amores, Angel/0000-0002-9307-3609	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAERT JL, 1996, IN PRESS INT J CANC; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BROWN AL, 1997, UNPUB DEV BIOL; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DELAUNOIT Y, 1997, IN PRESS BIOCH MOL M; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Janknecht R, 1996, ONCOGENE, V13, P1745; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kaya M, 1996, ONCOGENE, V12, P221; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; Laget MP, 1996, ONCOGENE, V12, P1325; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; OHagan RC, 1996, ONCOGENE, V13, P1323; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHARROCKS AD, 1993, NUCLEIC ACIDS RES, V21, P215, DOI 10.1093/nar/21.2.215; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; Shore P, 1996, MOL CELL BIOL, V16, P3338; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Taylor JM, 1997, MOL CELL BIOL, V17, P5550, DOI 10.1128/MCB.17.9.5550; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Weinberg ES, 1996, DEVELOPMENT, V122, P271; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	48	52	53	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					93	104		10.1038/sj.onc.1201911	http://dx.doi.org/10.1038/sj.onc.1201911			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671318				2022-12-28	WOS:000074677800011
J	Givol, I; Givol, D; Hughes, SH				Givol, I; Givol, D; Hughes, SH			Overexpression of p21(waf1/cip1) arrests the growth of chicken embryo fibroblasts that overexpress E2F1	ONCOGENE			English	Article						retrovirus; growth suppressor; cell cycle; E2F; waf1/cip1	RETINOBLASTOMA SUSCEPTIBILITY GENE; CYCLIN-DEPENDENT KINASES; S-PHASE ENTRY; TRANSCRIPTION FACTOR; CELL-CYCLE; TRANS-ACTIVATION; BINDING PROTEIN; DNA-SYNTHESIS; EXPRESSION; APOPTOSIS	P21(waf1/cip1) is a potent inhibitor of cell cycle progression and can inhibit the growth of both normal cells and cells transformed by a number of oncogenes. However, the ability of p21(waf1/cip1) to inhibit the growth of cells that overexpress the transcriptional transactivator E2F1 is controversial: it has been reported both that E2F1 can and cannot overcome the block in the cell cycle induced by p21(waf1/cip1). To avoid the complications that arise when such experiments are done with permanent cell lines, we tested the effects of overexpressing p21(waf1/cip1) and E2F1 in primary chicken embryo fibroblasts. In this system very high levels of E2F1 overexpression cause considerable apoptosis; however, the surviving cells still overexpress E2F1. These cells are transformed and their growth is blocked by overexpression of p21(waf1/cip1).	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Weizmann Institute of Science	Hughes, SH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA.							Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Givol I, 1995, ONCOGENE, V11, P2609; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4923; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Michieli P, 1996, ONCOGENE, V12, P775; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Petropoulos CJ, 1996, ONCOGENE, V12, P2611; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YMASAKI L, 1996, CELL, V85, P537; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	53	11	11	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3115	3122		10.1038/sj.onc.1201849	http://dx.doi.org/10.1038/sj.onc.1201849			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671390				2022-12-28	WOS:000074261300004
J	Takeda, H; Matozaki, T; Fujioka, Y; Takada, T; Noguchi, T; Yamao, T; Tsuda, M; Ochi, F; Fukunaga, K; Narumiya, S; Yamamoto, T; Kasuga, M				Takeda, H; Matozaki, T; Fujioka, Y; Takada, T; Noguchi, T; Yamao, T; Tsuda, M; Ochi, F; Fukunaga, K; Narumiya, S; Yamamoto, T; Kasuga, M			Lysophosphatidic acid-induced association of SHP-2 with SHPS-1: roles of RHO, FAK, and a SRC family kinase	ONCOGENE			English	Article						SHPS-1; SHP-2; LPA; SRC; FAK; tyrosine phosphorylation	PROTEIN-TYROSINE-PHOSPHATASE; FOCAL ADHESION KINASE; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; BOTULINUM C3 EXOENZYME; ACTIN STRESS FIBERS; SIGNAL-TRANSDUCTION; HOMOLOGY-2 DOMAINS; MAP KINASE; CELL-PROLIFERATION; COUPLED RECEPTORS	SHPS-1 is an similar to 120kDa glycosylated receptor like protein that contains three immunoglobulin-like domains in its extracellular region as well as four potential tyrosine phosphorylation and SRC homology 2 (SH2) domain binding sites in its cytoplasmic region. Lysophosphatidic acid (LPA) stimulated the rapid tyrosine phosphorylation of SHPS-1 and its subsequent association with SHP-2, a protein tyrosine phosphatase containing SH2 domains in Rat-1 fibroblasts. LAP-induced tyrosine phosphorylation of SHPS-1 was inhibited by Clostridium botulinum C3 exoenzyme (which inactivates RHO) but not by pertussis toxin, The protein kinase C activator phorbol ester, 12-O-tetradecanoylphorbol 13-acetate (TPA) also stimulated tyrosine phosphorylation of SHPS-1; however, down-regulation of protein kinase C by prolonged exposure of cells to TPA did not affect LAP-induced tyrosine phosphorylation of SHPS-1. LPA-induced tyrosine phosphorylation of SHPS-1 was markedly reduced in either focal adhesion kinase (FAK)-deficient mouse cells or CHO cells overexpressing the tyrosine kinase CSK. Overexpression of a catalytically inactivate SHP-2 markedly inhibited MAP kinase activation in response to low concentrations of LPA in CHO cells, whereas overexpression of a wild-type SHPS-1 did enhance this effect of LPA, Furthermore, MAP kinase activation in response to a low concentration of LPA was inhibited by botulinum C3 exoenzyme, These results indicate that LPA-induced tyrosine phosphorylation of SHPS-1 and its association with SHP-2 may be mediated by a RHO-dependent pathway that includes FAK and a SRC family kinase, Thus, in addition to its role in receptor tyrosine kinase-mediated MAP kinase activation, the formation of a complex between SHPS-1 and SHP-2 may, in part, play an important role in the activation of MAP kinase in response to low concentrations of LPA.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 650, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan; Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 108, Japan	Kobe University; Kyoto University; University of Tokyo	Matozaki, T (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kusunoki Cho, Kobe, Hyogo 650, Japan.							Adachi M, 1996, CELL, V85, P15; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; ILLC D, 1995, NATURE, V377, P539; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUMAGAI N, 1995, FEBS LETT, V366, P11, DOI 10.1016/0014-5793(95)00478-R; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MATOZAKI T, 1995, ADV PROTEIN PHOSPHAT, V9, P319; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; OKADA M, 1991, J BIOL CHEM, V266, P24249; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	1998	16	23					3019	3027		10.1038/sj.onc.1201839	http://dx.doi.org/10.1038/sj.onc.1201839			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662335				2022-12-28	WOS:000074125300009
J	Zhang, LS; Lau, YK; Xi, L; Hong, RL; Kim, DS; Chen, CF; Hortobagyi, GN; Chang, CJ; Hung, MC				Zhang, LS; Lau, YK; Xi, L; Hong, RL; Kim, DS; Chen, CF; Hortobagyi, GN; Chang, CJ; Hung, MC			Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties	ONCOGENE			English	Article						emodin; anthraquinone; HER-2/neu; tyrosine kinase; experimental metastasis	GROWTH-FACTOR-RECEPTOR; BREAST-CANCER CELLS; NEU ONCOGENE; LUNG-CANCER; PROGNOSTIC-SIGNIFICANCE; POINT MUTATION; TUMOR-CELL; EXPRESSION; GENE; C-ERBB-2	We have previously shown that emodin suppresses tyrosine kinase activity of HER-2/neu-encoded p185(neu) receptor tyrosine kinase. In this study, we examine the relationship between the chemical structure and the activity of emodin and nine derivatives, and identified that one methyl, one hydroxy, and one carbonyl functional groups are critical for the biological activities of emodin. We also found that one of the derivatives 10-(4-acetamidobenzylidene)-9-anthrone (DK-V-47) is more effective than emodin in repressing the tyrosine phosphorylation of p185(neu) and in inhibiting the proliferation and transformation of HER-2/neu-overexpressing human breast cancer cells. Using mutation-activated HER-2/neu transformed 3T3 cells, we also investigated whether emodin and DK-V-47 can inhibit malignant transformation induced solely by the HER-2/neu oncogene. We found that DK-V-47 is more potent than emodin in suppressing transformation phenotypes of activated HER-2/neu transformed 3T3 cells including anchorage-dependent and -independent growth, metastasis-associated properties. These results clearly indicate that the inhibition of p185(neu) tyrosine kinase by both emodin and DK-V-47 is capable of suppressing the HER-2/neu associated transformed phenotypes including the ability to induce metastatic potential. Our results also support the chemotherapeutic implications of the use of either emodin or DK-V-47 to target HER-2/neu-overexpressing cancer cells.	Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Natl Taiwan Univ, Dept Oncol, Taipei 10764, Taiwan; Purdue Univ, Dept Med Chem & Pharmacognosy, W Lafayette, IN 47907 USA; Natl Res Inst Chinese Med, Taipei 11211, Taiwan; Natl Yang Ming Med Coll, Taipei 11211, Taiwan; Univ Texas, MD Anderson Cancer Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; National Taiwan University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; National Research Institute of Chinese Medicine; National Yang Ming Chiao Tung University; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Box 79, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Hong, Ruey-Long/0000-0001-8100-7914	NCI NIH HHS [CA 60856, CA 50743, CA 58880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880, U01CA050743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JAYASURIYA H, 1992, J NAT PROD, V55, P696, DOI 10.1021/np50083a026; KIM DSH, IN PRESS NATL PROD L; Kiyokawa N, 1997, J BIOL CHEM, V272, P18656, DOI 10.1074/jbc.272.30.18656; LACROIX H, 1989, ONCOGENE, V4, P145; LIOTTA LA, 1986, CANCER RES, V46, P1; MCCANN AH, 1991, CANCER RES, V51, P3186; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; NICOLSON G L, 1991, Current Opinion in Oncology, V3, P75, DOI 10.1097/00001622-199102000-00012; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; SADASIVAN R, 1993, J UROLOGY, V150, P126, DOI 10.1016/S0022-5347(17)35413-7; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SCHOLAR EM, 1994, CANCER LETT, V87, P159, DOI 10.1016/0304-3835(94)90217-8; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; VELTRI RW, 1994, J CELL BIOCHEM, P249; VIJVER M, 1987, MOL CELL BIOL, V7, P2019; WEINER DB, 1990, CANCER RES, V50, P421; Xia WY, 1997, CLIN CANCER RES, V3, P3; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1988, ONCOGENE, V2, P283; YOSHIDA K, 1989, VIRCHOWS ARCH B, V57, P285, DOI 10.1007/BF02899093; YU DH, 1991, ONCOGENE, V6, P1991; Yu DH, 1996, ONCOGENE, V13, P1359; YU DH, 1994, CANCER RES, V54, P3150; YUSA K, 1990, J NATL CANCER I, V82, P1633, DOI 10.1093/jnci/82.20.1633; ZHAN HE, 1990, MOL CARCINOGEN, V3, P254; ZHANG LS, 1995, CANCER RES, V55, P3890; Zhang LS, 1996, ONCOGENE, V12, P571; ZHANG X, 1989, ONCOGENE, V4, P985	46	101	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	1998	16	22					2855	2863		10.1038/sj.onc.1201813	http://dx.doi.org/10.1038/sj.onc.1201813			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671406	Bronze			2022-12-28	WOS:000073988200004
J	Hamazaki, Y; Kojima, H; Mano, H; Nagata, Y; Todokoro, K; Abe, T; Nagasawa, T				Hamazaki, Y; Kojima, H; Mano, H; Nagata, Y; Todokoro, K; Abe, T; Nagasawa, T			Tec is involved in G protein-coupled receptor- and integrin-mediated signalings in human blood platelets	ONCOGENE			English	Article						Tec; platelet; thrombin; integrin	BETA-GAMMA-SUBUNITS; TYROSINE KINASE GENE; THROMBIN-STIMULATED PLATELETS; X-LINKED AGAMMAGLOBULINEMIA; HETEROTRIMERIC G-PROTEINS; HEMATOPOIETIC-CELLS; RABBIT PLATELETS; ACTIVATION; PHOSPHORYLATION; FAMILY	Tec is a non-receptor type tyrosine kinase which is tyrosine phosphorylated and activated upon stimulation of hematopoietic cells with various cytokines. The role of Tec in G protein-coupled receptor-and integrin-mediated signalings has not been elucidated. We therefore investigated the regulation of Tec in human blood platelets. Tec was rapidly tyrosine phosphorylated in response to platelet agonists which activate G protein-coupled receptors such as thromboxane A, analog (U46619), thrombin, and thrombin receptor activating peptide (TRAP). TRAP-induced phosphorylation in Tec was significantly reduced under the conditions which abrogate fibrinogen binding to GP IIb-IIIa and subsequent platelet aggregation. However, TRAP induced significant levels of the phosphorylation even under these conditions and also in thrombasthenic platelets which lack functional GP IIb-IIIa molecules, suggesting that activation of G-protein-coupled receptor causes the phosphorylation. To clarify whether integrin engagement by itself causes the phosphorylation in Tee, we examined the state of the phosphorylation in platelets activated by integrin engagement. Platelet adhesion to immobilized fibrinogen or collagen induced significant levels of the phosphorylation. Furthermore, Tec was translocated to cytoskeleton in response to TRAP in a manner dependent on platelet aggregation, suggesting that Tec can be a component of integrin-mediated signalings. These results collectively indicate that Tec is involved in G protein-coupled receptor-and integrin-mediated signalings in human blood platelets.	Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba, Ibaraki 305, Japan; Jichi Med Sch, Dept Biol Mol, Minami Kawachi, Tochigi 32904, Japan; RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 305, Japan	University of Tsukuba; Jichi Medical University; RIKEN	Kojima, H (corresponding author), Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba, Ibaraki 305, Japan.		Hamazaki, Y*/Q-3076-2019	Hamazaki, Y*/0000-0001-5866-7340				AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CLARK EA, 1994, J BIOL CHEM, V269, P28859; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DHAR A, 1990, MOL PHARMACOL, V37, P519; FAURE M, 1994, J BIOL CHEM, V269, P7851; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kojima H, 1995, THROMB HAEMOSTASIS, V74, P1541; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MACHIDE M, 1995, ONCOGENE, V11, P619; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1995, BLOOD, V85, P343; MANO H, 1993, ONCOGENE, V8, P417; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Miyazato A, 1996, CELL GROWTH DIFFER, V7, P1135; ODA A, 1992, J BIOL CHEM, V267, P20075; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; Yamashita Y, 1997, EXP HEMATOL, V25, P211	45	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2773	2779		10.1038/sj.onc.1201799	http://dx.doi.org/10.1038/sj.onc.1201799			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652744				2022-12-28	WOS:000073812200009
J	Zisch, AH; Kalo, MS; Chong, LD; Pasquale, EB				Zisch, AH; Kalo, MS; Chong, LD; Pasquale, EB			Complex formation between EphB2 and Src requires phosphorylation of tyrosine 611 in the EphB2 juxtamembrane region	ONCOGENE			English	Article						autophosphorylation sites; neuronal signaling pathways; receptor tyrosine kinase; two-hybrid system	PROTEIN KINASE-C; GROWTH-FACTOR; IN-VITRO; SIGNAL-TRANSDUCTION; NEURAL RETINA; COMMISSURAL AXONS; DOMAIN BINDING; CDNA CLONING; SH2 DOMAIN; RECEPTOR	The cellular components of the neuronal signaling pathways of Eph receptor tyrosine kinases are only beginning to be elucidated. Here we show that in vivo tyrosine phosphorylation sites of the Eph receptors EphA3, EphA4, and EphB2 in embryonic retina serve as binding sites for the Src-homology 2 (SH2) domain of Src kinase, Furthermore, tyrosine-phosphorylated EphB2 was detected in Src immunoprecipitates from transfected Cos cells, indicating that EphB2 and Src can physically associate. Interestingly, a form of Src with reduced electrophoretic mobility and increased tyrosine phosphorylation was detected in Cos cells expressing tyrosine-phosphorylated EphB2, suggesting a functional interaction between EphB2 and Src. Yeast two-hybrid analysis in conjunction with site-directed mutagenesis demonstrated that phosphorylated tyrosine 611 in the juxtamembrane region of EphB2 is crucial for the interaction with the SH2 domain of Src, In contrast, binding of the carboxy-terminal SH2 domain of phospholipase C gamma was not abolished upon mutation of tyrosine 611 in EphB2, Phosphopeptide mapping of autophosphorylated full-length EphB2, and wild-type and tyrosine to phenylalanine mutants of the EphB2 cytoplasmic domain fused to LexA, showed tyrosine 611 in the sequence motif YEDP as a major site of autophosphorylation in EphB2, Our mutational analysis also indicated that tyrosines 605 and 611 are important for EphB2 kinase activity. We propose Src kinase as a downstream effector that mediates the neuron's response to Eph receptor activation.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, La Jolla, CA 92037 USA.				NEI NIH HHS [EY105576] Funding Source: Medline; NICHD NIH HHS [HD25938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BIXBY JL, 1993, J NEUROSCI, V13, P3421; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Flanagan JG, 1997, CELL, V90, P403; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; FOX GM, 1995, ONCOGENE, V10, P897; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; Hall CL, 1996, ONCOGENE, V13, P2213; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; INGRAHAM CA, 1992, ONCOGENE, V7, P95; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Lombardo CR, 1995, BIOCHEMISTRY-US, V34, P16456, DOI 10.1021/bi00050a029; Maness P.F., 1992, Seminars in Cell Biology, V3, P117; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; SAJJADI FG, 1993, ONCOGENE, V8, P1807; Schindelholz B, 1997, J NEUROSCI, V17, P8391; SHAO HN, 1994, J BIOL CHEM, V269, P26606; Soans C, 1996, J CELL BIOL, V135, P781, DOI 10.1083/jcb.135.3.781; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; SUDOL M, 1993, ONCOGENE, V8, P823; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; TWAMLEYSTEIN GM, 1993, ONCOGENE, V7, P1893; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; ZHENG XF, 1989, ONCOGENE, V4, P99; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U; ZISCH AH, 1995, MOL CELL NEUROSCI, V6, P263, DOI 10.1006/mcne.1995.1021	83	100	103	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	1998	16	20					2657	2670		10.1038/sj.onc.1201823	http://dx.doi.org/10.1038/sj.onc.1201823			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632142				2022-12-28	WOS:000073698200010
J	Rubino, D; Driggers, P; Arbit, D; Kemp, L; Miller, B; Coso, O; Pagliai, K; Gray, K; Gutkind, S; Segars, J				Rubino, D; Driggers, P; Arbit, D; Kemp, L; Miller, B; Coso, O; Pagliai, K; Gray, K; Gutkind, S; Segars, J			Characterization of Brx, a novel Dbl family member that modulates estrogen receptor action	ONCOGENE			English	Article						estrogen receptor; signal transduction; Rho GTPase; Cdc42Hs; Dbl; Rho GEF; Lbc	GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; LIGAND-INDEPENDENT ACTIVATION; STEROID-HORMONE RECEPTORS; HUMAN BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; MEDIATED TRANSCRIPTION; SIGNALING PATHWAYS; STRUCTURAL SIMILARITIES; SEQUENCE SIMILARITY	Regulation of gene activation by the estrogen receptor (ER) is complex and involves co-regulatory proteins, oncoproteins (such as Fos and Jun), and phosphorylation signaling pathways. Here we report the cloning and initial characterization of a novel protein, Err, that contains a region of identity to the oncogenic Rho-guanine nucleotide exchange (Rho-GEF) protein Lbc, and a unique region capable of binding to nuclear hormone receptors, including the ER, Western and immunohistochemistry studies showed Brx to be expressed in estrogen-responsive reproductive tissues, including breast ductal epithelium, Err bound specifically to the ER via an interaction that required distinct regions of ER and Brx. Furthermore, overexpression of Brx in transfection experiments using an estrogen-responsive reporter revealed that Err augmented gene activation by the ER in an element-specific and ligand-dependent manner, Moreover, activation of ER by Brx could be specifically inhibited by a dominant-negative mutant of Cdc42Hs, but not by dominant negative mutants of RhoA or Rac1. Taken together, these data suggest that Err represents a novel modular protein that may integrate cytoplasmic signaling pathways involving Rho family GTPases and nuclear hormone receptors.	NICHHD, Off Sci Director, NIH, Bethesda, MD 20892 USA; NICHD, DEB, NIH, Bethesda, MD 20892 USA; NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Uniformed Services University of the Health Sciences - USA	Segars, J (corresponding author), NICHHD, Off Sci Director, NIH, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Rubino, Domenica/0000-0002-3072-2819				ADAMS JM, 1992, ONCOGENE, V7, P611; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ANZANO MA, 1994, CANCER RES, V54, P4614; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Beatson GW, 1896, LANCET, V2, P162, DOI DOI 10.1016/S0140-6736(01)72384-7; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CARR DW, 1992, J BIOL CHEM, V267, P13376; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1994, ONCOGENE, V9, P1057; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GALLAND F, 1992, ONCOGENE, V7, P585; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; MARKS MS, 1992, MOL ENDOCRINOL, V6, P219, DOI 10.1210/me.6.2.219; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nunez SB, 1997, MOL CELL ENDOCRINOL, V127, P27, DOI 10.1016/S0303-7207(96)03980-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OMALLEY BW, 1995, RECENT PROG HORM RES, V50, P333; ONATE SA, 1995, SCIENCE, V270, P1354; PASTERIS NG, 1994, CELL, V79, P669; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TOKSOZ D, 1994, ONCOGENE, V9, P621; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	76	68	73	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2513	2526		10.1038/sj.onc.1201783	http://dx.doi.org/10.1038/sj.onc.1201783			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627117				2022-12-28	WOS:000073672300009
J	Wood, KM; Roff, M; Hay, RT				Wood, KM; Roff, M; Hay, RT			Defective I kappa B alpha in Hodgkin cell lines with constitutively active NF-kappa B	ONCOGENE			English	Article						Hodgkin's lymphoma; NF-kappa B; I kappa B alpha	REED-STERNBERG CELLS; UBIQUITIN-PROTEASOME PATHWAY; DNA-BINDING ACTIVITY; TRANSCRIPTIONAL ACTIVATION; INDUCIBLE DEGRADATION; TERMINAL SEQUENCES; INDUCED APOPTOSIS; SIGNAL; EXPRESSION; DISEASE	The molecular mechanisms underlying Hodgkin's disease remain obscure, but it has been recognized that the neoplastic cells display high levels of constitutively active nuclear NF-kappa B. Here me demonstrate that although nuclear NF-kappa B is transcriptionally active, the Hodgkin cells fail to activate NF-KB dependent transcription in response to CD40 ligand, In three Hodgkin cell lines examined each had abnormalities in expression of I kappa B alpha which could account for the deregulated NF-kappa B. Although all three cell lines had greater than normal levels of I kappa B alpha mRNA no I kappa B alpha protein could be detected in the KM-H2 cells, while the L428 cell line contains a C-terminally truncated I kappa B alpha species that fails to associate with NF-kappa B. The HDLM-2 cell line contains a more slowly migrating form of I kappa B alpha that can associate with NF-kappa B, but increasing the level of this protein within the cell fails to inhibit nuclear NF-kappa B. Addition of recombinant I kappa B alpha to nuclear extracts from all three cell lines resulted in complete inhibition of NF-kappa B DNA binding activity and introduction of a plasmid expressing I kappa B alpha into the cells inhibited the transcriptional activity of an NF-kappa B dependent reporter plasmid, Thus the constitutive expression of NF-kappa B in Hodgkin cells is a direct consequence of the abnormal expression of I kappa B alpha rather than changes in NF-kappa B that render it refractory to inhibition by I kappa B proteins. These changes could, at least in part, account for the characteristic activated phenotype of Hodgkin cells and their pattern of cytokine secretion, which determine the pathological appearance and clinical manifestations of Hodgkin's disease.	Univ St Andrews, Sch Biol & Med Sci, St Andrews KY16 9AL, Fife, Scotland; Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	University of St Andrews; Newcastle University - UK	Hay, RT (corresponding author), Univ St Andrews, Sch Biol & Med Sci, Irvine Bldg, St Andrews KY16 9AL, Fife, Scotland.		Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CARBONE A, 1995, BLOOD, V85, P780, DOI 10.1182/blood.V85.3.780.bloodjournal853780; CARBONE A, 1995, AM J PATHOL, V146, P780; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GLAVAC D, 1994, HUM GENET, V93, P694, DOI 10.1007/BF00201573; GORSCHLUTER M, 1995, ANN ONCOL, V6, P477, DOI 10.1093/oxfordjournals.annonc.a059218; GRUSS HJ, 1994, BLOOD, V84, P2305; GRUSS HJ, 1995, EUR J IMMUNOL, V25, P2083, DOI 10.1002/eji.1830250742; Gruss HJ, 1997, IMMUNOL TODAY, V18, P156, DOI 10.1016/S0167-5699(97)84661-0; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Kadin Marshall E., 1994, Current Opinion in Oncology, V6, P456, DOI 10.1097/00001622-199409000-00002; KODURU PRK, 1993, AM J HEMATOL, V44, P117, DOI 10.1002/ajh.2830440209; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; MASON DY, 1994, AM J SURG PATHOL, V18, P526, DOI 10.1097/00000478-199405000-00014; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; OGRADY JT, 1994, AM J PATHOL, V144, P21; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAZZAGLI M, 1992, ANAL BIOCHEM, V204, P315, DOI 10.1016/0003-2697(92)90245-3; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Rodriguez MS, 1996, ONCOGENE, V12, P2425; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Stein H, 1993, Leuk Lymphoma, V10 Suppl, P99, DOI 10.3109/10428199309149120; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	62	113	115	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2131	2139		10.1038/sj.onc.1201735	http://dx.doi.org/10.1038/sj.onc.1201735			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572494				2022-12-28	WOS:000073177200011
J	Muller, C; Dusseau, C; Calsou, P; Salles, B				Muller, C; Dusseau, C; Calsou, P; Salles, B			Human normal peripheral blood B-lymphocytes are deficient in DNA-dependent protein kinase activity due to the expression of a variant form of the Ku86 protein	ONCOGENE			English	Article						DNA-PK; Ku autoantigen; B-lymphocytes; V(D)J recombination	STRAND-BREAK-REPAIR; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; SCID MUTATION; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; MAMMALIAN-CELLS; AUTOANTIGEN KU; BINDING; DEFECTS	The heterodimeric Ku protein, which comprises a 86 kDa (Ku86) amd a 70 kDa (Ku70) subunits, is an abundant nuclear DNA-binding protein which binds in vitro to DNA termini without sequence specificity, Ku is the DNA-targeting component of the large catalytic sub-unit of the DNA-dependent protein kinase complex (DNA-PKcs), that plays a critical role in mammalian double-strand break repair and lymphoid V(D)J recombination, By using electrophoretic mobility shift assays, we demonstrated that in addition to the major Ku.DNA complex usually detected in cell line extracts, a second complex with faster electrophoretic mobility was observed in normal peripheral blood lymphocytes (PBL) extracts, The presence of this faster migrating complex was restricted to B cells among the circulating lymphocyte population, Western blot analysis revealed that B cells express a variant form of the Ku86 protein with an apparent molecular weight of 69 kDa, and not the 86 kDa- full-length protein, Although the heterodimer Ku70/variant-Ku86 binds to DNA-ends, this altered form of the Ku heterodimer has a decreased ability to recruit the catalytic component of the complex, DNA-PKcs, which contributes to an absence of detectable DIVA-PK activity in B cells, These data provide a molecular basis for the increased sensitivity of B cells to ionizing radiation and identify a new mechanism of regulation of DNA-PK activity that operates in vivo.	CNRS, Inst Pharmacol & Biol Struct, UPR 9062, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Salles, B (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UPR 9062, 205 Route Narbonne, F-31077 Toulouse, France.		MULLER, Catherine/M-2185-2018; MULLER, Catherine/E-2060-2011; salles, bernard/B-8531-2008; calsou, patrick/AAB-5123-2020	Calsou, Patrick/0000-0001-7951-9806				AJMANI AK, 1995, J EXP MED, V181, P2049, DOI 10.1084/jem.181.6.2049; ANDERSON CW, 1994, J PROTEIN CHEM, V13, P500; BARRET JM, 1995, CARCINOGENESIS, V16, P1611, DOI 10.1093/carcin/16.7.1611; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; Danska JS, 1996, MOL CELL BIOL, V16, P5507; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; FALZON M, 1993, J BIOL CHEM, V268, P10546; Finnie NJ, 1996, PHILOS T ROY SOC B, V351, P173, DOI 10.1098/rstb.1996.0014; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; GUIDOS CJ, 1996, GENE DEV, V10, P1054; Han ZY, 1996, J BIOL CHEM, V271, P14098, DOI 10.1074/jbc.271.24.14098; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jongmans W, 1996, ONCOGENE, V13, P1133; KISHI H, 1983, J IMMUNOL, V131, P1961; KU GS, 1983, J IMMUNOL, V131, P2444; MAYER PJ, 1986, MUTAT RES, V166, P275, DOI 10.1016/0167-8817(86)90027-1; MCMILLAN TJ, 1994, INT J RADIAT BIOL, V65, P49, DOI 10.1080/09553009414550071; MINORI T, 1986, J BIOL CHEM, V261, P10375; MINORI T, 1981, J CLIN INVEST, V68, P611; MULLER C, 1994, INT J CANCER, V56, P749, DOI 10.1002/ijc.2910560523; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; PROSSER JS, 1976, INT J RADIAT BIOL, V30, P459, DOI 10.1080/09553007614551271; PRUSEK W, 1979, ARCH IMMUNOL THER EX, V27, P59; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SCHWARTZ JL, 1980, ENVIRON MUTAGEN, V2, P473, DOI 10.1002/em.2860020406; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; ZHU C, 1996, CELL, V876, P379	47	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1553	1560		10.1038/sj.onc.1201676	http://dx.doi.org/10.1038/sj.onc.1201676			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569022				2022-12-28	WOS:000072743200005
J	Xu, XX; Yi, TL; Tang, B; Lambeth, JD				Xu, XX; Yi, TL; Tang, B; Lambeth, JD			Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2	ONCOGENE			English	Article						Dab2; p96; DOC 2; Grb2; SH3 domain; ovarian cancer	NUCLEOTIDE EXCHANGE FACTOR; RECEPTOR TYROSINE KINASES; SRC HOMOLOGY-3 DOMAINS; SON-OF-SEVENLESS; SIGNAL-TRANSDUCTION; DROSOPHILA-ABL; ADAPTER PROTEIN; FACTOR HSOS1; RAS; IDENTIFICATION	Disabled-2 (Dab2), a mammalian structural homolog of Drosophila Disabled (Dab), is a mitogen-responsive phosphoprotein, It has been speculated to be a negative regulator of growth since its expression is lost in ovarian carcinomas, Dab2 contains a C-terminal proline-rich domain with sequences similar to those found in Sos, a guanine nucleotide exchange factor for Ras, The proline-rich sequences of Sos mediate the interaction of Sos with Grb2, an adaptor protein which coupled tyrosine kinase receptors to Sos, Herein, we have investigated the possibility that Dab2 interacts with Grb2, In experiments of co-immunoprecipitation from BAC1.2F5 macrophage cell lysates, significant quantities of Grb2 were associated with both Sos and Dab2, although Dab2 and Sos were not present in the same complex, Transfection of Dab2 into a Dab2-negative cell line (293 cells) decreased the amount of Grb2 associated with Sos, suggesting that Dab2 competes with Sos for binding to Grb2, Proline-rich peptides corresponding to Dab2 (#661-669) and to Sos (#1146-1161) inhibited the binding of Dab2 to Grb2, but were less effective in disrupting the Grb2-Sos complex, The expressed proline-rich domain of Dab2 (#600-730) bound Grb2, but other regions of Dab2 failed to bind Grb2. Both of the individual SH3 domains of Grb(2) bound to Sos (N-terminal SH3 domain > > C-terminal SH3 domain), but binding to Dab2 required the intact Grb2, suggesting cooperative binding using both SH3 domains of Grb2, These data indicate that Dab2 binds to the SH3 domains of Grb2 via its C-terminal proline-rich sequences, Dab2 may modulate growth factor/Ras pathways by competing with Sos for binding to Grb2.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Cleveland Clin Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Emory University; Emory University; Cleveland Clinic Foundation	Xu, XX (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NCI NIH HHS [R 01 CA75389-01, R01CA46508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046508, R01CA075389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; Byrne JL, 1996, ONCOGENE, V13, P2055; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LEMMON MA, 1994, J BIOL CHEM, V269, P31653; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1995, NATURE, V374, P94, DOI 10.1038/374094a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MIKI H, 1994, J BIOL CHEM, V269, P5489; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; WONG KK, 1993, INT J ONCOL, V3, P13; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; XU XX, 1993, MOL CELL BIOL, V270, P14184; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YI TL, 1991, BLOOD, V78, P2222	53	105	109	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	1998	16	12					1561	1569		10.1038/sj.onc.1201678	http://dx.doi.org/10.1038/sj.onc.1201678			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569023				2022-12-28	WOS:000072743200006
J	Flores, AM; Kassatly, RF; Cress, WD				Flores, AM; Kassatly, RF; Cress, WD			E2F-3 accumulation is regulated by polypeptide stability	ONCOGENE			English	Article						cell cycle; E2F; protein stability; Rb	TRANSCRIPTION FACTOR E2F; B-MYB TRANSCRIPTION; UBIQUITIN-PROTEASOME PATHWAY; RETINOBLASTOMA GENE-PRODUCT; BINDING PROTEIN; IN-VIVO; FAMILY; P107; EXPRESSION; PRB	E2F is a complex family of transcription factors which appears to regulate the transcription of genes required for the S phase of the mammalian cell cycle. In the present work, we have examined the mechanisms regulating E2F-3 accumulation in mouse fibroblasts. We have determined that E2F-3 DNA binding activity is restricted to the G(1)/S transition and S phase in both normal BALB/c-3T3 fibroblasts and in an SV40 virus-transformed BALB/c-3T3 derivative. Immunoblot analysis indicates that G(0) and G(1) cells have little or no E2F-3 polypeptide and that the increase in the DNA binding activity of E2F-3 at the G(1)/S boundary is reflected by an increase in total E2F-3 protein. In contrast to the E2F-3 polypeptide, RNAse protection assays demonstrate that the E2F-3 mRNA is clearly present in G(0) and G(1) cells. Finally, pulse/chase experiments indicate that the half-life of E2F-3 is approximately 40-fold greater in cells blocked in S phase relative to asynchronously growing cells. Together, these results indicate that the accumulation E2F-3 at S phase may be regulated, at least in part, at the level of protein stability.	Univ S Florida, H Lee Moffitt Canc Ctr, Mol Oncol Program, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Res Inst, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cress, WD (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Mol Oncol Program, Coll Med, 12902 Magnolia Dr, Tampa, FL 33612 USA.							ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Bennett JD, 1996, ONCOGENE, V13, P1073; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HUBER HE, 1994, J BIOL CHEM, V269, P6999; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Moberg K, 1996, MOL CELL BIOL, V16, P1436; OLSON JE, 1993, J CELL PHYSIOL, V154, P333, DOI 10.1002/jcp.1041540217; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; TAO Y, 1997, IN PRESS MOL CEL DEC; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011	43	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1289	1298		10.1038/sj.onc.1201633	http://dx.doi.org/10.1038/sj.onc.1201633			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546430				2022-12-28	WOS:000072422000007
J	Dong, JT; Sipe, TW; Hyytinen, ER; Li, CL; Heise, C; McClintock, DE; Grant, CD; Chung, LWK; Frierson, HF				Dong, JT; Sipe, TW; Hyytinen, ER; Li, CL; Heise, C; McClintock, DE; Grant, CD; Chung, LWK; Frierson, HF			PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate	ONCOGENE			English	Article						PTEN/MMAC1; prostate cancer; allelic loss; mutation; homozygous deletion	TUMOR-SUPPRESSOR GENE; GERMLINE MUTATIONS; COWDEN-DISEASE; MICROSATELLITE INSTABILITY; PTEN GENE; CANCER; DELETION; BREAST; CHROMOSOME; FREQUENT	Deletion of the q23-24 region of human chromosome 10 is one of the most frequent genetic alterations in prostate cancer, suggesting that inactivation of a tumor suppressor gene in this region is involved in the development or progression of this carcinoma. A candidate gene, PTEN/MMAC1, has been identified from this chromosomal region; mutations of this gene have been found in various advanced tumors and cell lines including those of prostate cancer. To further define the role of PTEN/MMAC1 in the development of prostate cancer and its spectrum of genetic alterations, we analysed 40 pT2 or pT3 prostate tumors for allelic loss, mutations, and homozygous deletions using PCR-based methods. Six tumors showed loss of heterozygosity for one of the ten markers analysed, while one tumor showed loss of two markers. None of the markers within PTEN/MMAC1 was lost. Direct sequencing of PCR amplified exons and intron/exon junctions of all 40 tumors revealed three sequence variants, one of which was a point mutation in exon 9, while the other two were polymorphisms. Using multiplex PCR, no homozygous deletions were detected in any of the neoplasms. Our results showing a low frequency of alterations of PTEN/MMAC1 in pT2 and pT3 prostate cancers suggest that this gene plays an insignificant role in the development of most low stage carcinomas of the prostate.	Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Urol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Dong, JT (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA.			Dong, Jin-Tang/0000-0003-2349-5782				*AM JOINT COMM CAN, 1997, AJCC CANC STAG MAN; Arch EM, 1997, AM J MED GENET, V71, P489, DOI 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.0.CO;2-B; ARPS S, 1993, CANCER GENET CYTOGEN, V66, P93, DOI 10.1016/0165-4608(93)90234-D; ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cairns P, 1997, CANCER RES, V57, P4997; Cunningham JM, 1996, CANCER RES, V56, P4475; Dong Jin-Tang, 1997, Current Opinion in Oncology, V9, P101; Dong JT, 1997, GENOMICS, V41, P25, DOI 10.1006/geno.1997.4618; GRAY IC, 1995, CANCER RES, V55, P4800; Guldberg P, 1997, CANCER RES, V57, P3660; Lacombe L, 1996, INT J CANCER, V69, P110, DOI 10.1002/(SICI)1097-0215(19960422)69:2<110::AID-IJC7>3.0.CO;2-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, CANCER RES, V57, P5254; LUNDGREN R, 1988, CANCER GENET CYTOGEN, V35, P103, DOI 10.1016/0165-4608(88)90128-8; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; Murakami YS, 1996, CANCER RES, V56, P2157; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; NIHEI N, 1995, GENE CHROMOSOME CANC, V14, P112, DOI 10.1002/gcc.2870140205; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rhei E, 1997, CANCER RES, V57, P3657; Risinger JI, 1997, CANCER RES, V57, P4736; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki H, 1998, CANCER RES, V58, P204; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Trybus TM, 1996, CANCER RES, V56, P2263; Tsou HC, 1997, AM J HUM GENET, V61, P1036, DOI 10.1086/301607; Wang SI, 1997, CANCER RES, V57, P4183	34	80	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1979	1982		10.1038/sj.onc.1202119	http://dx.doi.org/10.1038/sj.onc.1202119			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788441				2022-12-28	WOS:000076423500011
J	Rice, JC; Massey-Brown, KS; Futscher, BW				Rice, JC; Massey-Brown, KS; Futscher, BW			Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells	ONCOGENE			English	Article						BRCA1; CpG island; 5-methylcytosine; breast cancer; tumor suppressor	CLONAL CHROMOSOME-ABNORMALITIES; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; OVARIAN-CANCER; MESSENGER-RNA; LUNG-CANCER; MGMT GENE; CARCINOMAS; MUTATIONS; SITES	BRCA1 mRNA is reduced in sporadic breast cancer cells despite the lack of mutations. Because a CpG island is found at the 5' end of the BRCA1 gene, we hypothesized that the decreased BRCA1 mRNA in sporadic breast cancer was associated with aberrant cytosine methylation of the CpG island. We examined BRCA1 mRNA expression in normal human mammary epithelial cells (HMECs), peripheral blood lymphocytes (PBLs) and six sporadic breast cancer cell lines using RT-PCR. The normal breast cells expressed high levels of BRCA1 mRNA. The sporadic breast cancer cell lines and PBLs expressed lower levels of BRCA1 mRNA ranging from a 3-16-fold decrease compared to the normal breast cells. We identified a 600 bp region of the BRCA1 CpG island that possessed strong promoter activity (similar to 40-fold above control), and determined the cytosine methylation patterns of the 30 CpG sites within this region by sodium bisulfite genomic sequencing. The HMECs, PBLs and five of the sporadic breast cancer cell lines were largely unmethylated. However, one sporadic breast cancer cell line, UACC3199, was greater than or equal to 60% methylated at all 30 CpG sites (18 sites were 100% methylated) and was associated with an eightfold decrease in BRCA1 mRNA compared to normal breast cells. These findings suggest that aberrant cytosine methylation of the BRCA1 CpG island promoter may be one mechanism of BRCA1 repression in sporadic breast cancer.	Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Arizona Canc Ctr, Tucson, AZ 85724 USA; Arizona Canc Ctr, Bone Marrow Transplant Program, Tucson, AZ 85724 USA	University of Arizona; Arizona Center Cancer Care; Arizona Center Cancer Care	Futscher, BW (corresponding author), Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.		Rice, Judd C/B-7806-2009		NATIONAL CANCER INSTITUTE [R01CA065662, R29CA065662, P30CA023074] Funding Source: NIH RePORTER; NCI NIH HHS [CA65662, 3P30 CA23074-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dobrovic A, 1997, CANCER RES, V57, P3347; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREGER V, 1994, HUM GENET, V94, P491; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MELTZER P, 1991, BRIT J CANCER, V63, P727, DOI 10.1038/bjc.1991.164; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OTTERSON GA, 1995, ONCOGENE, V11, P1211; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; Pieper RO, 1996, J BIOL CHEM, V271, P13916, DOI 10.1074/jbc.271.23.13916; Qian XLC, 1997, CANCER RES, V57, P3672; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Stirzaker C, 1997, CANCER RES, V57, P2229; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; WELLS D, 1985, P NATL ACAD SCI USA, V82, P2834, DOI 10.1073/pnas.82.9.2834; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	36	202	212	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1807	1812		10.1038/sj.onc.1202086	http://dx.doi.org/10.1038/sj.onc.1202086			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778046				2022-12-28	WOS:000076303300006
J	Jarpe, MB; Widmann, C; Knall, C; Schlesinger, TK; Gibson, S; Yujiri, T; Fanger, GR; Gelfand, EW; Johnson, GL				Jarpe, MB; Widmann, C; Knall, C; Schlesinger, TK; Gibson, S; Yujiri, T; Fanger, GR; Gelfand, EW; Johnson, GL			Anti-apoptotic versus pro-apoptotic signal transduction: Checkpoints and stop signs along the road to death	ONCOGENE			English	Review						signal transduction; cell death	PROGRAMMED CELL-DEATH; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; PLECKSTRIN HOMOLOGY DOMAIN; ICE/CED-3 FAMILY PROTEASES; TUMOR-NECROSIS-FACTOR; ABL TYROSINE KINASE; NERVE GROWTH-FACTOR; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE	The activation of caspases is a final commitment step for apoptosis. It is now evident that signal transduction pathways involving specific protein kinases modulate the apoptotic response. Both pro-apoptotic and anti-apoptotic pathways integrate environmental cues that control the decision to undergo apoptosis. Pro- and anti-apoptotic signal pathways regulate the activation of the caspases. In this review we describe our current understanding of apoptotic signal transduction.	Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Div Basic Sci, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Johnson, GL (corresponding author), Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Div Basic Sci, Denver, CO 80206 USA.		Yujiri, Toshiaki/AAY-8150-2020; Widmann, Christian/N-9851-2013	Yujiri, Toshiaki/0000-0001-6838-3456; Widmann, Christian/0000-0002-6881-0363; Gibson, Spencer/0000-0003-0119-732X				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beckwith M, 1996, BLOOD, V88, P3502, DOI 10.1182/blood.V88.9.3502.bloodjournal8893502; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Brown L, 1997, NATURE, V387, P450, DOI 10.1038/387450a0; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Gulli LF, 1996, CELL GROWTH DIFFER, V7, P173; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Henderson CE, 1996, NEURON, V17, P579, DOI 10.1016/S0896-6273(00)80191-9; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ivanov VN, 1997, J BIOL CHEM, V272, P8558; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Musci MA, 1997, CLIN IMMUNOL IMMUNOP, V83, P205, DOI 10.1006/clin.1996.4315; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; PETTI RM, 1996, J BIOL CHEM, V271, P12687; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; PUNT JA, 1994, J EXP MED, V179, P709, DOI 10.1084/jem.179.2.709; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHMID DS, 1986, P NATL ACAD SCI USA, V83, P1881, DOI 10.1073/pnas.83.6.1881; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; VALENTINE MA, 1992, EUR J IMMUNOL, V22, P3141, DOI 10.1002/eji.1830221217; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	79	140	143	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1475	1482		10.1038/sj.onc.1202183	http://dx.doi.org/10.1038/sj.onc.1202183			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779994				2022-12-28	WOS:000076161900015
J	Mukhopadhyay, T; Multani, AS; Roth, JA; Pathak, S				Mukhopadhyay, T; Multani, AS; Roth, JA; Pathak, S			Reduced telomeric signals and increased telomeric associations in human lung cancer cell lines undergoing p53-mediated apoptosis	ONCOGENE			English	Article						p53; lung cancer; apoptosis; telomere; gene expression	WILD-TYPE P53; ACTIVATION; DEATH; INDUCTION; LENGTH; GROWTH	Transduction of a p53-negative H1299 human non-small cell lung cancer cell line with an adenoviral vector containing wild-type p53 (Ad5p53) induced apoptosis, Analysis of the Ad5p53-infected H1299 cells showed high levels of telomeric association prior to apoptotic nuclear fragmentation. Similar telomeric association was observed in stably transfected clones of the wtH226b cell line, which expressed exogenous wild-type p53 protein and also showed complex chromosomal abnormalities including dicentrics, rings and fragments, Fluorescence ill situ hybridization (FISH) analysis using a human telomeric DNA probe indicated reductions in telomere signals in both Ad5p53-infected H1299 cells and wtH226b-S cells. In contrast, stably transfected wtH226b-AS clones expressing antisense p53 cDNA showed no telomeric association and had high levels of telomeric signals associated with a faster growing phenotype, These results suggest that wild-type p53 is involved in shortening telomeres, a possibly early event in the p53-mediated apoptotic process and in the subsequent telomeric association that predisposes a cell to genetic instability and DNA fragmentation resulting in apoptotic cell death. Moreover, loss of telomeric signals may indicate a cell's decision to undergo programmed cell death and, if so, could, serve as a sensitive marker of p53-mediated apoptosis.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [R01 CA45187, P50-CA70907, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA070907, R01CA045187] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; HEALY KC, 1995, ONCOL RES, V7, P121; HIYAMA K, 1995, ONCOGENE, V10, P937; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; PATHAK S, 1994, INT J ONCOL, V4, P323; Pathak S., 1994, In Vivo (Attiki), V8, P843; Pathak S., 1996, Archivos de Zootecnia, V45, P141; PATHAK S, 1976, J REPROD MED, V17, P25; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Seegers JC, 1997, J STEROID BIOCHEM, V62, P253, DOI 10.1016/S0960-0760(97)00043-5; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	24	21	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					901	906		10.1038/sj.onc.1202011	http://dx.doi.org/10.1038/sj.onc.1202011			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780006				2022-12-28	WOS:000075448800011
J	Zhang, N; Chen, P; Gatei, M; Scott, S; Khanna, KK; Lavin, MF				Zhang, N; Chen, P; Gatei, M; Scott, S; Khanna, KK; Lavin, MF			An anti-sense construct of full-length ATM cDNA imposes a radiosensitive phenotype on normal cells	ONCOGENE			English	Article						ataxia-telangiectasia; ATM; anti-sense cDNA; radiosensitivity; cell cycle	ATAXIA-TELANGIECTASIA CELLS; CYCLE CHECKPOINT PATHWAY; ABL TYROSINE KINASE; IONIZING-RADIATION; DNA-SYNTHESIS; GENE-PRODUCT; C-ABL; DEFICIENT MICE; PROTEIN; DAMAGE	The cloning of a full-length cDNA for the gene (ATM) mutated in the human genetic disorder ataxia-telangiectasia (A-T) has been described recently. This cDNA, as well as a fragment representing a functional region from ATM, are capable of rescuing various aspects of the radiosensitive phenotype in A-T cells. We have subcloned full-length ATM cDNA in the opposite orientation in an EBV-based vector under the control of an inducible promoter to determine whether this anti-sense construct might sensitize control lymphoblastoid cells to ionizing radiation, The effectiveness of expression of this construct in control cells was monitored by loss of ATM protein which was evident over a period 6-12 h after induction. Under these conditions radiosensitivity was enhanced approximately threefold in control cells, approaching the degree of radiosensitivity observed in A-T cells. Expression of the anti-sense construct also increased the number of radiation-induced chromosomal breaks and led to the appearance of radioresistant DNA synthesis in these cells. Abrogation of the G1/S checkpoint was evident from the loss of the p53 response and that of its downstream effector, p21/WAF1, post-irradiation. The extent of accumulation of transfected cells in G2/M phase at 24 h post-irradiation was similar to that observed in A-T cells and the induction of stress-activated protein kinase by ionizing radiation was prevented by antisense ATM cDNA expression. These data demonstrate that full-length ATM anti-sense cDNA, by reducing the amount of ATM protein, is effective in imposing a series of known defects characteristic of the A-T phenotype, This inducible system provides an experimental model to further investigate mechanisms underlying radiosensitivity and cell cycle control.	Queensland Canc Fund, Res Labs, Brisbane, Qld 4029, Australia; Queensland Inst Med Res, Dept Surg, Brisbane, Qld 4029, Australia	Cancer Council Queensland; QIMR Berghofer Medical Research Institute	Lavin, MF (corresponding author), Queensland Canc Fund, Res Labs, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.		Khanna, Kum Kum/I-1747-2013; Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BODER E, 1985, ATAXIA TELANGIECTASI, V19, P1; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CANMAN CE, 1994, CANCER RES, V54, P5054; Chen P, 1996, INT J RADIAT BIOL, V69, P385, DOI 10.1080/095530096145940; CHEN P, 1994, CANCER GENET CYTOGEN, V76, P43, DOI 10.1016/0165-4608(94)90069-8; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; COLE J, 1988, INT J RADIAT BIOL, V54, P929, DOI 10.1080/09553008814552331; COQUERELLE TM, 1987, INT J RADIAT BIOL, V51, P209, DOI 10.1080/09553008714550711; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; FORAY N, 1997, IN PRESS INT J RAD B; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khanna KK, 1997, J BIOL CHEM, V272, P9489; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lakin ND, 1996, ONCOGENE, V13, P2707; LAVIN MF, 1992, CANCER GENET CYTOGEN, V60, P183, DOI 10.1016/0165-4608(92)90014-Y; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LAVIN MF, 1988, MUTAT RES, V193, P193, DOI 10.1016/0167-8817(88)90030-2; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MCFARLIN DE, 1972, MEDICINE, V51, P281, DOI 10.1097/00005792-197207000-00002; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; ROSIN MP, 1986, HUM GENET, V74, P335, DOI 10.1007/BF00280482; RUDOLPH NS, 1989, MUTAT RES, V211, P19, DOI 10.1016/0027-5107(89)90103-6; SANFORD KK, 1990, CHROMOSOMAL ABERRATI, P113; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SCOTT D, 1994, INT J RADIAT BIOL, V66, pS157, DOI 10.1080/09553009414551991; SCOTT D, 1982, INT J RADIAT BIOL, V42, P679, DOI 10.1080/09553008214551661; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHILOH Y, 1986, LANCET, V1, P689; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TAYLOR AMR, 1982, ATAXIA TELANGIECTASI, P53; Telatar M, 1996, AM J HUM GENET, V59, P40; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; ZIV Y, 1995, SOMAT CELL MOLEC GEN, V21, P99, DOI 10.1007/BF02255785	66	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	1998	17	7					811	818		10.1038/sj.onc.1202007	http://dx.doi.org/10.1038/sj.onc.1202007			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9779997				2022-12-28	WOS:000075448800002
J	Watson, RH; Neville, PJ; Roy, WJ; Hitchcock, A; Campbell, IG				Watson, RH; Neville, PJ; Roy, WJ; Hitchcock, A; Campbell, IG			Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis	ONCOGENE			English	Article						loss of heterozygosity; tumour suppressor gene; ovarian cancer	LOW-GRADE; CANCER; CARCINOMAS; MUTATION; TUMORS; DELETION; FREQUENT; PROTEIN; REGIONS; BENIGN	Forty early stage malignant and seven borderline ovarian tumours mere analysed for loss of heterozygosity (LOH) on chromosomes 6, 7, 9, 11 and 7, LOH involving at least one locus was observed in 32 (80%) early stage and six (86%) borderline tumours, Frequent LOH in the early stage tumours was detected on chromosome arms 7p (31%), 7q (50%), 9p (42%) and 11q (34%) suggesting that these chromosomes harbour tumour suppressor genes which are inactivated early in tumorigenesis, Borderline tumours exhibited a similar pattern of LOH to that observed in the early stage malignant tumours, indicating that the development of both malignant and borderline forms may involve inactivation of the same set of tumour suppressor genes. Together with our previous investigation of benign ovarian tumours this data supports the theory that malignant ovarian tumours may arise from benign and borderline precursors.	Princess Anne Hosp, Southampton SO16 5YA, Hants, England; Southampton Gen Hosp, Dept Histopathol, Southampton SO16 6YD, Hants, England	University of Southampton	Watson, RH (corresponding author), Princess Anne Hosp, Level F,Coxford Rd, Southampton SO16 5YA, Hants, England.		campbell, Ian G/F-6006-2011	Campbell, Ian/0000-0002-7773-4155				CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CAMPBELL IG, 1995, INT J CANCER, V63, P222, DOI 10.1002/ijc.2910630213; CHAMPENE MH, 1995, GENE CHROMOSOME CANC, V4, P304; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; CLIBY W, 1993, CANCER RES, V53, P2393; Davis M, 1996, CANCER RES, V56, P741; Devlin J, 1996, BRIT J CANCER, V73, P420, DOI 10.1038/bjc.1996.75; DODSON MK, 1993, CANCER RES, V53, P4456; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULKES WD, 1995, BRIT J CANCER, V72, P883, DOI 10.1038/bjc.1995.428; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; ISHWAD CS, 1995, GENE CHROMOSOME CANC, V14, P51, DOI 10.1002/gcc.2870140109; Kerr J, 1996, ONCOGENE, V13, P1815; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; Lane RP, 1996, GENOMICS, V35, P456, DOI 10.1006/geno.1996.0385; Latil A, 1995, CLIN CANCER RES, V1, P1385; Li DW, 1996, CARCINOGENESIS, V17, P1751, DOI 10.1093/carcin/17.8.1751; MILNER BJ, 1993, CANCER RES, V53, P2128; MULLENBACH R, 1989, TRENDS GENET, V5, P391; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; Roy WJ, 1997, ONCOGENE, V15, P2031, DOI 10.1038/sj.onc.1201372; SAITO S, 1992, CANCER RES, V52, P5815; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; Skomedal H, 1997, J PATHOL, V181, P158; TIBLETTI MG, 1996, CANCER RES, V56, P4493; Turkmen B, 1997, ELECTROPHORESIS, V18, P686, DOI 10.1002/elps.1150180505; Werness BA, 1997, HUM PATHOL, V28, P626, DOI 10.1016/S0046-8177(97)90087-3; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZHENG JP, 1995, J NATL CANCER I, V87, P1146, DOI 10.1093/jnci/87.15.1146; ZHENG JP, 1993, CANCER RES, V53, P4138	33	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					207	212		10.1038/sj.onc.1201945	http://dx.doi.org/10.1038/sj.onc.1201945			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674705				2022-12-28	WOS:000074706700009
J	Spinella, MJ; Kitareewan, S; Mellado, B; Sekula, D; Khoo, KS; Dmitrovsky, E				Spinella, MJ; Kitareewan, S; Mellado, B; Sekula, D; Khoo, KS; Dmitrovsky, E			Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells	ONCOGENE			English	Article						retinoic acid; differentiation; embryonal carcinoma; teratocarcinoma; retinoid receptors	ACUTE PROMYELOCYTIC LEUKEMIA; 2ND PRIMARY TUMORS; ACID RECEPTOR; NEURONAL DIFFERENTIATION; HUMAN TERATOCARCINOMAS; SELECTIVE LIGANDS; RESPONSE ELEMENT; BINDING-PROTEIN; CO-REPRESSOR; ALPHA	This study addresses the contributions of specific retinoid receptors during all-trans-retinoic acid (RA)-mediated differentiation and growth suppression of human embryonal carcinoma cells. The pleiotropic effects of RA are mediated bg retinoic acid receptors (RARs) and retinoid, X receptors (RXRs), members of the nuclear receptor family of transcription factors, After RA-treatment the multipotent human embryonal carcinoma cell line NTERA-2 clone D1 (NT2/D1) displays limited proliferative potential, reduced tumorigenicity, and morphologic and immunophenotypic neuronal maturation. RAR gamma over-expression in NT2/D1 cells signals mesenchymal NT2/D1 terminal differentiation while RAR alpha and RAR beta do not and RAR gamma overcomes retinoid resistance in an NT2/D1 clone (NT2/D1-R1) having deregulated RAR gamma expression, Since RAR gamma transfectants do not display neuronal maturation, this study sought to identify cooperating retinoid receptors engaged in NT2/D1 differentiation. Through gain of function experiments, this report highlights RXR beta as playing an important role along with RAR gamma in signaling differentiation of NTZ/DI cells. Stable over-expression of RXR beta, but not RXR alpha or RXR gamma, was found to signal NT2/D1 growth suppression and to induce a non-neuronal morphology and immunophenotype pe. Notably, co-transfection of RAR gamma, and RXR beta resulted in marked growth suppression and for the first time, expression of typical neuronal markers of NT2/D1 differentiation. To clarify the role of RXR beta and RAR gamma in this differentiation program, a modified transient fibroblast growth factor-4 (FGF4) promoter-enhancer reporter assay that reflects effective RA-mediated differentiation of NT2/D1 cells was employed, Transfection of RAR gamma or RXR beta in NT2/D1 cells augments transcriptional repression of the FGF4 reporter and RAR gamma and RXR beta co-transfection markedly repressed reporter activity, indicating the combined role of these receptors in RA-induced NT2/D1 differentiation. Taken together, these findings reveal specific retinoid receptors must cooperate to signal terminal growth suppression and maturation of NT2/D1 cells. Since the transcriptional repression of FGF4 is coupled to the effective maturation of human embryonal carcinoma cells, the described co-transfection strategy should prove useful to identify genes with positive or negative effects on the differentiation program of these tumor cells.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mem Hosp & Mol Pharmacol & Therapeut Program, Dept Med,Lab Mol Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Spinella, MJ (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mem Hosp & Mol Pharmacol & Therapeut Program, Dept Med,Lab Mol Med, New York, NY 10021 USA.		Spinella, Michael/B-7210-2014		NCI NIH HHS [R01-CA54494-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn MJ, 1995, ONCOGENE, V11, P2357; AHN MJ, 1995, ONCOGENE, V10, P2307; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1986, DIFFERENTIATION, V31, P119, DOI 10.1111/j.1432-0436.1986.tb00392.x; ANGULO A, 1995, J VIROL, V69, P3831, DOI 10.1128/JVI.69.6.3831-3837.1995; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; Collignon J, 1996, DEVELOPMENT, V122, P509; Costa SL, 1996, EXP CELL RES, V225, P35, DOI 10.1006/excr.1996.0154; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; DOLLE P, 1990, DEVELOPMENT, V110, P1133; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; Horn V, 1996, FASEB J, V10, P1071, DOI 10.1096/fasebj.10.9.8801169; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JETTEN AM, 1979, NATURE, V278, P180, DOI 10.1038/278180a0; Kastner P, 1997, DEVELOPMENT, V124, P313; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KRUYT FAE, 1991, MECH DEVELOP, V33, P171, DOI 10.1016/0925-4773(91)90025-2; KURIE JM, 1993, DIFFERENTIATION, V54, P123; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LaVistaPicard N, 1996, MOL CELL BIOL, V16, P4137; Lei W, 1997, J MOL ENDOCRINOL, V18, P167, DOI 10.1677/jme.0.0180167; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LOTAN R, 1995, CANCER RES, V55, P232; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; Mills KJ, 1996, CELL GROWTH DIFFER, V7, P327; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; Muto Y, 1996, NEW ENGL J MED, V334, P1561, DOI 10.1056/NEJM199606133342402; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; ONATE SA, 1995, SCIENCE, V270, P1354; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Sporn M.B., 1994, RETINOIDS BIOL CHEM; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	66	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	1998	16	26					3471	3480		10.1038/sj.onc.1201876	http://dx.doi.org/10.1038/sj.onc.1201876			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692555				2022-12-28	WOS:000074544100014
J	Fagioli, M; Alcalay, M; Tomassoni, L; Ferrucci, PF; Mencarelli, A; Riganelli, D; Grignani, F; Pozzan, T; Nicoletti, I; Grignani, F; Pelicci, PG				Fagioli, M; Alcalay, M; Tomassoni, L; Ferrucci, PF; Mencarelli, A; Riganelli, D; Grignani, F; Pozzan, T; Nicoletti, I; Grignani, F; Pelicci, PG			Cooperation between the RING+B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival	ONCOGENE			English	Article						PML; Ring; B-boxes; coiled-coil; apoptotic cell death	ACUTE PROMYELOCYTIC LEUKEMIA; GREEN FLUORESCENT PROTEIN; RAR-ALPHA; T(15-17) TRANSLOCATION; NUCLEAR MATRIX; ZINC FINGER; GENE; FUSION; EXPRESSION; BINDING	PML/RAR alpha is the abnormal protein product of the Acute Promyelocytic Leukemia-specific 15;17 translocation, Both the PML and RAR alpha components are required for the PML/RAR alpha biological activities, namely its capacity to block differentiation and to increase survival of haematopoietic precursors. The physiological role of PML and its contribution to the function of the fusion protein are unknown. PML; localizes to the cytoplasm and within specific nuclear bodies (NBs), In vitro, overexpression of PML correlates with suppression of cell transformation. The PML aminoterminal portion retained within the PML/RAR alpha protein contains the RING finger, two newly defined cystein/histidine-rich motifs called B-boxes (B1 and B2) and a coiled-coil region, We report here that PML has a growth suppressive activity in all the cell lines tested, regardless of their transformed phenotype, and that the cellular basis for the PML growth suppression is induction of apoptotic cell death. Analysis of various nuclear and cytoplasmic PML isoforms showed that the PML growth suppressive activity correlates with its nuclear localization. Analysis of the localization and growth suppressive activity demonstrated that: (i) the Ring + B1-B2 and coiled-coil regions are both indispensable and sufficient to target PML to the NBs; (ii) individual deletions of the various PML domains have no effect on its growth suppressor activity; (iii) the Ring + B1-B2 region exerts a partial growth suppressor activity but its fusion with the coiled-coil region is sufficient to recapitulate the suppressive function of wild type PML, These results indicate that PML is involved in cell survival regulation and that the PML component of the fusion protein (Ring+B1-B2 and coiled-coil regions) retains intact biological activity, thereby suggesting that the effects of PML/RAR alpha on survival derive from the activation of the incorporated PML sequence.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Perugia, Monteluce Policlin, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Study Mitochrondial Physiol, I-35121 Padua, Italy	IRCCS European Institute of Oncology (IEO); University of Perugia; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020; Alcalay, Myriam/AAB-4300-2019; Ferrucci, Pier Francesco/AAQ-9002-2020; Alcalay, Myriam/B-3182-2016; Grignani, Francesco/AAC-2565-2022	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Ferrucci, Pier Francesco/0000-0001-6255-5851				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALCALAY M, 1998, IN PRESS MOL CELL BI; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Boddy MN, 1996, ONCOGENE, V13, P971; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EPSTEIN AL, 1984, J VIROL, V50, P372, DOI 10.1128/JVI.50.2.372-379.1984; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gambacorta M, 1996, AM J PATHOL, V149, P2023; GANDINI D, 1994, BLOOD, V84, pA439; Gorczyca W., 1993, CANCER RES, V53, P945; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PAGLIACCI MC, 1993, LYMPHOKINE CYTOK RES, V12, P439; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; ROGAIA D, 1995, LEUKEMIA, V9, P1467; Stadler M, 1995, ONCOGENE, V11, P2565; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TKAHASHI M, 1988, MOL CELL BIOL, V8, P1853; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	51	59	60	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2905	2913		10.1038/sj.onc.1201811	http://dx.doi.org/10.1038/sj.onc.1201811			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671411				2022-12-28	WOS:000073988200009
J	Tzeng, YJ; Zimmermann, C; Guhl, E; Berg, B; Avantaggiati, ML; Graessmann, A				Tzeng, YJ; Zimmermann, C; Guhl, E; Berg, B; Avantaggiati, ML; Graessmann, A			SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors	ONCOGENE			English	Article						SV40 T-antigen; transgenic animals; apoptosis; immortalization; breast cancer; p53 missense mutation	LARGE T-ANTIGEN; EPITHELIAL-CELLS; TRANSGENIC MICE; BREAST-CANCER; C-MYC; GENE; PROTEIN; IMMORTALIZATION; SUPPRESSION; INDUCTION	We recently established transgenic animals (WAP-SV-T/t) carrying the early coding region of Simian Virus 40 (SV40) under the transcriptional control of the whey acidic milk protein promoter (WAP), which restricts the expression of the transgene to mammary gland epithelial cells (ME-cells). SV40 T/t-antigen synthesis causes premature mammary gland involution during late pregnancy by inducing apoptosis and leads to development of mammary tumors after the first lactation period in both p53 positive (WAP-SV-T/t) and p53 negative double transgenic animals (WAP-SV-T/t.p53 -/-), The high apoptotic rate persists in all of the T/t-antigen positive breast tumor cells, as well as in established ME-tissue culture cell lines. ME-cells which spontaneously switch off the expression of the WAP-SV-T/t transgene do not undergo apoptosis, However, these cells again exhibit an extensive DNA fragmentation when SV40 T/t-antigen synthesis is reintroduced, which indicates that it is the expression of T/t antigen which is the critical factor for induction of apoptosis, In addition, we isolated several ME-cell lines from different breast tumors which hale spontaneously lost the T/t-antigen yet remain maximally transformed. Strikingly, these cells contain a missense mutation of the p53 gene at codon 242 (p53(242)), which substitutes alanine for glycine, This mutation increases p53 stability and it reduces the transactivating function of p53, albeit without affecting the ability of the protein to interact with the DNA. This indicates that p53 missense mutations are selected for in breast tumors initially expressing T/t-antigen. Therefore, the p53(242) mutation is sufficient to maintain the transformed state after the ME-cells have switched off the WAP-SV-T/t transgene, Interestingly, the p53 minus state per se is not sufficient to induce ME-cell transformation since homozygous null mice for the p53 gene (p53-/-) fail to develop breast cancer.	Free Univ Berlin, Inst Biochem & Mol Biol, D-14195 Berlin, Germany; SUNY Buffalo, Sch Med, Dept Microbiol, Buffalo, NY 14214 USA	Free University of Berlin; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Graessmann, A (corresponding author), Free Univ Berlin, Inst Biochem & Mol Biol, Arnimallee 22, D-14195 Berlin, Germany.							Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Celis JE, 1994, CELL BIOL, P305; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GRAESSMANN M, 1976, P NATL ACAD SCI USA, V73, P366, DOI 10.1073/pnas.73.2.366; GUENAL I, 1995, FEBS LETT, V374, P384, DOI 10.1016/0014-5793(95)01157-A; HARTMANN A, 1997, TIG, V3, P27; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; HERMEKING H, 1995, ONCOGENE, V11, P1409; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenahan MK, 1996, ONCOGENE, V12, P1847; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTI A, 1994, ONCOGENE, V9, P1213; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Merlo GR, 1997, CELL GROWTH DIFFER, V8, P251; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; Muraoka M, 1996, ONCOGENE, V12, P1565; Namba M, 1996, CRIT REV ONCOGENESIS, V7, P19, DOI 10.1615/CritRevOncog.v7.i1-2.20; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sambrook J., 2002, MOL CLONING LAB MANU; Santarelli R, 1996, ONCOGENE, V12, P495; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Shibata MA, 1996, CANCER RES, V56, P2998; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Tzeng YJ, 1996, FEBS LETT, V380, P215, DOI 10.1016/0014-5793(96)00021-X; TZENG YJ, 1993, ONCOGENE, V8, P1965; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; ZHENG DQ, 1994, ONCOGENE, V9, P3345	40	29	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2103	2114		10.1038/sj.onc.1201733	http://dx.doi.org/10.1038/sj.onc.1201733			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572491				2022-12-28	WOS:000073177200008
J	Johnson, D; Frame, MC; Wyke, JA				Johnson, D; Frame, MC; Wyke, JA			Expression of the v-Src oncoprotein in fibroblasts disrupts normal regulation of the CDK inhibitor p27 and inhibits quiescence	ONCOGENE			English	Article						v-Src; p27; cellular transformation; CDK activity	DEPENDENT KINASE INHIBITOR; HUMAN CYCLIN-E; CELL-CYCLE; PROTEIN-KINASE; MICE LACKING; MAMMALIAN FIBROBLASTS; PHASE-TRANSITION; P27(KIP1); G(1); MITOGENESIS	To determine how an oncogenic tyrosine kinase disturbs cell cycle control we examined expression of cell cycle proteins and growth of fibroblasts reversibly transformed by a temperature sensitive mutant of v-Src (ts LA 29). ts LA 29 Rat-1 cells and normal Rat-1 cells had similar growth rates but the transformed cells traversed the G(1) phase of the cell cycle more rapidly and failed to exit cycle efficiently in response to serum starvation and cell confluence. Cyclin D1 and cyclin E levels were not elevated in growing ts LA 29 Rat-1 cells and the abbreviated GI was further accelerated by overexpression of cyclin E. A fall in cyclin E and cyclin A dependent kinase activities in Rat-1 cells in response to inhibitory growth conditions was abrogated in ts LA 29 Rat-1 cells and correlated with lack of p27 accumulation or cyclin A down regulation, the latter due to sustained cyclin A promoter activity. The expression of p27 mRNA was lower in ts LA 29 Rat-1 cells than Rat-1 cells and was elevated following v-Src inactivation concurrent with an increase in p27 promoter activity and temporary cell cycle exit. The suppression of mRNA or transcription is a novel way an oncoprotein can induce down regulation of p27 and contributes to the G(1) shortening and perturbed cell cycle regulation of the v-Src transformed cells.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Johnson, D (corresponding author), Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie CRC Labs, Mol Med Ctr, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.							BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FRAME MC, 1994, MOL BIOL CELL, V5, P1177, DOI 10.1091/mbc.5.11.1177; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kramer A, 1996, J BIOL CHEM, V271, P6579; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; PINES J, 1995, CELL CYCLE CONTROL, P144; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Spirin KS, 1996, CANCER RES, V56, P2400; Steeg PS, 1997, NAT MED, V3, P152, DOI 10.1038/nm0297-152; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; WELHAM MJ, 1990, ONCOGENE, V5, P161; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WIMMEL A, 1994, ONCOGENE, V9, P995; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; WYKE AW, 1995, CELL GROWTH DIFFER, V6, P1225; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZerfassThome K, 1996, ONCOGENE, V13, P2323	62	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					2017	2028		10.1038/sj.onc.1201727	http://dx.doi.org/10.1038/sj.onc.1201727			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591786				2022-12-28	WOS:000073079400014
J	Posern, G; Zheng, J; Knudsen, BS; Kardinal, C; Muller, KB; Voss, J; Shishido, T; Cowburn, D; Cheng, GH; Wang, BL; Kruh, GD; Burrell, SK; Jacobson, CA; Lenz, DM; Zamborelli, TJ; Adermann, K; Hanafusa, H; Feller, SM				Posern, G; Zheng, J; Knudsen, BS; Kardinal, C; Muller, KB; Voss, J; Shishido, T; Cowburn, D; Cheng, GH; Wang, BL; Kruh, GD; Burrell, SK; Jacobson, CA; Lenz, DM; Zamborelli, TJ; Adermann, K; Hanafusa, H; Feller, SM			Development of highly selective SH3 binding peptides for Crk and CRKL which disrupt Crk-complexes with DOCK180, SoS and C3G	ONCOGENE			English	Article						adapters; Crk; CRKL; SH3; peptide	PROTEIN-TYROSINE KINASE; PROLINE-RICH SEQUENCES; SRC HOMOLOGY-3 DOMAINS; C-CRK; ADAPTER PROTEINS; ABL; SPECIFICITY; RECEPTOR; IDENTIFICATION; PRODUCT	Many Src Homology 3 (SH3) domains function as molecular adhesives in intracellular signal transduction, Based on previous ultrastructural studies, short motifs which bind to the first SH3 domains of the adapters Crk and CRKL were selectively mutagenised to generate Crk/ CRKL SH3-binding peptides of very high affinity and selectivity, Affinities were increased up to 20-fold compared to the best wildtype sequences, while the selectivity against a similar SH3 domain [Grb2SH3(N)] was not only retained, but sometimes increased. Blot techniques with CST-fusion peptides and in solution precipitation assays with biotinylated high affinity Crk binding peptides (HACBPs) were subsequently used to analyse the binding of these sequences to a large panel of SH3 domain-containing fusion proteins. Only those proteins which contained the CrkSH3(1) or CRKLSH3(1) domains bound efficiently to the HACBPs. A GST-HACBP fusion protein precipitated Crk and CRKL proteins out of S-35-labelled and unlabelled cell lysates, Very little binding of other cellular proteins to HACBP was detectable, indicative of a great preference for Crk and CRKL when compared to the wide variety of other endogenous cellular proteins. Moreover, HACBP disrupted in vitro preexisting Crk-complexes with DOCK180 and the exchange factors SoS and C3G, which are known targets of Crk adapters, in a concentration dependent manner. HACBP-based molecules should therefore be useful as highly selective inhibitors of intracellular signalling processes involving Crk and CRKL.	Bavarian Julius Maximilians Univ, Inst Med Radiat & Cell Res MSZ, Mol Oncol Lab, D-97078 Wurzburg, Germany; Rockefeller Univ, Mol Oncol Lab, New York, NY 10021 USA; Rockefeller Univ, Phys Biochem Lab, New York, NY 10021 USA; MIT, Cambridge, MA 02139 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; AMGEN Boulder Inc, Peptide Technol Grp, Boulder, CO 80301 USA; Lower Saxony Inst Peptide Res IPF, D-30625 Hannover, Germany	University of Wurzburg; Rockefeller University; Rockefeller University; Massachusetts Institute of Technology (MIT); University of Pennsylvania; Fox Chase Cancer Center	Feller, SM (corresponding author), Bavarian Julius Maximilians Univ, Inst Med Radiat & Cell Res MSZ, Mol Oncol Lab, Tusert Versbacher Str 5, D-97078 Wurzburg, Germany.		Cowburn, David/A-8448-2008	Cowburn, David/0000-0001-6770-7172; Zheng, Jie/0000-0001-6524-6800	NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44356] Funding Source: Medline; NIGMS NIH HHS [GM-47021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; COWBURN D, 1995, J BIOL CHEM, V270, P26738, DOI 10.1074/jbc.270.45.26738; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; FELLER SM, 1995, METHOD ENZYMOL, V255, P369; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GREEN SA, 1985, J BIOL CHEM, V260, P9867; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sattler M, 1996, ONCOGENE, V12, P839; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TENHOEVE J, 1994, CANCER RES, V54, P2563; Torres M, 1996, ONCOGENE, V12, P77; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang BL, 1996, ONCOGENE, V12, P1921; Wang BL, 1996, ONCOGENE, V13, P1379; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4	43	67	68	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	1998	16	15					1903	1912		10.1038/sj.onc.1201714	http://dx.doi.org/10.1038/sj.onc.1201714			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591773	Bronze			2022-12-28	WOS:000073079400001
J	Whelan, RDH; Parker, PJ				Whelan, RDH; Parker, PJ			Loss of protein kinase C function induces an apoptotic response	ONCOGENE			English	Article						protein kinase C; dominant negative; apoptosis	PHORBOL ESTER RECEPTOR; DOWN-REGULATION; PERMISSIVE ACTIVATION; FLOW-CYTOMETRY; ISOTYPE-ALPHA; CELL-DEATH; PKC; DIFFERENTIATION; INVOLVEMENT; SUPPRESSION	A correlation has been observed between the dephosphorylation and downregulation of cPKC and the induction of apoptosis. This relationship is shown to be causal in COS cells where expression of dominant negative PKC alpha is shown to induce apoptosis. This response is rescued by co-expression of wild-type PKC alpha. The results demonstrate that PKC provides a survival signal that can be supplied by PKC alpha alone.	Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England	Cancer Research UK	Parker, PJ (corresponding author), Imperial Canc Res Fund, Prot Phosphorylat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933				Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; BORNANCIN F, 1997, IN PRESS J BIOL CHEM; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; Chmura SJ, 1996, CANCER RES, V56, P2711; DEKKER LV, 1992, FEBS LETT, V312, P195, DOI 10.1016/0014-5793(92)80934-9; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Emoto Y, 1996, BLOOD, V87, P1990; Freemerman AJ, 1996, MOL PHARMACOL, V49, P788; Geier A, 1996, CANCER INVEST, V14, P435, DOI 10.3109/07357909609018901; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KILEY S, 1990, J BIOL CHEM, V265, P15704; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Leszczynski D, 1996, LIFE SCI, V58, P599, DOI 10.1016/0024-3205(95)02329-1; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; Pongracz J, 1996, LEUKEMIA RES, V20, P319, DOI 10.1016/0145-2126(95)00074-7; Romanova LY, 1996, BIOCHEMISTRY-US, V35, P9900, DOI 10.1021/bi9525886; Rusnak JM, 1996, EXP CELL RES, V224, P189, DOI 10.1006/excr.1996.0127; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Sakakura C, 1996, FEBS LETT, V379, P177, DOI 10.1016/0014-5793(95)01508-6; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Tchilian EZ, 1996, IMMUNOLOGY, V87, P566, DOI 10.1046/j.1365-2567.1996.515580.x; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x; Zong ZP, 1996, BIOCHEM BIOPH RES CO, V219, P480, DOI 10.1006/bbrc.1996.0259	32	131	135	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1939	1944		10.1038/sj.onc.1201725	http://dx.doi.org/10.1038/sj.onc.1201725			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591777				2022-12-28	WOS:000073079400005
J	Kobayashi, T; Ruan, SB; Clodi, K; Kliche, KO; Shiku, H; Andreeff, M; Zhang, W				Kobayashi, T; Ruan, SB; Clodi, K; Kliche, KO; Shiku, H; Andreeff, M; Zhang, W			Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents	ONCOGENE			English	Article						Bax; Bcl-2; apoptosis; K562; chemotherapeutic agents	ANNEXIN-V; HUMAN P53; IN-VIVO; DEATH; BCL-2; EXPRESSION; PHOSPHATIDYLSERINE; INHIBITION; CISPLATIN; BCL-X(L)	Bax and Bcl-2 are a pair of important genes that control programmed cell death, or apoptosis, with Bax being the apoptosis promoter and Bcl-2 the apoptosis protector. Although the detailed mechanism is unknown, the protein products of these two genes form protein dimers with each other and the relative ratio of the two proteins is believed to be a determinant of the balance between life and death. In our preliminary study, we found that K562 erythroleukemia cells have an extremely low level of endogenous Bcl-2 expression and a fairly high level of endogenous Bax expression. We constructed Bax and Bcl-2 expression vectors and transfected them into K562 cells. We found that transfection of Bax vector increased the expression of Bax protein; a shortened form of Bax also appeared. Cell death analysis using the Annexin V assay showed that the Bax vector caused significantly more apoptotic cells that the Bcl-2 or pCI-neo vector did. After selection with G418, Bax, Bcl-2 and pCI-neo stably transfected cells were established. These three cell Lines were examined for their response to the chemotherapeutic agents ara-C, doxorubicin, etoposide and SN-38. Bax-K562 cells showed significantly higher fractions of apoptotic cells than pCI-neo-K562 cells when treated with ara-C, doxorubicin or SN-38. No sensitization effect was seen when etoposide was used. In contrast, Bcl-2-K562 cells had fewer apoptotic cells than pCI-neo-K562 cells after treatment with all these agents. Therefore, Bax may sensitize K562 cells to apoptosis induced by a wide range of, but not all, chemotherapeutic agents.	Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Hematol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Mie Univ, Sch Med, Dept Internal Med 2, Tsu, Mie 514, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Mie University	Zhang, W (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA55164, CA57639, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164, R01CA057639, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boersma AWM, 1996, CYTOMETRY, V24, P123, DOI 10.1002/(SICI)1097-0320(19960601)24:2<123::AID-CYTO4>3.0.CO;2-K; Ibrado AM, 1996, CANCER RES, V56, P4743; Kobayashi T, 1995, ONCOGENE, V11, P2311; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Simonian PL, 1996, J BIOL CHEM, V271, P32073, DOI 10.1074/jbc.271.50.32073; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	23	71	79	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1587	1591		10.1038/sj.onc.1201681	http://dx.doi.org/10.1038/sj.onc.1201681			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569026				2022-12-28	WOS:000072743200009
J	Ostrowski, J; Florio, SK; Denis, GV; Suzuki, H; Bomsztyk, K				Ostrowski, J; Florio, SK; Denis, GV; Suzuki, H; Bomsztyk, K			Stimulation of p85/RING3 kinase in multiple organs after systemic administration of mitogens into mice	ONCOGENE			English	Article						RING3 nuclear kinase; EGF; IL-1; leukemia	ACTIVATED-PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR; MOUSE-LIVER; MAP KINASE; CASCADE; PHOSPHORYLATES; INTERLEUKIN-1; DOMAIN	Using an autophosphorylation membrane assay, we examined activation of kinases in different organs after intraperitoneal injections of mitogens and cytokines into mice, In the multiple organs examined administration of either epidermal growth factor (EGF), phorbol 12-myristate 13-acetate (PMA) or interleukin-1 beta (IL-1 beta) activated a number of kinases, Most notably among those was a kinase of approximately 85 kDa (p85) that was activated by EGF, PMA and IL-1 beta in the lung, kidney, brain, liver and heart, The size and properties of this enzyme are indistinguishable from the RING3 kinase that has a very high activity in leukocytes of patients with leukemia, In animals treated with PMA, antibodies against RING3 kinase immunoprecipitated PMA-responsive p85 activity from the lung and brain suggesting that p85 and RING3 kinases are the same enzymes, Activation of p85/RING3 kinase by growth factors in multiple organs might reflect involvement of this enzyme in the pathogenesis of leukemias and other proliferative diseases.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA; Ctr Canc, Dept Gastroenterol, Warsaw, Poland	University of Washington; University of Washington Seattle; Boston University	Bomsztyk, K (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.			Ostrowski, Jerzy/0000-0003-1363-3766; Denis, Gerald/0000-0001-9886-0401	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45134, GM42508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPINI G, 1994, HEPATOLOGY, V20, P494, DOI 10.1002/hep.1840200231; Beck S, 1992, DNA Seq, V2, P203, DOI 10.3109/10425179209020804; BIRD TA, 1994, FEBS LETT, V338, P31, DOI 10.1016/0014-5793(94)80111-8; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Denis GV, 1996, GENE DEV, V10, P261, DOI 10.1101/gad.10.3.261; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DINARELLO CA, 1991, BLOOD, V77, P1627; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; LAURENCE DJR, 1990, TUMOR BIOL, V11, P229, DOI 10.1159/000217659; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; OBRIAN CA, 1989, CANCER METAST REV, V8, P199, DOI 10.1007/BF00047337; RACHIE NA, 1993, J BIOL CHEM, V268, P22143; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976	25	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	1998	16	9					1223	1227		10.1038/sj.onc.1201624	http://dx.doi.org/10.1038/sj.onc.1201624			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528865				2022-12-28	WOS:000072336000014
J	Praml, C; Amler, LC; Dihlmann, S; Finke, LH; Schlag, P; Schwab, M				Praml, C; Amler, LC; Dihlmann, S; Finke, LH; Schlag, P; Schwab, M			Secretory Type II Phospholipase A(2) (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa	ONCOGENE			English	Article						secretory phospholipase A(2); PLA2G2A; Mom1; Min; FAP; 1p; colorectal cancer	FAMILIAL ADENOMATOUS POLYPOSIS; MULTIPLE INTESTINAL NEOPLASIA; MAJOR MODIFIER; MOM1 LOCUS; CANCER; GENE; IDENTIFICATION; MUTATION; MOUSE; COLI	There is good evidence now that the secretory, type II phospholipase A(2) (Pla2g2a) gene represents the Mom1 locus, a genetic modifier of tumor resistance in the multiple intestinal neoplasia (Min) mouse. Previously we have mapped the human homolog PLA2G2A to 1p35-36.1 within a region that is the target of frequent deletions in sporadic colorectal tumors. Here we show 64% loss of heterozygosity (LOH) at the PLA2G2A locus in primary tumors. We studied PLA2G2A expression in both colorectal tumor cell lines and normal mucosa. Most of the lines lacked detectable PLA2G2A transcripts by Northern analysis. Large differences in expression were seen among normal mucosa of different patients with sporadic tumors. We analysed the coding region of PLA2G2A in eight colorectal cancer cell lines with hemizygous deletion at 1p35-36/PLA2G2A, in none we did detect a mutation. Biallelic expression of PLA2G2A was observed in a cell line heterozygous for an exon 3 polymorphism, rendering unlikely that imprinting is a pathway participating in the loss of PLA2G2A function. It remains uncertain if PLA2G2A, in particular its apparent lack of expression in tumor cells, might be a factor in human colorectal tumorigenesis.	Deutsch Krebsforschungszentrum, Dept Cytogenet 0825, D-69120 Heidelberg, Germany; Humboldt Univ, Abt Chirurg & Chirurg Onkol, Robert Rossle Klin, Max Delbruck Ctr,Virchow Klinikum, D-13125 Berlin, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Schwab, M (corresponding author), Deutsch Krebsforschungszentrum, Dept Cytogenet 0825, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.			Dihlmann, Susanne/0000-0002-3737-7755				BRUDERLEIN S, 1990, GENE CHROMOSOME CANC, V2, P63, DOI 10.1002/gcc.2870020112; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dihlmann S, 1997, ONCOL RES, V9, P119; Dobbie Z, 1996, HUM GENET, V98, P386, DOI 10.1007/s004390050226; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V117, P217; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NEVALAINEN TJ, 1995, LAB INVEST, V72, P201; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PRAML C, 1995, ONCOGENE, V11, P1357; PRAML C, 1995, CANCER RES, V55, P5504; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; RIGGINS GJ, 1995, CANCER RES, V55, P5184; Spirio LN, 1996, CANCER RES, V56, P955; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tomlinson IPM, 1996, J MED GENET, V33, P268, DOI 10.1136/jmg.33.4.268; Tomlinson IPM, 1996, ANN HUM GENET, V60, P369, DOI 10.1111/j.1469-1809.1996.tb00434.x	27	26	26	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					2009	2012		10.1038/sj.onc.1202121	http://dx.doi.org/10.1038/sj.onc.1202121			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788445				2022-12-28	WOS:000076423500015
J	Dhanasekaran, N; Reddy, EP				Dhanasekaran, N; Reddy, EP			Signaling by dual specificity kinases	ONCOGENE			English	Review						oncogene; apoptosis; cell transformation; MAP kinase; MEKK; MEK; MKK; ERK; JNK; signal transduction	ACTIVATED PROTEIN-KINASE; JUN NH2-TERMINAL KINASE; MAMMALIAN SOMATIC-CELLS; N-TERMINAL KINASE; P38 MAP KINASE; NIH 3T3 CELLS; C-JUN; TRANSDUCTION PATHWAY; TYROSINE PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY	Dual specificity kinases that phosphorylate the Thr- and Tyr-residues within the TXY motif of MAP-kinases of play a central role in the regulation of various processes of cell growth. These dual specificity kinases also known as MAP kinase kinases are constituents of the sequential kinase signaling modules. Seven distinct mammalian MAP kinases kinases have been identified. Same of the unique signaling properties of these kinases are discussed here.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA.		Reddy, E. Premkumar/F-6233-2011					Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; AFTI A, 1997, J BIOL CHEM, V272, P1429; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROTT BK, 1993, CELL GROWTH DIFFER, V4, P921; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FUKUNAGA R, 1997, EMBO J, V16, P1909; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5; HAN JH, 1993, J BIOL CHEM, V268, P25009; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P318; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MATSUDA S, 1994, J LEUKOCYTE BIOL, V56, P548, DOI 10.1002/jlb.56.5.548; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SETH A, 1992, J BIOL CHEM, V267, P24796; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; WANG XS, 1997, J BIOL CHEM, V271, P31607; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	117	240	256	1	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1447	1455		10.1038/sj.onc.1202251	http://dx.doi.org/10.1038/sj.onc.1202251			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779990				2022-12-28	WOS:000076161900011
J	Thate, C; Englert, C; Gessler, M				Thate, C; Englert, C; Gessler, M			Analysis of WT1 target gene expression in stably transfected cell lines	ONCOGENE			English	Article						Wilms' tumour; WT1; zinc finger protein; differential display PCR; CSF1	WILMS-TUMOR GENE-WT1; DENYS-DRASH-SYNDROME; GROWTH-FACTOR-A; PRODUCT; BINDING; DNA; TRANSCRIPTION; MUTATIONS; RECEPTOR; SEQUENCE	The Wilms' tumour suppressor gene WT1 encodes a zinc finger protein that is mutated in a subset of Wilms' tumours. Mutation screening and animal studies revealed essential roles during development and later function of the kidneys and the entire genitourinary system. Sequence similarity suggested a possible role for WT1 as a transcription factor. Indeed, sequence specific DNA binding and transcriptional activation or repression potential could be demonstrated in transient transfection assays with various reporter constructs. To identify endogenous WT1 target genes we established HEK293 cell lines expressing the different WT1 isoforms in a tetracycline dependent manner. Differential display PCR (ddPCR) was performed on RNA from stable WT1 transfected HEK293 cell lines and two other WT1 transfected lines (G401 and Saos-2), In an extended survey of several thousand ddPCR bands only few differences in intensity were seen and none of these could unambiguously be verified as being WT1 regulated by subsequent Northern blot analysis, In addition, almost none of the WT1 target genes identified to date in transient co-transfection assays could be confirmed by either ddPCR or Northern hybridization in the three stable transfected cell lines. Among the nine genes expressed, the only exceptions were CSF1 and to a lesser extent IGF1R being induced in Saos-2/G401 and HEK293 cells, respectively. At least two of the cell lines tested had previously shown clear biological effects though - either WT1 dependent apoptosis (Saos-2) or greatly reduced tumorigenicity (G401). This suggests that WT1 may regulate only a very small set of genes that escape the detection methods used or it may not act as a transcription factor that influences steady state levels of mRNA.	Univ Wurzburg, Theodor Boveri Inst Biowissensch, D-97074 Wurzburg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	University of Wurzburg; Helmholtz Association; Karlsruhe Institute of Technology	Gessler, M (corresponding author), Univ Wurzburg, Theodor Boveri Inst Biowissensch, Hubland, D-97074 Wurzburg, Germany.			Thaete, Claudia/0000-0002-2739-5669; Gessler, Manfred/0000-0002-7915-6045; Englert, Christoph/0000-0002-5931-3189				Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Charlieu JP, 1995, J CELL SCI, P95; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; KENT J, 1995, ONCOGENE, V11, P1781; Kikuchi H, 1998, J MED GENET, V35, P45, DOI 10.1136/jmg.35.1.45; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; Klamt B, 1998, HUM MOL GENET, V7, P709, DOI 10.1093/hmg/7.4.709; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LANGERAK AW, 1995, GENE CHROMOSOME CANC, V12, P87, DOI 10.1002/gcc.2870120203; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LINSKENS MHK, 1995, NUCLEIC ACIDS RES, V23, P3244, DOI 10.1093/nar/23.16.3244; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MCMASTER ML, 1995, CELL GROWTH DIFFER, V6, P1609; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY JC, 1995, J BIOL CHEM, V270, P29976; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Vicanek C, 1997, KIDNEY INT, V52, P614, DOI 10.1038/ki.1997.374; Wan JS, 1996, NAT BIOTECHNOL, V14, P1685, DOI 10.1038/nbt1296-1685; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1992, J BIOL CHEM, V267, P21999	36	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	1998	17	10					1287	1294		10.1038/sj.onc.1202055	http://dx.doi.org/10.1038/sj.onc.1202055			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771972				2022-12-28	WOS:000075803300011
J	Hui, R; Ball, JR; Macmillan, RD; Kenny, FS; Prall, OWJ; Campbell, DH; Cornish, AL; McClelland, RA; Daly, RJ; Forbes, JF; Blamey, RW; Musgrove, EA; Robertson, JFR; Nicholson, RI; Sutherland, RL				Hui, R; Ball, JR; Macmillan, RD; Kenny, FS; Prall, OWJ; Campbell, DH; Cornish, AL; McClelland, RA; Daly, RJ; Forbes, JF; Blamey, RW; Musgrove, EA; Robertson, JFR; Nicholson, RI; Sutherland, RL			EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival	ONCOGENE			English	Article						EMS1; cyclin D1; breast cancer; prognosis	CHROMOSOME 11Q13 REGION; ONCOGENE AMPLIFICATION; PROGNOSTIC VALUE; HUMAN CARCINOMAS; POOR PROGNOSIS; CONTACT SITES; CELL-LINES; OVEREXPRESSION; PHOSPHORYLATION; IDENTIFICATION	The EMS1 and CCND1 genes at chromosome 11q13 are amplified in about 15% of primary breast cancers but appear to confer different phenotypes in ER positive and ER negative tumours, Since there are no published data on EMS1 expression in large series of breast cancers we examined the relationship of EMS1 expression with EMSI gene copy number and expression of mRNAs for cyclin D1 and ER, In a subset of 129 patients, where matched tumour RNA and DNA was available, EMS1 mRNA overexpression was associated predominantly with gene amplification (P=0.0061), whereas cyclin DT mRNA overexpression was not (P=0.3142). In a more extensive series;of 351 breast cancers, there was no correlation between cyclin D1 and EMS1 expression in the EMS1 and cyclin D1 overexpressors (P=0.3503). Although an association between EMS1 mRNA expression and ER positivity was evident (P=0.0232), when the samples were divided into quartiles of EMSI or cyclin D1 mRNA expression, the increase in the proportion of ER positive tumours in the ascending EMS1 mRNA quartiles was not statistically significant (P=0.0951), In marked contrast there was a significant stepwise increase in ER positivity in ascending quartiles of cyclin D1 mRNA (P=0.030), A potential explanation for this difference was provided by the observation that in ER positive breast cancer cells oestradiol treatment resulted in increased cyclin D1 gene expression but was without effect on EMS1, The relationship between EMSI expression and clinical outcome was examined in a subset of 234 patients with median follow-up of 74 months, High EMSI expression was associated with age >50 years (P=0.0001), postmenopausal status (P=0.0008), lymph node negativity (P=0.019) and an apparent trend for worse prognosis in the ER negative subgroup, These data demonstrate that overexpression of EMS1 mRNA is largely due to EMSI gene amplification, is independent of cyclin DI and ER expression and, in contrast to cyclin D1, is not regulated by oestrogen, Independent overexpression of these genes may confer different phenotypes and disease outcomes in breast cancer as has been inferred from recent studies of EMSI and CCND1 gene amplification.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Mater Misericordiae Hosp, Dept Surg Oncol, Waratah, NSW 2298, Australia; City Hosp Nottingham, Dept Surg, Nottingham NG5 1PB, England; Univ Wales Coll Med, Breast Canc Unit, Tenovus Canc Res Ctr, Cardiff CF4 4XX, S Glam, Wales	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Cardiff University	Sutherland, RL (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.		Ball, Jonathon/K-1076-2015; Daly, Roger J/C-8179-2009; Sutherland, Robert L/A-8378-2008	Ball, Jonathon/0000-0003-0594-8063; Daly, Roger/0000-0002-5739-8027; Campbell, Douglas/0000-0001-9699-1854				ADNANE J, 1989, ONCOGENE, V4, P1389; Altucci L, 1996, ONCOGENE, V12, P2315; BARTKOVA J, 1995, ONCOGENE, V10, P775; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BERNS EMJJ, 1995, GENE, V159, P11, DOI 10.1016/0378-1119(94)00534-Y; BERNS EMJJ, 1992, EUR J CANCER, V28A, P697, DOI 10.1016/S0959-8049(05)80129-7; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; Bringuier PP, 1996, ONCOGENE, V12, P1747; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FANTL V, 1993, CANCER SURV, V18, P77; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; GAFFEY MJ, 1993, MODERN PATHOL, V6, P654; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Hui R, 1996, CLIN CANCER RES, V2, P923; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Patel AM, 1996, ONCOGENE, V12, P31; Pelosio P, 1996, ANN ONCOL, V7, P695; PETERS G, 1995, BREAST CANCER RES TR, V33, P125, DOI 10.1007/BF00682720; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; Seshadri R, 1996, CLIN CANCER RES, V2, P1177; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; vanDiest PJ, 1997, AM J PATHOL, V150, P705; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	36	75	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1053	1059		10.1038/sj.onc.1202023	http://dx.doi.org/10.1038/sj.onc.1202023			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747885				2022-12-28	WOS:000075560900014
J	Hallberg, B; Ashcroft, M; Loeb, DM; Kaplan, DR; Downward, J				Hallberg, B; Ashcroft, M; Loeb, DM; Kaplan, DR; Downward, J			Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc but does not involve phosphoinositide 3-OH kinase	ONCOGENE			English	Article						Ras; Trk; NGF; phosphatidylinositol 3-kinase; apoptosis; PKB	PHEOCHROMOCYTOMA PC12 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; TYROSINE KINASE; PROTEIN-KINASE; NEURONAL DIFFERENTIATION; ACTIVATION; RECEPTOR; NGF	The TrkA receptor protein tyrosine kinase is involved in signalling PC12 cell differentiation and cessation of cell division in response to nerve growth factor (NGF), To assess the importance of adaptor proteins and Pas in NGF control of phosphoinositide 3-OH kinase (PI 3-kinase), specific receptor mutations in Trk have been employed.. We show that phosphorylation of tyrosine 490, but not 785, of Trk is essential for activation of both Ras and PI 3-kinase in vivo, correlating with tyrosine phosphorylation of Shc and binding of Shc to the adaptor Grb2 and the Pas exchange factor Sos. A mutant receptor that lacks Y490 and Y785, but contains an introduced YxxM motif which binds the regulatory domain of PI 3-kinase, is unable to activate Pas despite causing increased PI 3-kinase activity. This indicates clearly that activation of PI 3-kinase by itself is not sufficient to cause activation of Pas, arguing against a model in which PI 3-kinase acts upstream of Pas, The Shc site of Trk is thus crucial for the activation of Pas and PI 3-kinase.	Imperial Canc Res Fund, London WC2A 3PX, England; Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Cancer Research UK; Umea University; McGill University; Columbia University	Downward, J (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BASU T, 1994, ONCOGENE, V9, P3483; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTER AN, 1992, J BIOL CHEM, V267, P14563; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jackson TR, 1996, J CELL SCI, V109, P289; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOZERI O, 1992, ONCOGENE, V7, P2259; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	41	44	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					691	697		10.1038/sj.onc.1201980	http://dx.doi.org/10.1038/sj.onc.1201980			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715270				2022-12-28	WOS:000075337200003
J	McKay, BC; Ljungman, M; Rainbow, AJ				McKay, BC; Ljungman, M; Rainbow, AJ			Persistent DNA damage induced by ultraviolet light inhibits p21(waf1) and bax expression: implications for DNA repair, UV sensitivity and the induction of apoptosis	ONCOGENE			English	Article						apoptosis; DNA repair; E2F-1; E2F-4; viral tumour antigens; p21(waf1)	TRANSCRIPTION-COUPLED REPAIR; CYCLIN-DEPENDENT KINASES; LI-FRAUMENI SYNDROME; PIGMENTOSUM GROUP-C; LARGE T-ANTIGEN; CELL-CYCLE; XERODERMA-PIGMENTOSUM; EXCISION-REPAIR; G(1) ARREST; P53-DEPENDENT APOPTOSIS	Ultraviolet light (UV) induced DNA lesions efficiently block transcript elongation and induce the p53 response. Although p53 contributes to transcriptional activation of the p21(WAF1) and bax genes, accumulation of these proteins requires that these genes are free of UV induced pyrimidine dimers. We assessed the level of expression of p53 and the p53 regulated p21(WAF1) and bax gene products in normal diploid fibroblasts (NDF) and several nucleotide excision repair deficient fibroblasts following UV-irradiation. At low UV fluences, increased expression of p53, p21(WAF1) and bax was only observed in fibroblasts deficient in transcription coupled repair (TCR). Whereas p53 protein levels increased in all cell types at high UV fluences, p21(WAF1) levels initially decreased and then recovered in a manner dependent on TCR. At later times, expression of p21(WAF1) and bax was only elevated in TCR-proficient cells. The lack of TCR strongly correlated with an enhanced induction of apoptosis. Furthermore, we assessed the effect of modulation of the p53/p21(WAF1)/pRb pathway on clonogenic survival following UV irradiation. Expression of E2F-1, E2F-4, and the large tumour antigens of SV40 and Polyomavirus conferred UV sensitivity to NDF whereas p21(WAF1) protected cells against UV treatment. We propose that the fluence dependent attenuation of protective functions of p53 by blockage of transcription favours apoptosis following UV exposure.	McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; Univ Michigan, Ctr Comprehens Canc, Div Canc Biol, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	McMaster University; University of Michigan System; University of Michigan	Rainbow, AJ (corresponding author), McMaster Univ, Dept Biol Life Sci, Bldg 218A,1280 Main St W, Hamilton, ON L8S 4K1, Canada.		McKay, Bruce C/I-4081-2013	McKay, Bruce C/0000-0002-7921-1331				Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARREAU M, 1992, MUTAT RES, V274, P57, DOI 10.1016/0921-8777(92)90043-3; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; deLaat A, 1996, PHOTOCHEM PHOTOBIOL, V63, P492; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Doherty J, 1997, ONCOGENE, V14, P1923, DOI 10.1038/sj.onc.1201025; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; EASTHAM JA, 1995, CANCER RES, V55, P5151; EVANS MK, 1993, J BIOL CHEM, V268, P4839; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GomezManzano C, 1997, J NATL CANCER I, V89, P1036, DOI 10.1093/jnci/89.14.1036; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GRAHAM F, 1991, GENE TRANSFER EXPRES, V7; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IMRAY P, 1983, MUTAT RES, V112, P301, DOI 10.1016/0167-8817(83)90005-6; KARENTZ D, 1986, MUTAT RES, V165, P165, DOI 10.1016/0167-8817(86)90051-9; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ljungman M, 1996, ONCOGENE, V13, P823; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu X, 1996, ONCOGENE, V13, P413; Luna RMDO, 1996, GENOMICS, V33, P352, DOI 10.1006/geno.1996.0210; MASSIE B, 1986, MOL CELL BIOL, V6, P2872, DOI 10.1128/MCB.6.8.2872; MAYNE LV, 1982, CANCER RES, V42, P1473; McDonald E, 1996, CANCER RES, V56, P2250; McKay BC, 1997, PHOTOCHEM PHOTOBIOL, V66, P659, DOI 10.1111/j.1751-1097.1997.tb03203.x; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; MIYASHITA T, 1995, CELL, V80, P293; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORSY MA, 1993, J CLIN INVEST, V92, P1580, DOI 10.1172/JCI116739; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SMITH ML, 1995, ONCOGENE, V10, P1053; Tolbert DM, 1996, CANCER RES, V56, P3324; Tu YQ, 1997, J BIOL CHEM, V272, P20747, DOI 10.1074/jbc.272.33.20747; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; vanLaar T, 1995, BIOCHEM BIOPH RES CO, V217, P769, DOI 10.1006/bbrc.1995.2839; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZEIGLER A, 1994, NATURE, V372, P773	73	85	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					545	555		10.1038/sj.onc.1201963	http://dx.doi.org/10.1038/sj.onc.1201963			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704920				2022-12-28	WOS:000075195300002
J	Austen, M; Cerni, C; Luscher-Firzlaff, JM; Luscher, B				Austen, M; Cerni, C; Luscher-Firzlaff, JM; Luscher, B			YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc	ONCOGENE			English	Article						transformation; c-Myc; YY1; Myc/Max DNA-binding; protein-protein interaction; gene transcription	ADENOVIRUS E1A PROTEINS; ZINC-FINGER PROTEIN; N-TERMINAL DOMAIN; CASEIN KINASE-II; TRANSCRIPTIONAL ACTIVATION; VIRAL ONCOPROTEINS; BURKITTS-LYMPHOMA; TUMOR-SUPPRESSOR; FOS PROMOTER; NF-E1 YY-1	The proto-oncoprotein c-Myc and the multifunctional transcriptional regulator YY1 have been shown previously to interact directly in a manner that excludes Max from the complex (Shrivastava et al., 1993). As binding to Max is necessary for all known c-Myc activities we have analysed the influence of YY1 on c-Myc function. We demonstrate that YY1 is a potent inhibitor of c-Myc transforming activity. The region in YY1 required for inhibition corresponds to a functional DNA-binding domain and is distinct from the domains necessary for direct binding to c-Myc. Furthermore the transactivation domain of YY1 was not necessary suggesting that gene regulation by YY1, for example through DNA bending or displacement of regulators from DNA, could be the cause for the negative regulation of c-Myc. This model of indirect regulation of c-Myc by YY1 was supported by the finding that although YY1 did not bind to the c-Myc transactivation domain (TAD) in vitro it was able to inhibit transactivation by Gal4-MycTAD fusion proteins in transient transfections. As for the inhibition of transformation, an intact DNA-binding domain of YY1 was necessary and sufficient for this effect. In addition YY1 did not alter c-Myc/Max DNA binding, further supporting an indirect mode of action. Our findings point to a role of YY1 as a negative regulator of cell growth with a possible involvement in tumor suppression.	Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany; Univ Vienna, Inst Tumorbiol & Krebsforsch, A-1090 Vienna, Austria	Hannover Medical School; University of Vienna	Luscher, B (corresponding author), Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany.		Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				ALBERT T, 1994, ONCOGENE, V9, P759; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BASU A, 1993, J BIOL CHEM, V268, P4188; BECKER KG, 1994, GENE, V150, P259, DOI 10.1016/0378-1119(94)90435-9; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; CERNI C, 1995, ONCOGENE, V11, P587; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GASTON K, 1994, FEBS LETT, V347, P289, DOI 10.1016/0014-5793(94)00567-2; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Houbaviy HB, 1996, P NATL ACAD SCI USA, V93, P13577, DOI 10.1073/pnas.93.24.13577; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1992, NUCLEIC ACIDS RES, P3317; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutterbach B, 1997, ONCOGENE, V14, P967, DOI 10.1038/sj.onc.1200920; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NEVINS JR, 1992, SCIENCE, V258, P424; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PISANESCHI G, 1994, BIOCHEM BIOPH RES CO, V205, P1236, DOI 10.1006/bbrc.1994.2797; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1997, RETROVIRAL ONCOGENES, V1, P1; PULVERER BJ, 1994, ONCOGENE, V9, P59; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SHENK T, 1991, ADV CANCER RES, V57, P47; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YANO T, 1993, ONCOGENE, V8, P2741; ZHOU QJ, 1995, J VIROL, V69, P7402, DOI 10.1128/JVI.69.12.7402-7409.1995	87	68	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	1998	17	4					511	520		10.1038/sj.onc.1201968	http://dx.doi.org/10.1038/sj.onc.1201968			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696045				2022-12-28	WOS:000075043000014
J	Heriche, JK; Chambaz, EM				Heriche, JK; Chambaz, EM			Protein kinase CK2 alpha is a target for the Abl and Bcr-Abl tyrosine kinases	ONCOGENE			English	Article						CK2; Abl; Bcr-Abl; signal transduction	GLYCOGEN-SYNTHASE KINASE-3; CASEIN KINASE; GROWTH-FACTOR; BETA-SUBUNIT; PHOSPHORYLATION; CELLS; ACTIVATION	Protein kinase CK2 is a ubiquitous serine-threonine kinase in which a catalytic alpha subunit often associates with a beta subunit, CK2 alpha is required for cell survival in yeast and has been proposed to be involved in cell growth control; however, its regulation in cells remains unclear. Here we present evidence that CK2 alpha may be an associated substrate for the normal and oncogenic forms of the Abl tyrosine kinase. By probing CK2 alpha with antiphosphotyrosine antibodies, we found that CK2 alpha can be phosphorylated on tyrosine in quiescent cells. In vitro phosphorylation of CK2 alpha-containing immunoprecipitates showed that CK2 alpha is substrate of an associated tyrosine kinase activity. Immunoprecipitation experiments revealed that CK2 alpha is associated with normal c-Abl in mouse NIH3T3 fibroblasts and with the Bcr-Abl fusion protein in K562 human myeloid leukemia cells. Coexpression of Bcr-Abl and CK2 alpha in NIH3T3 cells also leads to the formation of a Bcr-Abl/CK2 alpha complex and to the inhibition of CK2 alpha activity, Bcr-Abl-induced inhibition of CK2 alpha could be reverted by incubating CK2 alpha with a tyrosine phosphatase. These observations clearly support the idea that a signal transduction pathway contributes to CK2 regulation and point to CK2 alpha as a possible mediator of Bcr-Abl effects.	INSERM, U244, F-38054 Grenoble, France; CEA Grenoble, Dept Biol Mol & Struct, Lab Biochim Regulat Cellulaires Endocrines, F-38054 Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CEA	Heriche, JK (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.			Heriche, Jean-Karim/0000-0001-6867-9425				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; GLOVER CVC, 1983, J BIOL CHEM, V258, P3258; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; SCHMIDTSPANIOL I, 1993, CELL MOL BIOL RES, V39, P761; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	21	41	41	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					13	18		10.1038/sj.onc.1201900	http://dx.doi.org/10.1038/sj.onc.1201900			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671309				2022-12-28	WOS:000074677800002
J	Bandera, CA; Muto, MG; Welch, WR; Berkowitz, RS; Mok, SC				Bandera, CA; Muto, MG; Welch, WR; Berkowitz, RS; Mok, SC			Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum	ONCOGENE			English	Article						allelic loss; chromosome 17; microsatellite instability; peritoneal neoplasia; ovarian cancer	EPITHELIAL OVARIAN-CARCINOMA; UNIFOCAL ORIGIN; PROPHYLACTIC OOPHORECTOMY; CANCER; HETEROZYGOSITY; FAMILIES; BREAST	We extend the evaluation of allelic loss patterns on chromosome 17 to Dapillary serous carcinoma of the peritoneum (PSCP) which is histologically identical to papillary serous ovarian carcinoma (PSOC), DNA was obtained from 11 archival cases of PSCP, with 1-11 tumor sites per case. Using ten loci spanning chromosome 17, loss of heterozygosity (LOH) was identified in all 11 cases (100%). Furthermore, 75-100% of informative cases exhibited LOH at the loci p53, D17S1322 (intragenic to the tumor suppressor gene BRCA1), D17S1327 and MPO. PSCP cases exhibit a higher rate of LOH at most loci when compared with PSOC, Alternating allelic loss at different tumor sites was identified in three cases supporting a multifocal origin of PSCP, Microsatellite instability (MI) is an uncommon event which was identified in four cases. These data implicate chromosome 17 as a potential Location of genetic events important in the pathogenesis of PSCP as well as ovarian cancer.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Lab Div Gynecol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Womens & Perinatal Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mok, SC (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Lab Div Gynecol Oncol, Boston, MA 02115 USA.				NCI NIH HHS [R01CA69453, R01CA63381, R01CA69291] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069291, R01CA069453, R01CA063381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTARAS MM, 1991, GYNECOL ONCOL, V40, P230, DOI 10.1016/0090-8258(91)90322-V; CHEN KTK, 1985, OBSTET GYNECOL, V66, P935; DALRYMPLE JC, 1989, CANCER, V64, P110, DOI 10.1002/1097-0142(19890701)64:1<110::AID-CNCR2820640120>3.0.CO;2-5; EASTON DF, 1993, AM J HUM GENET, V52, P678; ECCLES DM, 1990, ONCOGENE, V5, P1599; ECCLES DM, 1992, ONCOGENE, V7, P1069; GREENBLATT MS, 1994, CANCER RES, V54, P4855; JACOBS IJ, 1992, J NATL CANCER I, V84, P1793, DOI 10.1093/jnci/84.23.1793; Kowalski LD, 1997, CANCER, V79, P1587, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1587::AID-CNCR22>3.3.CO;2-S; LEE JH, 1990, CANCER RES, V50, P2724; LI SB, 1993, GYNECOL ONCOL, V51, P21, DOI 10.1006/gyno.1993.1240; LYNCH HT, 1986, AM J MED, V81, P1073, DOI 10.1016/0002-9343(86)90411-0; MOK CH, 1992, CANCER RES, V52, P5119; MUTO MG, 1995, CANCER RES, V55, P490; NAROD SA, 1995, AM J HUM GENET, V56, P254; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P2751, DOI 10.1002/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J; SATO T, 1991, CANCER RES, V51, P5118; TAKAHASHI H, 1995, CANCER RES, V55, P2998; TOBACMAN JK, 1982, LANCET, V2, P795; TRUONG LD, 1990, HUM PATHOL, V21, P99, DOI 10.1016/0046-8177(90)90081-F; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; Wertheim I, 1996, ONCOGENE, V12, P2147	22	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3455	3459		10.1038/sj.onc.1201901	http://dx.doi.org/10.1038/sj.onc.1201901			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692553				2022-12-28	WOS:000074544100012
J	Blaydes, JP; Wynford-Thomas, D				Blaydes, JP; Wynford-Thomas, D			The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2	ONCOGENE			English	Article						p53; mdm2; p21(WAF-1); cell proliferation	TUMOR-SUPPRESSOR GENE; TRANSCRIPTIONAL ACTIVATION; ONCOPROTEIN MDM2; MUTANT P53; PROTEIN; TRANSACTIVATION; SENESCENCE; EXPRESSION; INDUCTION; MUTATIONS	Loss of function of the tumour suppressor gene p53 is a key event in most human cancers. Although usually occurring through mutation, in some tumour types this appears to be achieved via an indirect mechanism involving inappropriate expression of functional inhibitor, mdm2, which binds to the transactivation domain of p53. This interaction offers an ideal potential target for novel cancer therapies. However, therapeutic specificity may depend on the extent to which this p53-inhibitory action of mdm2 is also required by normal cells. Transgenic data have already established that mdm2 is needed to prevent embryonic lethality, but the situation in adult cells is still unclear. Here we show that micro-injection of normal human fibroblasts with an antibody directed against the p53-binding domain of mdm2 induces expression of p53-responsive genes, and furthermore results in p53-dependent growth arrest. We conclude that normal cell proliferation can be dependent on negative regulation of p53 by mdm2, a finding which raises an important note of caution for mdm2-directed cancer therapies.	Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Wynford-Thomas, D (corresponding author), Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.		Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				ABARZUA P, 1995, CANCER RES, V55, P3490; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1994, ONCOGENE, V9, P1885; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bottger V, 1996, ONCOGENE, V13, P2141; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OCALUAN RM, 1995, NATURE, V378, P203; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	32	58	58	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3317	3322		10.1038/sj.onc.1201880	http://dx.doi.org/10.1038/sj.onc.1201880			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681831				2022-12-28	WOS:000074343600013
J	Lee, H; Maihle, NJ				Lee, H; Maihle, NJ			Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues	ONCOGENE			English	Article						c-erbB3; alternative processing; truncated growth factor receptors; gene structure; epidermal growth factor receptor homologues	GROWTH-FACTOR RECEPTOR; GENE ENCODES; CAENORHABDITIS-ELEGANS; MONOCLONAL-ANTIBODY; TYROSINE KINASE; TRUNCATED FORM; LET-23 GENE; PROTEIN; TUMORS; DOMAIN	ErbB-3 is a member of the epidermal growth factor receptor (EGFR/ErbB) family. In addition to the previously reported 6.2 kb full-length and 1.4 kb truncated c-erbB3 transcripts, we have observed a 1.7 kb c-erbB3 human transcript in Northern blots that specifically hybridizes to a probe of the extracellular domain of the receptor. Using 3'-RACE we have isolated four novel c-erbB3 cDNA clones of 1.6, 1.7, 2.1 and 2.3 kb from a human ovarian carcinoma-derived cell line. All four alternate transcripts are synthesized by readthrough of an intron and use of an alternative polyadenylation signal within this intron. Identical c-erbB3 transcripts are expressed in normal human placental tissues. Expression of these alternate transcripts is tissue-specific as indicated by Northern blot and RNase protection analyses. Fibroblasts transfected with expression vectors carrying these alternate c-erbB3 cDNA clones stably express truncated ErbB-3 products. Three of these four cDNA clones express a receptor product that is secreted. Immunoprecipitation analysis of primary cultures of human ovarian carcinomas also demonstrate the expression of a 90 kDa ErbB-3 related protein that is secreted. Furthermore, we demonstrate conservation of the exon-intron junctions between members of the erbB gene family in those regions of the gene encoding the extracellular domain. This gene structure is also conserved in the c-erbB1 homologues of Drosophila and C. elegans. Growth regulatory roles for related truncated ErbB products recently have been reported. It is, therefore, possible that the products of these four alternate c-erbB3 transcripts may also play important growth regulatory roles in normal and transformed cells.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Maihle, NJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.				NCI NIH HHS [CA65800, CA09441, CA57534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009441, R01CA057534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1980, CELL, V20, P381; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BUICK RN, 1985, CANCER RES, V45, P3668; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; CLIFFORD R, 1994, GENETICS, V137, P531; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; Frohman Michael A., 1994, P14; KAN JLC, 1995, J BIOL CHEM, V270, P1823, DOI 10.1074/jbc.270.4.1823; KATOH M, 1993, BIOCHEM BIOPH RES CO, V192, P1189, DOI 10.1006/bbrc.1993.1542; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MAIHLE NJ, 1991, P NATL ACAD SCI USA, V88, P1825, DOI 10.1073/pnas.88.5.1825; MAIHLE NJ, 1988, MOL CELL BIOL, V8, P1970; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLET A, 1995, ONCOGENE, V10, P319; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RAJKUMAR T, 1993, J PATHOL, V170, P271, DOI 10.1002/path.1711700309; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; Reiter JL, 1996, NUCLEIC ACIDS RES, V24, P4050, DOI 10.1093/nar/24.20.4050; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Sakai T, 1996, J MOL BIOL, V256, P548, DOI 10.1006/jmbi.1996.0107; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SIMPSON BJB, 1995, BRIT J CANCER, V71, P758, DOI 10.1038/bjc.1995.147; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	30	51	68	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3243	3252		10.1038/sj.onc.1201866	http://dx.doi.org/10.1038/sj.onc.1201866			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681822				2022-12-28	WOS:000074343600004
J	Droin, N; Dubrez, L; Eymin, B; Renvoize, C; Breard, J; Dimanche-Boitrel, MT; Solary, E				Droin, N; Dubrez, L; Eymin, B; Renvoize, C; Breard, J; Dimanche-Boitrel, MT; Solary, E			Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis	ONCOGENE			English	Article						apoptosis; caspases; etoposide; human tumor cells	INTERLEUKIN-1-BETA CONVERTING-ENZYME; TOPOISOMERASE-II INHIBITORS; CAENORHABDITIS-ELEGANS; POLY(ADP-RIBOSE) POLYMERASE; IL-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE; CYSTEINE PROTEASES; MESSENGER-RNA; HL-60 CELLS; DEATH	Caspases are aspartate-specific cysteine proteases that play a pivotal role in drug-induced cell death. We designed RT-PCR assays to analyse the expression of CASP-3, CASP-4, CASP-6 and the long and short isoforms of CASP-2 genes in human cells. These genes heterogeneously coexpress in leukemic cell lines and bone marrow samples from patients with de nova acute myelogenous leukemia at diagnosis. Treatment of U937 and HL60 leukemic cells and HT29 colon carcinoma cells with the topoisomerase IT inhibitor etoposide upregulates CASP-2 and CASP-3 genes in these cells before inducing their apoptosis. This effect of etoposide is not observed in K562 cells and bcl-2-transfected U937 cells which are less sensitive to drug-induced apoptosis. Nuclear run-on experiments demonstrate that etoposide increases GASP gene transcription in U937 cells, an effect that is prevented by Bcl-2 overexpression. Upregulation of GASP genes is associated with an enhanced synthesis of related procaspases that precedes the appearance of apoptosis markers including caspase-3 activation, poly(ADP-ribose) polymerase cleavage and internucleosomal DNA fragmentation. These results suggest that the ability of tumor cells to upregulate CASP-2 and CASP-3 genes in response to cytotoxic drugs could be predictive of their sensitivity to drug-induced apoptosis.	UFR Med, Biol & Therapy Canc Grp, INSERM, CJF 94 08, F-21000 Dijon, France; UFR Pharm, INSERM, U461, Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm)	Solary, E (corresponding author), UFR Med, Biol & Therapy Canc Grp, INSERM, CJF 94 08, 7 Blvd Jeanne dArc, F-21000 Dijon, France.		Eymin, Beatrice/M-1962-2013; Dubrez, Laurence/I-4971-2016; Dimanche-Boitrel, Marie-Therese M/I-4642-2015; Laurence, Dubrez/P-9472-2019; Droin, Nathalie M/Y-5506-2018; eymin, beatrice/U-4670-2019	Eymin, Beatrice/0000-0002-7311-3810; Dubrez, Laurence/0000-0002-7030-2181; Laurence, Dubrez/0000-0002-7030-2181; Droin, Nathalie M/0000-0002-6099-5324; eymin, beatrice/0000-0002-7311-3810; Solary, Eric/0000-0002-8629-1341; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; CHAPMAN RS, 1994, CANCER RES, V54, P5131; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; DUBREZ J, 1996, EMBO J, V15, P504; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Eymin B, 1997, CANCER RES, V57, P686; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMR.T, 1996, P NATL ACAD SCI USA, V93, P7404; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; Greidinger EL, 1996, FEBS LETT, V390, P299, DOI 10.1016/0014-5793(96)00678-3; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HENTGARTNER MO, 1994, CELL, V76, P665; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAMESAKI S, 1993, CANCER RES, V53, P4251; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KIMOSHITA M, 1997, J CER BLOOD FLOW MET, V17, P507; KOOS RD, 1989, BIOCHEM BIOPH RES CO, V165, P82, DOI 10.1016/0006-291X(89)91036-X; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P200; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; Pommier Yves, 1997, P153; RENVOIZE C, 1997, IN PRESS J IMMUNOL; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOLARY E, 1994, LEUKEMIA LYMPHOMA, V15, P21, DOI 10.3109/10428199409051674; SOLARY E, 1993, BLOOD, V81, P1359; SRIVASTAVA KK, 1993, BIOTECHNIQUES, V15, P226; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	58	73	78	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2885	2894		10.1038/sj.onc.1201821	http://dx.doi.org/10.1038/sj.onc.1201821			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671409				2022-12-28	WOS:000073988200007
J	Falasca, M; Iurisci, C; Carvelli, A; Sacchetti, A; Corda, D				Falasca, M; Iurisci, C; Carvelli, A; Sacchetti, A; Corda, D			Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts; a possible mechanism of autocrine control of cell proliferation	ONCOGENE			English	Article						lysophospholipids; glycerophosphoinositols; inositol 1 : 2-cyclic phosphate; lipid metabolism; ras oncogene; thyroid cells	THYROID EPITHELIAL-CELLS; AORTIC ENDOTHELIAL-CELLS; LYMPHOCYTE-T ACTIVATION; MURINE SARCOMA-VIRUS; PROTEIN-KINASE-C; PHOSPHOLIPASE-C; INOSITOL 2-PHOSPHATE; SIGNALING PATHWAYS; ADENYLATE-CYCLASE; IONOPHORE A23187	Lysophosphatidylinositol (LysoPtdIns) is formed by a constitutively-active phosphoinositide-specific phospholipase A(2) in Ras-transformed cells and can stimulate cell proliferation. To evaluate whether LysoPtdIns could function as an autocrine modulator of cell growth, we examined whether LysoPtdIns can be released in the medium of Ras-transformed FRT-Fibro fibroblasts and thyroid cells. Here, we report that LysoPtdIns accumulates in the extracellular space of these lines and reaches levels up to tenfold higher than in the case of normal cells. Moreover, the ionophore A23187 increased the levels of the lysolipid in the extracellular medium. Extracellular LysoPtdIns was rapidly hydrolyzed to inositol 1:2-cyclic phosphate. LysoPtdIns induced thymidine incorporation in FRT-Fibro Ha-Ras fibroblasts, whereas inositol cyclic 1:2-cyclic phosphate did not affect cell growth per se, nor did it interfere with the LysoPtdIns mitogenic activity. We hypothesize that in Ras-transformed fibroblasts the formation and release of LysoPtdIns may function as an autocrine mechanism that participates in the Ras-dependent stimulation of cell growth.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Corda, D (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Via Nazl, I-66030 Santa Maria Imbaro, Chieti, Italy.		Corda, Daniela/K-6385-2016; Sacchetti, Andrea/H-8763-2019; Falasca, Marco/S-4020-2016	Corda, Daniela/0000-0002-3614-751X; Falasca, Marco/0000-0002-9801-7235				ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; ALONSO T, 1990, BIOCHEM BIOPH RES CO, V171, P14, DOI 10.1016/0006-291X(90)91349-W; AMBESIIMPIOMBAT.FS, 1989, FRTL 5 TODAY; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ASAOKA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1378, DOI 10.1016/0006-291X(91)91046-F; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; BARAN DT, 1988, ENDOCRINOLOGY, V122, P930, DOI 10.1210/endo-122-3-930; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BICKNELL R, 1988, P NATL ACAD SCI USA, V85, P5961, DOI 10.1073/pnas.85.16.5961; BILLAH MM, 1982, J BIOL CHEM, V257, P5196; BIRRELL GB, 1995, BIOCHEM BIOPH RES CO, V211, P318, DOI 10.1006/bbrc.1995.1813; CHIARIOTTI L, 1992, ONCOGENE, V7, P2507; COLETTA G, 1983, MOL CELL BIOL, V3, P2099; Corda D, 1996, ANTICANCER RES, V16, P1341; DAWSON RMC, 1971, BIOCHEM J, V122, P605, DOI 10.1042/bj1220605; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Falasca M, 1997, MOL BIOL CELL, V8, P443, DOI 10.1091/mbc.8.3.443; FALASCA M, 1995, ONCOGENE, V10, P2113; Falasca M, 1996, EUR J BIOCHEM, V241, P386, DOI 10.1111/j.1432-1033.1996.00386.x; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; FRANCEL P, 1988, BIOCHEM BIOPH RES CO, V152, P724, DOI 10.1016/S0006-291X(88)80098-6; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GRAHAM RA, 1987, J BIOL CHEM, V262, P35; HONG SL, 1985, THROMB RES, V38, P1; HONG SL, 1982, J BIOL CHEM, V257, P7151; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; IMAGAWA W, 1995, EXP CELL RES, V216, P178, DOI 10.1006/excr.1995.1022; KAYA H, 1989, J BIOL CHEM, V264, P4972; KIM JW, 1989, BIOCHEM BIOPH RES CO, V163, P177, DOI 10.1016/0006-291X(89)92117-7; KOLAROVIC L, 1986, ANAL BIOCHEM, V156, P244, DOI 10.1016/0003-2697(86)90179-X; LAMBERT TL, 1986, J BIOL CHEM, V261, P5288; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MARCOCCI C, 1983, J ENDOCRINOL INVEST, V6, P463, DOI 10.1007/BF03348346; MARTIN TM, 1986, J BIOL CHEM, V262, P13086; METZ SA, 1986, BIOCHEM BIOPH RES CO, V138, P720, DOI 10.1016/S0006-291X(86)80556-3; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; ROSS TS, 1991, J BIOL CHEM, V266, P9086; ROSS TS, 1991, J BIOL CHEM, V266, P851; ROSS TS, 1992, J BIOL CHEM, V267, P19924; SASAKAWA N, 1995, BIOCHEM PHARMACOL, V50, P137, DOI 10.1016/0006-2952(95)00059-9; SEKAR MC, 1993, BIOCHEM BIOPH RES CO, V192, P1079, DOI 10.1006/bbrc.1993.1527; SMITH DM, 1992, J LEUKOCYTE BIOL, V52, P670, DOI 10.1002/jlb.52.6.670; TING AE, 1991, EUR J CELL BIOL, V56, P401; TING AE, 1990, J BIOL CHEM, V265, P5337; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VOLWERK JJ, 1992, J CELL PHYSIOL, V151, P613, DOI 10.1002/jcp.1041510322; WEILTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; ZOELLER RA, 1987, J BIOL CHEM, V262, P17212	55	49	51	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2357	2365		10.1038/sj.onc.1201758	http://dx.doi.org/10.1038/sj.onc.1201758			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620553				2022-12-28	WOS:000073428000008
J	Miller, WE; Cheshire, JL; Baldwin, AS; Raab-Traub, N				Miller, WE; Cheshire, JL; Baldwin, AS; Raab-Traub, N			The NPC derived C15 LMP1 protein confers enhanced activation of NF-kappa B and induction of the EGFR in epithelial cells	ONCOGENE			English	Article						Epstein-Barr Virus; LMP1; NPC; sequence variation; EGFR; NF-kappa B; TRAF	EPSTEIN-BARR-VIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; TERMINAL CYTOPLASMIC DOMAIN; LATENT MEMBRANE-PROTEIN; NASOPHARYNGEAL CARCINOMA; FACTOR RECEPTOR; TRANSFORMING PROTEIN; REGULATORY SEQUENCE; NUCLEAR FACTOR; EXPRESSION	The Epstein-Barr Virus (EBV) LMP1 protein is frequently expressed in nasopharyngeal carcinoma and is essential for the transforming effects of EBV. Analysis of LMP1 genes isolated from tumor biopsies has revealed considerable sequence variation including deletion of amino acids 343-352. Several studies have suggested that this sequence variation could enhance the transforming potential of LMP1. LMP1 has profound effects on cellular gene expression mediated in part through activation of the NF-kappa B transcription factor. In addition, LMP1 engages the TRAF signaling pathway resulting in the induction of EGFR expression, In this study, the LMP1 proteins derived from the laboratory strain B95-8 and the NPC strain C15 were analysed for their ability to activate NF-kappa B and also to induce expression of the EGFR. The data suggest that the C15-LMP1 protein activates NF-kappa B more efficiently and induces higher levels of the EGFR. Analysis of chimeric LMP1 proteins indicates that the amino terminal 181 amino acids of C15-LMP1 confer this increased signaling capability, and that deletion of amino acids 343-352 does not affect these properties. Finally, these data provide evidence that five amino acid changes within the transmembrane domain in the C15-LMP1 protein lead to enhanced NF-kappa B activation and EGFR induction.	Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Curriculum Genet, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Raab-Traub, N (corresponding author), Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.			Miller, William/0000-0001-6900-4884	NATIONAL CANCER INSTITUTE [P01CA019014, R01CA032979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011644] Funding Source: NIH RePORTER; NCI NIH HHS [CA19014, CA32979] Funding Source: Medline; NIDCR NIH HHS [DE11644] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABDELHAMID M, 1992, VIROLOGY, V190, P168, DOI 10.1016/0042-6822(92)91202-6; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BUSSON P, 1992, INT J CANCER, V50, P863, DOI 10.1002/ijc.2910500605; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; CHEN ML, 1992, ONCOGENE, V7, P2130; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Devergne O, 1996, MOL CELL BIOL, V16, P7098; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; GILLIGAN KJ, 1991, J VIROL, V65, P6252, DOI 10.1128/JVI.65.11.6252-6259.1991; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOWLEY PM, 1996, PAPILLOMAVIRINAE VIR, P2045; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HU LF, 1993, ONCOGENE, V8, P1575; HUEN DS, 1995, ONCOGENE, V10, P549; IZUMI KM, 1994, J VIROL, V68, P4369, DOI 10.1128/JVI.68.7.4369-4376.1994; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Kieff E, 1996, VIROLOGY, P2343; KNECHT H, 1995, ONCOGENE, V10, P523; KNECHT H, 1993, BLOOD, V82, P2937; Knecht H, 1996, BLOOD, V87, P876, DOI 10.1182/blood.V87.3.876.bloodjournal873876; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Li SN, 1996, ONCOGENE, V12, P2129; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; MILLER WE, 1994, J GEN VIROL, V75, P2729, DOI 10.1099/0022-1317-75-10-2729; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Raab-Traub N, 1992, Semin Cancer Biol, V3, P297; RAABTRAUB N, 1987, INT J CANCER, V39, P25, DOI 10.1002/ijc.2910390106; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RAJADURAI P, 1995, NEW ENGL J MED, V333, P693; RICKINSON AB, 1987, J VIROL, V61, P1310, DOI 10.1128/JVI.61.5.1310-1317.1987; Rickinson AB, 1996, VIROLOGY, P2397; Rothenberger S, 1997, ONCOGENE, V14, P2123, DOI 10.1038/sj.onc.1201032; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; SAMPLE J, 1994, J GEN VIROL, V75, P2741, DOI 10.1099/0022-1317-75-10-2741; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; SMITH PR, 1991, NUCLEIC ACIDS RES, V19, P2435, DOI 10.1093/nar/19.9.2435; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	57	70	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1869	1877		10.1038/sj.onc.1201696	http://dx.doi.org/10.1038/sj.onc.1201696			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583684				2022-12-28	WOS:000072994600010
J	Capoulade, C; Bressac-de Paillerets, B; Lefrere, I; Ronsin, M; Feunteun, J; Tursz, T; Wiels, J				Capoulade, C; Bressac-de Paillerets, B; Lefrere, I; Ronsin, M; Feunteun, J; Tursz, T; Wiels, J			Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells	ONCOGENE			English	Article						MDM2; p53; Burkitt's lymphoma; enhanced translation	ACUTE LYMPHOBLASTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; HEMATOLOGIC MALIGNANCIES; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; INDUCED APOPTOSIS; ONCOPROTEIN MDM2; MUTANT P53; PROTEIN; MUTATIONS	Numerous studies have indicated that inactivation of p53 is one of the essential requirements for the unrestrained growth of tumoral cells, When the status of the p53 gene was examined in various types of lymphoid malignancies, mutations in p53 have been predominantly detected in Burkitt's lymphoma (BL) cells, therefore suggesting that alteration of p53 could specifically contribute to the malignant phenotype of these tumoral cells, In addition to mutations, functional inactivation of p53 can also occur through interaction of the wild-type gene product with various viral or cellular proteins, The cellular MDM2 protein, for example, is able to inhibit p53 tumor suppressor function by concealing its transactivation domain, Mdm2 gene amplification has been described in several types of sarcomas, resulting in overexpression of the MDM2 protein, In this study, we have examined the status of MDM2 and p53 in 20 BL cell lines, Four were found to contain wild-type p53 and to overexpress MDM2 protein, Within these BL cells, both molecules are physically associated since they can be co-precipitated and p53 is inactivated as cells neither arrest in G1 nor enter apoptosis following gamma-radiation. We also report that the high level of the MDM2 protein in BL cells is neither associated with an amplification of the mdm2 gene nor with an elevated level of RNA or an increased protein stability, but is rather due to an enhanced translation ability of the mdm2 RNA, These results indicate that in certain BL cells, overexpression of MDM2 protein regulated at the posttranscriptional level, induces an escape from p53-controlled cell growth.	Inst Gustave Roussy, CNRS, URA 1156, Lab Biol Tumeurs Humaines, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS, URA 1967, Lab Genet Oncol, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS, URA 1967, Lab Diagnost Mol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Wiels, J (corresponding author), Inst Gustave Roussy, CNRS, URA 1156, Lab Biol Tumeurs Humaines, Rue Camille Desmoulins, F-94805 Villejuif, France.		Wiels, Joëlle/AGL-2319-2022; Feunteun, Jean/AAZ-1267-2020; Paillerets, Brigitte Bressac-de/D-8954-2018	Wiels, Joëlle/0000-0002-3313-2937; Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; Feunteun, Jean/0000-0003-1212-9189				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BERBERICH S, 1994, ONCOGENE, V9, P1469; BHATIA KG, 1992, CANCER RES, V52, P4273; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HSU B, 1995, ONCOGENE, V11, P175; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CANCER RES, V53, P2231; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUNA RMD, 1995, NATURE, V378, P203; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; Marks DI, 1996, BRIT J HAEMATOL, V92, P890, DOI 10.1046/j.1365-2141.1996.439978.x; Marks DI, 1997, J CLIN ONCOL, V15, P1158, DOI 10.1200/JCO.1997.15.3.1158; Marks DI, 1996, BLOOD, V87, P1155, DOI 10.1182/blood.V87.3.1155.bloodjournal8731155; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; PREUDHOMME C, 1995, J CLIN ONCOL, V13, P812, DOI 10.1200/JCO.1995.13.4.812; RAMQVIST T, 1993, ONCOGENE, V8, P1495; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHEIKH MS, 1993, CANCER RES, V53, P3226; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WIMAN KG, 1991, ONCOGENE, V6, P1633; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608	53	107	109	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1603	1610		10.1038/sj.onc.1201702	http://dx.doi.org/10.1038/sj.onc.1201702			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569028				2022-12-28	WOS:000072743200011
J	Rudra-Ganguly, N; Zheng, JP; Hoang, AT; Roy-Burman, P				Rudra-Ganguly, N; Zheng, JP; Hoang, AT; Roy-Burman, P			Downregulation of human FGF8 activity by antisense constructs in murine fibroblastic and human prostatic carcinoma cell systems	ONCOGENE			English	Article						FGF8; antisense RNA; prostate cancer cells; retroviral vector	INDUCED GROWTH-FACTOR; BREAST-CANCER CELLS; MOLECULAR-CLONING; BONE FIBROBLASTS; FACTOR-VIII; ANDROGEN; GENE; EXPRESSION; FAMILY; MAINTENANCE	Previously, we described cloning of three alternatively spliced mRNA forms of human FGF8, a, b, and e, of which the b form is the major expressed species in both normal and tumor prostatic epithelial cells. In this report, we describe construction and overexpression of sense and antisense sequences of either the full length FGF8b coding region (215-amino acids or 215aa), 103aa N-terminal part or a smaller N-terminal region (34aa), each including the 23aa putative signal peptide domain, via a retrovirus system. While the morphologic transforming activities of the sense 215aa and 103aa constructs were similar in NIH3T3 cells, 103aa displayed reduced soft agar clonogenic activity, The 34aa construct was practically inert in these assays, although its expression could mimic the ability of 215aa or 103aa in conferring cell growth under reduced serum condition. Overexpression of any of the three constructs in antisense orientation, however, was similarly effective in reversing the morphology and anchorage-independent growth property of FGF8b-transfected NIH3T3 cells, The expression of the antisense 215aa construct significantly reduced the growth rate of the human prostatic carcinoma DU145 cells and inhibited their soft agar clonogenic activity and in vivo tumorigenicity in nude mice, Taken together, these results identify N-terminal portions of FGF8 protein isoform for having the domains necessary for one or more of the biologic effects examined, and suggest that low levels of FGF8 expressed in prostatic epithelial cells may contribute significantly to their growth and tumorigenic properties.	Univ So Calif, Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Roy-Burman, P (corresponding author), Univ So Calif, Sch Med, Dept Pathol, 2011 Zonal Ave,HMR 212, Los Angeles, CA 90033 USA.				NATIONAL CANCER INSTITUTE [R01CA059705, T32CA009320] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09320, CA59705] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; Gibson I, 1996, CANCER METAST REV, V15, P287, DOI 10.1007/BF00046343; GLEAVE M, 1991, CANCER RES, V51, P3753; GLEAVE ME, 1992, J UROLOGY, V147, P1151, DOI 10.1016/S0022-5347(17)37506-7; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JUNKER U, 1994, ANTISENSE RES DEV, V4, P165, DOI 10.1089/ard.1994.4.165; KOBAYASHI M, 1995, ANTISENSE RES DEV, V5, P141, DOI 10.1089/ard.1995.5.141; KOUHARA H, 1994, ONCOGENE, V9, P455; Leung HY, 1996, ONCOGENE, V12, P1833; LORENZI MV, 1995, ONCOGENE, V10, P2051; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; Payson RA, 1996, ONCOGENE, V13, P47; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; WHITE RA, 1995, GENOMICS, V30, P109, DOI 10.1006/geno.1995.0020; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123	30	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1487	1492		10.1038/sj.onc.1201652	http://dx.doi.org/10.1038/sj.onc.1201652			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525747				2022-12-28	WOS:000072572400012
J	Pierce, AM; Fisher, SM; Conti, CJ; Johnson, DG				Pierce, AM; Fisher, SM; Conti, CJ; Johnson, DG			Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development	ONCOGENE			English	Article						E2F; Rb; ras; cyclin D1; mouse skin model	TRANSCRIPTION FACTOR E2F1; S-PHASE ENTRY; RETINOBLASTOMA GENE-PRODUCT; GROWTH SUPPRESSION; CELL-PROLIFERATION; FIBROBLASTS LEADS; KINASE-ACTIVITY; DNA-SYNTHESIS; CYCLIN D1; PROTEIN	In cell culture studies, overexpression of the E2F1 transcription factor has been shown to stimulate proliferation, induce apoptosis, and cooperate with an activated ras gene to oncogenically transform primary rodent cells. To study the effect of increased E2F1 activity on epithelial growth and tumorigenesis in vivo, transgenic mice expressing E2F1 under the control of a keratin 5 (K5) promoter were generated. Expression of E2F1 in the epidermis results in hyperplasia but does not inhibit terminal differentiation. In a transgenic line expressing high levels of E2F1, mice have decreased hair growth likely as a result of aberrant apoptosis in developing hair follicles. Coexpression of a cyclin D1 transgene with E2F1 augments epidermal hyperplasia and further disrupts hair follicle development suggesting that hypophosphorylated Rb antagonizes the proliferative and apoptotic-promoting activities of E2F1. Finally, the E2F1 transgene is found to cooperate with a v-Ha-ras transgene to induce skin tumors in double transgenic animals. These findings confirm that many of the activities ascribed to E2F1 through in vitro studies can be reproduced in vivo and demonstrate for the first time that deregulated E2F activity can contribute to tumor development.	Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.			Johnson, David/0000-0002-6223-1790	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD053229] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042157] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42157] Funding Source: Medline; NICHD NIH HHS [N01-HD-5-3229] Funding Source: Medline; NIGMS NIH HHS [GM55521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; ALDAZ CM, 1989, SKIN TUMORS EXPT CLI, P227; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Geng Y, 1996, ONCOGENE, V12, P1173; Guy CT, 1996, MOL CELL BIOL, V16, P685; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MISSERO C, 1993, J CELL BIOL, V121, P1109, DOI 10.1083/jcb.121.5.1109; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; SALA A, 1994, CANCER RES, V54, P1402; SCHULZE A, 1994, ONCOGENE, V9, P3475; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHAO ZH, 1995, ONCOGENE, V10, P221; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang SY, 1997, MOL CARCINOGEN, V18, P142, DOI 10.1002/(SICI)1098-2744(199703)18:3<142::AID-MC3>3.3.CO;2-J; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	49	126	130	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	1998	16	10					1267	1276		10.1038/sj.onc.1201666	http://dx.doi.org/10.1038/sj.onc.1201666			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546428				2022-12-28	WOS:000072422000005
J	Fuchs, SY; Fried, VA; Ronai, Z				Fuchs, SY; Fried, VA; Ronai, Z			Stress-activated kinases regulate protein stability	ONCOGENE			English	Review						signal transduction; protein stability; stress kinases; regulation of protein ubiquitination; p53; ATF2; c-Jun; NF kappa B; JAK-STAT	KAPPA-B-ALPHA; UBIQUITIN-PROTEASOME PATHWAY; SITE-SPECIFIC PHOSPHORYLATION; SIGNAL-TRANSDUCTION PATHWAY; TUMOR-SUPPRESSOR PROTEIN; RECEPTOR TYROSINE KINASE; C-JUN KINASE; BETA-CATENIN; IN-VIVO; INDUCED DEGRADATION	Proteasome inhibitors have been used to demonstrate that many proteins of the signal transduction pathways are regulated by degradation via the ubiquitin-proteasome pathway. The key question is what events target specific proteins for ubiquitination at one time and prevent ubiquitination at other times? In this review, we develop the notion that there is a direct relationship between the phosphorylation/dephosphorylation cascade of the signal transduction pathways and the targeting of the regulatory proteins for ubiquitination. We present examples where phosphorylation appears to alter the interaction between the targeting systems and the substrate by modifying the targeting system, the substrate, or both. These interacting systems are seen in the response of p53, c-jun and ATF-2 in cells subjected to stress or DNA damage and to the normal regulated response in a variety of pathways including the I kappa B-NF kappa B and JAK-STAT pathways, The interweaving of the two post-translational networks, phosphorylation and ubiquitination, provides a powerful insight into global regulatory control pathways.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; New York Medical College	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Adler V, 1996, CARCINOGENESIS, V17, P2073, DOI 10.1093/carcin/17.9.2073; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chun K T, 1996, Prog Cell Cycle Res, V2, P115; CONNOR LH, 1995, J ROY ANTHROPOL INST, V1, P537, DOI 10.2307/3034574; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; FUCHS SY, 1998, IN PRESS ONCOGENE, V17; FUCHS SY, 1998, IN PRESS GENES DEV; FUCHS SY, 1998, IN PRESS P NATL ACAD; Grimley PM, 1998, BLOOD, V91, P3017, DOI 10.1182/blood.V91.8.3017.3017_3017_3027; Harhaj EW, 1997, J BIOL CHEM, V272, P5409, DOI 10.1074/jbc.272.9.5409; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; ISAKSSON A, 1996, BIOCHIM BIOPHYS ACTA, V1288, P21; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lee HW, 1997, MOL PHARMACOL, V51, P439; LEEMILLER SP, 1992, MOL CELL BIOL, V12, P5041; LIN A, 1994, SCIENCE, V266, P286; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; MAHESWARAN S, 1995, GENE DEV, V9, P143; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MENON SD, 1995, J BIOL CHEM, V270, P1881; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Sears C, 1998, J BIOL CHEM, V273, P1409, DOI 10.1074/jbc.273.3.1409; SEEDORF K, 1995, J BIOL CHEM, V270, P18953, DOI 10.1074/jbc.270.32.18953; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; YAN MH, 1994, NATURE, V372, P798; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; YEE NS, 1994, J BIOL CHEM, V269, P31991; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	87	135	136	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1483	1490		10.1038/sj.onc.1202184	http://dx.doi.org/10.1038/sj.onc.1202184			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779995				2022-12-28	WOS:000076161900016
J	Iglesias, M; Yen, K; Gaiotti, D; Hildesheim, A; Stoler, MH; Woodworth, CD				Iglesias, M; Yen, K; Gaiotti, D; Hildesheim, A; Stoler, MH; Woodworth, CD			Human papillomavirus type 16 E7 protein sensitizes cervical keratinocytes to apoptosis and release of interleukin-1 alpha	ONCOGENE			English	Article						apoptosis; cervical carcinoma; human; papillomavirus; interleukin-1; keratinocyte	EPITHELIAL-CELLS; GENE-EXPRESSION; DIFFERENTIAL REGULATION; GROWTH-FACTOR; DNA; CARCINOMA; RECEPTOR; PROLIFERATION; FIBROBLASTS; INFECTION	Interleukin-1 alpha. (IL-1 alpha) is a multifunctional cytokine that promotes inflammation, tissue remodeling and epithelial hyperplasia, Keratinocytes produce and sequester large amounts of biologically active IL-1 alpha which can be released after injury or infection. We show that high level expression of human papillomavirus (HPV) type 16 E6 and E7 oncoproteins enhanced release of IL-1 alpha from cultures of normal cervical keratinocytes (relative effectiveness E7>E6/E7 much greater than E6> control). The amount of IL-1 alpha. released was directly related to the ability of E7 or E6/E7 to stimulate apoptosis, E7 proteins that bound the retinoblastoma protein (Rb) strongly (HPV-16 and -18) induced more IL-1 alpha release than those that bound poorly (HPV-6 and an HPV-16 E7 24gly mutant). Furthermore, overexpression of the E2F-1 transcription factor, a downstream target of Rb, induced extensive apoptosis and IL-1 alpha release. Apoptosis and IL-1 alpha release in response to growth factor removal occurred in part through a p53-independent pathway as coexpression of E6 and downregulation of p53 did not prevent either response. Immunohistochemical analyses showed that IL-1 alpha. was expressed by keratinocytes in normal cervical epithelia, low and high grade dysplasias, and cervical carcinomas. However, HPV-16 E6/E7 RNA expression and apoptosis increased in parallel in proliferating keratinocytes in severe dysplasias and carcinomas suggesting that IL-1 alpha release is associated with progression to high grade disease. Thus, high level expression of the HPV-16 E7 protein sensitizes keratinocytes to apoptosis which results in release of IL-1 alpha.	NCI, Biol Lab, Bethesda, MD 20892 USA; NCI, Environm Epidemiol Branch, Bethesda, MD 20892 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22901 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Virginia	Woodworth, CD (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, Bldg 37,Room 3B25, Bethesda, MD 20892 USA.							ANSEL JC, 1988, J IMMUNOL, V140, P2274; Brown J, 1997, J CELL BIOCHEM, V66, P245, DOI 10.1002/(SICI)1097-4644(19970801)66:2<245::AID-JCB11>3.0.CO;2-G; BRYAN D, 1995, CELL GROWTH DIFFER, V6, P1245; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; Castrilli G, 1997, BRIT J CANCER, V75, P855, DOI 10.1038/bjc.1997.152; COLLINS RH, 1987, NEW ENGL J MED, V316, P1654, DOI 10.1056/NEJM198706253162609; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CORREA P, 1992, CANCER RES, V52, P6735; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FAN TPD, 1993, BRIT J PHARMACOL, V110, P43, DOI 10.1111/j.1476-5381.1993.tb13769.x; Frazer IH, 1996, CURR OPIN IMMUNOL, V8, P484, DOI 10.1016/S0952-7915(96)80035-5; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Isacson C, 1996, CANCER RES, V56, P669; Kim CY, 1997, CANCER RES, V57, P4200; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KUPPER TS, 1995, J INVEST DERMATOL, V105, pS62, DOI 10.1111/1523-1747.ep12316087; Li DQ, 1997, J CELL PHYSIOL, V172, P361, DOI 10.1002/(SICI)1097-4652(199709)172:3<361::AID-JCP10>3.0.CO;2-9; Merrick DT, 1996, CELL GROWTH DIFFER, V7, P1661; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Montague JW, 1996, EXPERIENTIA, V52, P957, DOI 10.1007/BF01920104; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; OBERYSZYN TM, 1993, MOL CARCINOGEN, V7, P238, DOI 10.1002/mc.2940070406; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; Riethdorf L, 1996, AM J PATHOL, V149, P1469; RORKE EA, 1995, EXP CELL RES, V216, P65, DOI 10.1006/excr.1995.1008; ROSL F, 1994, J VIROL, V68, P2142; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shoji Y, 1996, J CLIN PATHOL, V49, P134, DOI 10.1136/jcp.49.2.134; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STONE KM, 1995, CLIN INFECT DIS   S1, V20, P591; VIDALVANACLOCHA F, 1994, CANCER RES, V54, P2667; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Wood LC, 1996, J INVEST DERMATOL, V106, P397, DOI 10.1111/1523-1747.ep12343392; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WOODWORTH CD, 1993, AM J PATHOL, V142, P1544; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840; Woodworth CD, 1996, CELL GROWTH DIFFER, V7, P811; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	52	52	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1195	1205		10.1038/sj.onc.1202054	http://dx.doi.org/10.1038/sj.onc.1202054			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771962				2022-12-28	WOS:000075803300001
J	Stoppler, H; Stoppler, MC; Johnson, E; Simbulan-Rosenthal, CM; Smulson, ME; Iyer, S; Rosenthal, DS; Schlegel, R				Stoppler, H; Stoppler, MC; Johnson, E; Simbulan-Rosenthal, CM; Smulson, ME; Iyer, S; Rosenthal, DS; Schlegel, R			The E7 protein of human papillomavirus type 16 sensitizes primary human keratinocytes to apoptosis	ONCOGENE			English	Article						HPV E6 and E7 oncogenes; apoptosis; p53; primary keratinocytes; extended life span	MAMMARY EPITHELIAL-CELLS; RAT EMBRYO FIBROBLASTS; S-PHASE ENTRY; E6 ONCOPROTEIN; P53 PROTEIN; MUTATIONAL ANALYSIS; TRANSFORMING GENE; WILD-TYPE; HA-RAS; IMMORTALIZATION	The 'high risk' human papillomaviruses are associated with the development of anogenital carcinomas and their E6 and E7 genes possess immortalizing and transforming functions in several in vitro culture systems, Recently the E6 gene has also been shown to enhance the apoptosis of human mammary epithelial cells, To determine the apoptotic activity of these oncogenes in the natural host cell, we infected genital keratinocytes with retroviruses expressing either HPV-16 E6, E7, or both the E6 and E7 (E6/7) genes. Apoptosis was quantitated under normal growth conditions or when induced by tumor necrosis factor alpha/cycloheximide or sulfur mustard. In contrast to previous findings with mammary epithelial cells, the E6 gene did not significantly augment either spontaneous or induced apoptosis, E6 also did not suppress apoptosis in normal keratinocytes (despite dramatically reducing their p53 levels), suggesting that p53-independent events mediated this effect, In contrast, E7 increased both spontaneous and induced apoptosis as well as the cellular levels of p53 and p21 protein. Interestingly, coexpression of E6 abrogated E7-facilitated apoptosis by tumor necrosis factor alpha nearly completely, but had only a minor protective effect on sulfur mustard induced apoptosis in these cells, demonstrating at least in part the p53-dependence and -independence of these two apoptotic pathways, Finally, our results indicate that the apoptosis of normal and E7-expressing keratinocytes is differentially affected by E6 expression and that E7, when unaccompanied by E6, sensitizes keratinocytes to apoptosis.	Georgetown Univ, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Univ Marburg, Inst Pharmacol & Toxicol, D-35033 Marburg, Germany; Univ Marburg, Klinikum Lahnberge, Dept Pathol, D-35043 Marburg, Germany; Georgetown Univ, Dept Pathol, Mol Pathol Program, Washington, DC 20007 USA	Georgetown University; Philipps University Marburg; Philipps University Marburg; Georgetown University	Rosenthal, DS (corresponding author), Georgetown Univ, Dept Biochem & Mol Biol, 3900 Reservoir Rd, Washington, DC 20007 USA.		Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014	Rosenthal, Dean/0000-0002-7624-0209; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342	NATIONAL CANCER INSTITUTE [R01CA053371] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA53371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Dabrowska MI, 1996, TOXICOL APPL PHARM, V141, P568, DOI 10.1006/taap.1996.0324; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; LIU ZJ, 1994, VIROLOGY, V201, P388, DOI 10.1006/viro.1994.1306; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUNGER K, 1989, J VIROL, V63, P4417; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PEACOCK JW, 1990, ONCOGENE, V5, P1769; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rosenthal DS, 1998, J INVEST DERMATOL, V111, P64, DOI 10.1046/j.1523-1747.1998.00250.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; TANAKA A, 1989, J VIROL, V63, P1465, DOI 10.1128/JVI.63.3.1465-1469.1989; Thomas M, 1996, ONCOGENE, V13, P265; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; VILLA LL, 1991, VIROLOGY, V181, P374; VILLA LL, 1992, MOL CARCINOGEN, V6, P5, DOI 10.1002/mc.2940060103; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; Yu YJ, 1997, ONCOGENE, V14, P1661, DOI 10.1038/sj.onc.1201026	68	88	92	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	1998	17	10					1207	1214		10.1038/sj.onc.1202053	http://dx.doi.org/10.1038/sj.onc.1202053			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771963				2022-12-28	WOS:000075803300002
J	Sharma, SV				Sharma, SV			Rapid recruitment of p120RasGAP and its associated protein, p190RhoGAP, to the cytoskeleton during integrin mediated cell-substrate interaction	ONCOGENE			English	Article						p120RasGAP; p190RhoGAP; cell-substrate interaction; integrins; cytoskeleton	FOCAL ADHESION KINASE; GTPASE-ACTIVATING PROTEIN; ACTIN STRESS FIBERS; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; RHO-FAMILY; DEPHOSPHORYLATION; INSULIN	The interaction of cells with their substrate triggers cascades of signal transduction that result in profound changes in cell morphology. The nature of these signals and how they are integrated to orchestrate changes in cell shape are beginning to be elucidated. In particular, adhesive interactions between cells and their substrate, mediated by cell-surface integrins and extracellular matrix (ECM) proteins, appear to result in massive rearrangement of the cell cytoskeleton via the small G-protein, Rho. Here we show that in mouse fibroblasts, the interaction between cells and their substrate results in the rapid recruitment to the cytoskeleton of RasGAP (p120RasGAP), its associated protein of 190 kilodaltons, the GTPase activating protein for RhoA (p190RhoGAP) and the focal adhesion kinase (p125FAK). Similar results were obtained when cells were plated on ECM proteins, such as fibronectin, suggesting that the phenomenon is integrin mediated. These studies suggest that in fibroblasts, cell-substrate interaction triggered by integrin engagement result in the recruitment to the cytoskeleton of signaling molecules such as p120RasGAP, p190RhoGAP and p125FAK and may be involved in the formation of membrane cytoskeleton-associated signaling complexes that are important in cytoarchitectural reorganization.	Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Sharma, SV (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA.				NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER; NCI NIH HHS [CA55983] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BARRY ST, 1994, J CELL SCI, V107, P2033; BENZEEV A, 1979, CELL, V17, P859, DOI 10.1016/0092-8674(79)90326-X; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; Bottazzi ME, 1997, TRENDS CELL BIOL, V7, P348, DOI 10.1016/S0962-8924(97)01114-8; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Bussey H, 1996, SCIENCE, V272, P224, DOI 10.1126/science.272.5259.224; Bussey H, 1996, SCIENCE, V273, P203, DOI 10.1126/science.273.5272.203; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHANG JH, 1993, ONCOGENE, V8, P959; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gille J, 1996, ANN NY ACAD SCI, V797, P93, DOI 10.1111/j.1749-6632.1996.tb52952.x; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hotchin NA, 1996, CANCER SURV, V27, P311; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110; Konstantopoulos N, 1996, BIOCHEM J, V314, P387, DOI 10.1042/bj3140387; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PATCH LA, 1995, J CELL SCI, V108, P1371; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Sharma SV, 1997, ONCOGENE, V14, P2641, DOI 10.1038/sj.onc.1201115; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tobe K, 1996, MOL CELL BIOL, V16, P4765; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang DZM, 1997, CANCER RES, V57, P2478; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHAO JF, 1995, ONCOGENE, V11, P161; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	75	33	34	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	1998	17	3					271	281		10.1038/sj.onc.1201921	http://dx.doi.org/10.1038/sj.onc.1201921			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690509				2022-12-28	WOS:000074947500002
J	Caldas, C; Kim, MH; MacGregor, A; Cain, D; Aparicio, S; Wiedemann, LM				Caldas, C; Kim, MH; MacGregor, A; Cain, D; Aparicio, S; Wiedemann, LM			Isolation and characterization of a Pufferfish MLL (mixed lineage leukemia)-like gene (fMll) reveals evolutionary conservation in vertebrate genes related to Drosophila trithorax	ONCOGENE			English	Article						MLL; HRX; ALL-1; TRX; evolutionary conservation; Fugu rubripes; genomic sequence	11Q23 CHROMOSOMAL TRANSLOCATIONS; ALL-1 GENE; MOLECULAR ANALYSIS; ACTIVATION DOMAIN; SEQUENCE-ANALYSIS; TOPOISOMERASE-II; FUGU RUBRIPES; REGION; BREAKPOINT; ALIGNMENT	The MLL gene is interrupted and fused to a number of partner genes as a result of chromosomal translocations in human leukemias. MLL is a very large protein with a unique domain structure and large regions of homology to Drosophila trx. To define the key structural and functional domains of the MLL protein in vertebrates, me have cloned the genomic region encoding an MLL-like gene in the compact model vertebrate genome of Fugu rubripes. While the similarity between the mouse and human MLL proteins is very high, a lower overall similarity is present between the Fugu and mammalian proteins. Several new highly conserved regions were identified in the portion of the protein included in the MLL leukemia-associated fusion proteins. The conserved nature of regions of similarity between vertebrate forms of MLL and the Drosophila TRX proteins, as well as other domains previously suggested to have a functional role in MLL (including the AT hooks and the DNA methyltransferase domain), was also observed. There; fore, strong evolutionary constraints limited sequence divergence within these domains, The information derived from this comparative analysis will form the basis for the functional study of the MLL protein, particularly as it relates to human leukemogenesis.	Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Wellcome CRC Inst, Cambridge CB2 1QR, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Wiedemann, LM (corresponding author), Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, Fulham Rd, London SW3 6JB, England.		Caldas, Carlos/U-7250-2019; Caldas, Carlos/A-7543-2008; Wiedemann, Leanne/E-3316-2010	Caldas, Carlos/0000-0003-3547-1489; Aparicio, Samuel/0000-0002-0487-9599; Wiedemann, Leanne/0000-0002-0964-4676	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APARICIO S, 1995, P NATL ACAD SCI USA, V92, P1684, DOI 10.1073/pnas.92.5.1684; BAXENDALE S, 1995, NAT GENET, V10, P67, DOI 10.1038/ng0595-67; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Bonfield JK, 1996, DNA SEQUENCE, V6, P109, DOI 10.3109/10425179609010197; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; Caldas C, 1998, GENE, V208, P167, DOI 10.1016/S0378-1119(97)00640-9; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; DJABALI M, 1992, NAT GENET, V2, P112; DOMER PH, 1995, LEUKEMIA, V9, P1305; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; Greaves MF, 1996, LEUKEMIA, V10, P372; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; Henikoff S, 1997, TRENDS GENET, V13, P293, DOI 10.1016/S0168-9525(97)01219-5; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MACRAE AD, 1995, GENOMICS, V25, P436, DOI 10.1016/0888-7543(95)80044-M; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; MBANGKOLLO D, 1995, DNA CELL BIOL, V14, P475, DOI 10.1089/dna.1995.14.475; Nam DK, 1996, GENE, V178, P169, DOI 10.1016/0378-1119(96)00364-2; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; Prasad R, 1997, ONCOGENE, V15, P549, DOI 10.1038/sj.onc.1201211; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RASIO D, 1996, CANCER RES, V56, P176; Sandford R, 1997, HUM MOL GENET, V6, P1483, DOI 10.1093/hmg/6.9.1483; Sathasivam K, 1997, HUM MOL GENET, V6, P2141, DOI 10.1093/hmg/6.12.2141; SCHINDLER U, 1993, PLANT J, V4, P137, DOI 10.1046/j.1365-313X.1993.04010137.x; Schuddekopf K, 1996, P NATL ACAD SCI USA, V93, P9661, DOI 10.1073/pnas.93.18.9661; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; Strissel Gbroeker Pamela L., 1996, Blood, V87, P1912; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TILLIB S, 1995, MECH DEVELOP, V53, P113, DOI 10.1016/0925-4773(95)00429-7; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Venkatesh B, 1997, P NATL ACAD SCI USA, V94, P12462, DOI 10.1073/pnas.94.23.12462; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	52	27	27	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3233	3241		10.1038/sj.onc.1201873	http://dx.doi.org/10.1038/sj.onc.1201873			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681821				2022-12-28	WOS:000074343600003
J	Wang, QM; Luo, X; Kheir, A; Coffman, FD; Studzinski, GP				Wang, QM; Luo, X; Kheir, A; Coffman, FD; Studzinski, GP			Retinoblastoma protein-overexpressing HL60 cells resistant to 1,25-dihydroxyvitamin D-3 display increased CDK2 and CDK6 activity and shortened G1 phase	ONCOGENE			English	Article						retinoblastoma; vitamin D; human leukemia; cell cycle; cyclins	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; HL-60 CELLS; CYCLE PROGRESSION; RESTRICTION POINT; GENE-EXPRESSION; SP1-MEDIATED TRANSCRIPTION; MONOCYTIC DIFFERENTIATION; MACROPHAGE PROLIFERATION; LINE HL-60	Drug resistance that occurs during cancer chemotherapy has been a major problem in controlling neoplastic progression. To study the cellular mechanisms of acquired drug resistance we developed 1,25-dihydroxy-vitamin D-3 (1,25D(3))-resistant sublines of promyelocytic leukemia HL60 cells which have increased proliferation rates (Exp, Cell Xes., 224, 312, 1996; Cancer Res., 50, 5513, 1996), We report here that the resistant sublines display varying degrees of shortening of the G1 phase as compared to the parental HL60-G cells. Protein levels of cyclins E, D1, D2 and D3 are elevated in these resistant cell lines, and cyclin D1 is especially high in 40AF cells, which has the shortest G1 length. The protein levels of cyclin-dependent kinase (Cdk)2, Cdk4 and Cdk6 are not altered in the resistant sublines. Both Cdk2 and Cdk6-associated kinase activites are increased in the resistant sublines, but not Cdk4 kinase activity. Protein levels of p27(Kip1) are not consistently altered in the resistant sublines as compared to the parental HL60-G cells, but are reduced relative to HL60-G cells arrested by 96 h treatment with 1,25D(3). Interestingly, the resistant cell lines constitutively express high levels of retinoblastoma protein (pRb), and pRb is highly phosphorylated, indicating that the G1 cyclin/Cdk complexes in the resistant cells are physiologically active. The results suggest that the increased activity of cyclin D/Cdk6, and perhaps cyclin E/Cdk2, lead to rapid hyperphosphorylation of pRb and consequently a shorter early G1 phase, and that in the resistant cells the increased ratio of cyclin E to p27(Kip1) results in activation of Cdk2 and contributes to the abrogation of the 1,25D(3)-induced block to the S phase entry. Additionally, it is apparent that constitutively increased levels of pRb are compatible with increased rates of cell proliferation.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Studzinski, GP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, 185 S Orange Ave, Newark, NJ 07103 USA.				PHS HHS [R01-44722] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bergh G, 1997, BLOOD, V89, P2938, DOI 10.1182/blood.V89.8.2938; BRELVI ZS, 1986, J CELL BIOL, V102, P2234, DOI 10.1083/jcb.102.6.2234; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DOU QP, 1993, CANCER RES, V53, P1493; GALLAGHER R, 1979, BLOOD, V54, P713; GODYN JJ, 1994, CELL PROLIFERAT, V27, P37, DOI 10.1111/j.1365-2184.1994.tb01404.x; GONG J, 1995, LEUKEMIA, V9, P893; HAUSSLER MR, 1969, P NATL ACAD SCI USA, V62, P155, DOI 10.1073/pnas.62.1.155; HOLICK MF, 1971, BIOCHEMISTRY-US, V10, P2799; HUME DA, 1982, ADV EXP MED BIOL, V155, P261; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, ONCOGENE, V8, P3447; Juan G, 1996, CELL PROLIFERAT, V29, P259, DOI 10.1046/j.1365-2184.1996.01000.x; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kolla Sarah S, 1994, Molecular and Cellular Differentiation, V2, P169; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KURIBAYASHI T, 1983, ENDOCRINOLOGY, V113, P1992, DOI 10.1210/endo-113-6-1992; LASKY SR, 1994, BLOOD, V84, P4238; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sanchez I, 1996, CURR OPIN CELL BIOL, V8, P318, DOI 10.1016/S0955-0674(96)80004-4; SAWYER RT, 1986, J LEUKOCYTE BIOL, V39, P77, DOI 10.1002/jlb.39.1.77; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; SLADEK TL, 1992, J VIROL, V66, P1059, DOI 10.1128/JVI.66.2.1059-1065.1992; Studzinski George P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P279; Studzinski GP, 1997, EXP CELL RES, V232, P376, DOI 10.1006/excr.1997.3484; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; Wajchman HJ, 1996, EXP CELL RES, V224, P312, DOI 10.1006/excr.1996.0141; Wang QM, 1997, CANCER RES, V57, P2851; Wang QM, 1996, CANCER RES, V56, P264; Wang XN, 1997, J NATL CANCER I, V89, P1199, DOI 10.1093/jnci/89.16.1199; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Yang Xiao-He, 1995, Gene Expression, V4, P195; ZHANG F, 1994, CELL PROLIFERAT, V27, P643, DOI 10.1111/j.1365-2184.1994.tb01379.x	53	18	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2729	2737		10.1038/sj.onc.1201803	http://dx.doi.org/10.1038/sj.onc.1201803			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652739				2022-12-28	WOS:000073812200004
J	Anderson, DH; Ismail, PM				Anderson, DH; Ismail, PM			V-fps causes transformation by inducing tyrosine phosphorylation and activation of the PDGF beta receptor	ONCOGENE			English	Article						Fps/Fes; PDGF beta receptor; down-regulation; tyrosine phosphorylation	GROWTH-FACTOR RECEPTORS; COLONY-STIMULATING FACTOR; FUJINAMI SARCOMA-VIRUS; C-FES PROTEIN; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; TRANSGENIC MICE; KINASE FUNCTION; SRC ONCOGENE; FACTOR-I	The v-fps oncogene encodes an activated tyrosine kinase which is capable of transforming fibroblasts. In this report, we provide evidence that within a few minutes of activation of the tyrosine kinase activity of v-Fps, tyrosine phosphorylation of the platelet derived growth factor (PDGF) beta receptor is observed. Further, sustained expression of activated v-Fps results in a downregulation of the PDGF receptor both at the level of the mRNA (similar to 4-8-fold), but even more markedly at the level of the receptor protein (>100-fold). The kinase activity of the v-Fps oncoprotein was found to be required for both the induction of PDGF receptor tyrosine phosphorylation and ultimately the reduced receptor protein levels. Tyrosine phosphorylation of a kinase inactive PDGF receptor was also demonstrated in cells which also express v-fps, but this was not sufficient to induce transformation. Only cells expressing both v-fps and a wild type PDGF receptor were able to form colonies in soft agar. These findings suggest that wild type v-fps may use tyrosine phosphorylation of the PDGF beta receptor to constitutively activate the kinase activity of the receptor, resulting in a sustained proliferative signal and fibroblast transformation.	Saskatoon Canc Ctr, Res Unit, Saskatoon, SK S7N 4H4, Canada	University of Saskatchewan	Anderson, DH (corresponding author), Saskatoon Canc Ctr, Res Unit, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.							BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; CARE A, 1994, ONCOGENE, V9, P739; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FOSTER DA, 1985, CELL, V42, P105, DOI 10.1016/S0092-8674(85)80106-9; FUKUI Y, 1991, ONCOGENE, V6, P407; GARRETT JS, 1984, P NATL ACAD SCI-BIOL, V81, P7466, DOI 10.1073/pnas.81.23.7466; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; Hawking F, 1978, Adv Pharmacol Chemother, V15, P289, DOI 10.1016/S1054-3589(08)60486-X; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; HUANG SS, 1988, J BIOL CHEM, V263, P12608; INGMANBAKER J, 1984, J VIROL, V50, P572, DOI 10.1128/JVI.50.2.572-578.1984; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANFRANCONE L, 1989, INT J CANCER, P35; LETWIN K, 1988, ONCOGENE, V3, P621; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MARU Y, 1995, MOL CELL BIOL, V15, P835; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MORAN MF, 1988, ONCOGENE, V3, P665; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; PANTAZIS P, 1990, EUR J HAEMATOL, V45, P127; PANTAZIS P, 1991, P NATL ACAD SCI USA, V88, P2481, DOI 10.1073/pnas.88.6.2481; PARK WY, 1995, BIOCHEM BIOPH RES CO, V211, P447, DOI 10.1006/bbrc.1995.1834; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAKE JB, 1991, J BIOL CHEM, V266, P5348; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SODROSKI JG, 1984, P NATL ACAD SCI-BIOL, V81, P3039, DOI 10.1073/pnas.81.10.3039; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TZENG DY, 1985, BLOOD, V66, P179; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; YAN XQ, 1993, J IMMUNOL, V150, P2440; YAN XQ, 1994, ONCOGENE, V9, P163; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	64	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	1998	16	18					2321	2331		10.1038/sj.onc.1201780	http://dx.doi.org/10.1038/sj.onc.1201780			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620549				2022-12-28	WOS:000073428000004
J	Knudsen, ES; Wang, JYJ				Knudsen, ES; Wang, JYJ			Hyperphosphorylated p107 and p130 bind to T-antigen: identification of a critical regulatory sequence present in RB but not in p107/p130	ONCOGENE			English	Article						cell cycle; E1A; E2F-1; E2F-4; tumor suppressor	RETINOBLASTOMA GENE-PRODUCT; CYCLIN-DEPENDENT KINASE; TUMOR-SUPPRESSOR PROTEINS; E2F TRANSCRIPTION FACTOR; CELL-CYCLE; GROWTH SUPPRESSION; FAMILY MEMBERS; IN-VIVO; PHOSPHORYLATION; PRB	The retinoblastoma tumor suppressor RE and its related proteins, p107 and p130, are targets of several viral oncoproteins, including SV40 large T-antigen (T-Ag) and adenovirus E1A. T-Ag and E1A each contains an LXCXE-peptide motif through which binding to the conserved 'A/B pocket' present in RE, p107 and p130 is achieved, The LXCXE-binding activity of RB, we have previously shown, is inhibited by phosphorylation at Thr 821 and 826 in the C-terminal region of RE. Thr 821 and its surrounding sequence is unique to RE and not found in p107 or p130. Interestingly, hyperphosphorylation of p107 does not disrupt its ability to bind T-Ag or to inhibit the transactivating function of E1A. Insertion of a fourteen amino acid sequence of RE containing Thr 821 into p107 prevents binding of T-Ag and E1A to phosphorylated p107. These results show that the RE sequence surrounding Thr 821 plays a critical role in the regulation of the 'A/B pocket' function. In addition, these data indicate that the protein binding functions of RE and p107 are not equivalently regulated by phosphorylation.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Dept Biol, 0322,Bonner Hall 3326,9500 Gilman Dr, La Jolla, CA 92093 USA.				NCI NIH HHS [CA58320, R01 CA058320] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BEIJERSBERGEN RL, 1996, BIOCHIM BIOPHYS ACTA, P1287; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Gibbs E, 1996, J BIOL CHEM, V271, P22847, DOI 10.1074/jbc.271.37.22847; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HAMEL PA, 1992, ONCOGENE, V7, P693; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kaelin WG, 1997, CANCER INVEST, V15, P243, DOI 10.3109/07357909709039722; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KNUDSEN ES, 1997, MOL CELL BIOL, V22, P1773; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LIN BTY, 1992, CIBA F SYMP, V170, P227; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	61	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1655	1663		10.1038/sj.onc.1201682	http://dx.doi.org/10.1038/sj.onc.1201682			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582013				2022-12-28	WOS:000072807600003
J	Hiyama, H; Iavarone, A; Reeves, SA				Hiyama, H; Iavarone, A; Reeves, SA			Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F	ONCOGENE			English	Article						E2F; p21; cell cycle; transcription	PROTEIN FAMILY MEMBERS; RETINOBLASTOMA PROTEIN; IN-VIVO; C-MYC; P53-INDEPENDENT EXPRESSION; FUNCTIONAL INTERACTION; PROMOTER; BINDING; ARREST; GROWTH	The control of cell cycle progression is orchestrated by an extraordinary diverse and dynamic in function group of proteins. Critical in the progression are the actions of the E2F family of transcription factors which regulate the expression of genes necessary for the G(1)/S transition and the WAF/CIP/KIP family of cdk inhibitors which can inhibit cell cycle progression. In this report, we have identified E2F binding sites in both the human and mouse p21 promoters that bind E2F protein complexes from nuclear extracts in a cell cycle-dependent manner. In ectopic expression experiments we determined that E2F1, but not E2F4, can strongly transactivate the human p21 gene through these E2F binding sites which are located in the -215/+1 region of the p21 gene. The transactivation of the p21 gene through regulatory elements within the -215/+1 region of the promoter was correlated with increased levels of endogenous E2F1 and p21 proteins at the G(1)/S boundary. The significance of transactivation of the p21 gene by E2F is that p21 function is important in cell cycle progression as well as for cell cycle arrest. Indeed, E2F- induced levels of p21 protein during the G(1)/S transition is consistent with the recent findings demonstrating that p21 acts as an assembly factor for kinase active cyclin/cdk/p21 complexes.	Massachusetts Gen Hosp, Ctr Neurosci, Neurosurg Serv, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Mem Sloan Kettering Canc Ctr, Cell Biol & Genet Program, New York, NY 10021 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center	Reeves, SA (corresponding author), Massachusetts Gen Hosp, Ctr Neurosci, Neurosurg Serv, Boston, MA 02129 USA.							BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Botz J, 1996, MOL CELL BIOL, V16, P3401; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JUNG JM, 1995, ONCOGENE, V11, P2021; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LAU LF, 1991, GENES INDUCED SERUM, P165; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Liu Y, 1996, CANCER RES, V56, P31; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Magae J, 1996, J CELL SCI, V109, P1717; Marchetti A, 1996, ONCOGENE, V12, P1319; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MAYOL X, 1995, ONCOGENE, V11, P801; MICHIELI P, 1994, CANCER RES, V54, P3391; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MOLNAR G, 1994, MOL CELL BIOL, V14, P5254; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	59	112	112	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1513	1523		10.1038/sj.onc.1201667	http://dx.doi.org/10.1038/sj.onc.1201667			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569018				2022-12-28	WOS:000072743200001
J	Lebowitz, PF; Prendergast, GC				Lebowitz, PF; Prendergast, GC			Non-Ras targets of farnesyltransferase inhibitors: focus on Rho	ONCOGENE			English	Review						protein prenylation; transformation; apoptosis; cell adhesion; signal transduction	FARNESYL TRANSFERASE INHIBITORS; ENDOTHELIAL GROWTH-FACTOR; TUMOR-CELL LINES; H-RAS; TRANSFORMED-CELLS; ACTIN CYTOSKELETON; IN-VIVO; GERANYLGERANYLTRANSFERASE-I; PROTEIN PRENYLTRANSFERASES; SIGNALING PATHWAY	Farnesyltransferase inhibitors (FTIs) are a novel class of cancer therapeutics whose development was based on the discovery that the function of oncogenic Ras depends upon its posttranslational farnesylation. Significantly, experiments in animal models have shown that FTIs have promise as nontoxic cancer therapeutics. However, cell biological studies have suggested that FTIs may act at a level beyond that of suppressing Ras function, so the exact mechanism of action has emerged as a question of major interest. Here, we review evidence that proteins other than Ras are important targets for inhibition, summarize findings suggesting a role for farnesylated Rho proteins prompted by studies on RhoB, and suggest a new model for how FTIs exert their biological effects. The 'FIT-Rho hypothesis' proposes that FTIs act in part by altering Rho-dependent cell adhesion signals which are linked to pathways controlling cell cycle and cell survival and which are subverted or defective in neoplastic cells. This model offers a novel framework for addressing the questions about FTI biology, including the basis for Lack of toxicity to normal cells, cytotoxic verses cytostatic effects on tumor cells, and the persistence and drug resistance of malignant cells in FTI-treated animals.	Wistar Inst, Philadelphia, PA 19104 USA	The Wistar Institute	Prendergast, GC (corresponding author), Wistar Inst, Philadelphia, PA 19104 USA.							ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; COX AD, 1994, J BIOL CHEM, V269, P1; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DALTON MB, 1995, CANCER RES, V55, P3295; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; Foster R, 1996, MOL CELL BIOL, V16, P2689; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Graham SM, 1996, MOL CELL BIOL, V16, P6132; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hotchin NA, 1996, CANCER SURV, V27, P311; JAHNER D, 1991, ONCOGENE, V6, P1259; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; JIMENEZ B, 1995, ONCOGENE, V10, P811; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Krajewska M, 1996, CANCER RES, V56, P2422; Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014-5793(97)00444-4; Larcher F, 1996, CANCER RES, V56, P5391; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LEBOWITZ PF, 1998, IN PRESS CELL ADHES; Leonard DM, 1997, J MED CHEM, V40, P2971, DOI 10.1021/jm970226l; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; MANNE V, 1995, ONCOGENE, V10, P1763; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Miquel K, 1997, CANCER RES, V57, P1846; Miyake M, 1996, FEBS LETT, V378, P15, DOI 10.1016/0014-5793(95)01416-0; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nagase T, 1996, INT J CANCER, V65, P620, DOI 10.1002/(SICI)1097-0215(19960301)65:5<620::AID-IJC11>3.0.CO;2-B; NAGASU T, 1995, CANCER RES, V55, P5310; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Prendergast GC, 1996, CANCER RES, V56, P2626; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAK J, 1995, CANCER RES, V55, P4575; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sebti Said, 1997, Current Opinion in Oncology, V9, P557, DOI 10.1097/00001622-199711000-00011; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SHIH TY, 1982, J BIOL CHEM, V257, P1767; SUN JZ, 1995, CANCER RES, V55, P4243; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; ZALCMAN G, 1995, ONCOGENE, V10, P1935; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	76	193	197	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1439	1445		10.1038/sj.onc.1202175	http://dx.doi.org/10.1038/sj.onc.1202175			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779989				2022-12-28	WOS:000076161900010
J	Faure, S; Morin, N; Doree, M				Faure, S; Morin, N; Doree, M			Inactivation of protein kinase A is not required for c-mos translation during meiotic maturation of Xenopus oocytes	ONCOGENE			English	Article						c-mos oncogene; protein kinase A translation; oocyte maturation	MAP KINASE; CYTOPLASMIC POLYADENYLATION; MESSENGER-RNA; FROG OOCYTES; SOMATIC-CELLS; ACTIVATION; CYCLIN; PHOSPHATASE; METAPHASE; NUCLEAR	It has been shown previously that protein kinase A (PKA) maintains Xenopus oocytes arrested at G2, at least in part by preventing c-mos translation, but how PKA controls c-mos translation is not known. Using microinjection of recombinant c-mos, which still activates MAP kinase in the presence of active PKA, we have found that PKA does not exert any effect on translation of endogenous c-mos if MAP kinase is first activated, Even though they accumulate c-mos and contain MAP kinase activity as high as control oocytes, oocytes do not exit G2 in the presence of active PKA, These results are discussed in connection with recent findings on regulation of c-raf activity.	CNRS, Ctr Rech Biochim Macromol, Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Doree, M (corresponding author), CNRS, Ctr Rech Biochim Macromol, 1919 Route Mende, F-34293 Montpellier 5, France.		FAURE, Sandrine/N-6506-2018	FAURE, Sandrine/0000-0002-8902-8274; Morin, Nathalie/0000-0001-8677-1401				Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DAAR I, 1993, J CELL BIOL, V120, P1197, DOI 10.1083/jcb.120.5.1197; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; GABRIELLI BG, 1993, SCIENCE, V259, P1766, DOI 10.1126/science.8456304; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GEBAUER F, 1994, EMBO J, V13, P5712, DOI 10.1002/j.1460-2075.1994.tb06909.x; GODEAU F, 1978, CR ACAD SCI D NAT, V286, P685; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; HUCHON D, 1979, BIOL CELLULAIRE, V35, P15; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KISHIMOTO T, 1982, EXP CELL RES, V137, P121, DOI 10.1016/0014-4827(82)90014-3; Kuge H, 1995, EMBO J, V14, P6301, DOI 10.1002/j.1460-2075.1995.tb00320.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1991, METHOD ENZYMOL, V201, P291; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MALLER J, 1977, J BIOL CHEM, V525, P1712; MALLER JL, 1983, ADV CYCL NUCL RES<D>, V15, P295; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; MELTON DA, 1979, CELL, V18, P1165, DOI 10.1016/0092-8674(79)90229-0; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; RIME H, 1994, BIOL CELL, V82, P11, DOI 10.1016/0248-4900(94)90061-2; RIME H, 1992, DEV BIOL, V151, P105, DOI 10.1016/0012-1606(92)90217-5; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; Shibuya EK, 1996, CELL GROWTH DIFFER, V7, P235; SPEAKER MG, 1977, NATURE, V267, P848, DOI 10.1038/267848a0; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666	44	19	20	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1215	1221		10.1038/sj.onc.1202056	http://dx.doi.org/10.1038/sj.onc.1202056			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771964				2022-12-28	WOS:000075803300003
J	Care, A; Silvani, A; Meccia, E; Mattia, G; Peschle, C; Colombo, MP				Care, A; Silvani, A; Meccia, E; Mattia, G; Peschle, C; Colombo, MP			Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence	ONCOGENE			English	Article						bFGF; homeobox gene, SkBr3 cell line; retroviral vector; intracrine loop	HOMEOBOX GENES; TUMORS; MICE; LEUKEMIA; PROMOTER; CANCER	Several melanomas, carcinomas, glioblastomas and leukemias showed coordinated expression of HOXB7 and bFGF with exception of the SkBr3 mammary carcinoma that was negative for both. Transduction of HOXB7 gene into SkBr3 cells, induced bFGF expression, increased growth rate, independence from serum withdrawal and ability to form colonies in semisolid medium. ELISA assay showed that most of bFGF was associated to cell lysate when cells were cultured at 1% serum whereas in cells kept to 10% serum bFGF was detected both within cell lysate or secreted into cell supernatants. Antisense oligos to bFGF inhibited the growth of cells cultured in 1%, indicating that beside the possible activation of additional genes other than bFGF by HOXB7 transduction, only bFGF induction accounts for the observed results. Moreover, since inhibition of cell proliferation occurred in cells kept in 1% but not 10% serum, a bFGF intracrine loop appears operative in serum starved SkBr3/HOXB7 cells. Also, these results further indicate bFGF as target of HOXB7.	Ist Nazl Studio & Cura Tumori, Div Expt Oncol D, I-20133 Milan, Italy; Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Istituto Superiore di Sanita (ISS)	Colombo, MP (corresponding author), Ist Nazl Studio & Cura Tumori, Div Expt Oncol D, Via Venezian 1, I-20133 Milan, Italy.		Colombo, Mario P./V-7166-2017; Silvani, Antonio/AAA-4600-2019; CARE', Alessandra/H-5090-2016; Mattia, Gianfranco/K-5194-2016; felli, nadia/G-2088-2012	Colombo, Mario P./0000-0003-0042-7955; Silvani, Antonio/0000-0002-4791-1042; CARE', Alessandra/0000-0003-4106-3342; Mattia, Gianfranco/0000-0001-7047-6360; felli, nadia/0000-0001-6763-3361; meccia, ettore/0000-0003-2076-5951				CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; Care A, 1996, MOL CELL BIOL, V16, P4842; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DEGUCHI Y, 1993, CANCER RES, V53, P373; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FERNIG DG, 1993, INT J CANCER, V54, P629, DOI 10.1002/ijc.2910540418; FLAMME I, 1992, DEVELOPMENT, V116, P435; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; GOOMER RS, 1994, P NATL ACAD SCI USA, V91, P7985, DOI 10.1073/pnas.91.17.7985; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; KERBEL RS, 1992, AM J PATHOL, V141, P519; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; MAVILIO F, 1993, EUR J BIOCHEM, V212, P273, DOI 10.1111/j.1432-1033.1993.tb17660.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; PEYRAT JP, 1992, J STEROID BIOCHEM, V43, P87, DOI 10.1016/0960-0760(92)90191-K; Quaranta MT, 1996, J IMMUNOL, V157, P2462; Sambrook J., 2002, MOL CLONING LAB MANU; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; STCHOWIAK EK, 1997, ONCOGENE, V14, P2201; TREMPE G, 1973, IN VITRO CELL DEV B, V8, P433	28	78	81	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3285	3289		10.1038/sj.onc.1201875	http://dx.doi.org/10.1038/sj.onc.1201875			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681827				2022-12-28	WOS:000074343600009
J	Yoshida, Y; Matsuda, S; Ikematsu, N; Kawamura-Tsuzuku, J; Inazawa, J; Umemori, H; Yamamoto, T				Yoshida, Y; Matsuda, S; Ikematsu, N; Kawamura-Tsuzuku, J; Inazawa, J; Umemori, H; Yamamoto, T			ANA, a novel member of Tob/BTG1 family, is expressed in the ventricular zone of the developing central nervous system	ONCOGENE			English	Article						Tob/BTG1 family; antiproliferative activity; ventricular zone; cartilage	SONIC HEDGEHOG; MESSENGER-RNA; GENE; CELL; PROTEIN; ALLELOTYPE; CARCINOMA; INDUCTION; PRODUCT; PC3	Using a polymerase chain reaction-mediated cloning procedure, we have identified a novel member, termed ANA (from Abundant in Nueroepithelium Area), of Tob/BTG1 family of antiproliferative genes, Molecular cloning and analysis of cDNAs revealed that the human and mouse ANA encoded a protein of 252 amino acids, The amino-terminal half of ANA was homologous to the previously characterized antiproliferative gene products, BTG1, PC3/TIS21/BTG2, and Tob, The human, ANA gene was localized at chromosome 21q11.2-q21.1, ANA ,vas expressed in a variety of tissues and cell lines, its expression being high in the ovary, testis, prostate, thymus, and lung. Further analysis revealed that ANA expression was high in the ventricular zone of the developing central nervous system, Finally, overexpression of ANA impaired serum-induced cell cycle progression from the G(0)/G(1) to S phase. In conclusion, ANA is a fourth member of the Tob/BTG1 family that might play roles in neurogenesis in the central nervous system.	Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 108, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 108, Japan	University of Tokyo; University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.			Umemori, Hisashi/0000-0001-7198-2062				AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GILBERT SF, 1994, DEV BIOL, P244; GRAHAM A, 1991, DEVELOPMENT, V112, P255; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; IACOPETTI P, 1994, MECH DEVELOP, V47, P127, DOI 10.1016/0925-4773(94)90085-X; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; JOHNSTON MC, 1985, TERATOLOGY, V31, pA26; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MANTAGNOLI A, 1996, CELL GROWTH DIFFER, V7, P1327; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Matsuda S, 1996, ONCOGENE, V12, P705; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sambrook J., 2002, MOL CLONING LAB MANU; SATO S, 1994, CANCER RES, V54, P5652; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; TAN SS, 1985, CELL TISSUE RES, V240, P403; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8	27	93	102	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2687	2693		10.1038/sj.onc.1201805	http://dx.doi.org/10.1038/sj.onc.1201805			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632145				2022-12-28	WOS:000073698200013
J	Houldsworth, J; Xiao, H; Murty, VVVS; Chen, WY; Ray, B; Reuter, VE; Bosl, GJ; Chaganti, RSK				Houldsworth, J; Xiao, H; Murty, VVVS; Chen, WY; Ray, B; Reuter, VE; Bosl, GJ; Chaganti, RSK			Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation	ONCOGENE			English	Article						TP53; mutation; resistance; germ cell tumor	P53 PROTEIN; TESTICULAR CANCER; SUPPRESSOR GENE; GROWTH ARREST; APOPTOSIS; EXPRESSION; TESTIS; DEATH	Male germ cell tumors (GCTs) are uniquely sensitive to cisplatin-based chemotherapy, with more than 90% of newly diagnosed cases cured. The underlying cause for resistance to treatment in 20-30% of metastatic lesions remains to be identified. Unlike other solid tumors, no mutations in the TP53 gene have been identified to date in random panels of GCT specimens, which could account for the exquisite sensitivity of these tumors to genotoxic insult. However, in a panel of resistant GCTs that did either not respond to cisplatin-based chemotherapy or subsequently relapsed and resulted in the death of the patient, we have now identified a subset of tumors to contain TP53 mutations within exons 6-9. A cell line derived from one of these tumors (228A) displayed the same TP53 mutation as the tumor specimen, expressed only mutant TP53 mRNA, and exhibited a relative resistance to cisplatin in vitro in comparison to a cell line (218A) derived from a responsive tumor with wild-type TP53. The resistant cell line displayed a much reduced apoptotic cell death and did not exhibit an induction of transcription of the p53-responsive genes WAF1 and MDM2 following cisplatin treatment, compared to that observed in the sensitive cell line. The levels of bax, an agonist of apoptosis, were found to be reduced in the resistant cell line. The simplest explanation for the resistance of this subset of GCTs that are resistant to cisplatin-based chemotherapy, is the inability of the cells to mount an apoptotic response following exposure due to a functionally inactivating mutation in the TP53 gene.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chaganti, RSK (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.							BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARTKOVA J, 1991, INT J CANCER, V49, P196, DOI 10.1002/ijc.2910490209; BOSL GJ, 1997, CANC PRINCIPLES PRAC; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHAGANTI RSK, 1996, COMPREHENSIVE TXB GE, P932; Chresta CM, 1996, CANCER RES, V56, P1834; ELDIERY WS, 1993, CELL, V75, P817; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; PENG HQ, 1993, CANCER RES, V53, P3574; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; ULBRIGHT TM, 1993, AM J SURG PATHOL, V17, P1075, DOI 10.1097/00000478-199311000-00001; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XU L, 1994, INT J CANCER, V59, P383, DOI 10.1002/ijc.2910590316; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	22	126	129	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2345	2349		10.1038/sj.onc.1201770	http://dx.doi.org/10.1038/sj.onc.1201770			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620551				2022-12-28	WOS:000073428000006
J	Dono, R; James, D; Zeller, R				Dono, R; James, D; Zeller, R			A GR-motif functions in nuclear accumulation of the large FGF-2 isoforms and interferes with mitogenic signalling	ONCOGENE			English	Article						fibroblast growth factor; FGF2; NLS; nuclear retention; mitotic arrest; proliferation	FIBROBLAST GROWTH-FACTOR; TRANSLOCATION SEQUENCE; BIOLOGICAL-ACTIVITY; ENDOTHELIAL-CELLS; MESSENGER-RNA; FACTOR FAMILY; FACTOR-II; LOCALIZATION; BFGF; EXPRESSION	Nuclear translocation has been documented for members of the fibroblast growth factor (FGF) family in addition to their roles as extra-cellular signalling molecules. Fusing different parts of the chicken FGF-2. open reading frame to pyruvate kinase shows that direct nuclear accumulation is mediated by the amino-termini of the two leucine initiated FGF-2 isoforms (Leu-isoforms; 21.5 and 20.0 kDa), An evolutionarily conserved glycine-arginine (GR)-motif is present in the 21.5 kDa Leu-isoform and a shorter GR-repeat in the 20.0 kDa Leu-isoform, whereas no such repeats are present in the 18.5 kDa FGF-2 isoform (Met-isoform), Expression in NIH3T3 fibroblasts shows that the 21.5 kDa Leu-isoform is predominantly nuclear, whereas the Met-isoform is predominantly cytoplasmic. Most importantly, insertion of the GR-motif into the Met-isoform results in a protein with characteristics similar to the Leu-isoforms, as shown by nuclear accumulation of the chimeric M-GR-protein. Furthermore, only NIH3T3 fibroblasts expressing the Met-isoform proliferate under serum starvation conditions, whereas cells expressing either the M-GR- Or Leu-isoforms stay growth arrested. These studies show that the GR-signal mediates nuclear translocation of endogenous Leu-isoforms and blocks their mitogenic activity.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Zeller, R (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		James, Dominic/G-6435-2016; DONO, ROSANNA/I-7821-2016; Zeller, Rolf/C-2610-2013	James, Dominic/0000-0002-0452-2178; Zeller, Rolf/0000-0002-3186-7403				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Borja AZM, 1996, DEV BIOL, V180, P680, DOI 10.1006/dbio.1996.0337; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; LIN Y, 1996, J BIOL CHEM, V271, P5303; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Moffett J, 1996, P NATL ACAD SCI USA, V93, P2470, DOI 10.1073/pnas.93.6.2470; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; POWELL PP, 1991, J CELL PHYSIOL, V148, P202, DOI 10.1002/jcp.1041480204; PRESTA M, 1993, GROWTH FACTORS, V9, P269, DOI 10.3109/08977199308991587; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; RIESE J, 1995, MECH DEVELOP, V49, P13, DOI 10.1016/0925-4773(94)00296-Y; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SHERMAN L, 1993, DEVELOPMENT, V118, P1313; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SIOMI H, 1995, J CELL BIOL, V129, P511; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; TESSLER S, 1990, J CELL PHYSIOL, V145, P310, DOI 10.1002/jcp.1041450216; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WOODWARD WR, 1992, J NEUROSCI, V12, P142; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; ZAGZAG D, 1990, CANCER RES, V50, P7393; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZUNIGA A, 1993, DEV BIOL, V157, P110, DOI 10.1006/dbio.1993.1116	50	31	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2151	2158		10.1038/sj.onc.1201746	http://dx.doi.org/10.1038/sj.onc.1201746			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572496				2022-12-28	WOS:000073177200013
J	Lembo, M; Sacchi, C; Zappador, C; Bellomo, G; Gaboli, M; Pandolfi, PP; Gariglio, M; Landolfo, S				Lembo, M; Sacchi, C; Zappador, C; Bellomo, G; Gaboli, M; Pandolfi, PP; Gariglio, M; Landolfo, S			Inhibition of cell proliferation by the interferon-inducible 204 gene, a member of the Ifi 200 cluster	ONCOGENE			English	Article						interferon; interferon-inducible genes; p204; cell cycle; growth inhibition	TUMOR-SUPPRESSOR GENES; CONSTITUTIVE EXPRESSION; RETINOBLASTOMA PROTEIN; CYCLE PROGRESSION; TRANSGENIC MICE; INFLUENZA-VIRUS; 3T3 CELLS; GROWTH; TRANSCRIPTION; ARREST	The role of the IFN-inducible p204 as growth regulator was investigated by transfecting an expression vector constitutively expressing p204 into several cell lines, Like PRE and p107, p204 is a potent growth inhibitor in sensitive cells, as demonstrated by the cell focus assay, Since stable transfectants of sensitive lines constitutively overexpressing p204 could not be established in vitro, we inserted the 204 cDNA into a vector bearing an heavy-metal-inducible promoter, Here we show that proliferation of B6MEF fibroblasts lacking endogenous p204 is strongly inhibited by transient p204 expression in the nucleus, p204 delays G(1) progression into the S-phase and cells accumulate with a DNA content equivalent to cells arrested in late G(1). Moreover, the role of p204 in the control of cell growth in vivo was investigated by generating transgenic mice in which the Ifi 204 gene was constitutively expressed in all tissues, To this end, expression vectors bearing the 204 cDNA under the control of the SV40 viral promoter were constructed, The overexpression of the p204 transgene achieved by injecting fertilized mouse eggs with these vectors was compatible with embryo development up to the four-cell stage in an in vitro follow-up of 4.5 days, However, no viable animals with an intact copy of the transgene were obtained, suggesting that high and constitutive levels of p204 expression can impair normal embryo development, These findings indicate that p204 plays a negative role in growth regulation and provide new information about the molecular mechanisms exploited by IFNs to inhibit cell proliferation.	Med Sch Torino, Dept Microbiol & Publ Hlth, Turin, Italy; Med Sch Novara, Dept Med Sci, Novara, Italy; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; CNR, Ctr Immunogenet & Expt Oncol, I-10126 Turin, Italy	University of Eastern Piedmont Amedeo Avogadro; Memorial Sloan Kettering Cancer Center; Consiglio Nazionale delle Ricerche (CNR)	Landolfo, S (corresponding author), Med Sch Torino, Dept Microbiol & Publ Hlth, Turin, Italy.			Gariglio, Marisa/0000-0002-5187-0140				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALKWILL F, 1978, NATURE, V274, P798, DOI 10.1038/274798a0; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BURRUS GR, 1992, J CELL BIOCHEM, V48, P190, DOI 10.1002/jcb.240480210; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; DAWSON MJ, 1995, J CELL BIOCHEM, V57, P39, DOI 10.1002/jcb.240570106; Demaeyer E., 1988, INTERFERONS OTHER RE; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVINGER M, 1981, J BIOL CHEM, V256, P2113; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; FRIESEN HJ, 1981, ARCH BIOCHEM BIOPHYS, V206, P432, DOI 10.1016/0003-9861(81)90111-9; GARIGLIO M, 1992, VIROLOGY, V187, P115, DOI 10.1016/0042-6822(92)90300-E; GARIGLIO M, 1994, EUR J BIOCHEM, V221, P731, DOI 10.1111/j.1432-1033.1994.tb18786.x; Gariglio M, 1996, J CELL BIOCHEM, V60, P83, DOI 10.1002/(SICI)1097-4644(19960101)60:1<83::AID-JCB11>3.3.CO;2-#; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HOGAN B, 1994, MANIPULATING MOUSE E, P226; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KERR IM, 1992, J INTERFERON RES, V12, P237, DOI 10.1089/jir.1992.12.237; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; LANDOLFO S, 1995, PHARMACOL THERAPEUT, V65, P415, DOI 10.1016/0163-7258(95)98599-L; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Min W, 1996, MOL CELL BIOL, V16, P359; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAVLOVIC J, 1992, J VIROL, V66, P2564, DOI 10.1128/JVI.66.4.2564-2569.1992; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; Sambrook J., 2002, MOL CLONING LAB MANU; SEN GC, 1992, J BIOL CHEM, V267, P5017; SOKAWA Y, 1977, NATURE, V268, P236, DOI 10.1038/268236a0; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	56	51	52	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1543	1551		10.1038/sj.onc.1201677	http://dx.doi.org/10.1038/sj.onc.1201677			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569021				2022-12-28	WOS:000072743200004
J	Matsumoto, K; Saitoh, K; Koike, C; Narita, T; Yasugi, S; Iba, H				Matsumoto, K; Saitoh, K; Koike, C; Narita, T; Yasugi, S; Iba, H			Differential expression of fos and jun family members in the developing chicken gastrointestinal tract	ONCOGENE			English	Article						AP-1; chicken embryo; fos family; jun family; Sonic hedgehog; Indian hedgehog	TISSUE-SPECIFIC EXPRESSION; C-FOS; GENE-EXPRESSION; CELLULAR-TRANSFORMATION; MOUSE DEVELOPMENT; PEPSINOGEN GENE; NERVOUS-SYSTEM; AP-1 COMPLEX; FRA-2 GENE; ONCOGENE	We have analysed the expression patterns of all the known fos/jun family genes, which encode the components of the transcription factor AP-1, in the chicken embryonic digestive tract that develops into the esophagus, proventriculus, gizzard, small intestine, ceca and large intestine, From soon after formation of the tubular structure, each gene transcript was localized in distinct domains of the epithelium and mesenchyme in all of these major gastrointestinal organs, independently of the anterior-posterior axis, fra-2 was expressed predominantly in epithelium, which also expressed junD, while low-level expression of junD was also detected in smooth muscle cell precursors in mesenchyme, Expression of c-jun and c-fos was detectable in both mesenchyme and epithelium through the whole tract, In the differentiated proventriculus, the developed glandular epithelium expressed c-jun and junD, but not fra-2, while luminal epithelium expressed fra-2 and junD, but not c-jun. These results suggest that distinct Fos/Jun protein heterodimers play important roles in maintaining the epithelial-mesenchymal interactions. Similar expression patterns to those of fra-2 and junD were established from earlier stages by Sonic hedgehog gene and the Indian hedgehog gene, respectively, both of which are important in forming the inductive network between epithelium and mesenchyme of the digestive tract.	Univ Tokyo, Inst Med Sci, Dept Gene Regulat, Minato Ku, Tokyo 108, Japan; Tokyo Metropolitan Univ, Fac Sci, Dept Biol, Hachioji, Tokyo 19203, Japan	University of Tokyo; Tokyo Metropolitan University	Iba, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Gene Regulat, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bellusci S, 1997, DEVELOPMENT, V124, P53; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BRITT M, 1991, ONCOGENE, V6, P1959; CARRASCO D, 1995, ONCOGENE, V10, P1069; CAUBET JF, 1989, MOL CELL BIOL, V9, P2269, DOI 10.1128/MCB.9.5.2269; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FOLETTA VC, 1994, ONCOGENE, V9, P3305; FUJIWARA KT, 1987, J VIROL, V61, P4012, DOI 10.1128/JVI.61.12.4012-4018.1987; FUKUDA K, 1994, DEVELOPMENT, V120, P3487; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARTL M, 1991, ONCOGENE, V6, P1623; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; NARITA T, 1998, IN PRESS DEV GROWTH, V39; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; REZZONICO R, 1995, ONCOGENE, V11, P1069; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; SATO K, 1997, IN PRESS DEV GROWTH, V38; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SONOBE MH, 1995, ONCOGENE, V10, P689; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P3994, DOI 10.1073/pnas.94.8.3994; Welter JF, 1995, ONCOGENE, V11, P2681; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YASUGI S, 1994, INT J DEV BIOL, V38, P273; YASUGI S, 1981, J BIOCHEM-TOKYO, V89, P311, DOI 10.1093/oxfordjournals.jbchem.a133195; YASUGI S, 1993, DEV GROWTH DIFFER, V35, P1; YASUGI S, 1995, TISS CULT RES COMMUN, V14, P177; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715	35	19	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1611	1616		10.1038/sj.onc.1201675	http://dx.doi.org/10.1038/sj.onc.1201675			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569029				2022-12-28	WOS:000072743200012
J	Denissenko, MF; Pao, A; Pfeifer, GP; Tang, MS				Denissenko, MF; Pao, A; Pfeifer, GP; Tang, MS			Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers	ONCOGENE			English	Article						BPDE; DNA repair; mutation; p53	BENZO<A>PYRENE DIOL EPOXIDE; TUMOR-SUPPRESSOR GENE; HUMAN FIBROBLASTS; SKIN-CANCER; HPRT GENE; CHO CELLS; TRANSCRIPTION; SPECIFICITY; CARCINOGEN; BINDING	Using UvrABC incision in combination with ligation-mediated PCR (LMPCR) we have previously shown that benzo(a)pyrene diol epoxide (BPDE) adduct formation along the nontranscribed strand of the human p53 gene is highly selective; the preferential binding sites coincide with the major mutation hotspots found in human lung cancers. Both sequence-dependent adduct formation and repair may contribute to these mutation hotspots in tumor tissues. To test this possibility, we have extended our previous studies by mapping the BPDE adduct distribution in the transcribed strand of the p53 gene and quantifying the rates of repair for individual damaged bases in exons 5, 7, and 8 for both DNA strands of this gene in normal human fibroblasts. We found that: (i) on both strands, BPDE adducts preferentially form at CpG sequences, and (ii) repair of BPDE adducts in the transcribed DIVA strand is consistently faster than repair of adducts in the nontranscribed strand, while repair at the major damage hotspots (guanines at codons 157, 248 and 273) in the nontranscribed strand is two to four times slower than repair at other damage sites. These results strongly suggest that both preferential adduct formation and slow repair lead to hotspots for mutations at codons 157, 248 and 273, and that the strand bias of bulky adduct repair is primarily responsible for the strand bias of G to T transversion mutations observed in the p53 gene in human cancers.	Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA	University of Texas System; UTMD Anderson Cancer Center; City of Hope; Beckman Research Institute of City of Hope	Tang, MS (corresponding author), Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA.				NATIONAL CANCER INSTITUTE [R01CA065652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008389, R01ES003124] Funding Source: NIH RePORTER; NCI NIH HHS [CA65652] Funding Source: Medline; NIEHS NIH HHS [ES08389, ES03124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BELAND FA, 1989, PATHOBIOLOGY NEOPLAS, P57; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BOLES TC, 1984, P NATL ACAD SCI-BIOL, V81, P5623, DOI 10.1073/pnas.81.18.5623; Butler AP, 1997, CARCINOGENESIS, V18, P239, DOI 10.1093/carcin/18.2.239; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Harvey R. G., 1991, POLYCYCLIC AROMATIC; HARVEY RG, 1981, ACCOUNTS CHEM RES, V14, P218, DOI 10.1021/ar00067a004; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; JONES PA, 1991, CANCER RES, V51, P3617; KANEKO M, 1982, CHEM-BIOL INTERACT, V38, P261, DOI 10.1016/0009-2797(82)90057-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MACLEOD MC, 1985, CANCER RES, V45, P51; MACLEOD MC, 1988, MUTAT RES, V199, P243, DOI 10.1016/0027-5107(88)90252-7; Maxam A M, 1980, Methods Enzymol, V65, P499; OSBORNE MR, 1990, CHEM-BIOL INTERACT, V75, P131, DOI 10.1016/0009-2797(90)90113-2; PELKONEN O, 1982, PHARMACOL REV, V34, P189; Ruddon R. W., 1995, CANC BIOL; SMITH BL, 1993, J BIOL CHEM, V268, P20620; STEVENS CW, 1985, MUTAT RES, V152, P5, DOI 10.1016/0027-5107(85)90040-5; Tang Moon-Shong, 1996, P139; TANG MS, 1992, BIOCHEMISTRY-US, V31, P8429, DOI 10.1021/bi00151a006; TANG MS, 1994, J BIOL CHEM, V269, P12749; THRALL BD, 1994, BIOCHEMISTRY-US, V33, P2210, DOI 10.1021/bi00174a030; TORNALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, 1995, ONCOGENE, V10, P1493; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; VENKATACHALAM S, 1995, CARCINOGENESIS, V16, P2029, DOI 10.1093/carcin/16.9.2029; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; WEI D, 1995, P NATL ACAD SCI USA, V92, P2204, DOI 10.1073/pnas.92.6.2204; WEINSTEIN IB, 1981, J SUPRAMOL STR CELL, V17, P99, DOI 10.1002/jsscb.380170202	43	139	145	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1241	1247		10.1038/sj.onc.1201647	http://dx.doi.org/10.1038/sj.onc.1201647			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546425				2022-12-28	WOS:000072422000002
J	Habano, W; Sugai, T; Nakamura, S				Habano, W; Sugai, T; Nakamura, S			Mismatch repair deficiency leads to a unique mode of colorectal tumorigenesis characterized by intratumoral heterogeneity	ONCOGENE			English	Article						mismatch repair gene; intratumoral heterogeneity; subpopulation analysis	NONPOLYPOSIS COLON-CANCER; POLYMERASE CHAIN-REACTION; CRYPT-ISOLATION TECHNIQUE; IN-SITU HYBRIDIZATION; MICROSATELLITE INSTABILITY; ALLELE LOSS; GENOMIC INSTABILITY; REPLICATION ERRORS; DNA CONTENT; GENE	In order to determine the effects of mismatch repair (MMR) deficiencies in sporadic colorectal carcinomas, 45 such cancers were examined using a sensitive method called crypt isolation technique, Loss of heterozygosity (LOH) in the MSH2 or MLH1 gene was more frequently observed in replication error (RER) (+) carcinomas than in RER (-) carcinomas, which implied that loss of one normal allele could partly affect repair capacity, MSH2 gene defects at both alleles were observed in two carcinomas, which showed severe repair deficiencies, Interestingly, unlike the situation observed in the p53 gene, the MSH2 and MLH1 genes did not show complete LOH, Novel crypt isolation-based subpopulation (CISP) analysis demonstrated that at least two distinct carcinoma subpopulations existed in most carcinomas that showed incomplete LOH; one with and one without LOH, In one carcinoma that had germline mutation and somatic incomplete LOH of the MSH2 gene, the mutator phenotype was only observed in populations affected in both alleles, Thus, the MSH2 gene appears to possess the two hits mechanism of tumor suppressor genes, However, unlike the tumor suppressor genes, MMR gene defects lead to a unique mode of colorectal tumorigenesis characterized by intratumoral heterogeneity.	Iwate Med Univ, Sch Med, Cent Clin Lab, Div Pathol, Morioka, Iwate 020, Japan	Iwate Medical University	Nakamura, S (corresponding author), Iwate Med Univ, Sch Med, Cent Clin Lab, Div Pathol, 19-1 Uchimaru, Morioka, Iwate 020, Japan.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bocker T, 1996, J PATHOL, V179, P15; BOLAND CR, 1995, NAT MED, V1, P902, DOI 10.1038/nm0995-902; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAWKWELL L, 1993, BRIT J CANCER, V67, P1262, DOI 10.1038/bjc.1993.236; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; ENDO Y, 1995, PATHOL INT, V45, P602, DOI 10.1111/j.1440-1827.1995.tb03509.x; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GRIFFITHS DFR, 1988, NATURE, V333, P461, DOI 10.1038/333461a0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Habano W, 1996, LAB INVEST, V74, P933; HAHN M, 1995, BIOTECHNIQUES, V18, P1040; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACOBY RF, 1995, GASTROENTEROLOGY, V109, P73, DOI 10.1016/0016-5085(95)90270-8; KIM HG, 1994, AM J PATHOL, V145, P148; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kobayashi M, 1996, AM J PATHOL, V149, P1575; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; LOTHE RA, 1993, CANCER RES, V53, P5849; Lu SL, 1996, JPN J CANCER RES, V87, P279, DOI 10.1111/j.1349-7006.1996.tb00218.x; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; NAKAMURA S, 1994, GASTROENTEROLOGY, V106, P100, DOI 10.1016/S0016-5085(94)94651-5; NAKAMURA S, 1993, GUT, V34, P1240, DOI 10.1136/gut.34.9.1240; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAN LX, 1995, HISTOPATHOLOGY, V26, P201, DOI 10.1111/j.1365-2559.1995.tb01434.x; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, CANCER RES, V55, P5548; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; RUSCHOFF J, 1995, VIRCHOWS ARCH, V426, P215; SASAKI K, 1988, CANCER, V62, P2569, DOI 10.1002/1097-0142(19881215)62:12<2569::AID-CNCR2820621220>3.0.CO;2-0; SAUTER G, 1994, AM J PATHOL, V144, P756; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tomlinson IPM, 1996, BRIT J CANCER, V74, P1514, DOI 10.1038/bjc.1996.582; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Yoshida T, 1996, J SURG ONCOL, V63, P9; YOUNG J, 1995, GENE CHROMOSOME CANC, V12, P251, DOI 10.1002/gcc.2870120403	44	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	1998	16	10					1259	1265		10.1038/sj.onc.1201651	http://dx.doi.org/10.1038/sj.onc.1201651			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546427				2022-12-28	WOS:000072422000004
J	Yokote, K; Hellman, U; Ekman, S; Saito, Y; Ronnstrand, L; Saito, Y; Heldin, CH; Mori, S				Yokote, K; Hellman, U; Ekman, S; Saito, Y; Ronnstrand, L; Saito, Y; Heldin, CH; Mori, S			Identification of Tyr-762 in the platelet-derived growth factor alpha-receptor as the binding site for Crk proteins	ONCOGENE			English	Article						PDGF alpha-receptor; Crk autophosphorylation site; C3G	CHRONIC MYELOGENOUS LEUKEMIA; SMOOTH-MUSCLE CELLS; PDGF BETA-RECEPTOR; PHOSPHORYLATION-DEPENDENT MANNER; SOLID-PHASE SYNTHESIS; COMPLEXES IN-VIVO; SIGNALING PATHWAYS; SH3 DOMAIN; TYROSINE PHOSPHORYLATION; C-CRK	Tyr-762 is an autophosphorylation site in the human platelet-derived growth factor (PDGF) alpha-receptor. In order to investigate whether phosphorylated Tyr-762 serves as a docking site for downstream signal transduction molecules, affinity purification using an immobilized synthetic peptide containing phosphorylated Tyr-762 and its surrounding amino acid residues was performed. Proteins in HeLa cell lysate of molecular sizes 27, 38 and 40 kDa bound to the phosphorylated, but not to the unphosphorylated peptide, Analyses of partial amino acid sequences of the purified proteins indicated that they were identical to CrkI, CrkII and CrkL respectively. The wild-type PDGF alpha-receptor, when expressed in porcine aortic endothelial cells, formed complexes with CrkII and CrkL upon ligand stimulation, which was specifically inhibited by a synthetic peptide containing phosphorylated Tyr-762, Replacement of Tyr-762 with a phenylalanine residue in the PDGF alpha-receptor abrogated ligand-induced binding of Crk proteins, Tyrosine phosphorylation of CrkII and CrkL increased by 1.8- and 1.3-fold, respectively, upon ligand stimulation of the wild-type alpha-receptor, In contrast, the Y762F mutant PDGF alpha-receptor failed to induce tyrosine phosphorylation of Crk proteins, CrkII and CrkL constitutively formed complex with the guanine nucleotide exchange factor C3G, in unstimulated as well as PDGF-stimulated cells, Moreover, the activated wild-type PDGF alpha-receptor but not the Y762F mutant receptor was found in a C3G immunoprecipitate, suggesting that a ternary complex between the activated PDGF alpha-receptor, Crk and C3G was formed. DNA synthesis stimulated by PDGF-BB as well as PDGF-induced MAP kinase activation was similar in cells expressing wild-type and mutant receptors. Interestingly, the activated PDGF beta-receptor was found not to bind Crk proteins. Instead, Tyr-771 of the beta-receptor, which is localized at an analogous position to Tyr-762 in the alpha-receptor, binds RasGAP, RasGAP is not bound to the alpha-receptor. Thus, this region in the kinase inserts of the two receptors may be important for the divergency in signaling from the two PDGF receptors.	Chiba Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Chiba 260, Japan; Ludwig Inst Canc Res, Uppsala Branch, S-75124 Uppsala, Sweden	Chiba University; Ludwig Institute for Cancer Research	Yokote, K (corresponding author), Chiba Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 1-8-1 Inohana, Chiba 260, Japan.		Ekman, Simon/AAB-9387-2021; Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				ANDREWS DM, 1991, INT J PEPT PROT RES, V38, P469; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BAZENET CE, 1994, ONCOGENE, V9, P517; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BEITZ JG, 1991, P NATL ACAD SCI USA, V88, P2021, DOI 10.1073/pnas.88.5.2021; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLOCK LH, 1989, P NATL ACAD SCI USA, V86, P2388, DOI 10.1073/pnas.86.7.2388; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DILIBERTO PA, 1992, J BIOL CHEM, V267, P11888; DO MS, 1992, ONCOGENE, V7, P1567; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HELDIN CH, 1994, GUIDEBOOK CYTOKINES; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HENRIKSEN R, 1993, CANCER RES, V53, P4550; HOSANG M, 1989, J CELL PHYSIOL, V140, P558, DOI 10.1002/jcp.1041400322; INUI H, 1994, J BIOL CHEM, V269, P30546; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALHANY KE, 1992, J CELL PHYSIOL, V150, P386, DOI 10.1002/jcp.1041500223; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; Smit L, 1996, ONCOGENE, V13, P381; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Yokote K, 1996, J BIOL CHEM, V271, P5101; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	70	41	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	1998	16	10					1229	1239		10.1038/sj.onc.1201641	http://dx.doi.org/10.1038/sj.onc.1201641			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546424				2022-12-28	WOS:000072422000001
J	Xiao, G; White, D; Bargonetti, J				Xiao, G; White, D; Bargonetti, J			p53 binds to a constitutively nucleosome free region of the mdm2 gene	ONCOGENE			English	Article						p53; mdm2; nucleosome; chromatin; transcription	WILD-TYPE P53; DNA-BINDING; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; HISTONE DEACETYLASE; PROTEINS BIND; T-ANTIGEN; CHROMATIN	The mdm2 oncogene is a p53 responsive gene which contains both a p53 independent and a p53 dependent promoter (P1 and P2 respectively), We have utilized ligation mediated PCR genomic footprinting in order to investigate the intra-nuclear binding of p53 to the mdm2 P2 promoter. The DNase I protection pattern in nuclei from murine cells lacking p53 has been compared to the protection pattern in cells containing a temperature sensitive p53-Val135. At 32 degrees C p53-Val135 assumes a wild-type conformation while at 37 degrees C this p53 is conformationally mutant. We observed clear wild-type p53 dependent protection of the putative p53 response elements (REs) as well as protection of the adjacent TATA box. Interestingly the protection pattern observed with purified wild-type p53 on naked DNA showed less nucleotide sequence protection than the protection observed to be p53 dependent in nuclei. Constitutive DNase I hypersensitivity at both the mdm2 P1 and P2 promoters was detected by indirect Southern blot analysis. DNase I hypersensitivity reflects altered chromatin conformations resulting, most likely, from the absence of nucleosomes. Taken together our findings suggest that the mdm2 P2 promoter is maintained in a nucleosome free state which is pre-primed for transcriptional activation by p53.	CUNY, Inst Biomolec Struct & Funct, New York, NY 10021 USA; CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; CUNY, Grad Sch, New York, NY 10021 USA	City University of New York (CUNY) System; City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System	Bargonetti, J (corresponding author), CUNY, Inst Biomolec Struct & Funct, 695 Pk Ave, New York, NY 10021 USA.			Bargonetti, Jill/0000-0003-2692-0991	NCRR NIH HHS [RR-03037] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN XB, 1995, CANCER RES, V55, P4257; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HE J, 1994, GENE CHROMOSOME CANC, V11, P91, DOI 10.1002/gcc.2870110205; Hecker D, 1996, ONCOGENE, V12, P953; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUNA RMD, 1995, NATURE, V378, P203; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; REFENBERGER G, 1993, CANCER RES, V53, P2736; SHEIKH MS, 1993, CANCER RES, V53, P3226; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	72	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1171	1181		10.1038/sj.onc.1201631	http://dx.doi.org/10.1038/sj.onc.1201631			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528859				2022-12-28	WOS:000072336000008
J	Zhang, LJ; Zhan, SL; Navid, F; Li, QD; Choi, YH; Kim, M; Seth, P; Helman, LJ				Zhang, LJ; Zhan, SL; Navid, F; Li, QD; Choi, YH; Kim, M; Seth, P; Helman, LJ			AP-2 may contribute to IGF-II overexpression in rhabdomyosarcoma	ONCOGENE			English	Article						IGF-II; AP-2; tumor cells	TRANSCRIPTION FACTOR AP-2; GROWTH FACTOR-II; GENE-EXPRESSION; INDUCIBLE ENHANCER; MAMMARY-CARCINOMA; CYCLIC-AMP; CELL-LINE; PROMOTER; EMBRYOGENESIS; ACTIVATION	The human insulin-like growth factor II gene is regulated in a development-dependent manner and is not expressed in most adult tissues. However, high levels of insulin-like growth factor II mRNA are detected in many human tumors including rhabdomyosarcoma, an embryonal tumor of skeletal muscle origin. In this study, we demonstrate that the developmentally regulated transcription factor AP-2 is expressed at higher levels in human fetal skeletal muscle and rhabdomyosarcoma cells compared to human adult skeletal muscle, Endogenous insulin-like growth factor II mRNA derived from the P3 as well as transfected P3 promoter activity were modestly and consistently increased to the same extent following treatment of the rhabdomyosarcoma cell line RD with forskolin, a compound implicated in AP-2 transactivation, This effect of AP-2 on increased transcriptional activity was confirmed by nuclear run-on assays. Expression of AP-2B, a dominant-negative inhibitor of AP-2, suppressed the P3 promoter activity in AP-2 expressing RD cells. Furthermore, five AP-2 protected regions corresponding to six AP-2 specific binding sites were detected in the insulin-like growth factor II P3 promoter. These data together suggest that AP-2 may contribute to the high expression of IGF-II in rhabdomyosarcoma cells.	NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; NCI, Med Ovarian Canc Sect, NIH, Bethesda, MD 20892 USA; NCI, Cell Signaling & Oncogenesis Sect, NIH, Bethesda, MD 20892 USA; NCI, Med Breast Canc Sect, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Helman, LJ (corresponding author), NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bldg 10,Rm 13N240, Bethesda, MD 20892 USA.			Choi, Yung Hyun/0000-0002-1454-3124				BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CROUCH GD, 1993, EXP CELL RES, V204, P210, DOI 10.1006/excr.1993.1026; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; ELBADRY OM, 1989, J CLIN INVEST, V84, P829, DOI 10.1172/JCI114243; Gong DW, 1996, J BIOL CHEM, V271, P3971; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MINNITI CP, 1994, AM J CLIN PATHOL, V101, P198, DOI 10.1093/ajcp/101.2.198; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; RAJ NBK, 1983, P NATL ACAD SCI-BIOL, V80, P3923, DOI 10.1073/pnas.80.13.3923; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhang LJ, 1996, CANCER RES, V56, P1367	31	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1261	1270		10.1038/sj.onc.1202050	http://dx.doi.org/10.1038/sj.onc.1202050			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771969				2022-12-28	WOS:000075803300008
J	Zhu, WJ; Eicher, A; Leber, B; Andrews, DW				Zhu, WJ; Eicher, A; Leber, B; Andrews, DW			At the onset of transformation polyomavirus middle-T recruits shc and src to a perinuclear compartment coincident with condensation of endosomes	ONCOGENE			English	Article						middle-T antigen; polyomavirus; perinuclear; shc; transformation	SIZED TUMOR-ANTIGEN; CELLULAR-LOCALIZATION; PROTEIN PHOSPHATASE; MEMBRANE-PROTEINS; EGF RECEPTOR; RAT-CELLS; VIRUS; BINDING; ASSOCIATION; ACTIVATION	To examine the early cellular changes that accompany transformation, middle-T antigen (the transforming protein of polyomavirus), was expressed from an inducible promoter in Rat2 fibroblasts and in normal diploid human fibroblast (MRCS) cells using a replication defective adenovirus vector. The earliest detectable expression of middle-T antigen correlated closely with the initial changes in cellular morphology. At this time, expression of middle-T antigen resulted in the redistribution of shc and src to a brefeldin A resistant perinuclear compartment coincident with the formation of kinase active complexes containing middle-T antigen, she and src. The first detectable changes directly related to altered morphology was reorganization of actin filaments, and the condensation of tubular endosomes in the perinuclear region of the cell. These results suggest a potential role for perinuclear localized mT molecules in some of the morphologic changes associated with the initial phase of cellular transformation.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada.			Andrews, David/0000-0002-9266-7157; Leber, Brian/0000-0001-5502-1480				AGUZZI A, 1991, ONCOGENE, V6, P113; ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; BALLMERHOFER K, 1985, EMBO J, V4, P2321, DOI 10.1002/j.1460-2075.1985.tb03933.x; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; BRUNETTI CR, 1995, J VIROL, V69, P3517, DOI 10.1128/JVI.69.6.3517-3528.1995; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CARLEY WW, 1981, J CELL BIOL, V90, P797, DOI 10.1083/jcb.90.3.797; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CHENG SH, 1990, MOL CELL BIOL, V10, P5569, DOI 10.1128/MCB.10.10.5569; CHENG SH, 1990, EMBO J, V7, P384; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COOK DN, 1990, J VIROL, V64, P2392, DOI 10.1128/JVI.64.5.2392-2395.1990; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1986, EMBO J, V5, P491, DOI 10.1002/j.1460-2075.1986.tb04238.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; DRUCKER B, 1990, J VIROL, V64, P4454; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GRIFFIN BE, 1983, ADV CANCER RES, V39, P183, DOI 10.1016/S0065-230X(08)61036-2; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; ITO Y, 1977, P NATL ACAD SCI USA, V74, P4666, DOI 10.1073/pnas.74.10.4666; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; Kim PK, 1997, BIOCHEMISTRY-US, V36, P8873, DOI 10.1021/bi970090t; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORNBLUTH S, 1997, J VIROL, V64, P1584; KRAUZEWICZ N, 1994, ONCOGENE, V9, P2283; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; Messerschmitt A, 1996, J GEN VIROL, V77, P17, DOI 10.1099/0022-1317-77-1-17; OKAMURA H, 1994, ONCOGENE, V9, P2293; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; RASSOULZADEGAN M, 1990, ONCOGENE, V5, P1507; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SCHAFFHAUSEN BS, 1982, MOL CELL BIOL, V2, P1187, DOI 10.1128/MCB.2.10.1187; SEGAWA K, 1982, P NATL ACAD SCI-BIOL, V79, P6812, DOI 10.1073/pnas.79.22.6812; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TEMPLETON D, 1984, MOL CELL BIOL, V4, P282, DOI 10.1128/MCB.4.2.282; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; TUCKER RW, 1978, CELL, V13, P629, DOI 10.1016/0092-8674(78)90213-1; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Yi XD, 1997, J VIROL, V71, P6279, DOI 10.1128/JVI.71.9.6279-6286.1997; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	61	10	10	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					565	576		10.1038/sj.onc.1201979	http://dx.doi.org/10.1038/sj.onc.1201979			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704922				2022-12-28	WOS:000075195300004
J	Matsuo, T; Thiele, CJ				Matsuo, T; Thiele, CJ			p27(Kip1): a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line	ONCOGENE			English	Article						neuroblastoma; retinoids; cell cycle; p27(Kip1); N-myc; G1 cyclin; cdk	DEPENDENT KINASE INHIBITOR; HUMAN NEURO-BLASTOMA; POTENTIAL MEDIATOR; CDK2 ACTIVITY; CYCLIN-E; DIFFERENTIATION; EXPRESSION; INDUCTION; G(1); ACTIVATION	Retinoic acid (RA) treatment of SMS-KCNR neuroblastoma (NB) cells leads to G1 growth arrest and neuronal differentiation. To investigate the molecular mechanisms by which RA alters cell growth, we analysed the expression and activity of components of the cell cycle machinery after culture in RA. Within 2 days of RA treatment and prior to the arrest of NE cells in the G1 phase of the cell cycle, there is a complete downregulation of G1 cyclin/Cdk activities. Protein levels for the G1 cyclin/Cdks were essentially unchanged during this time although there was a decrease in the steady-state levels of p67(N-Myc) and hyperphosphorylated Rb proteins. The Cdk inhibitors, p21(Cipl) and p27(Kip1) were constitutively expressed in KCNR while p15(INK4B) and p16(INK4A) were not detected. RA induced an increase in the expression of p27(Kip1) but not p21(Cip1). Furthermore, coincident with the decrease in kinase activity there was an increase in G1 cyclin/Cdk bound p27(Kip1). These results indicate that changes in the level of p27(Kip1) and its binding to G1 cyclin/Cdks may play a key role in RA induced growth arrest of NB cells.	NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thiele, CJ (corresponding author), NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, 10 Ctr Dr,MSC-1928, Bethesda, MD 20892 USA.							COHEN PS, 1995, CANCER RES, V55, P2380; Cushing H, 1927, AM J PATHOL, V3, P203; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gaetano C, 1997, J BIOL CHEM, V272, P12195, DOI 10.1074/jbc.272.18.12195; GAETANO C, 1992, CANCER RES, V52, P4402; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Iavarone A, 1997, NATURE, V387, P417; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIDELL N, 1982, J NATL CANCER I, V68, P589; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang QM, 1996, CANCER RES, V56, P264; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	44	75	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3337	3343		10.1038/sj.onc.1201830	http://dx.doi.org/10.1038/sj.onc.1201830			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681834				2022-12-28	WOS:000074343600016
J	Ojaniemi, M; Langdon, WY; Vuori, K				Ojaniemi, M; Langdon, WY; Vuori, K			Oncogenic forms of Cbl abrogate the anchorage requirement but not the growth factor requirement for proliferation	ONCOGENE			English	Article						anchorage-independent growth; integrin signaling; oncogene	MEDIATED CELL-ADHESION; PRODUCT C-CBL; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; PROTEIN PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGEN RECEPTOR; EGF STIMULATION; SH3 DOMAIN; EXTRACELLULAR-MATRIX	Recent studies have demonstrated that Chi, the 120 kDa protein product of the c-cbl proto-oncogene, becomes tyrosine phosphorylated in response to stimulation of growth factor receptors and upon integrin-mediated cell adhesion. As a result, Cbl forms complexes with SH2 and SH3 domain-containing proteins, pointing to its role in signal transduction. The cellular form of CM can be rendered into transforming by naturally occurring or engineered mutations to its amino acid sequence. To gain insight into the mechanisms how oncogenic forms of Cbl render cells tumorigenic and what the function of the cellular CM might be, we have undertaken an analysis of NIH3T3 cells transfected with mild-type and oncogenic forms of Chi. We demonstrate that unlike cellular Cbl, the mutant forms of Cbl are tyrosine phosphorylated in an adhesion-independent manner and interact with and activate SH2-containing signaling molecules in both suspended and adherent cells. Our data further show that oncogenic forms of Cbl induce anchorage-independent but serum-dependent growth. These results support the view that transformation by oncogenic forms of Cbl results from constitutive activation of integrin-dependent, rather than growth factor-dependent signaling events and, as a corollary, suggest that cellular Chi might be a functionally important mediator of integrin signaling.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; Univ Western Australia, Dept Pathol, Nedlands, WA 6009, Australia	Sanford Burnham Prebys Medical Discovery Institute; University of Western Australia	Vuori, K (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA.				NCI NIH HHS [CA72560, CA76037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA072560, R01CA076037] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; JONGEWARD GD, 1995, GENETICS, V139, P1553; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kontani K, 1996, J BIOL CHEM, V271, P1534; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; TUCKER R W, 1981, Journal of Supramolecular Structure and Cellular Biochemistry, V15, P29, DOI 10.1002/jsscb.1981.380150104; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	45	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3159	3167		10.1038/sj.onc.1201859	http://dx.doi.org/10.1038/sj.onc.1201859			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671395				2022-12-28	WOS:000074261300009
J	Sekido, Y; Ahmadian, M; Wistuba, II; Latif, F; Bader, S; Wei, MH; Duh, FM; Gazdar, AF; Lerman, MI; Minna, JD				Sekido, Y; Ahmadian, M; Wistuba, II; Latif, F; Bader, S; Wei, MH; Duh, FM; Gazdar, AF; Lerman, MI; Minna, JD			Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene	ONCOGENE			English	Article						breast cancer; chromosome 3; homozygous deletion; somatic mutation; breakpoint cloning; lung cancer	CELL LUNG-CANCER; CHROMOSOME 3P; HUMAN SEMAPHORIN; LINE U2020; FHIT GENE; CARCINOMAS; HETEROZYGOSITY; IDENTIFICATION; 3P14.2	Chromosome 3p abnormalities and allele loss are frequent in lung and breast cancers, and several lung cancer cell lines exhibit homozygous deletions of 3p indicating potential sites of tumor suppressor genes at regions 3p21.3, 3p14.2 and 3p12. We have identified and characterized a nem 3p21.3 homozygous deletion in a breast cancer cell line and the primary tumor that overlaps those previously described in small cell lung cancer (SCLC), This homozygous deletion is approximately 220 kb in length and represents a somatically acquired change in the primary breast cancer. Cloning and sequencing of the breakpoint demonstrated that this resulted from an interstitial deletion and precisely pinpoints this deletion within the three SCLC homozygous deletions previously reported. This deletion significantly narrows the minimum common deleted region to 120 kb and is distinct from the previously reported region that suppresses tumor formation of the murine A9 fibrosarcoma cells, These findings suggest that a common homozygous deletion region on 3p21.3 is important in both lung and breast cancers. It is likely that this very well characterized region either contains one tumor suppressor gene common to both tumor types or two closely linked tumor suppressor genes specific for each tumor.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, SAIC Frederick, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Biol Carcinogenesis & Dev Program, SAIC Frederick, Frederick, MD 21702 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Sekido, Yoshitaka/P-9756-2015	Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [R01CA071618] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA71618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmadian M, 1997, CANCER RES, V57, P3664; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BUCHHAGEN DL, 1994, INT J CANCER, V57, P473, DOI 10.1002/ijc.2910570406; CHEN LC, 1994, CANCER RES, V54, P3021; DALY MC, 1993, ONCOGENE, V8, P1721; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DRABKIN HA, 1992, GENE CHROMOSOME CANC, V5, P67, DOI 10.1002/gcc.2870050110; Fong KM, 1997, CANCER RES, V57, P2256; Hayashi S, 1997, CANCER RES, V57, P1981; HIBI K, 1992, ONCOGENE, V7, P445; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1994, CANCER RES, V54, P4183; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; Latif F, 1997, HUM GENET, V99, P334, DOI 10.1007/s004390050368; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Negrini M, 1996, CANCER RES, V56, P3173; Ong ST, 1997, GENE CHROMOSOME CANC, V20, P16, DOI 10.1002/(SICI)1098-2264(199709)20:1<16::AID-GCC3>3.0.CO;2-C; PANDIS N, 1995, GENE CHROMOSOME CANC, V12, P173, DOI 10.1002/gcc.2870120304; PANDIS N, 1993, GENE CHROMOSOME CANC, V6, P151, DOI 10.1002/gcc.2870060304; Roche J, 1996, ONCOGENE, V12, P1289; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1991, CANCER RES, V51, P5794; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Todd MC, 1996, ONCOGENE, V13, P2387; Todd S, 1997, CANCER RES, V57, P1344; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; Xiang RH, 1996, GENOMICS, V32, P39, DOI 10.1006/geno.1996.0074; YAMAKAWA K, 1993, ONCOGENE, V8, P327	35	123	137	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3151	3157		10.1038/sj.onc.1201858	http://dx.doi.org/10.1038/sj.onc.1201858			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671394				2022-12-28	WOS:000074261300008
J	Zurovec, M; Petrenko, O; Roll, R; Enrietto, PJ				Zurovec, M; Petrenko, O; Roll, R; Enrietto, PJ			A chicken c-Rel-estrogen receptor chimeric protein shows conditional nuclear localization, DNA binding, transformation and transcriptional activation	ONCOGENE			English	Article						c-Rel; NF-kappa B; transformation; apoptosis	NF-KAPPA-B; V-REL; EXHIBIT DEFECTS; FUSION PROTEIN; IN-VITRO; EXPRESSION; CELLS; ALPHA; INHIBITOR; VIRUS	In this report, we characterize the biological and biochemical properties of a conditional protein containing chicken c-Rel fused to the hormone-binding domain of the human estrogen receptor. This chimeric c-RelER protein causes estrogen-dependent, but otherwise c-Rel-specific, transformation of avian fibroblasts in vitro. Our results demonstrate that c-RelER heterodimerizes with wild-type c-Rel and forms specific complexes with I kappa B-alpha. Estrogen causes translocation of c-RelER to the nucleus and stabilizes its binding to DNA. Hormone-activated c-RelER induces transcription of at least four cellular genes that are constitutively active in wild-type c-Rel-transformed fibroblasts. Two distinct cell populations were examined that differed with respect to their growth phenotypes. The growth of fibroblasts with moderate expression levels of c-RelER was stimulated by estrogen. In contrast, the addition of estrogen to cells with high c-RelER expression levels resulted in inhibition of cytokinesis and the arrest of growth. The carboxy terminal transactivation domain of c-Rel was required for the induction of these effects since neither v-Rel nor c-Rel deletion mutants were able to induce similar changes. Taken together, our results demonstrate that high levels of c-Rel expression can affect cell cycle control and/or cytokinesis. Furthermore, they also indicate that the biological properties of c-Rel in cell growth and differentiation will potentially differ depending on the level of expression.	SUNY Stony Brook, Dept Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zurovec, M (corresponding author), Univ S Bohemia, Fac Biol, Branisovska 31, Ceske Budejovice 37005, Czech Republic.		Zurovec, Michal/AAE-8185-2021; Zurovec, Michal/H-2562-2014	Zurovec, Michal/0000-0002-0913-166X; Zurovec, Michal/0000-0002-0913-166X	FOGARTY INTERNATIONAL CENTER [F05TW004933] Funding Source: NIH RePORTER; FIC NIH HHS [1FO TW04933-01] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gilmore TD, 1996, ONCOGENE, V13, P1367; GREEN S, 1991, OESTROGEN RECEPTOR P, P15; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1994, J VIROL, V68, P2371; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KUMAR V, 1986, EMBO J, V5, P2331; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P667; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; PETRENKO O, 1995, GENE, V160, P305, DOI 10.1016/0378-1119(95)00210-W; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WAKELING AE, 1988, J STEROID BIOCHEM, V31, P645, DOI 10.1016/0022-4731(88)90014-3; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	44	9	9	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3133	3142		10.1038/sj.onc.1201860	http://dx.doi.org/10.1038/sj.onc.1201860			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671392				2022-12-28	WOS:000074261300006
J	de Launoit, Y; Audette, M; Pelczar, H; Plaza, S; Baert, JL				de Launoit, Y; Audette, M; Pelczar, H; Plaza, S; Baert, JL			The transcription of the intercellular adhesion molecule-1 is regulated by Ets transcription factors	ONCOGENE			English	Article						ICAM-1; Ets; ERM; transcription factor	INTERFERON-GAMMA; GENE-EXPRESSION; ONCOGENE FAMILY; RETINOIC ACID; ICAM-1 GENE; C-JUN; PROMOTER; BINDING; DISTINCT; CELLS	The Ets family of transcription factors comprises several members which are involved to regulate gene transcription. Although several consensus binding sites for Ets proteins can be found in a wide series of promoter, only a limited number of them are indeed activated by these transcription factors, The human intercellular adhesion molecule-1 (ICAM-1) plays a crucial role in immune responses by enabling the binding of effector cells to various target cell types. ICAM-1 is constitutively expressed at different levels in the absence of stimuli in different cell types, and its expression is upregulated by several proinflammatory cytokines. We hale here examined the transcriptional regulation of human ICAM-1 expression by Ets proteins, and more particularly by ERM, a member of this family of transcription factors, Transient transfection assays revealed that Ets-2 and ERM significantly activate the transcription of ICAM-1 promoter, whereas the less-related Ets family member, Spi-1/Pu.1, failed to do so, Transfection of a series of ICAM-1 promoter deletion mutants together with ERM expression plasmids have shown that an Ets responsive element is located within the first 176 bp upstream from the translational start site. Electrophoretic mobility shift assays and DNase I footprinting analysis have enabled us to identify two Ets binding sites at positions -158 and -138 from the ATG, respectively. Site directed mutagenesis of these elements has shown that the distal site is the major element required for the ERM-mediated activation of the ICAM-1 promoter, We can thus conclude that expression of ICAM-1 can be regulated by Ets transcription factors.	Inst Pasteur, Inst Biol, UMR 319 CNRS, F-59021 Lille, France; CHU Laval, Res Ctr, Mol Endocrinol Lab, Quebec City, PQ G1V 4G2, Canada; Inst Pasteur, Inst Biol, EP 560 CNRS, F-59021 Lille, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Laval University; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	de Launoit, Y (corresponding author), Inst Pasteur, Inst Biol, UMR 319 CNRS, 1 Rue Calmette,BP 447, F-59021 Lille, France.		plaza, serge/F-5290-2015					ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ALTMANN DM, 1989, NATURE, V338, P512, DOI 10.1038/338512a0; AOUDJIT F, 1994, INT J CANCER, V58, P543, DOI 10.1002/ijc.2910580416; Aoudjit F, 1997, CELL GROWTH DIFFER, V8, P335; AOUDJIT F, 1995, CELL GROWTH DIFFER, V6, P515; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Crepieux Pascale, 1993, Gene Expression, V3, P215; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; JAHNKE A, 1995, EUR J BIOCHEM, V228, P439; Janknecht R, 1996, ONCOGENE, V13, P1745; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JEON IS, 1995, ONCOGENE, V10, P1229; JOHNSON JP, 1991, CHEM IMMUNOL, V50, P143; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Laget MP, 1996, ONCOGENE, V12, P1325; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; NATALI P, 1990, CANCER RES, V50, P1271; PLAZA S, 1995, ONCOGENE, V10, P329; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; SATO H, 1993, ONCOGENE, V8, P395; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; STRATOWA C, 1995, IMMUNOBIOLOGY, V193, P293, DOI 10.1016/S0171-2985(11)80558-9; VOGETSEDER W, 1989, INT J CANCER, V43, P768, DOI 10.1002/ijc.2910430504; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WAWRYK SO, 1991, INT IMMUNOL, V3, P83, DOI 10.1093/intimm/3.1.83; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	47	57	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	1998	16	16					2065	2073		10.1038/sj.onc.1201726	http://dx.doi.org/10.1038/sj.onc.1201726			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572487				2022-12-28	WOS:000073177200004
J	Webster, MA; Martin-Soudant, N; Nepveu, A; Cardiff, RD; Muller, WJ				Webster, MA; Martin-Soudant, N; Nepveu, A; Cardiff, RD; Muller, WJ			The induction of uterine leiomyomas and mammary tumors in transgenic mice expressing polyomavirus (PyV) large T (LT) antigen is associated with the ability of PyV LT antigen to form specific complexes with retinoblastoma and CUTL1 family members	ONCOGENE			English	Article						polyomavirus LT; CUTL1; leiomyomas; mammary tumors; transgenic	PROTEIN; GENE; PROMOTER; IMMORTALIZATION; TRANSCRIPTION; HYBRIDIZATION; ONCOGENE; BINDING	The inactivation of certain tumor suppressor genes is thought to play an important role in the genesis of a number of tumor types. For example, inactivation of the Retinoblastoma (Rb) tumor suppressor is frequently observed in a proportion of sporadic human breast cancers. While these studies suggest that inactivation of key tumor suppressor genes may play an important role in the induction of mammary cancers, direct evidence supporting this contention is lacking. Because polyomavirus (PyV) Large T (LT) antigen is known to associate with and inactivate certain members of the Rb family (p105Rb, p107, p130), we have derived transgenic mice which express PyV LT antigen in the mammary epithelium, As expected mammary epithelial-specific expression of PyV LT antigen resulted in the induction of mammary tumors which correlated with their capacity to associate with Rb family members. In addition to mammary carcinomas, female transgenic mice expressing the PyV LT transgene frequently develop uterine leiomyomas, Because loss of heterozygosity involving the human CUTL1 (Cut like 1) gene located at chromosomal position 7q22 has been recently implicated in sporadic human uterine leiomyomas, we tested the hypothesis that PyV LT antigen may also form specific complexes with CUTL1, The results of these analyses revealed that specific complexes of CUTL1 and PyV LT antigen could be detected in both leiomyomas and mammary tumors. Taken together, these observations suggest that PyV LT antigen may be involved in inducing these tumors by sequestering both CUTL1 and Rb growth regulatory proteins.	McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Pathol, Hamilton, ON L8S 4K1, Canada; McGill Univ, Royal Victoria Hosp, Dept Med & Oncol, Montreal, PQ H3A 1A1, Canada; Univ Calif Davis, Sch Med, Dept Med Pathol, Davis, CA USA	McMaster University; McMaster University; McMaster University; McGill University; Royal Victoria Hospital; University of California System; University of California Davis	Muller, WJ (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada.		/AAB-8315-2020					CHALIFOUR LE, 1992, MOL CARCINOGEN, V5, P178, DOI 10.1002/mc.2940050304; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEMIEUX N, 1994, GENOMICS, V24, P191, DOI 10.1006/geno.1994.1603; LI M, 1996, CELL GROWTH DIFFER, V1, P3; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OZISIK YY, 1996, CANC GEN CYTOGEN, V71, P1; PAQUISFLUCKLINGER V, 1993, ONCOGENE, V8, P2087; Pilon AA, 1996, J VIROL, V70, P4457, DOI 10.1128/JVI.70.7.4457-4465.1996; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Romagnolo B, 1996, J CLIN INVEST, V98, P777, DOI 10.1172/JCI118850; SARGENT MS, 1994, CANCER GENET CYTOGEN, V77, P65, DOI 10.1016/0165-4608(94)90151-1; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Shibata MA, 1996, CANCER RES, V56, P2998; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VARLEY JM, 1989, ONCOGENE, V4, P725; VONDERHAAR BK, 1979, ENDOCRINOLOGY, V104, P409, DOI 10.1210/endo-104-2-409; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zeng WR, 1997, ONCOGENE, V14, P2355, DOI 10.1038/sj.onc.1201076	34	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1963	1972		10.1038/sj.onc.1201707	http://dx.doi.org/10.1038/sj.onc.1201707			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591780				2022-12-28	WOS:000073079400008
J	Bristow, RG; Hu, QY; Jang, A; Chung, S; Peacock, J; Benchimol, S; Hill, R				Bristow, RG; Hu, QY; Jang, A; Chung, S; Peacock, J; Benchimol, S; Hill, R			Radioresistant MTp53-expressing rat embryo cell transformants exhibit increased DNA-dsb rejoining during exposure to ionizing radiation	ONCOGENE			English	Review						p53; H-ras; radioresistance; apoptosis; cell cycle arrests; DNA repair	P53-DEPENDENT G(1) ARREST; C-TERMINAL DOMAIN; P53 TUMOR-SUPPRESSOR; LI-FRAUMENI SYNDROME; DOUBLE-STRAND BREAKS; ACTIVATED H-RAS; WILD-TYPE P53; INDUCED APOPTOSIS; MUTANT P53; CLONOGENIC SURVIVAL	Recent data suggest that aberrant function of the wild type p53 protein (WTp53) may alter cellular survival following DNA damage through cellular pathways involving apoptosis and cell-cycle checkpoints, but little is known concerning it's possible role in DNA repair. In the present study, the ionizing radiation sensitivity was determined for a series of rat embryo fibroblast (REF) cell lines transfected with an activated form of the H-ras oncogene alone, or in combination with a variety of missense-mutant p53 (MTp53) alleles. Transformed REF clones which expressed exogenous MTp53 and p21(ras) proteins (CLASS II clones) were generally radioresistant in culture as determined by higher values surviving fraction after 2 Gy (SF2 value) radiation dose required to reduce survival to a fraction of 0.1 (D10 value), compared either to transformed REF clones expressing p21(ras) protein alone (CLASS I clones), or to non-transfected REF control cell lines expressing baseline endogenous levels of p21(ras) and WTp53 protein. The increased radioresistance observed in the CLASS II clones (following both HDR-and LDR-irradiation), was significantly correlated with increased expression of MTp53 protein, and a decreased radiation-induced G1 arrest response, The variability observed in clonogenic radiosensitivity among REF clones was not explained by differential radiation-induced apoptosis. Using the Comet assay performed after continuous low dose-rate (LDR)irradiation, MTp53-expressing REF clones were also found to be more proficient at the rejoining of DNA double-strand breaks (DNA-dsb), compared to WTp53-expressing REF clones. These results suggest that an enhanced DNA and cellular repair capacity may, in part, explain the increased radiation survival observed in some MTp53-expressing transformed fibroblasts and tumours.	Princess Margaret Hosp, Ontario Canc Inst, Dept Res, Div Expt Therapeut, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Ontario Canc Inst, Dept Res, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Radiat Oncol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto	Bristow, RG (corresponding author), Erasmus Univ, Room EE734,Dr Molenwaterplein 50, NL-3015 GE Rotterdam, Netherlands.			Bristow, Robert/0000-0002-8553-9544; Hill, Richard Peter/0000-0001-5331-8045; Benchimol, Samuel/0000-0003-3433-890X				AFZAL V, 1995, MUTAGENESIS, V10, P457, DOI 10.1093/mutage/10.5.457; ALDRIDGE DR, 1995, BRIT J CANCER, V71, P571, DOI 10.1038/bjc.1995.111; ALLALUNISTURNER MJ, 1995, CANCER RES, V55, P5200; ALLALUNISTURNER MJ, 1997, RADIAT RES, V147, P284; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; BLONDAL JA, 1994, SEMIN CANCER BIOL, V5, P177; Brezden CB, 1996, ONCOGENE, V12, P201; BRISTOW RG, 1994, ONCOGENE, V9, P1527; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Bristow RG, 1996, INT J RADIAT ONCOL, V34, P341, DOI 10.1016/0360-3016(95)02023-3; BRISTOW RG, 1990, INT J RADIAT ONCOL, V18, P331, DOI 10.1016/0360-3016(90)90098-5; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CASSONI AM, 1992, EUR J CANCER, V28A, P1610, DOI 10.1016/0959-8049(92)90052-4; CHANG WP, 1992, CARCINOGENESIS, V13, P923, DOI 10.1093/carcin/13.6.923; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHEONG N, 1993, INT J RADIAT BIOL, V63, P623, DOI 10.1080/09553009314450811; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Daza P, 1997, INT J RADIAT BIOL, V72, P91, DOI 10.1080/095530097143572; DeFrank JS, 1996, CANCER RES, V56, P5365; DENG C, 1995, CELL, V82, P657; DeWeese TL, 1997, INT J RADIAT ONCOL, V37, P145, DOI 10.1016/S0360-3016(96)00448-8; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULLIC V, 1994, CELL, V76, P1013; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; FAN SJ, 1994, CANCER RES, V54, P5824; Fernandes RS, 1996, ANTICANCER RES, V16, P1691; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FUKS Z, 1995, IMP ADV ONCOL, V1, P19; Gallo O, 1996, CLIN CANCER RES, V2, P1577; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; Gupta N, 1996, RADIAT RES, V145, P289, DOI 10.2307/3578984; Hill R. P., 1992, BASIC SCI ONCOLOGY, P259; HOY CA, 1989, CYTOMETRY, V10, P718, DOI 10.1002/cyto.990100608; Hu QY, 1996, RADIAT RES, V146, P636, DOI 10.2307/3579379; Huang LC, 1996, CANCER RES, V56, P2940; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Kanaar Roland, 1997, Genes and Function, V1, P165; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khanna KK, 1996, CELL DEATH DIFFER, V3, P315; KIKUCHIYANOSHITA R, 1995, ONCOGENE, V11, P1339; Kitada S, 1996, ONCOGENE, V12, P187; Koch WM, 1996, JNCI-J NATL CANCER I, V88, P1580, DOI 10.1093/jnci/88.21.1580; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI CY, 1995, ONCOGENE, V11, P1885; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Linke SP, 1997, CANCER RES, V57, P1171; LITTLE JB, 1994, RADIAT RES, V140, P299, DOI 10.2307/3579106; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; Mateos S, 1996, INT J RADIAT BIOL, V69, P687, DOI 10.1080/095530096145427; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; MCMILLAN TJ, 1994, INT J RADIAT BIOL, V65, P49, DOI 10.1080/09553009414550071; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIRZAYANS R, 1995, BRIT J CANCER, V71, P1221, DOI 10.1038/bjc.1995.237; MORGAN WF, 1995, CANCER METAST REV, V14, P49, DOI 10.1007/BF00690211; Muller BF, 1996, ONCOGENE, V12, P1941; NAGASAWA H, 1995, CANCER RES, V55, P1842; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nunez MI, 1996, RADIOTHER ONCOL, V39, P155, DOI 10.1016/0167-8140(96)01732-X; OLIVE PL, 1994, CANCER RES, V54, P3939; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; Pocard M, 1996, ONCOGENE, V12, P875; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; POWELL SN, 1994, INT J RADIAT ONCOL, V29, P1035, DOI 10.1016/0360-3016(94)90399-9; RADFORD IR, 1994, INT J RADIAT BIOL, V66, P557, DOI 10.1080/09553009414551621; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROVINSKI B, 1988, ONCOGENE, V2, P445; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; Schwartz JL, 1996, RADIAT RES, V146, P139, DOI 10.2307/3579585; Schwartz JL, 1996, BRIT J CANCER, V74, P37, DOI 10.1038/bjc.1996.312; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAULSKY G, 1991, CANCER RES, V51, P5232; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siles E, 1996, BRIT J CANCER, V73, P581, DOI 10.1038/bjc.1996.101; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH ML, 1995, ONCOGENE, V10, P1053; STAPPER NJ, 1995, INT J CANCER, V62, P58; STEEL GG, 1991, RADIOTHER ONCOL, V20, P71; TISTY T, 1995, METHOD ENZYMOL, V254, P125; TSANG NM, 1995, ONCOGENE, V10, P2403; TSANG NM, 1994, RADIAT RES, V140, P172, DOI 10.2307/3578900; Vidair CA, 1996, CANCER RES, V56, P4116; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; WHITE E, 1994, COLD SPRING HARB SYM, V59, P395, DOI 10.1101/SQB.1994.059.01.044; Williams KJ, 1997, ONCOGENE, V14, P277, DOI 10.1038/sj.onc.1200838; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YIN DX, 1995, CANCER RES, V55, P4922; ZOLZER F, 1995, RADIOTHER ONCOL, V37, P20, DOI 10.1016/0167-8140(95)01618-Q	106	39	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1789	1802		10.1038/sj.onc.1201935	http://dx.doi.org/10.1038/sj.onc.1201935			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583677				2022-12-28	WOS:000072994600003
J	Bertolotto, C; Bille, K; Ortonne, JP; Ballotti, R				Bertolotto, C; Bille, K; Ortonne, JP; Ballotti, R			In B16 melanoma cells, the inhibition of melanogenesis by TPA results from PKC activation and diminution of microphthalmia binding to the M-box of the tyrosinase promoter	ONCOGENE			English	Article						tyrosinase; TPA; PKC; cAMP; microphthalmia	PROTEIN-KINASE-C; NORMAL HUMAN MELANOCYTES; MESSENGER-RNA LEVELS; STIMULATING HORMONE; DOWN-REGULATION; RETINOIC ACID; MAMMALIAN TYROSINASE; GENE-PRODUCT; EXPRESSION; ALPHA	In B16 melanoma cells, cAMP-induced melanogenesis is inhibited by the tumor promoting phorbol ester, TPA, However, the role of PKC activation or depletion in the inhibition of melanogenesis by TPA remains controversial, In this report, using specific PKC inhibitors, ne demonstrated that PKC inhibition does not impair cAMP-induced melanin synthesis and tyrosinase expression, Further, the inhibition of melanogenesis by TPA results from a decrease of the tyrosinase promoter transcriptional activity and this effect is mimicked by over-expression of a constitutively active form of PKC alpha, These findings clearly demonstrate that PKC activation accounts for the inhibition of melanin synthesis by TPA, Additional experiments were undertaken to elucidate the mechanism by which TPA inhibits the tyrosinase gene transcription, Deletions and mutation in the tyrosinase promoter showed that TPA acts on a M-box which is involved in tissue-specific expression and regulation ba cAMP of the tyrosinase gene, We showed that TPA decreases the binding of microphthalmia, a basic helix-loop-helix transcription factor, to the M-box. Since microphthalmia, strongly stimulates the transcriptional activity of the promoter we propose that TPA, through PKC activation, decreases microphthalmia binding to the M-box of the tyrosinase promoter, thereby leading to a reduced tyrosinase expression and melanogenesis inhibition.					Bertolotto, Corine/AAF-6634-2021; Bertolotto-Ballotti, Corine/O-2155-2016; BALLOTTI, Robert/F-8825-2013	Bertolotto, Corine/0000-0001-6971-7753; BALLOTTI, Robert/0000-0002-7322-4908				ABDELMALEK Z, 1992, J CELL PHYSIOL, V150, P416, DOI 10.1002/jcp.1041500226; ABERDAM E, 1993, J CELL SCI, V106, P1015; ANDO H, 1995, J CELL PHYSIOL, V163, P608, DOI 10.1002/jcp.1041630322; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; BROOKS G, 1993, J BIOL CHEM, V268, P23868; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; FRIEDMANN PS, 1990, J CELL PHYSIOL, V142, P334, DOI 10.1002/jcp.1041420216; FULLER BB, 1990, MOL CELL ENDOCRINOL, V72, P81, DOI 10.1016/0303-7207(90)90097-R; FULLER BB, 1979, LIFE SCI, V24, P2405, DOI 10.1016/0024-3205(79)90448-X; GANSS R, 1994, J BIOL CHEM, V269, P29808; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; GRUBER JR, 1995, EXP CELL RES, V221, P377, DOI 10.1006/excr.1995.1388; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUNT G, 1994, J CELL SCI, V107, P205; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x; KUZUMAKI T, 1993, EXP CELL RES, V207, P33, DOI 10.1006/excr.1993.1159; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; Mahalingam H, 1996, J CELL PHYSIOL, V168, P549, DOI 10.1002/(SICI)1097-4652(199609)168:3<549::AID-JCP7>3.0.CO;2-P; Oka M, 1996, J INVEST DERMATOL, V106, P377, DOI 10.1111/1523-1747.ep12343168; OKA M, 1993, J INVEST DERMATOL, V100, pS204, DOI 10.1111/1523-1747.ep12465200; OKA M, 1995, J INVEST DERMATOL, V105, P567, DOI 10.1111/1523-1747.ep12323485; PARK HY, 1993, J BIOL CHEM, V268, P11742; Park HY, 1996, EXP CELL RES, V227, P70, DOI 10.1006/excr.1996.0251; STOCKER KM, 1991, DEVELOPMENT, V111, P635; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; YAVUZER U, 1995, ONCOGENE, V10, P123; YOKOYAMA K, 1994, J BIOL CHEM, V269, P27080; YOKOYAMA K, 1994, BBA-GENE STRUCT EXPR, V1217, P317, DOI 10.1016/0167-4781(94)90292-5	33	49	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1665	1670		10.1038/sj.onc.1201685	http://dx.doi.org/10.1038/sj.onc.1201685			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582014				2022-12-28	WOS:000072807600004
J	Poon, RYC; Hunter, T				Poon, RYC; Hunter, T			Expression of a novel form of p21(Cip1/Waf1) in UV-irradiated and transformed cells	ONCOGENE			English	Article						cell cycle; CDK inhibitor; cyclin; proteasome	CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR GENE; INHIBITS DNA-REPLICATION; PROTEIN-KINASE; CDK INHIBITOR; TERMINAL DIFFERENTIATION; POTENTIAL MEDIATOR; NUCLEAR ANTIGEN; BINDING DOMAINS; MICE DEFICIENT	The tumor suppressor p53 and its target the CDK inhibitor p21 (Cip1/Waf1) are key components of the cellular response to DNA damage. Insight into how p21 is regulated in normal cells, and how it may be deregulated in tumor cells is important for the understanding of tumorigenesis. p21 was induced in normal human diploid fibroblasts after UV irradiation-induced DNA damage, but, at a high dose of UV irradiation, a faster mobility form of p21 on SDS-PAGE (designated p21 Delta) was expressed. Surprisingly, in a variety of growing transformed cell lines, the level of p21 was low but p21 Delta was prominent. We found that p21 Delta appeared to be derived through a loss of around 10 amino acids from the C-terminus of p21, which theoretically would remove the PCNA binding domain, a second cyclin binding domain and the nuclear localization signal sequence. Several characteristics distinguish p21 from p21 Delta. Both the full length p21 and p21 Delta could be stabilized by a proteasome inhibitor, but only the full length p21 was associated with Cdk2 and PCNA. Consistent with this, gel filtration chromatography revealed that all the full length p21 in the cell was complexed to other proteins, whereas a significant portion of p21 Delta was in monomeric form. Moreover, p21 was mainly localized to the nucleus, but p21 Delta was mainly localized to the cytoplasm. We propose that the decrease in p21 and increase in p21 Delta could contribute to the deregulation of the cell cycle, and could be a mechanism involved in cellular transformation.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Hong Kong University of Science & Technology; Salk Institute	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong.			Poon, Randy/0000-0001-5571-6231	NCI NIH HHS [CA14195, CA39780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, R35CA039780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; AUSUBEL RM, 1991, CURRENT PROTOCOLS MO; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN L, 1996, NATURE, V16, P4673; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOUBIN F, 1995, ONCOGENE, V10, P2281; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HUPPI K, 1994, ONCOGENE, V9, P3017; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JIANG HP, 1994, ONCOGENE, V9, P3397; KAKUNAGA T, 1978, P NATL ACAD SCI USA, V75, P1334, DOI 10.1073/pnas.75.3.1334; KASTAN MB, 1991, CANCER RES, V51, P6304; LEE KAW, 1994, CELL BIOL LAB HDB; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MICHIELI P, 1994, CANCER RES, V54, P3391; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MURRAY A, 1993, CELL CYCLE; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; QUELLE DE, 1995, CELL, V83, P993; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Tchou WW, 1996, J BIOL CHEM, V271, P29556, DOI 10.1074/jbc.271.47.29556; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TROLL W, 1993, PROTEASE INHIBITORS; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1992, CELL, V71, P50; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	78	48	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1333	1343		10.1038/sj.onc.1201897	http://dx.doi.org/10.1038/sj.onc.1201897			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546435				2022-12-28	WOS:000072422000012
J	Habano, W; Nakamura, S; Sugai, T				Habano, W; Nakamura, S; Sugai, T			Microsatellite instability in the mitochondrial DNA of colorectal carcinomas: Evidence for mismatch repair systems in mitochondrial genome	ONCOGENE			English	Article						genomic instability; mitochondrial DNA; colorectal carcinoma	CRYPT-ISOLATION TECHNIQUE; II RECEPTOR GENE; CANCER-CELLS; NUCLEAR-DNA; MUTATIONS; DISEASES; COLON; CARCINOGENESIS; DEFICIENCY; EXPRESSION	The role, if any, that alterations play in the carcinogenic process remains unclear. To determine whether mtDNA instability occurs in cancers, nine microsatellite sequences in the mtDNA mere examined in 45 sporadic colorectal carcinomas. Alteration in a polycytidine (C)n tract within a noncoding displacement-loop (D-loop) region was detected in 20 carcinomas (44%), three of which also exhibited frameshift mutations in a polyadenosine (A)8 or polycytidine (C)6 tract within NADH dehydrogenase (ND) genes. Interestingly, all three mutant genes were predicted to encode truncated ND proteins, which lacked a large portion of the C-terminus. These results suggested that certain repair systems, like the mismatch repair systems in the nuclear genome, are required for mtDNA maintenance and that defects in these systems can lead to target mitochondrial gene mutations in colorectal carcinomas.	Iwate Univ, Sch Med, Cent Clin Lab, Div Pathol, Morioka, Iwate 020, Japan	Iwate University	Nakamura, S (corresponding author), Iwate Univ, Sch Med, Cent Clin Lab, Div Pathol, 19-1 Uchimaru, Morioka, Iwate 020, Japan.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALLEN JA, 1980, NATURE, V287, P244, DOI 10.1038/287244a0; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BACKER JM, 1980, SCIENCE, V209, P297, DOI 10.1126/science.6770466; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; BERNARDI G, 1979, TRENDS BIOCHEM SCI, V4, P197, DOI 10.1016/0968-0004(79)90079-3; BISHOP JM, 1993, CELL, V75, P235; BOYER JC, 1995, CANCER RES, V55, P6063; BURGART LJ, 1995, AM J PATHOL, V147, P1105; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; FUKUDA M, 1985, J MOL BIOL, V186, P257, DOI 10.1016/0022-2836(85)90102-0; Habano W, 1996, LAB INVEST, V74, P933; Habano W, 1998, ONCOGENE, V16, P1259, DOI 10.1038/sj.onc.1201651; HEERDT BG, 1994, CANCER RES, V54, P3912; HEERDT BG, 1990, CANCER RES, V50, P1596; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JONASSON J, 1977, J CELL SCI, V24, P255; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NAKAMURA S, 1994, GASTROENTEROLOGY, V106, P100, DOI 10.1016/S0016-5085(94)94651-5; NAKAMURA S, 1993, GUT, V34, P1240, DOI 10.1136/gut.34.9.1240; OBERLEY LW, 1979, CANCER RES, V39, P1141; OZAWA T, 1995, BBA-MOL BASIS DIS, V1271, P177, DOI 10.1016/0925-4439(95)00026-Z; PARSONS R, 1995, CANCER RES, V55, P5548; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Parsons TJ, 1997, NAT GENET, V15, P363, DOI 10.1038/ng0497-363; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; REENAN RAG, 1992, GENETICS, V132, P975; SAGER R, 1985, ADV CANCER RES, V44, P43, DOI 10.1016/S0065-230X(08)60025-1; SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WILKIE D, 1983, INT REV CYTOL, P157; Yoshida T, 1996, J SURG ONCOL, V63, P9	41	135	154	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	1998	17	15					1931	1937		10.1038/sj.onc.1202112	http://dx.doi.org/10.1038/sj.onc.1202112			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788436				2022-12-28	WOS:000076423500006
J	Nikiforov, YE; Nikiforova, M; Fagin, JA				Nikiforov, YE; Nikiforova, M; Fagin, JA			Radiation-induced post-Chernobyl pediatric thyroid carcinomas	ONCOGENE			English	Article						minisatellites; microsatellites; radiation; thyroid tumors; Chernobyl; genomic instability	INDUCED GENOMIC INSTABILITY; POLYMERASE CHAIN-REACTION; HUMAN MINISATELLITE; HYPERVARIABLE LOCI; IONIZING-RADIATION; MUTATION PROCESSES; SOMATIC MUTATIONS; RET PROTOONCOGENE; NUCLEAR ACCIDENT; VNTR-LOCUS	Exposure to ionizing radiation induces different forms of genomic instability in cultured cells and experimental animals. A higher rate of germline mutations at human hypervariable minisatellite loci was reported in children born from parents exposed to radiation after Chernobyl, implicating genome destabilization as a possible mechanism responsible for late radiation effects in humans. To test if radiation-induced carcinogenesis in the thyroid gland may be associated with somatic minisatellite instability or microsatellite instability, we utilized a PCR-based approach to study normal and tumor DNA from 17 pediatric post-Chernobyl papillary thyroid carcinomas for mutations at three different minisatellite loci (D1S80, D17S30, ApoB), and 27 microsatellite loci of di-, tri-, or tetranucleotide repeats. Minisatellite instability was found in three (18%) tumors, with one of them exhibiting mutations in all three minisatellite loci, whereas two others showed mutations in one of two informative markers. By contrast, none of 20 sporadic thyroid cancers from patients with no history of radiation exposure was positive for minisatellite instability. Microsatellite analysis of post-Chernobyl tumors revealed a mutation in one (6%) tumor only at the locus of D10S1412, whereas all other 26 microsatellite markers showed identical patterns in each normal/tumor pair. Our results suggest that somatic cell microsatellite instability does not contribute to radiation-induced thyroid carcinogenesis. However, somatic minisatellite mutation events are present in a subset of radiation-induced, but not sporadic, thyroid cancers, suggesting that this type of genomic instability may play a role in radiation-induced tumorigenesis in the thyroid gland.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Fagin, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA.				NATIONAL CANCER INSTITUTE [R01CA050706, R29CA050706, R01CA072597] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72597, CA 50706] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; BOERWINKLE E, 1989, P NATL ACAD SCI USA, V86, P212, DOI 10.1073/pnas.86.1.212; BOGDANOVA T, 1995, THYROID S1, V5, P28; Dubrova YE, 1996, NATURE, V380, P683, DOI 10.1038/380683a0; DUBROVA YE, 1993, NAT GENET, V5, P92, DOI 10.1038/ng0993-92; FELBER M, 1994, CANCER BIOCHEM BIOPH, V14, P163; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; HOFFOLSEN P, 1995, HUM MUTAT, V5, P329, DOI 10.1002/humu.1380050410; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; IVEY JN, 1994, J FORENSIC SCI, V39, P52; JEFFREYS AJ, 1995, ELECTROPHORESIS, V16, P1577, DOI 10.1002/elps.11501601261; Jeffreys AJ, 1997, HUM MOL GENET, V6, P129, DOI 10.1093/hmg/6.1.129; JEFFREYS AJ, 1987, BIOCHEM SOC T, V15, P309, DOI 10.1042/bst0150309; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; KADHIM MA, 1995, INT J RADIAT BIOL, V67, P287, DOI 10.1080/09553009514550341; KARRAN P, 1995, SCIENCE, V268, P1857, DOI 10.1126/science.7604258; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; KRONENBERG A, 1994, INT J RADIAT BIOL, V66, P603, DOI 10.1080/09553009414551691; LITTLE JB, 1994, RADIAT RES, V140, P299, DOI 10.2307/3579106; MATSUO K, 1991, MOL ENDOCRINOL, V5, P1873, DOI 10.1210/mend-5-12-1873; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; MURNANE JP, 1993, SEMIN CANCER BIOL, V4, P93; Nikiforov Y, 1996, J CLIN ENDOCR METAB, V81, P9, DOI 10.1210/jc.81.1.9; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 1996, ONCOGENE, V13, P687; PAQUETTE B, 1994, CANCER RES, V54, P3173; PASINI B, 1995, ONCOGENE, V11, P1737; SADAMOTO S, 1994, INT J RADIAT BIOL, V65, P549, DOI 10.1080/09553009414550641; SAJANTILA A, 1992, AM J HUM GENET, V50, P816; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SINGH L, 1995, ELECTROPHORESIS, V16, P1586, DOI 10.1002/elps.11501601262; STSJAZHKO VA, 1995, BMJ-BRIT MED J, V310, P801, DOI 10.1136/bmj.310.6982.801; WOLFF RK, 1988, GENOMICS, V3, P347, DOI 10.1016/0888-7543(88)90126-7; ZEDENIUS J, 1995, HUM GENET, V96, P27, DOI 10.1007/BF00214182	37	24	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1983	1988		10.1038/sj.onc.1202120	http://dx.doi.org/10.1038/sj.onc.1202120			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788442				2022-12-28	WOS:000076423500012
J	Oehrl, W; Kardinal, C; Ruf, S; Adermann, K; Groffen, J; Feng, GS; Blenis, J; Tan, TH; Feller, SM				Oehrl, W; Kardinal, C; Ruf, S; Adermann, K; Groffen, J; Feng, GS; Blenis, J; Tan, TH; Feller, SM			The germinal center kinase (GCK)-related protein kinases HPK1 and KHS are candidates for highly selective signal transducers of Crk family adapter proteins	ONCOGENE			English	Article						Crk; CRKL; SH3; HPK1; KHS; kinase; adapter	N-TERMINAL KINASE; PROLINE-RICH SEQUENCES; SRC HOMOLOGY-3 DOMAINS; CELL ANTIGEN RECEPTOR; SH3 DOMAIN; C-CRK; GROWTH-FACTOR; EXCHANGE FACTOR; TYROSINE PHOSPHORYLATION; JUN KINASE	Adapter proteins function by mediating the rapid and specific assembly of multi-protein complexes during the signal transduction which guards proliferation, differentiation and many functions of higher eukaryotic cells, To understand their functional roles in different cells it is important to identify the selectively interacting proteins in these cells. Two novel candidates for signalling partners of Crk family adapter proteins, the hematopoietic progenitor kinase 1 (HPK1) and the kinase homologous to SPS1/STE20 (KHS), were found to bind with great selectivity to the first SH3 domains of c-Crk and CRKL. While KHS bound exclusively to Crk family proteins, HPK1 also interacted with both SH3 domains of Grb2 and weakly with Nck, but not with more than 25 other SH3 domains tested. The interaction of HPK1 with c-Crk and CRKL was studied in more detail. HPK1-binding to the first SH3 domain of CRKL is direct and occurs via proline-rich motifs in the C-terminal, non-catalytic portion of HPK1. In vitro complexes were highly stable and in vivo complexes of c-Crk and CRKL with HPK1 were detectable by co-immnnoprecipitation with transiently transfected cells but also with endogenous proteins. Furthermore, c-Crk II and, to a lesser extent, CRKL were substrates for HPK1, These results make it likely that HPK1 and KHS participate in the signal transduction of Crk family adapter proteins in certain cell types.	Univ Wurzburg, Oncol Mol Lab, Inst Med Radiat & Cell Res, MSZ, D-97078 Wurzburg, Germany; Lower Saxony Inst Peptide Res, IPF, D-30625 Hannover, Germany; Childrens Hosp, Dept Mol Pathol, Los Angeles, CA 90027 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	University of Wurzburg; Children's Hospital Los Angeles; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Harvard University; Harvard Medical School; Baylor College of Medicine	Feller, SM (corresponding author), Univ Wurzburg, Oncol Mol Lab, Inst Med Radiat & Cell Res, MSZ, D-97078 Wurzburg, Germany.		Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010; Heisterkamp, Nora/C-1698-2012	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049875] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI38649] Funding Source: Medline; NIGMS NIH HHS [R01-GM49875] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1995, METHOD ENZYMOL, V255, P369; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FORD AM, 1992, BLOOD, V79, P1962, DOI 10.1182/blood.V79.8.1962.bloodjournal7981962; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Husson H, 1997, ONCOGENE, V14, P2331, DOI 10.1038/sj.onc.1201074; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; Osada S, 1997, ONCOGENE, V14, P2047, DOI 10.1038/sj.onc.1201043; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Sattler M, 1996, ONCOGENE, V12, P839; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Smit L, 1996, ONCOGENE, V13, P381; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Torres M, 1996, ONCOGENE, V12, P77; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang BL, 1996, ONCOGENE, V13, P1379; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	58	49	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	1998	17	15					1893	1901		10.1038/sj.onc.1202108	http://dx.doi.org/10.1038/sj.onc.1202108			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788432				2022-12-28	WOS:000076423500002
J	Yang, XL; Chernenko, G; Hao, YW; Ding, ZH; Pater, MM; Pater, A; Tang, SC				Yang, XL; Chernenko, G; Hao, YW; Ding, ZH; Pater, MM; Pater, A; Tang, SC			Human BAG-1/RAP46 protein is generated as four isoforms by alternative translation initiation and overexpressed in cancer cells	ONCOGENE			English	Article						four hBAG-1 isoforms; alternative translation initiation; subcellular localization; overexpression; cancer	BCL-2 PROTOONCOGENE EXPRESSION; SUBCELLULAR-DISTRIBUTION; CDNA CLONING; BAG-1; IDENTIFICATION; LOCALIZATION; CARCINOMA; RECEPTOR; APOPTOSIS; PRODUCTS	Previously, a Bcl-2-interacting protein, BAG-I, was cloned from mouse cells and was shown to interact with several other proteins and to be important for inhibition of apoptosis. Human BAG-1 (hBAG-1) cDNA, recently isolated by us and two other groups, has been shown to be identical to a hormone receptor-binding protein, RAP46. However, different molecular masses of hBAG-1 protein products were noted by these three groups. Here we demonstrated that hBAG-1 protein was expressed as four isoforms, designated p50, p46, p33 and p29, with apparent molecular masses of 50 kDa, 46 kDa, 33 kDa and 29 kDa, respectively. Deletion, site-directed mutagenesis and in vitro transcription/translation analysis showed that the four protein products of hBAG-1 were expressed by alternative initiation from four different start codons through a leaky scanning mechanism. Furthermore, we demonstrated that the distinct forms of hBAG-1. have different subcellular localizations, suggesting that they may have distinct functions in the cells. Characterization of hBAG-1 RNA and protein also showed that hBAG-1 was overexpressed in human cervical, breast and lung cancer cell lines. Taken together, these data clarify the conflicting observations reported in the literature and suggest that hBAG-1 is expressed as four forms of protein products, which may play a differential role in apoptosis and oncogenesis of human cells.	Mem Univ Newfoundland, Fac Med, St Johns, NF A1B 3V6, Canada; Newfoundland Canc Treatment & Res Fdn, Dr H Bliss Murphy Canc Ctr, St Johns, NF A1B 3V6, Canada	Memorial University Newfoundland	Tang, SC (corresponding author), Mem Univ Newfoundland, Fac Med, 300 Prince Philip Dr, St Johns, NF A1B 3V6, Canada.							AOKI M, 1993, J BIOL CHEM, V268, P22723; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; HALDAR S, 1994, CANCER RES, V54, P2095; IKEGAKI N, 1994, CANCER RES, V54, P6; Joh T, 1997, ONCOGENE, V15, P1681, DOI 10.1038/sj.onc.1201332; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LIANG XH, 1995, J CELL BIOCHEM, V57, P509, DOI 10.1002/jcb.240570316; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; Lu QL, 1996, HUM PATHOL, V27, P102, DOI 10.1016/S0046-8177(96)90362-7; ORRENIUS S, 1995, J INTERN MED, V237, P529, DOI 10.1111/j.1365-2796.1995.tb00881.x; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; Sambrook J., 2002, MOL CLONING LAB MANU; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Takayama S, 1996, GENOMICS, V35, P494, DOI 10.1006/geno.1996.0389; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Yang XL, 1997, J CELL BIOCHEM, V66, P309, DOI 10.1002/(SICI)1097-4644(19970901)66:3<309::AID-JCB4>3.3.CO;2-Y; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	27	123	128	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					981	989		10.1038/sj.onc.1202032	http://dx.doi.org/10.1038/sj.onc.1202032			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747877				2022-12-28	WOS:000075560900006
J	Castagnino, P; Soriano, JV; Montesano, R; Bottaro, DP				Castagnino, P; Soriano, JV; Montesano, R; Bottaro, DP			Induction of tissue inhibitor of metalloproteinases-3 is a delayed early cellular response to hepatocyte growth factor	ONCOGENE			English	Article						hepatocyte growth factor; TIMP-3; metalloproteinase; cell proliferation; gene induction	ERYTHROID-POTENTIATING ACTIVITY; FACTOR SCATTER FACTOR; RECEPTOR TYROSINE KINASE; CHICKEN-EMBRYO FIBROBLASTS; MET PROTOONCOGENE PRODUCT; HUMAN SKIN FIBROBLASTS; KIDNEY-CELLS REQUIRES; TIMP GENE FAMILY; NIH 3T3 CELLS; EPITHELIAL-CELLS	Hepatocyte growth factor (HGF) stimulates mitogenic, motogenic, and morphogenic responses in various cell types. We analysed HGF-responsive cells by differential display PCR to identify HGF-induced genes that mediate these biological events. One of the genes identified encoded a member of the tissue inhibitor of metalloproteinases (TIMP) family, TIMP3. HGF transiently induced TIMP-3 mRNA in keratinocytes as well as kidney and mammary epithelial cells maximally between 4 and 6 h post-stimulation. Increased TIMP3 protein secretion returned to basal levels within 18 h, while the expression of gelatinases A and B remained unchanged, suggesting that temporary suppression of matrix degradation is a delayed early response to HGF. Ectopic overexpression of TIMP-3 in cultured leiomyosarcoma cells conferred an epithelial morphology, reduced cell growth rate, anchorage-independent growth, and matrix invasion in vitro. Antisense suppression of TIMP3 was associated with a scattered, fibroblastic cell morphology, as well as enhanced proliferation, anchorage-independent growth, and matrix invasion. A survey of tumor cell lines revealed an inverse relationship between metastatic potential and TIMP3 expression level. These data suggest that early, transient TIMP3 expression mediates specific HGF-induced phenotypic changes, and that loss of TIMP3 expression may enhance the invasion potential of certain tumors.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Ctr Med Univ Geneva, Dept Morphol, Geneva, Switzerland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Geneva	Bottaro, DP (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.		Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				ALBINI A, 1987, CANCER RES, V47, P3239; ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; AVALOS BR, 1988, BLOOD, V71, P1721; BARDELLI A, 1992, ONCOGENE, V7, P1973; BERTAUX B, 1990, PATHOL BIOL, V38, P1029; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; BLENIS J, 1984, J BIOL CHEM, V259, P1563; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; Dunsmore SE, 1996, J BIOL CHEM, V271, P24576, DOI 10.1074/jbc.271.40.24576; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GOHDA E, 1994, CYTOKINE, V6, P633, DOI 10.1016/1043-4666(94)90051-5; GOLDE DW, 1980, P NATL ACAD SCI-BIOL, V77, P593, DOI 10.1073/pnas.77.1.593; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Hurskainen T, 1996, J HISTOCHEM CYTOCHEM, V44, P1379, DOI 10.1177/44.12.8985130; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JONES SE, 1994, FEBS LETT, V352, P171, DOI 10.1016/0014-5793(94)00951-1; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LONGATI P, 1994, ONCOGENE, V9, P49; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; PELICCI G, 1995, ONCOGENE, V10, P1631; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PONZETTO C, 1991, J BIOL CHEM, V266, P22087; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RON D, 1993, J BIOL CHEM, V268, P2984; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SAKURAI H, 1997, AM J PHYSIOL, V272, P139; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Soloway PD, 1996, ONCOGENE, V13, P2307; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SPONSEL HT, 1994, AM J PHYSIOL, V267, pF257, DOI 10.1152/ajprenal.1994.267.2.F257; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; STASKUS PW, 1991, J BIOL CHEM, V266, P449; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; STOKER M, 1985, J CELL SCI, V77, P209; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WATANABE S, 1994, BIOCHEM BIOPH RES CO, V199, P1453, DOI 10.1006/bbrc.1994.1394; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WESTBROOK CA, 1984, J BIOL CHEM, V259, P9992; WICK M, 1994, J BIOL CHEM, V269, P18953; WOJTA J, 1994, BLOOD, V84, P151; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZHU H, 1994, J BIOL CHEM, V269, P29943	81	23	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					481	492		10.1038/sj.onc.1201957	http://dx.doi.org/10.1038/sj.onc.1201957			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696042	Green Published			2022-12-28	WOS:000075043000011
J	Benkhelifa, S; Provot, S; Lecoq, O; Pouponnot, C; Calothy, G; Felder-Schmittbuhl, MP				Benkhelifa, S; Provot, S; Lecoq, O; Pouponnot, C; Calothy, G; Felder-Schmittbuhl, MP			mafA, a novel member of the maf proto-oncogene family, displays developmental regulation and mitogenic capacity in avian neuroretina cells	ONCOGENE			English	Article						maf; neuroretina; transcription factor; oncogene	RETINA-SPECIFIC GENE; ZIPPER TRANSCRIPTION FACTOR; NUCLEAR ONCOPROTEIN; BASIC DOMAIN; FACTOR NF-E2; FACTOR NRL; V-MAF; PROTEINS; EXPRESSION; FOS	Transcription factors of the Maf proto-oncogene family have been shown to participate in the regulation of several differentiation specific genes. We previously reported that a member(s) of this family is involved in the regulation of the neuroretina specific gene, QR1, through a promoter region, designated the A box, that is closely related to the Maf recognition element (MARE). We undertook an identification of Maf family genes expressed in the quail neuroretina (QNR) and we report the isolation of mafA, a gene encoding a novel member of the large Maf proteins subgroup. Expression of this gene is developmentally regulated in the neuroretina, MafA is able to bind to MARE sequence and to heterodimerize with v-Maf, MafB, Jun and Fos, but not with the small MafF and MafK proteins. Accordingly, it is able to transactivate the QR1 promoter A box. We also show that increased expression of mafA induces sustained proliferation of postmitotic QNR cells.	Inst Curie, UMR 145 CNRS, F-91405 Orsay, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Felder-Schmittbuhl, MP (corresponding author), Inst Curie, UMR 145 CNRS, F-91405 Orsay, France.			Benkhelifa-Ziyyat, Sofia/0000-0002-8088-5288; PROVOT, SYLVAIN/0000-0003-4087-4450				ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BARNSTABLE CJ, 1987, MOL NEUROBIOL, V1, P9, DOI 10.1007/BF02935263; BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Casado FJ, 1996, MECH DEVELOP, V54, P237, DOI 10.1016/0925-4773(95)00482-3; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; CRISANTICOMBES P, 1977, CELL TISSUE RES, V185, P159; EYCHENE A, 1992, ONCOGENE, V7, P1315; Farjo Q, 1997, GENOMICS, V45, P395, DOI 10.1006/geno.1997.4964; FARJO Q, 1993, GENOMICS, V18, P216, DOI 10.1006/geno.1993.1458; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 1996, ONCOGENE, V12, P53; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; Liu Q, 1996, ONCOGENE, V12, P207; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PIERANI A, 1995, MOL CELL BIOL, V15, P642; PIERANI A, 1993, MOL CELL BIOL, V13, P3401, DOI 10.1128/MCB.13.6.3401; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Sakai M, 1997, ONCOGENE, V14, P745, DOI 10.1038/sj.onc.1200869; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266	40	53	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					247	254		10.1038/sj.onc.1201898	http://dx.doi.org/10.1038/sj.onc.1201898			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674710				2022-12-28	WOS:000074706700014
J	Mukhopadhyay, T; Roth, JA				Mukhopadhyay, T; Roth, JA			Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis	ONCOGENE			English	Article						p53; lung cancer; apoptosis; methoxyestradiol; gene expression	LUNG-CANCER CELLS; IN-VIVO; GENE; ADENOVIRUS; INDUCTION	Because 2-methoxyestradiol (2-MeOE2) induces and stabilizes wild-type p53 protein (wt p53) in human lung cancer cell lines posttranscriptionally, we sought to study its effects on Ad5p53-transduced lung cancer cell lines at a low multiplicity of infection (1 MOI). Treating these cells with 2-MeOE2 resulted in superinduction of wt p53 protein expression followed by apoptosis, as shown by terminal deoxynucleotidyl transferase (TdT) staining, and upregulation of wt p53 expression, as shown by Western blot analysis. When transduced with Ad5p53 alone at 1 MOI, the cell lines grew rapidly. Moreover, adenoviral-vector-mediated p53 gene transfer followed by 2-MeOE2 treatment caused 80% growth inhibition in the cell lines regardless of their p53 status, Thus, p53 superinduction and apoptosis after 2-MeOE2 treatment in Ad5p53-transduced cells appears to be a unique strategy with significant implications for cancer gene therapy.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Surg, Sect Thorac Mol Oncol, Box 109,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P50CA070907, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA70907, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attalla H, 1996, BIOCHEM BIOPH RES CO, V228, P467, DOI 10.1006/bbrc.1996.1683; CAI DW, 1993, HUM GENE THER, V4, P617, DOI 10.1089/hum.1993.4.5-617; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; FOTIS T, 1994, NATURE, V368, P237; FUJIWARA T, 1994, CANCER RES, V54, P2287; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maxwell SA, 1996, ELECTROPHORESIS, V17, P1772, DOI 10.1002/elps.1150171115; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Seegers JC, 1997, J STEROID BIOCHEM, V62, P253, DOI 10.1016/S0960-0760(97)00043-5; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TISHLER RB, 1995, CANCER RES, V55, P6021; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	20	59	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					241	246		10.1038/sj.onc.1201909	http://dx.doi.org/10.1038/sj.onc.1201909			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674709				2022-12-28	WOS:000074706700013
J	Percesepe, A; Kristo, P; Aaltonen, LA; de Leon, MP; de la Chapelle, A; Peltomaki, P				Percesepe, A; Kristo, P; Aaltonen, LA; de Leon, MP; de la Chapelle, A; Peltomaki, P			Mismatch repair genes and mononucleotide tracts as mutation targets in colorectal tumors with different degrees of microsatellite instability	ONCOGENE			English	Article						mismatch repair; microsatellite instability; colorectal cancer; mutation analysis; HNPCC	II RECEPTOR GENE; SACCHAROMYCES-CEREVISIAE; SOMATIC MUTATIONS; COLON-CANCER; DNA; CARCINOGENESIS; CELLS; MSH3; CARCINOMAS; POLYMERASE	Microsatellite instability occurs in 15% of colorectal carcinomas and may be due to replication errors (RER). The pattern of instability - 'severe' vs 'mild' - and the tumorigenic pathway, as reflected by the involvement of functionally important genes, may vary according to the underlying gene(s), We defined 'mild' RER as mono- or tetranucleotide repeat instability in the absence of widespread instability at dinucleotide repeats and studied 15 colorectal tumors with this phenotype for mutations in the DNA mismatch repair genes MSH2, MLH1, MSH3, and MSH6. No mutations were found, suggesting that these genes were not implicated. We then compared colorectal cancers with 'mild' RER (n = 15), and those with 'severe' RER without (n = 11) or with (n = 22) detectable mutations in MSH2 or MLH1 to assess the involvement of mononucleotide repeats contained in the coding regions of MSH3, MSH6, BAX, and TGF beta RII, The combined mutation rates of the above mentioned loci varied significantly between the three groups of tumors, being 0%, 25% and 52%, respectively. Furthermore, the individual genes showed specific patterns of involvement; for example, among tumors with 'severe' RER, TGF beta RII displayed uniformly high mutation rates while MSH3, MSH6, and BAX were more frequently altered in tumors that also showed MSH2 or MLH1 mutations. Our findings suggest that different subcategories exist among unstable tumors, defined by the RER pattern on the one hand and tumorigenic pathway on the other, and structural changes of MSH2 and MLH1 are likely to explain only a proportion of these cases.	Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Modena, Dept Internal Med, I-41100 Modena, Italy; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA	University of Helsinki; Universita di Modena e Reggio Emilia; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Percesepe, A (corresponding author), Univ Helsinki, Haartman Inst, Dept Med Genet, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.		Aaltonen, Lauri/A-5375-2010; Percesepe, Antonio/A-6076-2012; de Leon, Maurizio Ponz/A-9356-2015	Aaltonen, Lauri/0000-0001-6839-4286; Percesepe, Antonio/0000-0002-3268-6786; de Leon, Maurizio Ponz/0000-0003-4465-1043; Peltomaki, Paivi/0000-0001-8819-2980	NATIONAL CANCER INSTITUTE [U01CA067941, R01CA067941] Funding Source: NIH RePORTER; NCI NIH HHS [CA67941] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Akiyama Y, 1997, CANCER RES, V57, P3920; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; Canzian F, 1996, CANCER RES, V56, P3331; Chadwick RB, 1996, BIOTECHNIQUES, V20, P676; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; Dunlop MG, 1997, HUM MOL GENET, V6, P105, DOI 10.1093/hmg/6.1.105; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jager AC, 1997, AM J HUM GENET, V61, P129, DOI 10.1086/513896; Kane MF, 1997, CANCER RES, V57, P808; KIM HG, 1994, AM J PATHOL, V145, P148; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOEB LA, 1991, CANCER RES, V51, P3075; LOTHE RA, 1993, CANCER RES, V53, P5849; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; Nicolaides NC, 1996, GENOMICS, V31, P395, DOI 10.1006/geno.1996.0067; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1995, CANCER RES, V55, P5548; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; STRAND M, 1995, P NATL ACAD SCI USA, V92, P10418, DOI 10.1073/pnas.92.22.10418; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WIJNEN J, 1994, HUM MOL GENET, V3, P2268, DOI 10.1093/hmg/3.12.2268-a; Wu Y, 1997, GENE CHROMOSOME CANC, V18, P269, DOI 10.1002/(SICI)1098-2264(199704)18:4<269::AID-GCC4>3.0.CO;2-Z	41	60	64	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					157	163		10.1038/sj.onc.1201944	http://dx.doi.org/10.1038/sj.onc.1201944			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674699				2022-12-28	WOS:000074706700003
J	Yue, JB; Buard, A; Mulder, KM				Yue, JB; Buard, A; Mulder, KM			Blockade of TGF beta(3) up-regulation of p27(Kip1) and p21(Cip1) by expression of RasN17 in epithelial cells	ONCOGENE			English	Article						TGF beta; p21(Cip1); P27(Kip1); Ras, cell cycle; intestinal epithelial cells	GROWTH-FACTOR-BETA; CYCLIN-DEPENDENT KINASES; TGF-BETA; CDK; INHIBITOR; ARREST; ACTIVATION; PROTEIN; P21; SENSITIVITY	Our previous data demonstrated that Ras activation is necessary and sufficient for transforming growth factor beta (TGF beta)-mediated Erk1 activation, and is partially required for the inhibition of cyclin-dependent kinase 2 (Cdk2) activity, cyclin A expression and DNA synthesis by TGF beta (KM Mulder and SL Morris, J. Biol. Chem., 267: 5029-5031, 1992; MT Hartsough and KM Mulder, J. Biol. Chem., 270: 7117-7124, 1995; and MT Hartsough et nl., J. Biol. Chem., 271: 22368-22375, 1996). Here, we examined the kinetics and role of Ras in TGF beta(3)-mediated effects on specific G(1) cell cycle components in TGF beta-sensitive (4-1) and TGF beta-resistant (4-6) intestinal epithelial cells (IEC's). Our results indicate that inactivation of Ras by stable, inducible expression of a dominant-negative mutant of Ras (RasN17) completely abrogated the ability of TGF beta(3) to up-regulate both CKI's. In contrast, the ability of TGF beta(3) to up-regulate p27(Kip1) and p21(Cip1) was maintained in ZnCl2-treated control cells. Inactivation of Ras also completely blocked the rapid TGF beta-mediated increase in new synthesis of p27(Kip1) protein. Moreover, up-regulation of p21(Cip1) protein levels and new synthesis of p27(Kip1), as well as the association of these CKI's with Cdk2, preceded the decrease in Cdk2 activity by TGF beta. Collectively, our results suggest that p21(Cip1) and p27(Kip1) are upstream effecters of the TGF beta-mediated inhibition of Cdk2 activity in IEC 4-1 cells, and demonstrate that Ras activation is obligatory for TGF beta-mediated upregulation of these CKIs in untransformed epithelial cells.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Mulder, KM (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA.		Yue, Jianbo/AAC-4588-2019; Yue, Jianbo/C-4463-2009; Yue, Jianbo/K-8002-2015	Yue, Jianbo/0000-0001-6384-5447	NCI NIH HHS [K04 CA59552, CA54816, CA51452] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051452, R01CA051452, K04CA059552, R01CA054816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; DERYNCK R, 1994, TIBS, V19, P539; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; Florenes VA, 1996, ONCOGENE, V13, P2447; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; Frey RS, 1997, CANCER RES, V57, P628; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HARPER JW, 1993, CELL, V75, P805; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Iavarone A, 1997, NATURE, V387, P417; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; MULDER KM, 1992, J BIOL CHEM, V267, P5029; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1	36	35	36	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					47	55		10.1038/sj.onc.1201903	http://dx.doi.org/10.1038/sj.onc.1201903			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671313				2022-12-28	WOS:000074677800006
J	Krosl, J; Baban, S; Krosl, G; Rozenfeld, S; Largman, C; Sauvageau, G				Krosl, J; Baban, S; Krosl, G; Rozenfeld, S; Largman, C; Sauvageau, G			Cellular proliferation and transformation induced by HOXB4 and HOXB3 proteins involves cooperation with PBX1	ONCOGENE			English	Article						oncogenes; proliferation; Hox; Pbx; cancer	HOMEODOMAIN-DNA INTERACTIONS; ACUTE MYELOID-LEUKEMIA; HOMEOBOX GENES; CRYSTAL-STRUCTURE; GROWTH-FACTOR; PRE-B; TRANSLOCATION; EXPRESSION; E2A-PBX1; BINDING	The products of PBX homeobox genes, which mere initially discovered in reciprocal translocations occurring in human leukemias, have been shown to cooperate in the in vitro DNA binding with HOX proteins. Despite the growing body of data implicating Hox genes in the development of various cancers, little is known about the role of HOX-PBX interactions in the regulation of proliferation and induction of transformation of mammalian cells. We build on the existing model of Hox-induced transformation of Rat-1 cells to show that both cellular transformation and proliferation induced by Hoxb4 and Hoxb3 are greatly modulated by the levels of available PBX1 present in these cells. Furthermore, we show that the transforming capacity of these two HOX proteins depends on their conserved tetrapeptide and homeodomain regions which mediate binding to PBX and DNA, respectively. Taken together, results of this study demonstrate that cooperation between HOX and PBX proteins modulates cellular proliferation and strongly suggest that cooperative DIVA binding by these two groups of proteins represent the basis for Hox-induced cellular transformation.	Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3J 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1A4, Canada; Univ Calif San Francisco, Dept Med, Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Sauvageau, G (corresponding author), Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.			Sauvageau, Guy/0000-0002-4333-7266				BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Care A, 1996, MOL CELL BIOL, V16, P4842; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; JIANG W, 1993, ONCOGENE, V8, P3447; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; Maconochie MK, 1997, GENE DEV, V11, P1885, DOI 10.1101/gad.11.14.1885; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NEUTEBOOM ST, 1995, P NATL ACAD SCI USA, V92, P9196; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; ROCCO GD, 1997, EMBO J, V16, P3644; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; SUN B, 1995, EMBO J, V14, P520, DOI 10.1002/j.1460-2075.1995.tb07028.x; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Zhao JJG, 1996, EMBO J, V15, P1313, DOI 10.1002/j.1460-2075.1996.tb00473.x	40	71	78	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3403	3412		10.1038/sj.onc.1201883	http://dx.doi.org/10.1038/sj.onc.1201883			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692548				2022-12-28	WOS:000074544100007
J	Kohno, T; Shinmura, K; Tosaka, M; Tani, M; Kim, SR; Sugimura, H; Nohmi, T; Kasai, H; Yokota, J				Kohno, T; Shinmura, K; Tosaka, M; Tani, M; Kim, SR; Sugimura, H; Nohmi, T; Kasai, H; Yokota, J			Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA	ONCOGENE			English	Article						8-hydroxyguanine; DNA repair; genetic polymorphism; alternative splicing; hOGG1 gene	CELL LUNG-CARCINOMA; TUMOR-SUPPRESSOR GENE; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; GLYCOSYLASE; CANCER; PROTEIN; 7,8-DIHYDRO-8-OXOGUANINE; 8-OXOGUANINE; MUTATIONS	The hOGG1 gene encodes a DNA glycosylase that excises 8-hydroxyguanine (oh(8)Gua) from damaged DNA, Structural analyses of the hOGG1 gene and its transcripts were performed in normal and lung cancer cells. Due to a genetic polymorphism at codon 326, hOGG1-Ser(326) and hOGG1-Cys(326) proteins were produced in human cells. Activity in the repair of oh8Gua was greater in hOGG1-Ser(326) protein than in hOGG1-Cys(326) protein in the complementation assay of an E, coli mutant defective in the repair of oh8Gua. Two isoforms of hOGG1 transcripts produced by alternative splicing encoded distinct hOGG1 proteins: one with and the other without a putative nuclear localization signal. Loss of heterozygosity at the hOGG1 locus was frequently (15/ 23, 62.2%) detected in lung cancer cells, and a cell Line NCI-H526 had a mutation leading to the formation of the transcripts encoding a truncated hOGG1 protein. However, the oh(8)Gua levels in nuclear DNA were similar among lung cancer cells and leukocytes irrespective of the type of hOGG1 proteins expressed. These results suggest that the oh(8)Gua levels are maintained at a steady level, even though multiple hOGG1 proteins are produced due to genetic polymorphisms, mutations and alternative splicing of the hOGG1 gene.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 104, Japan; Natl Inst Hlth Sci, Div Genet & Mutagenesis, Setagaya Ku, Tokyo 158, Japan; Hamamatsu Univ Sch Med, Dept Pathol 1, Hamamatsu, Shizuoka 43131, Japan; Univ Occupat & Environm Hlth, Dept Environm Oncol, Yahatanishi Ku, Kitakyushu, Fukuoka 807, Japan	National Cancer Center - Japan; National Institute of Health Sciences - Japan; Hamamatsu University School of Medicine; University of Occupational & Environmental Health - Japan	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 104, Japan.		Shinmura, Kazuya/K-8940-2012	Shinmura, Kazuya/0000-0003-4963-746X				Aburatani H, 1997, CANCER RES, V57, P2151; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Asami S, 1996, CANCER RES, V56, P2546; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BABA S, 1995, HUM MOL GENET, V4, P1083, DOI 10.1093/hmg/4.6.1083; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Garuti R, 1996, J LIPID RES, V37, P1459; GAZDAR AF, 1994, ANTICANCER RES, V14, P261; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HIBI K, 1992, ONCOGENE, V7, P445; HOSOE S, 1994, LUNG CANCER-J IASLC, V10, P297, DOI 10.1016/0169-5002(94)90659-9; HUANG CH, 1993, J BIOL CHEM, V268, P25902; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KASAI H, 1991, OXIDATIVE STRESS OXI, P99; KOHNO T, 1995, HUM MOL GENET, V4, P667, DOI 10.1093/hmg/4.4.667; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MALINS DC, 1991, CANCER RES, V51, P5430; Maniatis T., 1982, MOL CLONING LAB MANU; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; Nakajima M, 1996, CARCINOGENESIS, V17, P787, DOI 10.1093/carcin/17.4.787; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2; Perera FP, 1996, JNCI-J NATL CANCER I, V88, P496, DOI 10.1093/jnci/88.8.496; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Shinmura K, 1997, MUTAT RES-DNA REPAIR, V385, P75, DOI 10.1016/S0921-8777(97)00041-4; SHISEKI M, 1994, CANCER RES, V54, P5643; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SUZUKI M, 1995, IN PRESS MUT RES; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	41	388	409	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3219	3225		10.1038/sj.onc.1201872	http://dx.doi.org/10.1038/sj.onc.1201872			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681819				2022-12-28	WOS:000074343600001
J	Gallia, GL; Khalili, K				Gallia, GL; Khalili, K			Evaluation of an autoregulatory tetracycline regulated system	ONCOGENE			English	Article						tetracycline; inducible promoter; gene expression regulation; transactivator	INDUCIBLE GENE-EXPRESSION; S-PHASE ENTRY; TRANSGENIC MICE; DEREGULATED EXPRESSION; CYCLIN-E; APOPTOSIS; ACCELERATION; SUPPRESSION; PROMOTER; CELLS	Tetracycline controlled gene expression systems have become powerful tools in the analysis of gene function in mammalian cell culture as well as transgenic animals and plants. The original description of a tetracycline-regulated gene expression system is based on two plasmids, one of which constitutively expresses a tetracycline-controlled transactivator protein (tTA), a fusion protein between the tetracycline repressor of E. coli and the transcriptional activation domain of the VP16 protein of herpes simplex virus. The second plasmid contains the gene to be regulated by tTA under the control of an inducible promoter which consists of seven copies of the tetracycline resistance operator (tetO). Since this original description, many modifications have been described. In this report, we evaluate an autoregulatory tetracycline controlled system, in which the tTA is itself under the control of the tetO. We demonstrate that this autoregulatory tetracycline system produces adverse effects including cellular morphologic changes, growth rate attenuation and alterations in cell cycle distribution.	Allegheny Univ Hlth Sci, Dept Neurol, Ctr NeuroVirol & NeuroOncol, Philadelphia, PA 19102 USA; Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA	Drexel University; Jefferson University	Khalili, K (corresponding author), Allegheny Univ Hlth Sci, Dept Neurol, Ctr NeuroVirol & NeuroOncol, Broad & Vine,MS 406, Philadelphia, PA 19102 USA.							BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; CHEN YQ, 1995, CANCER RES, V55, P4536; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FISHMAN GI, 1994, J CLIN INVEST, V93, P1864, DOI 10.1172/JCI117174; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gil P, 1996, EMBO J, V15, P1678, DOI 10.1002/j.1460-2075.1996.tb00513.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; Iida A, 1996, J VIROL, V70, P6054, DOI 10.1128/JVI.70.9.6054-6059.1996; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Masgrau C, 1997, PLANT J, V11, P465, DOI 10.1046/j.1365-313X.1997.11030465.x; Qin XQ, 1997, ONCOGENE, V14, P53, DOI 10.1038/sj.onc.1200809; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; WEINMANN P, 1994, PLANT J, V5, P559, DOI 10.1046/j.1365-313X.1994.5040559.x; WIMMEL A, 1994, ONCOGENE, V9, P995	26	37	40	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1879	1884		10.1038/sj.onc.1201706	http://dx.doi.org/10.1038/sj.onc.1201706			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583685				2022-12-28	WOS:000072994600011
J	Erber, R; Conradt, C; Homann, N; Enders, C; Finckh, M; Dietz, A; Weidauer, H; Bosch, FX				Erber, R; Conradt, C; Homann, N; Enders, C; Finckh, M; Dietz, A; Weidauer, H; Bosch, FX			TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer	ONCOGENE			English	Article						TP53; mutation types; clinical course; head and neck cancer	HUMAN P53 MUTANTS; COLORECTAL-CANCER; GENE; PROTEIN; EXPRESSION; TUMORS; GAIN; TRANSACTIVATION; PROGRESSION; SURVIVAL	Recent studies have suggested that different mutation types within the core domain of the tumour suppressor protein p53, i.e. DNA contact mutations and structural mutations, confer different biological properties, We have analysed in 86 head and neck squamous cell carcinomas (HNSCC), whether these p53 mutation types have a differential clinical impact, Thirty-seven missense mutations were identified, Thirteen of these (36%) were DNA contact mutations, occurring in the L3 loop, in the H2 loop sheet helix motif, in the S10 beta strand and in Zinc binding residues, Microsatellite marker analysis revealed a selective association between these mutations and the loss of wild-type alleles (100% LOH vs 50% LOH in tumours with structural mutations; P=0.0034, Fisher's exact, 2-tailed), In comparison to structural mutations or to the absence of mutations in the core domain, DNA contact mutations were associated with higher tumour stages (84.6% vs 62%), a higher incidence of lymph node metastasis (91.7% vs 56%; P=0.014, Fisher's exact, 2-tailed), a shortened recurrence-free survival (8.1 months vs 23.7 months, P=0.047, log rank test) and overall survival (11 months vs 29.2 months; P=0.003, log rank test), The latter was also the case when only stage IV tumours were analysed (P=0.0055, log rank test), These data indicate that in HNSCC, TP53 DNA contact mutations confer a strong selection pressure to eliminate mild-type alleles, and that they result in an accelerated tumour progression and reduced therapeutic responsiveness.	Heidelberg Univ, Hals Nasen Ohren Klin, Mol Biol Lab, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Med Biometrie, D-69120 Heidelberg, Germany; Klinikum Buch, Hals Nasen Ohren Klin, D-13122 Berlin, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Bosch, FX (corresponding author), Heidelberg Univ, Hals Nasen Ohren Klin, Mol Biol Lab, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.		Erber, Ralf/B-6790-2008; Erber, Ralf/AAF-3002-2020					Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BOYLE JO, 1993, CANCER RES, V53, P4477; BRACHMAN DG, 1992, CANCER RES, V52, P4832; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FORRESTER K, 1995, ONCOGENE, V10, P2103; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GOH HS, 1995, CANCER RES, V55, P5217; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HSIAO M, 1994, AM J PATHOL, V145, P702; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1995, ONCOGENE, V10, P2387; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NEES M, 1993, CANCER RES, V53, P4189; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; ROLLEY N, 1995, ONCOGENE, V11, P763; SODER AI, 1995, CANCER RES, V55, P5030; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041	27	125	126	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	1998	16	13					1671	1679		10.1038/sj.onc.1201690	http://dx.doi.org/10.1038/sj.onc.1201690			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582015				2022-12-28	WOS:000072807600005
J	Yuan, ZM; Utsugisawa, T; Ishiko, T; Nakada, S; Huang, YY; Kharbanda, S; Weichselbaum, R; Kufe, D				Yuan, ZM; Utsugisawa, T; Ishiko, T; Nakada, S; Huang, YY; Kharbanda, S; Weichselbaum, R; Kufe, D			Activation of protein kinase C delta by the c-Abl tyrosine kinase in response to ionizing radiation	ONCOGENE			English	Article						protein kinase C delta; c-Abl tyrosine kinase; ionizing radiation; genotoxic stress	STRESS-RESPONSE; SH3 DOMAINS; PHOSPHORYLATION; GROWTH; DNA; CELL; PATHWAY; ARREST; GENE; P53	The c-Abl protein tyrosine kinase is activated by ionizing radiation (IR) and certain other DNA-damaging agents. The present studies demonstrate that c-Abl associates constitutively with protein kinase C delta (PkC delta). The results show that the SH3 domain of c-Abl interacts directly with PKC delta. c-Abl phosphorylates and activates PKC delta in vitro. We also show that IR treatment of cells is associated with c-Abl-dependent phosphorylation of PKC delta and translocation of PKC delta to the nucleus. These findings support a functional interaction between c-Abl and PKC delta in the cellular response to genotoxic stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Pharmacol, Boston, MA 02115 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago	Yuan, ZM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Pharmacol, 44 Binney St, Boston, MA 02115 USA.		Utsugisawa, Taiju/ABD-7059-2021					Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOGA A, 1995, ONCOGENE, V11, P791; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1996, CANCER RES, V56, P3617; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MATTIONI T, 1995, ONCOGENE, V10, P1325; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MOORE KL, 1994, DEV BIOL, V164, P444, DOI 10.1006/dbio.1994.1214; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	46	129	131	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1643	1648		10.1038/sj.onc.1201698	http://dx.doi.org/10.1038/sj.onc.1201698			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582011				2022-12-28	WOS:000072807600001
J	Liedtke, M; Pandey, P; Kumar, S; Kharbanda, S; Kufe, D				Liedtke, M; Pandey, P; Kumar, S; Kharbanda, S; Kufe, D			Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase	ONCOGENE			English	Article						Bcr-Abl; SHPTP1; SAP kinase transformation	C-ABL; DNA-DAMAGE; IONIZING-RADIATION; STRESS-RESPONSE; ADAPTER PROTEIN; ONCOGENE; GROWTH; FIBROBLASTS; ACTIVATION; PATHWAY	The oncogenic Bcr-Abl variant of the c-Abl tyrosine kinase transforms cells by a mechanism dependent on activation of the stress-activated protein kinase (SAPK). Other work has shown that c-Abl interacts with the SHPTP1 protein tyrosine phosphatase in induction of SAPK activity by genotoxic stress. The present studies demonstrate that Bcr-Abl binds constitutively to SHPTP1. We show that Bcr-Abl phosphorylates SHPTP1 on C-terminal Y536 and Y564 sites. The functional significance of the Bcr-Abl/SHPTP1 interaction is supported by the finding that SHPTP1 regulates Bcr-Abl-induced SAPK activity. Importantly, SHPTP1 also decreases Bcr-Abl-dependent transformation of fibroblasts. These findings indicate that SHPTP1 functions as a tumor suppressor in cells transformed by Bcr-Abl.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Liedtke, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER; NCI NIH HHS [CA66996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; GOGA A, 1995, ONCOGENE, V11, P791; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Raitano AB, 1997, BBA-REV CANCER, V1333, pF201, DOI 10.1016/S0304-419X(97)00023-1; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; YAN MH, 1994, NATURE, V372, P798; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	26	24	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1889	1892		10.1038/sj.onc.1202117	http://dx.doi.org/10.1038/sj.onc.1202117			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788431	Bronze			2022-12-28	WOS:000076423500001
J	Kumar, CC				Kumar, CC			Signaling by integrin receptors	ONCOGENE			English	Review						integrins; cell adhesion; cell survival; focal adhesion complexes	FOCAL ADHESION KINASE; CELL-CYCLE PROGRESSION; ACTIN STRESS FIBERS; PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; ACTIVATED PROTEIN-KINASE; SRC FAMILY KINASES; SMALL GTPASE-RHO; EXTRACELLULAR-MATRIX; MEDIATED ACTIVATION; AKT PROTOONCOGENE	Adhesive interactions are critical for the proliferation, survival and function of all cells. Integrin receptors as the major family of adhesion receptors have been the focus of study for more than a decade. These studies have tremendously enhanced our understanding of the integrin-mediated adhesive interactions and have unraveled novel integrin functions in cell survival mechanisms and in the activation of divergent signaling pathways. The signals from integrin receptors are integrated from those originating from growth factor receptors in order to organize the cytoskeleton, stimulate cell proliferation and rescue cells from matrix detachment-induced programmed cell death. These functions are critical in the regulation of multiple processes such as tissue development, inflammation, angiogenesis, tumor cell growth and metastasis and programmed cell death.	Schering Plough Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA	Merck & Company; Schering-Plough Research Institute	Kumar, CC (corresponding author), Schering Plough Res Inst, Dept Tumor Biol, 2015,Galloping Hill Rd, Kenilworth, NJ 07033 USA.							Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHIRZANOWSKAWON.M, 1996, J CELL BIOL, V133, P1403; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FLORES ME, 1992, EXP CELL RES, V201, P526, DOI 10.1016/0014-4827(92)90305-R; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIANCOTTI F, 1977, CURR OPIN CELL BIOL, V9, P691; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1994, BIOESSAYS, V16, P663, DOI 10.1002/bies.950160912; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KENNEDY S, 1997, GENE DEV, V11, P703; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIERSCHBACHER MD, 1994, J CELL BIOCHEM, V56, P150, DOI 10.1002/jcb.240560205; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TOKSOZ D, 1994, ONCOGENE, V9, P621; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	92	229	244	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1365	1373		10.1038/sj.onc.1202172	http://dx.doi.org/10.1038/sj.onc.1202172			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779984				2022-12-28	WOS:000076161900005
J	Schwartzberg, PL				Schwartzberg, PL			The many faces of Src: multiple functions of a prototypical tyrosine kinase	ONCOGENE			English	Review						Src; tyrosine kinase; PDGF-R; integrin	FOCAL ADHESION KINASE; EPIDERMAL GROWTH-FACTOR; C-SRC; SH3 DOMAIN; CELL-TRANSFORMATION; BINDING-SITE; PROTEIN; FAMILY; ACTIVATION; PHOSPHORYLATION	c-src was first isolated as the normal cellular homologue of v-src, the transforming gene of Rous Sarcoma virus (Stehelin et al., 1976). As the first proto-oncogene described and one of the first molecules demonstrated to have tyrosine kinase activity, Src has provided a prototype for understanding signal transduction involving tyrosine phosphorylation. Comparison between c-src and activated or transforming mutants of Src including v-src, combined with recent data on the structure of Src family kinases has provided new insight into their regulation. In this review, I will discuss the function of the various domains of Src in light of these mutational and structural studies.	Natl Human Genome Res Inst, Lab Genet Dis Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Schwartzberg, PL (corresponding author), Natl Human Genome Res Inst, Lab Genet Dis Res, NIH, Bethesda, MD 20892 USA.							Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BOCKHOLT SM, 1995, CELL ADHES COMMUN, V3, P91, DOI 10.3109/15419069509081279; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLY CM, 1994, J NEUROCHEM, V62, P923; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOLDBERG AR, 1980, COLD SPRING HARB SYM, V44, P991, DOI 10.1101/SQB.1980.044.01.107; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Lowell CA, 1996, BLOOD, V87, P1780; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEFF L, 1996, J BONE MINER RES, V11, pS290; OKAMURA H, 1994, ONCOGENE, V9, P2293; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; SHALLOWAY D, 1992, CIBA F SYMP, V170, P248; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Swierczynski SL, 1996, DEV BIOL, V179, P135, DOI 10.1006/dbio.1996.0246; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	65	123	128	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1463	1468		10.1038/sj.onc.1202176	http://dx.doi.org/10.1038/sj.onc.1202176			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779992	Bronze			2022-12-28	WOS:000076161900013
J	Kelley, LL; Hicks, GG; Hsieh, FF; Prasher, JM; Green, WF; Miller, MD; Eide, EJ; Ruley, HE				Kelley, LL; Hicks, GG; Hsieh, FF; Prasher, JM; Green, WF; Miller, MD; Eide, EJ; Ruley, HE			Endogenous p53 regulation and function in early stage Friend virus-induced tumor progression differs from that following DNA damage	ONCOGENE			English	Article						p53; p21; activation; differentiation; erythroleukemia	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; CELL-CYCLE ARREST; ERYTHROPOIETIN RECEPTOR; ERYTHROLEUKEMIA-CELLS; TRANSCRIPTION FACTOR; TRANSGENIC MICE; GROWTH ARREST; GLOBIN GENE; E7 GENE	Erythroleukemia induced by the anemia strain of Friend virus occurs in two stages, The first stage results in rapid expansion of pre-leukemic proerythroblasts (FVA cells) dependent on erythropoietin (Epo) for differentiation and survival in vitro. The second stage is characterized by emergence of erythroleukemic clones (MEL cells) which typically bear activation of the ets-oncogene, PU.1/spi.1, and loss of functional p53. We developed a Friend virus-sensitive, p53-deficient mouse model to investigate the biological advantage conferred by p53-loss during tumor progression. Here we report p53 was not required for cell survival or growth arrest during differentiation of FVA cells, nor was p53 required for induction of apoptosis upon Epo withdrawal. However, we detected induction of the p21(Cip1) cyclin-dependent kinase inhibitor gene during differentiation, which was markedly enhanced in the presence of p53. p53-dependent expression of p21(Cip1) occurred in the absence of an increase in p53 mRNA and protein levels and was specific for p21(Cip1) since expression of gadd45, mdm-2, cyclin G and bax were unaffected by p53. In contrast, treatment of FVA cells with DNA damaging agents led to rapid accumulation of p53 protein resulting in transcription of multiple p53-regulated genes, leading to either apoptosis or growth arrest, depending on the agent used. These data demonstrate that p53-dependent activities during differentiation of preleukemic erythroblasts are distinct from those observed in response to genotoxic agents. We propose that enhancement of p53-dependent gene expression during differentiation may represent a tumor suppressor function which is necessary to monitor differentiation of preleukemic cells and which is selected against during tumor progression.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Oncol Sci, Salt Lake City, UT 84132 USA; Vanderbilt Univ, Dept Microbiol & Immunol, Nashville, TN 37212 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Vanderbilt University	Kelley, LL (corresponding author), Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA.			Hicks, Geoffrey/0000-0003-4688-2312	NCI NIH HHS [R01CA69169, 5P30CA42014] Funding Source: Medline; NIDDK NIH HHS [P50DK49219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069169, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONDURANT MC, 1985, MOL CELL BIOL, V5, P675, DOI 10.1128/MCB.5.4.675; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLEY LL, 1992, J CELL PHYSIOL, V151, P487, DOI 10.1002/jcp.1041510307; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KELLEY LL, 1993, BLOOD, V82, P2340; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOURY MJ, 1984, J CELL PHYSIOL, V121, P526, DOI 10.1002/jcp.1041210311; KOURY ST, 1988, EXP HEMATOL, V16, P758; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI JP, 1995, J VIROL, V69, P1714, DOI 10.1128/JVI.69.3.1714-1719.1995; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Ruley H. Earl, 1996, P37; SAWYER ST, 1987, METHOD ENZYMOL, V147, P340; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WEINBERG WC, 1995, ONCOGENE, V10, P2271; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	53	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1119	1130		10.1038/sj.onc.1202037	http://dx.doi.org/10.1038/sj.onc.1202037			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764822				2022-12-28	WOS:000075598400007
J	McHenry, JZ; Leon, A; Matthaei, KI; Cohen, DR				McHenry, JZ; Leon, A; Matthaei, KI; Cohen, DR			Overexpression of fra-2 in transgenic mice perturbs normal eye development	ONCOGENE			English	Article						AP-1; fra-2; anterior segment dysgenesis; transgenic	HELIX-ZIPPER PROTEIN; C-FOS; GENE; JUN; TRANSCRIPTION; EXPRESSION; CELLS; PHOSPHORYLATION; TRANSFORMATION; AP-1	The major components of transcription factor AP-1 (Activator Protein 1) are encoded by the two families of genes related to the proto-oncogenes c-fos and c-jun. The fos-related antigen-2 (fra-2) gene is the most recently described member of the Fos family. To determine the oncogenic potential of fra-2, transgenic mice were generated which over-express fra-2 in a number of tissues. No tumours were evident in any transgenic mice up to 18 months of age, although eye development was severely disrupted in these animals. Corneal abnormalities could be observed histologically as early as embryonic day 15.5 and eyelid fusion failed to occur. Adult eyes were characterized by generalized anterior segment dysgenesis similar to that previously reported in transgenic mice over-expressing transforming growth factor alpha (TGF alpha), and occasionally microphthalmia. Expression of fra-2 was shown to increase following TGF alpha. treatment of cells in vitro, suggesting that AP-1 complexes containing Fra-2 contribute to TGF alpha signalling events.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Cell Biol, Canberra, ACT 0200, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Neurosci, Canberra, ACT 0200, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; John Curtin School of Medical Research; Australian National University; John Curtin School of Medical Research	Cohen, DR (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Cell Biol, Canberra, ACT 0200, Australia.		Klaus, Matthaei/D-8691-2011	Cohen, Donna/0000-0002-0419-9542				BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CARRASCO D, 1995, ONCOGENE, V10, P1069; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; FOLETTA VC, 1994, ONCOGENE, V9, P3305; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; GOTZ W, 1995, OPHTHALMIC GENET, V16, P85, DOI 10.3109/13816819509059967; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OEHLER T, 1993, ONCOGENE, V8, P1141; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; RENEKER LXW, 1995, DEVELOPMENT, V121, P1669; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	27	22	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1131	1140		10.1038/sj.onc.1202044	http://dx.doi.org/10.1038/sj.onc.1202044			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764823				2022-12-28	WOS:000075598400008
J	Schwahn, DJ; Medina, D				Schwahn, DJ; Medina, D			p96, a MAPK-related protein, is consistently downregulated during mouse mammary carcinogenesis	ONCOGENE			English	Article						mammary carcinogenesis; p96; mammary epithelium; hyperplasia	PHOSPHOTYROSINE INTERACTION DOMAIN; COLONY-STIMULATING FACTOR-1; GROWTH-FACTOR RECEPTOR; DIFFERENTIAL DISPLAY; GENE-EXPRESSION; MESSENGER-RNA; PRODUCT; BINDING; CSF-1; PROTOONCOGENE	Differential display PCR [DD-PCR] was applied to identify mRNAs differentially expressed between two consecutive stages of an in vivo model of mouse mammary carcinogenesis. The extended life 12 [EL12] and transformed mammary 12 [TM12] outgrowths differ in morphology, ovarian hormone dependence, and tumorigenicity, yet the TM12 outgrowth arose spontaneously from the EL12 outgrowth. A fragment of the mouse p96 gene was identified using DD-PCR. The differential expression of p96 was confirmed using RNase protection assays. Examination of the RNA expression patterns of the p96 isoforms during normal mammary gland development showed high levels in the involuting mammary gland and in preneoplastic hyperplasias. In contrast, p96 isoform mRNA levels were consistently decreased in mammary tumors derived from the in vivo hyperplasias. Examination of p96 protein levels revealed a decrease in p96 protein in a number of mammary tumors as compared to their hyperplastic precursors further supporting the observations that p96 gene expression is consistently downregulated in mammary tumors. The functional activity of p96 protein has not been resolved, however the observation that p96 gene expression is downregulated in two different tumor systems (human ovarian tumors and mouse mammary tumors) warrants more extensive investigation on its role in normal and neoplastic cell growth.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Medina, D (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA63137] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063137] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BORYCKI AG, 1995, ONCOGENE, V10, P1799; CALLARD D, 1994, BIOTECHNIQUES, V16, P1096; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P15; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; Jackowski S, 1997, MOL REPROD DEV, V46, P24; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MEDINA D, 1993, CANCER RES, V53, P668; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; MEDINA D, 1993, CANCER RES, V53, P663; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Nowicki A, 1996, INT J CANCER, V65, P112, DOI 10.1002/(SICI)1097-0215(19960103)65:1<112::AID-IJC19>3.3.CO;2-R; POLLARD JW, 1994, P NATL ACAD SCI USA, V91, P9312, DOI 10.1073/pnas.91.20.9312; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; ZHANG LX, 1993, MOL CARCINOGEN, V8, P123, DOI 10.1002/mc.2940080209	24	45	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1173	1178		10.1038/sj.onc.1202038	http://dx.doi.org/10.1038/sj.onc.1202038			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764828				2022-12-28	WOS:000075598400013
J	Grombacher, T; Eichhorn, U; Kaina, B				Grombacher, T; Eichhorn, U; Kaina, B			P53 is involved in regulation of the DNA repair gene O-6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents	ONCOGENE			English	Article						p53; alkyltransferase; MGMT; DNA repair; inducible response	WILD-TYPE P53; CELL NUCLEAR ANTIGEN; RAT HEPATOMA-CELLS; NUCLEOTIDE EXCISION-REPAIR; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; MAMMALIAN-CELLS; IONIZING-RADIATION; MESSENGER-RNA; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; TRANSGENIC MICE	The DNA repair protein O-6-methlguanine-DNA methyltransferase (MGMT) is inducible stress. MGMT induction results from activation of the MGMT gene which Is a specific response to DNA damage, A possible factor involved in triggering MGMT induction might be p53, because both p53 and MGMT are activated by DNA breaks, To study the effect of p53 on induction of the MGMT gene, we compared the presence of functional wild-type (wt) and mutant p53 with MGMT expression level in various mouse fibroblasts and rat hepatoma cell lines upon genotoxic treatment. Cells which responded to ionizing radiation (IR) by MGMT induction displayed functional p53, whereas in cells not expressing wt p53, MGMT induction was not observed. Also, the cloned MGMT promoter was inducible by IR upon transfection into p53 wt cells, but not in cells deficient for p53, Thus, expression of wt p53 appears to be required for induction of MGMT mRNA and protein by IR, On the other hand, transfection of a MGMT-promoter-CAT construct together with p53 (either wt or mutant) in cells expressing wt p53 markedly reduced the basal activity of the MGMT promoter whereas cotransfection with a p53 antisense construct slightly increased MGMT promoter activity. Furthermore, cotransfection of MGMT promoter with wt or mutant p53 in p53 wt cells reduced radiation evoked MGMT promoter induction. Thus, transfection mediated high level expression of p53 has inhibitory effect both on basal MGMT promoter activity and its activation by IR, The results give evidence for involvement of p53 in DNA damage-induced MGMT promoter activation.	Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Kaina, B (corresponding author), Univ Mainz, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.							Becker K, 1996, CANCER RES, V56, P3244; Becker K, 1997, CANCER RES, V57, P3335; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN CL, 1990, CARCINOGENESIS, V11, P1217, DOI 10.1093/carcin/11.7.1217; CHAN CL, 1992, CANCER RES, V52, P1804; DINCALCI M, 1988, CANC TREAT REV, V15, P5723; Dosch J, 1996, ONCOGENE, V13, P1927; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FRITZ G, 1992, BIOCHIM BIOPHYS ACTA, V1171, P35, DOI 10.1016/0167-4781(92)90137-O; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; FUKUHARA M, 1992, JPN J CANCER RES, V83, P72, DOI 10.1111/j.1349-7006.1992.tb02354.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Grombacher T, 1996, CARCINOGENESIS, V17, P2329, DOI 10.1093/carcin/17.11.2329; GROMBACHER T, 1995, BBA-MOL BASIS DIS, V1270, P63, DOI 10.1016/0925-4439(94)00073-Y; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; HARRIS LC, 1992, CANCER RES, V52, P6404; Harris LC, 1996, CANCER RES, V56, P2029; KAINA B, 1993, ENVIRON MOL MUTAGEN, V22, P283, DOI 10.1002/em.2850220418; Kaina B, 1997, CANCER RES, V57, P2721; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; LAVAL F, 1991, BIOCHEM BIOPH RES CO, V176, P1086, DOI 10.1016/0006-291X(91)90395-N; LAVAL F, 1990, MUTAT RES, V233, P211, DOI 10.1016/0027-5107(90)90164-Y; LEFEBVRE P, 1993, DNA CELL BIOL, V12, P233, DOI 10.1089/dna.1993.12.233; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Margan U, 1996, BERL MUNCH TIERARZTL, V109, P1; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PEGG AE, 1990, CANCER RES, V50, P6119; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Rafferty JA, 1996, ONCOGENE, V12, P693; SCHMEROLD I, 1986, CANCER RES, V46, P245; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; WILSON RE, 1993, CARCINOGENESIS, V14, P679, DOI 10.1093/carcin/14.4.679; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Yurochko AD, 1997, J VIROL, V71, P4638, DOI 10.1128/JVI.71.6.4638-4648.1997	48	117	121	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					845	851		10.1038/sj.onc.1202000	http://dx.doi.org/10.1038/sj.onc.1202000			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780001				2022-12-28	WOS:000075448800006
J	Espanel, X; Le Cam, L; North, S; Sardet, C; Brun, G; Gillet, G				Espanel, X; Le Cam, L; North, S; Sardet, C; Brun, G; Gillet, G			Regulation of E2F-1 gene expression in avian cells	ONCOGENE			English	Article						E2F; retina; differentiation; transcription; genomic footprinting	UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR; S-PHASE; DIFFERENTIATION; PROLIFERATION; DEGRADATION; APOPTOSIS; INDUCTION; ELEMENTS; PROMOTER	E2F-1 is the prototype of a family of transcription factors playing a central role in the control of cell proliferation and apoptosis, E2F DNA binding activity is down-regulated during cellular differentiation, which is correlated with cell division arrest. We report here that the expression of E2F-1 itself is down-regulated in the developing quail neural retina between embryonic days E8-E10, This event occurs just after the massive arrest of the quail neuroretina cell division (E7-E8), To gain further insight into the regulatory mechanisms monitoring E2F-1 expression in differentiating neurons, we have cloned the quail E2F-1 promoter. In vivo DNA footprintings of this promoter have shown that a number of potential SP-1 and C/EBP response elements are constitutively occupied in the entire quail neuroretina of E5 and E14, whereas the two consensus palindromic E2F binding sites are only protected at E5, This suggests that these E2F elements participate in down-regulation of E2F-1 gene expression during avian neuroretina development. CAT reporter assays have shown that E2F-1 in association with its partner DP-1 transactivates its own promoter, whereas p105(Rb) inhibits the E2F-1 promoter. Both E2F-1/DP-1 and pl05(Rb) require the presence of the E2F binding sites to mediate their effects. However, experiments performed with deletion mutants of the promoter strongly suggest that other regions located upstream of the E2F binding sites also mediate part of the E2F-1 transactivating effect on its own promoter. Altogether, these results suggest that the down-regulation of E2F-1 gene expression in differentiating neurons could be due, in part, to the E2F/Rb complexes binding to the E2F-1 promoter.	Inst Biol & Chim Prot, UPR 412 CNRS, F-69367 Lyon 07, France; Ecole Normale Super Lyon, UMR 49 CNRS, Lab Biol Mol & Cellulaire, F-69364 Lyon 07, France; CNRS, UMR 9942, Ctr Mol Genet, F-34033 Montpellier 01, France	Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS)	Gillet, G (corresponding author), Inst Biol & Chim Prot, UPR 412 CNRS, 7 Passage Vercors, F-69367 Lyon 07, France.		Le Cam, Laurent/O-1408-2016; gillet, germain/A-9095-2013	GILLET, Germain/0000-0002-1514-327X; LE CAM, Laurent/0000-0003-0325-878X				ALTSHULER DM, 1991, P RET RES F, V3, P37; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; CORBEIL HB, 1995, ONCOGENE, V11, P909; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Espanel X, 1997, INT J DEV BIOL, V41, P469; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GILLET G, 1993, ONCOGENE, V8, P565; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUGUES SH, 1987, J VIROL, V61, P3004; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kaisse Ellen M., 1985, PHONOLOGY YB, V2, P1, DOI DOI 10.1017/S0952675700000361; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; Lin SY, 1996, MOL CELL BIOL, V16, P1668; METIVIER C, 1993, ONCOGENE, V8, P2311; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; Neuman E, 1996, GENE, V173, P163, DOI 10.1016/0378-1119(96)00184-9; North S, 1996, CELL GROWTH DIFFER, V7, P339; PASTEAU S, 1995, ONCOGENE, V11, P1475; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARDET C, 1997, E2FS RETINOBLASTOMA; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	36	7	8	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	1998	17	5					585	594		10.1038/sj.onc.1201962	http://dx.doi.org/10.1038/sj.onc.1201962			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704924				2022-12-28	WOS:000075195300006
J	Battista, S; de Nigris, F; Fedele, M; Chiappetta, G; Scala, S; Vallone, D; Pierantoni, GM; Megar, T; Santoro, M; Viglietto, G; Verde, P; Fusco, A				Battista, S; de Nigris, F; Fedele, M; Chiappetta, G; Scala, S; Vallone, D; Pierantoni, GM; Megar, T; Santoro, M; Viglietto, G; Verde, P; Fusco, A			Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo	ONCOGENE			English	Article						transformation; AP-1; fra-1; thyroid carcinomas	C-JUN; TRANSCRIPTIONAL ACTIVATION; NEOPLASTIC TRANSFORMATION; BINDING-ACTIVITY; DELETION MUTANT; DNA-BINDING; EXPRESSION; FOS; ONCOGENE; LINE	We have recently reported that neoplastic transformation of two rat thyroid epithelial cell lines by retroviruses carrying the v-mos and v-ras Ki oncogenes is associated with a drastic increase of AP-1 activity. The most important effects were represented by the dramatic junB and fra-1 gene induction, which was abolished by the block of the transformation-induced HMGI-C protein synthesis. Here, we have further characterized the transformation-dependent AP-1 activity, by analysing the expression of different jun- and fos-related components, in rat thyroid cell lines transformed by several oncogenes, in human thyroid carcinoma cell lines, and in naturally occurring human thyroid rumours. A significant increase of Fra-1 and JunB protein levels was detected in all oncogene transformed rat thyroid cell lines, Fra-1 gene induction was demonstrated to occur also in human thyroid carcinoma cell lines and tissues, Conversely, c-Jun and JunD proteins, rather than JunB, accumulated in human thyroid carcinoma cell lines. An induction of AP-1 target genes was also detected both in rat and human thyroid transformed cell lines. Therefore, in vivo and in vitro thyroid cell transformation is associated with important compositional changes in the AP-1 complex and an increased transcriptional activity.	Ist Nazl Tumori, Fdn Senatore Pascale Oncol Sperimentale D & E, I-80131 Naples, Italy; CNR, Ist Int Genet & Biofis, I-80125 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria	Fusco, A (corresponding author), Ist Nazl Tumori, Fdn Senatore Pascale Oncol Sperimentale D & E, Via M Semmola, I-80131 Naples, Italy.		Pierantoni, Giovanna Maria/O-7527-2015; Viglietto, Giuseppe/AAC-2852-2019; Fedele, Monica/C-1417-2015; Battista, Sabrina/AAY-2981-2020; Scala, Stefania/K-1380-2016	Pierantoni, Giovanna Maria/0000-0003-4078-8528; Viglietto, Giuseppe/0000-0003-2327-7515; Fedele, Monica/0000-0002-9171-1312; Battista, Sabrina/0000-0001-5899-9759; Scala, Stefania/0000-0001-9524-2616; de nigris, filomena/0000-0002-2322-1557; Fusco, Alfredo/0000-0003-3332-5197				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P2261, DOI 10.1128/MCB.8.5.2261; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN PH, 1993, ONCOGENE, V8, P877; Cerutti J, 1996, CLIN CANCER RES, V2, P119; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; DECESARE D, 1995, ONCOGENE, V11, P365; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GACK S, 1994, J BIOL CHEM, V269, P10363; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GRUDA MC, 1994, ONCOGENE, V9, P2537; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Joseloff E, 1997, MOL CARCINOGEN, V18, P26, DOI 10.1002/(SICI)1098-2744(199701)18:1<26::AID-MC4>3.0.CO;2-P; KARDALINOU E, 1993, J CELL BIOCHEM, V52, P375, DOI 10.1002/jcb.240520402; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li JJ, 1996, CANCER RES, V56, P483; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MATSUI M, 1990, ONCOGENE, V5, P249; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Rosenberger SF, 1996, ONCOGENE, V12, P2301; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Vandel L, 1996, MOL CELL BIOL, V16, P1881; VIGLIETTO G, 1995, ONCOGENE, V11, P1569	49	54	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	1998	17	3					377	385		10.1038/sj.onc.1201953	http://dx.doi.org/10.1038/sj.onc.1201953			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690519				2022-12-28	WOS:000074947500012
J	Ben-Yosef, T; Yanuka, O; Halle, D; Benvenisty, N				Ben-Yosef, T; Yanuka, O; Halle, D; Benvenisty, N			Involvement of Myc targets in c-myc and N-myc induced human tumors	ONCOGENE			English	Article						Myc; oncogenesis; target genes	BREAST-CANCER-CELLS; ORNITHINE DECARBOXYLASE GENE; HUMAN NEUROBLASTOMA-CELLS; PROTHYMOSIN-ALPHA-GENE; HUMAN NEURO-BLASTOMA; DNA-BINDING; INDUCED APOPTOSIS; EMBRYONIC LETHALITY; ONCOGENE EXPRESSION; CONTINUOUS CULTURE	The myc proto-oncogenes are transcription factors that directly regulate the expression of other genes, by binding to the specific DNA sequence, CACGTG, Among the target genes for c-Myc regulation are ECA39, p53, ornithine decarboxylase (ODC), alpha-prothymosin and Cdc25A, In this study we examined the involvement of c-Myc target genes in human oncogenesis induced by c-myc or N-myc. In MCF-7 breast cancer cells, the induction of c-myc expression by estrogen was followed by the induction of all the Myc targets that we examined, indicating that those genes can serve as c-Myc targets in human oncogenesis, Moreover, in breast tumors exhibiting c-myc overexpression, several Myc targets were also overexpressed. A clear correlation between the expression of c-myc and its targets was also detected in Burkitt's lymphomas, which involve a specific translocation of c-myc gene, but not in other lymphoma cells. Yet, in cells derived from a neuronal origin the pattern of expression of Myc targets was more complex, In a neuroepithelioma cell line that overexpresses c-myc, only some targets were expressed. In addition in neuroblastomas, in which N-myc is amplified and overexpressed, only ODC was overexpressed in all cell lines, while all other target genes were expressed in only some of the cell lines. The more complex expression pattern found for the Myc targets in neuroblastomas suggests that genes that were identified originally as targets for c-Myc regulation may be regulated by N-Myc, but other cell specific factors are also needed for transcription of the target genes.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel; Shaare Zedek Med Ctr, Cell Canc Res Lab, IL-91031 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Shaare Zedek Medical Center	Benvenisty, N (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel.							ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BENBASSAT H, 1980, INT J CANCER, V25, P583, DOI 10.1002/ijc.2910250506; BENBASSAT H, 1992, LEUKEMIA LYMPHOMA, V6, P513, DOI 10.3109/10428199209053591; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BenYosef T, 1996, ONCOGENE, V13, P1859; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHEN ZP, 1991, BIOCHIM BIOPHYS ACTA, V1133, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DESIDERIO MA, 1995, CELL GROWTH DIFFER, V6, P505; DUBIK D, 1987, CANCER RES, V47, P6517; DUBIK D, 1988, J BIOL CHEM, V263, P12705; Eden A, 1996, J BIOL CHEM, V271, P20242, DOI 10.1074/jbc.271.34.20242; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUERIN M, 1988, ONCOGENE RES, V3, P21; HAMANN U, 1991, ONCOGENE, V6, P1745; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANDSCHULTZ WH, 1987, SCIENCE, V240, P1759; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LIMA G, 1985, CANCER RES, V45, P2466; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Lutz W, 1996, ONCOGENE, V13, P803; MA A, 1993, ONCOGENE, V8, P1093; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RASCHELLA G, 1991, CANCER LETT, V56, P45, DOI 10.1016/0304-3835(91)90192-K; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt EV, 1996, NAT GENET, V14, P8, DOI 10.1038/ng0996-8; Schuldiner O, 1996, P NATL ACAD SCI USA, V93, P7143, DOI 10.1073/pnas.93.14.7143; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; THOMAS P, 1981, P NATL ACAD SCI USA, V77, P5201; THOMAS T, 1989, CANCER RES, V49, P5852; THOMPSON AM, 1990, BRIT J CANCER, V62, P78, DOI 10.1038/bjc.1990.233; TONIN PN, 1989, ONCOGENE, V4, P1117; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; YEGER H, 1988, DIFFERENTIATION, V39, P216, DOI 10.1111/j.1432-0436.1988.tb00095.x; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	75	81	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					165	171		10.1038/sj.onc.1201939	http://dx.doi.org/10.1038/sj.onc.1201939			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674700				2022-12-28	WOS:000074706700004
J	Brenner, AJ; Stampfer, MR; Aldaz, CM				Brenner, AJ; Stampfer, MR; Aldaz, CM			Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation	ONCOGENE			English	Article						p16(INK4a); p21(WAF1); immortal; extended life; breast	HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN FIBROBLASTS; BREAST-CANCER; IMMORTALIZATION; CULTURE; METHYLATION; GENE; P16(INK4A); CODELETION; P16/CDKN2	Aberrations affecting the tumor suppressor gene p16(INK4a) have been described for a variety of tumors. In breast cancer, approximately 50% of tumors show low or lack p16 expression. While evidence provided by some studies has implicated a possible role for p16 in normal replicative senescence, other studies have suggested that the Rb, pathway through which p16 functions, may not be involved in senescence control. Previously we observed that all immortal lines derived from normal mammary epithelium which were analysed for p16 displayed inactivation of this gene through distinct mechanisms, supporting p16 inactivation as a possible necessary event in escape from senescence. To further clarify this issue, we have analysed p16 expression in a panel of normal finite lifespan human mammary epithelial cells (HMEC) from initial propagation through growth arrest, using media which confer different replicative capacity. Approximately 10-25-fold increase in pld expression was observed for all normal HMEC with initial onset of a senescence phenotype following 15-25 population doublings in culture. These cells also displayed expression of the senescence associated beta-galactosidase, Interestingly, HMEC with additional long term replicative capacity (approximately 80 population doublings) arose from these growth arrested cultures, showing lack of pld expression. This extended growth capacity appears to be associated with a methylation phenomenon since treatment of these cells with the methylation inhibitor 5-aza-2-deoxycytidine resulted in growth arrest concurrent with reacquisition of p16 expression and senescence associated beta-galactosidase. Analysis of p21waf1 expression revealed no change in expression during growth in vitro. These results support p16(INK4a) as the 9p senescence gene and suggest a role for p16 loss in the escape from initial onset of senescence and in acquisition of an extended life span of human mammary epithelial cells.	Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Res, Smithville, TX 78957 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Aldaz, CM (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Res, Smithville, TX 78957 USA.		Aldaz, C. Marcelo/E-7868-2011	Aldaz, C. Marcelo/0000-0002-2453-2939	NCI NIH HHS [CA-24844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA024844, R01CA024844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARRETT JC, 1994, COLD SPRING HARB SYM, V59, P411, DOI 10.1101/SQB.1994.059.01.046; BRENNER AJ, 1995, CANCER RES, V55, P2892; Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DREYLING MH, 1995, CANCER RES, V55, P984; Foster SA, 1996, ONCOGENE, V12, P1773; GERADTS J, 1995, CANCER RES, V55, P6006; Gollahon LS, 1996, ONCOGENE, V12, P715; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HERMAN JG, 1995, CANCER RES, V55, P4525; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; STAMPFER M, 1994, CANC SURVEYS, V18, P7; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; STAMPFER MR, 1982, IN VITRO CELL DEV B, V18, P531; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; XIAO S, 1995, ONCOGENE, V11, P511; XIAO S, 1995, CANCER RES, V55, P2968; YANG LQ, 1995, EXP CELL RES, V221, P126, DOI 10.1006/excr.1995.1359	30	218	224	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					199	205		10.1038/sj.onc.1201919	http://dx.doi.org/10.1038/sj.onc.1201919			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674704				2022-12-28	WOS:000074706700008
J	Kondo, S; Kondo, Y; Li, GY; Silverman, RH; Cowell, JK				Kondo, S; Kondo, Y; Li, GY; Silverman, RH; Cowell, JK			Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA	ONCOGENE			English	Article						telomerase; brain tumors; nude mice; RNAse L; apoptosis	IMMORTAL CELLS; TUMOR; ACTIVATION; CHIMERAS	Telomerase is the RNA-protein complex which elongates telomeric DNA (TTAGGG)(n) and appears to play an important role in cellular immortalization. The almost exclusive expression of telomerase in tumor cells, and not in most normal cells, offers an exciting opportunity for therapy by inhibiting its function. Here, we have investigated the effect of inhibition of telomerase on the growth and survival of human malignant glioma cells in vitro and in vivo by using a 19-mer antisense oligonucleotide against human telomerase RNA linked to a 2',5'-oligoadenylate (2-5A), 2-5A antisense functions by activating the endoribonuclease, RNase L, resulting in the degradation of single stranded, targeted RNA. We have shown that the 2-5A antisense treatment effectively suppressed tumor cell growth and survival in vitro. Furthermore, treatment of tumors grown in nude mice with the antisense oligonucleotide inhibited survival of the tumor cells. TUNEL assays suggest that this effect is mediated through the induction of apoptosis. Targeting telomerase RNA with 2-5A antisense, therefore, may represent an effective and novel approach for treatment of a broad range of cancers.	Cleveland Clin Fdn, Dept Neurosurg, Brain Tumor Ctr, Ctr Canc, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Cowell, JK (corresponding author), Cleveland Clin Fdn, Dept Neurosurg, Brain Tumor Ctr, Ctr Canc, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950	NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [1 PO1 CA 62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cirino NM, 1997, P NATL ACAD SCI USA, V94, P1937, DOI 10.1073/pnas.94.5.1937; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DEEN DF, 1993, J NEURO-ONCOL, V16, P243, DOI 10.1007/BF01057041; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DONG BH, 1994, J BIOL CHEM, V269, P14153; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S., UNPUB; KRAUSE D, 1986, J BIOL CHEM, V261, P6836; LANGFORD LA, 1995, LANCET, V346, P1267, DOI 10.1016/S0140-6736(95)91865-5; LESIAK K, 1993, BIOCONJUGATE CHEM, V4, P467, DOI 10.1021/bc00024a008; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; MAITRA RK, 1995, J BIOL CHEM, V270, P15071, DOI 10.1074/jbc.270.25.15071; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; SALSER W, 1977, COLD SPRING HARB SYM, V42, P985; SCHOENBERG BS, 1983, ONCOLOGY NERVOUS SYS, P1; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; XIAO W, 1994, BIOORG MED CHEM LETT, V4, P2609, DOI 10.1016/S0960-894X(01)80294-8; Xiao W, 1996, ANTISENSE NUCLEIC A, V6, P247, DOI 10.1089/oli.1.1996.6.247; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	32	177	202	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	1998	16	25					3323	3330		10.1038/sj.onc.1201885	http://dx.doi.org/10.1038/sj.onc.1201885			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681832	Bronze			2022-12-28	WOS:000074343600014
J	Perletti, GP; Concari, P; Brusaferri, S; Marras, E; Piccinini, F; Tashjian, AH				Perletti, GP; Concari, P; Brusaferri, S; Marras, E; Piccinini, F; Tashjian, AH			Protein kinase C epsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway	ONCOGENE			English	Article						PKC epsilon; Raf-1; colon cancer; oncogene		We have shown previously that overexpression of the epsilon isoform of protein kinase C (PKC epsilon) in rat colonic epithelial cells causes malignant transformation, possibly by interacting with the ras signal transduction pathway (Oncogene 12: 847, 1996). We have now performed experiments to examine certain early steps in the ras signaling pathway. A marked increase of Raf-1 phosphorylation was detected in tumorigenic ras-transformed D/ras as well as in D/epsilon cells (overexpressing PKC epsilon), compared to the nontumorigenic D/WT parental Line. Moreover, in the PKC epsilon-transformed D/epsilon cell line, stable transfection with a dominant-negative raf-1 (DNraf) sequence caused complete regression of the neoplastic phenotype. These results suggested that PKC epsilon-induced transformation was associated with increased Raf-1 activation, and that DNraf could block the oncogenic effect of PKC epsilon, Furthermore, transfection of D/WT cells with dominant-negative ras induced arrest of cell growth, and subsequent transfection,vith PKC epsilon cDNA enhanced cell proliferation and induced neoplastic transformation. These results suggest that ras acts upstream of PKC epsilon, and that overexpression of PKC epsilon circumvents the block in cell proliferation caused by dominant-negative ras. We conclude that PKC epsilon exerts its oncogenic activity in rat colonic cells by affecting the ras signaling cascade at the level of Raf-1 activation.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Milan, Ist Farmacol, I-20129 Milan, Italy	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; University of Milan	Tashjian, AH (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.				NIEHS NIH HHS [ES 00002] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BLIND E, 1995, ENDOCRINOLOGY, V136, P4271, DOI 10.1210/en.136.10.4271; CACACE AM, 1993, ONCOGENE, V8, P2095; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CCACE AM, 1996, ONCOGENE, V13, P2517; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Perletti GP, 1996, INT J ONCOL, V9, P171; Perletti GP, 1996, ONCOGENE, V12, P847; PORIES SE, 1993, GASTROENTEROLOGY, V104, P1346, DOI 10.1016/0016-5085(93)90343-B	12	71	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3345	3348		10.1038/sj.onc.1201871	http://dx.doi.org/10.1038/sj.onc.1201871			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681835				2022-12-28	WOS:000074343600017
J	Altomare, DA; Lyons, GE; Mitsuuchi, Y; Cheng, JQ; Testa, JR				Altomare, DA; Lyons, GE; Mitsuuchi, Y; Cheng, JQ; Testa, JR			Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin	ONCOGENE			English	Article						Akt; serine-threonine kinase; oncogene; expression; insulin; phosphatidylinositol 3-kinase	RAC-PROTEIN KINASE; HUMAN PANCREATIC-CANCER; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3-KINASE; HEAT-SHOCK; C-AKT; ONCOGENE; CELLS; AMPLIFICATION; LOCALIZATION	Akt2 encodes a protein-serine/threonine kinase containing a pleckstrin homology domain characteristic of many signaling molecules. Although there has been extensive interest in the mechanism by which the closely-related Akt kinase participates in phosphatidylinositol S-kinase-mediated signaling, comparatively little is known regarding the expression and function of Akt2. This manuscript is the first to describe Akt2 mRNA expression in the developing mouse and the activation of AKT2 by insulin. These studies demonstrate that Akt2 is especially abundant in brown fat and, to a lesser extent, skeletal muscle and liver, tissues which are highly insulin-responsive and play a role in glucose metabolism. Endogenous Akt2 expression also is upregulated in fully-differentiated C2Cl2 myotubes and 3T3-L1 adipocytes, suggesting that these murine cell lines represent useful in vitro models for studies of Akt2 function. We show that HA-tagged AKTZ is activated in response to insulin stimulation in vitro and that activation of AKT2 is not induced in cells pretreated with wortmannin, an inhibitor of phosphatidylinositol 3-kinase. These data suggest that Akr2 expression is fundamental to the differentiated state of fat and muscle cells and that activation of AKT2 kinase by insulin is mediated through the phosphatidylinositol 3-kinase signaling pathway.	Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA	Fox Chase Cancer Center; University of Wisconsin System; University of Wisconsin Madison	Testa, JR (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [R01 CA077429, P30 CA006927, CA-06927, CA-09035] Funding Source: Medline; NICHD NIH HHS [HD29471] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029471] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA077429, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALTOMARE DA, 1995, ONCOGENE, V11, P1055; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1993, ONCOGENE, V8, P745; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GUO K, 1995, MOL CELL BIOL, V15, P3823; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Klaus S, 1997, BIOESSAYS, V19, P215, DOI 10.1002/bies.950190307; Kobayashi M, 1996, NEUROSCI LETT, V213, P103, DOI 10.1016/0304-3940(96)12845-7; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; Matsuzaki H, 1996, FEBS LETT, V396, P305, DOI 10.1016/0014-5793(96)01120-9; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034	30	104	106	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2407	2411		10.1038/sj.onc.1201750	http://dx.doi.org/10.1038/sj.onc.1201750			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620559				2022-12-28	WOS:000073428000014
J	Lee, YI; Lee, S; Lee, Y; Bong, YS; Hyun, SW; Do Yoo, Y; Kim, SJ; Kim, YW; Poo, HR				Lee, YI; Lee, S; Lee, Y; Bong, YS; Hyun, SW; Do Yoo, Y; Kim, SJ; Kim, YW; Poo, HR			The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4	ONCOGENE			English	Article						hepatitis B virus; insulin-like growth factor-II; hepatocellular carcinoma; transactivation	BOX-BINDING-PROTEINS; LONG TERMINAL REPEAT; DNA-BINDING; SP1-MEDIATED TRANSCRIPTION; TRANS-ACTIVATION; MESSENGER-RNA; EXPRESSION; LIVER; CELLS; SEQUENCES	Human hepatitis B virus (HBV) is one of the causative agents of hepatocellular carcinoma (HCC). The virus encodes a 17 kDa protein, X, which is known to be a causative agent in the formation of HCC. An insulin-like growth factor-II (IGF-II) is expressed during the formation of HCC. Among the four promoters of the IGF-II gene, promoters 2, 3 and 4 become activated during the formation of HCC. The high frequency of detection of hepatitis B virus X (HBV-X) antigen in liver cells from patients with chronic hepatitis, cirrhosis, and liver cancer suggested that the expressions of HBV-X and IGF-II are associated. Studies were carried out to test the relationship between the HBV-X gene product and the activation of IGF-II promoter 4, We demonstrated that the HBV-X protein increases the endogenous IGF-II expression from promoter 3 and 4 of IGF-II gene. Analysis of the fourth promoter of IGF-II gene showed that the HBV-X gene product positively regulates transcription. Two copies of a motif are responsible for conferring HBV-X regulation on the fourth promoter of IGF-II. These motifs have been identified as Sp1 binding sites, Sp1 binding to IGF-II P4 promoter was identified by gel mobility shift assay using purified Sp1. By using a GAL4-Sp1 fusion protein it was demonstrated that HBV-X positively regulates the Sp1 mediated transcriptional activity of IGF-II in vivo. A protein-affinity chromatography experiment showed that HBV-X protein does not bind directly to Sp1, but HBV-X does augment the DNA binding activity of the phosphorylated form of Sp1 in HepG2 cells. Sp1 was phosphorylated by HBV-X and its DNA-binding activity was up-regulated upon HBV-X transfections. Various HBV-X mutant expression vectors were used for the demonstration of specific interactions between Sp1 and HBV-X. These results indicate that HBV-X functions as a positive regulator of transcription, and that Sp1 is a direct target for the transcriptional regulation of IGF-II. Increasing the DNA binding ability of the phosphorylated form of Sp1 by HBV-X might be an important mechanism for regulating the IGF-II gene expression and possibly promoting cell division during hepatic carcinogenesis. Our experimental results suggest that expression of HBV-X might induce the expression of IGF-II and the IGF-II might play a role in hepatitis B virus pathogenesis during the formation of HCC.	Korea Adv Inst Sci & Technol, Korea Res Inst Biosci & Biotechnol, Mol Cell Biol Res Div, Liver Cell Signal Transduct Lab, Taejon 305606, South Korea; NCI, Chemoprevent Lab, NIH, Bethesda, MD 20892 USA	Korea Advanced Institute of Science & Technology (KAIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lee, YI (corresponding author), Korea Adv Inst Sci & Technol, Korea Res Inst Biosci & Biotechnol, Mol Cell Biol Res Div, Liver Cell Signal Transduct Lab, Taejon 305606, South Korea.							BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; CARIANI E, 1988, CANCER RES, V48, P6844; CAROLYN ND, 1991, HEPATOLOGY, V13, P310; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN XR, 1992, ONCOGENE, V7, P1805; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHOU PY, 1978, ADV ENZYMOLOGY RELAT, V0047, P00145; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DARVILLE CN, 1991, HEPATOLOGY, V13, P310, DOI 10.1002/hep.1840130217; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; FLORINI JR, 1992, GROWTH REGULAT, V2, P23; FLORINI JR, 1986, AM J PHYSIOL, V250, pC771, DOI 10.1152/ajpcell.1986.250.5.C771; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY A, 1987, DNA-J MOLEC CELL BIO, V6, P283, DOI 10.1089/dna.1987.6.283; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HYUN SW, 1993, FEBS LETT, V332, P153, DOI 10.1016/0014-5793(93)80503-M; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM YH, 1993, BIOCHEM BIOPH RES CO, V197, P894, DOI 10.1006/bbrc.1993.2563; KIM YS, 1984, KOREAN BIOCH J, V17, P7076; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; LAMAS E, 1989, FALK S OCT 15 17 BAS, V55, P45; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LO SJ, 1988, VIROLOGY, V167, P289, DOI 10.1016/0042-6822(88)90081-5; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NANCY CA, 1991, NUCLEIC ACIDS RES, V19, P2499; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RITTER SE, 1991, VIROLOGY, V182, P841, DOI 10.1016/0042-6822(91)90626-M; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SOARES MB, 1985, NUCLEIC ACIDS RES, V13, P1119, DOI 10.1093/nar/13.4.1119; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; TAKADA S, 1994, ONCOGENE, V9, P341; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; VEDA K, 1996, J VIROL, V70, P1375; WANG WL, 1991, CANCER RES, V51, P4971; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YANG D, 1993, CANCER RES, V53, P2020; Yang DY, 1996, J VIROL, V70, P6260, DOI 10.1128/JVI.70.9.6260-6268.1996; YANG DY, 1991, CARCINOGENESIS, V12, P1893, DOI 10.1093/carcin/12.10.1893; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427	68	71	79	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	1998	16	18					2367	2380		10.1038/sj.onc.1201760	http://dx.doi.org/10.1038/sj.onc.1201760			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620554				2022-12-28	WOS:000073428000009
J	Castillo, AI; Tolon, RM; Aranda, A				Castillo, AI; Tolon, RM; Aranda, A			Insulin-like growth factor-1 stimulates rat prolactin gene expression by a Ras, ETS and phosphatidylinositol 3-kinase dependent mechanism	ONCOGENE			English	Article						prolactin; IGF-1; pituitary cells; Ras; Pl-3 kinase	THYROTROPIN-RELEASING-HORMONE; TRANSCRIPTION FACTOR; PROTEIN-KINASE; SIGNALING PATHWAYS; THYROID-HORMONE; NEUROENDOCRINE CELLS; NEGATIVE REGULATION; RESPONSE ELEMENT; PHORBOL ESTER; PROMOTER	We have examined the influence of insulin-like growth factor I(IGF-1) on prolactin gene expression in rat pituitary GH4C1 cells. Incubation with IGF-1 increases prolactin mRNA levels and activates the prolactin promoter in transient transfection assays. A similar degree of activation is observed with constructs extending to -3000 and -176 base pairs of the prolactin 5' flanking region, indicating that the IGF-I response element is located in the proximal promoter sequences. A plasmid containing 101 base pairs shows a partial stimulation by IGF-1, and the response is lost in a deletion to -76 base pairs. The Ras oncoproteins have been implicated as a critical signaling component in mediating the effect of growth factor receptor tyrosine kinases. Expression of oncogenic Ras(Val12) mimics the effect of IGF-1 on the prolactin promoter, and a dominant negative Ras, Ras(Asn17), blocks IGF-1-mediated stimulation. Dominant negative mitogen-activated protein kinase (MAPK) also reduces the activation of the prolactin promoter by IGF-1. Ets transcription factors have been described to lie downstream of Ras and MAPK in the signaling pathway leading to prolactin gene activation. Mutation of two Ets binding sites in the promoter region between -101 and -76 abolishes the response to IGF-1. Furthermore, a dominant negative Ets vector strongly reduces the response of the prolactin promoter to IGF-1 and Ras. The endogenous concentration of Ets-related proteins is not limiting in GH4C1 cells for the IGF-1 effect. However, c-Ets-1 and GHF-1 act synergistically in HeLa cells with the IGF-1 receptor, reconstituting pituitary IGF-1 responsiveness. The response to IGF-1 in GH4C1 cells is still observed after transfection with Ras(Val12) suggesting that, although Ras is required, IGF-1 could stimulate other pathway/s in addition to Ras. Wortmanin, an inhibitor of phosphatidylinositol-3 kinase (Pl-3 kinase), also prevents the response of the prolactin promoter to IGF-1. These results show that both the Ras/MAPK/Ets pathway, as well as the activation of Pl-3 kinase are involved in the signaling mechanism leading to prolactin expression by IGF-1 in GH4C1 cells.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Tolón, Rosa/AAA-9401-2019; Tolón, Rosa M M/N-4364-2015; Aranda, Ana/ABG-8820-2020; Castillo, Ana/I-1269-2017	Tolón, Rosa M M/0000-0003-1087-4505; Aranda, Ana/0000-0002-8338-9589; Castillo, Ana/0000-0002-2873-1206; Rafael, Rosa M/0000-0002-4441-1691				BERWAER M, 1993, MOL CELL ENDOCRINOL, V92, P1, DOI 10.1016/0303-7207(93)90068-U; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAMPER SA, 1985, J BIOL CHEM, V260, P2246; CASTILLO AI, 1997, IN PRESS ENDOCRINOLO; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; DAY RN, 1989, MOL ENDOCRINOL, V3, P931, DOI 10.1210/mend-3-6-931; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GarciaVillalba P, 1996, MOL CELL BIOL, V16, P318; GUBBINS EJ, 1980, J BIOL CHEM, V255, P8655; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JACOB KK, 1994, J BIOL CHEM, V269, P25515; KATO H, 1993, J BIOL CHEM, V268, P2655; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MELMED S, 1986, ENDOCRINOLOGY, V118, P1483, DOI 10.1210/endo-118-4-1483; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MONTE D, 1995, ONCOGENE, V11, P771; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OBERWETTER JM, 1993, MOL ENDOCRINOL, V7, P915, DOI 10.1210/me.7.7.915; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; PICKETT CA, 1994, P NATL ACAD SCI USA, V91, P8612, DOI 10.1073/pnas.91.18.8612; PICKETT CA, 1995, MOL CELL BIOL, V15, P677; PRAGER D, 1988, J BIOL CHEM, V263, P16589; ROSENFELD RG, 1985, ENDOCRINOLOGY, V117, P2008, DOI 10.1210/endo-117-5-2008; SANCHEZPACHECO A, 1995, MOL CELL BIOL, V15, P6322; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SEEBURG PH, 1977, NATURE, V270, P486, DOI 10.1038/270486a0; STANLEY F, 1988, J BIOL CHEM, V263, P13444; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; SUPOWIT SC, 1984, P NATL ACAD SCI-BIOL, V81, P2975, DOI 10.1073/pnas.81.10.2975; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEBSTER J, 1994, MOL ENDOCRINOL, V8, P539, DOI 10.1210/me.8.5.539; YAMASHITA S, 1987, J CLIN INVEST, V79, P449, DOI 10.1172/JCI112832	49	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1981	1991		10.1038/sj.onc.1200204	http://dx.doi.org/10.1038/sj.onc.1200204			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591782				2022-12-28	WOS:000073079400010
J	Stilgenbauer, S; Nickolenko, J; Wilhelm, J; Wolf, S; Weitz, S; Dohner, K; Boehm, T; Dohner, H; Lichter, P				Stilgenbauer, S; Nickolenko, J; Wilhelm, J; Wolf, S; Weitz, S; Dohner, K; Boehm, T; Dohner, H; Lichter, P			Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma	ONCOGENE			English	Article						deletion mapping; FISH; exon amplification; DIRVISH	RETINOBLASTOMA GENE; D13S25 LOCUS; INSITU HYBRIDIZATION; DELETIONS; AMPLIFICATION; REGION; DNA; CYTOGENETICS; CLONES	Deletions affecting the interval between the RB1 gene and marker D13S25 at band 13q14 are the most frequent genetic abnormalities of B-cell chronic lymphocytic leukemia (B-CLL) and indicate the presence of a novel tumor suppressor gene in this region. In the current study, a high resolution physical map of fragments spanning one megabasepair (Mb) of genomic DNA at the critical 13q14 segment was constructed. To define the minimal region of loss within the RB1 and D13S25 interval, we screened 322 B-CLLs for deletions at either of the two loci. Thirty mantle cell lymphomas (MCLs) were included in the analysis because we observed a 13q14 deletion pattern similar to B-CLL in this disease, The incidence of 13q14 deletions was 51% in B-CLL and 70% in MCL, respectively. No frequent loss of the BRCA2 gene at band 13q12 was found. Detailed deletion mapping at band 13q14 with probes from the RB1-D13S25 interval lead to the identification of a critical deletion region 400 kb in size. Within this region two segments were most frequently affected, one at D13S272 120 kb in size and another 240 kb distal of D13S272 80 kb in size. From these two segments expressed sequences were identified as candidates for the putative 13q14 tumor suppressor gene involved in the pathogenesis of B-CLL and MCL.	Deutsch Krebsforschungszentrum, Abt Org Komplexer Genome, D-69120 Heidelberg, Germany; Med Klin & Poliklin 5, D-69115 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Abt Expt Therapie, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Lichter, P (corresponding author), Deutsch Krebsforschungszentrum, Abt Org Komplexer Genome, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Döhner, Hartmut/C-8933-2016; Stilgenbauer, Stephan/ABE-6609-2020	Döhner, Hartmut/0000-0003-2116-5536; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOHLANDER SK, 1992, GENOMICS, V13, P1322, DOI 10.1016/0888-7543(92)90057-Y; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; Bullrich F, 1996, BLOOD, V88, P3109, DOI 10.1182/blood.V88.8.3109.bloodjournal8883109; CHAPMAN RM, 1994, ONCOGENE, V9, P1289; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; DEVILDER MC, 1995, CANCER RES, V55, P1355; Dohner H, 1997, BLOOD, V89, P2516, DOI 10.1182/blood.V89.7.2516; DOHNER H, 1997, LEUKEMIA S2, V11, P19; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GarciaMarco JA, 1996, BLOOD, V88, P1568; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; Kalachikov S, 1997, GENOMICS, V42, P369, DOI 10.1006/geno.1997.4747; LEHRACH H., 1990, GENOME ANAL, P39; LENGAUER C, 1992, GENOMICS, V13, P826, DOI 10.1016/0888-7543(92)90160-T; LICHTER P, 1995, METHOD ENZYMOL, V254, P334; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIU Y, 1992, GENE CHROMOSOME CANC, V4, P250, DOI 10.1002/gcc.2870040310; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; LIU Y, 1993, P NATL ACAD SCI USA, V90, P8697, DOI 10.1073/pnas.90.18.8697; NEHLS M, 1994, ONCOGENE, V9, P2169; Panayiotidis P, 1997, BRIT J HAEMATOL, V97, P844, DOI 10.1046/j.1365-2141.1997.1322949.x; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; SCHUTTE M, 1995, CANCER RES, V55, P4570; STILGENBAUER S, 1993, BLOOD, V81, P2118; STILGENBAUER S, 1995, CANCER RES, V55, P3475	27	119	124	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1891	1897		10.1038/sj.onc.1201764	http://dx.doi.org/10.1038/sj.onc.1201764			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583687				2022-12-28	WOS:000072994600013
J	Sasahara, M; Amano, S; Sato, H; Yang, JG; Hayase, Y; Kaneko, M; Sato, I; Suzaki, M; Hazama, F				Sasahara, M; Amano, S; Sato, H; Yang, JG; Hayase, Y; Kaneko, M; Sato, I; Suzaki, M; Hazama, F			Normal developing rat brain expresses a platelet-derived growth factor B chain (c-sis) mRNA truncated at the 5 ' end	ONCOGENE			English	Article						platelet-derived growth factor; cloning; in situ hybridization; truncation; development; neuron	CENTRAL-NERVOUS-SYSTEM; SIMIAN SARCOMA-VIRUS; PDGF RECEPTOR GENES; MESSENGER-RNA; NEURONS; PROMOTER; IMMUNOREACTIVITY; PURIFICATION; INDUCTION; PITUITARY	The 5' untranslated sequence (5' UTS) of platelet-derived growth factor B (PDGF-B/c-sis) mRNA is highly preserved through evolution, and inhibits translation of downstream coding sequences, In this study, using Northern analysis we identified two PDGF-B/c-sis mRNAs (3.5 kb and 2.6 kb) expressed in normal developing rat brain. In contrast to the constitutive expression of 3.5 kb mRNA, the expression of 2.6 kb mRNA increased markedly in accordance with those stages of brain development at which we had previously demonstrated an increased immunoreactivity for PDGF-B/c-SIS in neurons (Sasahara ef al., 1992). By PCR cloning and the RNase protection assay, we determined the complete sequence of rat PDGF-B/c-sis, and found that the 2.6 kb transcript was a form of the 3.5 kb message truncated at the 5' end, and that the predominant 2.6 kb mRNA commenced 15 nt upstream of the signal peptide, Accordingly, it is suggested that the truncation of 5' UTS contributes to the expression of PDGF-B/c-SIS protein in the CNS, Lack of translational inhibitory 5' UTS of PDGF-B/c-sis transcript and resultant efficient protein translation have been reported in only a few transformed cells and cultured umbilical vein endothelial cells, We have extended this knowledge to the developing rat brain, and suggest that a similar mechanism could operate widely in non-transformed tissue in vivo.	Shiga Univ Med Sci, Dept Pathol, Otsu, Shiga 52021, Japan; Shiga Univ Med Sci, Dept Biol, Otsu, Shiga 52021, Japan; Shiga Univ Med Sci, Dept Neurosurg, Otsu, Shiga 52021, Japan; Shiga Univ Med Sci, Cent Res Lab, Otsu, Shiga 52021, Japan; Mochida Pharmaceut Co, Tokyo 160, Japan; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia	Shiga University of Medical Science; Shiga University of Medical Science; Shiga University of Medical Science; Shiga University of Medical Science; Mochida Pharmaceutical Co Ltd; University of Sydney	Sasahara, M (corresponding author), Shiga Univ Med Sci, Dept Pathol, Otsu, Shiga 52021, Japan.							ADAMS TE, 1995, MOL CELL ENDOCRINOL, V108, P23, DOI 10.1016/0303-7207(95)92575-9; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BESMER P, 1983, J VIROL, V46, P606, DOI 10.1128/JVI.46.2.606-613.1983; BONTHRON DT, 1991, GENOMICS, V10, P287, DOI 10.1016/0888-7543(91)90515-G; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHENG B, 1995, J NEUROSCI, V15, P7095; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P2815, DOI 10.1093/nar/23.15.2815; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; FEN Z, 1991, ONCOGENE, V6, P953; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HORVATH P, 1995, CELL GROWTH DIFFER, V6, P1103; HUTCHINS JB, 1992, DEV BRAIN RES, V67, P121, DOI 10.1016/0165-3806(92)90213-G; IIHARA K, 1994, J CEREBR BLOOD F MET, V14, P818, DOI 10.1038/jcbfm.1994.102; Iihara K, 1996, J CEREBR BLOOD F MET, V16, P941, DOI 10.1097/00004647-199609000-00018; Krupinski J, 1997, STROKE, V28, P564, DOI 10.1161/01.STR.28.3.564; LANS MS, 1994, J BIOL CHEM, V269, P14170; LOY R, 1980, ANAT EMBRYOL, V159, P257, DOI 10.1007/BF00317650; MALDONADO PE, 1988, J MEMBRANE BIOL, V106, P203, DOI 10.1007/BF01872158; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEKADA A, 1996, ACTA HISTOCHEM CYT S, V29, P1057; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; POKORNY J, 1981, BRAIN RES BULL, V7, P113, DOI 10.1016/0361-9230(81)90075-7; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; REDDY UR, 1992, J NEUROSCI RES, V31, P670, DOI 10.1002/jnr.490310411; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; Sambrook J, 1989, MOL CLONING; SASAHARA A, 1992, DEV BRAIN RES, V68, P41, DOI 10.1016/0165-3806(92)90246-S; SASAHARA M, 1995, MOL BRAIN RES, V32, P63, DOI 10.1016/0169-328X(95)00060-6; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; SMITS A, 1993, EUR J NEUROSCI, V5, P986, DOI 10.1111/j.1460-9568.1993.tb00950.x; TAKAYAMA S, 1994, BRAIN RES, V653, P131, DOI 10.1016/0006-8993(94)90381-6; Valenzuela CF, 1996, J BIOL CHEM, V271, P16151, DOI 10.1074/jbc.271.27.16151; VANDENOUWELAND AMW, 1996, NUCLEIC ACIDS RES, V14, P756; VIGNAIS L, 1995, NEUROREPORT, V6, P1993, DOI 10.1097/00001756-199510010-00010; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEIS JH, 1994, NUCLEIC ACIDS RES, V22, P3427, DOI 10.1093/nar/22.16.3427; YEH HJ, 1993, P NATL ACAD SCI USA, V90, P1952, DOI 10.1073/pnas.90.5.1952; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	46	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	1998	16	12					1571	1578		10.1038/sj.onc.1201679	http://dx.doi.org/10.1038/sj.onc.1201679			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569024				2022-12-28	WOS:000072743200007
J	Flaman, JM; Robert, V; Lenglet, S; Moreau, V; Iggo, R; Frebourg, T				Flaman, JM; Robert, V; Lenglet, S; Moreau, V; Iggo, R; Frebourg, T			Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast	ONCOGENE			English	Article						p53; transcription; cell cycle; apoptosis; functional assay	DNA-BINDING; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; PROTEIN; GENE; SUPPRESSION; DOMAIN	Recent studies have suggested that a rare class of p53 mutants found in tumours has a subtle transcriptional defect affecting bax induction but not p21 induction. We have therefore developed simple functional assays in yeast which can be used to identify these mutants. Analysis of 51 different mutations observed in human tumours showed that all mutants tested scored as mutant with the bax reporter strain but nine scored as wild-type with the p21 reporter strain. These results, which can be explained by the lower affinity of the p53 protein for the bax site, may suggest that p21 is not the key target of p53 mutations in tumours. Since p21 status has recently been shown to modulate the chemotherapeutic and radiotherapeutic sensitivities of cancerous cells, the functional assays described here may have important clinical implications.	CHU Rouen, Genet Mol Lab, F-76031 Rouen, France; IFRMP, F-76821 Mont St Aignan, France; Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	CHU de Rouen; Swiss Institute Experimental Cancer Research	Frebourg, T (corresponding author), CHU Rouen, Genet Mol Lab, F-76031 Rouen, France.		LENGLET, Sébastien/N-8923-2013; Frebourg, Thierry/AAK-8390-2020; Iggo, Richard/G-3546-2014; Flaman, Jean-Michel/K-8415-2018	LENGLET, Sébastien/0000-0002-4853-8163; Flaman, Jean-Michel/0000-0003-3544-0199				Beroud C, 1996, NUCLEIC ACIDS RES, V24, P147, DOI 10.1093/nar/24.1.147; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FREBOURG T, 1992, CANCER RES, V52, P6976; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MIYASHITA T, 1995, CELL, V80, P293; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SIKORSKI RS, 1989, GENETICS, V122, P19; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	29	73	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1369	1372		10.1038/sj.onc.1201889	http://dx.doi.org/10.1038/sj.onc.1201889			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546439	Bronze			2022-12-28	WOS:000072422000016
J	Brake, RL; Kees, UR; Watt, PM				Brake, RL; Kees, UR; Watt, PM			Multiple negative elements contribute to repression of the HOX11 proto-oncogene	ONCOGENE			English	Article						HOX11 promoter; negative element; repressor; silencing; transcription	ACUTE LYMPHOBLASTIC-LEUKEMIA; T-CELL RECEPTOR; BETA-INTERFERON GENE; RNA-POLYMERASE-II; C-MYB EXPRESSION; DROSOPHILA DEVELOPMENT; REGULATORY ELEMENTS; HOMEOBOX GENE; TRANSCRIPTIONAL REPRESSION; CHROMOSOME-TRANSLOCATION	The HOX11 proto-oncogene is normally expressed in embryogenesis where it directs the synthesis of the spleen. In adult tissues, HOX11 expression is silenced by an unknown mechanism. Aberrant expression of HOX11 occurs in T-cell acute lymphoblastic leukaemia (T-ALL), where it is thought to be involved in T-cell immortalization, The deregulated expression of HOX11 is frequently associated with chromosomal translocations which juxtapose a T-cell receptor (TCR) gene upstream of the HOX11 gene. In these cases, it is presumed that the activation of HOX11 expression results from bringing the gene under the control of TCR enhancer elements. However, activation of HOX11 also occurs in the absence of an associated translocation in both T-ALL and erythroleukaemia cells, implying that an alternative activation mechanism may exist, We hypothesized that HOX11 may be repressed in normal T-cells and erythroid cells by the action of negative elements which may be deleted or mutated in leukaemia. We therefore conducted a search for negative elements in the human HOX11 promoter which may function to silence its expression in normal cells of the haematopoietic lineages. Since little sequence of the HOX11 promoter was available, we began our investigation by sequencing over 4.5 kilobases of untranslated DNA from upstream of HOX11, The human sequence that overlaps with the 2.1 kb of murine Hox11 is highly conserved, suggesting that a large region of DNA upstream of HOX11 may have a regulatory function. We then used transfection assays to test the ability of portions of the promoter to drive transcription of a reporter gene. These studies identified four negative elements. Two of them (NRE2 and NRE4) function in all cell lines tested, while the remaining two (NRE1 and NRE3) appear to be cell-type specific. The DNA sequences of three elements are conserved between the human and mouse HOX11/Hox11 promoters, We propose a model in which the combined action of these negative elements contributes to the overall repression of HOX11 expression in normal blood cells.	TVW, Telethon Inst Child Hlth Res, Perth, WA 6872, Australia	Telethon Kids Institute; University of Western Australia	Kees, UR (corresponding author), TVW, Telethon Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.							ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Arai Y, 1997, GENE, V193, P73, DOI 10.1016/S0378-1119(97)00088-7; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BROWN WM, 1994, INT J BIOCHEM, V26, P1403, DOI 10.1016/0020-711X(94)90184-8; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVEL, V121, P2929; DUBE ID, 1991, BLOOD, V78, P2996; Gerard M, 1996, GENE DEV, V10, P2326, DOI 10.1101/gad.10.18.2326; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; Gottgens B, 1997, ONCOGENE, V15, P2419, DOI 10.1038/sj.onc.1201426; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; GUERRA J, 1995, BLOOD, V86, P1873, DOI 10.1182/blood.V86.5.1873.bloodjournal8651873; GUTMAN A, 1994, MOL CELL BIOL, V14, P8143, DOI 10.1128/MCB.14.12.8143; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Ip YT, 1997, CURR BIOL, V7, pR216, DOI 10.1016/S0960-9822(06)00104-7; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAGAN J, 1994, CANCER RES, V54, P226; Kees UR, 1998, CANCER GENET CYTOGEN, V100, P159, DOI 10.1016/S0165-4608(97)00030-7; KEES UR, 1994, GENE CHROMOSOME CANC, V9, P129, DOI 10.1002/gcc.2870090209; KEES UR, 1989, BLOOD, V74, P369; KEES UR, 1987, LEUKEMIA RES, V11, P489, DOI 10.1016/0145-2126(87)90082-8; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; LANEY JD, 1996, DEVEL, V122, P2302; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MACINTYRE EA, 1992, BLOOD, V80, P1511; Martin CS, 1996, BIOTECHNIQUES, V21, P520; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MILLER CW, 1984, BLOOD, V63, P195; MING L, 1992, ONCOGENE, V7, P1325; MOTUM PI, 1993, EXP HEMATOL, V21, P852; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; PIRROTTA V, 1991, ADV GENET, V29, P301, DOI 10.1016/S0065-2660(08)60110-8; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; SALVATI PD, 1995, ONCOGENE, V11, P1333; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WOODRUFF KA, 1995, ONCOGENE, V10, P1335; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	59	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1787	1795		10.1038/sj.onc.1202078	http://dx.doi.org/10.1038/sj.onc.1202078			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778044				2022-12-28	WOS:000076303300004
J	Dong, ZG; Huang, CS; Ma, WY; Malewicz, B; Baumann, WJ; Kiss, Z				Dong, ZG; Huang, CS; Ma, WY; Malewicz, B; Baumann, WJ; Kiss, Z			Increased synthesis of phosphocholine is required for UV-induced AP-1 activation	ONCOGENE			English	Article						AP-1; UV irradiation; phosphocholine phosphatidylcholine; MAP kinase	PROTEIN-KINASE-C; NUCLEAR MAGNETIC-RESONANCE; NIH 3T3 FIBROBLASTS; SIGNAL-TRANSDUCTION; GROWTH-FACTORS; ULTRAVIOLET-LIGHT; CHOLINE-PHOSPHATE; PHOSPHOLIPASE-D; PHORBOL ESTER; DNA-SYNTHESIS	Exposure of mammalian cells to UV irradiation stimulates phosphatidylcholine hydrolysis and activates the transcription factor AP-1. Since phosphocholine (PCho), a phospholipid metabolite, is a potential regulator of mitogenesis and carcinogenesis, we examined the effect of UV exposure on the formation of PCho and the possible mediatory role of PCho in UVB-and UVC-induced activation of AP-1 in mouse JB6 epidermal cells. We found that both UVB and UVC irradiation resulted in increased PCho levels. Hemicholinium-3 (HC-3), an inhibitor of choline kinase, strongly inhibited UV-induced AP-1 activity. By contrast, relatively low levels of PCho (80 mu M) or choline (20 mu M) nearly doubled UV-induced AP-1 activity, while higher (2-20 mM) concentrations of PCho alone stimulated AP-1 activity 6-8-fold. Importantly, HC-3 inhibited only the stimulatory effect of choline, but not of PCho, on AP-1 activity. Of the mitogen-activated protein (MAP) kinases involved in the regulation of AP-1 activity, UVC stimulated the MAP kinase family ERK-1/ERK-2, JNK as well as p38 kinase activity. These UVC effects were all inhibited by HC-3. With UVB, by contrast, only the activation of ERK-1/ERK-2 was inhibited by HC-3. The data suggest that increased formation of PCho is required for UV-induced activation of AP-1 by an ERK-1/ERK-2-dependent mechanism.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16Th Ave NE, Austin, MN 55912 USA.			Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R29CA074916] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004654] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009292] Funding Source: NIH RePORTER; NCI NIH HHS [CA74916] Funding Source: Medline; NCRR NIH HHS [RR04654] Funding Source: Medline; NIAAA NIH HHS [AA09292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1995, INDUCED GENE EXPRESS, P63; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; CARSBERG CJ, 1995, BIOCHEM J, V305, P471, DOI 10.1042/bj3050471; Chung TW, 1997, J BIOL CHEM, V272, P3064, DOI 10.1074/jbc.272.5.3064; CUADRADO A, 1993, ONCOGENE, V8, P2959; DALY PF, 1987, J BIOL CHEM, V262, P14875; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DONG ZG, 1995, INT J ONCOL, V7, P359; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; EVANS FE, 1977, P NATL ACAD SCI USA, V74, P4909, DOI 10.1073/pnas.74.11.4909; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; *IARC, 1992, IARC MON EV CARC RIS, V55; ISHIDATE K, 1980, BIOCHEM BIOPH RES CO, V96, P946, DOI 10.1016/0006-291X(80)91446-1; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kiss Z, 1996, ARCH BIOCHEM BIOPHYS, V335, P191, DOI 10.1006/abbi.1996.0497; KISS Z, 1995, FEBS LETT, V358, P243, DOI 10.1016/0014-5793(94)01434-3; KISS Z, 1994, BIOCHEM J, V300, P751, DOI 10.1042/bj3000751; Kiss Z, 1997, FEBS LETT, V412, P197, DOI 10.1016/S0014-5793(97)00776-X; KISS Z, 1995, FEBS LETT, V357, P279, DOI 10.1016/0014-5793(94)01371-7; Kiss Z, 1996, BIOCHEM BIOPH RES CO, V218, P505, DOI 10.1006/bbrc.1996.0090; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAVON G, 1977, P NATL ACAD SCI USA, V74, P87, DOI 10.1073/pnas.74.1.87; PAULSON BK, 1989, BIOCHIM BIOPHYS ACTA, V1004, P274, DOI 10.1016/0005-2760(89)90278-6; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; RONAI ZA, 1988, J VIROL, V62, P1057, DOI 10.1128/JVI.62.3.1057-1060.1988; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; TOMONO M, 1995, BIOCHEM BIOPH RES CO, V213, P980, DOI 10.1006/bbrc.1995.2225; WARDEN CH, 1985, J BIOL CHEM, V260, P6006	46	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1845	1853		10.1038/sj.onc.1202084	http://dx.doi.org/10.1038/sj.onc.1202084			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778051				2022-12-28	WOS:000076303300011
J	Alberti, L; Borrello, MG; Ghizzoni, S; Torriti, F; Rizzetti, MG; Pierotti, M				Alberti, L; Borrello, MG; Ghizzoni, S; Torriti, F; Rizzetti, MG; Pierotti, M			Grb2 binding to the different isoforms of Ret tyrosine kinase	ONCOGENE			English	Article						Ret; Grb2; receptor tyrosine kinase; oncogene	PAPILLARY THYROID CARCINOMAS; GROWTH-FACTOR RECEPTOR; CELL-LINE; NEUROTROPHIC FACTOR; PHOSPHOTYROSINE PHOSPHATASE; DOCKING SITE; GDNFR-ALPHA; RI-ALPHA; PROTOONCOGENE; SHC	The RET proto-oncogene encodes two isoforms of a receptor tyrosine kinase which plays a role in neural crest and kidney development. Ret ligands have been recently identified as the neuron survival factor GDNF (Glial-Derived Neurotrophic Factor) and Neurturin. Somatic rearrangements of RET, designated RET/PTCs, have been frequently detected in papillary thyroid carcinomas. In addition, distinct germ-line mutations of RET gene have been associated with the inherited cancer syndromes MEN (Multiple Endocrine Neoplasia) 2A, 2B and FMTC (Familial Medullar Thyroid Carcinomas) as well as with the congenital megacolon or Hirschsprung's disease, thus enlightening a significant role of this receptor gene in diverse human pathologic conditions. In this study, by performing classical inhibition experiments using synthetic phosphopeptides and by site-directed mutagenesis of the putative docking site, we have determined that for Grb2 the latter is provided by the tyrosine 620 of Ret/ptc2 long isoform (corresponding to Tyr 1096 on proto-Ret). However, in intact cells, the interaction of Grb2 with the two short and long Ret isoforms expressed separately is of similar strength, thus suggesting that Ret short isoform interaction with Grb2 could be mediated not only by Shc but also by a molecule that binds preferentially to this isoform. This possibility is supported by the evidence that the mutant Ret/ptc2Y620F long isoform displays a weak coimmunoprecipitation with Grb2 and that this mutant, lacking the docking site for Grb2 but owing all the others phosphotyrosines, surprisingly displays a reduced transforming activity compared to that of the two WTs oncogenes. We thus conclude that in intact cells both Ret isoforms bind to Grb2, although with different modalities, In addition, the present results are in agreement with the possibility that different signal transduction pathways are associated with the two isoforms of Ret.	Ist Nazl Tumori, Div Expt Oncol A, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Borrello, MG (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Via Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Borrello, Maria Grazia/C-3161-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Borrello, Maria Grazia/0000-0002-6854-2848				Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; LANZI C, 1992, ONCOGENE, V7, P2189; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LORENZO MJ, 1995, ONCOGENE, V10, P1377; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MYERS SM, 1995, ONCOGENE, V11, P2039; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Suvanto P, 1997, HUM MOL GENET, V6, P1267, DOI 10.1093/hmg/6.8.1267; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; Tortora G, 1997, ONCOGENE, V14, P923, DOI 10.1038/sj.onc.1200906; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	75	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1079	1087		10.1038/sj.onc.1202046	http://dx.doi.org/10.1038/sj.onc.1202046			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764818				2022-12-28	WOS:000075598400003
J	Jones, N; Dumont, DJ				Jones, N; Dumont, DJ			The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R	ONCOGENE			English	Article						signal transduction; endothelial cells; angiopoietins; Tek/Tie2; receptor tyrosine kinase	GTPASE-ACTIVATING PROTEIN; IRS-1 PTB DOMAIN; TYROSINE KINASE; INSULIN-RECEPTOR; ENDOTHELIAL-CELLS; ADAPTER PROTEIN; TIE2 RECEPTOR; MOLECULAR-CLONING; 2-HYBRID SYSTEM; VASCULAR SYSTEM	Tek/Tie2 is an endothelial cell-specific receptor tyrosine kinase that has been shown to play a role in vascular development of the mouse. Targeted mutagenesis of both Tek and its agonistic ligand, Angiopoietin-1, result in embryonic lethality, demonstrating that the signal transduction pathway(s) mediated by this receptor are crucial for normal embryonic development. In an attempt to identify downstream signaling partners of the Tek receptor, we have used the yeast two-hybrid system to identify phosphotyrosine-dependent interactions. Using this approach, we have identified a novel docking molecule called Dok-R, which has sequence and structural homology to p62(dok) and IRS-3. Mapping of the phospho tyrosine-interaction domain within Dok-R shows that Dok-R interacts with Tek through a PTB domain. Dok-R is coexpressed with Tek in a number of endothelial cell lines. We show that coexpression of Dok-R with activated Tek results in tyrosine phosphorylation of Dok-R and that rasGAP and Nck coimmunoprecipitate with phosphorylated Dok-R. Furthermore, Dok-R is constitutively bound to Crk presumably through the proline rich tail of Dok-R. The cloning of Dok-R represents the first downstream substrate of the activated Tek receptor, and suggests that Tek can signal through a multitude of pathways.	Univ Toronto, AMGEN, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Dumont, DJ (corresponding author), Univ Toronto, AMGEN, Toronto, ON M5G 2C1, Canada.							Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HUANG LW, 1995, ONCOGENE, V11, P2097; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PANDEY A, 1994, J BIOL CHEM, V269, P30154; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rockow S, 1996, ONCOGENE, V12, P2351; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TANAKA S, 1993, MOL CELL BIOL, V14, P5495; Tang JP, 1997, ONCOGENE, V15, P1823, DOI 10.1038/sj.onc.1201351; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIEGLER SF, 1993, ONCOGENE, V8, P663	66	125	132	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1097	1108		10.1038/sj.onc.1202115	http://dx.doi.org/10.1038/sj.onc.1202115			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764820				2022-12-28	WOS:000075598400005
J	Ledda-Columbano, GM; Curto, M; Piga, R; Zedda, AI; Menegazzi, M; Sartori, C; Shinozuka, H; Bluethmann, H; Poli, V; Ciliberto, G; Columbano, A				Ledda-Columbano, GM; Curto, M; Piga, R; Zedda, AI; Menegazzi, M; Sartori, C; Shinozuka, H; Bluethmann, H; Poli, V; Ciliberto, G; Columbano, A			In vivo hepatocyte proliferation is inducible through a TNF and IL-6-independent pathway	ONCOGENE			English	Article						cell proliferation; TNF; IL-6; TCPOBOP; ciprofibrate; liver	TUMOR-NECROSIS-FACTOR; PEROXISOME PROLIFERATOR; LIVER-REGENERATION; MOUSE-LIVER; C-FOS; BINDING-PROTEINS; MICE LACKING; RECEPTOR; GROWTH; ALPHA	Recent studies in mice harboring a targeted disruption of genes encoding TNF receptor 1 (TNFR-1) or Interleukin 6 (IL-6) suggested a critical role for TNF and IL-6 in initiation of liver regeneration after 2/3 partial hepatectomy. However, hepatocyte proliferation can also occur following treatment with agents that do not induce tissue loss (primary mitogens). To determine whether the above cytokines could also be involved in mitogen-induced liver cell proliferation, we studied the hepatocyte proliferative response after treatment with primary mitogens in mice knock-out for TNFR-1 or IL-6. Our results showed no difference in the proliferative response of the liver between the wild type and the knock-out mice following treatment with the mitogens I,4-bis[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP), or the peroxisome proliferator, ciprofibrate, suggesting that TNF or IL-6 may not play a major role in this type of proliferation. Gel shift assay indicated that TCPOBOP-induced hepatocyte proliferation is not associated with activation of STAT3 transcription factor, a major target of IL-6 and other growth factors/cytokines. Our results thus indicate that hepatocyte proliferation can be induced by at least two different pathways; compensatory regeneration being TNF and IL-6-dependent, and mitogen-induced direct hyperplasia which does not require TNF or IL-6.	Univ Cagliari, Dipartimento Tossicol, Sez Oncol & Patol Mol, Cagliari, Italy; Univ Rome, Dipartimento Biol Cellulare & Sviluppo, Rome, Italy; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Verona, Ist Sci Biochim, I-37100 Verona, Italy; Hoffman LaRoche, Basel, Switzerland; IRBM, Rome, Italy	University of Cagliari; Sapienza University Rome; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Verona; Roche Holding; Merck & Company	Ledda-Columbano, GM (corresponding author), Univ Cagliari, Dipartimento Tossicol, Sez Oncol & Patol Mol, Cagliari, Italy.		Menegazzi, Marta/AAE-7079-2019; Columbano, Amedeo/C-7463-2011; Ciliberto, Gennaro/J-4131-2017; Poli, Valeria/A-9215-2012	Menegazzi, Marta/0000-0003-1310-9227; Columbano, Amedeo/0000-0002-6956-9030; Ciliberto, Gennaro/0000-0003-2851-8605; Poli, Valeria/0000-0002-3739-3966				AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; Beebe LE, 1996, BIOCHEM PHARMACOL, V52, P1507, DOI 10.1016/S0006-2952(96)00525-4; BENEDETTI L, 1994, ARCH BIOCHEM BIOPHYS, V309, P1, DOI 10.1006/abbi.1994.1075; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Columbano A, 1996, FASEB J, V10, P1118, DOI 10.1096/fasebj.10.10.8751714; Columbano A, 1997, ONCOGENE, V14, P857, DOI 10.1038/sj.onc.1200891; CONI P, 1993, HEPATOLOGY, V17, P1109, DOI 10.1002/hep.1840170626; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; Higgins GM, 1931, ARCH PATHOL, V12, P186; HONKAKOSKI P, 1992, BIOCHEM PHARMACOL, V43, P2121, DOI 10.1016/0006-2952(92)90170-N; KELLER H, 1995, MOL ENDOCRINOL, V9, P794, DOI 10.1210/me.9.7.794; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; Kubo Y, 1996, HEPATOLOGY, V23, P104, DOI 10.1002/hep.510230115; LEVINE WG, 1977, BIOCHEM PHARMACOL, V26, P939, DOI 10.1016/0006-2952(77)90470-1; MANENTI G, 1987, CHEM-BIOL INTERACT, V64, P83, DOI 10.1016/0009-2797(87)90062-7; MENGAZZI M, 1997, HEPATOLOGY, V25, P585; Ohmura T, 1996, AM J PATHOL, V148, P815; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TRAUTWEIN C, 1994, GUT, V35, P1163, DOI 10.1136/gut.35.9.1163; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WHITE TEK, 1993, BIOCHEM BIOPH RES CO, V193, P956, DOI 10.1006/bbrc.1993.1718; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	33	81	81	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1039	1044		10.1038/sj.onc.1202018	http://dx.doi.org/10.1038/sj.onc.1202018			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747883				2022-12-28	WOS:000075560900012
J	Maerz, WJ; Baselga, J; Reuter, VE; Mellado, B; Myers, ML; Bosl, GJ; Spinella, MJ; Dmitrovsky, E				Maerz, WJ; Baselga, J; Reuter, VE; Mellado, B; Myers, ML; Bosl, GJ; Spinella, MJ; Dmitrovsky, E			FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas	ONCOGENE			English	Article						human embryonal carcinomas; fibroblast growth factor-4; all-trans-retinoic acid; differentiation; tumorigenicity	FIBROBLAST GROWTH-FACTOR; GERM-CELL TUMORS; HUMAN TERATOCARCINOMA CELL; K-FGF; FACTOR-IV; RECEPTOR EXPRESSION; TRANSFORMING GENE; F9 CELLS; LINE; FAMILY	A subset of male germ cell cancers presenting with advanced stage abundantly express the fibroblast growth factor-4 (FGF4), FGF4 expression is restricted in vitro to undifferentiated embryonal carcinomas (ECs), During induced differentiation, FGF4 expression is repressed in maturation sensitive but not resistant human ECs, suggesting FGF4 plays an important role in malignant growth or differentiation of ECs, To explore these FGF4 signals in male germ cell cancers, the multipotent human EC NTERA-2 clone D1 (NT2/D1) cell line was studied, All-trans-retinoic acid (RA)-treatment of these cells induces re neuronal phenotype and represses tumorigenicity and FGF4 expression, In contrast, RA-treatment of retinoid resistant lines derived from NT2/D1 cells failed to repress FGF4 expression, This implicated FGF4 directly in regulating human EC growth or differentiation, To evaluate further this FGF4 role, FGF4 was constitutively over-expressed in NT2/D1 cells using a CMV-driven expression vector containing the neomycin resistance gene, Three stable transfectants expressing exogenous FGF4 were studied as was a control transfectant only expressing the neomycin resistance gene, RA-treatment repressed endogenous but not exogenous FGF4 expression, RA-treatment of these transfectants induced morphologic and immunophenotypic maturation, changes in RA-regulated genes, and a G1 cell cycle arrest in a manner similar to parental NT2/D1 cells, This indicated FGF4 over-expression did not block RA-mediiated differentiation, As expected, RA-treatment repressed tumorigenicity of the control transfectant after subcutaneous injection into athymic mice. Despite RA-treatment, this repressed tumorigenicity was overcome in all the transfectants over-expressing FGF4, The histopathology and neovascularization did not appreciably differ between xenograft tumors derived from FGF4 over-expressing versus control transfectants. FGF4 expression studies were extended to patient-derived germ cell tumors using total cellular RNA Northern analysis and an immunohistochemical assay developed to detect FGF4 protein expression, Germ cell tumors with EC components were significantly more likely to express FGF4 mRNA (P less than or equal to 0.0179) than other examined germ cell tumors without EC components, Immunohistochemical results from 43 germ cell tumors demonstrated increased FGF4 expression especially in non-seminomas having EC components, Thus, FGF4 promotes directly malignant growth of cultured ECs, overcomes the antitumorigenic actions of RA, and is selectively expressed in specific histopathologic subsets of germ cell tumors. Taken together, these findings indicate how differentiation and anti-tumorigenic retinoic acid signals can be dissociated in germ cell cancer.	Mem Hosp, Mol Med Lab, New York, NY 10021 USA; Mem Hosp, Dept Med, New York, NY 10021 USA; Mem Hosp, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Dmitrovsky, E (corresponding author), Mem Hosp, Mol Med Lab, 1275 York Ave, New York, NY 10021 USA.		Spinella, Michael/B-7210-2014		NATIONAL CANCER INSTITUTE [R01CA054494, U01CA060126, R01CA060126] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA 54494-06, CA 60126] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANKO T, 1994, DEV BIOL, V161, P141, DOI 10.1006/dbio.1994.1016; Alanko T, 1996, EXP CELL RES, V228, P306, DOI 10.1006/excr.1996.0330; Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1984, LAB INVEST, V50, P147; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Baldassarre G, 1996, INT J CANCER, V66, P538, DOI 10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3; BASELGA J, 1993, ONCOGENE, V8, P3257; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CAMPBELL WJ, 1992, IN VITRO CELL DEV-AN, V28A, P61; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; CROUCH GD, 1991, CANCER RES, V51, P4882; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JUNG M, 1994, CANCER RES, V54, P5194; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; Miller K, 1996, CELL GROWTH DIFFER, V7, P203; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; MUMMERY CL, 1993, BIOCHEM BIOPH RES CO, V191, P188, DOI 10.1006/bbrc.1993.1201; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; PERTOVAARA L, 1993, BIOCHEM BIOPH RES CO, V191, P149, DOI 10.1006/bbrc.1993.1196; Quito FL, 1996, BLOOD, V87, P1282, DOI 10.1182/blood.V87.4.1282.bloodjournal8741282; RUSCH V, 1995, CANCER RES, V55, P1365; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHOFIELD PN, 1991, FEBS LETT, V280, P8, DOI 10.1016/0014-5793(91)80192-6; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STROHMEYER T, 1991, CANCER RES, V51, P1811; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TALARICO D, 1993, MOL CELL BIOL, V13, P1998, DOI 10.1128/MCB.13.4.1998; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; VELCICH A, 1989, ONCOGENE RES, V5, P31; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	50	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	1998	17	6					761	767		10.1038/sj.onc.1201992	http://dx.doi.org/10.1038/sj.onc.1201992			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715278				2022-12-28	WOS:000075337200011
J	Erickson, S; Sangfelt, O; Heyman, M; Castro, J; Einhorn, S; Grander, D				Erickson, S; Sangfelt, O; Heyman, M; Castro, J; Einhorn, S; Grander, D			Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence	ONCOGENE			English	Article						T-lymphocytes; p16; p15 senescence	DEPENDENT KINASE INHIBITORS; CELL-CYCLE CONTROL; REPLICATIVE SENESCENCE; TUMOR SUPPRESSION; HUMAN-FIBROBLASTS; MAMMALIAN-CELLS; TGF-BETA; EXPRESSION; GENE; INACTIVATION	Little is known about the molecular background to senescence in T-lymphocytes. In fibroblast systems replicative senescence has been shown to correlate with a number of changes in the expression of the proteins normally regulating progression through the G1 phase of the cell cycle, and recently the Ink4 inhibitor p16 was implicated as a central regulator of replicative senescence in human fibroblasts. It has, however, been claimed that p16 is not expressed in T-lymphocytes, In the present study we have analysed G1 regulating proteins in ageing human T-lymphocytes, We show that PHA and IL-2 stimulated T-lymphocytes cease to proliferate after around 20 population doublings, these cells can not thereafter be restimulated to growth, and were also found to exhibit markers for senescence, We found that T-lymphocytes accumulate p16 and p15 protein during successive population doublings and display high levels of these proteins as they enter into replicative senescence. There was also an increased binding of p16 to the Cdk6 kinase in senescent cells, and a decreased Cdk6 as well as Cdk2 kinase activity. The levels of other G1 regulating proteins were also altered in the senescent cells, such as slightly elevated levels of p21/WAF1, and downregulation of Cdk2 and cyclinD3, The levels off p27/Kipl is down regulated in proliferating cells but rise to approximately 15% of the levels in un-stimulated quiescent cells. As a high proportion of T-cell childhood acute lymphoblastic leukaemias have deletions of both p15 and p16, our data suggest that inactivation of these genes makes it possible for leukemic cells to avoid senescence.	Karolinska Hosp & Inst, Dept Pathol & Oncol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Grander, D (corresponding author), Karolinska Hosp & Inst, Dept Pathol & Oncol, S-17176 Stockholm, Sweden.							Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ATADJA P, 1995, P NATL ACAD SI US, V92, P8328; Batova A, 1997, CANCER RES, V57, P832; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Effros RB, 1996, EXP GERONTOL, V31, P21, DOI 10.1016/0531-5565(95)00017-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GOLDSTEIN S, 1994, J CELL PHYSIOL, V161, P571, DOI 10.1002/jcp.1041610321; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Herman JG, 1996, CANCER RES, V56, P722; Heyman M, 1996, LEUKEMIA LYMPHOMA, V23, P235, DOI 10.3109/10428199609054826; HIRAMA T, 1995, BLOOD, V86, P841; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Kamb A, 1994, Nat Genet, V8, P23; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; LOIS AF, 1995, CANCER RES, V55, P4010; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PERILLO NL, 1993, EXP CELL RES, V207, P131, DOI 10.1006/excr.1993.1171; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Reznikoff CA, 1996, CANCER RES, V56, P2886; RYAN QC, 1993, CELL IMMUNOL, V149, P65, DOI 10.1006/cimm.1993.1136; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; SONODA Y, 1995, ONCOGENE, V11, P2145; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TAM SW, 1994, CANCER RES, V54, P5816; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; ULLBERG M, 1983, SCAND J IMMUNOL, V17, P365, DOI 10.1111/j.1365-3083.1983.tb00801.x	44	82	85	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					595	602		10.1038/sj.onc.1201965	http://dx.doi.org/10.1038/sj.onc.1201965			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704925				2022-12-28	WOS:000075195300007
J	Fenstermaker, RA; Ciesielski, MJ; Castiglia, GJ				Fenstermaker, RA; Ciesielski, MJ; Castiglia, GJ			Tandem duplication of the epidermal growth factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells	ONCOGENE			English	Article						epidermal growth factor receptor; mutation; genetic recombination; glioma; intron; oncogene	HUMAN GLIOBLASTOMA; EGF-RECEPTOR; MALIGNANT GLIOMAS; BRAIN-TUMORS; FACTOR-ALPHA; C-MYB; GENE; EXPRESSION; TRANSFORMATION; AMPLIFICATION	Amplification and rearrangement of the epidermal growth factor receptor (EGFR) gene occur frequently in malignant gliomas. Rearrangement may also lead to the expression of potentially oncogenic EGFR deletion mutants. Data presented here indicate the existence of a 190 kDa mutant form of the EGFR in A-172 glioma cells that is substantially different from the deletion mutants characterized previously. The EC;FR-like protein is expressed along with the 170 kDa wild type EGFR. It is detectable with antibodies to both extracellular and intracellular regions of the EGFR, but is not crossreactive with other HER-family members, The wild type and mutant receptors undergo phosphorylation in response to treatment with TGF alpha and are associated with expression of both 10.5 kb and 11.5 kb EGFR-related transcripts. Combined reverse transcription-polymerase chain reaction (RT-PCR) identifies a unique transcript in A-172 cells that encodes an in-frame, tandem duplication of both tyrosine kinase and calcium internalization (TK/CAIN) domains (exons 18 through 26). The duplication of these domains is associated with a specific genomic rearrangement between potential v-myb and c-myb consensus binding sites within introns 26 and 17 of the EGFR gene resulting in the formation of a chimeric intron.	Roswell Pk Canc Inst, Dept Neurosurg, Buffalo, NY 14263 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14209 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Fenstermaker, RA (corresponding author), Roswell Pk Canc Inst, Dept Neurosurg, Elm & Carlton St, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056-21] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGNES F, 1994, GENE, V145, P283, DOI 10.1016/0378-1119(94)90021-3; BASAU A, 1989, MOL CELL BIOL, V9, P671; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BIGNER SH, 1990, CANCER RES, V50, P8017; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BOGLER O, 1995, CANCER RES, V55, P2746; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; Deng QL, 1996, NUCLEIC ACIDS RES, V24, P766, DOI 10.1093/nar/24.4.766; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Frisa PS, 1996, CELL GROWTH DIFFER, V7, P223; HALEY JD, 1989, ONCOGENE, V4, P273; HernandezMunain C, 1996, J EXP MED, V183, P289, DOI 10.1084/jem.183.1.289; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; HUMPHREY PA, 1988, CANCER RES, V48, P2231; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; MAHALEY MS, 1991, J NEURO-ONCOL, V11, P85, DOI 10.1007/BF02390173; MARUNO M, 1991, J NEUROSURG, V75, P97, DOI 10.3171/jns.1991.75.1.0097; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Moscatello DK, 1996, ONCOGENE, V13, P85; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PANNEERSELVAM K, 1995, EUR J BIOCHEM, V230, P951, DOI 10.1111/j.1432-1033.1995.tb20641.x; PELLEY RJ, 1988, J VIROL, V54, P304; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; RASHEED BKA, 1994, CANCER RES, V54, P1324; SCHLEGEL J, 1994, INT J CANCER, V56, P72; STECK PA, 1988, CANCER RES, V48, P5433; SU HHJ, 1997, J BIOL CHEM, V272, P2927; Ueki K, 1996, CANCER RES, V56, P150; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WELTER C, 1990, CANCER LETT, V52, P57, DOI 10.1016/0304-3835(90)90077-B; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMOMOTO T, 1983, CELL, V34, P225; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812	47	27	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3435	3443		10.1038/sj.onc.1202156	http://dx.doi.org/10.1038/sj.onc.1202156			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692551				2022-12-28	WOS:000074544100010
J	Marchetti, D; Parikh, N; Sudol, M; Gallick, GE				Marchetti, D; Parikh, N; Sudol, M; Gallick, GE			Stimulation of the protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic melanoma cells	ONCOGENE			English	Article						c-Yes, c-Src; neurotrophins; nerve growth factor; neurotrophin-3; brain-metastatic melanoma	NERVE GROWTH-FACTOR; HUMAN-MALIGNANT MELANOMA; ELEVATED EXPRESSION; HUMAN MELANOCYTES; TUMOR-METASTASIS; NUDE-MICE; PP60C-SRC; PARACRINE; RECEPTOR; INVASION	The c-Yes proto-oncogene (pp62(c-Yes)) encodes a nonreceptor-type protein tyrosine kinase (NRPTK) of the Src family. c-Yes activities and protein levels are elevated in human melanoma and melanocyte cell lines. Because the neurotrophins (NT) are important in the progression of melanoma to the brain-metastatic phenotype, we determined whether NT stimulate c-Yes activity in human MeWo melanoma cells and two variant sublines with opposite metastatic capabilities, 3 S 5 and 70W, The highly brain-metastatic 70W subline had an intrinsically higher c-Yes activity than parental MeWo or poorly metastatic 3 S 5 cells, c-Yes kinase was further induced by the prototypic human NT, nerve growth factor (NGF) in a dose and time-dependent manner. In contrast, c-Src activity (pp60(c-Src)) was similar in all these cells and unaffected by NGF exposure. Additionally, human NGF and neurotrophin-3 stimulated c-Yes in brain-metastatic 70W cells. The magnitude of c-Yes activation correlated with the degree of invasion of 70 W cells following incubation of these neurotrophins. To further examine NT stimulation of c-Yes in melanoma cells, three additional cell lines were examined. Metastatic TXM-13 and TXM-18 increased c-Yes activity in response to NGF. In contrast, no increase was observed in low-metastatic TXM-40 cells. Together, these data suggest that altered c-Yes expression may play a role in the malignant progression of the human melanocyte towards the brain-metastatic phenotype and that NT enhance the activity of c-Yes in signaling penetration into the matrix of NT-rich stromal microenvironments such as the brain.	Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	University of Texas System; UTMD Anderson Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Marchetti, D (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA.				NCI NIH HHS [CA 63617, R-29 CA 64178, CA 01605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064178] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKSLEN LA, 1987, INVAS METAST, V7, P253; ALBINO AP, 1991, CANCER RES, V51, P4815; BARBACID M, 1993, ONCOGENE, V8, P2033; BARNEKOW A, 1987, CANCER RES, V47, P235; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; FANNING P, 1992, CANCER RES, V52, P1457; GOLDEN A, 1988, SRC ONCOGENE ONCOGEN, P149; GRANDORI C, 1991, ONCOGENE, V6, P1063; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUTMAN M, 1994, ANTICANCER RES, V14, P1759; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HERLYN M, 1985, CANCER RES, V45, P5670; HERRMANN JL, 1993, MOL BIOL CELL, V4, P1205, DOI 10.1091/mbc.4.11.1205; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; ISHIKAWA M, 1988, CANCER RES, V48, P665; ISHIKAWA M, 1988, CANCER RES, V48, P4897; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LOGANZO F, 1993, ONCOGENE, V8, P2637; Marchetti D, 1996, CANCER RES, V56, P2856; MARCHETTI D, 1993, INT J CANCER, V55, P692, DOI 10.1002/ijc.2910550430; Marchetti D, 1997, ADV ENZYME REGUL, V37, P111, DOI 10.1016/S0065-2571(96)00019-2; Marchetti D, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P99, DOI 10.1038/jidsymp.1997.19; MARCHETTI D, 1995, INT J ONCOL, V7, P87; NICOLSON GL, 1993, EXP CELL RES, V204, P171, DOI 10.1006/excr.1993.1022; NICOLSON GL, 1986, INT J CANCER, V38, P289, DOI 10.1002/ijc.2910380221; NICOLSON GL, 1993, CANCER METAST REV, V12, P325, DOI 10.1007/BF00665961; NICOLSON GL, 1994, CRIT REV ONCOGENESIS, V5, P451, DOI 10.1615/CritRevOncog.v5.i5.20; NICOLSON GL, 1994, J NEURO-ONCOL, V18, P139, DOI 10.1007/BF01050420; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Steck Peter A., 1993, P371; SUDOL M, 1988, BRAIN RES REV, V13, P391, DOI 10.1016/0165-0173(88)90014-8; SUDOL M, 1989, MOL CELL BIOL, V9, P4545, DOI 10.1128/MCB.9.10.4545; SUDOL M, 1992, MOL BASIS HUMAN CANC; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WRIGHT DC, 1989, CANCER PRINCIPLES PR, P2245; ZHANG RD, 1991, CANCER RES, V51, P2029; ZHAO YH, 1990, ONCOGENE, V5, P1629	49	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	1998	16	25					3253	3260		10.1038/sj.onc.1201877	http://dx.doi.org/10.1038/sj.onc.1201877			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681823	Bronze			2022-12-28	WOS:000074343600005
J	Varley, JM; Chapman, P; McGown, G; Thorncroft, M; White, GRM; Greaves, MJ; Scott, D; Spreadborough, A; Tricker, KJ; Birch, JM; Evans, DGR; Reddel, R; Camplejohn, RS; Burn, J; Boyle, JM				Varley, JM; Chapman, P; McGown, G; Thorncroft, M; White, GRM; Greaves, MJ; Scott, D; Spreadborough, A; Tricker, KJ; Birch, JM; Evans, DGR; Reddel, R; Camplejohn, RS; Burn, J; Boyle, JM			Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family	ONCOGENE			English	Article						Li-Fraumeni; TP53; splicing	CANCER-PRONE FAMILY; P53 MUTATIONS; BREAST-CANCER; IRRADIATION; POLYMORPHISM; GENOME; BLOOD; ASSAY	We report an extensive Li-Fraumeni-like family in which there is an unusual spectrum of tumours at relatively late onset. A germline TP53 splice donor mutation in exon 4 is present in all affected family members available for testing. The mutation abolishes correct splicing of intron 4 and techniques of RT-PCR have identified three different aberrant transcripts from the mutant TP53 allele. Using the yeast functional assay to analyse transcripts in cells from a number of family members with the mutant allele, TP53 appears wild-type, Functional studies have been carried out on cells from patients with and without cancer who carry the germline mutation, and on cells from unaffected individuals from the same family who do not carry the mutation. Using a number of functional endpoints known to distinguish between cells carrying mutant or wild-type TP53 alleles, we were unable to discriminate normal (wt/wt) from heterozygous (wt/mut) cells by lymphocyte apoptosis and fibroblast survival following low dose rate ionising radiation exposure. However germline mutation carriers show increased sensitivity to radiation-induced chromosome damage in the G(2) phase of the cell cycle, and decreased transient and permanent G(1) arrest. These studies demonstrate the importance of fully characterising the effects of TP53 germline mutations, and may explain some of the phenotypic features of this family.	Paterson Inst Canc Res, CRC, Mol Genet Sect, Manchester M20 9BX, Lancs, England; Univ Newcastle Upon Tyne, Dept Human Genet, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Paterson Inst Canc Res, CRC, Paediat & Familial Canc Res Grp, Manchester M20 9BX, Lancs, England; St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; Childrens Med Res Inst, Sydney, NSW 2145, Australia; St Thomas Hosp, Richard Dimbleby Dept Canc Res, London SE1 7EH, England	Paterson Institute for Cancer Research; Newcastle University - UK; Paterson Institute for Cancer Research; University of Manchester; Children's Medical Research Institute - Australia; University of Sydney; Guy's & St Thomas' NHS Foundation Trust	Varley, JM (corresponding author), Paterson Inst Canc Res, CRC, Mol Genet Sect, Wilmslow Rd, Manchester M20 9BX, Lancs, England.		Reddel, Roger R/A-6635-2014; Evans, D Gareth/AAB-4308-2022	Reddel, Roger R/0000-0002-6302-6107; Evans, D Gareth/0000-0002-8482-5784; Burn, John/0000-0002-9823-2322				BIRCH JM, 1994, CANCER RES, V54, P1298; BOYLE JM, 1998, IN PRESS BR J CANC; CAMPLEJOHN RS, 1995, BRIT J CANCER, V72, P654, DOI 10.1038/bjc.1995.390; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; Heineman EF, 1996, CANCER, V77, P549, DOI 10.1002/(SICI)1097-0142(19960201)77:3<549::AID-CNCR18>3.0.CO;2-4; HOGGARD N, 1995, GENE CHROMOSOME CANC, V12, P24, DOI 10.1002/gcc.2870120105; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Lomax ME, 1997, ONCOGENE, V14, P1869, DOI 10.1038/sj.onc.1201133; MACGEOCH C, 1995, J MED GENET, V32, P186, DOI 10.1136/jmg.32.3.186; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mitchell ELD, 1997, INT J RADIAT BIOL, V72, P435, DOI 10.1080/095530097143202; PARSHAD R, 1993, RADIAT RES, V136, P236, DOI 10.2307/3578616; SCOTT D, 1993, NATO ASI SERIES H, V77, P101; Sproston ARM, 1996, INT J RADIAT BIOL, V70, P145, DOI 10.1080/095530096145139; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; Williams KJ, 1997, ONCOGENE, V14, P277, DOI 10.1038/sj.onc.1200838	27	45	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3291	3298		10.1038/sj.onc.1201878	http://dx.doi.org/10.1038/sj.onc.1201878			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681828				2022-12-28	WOS:000074343600010
J	Bugge, TH; Lund, LR; Kombrinck, KK; Nielsen, BS; Holmback, K; Drew, AF; Flick, MJ; Witte, DP; Dano, K; Degen, JL				Bugge, TH; Lund, LR; Kombrinck, KK; Nielsen, BS; Holmback, K; Drew, AF; Flick, MJ; Witte, DP; Dano, K; Degen, JL			Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice	ONCOGENE			English	Article						cancer; gene targeting; mammary carcinoma; metastasis; plasminogen	LEWIS LUNG-CARCINOMA; ASCITES TUMOR-GROWTH; BREAST-CANCER; UROKINASE RECEPTOR; MESSENGER-RNA; ACTIVATOR ACTIVITY; COLORECTAL-CANCER; STROMA FORMATION; MELANOMA-CELLS; INHIBITION	To investigate the role of plasmin(ogen) in mammary tumor development and progression, plasminogen-deficient mice were crossed with transgenic mice expressing Polyoma middle T antigen under the control of the mouse mammary tumor virus long terminal repeat. Virgin females carrying the Polyoma middle T antigen uniformly developed multiple, bilateral mammary tumors, regardless of the presence or absence of circulating plasminogen. Both the age at which these tumors became palpable and subsequent tumor growth were indistinguishable between plasminogen-deficient mice and plasminogen-expressing littermates. Hoowever, plasminogen was found to greatly modify the metastatic potential in this model system; lung metastasis in plasminogen-deficient mice was significantly reduced as compared to littermate controls with respect to frequency of occurrence, total number of metastases, and total metastatic tumor burden. Plasminogen activators, as well as other key factors that govern the conversion of plasminogen to plasmin, were expressed within the mammary tumors, suggesting that the plasminogen/plasmin system may promote metastasis by contributing to tumor-associated extracellular proteolysis. The data provide direct evidence that plasmin(ogen) is a tumor progression factor in PymT-induced mammary cancer, and support the hypothesis that hemostatic factors play an important role in tumor biology.	Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA; Childrens Hosp Res Fdn, Div Pathol, Cincinnati, OH 45229 USA; Finsen Lab, DK-2100 Copenhagen, Denmark	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Degen, JL (corresponding author), Childrens Hosp Res Fdn, Div Dev Biol, IDR NRB Room 2025,3333 Burnet Ave, Cincinnati, OH 45229 USA.				NHLBI NIH HHS [HL47826] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047826] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson IC, 1996, CANCER RES, V56, P715; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BROWN LF, 1988, CANCER RES, V48, P1920; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; Bugge TH, 1997, BLOOD, V90, P4522; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Coleman JL, 1997, CELL, V89, P1111, DOI 10.1016/S0092-8674(00)80298-6; COLLEN D, 1994, MOL BASIS BLOOD DIS, P725; Conway JG, 1996, CLIN EXP METASTAS, V14, P115, DOI 10.1007/BF00121208; CRAWFORD HC, 1994, INVAS METAST, V14, P234; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Drew AF, 1998, BLOOD, V91, P1616, DOI 10.1182/blood.V91.5.1616.1616_1616_1624; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; DUFFY MJ, 1990, CANCER RES, V50, P6827; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; DVORAK HF, 1992, ANN NY ACAD SCI, V667, P101, DOI 10.1111/j.1749-6632.1992.tb51603.x; FOEKENS JA, 1992, CANCER RES, V52, P6101; FRAKI JE, 1983, BRIT J DERMATOL, V108, P39, DOI 10.1111/j.1365-2133.1983.tb04577.x; GANESH S, 1994, CANCER RES, V54, P4065; GRODAHLHANSEN J, 1993, CANCER RES, V53, P2513; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HARRIS NL, 1982, AM J PATHOL, V108, P119; HEARING VJ, 1988, CANCER RES, V48, P1270; HEINERT G, 1988, J UROLOGY, V140, P1466; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; Holmback K, 1996, EMBO J, V15, P5760, DOI 10.1002/j.1460-2075.1996.tb00962.x; JANICKE F, 1989, LANCET, V2, P1049; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; KOBAYASHI H, 1994, INT J CANCER, V57, P727, DOI 10.1002/ijc.2910570520; KOHN EC, 1995, CANCER RES, V55, P1856; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Martin DC, 1996, ONCOGENE, V13, P569; Min HY, 1996, CANCER RES, V56, P2428; MOCHAN E, 1984, J RHEUMATOL, V11, P123; MUELLER BM, 1995, P NATL ACAD SCI USA, V92, P205, DOI 10.1073/pnas.92.1.205; MULCAHY HE, 1994, LANCET, V344, P583, DOI 10.1016/S0140-6736(94)91968-2; NAGY JA, 1995, CANCER RES, V55, P376; NAGY JA, 1995, CANCER RES, V55, P369; NEKARDA H, 1994, LANCET, V343, P117, DOI 10.1016/S0140-6736(94)90845-1; Nielsen BS, 1996, LAB INVEST, V74, P168; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; OKA T, 1991, CANCER RES, V51, P3522; OSSOWSKI L, 1991, CANCER RES, V51, P274; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PEDERSEN H, 1994, CANCER RES, V54, P4671; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PYKE C, 1991, CANCER RES, V51, P4067; PYKE C, 1993, CANCER RES, V53, P1911; PYKE C, 1991, AM J PATHOL, V138, P1059; Rabbani SA, 1995, INT J CANCER, V63, P840, DOI 10.1002/ijc.2910630615; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROMER J, 1991, J INVEST DERMATOL, V97, P803, DOI 10.1111/1523-1747.ep12486833; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1987, ACTA OPHTHALMOL, V65, P3; SAPPINO AP, 1987, CANCER RES, V47, P4043; Schuster V, 1997, BLOOD, V90, P958, DOI 10.1182/blood.V90.3.958.958_958_966; SCHWARTZ MK, 1995, CLIN CHIM ACTA, V237, P67, DOI 10.1016/0009-8981(95)06065-L; Shapiro RL, 1996, CANCER RES, V56, P3597; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SKRIVER L, 1984, Journal of Cell Biology, V99, P752; SLEDGE GW, 1995, J NATL CANCER I, V87, P1546, DOI 10.1093/jnci/87.20.1546; SOEDA E, 1980, NATURE, V283, P445, DOI 10.1038/283445a0; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Tsirka SE, 1997, J NEUROSCI, V17, P543; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Xiao Q, 1997, P NATL ACAD SCI USA, V94, P10335, DOI 10.1073/pnas.94.19.10335; YU H, 1990, CANCER RES, V50, P7623	80	130	135	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3097	3104		10.1038/sj.onc.1201869	http://dx.doi.org/10.1038/sj.onc.1201869			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671388				2022-12-28	WOS:000074261300002
J	Cowell, JK; Bia, B				Cowell, JK; Bia, B			A novel missense mutation in patients from a retinoblastoma pedigree showing only mild expression of the tumor phenotype	ONCOGENE			English	Article						retinoblastoma; missense mutation; incomplete penetrance; SSCP	ONCOGENIC POINT MUTATIONS; GERM-LINE MUTATIONS; RB1 GENE; HEREDITARY RETINOBLASTOMA; FAMILIAL RETINOBLASTOMA; INCOMPLETE PENETRANCE; MECHANISMS; SPECTRUM; IDENTIFICATION; SITES	We have used single strand conformation polymorphism analysis to study the 27 exons of the RB1 gene in individuals from a family showing 'mild' expression of the retinoblastoma phenotype. In this family affected individuals developed unilateral tumors and, as a result of linkage analysis, unaffected mutation carriers were also identified within the pedigree. A single band shift using SSCP was identified in exon 21 which resulted in a missense mutation converting a cys-->arg at nucleotide position 28 in the exon. The mutation destroyed an NdeI restriction enzyme site. Analysis of all family members demonstrated that the missense mutation co-segregated with patients with tumors or who, as a result of linkage analysis had been predicted to carry the predisposing mutation. These observations point to another region of the RBI gene where mutations only modify the function of the gene and raise important questions for genetic counseling in families with these distinctive phenotypes.	Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Cowell, JK (corresponding author), Cleveland Clin Fdn, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950				BLANQUET V, 1995, HUM MOL GENET, V4, P383, DOI 10.1093/hmg/4.3.383; BLANQUET V, 1993, HUM MOL GENET, V2, P975, DOI 10.1093/hmg/2.7.975; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; CONNOLLY MJ, 1983, HUM GENET, V65, P122, DOI 10.1007/BF00286647; Cowell JK, 1996, ONCOGENE, V12, P431; Cowell JK, 1996, EUR J CANCER, V32A, P1749, DOI 10.1016/0959-8049(96)00201-8; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DRAPER GJ, 1992, BRIT J CANCER, V66, P211, DOI 10.1038/bjc.1992.244; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; HOGG A, 1992, ONCOGENE, V7, P1445; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRATZKE RA, 1994, ONCOGENE, V9, P1321; LIU ZX, 1995, GENE CHROMOSOME CANC, V14, P277, DOI 10.1002/gcc.2870140406; Lohmann DR, 1996, AM J HUM GENET, V58, P940; LOHMANN DR, 1994, HUM MOL GENET, V3, P2187, DOI 10.1093/hmg/3.12.2187; MACKLIN MT, 1960, AM J HUM GENET, V12, P1; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; ONADIM Z, 1993, BRIT J CANCER, V68, P958, DOI 10.1038/bjc.1993.461; ONADIM ZO, 1990, ARCH DIS CHILD-FETAL, V65, P651, DOI 10.1136/adc.65.7_Spec_No.651; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SHIMIZU T, 1994, AM J HUM GENET, V54, P793; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	29	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3211	3213		10.1038/sj.onc.1201833	http://dx.doi.org/10.1038/sj.onc.1201833			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671401				2022-12-28	WOS:000074261300015
J	Lee, HY; Chaudhary, J; Walsh, GL; Hong, WK; Kurie, JM				Lee, HY; Chaudhary, J; Walsh, GL; Hong, WK; Kurie, JM			Suppression of c-Fos gene transcription with malignant transformation of human bronchial epithelial cells	ONCOGENE			English	Article						Jun N-terminal kinase; extra-cellular signal-related kinase	SERUM RESPONSE ELEMENT; SIGNAL-TRANSDUCTION PATHWAYS; MONOCLONAL-ANTIBODY; SEQUENCE ELEMENTS; PROTO-ONCOGENE; ACTIVATION; GROWTH; INDUCTION; BINDING; EXPRESSION	The Activator Protein-1 (AP-1) complex is a dimeric transcription factor composed of fos and jun proteins that regulates cellular growth and differentiation. We previously demonstrated a reduction in basal AP-1 transcriptional activity associated with the malignant transformation of human bronchial epithelial (HBE) cells that was, in part, a consequence of decreased c-fos expression. In this study, we investigated the mechanisms underlying the reduction in c-fos expression associated with the malignant transformation of HBE cells. c-Fos gene transcription was lower in tumorigenic HBE cells than in normal HBE cells, and the reduction in transcription involved c-fos gene promoter elements from -327 to +40. DNasel footprinting and band shift analyses of motifs within this c-fos promoter region, including a cyclic AMP response element (CRE), serum response element (SRE), sis-inducible element (SIE), and a YY1 site, revealed that binding to these motifs was greater in tumorigenic HBE cells than in normal HBE cells. Site-directed mutagenesis of the CRE partially relieved the repression of c-fas promoter activity in tumorigenic HBE cells. Further, the activity of the Jun N-terminal Kinase (JNK)-dependent pathway, which was a positive regulator of the c-fos promoter, was greater in normal HBE cells than in tumorigenic HBE cells. These findings demonstrate a transcriptionally-mediated suppression of c-fos gene expression associated with the malignant transformation of HBE cells. The decreased activity of the c-fos promoter in tumorigenic 1170I cells appeared to involve suppression through a CRE site and reduced activation by JNK-dependent pathways.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Washington State Univ, Dept Genet & Cell Biol, Pullman, WA 99164 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Washington State University	Kurie, JM (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Lee, Ho-Young/0000-0001-7556-9312	NCI NIH HHS [R29-CA67353, P50-CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907, R29CA067353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BUSCHER M, 1988, ONCOGENE, V3, P301; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; CURRAN T, 1985, CANCER SURV, V4, P655; FAN Z, 1993, CANCER RES, V53, P4637; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIM YH, 1995, CANCER RES, V55, P5603; KLEINSZANTO AJP, 1992, P NATL ACAD SCI USA, V89, P6693, DOI 10.1073/pnas.89.15.6693; Lee HY, 1997, CELL GROWTH DIFFER, V8, P283; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Putnam E A, 1992, Surg Oncol, V1, P49, DOI 10.1016/0960-7404(92)90056-Q; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REDDEL RR, 1988, CANCER RES, V48, P1904; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Rusch V, 1997, CLIN CANCER RES, V3, P515; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SOBOL RE, 1987, J NATL CANCER I, V79, P403; TALMAGE DA, 1994, ONCOGENE, V9, P3557; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WHALEY PD, 1995, ENDOCRINOLOGY, V136, P3046, DOI 10.1210/en.136.7.3046; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	45	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3039	3046		10.1038/sj.onc.1201843	http://dx.doi.org/10.1038/sj.onc.1201843			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662337				2022-12-28	WOS:000074125300011
J	Sacchi, N; Tamanini, F; Willemsen, R; Denis-Donini, S; Campiglio, S; Hoogeveen, AT				Sacchi, N; Tamanini, F; Willemsen, R; Denis-Donini, S; Campiglio, S; Hoogeveen, AT			Subcellular localization of the oncoprotein MTG8 (CDR/ETO) in neural cells	ONCOGENE			English	Article						MTG8 protein; neural cells; cellular localization	ACUTE MYELOID-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; FUSION TRANSCRIPT; AML1; GENE; IDENTIFICATION; PROTEIN; ETO; TRANSLOCATIONS; BREAKPOINTS	The t(8;21) translocation associated with acute myeloid leukemia (AML) disrupts two genes, the AML1 gene also known as the core binding factor A2 (CBFA2) on chromosome 21, and a gene on chromosome 8, hereafter referred to as MTG8, but also known as CDR and ETO, Extensive information is available on AML1, a member of the CBF family of transcription factors, containing a highly conserved domain, the runt box, of the Drosophila segmentation gene runt. This gene is essential for the hematopoietic development and is found disrupted in several leukemias, In contrast, the function of the MTG8 gene is poorly understood. The predicted protein sequence shows two unusual, putative zinc-fingers, three proline-rich regions, a PEST domain and several phosphorylation sites. In addition, we found a region encompassing aa 443-514 predicted to have a significant propensity to form coiled coil structures. MTG8 displays a high degree of similarity with nervy, a homeotic target gene of Drosophila, expressed in the nervous system. Human and mouse wild-type MTG8 are also highly expressed in brain relative to other tissues. For these reasons, we set out to investigate the expression and subcellular localization of the MTG8 protein in neural cells. Immunohistochemical experiments in a 12.5-day-old mouse embryo clearly showed that the protein was expressed in the neural cells of the developing brain and the spinal cord. In primary cultures of hippocampal neurons of 2-3 day-old mice, MTG8 was found in the nucleus, in the cytoplasm and as fine granules in the neurites, Cytoplasmic localization of the protein was observed in Purkinje cells of both human and mouse cerebellum. The molecular mass of MTG8 in total human and mouse brain was analysed by immunoblotting and determined to be between 70 and 90 kDa, Isoforms with the same molecular mass were demonstrated in synaptosomes isolated from mouse forebrain, The evidence of MTG8 in the nucleus and cytoplasm of neural cells suggests a specific mechanism regulating the subcellular localization of the protein.	Univ Milan, Sch Med, Dept Biol & Genet, Milan, Italy; Univ Milan, Sch Biol Sci, Dept Biol, Milan, Italy; Erasmus Univ, Sch Med, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; CNR, Ctr Cytopharmacol, I-20133 Milan, Italy	University of Milan; University of Milan; Erasmus University Rotterdam; Consiglio Nazionale delle Ricerche (CNR)	Sacchi, N (corresponding author), Univ Milan, Sch Med, Dept Biol & Genet, Milan, Italy.							Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; ERA T, 1995, LEUKEMIA, V9, pS26; ERA T, 1995, GENE CHROMOSOME CANC, V13, P25, DOI 10.1002/gcc.2870130105; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Erickson PF, 1996, BLOOD, V88, P1813; FEINSTEIN PG, 1995, GENETICS, V140, P573; HARLOW E, 1988, ANTIBODIES; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; LI CY, 1987, J HISTOCHEM CYTOCHEM, V35, P1457, DOI 10.1177/35.12.2824601; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCIFORA G, 1993, BLOOD, V82, P712; NUCIFORA G, 1995, BLOOD, V86, P1; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; RAO A, 1991, J NEUROSCI, V11, P2881; Sacchi N, 1996, ONCOGENE, V12, P437; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Saunders MJ, 1996, LEUKEMIA, V10, P1139; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Tamanini F, 1997, HUM MOL GENET, V6, P1315, DOI 10.1093/hmg/6.8.1315; TIGHE JE, 1994, BLOOD, V84, P2115, DOI 10.1182/blood.V84.7.2115.bloodjournal8472115; VANDELOCHT LTF, 1994, LEUKEMIA, V8, P1780; WANG J, 1997, CANCER RES, V12, P2951; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	34	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	1998	16	20					2609	2615		10.1038/sj.onc.1201824	http://dx.doi.org/10.1038/sj.onc.1201824			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632137				2022-12-28	WOS:000073698200005
J	Huang, C; Taki, T; Adachi, M; Konishi, T; Higashiyama, M; Miyake, M				Huang, C; Taki, T; Adachi, M; Konishi, T; Higashiyama, M; Miyake, M			Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer	ONCOGENE			English	Article						p53; mutation; prognostic factor; SSCP; lung cancer	TUMOR-SUPPRESSOR GENE; MUTANT P53; CYCLE; SURVIVAL; PROTEIN; TRANSACTIVATION; OVEREXPRESSION; ACCUMULATION; ONCOPROTEIN; MODULATION	This study was performed to clarify the different effects of each mutant exon of p53 as indicators of a poor prognosis in patients with non-small cell lung cancer (NSCLC), Tumor tissues of 204 patients with NSCLC were analysed; 96 tumors were stage I, 22 stage II, and 86 stage III. DNA was extracted from frozen specimens and polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing were performed to investigate mutations of p53 from exon 5 to exon 8, Seventy-five patients with NSCLC (36.8%) had mutations in p53 which included 72 cases of missense mutations and three cases of non-missense mutations, The overall survival rate of patients with mutant p53 adenocarcinomas was strikingly worse than that of patients whose tumors had wild-type p53 (35.7% vs 53.8%; P = 0.041), but no significant difference in survival was found in the patients with NSCLC and squamous cell carcinoma, Mutations in exon 5 of p53 occurred in 33 cases (16.2%), mutation in exon 6 was detected in only one case (0.5%), mutations in exon 7 in 20 cases (9.8%), and mutations in exon 8 in 18 cases (8.8%), The overall survival rate of patients with mutations in exon 7 was worse than that of patients with wild-type p53 in NSCLCs and adenocarcinomas (42.9% vs 56.0%; P = 0.025 and 33.3% vs 53.8%; P = 0.048, respectively), whereas the overall survival of patients with mutations in exon 5 was almost the same as that of patients with wild-type p53, In addition, the overall survival rate of patients with mutations in exon 8 was strikingly worse than that of patients with wild-type p53 in NSCLCs, adenocarcinomas and squamous cell carcinomas (22.9% vs 56.0%; P < 0.001, 19.0% vs 53.8%; P = 0.004 and 33.3% vs 62.5%; P = 0.042, respectively). Multivariate analysis with the Cox regression model of patients with NSCLC, adenocarcinoma and squamous cell carcinoma indicated that mutations in exon 8 mere best correlated with the overall survival rate, followed by lymph node status (P < 0.001, P = 0.015 and P = 0.006, respectively), and mutations in exon 7 of NSCLC were also revealed to have good correlation, followed by lymph node status and mutations in exon 8 (P = 0.031), Mutation of p53 was a poor prognostic factor for adenocarcinoma as described previously, Moreover, mutations in exon 8 were more useful indicators of prognosis not only for adenocarcinoma but also for NSCLC, Worse overall survival of the patients with mutations in exon 8 of p53 was suggested to be associated with codon 273 mutations as well as mutations between codon 280 and 285 included into the H2 alpha helix corresponding to residues 278-286, These results suggested that abnormal conformation of H2 alpha helix might play an important role not only in the loss of normal function but also in the acquisition of tumorigenesis, Investigation of mutations in exon 8, especially codon 273 mutation and mutant H2 alpha helix was considered to be a clinically useful approach for determining the prognosis of patients with NSCLC.	Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Kita Ku, Osaka 530, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Oncol 5, Kita Ku, Osaka 530, Japan; Ctr Adult Dis, Dept Surg, Osaka 537, Japan	Kitano Hospital; Kitano Hospital	Miyake, M (corresponding author), Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Kita Ku, 13-3 Kamiyama Cho, Osaka 530, Japan.							CHIBA I, 1990, ONCOGENE, V5, P1603; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; COX DR, 1972, J R STAT SOC B, V34, P187; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EBINA M, 1994, CANCER RES, V54, P2496; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Fukuyama Y, 1997, BRIT J CANCER, V75, P1125, DOI 10.1038/bjc.1997.194; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HANN BC, 1995, NAT GENET, V9, P221, DOI 10.1038/ng0395-221; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HERMANEK P, 1987, TNM CLASSIFICATION M, P75; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P1; Iwamoto KS, 1996, CANCER RES, V56, P3862; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATSURAGI K, 1995, BIOMED RES-TOKYO, V16, P273, DOI 10.2220/biomedres.16.273; Kawamura M, 1996, ONCOGENE, V12, P2361; LEE JS, 1995, J CLIN ONCOL, V13, P1893, DOI 10.1200/JCO.1995.13.8.1893; LEVINE AJ, 1992, CANCER SURV, V12, P59; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARTIN HM, 1992, INT J CANCER, V50, P859, DOI 10.1002/ijc.2910500604; MCLAREN R, 1992, BRIT J CANCER, V66, P735, DOI 10.1038/bjc.1992.348; MITSUDOMI T, 1993, JNCI-J NATL CANCER I, V85, P2018, DOI 10.1093/jnci/85.24.2018; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Park DJ, 1996, MOL CARCINOGEN, V16, P101, DOI 10.1002/(SICI)1098-2744(199606)16:2<101::AID-MC6>3.0.CO;2-L; PASSLICK B, 1995, J THORAC CARDIOV SUR, V109, P1205, DOI 10.1016/S0022-5223(95)70204-0; QUINLAN DC, 1992, CANCER RES, V52, P4828; Sambrook J., 1989, MOL CLONING LAB MANU, pE3; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Velculescu VE, 1996, CLIN CHEM, V42, P858; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZENG ZS, 1994, J CLIN ONCOL, V12, P2043, DOI 10.1200/JCO.1994.12.10.2043	41	69	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2469	2477		10.1038/sj.onc.1201776	http://dx.doi.org/10.1038/sj.onc.1201776			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627113				2022-12-28	WOS:000073672300005
J	Hanford, MG; Rushton, BC; Gowen, LC; Farber, RA				Hanford, MG; Rushton, BC; Gowen, LC; Farber, RA			Microsatellite mutation rates in cancer cell lines deficient or proficient in mismatch repair	ONCOGENE			English	Article						microsatellite instability; mismatch repair; colorectal cancer; fluctuation analysis	NONPOLYPOSIS COLON-CANCER; COLORECTAL-CANCER; GENOMIC INSTABILITY; HOMOLOG; GENE; DNA; HYPERMUTABILITY; SEQUENCES; HMSH2	A selectable system has been used to determine mutation rates within a microsatellite sequence in human cancer cell lines with or without defects in mismatch repair. A sequence consisting of 17 repeats of poly (dC-dA).poly(dT-dG) [abbreviated as (Ca)(17)] was inserted near the 5' end of the bacterial neomycin-resistance gene in a plasmid vector, such that the reading frame of the neo gene is disrupted. This plasmid was introduced into cancer cell lines, where it became integrated into the cellular genome. Clones with insertions or deletions of CA-repeats that restored the normal reading frame of the neo gene were selected in G418, and mutation rates were determined by fluctuation analysis. The rates of reversion in LoVo cells, which are deficient for hMSH2, were about one in a thousand per generation, which is approximately two orders of magnitude higher than in the repair-proficient HT-1080 human fibrosarcoma cell line. The mutation rates in H6 cells, which are derived from the hMLH1-deficient HCT116 line, were more heterogeneous than in LoVo, but all were considerably higher than in the repair-proficient line. Nearly all of the revertants of the repair-deficient lines had deletions of a single CA-repeat from the microsatellite sequence, whereas repair-proficient cells had a broader spectrum of mutations.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Farber, RA (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, CB 7525, Chapel Hill, NC 27599 USA.				NCI NIH HHS [CA63264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063264] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRATTAIN MG, 1993, CELL, V75, P1227; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Bubb VJ, 1996, ONCOGENE, V12, P2641; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; DREWINKO B, 1976, CANCER RES, V36, P467; FARBER RA, 1994, HUM MOL GENET, V3, P253, DOI 10.1093/hmg/3.2.253; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HAUGE XY, 1993, HUM MOL GENET, V2, P411, DOI 10.1093/hmg/2.4.411; HONCHEL R, 1995, SEMIN CELL BIOL, V6, P45, DOI 10.1016/1043-4682(95)90014-4; KAHN SM, 1995, CARCINOGENESIS, V16, P1223, DOI 10.1093/carcin/16.5.1223; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOTHE RA, 1993, CANCER RES, V53, P5849; Luria SE, 1943, GENETICS, V28, P491; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Riedinger KL, 1996, ENVIRON MOL MUTAGEN, V28, P276, DOI 10.1002/(SICI)1098-2280(1996)28:3<276::AID-EM12>3.0.CO;2-C; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Sia EA, 1997, MUTAT RES-DNA REPAIR, V383, P61, DOI 10.1016/S0921-8777(96)00046-8; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; TALBOT CC, 1995, HUM MOL GENET, V4, P1193, DOI 10.1093/hmg/4.7.1193; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367	35	35	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2389	2393		10.1038/sj.onc.1201751	http://dx.doi.org/10.1038/sj.onc.1201751			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620556				2022-12-28	WOS:000073428000011
J	Yu, DH; Liu, BL; Tian, J; Sun, DT; Price, JE; Singletary, SE; Ibrahim, N; Hortobagyi, GN; Hung, MC				Yu, DH; Liu, BL; Tian, J; Sun, DT; Price, JE; Singletary, SE; Ibrahim, N; Hortobagyi, GN; Hung, MC			Overexpression of both p185(c-erbB2) and p170(mdr-1) renders breast cancer cells highly resistant to taxol	ONCOGENE			English	Article						HER-2/neu; oncogene; p-glycoprotein; breast cancer; taxol	TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; MULTIDRUG-RESISTANCE; NEU ONCOGENE; C-ERBB-2 EXPRESSION; PROTO-ONCOGENE; DNA-REPAIR; GENE; MECHANISMS	We recently found that overexpression of p185(c-erbB2) in c-erbB2 transfected MDA-MB-435 breast cancer cells (435.eB transfectants) confers a 5-9-fold increase in Taxol resistance. To examine whether Taxol resistance is a common phenomenon in other c-erbB2 overexpressing breast cancer cell lines, we tested a panel of human breast cancer cell lines established from different patients and expressing p185(c-erbB2) at different levels for their sensitivity to Taxol and Taxotere, a synthetic taxoid. Higher expression of p185(c-erbB2) in these breast cancer cell Lines indeed correlated well with resistance to Taxol and Taxotere, and the degree of resistance was about 100-fold that in c-erbB2-overexpressing 435.eB transfectants, demonstrating that these breast cancer cells are highly resistant to Taxol, Since mdr-1-encoded p-glycoprotein (p170(mdr-1)) has been implicated in Taxol resistance, we next examined the p170(mdr-1) levels in these breast cancer cell lines that are highly resistant to Taxol, Higher levels of p170(mdr-1) expression were found in several breast cancer cell lines that are highly resistant to Taxol, Since these same breast cancer cell lines also expressed higher levels of p185(c-erbB2), we sought to determine the relative contribution of p185(c-erbB2) and p170(mdr-1) overexpression to Taxol resistance. We first specifically down-regulated cell surface p185(c-erbB2) using anti-p185(c-erbB2) monoclonal antibodies and assayed sensitivity of these cells to Taxol, We next specifically inactivated p170(mdr-1) function using p170(mdr-1) blockers (thioridazine or verapamil) and again assayed Taxol sensitivity. Both p185(c-erbB2) down-regulation and p170(mdr-1) blockade significantly sensitized the breast cancer cell lines to Taxol, The results indicate that overexpression of either p185(c-erbB2) or p170(mdr-1) renders human breast cancer cells resistant to Taxol. Furthermore, p185(c-erbB2) synergizes with p170(mdr-1) conferring higher degrees of Taxol resistance. Finally, combination therapy (down-regulation of p185(c-erbB2) plus blocking p170(mdr-1) plus administration of Taxol) may be beneficial to breast cancer patients whose tumors express high levels of both p185(c-erbB2) and p170(mdr-1).	Univ Texas, Md Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Cell Biol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yu, DH (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Surg Oncol, Box 107,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381; Liu, Bolin/0000-0003-0150-8650	NCI NIH HHS [CA58880, CA60488, CA60856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058880, R29CA060488, R01CA060856, R01CA060488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ARTEAGA CL, 1994, CANCER RES, V54, P3758; BACUS SS, 1992, CANCER RES, V52, P2580; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERKOVA N, 1995, ANTICANCER RES, V15, P863; CHEVALLIER B, 1995, J CLIN ONCOL, V13, P314, DOI 10.1200/JCO.1995.13.2.314; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; EFFERTH T, 1993, CANCER LETT, V70, P197, DOI 10.1016/0304-3835(93)90231-W; FOJO AT, 1987, J CLIN ONCOL, V5, P1922, DOI 10.1200/JCO.1987.5.12.1922; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANCOCK MC, 1991, CANCER RES, V51, P4575; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LACROIX H, 1989, ONCOGENE, V4, P145; MILLER SJ, 1994, INT J ONCOL, V4, P599; MOSCOW JA, 1988, J NATL CANCER I, V80, P14, DOI 10.1093/jnci/80.1.14; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NOOTER K, 1991, BRIT J CANCER, V63, P663, DOI 10.1038/bjc.1991.152; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; SCHNEIDER J, 1994, J NATL CANCER I, V86, P850, DOI 10.1093/jnci/86.11.850; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; Tan M, 1997, CANCER RES, V57, P1199; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; Tsai CM, 1996, CANCER RES, V56, P1068; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; Yu DH, 1996, ONCOGENE, V13, P1359; Zhang LS, 1996, ONCOGENE, V12, P571	30	123	133	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2087	2094		10.1038/sj.onc.1201729	http://dx.doi.org/10.1038/sj.onc.1201729			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572489				2022-12-28	WOS:000073177200006
J	Knowlden, JM; Gee, JMW; Seery, LT; Farrow, L; Gullick, WJ; Ellis, IO; Blamey, RW; Robertson, JFR; Nicholson, RI				Knowlden, JM; Gee, JMW; Seery, LT; Farrow, L; Gullick, WJ; Ellis, IO; Blamey, RW; Robertson, JFR; Nicholson, RI			C-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer	ONCOGENE			English	Article						c-erbB3; c-erbB4; ER; EGFR; cell proliferation; endocrine response; RT-PCR	EPIDERMAL GROWTH-FACTOR; POLYMERASE CHAIN-REACTION; ESTROGEN-RECEPTOR; MONOCLONAL-ANTIBODY; CELL-LINES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; FAMILY MEMBERS; HEREGULIN; DIFFERENTIATION	We examined c-erbB3 and c-erbB4 mRNA expression in 47 primary breast cancer samples by simultaneous RT-PCR and have investigated correlations between these parameters and the expression of both ER and EGFR mRNA and protein as measured by RT-PCR and ICA and with Ki67 immunostaining, A direct association was found between c-erbB3 and c-erbB4 mRNA and ER marker status measured by either RT-PCR (c-erbB3 P = 0.0003; c-erbB4 P = 0.02) or ICA (c-erbB-3 P = 0.002; c-erbB4 P = 0.01). Inverse associations were seen between c-erbB3 and c-erbB4 mRNA marker status and EGFR membrane protein (c-erbB3: P = 0.003; c-erbB4: P = 0.003) and mRNA (c-erbB4: P = 0.009) status. These associations were reinforced by Spearman Rank Correlation Tests. A significant relationship was seen between Ki67 and c-erbB4 mRNA status and level. Measurements of c-erbB3 protein levels in tumour samples removed from a further 89 patients of known response to endocrine therapy: (i) confirmed the relationship between c-erbB3 and ER and (ii) identified that patients whose ER positive tumours expressed high levels of c-erbB3 were most likely to benefit from endocrine measures. A non-significant trend was recorded between c-erbB3 levels and Ki67 immunostaining, These results clearly demonstrate that increased c-erbB3 and c-erbB4 expression appears to be associated with the prognostically-favourable ER phenotype.	Univ Wales, Coll Med, Tenovus Canc Res Ctr, Cardiff CF4 4XX, S Glam, Wales; Hammersmith Hosp, Imperial Canc Res Fund, Mol Oncol Unit, London W12 0NN, England; City Hosp, Dept Histopathol, Nottingham NG5 1PB, England; City Hosp, Dept Surg, Nottingham NG5 1PB, England	Cardiff University; Cancer Research UK; Imperial College London; University of Nottingham; University of Nottingham	Knowlden, JM (corresponding author), Univ Wales, Coll Med, Tenovus Canc Res Ctr, Heath Pk, Cardiff CF4 4XX, S Glam, Wales.		Gee, Julia MW/N-3995-2014	Gee, Julia MW/0000-0001-6483-2015; Ellis, Ian/0000-0001-5292-8474				ALIMANDI M, 1995, ONCOGENE, V10, P1813; BACUS SS, 1993, CANCER RES, V53, P5251; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; Brotherick I, 1995, CANCER IMMUNOL IMMUN, V41, P280, DOI 10.1007/BF01517215; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHAN SDH, 1995, J BIOL CHEM, V270, P22608, DOI 10.1074/jbc.270.38.22608; DAFFADA AAI, 1994, J MOL ENDOCRINOL, V13, P265, DOI 10.1677/jme.0.0130265; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRYE RA, 1989, ONCOGENE, V4, P1153; FUQUA SAW, 1990, J NATL CANCER I, V82, P858, DOI 10.1093/jnci/82.10.858; GASPARINI G, 1994, EUR J CANCER, V30A, P16, DOI 10.1016/S0959-8049(05)80010-3; GEE JMW, 1994, INT J CANCER, V59, P619, DOI 10.1002/ijc.2910590508; GEE JMW, 1996, HORMONE DEPENDENT CA, P169; GERDES J, 1984, J IMMUNOL, V133, P1710; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Gullick WJ, 1996, CANCER SURV, V27, P339; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HAYWARD JL, 1977, CANCER, V39, P1289, DOI 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F; JORDAN VC, 1993, BRIT J PHARMACOL, V110, P507, DOI 10.1111/j.1476-5381.1993.tb13840.x; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; Knowlden JM, 1997, CLIN CANCER RES, V3, P2165; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LONARDO F, 1990, New Biologist, V2, P992; MANNING DL, 1995, ACTA ONCOL, V34, P641, DOI 10.3109/02841869509094041; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; NICHOLSON RI, 1994, BREAST CANCER RES TR, V29, P117, DOI 10.1007/BF00666187; NICHOLSON RI, 1991, EUR J CANCER, V27, P908, DOI 10.1016/0277-5379(91)90145-4; NICHOLSON RI, 1993, EUR J CANCER, V29A, P1018, DOI 10.1016/S0959-8049(05)80215-1; NICHOLSON RI, 1992, RECENT ADV ENDOCRINO, P150; NICHOLSON RI, 1996, HORMONES CANC, P227; OBRIAN JP, 1991, MOL CELL BIOL, V11, P5016; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RAJKUMAR T, 1994, BRIT J CANCER, V70, P459, DOI 10.1038/bjc.1994.328; RAJKUMAR T, 1993, J PATHOL, V170, P271, DOI 10.1002/path.1711700309; RAJKUMAR T, 1995, BREAST, V4, P84, DOI 10.1016/0960-9776(95)90001-2; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WOLF DM, 1993, BREAST CANCER RES TR, V27, P27, DOI 10.1007/BF00683191	49	106	113	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1949	1957		10.1038/sj.onc.1202107	http://dx.doi.org/10.1038/sj.onc.1202107			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788438				2022-12-28	WOS:000076423500008
J	Kerkhoff, E; Rapp, UR				Kerkhoff, E; Rapp, UR			Cell cycle targets of Ras/Raf signalling	ONCOGENE			English	Review						Ras; Raf; cell cycle	NIH 3T3 CELLS; PC12 PHEOCHROMOCYTOMA CELLS; C-MYC; PROTEIN-KINASE; DEPENDENT KINASES; BIOCHEMICAL-PROPERTIES; COOPERATING ONCOGENES; INDUCED PROLIFERATION; RAPID INDUCTION; GENE-EXPRESSION	The regulation of cell proliferation in multicellular organisms is a complex process, which is primarily regulated by external growth factors provided by surrounding cells. Once induced to proliferate, the passage through the mitotic cell cycle is directed by the components of the so called cell cycle machinery. Over the last years research on growth factor signal-transduction and the components of the cell cycle system has lead to a detailed knowledge of the mechanisms by which growth factors transmit their signals and of the relationship between the components of the cell cycle machinery. The remaining question how the growth factor mediated signal-transduction cascades couple with the cell cycle regulators has recently been a focus of interest.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, USZ, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, USZ, Versbacher Str 5, D-97078 Wurzburg, Germany.							AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; Cleveland J L, 1988, Oncogene Res, V3, P357; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Cooper G.M., 1995, ONCOGENES; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Draetta G.F., 1997, CURR BIOL, V7, P50; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FILMUS J, 1994, ONCOGENE, V9, P3627; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERBER B, 1994, ONCOGENE, V9, P1295; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kerkhoff E, 1998, CANCER RES, V58, P1636; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PENN LJ, 1990, EMBO J, P1113; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RAPP UR, 1994, ONCOGENE, V9, P3493; RAPP UR, 1994, FOS JUN FAMILIES TRA, P221; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TEMIN HM, 1971, J CELL PHYSIOL, V78, P161, DOI 10.1002/jcp.1040780202; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WATERS CM, 1991, ONCOGENE, V6, P797; Winston JT, 1996, ONCOGENE, V12, P127; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAN GZ, 1995, J NEUROSCI, V15, P6200; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	78	220	221	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1457	1462		10.1038/sj.onc.1202185	http://dx.doi.org/10.1038/sj.onc.1202185			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779991				2022-12-28	WOS:000076161900012
J	Gomez, J; Martinez, C; Gonzalez, A; Garcia, A; Rebollo, A				Gomez, J; Martinez, C; Gonzalez, A; Garcia, A; Rebollo, A			The Bcl-2 gene is differentially regulated by IL-2 and IL-4: role of the transcription factor NF-AT	ONCOGENE			English	Article						Bcl-2; calcineurin; IL-4; IL-2; NF-AT	PROTEIN-KINASE-C; HUMAN INTERLEUKIN-2 RECEPTOR; T-CELL LINE; CYCLOSPORINE-A; B-CELLS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; HIGH-AFFINITY; GAMMA-CHAIN; EXPRESSION	The murine TS1 alpha beta T cell line expresses the anti-apoptotic protein Bcl-2 upon IL-2 stimulation, whereas IL-4-mediated growth of this cell line proceeds in the absence of Bcl-2 expression. In addition, IL-4 stimulation inhibits Bcl-2 expression and modulates its mRNA level. IL-2-induced DNA binding activity for these transcription factors is sensitive to phosphatidylinositol 3 kinase inhibitor wortmannin and to Rho inhibitor Clostridium difficile toxin B, which inhibit IL-2-induced Bcl-2 expression. IVF-AT transcription factor appears to be the most important in the control Bcl-2 expression, since inhibition of the calcium-calmodulin-dependent phosphatase calcineurin, which regulates NF-AT activity, downregulates Bcl-2 expression in IL-2-stimulated cells, Constitutive expression of this phosphatase also upregulates Bcl-2 expression in IL-4-stimulated cells. In addition, a dominant negative NF-AT expression vector downregulates Bcl-2 expression in IL-2-stimulated cells. These results suggest that IL-2 induction of Bcl-2 expression may be directly or indirectly mediated by NF-AT.	Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Inst Pasteur, Grp Dev Cellulaire, F-75015 Paris, France	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Rebollo, A (corresponding author), Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Rebollo, Angelita/P-2118-2017	Rebollo, Angelita/0000-0002-1293-9686				Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204; BROOME HE, 1995, IMMUNOLOGY, V84, P375; BROOME HE, 1995, J IMMUNOL, V155, P2311; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Cohen SBA, 1997, IMMUNOLOGY, V92, P1, DOI 10.1046/j.1365-2567.1997.00348.x; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DEJONG D, 1994, CANCER RES, V54, P256; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1824; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOMEZ J, 1994, EXP CELL RES, V213, P178, DOI 10.1006/excr.1994.1188; Gomez J, 1997, J IMMUNOL, V158, P1516; Gomez J, 1997, EUR J IMMUNOL, V27, P1610, DOI 10.1002/eji.1830270704; Gomez J, 1997, EUR J IMMUNOL, V27, P2793, DOI 10.1002/eji.1830271108; GOMEZ J, 1995, EXP CELL RES, V218, P105, DOI 10.1006/excr.1995.1136; GOMEZ J, 1995, EUR J IMMUNOL, V25, P2673, DOI 10.1002/eji.1830250941; GOMEZ J, 1996, J IMMUNOL, V157, P2772; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; HANADA M, 1993, CANCER RES, V53, P4978; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; Katoh S, 1997, NEUROSCI LETT, V232, P71, DOI 10.1016/S0304-3940(97)00582-X; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; KRAJEWSKI S, 1993, CANCER RES, V53, P47017; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MAKOVER D, 1991, ONCOGENE, V6, P455; MANIATIS T, 1989, MOL CLONING LAB HDB; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MINAMI Y, 1995, CURR OPIN CELL BIOL, V7, P156, DOI 10.1016/0955-0674(95)80023-9; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLIVER FJ, 1993, BIOCHEM BIOPH RES CO, V194, P126, DOI 10.1006/bbrc.1993.1794; PITTON C, 1993, CYTOKINE, V5, P362, DOI 10.1016/1043-4666(93)90069-H; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rebollo A, 1996, ADV IMMUNOL, V63, P127, DOI 10.1016/S0065-2776(08)60856-1; REBOLLO A, 1995, CYTOKINE, V7, P277, DOI 10.1006/cyto.1995.0033; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; Sekiya M, 1997, BIOCHEM BIOPH RES CO, V239, P401, DOI 10.1006/bbrc.1997.7478; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SENTMAN CL, 1991, CELL, V67, P878; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8	74	32	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1235	1243		10.1038/sj.onc.1202049	http://dx.doi.org/10.1038/sj.onc.1202049			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771966				2022-12-28	WOS:000075803300005
J	Taylor, GA; Jeffers, M; Webb, CP; Koo, HM; Anver, M; Sekiguchi, K; Woude, GFV				Taylor, GA; Jeffers, M; Webb, CP; Koo, HM; Anver, M; Sekiguchi, K; Woude, GFV			Decreased fibronectin expression in Met/HGF-mediated tumorigenesis	ONCOGENE			English	Article						Met; HGF; fibronectin; TGF beta	HEPATOCYTE GROWTH-FACTOR; C-MET RECEPTOR; SCATTER FACTOR; EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; PROTOONCOGENE; INDUCTION; MUTATIONS; METASTASIS; ADHESION	The tyrosine kinase receptor Met and its ligand, hepatocyte growth factor (HGF)/scatter factor are involved in the etiology and progression of a number of human cancers. Coexpression of Met and HGF in mesenchymal cells increases the tumorigenic and metastatic potential of the cells. In the studies described here, we used differential display screening to identify changes in gene expression that are initiated by Met/HGF, and that may lead to these phenotypes. We learned that Met/HGF signaling resulted in greatly decreased fibronectin mRNA production in three different human and mouse tumor cell lines; these decreases in fibronectin mRNA were paralleled by decreases in fibronectin protein. We also found a progressive decrease in fibronectin in tumor explants and metastases derived from the Met/HGF transformed cells. The absence of fibronectin expression is a frequent cancer phenotype; our results indicate that decreases in fibronectin correlate with, but are not essential for, MetHGF/SF-mediated tumorigenesis.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Sci Applicat Int Corp, Frederick, MD 21702 USA; Osaka Med Ctr Maternal & Child Hlth, Inst Res, Osaka 59002, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Woude, GFV (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA.		Webb, Craig/I-8123-2012					Akamatsu H, 1996, CANCER RES, V56, P4541; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998; Faletto D L, 1993, EXS, V65, P107; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HYNES RO, 1990, FIBRONECTINS, P301; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Koochekpour S, 1997, CANCER RES, V57, P5391; Laterra J, 1997, LAB INVEST, V76, P565; Matsumoto K, 1993, EXS, V65, P225; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUOSLAHTI E, 1984, CANCER METAST REV, V3, P43, DOI 10.1007/BF00047692; SAITOH K, 1994, J PATHOL, V174, P191, DOI 10.1002/path.1711740308; SANTOS OFP, 1993, DEV BIOL, V160, P293, DOI 10.1006/dbio.1993.1308; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; STREIT A, 1995, DEVELOPMENT, V121, P813; Taipale J, 1996, J BIOL CHEM, V271, P4342; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597	31	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1179	1183		10.1038/sj.onc.1202004	http://dx.doi.org/10.1038/sj.onc.1202004			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764829				2022-12-28	WOS:000075598400014
J	Blaydes, JP; Hupp, TR				Blaydes, JP; Hupp, TR			DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site	ONCOGENE			English	Article						p53; CK2; DRB; UV-irradiation; phosphorylation	CASEIN KINASE-II; C-TERMINAL DOMAIN; RNA-POLYMERASE-II; WILD-TYPE P53; TRANSCRIPTIONALLY ACTIVE P53; TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE ARREST; BINDING ACTIVITY; IN-VITRO; HEAT-SHOCK	The sequence-specific DNA binding activity of p53 is negatively regulated by a C-terminal domain whose phosphorylation in vitro can activate the latent DNA binding function of the protein. The DNA binding activity of p53 is a core component of its stress-activated transcription function, yet it is not yet clear whether phosphorylation within the C-terminal domain plays a role in the p53 damage response in vise. As the casein kinase 2 (CK2) site at serine 392 is the C-terminal phosphorylation motif that exhibits the most pronounced conservation at the primary amino acid level, we have focused on determining whether the CK2 site is modified in vivo and whether radiation effects the extent of that phosphorylation. Using antibodies that can detect serine 392-phosphorylation of p53, we demonstrate that UV radiation can trigger extensive phosphorylation at the CK2 site. The CK2 inhibitor, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), can partially inhibit the UV-induced phosphorylation at serine 392, suggesting that CK2 is one of the major serine 392-kinases. However, a striking increase in UV-induced serine 392 phosphorylation and p53 transactivation function at higher levels of DRB suggests that a DRB-resistant/stress-activated pathway may target serine 392 irt vivo. These data demonstrate that radiation-induced phosphorylation of p53 can occur in vivo at serine 392 and implicate a CK2-independent signal cascade that can function to modulate serine 392 phosphorylation in cells.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	University of Dundee	Hupp, TR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				ABARZUA P, 1995, CANCER RES, V55, P3490; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; BARETTINO D, 1988, BIOCHEM CELL BIOL, V66, P1177, DOI 10.1139/o88-135; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL C, 1993, CANCER RES, V53, P2697; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1994, ONCOGENE, V9, P3249; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; FUCHS B, 1995, EUR J BIOCHEM, V228, P2866; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALL PA, 1993, ONCOGENE, V8, P203; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Harlow E., 1988, ANTIBODIES LAB MANUA; Hecker D, 1996, ONCOGENE, V12, P953; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1991, CANCER RES, V51, P6304; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MacCallum DE, 1996, ONCOGENE, V13, P2575; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Nikiforov MA, 1996, ONCOGENE, V13, P1709; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SEHGAL PB, 1975, SCIENCE, V190, P282, DOI 10.1126/science.1179208; SEHGAL PB, 1976, SCIENCE, V194, P431, DOI 10.1126/science.982026; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SOUSSI T, 1990, ONCOGENE, V5, P945; STONEWOLFF DS, 1981, MUTAT RES, V82, P147, DOI 10.1016/0027-5107(81)90146-9; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; TARUNINA M, 1993, ONCOGENE, V8, P3165; THIAGALINGAM S, 1995, P NATL ACAD SCI USA, V92, P6062, DOI 10.1073/pnas.92.13.6062; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TISHLER RB, 1995, CANCER RES, V55, P6021; TRIGON S, 1995, J BIOL CHEM, V270, P13091, DOI 10.1074/jbc.270.22.13091; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; VOJTESEK B, 1995, ONCOGENE, V10, P389; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; ZANDOMENI RO, 1989, BIOCHEM J, V262, P469, DOI 10.1042/bj2620469	83	100	102	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1045	1052		10.1038/sj.onc.1202014	http://dx.doi.org/10.1038/sj.onc.1202014			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747884				2022-12-28	WOS:000075560900013
J	Gollahon, LS; Kraus, E; Wu, TA; Yim, SO; Strong, LC; Shay, JW; Tainsky, MA				Gollahon, LS; Kraus, E; Wu, TA; Yim, SO; Strong, LC; Shay, JW; Tainsky, MA			Telomerase activity during spontaneous immortalization of Li-Fraumeni syndrome skin fibroblasts	ONCOGENE			English	Article						p53; telomeres; ALT pathway; senescence; cell hybrids	MAMMARY EPITHELIAL-CELLS; HUMAN PAPILLOMAVIRUS TYPE-16; CELLULAR SENESCENCE; CANCER SYNDROME; TUMOR-ANTIGEN; MUTANT P53; TRANSFORMATION; E6; GROWTH; DNA	Li-Fraumeni Syndrome (LFS) is characterized by heterozygous germline mutations in the p53 gene. Accompanied by genomic instability and loss or mutation of the remaining wild type p53 allele, a low frequency of spontaneous immortalization in LFS fibroblasts occurs. It is believed that the loss of p53 wild type function contributes to immortalization of these LFS fibroblasts, but it is not clear if this is sufficient. Because stabilization of telomere length is also thought to be a necessary step in immortalization, telomerase activity, expression of the telomerase RNA component (hTR) and telomere length were ana:lysed at various passages during the spontaneous immortalization of LFS skin fibroblasts. One LFS strain which immortalized, MDAH087 (087), had no detectable telomerase activity whereas another LFS strain which immortalized, MDAH041 (041), had detectable telomerase activity. In preimmortal cells from both strains, hTR was not detected by in situ hybridization. Immortal 087 cells remained negative for hTR, while immortal 041 cells demonstrated strong hTR in situ hybridization signals. 087 cells had long and heterogenous telomeres whereas telomeres; of 041 cells had short, stable telomere lengths. Tumorigenicity studies in nude mice with ras-transformed 087 and 041 cells resulted in both cell lines giving rise to tumors and retaining telomerase status. Overall these results suggest that strain specificity may be important in telomerase re-activation and that both abrogation of p53 function and a mechanism to maintain telomeres are necessary for immortalization.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Expt Pediat, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Gollahon, LS (corresponding author), Texas Tech Univ, Dept Biol Sci, POB 43131, Lubbock, TX 79409 USA.		Shay, Jerry W/F-7878-2011	Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [T32CA009299, P01CA034936, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-P01 34936, CA-16672, CA-09299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; Avilion AA, 1996, CANCER RES, V56, P645; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; Barrett J. Carl, 1993, P61; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gao QS, 1996, CANCER RES, V56, P3129; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; Gollahon LS, 1996, ONCOGENE, V12, P715; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Greider CW, 1991, CURR OPIN CELL BIOL, V3, P444, DOI 10.1016/0955-0674(91)90072-7; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Holt Shawn E., 1996, Methods in Cell Science, V18, P237, DOI 10.1007/BF00132889; Hsiao RS, 1997, ANTICANCER RES, V17, P827; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; JORDAN C, 1990, IN SITU HYBRIDIZATIO, P61; Karlsson C, 1996, CANCER RES, V56, P241; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; LEMOINE NR, 1990, ONCOGENE, V5, P1833; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PIATYSZEK MA, 1996, METHODS CELL SCI, V17, P1; RAINEY WH, 1994, J CLIN ENDOCR METAB, V78, P705, DOI 10.1210/jc.78.3.705; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROSS SR, 1978, PERSISTENT VIRUSES, V11, P469; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SASAKI M, 1994, CANCER RES, V54, P6090; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1993, ONCOGENE, V8, P1407; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1994, METH MOL G, V5, P263; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; TAINSKY MA, 1995, CANCER METAST REV, V14, P43, DOI 10.1007/BF00690210; TSUTSUI T, 1995, CARCINOGENESIS, V16, P25, DOI 10.1093/carcin/16.1.25; Tsutsui T, 1997, MOL CARCINOGEN, V18, P7, DOI 10.1002/(SICI)1098-2744(199701)18:1<7::AID-MC2>3.0.CO;2-F; VANDERHAEGEN BA, 1993, IN VITRO CELL DEV-AN, V29A, P180, DOI 10.1007/BF02634177; WATANABE S, 1993, JPN J CANCER RES, V84, P1043, DOI 10.1111/j.1349-7006.1993.tb02799.x; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; Yashima K, 1998, CLIN CANCER RES, V4, P229	74	48	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					709	717		10.1038/sj.onc.1201987	http://dx.doi.org/10.1038/sj.onc.1201987			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715272				2022-12-28	WOS:000075337200005
J	Schwartz, MA; Meredith, JE; Kiosses, WB				Schwartz, MA; Meredith, JE; Kiosses, WB			An activated Rac mutant functions as a dominant negative for membrane ruffling	ONCOGENE			English	Article						Rho family small GTP binding protein; signal transduction; actin cytoskeleton	CELL-CYCLE PROGRESSION; PROTEIN-KINASE; ACTIN POLYMERIZATION; SMALL GTPASES; CDC42; RHO; CASCADE	Previous studies have shown that point mutations in the effector domain of Rad block specific downstream pathways such as PAK, JNK/SAPK kinases and membrane ruffling, Specifically, the F37A mutation, made in a constitutively activated Q61L background, activates PAK but fails to induce membrane ruffles. We now show that Q61L/F37A Rac not only fails to induce ruffling but potently blocks membrane ruffling induced by serum or PDGF, In the presence of serum, cells do extend filopodia, suggesting that this mutant only blocks a subset of the effecters that induce cytoskeletal reorganization. At later times, this rac mutant induces membrane blebbing, but not apoptosis, These results show that Q61L/F37A Rac, is constitutively activated with respect to PAK activation but functions as a dominant negative for another pathway, membrane ruffling, That an effector domain point mutant can simultaneously function as a dominant negative and dominant positive for different pathways implies that effects of these variants on cell functions must be interpreted with caution.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schwartz, MA (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243	NIGMS NIH HHS [R01 GM27214] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; Fedier A, 1997, CELL MOTIL CYTOSKEL, V37, P326; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	15	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					625	629		10.1038/sj.onc.1201977	http://dx.doi.org/10.1038/sj.onc.1201977			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704928				2022-12-28	WOS:000075195300010
J	Landgren, E; Klint, P; Yokote, K; Claesson-Welsh, L				Landgren, E; Klint, P; Yokote, K; Claesson-Welsh, L			Fibroblast growth factor receptor 1 mediates chemotaxis independently of direct SH2 domain protein binding	ONCOGENE			English	Article						FGF receptor; chemotaxis	PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; SIGNAL-TRANSDUCTION; POINT MUTATION; AUTOPHOSPHORYLATION SITES; KINASE INSERT; CDNA CLONING; ACTIVATION; EXPRESSION; FAMILY	Endothelial cells expressing fibroblast growth factor receptor-1 (FGFR-1) migrate and proliferate in response to treatment with FGF. We analysed ligand-induced migration and proliferation of porcine aortic endothelial cells expressing wild-type FGFR-1, point-mutated Y766F FGFR-1, unable to activate phospholipase C-gamma 1 (PLC-gamma 1), or carboxyl-terminally truncated FGFR-1, lacking either 48 (from amino acid 774 in the FGFR-1 sequence) or 63 (from amino acid 759) amino acid residues of the C-terminal tail. The truncated CT63 FGFR-1 mutant failed to mediate chemotaxis, but was in response to ligand stimulation capable of mediating proliferation of the cells, stimulation of MAP kinase activity and tyrosine phosphorylation of FRS2, an FGFR-1 specific signaling molecule. The defect in migration-capacity of CT63 was not due to loss of Y766, and thereby PLC-gamma 1 activation, since cells expressing the mutant Y7766F FGFR-1 migrated as efficiently as the wild-type receptor cells. Induction of phospholipase A(2) (PLA(2)) activity by the activated FGFR-1 was dependent on the presence of Y766, and was therefore also not critical for the chemotactic response. Although the FGFR-1 only very inefficiently mediates activation of phosphatidylinositol 3' kinase (PI 3-kinase), the PI 3-kinase inhibitor wortmannin suppressed wild-type FGFR-1 mediated migration. We conclude that the signal transduction pathway for FGFR-1 mediated migration is independent of phosphotyrosine residues in the receptor and requires activation of a wortmannin-sensitive enzyme.	Biomed Ctr, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Chiba Univ, Sch Med, Dept Internal Med, Chuo Ku, Chiba 260, Japan	Chiba University	Claesson-Welsh, L (corresponding author), Biomed Ctr, Dept Med Biochem & Microbiol, Box 575, S-75123 Uppsala, Sweden.							ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLYMAN RI, 1994, CELL ADHES COMMUN, V1, P333, DOI 10.3109/15419069409097264; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LANDGREN E, 1995, ONCOGENE, V10, P2027; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Roghani M, 1996, J BIOL CHEM, V271, P31154, DOI 10.1074/jbc.271.49.31154; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SA G, 1994, J BIOL CHEM, V269, P3219; SHAOUL E, 1995, ONCOGENE, V10, P1553; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; WENNSTROM S, 1994, ONCOGENE, V9, P651; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816	34	42	42	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					283	291		10.1038/sj.onc.1201936	http://dx.doi.org/10.1038/sj.onc.1201936			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690510				2022-12-28	WOS:000074947500003
J	Karnik, P; Chen, P; Paris, M; Yeger, H; Williams, BRG				Karnik, P; Chen, P; Paris, M; Yeger, H; Williams, BRG			Loss of heterozygosity at chromosome 11p15 in Wilms tumors: identification of two independent regions	ONCOGENE			English	Article						Wilms tumor; tumor suppressor genes; chromosome 11p15; loss of heterozygosity	BECKWITH-WIEDEMANN SYNDROME; LOCUS; GENE; LOCALIZATION; DELETION; TRANSCRIPTS; FRAGMENTS; D11S988	Loss of heterozygosity (LOH) on the short arm of chromosome 11 is the most frequent genetic alteration in Wilms tumors, indicating that one or more tumor suppressor genes that map to this chromosomal region are involved in the development of the disease, The WT1 gene located on 11p13 has been characterized but mutations in this gene occur in only about 10% of Wilms tumors, A second locus (WT2) at chromosome 11p15 has also been described in Wilms tumors but thus far efforts to clone the WT2 gene(s) have been frustrated by the large size (similar to 10 Mb) of this region. Using a high-density marker LOH analysis of 11p15.5-15.4, we have refined the location of a Wilms tumor suppressor gene between the markers D11S1318-D11S1288 (similar to 800 kb) within 11p15.5, We have also identified a second, novel region of LOH that spans the markers D11S1338-D11S1323 (similar to 336 kb) at 11p15.5-p15.4. Thus a second distinct locus, in addition to the previously defined WT2, on chromosome 11p15.5, appears to play a role in the development of Wilms tumors.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Hosp Sick Children, Toronto, ON M5G 1X8, Canada	Cleveland Clinic Foundation; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Karnik, P (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; Baffa R, 1996, CANCER RES, V56, P268; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1992, GENE CHROMOSOME CANC, V5, P326, DOI 10.1002/gcc.2870050408; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1995, HEMATOL ONCOL CLIN N, V9, P1201, DOI 10.1016/S0889-8588(18)30041-8; Hannigan GE, 1997, GENOMICS, V42, P177, DOI 10.1006/geno.1997.4719; Hoovers JMN, 1995, P NATL ACAD SCI USA, V92, P12456, DOI 10.1073/pnas.92.26.12456; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; KARNIK P, 1995, HUM MOL GENET, V4, P1889, DOI 10.1093/hmg/4.10.1889; KARNIK P, 1998, IN PRESS HUMAN MOL G; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PING AJ, 1989, AM J HUM GENET, V44, P720; Reid LH, 1997, GENOMICS, V43, P366, DOI 10.1006/geno.1997.4826; Reid LH, 1996, HUM MOL GENET, V5, P239, DOI 10.1093/hmg/5.2.239; SAIT SNJ, 1994, GENE CHROMOSOME CANC, V11, P97; Sotelo-Avila C, 1976, Perspect Pediatr Pathol, V3, P255; Tran YK, 1996, CANCER RES, V56, P2916; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; VIEL A, 1992, BRIT J CANCER, V66, P1030, DOI 10.1038/bjc.1992.405; WINQVIST R, 1995, CANCER RES, V55, P2660; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C	28	35	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					237	240		10.1038/sj.onc.1201959	http://dx.doi.org/10.1038/sj.onc.1201959			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674708				2022-12-28	WOS:000074706700012
J	Vooijs, M; van der Valk, M; te Riele, H; Berns, A				Vooijs, M; van der Valk, M; te Riele, H; Berns, A			Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse	ONCOGENE			English	Article						Rb inactivation; tissue-specific; Flp site-specific DNA recombination; pituitary gland tumor; tumor progression; mouse model for sporadic cancer	SITE-SPECIFIC RECOMBINATION; EMBRYONIC STEM-CELLS; LOCUS-CONTROL REGION; TRANSGENIC MICE; DNA RECOMBINATION; SWITCH RECOMBINATION; MAMMALIAN-CELLS; CRE RECOMBINASE; CHIMERIC MICE; IN-VIVO	The yeast-derived Flp-frt site-specific DNA recombination system was used to achieve pituitary-specific inactivation of the retinoblastoma (Rb) tumor suppressor gene. Whereas mice carrying only frt sites in both alleles of Iib remain tumor free, tumorigenesis ensues when the Flp recombinase is expressed. The rate of tumorigenesis in these mice depends both on the expression level of the Flp recombinase and on the presence of frt sites in one or both Rb alleles. This permitted a more accurate definition of the consecutive steps in pituitary tumorigenesis. Our study illustrates the potential of this approach for studying sporadic cancer in a defined mouse model.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Vooijs, Marc/K-3522-2019					Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Betz UAK, 1996, CURR BIOL, V6, P1307, DOI 10.1016/S0960-9822(02)70717-3; Brown MA, 1997, TRENDS GENET, V13, P202, DOI 10.1016/S0168-9525(97)01132-3; Buchholz F, 1996, NUCLEIC ACIDS RES, V24, P4256, DOI 10.1093/nar/24.21.4256; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; FIERING S, 1993, P NATL ACAD SCI USA, V90, P8469, DOI 10.1073/pnas.90.18.8469; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HAMMER GD, 1990, MOL ENDOCRINOL, V4, P1689, DOI 10.1210/mend-4-11-1689; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HARVEY M, 1995, CANCER RES, V55, P1146; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU NP, 1994, ONCOGENE, V9, P1021; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOW MJ, 1993, J BIOL CHEM, V268, P24967; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	56	104	108	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	1998	17	1					1	12		10.1038/sj.onc.1202169	http://dx.doi.org/10.1038/sj.onc.1202169			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671308				2022-12-28	WOS:000074677800001
J	Takahama, Y; Ochiya, T; Sasaki, H; Baba-Toriyama, H; Konishi, H; Nakano, H; Terada, M				Takahama, Y; Ochiya, T; Sasaki, H; Baba-Toriyama, H; Konishi, H; Nakano, H; Terada, M			Molecular cloning and functional analysis of cDNA encoding a rat leukemia inhibitory factor: towards generation of pluripotent rat embryonic stem cells	ONCOGENE			English	Article						sequence; gene targeting; gene expression; LIF; ES cell	KREBS ASCITES-CELLS; CONDITIONED MEDIUM; FEEDER CELLS; FACTOR LIF; IN-VITRO; DIFFERENTIATION; PURIFICATION; EXPRESSION; LINES; CARCINOMA	Embryonic stem (ES) cells are pluripotent cell lines established directly from the early embryo. Maintenance of the stem-cell phenotype of ES cells in vitro requires the presence of a feeder layer of fibroblasts or of a soluble factor, differentiation inhibitory activity (DIA) such as leukemia inhibitory factor (LIF). Here we report the cloning of complete rat LIF cDNA and its nucleotide sequence so as to facilitate studies of rat ES cell technologies on tumor biology. The nucleotide sequence of the rat LIF cDNA indicated that the rat LIF has 91% amino acid sequence identity with murine LIF. The cloned rat LTP cDNA has a putative biological activity as a differentiation-inducing factor on the murine myeloid leukemia cell line MI cells. Culture supernatant of the rat LIF cDNA-transduced rat fibroblast cell line could maintain the stem-cell phenotype of rat ES cells which shelved alkaline phosphatase activity, and this effect was much stronger than that by murine LIF. The availability of rat LIF which shows DIA will assist the in vitro analysis of rat ES cells, and culture of these cells is a route for the generation of gene targeting in rat.	Natl Canc Ctr, Res Inst, Div Genet, Tokyo 104, Japan; Natl Canc Ctr, Res Inst, Chemotherapy Div, Tokyo 104, Japan; Nara Med Univ, Dept Surg 1, Kashihara, Nara 634, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Nara Medical University	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Div Genet, Tokyo 104, Japan.		Ochiya, Takahiro/AAH-7585-2019					ABE E, 1986, P NATL ACAD SCI USA, V83, P5958, DOI 10.1073/pnas.83.16.5958; Akiyama N, 1997, CANCER RES, V57, P3548; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FIRST NL, 1994, REPROD FERT DEVELOP, V6, P553, DOI 10.1071/RD9940553; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GODARD A, 1988, BLOOD, V71, P1618; GOUGH NM, 1989, CANCER CELL-MON REV, V1, P77; GOUGH NM, 1988, P NATL ACAD SCI USA, V85, P2623, DOI 10.1073/pnas.85.8.2623; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; HILTON DJ, 1988, ANAL BIOCHEM, V173, P359, DOI 10.1016/0003-2697(88)90200-X; HOGAN B, 1986, MANIPULATING MOUSE E, P207; IANNACCONE PM, 1994, DEV BIOL, V163, P288, DOI 10.1006/dbio.1994.1146; Ide H, 1997, ONCOGENE, V14, P1377, DOI 10.1038/sj.onc.1200964; Joyner A. L., 1993, GENE TARGETING PRACT, P36; KINOSHITA K, 1994, FEBS LETT, V337, P221, DOI 10.1016/0014-5793(94)80195-9; Kishi T, 1997, BIOCHEM BIOPH RES CO, V232, P5, DOI 10.1006/bbrc.1997.6218; KOOPMAN P, 1984, EXP CELL RES, V154, P233, DOI 10.1016/0014-4827(84)90683-9; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PAGLIA D, 1995, J INTERF CYTOK RES, V15, P455, DOI 10.1089/jir.1995.15.455; Pain B, 1996, DEVELOPMENT, V122, P2339; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; Savatier P, 1996, ONCOGENE, V12, P309; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SMITH TA, 1983, EXP CELL RES, V145, P458, DOI 10.1016/0014-4827(83)90025-3; SUKOYAN MA, 1992, MOL REPROD DEV, V33, P418, DOI 10.1002/mrd.1080330408; SUN L, 1995, MOL MAR BIOL BIOTECH, V4, P193; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; TOMIDA M, 1984, J BIOL CHEM, V259, P978; WHEELER MB, 1994, REPROD FERT DEVELOP, V6, P288; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; ZIOMEK CA, 1990, J HISTOCHEM CYTOCHEM, V38, P437, DOI 10.1177/38.3.1689343	37	19	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	1998	16	24					3189	3196		10.1038/sj.onc.1201826	http://dx.doi.org/10.1038/sj.onc.1201826			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671398				2022-12-28	WOS:000074261300012
J	Goller, ME; Iacovoni, JS; Vogt, PK; Kruse, U				Goller, ME; Iacovoni, JS; Vogt, PK; Kruse, U			Glutaredoxin is a direct target of oncogenic jun	ONCOGENE			English	Article						jun; target gene; glutaredoxin; cytochrome P450; growth associated protein (GAP)-43; differential expression; subtractive hybridization	MESSENGER-RNAS; LEUCINE ZIPPER; TRANSFORMATION; DNA; FAMILY; FOS; TRANSACTIVATION; FIBROBLASTS; PROTEINS	We have analysed differential gene expression in v-jun-transformed chicken embryo fibroblasts (CEF) compared to normal CEF by using the directional tag PCR subtraction method. From a first generation of putative Jun targets four clones were selected for study; they are upregulated in jun-transformed cells. Three of these clones showed homology to known genes: glutaredoxin, growth associated protein (GAP)-43/neuromodulin, and phenobarbital-induced cytochrome P450. The expression of these genes was analysed in fibroblasts transformed by various oncogenes. Expression of the glutaredoxin mRNA could be induced by a Jun-estrogen receptor chimaera in the absence of de novo protein biosynthesis. Based on this observation we conclude that glutaredoxin is a direct target of v-Jun.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, BCC239,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAIZER L, 1990, MOL BRAIN RES, V7, P61, DOI 10.1016/0169-328X(90)90074-N; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BUSSLINGER M, 1994, FOS JUN FAMILIES TRA, P1833; Hadman M, 1996, ONCOGENE, V12, P135; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HANSEN AJ, 1989, DNA-J MOLEC CELL BIO, V8, P179, DOI 10.1089/dna.1.1989.8.179; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1992, ONCOGENE, V7, P1119; Picard Didier, 1993, Trends in Cell Biology, V3, P278, DOI 10.1016/0962-8924(93)90057-8; Sambrook J., 2002, MOL CLONING LAB MANU; USUI H, 1994, J NEUROSCI, V14, P4915	20	23	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2945	2948		10.1038/sj.onc.1201819	http://dx.doi.org/10.1038/sj.onc.1201819			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671415				2022-12-28	WOS:000073988200013
J	Kim, JH; Shirouzu, M; Kataoka, T; Bowtell, D; Yokoyama, S				Kim, JH; Shirouzu, M; Kataoka, T; Bowtell, D; Yokoyama, S			Activation of Ras and its downstream extracellular signal-regulated protein kinases by the CDC25 homology domain of mouse Son-of-sevenless 1 (mSos1)	ONCOGENE			English	Article						Son-of-sevenless (Sos); Dbl-homology (DH) domain; Ras; ERK; guanine nucleotide exchange factor; Pleckstrin homology (PH) domain	NUCLEOTIDE EXCHANGE FACTOR; TYROSINE KINASE; PLECKSTRIN; GRB2; RECEPTOR; PATHWAY; BINDING; SOS1; TRANSDUCTION; ASSOCIATION	A fragment consisting of residues 584-1071 of the mouse Son-of-sevenless 1 (mSos1) protein was found to be sufficient for stimulation of the guanine nucleotide exchange of Ras in vitro, which defines the CDC25 homology (CDC25H) domain of mSos1, Furthermore, we found that the CDC25H-domain fragment activated the extracellular signal-regulated protein kinases (ERKs), and was mainly membrane localized, when expressed in unstimulated human embryonic kidney 293 cells, Then, we examined the roles of other mSos1 domains in autoinhibition of the CDC25H-domain functions in unstimulated cellular environments. First, longer fragments that have the CDC25H domain and the following proline-rich Grb2-binding domain exhibited negligible membrane localization, and accordingly much lower ERK-activation activities, under serum-starved conditions. On the other hand, the preceding Pleckstrin-homology (PH) domain affects neither the ERK-activation activity nor the membrane-localization activity of the CDC25H domain. By contrast, the cells expressing a fragment containing the Dbl homology (DH) domain in addition to the PH and CDC25H domains exhibited remarkably low ERK activities under serum-starved conditions. This autoinhibitory effect of the DH domain on the CDC25H-domain function was shown to be relieved when cells were stimulated with epidermal growth factor. The DH-domain extention affected neither the irt vitro guanine nucleotide exchange activity nor the membrane-localization activity of the CDC25H domain. Therefore, one of the roles of the DH domain is to exert an autoinhibition over the CDC25H-domain function on the cell membrane, in the absence, but not in the presence, of extracellular stimuli.	Inst Phys & Chem Res, Cellular Signaling Lab, Wako, Saitama 35101, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 113, Japan; Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, Kobe, Hyogo 650, Japan; Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia	RIKEN; University of Tokyo; Kobe University; Peter Maccallum Cancer Center	Yokoyama, S (corresponding author), Inst Phys & Chem Res, Cellular Signaling Lab, 2-1 Hirosawa, Wako, Saitama 35101, Japan.		Yokoyama, Shigeyuki/N-6911-2015; Bowtell, David/H-1007-2016; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; Bowtell, David/0000-0001-9089-7525; 				Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P7100; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHARDIN P, 1993, SCIENCE, V260, P1388; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Garreau H, 1996, BIOL CELL, V86, P93, DOI 10.1016/0248-4900(96)84771-X; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hu YL, 1996, ONCOGENE, V12, P1865; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KIMURA M, 1994, BBA-GENE STRUCT EXPR, V1219, P653, DOI 10.1016/0167-4781(94)90224-0; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WHELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	12	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2597	2607		10.1038/sj.onc.1201822	http://dx.doi.org/10.1038/sj.onc.1201822			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632136				2022-12-28	WOS:000073698200004
J	Omri, B; Blancher, C; Neron, B; Marty, MC; Rutin, J; Molina, TJ; Pessac, B; Crisanti, P				Omri, B; Blancher, C; Neron, B; Marty, MC; Rutin, J; Molina, TJ; Pessac, B; Crisanti, P			Retinal dysplasia in mice lacking p56(lck)	ONCOGENE			English	Article						Lck; neuroretina; dysplasia	TYROSINE KINASE; INDUCED RETINOPATHY; NEURAL RETINA; NEURONS; FYN; RAT; LCK; PROTOONCOGENE; EXPRESSION; LSTRA	The product of the proto-oncogene p56(lck) is a nonreceptor tyrosine kinase member of the Src family. It is found in T cells (Marth ef al,, 1985, 1988) and in the mouse brain (Omri et al., 1996; Van Tan et al., 1996). In this report, we describe experiments showing that Lck is present in the mouse retina neurons. Lck gene expression was identified after isolating and sequencing the specific 5' and 3' part of the cDNA obtained by RT-PCR. In adult retina Lck immunoreactivity was most abundant in photoreceptor cells and within the outer plexiform layers. Staining was also observed in the inner nuclear and plexiform layers. In transgenic mice, the disruption of the Lck gene had serious consequences on the organization of the retina causing retinal dysplasia. These mice have partial retinal detachment with infolding and rosette formation in the photoreceptor sheet. These retinal abnormalities observed in Lck deficient mice lead to the loss of normal architecture of the photoreceptor and the inner nuclear layers, and provide an important role of Lck protein in the retina development. The lack of the Lck protein produces a spectrum of retinal pathology that resembles human retinopathy of prematurity (ROP).	CNRS, UPR 9035, F-75270 Paris 06, France; Hotel Dieu, Fac Med Broussais, Dept Pathol, F-75270 Paris, France; Univ Paris 06, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Sorbonne Universite	Crisanti, P (corresponding author), CNRS, UPR 9035, F-75270 Paris 06, France.		Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754				CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; FISCHER S, 1987, BIOCHEM BIOPH RES CO, V143, P819, DOI 10.1016/0006-291X(87)90322-6; FLEXNER RA, 1981, J HOPKINS HOSP B, V2, P115; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; HAMMER ME, 1986, AM J OPHTHALMOL, V102, P1; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; INGRAHAM CA, 1992, ONCOGENE, V7, P95; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Omri B, 1996, J NEUROCHEM, V67, P1360; OMRI B, 1994, INT IMMUNOL, V6, P377, DOI 10.1093/intimm/6.3.377; PENN JS, 1992, CURR EYE RES, V11, P939, DOI 10.3109/02713689209033492; POPOFF N, 1969, J ULTRA MOL STRUCT R, V29, P535, DOI 10.1016/S0022-5320(69)90072-0; QUINN GE, 1990, DOC OPHTHALMOL, V74, P223, DOI 10.1007/BF02482612; RAJAOFETRA N, 1992, DEV BRAIN RES, V67, P237, DOI 10.1016/0165-3806(92)90224-K; SADDA SR, 1994, INVEST OPHTH VIS SCI, V35, P1202; SILVERSTEIN AM, 1971, AM J OPHTHALMOL, V72, P13, DOI 10.1016/0002-9394(71)91586-8; SIRA BS, 1985, SURV OPHTHALMOL, V33, P1; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; TSO MOM, 1969, ARCH PATHOL, V88, P664; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; VanTan H, 1996, J NEUROCHEM, V67, P2306; YAGI T, 1994, DEV GROWTH DIFFER, V36, P543; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZIERLER S, 1988, RETINOPATHY PREMATUR, P23	28	28	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2351	2356		10.1038/sj.onc.1201761	http://dx.doi.org/10.1038/sj.onc.1201761			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620552				2022-12-28	WOS:000073428000007
J	Zamzami, N; Brenner, C; Marzo, I; Susin, SA; Kroemer, G				Zamzami, N; Brenner, C; Marzo, I; Susin, SA; Kroemer, G			Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins	ONCOGENE			English	Review						mitochondrial transmembrane potential; permeability transition; programmed cell death; proteases	PROGRAMMED CELL-DEATH; NF-KAPPA-B; MITOCHONDRIAL PERMEABILITY TRANSITION; YEAST 2-HYBRID SYSTEM; TRANSGENIC MICE; CYCLE PROGRESSION; POLY(ADP-RIBOSE) POLYMERASE; LYMPHOCYTE APOPTOSIS; CONSERVED DOMAINS; POLYCYSTIC KIDNEY	Bcl-2 is the prototype of a class of oncogenes which regulates apoptosis, Bcl-2-related gene products with either death-promoting and death-inhibitory activity are critically involved in numerous disease states and thus constitute prime targets for therapeutic interventions. The relative amount of death agonists and antagonists from the Bcl-2 family constitutes a regulatory rheostat whose function is determined, at least in part, by selective protein-protein interactions. Bcl-2 and its homologs insert into intracellular membranes including mitochondria, the endoplasmatic reticulum and the nuclear envelope. Many of the molecular genetic, ultrastructural, crystallographic and functional studies suggest that Bcl-2-related molecules exert their apoptosis-regulatory effects via regulating mitochondrial alterations preceding the activation of apoptogenic proteases and nucleases, Via a direct effect on mitochondrial membranes, Bcl-2 prevents all hallmarks of the early stage of apoptosis including disruption of the inner mitochondrial transmembrane potential and the release of apoptogenic protease activators from mitochondria, The mitochondrial permeability transition (PT) pore, also called mitochondrial megachannel or multiple conductance channel, is a multiprotein complex formed at the contact site between the mitochondrial inner and outer membranes, exactly at the same localization at which Bax, Bcl-2, and Bcl-X-L are particularly abundant. The PT pore participates in the regulation of matrix Ca2+, pH, Delta Psi(m), and volume and functions as a Ca2+-, voltage-, pH-, and redox-gated channel with several levels of conductance and little if any ion selectivity. Experiments involving the purified PT pore complex indicate that Bax, Bcl-2, and Bcl-X, exert at least part of their apoptosis-regulatory function by facilitating (Bax) or inhibiting (Bcl-2, Bcl-X-L) PT pore opening. These findings clarify the principal (but not exclusive) mechanism of Bcl-2-mediated cytoprotection.	CNRS, UPR420, F-94801 Villejuif, France; Univ Technol Compiegne, CNRS, UPRES 16022, F-60200 Compiegne, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne	Kroemer, G (corresponding author), CNRS, UPR420, 19 Rue Guy Moquet, F-94801 Villejuif, France.		Kroemer, Guido/AAY-9859-2020; Marzo, Isabel/E-6918-2016; KROEMER, Guido/B-4263-2013; Susin, Santos A/Q-6754-2017; brenner, catherine/AAE-8632-2020	Marzo, Isabel/0000-0002-2315-9079; KROEMER, Guido/0000-0002-9334-4405; Susin, Santos A/0000-0002-3366-1628; 				ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; BERNARDI P, 1996, J BIOENERG BIOMEMBR, V28, P129; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Blagosklonny MV, 1997, CANCER RES, V57, P130; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Boulakia CA, 1996, ONCOGENE, V12, P529; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; Castedo M, 1996, J IMMUNOL, V157, P512; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chernyak BV, 1997, FEBS LETT, V418, P131, DOI 10.1016/S0014-5793(97)01361-6; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DALLAPORTA B, 1998, IN PRESS; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Decaudin D, 1997, CANCER RES, V57, P62; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; delPeso L, 1997, SCIENCE, V278, P687; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Distelhorst CW, 1996, ONCOGENE, V12, P2051; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; EVANS EK, 1997, EMBO J, V16, P7272; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Flora PK, 1996, EUR J IMMUNOL, V26, P2243, DOI 10.1002/eji.1830260941; Fromm L, 1997, DEV GENET, V20, P276, DOI 10.1002/(SICI)1520-6408(1997)20:3<276::AID-DVG10>3.0.CO;2-6; Furuchi T, 1996, DEVELOPMENT, V122, P1703; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Haldar S, 1997, CANCER RES, V57, P229; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hedley DW, 1996, LEUKEMIA, V10, P1143; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; HENNET T, 1993, CANCER RES, V53, P1456; Herrmann JL, 1997, EXP CELL RES, V234, P442, DOI 10.1006/excr.1997.3653; Hilton M, 1997, CURR BIOL, V7, P798, DOI 10.1016/S0960-9822(06)00339-3; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; HIRSCH T, IN PRESS EXP CELL RE; HIRSCH T, 1998, IN PRESS J IMMUNOL; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hsu SY, 1996, ENDOCRINOLOGY, V137, P4837, DOI 10.1210/en.137.11.4837; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; KAMADA S, 1995, CANCER RES, V55, P354; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; Kinnally KW, 1996, J BIOENERG BIOMEMBR, V28, P115, DOI 10.1007/BF02110641; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; KURSCHNER C, 1995, MOL BRAIN RES, V30, P165, DOI 10.1016/0169-328X(95)00013-I; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lesage S, 1997, J IMMUNOL, V159, P4762; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Macho A, 1997, J IMMUNOL, V158, P4612; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marin MC, 1996, ONCOGENE, V12, P2259; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MARZO I, 1998, IN PRESS J EXP MED; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; McConkey DJ, 1996, J BIOL CHEM, V271, P22398, DOI 10.1074/jbc.271.37.22398; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; METIVIER D, 1998, IN PRESS IMMUNOL LET; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIOSSEC D, 1997, J BIOL CHEM, V272, P13459; MORAN O, 1992, J BIOENERG BIOMEMBR, V24, P91, DOI 10.1007/BF00769535; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Paumen MB, 1997, BIOCHEM BIOPH RES CO, V231, P523, DOI 10.1006/bbrc.1997.6089; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Penninger JM, 1998, ADV IMMUNOL, V68, P51, DOI 10.1016/S0065-2776(08)60558-1; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; PETIT PX, 1998, IN PRESS FEBS LETT; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Rao L, 1997, ONCOGENE, V15, P1587, DOI 10.1038/sj.onc.1201323; RATTS VS, 1995, ENDOCRINOLOGY, V136, P3665, DOI 10.1210/en.136.8.3665; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; RIPARBELLI MG, 1995, EXP CELL RES, V221, P363, DOI 10.1006/excr.1995.1386; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Roth KA, 1996, J NEUROSCI, V16, P1753; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SENTMAN CL, 1991, CELL, V67, P881; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, ONCOGENE, V12, P2251; SHIMIZU S, 1998, IN PRESS P NATL ACAD; Shindler KS, 1997, J NEUROSCI, V17, P3112; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; SMETS LA, 1994, BLOOD, V84, P1613; Sorenson CM, 1996, AM J PHYSIOL-RENAL, V271, pF184, DOI 10.1152/ajprenal.1996.271.1.F184; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tanabe H, 1997, EUR J NEUROSCI, V9, P848, DOI 10.1111/j.1460-9568.1997.tb01434.x; TANAKA S, 1993, J BIOL CHEM, V268, P10920; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Torgler CN, 1997, CELL DEATH DIFFER, V4, P263, DOI 10.1038/sj.cdd.4400239; Uhlmann EJ, 1996, CANCER RES, V56, P2506; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VOEHRINGER DW, 1998, IN PRESS P NATL ACAD; Wang H, 1996, ONCOGENE, V13, P373; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WiedauPazos M, 1996, FREE RADICAL RES, V24, P205, DOI 10.3109/10715769609088018; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yamamura K, 1996, CANCER RES, V56, P3546; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yasuhara N, 1997, ONCOGENE, V15, P1921, DOI 10.1038/sj.onc.1201370; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YING XM, 1994, NATURE, V369, P321; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; ZAMZAMI N, 1998, IN PRESS ONCOGENE; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang XJ, 1997, PROSTATE, V32, P16, DOI 10.1002/(SICI)1097-0045(19970615)32:1<16::AID-PROS3>3.0.CO;2-A; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; ZHOU H, 1997, CELL, V90, P405; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	197	348	369	1	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2265	2282		10.1038/sj.onc.1201989	http://dx.doi.org/10.1038/sj.onc.1201989			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619836				2022-12-28	WOS:000073298000012
J	Agami, R; Shaul, Y				Agami, R; Shaul, Y			The kinase activity of c-Abl but not v-Abl is potentiated by direct interaction with RFXI, a protein that binds the enhancers of several viruses and cell-cycle regulated genes	ONCOGENE			English	Article						EP element; HBV enhancer; c-Abl tyrosine kinase; DNA binding; RFX1; transcription	HEPATITIS-B VIRUS; RNA POLYMERASE-II; TYROSINE KINASE; TRANSCRIPTION FACTORS; TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; ACTIVITY INVITRO; PROMOTER REGION; NUCLEAR-PROTEIN; SH3 DOMAINS	c-Abl, the non-receptor tyrosine kinase is associated with EP, a DNA element found in promoters/enhancers of different viruses and cell-cycle regulated genes. EP-DNA binds RFXI, a member of a novel family of DNA-binding proteins that is conserved through evolution and in yeast, it controls differentiation and exit from the mitotic cycle to G(0). EP-associated proteins are preferentially tyrosine phosphorylated and the associated c-Abl has strong tyrosine kinase activity. Here we investigated the molecular mechanism underlying this c-Abl kinase activity. We show that RFXI and c-Abl are in direct interaction, in vitro and in cell extracts, through the RFXI proline rich (PxxP) motif and the c-Abl SH3 domain. Remarkably, this interaction significantly potentiates c-Abl but not v-Abl auto-kinase activity. Collectively, we describe a novel mechanism of c-Abl recruitment to a defined DNA-cis element with its concomitant kinase activation. We propose that this mechanism may act to regulate cell-cycle control genes.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		agami, reuven/GOG-8289-2022	Agami, Reuven/0000-0002-2848-2473				ANAFI M, 1992, J BIOL CHEM, V267, P4518; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; Dikstein R, 1996, P NATL ACAD SCI USA, V93, P2387, DOI 10.1073/pnas.93.6.2387; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GARCIA AD, 1993, J VIROL, V67, P3940, DOI 10.1128/JVI.67.7.3940-3950.1993; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GHAZAL P, 1988, MOL CELL BIOL, V8, P1809, DOI 10.1128/MCB.8.4.1809; HONIGWACHS J, 1989, J VIROL, V63, P919, DOI 10.1128/JVI.63.2.919-924.1989; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LABRIE C, 1995, NUCLEIC ACIDS RES, V23, P3732, DOI 10.1093/nar/23.18.3732; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; SAFRANY G, 1995, EUR J BIOCHEM, V230, P1066, DOI 10.1111/j.1432-1033.1995.tb20657.x; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1994, TRENDS BIOCHEM SCI, V19, P373, DOI 10.1016/0968-0004(94)90114-7; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WU SY, 1995, MOL CELL BIOL, V15, P1479; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZAJAC KM, 1988, SCIENCE, V240, P1176; ZHANG XY, 1991, VIROLOGY, V182, P865, DOI 10.1016/0042-6822(91)90631-K; ZHANG XY, 1990, CANCER RES, V50, P6865; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253	67	24	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	1998	16	14					1779	1788		10.1038/sj.onc.1201708	http://dx.doi.org/10.1038/sj.onc.1201708			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583676				2022-12-28	WOS:000072994600002
J	Lau, QC; Brusselbach, S; Muller, R				Lau, QC; Brusselbach, S; Muller, R			Abrogation of c-Raf expression induces apoptosis in tumor cells	ONCOGENE			English	Article						apoptosis; programmed cell death; Raf; antisense; phosphorothioate ODN	BCL-2 PROTEIN; KINASE RAF-1; ACTIVATION; DEATH	Signal transduction pathways involving the c-Raf protein kinase are frequently activated in tumor cells. We have addressed the relevance of this activation by a loss-of-function approach, An anti-sense phosphorothioate oligonucleotide (ODN) specifically targeted against c-raf mRNA (Monia ef al., 1996a) was used to block c-Raf protein expression in four different cell lines derived from lung, cervical, prostate and colon carcinomas. Concomitant with the abrogation of c-Raf expression we observed the occurrence of classical apoptotic markers, including chromatin condensation, inter-nucleosomal DNA cleavage, annexin V binding and cleavage of PARP, which was followed by cell death, affecting most of the cell population. This induction of apoptosis occurred independent of the p53 status of the cell. These findings demonstrate that c-Raf can protect tumor cells from undergoing programmed cell death, and suggest that the interference with c-Raf expression or function by ODNs or specific drugs could represent a powerful means for improving the efficacy of anti-cancer therapy.	Univ Marburg, Inst Mol Biol & Tumorforsch IMT, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch IMT, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				Blagosklonny MV, 1996, CANCER RES, V56, P1851; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KINZLER KW, 1994, NEW ENGL J MED, V331, P49, DOI 10.1056/NEJM199407073310113; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; Monia BP, 1996, P NATL ACAD SCI USA, V93, P15481, DOI 10.1073/pnas.93.26.15481; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Reed J C, 1996, Behring Inst Mitt, P72; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293	19	68	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1899	1902		10.1038/sj.onc.1201709	http://dx.doi.org/10.1038/sj.onc.1201709			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583688				2022-12-28	WOS:000072994600014
J	Larcher, F; Murillas, R; Bolontrade, M; Conti, CJ; Jorcano, JL				Larcher, F; Murillas, R; Bolontrade, M; Conti, CJ; Jorcano, JL			VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development	ONCOGENE			English	Article						angiogenesis; skin carcinogenesis; epidermis; transgenic mice	ENDOTHELIAL GROWTH-FACTOR; V-HA-RAS; RECEPTOR TYROSINE KINASE; MOUSE SKIN; PERMEABILITY FACTOR; MALIGNANT PROGRESSION; EPIDERMAL-KERATINOCYTES; ALPHA-6-BETA-4 INTEGRIN; FACTOR EXPRESSION; CARCINOGENESIS	Upregulation of keratinocyte-derived VEGF-A expression has recently been established in non-neoplastic processes of skin such as wound healing, blistering diseases and psoriasis, as well as in skin neoplasia, To further characterize the effects of VEGF-A in skin in vivo, we have developed transgenic mice expressing the mouse VEGF(120) under the control of a 2,4 kb 5' fragment of keratin K6 gene regulatory sequences that confers transgene inducibility upon hyperproliferative stimuli. As expected from the inducible nature of the transgene, two of the three founder mice obtained (V27 and V208), showed no apparent phenotype, However, one founder (V2), mosaic for transgene integration, developed scattered red spots throughout the skin at birth, The transgenic offspring derived from this founder developed a striking phenotype characterized by swelling and erythema, resulting in early postnatal lethality. Histological examination of the skin of these transgenics demonstrated highly increased vascularization and edema leading to disruption of skin architecture. Expression of the transgene was silent in adult animals of lines derived from founders V27 and V208, Phorbol ester-induced hyperplasia resulted in transgene induction and increased cutaneous vascularization in adult transgenic mice of these lines. Skin carcinogenesis experiments performed on hemizygous crosses of V208 mice with activated H-ras-carrying transgenic mice (TG.AC) resulted in accelerated papilloma development and increased tumor burden. Previous results from our laboratory showed that VEGF upregulation is a major angiogenic stimulus in mouse epidermal carcinogenesis. By overexpressing VEGF in the skin of transgenic mice we now move a step further toward showing that VEGF mediated angiogenesis is a rate-limiting step in the genesis of premalignant lesions, such as mouse skin papilloma, Our transgenic mice constitute an interesting :model system for in vivo study of the cutaneous angiogenic process and its relevance in tumorigenesis and other skin diseases.	Ctr Invest Energet Mediamnientales & Tecnol, Dept Cell & Mol Biol, Madrid 28040, Spain; Univ Texas, Md Anderson Canc Ctr, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Jorcano, JL (corresponding author), Ctr Invest Energet Mediamnientales & Tecnol, Dept Cell & Mol Biol, Madrid 28040, Spain.		MURILLAS, RODOLFO/H-8121-2017; Larcher, Fernando/J-1527-2016	MURILLAS, RODOLFO/0000-0001-9813-1006; Larcher, Fernando/0000-0002-6771-3561; Bolontrade, Marcela/0000-0002-8664-5541	NCI NIH HHS [CA 76540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; ALDAZ CM, 1988, CANCER RES, V48, P3253; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BALLAUN C, 1995, J INVEST DERMATOL, V104, P7, DOI 10.1111/1523-1747.ep12613450; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1995, J INVEST DERMATOL, V104, P744, DOI 10.1111/1523-1747.ep12606974; Cano A, 1996, INT J CANCER, V65, P254; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Detmar M, 1996, J INVEST DERMATOL, V106, P207, DOI 10.1111/1523-1747.ep12340457; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DETMAR M, 1995, J INVEST DERMATOL, V105, P44, DOI 10.1111/1523-1747.ep12312542; FERRARA N, 1996, EUR J CANCER, V32, P2143; FERRARA N, 1996, NATURE, V380, P389; FLAMME I, 1995, DEV BIOL, V171, P399, DOI 10.1006/dbio.1995.1291; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FOWLIS D, 1996, CELL GROWTH DIFFER, V3, P81; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GIMENEZCONTI I, 1990, CARCINOGENESIS, V11, P1995, DOI 10.1093/carcin/11.11.1995; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOMEZ M, 1992, EXP CELL RES, V201, P250, DOI 10.1016/0014-4827(92)90272-A; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; HANNAHAN D, 1996, CELL, V86, P353; HANSEN LA, 1994, P NATL ACAD SCI USA, V91, P7822, DOI 10.1073/pnas.91.16.7822; HOGAN B, 1986, MANIPULATING MOUSE E; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Larcher F, 1996, CANCER RES, V56, P5391; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; MALHOTRA R, 1989, LAB INVEST, V61, P162; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MORBIDELLI L, 1998, IN PRESS ANGIOGENEIS, V1; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; RAK J, 1995, CANCER RES, V55, P4575; Ramirez A, 1998, DNA CELL BIOL, V17, P177, DOI 10.1089/dna.1998.17.177; RAMIREZ A, 1995, P NATL ACAD SCI USA, V92, P4783, DOI 10.1073/pnas.92.11.4783; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schweizer Juergen, 1993, P33; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; SmithMcCune K, 1997, CANCER RES, V57, P1294; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; TENNENBAUM T, 1993, CANCER RES, V53, P4803; WANG XJ, 1995, ONCOGENE, V10, P279; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; YUSPA SH, 1994, CANCER RES, V54, P1178	58	185	199	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					303	311		10.1038/sj.onc.1201928	http://dx.doi.org/10.1038/sj.onc.1201928			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690512				2022-12-28	WOS:000074947500005
J	von Knethen, A; Lotero, A; Brune, B				von Knethen, A; Lotero, A; Brune, B			Etoposide and cisplatin induced apoptosis in activated RAW264.7 macrophages is attenuated by cAMP-induced gene expression	ONCOGENE			English	Article						cisplatin; etoposide; resistance; macrophages; p53; cAMP	PROSTAGLANDIN-H SYNTHASE-2; OXIDE-INDUCED APOPTOSIS; CELL-DEATH; CYCLOOXYGENASE EXPRESSION; INDUCIBLE CYCLOOXYGENASE; ALVEOLAR MACROPHAGES; TRANSCRIPTION FACTOR; THYMOCYTE APOPTOSIS; COLORECTAL-CANCER; DNA-REPAIR	Previous observations suggest expression of cyclooxygenase-2 to convey macrophage protection towards apoptotic cell death. We reasoned prostaglandin formation and in turn a cAMP increase as the underlying protective principle. Here we report that exposure of macrophages to lipopolysaccharide/interferon-gamma or lipophilic cAMP analogs such as dibutyryl-cAMP or 8-bromo-cAMP for 15 h attenuated DNA fragmentation and accumulation of the tumor suppressor p53 in response to the chemotherapeutic agents cisplatin and etoposide, compared to cells that received chemotherapeutic agents only. In contrast, a Ih lasting preexposure period revealed no protection. The demand for a long incubation period with cAMP-derivates implied cAMP-mediated gene activation as the underlying principle, Therefore, we treated cells with oligonucleotides containing a cAMP-response element (CRE) binding site. Using this decoy-approach we scavanged activated cAMP response element binding protein prior to its promoter activating ability. Incubating macrophages with decoy, but not with control oligonucleotides, reduced cAMP evoked protection and simultanously restored p53 accumulation in response to chemotherapeutic agents. Our studies demonstrate that cAMP-initiated gene activation regulates the sensitivity towards DNA damaging agents via inhibition of a p53 dependent pathway.	Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, D-91054 Erlangen, Germany; Univ Alcala de Henares, Fac Med, Dept Biochem & Mol Biol, Alcala De Henares 28871, Spain	University of Erlangen Nuremberg; Universidad de Alcala	Brune, B (corresponding author), Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, Loschgestr 8, D-91054 Erlangen, Germany.							ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; Brune B, 1996, BIOCHEM BIOPH RES CO, V229, P396, DOI 10.1006/bbrc.1996.1816; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; Chen ZH, 1996, CANCER RES, V56, P5224; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; DiBattista JA, 1997, J CELL BIOCHEM, V65, P408, DOI 10.1002/(SICI)1097-4644(19970601)65:3<408::AID-JCB10>3.3.CO;2-H; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DuBois RN, 1996, CANCER RES, V56, P733; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Eischen Christine M., 1997, Blood, V90, P935; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; Fulda S, 1997, CANCER RES, V57, P3823; Gallagher WM, 1997, ONCOGENE, V14, P185; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; Karim S, 1997, BIOCHEM J, V326, P593, DOI 10.1042/bj3260593; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJNO G, 1995, AM J PATHOL, V146, P3; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MCDONNELL TJ, 1995, SEMIN CANCER BIOL, V6, P53, DOI 10.1006/scbi.1995.0007; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; Pang LH, 1997, BIOCHEM PHARMACOL, V53, P493, DOI 10.1016/S0006-2952(96)00737-X; Perego P, 1996, CANCER RES, V56, P556; PETERSON HI, 1983, INVAS METAST, V3, P151; Quinn MR, 1996, IMMUNOL LETT, V50, P185, DOI 10.1016/0165-2478(96)02542-4; Ramanathan RK, 1997, SEMIN ONCOL, V24, P440; REDDY BS, 1987, CANCER RES, V47, P5340; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; Ruchaud S, 1997, ONCOGENE, V15, P827, DOI 10.1038/sj.onc.1201248; Sandler AB, 1997, SEMIN ONCOL, V24, P463; SANO H, 1995, CANCER RES, V55, P3785; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Sharma HW, 1996, ANTICANCER RES, V16, P589; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Torgersen KM, 1997, J BIOL CHEM, V272, P5495, DOI 10.1074/jbc.272.9.5495; Tortora G, 1997, P NATL ACAD SCI USA, V94, P12586, DOI 10.1073/pnas.94.23.12586; Tortora G, 1997, CANCER RES, V57, P5107; Trump BF, 1997, TOXICOL PATHOL, V25, P82, DOI 10.1177/019262339702500116; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VASSAULT A, 1983, METHOD ENZYMAT AN, V1, P118; VonKnethen A, 1997, FASEB J, V11, P887; Walker BAM, 1997, J IMMUNOL, V158, P2926; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang YM, 1996, ONCOGENE, V12, P2223; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; ZHANG F, 1995, BIOCHEM J, V312, P135, DOI 10.1042/bj3120135	73	53	54	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	1998	17	3					387	394		10.1038/sj.onc.1201926	http://dx.doi.org/10.1038/sj.onc.1201926			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690520				2022-12-28	WOS:000074947500013
J	Risse-Hackl, G; Adamkiewicz, J; Wimmel, A; Schuermann, M				Risse-Hackl, G; Adamkiewicz, J; Wimmel, A; Schuermann, M			Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins	ONCOGENE			English	Article						AP-1; Jun; Fos; Fra-1, Ras; lung cancer; transdifferentiation	TRANSCRIPTION FACTOR AP-1; PROGRAMMED CELL-DEATH; FOS-RELATED ANTIGEN; C-FOS; LUNG-CANCER; JUN PROTEINS; TUMOR PROGRESSION; GENE-EXPRESSION; PROMOTER ACTIVITY; GROWTH-FACTORS	Transitions from small cell (SCLC) to non-small cell lung cancer (NSCLC) cells have been documented both in vitro and in vivo and are thought to be an important step during tumor progression of human small cell lung cancer towards a treatment-resistant tumor state. We have screened NSCLC and SCLC cell lines for differences in the composition of nuclear transcription factors using consensus oligonucleotide sequences (SRE, Ets, TRE, CRE, B-motif, GAS, E-box), We found NSCLC cells to exhibit significantly higher AP-1 binding activity than SCLC cells consistent with the increased expression of CD44, an AP-1 target gene. To gain more insight into the molecular mechanisms underlying these differences, we analysed SCLC cell lines (NCI-N592 and NCI-H69) which were phenotypically transformed into NSCLC-type cells by transfection with activated H-l ns and c-myc oncogenes, In these cells, I as-induced transition is accompanied by a strong induction of AP-l-binding activity along with increased expression of CD 44 mRNA and protein. When analysing the composition of the AP-1 complex in more detail and comparing ras-induced versus phorbol ester-induced changes, we found Fra-1 to be the major component induced in ras-transfected but not in phorbol-ester treated or non-treated parental SCLC cells. This finding is paralleled by the observation that among the various members of the Fos and Jun family analysed (c-Fos, FosB, Fra-1, Fra-2, c-Jun, JunD, JunB) fra-1 is the only gene to be exclusively expressed in NSCLC cells but not in cells of SCLC origin. Our data, thus, point to a histiotype-related mechanism of recruitment among AP-1 proteins which may have bearings on the fate of lung cancer development.	Univ Marburg, Hamatol Onkol Abt, Zentrum Innere Med, D-35033 Marburg, Germany; Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35037 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Schuermann, M (corresponding author), Univ Marburg, Hamatol Onkol Abt, Zentrum Innere Med, Baldingerstr, D-35033 Marburg, Germany.							ADAMKIEWICZ J, 1990, ONCOGENE, V5, P525; ADAMKIEWICZ J, 1993, INT J ONCOL, V2, P503; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; Barr LF, 1996, CELL GROWTH DIFFER, V7, P1149; BARR LF, 1991, CANCER RES, V51, P5514; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; BURGER C, 1994, MOL CELL DIFFER, V2, P373; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1990, CRIT REV ONCOGEN, V1, P6184; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; Givehchian M, 1996, ONCOGENE, V12, P1137; GOLDSTONE SD, 1994, ONCOGENE, V9, P2305; HANNAN RD, 1993, J MOL CELL CARDIOL, V25, P1137, DOI 10.1006/jmcc.1993.1127; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOFMANN M, 1993, CANCER RES, V53, P1516; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JAMAL HH, 1994, ONCOGENE, V9, P417; Kalemkerian GP, 1993, LUNG CANCER, P57; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; MABRY M, 1988, P NATL ACAD SCI USA, V85, P6523, DOI 10.1073/pnas.85.17.6523; MABRY M, 1991, CANCER CELL-MON REV, V3, P53; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUI M, 1990, ONCOGENE, V5, P249; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MELAMED D, 1993, CELL GROWTH DIFFER, V4, P689; MIANO JM, 1993, AM J PATHOL, V142, P715; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; PARK K, 1992, J BIOL CHEM, V267, P10810; PENNO MB, 1994, CANCER RES, V54, P1381; PERSICO AM, 1993, MOL BRAIN RES, V20, P91, DOI 10.1016/0169-328X(93)90113-4; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROGGLI VL, 1985, HUM PATHOL, V16, P569, DOI 10.1016/S0046-8177(85)80106-4; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SATO H, 1993, ONCOGENE, V8, P395; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; SIDEROVSKI DP, 1990, DNA CELL BIOL, V9, P579, DOI 10.1089/dna.1990.9.579; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STEPHENS JM, 1993, MOL CELL BIOCHEM, V123, P63, DOI 10.1007/BF01076476; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TROEN BR, 1991, CELL GROWTH DIFFER, V2, P23; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WANG ZQ, 1993, J BONE MINER RES, V8, P839; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WIMMEL A, 1997, LUNG CANCER, V16, P239; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	70	47	49	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3057	3068		10.1038/sj.onc.1201845	http://dx.doi.org/10.1038/sj.onc.1201845			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662339				2022-12-28	WOS:000074125300013
J	Maggiora, P; Marchio, S; Stella, MC; Giai, M; Belfiore, A; De Bortoli, M; Di Renzo, MF; Costantino, A; Sismondi, P; Comoglio, PM				Maggiora, P; Marchio, S; Stella, MC; Giai, M; Belfiore, A; De Bortoli, M; Di Renzo, MF; Costantino, A; Sismondi, P; Comoglio, PM			Overexpression of the RON gene in human breast carcinoma	ONCOGENE			English	Article						protein-tyrosine kinase; RON; breast neoblasts	HEPATOCYTE GROWTH-FACTOR; MACROPHAGE-STIMULATING PROTEIN; RECEPTOR TYROSINE KINASE; SCATTER FACTOR-RECEPTOR; MET PROTOONCOGENE; OVARIAN-CANCER; IDENTIFICATION; CELLS; EXPRESSION; TRANSFORMATION	Constitutive activation of the RON gene, known to code for the tyrosine-kinase receptor for Macrophage Stimulating Protein (also known as Scatter Factor 2), has been shown to induce invasive-metastatic phenotype in vitro. As yet, nothing is known about the expression of this novel member of the MET-oncogene family in spontaneously occurring human cancers. Here we report that Ron is expressed at abnormally high levels in about 50% primary breast carcinomas (35/74 patients). Among these, the expression is increased more than 20-fold in 12 cases and the overexpressed protein is constitutively phosphorylated on tyrosine residues. Notably, Ron is only barely detectable in epithelial cells of the mammary gland, and its expression remains unchanged in benign breast lesions (including adenomas and papillomas). Overexpression was observed in different histotypic variants of carcinomas; it is associated with the disease at any stage and correlates with the post-menopausal status. In breast carcinoma cells grown im vitro, activation of the Ron receptor resulted in proliferation, migration and invasion through reconstituted basement membranes. Altogether, these data suggest a role for the RON gene in progression of human breast carcinomas to the invasive-metastatic phenotype.	Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Turin, Italy; Univ Turin, Sch Med, Dept Gynecol Oncol, I-10060 Turin, Italy; Univ Turin, Dept Biol, LMCB, I-10123 Turin, Italy; Univ Catania, Sch Med, Dept Endocrinol, I-95123 Catania, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; University of Turin; University of Catania	Comoglio, PM (corresponding author), Univ Turin, Sch Med, Inst Canc Res, Str Prov 142,Km 3-95, I-10060 Turin, Italy.		DI RENZO, Maria Flavia/B-6091-2012; Marchiò, Serena/G-9054-2017; De Bortoli, Michele/B-5418-2013; Belfiore, Antonino/B-4652-2011	DI RENZO, Maria Flavia/0000-0002-5093-3373; Marchiò, Serena/0000-0001-8214-0776; De Bortoli, Michele/0000-0002-6666-9052; Belfiore, Antonino/0000-0002-6181-4193; Sismondi, Piero/0000-0002-2505-5716; Comoglio, Paolo/0000-0002-7056-5328				BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; BYERS S, 1994, BREAST CANCER RES TR, V31, P203, DOI 10.1007/BF00666154; Collesi C, 1996, MOL CELL BIOL, V16, P5518; DELGATTO F, 1995, BBA-GENE STRUCT EXPR, V1263, P93, DOI 10.1016/0167-4781(95)00082-R; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; Gambarotta G, 1996, ONCOGENE, V13, P1911; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORDANO S, 1997, P NATL ACAD SCI USA, V94, P11445; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; Hartmann A, 1997, TRENDS GENET, V13, P27, DOI 10.1016/S0168-9525(96)10043-3; HENNIPMAN A, 1989, CANCER RES, V49, P516; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; KOBAYASHI H, 1992, CANCER RES, V52, P3610; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; Lin JC, 1996, ONCOGENE, V13, P2001; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAGY J, 1995, J SURG ONCOL, V60, P95, DOI 10.1002/jso.2930600206; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RONSIN C, 1993, ONCOGENE, V8, P1195; SAINSBURY JRC, 1985, LANCET, V1, P364; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TOI M, 1994, BREAST CANCER RES TR, V29, P51, DOI 10.1007/BF00666181; Tuck AB, 1996, AM J PATHOL, V148, P225; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WERNERT N, 1994, CANCER RES, V54, P5683; YAMASHITA J, 1994, CANCER RES, V54, P1630	42	176	193	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2927	2933		10.1038/sj.onc.1201812	http://dx.doi.org/10.1038/sj.onc.1201812			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671413				2022-12-28	WOS:000073988200011
J	Sharma, SV; Agatsuma, T; Nakano, H				Sharma, SV; Agatsuma, T; Nakano, H			Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol	ONCOGENE			English	Article						radicicol; molecular chaperones; transformation suppression; HSP90; Raf	HEAT-SHOCK PROTEIN; KINASE KINASE KINASE; ROUS-SARCOMA VIRUS; MAP KINASE; FARNESYLTRANSFERASE INHIBITORS; HETEROPROTEIN COMPLEX; TYROSINE KINASE; RAS; RAF-1; ACTIVATION	Radicicol, a macrocyclic anti-fungal antibiotic, has the ability to suppress transformation by diverse oncogenes such as Src, Ras and Mos. Despite this useful property, the mechanism by which radicicol exerts its anti-transformation effects is currently unknown, To understand the transformation-suppressing effects of radicicol, a biotinylated derivative of radicicol was chemically synthesized and used as a probe in a Western-blot format to visualize cellular proteins that interact with radicicol, In transformed and untransformed mouse fibroblasts, the most prominent cellular protein that bound to radicicol had a molecular weight of approximately 90 kDa, Further analysis revealed that this protein was the mouse homologue of the 90 kDa heat shock protein (HSP90). This was confirmed by demonstrating the ability of radicicol to specifically bind purified human HSP90, Specificity of binding was demonstrated by the inhibition of binding of biotinylated radicicol by the native drug, Taken together with other studies the present observations suggest that the anti-transformation effects of radicicol may be mediated, at least in part, by the association of radicicol with HSP90 and the consequent dissociation of the Raf/HSP90 complex leading to the attenuation of the Ras/MAP kinase signal transduction pathway.	Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 194, Japan	University of Tennessee System; University of Tennessee Health Science Center; Kyowa Kirin Ltd	Sharma, SV (corresponding author), Univ Tennessee, Dept Microbiol & Immunol, 858 Madison Ave, Memphis, TN 38163 USA.				NCI NIH HHS [R01 CA55983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; AYER WA, 1980, CAN J MICROBIOL, V26, P766, DOI 10.1139/m80-133; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Gibbs JB, 1996, BREAST CANCER RES TR, V38, P75, DOI 10.1007/BF01803786; GRENERT JP, 1997, IN PRESS J BIOL CHEM; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Koblan KS, 1996, BIOCHEM SOC T, V24, P688, DOI 10.1042/bst0240688; KWON HJ, 1995, J BIOCHEM-TOKYO, V118, P221, DOI 10.1093/oxfordjournals.jbchem.a124882; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Marais R, 1996, CANCER SURV, V27, P101; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARSHALL CJ, 1995, ANN ONCOL, V6, P63; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOORE SK, 1990, DNA CELL BIOL, V9, P387, DOI 10.1089/dna.1990.9.387; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Oliff A, 1996, SCI AM, V275, P144, DOI 10.1038/scientificamerican0996-144; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; REBBE NF, 1989, J BIOL CHEM, V264, P15006; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Sharma SV, 1997, ONCOGENE, V14, P2641, DOI 10.1038/sj.onc.1201115; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; ZHAO JF, 1995, ONCOGENE, V11, P161	45	235	239	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2639	2645		10.1038/sj.onc.1201790	http://dx.doi.org/10.1038/sj.onc.1201790			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632140				2022-12-28	WOS:000073698200008
J	Matsuoka, M; Tani, K; Asano, S				Matsuoka, M; Tani, K; Asano, S			Interferon-alpha-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p19(Ink4D) and p21(Cip1) in mouse macrophages	ONCOGENE			English	Article						p19(Ink4D); p21(Cip1); interferon-alpha	CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR GENE; TGF-BETA; PROTEIN-KINASE; POTENTIAL MEDIATOR; CATALYTIC SUBUNIT; MAMMALIAN-CELLS; GROWTH ARREST; G(1) CYCLINS	The mechanism of cell cycle arrest induced by interferon-alpha (IFN-alpha) was analysed using a mouse macrophage cell line, BAC1.2F5A. IFN-alpha added in media before mid-G1 prohibited cells from entering S phase. The blockage of G1/S transition was associated with diminuition of both cyclin D1/cdk4- and cyclin E/cdk2-associated kinase activities. G1 cyclin-associated kinase activities were down-regulated quickly after the addition of IFN-alpha. Cells treated with IFN-alpha contained excess amounts of cdk inhibitors which down-regulated G1 cyclin/cdk-associated kinase activities in the proliferating cells and this action was counteracted by exogenously-supplied recombinant cgclin D2/cdk4 complexes, In parallel, accumulation of p19(Ink4D) and p21(Cip1), and their attachment to cdks mere upregulated quickly after the addition of IFN-alpha. Expression of p19(Ink4D) and p21(Cip1) was potentiated transcriptionally. We concluded that increased attachment of upregulated cdk inhibitors including p19(Ink4D) and p21(Cip1) to G1 cyclin/cdk complexes contributed to diminuition of G1 cyclin/cdk-associated kinase activities and resulting G1 phase arrest during the early phase of treatment with IFN-alpha.	Univ Tokyo, Inst Med Sci, Dept Hematol Oncol, Minato Ku, Tokyo 108, Japan	University of Tokyo	Matsuoka, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Hematol Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.							CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1411; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Gorospe M, 1996, MOL CELL BIOL, V16, P762; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAVARONE A, 1997, NATURE, V387, P417; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI Y, 1994, ONCOGENE, V9, P2261; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V368, P753; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PESTKA S, 1987, ANN REV BIOCH, V56, P72; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUELLE DE, 1995, ONCOGENE, V11, P635; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3453; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU J, 1995, MOL CELL BIOL, V14, P8018	66	51	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2075	2086		10.1038/sj.onc.1201745	http://dx.doi.org/10.1038/sj.onc.1201745			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572488				2022-12-28	WOS:000073177200005
J	Chaturvedi, P; Reddy, MVR; Reddy, EP				Chaturvedi, P; Reddy, MVR; Reddy, EP			Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation	ONCOGENE			English	Article						STATs; JAKs; Src kinases; IL-3; myeloid cell proliferation	PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; GRANULOCYTIC DIFFERENTIATION; CYTOKINE; INTERLEUKIN-3; FAMILY; BINDS; GAMMA; LINE	Interaction of IL-3 with its receptor is known to activate STAT-3 via phosphorylation of Tyrosine 701, which facilitates its dimerization and translocation to the nucleus, leading to the transcription of its target genes, In this communication, we have investigated the nature of tyrosine kinases that mediate STAT-3 phosphorylation during IL-3-mediated activation of myeloid cell proliferation, Our results show that interaction of IL-3 with its receptor leads to the activation of c-Src kinase activity, which in turn facilitates the binding of c-Src to STAT-3, This association leads to the phosphorylation of STAT-3, allowing this transcription factor to translocate to the nucleus, Expression of a dominant negative mutant of src (AMSrc) in these cells results in a block to IL-3 mediated phosphorylation of STAT-3, and its ability to bind to DNA, On the other hand, expression of a dominant negative mutant of JAK2 (JTK2KE) had no effect on IL-3-mediated activation of STAT-3. Our results also show that AMSrc does not affect the phosphorylation of JAK2, suggesting that JAK and STAT phosphorylation events are mediated by two independent pathways, Inhibition of c-Src activation by AMSrc, which leads to a block to STAT-3 activation, results in a dramatic inhibition of cell proliferation mediated by IL-3, Howe,er, expression of AMSrc does not activate apoptotic pathways, In contrast, expression of JAK2KE results in accelerated apoptosis of 32Dc13 cells grown in the absence of IL-3 with concomitant down-regulation of Erk-2 kinase activity. These results suggest that Src family kinases mediate the phosphorylation of STATs and play a critical role in signal transduction pathways associated with myeloid cell proliferation while JAK kinases mediate the activation of Erk-2 pathway which appears to provide antiapoptotic signals, Thus the activation of JAKs and STATs appear to be two independent but related events, which dictate two separate biological outcomes, the combination of which results in proliferation and survival of myeloid precursor cells.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA68239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Gaozza E, 1997, ONCOGENE, V15, P3127, DOI 10.1038/sj.onc.1201575; Giordano V, 1997, J IMMUNOL, V158, P4097; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEHMANN J, 1994, J IMMUNOL, V153, P165; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P5133; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBrien K, 1997, GENE, V184, P115, DOI 10.1016/S0378-1119(96)00583-5; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; ROVERA G, 1987, ONCOGENE, V1, P29; SACHS L, 1994, P SOC EXP BIOL MED, V206, P170; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Watanabe S, 1996, J ALLERGY CLIN IMMUN, V98, pS183, DOI 10.1016/S0091-6749(96)70065-9; Watanabe Sumiko, 1997, Leukemia (Basingstoke), V11, P76; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	39	125	127	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1749	1758		10.1038/sj.onc.1201972	http://dx.doi.org/10.1038/sj.onc.1201972			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582023				2022-12-28	WOS:000072807600013
J	Tibiletti, MG; Trubia, M; Ponti, E; Sessa, L; Acquati, F; Furlan, D; Bernasconi, B; Fichera, M; Mihalich, A; Ziegler, A; Volz, A; Facco, C; Riva, C; Cremonesi, L; Ferrari, M; Taramelli, R				Tibiletti, MG; Trubia, M; Ponti, E; Sessa, L; Acquati, F; Furlan, D; Bernasconi, B; Fichera, M; Mihalich, A; Ziegler, A; Volz, A; Facco, C; Riva, C; Cremonesi, L; Ferrari, M; Taramelli, R			Physical map of the D6S149-D6S193 region on chromosome 6q27 and its involvement in benign surface epithelial ovarian tumours	ONCOGENE			English	Article						chromosome 6q27; physical map; YAC clones; deletion; benign ovarian tumors	LOW-GRADE; LONG ARM; HETEROZYGOSITY; TUMORS; CARCINOMAS; DELETION	A detailed long range restriction map of the region defined by markers D6S149 and D6S193 on chromosome 6q27 has been constructed, This was achieved by YAC cloning and contig assembling of the same region, Seven YAC clones were found to span the almost 1000 Kb region flanked by the two markers which on the genetic map resulted to be 1.9 cM apart, With some of the characterized YAC clones we undertook a molecular cytogenetic analysis of 20 benign ovarian tumors, The rationale for this was the recent mapping to a region of chromosome 6q27, flanked by markers D6281 and D6S133, of a locus for the SV40-mediated immortalization of human cells (SEN6 gene), Noteworthy we found that the the D6S149-D6S193 region (comprised in the larger D6S281-D6S133 physical interval) was altered in all samples analysed adding support to the occurrence of a immortalization step in this type of tumors.	Hosp San Raffaele, Lab Genet Base, I-20132 Milan, Italy; Univ Pavia, Dipartimento Patol, Varese, Italy; Osped Circolo Varese, Serv Anat Patol, Varese, Italy; IRCCS, Milan, Italy; Free Univ Berlin, Inst Expt Onkol & Transplantat Med, D-1000 Berlin, Germany	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Pavia; Free University of Berlin	Taramelli, R (corresponding author), Hosp San Raffaele, Lab Genet Base, Via Olgettina 60, I-20132 Milan, Italy.		Fichera, Marco/K-9220-2016; FURLAN, DANIELA/AAB-8271-2022; RIVA, CRISTINA/K-5063-2016	Fichera, Marco/0000-0002-8225-6880; FURLAN, DANIELA/0000-0002-5958-5379; RIVA, CRISTINA/0000-0001-9884-038X; Mihalich, Alessandra/0000-0002-1835-8241				Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; DalCin P, 1996, GENE CHROMOSOME CANC, V16, P68, DOI 10.1002/(SICI)1098-2264(199605)16:1<68::AID-GCC10>3.0.CO;2-H; DALPRA L, 1986, HUM REPROD, V12, P103; DIETRICH CU, 1995, INT J CANCER, V60, P49, DOI 10.1002/ijc.2910600107; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; IWABUCHI H, 1995, CANCER RES, V55, P6172; Liao F, 1997, GENOMICS, V40, P175, DOI 10.1006/geno.1996.4544; LIU E, 1995, J NATL CANCER I, V87, P1099, DOI 10.1093/jnci/87.15.1099; Mitelman F, 1995, ISCN INT SYSTEM HUMA; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; SALAZAR H, 1997, J NATL CANC, V188, P1810; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; SATO T, 1991, CANCER RES, V51, P5188; Tibiletti MG, 1996, CANCER RES, V56, P4493; Trubia M, 1997, GENOMICS, V42, P342, DOI 10.1006/geno.1997.4679; WAN MH, 1994, INT J ONCOL, V5, P1043; WOLF NG, 1996, J PATHOL, P511; ZHENG J, 1995, J NATL CANC, V1, P1146; ZHENG JP, 1991, CANCER RES, V51, P4045	22	25	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1639	1642		10.1038/sj.onc.1201654	http://dx.doi.org/10.1038/sj.onc.1201654			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569033				2022-12-28	WOS:000072743200016
J	Jensen, DE; Proctor, M; Marquis, ST; Gardner, HP; Ha, SI; Chodosh, LA; Ishov, AM; Tommerup, N; Vissing, H; Sekido, Y; Minna, J; Borodovsky, A; Schultz, DC; Wilkinson, KD; Maul, GG; Barlev, N; Berger, SL; Prendergast, GC; Rauscher, FJ				Jensen, DE; Proctor, M; Marquis, ST; Gardner, HP; Ha, SI; Chodosh, LA; Ishov, AM; Tommerup, N; Vissing, H; Sekido, Y; Minna, J; Borodovsky, A; Schultz, DC; Wilkinson, KD; Maul, GG; Barlev, N; Berger, SL; Prendergast, GC; Rauscher, FJ			BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression	ONCOGENE			English	Article						ubiquitin hydrolase; BRCA1; chromosome 3p21.3; RING finger	CARBOXYL-TERMINAL HYDROLASE; ONSET BREAST-CANCER; OVARIAN-CANCER; DEUBIQUITINATING ENZYME; SACCHAROMYCES-CEREVISIAE; FAMILIAL BREAST; GENE BRCA1; 185DELAG MUTATION; MESSENGER-RNA; JEWISH WOMEN	We have identified a novel protein, BAP1, which binds to the RING finger domain of the Breast/Ovarian Cancer Susceptibility Gene product, BRCA1, BAP1 is a nuclear-localized, ubiquitin carboxy-terminal hydrolase, suggesting that deubiquitinating enzymes may play a role in BRCA1 function, BAP1 binds to the wild-type BRCA1-RING finger, but not to germline mutants of the BRCA1-RING finger found in breast cancer kindreds, BAP1 and BRCA1 are temporally and spatially coexpressed during murine breast development and remodeling, and show overlapping patterns of subnuclear distribution, BAP1 resides on human chromosome 3p21.3; intragenic homozgyous rearrangements and deletions of BAP1 have been found in lung carcinoma cell lines, BAP1 enhances BRCA1-mediated inhibition of breast cancer cell growth and is the first nuclear-localized ubiquitin carboxy-terminal hydrolase to be identified, BAP1 may be a new tumor suppressor gene which functions in the BRCA1 growth control pathway.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; John F Kennedy Inst, DK-2600 Glostrup, Denmark; Univ Copenhagen, Panum Inst, Dept Med Genet, DK-2200 Copenhagen, Denmark; Novo Nordisk AS, Dept Mol Genet, DK-2880 Bagsvaerd, Denmark; Emory Univ, Dept Biochem, Atlanta, GA 30322 USA; Univ Penn, Sch Med, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA	The Wistar Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Copenhagen; Novo Nordisk; Emory University; University of Pennsylvania	Rauscher, FJ (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.		Ferris, Laura/I-7689-2012; Ishov, Alexander/E-4912-2010; Sekido, Yoshitaka/P-9756-2015; Barlev, Nikolai A/K-5268-2017; Tommerup, Niels/T-8776-2017	Barlev, Nikolai A/0000-0001-7111-2446; Tommerup, Niels/0000-0003-2304-0112; Berger, Shelley/0000-0001-5398-4400; Sekido, Yoshitaka/0000-0002-2428-3848	NCI NIH HHS [CA71513] Funding Source: Medline; NIGMS NIH HHS [GM30308] Funding Source: Medline; NCPDCID CDC HHS [NCI P50] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCPDCID CDC HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; BROWN MT, 1995, GENE, V160, P111, DOI 10.1016/0378-1119(95)00163-Z; BUCHHAGEN DL, 1994, INT J CANCER, V57, P473, DOI 10.1002/ijc.2910570406; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; CIECHANOVER A, 1994, BIOL CHEM H-S, V375, P565; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1993, AM J HUM GENET, V52, P678; Everett RD, 1997, EMBO J, V16, P566, DOI 10.1093/emboj/16.3.566; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GRAY DA, 1995, ONCOGENE, V10, P2179; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HONORE B, 1991, FEBS LETT, V280, P235, DOI 10.1016/0014-5793(91)80300-R; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Huang YZ, 1996, DEVELOPMENT, V122, P3207; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Isaksson A, 1996, BBA-REV CANCER, V1288, pF21, DOI 10.1016/0304-419X(96)00011-X; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Jiang WD, 1996, MOL GEN GENET, V251, P153; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Muto MG, 1996, CANCER RES, V56, P1250; NAKAMURA T, 1992, ONCOGENE, V7, P733; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; Phelps RM, 1996, J CELL BIOCHEM, P32; Rao VN, 1996, ONCOGENE, V12, P523; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sellers WR, 1996, BBA-REV CANCER, V1288, pM1, DOI 10.1016/0304-419X(96)00014-5; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thiberville L, 1995, INT J CANCER, V64, P371, DOI 10.1002/ijc.2910640604; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WILKINSON KD, 1986, BIOCHEMISTRY-US, V25, P6644, DOI 10.1021/bi00369a047; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zabludoff SD, 1996, ONCOGENE, V13, P649; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; Zhu YA, 1997, J BIOL CHEM, V272, P51	92	532	552	2	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	1998	16	9					1097	1112		10.1038/sj.onc.1201861	http://dx.doi.org/10.1038/sj.onc.1201861			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528852				2022-12-28	WOS:000072336000001
J	Ahmadian, A; Ren, ZP; Williams, C; Ponten, F; Odeberg, J; Ponten, J; Uhlen, M; Lundeberg, J				Ahmadian, A; Ren, ZP; Williams, C; Ponten, F; Odeberg, J; Ponten, J; Uhlen, M; Lundeberg, J			Genetic instability in the 9q22.3 region is a late event in the development of squamous cell carcinoma	ONCOGENE			English	Article						p53; 9q22.3; loss of heterozygosity; squamous cell carcinoma; dysplasia	HUMAN P53 GENE; HUMAN HOMOLOG; HUMAN SKIN; ALLELE LOSS; BASAL; CANCER; MUTATIONS; CHROMOSOME-9; HETEROZYGOSITY; POLYMORPHISM	Squamous cell carcinoma (SCC) of the skin represents a group of neoplasms which is associated with exposure to UV light. Recently, we obtained data suggesting that invasive skin cancer and its precursors derive from one original neoplastic clone. Here, the analysis were extended by loss of heterozygosity (LOH) analysis in the chromosome 9q22.3 region. A total of 85 samples, taken from twenty-two sections of sun-exposed sites, corresponding to normal epidermis, morphological normal cells with positive immune-staining for the p53 protein (p53 patches), dysplasias, cancer in situ (CIS) and squamous cell carcinomas (SCC) of the skin were analysed. Overall, about 70% of p53 patches had mutations in the p53 gene but not LOH in the p53 gene or 9q22.3 region. Approximately 70% of the dysplasias showed p53 mutations of which about 40% had LOH in the p53 region but not in the 9q22.3 region. In contrast, about 65% of SCC and CIS displayed LOH in the 9q22.3 region, as well as frequent (80%) mutations and/or LOH in the p53 gene. These findings strongly suggest that alterations in the p53 gene is an early event in the progression towards SCC, whereas malignant development involves LOH and alterations in at least one (or several) tumor suppressor genes located in chromosome 9q22.3.	Royal Inst Technol, Dept Biochem & Biotechnol, S-10044 Stockholm, Sweden; Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden	Royal Institute of Technology; Uppsala University; Uppsala University Hospital	Lundeberg, J (corresponding author), Royal Inst Technol, Dept Biochem & Biotechnol, S-10044 Stockholm, Sweden.		Williams, Cecilia/A-6677-2009; Uhlen, Mathias/B-3262-2016; Odeberg, Jacob O/O-3336-2014; Uhlen, Mathias/AAV-8746-2021; Odeberg, Jacob/I-8314-2016	Williams, Cecilia/0000-0002-0602-2062; Uhlen, Mathias/0000-0002-4858-8056; Odeberg, Jacob O/0000-0003-0996-1644; Odeberg, Jacob/0000-0003-0996-1644				BERG C, 1995, CLIN CHEM, V41, P1461; EKLUND LK, 1997, IN PRESS MOL CARCINO; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holmberg E, 1996, BRIT J CANCER, V74, P246, DOI 10.1038/bjc.1996.345; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Ponten F, 1997, MUTAT RES-GENOMICS, V382, P45, DOI 10.1016/S1383-5726(97)00008-3; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; QUINN AG, 1994, J INVEST DERMATOL, V102, P300, DOI 10.1111/1523-1747.ep12371786; QUINN AG, 1994, CANCER RES, V54, P4756; REHMAN I, 1994, LANCET, V344, P788, DOI 10.1016/S0140-6736(94)92343-4; Ren ZP, 1996, ONCOGENE, V12, P765; Ren ZP, 1997, AM J PATHOL, V150, P1791; Unden AB, 1997, CANCER RES, V57, P2336; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; ZAPHIROPOULOS PG, 1994, BIOCHEM BIOPH RES CO, V201, P1495, DOI 10.1006/bbrc.1994.1873	25	40	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1837	1843		10.1038/sj.onc.1202080	http://dx.doi.org/10.1038/sj.onc.1202080			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778050				2022-12-28	WOS:000076303300010
J	McGarvey, TW; Maruta, Y; Tomaszewski, JE; Linnenbach, AJ; Malkowicz, SB				McGarvey, TW; Maruta, Y; Tomaszewski, JE; Linnenbach, AJ; Malkowicz, SB			PTCH gene mutations in invasive transitional cell carcinoma of the bladder	ONCOGENE			English	Article						PTCH; transitional cell carcinoma of the bladder; mutations	DROSOPHILA PATCHED GENE; TUMOR-SUPPRESSOR LOCI; SONIC HEDGEHOG; HUMAN HOMOLOG; MICROSATELLITE ALTERATIONS; REGULATES EXPRESSION; MEMBRANE-PROTEIN; ALLELIC LOSSES; CANCER; CHROMOSOME-9	LOH analysis suggests that multiple tumor suppressor genes play a role in the development of human TCC. The human homolog of the Drosophila PTCH was recently cloned and mapped to the BCNS locus on 9q22.3, a chromosomal region commonly deleted in TCCs. We first examined the steady state mRNA transcription of the PTCH, SMOH and GL13 genes of the HH signal transduction pathway in TCC cell lines and normal urothelium. Normal urothelium and TCC cell lines express these three genes within the PTCH signal transduction pathway. We then screened for PTCH mutations in 'hot spot' exons 6, 8, 13 and 16 by PCR/SSCP analysis of genomic DNAs from 54 TCC tumor samples and control autologous peripheral blood lymphocytes. DNA sequence analysis confirmed TCC-specific mutations in two of 54 patients (3.7%). These mutations resulted a single amino acid substitution and two frame shifts. One tumor had PTCH mutations in exon 16 as well as exon 13 and one tumor had a mutation in exon 13 alone. Both TCC tumors that contained PTCH mutations had a loss of heterozygosity at 9q. Although the PTCH protein has an unknown function in urothelial cells, the detection of the PTCH, SMOH and GL13 transcripts in normal urothelium and TCC cell lines and rare PTCH mutations in tumor samples suggest that the HH pathway may have a role in controlling the proliferation of urothelial cells and that PTCH mutations may contribute to the development of a subset of TCCs.	Univ Penn, Med Ctr, Dept Surg, Div Urol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pathol, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); The Wistar Institute	Malkowicz, SB (corresponding author), Univ Penn, Med Ctr, Dept Surg, Div Urol, 1 Rhoads,3400 Spruce St, Philadelphia, PA 19104 USA.							Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; CATALONA WJ, 1988, CAMPBELLS UROLOGY, P1094; CHANG WYH, 1995, CANCER RES, V55, P3246; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chidambaram A, 1996, CANCER RES, V56, P4599; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; DOMINGUEZ M, 1996, NATURE, V372, P1621; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hepker J, 1997, DEVELOPMENT, V124, P549; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kallassy M, 1997, CANCER RES, V57, P4731; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KNOWLES MA, 1994, CANCER RES, V54, P531; Li MM, 1996, AM J PATHOL, V149, P229; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; Maesawa C, 1998, GENE CHROMOSOME CANC, V21, P276, DOI 10.1002/(SICI)1098-2264(199803)21:3<276::AID-GCC15>3.3.CO;2-H; MALKOWICZ SB, 1994, CLIN MANUAL UROLOGY, P419; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; ORLOW I, 1994, CANCER RES, V54, P2848; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Raffel C, 1997, CANCER RES, V57, P842; RUPPERT JM, 1993, CANCER RES, V53, P5093; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; Simoneau AR, 1996, CANCER RES, V56, P5039; SPRUCK CH, 1994, CANCER RES, V54, P784; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Unden AB, 1996, CANCER RES, V56, P4562; Unden AB, 1997, CANCER RES, V57, P2336; WALDMAN FM, 1991, CANCER RES, V51, P3807; WINGO PA, 1997, CA CANC J CLIN, V45, P8; Xie JW, 1997, CANCER RES, V57, P2369; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	45	74	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1167	1172		10.1038/sj.onc.1202045	http://dx.doi.org/10.1038/sj.onc.1202045			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764827				2022-12-28	WOS:000075598400012
J	Wood, DE; Thomas, A; Devi, LA; Berman, Y; Beavis, RC; Reed, JC; Newcomb, EW				Wood, DE; Thomas, A; Devi, LA; Berman, Y; Beavis, RC; Reed, JC; Newcomb, EW			Bax cleavage is mediated by calpain during drug-induced apoptosis	ONCOGENE			English	Article						drug-induced apoptosis; calpain; Bax cleavage; HL-60 cells; mitochondrial membranes	PROGRAMMED CELL-DEATH; RAT-LIVER MITOCHONDRIA; CYTOCHROME-C; ENDOPLASMIC-RETICULUM; LIMITED PROTEOLYSIS; NEUTRAL PROTEASE; HL-60 CELLS; ION-CHANNEL; BCL-2; INHIBITION	The anti-apoptotic molecule Bcl-2 is located in the mitochondrial and endoplasmic reticulum membranes as well as the nuclear envelope. Although its location has not been as rigorously defined, the pro-apoptotic molecule Pax appears to be mainly a cytosolic protein which translocates to the mitochondria upon induction of apoptosis, Here me identify a protease activity in mitochondria-enriched membrane fractions from HL-60 cells capable of cleaving Pax which is absent from the cytosolic fraction, Pax protease activity is blocked in vitro by cysteine protease inhibitors including E-64 which distinguishes it from all known caspases and granzyme B, both of which are involved in apoptosis, Protease activity is also blocked by inhibitors against the calcium-activated neutral cysteine endopeptidase calpain, Partial purification of the Pax protease activity from HL-60 cell membrane fractions by column chromatography revealed that a calpain-like activity was the protease responsible for Pax cleavage, In addition, purified calpain enzymes cleaved Pax in a calcium-dependent manner. Pretreatment of HL-60 cells with the specific calpain inhibitor calpeptin effectively blocked both drug-induced Pax cleavage and calpain activation, but not PARP cleavage or cell death. These results suggest that calpains and caspases are activated during drug-induced apoptosis and that calpains, along with caspases, may be involved in modulating cell death by acting selectively on cellular substrates.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA; Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Burnham Inst, La Jolla, CA 92037 USA	New York University; New York University; Sanford Burnham Prebys Medical Discovery Institute	Newcomb, EW (corresponding author), NYU, Med Ctr, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.		Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001788, R01NS026880, R29NS026880] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 01788, NS 26880] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguilar HI, 1996, GASTROENTEROLOGY, V110, P558, DOI 10.1053/gast.1996.v110.pm8566604; AKAO Y, 1994, CANCER RES, V54, P2468; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BEER DG, 1982, BIOCHEM BIOPH RES CO, V109, P1276, DOI 10.1016/0006-291X(82)91915-5; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BOYD JM, 1995, ONCOGENE, V11, P1921; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CROALL DE, 1986, BIOCHIM BIOPHYS ACTA, V882, P287, DOI 10.1016/0304-4165(86)90250-3; Decaudin D, 1997, CANCER RES, V57, P62; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; GEERAERTS MD, 1991, AM J PHYSIOL, V261, pC889, DOI 10.1152/ajpcell.1991.261.5.C889; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; JURGENSMEIER JM, 1998, IN PRESS P NATL ACAD; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; KENNEY DM, 1994, BRIT J HAEMATOL, V87, P773, DOI 10.1111/j.1365-2141.1994.tb06737.x; Kim CN, 1997, CANCER RES, V57, P3115; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NICHOLS JC, 1994, GASTROENTEROLOGY, V106, P168, DOI 10.1016/S0016-5085(94)95147-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PINTER M, 1992, BIOCHEMISTRY-US, V31, P8201, DOI 10.1021/bi00150a012; POE M, 1991, J BIOL CHEM, V266, P98; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Squier MKT, 1997, J IMMUNOL, V158, P3690; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TAVARES A, 1991, BIOMED BIOCHIM ACTA, V50, P523; Thomas A, 1996, ONCOGENE, V12, P1055; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zhao H, 1997, J BIOL CHEM, V272, P21625, DOI 10.1074/jbc.272.34.21625	71	299	309	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1069	1078		10.1038/sj.onc.1202034	http://dx.doi.org/10.1038/sj.onc.1202034			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764817	Green Published			2022-12-28	WOS:000075598400002
J	Rose, DW; Xiao, S; Pillay, TS; Kolch, W; Olefsky, JM				Rose, DW; Xiao, S; Pillay, TS; Kolch, W; Olefsky, JM			Prolonged vs transient roles for early cell cycle signaling components	ONCOGENE			English	Article						insulin IGF-I; DNA synthesis; microinjection	INSULIN-RECEPTOR SUBSTRATE-1; EPIDERMAL GROWTH-FACTOR; NUCLEOTIDE-RELEASING-FACTOR; PHOSPHOTYROSINE PHOSPHATASE SYP; PROTEIN-TYROSINE-PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; SH2 DOMAIN; FACTOR-I; C-FOS	Both p21ras and phosphatidylinositol 3-kinase (PI 3-k) are critical elements in signaling pathways mediating insulin/IGF-I induced cell cycle progression. For example, microinjection of antibodies, peptides, or recombinant proteins which block the interaction of the SH2 domains of the PI 3-k p85 alpha subunit with tyrosine phosphorylated intracellular targets blocks insulin mediated DNA synthesis. We report here that this inhibitory phenotype is observed whether the injections are made into quiescent cells (the standard approach), or at any time point during G(1) phase subsequent to stimulation. This observation is not true, however, for the major substrate of the insulin/IGF-I receptor (IRS-1) despite the well known interaction of p85 with IRS-1, Antibodies to IRS-1 are inhibitory only when injected during the first 15 min of G(1) phase, as are antibodies to another major IRS-1 binding protein, the tyrosine phosphatase SHP2. We also have microinjected reagents which target proteins involved in the formation of rasGTP and which mediate some of the downstream effects of ras activation. Reagents which target the formation of rasGTP (Shc and dominant negative ras protein) inhibit DNA synthesis only at points early in G(1), as do reagents which target components of the MAP kinase pathway. Injection of antibodies to p21ras itself, or a recombinant Raf-l protein domain which binds to the effector region of ras in a GTP-dependent manner, results in the inhibition of cell cycle progression throughout G(1) phase. The results point to a continuous requirement for both PI 3-k and ras activity until cellular commitment to DNA synthesis, although some of the molecules which are both upstream and downstream of these activities are only required transiently. Our results are also consistent with a Raf-l independent ras activity late in G(1), as well as IRS-1 independent effects of PI 3-kinase.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Vet Adm Med Ctr, San Diego, CA 92161 USA; Haematologikum, GSF, Whittier Diabet Res Program, D-81377 Munich, Germany; Haematologikum, GSF, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Rose, DW (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA.		Admin, SBI/HGB-2738-2022; Kolch, Walter/ABF-2102-2021	pillay, tahir/0000-0002-9982-9710; Kolch, Walter/0000-0001-5777-5016	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 1996, CELL, V85, P15; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; FENG GS, 1994, ONCOGENE, V9, P1545; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAPLAN JB, 1994, ONCOL RES, V6, P611; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KODAKI T, 1995, BIOCHEM SOC T, V23, pS195, DOI 10.1042/bst023195s; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOLCH W, 1990, ONCOGENE, V5, P713; Kolch W, 1996, ONCOGENE, V13, P1305; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANGLOIS WJ, 1994, ENDOCRINOLOGY, V135, P2412, DOI 10.1210/en.135.6.2412; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	62	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	1998	17	7					889	899		10.1038/sj.onc.1201997	http://dx.doi.org/10.1038/sj.onc.1201997			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780005				2022-12-28	WOS:000075448800010
J	Santos, J; Herranz, M; Perez de Castro, I; Pellicer, A; Fernandez-Piqueras, J				Santos, J; Herranz, M; Perez de Castro, I; Pellicer, A; Fernandez-Piqueras, J			A new candidate site for a tumor suppressor gene involved in mouse thymic lymphomagenesis is located on the distal part of chromosome 4	ONCOGENE			English	Article						mouse thymic lymphomas; gamma-irradiation; loss of heterozygosity; microsatellites; distal chromosome 4 region; tumor suppressor genes	ALLELIC LOSS; INTESTINAL NEOPLASIA; MAJOR MODIFIER; HETEROZYGOSITY; NEUROBLASTOMA; ABNORMALITIES; DELETION; REGION; 1P36; PHEOCHROMOCYTOMAS	In a previous work we provided preliminary evidence of the existence of a putative tumor suppressor gene region on the distal part of chromosome 4 in gamma-radiation-induced T-cell lymphomas of (C57BL/6JxRF/J) Fl hybrid mice. This region, named as TLSR2 (Thymic Lymphoma Suppressor Region 2), was located centered at D4Mit54. A more detailed allelotype analysis in the mentioned tumors with new informative microsatellites on distal chromosome 4 region, as well as in thymic lymphomas induced with gamma-rays in Fl hybrids generated from reciprocal crosses between the strains C57BL/6J and BALB/cJ, and having in mind the new map position of D4Mit205b, allowed us to confirm the existence of TLSR2 and to define it more precisely as centered at D4Mit205b, In addition, we identified a new candidate region, named as TLSR3 (Thymic Lymphoma Suppressor Re,Region 3), located between the Mom-l locus and D4Mit68, as the site of another putative tumor suppressor region involved in thymic lymphomagenesis.	Univ Autonoma Madrid, Fac Ciencias, Lab Genet Mol Humana, Dept Biol, E-28049 Madrid, Spain; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	Autonomous University of Madrid; New York University	Fernandez-Piqueras, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Lab Genet Mol Humana, Dept Biol, E-28049 Madrid, Spain.		MARTINEZ, ANTONIO PELLICER/C-4832-2015; de Castro, Ignacio Pérez/A-6260-2012; Santos, Javier/ABF-5755-2021	de Castro, Ignacio Pérez/0000-0002-8822-8274; Santos, Javier/0000-0002-4168-6251; Pellicer, Angel/0000-0002-5062-0692				ABBOTT CM, 1994, MAMM GENOME, V5, pS51; BARDI G, 1993, CANCER RES, V53, P1895; BELLO MJ, 1994, INT J CANCER, V57, P172, DOI 10.1002/ijc.2910570207; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P296, DOI 10.1002/gcc.2870090411; BIECHE I, 1994, CANCER RES, V54, P4274; CHENG NC, 1995, ONCOGENE, V10, P291; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DING SF, 1992, BRIT J CANCER, V65, P809, DOI 10.1038/bjc.1992.173; DOVE WF, 1994, COLD SPRING HARB SYM, V59, P501, DOI 10.1101/SQB.1994.059.01.055; FONG CT, 1992, CANCER RES, V52, P1780; HERZOG CR, 1995, ONCOGENE, V11, P1811; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KHOSLA S, 1991, J CLIN INVEST, V87, P1691, DOI 10.1172/JCI115186; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; MATHEW S, 1994, CANCER RES, V54, P6265; Mock BA, 1996, MAMM GENOME, V6, pS73; MOLEY JF, 1992, CANCER RES, V52, P770; QUELLE DE, 1995, ONCOGENE, V11, P635; Radany EH, 1997, P NATL ACAD SCI USA, V94, P8664, DOI 10.1073/pnas.94.16.8664; Santos J, 1996, ONCOGENE, V12, P669; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SIMON D, 1991, ONCOGENE, V6, P765; SOKOVA OI, 1992, CANCER GENET CYTOGEN, V58, P24, DOI 10.1016/0165-4608(92)90128-U; SREEKANTAIAH C, 1993, AM J PATHOL, V142, P293; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Zhuang SM, 1996, CANCER RES, V56, P3338	27	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					925	929		10.1038/sj.onc.1202009	http://dx.doi.org/10.1038/sj.onc.1202009			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780010				2022-12-28	WOS:000075448800015
J	Winters, ZE; Ongkeko, WM; Harris, AL; Norbury, CJ				Winters, ZE; Ongkeko, WM; Harris, AL; Norbury, CJ			p53 regulates Cdc2 independently of inhibitory phosphorylation to reinforce radiation-induced G2 arrest in human cells	ONCOGENE			English	Article						p53; cell cycle; checkpoint; G2; Cdc2; phosphorylation	CYCLIN-DEPENDENT KINASES; P34CDC2 PROTEIN-KINASE; HUMAN CANCER-CELLS; TYROSINE PHOSPHORYLATION; DNA-DAMAGE; CHECKPOINT CONTROL; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; TYR15 PHOSPHORYLATION; G(2) DELAY	We have investigated the influence of p53 on radiation-induced G2 cell cycle arrest using human H1299 cells expressing temperature-sensitive p53. Gamma-irradiated cells lacking p53 arrested transiently in G2 with Cdc2 extensively phosphorylated at the inhibitory sites Thr14 and Tyr15, and with both Cdc2 and cyclin B1 restricted to the cytoplasm. Activation of p53 by temperature shift resulted in a more protracted G2 arrest that could not be overridden by checkpoint-abrogating drugs. Surprisingly, this enhancement of G2 arrest was associated with a marked lack of inhibitory phosphorylation of Cdc2 and with the nuclear localization of both Cdc2 and cyclin B1. While transient expression of an A14F15 mutant form of Cdc2 that is not subject to inhibitory phosphorylation induced mitotic catastrophe in cells lacking p53, the p53-expressing cells were relatively refractory to this effect. Enforced expression of p21(WAF1/CIP1) was sufficient to confer nuclear localization on Cdc2 in the p53 null cells, though immunodepletion experiments demonstrated that only a small proportion of Cdc2 was stably associated with p21(WAF1/CIP1) in the p53-expressing cells. We conclude that a p53-dependent pathway can operate after exposure of human cells to ionising radiation to promote G2 arrest accompanied by nuclear translocation rather than inhibitory phosphorylation of Cdc2.	Univ Oxford, Inst Mol Med, Oncol Mol Lab, Imperial Canc Res Fund,John Radcliffe Hosp, Oxford OX3 9DS, England	University of Oxford	Norbury, CJ (corresponding author), Univ Oxford, Inst Mol Med, Oncol Mol Lab, Imperial Canc Res Fund,John Radcliffe Hosp, Oxford OX3 9DS, England.		Harris, Adrian L/ABA-3343-2020; Winters, Zoe Ellen/GYE-7947-2022	Harris, Adrian L/0000-0003-1376-8409; 				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; ANDREASSEN PR, 1992, P NATL ACAD SCI USA, V89, P2272, DOI 10.1073/pnas.89.6.2272; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CohenJonathan E, 1997, RADIAT RES, V147, P277, DOI 10.2307/3579333; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; FAN SJ, 1995, CANCER RES, V55, P1649; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HERZINGER T, 1995, ONCOGENE, V11, P2151; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kao GD, 1997, CANCER RES, V57, P753; KASTAN MB, 1991, CANCER RES, V51, P6304; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Lee TH, 1996, P NATL ACAD SCI USA, V93, P352, DOI 10.1073/pnas.93.1.352; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; McDonald E, 1996, CANCER RES, V56, P2250; Moore DD, 1995, GLOB MOB SURV; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MUSK SRR, 1990, INT J RADIAT BIOL, V57, P1105, DOI 10.1080/09553009014551221; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; Skladanowski A, 1997, CANCER RES, V57, P818; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; TAM SW, 1992, CELL GROWTH DIFFER, V3, P811; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VOJTESEK B, 1993, BRIT J CANCER, V67, P1254, DOI 10.1038/bjc.1993.234; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YAMATO K, 1995, ONCOGENE, V11, P1; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Ye XS, 1997, EMBO J, V16, P182, DOI 10.1093/emboj/16.1.182; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x	59	61	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					673	684		10.1038/sj.onc.1201991	http://dx.doi.org/10.1038/sj.onc.1201991			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715268				2022-12-28	WOS:000075337200001
J	Coppee, F; Depoortere, F; Bartek, J; Ledent, C; Parmentier, M; Dumont, JE				Coppee, F; Depoortere, F; Bartek, J; Ledent, C; Parmentier, M; Dumont, JE			Differential patterns of cell cycle regulatory proteins expression in transgenic models of thyroid tumours	ONCOGENE			English	Review						cyclins; cdk(s); CKI; thyroid; HPV 16 E7; cAMP	PAPILLOMAVIRUS TYPE-16 E7; GROWTH-FACTOR-BETA; 10T1/2 MOUSE FIBROBLASTS; D-CDK COMPLEXES; INHIBITOR P27(KIP1); RETINOBLASTOMA GENE; DEPENDENT KINASES; P53-INDEPENDENT EXPRESSION; SUBCELLULAR-LOCALIZATION; MYOGENIC DIFFERENTIATION	Cell cycle proteins regulate the transitions from G1 to S and G2 to M phases. In higher eukaryotes, their function is controlled by intracellular cascades regulated by extracellular growth factors, We have studied m previously described transgenic mouse models for thyroid proliferative diseases the expression of the key proteins regulating the cell cycle by Western blotting and immunohistochemistry, and have correlated the observations with the known actions of the transgenes on the signal transduction cascades. In the adenosine A(2a) receptor model, the cyclic AMP pathway, upstream of the Rb family cell division block, is constitutively activated. In the model expressing HPV 16 E7 protein, the Rb-like proteins are inhibited, Cyclin-dependent kinases cdk4, cdk2 and cdc2, and the associated cyclins D, E and A have been studied. Cyclin D3 appears as the major cyclin D subtype expressed in mouse thyroid epithelial cells in normal and transgenic mice. In the adenosine A(2a)R model, all cell cycle proteins tested were accumulated. In the E7 model, all cell cycle proteins except for D-type cyclins and cdk4 were also accumulated. A similar pattern was observed in thyroids coexpressing both transgenes, suggesting a dominant effect of E7 over the consequences of the cAMP cascade activation. The cyclin-dependent kinase inhibitors p21(cip1/waf1) and pt27(kip1) were not downregulated in these proliferating thyroids which suggest other roles than the inhibition of the cell cycle progression.	Free Univ Brussels, IRIBHN, B-1070 Brussels, Belgium; Danish Canc Soc, Div Canc Biol, DK-2100 Copenhagen, Denmark	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Danish Cancer Society	Coppee, F (corresponding author), Free Univ Brussels, IRIBHN, 808 Route Lennik,Campus Erasme, B-1070 Brussels, Belgium.		Bartek, Jiri/G-5870-2014	Parmentier, Marc/0000-0001-8081-4685				Akagi M, 1996, JPN J CANCER RES, V87, P377, DOI 10.1111/j.1349-7006.1996.tb00233.x; Akiyama T, 1997, CANCER RES, V57, P1495; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Baptist M, 1996, J CELL PHYSIOL, V166, P256; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BATES S, 1994, ONCOGENE, V9, P1633; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHRISTOPHE D, 1990, TRENDS ENDOCRIN MET, V1, P351, DOI 10.1016/1043-2760(90)90083-F; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coppee F, 1996, ONCOGENE, V13, P1471; Coulonval K, 1997, EXP CELL RES, V233, P395, DOI 10.1006/excr.1997.3582; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Depoortere F, 1996, J CELL SCI, V109, P1759; DEPOORTERE F, 1998, J CELL SCI, V140, P1; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; GRANA X, 1995, ONCOGENE, V11, P211; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; Ishida A, 1997, J BIOL CHEM, V272, P10050; JARKUS J, 1996, ONCOGENE, V12, P2369; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIESS M, 1995, ONCOGENE, V10, P159; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOTANI S, 1995, ONCOGENE, V10, P663; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1995, ONCOGENE, V10, P1789; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lloyd RV, 1997, AM J PATHOL, V150, P401; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, ONCOGENE, V10, P2125; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; Marchetti A, 1996, ONCOGENE, V12, P1319; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; NADEL A, 1997, J PATHOL, V183, P156; NEVINS JR, 1992, SCIENCE, V258, P424; OTHANI K, 1995, P NATL ACAD SCI USA, V92, P12146; OTHSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Palmero I, 1996, CANCER SURV, V27, P351; PALMERO I, 1993, ONCOGENE, V8, P1049; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pei XF, 1996, CARCINOGENESIS, V17, P1395, DOI 10.1093/carcin/17.7.1395; Pirson I, 1996, J CELL PHYSIOL, V168, P59, DOI 10.1002/(SICI)1097-4652(199607)168:1<59::AID-JCP8>3.0.CO;2-7; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Qian X, 1996, ENDOCRINOLOGY, V137, P3051, DOI 10.1210/en.137.7.3051; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Ravitz MJ, 1996, J CELL PHYSIOL, V168, P510, DOI 10.1002/(SICI)1097-4652(199609)168:3<510::AID-JCP3>3.0.CO;2-S; RAVITZ MJ, 1995, CANCER RES, V55, P1413; ROGER PP, 1985, EUR J BIOCHEM, V152, P239, DOI 10.1111/j.1432-1033.1985.tb09189.x; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; SUAREZ HG, 1991, ONCOGENE, V6, P677; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; TAM SW, 1994, ONCOGENE, V9, P2663; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; Tikoo R, 1997, J BIOL CHEM, V272, P442; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Tron VA, 1996, AM J PATHOL, V149, P1139; Usuda H, 1996, VIRCHOWS ARCH, V428, P159; Vassart G, 1996, ANN ENDOCRINOL-PARIS, V57, P50; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; Ward AC, 1996, BIOCHEM BIOPH RES CO, V224, P10, DOI 10.1006/bbrc.1996.0976; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZerfassThome K, 1996, ONCOGENE, V13, P2323	104	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					631	641		10.1038/sj.onc.1201966	http://dx.doi.org/10.1038/sj.onc.1201966			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704929				2022-12-28	WOS:000075195300011
J	Ferguson, AT; Lapidus, RG; Davidson, NE				Ferguson, AT; Lapidus, RG; Davidson, NE			Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression	ONCOGENE			English	Article						breast cancer; CpG island; DNA methylation; estrogen receptor; histone acetyltransferase; progesterone receptor	BREAST-CANCER CELLS; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; BINDING-PROTEIN; ESTROGEN-RECEPTOR; TRANSCRIPTION; SEQUENCE; INACTIVATION	Progesterone receptor (PR) is an estrogen-stimulated gene which has a CpG island that is heavily methylated in a significant fraction of estrogen receptor (ER)negative/PR-negative human breast cancers and cell lines, including MDA-MB-231 cells. Treatment of MDA-MB-231 cells with the demethylating agent, 5-aza-2'-deoxycytidine (deoxyC) led to demethylation and expression of ER and PR, However, simultaneous treatment with antiestrogen prevented PR transcription, suggesting that demethylation of PR alone is not sufficient to reactivate the PR gene. To examine the effects of ER on the methylation status of the PR CpG island, we stably transfected MDA-MB-231 cells with an inducible expression vector for ER, Surprisingly, in two cell clones, we found that induction of PR gene expression by ligand-bound ER does not require demethylation of the PR CpG island. In contrast, induction of PR transcription was inhibited by blocking the interaction of ER with SRC-1A, a coactivator of ER function. For the first time, we show that a transcription factor with the potential to remodel heterochromatin can activate gene expression without altering the methylation status of the CpG island. These results raise the possibility that demethylation and histone acetylation are distinct but complementary mechanisms for destabilizing heterochromatin and activating transcription.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Davidson, NE (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 422 N Bond St, Baltimore, MD 21231 USA.							ABRAHAM SE, 1993, ONCOGENE, V8, P1639; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Beato M, 1996, J STEROID BIOCHEM, V56, P47, DOI 10.1016/0960-0760(95)00223-5; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; FERGUSON AT, 1995, CANCER RES, V55, P2279; Graham JD, 1995, J BIOL CHEM, V270, P30693, DOI 10.1074/jbc.270.51.30693; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hsieh CL, 1997, MOL CELL BIOL, V17, P5897, DOI 10.1128/MCB.17.10.5897; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KLEMPNAUER KH, 1993, ONCOGENE, V8, P111; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; LEVINE A, 1993, J BIOL CHEM, V268, P21754; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; ONATE SA, 1995, SCIENCE, V270, P1354; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	37	32	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					577	583		10.1038/sj.onc.1201961	http://dx.doi.org/10.1038/sj.onc.1201961			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704923				2022-12-28	WOS:000075195300005
J	Akiri, G; Nahari, D; Finkelstein, Y; Le, SY; Elroy-Stein, O; Levi, BZ				Akiri, G; Nahari, D; Finkelstein, Y; Le, SY; Elroy-Stein, O; Levi, BZ			Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription	ONCOGENE			English	Article						vascular endothelial growth factor (VEGF); internal ribosome entry site (IRES); 5 ' untranslated region; translational regulation; angiogenesis	FACTOR MESSENGER-RNA; SMOOTH-MUSCLE CELLS; FACTOR GENE; PERMEABILITY FACTOR; EPITHELIAL-CELLS; IN-VIVO; HYPOXIA; PROTEIN; ANGIOGENESIS; SEQUENCES	Vascular Endothelial Growth Factor (VEGF) is very potent angiogenic agent that has a central role in normal physiological angiogenesis as well as in tumor angiogenesis, VEGF expression is induced by hypoxia and hypoglycemia, and thus was suggested to promote neovascularization during tumor outgrowth, Yet, the molecular mechanism that governs VEGF expression is not fully characterized, VEGF induction is attributed in part to increased levels of transcription and RNA stability, Previously, we demonstrated that the 5' Untranslated Region (5' UTR) of VEGF has an important regulatory role in its expression. VEGF has an exceptionally long 5' UTR (1038 bp) which is highly rich in G+C nucleotides, This suggests that secondary structures in the 5' UTR might be essential for VEGF expression through transcriptional and post-transcriptional control mechanisms, as demonstrated for other growth factors, In this communication, we provide evidence that a computer predicted Internal Ribosome Entry Site (IRES) structure is biologically active and is located at the 3' end of the UTR, In addition, the results demonstrate that an alternative transcriptional initiation site for VEGF exists in the 5' UTR of VEGF, This alternative initiation site is 633 bp downstream of the main transcription start site and the resulting 5' UTR includes mainly the IRES structure. Therefore, our results suggest that VEGF is subjected to regulation at either translational level through a mechanism of ribosome internal initiation and/or transcriptional level through alternative initiation.	Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; NCI, Lab Expt & Computat Biol, DBS, NIH, Frederick, MD 21702 USA; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel	Technion Israel Institute of Technology; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tel Aviv University	Levi, BZ (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel.			Elroy-Stein, Orna/0000-0002-3716-1540				ADAMO ML, 1991, MOL ENDOCRINOL, V5, P1677, DOI 10.1210/mend-5-11-1677; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P2815, DOI 10.1093/nar/23.15.2815; DOLECKI GJ, 1991, BIOCHEM BIOPH RES CO, V180, P572, DOI 10.1016/S0006-291X(05)81103-9; FEN Z, 1991, ONCOGENE, V6, P953; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Furbass R, 1997, ENDOCRINOLOGY, V138, P2813, DOI 10.1210/en.138.7.2813; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Guerrin M, 1997, ONCOGENE, V14, P463, DOI 10.1038/sj.onc.1200846; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; Joukov V, 1996, EMBO J, V15, P290; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAGGERUD SM, 1995, ANTICANCER RES, V15, P683; LE SY, 1993, NUCLEIC ACIDS RES, V21, P2173, DOI 10.1093/nar/21.9.2173; Le SY, 1996, VIRUS GENES, V12, P135, DOI 10.1007/BF00572952; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MAGLIONE D, 1993, GROWTH FACTORS, V8, P141, DOI 10.3109/08977199309046934; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; MINCHENKO A, 1994, LAB INVEST, V71, P374; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STAVRI GT, 1995, FEBS LETT, V358, P311, DOI 10.1016/0014-5793(94)01458-D; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Townson S, 1996, BIOCHEM BIOPH RES CO, V220, P922, DOI 10.1006/bbrc.1996.0507; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WEISZ A, 1992, J BIOL CHEM, V267, P25589; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774	52	213	227	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					227	236		10.1038/sj.onc.1202019	http://dx.doi.org/10.1038/sj.onc.1202019			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674707				2022-12-28	WOS:000074706700011
J	Li, RZ; Sutphin, PD; Schwartz, D; Matas, D; Almog, N; Wolkowicz, R; Goldfinger, N; Pei, HP; Prokocimer, M; Rotter, V				Li, RZ; Sutphin, PD; Schwartz, D; Matas, D; Almog, N; Wolkowicz, R; Goldfinger, N; Pei, HP; Prokocimer, M; Rotter, V			Mutant p53 protein expression interferes with p53-independent apoptotic pathways	ONCOGENE			English	Article						p53-dependent; p53-independent; apoptosis; chemotherapeutic drugs	WILD-TYPE P53; MYELOID LEUKEMIC-CELLS; P53-DEPENDENT APOPTOSIS; INDEPENDENT PATHWAYS; CANCER-CHEMOTHERAPY; DNA-DAMAGE; IONIZING-RADIATION; GAMMA-IRRADIATION; FUNCTIONAL P53; LYMPHOID-CELLS	Loss of normal p53 function was found frequently to interfere with response of cancer cells to conventional anticancer therapies. Since more than half of all human cancers possess p53 mutations, we decided to explore the involvement of mutant p53 in drug induced apoptosis. To further evaluate the relationship between the p53-dependent and p53-independent apoptotic pathways, and to elucidate the function of mutant p53 in modulating these processes, we investigated the role of a p53 temperature-sensitive (ts) mutant in a number of apoptotic pathways induced by chemotherapeutic drugs that are currently used in cancer therapy. To that end, me studied the M1/2, myeloid p53 non-producer cells, and M1/2-derived temperature-sensitive I; mutant p53 expressing clones. Apoptosis caused by DIVA damage induced with gamma-irradiation, doxorubicin or cisplatin, was enhanced in cells expressing wild type p53 as compared to that seen in parental p53 non-producer cells; mutant p53 expressing clones mere found to be more resistant to apoptosis induced by these factors. Actinomycin D, a potent inhibitor of transcription, as well as a DNA. damaging agent, abrogated the restraint apoptosis mediated by mutant p53. These observations suggest that while loss of wild type p53 function clearly reduces the rate of apoptosis, p53 mutations may result in a gain of function which significantly interferes with chemotherapy induced apoptosis. Therefore, to achieve a successful cancer therapy, it is critical to consider the specific relationship between a given mutation in p53 and the chemotherapy selected.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Allred D. C., 1993, BREAST CANCER RES TR, V27, P131; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAPRANICO G, 1992, EUR J CANCER, V28A, P2055, DOI 10.1016/0959-8049(92)90255-Z; Chresta CM, 1996, CANCER RES, V56, P1834; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORY S, 1994, PHILOS T R SOC B, V345, P289, DOI 10.1098/rstb.1994.0108; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, V1, P261; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIJIT FJ, 1988, CANCER RES, V48, P6058; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; GLYNN JM, 1991, BIOCHEM SOC T, V20, pS84; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Hamada M, 1996, J CANCER RES CLIN, V122, P360, DOI 10.1007/BF01220804; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HICKMAN JA, 1994, PHILOS T ROY SOC B, V345, P319, DOI 10.1098/rstb.1994.0112; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; Iwamoto KS, 1996, CANCER RES, V56, P3862; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LEVINE JA, 1997, CELL, V88, P323; LEWIS JG, 1995, J LEUKOCYTE BIOL, V57, P635, DOI 10.1002/jlb.57.4.635; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LING YH, 1993, CANCER RES, V53, P1845; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOTEM J, 1994, CELL GROWTH DIFFER, V5, P321; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAKRIS A, 1995, LANCET, V345, P1181, DOI 10.1016/S0140-6736(95)91014-X; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MASTERS JRW, 1993, INT J CANCER, V53, P340, DOI 10.1002/ijc.2910530228; Oliver R T, 1996, Curr Opin Oncol, V8, P252; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Peled A, 1996, CANCER RES, V56, P2148; Peled A, 1996, EXP HEMATOL, V24, P728; ROSENBERG B, 1985, CANCER, V55, P2303, DOI 10.1002/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; Soddu S, 1996, J CELL BIOL, V134, P1; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; WYLLIE AH, 1994, PHILOS T R SOC B, V345, P237, DOI 10.1098/rstb.1994.0099; WYLLIE FS, 1995, ONCOGENE, V10, P49; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZALESKIS G, 1994, MOL PHARMACOL, V46, P901; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; ZHUANG SM, 1995, CANCER RES, V55, P486	81	123	127	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3269	3277		10.1038/sj.onc.1201867	http://dx.doi.org/10.1038/sj.onc.1201867			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681825				2022-12-28	WOS:000074343600007
J	Maier, D; Zhang, ZW; Taylor, E; Hamou, MF; Gratzl, O; Van Meir, EG; Scott, RJ; Merlo, A				Maier, D; Zhang, ZW; Taylor, E; Hamou, MF; Gratzl, O; Van Meir, EG; Scott, RJ; Merlo, A			Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas	ONCOGENE			English	Article						deletion mapping; chromosome 10q23.3 and 10q25-26; PTEN/MMAC1	GLIOBLASTOMA-MULTIFORME; LONG ARM; HETEROZYGOSITY; CANCER; LOCI; PROGRESSION; METHYLATION; CARCINOMA; 10Q23-25	The l0q25-26 region between the dinucleotide markers D10S587 and D10S216 is deleted in glioblastomas and, as we have recently shown, in low-grade oligodendrogliomas. We further refined somatic mapping on 10q23-tel and simultaneously assessed the role of the candidate tumor suppressor gene PTEN/MMAC1 in glial neoplasms by sequence analysis of eight low-grade and 24 high-grade gliomas. These tumors were selected for partial or complete loss of chromosome 10 based on deletion mapping with increased microsatellite marker density at 10q23-tel. Three out of eight (38%) low-grade and 3/24 (13%) high-grade gliomas exclusively target 10q25-26.We did not find a tumor only targeting 10q23.3, and most tumors (23/32, 72%) showed large deletions on 10q including both regions. The sequence analysis of PTEN/MMAC1 revealed nucleotide alterations in 1/8 (12.5%) low-grade gliomas in a tumor with LOH at l0q21-qtel and in 5/21 (24%) high-grade gliomas displaying LOH that always included 10q23-26. Our refined mapping data point to the 10q25-26 region as the primary target on 10q, an area that also harbors the DMBT1 candidate tumor suppressor gene. The fact that we find hemizygous deletions at 10q25-qtel in low-grade astrocytomas and oligodendrogliomas - two histologically distinct entities of gliomas - suggests the existence of a putative suppressor gene involved early in glial tumorigenesis.	Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Univ Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland	University of Basel; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Merlo, A (corresponding author), Univ Basel Hosp, Dept Res, Schanzenstr 46, CH-4031 Basel, Switzerland.		Scott, Rodney J/B-2827-2013	Scott, Rodney J/0000-0001-7724-3404; Van Meir, Erwin G./0000-0003-2444-7707				Albarosa R, 1996, AM J HUM GENET, V58, P1260; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; GRAY IC, 1995, CANCER RES, V55, P4800; HERBST RA, 1994, CANCER RES, V54, P3111; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; JAMES CD, 1988, CANCER RES, V48, P5546; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P640; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MORITA R, 1991, CANCER RES, V51, P5817; Moschonas N. K., 1996, Cytogenetics and Cell Genetics, V72, P99, DOI 10.1159/000134172; Nagase S, 1997, CANCER RES, V57, P1630; PEIFFER SL, 1995, CANCER RES, V55, P1922; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; REMPEL SA, 1993, CANCER RES, V53, P2386; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Wang SI, 1997, CANCER RES, V57, P4183	31	74	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3331	3335		10.1038/sj.onc.1201832	http://dx.doi.org/10.1038/sj.onc.1201832			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681833				2022-12-28	WOS:000074343600015
J	Burchert, A; Attar, EC; McCloskey, P; Fridell, YWC; Liu, ET				Burchert, A; Attar, EC; McCloskey, P; Fridell, YWC; Liu, ET			Determinants for transformation induced by the Axl receptor tyrosine kinase	ONCOGENE			English	Article						receptor tyrosine kinase; retroviruses, mutations; transformations; Axl	GROWTH-FACTOR RECEPTOR; LONG TERMINAL REPEAT; ALTERED AUTOPHOSPHORYLATION SITES; MURINE LEUKEMIA-VIRUS; POINT MUTATION; PROTO-ONCOGENE; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; CELLS; GENE	The Axl receptor tyrosine kinase is a transforming oncogene in NIH3T3 cells, In order to define structural requirements of the Axl receptor necessary for transformation me passaged recombinant retroviruses carrying the axl cDNA in NIH3T3 cells, generating randomly mutated axl variants. Using this strategy, we have isolated three axl viral strains (1B1, SV8, and FFa4) that show augmented 3T3 cell transforming capacity associated with elevated p140(Axl). Upon sequencing, the 1B1 and SV8 proviruses possessed only silent mutations, making p140(Axl) overexpression the most likely explanation for their increased transformation activity. However, the characterization of FFa4 revealed a deletion of sequences encoding the carboxy-terminal 45 amino acids leading to the generation of a chimeric transcript comprised of a truncated Axl receptor with a segment of the 3' UTR region. Mutational analysis revealed that the transforming activity of FFa4 was specific to the formation of the chimeric receptor rather than to the carboxyl-terminal truncation, Intriguingly, none of the viral strains were able to transform the murine cell lines. NR-6 and 32D despite equivalent expression of surface p140(Axl) protein. Further analysis showed that Axl's transforming potential is dependent on the host cell type, the presence of a putative pp190 as a facilitator for transformation, and the level of p140(Axl) expression, Taken together, these results underscore the complexity of Axl biology which is dependent on receptor stoichiometry and the cellular background.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Liu, ET (corresponding author), NCI, Div Clin Sci, NIH, 31-3A11,31 Ctr Dr,MSC 2440, Bethesda, MD 20892 USA.		Liu, Edison/C-4141-2008; Burchert, Andreas/S-9563-2017	Burchert, Andreas/0000-0002-8411-8844	NATIONAL CANCER INSTITUTE [R01CA049240, P50CA058223] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA49240, CA58223-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALVAREZ CV, 1995, J BIOL CHEM, V270, P16271, DOI 10.1074/jbc.270.27.16271; ANDO A, 1992, J BIOL CHEM, V267, P12788; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER TH, 1995, VIROLOGY, V212, P277, DOI 10.1006/viro.1995.1484; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAN H, 1988, VIROLOGY, V166, P58, DOI 10.1016/0042-6822(88)90146-8; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; Goruppi S, 1996, ONCOGENE, V12, P471; GREZ M, 1991, J VIROL, V65, P4691, DOI 10.1128/JVI.65.9.4691-4698.1991; HANECAK R, 1991, J VIROL, V65, P5357, DOI 10.1128/JVI.65.10.5357-5363.1991; HERBST R, 1995, ONCOGENE, V10, P369; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; LAI C, 1994, ONCOGENE, V9, P2567; Li RH, 1996, J NEUROSCI, V16, P2012; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; MCCLOSKEY P, 1994, CELL GROWTH DIFFER, V5, P1105; MCMANUS MJ, 1995, J VIROL, V69, P3631, DOI 10.1128/JVI.69.6.3631-3638.1995; MEDORI R, 1992, BIOTECHNIQUES, V12, P346; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MONK RJ, 1992, J VIROL, V66, P3683, DOI 10.1128/JVI.66.6.3683-3689.1992; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; QUONG RYY, 1994, MELANOMA RES, V4, P313, DOI 10.1097/00008390-199410000-00008; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Taylor ICA, 1995, ONCOGENE, V11, P2619; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Zhang QK, 1996, J VIROL, V70, P8089, DOI 10.1128/JVI.70.11.8089-8097.1996	53	46	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3177	3187		10.1038/sj.onc.1201865	http://dx.doi.org/10.1038/sj.onc.1201865			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671397				2022-12-28	WOS:000074261300011
J	Lim, CP; Jain, N; Cao, XM				Lim, CP; Jain, N; Cao, XM			Stress-induced immediate-early gene, egr-1, involves activation of p38/JNK1	ONCOGENE			English	Article						egr-1; stress; MAP kinases; p38/JNK1	SIGNAL-TRANSDUCTION PATHWAYS; SERUM RESPONSE ELEMENT; MAP KINASE KINASE; C-FOS PROMOTER; PROTEIN-KINASE; TERNARY COMPLEX; SODIUM ARSENITE; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; PLASMA-MEMBRANE	The Ras/Raf/MAP kinase (ERK) pathway is a major signaling pathway induced by growth factors in mammalian cells. Two other types of mammalian MAP kinases, JNK (SAPK) and p38 (RK, CSBP), are induced by environmental stress. Although the immediate-early gene, egr-1, is induced by growth factors, cytokines, differentiation signals and DNA damaging agents, less is known about its induction by environmental stress and the mechanism involved. Here we report that in NIH3T3 cells, egr-1 is induced by various stress treatments such as heat shock, sodium arsenite, ultraviolet (U.V.) radiation, and anisomycin. p38 and JNK1, but not ERK2, were activated by these stress treatments. Induction of egr-1 by anisomycin is inhibited by a specific inhibitor of p38, SE 203580. We also show that p38 and JNK1 activated by their upstream kinases induce egr-1 promoter activity through activation of the ternary complex factor, Elk-l. The stress treatments also lead to an increase in Egr-1 protein phosphorylation and its DNA binding activity. Together, our data suggest that induction of egr-1 gene by growth factors and stress are mediated through different subgroups of MAP kinases which may also differentially affect egr-1 function on its target genes.	Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Cao, XM (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore.							Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CAO XM, 1992, J BIOL CHEM, V267, P1345; CAO XM, 1992, J BIOL CHEM, V267, P12991; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG RN, 1995, ENVIRON MOL MUTAGEN, V25, P188, DOI 10.1002/em.2850250304; HUANG RP, 1995, ONCOGENE, V10, P467; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; JOHNSTON D, 1980, J BIOL CHEM, V255, P6975; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KHARBANDA S, 1993, BIOCHEMISTRY-US, V32, P9137, DOI 10.1021/bi00086a019; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; van Wijk R, 1985, Int J Hyperthermia, V1, P147, DOI 10.3109/02656738509029281; VANWIJK R, 1993, J CELL PHYSIOL, V155, P265, DOI 10.1002/jcp.1041550207; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	61	147	151	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	1998	16	22					2915	2926		10.1038/sj.onc.1201834	http://dx.doi.org/10.1038/sj.onc.1201834			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671412				2022-12-28	WOS:000073988200010
J	Chiariello, M; Visconti, R; Carlomagno, F; Melillo, RM; Bucci, C; de Franciscis, V; Fox, GM; Jing, SQ; Coso, OA; Gutkind, JS; Fusco, A; Santoro, M				Chiariello, M; Visconti, R; Carlomagno, F; Melillo, RM; Bucci, C; de Franciscis, V; Fox, GM; Jing, SQ; Coso, OA; Gutkind, JS; Fusco, A; Santoro, M			Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret	ONCOGENE			English	Article						tyrosine kinase; transformation; jun; MEN2; thyroid	GTP-BINDING PROTEINS; THYROID PAPILLARY CARCINOMAS; SIGNALING PATHWAY; GROWTH-FACTOR; HIRSCHSPRUNGS-DISEASE; ACTIVATION DOMAIN; RET/PTC1 ONCOGENE; ADAPTER PROTEINS; RESPONSE GENES; AP-1 ACTIVITY	The RET proto-oncogene encodes a functional receptor tyrosine kinase (Ret) for the Glial cell line Derived Neurotrophic Factor (GDNF). RET is involved in several neoplastic and non-neoplastic human diseases. Oncogenic activation of RET is detected in human papillary thyroid tumours and in multiple endocrine neoplasia type 2 syndromes. Inactivating mutations of RET have been associated to the congenital megacolon, i.e. Hirschprung's disease. In order to identify pathways that are relevant for Ret signalling to the nucleus, we have investigated its ability to induce the c-Jun NH2-terminal protein kinases (JNK). Here we show that triggering the endogenous Pet, expressed in PC12 cells, induces JNK activity; moreover, Ret is able to activate JNK either when transiently transfected in COS-1 cells or when stably expressed in NIH3T3 fibroblasts or in PC Cl 3 epithelial thyroid cells. JNK activation is dependent on the Pet kinase function, as a kinase-deficient RET mutant, associated with Hirschsprung's disease, fails to activate JNK. The pathway leading to the activation of JNK by RET is clearly divergent from that leading to the activation of ERK: substitution of the tyrosine 1062 of Pet, the Shc binding site, for phenylalanine abrogates ERK but not JNK activation. Experiments conducted with dominant negative mutants or with negative regulators demonstrate that JNK activation by Pet is mediated by Rho/Rac related small GTPases and, particularly, by Cdc42.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Amgen Inc, Thousand Oaks, CA 91320 USA; NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Amgen; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	Santoro, M (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.		Bucci, Cecilia/F-6699-2012; Gutkind, J. Silvio/J-1201-2016; melillo, rosa marina/O-5255-2015; Chiariello, Mario/O-3642-2014; Visconti, Roberta/C-5299-2009; Gutkind, J. Silvio/A-1053-2009	Bucci, Cecilia/0000-0002-6232-6183; Gutkind, J. Silvio/0000-0002-5150-4482; Chiariello, Mario/0000-0001-8434-5177; Visconti, Roberta/0000-0001-7613-3801; MELILLO, Rosa Marina/0000-0002-9233-5275; Fusco, Alfredo/0000-0003-3332-5197				Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CALIFANO D, 1995, ONCOGENE, V11, P107; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRIECO D, 1995, ONCOGENE, V11, P113; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro M, 1996, ONCOGENE, V12, P1821; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	71	104	108	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2435	2445		10.1038/sj.onc.1201778	http://dx.doi.org/10.1038/sj.onc.1201778			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627110	Green Accepted			2022-12-28	WOS:000073672300002
J	Di Como, CJ; Prives, C				Di Como, CJ; Prives, C			Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	ONCOGENE			English	Review						p53; tumor-derived mutants; transactivation; Saccharomyces cerevisiae; FASAY	WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION DOMAIN; C-TERMINAL DOMAIN; DNA-BINDING; MUTANT P53; CELL-LINES; MONOCLONAL-ANTIBODIES; GENE-EXPRESSION; GROWTH ARREST; FISSION YEAST	p53 is a sequence-specific transcriptional activator with a number of known target genes which contain p53-responsive elements. Mutations in p53 have been identified ,within its sequence-specific DNA binding domain in more than half of all human tumors, although a subset of tumor-derived p53 mutants have retained the ability to bind DNA and activate transcription under certain conditions. In order to broaden our understanding of this transactivating ability, we examined the efficacy by which p53 mutants bind to and activate reporters in an Saccharomyces cerevisiae-based assay. Analysis of 19 human tumor-derived p53 mutants, spanning the DNA binding domain of p53 and including the 'hot-spot' class, revealed a broad array of transcriptional transactivation abilities at 24 degrees C, 30 degrees C and 37 degrees C, despite the fact that each mutant had originally been identified as being inactive for transactivation in yeast against a single p53-responsive RGC site-containing reporter. One class of mutants (P177L, R267W, C277Y and R283H) retained wild-type or near wild-type activity that is binding site-selective, even at physiological temperature (37 degrees C). Another class of mutants (V143A, M160I/A161T, H193R, Y220C and I254F), all positioned for maintaining the beta-scaffold of p53, also retained selective activity, but preferentially at sub-physiological temperatures (24 degrees and 30 degrees C). Strikingly, however, in contrast to the other tumor derived mutants, all of the previously identified 'hot-spot' mutants were completely inactive with all sites tested. Moreover, a double mutant, L22E/W23S, located within the activation region and previously shown to be transcriptionally inactive in fibroblasts, retained wildtype or near wild-type binding site-selective activity in yeast. Finally, we found that transcriptional activity in vivo does not necessarily correlate with DNA binding in vitro.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			DiComo, Charles/0000-0003-2818-9215				ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BRAIN R, 1994, ONCOGENE, V9, P1775; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DICOMO CJ, 1995, MOL CELL BIOL, V15, P1835; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gagnebin J, 1998, ONCOGENE, V16, P685, DOI 10.1038/sj.onc.1201568; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUTHRIE JA, 1991, METHODS ENZYMOLOGY, V194; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOVAR H, 1993, ONCOGENE, V8, P2683; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LEGROS Y, 1994, ONCOGENE, V9, P2071; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MILLER CW, 1993, ONCOGENE, V8, P1815; MIYASHITA T, 1995, CELL, V80, P293; NIEWOLIK D, 1995, ONCOGENE, V10, P881; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PICKSLEY SM, 1992, ONCOGENE, V7, P1649; PIENTENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rose M, 1990, LAB COURSE MANUAL ME; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Scolnick DM, 1997, CANCER RES, V57, P3693; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, ONCOGENE, V6, P2055; Shaw P, 1996, ONCOGENE, V12, P921; SIEGEL J, 1995, ONCOGENE, V11, P1363; Silhavy T. J., 1984, EXPT GENE FUSIONS; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; WAGNER P, 1991, ONCOGENE, V6, P1539; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	110	77	80	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2527	2539						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627118				2022-12-28	WOS:000073672300010
J	Evans, MF; Koreth, J; Bakkenist, CJ; Herrington, CS; McGee, JOD				Evans, MF; Koreth, J; Bakkenist, CJ; Herrington, CS; McGee, JOD			Allelic deletion at 11q23.3-q25 is an early event in cervical neoplasia	ONCOGENE			English	Article						human chromosome 11; clonality; HPV; cervix	CHROMOSOME-11 SUPPRESSES TUMORIGENICITY; HUMAN PAPILLOMAVIRUS INFECTION; TERM FOLLOW-UP; SQUAMOUS CARCINOMA; PROGNOSTIC FACTORS; EPITHELIAL-CELLS; UTERINE CERVIX; HPV GENOTYPES; CANCER; HETEROZYGOSITY	Twenty per cent of cervical intraepithelial neoplasias-III (CIN-III) progress to invasive cancer. Human papillomavirus (HPV) infection alone does not determine progression. GIN-III lesions were collected from 161 women. Each tissue was microdissected into a maximum of 32 contiguous units and assayed at multiple microsatellite loci on chromosome 11q, a region frequently deleted in invasive cervical and other cancers. Eight of 108 informative cases (7%) had 11q23.3-q25 deletions; focally intra-lesional in six tone with focal loss of alternate alleles), and pan-lesional in two cases. Hence, 11q deletion can occur early in cervical neoplasia, and possibly predisposes to invasion.	John Radcliffe Hosp, Nuffield Dept Pathol & Bacteriol, Oxford OX3 9DU, England	University of Oxford	McGee, JOD (corresponding author), John Radcliffe Hosp, Nuffield Dept Pathol & Bacteriol, Oxford OX3 9DU, England.		Herrington, C Simon/I-4895-2014; Herrington, C Simon/O-4688-2017	Herrington, C Simon/0000-0001-9177-8165; Herrington, C Simon/0000-0001-9177-8165				ALNAFUSSI AI, 1994, J CLIN PATHOL, V47, P799, DOI 10.1136/jcp.47.9.799; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; BURGHARDT E, 1983, OBSTET GYNECOL, V62, P117; BURGHARDT E, 1992, LANCET, V340, P1543, DOI 10.1016/0140-6736(92)92793-F; DOWNEY GP, 1994, LANCET, V344, P432, DOI 10.1016/S0140-6736(94)91768-X; FUJINAGA Y, 1991, J GEN VIROL, V72, P1039, DOI 10.1099/0022-1317-72-5-1039; Gabra H, 1996, CANCER RES, V56, P950; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HINCHLIFFE SA, 1995, BRIT J CANCER, V72, P943, DOI 10.1038/bjc.1995.438; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; Horikawa I, 1995, CANCER GENET CYTOGEN, V85, P97, DOI 10.1016/0165-4608(95)00147-6; HUETTNER PC, 1996, LAB INVESTIG S, V74, pA91; HUGHES JR, 1995, NONISOTOPIC METHODS, P145; KENTER GG, 1993, CANCER-AM CANCER SOC, V71, P397, DOI 10.1002/1097-0142(19930115)71:2&lt;397::AID-CNCR2820710221&gt;3.0.CO;2-G; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; Larson AA, 1997, CANCER RES, V57, P4171; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; Muliokandov MR, 1996, CANCER RES, V56, P197; MUNGER K, 1992, CANCER SURV, V12, P197; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; Park TW, 1996, J NATL CANCER I, V88, P355, DOI 10.1093/jnci/88.6.355; PECORARO G, 1991, AM J PATHOL, V138, P1; REMMINK AJ, 1995, INT J CANCER, V61, P306, DOI 10.1002/ijc.2910610305; RochaZavaleta L, 1997, BRIT J CANCER, V75, P1144, DOI 10.1038/bjc.1997.197; Romanini C., 1995, Journal of Obstetrics and Gynaecology (Abingdon), V15, P324, DOI 10.3109/01443619509030933; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; SPRIGGS AI, 1974, CHROMOSOMES CANCER, P423; SREEKANTAIAH C, 1991, CANCER GENET CYTOGEN, V53, P75, DOI 10.1016/0165-4608(91)90116-C; TOMLINSON IPM, 1995, J CLIN PATHOL, V48, P424, DOI 10.1136/jcp.48.5.424; TSUTSUMI K, 1992, AM J PATHOL, V140, P255; VANBOMMEL PFJ, 1993, GYNECOL ONCOL, V48, P333, DOI 10.1006/gyno.1993.1058; WAGGONER SE, 1990, GYNECOL ONCOL, V38, P407, DOI 10.1016/0090-8258(90)90082-V; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; YAJIMA A, 1979, TOHOKU J EXP MED, V129, P75, DOI 10.1620/tjem.129.75	39	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2557	2564		10.1038/sj.onc.1202039	http://dx.doi.org/10.1038/sj.onc.1202039			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627121				2022-12-28	WOS:000073672300013
J	Bull, EK; Chakrabarty, S; Brodsky, I; Haines, DS				Bull, EK; Chakrabarty, S; Brodsky, I; Haines, DS			mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells	ONCOGENE			English	Article						mdm2-P2 transcripts; p53 functional assay	NON-HODGKINS-LYMPHOMAS; WILD-TYPE P53; GENE; EXPRESSION; PROTEIN; ACTIVATION; INDUCTION; APOPTOSIS; OVEREXPRESSION; ONCOGENE	The mdm2-P2 promoter is a transcriptional target of the p53 tumor suppressor. The aim of this study was to determine if there is an association between the level of these transcripts and the status of the p53 gene in human leukemic cells, A correlation between mdm2-P2 transcript levels and p53 gene status was observed in all cell lines examined. Primary malignant cells from 10 leukemic patients were also analysed for both mdm2-P2 levels and p53 gene status, All five patients with detectable mdm2-P2 transcripts possessed wild-type p53 alleles, However, only two of five patients with undetectable mdm2-P2 transcripts possessed mutant p53, mdm2-P2 levels were also determined in primary leukemic cells from 14 additional cases both before and after in vitro exposure to cisplatin. The p53 gene was found to be wild-type in all cases where mdm2-P2 levels were induced by cisplatin, There were four cases where no, or only modest, increases in mdm2-P2 levels were detected after cisplatin exposure, Two of these patients were found to harbor mutant p53 while one other possessed leukemic cells with elevated levels of mdm2 protein, These results show that induction of mdm2-P2 transcripts can be used to predict the presence of transcriptionally active p53 in primary leukemic cells.	Allegheny Univ Hlth Sci, Barry Ashbee Leukemia Res Labs, Philadelphia, PA 19102 USA	Drexel University	Haines, DS (corresponding author), Allegheny Univ Hlth Sci, Barry Ashbee Leukemia Res Labs, MS412,Broad & Vine St, Philadelphia, PA 19102 USA.							BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Bukholm IK, 1997, J PATHOL, V181, P140, DOI 10.1002/(SICI)1096-9896(199702)181:2<140::AID-PATH745>3.0.CO;2-A; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chilosi M, 1996, BLOOD, V88, P4012, DOI 10.1182/blood.V88.10.4012.bloodjournal88104012; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Landers JE, 1997, CANCER RES, V57, P3562; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MAESTRO R, 1995, BLOOD, V85, P3239, DOI 10.1182/blood.V85.11.3239.bloodjournal85113239; Marks DI, 1996, BRIT J HAEMATOL, V92, P890, DOI 10.1046/j.1365-2141.1996.439978.x; Marks DI, 1997, J CLIN ONCOL, V15, P1158, DOI 10.1200/JCO.1997.15.3.1158; MARTINEZ JC, 1995, J PATHOL, V177, P27, DOI 10.1002/path.1711770106; MIYASHITA T, 1995, CELL, V80, P293; MOSNER J, 1994, ONCOGENE, V9, P3321; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Velculescu VE, 1996, CLIN CHEM, V42, P858; WATANABE T, 1994, BLOOD, V84, P3158; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	40	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2249	2257		10.1038/sj.onc.1201757	http://dx.doi.org/10.1038/sj.onc.1201757			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619834				2022-12-28	WOS:000073298000010
J	Healy, E; Belgaid, C; Takata, M; Harrison, D; Zhu, NW; Burd, DAR; Rigby, HS; Matthews, JNS; Rees, JL				Healy, E; Belgaid, C; Takata, M; Harrison, D; Zhu, NW; Burd, DAR; Rigby, HS; Matthews, JNS; Rees, JL			Prognostic significance of allelic losses in primary melanoma	ONCOGENE			English	Article						loss of heterozygosity; fractional allelic loss; tumour suppressor gene; proliferation; p53; p21(WAF1)	HUMAN-MALIGNANT MELANOMA; PRIMARY CUTANEOUS MELANOMA; TUMOR-SUPPRESSOR GENE; P53 PROTEIN; HOMOZYGOUS DELETIONS; METASTATIC MELANOMA; SPORADIC MELANOMA; FAMILIAL MELANOMA; CELL CARCINOMA; POOR-PROGNOSIS	Loss of genetic material, including loss of loci on chromosome arms 6q, 9p, and 10q, occurs frequently in cutaneous melanoma but infrequently in benign melanocytic nevi or other melanocytic lesions, suggesting that these genetic alterations are important in the development and progression of melanoma, To examine whether allelic loss is of prognostic importance in melanoma, disease-free survival was related to loss of heterozygosity on 6q, 9p and 10q in 83 individuals with sporadic primary cutaneous melanoma, Loss of chromosome arms 6q and 10q were each significantly associated with a poorer clinical outcome (P = 0.013 and P = 0.001 respectively). In a subgroup of 41 subjects whose primary tumours mere allelotyped, the fractional allelic loss (FAL) at 39 autosomal arms also significantly correlated with disease-free survival (P = 0.013), with an increase in FAL associated with a poorer outcome; this association remained significant when controlled for tumour thickness (P = 0.035). In addition, a greater proportion of cells were immunopositive for Ki67 antigen, p53 and p21(WAF1) protein in the primary melanomas than in the benign melanocytic nevi, however, only p53 overexpression was significantly associated with improved survival (P = 0.041).	Univ Newcastle Upon Tyne, Dept Dermatol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Newcastle Upon Tyne, Dept Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Frenchay Hosp, Dept Plast Surg, Bristol BS16 1LE, Avon, England; Frenchay Hosp, Dept Pathol, Bristol BS16 1LE, Avon, England	Newcastle University - UK; Newcastle University - UK	Rees, JL (corresponding author), Univ Newcastle Upon Tyne, Dept Dermatol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.		Matthews, John N S/H-7502-2013	Matthews, John N S/0000-0003-2559-037X; Healy, Eugene/0000-0001-5591-6970				ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; Barth A, 1995, J Am Coll Surg, V181, P193; Boni R, 1996, J AM ACAD DERMATOL, V35, P416, DOI 10.1016/S0190-9622(96)90607-6; BOUZUBAR N, 1989, BRIT J CANCER, V59, P943, DOI 10.1038/bjc.1989.200; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Collett D, 1994, MODELLING SURVIVAL D; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FIELD JK, 1995, BRIT J CANCER, V72, P1180, DOI 10.1038/bjc.1995.483; FLORENES VA, 1994, BRIT J CANCER, V69, P253, DOI 10.1038/bjc.1994.48; Flores JF, 1996, CANCER RES, V56, P5023; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FURIHATA M, 1993, CANCER RES, V53, P4823; Gabra H, 1996, CANCER RES, V56, P950; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GRUIS NA, 1995, AM J PATHOL, V146, P1199; HARPER JW, 1993, CELL, V75, P805; Healy E, 1996, J INVEST DERMATOL, V107, P318, DOI 10.1111/1523-1747.ep12363118; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Healy E, 1996, CANCER RES, V56, P589; HEATON KM, 1993, AM J SURG, V166, P648, DOI 10.1016/S0002-9610(05)80672-5; HERBST RA, 1994, CANCER RES, V54, P3111; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISHIDA T, 1993, CANCER RES, V53, P5000; ISSHIKI K, 1994, ONCOGENE, V9, P1649; ISSHIKI K, 1993, GENE CHROMOSOME CANC, V8, P178, DOI 10.1002/gcc.2870080307; JACKSON DP, 1992, PCR PRACTICAL APPROA, P29; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1995, ONCOGENE, V10, P1855; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kim SK, 1997, CANCER RES, V57, P400; LEE SM, 1995, BRIT MED BULL, V51, P609, DOI 10.1093/oxfordjournals.bmb.a072982; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; MAEDA K, 1994, CANCER, V73, P528, DOI 10.1002/1097-0142(19940201)73:3<528::AID-CNCR2820730306>3.0.CO;2-P; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MILLIKIN D, 1991, CANCER RES, V51, P5449; MONTANO X, 1994, ONCOGENE, V9, P1455; MORTON DL, 1993, CANCER-AM CANCER SOC, V71, P3737, DOI 10.1002/1097-0142(19930601)71:11<3737::AID-CNCR2820711143>3.0.CO;2-7; MUHONEN T, 1992, BRIT J CANCER, V66, P528, DOI 10.1038/bjc.1992.307; OHTA M, 1994, CANCER RES, V54, P5269; Prescher G, 1996, LANCET, V347, P1222; PUIG S, 1995, AM J HUM GENET, V57, P395; QUELLE DE, 1995, CELL, V83, P993; QUINLAN DC, 1992, CANCER RES, V52, P4828; RAMSAY JA, 1995, J INVEST DERMATOL, V105, P22, DOI 10.1111/1523-1747.ep12312431; Ray ME, 1997, P NATL ACAD SCI USA, V94, P3229, DOI 10.1073/pnas.94.7.3229; Rees JL, 1996, CLIN EXP DERMATOL, V21, P253, DOI 10.1111/j.1365-2230.1996.tb00089.x; ROSES DF, 1983, ANN SURG, V198, P65, DOI 10.1097/00000658-198307000-00013; SCHEISTROEN M, 1995, CANCER, V75, P72, DOI 10.1002/1097-0142(19950101)75:1<72::AID-CNCR2820750113>3.0.CO;2-G; *STATA CORP, 1997, STATA STAT SOFTW REL; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STRETCH JR, 1991, CANCER RES, V51, P5976; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; TAKAHASHI S, 1995, CANCER RES, V55, P4114; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; TRENT JM, 1990, NEW ENGL J MED, V322, P1508, DOI 10.1056/NEJM199005243222107; UMEBAYASHI Y, 1995, ARCH DERMATOL RES, V287, P718, DOI 10.1007/BF01105795; Valverde P, 1996, HUM MOL GENET, V5, P1663, DOI 10.1093/hmg/5.10.1663; VIDAL MJ, 1995, MELANOMA RES, V5, P243, DOI 10.1097/00008390-199508000-00006; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; Wang YP, 1996, ONCOGENE, V12, P1069; Weinberg RA, 1995, CANCER SURV, V25, P3; Wiest JS, 1997, CANCER RES, V57, P1	70	72	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2213	2218		10.1038/sj.onc.1200203	http://dx.doi.org/10.1038/sj.onc.1200203			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619830	Bronze			2022-12-28	WOS:000073298000006
J	Ruthardt, M; Orleth, A; Tomassoni, L; Puccetti, E; Riganelli, D; Alcalay, M; Mannucci, R; Nicoletti, I; Grignani, F; Fagioli, M; Pelicci, PG				Ruthardt, M; Orleth, A; Tomassoni, L; Puccetti, E; Riganelli, D; Alcalay, M; Mannucci, R; Nicoletti, I; Grignani, F; Fagioli, M; Pelicci, PG			The acute promyelocytic leukaemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies	ONCOGENE			English	Article						PML; PLZF; PML/RAR alpha; PLZF/RAR alpha; DNA-virus; INF	ALPHA FUSION PROTEIN; RAR-ALPHA; ZINC-FINGER; HEMATOPOIETIC PROGENITORS; INTERACTION MOTIF; LEUKEMIA-CELLS; POZ-DOMAIN; GENE; TRANSLOCATION; GROWTH	Acute promyelocytic leukaemia is characterized by translocations that involve the retinoic acid receptor a (RAR alpha) locus on chromosome 17 and the PML locus on 15 or the PLZF locus on 11. The resulting abnormal translocation products encode for PML/ RAR alpha or PLZF/RAR alpha fusion proteins. There is increasing experimental evidence that the APL-specific fusion proteins have similar biologic activities on differentiation and survival and that both components of the fusion proteins (PML or PLZF and RAR alpha) are indispensable for these biological activities. The physiologic function of PML or PLZF or whether PML and PLZF; contribute common structural or functional features to the corresponding fusion proteins is not known. We report here immunofluorescence studies on the cellular localization of PLZF and PLZF/RAR alpha and compare it with the localization of PML and PML/RAR alpha. PLZF localizes to nuclear domains of 0.3-0.5 microns, approximately 14 per cell in the KG1 myeloid cell line. These PLZF-bodies are morphologically similar to the domains reported for PML (PML-NBs). There is tight spatial relationship between about 30% of PLZ-NBs and PML-NBs: they partially overlap. However, PML and PLZF do not form soluble complexes in vivo. PLZF- and PML-NBs are functionally distinct. Adenovirus E4-ORF3 protein expression alters the structure of the PML-NBs and-interferon increases the number of PML-NBs and neither has any effect on PLZF NBs. The localization of PLZF/RAR alpha is different to that of PLZF and RAR alpha. The nuclear distribution pattern of PLZF/RAR alpha is one of hundreds of small dots (microspeckles) less than 0.1 micron. Expression of PLZF/RAR alpha did not provoke disruption of the PML-NBs. Go-expression of PML/RAR alpha and PLZF/RAR alpha in U937 cells revealed apparent colocalization. Overall the results suggest that the PML-and PLZF-NBs are distinct functional nuclear domains, but that they may share common regulatory pathways and/or targeting sequences, as revealed by the common localization of their corresponding fusion proteins.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Perugia, Monteluce Policlin, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy; Univ Frankfurt, Dept Hematol, D-6000 Frankfurt, Germany	IRCCS European Institute of Oncology (IEO); University of Perugia; Goethe University Frankfurt	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; Grignani, Francesco/AAC-2565-2022	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Ruthardt, Martin/0000-0003-1021-3811				ALCALAY M, 1997, UNPUB MOL CELL BIOL; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Boddy MN, 1996, ONCOGENE, V13, P971; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DANIEL MT, 1993, BLOOD, V82, P1858; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT R, 1995, J VIROL, V69, P7339, DOI 10.1128/JVI.69.11.7339-7344.1995; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1995, ONCOGENE, V11, P871; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; OHMAN K, 1993, VIROLOGY, V194, P50, DOI 10.1006/viro.1993.1234; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROGAIA D, 1995, LEUKEMIA, V9, P1467; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Sambrook J., 1989, MOL CLONING; Schul W, 1996, EMBO J, V15, P2883, DOI 10.1002/j.1460-2075.1996.tb00649.x; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Stadler M, 1995, ONCOGENE, V11, P2565; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	54	42	42	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1945	1953		10.1038/sj.onc.1201722	http://dx.doi.org/10.1038/sj.onc.1201722			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591778				2022-12-28	WOS:000073079400006
J	Subramaniam, PS; Cruz, PE; Hobeika, AC; Johnson, HM				Subramaniam, PS; Cruz, PE; Hobeika, AC; Johnson, HM			Type I interferon induction of the Cdk-inhibitor p21(WAF1) is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line	ONCOGENE			English	Article						interferon alpha; p21(WAF1); B-cell differentiation; apoptosis; cell cycle	SENSITIVE HEMATOPOIETIC-CELLS; RETINOBLASTOMA PROTEIN; C-MYC; INTERLEUKIN-6 SUPPRESS; ONCOGENE EXPRESSION; ALPHA-INTERFERON; DOWN-REGULATION; RB PROTEIN; GROWTH; GENE	We show, in this study, that type I IFN induction of the cyclin-dependent kinase (cdk) inhibitor p21(WAF1) in the human Burkitt lymphoma B cell-line Daudi and ensuing cell cycle arrest correlate with the terminal differentiation of these cells, and is ultimately followed by apoptosis and cell death. The expression of p21(WAF1) paralleled the onset of G1 arrest and the reduction of surface IgM expression which was used as a marker of the differentiation response, and the IFN treated cells acquired a typical plasma cell-like morphology. The type II IFN IFN gamma, which does not inhibit the growth of Daudi cells, did not induce the expression of p21(WAF1), nor affect the expression of surface IgM. The induction of p21(WAF1) which paralleled the inhibition of the phosphorylation of the retinoblastoma protein, pRB, was preceded by the strong reduction in c-myc levels, We propose that the coupled down-regulation of c-myc and induction of p21(WAF1) may be crucial to the induction of differentiation and G1 arrest in Daudi cells by type I IFN. Growth arrest and differentiation was followed by apoptosis and cell death, and was accompanied by the induction of the activity of the apoptotic ICE-family protease CPP32. G1 arrest and differentiation followed by apoptotic cell death are characteristics of terminal differentiation. Thus, our data suggest that the induction of p21(WAF1) and G1 arrest mediated by type I IFN in Daudi cells is part of terminal differentiation response in these cells, highlighting a role for type I IFN as B cell terminal differentiation factors.	Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Subramaniam, PS (corresponding author), Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA.				NATIONAL CANCER INSTITUTE [R01CA069959, R01CA038587] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38587, CA 69959] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERTOLINI JN, 1992, J IMMUNOL, V149, P1771; Blagosklonny MV, 1996, LEUKEMIA RES, V20, P101, DOI 10.1016/0145-2126(95)00103-4; BURKE LC, 1992, ONCOGENE, V7, P783; CLEMENS MJ, 1988, J CELL BIOCHEM, V38, P251, DOI 10.1002/jcb.240380404; COLLINS SJ, 1987, BLOOD, V70, P1233; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EXLEY R, 1987, P NATL ACAD SCI USA, V84, P6467, DOI 10.1073/pnas.84.18.6467; EXLEY R, 1987, INT J CANCER, V40, P53, DOI 10.1002/ijc.2910400110; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; HERMEKING H, 1995, ONCOGENE, V11, P1409; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; NOGUCHI PD, 1992, CURRENT PROTOCOLS IM, V1; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUBIN BY, 1983, J GEN VIROL, V64, P1743, DOI 10.1099/0022-1317-64-8-1743; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; TAMM I, 1987, MECHANISMS INTERFERO, V2, P25; THOMAS NSB, 1991, ONCOGENE, V6, P317; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TOMITA Y, 1982, INT J CANCER, V30, P161, DOI 10.1002/ijc.2910300206; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; YEN A, 1992, EUR J CELL BIOL, V57, P210; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479	30	48	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1885	1890		10.1038/sj.onc.1201712	http://dx.doi.org/10.1038/sj.onc.1201712			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583686				2022-12-28	WOS:000072994600012
J	Purrello, M; Di Pietro, C; Viola, A; Rapisarda, A; Stevens, S; Guermah, M; Tao, Y; Bonaiuto, C; Arcidiacono, A; Messina, A; Sichel, G; Grzeschik, KH; Roeder, R				Purrello, M; Di Pietro, C; Viola, A; Rapisarda, A; Stevens, S; Guermah, M; Tao, Y; Bonaiuto, C; Arcidiacono, A; Messina, A; Sichel, G; Grzeschik, KH; Roeder, R			Genomics and transcription analysis of human TFIID	ONCOGENE			English	Article						TAF(II)s; regulation of gene expression; signal transduction; cell proliferation and differentiation; oncogenesis; Cancer Genome Anatomy Project	TATA-BOX-BINDING; RNA-POLYMERASE-II; FUNCTIONAL INTERACTION; MULTIPLE INTERACTIONS; CCG1 GENE; SUBUNIT; PROTEIN; LOCALIZATION; ACTIVATION; COMPLEX	TFIID, a multisubunit protein comprised of TBP (TATA box-binding protein) and TAF(II)s (TBP-associated factors), has a central role in transcription initiation at class II promoters. TAF(II)s role as mediators of regulatory transcription factors, such as pRb and p53, and their involvement in signal transduction pathways suggest that some may participate in the control of cell proliferation and differentiation: therefore, they could be considered potential protooncogenes or antioncogenes. With the aim of starting to analyse these potential roles, we have determined the genomic position of nine human TAF(II) genes (TAF(II)250, TAF(II)135, TAF(II)100, TAF(II)80, TAF(II)55, TAF(II)43, TAF(II)31, TAF(II)28, TAF(II)20/15) and of two previously unknown sequences related to TAF(II)250 and TAF(II)31, respectively. Except for those encoding TAF(II)250 and TAF(II)31, these genes are present in a single copy and, with the exclusion of those for TAF(II)43 and TAF(II)28 (both at 6p21), are localized in different segments of the genome. Indeed, six of them map to a chromosomal region commonly altered in specific neoplasias, which defines them as candidates for in oncogenesis. Our experiments also that TAF(II) transcripts are synthesized ubiquitously, mostly at low levels similar to those of TBP. Interestingly, the amount of the major mRNA species detected by TAF(II)20/15 cDNA is higher, which suggests that the polypeptide it encodes may also perform functions independently of TFIID. TAF(II) isoforms, indicated by additional bands on Northern blots, may play a role in modulation of TFIID function. These data will be useful for analysing variations of TAF(II) mRNA phenotype during cell proliferation, differentiation and development, both normal and pathological.	Univ Catania, Ist Biol Gen, I-95124 Catania, Italy; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA; Univ Catania, Ist Patol Gen, I-95124 Catania, Italy; Univ Marburg, Med Zentrum Humangenet, D-35037 Marburg, Germany; Univ Catania, Dept Anim Biol, I-95124 Catania, Italy	University of Catania; Rockefeller University; University of Catania; Philipps University Marburg; University of Catania	Purrello, M (corresponding author), Univ Catania, Ist Biol Gen, I-95124 Catania, Italy.		Agatea, Lisa/L-8267-2016	DI PIETRO, Cinzia Santa/0000-0002-6036-4469				Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; BROWN CJ, 1989, SOMAT CELL MOLEC GEN, V15, P93, DOI 10.1007/BF01534674; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Dubrovskaya V, 1996, GENOMICS, V36, P556, DOI 10.1006/geno.1996.0509; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kazmierczak B, 1996, J NATL CANCER I, V88, P1234, DOI 10.1093/jnci/88.17.1234; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Lavigne AC, 1996, J BIOL CHEM, V271, P19774, DOI 10.1074/jbc.271.33.19774; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUBBERT M, 1991, BLOOD, V77, P909; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; PURRELLO M, 1994, GENOMICS, V23, P253, DOI 10.1006/geno.1994.1488; Purrello M, 1996, CYTOGENET CELL GENET, V75, P186, DOI 10.1159/000134479; PURRELLO M, 1994, GENOMICS, V22, P94, DOI 10.1006/geno.1994.1349; PURRELLO M, 1995, CYTOGENET CELL GENET, V69, P75, DOI 10.1159/000133942; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sanchez Y, 1996, P NATL ACAD SCI USA, V93, P2551, DOI 10.1073/pnas.93.6.2551; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; SCHEER E, 1995, GENOMICS, V29, P269, DOI 10.1006/geno.1995.1243; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; Strausberg RL, 1997, NAT GENET, V15, P415, DOI 10.1038/ng0497supp-415; SUZUKI S, 1997, MOL CELL BIOL, V17, P3284; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Xiao S, 1997, AM J PATHOL, V150, P901	40	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1633	1638		10.1038/sj.onc.1201673	http://dx.doi.org/10.1038/sj.onc.1201673			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569032				2022-12-28	WOS:000072743200015
J	Wark, G; Heyworth, CM; Spooncer, E; Czaplewski, L; Francis, JM; Dexter, TM; Whetton, AD				Wark, G; Heyworth, CM; Spooncer, E; Czaplewski, L; Francis, JM; Dexter, TM; Whetton, AD			Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha	ONCOGENE			English	Article						chronic myeloid leukaemia (CML); MIP-1 alpha; abl	CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; COLONY FORMATION INVITRO; TYROSINE KINASE; HEMATOPOIETIC-CELLS; BCR-ABL; FUNCTIONAL EXPRESSION; PROGENITOR CELLS; SELF-RENEWAL; PROLIFERATION	The clonogenic cells of chronic myeloid leukaemia (CML), unlike normal haemopoietic progenitor cells, are resistant to the growth inhibitory effects of the chemokine macrophage inflammatory protein-1 alpha (MIP-1 alpha). CML is also relatively resistant to chemotherapy and the disease is difficult to cure using conventional therapeutic routes, CML is associated with increased abl oncogene protein tyrosine kinase (PTK) activity. Here, we have tested the hypothesis that these aberrant responses to MIP-1 alpha and the relative resistance to chemotherapy are directly related to this increased abl PTK activity in primitive haemopoietic cells. to do this we have expressed a temperature sensitive abl PTK in a growth factor dependent, multipotent stem cell line (FDCP-Mix) in which growth is normally suppressed by MIB-1 alpha. In FDCP-Mix cells expressing the ts v-abl PTK and grown at the restrictive temperature for PTK activity the cells were relatively sensitive to cytotoxic agents such as cytosine arabinoside and 5-fluorouracil but MTP-1 alpha could induce growth inhibition and confer some degree of protection from these agents. At the permissive temperature for abl PTK, the cells were relatively resistant to cytotoxic drugs and MIP-1 alpha treatment neither induced growth inhibition nor protected the cells from cytotoxic drug induced cell death. This lack of response to MIP-1 alpha was not due to receptor down modulation as neither the affinity nor the number of I-125-MIP-1 alpha binding sites was altered by activating Abl PTK. However, MIP-1 alpha mediated increases in cytosolic Ca2+ levels were abrogated by switching cells to the permissive temperature for Abl PTK activity. These data suggest that the relative resistance of CML progenitor cells to therapeutic drugs and the lack of response to MIP-1 alpha occurs as a direct consequence of abl PTK activity and involves desensitisation of signal transduction events stimulated by MIP-1 alpha receptors. Thus one contributory mechanism to transformation of primitive haemopoietic cells is abrogation of response to a growth inhibitor.	Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Expt Hematol, Canc Res Campaign, Manchester M20 9BX, Lancs, England; British Biotech, Oxford OX4 5LY, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Dexter, TM (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Expt Hematol, Canc Res Campaign, Wilmslow Rd, Manchester M20 9BX, Lancs, England.			WHETTON, ANTHONY D/0000-0002-1098-3878				BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BHATIA R, 1995, J CLIN INVEST, V96, P931, DOI 10.1172/JCI118141; BROXMEYER HE, 1990, BLOOD, V76, P1110; BROXMEYER HE, 1989, J EXP MED, V170, P1583, DOI 10.1084/jem.170.5.1583; Broxmeyer HE, 1996, ANN HEMATOL, V73, P1, DOI 10.1007/s002770050192; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHAPMAN RS, 1994, CANCER RES, V54, P5131; CHASTY RC, 1995, BLOOD, V86, P4270, DOI 10.1182/blood.V86.11.4270.bloodjournal86114270; CLEMENTS JM, 1992, CYTOKINE, V4, P76, DOI 10.1016/1043-4666(92)90040-X; COUTINHO LH, 1993, HAEMOPOIESIS PRACTIC, P75; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DEXTER TM, 1994, BLOOD, V84, P673; DUNLOP DJ, 1992, BLOOD, V79, P2221; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; EAVES CJ, 1993, P NATL ACAD SCI USA, V90, P12015, DOI 10.1073/pnas.90.24.12015; EVANS CA, 1993, CANCER RES, V53, P1735; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HEYWORTH CM, 1995, GROWTH FACTORS, V12, P165, DOI 10.3109/08977199509036876; HOLYOAKE TL, 1993, STEM CELLS, V11, P122, DOI 10.1002/stem.5530110925; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; LORD BI, 1992, BLOOD, V79, P2605; MAJOR PP, 1981, BIOCHEM PHARMACOL, V30, P2221, DOI 10.1016/0006-2952(81)90091-5; METCALF D, 1989, CANCER RES, V49, P2305; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8; PARKINSON EK, 1993, J INVEST DERMATOL, V101, P113, DOI 10.1111/1523-1747.ep12363603; SPOONCER E, 1994, LEUKEMIA, V8, P620; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; WHETTON AD, 1986, EMBO J, V5, P3281, DOI 10.1002/j.1460-2075.1986.tb04640.x; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068	36	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	1998	16	10					1319	1324		10.1038/sj.onc.1201914	http://dx.doi.org/10.1038/sj.onc.1201914			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546433				2022-12-28	WOS:000072422000010
J	Wurl, P; Meye, A; Schmidt, H; Lautenschlager, C; Kalthoff, H; Rath, FW; Taubert, H				Wurl, P; Meye, A; Schmidt, H; Lautenschlager, C; Kalthoff, H; Rath, FW; Taubert, H			High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities	ONCOGENE			English	Article						soft tissue sarcoma; Mdm2; p53; immunohistochemistry; multivariate prognostic analysis	P53 MUTATION; ONCOPROTEIN MDM2; AMPLIFICATION; DOMAIN	Soft tissue sarcomas are a heterogenous group of neoplasms with various histological subtypes, Up to now, no individual causal molecular markers; for prognosis and therapeutic success have been identified, A tumorigenic connection between the oncogene product Mdm2 and tumor suppressor p53 is generally accepted, but their possible clinical relevance has not yet been investigated sufficiently in soft tissue sarcoma, In 86 primary soft tissue sarcoma of the extremities (RO-resected, T1/2 N0 M0), Mdm2 and p53 overexpression were investigated by immunohistochemistry. The results were adjusted to clinico-pathological characteristics and evaluated for their prognostic relevance by multivariate analysis, In Cox's multivariate analysis with stratification of Mdm2 to p53 results, we determined four groups which had different prognostic values for relapse-free and overall survival (Mdm2-/p53-<Mdm2-/p53+<Mdm2+/p53-<Mdm2+/p53+). The most striking finding was a relative risk (rr) for overall survival of 18.77 (P=0.006) for patients with Mdm2/p53 co-overexpression (n=40). It is noticeably higher than the additive risk from both factors. Coincident Mdm2/p53 overexpression is an independent molecular marker with the highest prognostic relevance described for soft tissue sarcoma, Thus, a high risk sarcoma group has been defined which we believe requires alternative therapeutic approaches.	Univ Halle Wittenberg, Clin Gen Surg, D-4010 Halle, Germany; Univ Halle Wittenberg, Inst Pathol, D-4010 Halle, Germany; Univ Halle Wittenberg, Inst Med Biometry & Informat, D-4010 Halle, Germany; Univ Kiel, Clin Gen Surg, Kiel, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; University of Kiel	Taubert, H (corresponding author), Univ Halle Wittenberg, Clin Gen Surg, D-4010 Halle, Germany.		Kalthoff, Holger/B-1618-2010	Taubert, Helge/0000-0002-9077-1727				Chen JD, 1996, MOL CELL BIOL, V16, P2445; CORDONCARDO C, 1994, CANCER RES, V54, P794; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEACH FS, 1993, CANCER RES, V53, P2231; LIN J, 1995, COLD SPRING HARB SYM, V49, P215; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OTTO A, 1993, ONCOGENE, V8, P2591; Reid AH, 1996, DIAGN MOL PATHOL, V5, P65, DOI 10.1097/00019606-199603000-00010; Taubert H, 1996, CANCER RES, V56, P4134; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wurl P, 1997, J CANCER RES CLIN, V123, P502, DOI 10.1007/s004320050095; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	18	66	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1183	1185		10.1038/sj.onc.1201646	http://dx.doi.org/10.1038/sj.onc.1201646			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528860				2022-12-28	WOS:000072336000009
J	Chen, RH; Su, YH; Chuang, RLC; Chang, TY				Chen, RH; Su, YH; Chuang, RLC; Chang, TY			Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase Akt-dependent pathway	ONCOGENE			English	Article						TGF-beta-induced apoptosis; insulin; PI 3-kinase; Akt	PROGRAMMED CELL-DEATH; PROTEIN-KINASE AKT; FACTOR-II; SIGNALING PATHWAY; RAT HEPATOCYTES; HEPATOMA-CELLS; RECEPTORS; EXPRESSION; INDUCTION; SURVIVAL	Insulin and insulin receptor substrate 1 (IRS-1) are capable of protecting liver cells from apoptosis induced by transforming growth factor-beta (TGF-beta), The Ras/mitogen-activated protein kinase (MAP kinase) and the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathways are both activated upon insulin stimulation and can protect against apoptosis under certain circumstances. We investigated which of these pathways is responsible for the protective effect of insulin on TGF-beta-induced apoptosis. An activated Pas, although elicited a strong mitogenic effect, could not protect Hep3B cells from TGF-beta-induced apoptosis, Furthermore, PD98059, a selective inhibitor of MEK, did not suppress the antiapoptotic effect of insulin. In contrast, the PI 3-kinase inhibitor, LY294002, efficiently blocked the effect of insulin. Protection against TGF-beta-induced apoptosis conferred by PI 3-kinase was further verified by stable transfection of an activated PI 3-kinase, Downstream targets of PI 3-kinase involved in this protection was further investigated. An activated Akt mimicked the antiapoptotic effect of insulin, whereas a dominant-negative Akt inhibited such effect. However, rapamycin, the p70(S6) kinase inhibitor, had no effect on the protectivity of insulin against TGF-beta-induced apoptosis, suggesting that the antiapoptotic target of PI 3-kinase/Akt pathway is independent or lies upstream of the p70S6 kinase, The mechanism by which PI 3-kinase/Akt pathway interferes with the apoptotic signaling of TGF-beta was explored. Activation of PI 3-kinase did not lead to a suppression of Smad hetero-oligomerization or nuclear translocation but blocked TGF-beta-induced caspase-3-like activity. In summary, the PI 3-kinase/Akt pathway, but not the Ras/MAP kinase pathway, protects against TGF-beta-induced apoptosis by inhibiting a step downstream of Smad but upstream of caspase-3.	Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 10764, Taiwan; Natl Taiwan Univ, Coll Sci, Inst Biol Chem, Taipei 10764, Taiwan	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University	Chen, RH (corresponding author), Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 10764, Taiwan.		Chen, Ruey-Hwa/G-6121-2019; Su, Yi-Hsien/F-2910-2014	Chen, Ruey-Hwa/0000-0001-8124-5832; 				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; CARIANI E, 1988, CANCER RES, V48, P6844; Chao JR, 1997, ONCOGENE, V14, P721, DOI 10.1038/sj.onc.1200884; CHEN RH, 1994, J BIOL CHEM, V269, P22868; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUANG LY, 1994, ANTICANCER RES, V14, P147; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Derynck R, 1994, CYTOKINE HDB, P319; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fan GS, 1996, ONCOGENE, V12, P1909; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LIN JK, 1992, CANCER RES, V52, P385; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; TAKAGI H, 1992, CANCER RES, V52, P5171; TANAKA S, 1996, CANCER RES, V56, P391; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG CY, 1995, CANCER RES, V55, P5101; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG D, 1993, CANCER RES, V53, P2020; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	53	160	170	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1959	1968		10.1038/sj.onc.1202111	http://dx.doi.org/10.1038/sj.onc.1202111			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788439				2022-12-28	WOS:000076423500009
J	Kuo, TH; Kim, HRC; Zhu, LP; Yu, YJ; Lin, HM; Tsang, W				Kuo, TH; Kim, HRC; Zhu, LP; Yu, YJ; Lin, HM; Tsang, W			Modulation of endoplasmic reticulum calcium pump by Bcl-2	ONCOGENE			English	Article						Bcl-2; endoplasmic reticulum calcium pump; gene expression	INTRACELLULAR CALCIUM; GENE-EXPRESSION; CELL-GROWTH; APOPTOSIS; CA2+; HOMEOSTASIS; RECEPTOR; CHANNEL; PROTEIN; THAPSIGARGIN	Members of the bcl-2 gene family encode proteins that function either to promote or to inhibit apoptosis. Despite numerous efforts, the mechanism of action of Bcl-2, an anti-apoptotic protein, is still not clear. In particular, the relation between Bcl-2 and the endoplasmic reticulum (ER) calcium store is not well-understood. In the present work, we examined the effect of Bcl-2 on the ER store. We demonstrate that overexpression of Bcl-2 in breast epithelial cells modulates ER store by upregulating calcium pump (SERCA) expression,without affecting the release channel (IP3R). The steady state levels of SERCA2 mRNA and protein were both increased in Bcl-2 expression clones. The increase in SERCA2 protein leads to accelerated calcium uptake and enhanced Ca2+ loading. In addition, we also show the detection of intracellular interaction between Bcl-2 and SERCA molecules by co-immunoprecipitation. Since high lumenal Ca2+ concentration of ER is essential for normal cell functions, the results suggest that Bcl-2 preserves the ER Ca2+ store by upregulating SERCA gene expression as well as by a possible interaction with the pump.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Kuo, TH (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA.				NCI NIH HHS [CA-64139] Funding Source: Medline; NHLBI NIH HHS [HL-39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064139, R29CA064139] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; CALPHAM DE, 1995, CELL, V80, P259; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; Cheng GM, 1996, ARCH BIOCHEM BIOPHYS, V329, P65, DOI 10.1006/abbi.1996.0192; Distelhorst CW, 1996, ONCOGENE, V12, P2051; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; FURUYA Y, 1994, CANCER RES, V54, P6167; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kuo TH, 1997, CELL CALCIUM, V21, P399, DOI 10.1016/S0143-4160(97)90051-8; KUO TH, 1992, BIOCHIM BIOPHYS ACTA, V1138, P343, DOI 10.1016/0925-4439(92)90013-D; LIU CM, 1978, J BIOL CHEM, V253, P5892; LODISH HF, 1992, J BIOL CHEM, V267, P12753; Marin MC, 1996, ONCOGENE, V12, P2259; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Preston GA, 1997, CANCER RES, V57, P537; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; UPADHYAY S, 1995, CANCER RES, V55, P4520; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZHAO H, 1990, J BIOL CHEM, V265, P21419; ZHU WH, 1995, LIFE SCI, V57, P2091, DOI 10.1016/0024-3205(95)02202-T; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	36	167	168	0	19	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1903	1910		10.1038/sj.onc.1202110	http://dx.doi.org/10.1038/sj.onc.1202110			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788433				2022-12-28	WOS:000076423500003
J	Komarova, EA; Diatchenko, L; Rokhlin, OW; Hill, JE; Wang, ZJ; Krivokrysenko, VI; Feinstein, E; Gudkov, AV				Komarova, EA; Diatchenko, L; Rokhlin, OW; Hill, JE; Wang, ZJ; Krivokrysenko, VI; Feinstein, E; Gudkov, AV			Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53	ONCOGENE			English	Article						p53; transcription; secretion; growth inhibition; radiation; chemotherapy	CELL-CYCLE; IN-VIVO; APOPTOSIS; FIBROBLASTS; GENE; RADIATION; ANGIOGENESIS; MICE	p53 tumor suppressor gene controls cell response to a variety of stresses inducing growth arrest or apoptosis in damaged cells. It largely determines the sensitivity of tumor and normal cells to radiation and chemotherapy, and, therefore, defines both the efficacy and limitations of anti-cancer treatment. To determine molecular mechanisms of p53-dependent stress response in normal tissues we identified and compared the spectra of radiation-responsive genes in cells of different origin and p53 status using a cDNA array hybridization technique. The majority of genes identified were p53-dependent and cell type specific, Several of the new p53 responders encode known secreted growth inhibitory factors, This suggests that p53, in addition to its intrinsic antiproliferation activity, can cause 'bystander effect' by inducing export of growth suppressive stimuli from damaged cells to neighboring cells. Consistently, a p53-dependent accumulation of factors, which causes growth inhibitory effects in a variety of cell lines, was found after gamma irradiation in the media from established and primary cell cultures and in the urine of irradiated mice. Moreover, p53-dependent factors released by normal human fibroblasts potentiated the cytotoxic effect of a chemotherapeutic drug on co-cultivated tumor cells. This suggests a previously unknown role for normal cells in chemo- and radiation therapy of cancer.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; CLONTECH Labs Inc, Palo Alto, CA 94303 USA; Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; QBI Enterprises Ltd, IL-74106 Ness Ziona, Israel	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Iowa	Gudkov, AV (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154; Hill, Jason/0000-0003-2512-1661	NATIONAL CANCER INSTITUTE [R01CA060730, R01CA075179] Funding Source: NIH RePORTER; NCI NIH HHS [CA60730, CA75179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adolph KW, 1997, GENE, V193, P5, DOI 10.1016/S0378-1119(97)00070-X; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GULLINO PM, 1995, ACTA ONCOL, V34, P439, DOI 10.3109/02841869509094005; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HERMEKING H, 1997, MOL CELL, V1, P1; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACCALLUM DE, 1996, ONCOGENE, V13, P2545; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MIYASHITA T, 1995, CELL, V80, P293; Nikiforov MA, 1997, ONCOGENE, V15, P3007, DOI 10.1038/sj.onc.1201723; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; OBRIEN PM, 1960, CANCER, V23, P451; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Qazilbash MH, 1997, GENE THER, V4, P675, DOI 10.1038/sj.gt.3300444; Rokhlin OW, 1997, CANCER RES, V57, P1758; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	32	120	126	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1089	1096		10.1038/sj.onc.1202303	http://dx.doi.org/10.1038/sj.onc.1202303			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764819				2022-12-28	WOS:000075598400004
J	Holmgren, L; Jackson, G; Arbiser, J				Holmgren, L; Jackson, G; Arbiser, J			P53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma	ONCOGENE			English	Article						angiogenesis; dormancy; neoplasia	WILD-TYPE P53; ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; IN-VIVO; EXPRESSION; CANCER; CELLS; APOPTOSIS; INHIBITOR; SUPPRESSION	The p53 tumor-suppressor gene is inactivated in over 50% of all human cancers, In normal cells, p53 induces growth arrest and apoptosis in response to DNA damage. We show that p53 acts as potent tumor-suppressor gene independent of its well-documented effects on tumor-cell proliferation and apoptosis. p53 activates target genes in a murine fibrosarcoma cell-line but does not affect tumor cell-cycle progression or survival. Exogenous expression of wt-p53 does, however, block the angiogenic potential of the tumor cells resulting in formation of dormant tumors in vivo. These data provide evidence that: (1) p53 acts as a tumor suppressor gene independent of its anti-proliferative effects; (2) By inhibiting angiogenesis p53 can indirectly induce apoptosis in vivo but not in vitro; (3) p53-gene therapy which alters a tumors angiogenic potential, can revert tumors to a dormant phenotype.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Harvard Univ, Childrens Hosp, Sch Med, Surg Res Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA	Karolinska Institutet; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Holmgren, L (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.							Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Folkman J, 1995, MOL BASIS CANC, P206; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Holmgren L, 1996, CANCER METAST REV, V15, P241, DOI 10.1007/BF00437478; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEYER JL, 1985, INT J RADIAT ONCOL, V11, P973, DOI 10.1016/0360-3016(85)90120-8; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; RAK J, 1995, CANCER RES, V55, P4575; Sambrook J., 2002, MOL CLONING LAB MANU; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TANAKA T, 1996, ANGIOGENESIS ANTAGON; TEICHER BA, 1992, CANCER RES, V52, P6702; Teicher BA, 1994, RADIAT ONCOL INVEST, V2, P269, DOI DOI 10.1002/ROI.2970020604; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG WW, 1994, CANCER GENE THER, V1, P5	28	40	42	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					819	824		10.1038/sj.onc.1201993	http://dx.doi.org/10.1038/sj.onc.1201993			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9779998				2022-12-28	WOS:000075448800003
J	Koga, H; Araki, N; Takeshima, H; Nishi, T; Hirota, T; Kimura, Y; Nakao, M; Saya, H				Koga, H; Araki, N; Takeshima, H; Nishi, T; Hirota, T; Kimura, Y; Nakao, M; Saya, H			Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain	ONCOGENE			English	Article						NF2 gene; MBPs binding domain; exon-missing; protein truncation test (PTT); nuclear microinjection	PROTEIN TRUNCATION TEST; COLI APC GENE; TUMOR-SUPPRESSOR; ADENOMATOUS POLYPOSIS; MUTATION; PRODUCT; MEMBRANE; MERLIN; CYTOSKELETON; SCHWANNOMAS	Neurofibromatosis 2 (NF2) is an inherited disorder characterized by a predisposition to multiple intracranial tumors. The protein encoded by the NF2 gene has striking similarities to ezrin, radixin and moesin (ERM) proteins which link membrane proteins to the cytoskeleton, Therefore, it can be speculated that the disruption of cytoskeletal organization by alterations in the Nn gene is involved in the development of tumors. It has been reported that the majority of NF2 mutations were nonsense or frameshift mutations that result in premature termination of translation. To facilitate the detection of these mutations, we performed protein truncation test and found that 11 of 14 NF2 patients had truncational mutations (79%). Seven of the 11 patients (64%) had a splicing abnormality which lead to absence of exons in the ERM homology domain. To examine the biological significance of the exon-missing mutations in the ERM homology domain, we expressed the wild-type (wt-NF2) and the various mutant NF2s (mu-NF2s) in a fibroblast cell line by using both liposome-mediated transfection and nuclear microinjection of the expression plasmids, The wt-NF2 showed intense punctate staining in the perinuclear cytoplasm in addition to overall staining of the submembranous area, whereas the mu-NF2s lacking exons in the ERM homology domain showed granular staining at the perinuclear region without any accumulation at the submembrane region. Microinjection of wt-NF2 cDNA into the nucleus of VA13 cells revealed that wt-NF2 protein induced a progressive elongation of cell processes. Furthermore, cells that expressed mu-NF2 had decreased adhesion, which resulted in detachment from the substratum. These findings suggested that the exon-missing mutations in the ERM-homology domain may affect cell membrane-cytoskeleton signaling and consequently disrupt cell-to-cell or cell-to-matrix interaction.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 860, Japan; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 860, Japan	Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 860, Japan.		Saya, Hideyuki/J-4325-2013					ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; Bala S, 1996, HUM GENET, V98, P528, DOI 10.1007/s004390050254; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; DENBAKKER MA, 1995, ONCOGENE, V10, P757; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; DeVitis LR, 1996, HUM GENET, V97, P632; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MACCOLLIN M, 1994, AM J HUM GENET, V55, P314; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; Nishi T, 1997, INT J ONCOL, V10, P1025; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBIO MP, 1994, CANCER RES, V54, P45; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.3.CO;2-2; SIEBERT PD, 1993, NUCLEIC ACIDS RES, V21, P2019, DOI 10.1093/nar/21.8.2019; StemmerRachamimov AO, 1997, J NEUROPATH EXP NEUR, V56, P735; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; Welling DB, 1996, HUM GENET, V98, P189, DOI 10.1007/s004390050188	26	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					801	810		10.1038/sj.onc.1202010	http://dx.doi.org/10.1038/sj.onc.1202010			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9779996				2022-12-28	WOS:000075448800001
J	Cheung, B; Hocker, JE; Smith, SA; Norris, MD; Haber, M; Marshall, GM				Cheung, B; Hocker, JE; Smith, SA; Norris, MD; Haber, M; Marshall, GM			Favorable prognostic significance of high-level retinoic acid receptor beta expression in neuroblastoma mediated by effects on cell cycle regulation	ONCOGENE			English	Article						retinoic acid receptor beta; neuroblastoma; cell cycle; p21; prognosis	HUMAN LUNG-CANCER; RESISTANCE-ASSOCIATED PROTEIN; BINDING-PROTEINS; RAR-ALPHA; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL PATTERN; UP-REGULATION; GENE; GROWTH; LINES	We have previously shown that ectopic overexpression of retinoic acid receptor (RAR) subtypes alpha, beta and gamma in human neuroblastoma cells had different effects on growth and retinoid sensitivity. Only overexpressed RAR beta induced profound growth inhibition in the absence of additional retinoid, and increased retinoid sensitivity. In this study, we measured mRNA expression levels of RAR alpha, beta, and gamma in 50 primary neuroblastoma tumor samples, and found a strong correlation between favorable patient prognosis and high-level RAR beta expression. Human neuroblastoma cells transfected with a vector expressing RARE demonstrated irreversible growth arrest following a 1 week exposure to all-trans-retinoic acid, whereas control cells continued to proliferate. In the absence of additional retinoid, RAR beta transfectants demonstrated a higher proportion of cells in the G(0)/G(1) phase of the cell cycle, increased p21(WAF1/CIP1) expression and specific binding to a retinoic acid response element. These were changes which we also observed in control neuroblastoma cells following retinoid treatment. Our data indicate that RAR beta is an important factor mediating the growth inhibitory effects of retinoids in neuroblastoma cells. The favorable effect of high-le vel RARE expression on prognosis in primary tumor tissue may occur through RAR beta effects on p21(WAF1/CIP1) expression and consequent G(0)/G(1) cell cycle arrest.	Sydney Childrens Hosp, Childrens Canc Inst Australia, Randwick, NSW 2031, Australia	Children's Cancer Institute	Marshall, GM (corresponding author), Sydney Childrens Hosp, Childrens Canc Inst Australia, High St, Randwick, NSW 2031, Australia.			Norris, Murray/0000-0002-0632-4589; Haber, Michelle/0000-0003-2036-8817; Cheung, Belamy/0000-0001-8784-860X				Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BORDOW SB, 1994, CANCER RES, V54, P5036; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; Brodeur Garrett M., 1997, P761; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cheung B, 1996, BIOCHEM BIOPH RES CO, V229, P349, DOI 10.1006/bbrc.1996.1804; CLAGETTDAME M, 1993, ARCH BIOCHEM BIOPHYS, V300, P684, DOI 10.1006/abbi.1993.1095; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GEBERT JF, 1991, ONCOGENE, V6, P1859; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KIM YH, 1995, CANCER RES, V55, P5603; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LUI Y, 1996, MOL CELL BIOL, V16, P1138; MACMILLAN RW, 1976, J PEDIATR SURG, V11, P461, DOI 10.1016/S0022-3468(76)80204-7; Mangelsdorf David J., 1994, P319; Manshouri T, 1997, BLOOD, V89, P2507, DOI 10.1182/blood.V89.7.2507; MARSHALL GM, 1995, ONCOGENE, V11, P485; MARSHALL GM, 1994, ANTICANCER RES, V13, P437; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; MORRISSKAY G, 1991, SEMINARS DEV BIOL, V2, P211; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; ROUSSELOT P, 1994, ONCOGENE, V9, P545; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUBERTE E, 1993, DEVELOPMENT, V118, P267; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SPANJAARD RA, 1995, J BIOL CHEM, V270, P17429, DOI 10.1074/jbc.270.29.17429; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; Woods WG, 1996, LANCET, V348, P1682, DOI 10.1016/S0140-6736(96)06020-5; WUARIN L, 1994, INT J CANCER, V56, P840, DOI 10.1002/ijc.2910560615; ZHANG XK, 1994, CANCER RES, V54, P5663	49	50	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					751	759		10.1038/sj.onc.1201982	http://dx.doi.org/10.1038/sj.onc.1201982			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715277				2022-12-28	WOS:000075337200010
J	Tanaka, Y; Fujii, M; Hayashi, K; Chiba, N; Akaishi, T; Shineha, R; Nishihira, T; Satomi, S; Ito, Y; Watanabe, T; Satake, M				Tanaka, Y; Fujii, M; Hayashi, K; Chiba, N; Akaishi, T; Shineha, R; Nishihira, T; Satomi, S; Ito, Y; Watanabe, T; Satake, M			The chimeric protein, PEBP2 beta/CBF beta-SMMHC, disorganizes cytoplasmic stress fibers and inhibits transcriptional activation	ONCOGENE			English	Article						PEBP2 beta/CBF beta; chimeric gene; acute myeloid leukemia; stress fibers; immunocytochemistry; transcription factor	ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; FETAL LIVER HEMATOPOIESIS; BINDING-FACTOR-BETA; DNA-BINDING; FUSION TRANSCRIPT; AML1 GENE; SUBCELLULAR-LOCALIZATION	The chromosomal inversion 16(p13;q22) associated with human acute myeloid leukemia generates the chimeric PEBP2 beta/CBF beta-SMMHC gene. The PEBP2 beta/CBF beta portion of the chimeric polypeptide harbors most of the amino acid sequence of the PEBP2 beta/CBF beta protein, the non-DNA. binding subunit of the heterodimeric transcription factor, PEBP2/CBF, whereas the SMMHC portion of the chimera consists of the rod domain of the smooth muscle myosin heavy chain molecule. In this study we examined the subcellular localization of the chimeric protein land its effect both on stress fibers and transcriptional activation by transfecting cDNA into tissue culture cells. The localization of the chimera was investigated by immunocytochemical staining of cells and was found to be both cytoplasmic and nuclear, One aspect of the effect of expression of the chimera was a drastic alteration of cell morphology, The cells appeared elongated and possessed long cytoplasmic processes. Double fluorescent labeling revealed disorganization of the stress fibers and an altered F-actin staining pattern in the transfected cells. Studies using a deletion mutant showed that both the PEBP2 beta/CBF beta and SMMHC domains are necessary for the induction of the morphological alteration, A significant proportion of the chimeric protein was retained in the cytoskeleton after detergent extraction of the cells and could be recuperated as a membrane fraction, suggesting that this is one of the probable sites of action of the PEBP2 beta/CBF beta-SMMHC protein. Another effect of the chimeric protein was inhibition of transcriptional activation dependent on the PEBP2/CBF binding DNA sequence. However, deregulation of PEBP2/CBF site dependent transcription by itself was not sufficient to induce cell morphological changes. Taken together, these results indicate that the PEBP2 beta/CBF beta-SMMHC chimeric protein acts at two levels, at the level of stress fiber organization and at the level of transcriptional activation. We suggest that the action of PEBP2 beta/CBF beta-SMMHC depends to a great extent on whether it is located in the cytoplasm or in the nucleus.	Tohoku Univ, Sch Med, Dept Surg 2, Aoba Ku, Sendai, Miyagi 98077, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 60601, Japan; Tohoku Univ, Dept Mol Immunol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 98077, Japan	Tohoku University; Kyoto University; Tohoku University	Satake, M (corresponding author), Tohoku Univ, Dept Mol Immunol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 98077, Japan.							Aelst L, 1997, GENE DEV, V11, P2295; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; CLAXTON DF, 1994, BLOOD, V83, P1750; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ERICKSON P, 1992, BLOOD, V80, P1825; Frank R, 1995, ONCOGENE, V11, P2667; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; LENNY N, 1995, ONCOGENE, V11, P1761; Leung T, 1996, MOL CELL BIOL, V16, P5313; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; LU J, 1995, MOL CELL BIOL, V15, P1651; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sacchi N, 1996, ONCOGENE, V12, P437; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SALGIA R, 1995, ONCOGENE, V11, P1149; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Tanaka Y, 1997, ONCOGENE, V15, P677, DOI 10.1038/sj.onc.1201235; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; YANAGISAWA K, 1991, BLOOD, V78, P451; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	55	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					699	708		10.1038/sj.onc.1201985	http://dx.doi.org/10.1038/sj.onc.1201985			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715271				2022-12-28	WOS:000075337200004
J	Pierce, A; Owen-Lynch, PJ; Spooncer, E; Dexter, TM; Whetton, AD				Pierce, A; Owen-Lynch, PJ; Spooncer, E; Dexter, TM; Whetton, AD			P210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia	ONCOGENE			English	Article						Bcr-Abl; chronic myeloid leukaemia; stem cell line	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; PHILADELPHIA-CHROMOSOME; TRANSFORMATION; GROWTH; PROTEIN; GENE; PROLIFERATION; INTERLEUKIN-3; CONSEQUENCES	Chronic myeloid leukaemia (CML) is a clonal disorder of the pluripotent haemopoietic stem cell, the hallmark of which is the constitutively activated Bcr-Abl protein tyrosine kinase. During the initial chronic phase of CML the primitive multipotent leukaemic progenitor cells remain growth factor dependant and are capable of producing terminally differentiated cells. Although the available evidence suggests that Bcr-Abl directly affects signalling pathways involved in controlling the development of primitive haemopoietic progenitors the identification of the specific biological consequences of Bcr - Abl activity in these progenitors has been hampered by the lack of suitable systems modelling CML, By transfecting the multipotent haemopoietic cell line FDCP-Mix with a temperature sensitive mutant of Bcr-Abl we have developed the first working model that mirrors the chronic phase of CML, FDCP-Mix cells expressing Bcr-Abl tyrosine kinase activity remain growth factor dependent and retain their ability to differentiate. Normal neutrophilic cells are formed in response to CSF and GM-CSF, In addition, the transfected FDCP-Mix cells grown at the permissive temperature for Bcr-Abl tyrosine kinase activity display enhanced survival and proliferation in low concentrations of growth factor, These findings are consistent with the initial subtle changes seen in CML progenitor cells during the chronic phase and confirm that Bcr-Abl effects are context specific, i.e, they depend on the origin and developmental potential of the transfected cells, This questions the significance of studies in non-haemopoietic and differentiation blocked haemopoietic cells.	Univ Manchester, Leukaemia Res Fund Cellular Dev Unit, Manchester M60 1QD, Lancs, England; Univ Manchester, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Expt Haematol, Manchester M20 9BX, Lancs, England	University of Manchester; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Whetton, AD (corresponding author), Univ Manchester, Leukaemia Res Fund Cellular Dev Unit, Sackville St, Manchester M60 1QD, Lancs, England.			WHETTON, ANTHONY D/0000-0002-1098-3878; Owen-Lynch, Penelope Jane/0000-0002-5928-2327; Pierce, Andrew/0000-0001-5995-2469				BEDI A, 1994, BLOOD, V83, P2038; CARLESSO N, 1994, ONCOGENE, V9, P149; CLARKSON B, 1993, LEUKEMIA, V7, P1683; COTTER TG, 1995, LEUKEMIA LYMPHOMA, V18, P231, DOI 10.3109/10428199509059612; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; DALEY GQ, 1991, ADV CANCER RES, V57, P151; Eaves C, 1985, Prog Clin Biol Res, V184, P403; EAVES C, 1994, BLOOD CELLS, V20, P83; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Gotoh A, 1997, Curr Opin Hematol, V4, P3; Hariharan I K, 1988, Oncogene Res, V3, P387; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LANEUVILLE P, 1992, BLOOD, V80, P1788; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; RASKIND WH, 1987, ADV CANCER RES, V49, P127, DOI 10.1016/S0065-230X(08)60796-4; SAWYERS CL, 1993, LEUKEMIA LYMPHOMA, V11, P101, DOI 10.3109/10428199309064268; SCHERLE PA, 1990, P NATL ACAD SCI USA, V87, P1908, DOI 10.1073/pnas.87.5.1908; SPOONCER E, 1994, LEUKEMIA, V8, P620; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; WANG J Y J, 1992, Current Biology, V2, P70, DOI 10.1016/0960-9822(92)90198-J; WETZLER M, 1993, LEUKEMIA LYMPHOMA, V11, P47, DOI 10.3109/10428199309047863; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	30	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	1998	17	5					667	672		10.1038/sj.onc.1201969	http://dx.doi.org/10.1038/sj.onc.1201969			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704934				2022-12-28	WOS:000075195300016
J	Naruse, K; Yamada, T; Sai, XR; Hamaguchi, M; Sokabe, M				Naruse, K; Yamada, T; Sai, XR; Hamaguchi, M; Sokabe, M			Pp125(FAK) is required for stretch dependent morphological response of endothelial cells	ONCOGENE			English	Article						uni-axial cyclic stretch; HVJ-liposome; antisense phosphorothioate oligodeoxynucleotides; stretch-activated ion channel	PROTEIN-TYROSINE KINASE; ACTIVATED ION CHANNELS; FOCAL ADHESIONS; HERBIMYCIN-A; PHOSPHORYLATION; ANTIBODIES; INHIBITOR; PAXILLIN; VINCULIN	In this study, critical signaling pathway required for the stretch induced morphological changes of human umbilical endothelial cells (HUVECs) was investigated. Uniaxial cyclic stretch (1 Hz, 20% in length) of the cells cultured on an elastic silicon membrane induced a gradual morphological change in the cells from a polygonal shape to an elongated spindle-like shape whose long axis was aligned perpendicular to the stretch axis, We found that protein tyrosine phosphorylation of cellular proteins increased and peaked at 20 min in response to cyclic stretch. Either treatment of cells with gadolinium (Gd3+), a potent blocker for stretch-activated channels, or removal of extracellular Ca2+ blocked the tyrosine phosphorylation of the proteins, suggesting that stretch-activated (SA) ion channels regulated stretch specific tyrosine phosphorylation, The major phosphorylated proteins had molecular masses of approximately 120-135 kDa, and 70 kDa, Immunoprecipitation experiments revealed that paxillin, focal adhesion kinase (pp125(FAK)) and pp130(CAS) were included in the 70 kDa and 120-135 kDa bands, respectively, The morphological change was inhibited by herbimycin A and genistein, inhibitors of tyrosine kinases, suggesting that tyrosine phosphorylation was required for the morphological change, In addition, the kinase activation of pp125(FAK) was observed in response to cyclic stretch, Moreover, suppression of pp125(FAK) expression by the antisense phosphorothioate oligodeoxynucleotides (S-ODN) in HUVECs resulted in inhibition of tyrosine phosphorylation of paxillin and the stretch-dependent morphological changes. These results suggest that an activation of tyrosine kinase(s) by an increase in intracellular Ca2+ and pp125(FAK) play a critical role in the unique morphological change specifically observed in endothelial cells subjected to uni-axial cyclic stretch.	Nagoya Univ, Sch Med, Dept Physiol, Showa Ku, Nagoya, Aichi 466, Japan; Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Showa Ku, Nagoya, Aichi 466, Japan	Nagoya University; Nagoya University	Naruse, K (corresponding author), Nagoya Univ, Sch Med, Dept Physiol, Showa Ku, 65 Tsuramai Cho, Nagoya, Aichi 466, Japan.		NARUSE, Keiji/B-1620-2011; Sokabe, Masahiro/I-1565-2012	naruse, keiji/0000-0003-4100-6444				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BIALECKI RA, 1992, AM J PHYSIOL, V263, pL602, DOI 10.1152/ajplung.1992.263.5.L602; BOWMAN CL, 1992, BRAIN RES, V584, P272, DOI 10.1016/0006-8993(92)90906-P; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CEMERIKIC D, 1993, AM J PHYSIOL, V264, pF697, DOI 10.1152/ajprenal.1993.264.4.F697; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; FRANKE RP, 1984, NATURE, V307, P648, DOI 10.1038/307648a0; GRIMBRONE MA, 1976, PROGR HEMOSTASIS THR, P1; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; IBA T, 1991, MICROVASC RES, V42, P245, DOI 10.1016/0026-2862(91)90059-K; ILLE D, 1995, NATURE, V377, P539; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MASUDA M, 1990, MORPHOGENESIS FUNCTI, P325; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; NARUSE K, 1998, IN PRESS AM J PHYSL; OHMORI H, 1985, J PHYSIOL-LONDON, V359, P189, DOI 10.1113/jphysiol.1985.sp015581; Okada Y, 1990, Neurosci Res Suppl, V12, pS5, DOI 10.1016/0921-8696(90)90004-M; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SHIRINSKY VP, 1989, J CELL BIOL, V109, P331, DOI 10.1083/jcb.109.1.331; SOKABE M, 1997, PROGR CELL RES, V6, P139; TURNER CE, 1989, J BIOL CHEM, V264, P11938; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	36	87	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	1998	17	4					455	463		10.1038/sj.onc.1201950	http://dx.doi.org/10.1038/sj.onc.1201950			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696039				2022-12-28	WOS:000075043000008
J	Sithanandam, G; Ramakrishna, G; Diwan, BA; Anderson, LM				Sithanandam, G; Ramakrishna, G; Diwan, BA; Anderson, LM			Selective mutation of K-ras by N-ethylnitrosourea shifts from codon 12 to codon 61 during fetal mouse lung maturation	ONCOGENE			English	Article						fetal lung; lung tumor; gestation stage; N-ethylnitrosourea; K-ras; mutation; K-ras p21	ONCOGENE ACTIVATION; GENE-MUTATIONS; DNA-DAMAGE; A/J MICE; TUMORS; 1-ETHYL-1-NITROSOUREA; CARCINOGENESIS; ADENOCARCINOMA; NITROSAMINES; MUTAGENESIS	Fetal mouse lung before gestation day 17 shows unique sensitivity to causation of rapidly growing tumors by N-ethylnitrosourea (ENU). Since mouse lung tumors present a mutated K-ras oncogene, we hypothesized that this special susceptibility might reflect an unusual vulnerability of the K-ras gene. Of the lung tumors caused by ENU exposure of BALB/c mice on gestation day 14, 8/25 had a codon 12 mutation in K-ras, vs 4/25 in codon 61, Of 15 tumors after day 16 exposure, three had codon 12 and four codon 61 changes. Tumors from day 18 exposure had only codon 61 mutations (11/16), all A:T to G:C changes (CGA), By contrast, codon 12 (GGT) changes included G:C to T:A, to A:T,and to C:G, These results show significant (P<0.01) shift in the sensitivity of particular K-ras codons to ENU mutation, during fetal mouse lung maturation. In a test of a possible relationship to expression of K-ras, K-ras p21 was measured in lungs of fetal mice, and found to increase markedly on day 18 in comparison to days 14 and 16, Both alkylation of DIVA and base damage due to reactive oxygen species are postulated as mechanisms for mutation by ENU, whose efficacies vary with state of fetal lung maturation and K-rns expression.	SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA; NCI, Comparat Carcinogenesis Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Sithanandam, G (corresponding author), SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA.							AHOTUPA M, 1987, BIOCHEM BIOPH RES CO, V146, P1047, DOI 10.1016/0006-291X(87)90753-4; AKASAKA S, 1994, MUTAT RES-DNA REPAIR, V315, P105, DOI 10.1016/0921-8777(94)90011-6; ANDERSON LM, 1989, FUND APPL TOXICOL, V12, P604, DOI 10.1016/0272-0590(89)90033-X; ANDERSON LM, 1985, NEW APPROACHES TOXIC, P179; Bal W, 1996, CHEM RES TOXICOL, V9, P535, DOI 10.1021/tx950157i; BARTSCH H, 1989, FREE RADICAL BIO MED, V7, P637, DOI 10.1016/0891-5849(89)90144-5; BRANSTETTER DG, 1987, CANCER RES, V47, P348; BRANSTETTER DG, 1988, CANCER RES, V48, P379; CHUNG FL, 1992, CARCINOGENESIS, V13, P1269, DOI 10.1093/carcin/13.7.1269; CORREA P, 1983, LANCET, V2, P595; Driscoll KE, 1997, CARCINOGENESIS, V18, P423, DOI 10.1093/carcin/18.2.423; Enright H, 1996, CARCINOGENESIS, V17, P1175, DOI 10.1093/carcin/17.5.1175; FRENKEL K, 1992, PHARMACOL THERAPEUT, V53, P127, DOI 10.1016/0163-7258(92)90047-4; Hanawalt PC, 1996, ENVIRON HEALTH PERSP, V104, P547, DOI 10.2307/3432821; Harty LC, 1996, CANCER EPIDEM BIOMAR, V5, P997; HILL DL, 1975, CANCER RES, V35, P296; Hoffmann D, 1996, CRIT REV TOXICOL, V26, P199, DOI 10.3109/10408449609017931; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; Horio Y, 1996, MOL CARCINOGEN, V17, P217, DOI 10.1002/(SICI)1098-2744(199612)17:4<217::AID-MC5>3.0.CO;2-A; HUANG X, 1995, CARCINOGENESIS, V16, P1753, DOI 10.1093/carcin/16.8.1753; Ichikawa T, 1996, CANCER LETT, V107, P165, DOI 10.1016/0304-3835(96)04351-0; JACKSON JH, 1997, ONCOGENE, V14, P2083; KAMIYA H, 1995, CARCINOGENESIS, V16, P833; KAUFFMAN SL, 1976, J NATL CANCER I, V57, P821, DOI 10.1093/jnci/57.4.821; KAWANO R, 1995, JPN J CANCER RES, V86, P802, DOI 10.1111/j.1349-7006.1995.tb03089.x; Keohavong P, 1996, CLIN CANCER RES, V2, P411; LEPAGE F, 1995, CARCINOGENESIS, V16, P2779; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MALKINSON AM, 1992, CANCER RES, V52, pS2670; Marker PC, 1997, GENETICS, V145, P435; MATZINGER SA, 1994, MOL CARCINOGEN, V11, P42, DOI 10.1002/mc.2940110108; Mooney LA, 1997, CARCINOGENESIS, V18, P503, DOI 10.1093/carcin/18.3.503; Munoz EF, 1996, CARCINOGENESIS, V17, P2741, DOI 10.1093/carcin/17.12.2741; Nakae D, 1997, CANCER RES, V57, P1281; OHMORI H, 1992, CARCINOGENESIS, V13, P851, DOI 10.1093/carcin/13.5.851; Ramakrishna G, 1998, CARCINOGENESIS, V19, P463, DOI 10.1093/carcin/19.3.463; RE FC, 1992, MOL CARCINOGEN, V5, P155, DOI 10.1002/mc.2940050211; REHM S, 1991, TOXICOL PATHOL, V19, P35, DOI 10.1177/019262339101900105; REID TM, 1994, ENVIRON HEALTH PERSP, V102, P57, DOI 10.2307/3431764; RICE JM, 1969, ANN NY ACAD SCI, V163, P813, DOI 10.1111/j.1749-6632.1969.tb24900.x; RICE JM, 1969, TRANSPLACENTAL CARCI, P71; Rodriguez H, 1997, CANCER RES, V57, P2394; Samson L, 1997, CARCINOGENESIS, V18, P919, DOI 10.1093/carcin/18.5.919; SHIBUYA T, 1993, MUTAT RES, V297, P3, DOI 10.1016/0165-1110(93)90005-8; SILINI EM, 1994, VIRCHOWS ARCH, V424, P367; SILLS RC, 1995, CARCINOGENESIS, V16, P1623, DOI 10.1093/carcin/16.7.1623; Sipowicz MA, 1997, CANCER LETT, V117, P87, DOI 10.1016/S0304-3835(97)00208-5; STORM SM, 1993, TOXICOL LETT, V67, P201, DOI 10.1016/0378-4274(93)90056-4; THOMALE J, 1994, J BIOL CHEM, V269, P1681; Thrane EV, 1997, EXP LUNG RES, V23, P35, DOI 10.3109/01902149709046046; VESSELINOVITCH S D, 1973, P14; WARNER RL, 1995, AM J RESP CELL MOL, V12, P649, DOI 10.1165/ajrcmb.12.6.7539274; Westra WH, 1996, CANCER RES, V56, P2224; YOU M, 1992, CARCINOGENESIS, V13, P1583, DOI 10.1093/carcin/13.9.1583; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Ziegler RG, 1996, CANCER CAUSE CONTROL, V7, P157, DOI 10.1007/BF00115646	56	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					493	502		10.1038/sj.onc.1201958	http://dx.doi.org/10.1038/sj.onc.1201958			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696043				2022-12-28	WOS:000075043000012
J	Tang, XX; Pleasure, DE; Brodeur, GM; Ikegaki, N				Tang, XX; Pleasure, DE; Brodeur, GM; Ikegaki, N			A variant transcript encoding an isoform of the human protein tyrosine kinase EPHB2 is generated by alternative splicing and alternative use of polyadenylation signals	ONCOGENE			English	Article						ephrin; functional diversity; neurodevelopment	RECEPTOR; FAMILY; EXPRESSION; LIGAND; GENE; SEQUENCES; REGION; MOUSE; FORMS; EHK-1	We previously isolated and characterized cDNA clones of DRT (EPHB2), encoding a receptor protein-tyrosine kinase of the EPH family, Northern blot analysis showed that EPHB2 transcripts are expressed in three sizes of approximately 4, 5, and 11 kb, suggesting that these transcripts are generated by alternative splicing and/or alternative use of polyadenylation sites. To explore this possibility, we isolated additional EPHB2 cDNA clones, including clone 5K-1, by re-screening the human fetal brain cDNA library. Nucleotide sequence analysis of clone 5K-1 revealed that it represents a variant transcript of EPHB2 (EPHB2v), Relative to the EPHB2 cDNA sequence previously reported, clone 5K-1 has two coding region deletions of 3 and 93 nucleotides. Nucleotide sequence analyses of EPHB2 genomic DNA fragments corresponding to these deletions suggest that the EPHB2v transcript is generated by alternative splicing. The 3' end of clone 5K-1 contains a polyadenosine stretch preceded by a potential polyadenylation signal, which is not used to generate the EPHB2 transcript, Taken together, these data indicate that EPHB2v is generated by both alternative splicing and alternative use of polyadenylation sites. The EPHB2v protein lacks one arginine residue that resides immediately following the EPHB2 transmembrane domain, In contrast, as a result of the frame shift caused by the 93 nucleotide deletion, the C-terminus of the EPHB2v protein is longer by 70 amino acids than that of EPHB2. We also show that the human neuroblastoma cell line SY5Y and NTera-2N neurons express high levels of EPHB2 and lower levels of EPHB2v, These structural variations found between the EPHB2 and EPHB2v proteins may reflect functional heterogeneity of EPHB2.	Childrens Hosp, Div Neurol Res, Philadelphia, PA 19104 USA; Childrens Hosp, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania	Ikegaki, N (corresponding author), Childrens Hosp, Div Neurol Res, Philadelphia, PA 19104 USA.				NCI NIH HHS [F32 CA75748] Funding Source: Medline; NINDS NIH HHS [NS08075, NS25044] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA075748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS008075, P50NS008075, R01NS025044] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Connor RJ, 1995, ONCOGENE, V11, P2429; Flanagan JG, 1997, CELL, V90, P403; IKEGAKI N, 1995, HUM MOL GENET, V4, P2033, DOI 10.1093/hmg/4.11.2033; Magal E, 1996, J NEUROSCI RES, V43, P735, DOI 10.1002/(SICI)1097-4547(19960315)43:6<735::AID-JNR10>3.0.CO;2-X; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PROUDFOOT N, 1982, NATURE, V298, P516, DOI 10.1038/298516a0; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SAJJADI FG, 1991, NEW BIOL, V3, P769; TAHIRA T, 1990, ONCOGENE, V5, P97; TAYLOR V, 1994, NEUROSCIENCE, V63, P163, DOI 10.1016/0306-4522(94)90014-0; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xing YD, 1996, BIOTECHNIQUES, V21, P186	17	7	10	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					521	526		10.1038/sj.onc.1201960	http://dx.doi.org/10.1038/sj.onc.1201960			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696046				2022-12-28	WOS:000075043000015
J	Huang, P				Huang, P			Excision of mismatched nucleotides from DNA: a potential mechanism for enhancing DNA replication fidelity by the wild-type p53 protein	ONCOGENE			English	Article						p53; 3 '-> 5 ' exonuclease; DNA replication fidelity; nucleotide excision	C-TERMINAL DOMAIN; POLYMERASE-ALPHA; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; INVITRO REPLICATION; T-ANTIGEN; CELLS; EPSILON; CYTOTOXICITY; DELTA	The tumor suppressor p53 plays a critical role in the regulation of the cell cycle and the maintenance of genetic stability. The 3'-->5' exonuclease activity of p53 has recently been recognized as a novel biochemical function of this molecule, but the biological significance of this activity remains elusive. Using an in vitro DNA replication assay with purified human DNA polymerases, p53 protein, and defined DNA primer/templates, we demonstrated that the wild-type (wt) p53 protein, but not the mutant p53 protein, specifically enhanced the DNA replication fidelity of polymerase (pol) alpha, an enzyme that lacks 3'-->5' exonuclease activity. The misincorporation of non-complementary deoxynucleotides into DNA by pol alpha was substantially decreased by p53. In contrast, wt p53 showed no significant effect on replication fidelity or the rates of DNA synthesis by human pol epsilon or the bacterial enzyme pol I. Inhibition of 3'-->5' exonuclease activity by guanosine monophosphate (GMP) abolished the ability of p53 to enhance the replication fidelity of pol alpha. Quantitative analyses revealed that the 3'-->5' exonuclease activity of p53 effectively removed mismatched nucleotides from DNA in preference over matched nucleotides. Furthermore, study in intact cells revealed that the wt p53 protein was co-localized with DNA synthesis activity in S phase cells. These results suggest a possibility that the 3'-->5' exonuclease of the wt p53 protein might provide the proof-reading function for DNA pol alpha. The preferential excision of mismatched nucleotides from the replicating DNA strand appears to be a potential biochemical mechanism by which p53 enhances DNA replication fidelity and thereby helps to maintain genomic integrity.	Univ Texas, Md Anderson Canc Ctr, Dept Clin Invest, Sect Mol & Cellular Pharmacol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Huang, P (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Clin Invest, Sect Mol & Cellular Pharmacol, Houston, TX 77030 USA.				NCI NIH HHS [CA28596, CA77339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA077339, R01CA028596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Arita D, 1997, JPN J CANCER RES, V88, P39, DOI 10.1111/j.1349-7006.1997.tb00299.x; BAKER CH, 1991, J MED CHEM, V34, P1879, DOI 10.1021/jm00110a019; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BOYER JC, 1993, CANCER RES, V53, P3270; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CLARKE AR, 1994, ONCOGENE, V9, P1767; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; COX LS, 1991, CELL, V66, P271, DOI 10.1016/0092-8674(91)90617-8; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ECKERT KA, 1993, NUCLEIC ACIDS RES, V21, P5212, DOI 10.1093/nar/21.22.5212; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GANDHI V, 1990, CANCER RES, V50, P3675; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HUANG P, 1991, CANCER RES, V51, P6110; Huang P, 1997, CANCER RES, V57, P3407; HUANG P, 1990, J BIOL CHEM, V265, P16617; HUANG P, 1991, MOL PHARMACOL, V39, P449; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERRIL CR, 1990, METHOD ENZYMOL, V182, P477; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; Miller SD, 1997, MOL CELL BIOL, V17, P2194, DOI 10.1128/MCB.17.4.2194; MILLS AD, 1989, J CELL SCI, V94, P471; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NEVINS JR, 1992, SCIENCE, V258, P424; Peled A, 1996, CANCER RES, V56, P2148; PENG H, 1995, AM J PATHOL, V148, P643; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; Staib C, 1996, VIROLOGY, V219, P237, DOI 10.1006/viro.1996.0241; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; vanLaar T, 1996, CYTOMETRY, V25, P21, DOI 10.1002/(SICI)1097-0320(19960901)25:1<21::AID-CYTO3>3.0.CO;2-H; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	62	68	71	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					261	270		10.1038/sj.onc.1201946	http://dx.doi.org/10.1038/sj.onc.1201946			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690508				2022-12-28	WOS:000074947500001
J	Song, JS; Swann, PG; Szallasi, Z; Blank, U; Blumberg, PM; Rivera, J				Song, JS; Swann, PG; Szallasi, Z; Blank, U; Blumberg, PM; Rivera, J			Tyrosine phosphorylation-dependent and -independent associations of protein kinase C-delta with Src family kinases in the RBL-2H3 mast cell line: regulation of Src family kinase activity by protein kinase C-delta	ONCOGENE			English	Article						PKC-delta; Src; Lyn; mast cell; Fc epsilon RI	HIGH-AFFINITY RECEPTOR; FOCAL ADHESION KINASE; BASOPHILIC LEUKEMIA-CELLS; N-TERMINAL REGION; IGE-RECEPTOR; IMMUNOGLOBULIN-E; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; CROSS-LINKING; GAMMA-CHAIN	Src kinases and protein kinase C (PKC) have been well studied for their role in oncogenic and normal cellular processes. Herein we report on a novel regulatory pathway mediated by the interaction of PKC-delta with p53/56(Lyn) (Lyn) and with p6o(Src) (Src) that results in the phosphorylation and increased activity of Lyn and Src, In the RBL-2H3 mast cell line, the interaction of PKC-delta with Lyn required the activation of the high affinity receptor for IgE (Fc epsilon RI) while the interaction with Src was constitutive. Increased complex formation of PKC-delta with Lyn or Src led to increased serine phosphorylation and activity of the Src family kinases, Conversely, Lyn was found to phosphorylate Lyn-associated and recombinant PKC-delta in vitro and the tyrosine 52 phosphorylated PKC-delta was recruited to associate with the Lyn SH2 domain. The constitutive association of PKC-delta with Src did not result in the tyrosine phosphorylation of PKC-delta prior to or after Fc epsilon RI engagement, However in cells over-expressing PKC-delta, Fc epsilon RI engagement resulted in the dramatic inhibition of Src activity and some inhibition of Lyn activity, Thus, the interaction and cross-talk of PKC-delta with Src family kinases suggests a novel and inter-dependent mechanism for regulation of enzymatic activity that may serve an important role in cellular responses.	NIAMS, Sect Chem Immunol, Bethesda, MD 20892 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; Inst Pasteur, F-75724 Paris 15, France	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Rivera, J (corresponding author), NIAMS, Sect Chem Immunol, Bethesda, MD 20892 USA.			Blank, Ulrich/0000-0002-2661-2983; Szallasi, Zoltan/0000-0001-5395-7509				ALEXANDER D R, 1990, New Biologist, V2, P1049; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CHACKALAPARAMPIL I, 1994, ONCOGENE, V9, P1947; Chang EY, 1997, J IMMUNOL, V159, P2624; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Draberova L, 1996, IMMUNOLOGY, V87, P141; EISEMAN E, 1992, NATURE, V355, P78; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FURUICHI K, 1984, J IMMUNOL, V133, P1513; Galron D, 1997, CELL IMMUNOL, V178, P141, DOI 10.1006/cimm.1997.1120; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; Holowka D, 1996, ANNU REV BIOPH BIOM, V25, P79; JOUNG I, 1995, P NATL ACAD SCI USA, V92, P5778, DOI 10.1073/pnas.92.13.5778; Kawakami Y, 1996, IMMUNOL LETT, V54, P113, DOI 10.1016/S0165-2478(96)02659-4; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; LAROSE L, 1995, J BIOL CHEM, V270, P3858, DOI 10.1074/jbc.270.8.3858; Lee JE, 1997, J IMMUNOL, V159, P61; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIU F, 1994, BIOCHEM BIOPH RES CO, V200, P1570, DOI 10.1006/bbrc.1994.1630; LIU FT, 1980, J IMMUNOL, V124, P2728; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MAO SY, 1995, BIOCHEMISTRY-US, V34, P1968, DOI 10.1021/bi00006a018; Mayer BJ, 1997, CURR BIOL, V7, pR295, DOI 10.1016/S0960-9822(06)00141-2; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; Moriya K, 1997, P NATL ACAD SCI USA, V94, P12539, DOI 10.1073/pnas.94.23.12539; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; Pathan NI, 1996, J BIOL CHEM, V271, P27517, DOI 10.1074/jbc.271.44.27517; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; SCHARENBERG AM, 1995, CHEM IMMUNOL, V61, P72; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Singer WD, 1996, J BIOL CHEM, V271, P4504; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; Song JS, 1996, J BIOL CHEM, V271, P26962, DOI 10.1074/jbc.271.43.26962; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yuan ZM, 1996, ONCOGENE, V13, P939; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	65	98	100	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3357	3368		10.1038/sj.onc.1201886	http://dx.doi.org/10.1038/sj.onc.1201886			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692543				2022-12-28	WOS:000074544100002
J	Takahashi, K; Sasaki, T; Mammoto, A; Hotta, I; Takaishi, K; Imamura, H; Nakano, K; Kodama, A; Takai, Y				Takahashi, K; Sasaki, T; Mammoto, A; Hotta, I; Takaishi, K; Imamura, H; Nakano, K; Kodama, A; Takai, Y			Interaction of radixin with Rho small G protein GDP/GTP exchange protein Dbl	ONCOGENE			English	Article						Rho; ERM; Dbl; Rho GEP; Rho GDI	GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEIN; GDP-DISSOCIATION INHIBITOR; SIGNAL-TRANSDUCTION; ONCOGENE PRODUCT; STRUCTURAL SIMILARITIES; HEMATOPOIETIC-CELLS; EXPRESSION CLONING; MEMBRANE; FAMILY	The Rho small G protein family, consisting of the Rho, Rac, and Cdc42 subfamilies, regulates various actin cytoskeleton-dependent cell functions. The Rho subfamily members regulate ERM (ezrin, radixin and moesin)dependent association of the actin cytoskeleton,vith the plasma membrane. Moreover, the N-terminal regions of ERM interact with Rho GDI, an inhibitory regulator of all the Rho family members, and reduce its inhibitory action, finally initiating the activation of the Rho family members. We show here that the N-terminal region of radixin furthermore interacts with DM, a stimulatory GDP/GTP exchange protein of the Rho family members. This interaction does not affect the Dbl activity to stimulate the GDP/GTP exchange reaction of RhoA, a member of the Rho subfamily. DM does not interact with radixin which is precomplexed with Rho GDI, and Rho GDI displaces Dbl from radixin. Thus, radixin plays an important role in activation of the Rho family members by recruiting their positive and negative regulators.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 565, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 565, Japan.							Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; ANDREOLI C, 1994, J CELL SCI, V107, P2509; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; GRAZIANI G, 1989, ONCOGENE, V4, P823; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; PASTERIS NG, 1994, CELL, V79, P669; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TOKSOZ D, 1994, ONCOGENE, V9, P621; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; UEDA T, 1990, J BIOL CHEM, V265, P9373; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	48	102	102	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3279	3284		10.1038/sj.onc.1201874	http://dx.doi.org/10.1038/sj.onc.1201874			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681826				2022-12-28	WOS:000074343600008
J	Pesche, S; Latil, A; Muzeau, F; Cussenot, O; Fournier, G; Longy, M; Eng, C; Lidereau, R				Pesche, S; Latil, A; Muzeau, F; Cussenot, O; Fournier, G; Longy, M; Eng, C; Lidereau, R			PTEN/MMAC1/TEP1 involvement in primary prostate cancers	ONCOGENE			English	Article						prostate cancer; chromosome arm 10q; LOH; PTEN	ALLELIC LOSS; MICROSATELLITE INSTABILITY; DISTINCT REGIONS; CHROMOSOME-10; HETEROZYGOSITY; DELETION; LOCI; GENE; PROGRESSION; ADENOCARCINOMA	The PTEN/MMAC1/TEP1 gene, located at 10q23.3, is a tumor suppressor gene responsible for the familial cancer syndromes Cowden disease and Bannayan-Zonana syndrome, and is commonly somatically mutated in several types of cancers. Mutations of the PTEN gene have been found in prostate cancer cell lines and LOH at 10q22-24 in prostate tumors have also been described with a high frequency. To determine the role of this gene in prostate tumorigenesis, we therefore analysed 22 primary tumors for loss of heterozygosity (LOH) within the 10q22-23 region such that tumors hemizygous at those loci may be examined for somatic PTEN mutations. Losses of heterozygosity of at least one locus was found in 12 (55%) of the 22 tumors DNAs. Among these, six tumors exhibited allele loss in the interval between D10S1765 and D10S541 wherein lies the PTEN gene. We searched the entire coding region of PTEN for somatic mutations in these six tumors. One somatic mutation (17%), a 1 bp deletion, was detected in exon 7 of the gene, in ode tumor, indicating that somatic mutations of the PTEN gene may occur in primary prostate tumors.	Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France; CHU St Louis, Dept Urol, F-75010 Paris, France; Hop Cavale Blanche, Dept Urol, F-29609 Brest, France; Ctr Reg Lutte Canc, Inst Bergonie, F-33076 Bordeaux, France; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England	Rene Huguenin Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Brest; Universite de Bretagne Occidentale; UNICANCER; Institut Bergonie; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Cambridge	Lidereau, R (corresponding author), Ctr Rene Huguenin, Lab Oncogenet, 9 Rue Gaston Latouche, F-92211 St Cloud, France.			Eng, Charis/0000-0002-3693-5145; cussenot, olivier/0000-0002-9912-0533				ALBRECHT S, 1992, CANCER-AM CANCER SOC, V70, P869, DOI 10.1002/1097-0142(19920815)70:4<869::AID-CNCR2820700424>3.0.CO;2-E; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOVA GS, 1993, CANCER RES, V53, P3869; CAIRNS P, 1994, CANCER RES, V54, P1422; Cairns P, 1997, CANCER RES, V57, P4997; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cooney KA, 1996, CANCER RES, V56, P1142; DAHIA PLM, IN PRESS CANC RES; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; GAO X, 1995, CANCER RES, V55, P1002; GRAY IC, 1995, CANCER RES, V55, P4800; Guldberg P, 1997, CANCER RES, V57, P3660; HERBST RA, 1994, CANCER RES, V54, P3111; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; Ittmann M, 1996, CANCER RES, V56, P2143; KARLBOM AE, 1993, HUM GENET, V92, P169; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Lacombe L, 1996, INT J CANCER, V69, P110, DOI 10.1002/(SICI)1097-0215(19960422)69:2<110::AID-IJC7>3.0.CO;2-3; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; Marsh DJ, 1997, CANCER RES, V57, P500; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MELLINGER GT, 1967, J UROLOGY, V97, P331, DOI 10.1016/S0022-5347(17)63039-8; MORITA R, 1991, CANCER RES, V51, P5817; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEIFFER SL, 1995, CANCER RES, V55, P1922; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; REMPEL SA, 1993, CANCER RES, V53, P2386; Rhei E, 1997, CANCER RES, V57, P3657; SCHRODER FH, 1992, PROSTATE, P129; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki H, 1998, CANCER RES, V58, P204; Tashiro H, 1997, CANCER RES, V57, P3935; Trybus TM, 1996, CANCER RES, V56, P2263; WATANABE M, 1995, BRIT J CANCER, V72, P562, DOI 10.1038/bjc.1995.374; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	46	114	121	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	1998	16	22					2879	2883		10.1038/sj.onc.1202081	http://dx.doi.org/10.1038/sj.onc.1202081			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671408				2022-12-28	WOS:000073988200006
J	Fujii, H; Biel, MA; Zhou, WB; Weitzman, SA; Baylin, SB; Gabrielson, E				Fujii, H; Biel, MA; Zhou, WB; Weitzman, SA; Baylin, SB; Gabrielson, E			Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer	ONCOGENE			English	Article						breast cancer; methylation; tumor suppressor gene; HIC-1; chromosome 17	ALLELIC LOSS; DNA HYPERMETHYLATION; CHROMOSOME 17P13.3; MUTATIONS; 17P; PROGRESSION; CARCINOMA; PROTEIN; LOCUS; D17S5	HIC-1 (hypermethylated in cancer) is a candidate tumor suppressor gene which is located at 17p13.3, a region which frequently undergoes allelic loss in breast and other human cancers, HIC-1 is proposed to be commonly inactivated in human cancers by hypermethylation of a normally unmethylated dense CpG island which encompasses the entire gene, To study whether HIC-1 inactivation may be important to the development of breast cancer, we first measured methylation of the HIC-1 gene in normal breast ductal tissues from microdissected frozen breast tissues and from epithelial cells purified from mammoplasty specimens. Surprisingly, in all normal breast ductal tissues we found approximately equal amounts of densely methylated HIC-1 and completely unmethylated HIC-1, This is in contrast to most normal tissues, in which all copies of HIC-1 are completely unmethylated. We then evaluated 39 primary breast cancer tissues and found virtually complete methylation of the HIC-1 gene in 26 (67%) of the cases. We also found loss of heterozygosity at the telomeric portion of chromosomal arm 17p in 22 of the 26 cases with strongly methylated HIC-1, suggesting that loss of an unmethylated HIC-1 allele mag contribute to the inactivation of HIC-1 in cells with a pre-existing methylated allele, Finally, by RNase protection analysis, HIC-1 was found to be expressed in microdissected normal breast ductal tissues and unmethylated tumors but not in tumors with hypermethylation of the HIC-1 gene. These results indicate that hypermethylation of HIC-1 and associated loss of HIC-1 expression is common in primary breast cancer. Furthermore, the HIC-1 gene is densely methylated in approximately one-half of the alleles in normal breast epithelium, which may predispose this tissue to inactivation of this gene by loss of heterozygosity.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21224 USA; Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA	Johns Hopkins University; Johns Hopkins University; Northwestern University	Gabrielson, E (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21224 USA.				NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER; NCI NIH HHS [CA/ES66204, CA 43318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; Batova A, 1997, CANCER RES, V57, P832; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CAVENEE WK, 1991, CANCER, V67, P2431, DOI 10.1002/1097-0142(19910515)67:10<2431::AID-CNCR2820671005>3.0.CO;2-#; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CORNELIS RS, 1994, CANCER RES, V54, P4200; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; DENG G, 1994, CANCER RES, V54, P499; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Fujii H, 1996, CANCER RES, V56, P5260; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1997, CANCER RES, V57, P837; MAKOS M, 1993, CANCER RES, V53, P2715; MAKOS M, 1993, CANCER RES, V53, P2719; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MAKOSWALES M, 1995, NAT MED, V1, P570; MERLO A, 1995, NAT MED, V1, P1; MIKI T, 1994, BLOOD, V83, P26; Morton RA, 1996, J UROLOGY, V156, P512, DOI 10.1016/S0022-5347(01)65916-0; Phillips NJ, 1996, CANCER LETT, V102, P85, DOI 10.1016/0304-3835(96)04169-9; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; SATO T, 1991, CANCER RES, V51, P5794; Schultz DC, 1996, CANCER RES, V56, P1997; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107	28	129	140	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2159	2164		10.1038/sj.onc.1201976	http://dx.doi.org/10.1038/sj.onc.1201976			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572497				2022-12-28	WOS:000073177200014
J	Dahl, R; Wani, B; Hayman, MJ				Dahl, R; Wani, B; Hayman, MJ			The Ski oncoprotein interacts with Skip, the human homolog of Drosophila Bx42	ONCOGENE			English	Article						Ski oncogene	HIGH-EFFICIENCY TRANSFORMATION; CEREVISIAE CHROMOSOME-I; V-SKI; MOLECULAR ANALYSIS; ESCHERICHIA-COLI; CDNA CLONES; SGS-4 GENE; ONCOGENE; CELLS; DNA	The v-Ski avian retroviral oncogene is postulated to act as a transcription factor. Since protein-protein interactions have been shown to play an important role in the transcription process, we attempted to identify Ski protein partners with the yeast two-hybrid system, Using v-Ski sequence as bait, the human gene skip (Ski Interacting Protein) was identified as encoding a protein which interacts with both the cellular and viral forms of Ski in the two-hybrid system, Skip is highly homologous to the Drosophila melanogaster protein Bx42 which is found associated with chromatin in transcriptionally active puffs of salivary glands, The Ski-Skip interaction is potentially important in Ski's transforming activity since Skip was demonstrated to interact with a highly conserved region of Ski required for transforming activity, Like Ski, Skip is expressed in multiple tissue types and is localized to the cell nucleus.	SUNY Stony Brook, Dept Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Microbiol, Stony Brook, NY 11794 USA.			Dahl, Richard/0000-0002-6341-5604	NATIONAL CANCER INSTITUTE [R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; BARTEL PL, 1993, CELL INTERACTIONS DE; BEUG H, 1995, ONCOGENE, V11, P59; BOGUSKI MS, 1995, TRENDS BIOCHEM SCI, V20, P295, DOI 10.1016/S0968-0004(00)89051-9; BOYER PL, 1993, ONCOGENE, V8, P457; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Colmenares C, 1990, Semin Cancer Biol, V1, P383; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; DIEHL BE, 1991, GENETICS, V127, P287; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; Folk P, 1996, GENE, V181, P229, DOI 10.1016/S0378-1119(96)00483-0; FRASCH M, 1989, CHROMOSOMA, V97, P272, DOI 10.1007/BF00371966; HARRIS SD, 1992, J MOL BIOL, V225, P53, DOI 10.1016/0022-2836(92)91025-K; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KAUFMAN RJ, 1985, MOL CELL BIOL, V5, P1750, DOI 10.1128/MCB.5.7.1750; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LARSEN J, 1992, ONCOGENE, V7, P1903; LEHMANN M, 1995, EMBO J, V14, P716, DOI 10.1002/j.1460-2075.1995.tb07050.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Park CY, 1996, GENE, V177, P93, DOI 10.1016/0378-1119(96)00278-8; Romero F, 1996, MOL CELL BIOL, V16, P37; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUMWEBER H, 1990, CHROMOSOMA, V99, P52, DOI 10.1007/BF01737289; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SLEEMAN JP, 1993, ONCOGENE, V8, P67; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831	43	96	111	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1579	1586		10.1038/sj.onc.1201687	http://dx.doi.org/10.1038/sj.onc.1201687			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569025				2022-12-28	WOS:000072743200008
J	Habib, AA; Gulcher, JR; Hognason, T; Zheng, LY; Stefansson, K				Habib, AA; Gulcher, JR; Hognason, T; Zheng, LY; Stefansson, K			The OMgp gene, a second growth suppressor within the NF1 gene	ONCOGENE			English	Article						Oligodendrocyte-Myelin glycoprotein; OMgp; neurofibromin; growth suppressor; NIH3T3 fibroblasts; PDGF signaling	NEUROFIBROMATOSIS TYPE-1 GENE; OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; PROTEIN-TYROSINE KINASES; NIH 3T3 CELLS; SIGNAL-TRANSDUCTION; SRC-FAMILY; SCHWANN-CELLS; T-CELLS; RAS; PHOSPHORYLATION	The Oligodendrocyte-Myelin glycoprotein gene (OMgp) is placed within an intron of the NF1 gene, Neurofibromin, the product of NF1, acts as a RasGAP and suppresses growth; inactivating mutations in NF1 lead to neurofibromatosis type 1. We report that OMgp also has growth suppressive effects and downregulates mitogenic signaling pathways closely related to those influenced by neurofibromin. Overexpression of OMgp alters mitogenic signaling in NIH3T3 fibroblasts. Cells overexpressing OMgp grow more slowly in serum compared to controls and show a partial G(1) block upon cell cycle analysis, PDGF is the primary mitogen for fibroblasts in serum, Overexpression of OMgp alters PDGF signaling in fibroblasts which results in a block of mitogenic signaling, PDGF induced activation of c-Src is blocked, as is the induction of c-Myc and c-Fos, while tyrosine phosphorylation of the PDGF beta receptor, PLC gamma 1 and induction of c-Jun are intact, Although a number of genes embedded within other genes have been described, the biological significance of this arrangement remains unknown, We demonstrate here that structurally unrelated products of two such genes may exercise closely related functions, Our data also raise the possibility of a role for OMgp in disorders of cell proliferation such as NF1.	Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02115 USA; DeCode Genet, IS-110 Reykjavik, Iceland	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Habib, AA (corresponding author), Harvard Univ, Sch Med, Inst Med, Room 807,77 Ave Louis Pasteur, Boston, MA 02115 USA.		Stefansson, Kari/AAE-7187-2019		NINDS NIH HHS [R0INS32977] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032977] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agarwal P, 1993, Methods Mol Biol, V15, P45, DOI 10.1385/0-89603-244-2:45; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1992, NATURE, V356, P663, DOI 10.1038/356663a0; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Cooper Jonathan A., 1993, V5, P44; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KIM HA, 1995, ONCOGENE, V11, P325; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MIKOL DD, 1993, GENOMICS, V17, P604, DOI 10.1006/geno.1993.1379; MIKOL DD, 1988, J CELL BIOL, V106, P1273, DOI 10.1083/jcb.106.4.1273; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MUIR D, 1990, ANAL BIOCHEM, V185, P377, DOI 10.1016/0003-2697(90)90310-6; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Riccardi V. M., 1992, NEUROFIBROMATOSIS PH; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VISKOCHIL D, 1991, MOL CELL BIOL, V11, P906, DOI 10.1128/MCB.11.2.906; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Weksberg R, 1996, NAT GENET, V12, P225, DOI 10.1038/ng0396-225; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	53	36	43	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1525	1531		10.1038/sj.onc.1201683	http://dx.doi.org/10.1038/sj.onc.1201683			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569019				2022-12-28	WOS:000072743200002
J	Gupta, K; Anand, G; Yin, XY; Grove, L; Prochownik, EV				Gupta, K; Anand, G; Yin, XY; Grove, L; Prochownik, EV			Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc	ONCOGENE			English	Article						Myc/Mad/leucine; zipper/helix-loop-helix	CELL-CYCLE PROGRESSION; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; OPPOSITE REGULATION; EMBRYO FIBROBLASTS; ONCOGENIC ACTIVITY; REPRESSOR SIN3; IN-VIVO; DIFFERENTIATION; MXI1	C-myc, a member of the basic helix-loop-helix-leucine zipper (bHLH-ZIP) protein family activates target in heterodimeric association with another bHLH-ZIP protein, Max. Max readily homodimerizes, competes with C-myc-Max heterodimers, and represses transcription. Four additional bHLH-ZIP proteins, Mad1, Mxi1, Mad3 and Mad4, heterodimerize with Max and also repress transcription of c-myc-responsive genes. We employed a yeast two-hybid approach to identify proteins which interact with Mxi. We identified a novel ZIP-containing protein, Mmip1 (Mad member-interacting protein 1) that strongly dimerizes with all four Mad members, but not with c-myc, Max, or with unrelated HLH proteins. The Mmip1-Mxi association is mediated by the ZIP domain of each polypeptide and is as strong or stronger than the associations between c-myc and Max or Max and Mxi1. In vitro, Mmip1 can inhibit DNA binding by Max-Mad heterodimers and, in vivo, can reverse the suppressive effects of Mad proteins on c-myc functions. Mmip1 is found in a variety of cells types, is induced by serum stimulation, and can be co-immunoprecipitated from fibroblasts in association with Mxi1. By interfering with the dimerization between Max and Mad family member proteins, Mmip1 can indirectly up-regulate the transcriptional activity of c-myc and suppress the antiproliferative actions of Mad proteins.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Hematol Oncol Sect, Pittsburgh, PA 15213 USA.				NHLBI NIH HHS [HL33741] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EDELHOFF S, 1994, ONCOGENE, V9, P665; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Langlands K, 1997, ANAL BIOCHEM, V249, P250, DOI 10.1006/abio.1997.2184; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LARSSON LG, 1994, ONCOGENE, V9, P1247; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MIN SY, 1992, ONCOGENE, V7, P1531; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHAPIRO DN, 1994, GENOMICS, V23, P282, DOI 10.1006/geno.1994.1496; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPENCER CA, 1991, ADV CANCER RES, V56, P1; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WECHSLER DS, 1994, GENOMICS, V21, P669, DOI 10.1006/geno.1994.1336; Zeng X, 1997, P NATL ACAD SCI USA, V94, P3673, DOI 10.1073/pnas.94.8.3673; ZERVOS, 1994, CELL, V79, P389; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZHU BY, 1993, PROTEIN SCI, V2, P383	68	24	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	1998	16	9					1149	1159		10.1038/sj.onc.1201634	http://dx.doi.org/10.1038/sj.onc.1201634			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528857				2022-12-28	WOS:000072336000006
J	DiGiovanna, MP; Lerman, MA; Coffey, RJ; Muller, WJ; Cardiff, RD; Stern, DF				DiGiovanna, MP; Lerman, MA; Coffey, RJ; Muller, WJ; Cardiff, RD; Stern, DF			Active signaling by Neu in transgenic mice	ONCOGENE			English	Article						HER-2/Neu/ErbB-2; transgenic mice; phosphorylation; breast cancer; activation; transforming growth factor-alpha (TGF alpha)	EPIDERMAL GROWTH-FACTOR; HUMAN BREAST-TUMORS; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; POINT MUTATION; MAMMARY-TUMORS; PROTOONCOGENE PRODUCT; ONCOGENIC ACTIVATION; METASTATIC DISEASE; CELLULAR-RESPONSE	Transgenic mice engineered to overexpress the HER-2/neu/erbB-2 protooncogene under the control of a mammary-specific promoter develop mammary tumors and are a model for human breast cancer. Signal transduction by Neu was examined in situ in the tumors of these transgenic mice. This was accomplished using the PN2A monoclonal antibody, which recognizes Neu only in the phosphorylated, and therefore actively signaling, state. Immunohistochemistry using PN2A demonstrated that Neu actively signals in the tumors of Neu transgenic mice. Expression of Neu was always accompanied by co-overexpression of the endogenous epidermal growth factor receptor. Qualitatively similar results were found in mammary tumors from mice bitransgenic for the neu and transforming growth factor-alpha genes (both driven by the mouse mammary tumor virus promoter). Early mammary lesions demonstrated distinctive patterns of Neu activation relative to expression levels. Overexpression and activation were separable both temporally and spatially. These results refine the multi-step model for the role of Neu in mammary neoplasia and establish phosphorylation-state specific antibodies as a powerful tool for investigating tumor progression.	Yale Univ, Sch Med, Dept Internal Med, Sect Med Oncol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06510 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; McMaster Univ, Inst Mol Biol, Hamilton, ON L8S 4K1, Canada; Univ Calif Davis, Sch Med, Dept Pathol, Livermore, CA 95616 USA	Yale University; Yale University; Yale University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; McMaster University; University of California System; University of California Davis	DiGiovanna, MP (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Med Oncol, 333 Cedar St, New Haven, CT 06510 USA.		Lerman, Melissa/AGG-2451-2022	Lerman, Melissa/0000-0003-1378-5292	NATIONAL CANCER INSTITUTE [R01CA046413, R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA45708, R01-CA46413] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DeckardJanatpour K, 1997, INT J ONCOL, V11, P235; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; DiGiovanna MP, 1996, BRIT J CANCER, V74, P802, DOI 10.1038/bjc.1996.439; DiGiovanna MP, 1997, ANAL BIOCHEM, V247, P167, DOI 10.1006/abio.1997.9919; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gulliford TJ, 1997, ONCOGENE, V15, P2219, DOI 10.1038/sj.onc.1201595; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KAPLAN PL, 1982, VIROLOGY, V123, P372, DOI 10.1016/0042-6822(82)90270-7; Krane IM, 1996, ONCOGENE, V12, P1781; LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MIKAMI Y, 1992, P NATL ACAD SCI USA, V89, P7335, DOI 10.1073/pnas.89.16.7335; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRESS MF, 1990, ONCOGENE, V5, P953; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; RIESE DJ, IN PRESS BIOESSAYS; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHIMMELPENNING H, 1992, VIRCHOWS ARCH A, V420, P433, DOI 10.1007/BF01600515; SEGATTO O, 1990, New Biologist, V2, P187; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUDA Y, 1990, EMBO J, V9, P181, DOI 10.1002/j.1460-2075.1990.tb08094.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	49	51	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1877	1884		10.1038/sj.onc.1202091	http://dx.doi.org/10.1038/sj.onc.1202091			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778054				2022-12-28	WOS:000076303300014
J	Kato, M; Takahashi, M; Akhand, AA; Liu, W; Dai, Y; Shimizu, S; Iwamoto, T; Suzuki, H; Nakashima, I				Kato, M; Takahashi, M; Akhand, AA; Liu, W; Dai, Y; Shimizu, S; Iwamoto, T; Suzuki, H; Nakashima, I			Transgenic mouse model for skin malignant melanoma	ONCOGENE			English	Article						malignant melanoma; Ret; transgenic mouse	METASTATIC CELL-LINES; MATRIX METALLOPROTEINASES; TUMOR PROGRESSION; RET; EXPRESSION; MICE; GENE; ESTABLISHMENT; ACTIVATION; MECHANISM	We report here on a novel metallothionein-I (MT)/ret transgenic mouse line in which skin melanosis, benign melanocytic tumor and malignant melanoma metastasizing to distant organs develop stepwise. The process of tumor development and its malignant transformation in this line may resemble that of the human giant congenital melanocytic nevus that is present at birth and that frequently gives rise to malignant melanoma during aging. We observed an increase in the expression level and activity of the ret transgene during the disease progression. That increase in transgene expression accompanied an activation of mitogen-activated protein kinases (MAPKs) and c-Jun as well as matrix metalloproteinases. These results suggest that progressive dysregulation of the expression level of the ret transgene might play a crucial role in the malignant transformation of melanocytic tumors developed in the MT/ret transgenic mouse line.	Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 4640021, Japan	Nagoya University; Nagoya University; Aichi Cancer Center	Nakashima, I (corresponding author), Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020; KATO, Masashi/I-7250-2014	Takahashi, Masahide/0000-0002-2803-2683; 				BALCH CM, 1989, PRINCIPLES PRACTICE, P1519; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; Chen S, 1996, J INVEST DERMATOL, V106, P1145, DOI 10.1111/1523-1747.ep12340194; CRAWFORD HC, 1994, INVAS METAST, V14, P234; DAVIES B, 1993, CANCER RES, V53, P5365; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; Iwata H, 1996, JPN J CANCER RES, V87, P602, DOI 10.1111/j.1349-7006.1996.tb00266.x; KATO M, 1994, CELL IMMUNOL, V159, P15, DOI 10.1006/cimm.1994.1291; KOH HK, 1992, TUMORS SKIN DERMATOL, P1753; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; OHMIYA N, 1995, CLIN EXP IMMUNOL, V100, P151; Pu MY, 1996, ONCOGENE, V13, P2615; Sakata K, 1996, JPN J CANCER RES, V87, P78, DOI 10.1111/j.1349-7006.1996.tb00203.x; SATO H, 1993, J BIOL CHEM, V268, P23460; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TANIGUCHI M, 1992, ONCOGENE, V7, P1491; YAMAGATA S, 1988, BIOCHEM BIOPH RES CO, V151, P158, DOI 10.1016/0006-291X(88)90573-6; YAMAMOTO K, 1989, CHEM RES TOXICOL, V2, P234, DOI 10.1021/tx00010a004	20	171	172	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1885	1888		10.1038/sj.onc.1202077	http://dx.doi.org/10.1038/sj.onc.1202077			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778055				2022-12-28	WOS:000076303300015
J	Offermanns, S; Simon, MI				Offermanns, S; Simon, MI			Genetic analysis of mammalian G-protein signalling	ONCOGENE			English	Review						G-protein; gene targeting; transgenic mouse; transmembrane signalling	CEREBELLAR PURKINJE-CELLS; LONG-TERM DEPRESSION; MICE LACKING MGLUR1; ALPHA-SUBUNITS; PHOSPHOLIPASE-C; ADENYLYL-CYCLASE; THROMBOXANE A(2); HUMAN PLATELETS; MUTANT MICE; ACTIVATION	Heterotrimeric G-proteins are important signalling proteins which function in all cells of the mammalian organism. Inactivating mutations in a variety of G-protein alpha-subunit genes in mice resulted in mostly unexpected phenotypes and have provided interesting new insight into their biological roles. Whereas the inactivation of some G alpha genes led to mild phenotypes suggesting the presence of redundant or compensatory mechanisms, other G-proteins appear to play highly specific biological or developmental roles. The purpose of this review is to summarize the current knowledge about G-protein functions based on gene-inactivation studies.	CALTECH, Div Biol 147 75, Pasadena, CA 91125 USA; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	California Institute of Technology; Free University of Berlin	Simon, MI (corresponding author), CALTECH, Div Biol 147 75, Pasadena, CA 91125 USA.		Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; Cooper G, 1997, ANNU REV MED, V48, P13, DOI 10.1146/annurev.med.48.1.13; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Gabbeta J, 1997, P NATL ACAD SCI USA, V94, P8750, DOI 10.1073/pnas.94.16.8750; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hofer D, 1996, P NATL ACAD SCI USA, V93, P6631, DOI 10.1073/pnas.93.13.6631; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Hornquist CE, 1997, J IMMUNOL, V158, P1068; HUNG DT, 1992, J BIOL CHEM, V267, P20831; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; JIANG HP, 1994, J BIOL CHEM, V269, P7593; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; Kano M, 1997, NEURON, V18, P71, DOI 10.1016/S0896-6273(01)80047-7; Kinnamon SC, 1996, CURR OPIN NEUROBIOL, V6, P506, DOI 10.1016/S0959-4388(96)80057-2; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LEE CW, 1994, J BIOL CHEM, V269, P25335; Lindemann B, 1996, CURR BIOL, V6, P1234, DOI 10.1016/S0960-9822(96)00704-X; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAYMOND JR, 1994, J BIOL CHEM, V269, P13073; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROUSTAN P, 1995, NEUROREPORT, V6, P1837, DOI 10.1097/00001756-199510020-00004; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Rudolph U, 1996, P NATL ACAD SCI USA, V93, P3209, DOI 10.1073/pnas.93.8.3209; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sowell MO, 1997, P NATL ACAD SCI USA, V94, P7921, DOI 10.1073/pnas.94.15.7921; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; SWEETON D, 1991, DEVELOPMENT, V112, P775; USHIKUBI F, 1994, MOL PHARMACOL, V46, P808; Valenzuela D, 1997, P NATL ACAD SCI USA, V94, P1727, DOI 10.1073/pnas.94.5.1727; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WEINSTEIN LS, 1993, CLIN BIOCHEM, V26, P333, DOI 10.1016/0009-9120(93)90109-J; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WILKIE TM, 1994, SOC GEN PHY, V49, P249; Wong GT, 1996, NATURE, V381, P796, DOI 10.1038/381796a0; WU DQ, 1992, J BIOL CHEM, V267, P25798; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	66	40	40	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1375	1381		10.1038/sj.onc.1202173	http://dx.doi.org/10.1038/sj.onc.1202173			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779985				2022-12-28	WOS:000076161900006
J	Zhao, JH; Inoue, T; Shoji, W; Nemoto, Y; Obinata, M				Zhao, JH; Inoue, T; Shoji, W; Nemoto, Y; Obinata, M			Direct association of YY-1 with c-Myc and the E-box binding protein in regulation of glycophorin gene expression	ONCOGENE			English	Article						c-Myc; YY-1; E-box binding protein; glycophorin; murine erythroleukemia cells	MURINE ERYTHROLEUKEMIA-CELLS; REGION-LIKE SEQUENCE; MOUSE GLYCOPHORIN; TRANSCRIPTIONAL REPRESSION; LEUCINE ZIPPER; DIFFERENTIATION; YY1; COMMITMENT; MAX; IDENTIFICATION	We previously reported that YY-1, a versatile transcription factor, regulates expression of glycophorin gene by binding to its locus control region-like region (Gp-LCR) in combination with E-box binding protein during murine erythroleukemia (MEL) cell differentiation. In the present work, we demonstrated that YY-I and c-Myc, a nuclear oncoprotein, were physically associated in vivo and that down regulation of c-Myc liberated free W-l from its complex, resulting in the functional binding of W-l to the Gp-LCR. We also showed that the E-box binding protein (EBP) which bound to E-box was physically associated with YY-1, facilitated binding of YY-I to the neighboring site and their combinatorial binding may stimulate the Gp-LCR mediated enhancement of erythroid-specific transcription of glycophorin gene in MEL cells.	Tohoku Univ, Dept Cell Biol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University	Obinata, M (corresponding author), Tohoku Univ, Dept Cell Biol, Inst Dev Aging & Canc, Aoba Ku, 4-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.		Watanabe, Mamoru/AHE-0489-2022					AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FREITAG SO, 1988, MOL CELL BIOL, V8, P1614; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GUALBERTO A, 1992, MOL CELL BIOL, V12, P38; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARUYAMA K, 1987, ONCOGENE, V1, P261; MATSUI Y, 1989, GENE, V77, P325, DOI 10.1016/0378-1119(89)90080-2; MAY M, 1994, EMBO J, V13, P1460, DOI 10.1002/j.1460-2075.1994.tb06400.x; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Nemoto Y, 1996, J BIOL CHEM, V271, P13542, DOI 10.1074/jbc.271.23.13542; OHMORI Y, 1993, ONCOGENE, V8, P379; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Shaw P E, 1994, Methods Mol Biol, V30, P79; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHOJI W, 1993, JPN J CANCER RES, V84, P885, DOI 10.1111/j.1349-7006.1993.tb02062.x; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAKADA S, 1992, JPN J CANCER RES, V83, P61, DOI 10.1111/j.1349-7006.1992.tb02352.x; TERAJIMA M, 1995, J BIOCHEM-TOKYO, V118, P593, DOI 10.1093/oxfordjournals.jbchem.a124951; TERAJIMA M, 1994, J BIOCHEM-TOKYO, V116, P1105, DOI 10.1093/oxfordjournals.jbchem.a124634; USHVA A, 1994, CELL, V76, P1115; YAMAMOTO T, 1989, CELL DIFFER DEV, V28, P129, DOI 10.1016/0922-3371(89)90049-X	46	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1009	1017		10.1038/sj.onc.1202026	http://dx.doi.org/10.1038/sj.onc.1202026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747880				2022-12-28	WOS:000075560900009
J	Giani, C; Casalini, P; Pupa, SM; De Vecchi, R; Ardini, E; Colnaghi, MI; Giordano, A; Menard, S				Giani, C; Casalini, P; Pupa, SM; De Vecchi, R; Ardini, E; Colnaghi, MI; Giordano, A; Menard, S			Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation	ONCOGENE			English	Article						c-erbB-2; oncogene; breast cancer; estrogens; proliferation; differentiation	RECEPTOR TYROSINE KINASES; NEU-ONCOGENE; RETINOBLASTOMA PROTEIN; OVARIAN-CANCER; PC12 CELLS; IN-VIVO; OVEREXPRESSION; HEREGULIN; ESTROGEN; ERBB-2	c-erbB-2, a member of the tyrosine kinase oncogene family, is overexpressed in about 30% of human breast tumors where it correlates with poor prognosis. In vitro studies have suggested that increased expression of the receptor plays an important role in malignant progression. To better understand the direct effects of p185(HER2) overexpression, a human c-erbB-2 expression vector was transfected into the hormone-dependent MCF-7 human breast carcinoma cell line and cell growth was analysed. Unexpectedly, colony formation assay revealed a reduction in the number and size of colonies as compared with mock-transfected cells. In hormone-deprived medium, c-erbB-2 transfected cells acquired growth capability, consistent with previous reports. By contrast, two c-erbB-2-transfected clones grown in complete medium showed a reduced proliferation rate despite the activation of a fully functional oncoprotein capable of autophosphorylation and induction of the MAPK pathway. The number of c-erbB-2-overexpressing cells in the S phase of the cell cycle was about one-half the number of control and mock-transfected cells. Also, overexpression of c-erbB-2 induced overexpression of p21(WAF1), pRB hypophosphorylation and a mature differentiated cell phenotype with production of lipid droplets. Functional inactivation of p185(HER2) by means of a specific single chain antibody indicated the c-erbB-2-dependence of the observed alterations. These data show that the exogenous overexpression of the c-erbB-2 gene in hormone-dependent breast cancer cells inhibits proliferation and induces differentiation.	Ist Nazl Tumori, Div Expt Oncol E, I-20133 Milan, Italy; Thomas Jefferson Univ, Jefferson Med Coll, S Barro Inst Canc Res & Mol Med, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University	Colnaghi, MI (corresponding author), Ist Nazl Tumori, Div Expt Oncol E, Via Venezian 1, I-20133 Milan, Italy.		Pupa, Serenella/K-6388-2016; Giordano, Antonio/F-1927-2010; menard, sylvie mm/C-7940-2011	Pupa, Serenella/0000-0002-4592-6830; Giordano, Antonio/0000-0002-5959-016X; 				BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; Bacus SS, 1996, ONCOGENE, V12, P2535; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Carlomagno C, 1996, J CLIN ONCOL, V14, P2702, DOI 10.1200/JCO.1996.14.10.2702; CENTIS F, 1992, HYBRIDOMA, V11, P267, DOI 10.1089/hyb.1992.11.267; CHEN PL, 1995, CRIT REV EUKAR GENE, V5, P79; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUGALL WC, 1994, ONCOGENE, V9, P2109; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; FELIP E, 1995, CANCER, V75, P2147, DOI 10.1002/1097-0142(19950415)75:8<2147::AID-CNCR2820750818>3.0.CO;2-8; Gorospe M, 1996, CELL GROWTH DIFFER, V7, P1609; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JANES PW, 1994, ONCOGENE, V9, P3601; KERN JA, 1994, J CLIN INVEST, V93, P516, DOI 10.1172/JCI117001; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; POLLER DN, 1992, BRIT J CANCER, V66, P583, DOI 10.1038/bjc.1992.318; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; TODD DM, 1992, DIAGN ONCOL, V2, P313; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	43	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					425	432		10.1038/sj.onc.1201954	http://dx.doi.org/10.1038/sj.onc.1201954			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696035				2022-12-28	WOS:000075043000004
J	Hock, B; Bohme, B; Karn, T; Feller, S; Rubsamen-Waigmann, H; Strebhardt, K				Hock, B; Bohme, B; Karn, T; Feller, S; Rubsamen-Waigmann, H; Strebhardt, K			Tyrosine-614, the major autophosphorylation site of the receptor tyrosine kinase HEK2, functions as multi-docking site for SH2-domain mediated interactions	ONCOGENE			English	Article						Eph-related kinases; HEK2; SH2-domains; signal transduction	COMMISSURAL AXONS; C-CRK; EPH; BINDING; PROTEIN; FAMILY; ACTIVATION; PROMOTES; GUIDANCE; DOMAIN	HEK2 belongs to the family of EPH-related receptor tyrosine kinases (RTK) which are involved in axonal pathfinding and the formation of the embryonic body plan. The knowledge about intracellular pathways of signal transduction mediated by EPH-related receptors is still limited, Many of the known key players of cellular signalling contain Src homology 2 (SH2) domains, which recognize phosphotyrosine motifs in RTKs, Thus, we examined the interactions of various SH2-containing molecules like PLC-gamma 1, rasGAP, p85 subunit of PI3-kinase, Src, Fyn, Crk, Nck, GrbZ and Shc with HEK2 using in vitro binding assays, immunoprecipitations and yeast Two-Hybrid assays. We found that rasGAP, Crk and Fyn bind in a SH2-dependent manner to autophosphorylated HEK2, rasGAP, which contains two SH2- and one SH3-domain, was shown to associate with its N-terminal SH2-domain to HEK2, Furthermore, we demonstrated that a single amino acid substitution (Y614F) clearly reduces the phosphotyrosine content of HEK2 and abrogates its ability to bind rasGAP, Crk and Fyn indicating that this residue functions as major phosphorylation and multi-docking site. The conservation of this predicted binding site among various EPH-related RTKs provides evidence that Fyn, Crk and rasGAP are key players in signal transduction of at least a subset of these receptors.	Chemotherapeut Forschungsinst, D-60596 Frankfurt, Germany; Med Inst Strahlenkunde & Zellforsch MSZ, Lab Mol Onkol, D-97078 Wurzburg, Germany; Bayer AG, Inst Virol, D-42096 Wuppertal, Germany	Bayer AG	Strebhardt, K (corresponding author), Chemotherapeut Forschungsinst, Georg Speyer Haus,Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.		Strebhardt, Klaus/E-8765-2011; karn, t/C-7452-2013; Karn, Thomas/AAE-7723-2019	karn, t/0000-0002-3264-6573; Karn, Thomas/0000-0002-3264-6573; Strebhardt, Klaus/0000-0003-2173-9763				Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BOHME B, 1993, ONCOGENE, V8, P2857; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; Braunger J, 1997, ONCOGENE, V14, P2619, DOI 10.1038/sj.onc.1201123; Ellis C, 1996, ONCOGENE, V12, P1727; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FOX GM, 1995, ONCOGENE, V10, P897; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; KARN T, 1993, ONCOGENE, V8, P3433; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	51	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	1998	17	2					255	260		10.1038/sj.onc.1201907	http://dx.doi.org/10.1038/sj.onc.1201907			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674711				2022-12-28	WOS:000074706700015
J	Cavrois, M; Leclercq, I; Gout, O; Gessain, A; Wain-Hobson, S; Wattel, E				Cavrois, M; Leclercq, I; Gout, O; Gessain, A; Wain-Hobson, S; Wattel, E			Persistent oligoclonal expansion of human T-cell leukemia virus type 1 infected circulating cells in patients with Tropical spastic paraparesis HTLV-1 associated myelopathy	ONCOGENE			English	Article						HTLV-1; ATLL; leukemogenesis; TSP/HAM	BLOOD MONONUCLEAR-CELLS; I PROVIRAL DNA; PERIPHERAL-BLOOD; HTLV-1-ASSOCIATED MYELOPATHY; IMMUNOSUPPRESSIVE TREATMENT; ASYMPTOMATIC CARRIERS; NEUROLOGICAL DISEASE; TRANSACTIVATOR TAX; MESSENGER-RNA; KAPPA-B	The pattern of HTLV-1 replication was assessed through PCR amplification of the 3' proviral integration sites in patients with TSP/HAM at different times. Integration sites mere sequenced and oligonucleotides specific for the flanking sequences were synthesized. Together with HTLV-1 LTR specific primers, clonotypic nested PCR was performed on peripheral blood from two patients. The frequencies of five clones studied ranged from 1/300 to 1/1500 PBMCs while four clones persisted for more than 1-5 years. It would seem that Tax driven expansion of T cells may persist for considerable periods of time in TSP/HAM despite strong cellular immunity. This may provide a background for the accumulation of subsequent mutations leading to malignancy.	Inst Rech Canc Lille, INSERM, U124, Paris, France; Hop La Pitie Salpetriere, Federat Neurol, Paris, France; Inst Pasteur, Unite Epidemiol Virus Oncogenes, Paris, France; Inst Pasteur, Unite Retrovirol Mol, Paris, France; Ctr Oscar Lambret, Unite Oncogenese Virale, F-59020 Lille, France; CHU Lille, Serv Malad Sang, F-59037 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UNICANCER; Centre Oscar Lambret; Universite de Lille - ISITE; CHU Lille	Wattel, E (corresponding author), Inst Rech Canc Lille, INSERM, U124, Paris, France.							BEILKE MA, 1991, J MED VIROL, V33, P64, DOI 10.1002/jmv.1890330113; Cavrois M, 1996, ONCOGENE, V12, P2419; CAVROIS M, 1995, RES VIROLOGY, V146, P179, DOI 10.1016/0923-2516(96)80578-4; Cavrois M, 1996, BLOOD, V88, P4646, DOI 10.1182/blood.V88.12.4646.bloodjournal88124646; CHO IM, 1995, AM J TROP MED HYG, V53, P412, DOI 10.4269/ajtmh.1995.53.412; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DUYAO MP, 1992, AIDS RES HUM RETROV, V8, P752; ELOVAARA I, 1993, J EXP MED, V177, P1567, DOI 10.1084/jem.177.6.1567; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FURUKAWA Y, 1995, BLOOD, V85, P1865, DOI 10.1182/blood.V85.7.1865.bloodjournal8571865; FURUKAWA Y, 1992, BLOOD, V80, P1012; GESSAIN A, 1990, BLOOD, V75, P428; GESSAIN A, 1992, J VIROL, V66, P2288, DOI 10.1128/JVI.66.4.2288-2295.1992; GESSAIN A, 1985, LANCET, V2, P407; GESSAIN A, 1991, J VIROL, V65, P1628, DOI 10.1128/JVI.65.3.1628-1633.1991; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JENKS PJ, 1995, CLIN INFECT DIS, V21, P992, DOI 10.1093/clinids/21.4.992; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; Newbound GC, 1996, J VIROL, V70, P2101, DOI 10.1128/JVI.70.4.2101-2106.1996; PARKER CE, 1994, J VIROL, V68, P2860, DOI 10.1128/JVI.68.5.2860-2868.1994; Plumelle Y, 1997, AM J CLIN PATHOL, V107, P81; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; ROBINSON RD, 1990, J TROP MED HYG, V94, P411; SETOYAMA M, 1994, INT J CANCER, V57, P760, DOI 10.1002/ijc.2910570525; SHINZATO O, 1991, BLOOD, V78, P2082; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TACHIBANA N, 1988, INT J CANCER, V42, P829, DOI 10.1002/ijc.2910420605; Tsukasaki K, 1997, BLOOD, V89, P948, DOI 10.1182/blood.V89.3.948; TSURUMI H, 1992, AM J HEMATOL, V41, P292, DOI 10.1002/ajh.2830410414; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; WATTEL E, 1992, J ACQ IMMUN DEF SYND, V5, P943; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; Wattel E, 1996, J ACQUIR IMMUNE D S1, V13, P92; Yin MJ, 1996, J BIOL CHEM, V271, P4781, DOI 10.1074/jbc.271.9.4781; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZANKE BW, 1989, TRANSPLANTATION, V48, P695; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	46	89	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					77	82		10.1038/sj.onc.1201906	http://dx.doi.org/10.1038/sj.onc.1201906			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671316				2022-12-28	WOS:000074677800009
J	Tanimura, S; Chatani, Y; Hoshino, R; Sato, M; Watanabe, S; Kataoka, T; Nakamura, T; Kohno, M				Tanimura, S; Chatani, Y; Hoshino, R; Sato, M; Watanabe, S; Kataoka, T; Nakamura, T; Kohno, M			Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering	ONCOGENE			English	Article						HGF; cell scattering; MAP kinase signaling pathway; MEK inhibitor	MET PROTOONCOGENE PRODUCT; FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; CARCINOMA-CELLS; RAS ACTIVATION; FAMILY; CASCADE; INHIBITION	Hepatocyte growth factor (HGF) markedly induced the spreading, dissociation and scattering of Madin-Darby canine kidney epithelial cells (MDCK) and human stomach adenocarcinoma cells (TMK1). Scattering of MDCK and TMK1 cells was induced by 12-O-tetradecanoyl-phorbol-13-acetate (PMA) and epidermal growth factor (EGF), respectively. In all these agent-stimulated cells, rapid activation of Raf-l, MAP kinase/ERK kinase (MEK), 41/43 kDa MAP kinases and p90(rsk) was commonly observed. In contrast, PMA neither induced the scattering nor activation of all these kinases in TMK1 cells. Pretreatment of MDCK and TMK1 cells with 2-(2-amino-3-methoxyphenyl) choromone (AMPC), a specific inhibitor of MEK, selectively inhibited the HGF-, PMA- and EGF-stimulated activities of MEM, 41/43 kDa MAP kinases and p90(rsk) in a dose dependent manner. AMPC-pretreatment, however, did not affect HGF-, PMA- or EGF-induced activation of Raf-l, nor HGF-induced activation of phosphatidylinositol 3-kinase in these cells. Importantly, HGF-, PMA- and EGF-induced scattering of MDCK and TMK1 cells was inhibited at doses of AMPC similar to those that gave comparable levels of inhibition of the activities of MER, 41/43 kDa MAP kinases and p90(rsk), These results suggest that activation of the 41/43 kDa MAP kinase signaling pathway is required for the motility response of MDCK and TMK1 cells induced by agents such as HGF, PMA and EGF.	Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, Nagasaki 8528131, Japan; Gifu Pharmaceut Univ, Gifu 502, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Suita, Osaka 565, Japan	Nagasaki University; Gifu Pharmaceutical University; Osaka University	Kohno, M (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, 1-14 Bunkyo Machi, Nagasaki 8528131, Japan.		Kohno, Michiaki/R-6532-2019	Kohno, Michiaki/0000-0002-7644-0059				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P273; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUDAY L, 1995, ONCOGENE, V11, P1327; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klippel A, 1996, MOL CELL BIOL, V16, P4117; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Schramek H, 1997, J BIOL CHEM, V272, P11426; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SMITH DB, 1990, CURRENT PROTOCOLS MO, V2; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883	44	90	95	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					57	65		10.1038/sj.onc.1201905	http://dx.doi.org/10.1038/sj.onc.1201905			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671314				2022-12-28	WOS:000074677800007
J	White, A; Lamb, PW; Barrett, JC				White, A; Lamb, PW; Barrett, JC			Frequent downregulation of the KAI1(CD82) metastasis suppressor protein in human cancer cell lines	ONCOGENE			English	Article						KAI1 (CD82); metastasis suppressor gene; prostate cancer; transmembrane four superfamily	LEUKEMIA-VIRUS TYPE-1; ANTIPROLIFERATIVE ANTIBODY; MONOCLONAL-ANTIBODY; SYNCYTIUM FORMATION; PROSTATE-CANCER; C33 ANTIGEN; T-CELLS; EXPRESSION; SURFACE; MOTILITY	KAI1 is a metastasis suppressor gene on human chromosome 11p11.2 that encodes a glycoprotein of the transmembrane four superfamily, Reduced KAI1 expression associates with malignant progression of human prostatic, lung and pancreatic cancers, but the role of KAI1 protein in the malignant progression of other human cancers remains to be elucidated. We analysed KAI1 protein in normal and cancer cells of the prostate, ovary, bladder, endometrium, lung and melanocytes by Western blot to determine if KAI1 may be involved in multiple cancers. We also investigated the relationship of KAI1 expression and two other transmembrane four superfamily proteins, CD81 and CD9, in the cells. We found that KAI1 protein was downregulated in 31/42 of the cancer cell lines analysed. Alternatively, some ovarian, bladder and endometrial cells had distinct, heterogeneous KAI1 protein band patterns in Western blots that were due primarily to N-linked glycosylation. Most of the cancer cells expressed two other transmembrane four superfamily proteins, CD81 and CD9, Downregulation of KAI1 protein may be an indicator of metastatic potential in cancers of urogenital, gynecological, and pulmonary origin and in melanomas, KAI1 may also have post-translational modifications specific to tissue type or malignant progression.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Barrett, JC (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.							Adachi M, 1996, CANCER RES, V56, P1751; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; ATKINSON B, 1985, HYBRIDOMA, V4, P243, DOI 10.1089/hyb.1985.4.243; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; DEAR TN, 1990, MOL ASPECTS MED, V11, P243, DOI 10.1016/0098-2997(90)90005-M; Dennis J W, 1991, Semin Cancer Biol, V2, P411; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; ENGEL P, 1994, LEUKEMIA LYMPHOMA, V13, P61, DOI 10.3109/10428199409052677; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; FUSENIG NE, 1991, HUMAN CANC PRIMARY C, P55; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; Guo XZ, 1996, CANCER RES, V56, P4876; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IMAI T, 1993, J IMMUNOL, V151, P6470; Kakizoe T, 1995, Int J Urol, V2 Suppl 2, P58, DOI 10.1111/j.1442-2042.1995.tb00480.x; KOHN EC, 1993, ANTICANCER RES, V13, P2553; Lagaudriere-Gesbert C, 1997, J IMMUNOL, V158, P2790; LEBELBINAY S, 1994, CELL IMMUNOL, V154, P468, DOI 10.1006/cimm.1994.1092; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NOJIMA Y, 1993, CELL IMMUNOL, V152, P249, DOI 10.1006/cimm.1993.1285; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SHARKEY FE, 1979, INT J CANCER, V24, P733, DOI 10.1002/ijc.2910240605; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; Ueda T, 1996, AM J PATHOL, V149, P1435	27	66	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3143	3149		10.1038/sj.onc.1201852	http://dx.doi.org/10.1038/sj.onc.1201852			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671393	Bronze			2022-12-28	WOS:000074261300007
J	Van Zee, KJ; Calvano, JE; Bisogna, M				Van Zee, KJ; Calvano, JE; Bisogna, M			Hypomethylation and increased gene expression of p16(INK4a) in primary and metastatic breast carcinoma as compared to normal breast tissue	ONCOGENE			English	Article; Proceedings Paper	88th Annual Meeting of the American-Association-for-Cancer-Research	APR 12-16, 1997	SAN DIEGO, CALIFORNIA	Amer Assoc Canc Res		methylation; expression; p16(INK4a); breast carcinoma; normal breast tissue	TUMOR-SUPPRESSOR GENE; DNA METHYLATION; HUMAN CANCERS; CELL-CYCLE; MUTATIONAL ANALYSIS; DELETIONS; INACTIVATION; P15(INK4B); ISLAND; MOUSE	Controversy continues to surround the role of p16(INK4a) in cell cycle control and carcinogenesis. Mutations, deletions and changes in methylation patterns of p16(INK4a) have been proposed as mechanisms leading to abnormal expression of the gene. We show here that primary and metastatic breast carcinomas demonstrate hypomethylation of p16(INK4a) which is associated,vith expression of p16(INK4a) mRNA, as compared to normal breast tissue which demonstrates a relative hypermethylation of p16(INK4a) associated with the absence of p16(INK4a) expression. These data suggest that methylation and lack of expression of p16(INK4a) is not a central mechanism in the development of breast carcinoma, but rather that the gene is functioning and expressed in breast carcinoma more frequently than in normal breast tissue. The role of p16(INK4a) is much more complex than has been previously hypothesized.	Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Canc Res Lab, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Van Zee, KJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Canc Res Lab, 1275 York Ave,MRI-1026, New York, NY 10021 USA.			Van Zee, Kimberly/0000-0001-9550-4647				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ARAP W, 1995, CANCER RES, V55, P1351; BAYLIN SB, 1992, AIDS RES HUM RETROV, V8, P811; Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Calvano JE, 1997, ANN SURG ONCOL, V4, P416, DOI 10.1007/BF02305555; Costello JF, 1996, CANCER RES, V56, P2405; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; RUSH EB, 1995, CANCER LETT, V89, P223, DOI 10.1016/0304-3835(95)03691-O; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; XU L, 1994, CANCER RES, V54, P5262; Zariwala M, 1996, ONCOGENE, V12, P451	25	39	41	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2723	2727						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652738				2022-12-28	WOS:000073812200003
J	Johnson, MR; Valentine, C; Basilico, C; Mansukhani, A				Johnson, MR; Valentine, C; Basilico, C; Mansukhani, A			FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells	ONCOGENE			English	Article						fibroblast growth factor; estrogen receptor; MAP kinase; STAT1; MCF-7 growth inhibition; breast cancer	FIBROBLAST GROWTH-FACTOR; HUMAN BREAST-CANCER; RECEPTOR SUPERFAMILY; GENE-EXPRESSION; TRANSGENIC MICE; MAMMARY-GLAND; INDUCTION; PATHWAYS; FAMILY; KINASE	Normal breast tissue as well as most breast tumors are dependent on estrogen for growth, Breast tumors often progress to a hormone-independent state which is associated with poor prognosis, It has been proposed that activation of growth factor signaling pathways in the tumor cells may free them from hormonal control. Certain growth factors can mimic estrogen responses by activating the estrogen receptor via its phosphorylation by mitogen-activated protein (MAP) kinase, In this report, however, we show that fibroblast growth factor (FGF), despite activating MAP kinase, is growth-inhibitory for estrogen-dependent MCF-7 breast cancer cells, MCF-7 cells treated with FGFs exhibit slower growth than controls in both the presence and absence of estrogen, with a concomitant increase in the number of cells in G0/G1, Expression of a constitutively activated FGF receptor in these cells further decreases their growth rate, which is no longer influenced by FGF treatment. Activation of the FGF signaling pathway also reduces the induction of an estrogen-responsive CAT reporter plasmid by estrogen, an effect which appears to be independent of serine 118 in the estrogen receptor, a MAP kinase target site. The inhibitory effects of FGF are probably mediated through the sustained induction of the cyclin kinase inhibitor p21/WAF1/CIP1, which is upregulated at the mRNA and protein level by FGF, FGF treatment also results in the phosphorylation of STAT1, This upregulation of p21 and phosphorylation of STAT1 is not detectable in T47D breast cancer cells upon which FGF has no inhibitory effect.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Basilico, C (corresponding author), NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.			Mansukhani, Alka/0000-0003-1020-3242	NCI NIH HHS [CA42568] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1991, ONCOGENE, V6, P659; Altucci L, 1996, ONCOGENE, V12, P2315; BANSAL GS, 1995, BRIT J CANCER, V72, P1420, DOI 10.1038/bjc.1995.524; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CHALBOS D, 1994, SEMIN CANCER BIOL, V5, P361; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DICKSON RB, 1986, SCIENCE, V232, P1540, DOI 10.1126/science.3715461; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Fenig E, 1997, CLIN CANCER RES, V3, P135; GOMM JJ, 1991, CANCER RES, V51, P4685; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HORWITZ KB, 1978, CANCER RES, V38, P2434; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; Li Y, 1997, ONCOGENE, V14, P1397, DOI 10.1038/sj.onc.1200983; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; Luqmani YA, 1996, EUR J CANCER, V32A, P518, DOI 10.1016/0959-8049(95)00563-3; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MCLESKEY SW, 1994, CANCER RES, V54, P523; MICHIELI P, 1994, CANCER RES, V54, P3391; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURAKAMI A, 1990, CELL GROWTH DIFFER, V1, P225; ORNITZ DM, 1996, J BIOL CHEM, V271, P1592; Payson RA, 1996, ONCOGENE, V13, P47; PETERS G, 1991, SEMIN VIROL, V2, P319; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Wang HS, 1997, CANCER RES, V57, P1750; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	48	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2647	2656		10.1038/sj.onc.1201789	http://dx.doi.org/10.1038/sj.onc.1201789			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632141				2022-12-28	WOS:000073698200009
J	Schiemann, WP; Nathanson, NM				Schiemann, WP; Nathanson, NM			Raf-1 independent stimulation of mitogen-activated protein kinase by leukemia inhibitory factor in 3T3-L1 cells	ONCOGENE			English	Article						cytokine; leukemia inhibitory factor; MAP kinase; signal transduction	TRANSDUCING RECEPTOR COMPONENT; SIGNAL-REGULATED KINASE-2; EPIDERMAL GROWTH-FACTOR; MAP KINASE; PC12 CELLS; SERINE PHOSPHORYLATION; C-RAF; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; MYELOID-LEUKEMIA	We show here that treatment of 3T3-L1 cells with leukemia inhibitory factor (LIF) stimulated Raf-l activity in a time-and dose-dependent manner, Although phorbol ester failed to activate Raf-l directly, a protein kinase C-stimulated signal was found to be necessary, but not sufficient, for LIF-mediated activation of Raf-l, Elevation of intracellular cAMP levels completely blocked Raf-l activation by LIF, but was without effect on the magnitude of mitogen-activated protein kinase (MAPK) stimulation by the cytokine, suggesting the presence of a Raf-l-independent, cAMP-insensitive MAPK kinase kinase (MAPKKK) pathway in 3T3-L1 cells, Mono Q-fractionation of LIF-stimulated 3T3-L1 extracts identified a single peak of MAPKKK activity that was largely insensitive to elevated intracellular levels of cAMP, and that failed to correlate with stimulation of either Raf-l or MEKK1 protein kinases, Our results demonstrate that LIF-mediated activation of the MAP kinase cascade in 3T3-L1 cells proceeds through both Raf-l-dependent and -independent pathways which differ in their sensitivity to inhibition by intracellular cAMP.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Nathanson, NM (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007750] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM07750] Funding Source: Medline; NINDS NIH HHS [NS30410] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMANN H, 1992, J BIOL CHEM, V267, P19744; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FAURE M, 1994, J BIOL CHEM, V269, P7851; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GARDNER AM, 1994, MEHTODS ENZYMOL, V238, P528; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; ICHIKAWA Y, 1970, J CELL PHYSIOL, V76, P175, DOI 10.1002/jcp.1040760207; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Keller JR, 1996, CURR TOP MICROBIOL, V211, P43; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRYIAKIS JM, 1992, NATURE, V358, P417; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; METCALF D, 1991, INT J CELL CLONING, V9, P95, DOI 10.1002/stem.5530090201; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PORRAS A, 1994, J BIOL CHEM, V269, P12741; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; SOZERI O, 1992, ONCOGENE, V7, P2259; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Taga T, 1996, J NEUROCHEM, V67, P1; THOMA B, 1994, J BIOL CHEM, V269, P6215; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YIN TG, 1994, J BIOL CHEM, V269, P3731; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	54	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2671	2679		10.1038/sj.onc.1201800	http://dx.doi.org/10.1038/sj.onc.1201800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632143				2022-12-28	WOS:000073698200011
J	Barzegar, C; Meazza, R; Pereno, R; Pottin-Clemenceau, C; Scudeletti, M; Brouty-Boye, D; Doucet, C; Taoufik, Y; Ritz, J; Musselli, C; Mishal, Z; Jasmin, C; Indiveri, F; Ferrini, S; Azzarone, B				Barzegar, C; Meazza, R; Pereno, R; Pottin-Clemenceau, C; Scudeletti, M; Brouty-Boye, D; Doucet, C; Taoufik, Y; Ritz, J; Musselli, C; Mishal, Z; Jasmin, C; Indiveri, F; Ferrini, S; Azzarone, B			IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops	ONCOGENE			English	Article						melanomas; IL-15; IL-15R; secretion pattern; tumor progression immunotherapy	NATURAL-KILLER-CELLS; RECEPTOR-GAMMA CHAIN; INTERLEUKIN-2 RECEPTOR; BETA-CHAIN; FUNCTIONAL INTERLEUKIN-2; GROWTH-FACTOR; ALPHA-CHAIN; EXPRESSION; LINE; IDENTIFICATION	IL-15 is a novel cytokine active through the IL-2R beta gamma. Since several human melanoma cell lines display functional IL-2Rs, we studied the IL-15/melanoma cells interactions. Ten out of 17 melanoma cell lines express the IL-15 transcript and four of them express levels of IL-15 mRNA similar to those detected in control activated monocytes, Nine out of ten cell lines also express two transcripts for the IL-15R alpha originated by the alternative splicing of exon'3'. Two melanoma cell lines, MELP and MELREO, derived from patients with rapidly progressive primary melanomas, co-express the two IL-15 transcripts, originated by alternative splicing of exon 'A'. Intracellular II-15 protein was only detected in these two cells lines and it is mainly retained in the Endoplasmic Reticulum (ER), However, a small amount of IL-15 is also found in the GoIgi apparatus and in the early endosomes, suggesting production and intercellular trafficking of endogenous IL-15 protein. Nevertheless, no biologically active IL-15 could be detected in the supernatant of all melanoma cells. The anti IL-15 blocking mAb M111 causes the up regulation of;HLA Class I in dense MELP and MELREO cultures, These data suggest that IL-15 is probably active through juxtacrine loops negatively controlling KLA Class I molecules expression. These data offer, for the first time, a likely explanation to the controversal issue of IL-15 secretion and constitute a natural model for understanding IL-15 routing. Moreover, me identify a subset of melanoma cells producing IL-15, possibly involved in tumor escape mechanisms.	Hop Paul Brousse, INSERM, U268, F-94807 Villejuif, France; IST, CBA, I-16132 Genoa, Italy; Fac Med, DIMI, I-16132 Genoa, Italy; INSERM, U4, CRI, F-94276 Le Kremlin Bicetre, France; Dana Farber Canc Inst, Boston, MA 02115 USA; CNRS, UPS 47, Lab Cytometrie, F-94800 Villejuif, France; Fac Med, DOCS, I-16132 Genoa, Italy	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Harvard University; Dana-Farber Cancer Institute; Centre National de la Recherche Scientifique (CNRS)	Azzarone, B (corresponding author), Hop Paul Brousse, INSERM, U268, F-94807 Villejuif, France.		Ritz, Jerome/C-7929-2009; Meazza, Raffaella/AAC-2425-2019; Azzarone, Bruno/AAH-9251-2019; Indiveri, Francesco/AAE-9086-2020	Ritz, Jerome/0000-0001-5526-4669; Meazza, Raffaella/0000-0003-0242-3157; Azzarone, Bruno/0000-0002-5962-3849; Induveri, Francesco/0000-0002-9280-2232; Ferrini, Silvano/0000-0001-7254-2616				ALILECHE A, 1993, ONCOGENE, V8, P1791; ALTOMONTE M, 1992, NEW ENGL J MED, V327, P959; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; Azzarone B, 1996, EUR CYTOKINE NETW, V7, P27; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; Care A, 1996, MOL CELL BIOL, V16, P4842; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Carson WE, 1995, J CLIN INVEST, V96, P2578, DOI 10.1172/JCI118321; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; deJong JLO, 1996, J IMMUNOL, V156, P1339; DOUCET C, 1997, MELANOMA RES S, V7, P75; Ferrini S, 1996, GENE THER, V3, P656; GAMERO AM, 1995, CANCER RES, V55, P4988; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HANS DS, 1996, ONCOGENE, V8, P1015; KATANO M, 1994, CANCER IMMUNOL IMMUN, V39, P161, DOI 10.1007/BF01533381; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KAWAMI H, 1993, BIOTHERAPY, V6, P33, DOI 10.1007/BF01877384; LENTER M, 1994, J BIOL CHEM, V269, P12263; Meazza R, 1996, ONCOGENE, V12, P2187; MEAZZA R, 1997, IN PRESS EUR J IMMUN; MOHAMADZADEH M, 1995, J IMMUNOL, V155, P4492; MORIMOTO K, 1994, BLOOD, V83, P657; Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; PLAISANCE S, 1993, INT J CANCER, V55, P164, DOI 10.1002/ijc.2910550129; RIMOLDI D, 1993, ANTICANCER RES, V13, P555; Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; WALDMANN TA, 1993, IMMUNOL TODAY, V14, P264, DOI 10.1016/0167-5699(93)90043-K	34	40	49	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2503	2512		10.1038/sj.onc.1201775	http://dx.doi.org/10.1038/sj.onc.1201775			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627116				2022-12-28	WOS:000073672300008
J	Godbout, R; Bisgrove, DA; Shkolny, D; Day, RS				Godbout, R; Bisgrove, DA; Shkolny, D; Day, RS			Correlation of B-FABP and GFAP expression in malignant glioma	ONCOGENE			English	Article						malignant glioma; glial fibrillary acidic protein; brain fatty acid binding protein; astrocytes; gene mapping	FIBRILLARY ACIDIC PROTEIN; COMPARATIVE GENOMIC HYBRIDIZATION; LIPID-BINDING PROTEIN; HUMAN ASTROCYTOMA-CELLS; COMPLEMENTARY-DNA; SUBVENTRICULAR ZONE; MESSENGER-RNA; CHICK RETINA; GENE FAMILY; LINES	The murine brain fatty acid binding protein (B-FABP) is encoded by a developmentally regulated gene that is expressed in radial glial cells and immature astrocytes. We have cloned the human B-FABP gene and have mapped it to chromosome 6q22-23. We show that B-FABP mRNA is expressed in human malignant glioma tumor biopsies and in a subset of malignant glioma cell lines, as well as in human fetal retina and brain. Malignant glioma tumors are characterized by cytoplasmic bundles of glial fibrillary acidic protein (GFAP), a protein normally expressed in mature astrocytes. Establishment of malignant glioma cell lines often results in loss of GFAP. The subset of malignant glioma cell lines that express GFAP mRNA also express B-FABP mRNA. Go-localization experiments in cell lines indicate that the same cells produce both GFAP and B-FABP. We suggest that some malignant gliomas may be derived from astrocytic precursor cells which can express proteins that are normally produced at different developmental stages in the astrocytic differentiation pathway.	Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada	University of Alberta	Godbout, R (corresponding author), Univ Alberta, Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.		Godbout, Roseline/I-4639-2016	Godbout, Roseline/0000-0002-4779-9265				BASS NM, 1993, MOL CELL BIOCHEM, V123, P191, DOI 10.1007/BF01076492; BIGNER DD, 1981, J NEUROPATH EXP NEUR, V40, P201, DOI 10.1097/00005072-198105000-00001; BONGCAMRUDLOFF E, 1991, CANCER RES, V51, P1553; BURTON PBJ, 1994, BIOCHEM BIOPH RES CO, V205, P1822, DOI 10.1006/bbrc.1994.2882; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; CHEN WJ, 1994, J CELL BIOL, V127, P813, DOI 10.1083/jcb.127.3.813; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; ENG LF, 1978, J HISTOCHEM CYTOCHEM, V26, P513, DOI 10.1177/26.7.357640; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; FENG L, 1995, DEVELOPMENT, V121, P1719; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; FULTS D, 1990, CANCER RES, V50, P5784; GILMAN AG, 1972, MOL PHARMACOL, V8, P410; GLATZ JFC, 1990, MOL CELL BIOCHEM, V98, P237, DOI 10.1007/BF00231390; GODBOUT R, 1992, ONCOGENE, V7, P1879; GODBOUT R, 1993, EXP EYE RES, V56, P95, DOI 10.1006/exer.1993.1014; GODBOUT R, 1993, GENE, V123, P195, DOI 10.1016/0378-1119(93)90124-L; GODBOUT R, 1995, EXP EYE RES, V60, P645, DOI 10.1016/S0014-4835(05)80006-5; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; GOTTSCHALK J, 1987, Zentralblatt fuer Allgemeine Pathologie und Pathologische Anatomie, V133, P319; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HUYNH HT, 1995, CANCER RES, V55, P2225; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; KELER T, 1992, P NATL ACAD SCI USA, V89, P4830, DOI 10.1073/pnas.89.11.4830; KURTZ A, 1994, DEVELOPMENT, V120, P2637; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E; LIANG BC, 1994, NEUROLOGY, V44, P533, DOI 10.1212/WNL.44.3_Part_1.533; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LINSKEY ME, 1995, NEUROSURGERY, V36, P1; LUSKIN MB, 1994, GLIA, V11, P211, DOI 10.1002/glia.440110302; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; RAKIC P, 1985, SCIENCE, V227, P1054, DOI 10.1126/science.3975601; RETTIG WJ, 1986, CANCER RES, V46, P6406; Rump R, 1996, EUR J CELL BIOL, V69, P135; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P6; RUTKA JT, 1993, CANCER RES, V53, P3624; RUTKA JT, 1994, CANCER RES, V54, P3267; Schlegel J, 1996, J NEUROPATH EXP NEUR, V55, P81, DOI 10.1097/00005072-199601000-00008; SCHMECHEL DE, 1979, ANAT EMBRYOL, V156, P115, DOI 10.1007/BF00300010; Schnutgen F, 1996, BIOL CHEM H-S, V377, P211; SMART I, 1961, J COMP NEUROL, V116, P349, DOI 10.1002/cne.901160307; TOHYAMA T, 1993, AM J PATHOL, V142, P883; VANDERMEULEN JDM, 1978, NEUROPATH APPL NEURO, V4, P177; VEERKAMP JH, 1995, PROG LIPID RES, V34, P17, DOI 10.1016/0163-7827(94)00005-7; VELASCO ME, 1980, CANCER, V45, P484, DOI 10.1002/1097-0142(19800201)45:3<484::AID-CNCR2820450312>3.0.CO;2-9; Weber RG, 1996, LAB INVEST, V74, P108; Xu LZ, 1996, J BIOL CHEM, V271, P24711; YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.1097; Young JK, 1996, GLIA, V16, P218	61	68	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1955	1962		10.1038/sj.onc.1201740	http://dx.doi.org/10.1038/sj.onc.1201740			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591779				2022-12-28	WOS:000073079400007
J	Voncken, JW; Kaartinen, V; Groffen, J; Heisterkamp, N				Voncken, JW; Kaartinen, V; Groffen, J; Heisterkamp, N			Bcr/Abl associated leukemogenesis in bcr null mutant mice	ONCOGENE			English	Article						P190 Bcr/Abl; bcr null mutant; pre-B leukemia/lymphoma; Ph translocation	POSITIVE HUMAN LEUKEMIAS; TYROSINE PHOSPHORYLATION; RAS TRANSFORMATION; ABL ONCOPROTEINS; TRANSGENIC MICE; KINASE-ACTIVITY; GENE ENCODES; PROTEIN; ONCOGENE; EXON	The BCR gene contributes to Philadelphia-positive leukemogenesis via a number of discrete mechanisms, one of which may be through interaction of its normal gene product with the Bcr/Abl oncoprotein. In the current study this hypothesis was tested in vivo by introducing a Bcr/Abl P190 transgene into mice lacking endogenous bcr protein. Our finding, that the P190 BCR/ABL oncogene is still capable of producing leukemia in these mice with indistinguishable latency and clinical pattern as in genetically matched counterparts, rules out any significant or major contribution of the bcr protein as a whole to leukemia development in these mice.	Dept Pathol, Sect Mol Carcinogenesis, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Res Inst, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles	Heisterkamp, N (corresponding author), Dept Pathol, Sect Mol Carcinogenesis, Ms 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Kaartinen, Vesa/AAU-5396-2021; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X	NCI NIH HHS [CA47456, CA 50248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050248, R55CA047456, R01CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LI WJ, 1989, ONCOGENE, V4, P127; LI WJ, 1988, ONCOGENE, V2, P559; Liu JX, 1996, CANCER RES, V56, P5120; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603	28	11	11	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					2029	2032		10.1038/sj.onc.1201730	http://dx.doi.org/10.1038/sj.onc.1201730			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591787				2022-12-28	WOS:000073079400015
J	Eshleman, JR; Donover, PS; Littman, SJ; Swinler, SE; Li, GM; Lutterbaugh, JD; Willson, JKV; Modrich, P; Sedwick, WD; Markowitz, SD; Veigl, ML				Eshleman, JR; Donover, PS; Littman, SJ; Swinler, SE; Li, GM; Lutterbaugh, JD; Willson, JKV; Modrich, P; Sedwick, WD; Markowitz, SD; Veigl, ML			Increased transversions in a novel mutator colon cancer cell line	ONCOGENE			English	Article						colon cancer; HPRT; mutator phenotype; transversions	DNA MISMATCH REPAIR; GROWTH-FACTOR-BETA; ESCHERICHIA-COLI; G.C->T.A TRANSVERSIONS; TUMOR-CELLS; MICROSATELLITE INSTABILITY; NUCLEAR EXTRACTS; HPRT GENE; MUTATIONS; YEAST	We describe a novel mutator phenotype in the Vaco411 colon cancer cell line which increases the spontaneous mutation rate 10-100-fold over background, This mutator results primarily in transversion base substitutions which are found infrequently in repair competent cells, Of the four possible types of transversions, only three were principally recovered, Spontaneous mutations recovered also included transitions and large deletions, but very few frameshifts were recovered, When compared to known mismatch repair defective colon cancer mutators, the distribution of mutations in Vaco411 is significantly different, Consistent with this difference, Vaco411 extracts are proficient in assays of mismatch repair, The Vaco411 mutator appears to be novel, and is not an obvious human homologue of any of the previously characterized bacterial or yeast transversion phenotypes, Several hypotheses by which this mutator may produce transversions are presented.	Univ Hosp Cleveland, Ireland Canc Ctr, Res Labs, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Dept Pathol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Dept Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Dept Gen Med Sci, Cleveland, OH 44106 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Oncol, Durham, NC 27710 USA	University Hospitals of Cleveland; University Hospitals of Cleveland; University Hospitals of Cleveland; University Hospitals of Cleveland; Duke University; Duke University; Howard Hughes Medical Institute; Duke University	Veigl, ML (corresponding author), Univ Hosp Cleveland, Ireland Canc Ctr, Res Labs, Suite 200,UCRC II,11001 Cedar Ave, Cleveland, OH 44106 USA.		Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578; Modrich, Paul/0000-0001-8708-9885	NCI NIH HHS [CA67409, CA66628-01A1] Funding Source: Medline; NIEHS NIH HHS [ES05540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA066628, R01CA067409] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1995, CANCER RES, V55, P2304; CARIELLO NF, 1994, MUTAT RES, V312, P173, DOI 10.1016/0165-1161(94)90023-X; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Eshleman JR, 1996, ONCOGENE, V12, P1425; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FANG WH, 1993, J BIOL CHEM, V268, P11838; FAZAKERLEY GV, 1986, EMBO J, V5, P3697, DOI 10.1002/j.1460-2075.1986.tb04702.x; GIVER CR, 1993, ENVIRON MOL MUTAGEN, V22, P138, DOI 10.1002/em.2850220305; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; KANG XL, 1992, GENETICS, V130, P285; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOHALMI SE, 1993, MUTAT RES, V289, P73, DOI 10.1016/0027-5107(93)90132-Y; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KUNZ BA, 1989, GENETICS, V122, P535; KUNZ BA, 1991, MOL CELL BIOL, V11, P218, DOI 10.1128/MCB.11.1.218; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LOEB LA, 1991, CANCER RES, V51, P3075; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; MCBAIN JA, 1984, CANCER RES, V44, P5813; MCGREGOR WG, 1991, SOMAT CELL MOLEC GEN, V17, P463, DOI 10.1007/BF01233170; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P9211, DOI 10.1073/pnas.87.23.9211; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PHEAR G, 1989, MOL CELL BIOL, V9, P1810, DOI 10.1128/MCB.9.4.1810; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SCHAAPER RM, 1989, EMBO J, V8, P3511, DOI 10.1002/j.1460-2075.1989.tb08516.x; SU SS, 1988, J BIOL CHEM, V263, P6829; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; WANG CY, 1995, CANCER RES, V55, P5101; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	44	11	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1125	1130		10.1038/sj.onc.1201629	http://dx.doi.org/10.1038/sj.onc.1201629			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528854				2022-12-28	WOS:000072336000003
J	Mancini, DN; Rodenhiser, DI; Ainsworth, PJ; O'Malley, FP; Singh, SM; Xing, WR; Archer, TK				Mancini, DN; Rodenhiser, DI; Ainsworth, PJ; O'Malley, FP; Singh, SM; Xing, WR; Archer, TK			CPG methylation within the 5 ' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site	ONCOGENE			English	Article						BRCA1; methylation; CpG dinucleotides; CREB	CANCER SUSCEPTIBILITY GENE; ESTROGEN-RECEPTOR GENE; DNA METHYLATION; BREAST-CANCER; OVARIAN-CANCER; SUPPRESSOR GENE; TRANSCRIPTION; EXPRESSION; MUTATIONS; ISLAND	Breast cancer is a genetic disease arising from a series of germ-line and/or somatic DNA changes in a variety of genes, including BRCA1 and BRCA2, DNA modifications have been shown to occur by a number of mechanisms that include DNA methylation, In some cases, the aberrant methylation of CpGs within 5' regulatory regions has led to suppression of gene activity. In this report we describe a variation in the pattern of DNA methylation within the regulatory region of the BRCA1 gene, We found no evidence of methylation at CpGs within the BRCA1 promoter in a variety of normal human tissues, However, screening of a series of randomly sampled breast carcinomas revealed the presence of CpG methylation adjacent to the BRCA1 transcription start site. One such methylated CpG occurs at a putative CREB (cAMP-responsive element binding) transcription factor binding site in the BRCA1 promoter, Gelshift assays with methylated and unmethylated BRCA1/CREB binding site oligonucleotides demonstrate that this site is sensitive to site-specific CpG methylation, These data suggest that aberrant DNA methylation at regulatory sequences in the BRCA1 locus may play a role in the transcriptional inactivation of the BRCA1 gene within subclones of breast tumors, This study represents the first evidence suggesting a role for DNA methylation in the transcriptional inactivation of the BRCA1 in human breast cancer.	London Hlth Sci Ctr, CHRI, SW Ontario Med Genet Program, London, ON N6C 2V5, Canada; Univ Western Ontario, London Reg Canc Ctr, London, ON, Canada; Univ Western Ontario, Dept Biochem, London, ON, Canada; Univ Western Ontario, Dept Obstet & Gynecol, London, ON, Canada; Univ Western Ontario, Dept Oncol, London, ON, Canada; Univ Western Ontario, Dept Pathol, London, ON, Canada; Univ Western Ontario, Dept Paediat, London, ON, Canada; Univ Western Ontario, Dept Zool, London, ON, Canada	London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Rodenhiser, DI (corresponding author), London Hlth Sci Ctr, CHRI, SW Ontario Med Genet Program, A4WT,800 Commiss Rd E, London, ON N6C 2V5, Canada.		Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644				Andrews JD, 1996, HUM MOL GENET, V5, P503, DOI 10.1093/hmg/5.4.503; ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; BENHATTAR J, 1989, NUCLEIC ACIDS RES, V17, P10179, DOI 10.1093/nar/17.24.10179; Brown MA, 1996, ONCOGENE, V12, P2507; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2290; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; FERGUSON AT, 1995, CANCER RES, V55, P2279; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huang THM, 1997, CANCER RES, V57, P1030; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Issa JPJ, 1996, CANCER RES, V56, P973; Issa JPJ, 1996, CANCER RES, V56, P3655; JOHNSON CA, 1995, BIOCHEM J, V305, P791, DOI 10.1042/bj3050791; Jones PA, 1996, CANCER RES, V56, P2463; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Maesawa C, 1996, CANCER RES, V56, P3875; Mancini D, 1997, AM J HUM GENET, V61, P80, DOI 10.1086/513898; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P1; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; PALVIMO JJ, 1991, NUCLEIC ACIDS RES, V19, P3921, DOI 10.1093/nar/19.14.3921; Rodenhiser D, 1996, ONCOGENE, V12, P2623; Rodenhiser DI, 1997, MUTAT RES-FUND MOL M, V373, P185, DOI 10.1016/S0027-5107(96)00171-6; Sambrook J., 2002, MOL CLONING LAB MANU; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TASHEVA ES, 1993, SOMAT CELL MOLEC GEN, V19, P275, DOI 10.1007/BF01233075; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Wang F, 1997, BIOCHEMISTRY-US, V36, P7793, DOI 10.1021/bi963100j; WEIH F, 1991, EMBO J, V10, P2559, DOI 10.1002/j.1460-2075.1991.tb07796.x; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259	41	170	193	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1161	1169		10.1038/sj.onc.1201630	http://dx.doi.org/10.1038/sj.onc.1201630			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528858				2022-12-28	WOS:000072336000007
J	Birch, JM; Blair, V; Kelsey, AM; Evans, DG; Harris, M; Tricker, KJ; Varley, JM				Birch, JM; Blair, V; Kelsey, AM; Evans, DG; Harris, M; Tricker, KJ; Varley, JM			Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome	ONCOGENE			English	Article						TP53; genotype; phenotype; Li-Fraumeni syndrome; familial cancer	GERMLINE P53 MUTATIONS; WILD-TYPE P53; BREAST-CANCER; MUTANT P53; PRONE FAMILIES; GENE; CHILDREN; PROTEINS; BINDING; TUMORS	The Li-Fraumeni cancer predisposition syndrome is associated with germline TP53 mutations in the majority of families. We have investigated cancer incidence in 34 Li-Fraumeni families, according to their constitutional TP53 mutation status. Families with germline missense mutations in the core DNA binding domain showed a more highly penetrant cancer phenotype than families with other TP53 mutations or no mutation. Cancer phenotype in families carrying such mutations was characterized by a higher cancer incidence and earlier ages at diagnosis, especially of breast cancer and brain tumours, compared with families carrying protein truncating or other inactivating mutations (P=0.03 for all cancers, P=0.006 for breast cancers, P=0.05 for brain tumours). Proband cancers showed significantly younger ages at diagnosis in those with missense mutations in the DNA binding domain than in those with protein inactivating mutations (P=0.031). In individuals with the former type of mutation, there was a significantly lower proportion of tumours which showed loss of the wild-type TP53 allele (P=0.004). These results are consistent with observations in experimental systems which demonstrate that certain mutations exhibit gain of function and/or dominant-negative properties. Our results support an enhanced oncogenic potential for such mutations in human populations.	Royal Manchester Childrens Hosp, CRC, Paediat & Familial Canc Res Grp, Manchester M27 1HA, Lancs, England; Royal Manchester Childrens Hosp, Dept Histopathol, Manchester M27 1HA, Lancs, England; Christie Hosp, Dept Histopathol, Manchester, Lancs, England; Christie Hosp, CRC, Mol Genet Sect, Paterson Inst Canc Res, Manchester, Lancs, England	Royal Manchester Children's Hospital; Royal Manchester Children's Hospital; Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Birch, JM (corresponding author), Royal Manchester Childrens Hosp, CRC, Paediat & Familial Canc Res Grp, Manchester M27 1HA, Lancs, England.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BIRCH JM, 1994, CANCER RES, V54, P1298; BIRCH JM, 1984, BRIT J CANCER, V49, P325, DOI 10.1038/bjc.1984.51; BIRCH JM, 1990, CANCER, V66, P2339; BORRESEN AL, 1992, CANCER RES, V52, P3234; BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113; BOYLE JM, 1998, IN PRESS BR J CANC; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN PC, 1995, CANCER GENET CYTOGEN, V82, P106, DOI 10.1016/0165-4608(94)00213-U; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HORIO Y, 1994, ONCOGENE, V9, P1231; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Kawamura M, 1996, ONCOGENE, V12, P2361; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MILLER CW, 1993, ONCOGENE, V8, P1815; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; PURDIE CA, 1994, ONCOGENE, V9, P603; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041; Varley JM, 1997, CANCER RES, V57, P3245; VARLEY JM, 1995, J MED GENET, V32, P942, DOI 10.1136/jmg.32.12.942; Varley JM, 1996, ONCOGENE, V12, P2437; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; WAGNER J, 1994, JNCI-J NATL CANCER I, V86, P1707, DOI 10.1093/jnci/86.22.1707	44	143	148	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1061	1068		10.1038/sj.onc.1202033	http://dx.doi.org/10.1038/sj.onc.1202033			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764816				2022-12-28	WOS:000075598400001
J	Bellacosa, A; Chan, TO; Ahmed, NN; Datta, K; Malstrom, S; Stokoe, D; McCormick, F; Feng, JN; Tsichlis, P				Bellacosa, A; Chan, TO; Ahmed, NN; Datta, K; Malstrom, S; Stokoe, D; McCormick, F; Feng, JN; Tsichlis, P			Akt activation by growth factors is a multiple-step process: the role of the PH domain	ONCOGENE			English	Article						Akt; PKB; protein kinase; PH domain; PI3-kinase; PDGF	PLECKSTRIN-HOMOLOGY DOMAIN; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; C-AKT; PHOSPHORYLATION; DYNAMIN; TARGET; PHOSPHATASE	The protein kinase encoded by the Akt proto-oncogene is activated by phospholipid binding, membrane translocation and phosphorylation. To address the relative roles of these mechanisms of Akt activation, we have employed a combination of genetic and pharmacological approaches, Transient transfection of NIH3T3 cells with wild-type Akt, pleckstrin homology (PH) domain mutants, generated on the basis of a PH domain structural model, and phosphorylation site Akt mutants provided evidence for a model of Akt activation consisting of three sequential steps: (1) a PH domain-dependent, growth factor-independent step, marked by constitutive phosphorylation of threonine 450 (T450) and perhaps serine 124 (S124), that renders the protein responsive to subsequent activation events; (2) a growth factor-induced, PI3-K-dependent membrane-translocation step; and (3) a PI3-K-dependent step, characterized by phosphorylation at T308 and S473, that occurs in the cell membrane and is required for activation, When forced to translocate to the membrane, wild-type Akt and PH domain Akt mutants that are defective in the first step become constitutively active, suggesting that the purpose of this step is to prepare the protein for membrane translocation, Both growth factor stimulation and forced membrane translocation, however, failed to activate a T308A mutant, This, combined with the finding that T308D/S473D double mutant is constitutively active, suggests that the purpose of the three-step process of Akt activation is the phosphorylation of the protein at T308 and S473, The proposed model provides a framework for a comprehensive understanding of the temporal and spatial requirements for Akt activation by growth factors.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA; Catholic Univ, Sch Med, Dept Med Genet, I-00168 Rome, Italy	Fox Chase Cancer Center; University of California System; University of California San Francisco; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Tsichlis, P (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Chan, Tung/0000-0001-6574-9555	NATIONAL CANCER INSTITUTE [P30CA006927, R01CA057436] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA57436] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zhang X, 1997, LEUKEMIA RES, V21, P849, DOI 10.1016/S0145-2126(97)00055-6; ZHUO S, 1993, J BIOL CHEM, V268, P17754	54	449	457	0	16	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					313	325		10.1038/sj.onc.1201947	http://dx.doi.org/10.1038/sj.onc.1201947			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690513				2022-12-28	WOS:000074947500006
J	Wang, XJ; Greenhalgh, DA; Jiang, AB; He, DC; Zhong, L; Medina, D; Brinkley, BR; Roop, DR				Wang, XJ; Greenhalgh, DA; Jiang, AB; He, DC; Zhong, L; Medina, D; Brinkley, BR; Roop, DR			Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis	ONCOGENE			English	Article						p53 mutants; c-ras(Ha); skin, chemical carcinogenesis; centrosome; genomic instability	GROWTH-FACTOR-ALPHA; TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; SKIN-CANCER; CELL-CYCLE; MOUSE SKIN; V-FOS; MUTATIONS; RAS; PROGRESSION	To develop an in vivo model for studying the role of the p53 tumor suppressor in skin carcinogenesis, a murine p53(172H) mutant (equivalent to human p53(175H)) was expressed in the epidermis of transgenic mice, utilizing a targeting vector based on the human keratin 1 gene (HK1.p53(m)), HK1.p53(m) mice developed normally and did not exhibit an obvious epidermal phenotype or develop spontaneous tumors. However, these mice demonstrated an increased susceptibility to a two-stage chemical carcinogenesis protocol, with the rate of formation and number of papillomas being dramatically increased as compared to non-transgenic controls, The majority of papillomas in control mice regressed after termination of 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment, whereas p53(m) papillomas progressed to carcinomas and metastases. In addition, more advanced malignancy, i.e., undifferentiated spindle cell carcinomas, were exclusively observed in p53(m) mice. Increased bromodeoxyuridine (BrdU) labeling, accompanied by decreased expression of p21, was observed in HK1.p53(m) papillomas. In situ examination of centrosomes in HK1.p53(m) papillomas also revealed marked abnormalities, with 75% of the cells containing greater than or equal to 3 centrosomes/cell, whereas centrosome numbers in papillomas from control animals remained normal. These data suggest that the accelerated tumorigenesis observed in chemically-treated p53(m) mice is most likely due to increased genomic instability resulting from an inhibition of G1 arrest and abnormal amplification of centrosomes.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Roop, DR (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R37CA041424, R01CA052607, R01CA041424] Funding Source: NIH RePORTER; NCI NIH HHS [CA41424, CA52607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUFFLER SD, 1995, CANCER RES, V55, P3888; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; BURNS PA, 1991, ONCOGENE, V6, P2363; CARDER P, 1993, ONCOGENE, V8, P1397; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Chung Su Y., 1994, Molecular and Cellular Differentiation, V2, P61; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DErrico M, 1997, CANCER RES, V57, P747; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Greenhalgh DA, 1996, CANCER RES, V56, P4413; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Jacks T, 1996, J CANCER RES CLIN, V122, P319, DOI 10.1007/BF01220798; JHAPPAN C, 1994, CELL GROWTH DIFFER, V5, P385; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE JM, 1994, ONCOGENE, V9, P3731; LI B, 1997, IN PRESS ONCOGENE; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MOLES JP, 1993, ONCOGENE, V8, P583; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; OConnor PM, 1997, CANCER SURV, V29, P151; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RUGGERI B, 1991, CANCER RES, V51, P6615; SCHAEFER DI, 1993, CANCER RES, V53, P4946; Wahl GM, 1997, CANCER SURV, V29, P183; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZHANG W, 1993, ONCOGENE, V8, P2555; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	51	60	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					35	45		10.1038/sj.onc.1201890	http://dx.doi.org/10.1038/sj.onc.1201890			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671312				2022-12-28	WOS:000074677800005
J	Chakravarti, D; Mailander, P; Franzen, J; Higginbotham, S; Cavalieri, EL; Rogan, EG				Chakravarti, D; Mailander, P; Franzen, J; Higginbotham, S; Cavalieri, EL; Rogan, EG			Detection of dibenzo[a,l]pyrene-induced H-ras codon 61 mutant genes in preneoplastic SENCAR mouse skin using a new PCR-RFLP method	ONCOGENE			English	Article						dibenzo[a,l]pyrene; SENCAR mouse; quantitative PCR; gleaning efficiency; in vivo mutation; DNA repair	MUTAGENIC SPECIFICITY; ADDUCTS; IDENTIFICATION; BENZO<A>PYRENE; PAPILLOMAS; MUTATIONS; EPOXIDE; TUMORS; ARISE; SITES	One of the key events in tumor initiation in mouse skin is mutational activation of the H-ras gene. Papillomas induced by the most carcinogenic environmental polycyclic aromatic hydrocarbon (PAH), dibenzo[a,l]pyrene (DB[a,l]P), in SENCAR mouse skin contain a specific H-ras codon 61 (CAA-->CTA) mutation. We describe here detection of these mutations in preneoplastic skin by measuring the frequency of an induced XbaI RFLP, created by the mutation. Development of the PCR-XbaI RFLP method, sensitive enough to detect 1 codon 61 mutant allele among 10 000 wild-type genes, is described. The results indicate that codon 61 mutations are induced 1 day (0.1%) after DB[a,l]P treatment on mouse skin, reach a high value (5%) by day 3, rapidly decline between days 7-9 and increase again during the clonal expansion of pre-papillomas into tumors. The detection of codon 61 mutations 1 day after DB[a,l]P exposure suggests that mutations occurred by pre-replication misrepair.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Rogan, EG (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, 600 S 42Nd St, Omaha, NE 68198 USA.				NCI NIH HHS [F32 CA 68761, CA36727, P01 CA49210] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA068761, P01CA049210, P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1985, CANCER RES, V45, P2753; Casale GP, 1997, FUND APPL TOXICOL, V36, P71, DOI 10.1006/faat.1997.2291; CHA RS, 1994, P NATL ACAD SCI USA, V91, P3749, DOI 10.1073/pnas.91.9.3749; CHAKRAVARTI D, 1995, P NATL ACAD SCI USA, V92, P10422, DOI 10.1073/pnas.92.22.10422; Chakravarti D., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P135; CHARY P, 1995, NUCLEIC ACIDS RES, V23, P1398, DOI 10.1093/nar/23.8.1398; DEVANESAN PD, 1993, CHEM RES TOXICOL, V6, P364, DOI 10.1021/tx00033a018; DROUIN EE, 1993, BIOCHEMISTRY-US, V32, P6555, DOI 10.1021/bi00077a009; Finch JS, 1996, CARCINOGENESIS, V17, P2551, DOI 10.1093/carcin/17.12.2551; GILL RD, 1991, ENVIRON MOL MUTAGEN, V18, P200, DOI 10.1002/em.2850180307; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; KEMP CJ, 1994, COLD SPRING HARB SYM, V59, P427, DOI 10.1101/SQB.1994.059.01.048; KOPPSCHNEIDER A, 1992, CARCINOGENESIS, V13, P973, DOI 10.1093/carcin/13.6.973; Lehmann AR, 1996, MUTAT RES-DNA REPAIR, V364, P245, DOI 10.1016/S0921-8777(96)00037-7; Li K.-M., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P127; NAKAJIMA H, 1993, RES COMMUN CHEM PATH, V79, P3; NAKAZAWA H, 1992, ONCOGENE, V7, P2295; NELSON MA, 1993, P NATL ACAD SCI USA, V90, P781; NELSON MA, 1992, P NATL ACAD SCI USA, V89, P6398, DOI 10.1073/pnas.89.14.6398; RODRIGUEZ H, 1993, CARCINOGENESIS, V14, P373, DOI 10.1093/carcin/14.3.373; RUANO G, 1989, NUCLEIC ACIDS RES, V17, P5407, DOI 10.1093/nar/17.13.5407; RYCHLIK W, 1995, BIOTECHNIQUES, V18, P84; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SAWYER TW, 1988, CARCINOGENESIS, V9, P1197, DOI 10.1093/carcin/9.7.1197; SCHAAPER RM, 1987, J MOL BIOL, V198, P187, DOI 10.1016/0022-2836(87)90305-6; SLAGA TJ, 1974, CANCER RES, V34, P771	26	43	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3203	3210		10.1038/sj.onc.1201853	http://dx.doi.org/10.1038/sj.onc.1201853			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671400				2022-12-28	WOS:000074261300014
J	Carter, S; Auer, KL; Reardon, DB; Birrer, M; Fisher, PB; Valerie, K; Schmidt-Ullrich, R; Mikkelsen, R; Dent, P				Carter, S; Auer, KL; Reardon, DB; Birrer, M; Fisher, PB; Valerie, K; Schmidt-Ullrich, R; Mikkelsen, R; Dent, P			Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells	ONCOGENE			English	Article						MAP kinase; p21(Cip-1); ionizing radiation; cell death	CYCLIN-DEPENDENT KINASES; GROWTH-FACTOR RECEPTOR; P53-INDEPENDENT PATHWAY; INDUCED APOPTOSIS; EGF RECEPTOR; DNA-DAMAGE; C-JUN; DIFFERENTIATION; STRESS; P21	The molecular mechanism(s) by which tumor cells survive after exposure to ionizing radiation are not fully understood. Exposure of A431 cells to low doses of radiation (1Gy) caused prolonged activations of the mitogen activated protein (MAP) kinase and stress activated protein (SAP) kinase pathways, and induced p21(Cip-1/WAF1) via a MAP kinase dependent mechanism. In contrast, higher doses of radiation (6 Gy) caused a much weaker activation of the MAP kinase cascade, but a similar degree of SAP kinase cascade activation. In the presence of MAP kinase blockade by the specific MEK1 inhibitor (PD98059) the basal activity of the SAP kinase pathway was enhanced twofold, and the ability of a 1 Gy radiation exposure to activate the SAP kinase pathway was increased similar to sixfold 60 min after irradiation, In the presence of MAP kinase blockade by PD98059 the ability of a single 1Gy exposure to cause double stranded DNA breaks (TUNEL assay) was enhanced at least threefold over the following 24-48h. The increase in DNA damage within 48 h was also mirrored by a similar decrease in A431 cell growth as judged by MTT assays over the next 4-8 days following radiation exposure. This report demonstrates that the MAP kinase cascade is a key cytoprotective pathway in A431 human squamous carcinoma cells which is activated in response to clinically used doses of ionizng radiation, Inhibition of this pathway potentiates the ability of low dose radiation exposure to induce cell death im vitro.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Immunol & Microbiol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; NIH, Bethesda, MD 20892 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Columbia University; National Institutes of Health (NIH) - USA	Dent, P (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [CA65896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama T, 1997, CANCER RES, V57, P1495; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; BOYLE W, 1990, CELL, V64, P573; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARMICHAEL J, 1987, CANCER RES, V47, P943; Chmura SJ, 1997, CANCER RES, V57, P1270; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; JARVIS DW, 1996, J BIOL CHEM, V271, P8275; JARVIS WD, 1997, IN PRESS MOL PHARM; JARVIS WD, 1997, FEBS LETT, V112, P9; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Liu Y, 1996, CANCER RES, V56, P31; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MOTHERSILL C, 1995, RADIAT RES, V142, P181, DOI 10.2307/3579027; Muschel RJ, 1997, VITAM HORM, V53, P1, DOI 10.1016/S0083-6729(08)60702-5; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; TOMBES RM, 1998, IN PRESS BIOCH J; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TSAI LH, 1993, ONCOGENE, V8, P1593; VALERIE K, 1995, MUTAT RES-DNA REPAIR, V336, P91, DOI 10.1016/0921-8777(94)00046-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	53	148	149	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2787	2796		10.1038/sj.onc.1201802	http://dx.doi.org/10.1038/sj.onc.1201802			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652746				2022-12-28	WOS:000073812200011
J	Fiddes, RJ; Janes, PW; Sivertsen, SP; Sutherland, RL; Musgrove, EA; Daly, RJ				Fiddes, RJ; Janes, PW; Sivertsen, SP; Sutherland, RL; Musgrove, EA; Daly, RJ			Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells	ONCOGENE			English	Article						heregulin; MAP kinase; erbB; cell cycle; breast cancer	EPIDERMAL-GROWTH-FACTOR; GTPASE-ACTIVATING PROTEIN; MAMMARY EPITHELIAL-CELLS; SIGNAL-REGULATED KINASE; FACTOR RECEPTOR FAMILY; PHOSPHOLIPASE-C-GAMMA; ERBB3 GENE-PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; DIFFERENTIATION	Members of the erbB family of receptor tyrosine kinases are commonly overexpressed in human breast cancer. However, the relative contribution of particular signalling pathways activated downstream of these receptors to the mitogenic response of transformed breast epithelial cells remains poorly characterized. Administration of heregulin-beta 2 (HRG), a ligand for erbB3 and erbB4, to growth arrested T-47D human breast cancer cells leads to activation of both the PI3-kinase and MAP kinase signalling pathways and potent stimulation of cell cycle progression. Specific inhibitors were used to assess the role of these pathways in HRG-induced mitogenesis and to identify underlying mechanisms in terms of regulation of gene expression. Treatment with the MEK inhibitor PD98059 led to a complete block of HRG-induced entry into S-phase, whilst administration of the PI3-kinase inhibitor wortmannin resulted in only modest inhibition. In addition, administration of PD98059 8 h after HRG was equipotent with simultaneous administration in inhibiting entry into S-phase, However, delaying addition for 14-16 h after HRG, when the cells were entering S-phase, was without effect. HRG stimulation led to sequential induction of c-myc, cyclin D1, cyclin E and cyclin A. gene expression and hyperphosphorylation of the retinoblastoma protein pRB, p21 (WAF1/CIP1/ SDI1) gene expression was rapidly induced by HRG, but significant changes in p27 (KIP1) protein levels were not detected. Preincubation with PD98059 blocked the HRG-dependent induction of cyclin DI mRNA, p21 and c-Myc protein and pRB phosphorylation, These findings demonstrate that MEK activation is critical to HRG-induced S-phase entry in these cells whilst PI3-kinase plays a minor role. Moreover, these data are compatible with HRG-induced activation of MEK being critical for a mid-G1 transition point and implicate c-myc and cyclin D1 as key targets of the MAP kinase pathway involved in this response.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; St Vincents Hosp, Garvan Inst Med Res, CRC Biopharmaceut Res, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Daly, RJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008; Daly, Roger J/C-8179-2009	Janes, Peter/0000-0002-9039-1097; Daly, Roger/0000-0002-5739-8027				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; Bacus SS, 1996, ONCOGENE, V12, P2535; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1997, NATURE, V387, P52; CHAN YL, 1984, J BIOL CHEM, V259, P224; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1994, CELL MOL BIOL RES, V40, P253; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FIDDES RJ, 1995, CELL GROWTH DIFFER, V6, P1567; FILMUS J, 1994, ONCOGENE, V9, P3627; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IVARAMAN VS, 1997, J CLIN INVEST, V99, P1478; JANES PW, 1994, ONCOGENE, V9, P3601; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIM HH, 1994, J BIOL CHEM, V269, P24747; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIU JJ, 1995, MOL CELL BIOL, V15, P364; Liu Y, 1996, CANCER RES, V56, P31; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUSGROVE EA, 1989, CANCER RES, V49, P2398; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1997, MOL ENDOCRINOL, V11, P54, DOI 10.1210/me.11.1.54; MUSGROVE EA, 1993, EUR J CANCER, V29, P21273; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; POWIS G, 1994, CANCER RES, V54, P2419; PRALL OWJ, 1998, UNPUB; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAINSBURY JRC, 1987, LANCET, V1, P1398; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P26226; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston JT, 1996, ONCOGENE, V12, P127; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	82	65	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2803	2813		10.1038/sj.onc.1201815	http://dx.doi.org/10.1038/sj.onc.1201815			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652748				2022-12-28	WOS:000073812200013
J	McCormack, SJ; Weaver, Z; Deming, S; Natarajan, G; Torri, J; Johnson, MD; Liyanage, M; Ried, T; Dickson, RB				McCormack, SJ; Weaver, Z; Deming, S; Natarajan, G; Torri, J; Johnson, MD; Liyanage, M; Ried, T; Dickson, RB			Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability	ONCOGENE			English	Article						c-myc; genomic instability; chromosome 11; mammary development	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; C-MYC; GENE AMPLIFICATION; HUMAN-BREAST; EPITHELIAL-CELLS; MICE; APOPTOSIS; CANCER	We have examined defects in mammary development and tumorigenesis in a transgenic model expressing the c-myc gene under the MMTV-LTR promoter, The stochastic tumors which arise from hyperplastic ductal and lobular lesions in this model are characterized by high rates both of apoptosis and of chromosomal instability, Since the p53 gene product is thought to be central in the maintenance of genomic integrity, in part due to its ability to induce apoptosis in cells harboring DNA damage, we examined its expression and possible mutation. Initially, we observed that unmutated p53 is strongly expressed in premalignant mammary glands and in mammary tumors derived from the MMTV-c-myc strain. We then mated the MMTV-myc strain to a p53-deficient strain as a means of examining the effect of this lesion on mammary development and tumorigenesis in the context of c-myc overexpression, A lack of both p53 alleles in the presence of c-myc overexpression resulted in a dramatic hyerplastic alteration in mammary gland development, Specifically, in female bitransgenic MMTV-c-myc/p53 null mice (MMTV-myc/p53(-/-)), lobular hyperplasias were observed at almost every ductal end bud as early as 32 days of age, In contrast, only mild ductal and lobular hyperplasias were seen in MMTV-myc mice that contained both p53 alleles (MMTV-myc/p53(+/+)); an intermediate phenotype occurred in mice with a single intact (MMTV-myc/p53(+/-)) p53 allele, Mammary carcinomas arose with a high frequency in MMTV-myc/p53(+/-) mice; the tumors were comparable in frequency, histology and apoptotic index to the tumors in MMTV-myc/p53(+/+) mice, Also, as previously observed (Elson et al,, 1995), lymphomas arose with extremely short latency in MMTV-myc/ p53(-/-) mice, precluding study of the fate of their hyperplastic mammary lesions in situ, The frequency of p53 mutations in MMTV-myc/p53(+/+) and MMTV-myc/ p53+/- mammary tumors and in cell lines derived from these tumors was examined by direct sequencing. No point mutations or deletions in p53 were observed in mammary tumors or cell lines from either genotype, Finally, a detailed chromosomal analysis using multicolor spectral karyotyping (SKY) revealed that there were multiple chromosomal alterations in the c-myc-overexpressing cells that contained either one or two unmutated p53 alleles, Variable ploidy changes, a common translocation of chromosome 11, and other chromosomal aberrations were observed. Our data thus support an interaction between c-Myc and p53 in mammary development, but suggest that loss of p53 is required neither for c-myc-dependent tumorigenesis nor for c-myc-dependent chromosomal instability.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA; Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA.				NCI NIH HHS [IP5OCA58185] Funding Source: Medline; NIA NIH HHS [R01AG1496-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Amundadottir LT, 1996, ONCOGENE, V13, P757; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BLYTH K, 1995, ONCOGENE, V10, P1717; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; BUCHBERG AM, 1989, GENETICS, V122, P153; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELSON A, 1995, ONCOGENE, V11, P181; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; MAI S, 1995, GENOME, V38, P780, DOI 10.1139/g95-099; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; Mai S, 1996, ONCOGENE, V12, P277; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; McCullagh P, 1989, GEN LINEAR MODELS, P151; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MIYASHITA T, 1995, CELL, V80, P293; Nass SJ, 1996, BIOCHEM BIOPH RES CO, V227, P248, DOI 10.1006/bbrc.1996.1497; Plummer SJ, 1997, ONCOGENE, V14, P2339, DOI 10.1038/sj.onc.1201073; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Schrock E, 1996, HUM GENET, V97, P256, DOI 10.1007/BF02265277; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOJTESEK B, 1993, J CELL SCI, V105, P607; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	44	73	77	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2755	2766		10.1038/sj.onc.1201804	http://dx.doi.org/10.1038/sj.onc.1201804			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652742				2022-12-28	WOS:000073812200007
J	Mok, SC; Chan, WY; Wong, KK; Cheung, KK; Lau, CC; Ng, SW; Baldini, A; Colitti, CV; Rock, CO; Berkowitz, RS				Mok, SC; Chan, WY; Wong, KK; Cheung, KK; Lau, CC; Ng, SW; Baldini, A; Colitti, CV; Rock, CO; Berkowitz, RS			DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer	ONCOGENE			English	Article						ovary; cancer; DOC-2; Dab; tumor suppressor	PROLINE-RICH PEPTIDES; SH3 DOMAINS; P53 GENE; BINDING; RAS; PHOSPHOTYROSINE; CARCINOMA; RNA; IDENTIFICATION; ACTIVATION	Using RNA fingerprinting (RAP) strategy and Northern blot analysis, we identified a differentially expressed sequence DOC-2 which is detectable in all normal human ovarian surface epithelial (HOSE) cell cultures but not in ovarian cancer cell lines and tissues. Subsequent cloning of DOC-2 from a cDNA library generated from the HOSE cells was carried out using the 3' and 5' RACE approach. A 3268 base pair full length cDNA of DOC-2 was isolated and sequenced. The predicted protein has a length of 770 amino acids. Homology search of all NCBI sequences indicated that the amino acid sequence of DOC-2 shares 93% homology with the mouse p96/mDab2 phosphoprotein and has a phosphotyrosine interacting domain (PID) and multiple SH3 binding motifs. Chromosomal localization by FISH showed that the DOC-2 gene is located on 5p13. Western blot analysis showed that the 105 kDa DOC-2 protein was down-regulated in all the carcinoma cell lines. In-situ immunohistochemistry performed on normal ovaries, and benign, borderline and invasive ovarian tumor tissues showed down regulation of DOC-2 protein particularly in serous ovarian tumor tissues. When DOC-2 was transfected into the ovarian carcinoma cell line SKOV3, the stable transfectants showed significantly reduced growth rate and ability to form tumors in nude mice. These data suggest that down-regulation of DOC-2 may play an important role in ovarian carcinogenesis.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol,Lab Gynecol Oncol, Boston, MA 02115 USA; Chinese Univ Hong Kong, Dept Anat, Shatin, Peoples R China; Pacific NW Lab, Richland, WA 99352 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38101 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Chinese University of Hong Kong; United States Department of Energy (DOE); Pacific Northwest National Laboratory; Baylor College of Medicine; Baylor College of Medicine; St Jude Children's Research Hospital	Mok, SC (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol,Lab Gynecol Oncol, Boston, MA 02115 USA.		genes, anthony/F-2541-2012; Wong, K.-k./AAA-6589-2020; Chan, Wood Yee/R-6692-2018; Baldini, Antonio/M-2355-2015	Wong, K.-k./0000-0002-0375-6669; Chan, Wood Yee/0000-0002-7114-1463; Baldini, Antonio/0000-0002-5330-0256; Cheung, Kwok Kuen/0000-0001-7367-9171	NCI NIH HHS [R01CA63381, R01CA69291, R01CA69453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069291, R01CA063381, R01CA069453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ENOMOTO T, 1991, AM J PATHOL, V139, P777; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FILMUS JE, 1985, CANCER RES, V45, P4468; JACOBS IJ, 1992, J NATL CANCER I, V84, P1793, DOI 10.1093/jnci/84.23.1793; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MARKS JR, 1991, CANCER RES, V51, P2979; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MOK SC, 1993, CANCER RES, V52, P5119; MOK SCH, 1993, CANCER RES, V53, P1489; OKAMOTO A, 1991, CANCER RES, V51, P5171; PIVER MS, 1992, GYNECOL ONCOL, P250; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; TSAO SW, 1991, ANTICANCER RES, V11, P1975; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VANTVEER LJ, 1988, ONCOGENE, V2, P157; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; WONG KK, 1993, INT J ONCOL, V3, P13; XU X, 1997, AM ASS CANC RES P, V38, P157; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YUNIS JJ, 1976, SCIENCE, V191, P1268, DOI 10.1126/science.1257746; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	31	141	146	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	1998	16	18					2381	2387		10.1038/sj.onc.1201769	http://dx.doi.org/10.1038/sj.onc.1201769			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620555				2022-12-28	WOS:000073428000010
J	Kilbey, A; Bartholomew, C				Kilbey, A; Bartholomew, C			Evi-1 ZF1 DNA binding activity and a second distinct transcriptional repressor region are both required for optimal transformation of Rat1 fibroblasts	ONCOGENE			English	Article						Evi-1; transcriptional repression; leukaemogenesis	ZINC-FINGER GENE; MYELOID-LEUKEMIA; PROTEIN; EXPRESSION; SEQUENCE; ACTIVATION; CELL; IDENTIFICATION; DOMAIN; FAMILY	The Evi-1 gene encodes a zinc finger transcriptional repressor protein that normally plays a role in development and is frequently activated in myeloid leukaemias, Evi-1 has two distinct DNA binding domains, ZF1 and ZF2, and a defined repressor domain but the function of the remainder of the molecule is unknown. The ZF2 and repressor domains have been shown to be required for transformation and we show here that ZF1 is also required. An alternative splice variant of Evi-1, designated Delta 324, encodes a protein which lacks a portion of the ZF1 DNA binding domain and the intervening amino acids 239-514 (designated IR) located between ZF1 and the repressor domain, We show that Delta 324 can neither bind ZF1, repress transcription through this site nor transform Rat1 fibroblasts, Reconstitution studies demonstrate that the defect in Delta 324 is partially complemented by recreating the ZF1 DNA binding activity. However, full function also requires the IR region which has transcriptional repressor activity. This study shows therefore, that ZF1, ZF2 and repressor domains and the IR region all contribute to the transformation efficiency of the Evi-1 protein.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow, Lanark, Scotland	Beatson Institute	Bartholomew, C (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow, Lanark, Scotland.							Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; BARTHOLOMEW C, 1994, ONCOGENE, V9, P939; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BORDEREAUX D, 1990, ONCOGENE, V5, P925; Brooks DJ, 1996, BRIT J CANCER, V74, P1518, DOI 10.1038/bjc.1996.583; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FUNABIKI T, 1994, ONCOGENE, V9, P1575; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; KUROKAWA M, 1995, ONCOGENE, V11, P833; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Ogawa S, 1996, ONCOGENE, V13, P183; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Soderholm J, 1997, LEUKEMIA, V11, P352, DOI 10.1038/sj.leu.2400584; Suzukawa K, 1997, GENOMICS, V42, P356, DOI 10.1006/geno.1997.4732	24	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2287	2291		10.1038/sj.onc.1201732	http://dx.doi.org/10.1038/sj.onc.1201732			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619838				2022-12-28	WOS:000073298000014
J	Pyronnet, S; Gingras, AC; Bouisson, M; Kowalski-Chauvel, A; Seva, C; Vaysse, N; Sonenberg, N; Pradayrol, L				Pyronnet, S; Gingras, AC; Bouisson, M; Kowalski-Chauvel, A; Seva, C; Vaysse, N; Sonenberg, N; Pradayrol, L			Gastrin induces phosphorylation of eIF4E binding protein 1 and translation initiation of ornithine decarboxylase mRNA	ONCOGENE			English	Article							PANCREATIC-CELL LINE; MESSENGER-RNA; FACTOR 4E; TRANSFORMATION; 4E-BP1; KINASE; GROWTH; CHOLECYSTOKININ; ASSOCIATION; STIMULATION	Gastrin via its G-protein coupled specific receptor induces transcription of c-fos and c-jun genes through a ras-MAPK pathway. Ornithine Decarboxylase (ODC), a growth regulated proto-oncogene, was chosen to investigate gastrin effects on translation initiation of mRNAs exhibiting a 5'UnTranslated Region (5'UTR) responsible for translation repression in quiescent cells. In AR4-2J tumoral cells, we first demonstrated that gastrin increases ODC mRNA translation. Transient transfections with various CAT chimeric constructs suggested a direct involvement of the 5'UTR in this observation. Translation of this group of mRNAs is enhanced by the availability of the cap-binding protein (eIF4E) that is increased after phosphorylation of its specific binding protein eIF4E-BP1, We found that AR4-2J cells overexpressed eIF4E protein which was not modulated by gastrin treatment. Rapamycin which inhibits 4E-BP1 phosphorylation, completely prevents gastrin-mediated increase of ODC translation indicating that 4E-BP1 could be involved in regulating ODC translation. Implication of 4E-BP1 in mediating gastrin effects is corroborated by the capacity of the ligand to affect 4E-BP1 phosphorylation, These results indicate that gastrin enhances ornithine decarboxylase mRNA translation through a rapamycin sensitive pathway and provide the first evidence in the control of 4E-BP1 phosphorylation after occupancy of a G protein-coupled receptor.	CHU Rangueil, Inst Louis Bugnard, IFR 31, INSERM,U151, F-31403 Toulouse 4, France; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); McGill University	Pradayrol, L (corresponding author), CHU Rangueil, Inst Louis Bugnard, IFR 31, INSERM,U151, F-31403 Toulouse 4, France.		Gingras, Anne-Claude/E-9982-2010; Pyronnet, Stéphane/P-2419-2014; Kowalski-Chauvel, Aline/O-9212-2014; SEVA, Catherine/O-9166-2014; Gingras, Anne-Claude/ABA-8341-2020	Gingras, Anne-Claude/0000-0002-6090-4437; SEVA, Catherine/0000-0002-4265-7372; Gingras, Anne-Claude/0000-0002-6090-4437				AMSTERDA.A, 1974, J CELL BIOL, V63, P1037, DOI 10.1083/jcb.63.3.1037; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BARNEJI J, 1983, CELL, V33, P729; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BERTRAND V, 1994, INT J CANCER, V56, P427, DOI 10.1002/ijc.2910560324; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; GREENS A, 1990, J BIOL CHEM, V265, P11810; HAYASHI SI, 1995, BIOCHEM J, V306, P1; HICKOK NJ, 1986, P NATL ACAD SCI USA, V83, P594, DOI 10.1073/pnas.83.3.594; JOHNSON LR, 1977, ANNU REV PHYSIOL, V39, P135, DOI 10.1146/annurev.ph.39.030177.001031; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; KUZYK CJ, 1986, AM J PHYSIOL, V251, pG597; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEIJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Pyronnet S, 1996, CANCER RES, V56, P1742; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sambrook J., 2002, MOL CLONING LAB MANU; SCEMAMA JL, 1989, AM J PHYSIOL, V256, pG846, DOI 10.1152/ajpgi.1989.256.5.G846; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SETHI T, 1992, CANCER RES, V52, P6031; SEVA C, 1994, REGUL PEPTIDES, V52, P31, DOI 10.1016/0167-0115(94)90018-3; SEVA C, 1990, CANCER RES, V50, P5829; SHANTZ LM, 1994, CANCER RES, V54, P2313; SINGH P, 1986, CANCER RES, V46, P1612; SOLOMON TE, 1987, GASTROENTEROLOGY, V92, P429, DOI 10.1016/0016-5085(87)90138-7; Sonenberg Nahum, 1993, Gene Expression, V3, P317; TAMORI A, 1995, CANCER RES, V55, P3500; TODISCO A, 1995, J BIOL CHEM, V270, P28337; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WALLON UM, 1990, FEBS LETT, V268, P161, DOI 10.1016/0014-5793(90)80998-X	36	33	33	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2219	2227		10.1038/sj.onc.1201748	http://dx.doi.org/10.1038/sj.onc.1201748			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619831				2022-12-28	WOS:000073298000007
J	Filatov, L; Golubovskaya, V; Hurt, JC; Byrd, LL; Phillips, JM; Kaufmann, WK				Filatov, L; Golubovskaya, V; Hurt, JC; Byrd, LL; Phillips, JM; Kaufmann, WK			Chromosomal instability is correlated with telomere erosion and inactivation of G2 checkpoint function in human fibroblasts expressing human papillomavirus type 16 E6 oncoprotein	ONCOGENE			English	Article						chromosome; instability; telomere; cell cycle; checkpoint	CELL-CYCLE CHECKPOINT; ATAXIA-TELANGIECTASIA CELLS; WILD-TYPE P53; GENE AMPLIFICATION; EPITHELIAL-CELLS; END ASSOCIATIONS; IMMORTAL CELLS; MUTANT P53; IN-VIVO; CANCER	Cell cycle checkpoints and tumor suppressor gene functions appear to be required for the maintenance of a stable genome in proliferating cells. In this study chromosomal destabilization was monitored in relation to telomere structure, lifespan control and G2 checkpoint function. Replicative senescence was inactivated in secondary cultures of human skin fibroblasts by expressing the human papillomavirus type 16 (HPV-16) E6 oncoprotein to inactivate p53, Chromosome aberrations were enumerated during in vitro aging of isogenic control (F5neo) and HPV-16E6-expressing (F5E6) fibroblasts. We found that structural and numerical aberrations in chromosomes were significantly increased in F5E6 cells during aging in vitro and fluorescence in situ hybridization (FISH) analysis using chromosome-specific probes demonstrated the occurrence of rearrangements involving chromosome 4 and 6 in genetically unstable F5E6 cells. Flow cytometry and karyotypic analyses revealed increased polyploidy and aneuploidy in F5E6 cells only at passages >16, although these cells displayed defective mitotic spindle checkpoint function associated with inactivation of p53 at passages 5 and 16, G2 checkpoint function was confirmed to be gradually but progressively inactivated during in vitro aging of E6-expressing cells. Aging of F5neo fibroblasts was documented during in vitro passaging by induction of a senescence-associated marker, pH 6.0 lysosomal beta-galactosidase, F5E6 cells displayed extension of in vitro lifespan and did not induce beta-galactosidase at high passage, Erosion of telomeres during in vitro aging of telomerase-negative F5neo cells was demonstrated by Southern hybridization and by quantitative FISH analysis on an individual cell level. Telomeric signals diminished continuously as F5neo cells aged in vitro being reduced by 80% near the time of replicative senescence. Telomeric signals detected by FISH also decreased continuously during aging of telomerase-negative F5E6 cells, but telomeres appeared to be stabilized at passage 34 when telomerase was expressed. Chromosomal instability in E6-expressing cells was correlated (P < 0.05) with both loss of telomeric signals and inactivation of C2 checkpoint function. The results suggest that chromosomal stability depends upon a complex interaction among the systems of telomere length maintenance and cell cycle checkpoints.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Kaufmann, WK (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.				NCI NIH HHS [CA42765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BOND JA, 1994, ONCOGENE, V9, P1885; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; COHEN MM, 1989, ADV HUM GENET, V18, P43; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Di Leonardo A, 1997, CANCER RES, V57, P1013; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EJIMA Y, 1986, MUTAT RES, V159, P117, DOI 10.1016/0027-5107(86)90120-X; Filatov LV, 1996, CANCER GENET CYTOGEN, V89, P136, DOI 10.1016/0165-4608(95)00363-0; FILATOV LV, 1987, MOL BIOL REP, V12, P117, DOI 10.1007/BF00368879; FILATOV LV, 1991, CANCER GENET CYTOGEN, V56, P11, DOI 10.1016/0165-4608(91)90357-Z; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GALLOWAY DA, 1994, COLD SPRING HARB SYM, V59, P297, DOI 10.1101/SQB.1994.059.01.034; Golubovskaya VM, 1997, ONCOGENE, V15, P1233, DOI 10.1038/sj.onc.1201278; GRANA X, 1995, ONCOGENE, V11, P211; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEALY KC, 1995, ONCOL RES, V7, P121; Henderson S, 1996, J CELL BIOL, V134, P1, DOI 10.1083/jcb.134.1.1; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; Ishikawa F, 1997, BIOCHEM BIOPH RES CO, V230, P1, DOI 10.1006/bbrc.1996.5928; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; KAUFMANN WK, 1995, CANCER RES, V55, P7; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; McClintock B, 1941, GENETICS, V26, P234; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OLOVNIKOV A M, 1971, Doklady Biochemistry, V201, P394; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Pandita TK, 1996, ONCOGENE, V13, P1423; PAULES RS, 1995, CANCER RES, V55, P1763; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schwartz JL, 1996, RADIAT RES, V146, P139, DOI 10.2307/3579585; SHAY JW, 1993, ONCOGENE, V8, P1407; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; SolinasToldo S, 1997, P NATL ACAD SCI USA, V94, P3854, DOI 10.1073/pnas.94.8.3854; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; TAYLOR AMR, 1976, NATURE, V260, P441, DOI 10.1038/260441a0; THERKELSEN AJ, 1995, CYTOGENET CELL GENET, V68, P115, DOI 10.1159/000133903; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651	62	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	1998	16	14					1825	1838		10.1038/sj.onc.1201711	http://dx.doi.org/10.1038/sj.onc.1201711			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583680				2022-12-28	WOS:000072994600006
J	Feilotter, HE; Nagai, MA; Boag, AH; Eng, C; Mulligan, LM				Feilotter, HE; Nagai, MA; Boag, AH; Eng, C; Mulligan, LM			Analysis of PTEN and the 10q23 region in primary prostate carcinomas	ONCOGENE			English	Article						prostate carcinoma; 10q23; PTEN; loss of heterozygosity	ALLELIC LOSS; DELETION; CHROMOSOME-10; ADENOCARCINOMA; GLIOMAS; CANCER; GENES; MAP	Deletions involving chromosome 10q23 occur frequently in prostatic carcinomas. Recently, a novel tumour suppressor gene, PTEN, mapping to this interval, has been identified, Mutation or deletion of PTEN has been observed in a proportion of prostate cancer cell lines; however, primary prostate carcinomas have not been studied, We have investigated the involvement of PTEN in primary prostatic adenocarcinomas using a panel of 51 matched normal and prostate tumour DNAs, Wie first determined the proportion of tumours with allele loss at loci in 10q23 which span the region containing the PTEN gene. Our results show that LOH involving 10q23 is common in primary prostate carcinomas. Twenty-five of 51 (49%) tumours showed loss of heterozygosity (LOH) over the region spanning the PTEN locus, We next directly analysed the PTEN gene for mutations of the coding region using single strand conformation polymorphism (SSCP) and sequence analyses, Of those tumours with LOH, only a single tumour nas found to carry a missense mutation in PTEN, No mutations in PTEN were identified in tumours without LOH. Our results suggest either that mutation of PTEN is a late event in prostate tumorigenesis, or that another tumour suppressor gene important in prostate cancer mag Lie close to PTEN in 10q23.	Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; USP, Fac Med, Dept Radiol, Disciplina Oncol, BR-09500900 Sao Paulo, Brazil; Harvard Univ, Sch Med, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Human Canc Genet Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med,Program Populat Sci, Boston, MA 02115 USA	Queens University - Canada; Universidade de Sao Paulo; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Mulligan, LM (corresponding author), Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada.		Nagai, Maria A/C-6162-2012	Nagai, Maria A/0000-0002-0728-4937; Eng, Charis/0000-0002-3693-5145				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Brothman AR, 1997, CANCER GENET CYTOGEN, V95, P116, DOI 10.1016/S0165-4608(96)00302-0; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; CHUMAKOV IM, 1995, NATURE, V377, P175; Cunningham JM, 1996, CANCER RES, V56, P4475; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FUJIMORI M, 1991, CANCER RES, V51, P89; Gray IC, 1997, GENOMICS, V43, P85, DOI 10.1006/geno.1997.4809; GRAY IC, 1995, CANCER RES, V55, P4800; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HERBST RA, 1994, CANCER RES, V54, P3111; Ittmann M, 1996, CANCER RES, V56, P2143; KERANGUEVEN F, 1996, ONCOGENE, V13, P339; Lalani EN, 1997, CANCER METAST REV, V16, P29, DOI 10.1023/A:1005792206377; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Marsh DJ, 1997, CANCER RES, V57, P500; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MORITA R, 1991, CANCER RES, V51, P5817; Moschonas N. K., 1996, Cytogenetics and Cell Genetics, V72, P99, DOI 10.1159/000134172; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PEIFFER SL, 1995, CANCER RES, V55, P1922; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Trybus TM, 1996, CANCER RES, V56, P2263; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153	28	167	174	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1743	1748		10.1038/sj.onc.1200205	http://dx.doi.org/10.1038/sj.onc.1200205			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582022				2022-12-28	WOS:000072807600012
J	Pinkas-Kramarski, R; Lenferink, AEG; Bacus, SS; Lyass, L; van de Poll, MLM; Klapper, LN; Tzahar, E; Sela, M; van Zoelen, EJJ; Yarden, Y				Pinkas-Kramarski, R; Lenferink, AEG; Bacus, SS; Lyass, L; van de Poll, MLM; Klapper, LN; Tzahar, E; Sela, M; van Zoelen, EJJ; Yarden, Y			The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin	ONCOGENE			English	Article						epidermal growth factor; ErbB/HER family; signal transduction; tyrosine kinase; oncogene	NEU DIFFERENTIATION FACTOR; FACTOR-RELATED PEPTIDES; HIGH-AFFINITY; FACTOR-ALPHA; HEREGULIN ISOFORMS; CELLULAR-RESPONSE; MAMMARY-TUMORS; ERBB RECEPTORS; NDF HEREGULIN; EGF RECEPTOR	The ErbB-1 receptor tyrosine kinase binds to six different growth factors, whose prototype is the epidermal growth factor (EGF). Two homologous epithelial receptors, ErbB-3 and ErbB-4, bind all isoforms of another family of growth factors, the Neu differentiation factors (NDFs/neuregulins). The fourth member of the ErbB family, ErbB-2, acts as the preferred heterodimeric partner of ligand-occupied complexes of the three other ErbB proteins. Here we report that at high concentrations, EGF can induce cell growth and differentiation in the absence of ErbB-1. This function is shared by betacellulin, but not by three other ligands, including the transforming growth factor alpha (TGF alpha). The functional receptor was identified as a heterodimer between ErbB-3 and ErbB-2, a previously identified oncogenic complex, When singly expressed, neither ErbB-3 nor ErbB-2 can mediate signaling by EGF. In addition, when co-expressed, blocking either receptor by using site-specific antibodies inhibited EGF and betacellulin activities, indicating strict cooperativity between ErbB-3 and ErbB-2, Through analysis of chimeras between EGF and TGF alpha, we identified the middle portion of EGF (loop B) as the site that enables activation of ErbB-2/ErbB-3. In conclusion, cooperative and promiscuous binding of stroma-derived growth factors by the epithelium-expressed ErbB-2/ErbB-3 heterodimer may be significant to cancer development. The mechanistic implications of our results for a model that attributes receptor dimerization to ligand bivalency, as well as to a recently proposed mechanism of secondary dimerization, are discussed.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Catholic Univ Nijmegen, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands; Adv Cellular Diagnost Inc, Elmhurst, IL 60126 USA	Weizmann Institute of Science; Weizmann Institute of Science; Radboud University Nijmegen	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		YARDEN, YOSEF/K-1467-2012; van Zoelen, Everardus J./D-9192-2012	Pinkas-Kramarski, Ronit/0000-0002-1000-369X	NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER; NCI NIH HHS [CA51712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM R, 1995, BBA-MOL CELL RES, V1266, P83, DOI 10.1016/0167-4889(94)00224-3; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BACUS SS, 1993, CANCER RES, V53, P5251; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Baulida J, 1996, J BIOL CHEM, V271, P5251; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CAMPION SR, 1993, J BIOL CHEM, V268, P1742; CARPENTER G, 1991, EPIDERMAL GROWTH FAC, P69; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HELDIN CH, 1996, CYTOKINE GROWTH F R, V7, P33; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; Jacobsen NE, 1996, BIOCHEMISTRY-US, V35, P3402, DOI 10.1021/bi952626l; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KATSUURA M, 1989, J BIOCHEM-TOKYO, V106, P87, DOI 10.1093/oxfordjournals.jbchem.a122826; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LEMOINE NR, 1992, J PATHOL, V168, P269, DOI 10.1002/path.1711680305; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOY FJ, 1993, BIOCHEMISTRY-US, V32, P7334, DOI 10.1021/bi00080a003; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RICHTER A, 1992, BIOCHEMISTRY-US, V31, P9546, DOI 10.1021/bi00155a006; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Stancovski I, 1994, Cancer Treat Res, V71, P161; Summerfield AE, 1996, J BIOL CHEM, V271, P19656, DOI 10.1074/jbc.271.33.19656; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; Zhang K, 1996, J BIOL CHEM, V271, P3884; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	62	74	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	1998	16	10					1249	1258		10.1038/sj.onc.1201642	http://dx.doi.org/10.1038/sj.onc.1201642			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546426				2022-12-28	WOS:000072422000003
J	Hellin, AC; Calmant, P; Gielen, J; Bours, V; Merville, MP				Hellin, AC; Calmant, P; Gielen, J; Bours, V; Merville, MP			Nuclear factor - kappa B-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug	ONCOGENE			English	Article						daunomycin; p53; transcriptional activation; NF-kappa B	DAUNORUBICIN-INDUCED APOPTOSIS; CELLULAR TUMOR-ANTIGEN; WILD-TYPE P53; TRANSCRIPTION FACTOR; DNA-BINDING; ONCOPROTEIN BCL-3; ALPHA PROTEOLYSIS; NECROSIS-FACTOR; SUPPRESSOR P53; CYCLE ARREST	Anthracycline drugs are widely used for the treatment of solid tumors and leukemia, but the molecular basis of their biological effect is still poorly understood, In the HCT 116 colon carcinoma cell line, which retains a wild-type inducible p53 gene, we show that the anthracycline daunomycin is a potent inducer of p53 and NF-kappa B transcription factors, Nuclear accumulation of p53 protein occurred because of increased protein stability and enhanced gene expression, In addition, daunomycin induced the p53 promoter through the binding of p50/p65 NF-kappa B heterodimers to the kappa B site in the p53 promoter, Under our conditions, the free radical scavengers NAC and PDTC were not able to block NF-kappa B activation or p53 induction, indicating that reactive oxygen intermediates were not involved in the cellular response to daunomycin stimulation. Overexpression of a stable unresponsive I kappa B alpha mutant in HCT116 cells resulted in a complete inhibition of the NF-kappa B activation but only a partial impairment of the p53 protein accumulation induced by daunomycin, We conclude that the p53-activating signal generated by daunomycin is partially regulated by NF-kappa B.	Univ Liege, Med Chem Lab, B-4000 Liege, Belgium; Univ Liege, Lab Med Oncol, B-4000 Liege, Belgium	University of Liege; University of Liege	Merville, MP (corresponding author), Univ Liege, Med Chem Lab, B-4000 Liege, Belgium.							ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; BAE L, 1995, CANCER RES, V55, P2387; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DEJARDIN E, 1995, ONCOGENE, V11, P1835; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DOROSHOW JH, 1986, P NATL ACAD SCI USA, V83, P4514, DOI 10.1073/pnas.83.12.4514; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; GINSBERG D, 1990, ONCOGENE, V5, P1285; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALOMBELLA VJ, 1994, CELL, V78, P77; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; PIRET B, 1995, EUR J BIOCHEM, V228, P444; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1989, ONCOGENE, V4, P945; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; SUN XG, 1995, MOL CELL BIOL, V15, P4489; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WU HY, 1994, J BIOL CHEM, V269, P20067; YAMAMOTO K, 1992, PROGR IMMUNOL, V8, P369	76	90	92	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1187	1195		10.1038/sj.onc.1201638	http://dx.doi.org/10.1038/sj.onc.1201638			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528861				2022-12-28	WOS:000072336000010
J	Esteve, P; Embade, N; Perona, R; Jimenez, B; del Peso, L; Leon, J; Arends, M; Miki, T; Lacal, JC				Esteve, P; Embade, N; Perona, R; Jimenez, B; del Peso, L; Leon, J; Arends, M; Miki, T; Lacal, JC			Rho-regulated signals induce apoptosis in vitro and in vivo by a p53-independent, but Bcl2 dependent pathway	ONCOGENE			English	Article						apoptosis; Rho proteins; p53; Bcl2; ceramides; TNF alpha	GTP-BINDING PROTEIN; NF-KAPPA-B; FAS-INDUCED APOPTOSIS; MYC-INDUCED APOPTOSIS; ACTIN STRESS FIBERS; CELL-DEATH; C-MYC; RAS TRANSFORMATION; GROWTH-FACTOR; ADP-RIBOSYLTRANSFERASE	Rho proteins are a branch of GTPases that belongs to the Ras superfamily which are critical elements of signal transduction pathways leading to a variety of cellular responses. This family of small GTPases has been involved in diverse biological functions such as cytoskeleton organization, cell growth and transformation, cell motility, migration, metastasis, and responses to stress. We report that several human Rho proteins including Rho A, Rho C and Rac I, are capable of inducing apoptosis in different cell systems like murine NIH3T3 fibroblasts and the human erythroleukemia K562 cell line, Since K562 cells are devoid of p53, apoptosis induced by Rho in this system is independent of p53, Rho-dependent apoptosis is mediated by the generation of ceramides, and it is drastically inhibited by ectopic expression of Bcl2, both under in vitro and in vivo conditions. Furthermore, the human oncogenes vav and ost that have been shown to function as guanine exchange factors for Rho proteins, were also able to induce apoptosis under similar conditions. Finally, we also report that the levels of endogenous Rho proteins are increased when U937 myeloid leukemia cells are exposed to apoptosis-inducing conditions such as TNF alpha treatment. Furthermore, TNF alpha-induced apoptosis in these cells is inhibited by expression of a dominant negative mutant of Rac 1 but it is not affected by a similar mutant of Rho A. These results suggest that Rho proteins play an important role in the physiological regulation of the apoptotic response to stress-inducing agents.	Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, Madrid, Spain; Univ Autonoma Madrid, Fac Med, Dept Bioquim, Madrid, Spain; Univ Cantabria, Dept Biol Mol, E-39005 Santander, Spain; Univ Edinburgh, Dept Pathol, Edinburgh, Midlothian, Scotland; NCI, LCMB, Bethesda, MD 20892 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Universidad de Cantabria; University of Edinburgh; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lacal, JC (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, Madrid, Spain.		Cuenca, Benilde Jimenez/K-9959-2014; Lacal, Juan Carlos/AAL-2235-2020; embade, Nieves/K-5190-2014; Leon, Javier/K-4615-2014; del Peso, Luis/K-9391-2014; Lacal, Juan Carlos/N-9064-2015	embade, Nieves/0000-0001-9878-3290; del Peso, Luis/0000-0003-4014-5688; Lacal, Juan Carlos/0000-0002-1908-2777; Leon, Javier/0000-0001-5803-0112; Jimenez Cuenca, Benilde/0000-0002-1806-6636				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; ARENDS MJ, 1994, MOL BIOL HISTOPATHOL, P151; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Bettaieb A, 1996, BLOOD, V88, P1465, DOI 10.1182/blood.V88.4.1465.bloodjournal8841465; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; del Peso L, 1997, ONCOGENE, V15, P3047; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Esteve P, 1995, ONCOGENE, V11, P2657; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; JIMENEZ B, 1995, ONCOGENE, V10, P811; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moorman JP, 1996, J IMMUNOL, V156, P4146; MORII N, 1992, J BIOL CHEM, V267, P20921; MOSCOW JA, 1994, GENE, V144, P229, DOI 10.1016/0378-1119(94)90382-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; PERONA R, 1993, ONCOGENE, V8, P1285; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Preston GA, 1996, MOL CELL BIOL, V16, P211; PROKOCIMER M, 1986, BLOOD, V68, P113; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAEZ R, 1994, ONCOGENE, V9, P2977; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	78	93	95	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1855	1869		10.1038/sj.onc.1202082	http://dx.doi.org/10.1038/sj.onc.1202082			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778052				2022-12-28	WOS:000076303300012
J	Porter, AC; Vaillancourt, RR				Porter, AC; Vaillancourt, RR			Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis	ONCOGENE			English	Review						phosphoinositide 3-kinase; cytoskeleton; apoptosis	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; MEDULLARY-THYROID CARCINOMA; SERINE-THREONINE KINASE; KAPOSIS-SARCOMA CELLS; TPR-MET ONCOPROTEIN; C-RET PROTOONCOGENE; ONCOSTATIN-M; PROTEIN-KINASE; BETA-CATENIN	Oncogenesis is a complicated process involving signal transduction pathways that mediate many different physiological events. Typically, oncogenes cause unregulated cell growth and this phenotype has been attributed to the growth-stimulating activity of oncogenes such as I as and src. In recent years, much research effort has focused an proteins that function downstream of Ras, leading to the identification of the Ras/Raf/MAPK pathway, because activation of this pathway leads to cellular proliferation. Activated receptor tyrosine kinases (RTKs) also utilize this pathway to mediate their growth-stimulating effects. However, RTKs activate many other signaling proteins that are not involved in the cellular proliferation process, pel se and me are learning that these pathways also contribute to the oncogenic process. In fact, RTKs and many of the proteins involved in RTK-dependent signal transduction can also function as oncogenes, For example, the catalytic subunit of phosphoinositide 3-kinase (PI3-K) was recently identified as an oncogenic protein. The scope of pathways that are activated by oncogenic RTKs is expanding. Thus, not only do RTKs activate Ras-dependent pathways that drive proliferation, RTKs activate PI3-K-dependent pathways which also contribute to the oncogenic mechanism. PI3-K can initiate changes in gene transcription, cytoskeletal changes through beta-catenin, changes in cell motility through the tumor suppressor, adenomatous polyposis coli (APC), and phosphorylation of BAD, a protein involved in apoptotic and anti-apoptotic signaling. There is also cross-talk between RTKs and the oncostatin cytokine receptor which may positively and negatively influence oncogenesis, For this review, we will focus on oncogenic RTKs and the network of cellular proteins that are activated by RTKs because multiple, divergent pathways are responsible for oncogenesis.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA	University of Arizona	Vaillancourt, RR (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.							Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOLINO A, 1995, ONCOGENE, V10, P2415; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burke CL, 1997, ONCOGENE, V14, P687, DOI 10.1038/sj.onc.1200873; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAWSON TP, 1995, CANCER RES, V55, P915; delPeso L, 1997, SCIENCE, V278, P687; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; ENG C, 1995, ONCOGENE, V10, P509; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Flick MB, 1997, ONCOGENE, V14, P2553, DOI 10.1038/sj.onc.1201092; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Jiang WG, 1997, HISTOL HISTOPATHOL, V12, P537; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; LONGATI P, 1994, ONCOGENE, V9, P49; Mak YF, 1996, CURR OPIN GENET DEV, V6, P82, DOI 10.1016/S0959-437X(96)90015-5; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nowak F, 1997, EXP CELL RES, V231, P251, DOI 10.1006/excr.1996.3468; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Pasdar M, 1997, CELL GROWTH DIFFER, V8, P451; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; PELICCI G, 1995, ONCOGENE, V10, P1631; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROMANO A, 1994, ONCOGENE, V9, P2923; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1994, ONCOGENE, V9, P509; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Spence MJ, 1997, CANCER RES, V57, P2223; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Takahashi A, 1997, EXP CELL RES, V231, P123, DOI 10.1006/excr.1996.3459; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOMA B, 1994, J BIOL CHEM, V269, P6215; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEINBERG RA, 1981, BIOCHIM BIOPHYS ACTA, V651, P25, DOI 10.1016/0304-419X(81)90003-2; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHU H, 1994, J BIOL CHEM, V269, P29943	106	270	288	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1343	1352		10.1038/sj.onc.1202171	http://dx.doi.org/10.1038/sj.onc.1202171			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779982				2022-12-28	WOS:000076161900003
J	Sudol, M				Sudol, M			From Src Homology domains to other signaling modules: proposal of the 'protein recognition code'	ONCOGENE			English	Review						protein modules; protein motifs; genetic code; phosphotyrosine; polyproline	INSULIN-RECEPTOR SUBSTRATE-1; YES-ASSOCIATED PROTEIN; PROLINE-RICH PEPTIDES; WW DOMAIN; SH3 DOMAINS; BINDING-SPECIFICITY; TYROSINE KINASES; STRUCTURAL BASIS; PHOSPHOLIPASE-C; PDZ DOMAINS	The study of oncogenes has illuminated many aspects of cellular signaling. The delineation and characterization of protein modules exemplified by Src Homology domains has revolutionized our understanding of the molecular events underlying signal transduction pathways. Several well characterized intracellular modules which mediate protein-protein interactions, namely SH2, SH3, PH, PTB, EH, PDZ, EVH1 and WW domains, are directly involved in the multitude of membrane, cytoplasmic and nuclear processes in multicellular and/or unicellular organisms. The modular character of these protein domains and their cognate motifs, the universality of their molecular function, their widespread occurrence, and the specificity as well as the degeneracy of their interactions have prompted us to propose the concept of the 'protein recognition code'. By a parallel analogy to the universal genetic code, we propose here that there will be a finite set of precise rules to govern and predict protein-protein interactions mediated by modules. Several rules of the 'protein recognition code' have already emerged.	CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Sudol, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem, 1 Gustave Levy Pl, New York, NY 10029 USA.							ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bork P, 1997, TRENDS BIOCHEM SCI, V22, P296, DOI 10.1016/S0968-0004(97)01084-0; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Evangelista C, 1996, TRENDS CELL BIOL, V6, P196, DOI 10.1016/0962-8924(96)40002-2; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIM WA, 1994, STRUCT BIOL, V1, P221; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Mahoney NM, 1997, NAT STRUCT BIOL, V4, P953, DOI 10.1038/nsb1197-953; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Niethammer M, 1996, J NEUROSCI, V16, P2157; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SIDDIQUI AS, 1995, PROTEIN SCI, V4, P872; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STICKER NL, 1997, NAT BIOTECHNOL, V15, P336; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388	64	189	196	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1469	1474		10.1038/sj.onc.1202182	http://dx.doi.org/10.1038/sj.onc.1202182			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779993				2022-12-28	WOS:000076161900014
J	Dirks, PB; Rutka, JT; Hubbard, SL; Mondal, S; Hamel, PA				Dirks, PB; Rutka, JT; Hubbard, SL; Mondal, S; Hamel, PA			The E2P-family proteins induce distinct cell cycle regulatory factors in pl6-arrested, U343 astrocytoma cells	ONCOGENE			English	Article						E2F-family; p16; astrocytomas; cell cycle; apoptosis	DIHYDROFOLATE-REDUCTASE GENE; E2F TRANSCRIPTION FACTOR; HUMAN MYC PROMOTER; RETINOBLASTOMA-PROTEIN; GROWTH SUPPRESSION; IN-VIVO; EXPRESSION PATTERNS; TRANS-ACTIVATION; BINDING PROTEIN; FAMILY PROTEINS	We previously demonstrated that P16(Ink4a) (p16) expression in p16-deficient U343 astrocytoma cells causes a G(1) cell cycle arrest, profound changes in cytoskeletal proteins and alterations in expression and activity of the pRB and E2F family proteins, We examine here the effects of expressing wild type or mutant versions of the downstream targets of p16 in U343 astrocytomas, We first attempted to block proliferation of U343 cells using the dominant mutant of pRB, Delta p34. Expression of this mutant in the human osteosarcoma, SAOS-2, potently blocked proliferation but did not affect the cell cycle of U343 cells. We next showed that expression of E2F-1, E2F-2, E2F-3 and E2F-4 are each able to overcome this p16-dependent cell cycle arrest but exhibit distinct biological activities, Adenoviral-mediated expression of E2F-1, E2F-2, E2F-3, or E2F-4 overcame the p16-dependent cell cycle block and induced alterations in cell morphology, E2F-5, only in conjunction with DP1, promoted cell cycle progression. For both E2F-1 and E2F-2, bat not E2F-3 or E2F-5/DP1, cell cycle re-entry was associated with almost quantitative cell death, Only small numbers of dying cells were observed in E2F-4-expressing cultures. Expression of the different E2F's altered the expression of distinct sets of cell cycle regulatory proteins. E2F-1 induced endogenous E2F-4 expression and also caused an increase in pRB, p107 and cyclin E levels. Expression of E2F-4 caused a weak increase in E2F-1 levels but also strongly induced pRB, p107, p130 and cyclin E, However, E2F-1 and E2F-4 clearly regulate expression of distinct genes, demonstrated when E2F-4 caused a threefold increase in the levels of cdk2 whereas E2F-1 failed to increase in this cyclin dependent kinase, Similarly, expression of E2F-1 or E2F-2 were shown to have distinct effects on the expression of cdk2, cyclin E and pRB despite both of these closely related E2F-family members potently inducing cell death, Thus, E2F-1, E2F-2, E2F-3 and E2F-4 are able to overcome the p16-dependent proliferative block in U343 astrocytoma cells, While overcoming this cell cycle block, each of the E2F's uniquely affect the expression of a number of cell cycle regulatory proteins and have distinct abilities to promote cell death.	Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Hosp Sick Children, Div Neurosurg, Toronto, ON M5S 1A8, Canada; Univ Toronto, Hosp Sick Children, Div Surg Res, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Hamel, PA (corresponding author), Univ Toronto, Dept Lab Med & Pathol, 100 Coll St, Toronto, ON M5S 1A8, Canada.							BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Botz J, 1996, MOL CELL BIOL, V16, P3401; BUCK V, 1995, ONCOGENE, V11, P31; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dirks PB, 1997, ONCOGENE, V15, P2037, DOI 10.1038/sj.onc.1201392; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1992, ONCOGENE, V7, P693; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hirai H, 1996, MOL CELL BIOL, V16, P6457; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KIESS M, 1995, ONCOGENE, V10, P159; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEE WH, 1988, J CELL BIOCHEM, V38, P213, DOI 10.1002/jcb.240380309; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUKAS J, 1995, CANCER RES, V55, P4818; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MUNCASTER MM, 1992, CANCER RES, V52, P654; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIMIZU M, 1995, MOL CELL BIOL, V15, P2882; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V12, P5620; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; Ueki K, 1996, CANCER RES, V56, P150; WADE M, 1995, J BIOL CHEM, V270, P9783, DOI 10.1074/jbc.270.17.9783; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU CL, 1995, MOL CELL BIOL, V15, P2536; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; YEAGER T, 1995, CANCER RES, V55, P493; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	69	46	50	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					867	876		10.1038/sj.onc.1202008	http://dx.doi.org/10.1038/sj.onc.1202008			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780003				2022-12-28	WOS:000075448800008
J	Butz, K; Geisen, C; Ullmann, A; Zentgraf, H; Hoppe-Seyler, F				Butz, K; Geisen, C; Ullmann, A; Zentgraf, H; Hoppe-Seyler, F			Uncoupling of p21(WAF1/CIP1/SDI1) mRNA and protein expression upon genotoxic stress	ONCOGENE			English	Article						p21(WAF1/CIP1/SDI1); DNA damage; p53; HPV; mdm-2	P53-MEDIATED G(1) ARREST; CYCLIN-DEPENDENT KINASES; POSITIVE CANCER-CELLS; P53-INDEPENDENT PATHWAY; DNA-DAMAGE; P21; INHIBITOR; P53; DIFFERENTIATION; INDUCTION	The p21(WAF1/CIP1SDI1) gene is an important regulator of crucial cellular processes, including cell cycle control, cellular differentiation, and the response to genotoxic stress, Induction of p21 gene expression upon DNA damage :is,widely believed to be p53-dependent. In the present study we analysed the expression of p21 following genotoxic stress, using different DNA-damaging agents and cellular systems. We found that the p21 response markedly varied between different cell lines and also for different genotoxic agents within the same cell line. Genotoxic induction of p21 mRNA expression can occur in the presence of p53-antagonists, such as overexpressed mdm-2 or human papillomavirus (HPV) E6, and in cells harbouring mutated p53 genes. Moreover, upon genotoxic stress, p21 mRNA and protein expression were found to be uncoupled in several cell lines. Thus, transcriptional and postranscriptional changes:in p21 expression following DNA damage are not necessarily linked to the intracellular p53 status but strongly depend on the individual cellular background and the type of DNA-damaging agent. Our findings indicate that p21 expression following genotoxic stress underlies a complex control and can be substantially modulated on the posttranscriptional level in a cell-specific manner.	Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.			Hoppe-Seyler, Felix/0000-0002-1864-300X				Boyer SN, 1996, CANCER RES, V56, P4620; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUTZ K, 1995, ONCOGENE, V10, P927; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Englert C, 1997, CANCER RES, V57, P1429; FUNK O, 1997, GENE DEV, V11, P2090; GUDAS J, 1995, ONCOGENE, V11, P253; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEBAER J, 1997, GENE DEV, V11, P847; Loignon M, 1997, CANCER RES, V57, P3390; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; McDonald E, 1996, CANCER RES, V56, P2250; MICHIELI P, 1994, CANCER RES, V54, P3391; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; WHITAKER SJ, 1992, EUR J CANCER, V28A, P273, DOI 10.1016/0959-8049(92)90432-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	43	46	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					781	787		10.1038/sj.onc.1201995	http://dx.doi.org/10.1038/sj.onc.1201995			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715280				2022-12-28	WOS:000075337200013
J	Fischer, J; Palmedo, G; von Knobloch, R; Bugert, P; Prayer-Galetti, T; Pagano, F; Kovacs, G				Fischer, J; Palmedo, G; von Knobloch, R; Bugert, P; Prayer-Galetti, T; Pagano, F; Kovacs, G			Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours	ONCOGENE			English	Article						MET tyrosine kinase; germline mutation; allelic duplication; papillary renal cell tumours	HEPATOCYTE GROWTH-FACTOR; NORMAL KIDNEY TISSUE; SCATTER FACTOR; EPITHELIAL-CELLS; RECEPTOR; CARCINOMA; TUMORS; CYTOGENETICS; ABERRATIONS	Previous karyotyping showed a combined trisomy of chromosome 7 and 17 in sporadic and hereditary papillary renal cell rumours (RCT). A recent molecular analysis revealed a mutation in the MET tyrosine kinase (chromosome 7q31) in the germline of four out of seven families with hereditary papillary RCT (HPRCT), We have analysed germline cells as well as multiple tumours obtained from HPRCT families and sporadic cases for alteration of the MET tyrosine kinase and for allelic duplication at chromosome 7 and 17. We have detected a germ line mutation in the MET tyrosine kinase in one of the two families with HPRCTs and also found the same mutation in the germ line of one patient with clinically recognized multiple, bilateral papillary RCTs but without family history. The mutant MET allele is consequently duplicated and overexpressed in tumour cells indicating that duplication of the mutant MET allele is necessary before cells enter the tumorigenic pathway. The lack of germline mutation in two members of another HPRT family and duplication of the same parental allele of chromosome 7 in multiple tumours suggests that a germ Line event other than mutation of MET tyrosine kinase is involved in the development of these tumours, Duplication of different alleles of chromosome 7 in sporadic and of chromosome 17 in both types of tumours excludes a germline mutation at these chromosomal sites.	Ruprecht Karls Univ, Dept Urol, Mol Oncol Lab, D-69120 Heidelberg, Germany; Univ Padua, Dept Urol, I-35128 Padua, Italy	Ruprecht Karls University Heidelberg; University of Padua	Kovacs, G (corresponding author), Ruprecht Karls Univ, Dept Urol, Mol Oncol Lab, Neuenheimer Feld 365, D-69120 Heidelberg, Germany.		von Knobloch, Prof. Dr. Rolf/GRF-5837-2022	von Knobloch, Prof. Dr. Rolf/0000-0002-0358-203X				BENTZ M, 1996, CYTOGENET CELL GENET, V75, P177; Bernues M, 1995, CANCER GENET CYTOGEN, V84, P123, DOI 10.1016/0165-4608(95)00044-5; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; Bugert P, 1996, AM J PATHOL, V149, P2081; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; Duh FM, 1997, ONCOGENE, V15, P1583, DOI 10.1038/sj.onc.1201338; EMANUEL A, 1992, GENE CHROMOSOME CANC, V4, P75, DOI 10.1002/gcc.2870040110; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Kovacs A, 1993, J UROL PATHOL, V1, P301; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; KOVACS G, 1989, AM J PATHOL, V134, P27; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P249, DOI 10.1002/gcc.2870030403; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; KOVACS G, 1989, CANCER GENET CYTOGEN, V37, P289, DOI 10.1016/0165-4608(89)90063-0; MOGHUL A, 1994, ONCOGENE, V9, P2045; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PLMEDO G, 1997, LAB INVEST, V77, P633; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; SACCONE S, 1992, GENOMICS, V13, P912, DOI 10.1016/0888-7543(92)90191-T; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZBAR B, 1995, J UROLOGY, V153, P907, DOI 10.1016/S0022-5347(01)67601-8	26	102	108	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					733	739		10.1038/sj.onc.1201983	http://dx.doi.org/10.1038/sj.onc.1201983			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715275	Bronze			2022-12-28	WOS:000075337200008
J	Zhang, JS; Nelson, M; McIver, B; Hay, ID; Goellner, JR; Grant, CS; Eberhardt, NL; Smith, DI				Zhang, JS; Nelson, M; McIver, B; Hay, ID; Goellner, JR; Grant, CS; Eberhardt, NL; Smith, DI			Differential loss of heterozygosity at 7q31.2 in follicular and papillary thyroid tumors	ONCOGENE			English	Article						7q31.2; LOH; thyroid cancer; FRA7G	SUPPRESSOR GENE; ONCOGENE ACTIVATION; BREAST-CANCER; FHIT GENE; CARCINOMAS; MUTATIONS; TUMORIGENESIS; NEOPLASMS; REGION; 3P14.2	We analysed 42 differentiated thyroid tumors including 15 follicular adenomas (FA), 13 papillary thyroid cancers (PTC) and 14 follicular thyroid carcinomas (FTC) with 13 microsatellite markers specific for the long arm of human chromosome 7 within 7q31; this region is deleted frequently in several other tumor types. Overall, 20 of the 42 samples analysed (48%) displayed LOH with one or more of the markers tested. LOH was detected most frequently (78%) in FTC, the most malignant of the thyroid tumors. A smallest common deleted region (SCDR) was defined in this tumor type flanked by markers D7S480 and D7S490, This SCDR is distinct fi:om D7S522, the most commonly deleted locus in many other tumors, which was deleted in only one FTC. D7S522 did show LOH in two of six informative PTCs, None of the PTC and only two of the FAs showed LOH in the FTC SCDR, Since FA is considered a premalignant stage of FTC, our results suggest that inactivation of a putative tumor suppressor at 7q31.2 may be acquired during adenoma to carcinoma progression. The absence of LOH at this locus amongst PTC suggests that inactivation of this tumor suppressor is specific for FTC, In conclusion, LOH at 7q31 is a frequent event in differentiated thyroid cancer, and we have defined a 2 cM SCDR specific for FTC.	Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, 200 1st St SW, Rochester, MN 55905 USA.		Hay, Ian/AAH-8508-2019	Hay, Ian/0000-0002-5527-3909	NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achille A, 1996, CANCER RES, V56, P3808; Devilee P, 1997, GENE CHROMOSOME CANC, V18, P193; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; GREBE SK, 1997, W J MED, V165, P156; Grebe SKG, 1997, J CLIN ENDOCR METAB, V82, P3684, DOI 10.1210/jc.82.11.3684; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; HERRMANN MA, 1991, J CLIN INVEST, V88, P1596, DOI 10.1172/JCI115472; HERRMANN ME, 1992, CANCER GENET CYTOGEN, V62, P144, DOI 10.1016/0165-4608(92)90253-5; HICKS DG, 1990, AM J PATHOL, V137, P553; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; ITO T, 1992, CANCER RES, V52, P1369; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; LEMOINE NR, 1989, ONCOGENE, V4, P159; Lin JC, 1996, ONCOGENE, V13, P2001; MATSUO K, 1991, MOL ENDOCRINOL, V5, P1873, DOI 10.1210/mend-5-12-1873; MCCONAHEY WM, 1986, MAYO CLIN PROC, V61, P978, DOI 10.1016/S0025-6196(12)62641-X; NAMBA H, 1990, J CLIN INVEST, V86, P120, DOI 10.1172/JCI114673; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; OAKAHASHI S, 1995, CANCER RES, V55, P4114; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SHRIDHAR V, 1997, IN PRESS ONCOGENE; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUAREZ HG, 1990, ONCOGENE, V5, P565; TEYSSIER JR, 1990, CANCER GENET CYTOGEN, V50, P249, DOI 10.1016/0165-4608(90)90184-C; Umbricht CB, 1997, CANCER RES, V57, P2144; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Williams GH, 1996, BRIT J CANCER, V74, P585, DOI 10.1038/bjc.1996.405; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488; Zedenius J, 1996, HUM GENET, V97, P299, DOI 10.1007/BF02185758; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; ZENKLUSEN JC, 1994, ONCOGENE, V9, P28177	38	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					789	793		10.1038/sj.onc.1201996	http://dx.doi.org/10.1038/sj.onc.1201996			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715281				2022-12-28	WOS:000075337200014
J	Chan, SY; Lee, DCW				Chan, SY; Lee, DCW			Sex difference in immunostaining of RET in the adult mouse kidney	ONCOGENE			English	Article						c-ret; RET; kidney	EPIDERMAL GROWTH-FACTOR; MICE LACKING GDNF; TYROSINE KINASE; NUCLEAR TRANSLOCATION; FACTOR RECEPTOR; FACTOR EGF; PROTOONCOGENE; EXPRESSION; LOCALIZATION; TRAFFICKING	The c-ret proto-oncogene encodes a receptor tyrosine kinase which is important for the development of the kidney and the enteric nervous system. During nephrogenesis, c-ret is expressed in the ureteric bud epithelium and later in its derivative, the collecting duct. This takes place during 11-17.5 days post-coitum (d.p.c.) in the mouse and our immunohistochemical study showed that the RET protein co-localized with the transcript. At 18.5 d.p.c. the kidney is fully differentiated. At 18.5 d.p.c., 1 week and 10 weeks old, RET was found in the proximal convoluted tubules, which is formed from the condensed mesenchyme, This suggests that c-ret may also play a role in kidney function. For the 10 weeks old kidney, RET immunostaining in male was concentrated on the basolateral side while female had a stronger staining in the whole cell. Furthermore, cytoplasmic staining was observed in male whereas both cytoplasmic and nuclear staining was found in female. c-ret transcript was detected by RT-PCR, and in situ hybridization showed its expression throughout the kidney. The reason for the sex-specific staining and the role of RET in kidney function remain to be determined.	Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong	University of Hong Kong	Chan, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong.			Chan, Siu Yuen/0000-0001-7262-1293				AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BACHINSKY DR, 1993, AM J PATHOL, V143, P598; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURTIS BM, 1990, J IMMUNOL, V144, P1295; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; HARRIS RC, 1991, AM J KIDNEY DIS, V17, P627, DOI 10.1016/S0272-6386(12)80336-2; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; HOLT SJ, 1994, BIOCHEM PHARMACOL, V47, P117, DOI 10.1016/0006-2952(94)90444-8; Ivanchuk SM, 1997, ONCOGENE, V14, P1811, DOI 10.1038/sj.onc.1201016; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JIANG LW, 1990, J CELL BIOL, V110, P559, DOI 10.1083/jcb.110.3.559; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kilkenny DM, 1996, ENDOCRINOLOGY, V137, P5078, DOI 10.1210/en.137.11.5078; Lee DCW, 1998, J UROLOGY, V159, P291, DOI 10.1016/S0022-5347(01)64084-9; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PODLECKI DA, 1987, J BIOL CHEM, V262, P3362; PROCHIANTZ A, 1995, BIOESSAYS, V17, P39, DOI 10.1002/bies.950170109; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; RAKOWICZSZULCZYNSKA EM, 1989, ARCH BIOCHEM BIOPHYS, V268, P456, DOI 10.1016/0003-9861(89)90313-5; RUGH R, 1994, MOUSE ITS REPROD DEV; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368	35	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					661	666		10.1038/sj.onc.1201970	http://dx.doi.org/10.1038/sj.onc.1201970			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704933				2022-12-28	WOS:000075195300015
J	Kisielewski, AE; Xiao, GH; Liu, SC; Klein-Szanto, AJP; Novara, M; Sina, J; Bleicher, K; Yeung, RS; Goodrow, TL				Kisielewski, AE; Xiao, GH; Liu, SC; Klein-Szanto, AJP; Novara, M; Sina, J; Bleicher, K; Yeung, RS; Goodrow, TL			Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck	ONCOGENE			English	Article						FHIT; squamous carcinogenesis; RT-PCR; westerns	TUMOR-SUPPRESSOR GENE; ALLELIC LOSS; LUNG-CANCER; 3P14.2; LINES; AMPLIFICATION; ONCOGENE; SITE; ALLELOTYPE; DELETIONS	The FHIT gene has been implicated as a tumor suppressor gene in human malignancies. To determine if FHIT alterations play a role in human squamous cell carcinogenesis of the head and neck (HNSCC), we examined the gene and its product by RT-PCR, SSCP, Northern, Southern, and Western blot analysis in primary HNSCC and/or HNSCC cell lines. Three of 32 tumor samples lacked detectable expression of FHIT by RT-PCR but showed amplification of a control gene of similar size. One of 29 primary tumors and 2/9 HNSCC cell lines exhibited aberrant transcripts generated by RT-PCR methods using one set of 40 cycles of amplification. FHIT mRNA expression was absent in seven HNSCC cell lines but detectable in primary keratinocytes by Northern analysis. Using specific polyclonal antiserum to the full-length I;HIT protein in immunoblot analyses, 4/9 cell lines analysed showed no expression of pFhit, two exhibited low levels of expression, and three expressed a putative truncated pFhit. One of 15 tumors analysed also exhibited an overexpressed truncated protein. PCR/SSCP and Southern analysis of one cell line DNA that expressed a truncated protein indicated that it sustained homozygous loss of FHIT exon 5. Our results suggest that alterations in FHIT at the DNA, RNA, and protein levels exist at a low but significant frequency in HNSCCs. Further studies regarding the potential biological activity of FHIT are needed to clarify the role of this gene in HIVSCC tumorigenesis.	Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA; Merck & Co Inc, Dept Genet Toxicol, West Point, PA 19486 USA	Fox Chase Cancer Center; Fox Chase Cancer Center; Merck & Company	Goodrow, TL (corresponding author), Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA.		Klein-Szanto, A./E-6218-2010		NCI NIH HHS [CA61889, CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R29CA061889, R01CA061889] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHSEE KW, 1994, CANCER RES, V54, P1617; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BARTKOVA J, 1995, CANCER RES, V55, P949; BERENSON JR, 1989, ONCOGENE, V4, P1111; BRACHMAN DG, 1994, SEMIN ONCOL, V21, P320; Druck T, 1997, CANCER RES, V57, P504; Fong KM, 1997, CANCER RES, V57, P2256; Gemma A, 1997, CANCER RES, V57, P1435; Hendricks DT, 1997, CANCER RES, V57, P2112; JOVANOVIC A, 1993, J ORAL PATHOL MED, V22, P459, DOI 10.1111/j.1600-0714.1993.tb00125.x; Kastury K, 1996, CANCER RES, V56, P978; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAMMIE GA, 1991, ONCOGENE, V6, P439; LATIF F, 1992, CANCER RES, V52, P1451; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Mao L, 1996, CANCER RES, V56, P5128; Mau S, 1996, CANCER RES, V56, P5484; MERRITT WD, 1990, ARCH OTOLARYNGOL, V116, P1394; NAWROZ H, 1994, CANCER RES, V54, P1152; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Sakata K, 1996, J ORAL PATHOL MED, V25, P302, DOI 10.1111/j.1600-0714.1996.tb00266.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHUURING E, 1992, ONCOGENE, V7, P355; SOMERS KD, 1990, ONCOGENE, V5, P915; Sozzi G, 1996, CANCER RES, V56, P2472; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Thiagalingam S, 1996, CANCER RES, V56, P2936; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Waber PG, 1996, ONCOGENE, V12, P365; Xiao GH, 1997, AM J PATHOL, V151, P1541; Yanagisawa K, 1996, CANCER RES, V56, P5579; ZHANG SY, 1994, CANCER RES, V54, P5050	34	31	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	1998	17	1					83	91		10.1038/sj.onc.1201910	http://dx.doi.org/10.1038/sj.onc.1201910			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671317				2022-12-28	WOS:000074677800010
J	Marston, NJ; Ludwig, RL; Vousden, KH				Marston, NJ; Ludwig, RL; Vousden, KH			Activation of p53 DNA binding activity by point mutation	ONCOGENE			English	Article						p53; DNA binding; cell cycle arrest; apoptosis	HUMAN CANCER-CELLS; WILD-TYPE P53; MONOCLONAL-ANTIBODIES; TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; MUTANT P53; PROTEIN; ARREST; TRANSFORMATION; APOPTOSIS	The p53 tumor suppressor protein can adopt both latent, non-DNA binding and active, DNA binding forms, and p53 activity is thought to be regulated in cells, at least in part, through a conformational shift which leads to sequence specific DNA binding. In vitro, this allosteric regulation of DNA binding by p53 has been shown to be mediated through the C-terminus of the protein. We show here that although deletion of the C-terminal 16 amino acids of p53 did not activate DNA binding, deletion of a further eight amino acids resulted in constitutive activation of DNA binding activity. Simultaneous mutation of the three lysine residues within these eight amino acids also resulted in constitutive DNA binding activity, although this was reduced when only two of these lysines were altered, The deletion or point mutants of p53 showing constitutive DNA binding activity did not display clear evidence of DNA binding site specificity, although some binding site preference was seen with the point mutants. Each of the constitutively active p53 mutants retained transcriptional activity and induced both cell cycle arrest and apoptosis in transiently transfected cells at rates comparable with the wild type protein.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, W 7th St, Frederick, MD 21702 USA.							ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; ATTARDI LD, 1996, EMBO J, V15, P3639; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fredersdorf S, 1996, AM J PATHOL, V148, P825; FREIDLANDER P, 1996, MOL CELL BIOL, V16, P4961; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAINAUT P, 1993, CANCER RES, V53, P4469; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JUVEN T, 1993, ONCOGENE, V8, P3411; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lu X, 1996, ONCOGENE, V13, P413; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MIYASHITA T, 1995, CELL, V80, P293; RENZING J, 1995, ONCOGENE, V10, P1865; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shaw P, 1996, ONCOGENE, V12, P921; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; TARUNINA M, 1993, ONCOGENE, V8, P3165; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINBERG WC, 1995, ONCOGENE, V10, P2271	50	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3123	3131		10.1038/sj.onc.1201856	http://dx.doi.org/10.1038/sj.onc.1201856			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671391				2022-12-28	WOS:000074261300005
J	Lee, CW; Sorensen, TS; Shikama, N; La Thangue, NB				Lee, CW; Sorensen, TS; Shikama, N; La Thangue, NB			Functional interplay between p53 and E2F through co-activator p300	ONCOGENE			English	Article						p53; E2F; p300; apoptosis; transcription	CELL-CYCLE CONTROL; TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA-PROTEIN; P53-DEPENDENT APOPTOSIS; P53-MEDIATED APOPTOSIS; DEPENDENT KINASES; GENE-PRODUCT; HELA-CELLS; S-PHASE; EXPRESSION	Both E2F and p53 are sequence specific transcription factors that regulate early cell cycle progression. The pathway of control mediated through E2F governs the transition from G1 into S phase whereas p53 in response to genotoxic stress can facilitate cell cycle arrest or apoptosis, The mechanisms which influence the outcome of p53 induction are not clear, although transcription of the p53 target gene, encoding the cdk-inhibitor p21(Waf1/Cip1), correlates with p53-mediated cell cycle arrest. Here using a combination of biochemical and functional assays we identify p300 as a co-activator required for p53-dependent transcriptional activation of Waf1/Cip1, Furthermore, we show that the cdk-inhibitor p21(Waf1/Cip1) autoregulates in a positive fashion transcription through modulating the activity of the p53/p300 complex, whilst negatively regulating the activity of E2F by preventing cdk-dependent phosphorylation of pRb. Consistent with a role for p21(Waf1/Cip1) in, the autoregulation of p53-dependent transcription, p300 augments the ability of p53 to cause G1 arrest and, conversely, cells undergoing p53-dependent apoptosis are rescued by p300. Thus, our data suggest that the ability of p300 to interact with p53 influences the physiological consequence of p53 activation. From previous studies it is known that cells expressing aberrant levels of E2F-1 can undergo p53-dependent apoptosis, In addition, we find that E2F-1 can cause apoptosis in p53(-\-) tumour cells and further p300, which also functions as a co-activator for the E2F/DP heterodimer, enhances the apoptotic activity of E2F-1, In conditions where E2F-1 and p53 co-operate in apoptosis E2F-1. can effectively compete for p300, causing a reduction in p53-dependent transcription. Thus, a functional interaction between p300 and either p53 or E2F-1 has a profound impact on early cell cycle progression, specifically in regulating the contrasting outcomes of cell cycle arrest and apoptosis. These results suggest a critical role for p300 in integrating and coordinating the functional interplay between the pathways of growth control mediated by E2F and p53.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Botz J, 1996, MOL CELL BIOL, V16, P3401; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P449; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Johnston Leland H., 1992, Trends in Cell Biology, V2, P353, DOI 10.1016/0962-8924(92)90041-K; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIYASHITA T, 1995, CELL, V80, P293; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Muraoka M, 1996, ONCOGENE, V12, P1565; NEVINS JR, 1992, SCIENCE, V258, P424; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; WALDMAN T, 1995, CANCER RES, V55, P5187; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	76	88	91	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2695	2710		10.1038/sj.onc.1201818	http://dx.doi.org/10.1038/sj.onc.1201818			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652736				2022-12-28	WOS:000073812200001
J	Burger, AM; Zhang, X; Li, H; Ostrowski, JL; Beatty, B; Venanzoni, M; Papas, T; Seth, A				Burger, AM; Zhang, X; Li, H; Ostrowski, JL; Beatty, B; Venanzoni, M; Papas, T; Seth, A			Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas	ONCOGENE			English	Article						molecular cloning; immunohistochemistry; FISH mapping; LOH; breast cancer	EPITHELIAL-CELLS; CANCER CELLS; IDENTIFICATION; EXPRESSION; HETEROZYGOSITY; INHIBITOR	To define genes that are essential to the initiation and progression of breast cancer we utilized subtractive hybridization and differential display cloning techniques and isolated over 950 cDNAs from breast cell-lines derived from matched normal and tumor tissue, Of these, 102 cDNAs mere characterized by DNA sequencing and Northern blot analysis, GenBank searches showed that one of these genes, T1A12 is identical to mac25, an insulin-like growth factor-binding protein related gene. Antibodies generated against the C-terminal region of the T1A12/mac25 protein were used to investigate its expression in 60 primary breast tissues. Sections of 12 benign, 16 ductal carcinoma in situ and 32 infiltrating ductal carcinoma specimens were examined, Strong immunoperoxidase staining was observed in luminal epithelial cells of normal lobules and ducts, in apocrine cells of cysts and fibroadenomas, Moderate to weak protein expression was found in hyperplastic and DCIS cells, but no specific staining was detected in invasive carcinoma cells. FISH mapping using a PAC clone localized the T1A12/mac25 gene to 4q12-13, Microsatellite length polymorphism was studied using markers for 4q in paired normal and tumor breast tissues. Thirty-three per cent (10/30) of the samples mere found to be polymorphic with D4S189 and D4S231 microsatellite markers and LOH was detected in 50% (5/10) of these informative samples. Our data indicate that T1A12/mac25 expression is abrogated during breast cancer progression concomitant with loss of heterozygosity on chromosome 4q, T1A12/mac25 may therefore have a tumor suppressor-like function and its expression could indicate a disease with a more favorable status, having a better prognosis.	Univ Toronto, MRC, Dept Lab Med & Pathobiol, Periodontal Physiol Grp, Toronto, ON M5S 1B2, Canada; Univ Toronto, Womens Coll Hosp, Toronto, ON M5S 1B2, Canada; Univ Freiburg, Tumor Biol Ctr, D-79106 Freiburg, Germany; Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA; Leeds Gen Infirm, Dept Pathol, Leeds LS2 9JT, W Yorkshire, England; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; Canc Therapy & Prevent Res Assoc, Rome, Italy	University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Freiburg; Medical University of South Carolina; Leeds General Infirmary; University of Leeds; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Seth, A (corresponding author), Univ Toronto, MRC, Dept Lab Med & Pathobiol, Periodontal Physiol Grp, Toronto, ON M5S 1B2, Canada.							Akaogi K, 1996, P NATL ACAD SCI USA, V93, P8384, DOI 10.1073/pnas.93.16.8384; Baserga R, 1997, ENDOCRINOLOGY, V138, P2217, DOI 10.1210/en.138.6.2217; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; BELL SM, 1991, BRIT J CANCER, V64, P174, DOI 10.1038/bjc.1991.264; BOCKER W, 1992, VIRCHOWS ARCH A, V421, P315, DOI 10.1007/BF01660978; BURGER A, IN PRESS ONCOGENE; Burger AM, 1996, INT J ONCOL, V8, P395; BURGER AM, 1996, MIANI SHORT REPORTS, V7, P65; CAWKWELL L, 1993, BRIT J CANCER, V67, P1292; CHEN JC, 1994, CELL PHYSL, V158, P69; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; CULOUSCOU JM, 1991, CANCER RES, V51, P2813; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FIGUEROA JA, 1993, J CELL BIOCHEM, V52, P196, DOI 10.1002/jcb.240520211; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HAMBLY RJ, 1994, THESIS U BRADFORD; KATO MV, 1996, ONCOGENE, V12, P1362; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MCGUIRE WL, 1992, J NATL CANCER I, V84, P1336, DOI 10.1093/jnci/84.17.1336; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; OH Y, 1996, J BIOL CHEM, V271, P33352; OOI GT, 1990, MOL CELL ENDOCRINOL, V71, pC39, DOI 10.1016/0303-7207(90)90243-2; PATTERSON H, 1992, EUR J CANCER, V28A, P258, DOI 10.1016/0959-8049(92)90428-5; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEKONEN F, 1992, CANCER RES, V52, P5204; Plymate SR, 1996, J CLIN ENDOCR METAB, V81, P3709, DOI 10.1210/jc.81.10.3709; POLLAK M, 1990, J NATL CANCER I, V82, P1693, DOI 10.1093/jnci/82.21.1693; RADFORD DM, 1995, CANCER RES, V55, P5180; SALESIOTIS AN, 1995, CANCER LETT, V91, P47, DOI 10.1016/0304-3835(95)03717-B; SATO H, 1995, BIOCHEM BIOPH RES CO, V214, P468, DOI 10.1006/bbrc.1995.2310; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SOUBEYRAN I, 1995, BREAST CANCER RES TR, V34, P119, DOI 10.1007/BF00665784; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TARMIN L, 1994, CANCER RES, V54, P6094; Tripathy D, 1992, Cancer Treat Res, V63, P15; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; WESTLEY BR, 1995, BRIT J CANCER, V72, P1065, DOI 10.1038/bjc.1995.465; WINQVIST R, 1993, CANCER RES, V53, P4486; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YEE D, 1994, CELL GROWTH DIFFER, V5, P73	41	119	132	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2459	2467		10.1038/sj.onc.1201772	http://dx.doi.org/10.1038/sj.onc.1201772			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627112				2022-12-28	WOS:000073672300004
J	Andres, JL; Fan, SJ; Turkel, GJ; Wang, JA; Twu, NF; Yuan, RQ; Lamszus, K; Goldberg, ID; Rosen, EM				Andres, JL; Fan, SJ; Turkel, GJ; Wang, JA; Twu, NF; Yuan, RQ; Lamszus, K; Goldberg, ID; Rosen, EM			Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents	ONCOGENE			English	Article						breast cancer; BRCA1; BRCA2; MCF-7; DNA damage; adriamycin	TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; SUSCEPTIBILITY GENE; IN-VIVO; P53; PROGRESSION; INHIBITION; INTERACTS; GROWTH	Germline mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 have been linked Ito the development of breast cancer, ovarian cancer, and other malignancies. Recent studies suggest that the BRCA1 and BRCA2 gene products may function in the sensing and/or repair of DNA damage. To investigate this possibility, we determined the effects of various DNA-damaging agents and other cytotoxic agents on the mRNA levels of BRCA1 and BRCA2 in the MCF-7 and other human breast cancer cell lines. We found that several agents, including adriamycin (a DNA intercalator and inhibitor of topoisomerase II), camptothecin (a topoisomerase I inhibitor), and ultraviolet radiation induced significant decreases in BRCA1 and BRCA2 mRNA levels. Decreased levels of BRCA1 and BRCA2 mRNAs were observed within 6-12 h after treatment with adriamycin and persisted for at least 72 h. Adriamycin also induced decreases in BRCA1 protein levels; but these decreases required several days. U.V. radiation induced dose-dependent down-regulation of BRCA1 and BRCA2 mRNAs, with significant decreases in both mRNAs at doses as low as 2.5 J/m(2), a dose that yielded very little cytotoxicity. Adriamycin-induced down-regulation of BRCA1 and BRCA2 mRNAs was first observed at doses that yielded relatively little cytotoxicity and little or no apoptotic DNA fragmentation, Adriamycin and U.V. radiation induced distinct dose- and time-dependent alterations in the cell cycle distribution; but these alterations did not correlate well with corresponding changes in BRCA1 and BRCA2 mRNA levels. However, the adriamycin-induced reduction in BRCA1 and BRCA2 mRNA levels was correlated with p53 functional status. MCF-7 cells transfected with a dominant negative mutant p53 (143 val-->ala) required at least tenfold higher doses of adriamycin to down-regulate BRCA1 and BRCA2 mRNAs than did parental MCF-7 cells or control-transfected MCF-7 clones. These results suggest that BRCA1 and BRCA2 may play roles in the cellular response to DNA-damaging agents and that there may be a p53-sensitive component to the regulation of BRCA1 and BRCA2 mRNA expression.	Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, New Hyde Park, NY 11040 USA	Northwell Health; Yeshiva University	Rosen, EM (corresponding author), Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Park, NY 11040 USA.				NATIONAL CANCER INSTITUTE [R01CA064869] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA64869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; EASTON DF, 1993, AM J HUM GENET, V52, P678; FAN SJ, 1995, CANCER RES, V55, P1649; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GUDAS J, 1996, CELL GROWTH DIFFER, V7, P712; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Larson JS, 1997, CANCER RES, V57, P3351; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; ROSEN EM, 1991, CANCER RES, V51, P5315; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Shao NS, 1996, ONCOGENE, V13, P1; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Spillman MA, 1996, ONCOGENE, V13, P1639; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1841, DOI 10.1093/carcin/14.9.1841; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395	42	77	77	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2229	2241		10.1038/sj.onc.1201752	http://dx.doi.org/10.1038/sj.onc.1201752			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619832				2022-12-28	WOS:000073298000008
J	Albrecht, JH; Poon, RYC; Ahonen, CL; Rieland, BM; Deng, CX; Crary, GS				Albrecht, JH; Poon, RYC; Ahonen, CL; Rieland, BM; Deng, CX; Crary, GS			Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver	ONCOGENE			English	Article						cyclins; cyclin-dependent kinases; liver regeneration; G1 phase	GROWTH-FACTOR-BETA; KINASE INHIBITOR P21; DEPENDENT KINASES; MICE LACKING; RESTRICTION POINT; GENE-EXPRESSION; MESSENGER-RNA; DNA-SYNTHESIS; TGF-BETA; P27(KIP1)	In tissue culture systems, p21 and p27 inhibit cyclin-dependent kinase (CDK) activity and cell cycle progression in response to numerous stimuli, but little is known about their involvement in cell growth in vivo. We examined the modulation of CDK activity by these proteins after 70% partial hepatectomy (PH), an in vivo model of synchronous hepatocyte cell cycle progression, After PH In BALB/c mice, p21 was induced during the prereplicative (G1) phase and was maximally expressed after peak hepatocyte DNA synthesis. p27 was present in quiescent liver and was minimally induced after PH. p21 and p27 immunoprecipitated with CDK2, CDK4, and cyclin D1 in the regenerating liver. The activity of CDK2-, CDK4- and cyclin D1-associated kinases was upregulated after PH, and maximal activity of these enzyme complexes corresponded to peak DNA synthesis. Immunodepletion experiments suggested that p27 plays a role in downregulating CDK2 activity before and after peak DNA synthesis. Compared to cogenic wild-type mice, p21-/-mice demonstrated evidence of markedly accelerated hepatocyte progression through G1 phase after PH: DNA synthesis, upregulation of cyclin A and PCNA, induction of cyclin D1- and CDK2-associated kinase activity, and appearance of a phosphorylated retinoblastoma protein (Rh) species occurred earlier in the p21-/-mice. These results suggest that p21 and p27 modulate CDK activity in the regenerating liver, and that p21 regulates the rate of progression through G1 phase of the cell cycle in vivo.	Hennepin Cty Med Ctr, Dept Med 865B, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Dept Pathol, Minneapolis, MN 55415 USA; Minneapolis Med Res Fdn, Minneapolis, MN 55404 USA; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong; NIDDKD, Biochem & Metab Lab, NIH, Bethesda, MD 20892 USA	Hennepin County Medical Center; Hennepin County Medical Center; Minneapolis Medical Research Foundation; Hong Kong University of Science & Technology; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Albrecht, JH (corresponding author), Hennepin Cty Med Ctr, Dept Med 865B, 701 Park Ave, Minneapolis, MN 55415 USA.		deng, chuxia/N-6713-2016	Poon, Randy/0000-0001-5571-6231				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; ALBRECHT JH, 1994, FEBS LETT, V347, P157, DOI 10.1016/0014-5793(94)00527-3; ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BUCHER NLR, 1963, INT REV CYTOL, V15, P245, DOI 10.1016/S0074-7696(08)61119-5; CASTRO A, 1994, BIOCHEM BIOPH RES CO, V201, P1072, DOI 10.1006/bbrc.1994.1814; Chen Y, 1996, J BIOL CHEM, V271, P19637, DOI 10.1074/jbc.271.33.19637; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; CORNELL RP, 1990, HEPATOLOGY, V11, P916, DOI 10.1002/hep.1840110603; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GRANA X, 1995, ONCOGENE, V11, P211; GREENBAUM LE, 1995, J CLIN INVEST, V96, P1351, DOI 10.1172/JCI118170; GRISHAM JW, 1962, CANCER RES, V22, P842; GUO K, 1995, MOL CELL BIOL, V15, P3823; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kren BT, 1996, FASEB J, V10, P559, DOI 10.1096/fasebj.10.5.8621056; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lin Bryan T. Y., 1992, V170, P227; LORUP C, 1977, CELL TISSUE KINET, V10, P477, DOI 10.1111/j.1365-2184.1977.tb00866.x; LOYER P, 1994, J BIOL CHEM, V269, P2491; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; LU XP, 1992, J BIOL CHEM, V267, P2841; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARX J, 1995, SCIENCE, V267, P963, DOI 10.1126/science.7863339; MEAD JE, 1990, CANCER RES, V50, P7023; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Paulsen J E, 1990, In Vivo, V4, P235; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POON RYC, 1994, J CELL SCI, V107, P2789; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sclafani RA, 1996, CURR OPIN CELL BIOL, V8, P788, DOI 10.1016/S0955-0674(96)80079-2; Serfas MS, 1997, CELL GROWTH DIFFER, V8, P951; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	65	169	174	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2141	2150		10.1038/sj.onc.1201728	http://dx.doi.org/10.1038/sj.onc.1201728			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572495				2022-12-28	WOS:000073177200012
J	Umikawa, M; Tanaka, K; Kamei, T; Shimizu, K; Imamura, H; Sasaki, T; Takai, Y				Umikawa, M; Tanaka, K; Kamei, T; Shimizu, K; Imamura, H; Sasaki, T; Takai, Y			Interaction of Rho1p target Bni1p with F-actin-binding elongation factor 1 alpha: implication in Rho1p-regulated reorganization of the actin cytoskeleton in Saccharomyces cerevisiae	ONCOGENE			English	Article						Rho; actin cytoskeleton; EF1 alpha	PROTEIN-KINASE-C; YEAST PROTEIN; BUDDING YEAST; IDENTIFICATION; DICTYOSTELIUM; GENE; FACTOR-1-ALPHA; TRANSFORMATION; MORPHOGENESIS; DROSOPHILA	The RHO1 gene encodes a homolog of mammalian RhoA small G protein in the yeast Saccharomyces cerevisiae. We have shown that Bni1p is one of the downstream targets of Rho1p and regulates reorganization of the actin cytoskeleton through the interaction with profilin, an actin monomer-binding protein. A Bni1p-binding protein was affinity purified from the yeast cytosol fraction and was identified to be Tef1p/Tef2p, translation elongation factor 1 alpha (EF1 alpha). EF1 alpha is an essential component of the protein synthetic machinery and also possesses the actin filament (F-actin)binding and -bundling activities. EF1 alpha bound to the 186 amino acids region of Bni1p, located between the FH1 domain, the proline-rich profilin-binding domain, and the FH2 domain, of which function is not known. The binding of Bni1p to EF1 alpha inhibited its F-actin-binding and -bundling activities. The BNI1 gene deleted in the EF1 alpha-binding region did not suppress the bni1 bnr1 mutation in which the actin organization was impaired. These results suggest that the Rho1p-Bni1p system regulates reorganization of the actin cytoskeleton through the interaction with both EF1 alpha and profilin.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 565, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 565, Japan.							Amberg DC, 1997, MOL BIOL CELL, V8, P729, DOI 10.1091/mbc.8.4.729; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; DEMMA M, 1990, J BIOL CHEM, V265, P2286; DHARMAWARDHANE S, 1991, CELL MOTIL CYTOSKEL, V20, P279, DOI 10.1002/cm.970200404; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; Edmonds BT, 1996, J CELL SCI, V109, P2705; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUAN C, 1987, GENE, V67, P21; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Higuchi R., 1989, PCR TECHNOLOGY, P61; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MARHOUL JF, 1995, GENETICS, V139, P537; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PETERSEN J, 1995, MOL CELL BIOL, V15, P3697; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; Sherman F., 1986, METHODS YEAST GENETI; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; Zahner JE, 1996, MOL CELL BIOL, V16, P1857	43	62	63	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					2011	2016		10.1038/sj.onc.1201724	http://dx.doi.org/10.1038/sj.onc.1201724			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591785				2022-12-28	WOS:000073079400013
J	Zhang, CC; Yang, JM; White, E; Murphy, M; Levine, A; Hait, WN				Zhang, CC; Yang, JM; White, E; Murphy, M; Levine, A; Hait, WN			The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells	ONCOGENE			English	Article						drug sensitivity; p53; MAP4; microtubule polymerization	DNA-DAMAGE; ANTICANCER AGENTS; CYCLE CHECKPOINT; GROWTH ARREST; APOPTOSIS; PROTEIN; CANCER; MUTATIONS; DEATH; TAXOL	Mutations in p53 change the sensitivity to cancer chemotherapeutic drugs, Whereas many drugs, including the vinca alkaloids, often become less effective when p53 is transcriptionally inactivated, several, most notably paclitaxel, may become more effective, In studying the underlying mechanism(s), we found that increased MAP4 expression, which occurs with transcriptionally silent p53, is associated with increased sensitivity to paclitaxel and decreased sensitivity to vinca alkaloids, Using murine fibroblasts transfected with MAP4, we directly demonstrated that the changes in drug sensitivity were associated with parallel alterations in drug-induced apoptosis and cell-cycle arrest, Immunofluorescent staining of the microtubule network revealed that cells with increased MAP4 expression displayed an increase in polymerized microtubules and an increased binding of fluorsceinated paclitaxel, Since MAP4 stabilizes polymerized microtubules, overexpression of this gene provides a plausible mechanism to explain the altered sensitivity to microtubule-active drugs in the presence of mutant p53.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Inst Canc, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Princeton University	Hait, WN (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ 08854 USA.		White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065; Murphy, Maureen/0000-0001-7644-7296	NATIONAL CANCER INSTITUTE [P20CA057124, R01CA066077, R01CA043888] Funding Source: NIH RePORTER; NCI NIH HHS [CA57124, CA43888, CA66077] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHAPIN SJ, 1995, BIOCHEMISTRY-US, V34, P2289, DOI 10.1021/bi00007a025; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Delia D, 1996, NAT MED, V2, P724, DOI 10.1038/nm0796-724; FAN S, 1996, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; GEWIRTZ DA, 1993, ONCOL RES, V5, P397; GUPTA RS, 1985, JNCI-J NATL CANCER I, V74, P159; GUPTA RS, 1988, BIOCHEM BIOPH RES CO, V153, P598, DOI 10.1016/S0006-291X(88)81137-9; HALL PA, 1993, ONCOGENE, V8, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hawkins DS, 1996, CANCER RES, V56, P892; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KONDO S, 1994, CANCER RES, V54, P2928; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Lobert S, 1996, BIOCHEMISTRY-US, V35, P6806, DOI 10.1021/bi953037i; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUTZKER S, 1996, DRUG RESISTANCE, P345; MERRITT AJ, 1994, CANCER RES, V54, P614; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Nguyen HL, 1997, J CELL SCI, V110, P281; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; SCUDIERO DA, 1988, CANCER RES, V48, P4827; TISHLER RB, 1995, CANCER RES, V55, P6021; VOLGELSTEIN B, 1992, CELL, V70, P523; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Yoshida T, 1996, CELL MOTIL CYTOSKEL, V33, P252, DOI 10.1002/(SICI)1097-0169(1996)33:4<252::AID-CM2>3.0.CO;2-B; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	42	136	140	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1617	1624		10.1038/sj.onc.1201658	http://dx.doi.org/10.1038/sj.onc.1201658			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569030				2022-12-28	WOS:000072743200013
J	O'Rourke, DM; Nute, EJL; Davis, JG; Wu, CJ; Lee, A; Murali, R; Zhang, HT; Qian, XL; Kao, CC; Greene, MI				O'Rourke, DM; Nute, EJL; Davis, JG; Wu, CJ; Lee, A; Murali, R; Zhang, HT; Qian, XL; Kao, CC; Greene, MI			Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly	ONCOGENE			English	Article						heterodimer; mutant epidermal growth factor receptor; p185neu; trans-receptor inhibition	GROWTH-FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; TYROSINE KINASE-ACTIVITY; NECROSIS-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; INTERMOLECULAR ASSOCIATION; EXTRACELLULAR DOMAIN; HUMAN GLIOBLASTOMAS; DOWN-REGULATION; POINT MUTATION	Mutant Epidermal Growth Factor Receptor (EGFR) oncoproteins lacking most of subdomains I and II of the extracellular region, a deletion which includes most of the first of two cysteine-rich sequences, have been observed in multiple human epithelial tumors, including malignant gliomas, These EGFR oncoproteins, designated Delta EGFR or EGFRvIII, confer increased tumorigenicity in vivo and are often coexpressed with full-length EGFR in human tumors, We have expressed an ectodomain-derived, carboxyl-terminal deletion mutant of the p185neu oncogene (T691stop) in human glioblastoma cells coexpressing endogenous EGFR and activated Delta EGFR oncoproteins, The p185neu ectodomain-derived mutant forms heterodimers with Delta EGFR proteins and reduces the phosphotyrosine content and kinase activity of Delta EGFR monomers, As a consequence of T691stop neu expression and surface localization, cell proliferation in conditions of full growth and reduced serum and anchorage-independent growth in soft agar was reduced in glioblastoma cells expressing either endogenous EGFR alone or coexpressing EGFR and elevated levels of Delta EGFRs. T691stop neu mutant receptors abrogate the dramatic growth advantage conferred by Delta EGFR in vivo, suggesting that physical associations primarily between subdomains III and IV of the p185neu and EGFR ectodomains are sufficient to modulate signaling from activated EGFR complexes, Receptor-based inhibitory strategies exploit the thermodynamic preference for erbB ectodomains to heterodimerize, thereby creating erbB receptor assemblies which are defective in signaling and do not internalize. Pharmaceuticals which mimic the p185neu ectodomain may therefore have important therapeutic applications in advanced human malignancies expressing erbB receptors.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	O'Rourke, DM (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 252 John Morgan Bldg,36th & Hamilton Walk, Philadelphia, PA 19104 USA.		O'Rourke, Donald/AAC-3376-2021	Zhang, Hongtao/0000-0001-9173-0049; O'Rourke, Donald/0000-0002-8479-7314; Murali, Ramachandran/0000-0002-8384-2793				Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARTER TH, 1994, CRIT REV ONCOGENESIS, V5, P389, DOI 10.1615/CritRevOncog.v5.i4.40; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; GROUSPORTA D, 1997, EMBO J, V16, P1647; GUY PM, 1992, J BIOL CHEM, V267, P13851; HALEY JD, 1989, ONCOGENE, V4, P273; Han YC, 1996, CANCER RES, V56, P3859; HE J, 1995, CANCER RES, V55, P4833; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELIN K, 1991, J BIOL CHEM, V266, P8363; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KOHDA D, 1993, J BIOL CHEM, V268, P1976; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LEVEA CM, 1993, RECEPTOR, V3, P293; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Louis DN, 1997, BRAIN PATHOL, V7, P755, DOI 10.1111/j.1750-3639.1997.tb01062.x; MASUI H, 1991, CANCER RES, V51, P6170; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1996, ONCOGENE, V13, P85; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; MURRAYRUST J, 1993, STRUCTURE, V1, P153, DOI 10.1016/0969-2126(93)90029-G; MYERS JN, 1992, RECEPTOR, V2, P1; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISHIKAWA R, 1995, CANCER RES, V55, P1941; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; ORourke DM, 1997, P ASSOC AM PHYSICIAN, V109, P209; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; QIAN XL, 1995, ONCOGENE, V10, P211; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; REIST CJ, 1995, CANCER RES, V55, P4375; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SOROKIN A, 1995, ONCOGENE, V11, P1531; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wikstrand CJ, 1997, CANCER RES, V57, P4130; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594	67	49	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1197	1207		10.1038/sj.onc.1201635	http://dx.doi.org/10.1038/sj.onc.1201635			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528862				2022-12-28	WOS:000072336000011
J	Ichaso, N; Rodriguez, RE; Martin-Zanca, D; Gonzalez-Sarmiento, R				Ichaso, N; Rodriguez, RE; Martin-Zanca, D; Gonzalez-Sarmiento, R			Genomic characterization of the human trkC gene	ONCOGENE			English	Article						trkC gene; intron/exon structure; promoter sequence	NEUROTROPHIN RECEPTOR TRKC; MESSENGER-RNA; MOLECULAR-CLONING; RAT TRKC; EXPRESSION; NEUROBLASTOMAS; AFFERENTS; MUTATIONS; ONCOGENE; FAMILY	The trkC gene encodes the high-affinity receptor for neurotrophin 3 and plays an important role in the regulation of the survival and differentiation of the mammalian nervous system and in heart development. Chromosomal rearrangements of trkC have been recently reported in congenital fibrosarcoma and it has been proposed that abnormal activation of this gene might be involved in tumor development. To facilitate the search for new mutations and rearrangements in the human trkC locus we have partially characterized its genomic organization by restriction mapping and have obtained the complete intron-exon structure. Our results show that human trkC consists of 20 exons, including two that encode the inserts present in the extracellular and tyrosine kinase domains, and another two that encode the carboxyl-terminal tail of the truncated TRKC isoform. Analysis of the 5' flanking region revealed the absence of TATA box, a very high content in C/G compatible with a CpG island and the presence of putative binding sites for the AP1, AP2, GC, ATF, BRN2, AML1 and Nkx2.5 transcription factors.	Univ Salamanca, Dept Med, Unidad Med Mol, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain; Univ Salamanca, CSIC, Inst Microbiol Bioquim, E-37008 Salamanca, Spain	University of Salamanca; University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Gonzalez-Sarmiento, R (corresponding author), Univ Salamanca, Dept Med, Unidad Med Mol, Avda Campo Charro S-N, Salamanca 37007, Spain.		Gonzalez-Sarmiento, Rogelio/V-5526-2019	Gonzalez-Sarmiento, Rogelio/0000-0002-2726-6795; Rodriguez Rodriguez, Raquel/0000-0003-1805-3066				AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARKER PA, 1993, J BIOL CHEM, V268, P15150; Chang BB, 1998, J BIOL CHEM, V273, P39, DOI 10.1074/jbc.273.1.39; Donovan MJ, 1996, NAT GENET, V14, P210, DOI 10.1038/ng1096-210; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; Greco A, 1996, ONCOGENE, V13, P2463; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCGREGOR LM, 1994, GENOMICS, V22, P267, DOI 10.1006/geno.1994.1383; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ryden M, 1996, BRIT J CANCER, V74, P773, DOI 10.1038/bjc.1996.435; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SEGAL RA, 1994, P NATL ACAD SCI USA, V91, P12867, DOI 10.1073/pnas.91.26.12867; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; Tessarollo L, 1997, P NATL ACAD SCI USA, V94, P14776, DOI 10.1073/pnas.94.26.14776; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; Yamashiro DJ, 1996, ONCOGENE, V12, P37	30	26	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1871	1875		10.1038/sj.onc.1202100	http://dx.doi.org/10.1038/sj.onc.1202100			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778053				2022-12-28	WOS:000076303300013
J	FitzGerald, MG; Marsh, DJ; Wahrer, D; Bell, D; Caron, S; Shannon, KE; Ishioka, C; Isselbacher, KJ; Garber, JE; Eng, C; Haber, DA				FitzGerald, MG; Marsh, DJ; Wahrer, D; Bell, D; Caron, S; Shannon, KE; Ishioka, C; Isselbacher, KJ; Garber, JE; Eng, C; Haber, DA			Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer	ONCOGENE			English	Article						PTEN/MMAC1; Cowden syndrome; breast cancer; genetic predisposition; yeast truncation assay		Heterozygous germline mutations in PTEN are responsible for most cases of Cowden Syndrome, a rare familial trait characterized by hamartomas and by predisposition to cancer of the breast and thyroid. The variable and often subtle clinical findings that characterize Cowden Syndrome are frequently unrecognized, raising the possibility that germline PTEN mutations may confer susceptibility to breast cancer in women who have not been diagnosed with this syndrome. To determine whether such mutations contribute to genetic predisposition to breast cancer within the general population, we analysed a cohort of women with early-onset breast cancer (<age 40), a subset of the population at increased risk for genetic susceptibility, Lymphoblast cell lines were analysed using either direct nucleotide sequencing (28 cases), denaturing gradient gel electrophoresis (DGGE) (34 cases) or a yeast-based truncation assay (110 cases). No definitive, truncating mutations were observed in 172 patients, Missense changes were noted in the germline of 2/60 patients analysed by direct nucleotide sequencing or DGGE, including a non-conservative amino acid substitution within the phosphatase domain, but neither showed loss of the wild-type allele in the corresponding breast tumor specimen, We conclude that germline mutations in PTEN are an uncommon cause of genetic predisposition to breast cancer within the general population.	Massachusetts Gen Hosp, Ctr Canc Risk Anal, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Boston, MA 02114 USA; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge, England; Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 980, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Program Populat Sci, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Cambridge; Tohoku University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc Risk Anal, Charlestown, MA 02129 USA.		Marsh, Deborah J/I-1491-2014	Marsh, Deborah J/0000-0001-5899-4931; Ishioka, Chikashi/0000-0002-3023-1227; Eng, Charis/0000-0002-3693-5145				CLAUS EB, 1991, AM J HUM GENET, V48, P232; Dahia PLM, 1997, CANCER RES, V57, P4710; DAHIA PLM, 1998, IN PRESS ONCOGENE; DURR WM, 1998, IN PRESS ONCOGENE; Eng C, 1997, J Genet Couns, V6, P181, DOI 10.1023/A:1025664119494; FEILOTTER HE, 1998, IN PRESS ONCOGENE; FEILOTTER HE, 1998, IN PRESS BR J CANC; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; Guldberg P, 1997, CANCER RES, V57, P3660; Ishioka C, 1997, P NATL ACAD SCI USA, V94, P2449, DOI 10.1073/pnas.94.6.2449; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Longy M, 1996, ANN GENET-PARIS, V39, P35; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rhei E, 1997, CANCER RES, V57, P3657; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tashiro H, 1997, CANCER RES, V57, P3935; Wang SI, 1997, CANCER RES, V57, P4183	25	45	46	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					727	731		10.1038/sj.onc.1201984	http://dx.doi.org/10.1038/sj.onc.1201984			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715274				2022-12-28	WOS:000075337200007
J	West, MJ; Stoneley, M; Willis, AE				West, MJ; Stoneley, M; Willis, AE			Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway	ONCOGENE			English	Article						c-myc; eIF-4G; rapamycin; S6 kinase; TOR; translation	EPSTEIN-BARR-VIRUS; INITIATION-FACTOR 4E; 5' UNTRANSLATED REGION; MESSENGER-RNA; PROTEIN-KINASE; GROWTH-FACTOR; S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; ORNITHINE DECARBOXYLASE; DEPENDENT TRANSLATION	Previous studies on the regulation of c-myc have focused on the transcriptional control of this proto-oncogene. We have investigated the signalling pathways involved under circumstances in which there is a translational upregulation in the levels of c-myc protein. We have demonstrated an up to tenfold serum-dependent increase of c-myc protein levels in Epstein-Barr virus immortalized B-cell lines 2-4 h after disruption of cellular aggregates, which is not accompanied by an equivalent increase in mRNA. Overall protein synthesis rates only increased threefold suggesting that the c-myc message was being selectively translated. We observed increases in the phosphorylation of p70 and p85 S6 kinases and of initiation factor eIF-4E binding protein 1 (4E-BP1) 1-2 h after stimulation, suggesting activation of the FRAP/TOR signalling pathway. The increased phosphorylation of 4E-BP1 led to a decrease in its association with eIF-4E and an increase in its association with the eIF-4G component of the eIF-4F initiation complex. The signalling; inhibitors rapamycin and wortmannin blocked the phosphorylation of 4E-BP1 and abolished the translational component of the c-myc response. Our data suggest that dissociation of eIF-4E from 4E-BP1, leading to an increase in the formation of the eIF-4F initiation complex, relieves the translation repression imposed ion the c-myc mRNA by its structured 5'UTR.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.			West, Michelle/0000-0002-9497-9365; Willis, Anne/0000-0002-1470-8531				ALLDAY MJ, 1994, J VIROL, V68, P3491, DOI 10.1128/JVI.68.6.3491-3498.1994; AMAN P, 1986, CURR TOP MICROBIOL, V132, P266; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BU X, 1991, FEBS LETT, V283, P219, DOI 10.1016/0014-5793(91)80592-Q; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHERNEY BW, 1994, P NATL ACAD SCI USA, V91, P12967, DOI 10.1073/pnas.91.26.12967; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; DEAN M, 1986, J BIOL CHEM, V261, P9161; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Flynn A, 1996, EUR J BIOCHEM, V236, P40, DOI 10.1111/j.1432-1033.1996.00040.x; GALLIE DR, 1994, J BIOL CHEM, V269, P7174; GRAY NK, 1994, MOL BIOL REP, V19, P195, DOI 10.1007/BF00986961; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JONES N, 1996, IMMUNOLOGY, V89, P26; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LAZARUS P, 1992, ONCOGENE, V7, P1037; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; LYONS RT, 1980, J BIOL CHEM, V255, P6330; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MAO XH, 1992, J BIOL CHEM, V267, P20444; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marshall CJ, 1996, FASEB J, V10, P7; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1995, J CELL SCI, V108, P1751; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORLEY SJ, 1995, BIOCHEM J, V312, P627, DOI 10.1042/bj3120627; NEPVEU A, 1987, ONCOGENE, V1, P243; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; Paulin FEM, 1996, ONCOGENE, V13, P505; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PROUD CG, 1994, NATURE, V371, P747, DOI 10.1038/371747a0; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REDPATH NT, 1992, ANAL BIOCHEM, V202, P340, DOI 10.1016/0003-2697(92)90115-N; Rosenwald IB, 1995, CANCER LETT, V98, P77, DOI 10.1016/0304-3835(95)90206-6; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WATERS CM, 1991, ONCOGENE, V6, P797; West MJ, 1995, ONCOGENE, V11, P2515; Young L S, 1992, Semin Cancer Biol, V3, P273	67	152	159	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					769	780		10.1038/sj.onc.1201990	http://dx.doi.org/10.1038/sj.onc.1201990			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715279				2022-12-28	WOS:000075337200012
J	Cartwright, P; Muller, H; Wagener, C; Holm, K; Helin, K				Cartwright, P; Muller, H; Wagener, C; Holm, K; Helin, K			E2F-6: a novel member of the E2F family is an inhibitor of E2F-dependent transcription	ONCOGENE			English	Article						E2F-6; inhibitor; cell cycle	RETINOBLASTOMA GENE-PRODUCT; UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE REGULATION; IN-VIVO; S-PHASE; GROWTH SUPPRESSION; E2F-BINDING SITE; BINDING PROTEIN; EXPRESSION; PROMOTER	The E2F family of transcription factors are essential for the regulation of genes required for appropriate progression through the cell cycle. Five members of the E2F family have been previously reported, namely E2F1-5. All five are key elements in transcriptional regulation of essential genes, and they can be divided into two functional groups, those that induce S-phase progression when overexpressed in quiescent cells (E2Fs 1-3), and those that do not (E2Fs 4-5). Here, we describe the identification of a novel member of this family, which we refer to as E2F-6, E2F-6 shares significant homology with E2Fs 1-5, especially within the DNA binding, heterodimerization and marked box domains. Unlike E2Fs 1-5, E2F-6 lacks a transactivation and a pocket protein binding domain, hence, forms a unique third group within the E2F family, E2F-6 is a nuclear protein that can form heterodimers with the DP proteins (both DP-I and DP-2) in vitro and in vivo. Our results show that the complex formed between E2F-6 and the DP proteins, possesses high DNA binding activity, displaying a preference for a TTTCCCGC E2F recognition site, which is slightly different to the E2F consensus site derived from the E2 promoter (TTTCGCGC). In contrast to the other members of the E2F family, ectopic expression of E2F-6 inhibits transcription from promoters possessing E2F recognition sites rather than activating transcription. In addition, overexpression of E2F-6 suppresses the transactivational effects of coexpression of E2F-1 and DP-1. The inhibitory effect of E2F-6 is dependent on its DIVA binding activity and its ability to form heterodimers with the DPs, Interestingly, ectopic expression of E2F-6 leads to accumulation of cells in S-phase, Our data suggest that E2F-6 expression delays the exit from S-phase rather than inducing S-phase, which further emphasizes the functional difference between E2F-6 and the previously known E2F family members.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Helin, K (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; Muller, Heiko/0000-0001-9873-3146				Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Botz J, 1996, MOL CELL BIOL, V16, P3401; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Geng Y, 1996, ONCOGENE, V12, P1173; Harlow E., 1988, ANTIBODIES LAB MANUA; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MELLILO RM, 1994, MOL CELL BIOL, V14, P8241; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Muller H, 1997, MOL CELL BIOL, V17, P5508; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wu CL, 1996, MOL CELL BIOL, V16, P3698; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	61	160	164	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					611	623		10.1038/sj.onc.1201975	http://dx.doi.org/10.1038/sj.onc.1201975			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704927				2022-12-28	WOS:000075195300009
J	Grundy, RG; Pritchard, J; Scambler, P; Cowell, JK				Grundy, RG; Pritchard, J; Scambler, P; Cowell, JK			Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour	ONCOGENE			English	Article						Wilms tumour; LOH 7p; WT tumour suppressor gene 7p 21-15	DENYS-DRASH SYNDROME; WT1 GENE; FAMILIAL PREDISPOSITION; DISTINCT REGIONS; POINT MUTATIONS; RENAL TUMORS; TRANSLOCATION; ABNORMALITIES; CHILDHOOD; LOCUS	Cytogenetic analysis of Wilms tumours (WT) have shown that abnormalities involving chromosome 7 occur in approximately 25% of tumours, In some cases, these abnormalities involve deletions of the short arm, and are seen as the sole cytogenetic change, strongly suggesting the presence of a tumour suppressor gene in this location. Since loss of heterozygosity (LOH) studies have been crucial in defining chromosomal regions involved in Wilms tumorigenesis, we have analysed 40 sporadic Wilms tumours using a panel of 10 microsatelite polymorphic markers distributed along the length of the chromosome arm. In our series, four tumours (10%) showed allelic loss for 7p markers which is twice the background rate of LOH in WT. The shortest common region of overlap of LOH was located between markers D7S517-D7S503 in band 7p21-15. In one tumour there was evidence for a homozygous, interstitial deletion at a locus within this region. These findings provide strong evidence for the existence of a tumour suppressor gene involved in Wilms tumorigenesis and defines the critical region of the chromosome involved.	Inst Child Hlth, Hematol Oncol Unit, London WC1N 1EH, England; Inst Child Hlth, Fetal Med Unit, London WC1N 1EH, England; Hosp Sick Children, Dept Hematol Oncol, London WC1, England	University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Grundy, RG (corresponding author), Middlesex Hosp, Dept Pediat & Adolescent Oncol, Mortimer St, London W1N 8AA, England.		Scambler, Peter/AAZ-6026-2020; Scambler, Peter J/C-4998-2008	Scambler, Peter/0000-0002-1487-4628; Scambler, Peter J/0000-0002-1487-4628; Cowell, John/0000-0002-2079-5950				AUSTRUY E, 1995, GENE CHROMOSOME CANC, V14, P285, DOI 10.1002/gcc.2870140407; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BAIRD PN, 1992, ONCOGENE, V7, P2141; BARNARD JL, 1984, EUR J PEDS, V141, P175; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; COPPES MJ, 1992, GENE CHROMOSOME CANC, V5, P326, DOI 10.1002/gcc.2870050408; COPPES MJ, 1994, NEW ENGL J MED, V331, P586; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; DEVILEE P, 1991, INT J CANCER, V47, P817, DOI 10.1002/ijc.2910470604; GREEN ED, 1994, HUM MOL GENET, V3, P489, DOI 10.1093/hmg/3.3.489; GRUNDY P, 1988, NATURE, V336, P375; GRUNDY PE, 1994, CANCER RES, V54, P2331; HEWITT M, 1991, J MED GENET, V28, P411, DOI 10.1136/jmg.28.6.411; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; HUFF V, 1991, AM J HUM GENET, V49, P44; KANEKO Y, 1991, CANCER RES, V51, P5937; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MAW M, 1986, CANCER RES, V52, P3094; MELONI AM, 1992, J UROLOGY, V148, P253, DOI 10.1016/S0022-5347(17)36565-5; Miozzo M, 1996, GENOMICS, V37, P310, DOI 10.1006/geno.1996.0565; MITLEMAN F, 1991, CYTOGENET CELL GENET, V58, P152; PEIER AM, 1995, CANCER GENET CYTOGEN, V79, P92, DOI 10.1016/0165-4608(94)00110-W; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARD J, 1995, J CLIN ONCOL, V13, P124, DOI 10.1200/JCO.1995.13.1.124; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Reynolds PA, 1996, GENE CHROMOSOME CANC, V17, P151, DOI 10.1002/(SICI)1098-2264(199611)17:3<151::AID-GCC2>3.0.CO;2-3; RIVERA H, 1985, ANN GENET-PARIS, V28, P52; RIVERA H, 1995, CANCER GENET CYTOGEN, V81, P97, DOI 10.1016/S0165-4608(94)00199-5; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SAWYER JR, 1993, CANCER GENET CYTOGEN, V69, P57, DOI 10.1016/0165-4608(93)90114-2; SCHWARTZ CE, 1991, GENOMICS, V10, P927, DOI 10.1016/0888-7543(91)90181-D; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; SLATER RM, 1985, CANCER GENET CYTOGEN, V14, P95, DOI 10.1016/0165-4608(85)90220-1; SOLIS V, 1988, CANCER GENET CYTOGEN, V34, P223, DOI 10.1016/0165-4608(88)90264-6; Tsui L C, 1995, Cytogenet Cell Genet, V71, P2; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WADEY RB, 1990, ONCOGENE, V5, P901; WANGWUU S, 1990, CANCER RES, V50, P2786; WILMORE HP, 1994, CANCER GENET CYTOGEN, V77, P93, DOI 10.1016/0165-4608(94)90221-6	46	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					395	400		10.1038/sj.onc.1201927	http://dx.doi.org/10.1038/sj.onc.1201927			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690521				2022-12-28	WOS:000074947500014
J	Wu, RC; Hohenstein, A; Park, JM; Qiu, XB; Mueller, S; Cadenas, E; Schonthal, AH				Wu, RC; Hohenstein, A; Park, JM; Qiu, XB; Mueller, S; Cadenas, E; Schonthal, AH			Role of p53 in aziridinylbenzoquinone-induced p21(waf1) expression	ONCOGENE			English	Article						p21; p53; quinones; aziridinylbenzoquinones	CYCLIN-DEPENDENT KINASES; DT-DIAPHORASE; P53-INDEPENDENT PATHWAY; ANTICANCER AGENTS; DNA-DAMAGE; OXIDATIVE STRESS; CELL-GROWTH; P21; SENSITIVITY; METABOLISM	Quinones are the second largest family of anticancer drugs clinically used in the United States. However, their exact mode of action at the cellular and molecular level is not completely understood. We have shown earlier that the quinone 3,6-diaziridinyl-1,4-benzoquinone (DZQ) leads to the increased expression of p21(waf1/cip/sdi1) protein, an inhibitor of cyclin-dependent kinases, Because p21 has been established as an important negative regulator of the cell cycle, we further investigated the molecular basis of p21 induction by DZQ. Here we report that the induction of p21 by DZQ is regulated at the transcriptional level, and requires the activation of p53, a tumor suppressor protein. In cells that lack functional p53 protein, DZQ-mediated p21 induction is greatly diminished. However, the introduction of a wild type p53 gene into p53-negative cells restores the strong DZQ-inducibility of p21. Restoration of wild type p53 status in HL60 myeloid leukemia cells significantly increases the cells' sensitivity to the cytotoxic effects of DZQ. Thus, our results indicate that the p53-p21 pathway may play a central role in mediating the gene-regulatory and cytotoxic effects of aziridinylbenzoquinones.	Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Schonthal, AH (corresponding author), Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, 2011 Zonal Ave,HMR-405, Los Angeles, CA 90033 USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653; Qiu, Xiao-Bo/0000-0003-2608-9376	NCI NIH HHS [R29CA74278-01] Funding Source: Medline; NHLBI NIH HHS [R01HL53467] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074278] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053467] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; CADENAS E, 1995, BIOCHEM PHARMACOL, V49, P127, DOI 10.1016/S0006-2952(94)00333-5; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; Coursen JD, 1997, MOL CARCINOGEN, V19, P191; CRESTEIL T, 1991, BIOCHEM PHARMACOL, V42, P1021, DOI 10.1016/0006-2952(91)90284-C; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; Gansauge S, 1997, FEBS LETT, V404, P6, DOI 10.1016/S0014-5793(97)00059-8; GIBSON NW, 1992, MOL PHARMACOL, V42, P531; GUTIERREZ PL, 1989, FREE RADICAL BIO MED, V6, P405, DOI 10.1016/0891-5849(89)90087-7; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hawkins DS, 1996, CANCER RES, V56, P892; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; LEE CS, 1992, BIOCHEMISTRY-US, V31, P3019, DOI 10.1021/bi00126a025; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Liu Y, 1996, CANCER RES, V56, P31; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martinez JD, 1997, CELL GROWTH DIFFER, V8, P941; MICHIELI P, 1994, CANCER RES, V54, P3391; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OConnor PM, 1997, CANCER RES, V57, P4285; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POWIS G, 1987, PHARMACOL THERAPEUT, V35, P57, DOI 10.1016/0163-7258(87)90105-7; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; QIU X, 1997, IN PRESS FREE RADIC; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; Renzing J, 1996, J CELL SCI, V109, P1105; ROSS D, 1996, COMPREHENSIVE TOXICO; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITSKAMPWILMS E, 1995, BRIT J CANCER, V72, P917, DOI 10.1038/bjc.1995.433; Vile GF, 1997, FEBS LETT, V412, P70, DOI 10.1016/S0014-5793(97)00748-5; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	50	6	6	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					357	365		10.1038/sj.onc.1201930	http://dx.doi.org/10.1038/sj.onc.1201930			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690517				2022-12-28	WOS:000074947500010
J	Bose, S; Wang, SI; Terry, MB; Hibshoosh, H; Parsons, R				Bose, S; Wang, SI; Terry, MB; Hibshoosh, H; Parsons, R			Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas	ONCOGENE			English	Article						breast carcinoma; carcinoma in situ; PTEN; chromosome 10; loss of heterozygosity	IN-SITU; CANCER; HETEROZYGOSITY; ALLELOTYPE; DELETION; REGION; FREQUENCY; 11Q13; P53	To determine the status of chromosome 10q23 in primary breast carcinomas, ill situ and invasive carcinomas were analysed for allelic loss using microsatellite markers spanning the 10q23 region. No LOH was seen in pure intraductal carcinomas (0/20 cases). On the other hand, LOH was observed in 40% (17/42) of invasive carcinomas (P=0.0005). Interestingly, in situ lesions found in invasive tumors displayed LOH. Allelic loss was also significantly associated with loss of the estrogen receptor (P=0.011). Thus, loss of the 10q23 is strongly associated with tumor progression.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Epidemiol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Parsons, R (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.			Terry, Mary Beth/0000-0002-4106-5033; Parsons, Ramon/0000-0002-6656-3514				*ACS, 1994, CANC FACTS FIG 1994; ALDAZ CM, 1995, CANCER RES, V55, P3976; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fujii H, 1996, CANCER RES, V56, P5260; GRAY IC, 1995, CANCER RES, V55, P4800; Guldberg P, 1997, CANCER RES, V57, P3660; Ittmann M, 1996, CANCER RES, V56, P2143; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; OSBORNE RJ, 1991, CANCER RES, V51, P6194; RADFORD DM, 1995, CANCER RES, V55, P3399; RADFORD DM, 1995, CANCER RES, V55, P5180; Rasheed BKA, 1997, CANCER RES, V57, P4187; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Rhei E, 1997, CANCER RES, V57, P3657; SATO T, 1990, CANCER RES, V50, P7184; SCHUURING E, 1992, ONCOGENE, V7, P355; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tashiro H, 1997, CANCER RES, V57, P3935; VARLEY JM, 1991, ONCOGENE, V6, P413; Wang SI, 1997, CANCER RES, V57, P4183; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; ZHUANG ZP, 1995, CANCER RES, V55, P467	32	92	107	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					123	127		10.1038/sj.onc.1201940	http://dx.doi.org/10.1038/sj.onc.1201940			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671321				2022-12-28	WOS:000074677800014
J	Li, Q; Jedlicka, A; Ahuja, N; Gibbons, MC; Baylin, SB; Burger, PC; Issa, JPJ				Li, Q; Jedlicka, A; Ahuja, N; Gibbons, MC; Baylin, SB; Burger, PC; Issa, JPJ			Concordant methylation of the ER and N33 genes in glioblastoma multiforme	ONCOGENE			English	Article						DNA methylation; glioblastoma multiforme; aging; estrogen receptor; N33	TUMOR-SUPPRESSOR GENE; RECEPTOR CPG ISLAND; ESTROGEN-RECEPTOR; DNA METHYLATION; EPITHELIAL-CELLS; HYPERMETHYLATION; EXPRESSION; INACTIVATION; GLIOMAS; CANCER	Methylation of promoter-associated CpG islands appears to be a potential way by which tumor suppressor genes are inactivated in cancer. Using Southern blot analysis, we have studied the methylation of several genes in glioblastoma multiforme (GBM), trying to determine their contribution to tumorigenesis. Genes studied included the estrogen receptor (ER), N33, the candidate tumor-suppressors P15, P16 and HIC1 and a control gene, c-abl, Hypermethylation of N33, ER, HIC1, P16, P15 and c-abl were found in 61%, 59%, 60%, 5%, 2% and 0% of GEM respectively. HIC1 methylation was detected in normal brain as well, but appeared to be more extensive in tumors. ER and N33 methylation were significantly more frequent in tumors from individuals over the age of 40 (70% and 88% vs 36% and 14%). In addition, there was a strong association between EX and N33 methylation, which were concordant in 81% of the cases (P< 0.01). ER and N33 methylation in GEM may therefore appear as a result of shared etiologic factors, which may relate in part to aging cell populations in the brain.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesia & Crit Care, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Issa, JPJ (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA.		Ahuja, Nita/H-1064-2011	Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [P30CA06973, 5UO1CA64928, 5RO1CA43318] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973, U01CA064928, R01CA043318] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Bondy ML, 1996, CANCER RES, V56, P1484; Costello JF, 1996, CANCER RES, V56, P2405; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Fueyo J, 1996, ONCOGENE, V13, P1615; Furnari FB, 1995, CANCER SURV, V25, P233; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1997, LEUKEMIA, V11, pS7; Issa JPJ, 1996, CANCER RES, V56, P973; Issa JPJ, 1997, CANCER RES, V57, P1678; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Issa JPJ, 1996, CANCER RES, V56, P3655; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; Jones PA, 1996, CANCER RES, V56, P2463; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MA ZQ, 1993, P NATL ACAD SCI USA, V90, P3740, DOI 10.1073/pnas.90.8.3740; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; MAKOS M, 1993, CANCER RES, V53, P2715; MAKOS M, 1993, CANCER RES, V53, P2719; MAMINTA MLD, 1991, MOL CELL ENDOCRINOL, V78, P61, DOI 10.1016/0303-7207(91)90186-V; Morton RA, 1996, J UROLOGY, V156, P512, DOI 10.1016/S0022-5347(01)65916-0; Ramirez VD, 1996, FRONT NEUROENDOCRIN, V17, P402, DOI 10.1006/frne.1996.0011; SAKAI T, 1991, AM J HUM GENET, V48, P880; SANTAGATI S, 1994, J NEUROCHEM, V63, P2058; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; VERTINO PM, 1993, CANCER RES, V53, P1684; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; ZAJCHOWSKI DA, 1993, CANCER RES, V53, P5004	37	62	65	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3197	3202		10.1038/sj.onc.1201831	http://dx.doi.org/10.1038/sj.onc.1201831			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671399				2022-12-28	WOS:000074261300013
J	Hayette, S; Gadoux, M; Martel, S; Bertrand, S; Tigaud, I; Magaud, JP; Rimokh, R				Hayette, S; Gadoux, M; Martel, S; Bertrand, S; Tigaud, I; Magaud, JP; Rimokh, R			FLRG (follistatin-related gene), a new target of chromosomal rearrangement in malignant blood disorders	ONCOGENE			English	Article						FLRG; follistatin; chromosomal translocation; carcinogenesis	FOLLICLE-STIMULATING-HORMONE; ACTIVIN-BINDING PROTEIN; EXPRESSION; DIFFERENTIATION; RECEPTORS; LYMPHOMAS; LEUKEMIAS; FAMILY; AGRIN; SPARC	We report here the molecular study of t(11;19)(q13;p13) translocation observed in a case of B-cell chronic lymphocytic leukemia. This translocation leads to the juxtaposition of the CCND1 gene on chromosome 11 to a new transcriptionnal unit on chromosome 19. The cDNA of this new evolutionarily conserved gene (named FLRG for Follistatin-Related Gene) codes for a secreted glycoprotein of the follistatin-module-protein family. FLRG is expressed in a wide range of human and murine adult tissues and its expression seems to be tightly regulated during murine embryogenesis. Its transcripts could not be detected in hematopoietic cells from all lineages and in particular in cells from lymphoid B and T lineage except in the t(11;19)-carrying leukemia described here. A great variability of expression is observed among the other tumoral cell lines analysed. Besides the t(11;19)-carrying leukemia described in this work, structural rearrangements of the FLRG locus have been found in a non-Hodgkin lymphoma, suggesting that it may play a role in leukemogenesis.	Ctr Leon Berard, INSERM, U453, F-69373 Lyon 08, France; Hop Edouard Herriot, Lab Cytogenet Mol, F-69437 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Lyon	Rimokh, R (corresponding author), Ctr Leon Berard, INSERM, U453, F-69373 Lyon 08, France.		HAYETTE, sandrine/Z-2283-2019; Rimokh, Ruth/G-7506-2014					Besecke LM, 1996, ENDOCRINOLOGY, V137, P3667, DOI 10.1210/en.137.9.3667; Graham A, 1996, DEVELOPMENT, V122, P473; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HINO M, 1995, FEBS LETT, V374, P69, DOI 10.1016/0014-5793(95)01078-S; HOCH W, 1994, EMBO J, V13, P2814, DOI 10.1002/j.1460-2075.1994.tb06575.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; Mendis DB, 1996, BRAIN RES, V730, P95; MICHEL U, 1993, MOL CELL ENDOCRINOL, V91, P1, DOI 10.1016/0303-7207(93)90248-I; MOKOTURA T, 1991, NATURE, V350, P512; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; PIERANI A, 1995, MOL CELL BIOL, V15, P642; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RIMOKH R, 1994, BLOOD, V83, P3689; RIMOKH R, 1993, BLOOD, V81, P3063; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; TANIWAKI M, 1994, BLOOD, V84, P2283, DOI 10.1182/blood.V84.7.2283.bloodjournal8472283; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; YAMASHITA T, 1992, BLOOD, V79, P304	23	97	112	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2949	2954		10.1038/sj.onc.1201807	http://dx.doi.org/10.1038/sj.onc.1201807			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671416				2022-12-28	WOS:000073988200014
J	McCarty, JH; Feinstein, SC				McCarty, JH; Feinstein, SC			Activation loop tyrosines contribute varying roles to TrkB autophosphorylation and signal transduction	ONCOGENE			English	Article						Shc; phospholipase C; Erk; proliferation; receptor tyrosine kinase	NERVE GROWTH-FACTOR; INSULIN-RECEPTOR; NEUROTROPHIC FACTOR; PROTEIN-KINASE; PHOSPHOLIPASE C-GAMMA-1; CRYSTAL-STRUCTURE; BINDING-SITES; BETA-SUBUNIT; NGF RECEPTOR; DOMAIN	The TrkB receptor tyrosine kinase (RTK) is a high affinity receptor for the neurotrophins brain derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5), Following exposure to BDNF or NT-4/5, TrkB is autophosphorylated on five cytoplasmic tyrosines: Y384, Y670, Y674, Y675, and Y785. Based on crystallographic analyses for others RTKs, TrkB tyrosines Y670, Y674, and Y675 are expected to lie within a putative kinase activation loop, Phosphorylation of these activation loop tyrosines is postulated to be a conserved event required for complete RTK activation, Here, we have assessed the importance these activation loop tyrosines play in regulating TrkB autophosphorylation, cytoplasmic signal transduction, and cell proliferation, We show that while tyrosine 670 is dispensable for BDNF-inducible TrkB autophosphorylation and the activation of certain signal transduction events, it is required for complete TrkB-mediated cellular proliferation, Combinatorial mutagenesis of tyrosines 674 and 675 only moderately affects TrkB autophosphorylation, but significantly impairs the BDNF-inducible stimulation of cytoplasmic signaling events and cellular proliferation, The combined mutation of all three activation loop tyrosines results in an inactive receptor, which is unable to autophosphorylate, stimulate signaling events, or induce mitogenesis, The data highlight the varying degrees of importance of the three activation loop tyrosines in TrkB mediated biological responses.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Feinstein, SC (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.				NATIONAL EYE INSTITUTE [R01EY010739] Funding Source: NIH RePORTER; NEI NIH HHS [EY 10739] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BORG P, 1995, CELL, V80, P693; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GUITON M, 1994, J BIOL CHEM, V269, P30370; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HEFTI F, 1994, J NEUROBIOL, V25, P1418, DOI 10.1002/neu.480251109; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Iwasaki Y, 1997, BIOCHEMISTRY-US, V36, P2694, DOI 10.1021/bi962057x; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LONGATI P, 1994, ONCOGENE, V9, P49; MARSH HN, 1993, J NEUROSCI, V13, P4281; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P43; MITRA G, 1991, ONCOGENE, V6, P2237; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PURVES D, 1988, BODY BRAIN; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Segal RA, 1996, J BIOL CHEM, V271, P20175, DOI 10.1074/jbc.271.33.20175; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3655; WATTS JD, 1992, J BIOL CHEM, V267, P901; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WIGLER M, 1979, CELL, V11, P223; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541; ZHANG B, 1991, J BIOL CHEM, V266, P990	54	23	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1691	1700		10.1038/sj.onc.1201688	http://dx.doi.org/10.1038/sj.onc.1201688			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582017				2022-12-28	WOS:000072807600007
